PMID	CUI	Preferred_name	sem_group	score
23313410	C0016529	Forced expiratory volume function	ortf	19.37
23313410	C0024109	Lung	bpoc	13.41
23313410	C0010674	Cystic Fibrosis	dsyn	11.49
23313410	C0001675	Adult	aggp	9.88
23313410	C0024115	Lung diseases	dsyn	6.91
23313410	C1836348	Severe disorder	fndg	3.78
23313410	C1306036	Forced expiratory volume procedure	diap	3.60
23313410	C1706450	Legal Adult	humn	3.57
23313410	C3273238	Regulatory Report	inpr	3.57
23313410	C0684224	Report (document)	inpr	3.57
23313410	C0700287	Reporting	hlca	3.57
23313410	C0809949	Admission activity	hlca	3.56
23313410	C0184666	Hospital admission	hlca	3.56
23313410	C2709248	Pulmonary (qualifier value)	qlco	3.56
23313410	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.56
23313410	C4050466	Borg Category-Ratio 10 Perceived Exertion Score 5	inpr	3.48
23313410	C1278908	Entire lung	bpoc	3.48
23313410	C0205082	Severe (severity modifier)	qlco	3.48
23313410	C4050465	Severe Extremity Pain	inpr	3.48
23313410	C0819757	Structure of parenchyma of lung	tisu	3.48
23313410	C0205447	One	qnco	3.42
23313410	C1882327	Percent of Predicted Value	qnco	3.42
23313410	C1561503	Precision - second	idcn	3.42
23313410	C1705190	Second Suffix	qlco	3.42
23313410	C0565930	per second	qnco	3.42
23313410	C0681842	prediction	idcn	3.42
23313410	C0205436	second (number)	qnco	3.42
23313410	C0457385	seconds	tmco	3.42
23313410	C3264621	ivacaftor	orch	13.05
23313410	C3264621	ivacaftor	phsu	13.05
23313410	C1518422	Negation	ftcn	5.18
23313410	C0587438	Day hospital	hcro	3.75
23313410	C0587438	Day hospital	mnob	3.75
23313410	C2986411	Improvement	cnce	3.68
23313410	C0418981	Medical therapy	topp	3.61
23313410	C1272689	Started	qlco	3.59
23313410	C4049713	Borg Category-Ratio 10 Perceived Exertion Score 10	inpr	3.56
23313410	C1273870	Management procedure	ocac	3.56
23313410	C0205289	Maximal (qualifier value)	qlco	3.56
23313410	C0806909	Maximum	qnco	3.56
23313410	C1546944	Event Seriousness - Significant	qlco	3.50
23313410	C0750502	Significant	idcn	3.50
23313410	C0237881	Statistical Significance	qnco	3.50
23313410	C0020440	Hypercapnia	fndg	12.90
23313410	C0035245	Respiratory physiology	ortf	6.62
23313410	C1882327	Percent of Predicted Value	qnco	3.68
23313410	C0681842	prediction	idcn	3.68
23313410	C0369768	Molecular oxygen saturation	moft	3.61
23313410	C0483415	Oxygen saturation test result	orga	3.61
23313410	C0442805	Increase	ftcn	3.59
23313410	C1882115	Normalize	resa	3.57
23313410	C2986411	Improvement	cnce	3.56
23313410	C3846005	Room air	fndg	3.46
23313410	C1561566	FEV1 Adverse Event	fndg	3.45
23313410	C0429706	Forced expiratory volume in 1 second finding	fndg	3.45
23313410	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.45
23313410	C1546944	Event Seriousness - Significant	qlco	3.43
23313410	C0750502	Significant	idcn	3.43
23313410	C0237881	Statistical Significance	qnco	3.43
23313410	C0024128	Lung Transplantation	topp	13.07
23313410	C3264621	ivacaftor	orch	12.89
23313410	C3264621	ivacaftor	phsu	12.89
23313410	C1524063	Use of	ftcn	3.61
23313410	C1516048	Assessed	acty	3.56
23313410	C0332152	Before	tmco	3.46
23313410	C0039798	therapeutic aspects	ftcn	45.07
23313410	C3264621	ivacaftor	orch	12.89
23313410	C3264621	ivacaftor	phsu	12.89
23313410	C0087111	Therapeutic procedure	topp	7.00
23313410	C0035245	Respiratory physiology	ortf	6.59
23313410	C0598463	Functional Status	fndg	5.18
23313410	C0750591	consider	idcn	5.18
23313410	C0205166	Long	qlco	3.98
23313410	C1706317	Long Variable	qlco	3.98
23313410	C1363945	Therapy Object (animal model)	fndg	3.56
23313410	C1547664	Diagnostic Radiology Modality	diap	3.54
23313410	C0695347	Modality	idcn	3.54
23313410	C0678226	Due to	ftcn	3.43
23313410	C0439231	month	tmco	3.43
23313410	C1533734	Administration procedure	topp	3.42
23313410	C1705169	Biomaterial Treatment	cnce	3.42
23313410	C2986411	Improvement	cnce	3.42
23313410	C1522326	Treating	ftcn	3.42
23313410	C3538994	Treatment Epoch	resa	3.42
23313410	C3887704	treatment - ActInformationManagementReason	hlca	3.42
24970923	C0298973	Ataxia Telangiectasia Mutated Proteins	aapp	25.54
24970923	C0298973	Ataxia Telangiectasia Mutated Proteins	enzy	25.54
24970923	C0014239	Endoplasmic Reticulum	celc	24.11
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.66
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.66
24970923	C0008203	Chlorides	inch	16.18
24970923	C0035280	Retention (Psychology)	menp	16.04
24970923	C0031843	physiological aspects	phsf	13.03
24970923	C0014139	Endocytosis	celf	11.49
24970923	C0596019	Chloride Ion	elii	7.49
24970923	C2984285	Endocytosis Pathway	ftcn	5.18
24970923	C1413365	CFTR gene	gngm	3.73
24970923	C0205161	Abnormal	qlco	3.57
24970923	C2699333	Abnormal Reference Range	inpr	3.57
24970923	C0439799	Channel	spco	3.57
24970923	C1706095	Channel Object	cnce	3.57
24970923	C0542341	Function	ftcn	3.57
24970923	C0700205	Function Axis	clas	3.57
24970923	C1705273	Mathematical Operator	inpr	3.57
24970923	C2347472	Percent of Abnormal Cells	qnco	3.57
24970923	C3840880	Traffic	fndg	3.57
24970923	C0231175	failed	ftcn	3.57
24970923	C2825142	Experimental Result	fndg	3.55
24970923	C1274040	Result	ftcn	3.55
24970923	C1546471	What subject filter - Result	idcn	3.55
24970923	C0333117	Retention of content	ftcn	3.43
24970923	C1753315	cellular entity retention	celf	3.43
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.40
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.40
24970923	C0040363	Togo	geoa	17.80
24970923	C0041260	Tryptophanase	aapp	17.80
24970923	C0041260	Tryptophanase	enzy	17.80
24970923	C0031843	physiological aspects	phsf	14.64
24970923	C1524059	mechanism of action qualifier	ftcn	13.14
24970923	C0005528	Biological Transport	celf	11.49
24970923	C0031330	Pharmacology	bmod	9.99
24970923	C0376649	Addresses (publication format)	inpr	8.34
24970923	C1413365	CFTR gene	gngm	7.33
24970923	C1442065	Address	spco	5.18
24970923	C0596019	Chloride Ion	elii	5.18
24970923	C0542341	Function	ftcn	5.18
24970923	C0700205	Function Axis	clas	5.18
24970923	C1705273	Mathematical Operator	inpr	5.18
24970923	C3495449	Mobility aid	medd	5.18
24970923	C1883351	To	qlco	5.18
24970923	C0750591	consider	idcn	5.18
24970923	C0599896	trafficking	celf	5.18
24970923	C1317949	transport (device)	mnob	5.18
24970923	C3539655	CDISC Findings Class	inpr	3.68
24970923	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	3.68
24970923	C2607943	findings aspects	ftcn	3.68
24970923	C0220806	Chemicals	chem	3.63
24970923	C0243067	defects aspect	ftcn	3.61
24970923	C0332185	Recent	tmco	3.50
24970923	C2986495	Synergistic	qlco	3.50
24970923	C1947967	Call (Instruction)	ftcn	3.48
24970923	C0679006	Decision	menp	3.48
24970923	C0700321	Small	qnco	3.48
24970923	C0053225	Benzoic Acid	orch	24.11
24970923	C0053225	Benzoic Acid	phsu	24.11
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
24970923	C0018873	HeLa Cells	cell	16.26
24970923	C3816745	1+	fndg	15.79
24970923	C2827734	1+ Score	qnco	15.79
24970923	C2981698	1+ Score, WHO	clas	15.79
24970923	C1321596	Miglustat	orch	14.64
24970923	C1321596	Miglustat	phsu	14.64
24970923	C0672708	Vorinostat	orch	14.64
24970923	C0672708	Vorinostat	phsu	14.64
24970923	C0053139	benzamide	orch	14.64
24970923	C0031843	physiological aspects	phsf	14.64
24970923	C0020314	Hydroxamic Acids	orch	13.22
24970923	C0076543	threitol	orch	13.08
24970923	C3838680	3+ Answer to Question	fndg	11.32
24970923	C2827736	3+ Score	qnco	11.32
24970923	C2981702	3+ Score, WHO	clas	11.32
24970923	C0439086	<3 (qualifier value)	qnco	11.32
24970923	C3838679	4+ Answer to question	fndg	10.90
24970923	C0740116	+2	qnco	7.36
24970923	C3833492	2+	fndg	7.36
24970923	C2827735	2+ Score	qnco	7.36
24970923	C2981700	2+ Score, WHO	clas	7.36
24970923	C0728893	+5	qnco	7.29
24970923	C0439084	>5	qnco	7.29
24970923	C1161334	Benzoicum acidum, benzoic acid, Homeopathic preparation	orch	5.18
24970923	C1161334	Benzoicum acidum, benzoic acid, Homeopathic preparation	phsu	5.18
24970923	C0542341	Function	ftcn	5.18
24970923	C0700205	Function Axis	clas	5.18
24970923	C1705273	Mathematical Operator	inpr	5.18
24970923	C1524063	Use of	ftcn	5.18
24970923	C3252847	VX 809	orch	5.18
24970923	C3252847	VX 809	phsu	5.18
24970923	C0557651	Room of building - Study	mnob	3.98
24970923	C2603343	Study	resa	3.98
24970923	C0369718	N not otherwise specified Antibody	aapp	3.68
24970923	C0369718	N not otherwise specified Antibody	imft	3.68
24970923	C0441922	N+ (tumor staging)	inpr	3.68
24970923	C1254042	Anatomical maturation	phsf	3.57
24970923	C0678723	Biologic Development	orgf	3.57
24970923	C0870861	Human maturation	phpr	3.57
24970923	C0205195	Combined	qlco	3.56
24970923	C3811910	combination - answer to question	fndg	3.56
24970923	C1947911	combination of objects	phob	3.56
24970923	C1413365	CFTR gene	gngm	3.44
24970923	C0205451	Five	qnco	3.43
24970923	C0672708	Vorinostat	orch	39.84
24970923	C0672708	Vorinostat	phsu	39.84
24970923	C1321596	Miglustat	orch	39.39
24970923	C1321596	Miglustat	phsu	39.39
24970923	C0061202	Genistein	bacs	25.76
24970923	C0061202	Genistein	orch	25.76
24970923	C0061202	Genistein	phsu	25.76
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
24970923	C3252847	VX 809	orch	18.41
24970923	C3252847	VX 809	phsu	18.41
24970923	C0034869	Records	inpr	16.17
24970923	C0917964	Colforsin	orch	16.12
24970923	C0917964	Colforsin	phsu	16.12
24970923	C0242625	Patch-Clamp Techniques	resa	13.18
24970923	C1524063	Use of	ftcn	5.18
24970923	C0178587	density	qnco	3.68
24970923	C1269647	Entire cell	cell	3.65
24970923	C1704632	Disease Response	fndg	3.59
24970923	C2911692	Response (communication)	menp	3.59
24970923	C1706817	Response (statement)	inpr	3.59
24970923	C0871261	Response process	orga	3.59
24970923	C3853788	Record - QueryRequestLimit	qnco	3.55
24970923	C3540027	Adrenergic and dopaminergic agents combinations	phsu	3.54
24970923	C3539975	Aluminium antacid compound combinations	phsu	3.54
24970923	C3539963	Amide local anesthetic combinations	orch	3.54
24970923	C3539963	Amide local anesthetic combinations	phsu	3.54
24970923	C3539979	Antiinfective irrigating solution combinations	phsu	3.54
24970923	C3540722	Beta-lactamase sensitive penicillin combinations	antb	3.54
24970923	C3540722	Beta-lactamase sensitive penicillin combinations	orch	3.54
24970923	C3539977	Calcium antacid compound combinations	phsu	3.54
24970923	C3540720	Caries prophylactic agent combinations	phsu	3.54
24970923	C3539972	Combination solutions for parenteral nutrition	phsu	3.54
24970923	C0453882	Combinations (Undergarment)	mnob	3.54
24970923	C3539968	Enema combinations	phsu	3.54
24970923	C3540026	Hepatitis vaccine combinations	aapp	3.54
24970923	C3540026	Hepatitis vaccine combinations	imft	3.54
24970923	C3540026	Hepatitis vaccine combinations	phsu	3.54
24970923	C0442805	Increase	ftcn	3.54
24970923	C0205217	Increased	qnco	3.54
24970923	C3540723	Insulins and analogs for injection, fast-acting combinations	phsu	3.54
24970923	C3539974	Insulins and analogs for injection, intermediate-acting combinations	phsu	3.54
24970923	C3539967	Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations	phsu	3.54
24970923	C3540719	Intermediate-acting sulfonamide combinations	orch	3.54
24970923	C3540719	Intermediate-acting sulfonamide combinations	phsu	3.54
24970923	C3539965	Local hemostatic combinations	phsu	3.54
24970923	C3539959	Long-acting sulfonamide combinations	orch	3.54
24970923	C3539959	Long-acting sulfonamide combinations	phsu	3.54
24970923	C3539956	Magnesium antacid compound combinations	phsu	3.54
24970923	C3854036	Other anti-dementia drug combinations in ATC	phsu	3.54
24970923	C3539973	Other antifungal combinations for topical use in ATC	phsu	3.54
24970923	C3539960	Other intestinal adsorbent combinations in ATC	phsu	3.54
24970923	C3540028	Other irrigating solution combinations in ATC	phsu	3.54
24970923	C3539976	Penicillins with extended spectrum combinations	antb	3.54
24970923	C3539976	Penicillins with extended spectrum combinations	orch	3.54
24970923	C3539961	Platelet aggregation inhibitor combinations excl. heparin	phsu	3.54
24970923	C3540740	Potassium supplement combinations	phsu	3.54
24970923	C3854307	Presence (property)	qlco	3.54
24970923	C0150312	Present	qnco	3.54
24970923	C0392148	Providing presence (regime/therapy)	topp	3.54
24970923	C3539182	Salt solution combinations	phsu	3.54
24970923	C3539181	Short-acting sulfonamide combinations	orch	3.54
24970923	C3539181	Short-acting sulfonamide combinations	phsu	3.54
24970923	C3539969	Specific immunoglobulin combinations	aapp	3.54
24970923	C3539969	Specific immunoglobulin combinations	imft	3.54
24970923	C3539969	Specific immunoglobulin combinations	phsu	3.54
24970923	C3539970	combination drugs used in erectile dysfunction	phsu	3.54
24970923	C3539978	expectorant combinations excluding combinations with cough suppressants	phsu	3.54
24970923	C3540724	expectorant combinations, excl. combinations with cough suppressants	phsu	3.54
24970923	C3540031	gonadotropin combinations	aapp	3.54
24970923	C3540031	gonadotropin combinations	horm	3.54
24970923	C3540031	gonadotropin combinations	phsu	3.54
24970923	C3539966	insulins and analogs for injection combinations, long-acting	phsu	3.54
24970923	C3539964	local opthalmologic anesthetic combinations	phsu	3.54
24970923	C3539955	lung surfactant combinations	phsu	3.54
24970923	C3539957	opium alkaloids and derivative combination cough suppressants	phsu	3.54
24970923	C3540030	other cough suppressant combinations in ATC	phsu	3.54
24970923	C3540721	other nasal preparation combinations in ATC	phsu	3.54
24970923	C3539971	otologic analgesic and anesthetic combinations	phsu	3.54
24970923	C3539954	topical antibiotic combinations	phsu	3.54
24970923	C3539962	vitamin D and analog combinations	phsu	3.54
24970923	C1719822	Follow	inpr	3.51
24970923	C0332283	Followed by	tmco	3.51
24970923	C1413365	CFTR gene	gngm	3.50
24970923	C0521116	Current (present time)	tmco	3.50
24970923	C1705970	Electrical Current	npop	3.50
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.96
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.96
24970923	C0033621	Protein C	aapp	12.88
24970923	C0033621	Protein C	bacs	12.88
24970923	C0033621	Protein C	phsu	12.88
24970923	C1413365	CFTR gene	gngm	6.89
24970923	C3540027	Adrenergic and dopaminergic agents combinations	phsu	5.18
24970923	C3539975	Aluminium antacid compound combinations	phsu	5.18
24970923	C3539963	Amide local anesthetic combinations	orch	5.18
24970923	C3539963	Amide local anesthetic combinations	phsu	5.18
24970923	C3539979	Antiinfective irrigating solution combinations	phsu	5.18
24970923	C3540722	Beta-lactamase sensitive penicillin combinations	antb	5.18
24970923	C3540722	Beta-lactamase sensitive penicillin combinations	orch	5.18
24970923	C3539977	Calcium antacid compound combinations	phsu	5.18
24970923	C3540720	Caries prophylactic agent combinations	phsu	5.18
24970923	C3539972	Combination solutions for parenteral nutrition	phsu	5.18
24970923	C0453882	Combinations (Undergarment)	mnob	5.18
24970923	C3539968	Enema combinations	phsu	5.18
24970923	C3540026	Hepatitis vaccine combinations	aapp	5.18
24970923	C3540026	Hepatitis vaccine combinations	imft	5.18
24970923	C3540026	Hepatitis vaccine combinations	phsu	5.18
24970923	C3540723	Insulins and analogs for injection, fast-acting combinations	phsu	5.18
24970923	C3539974	Insulins and analogs for injection, intermediate-acting combinations	phsu	5.18
24970923	C3539967	Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations	phsu	5.18
24970923	C3540719	Intermediate-acting sulfonamide combinations	orch	5.18
24970923	C3540719	Intermediate-acting sulfonamide combinations	phsu	5.18
24970923	C3539965	Local hemostatic combinations	phsu	5.18
24970923	C3539959	Long-acting sulfonamide combinations	orch	5.18
24970923	C3539959	Long-acting sulfonamide combinations	phsu	5.18
24970923	C3539956	Magnesium antacid compound combinations	phsu	5.18
24970923	C3854036	Other anti-dementia drug combinations in ATC	phsu	5.18
24970923	C3539973	Other antifungal combinations for topical use in ATC	phsu	5.18
24970923	C3539960	Other intestinal adsorbent combinations in ATC	phsu	5.18
24970923	C3540028	Other irrigating solution combinations in ATC	phsu	5.18
24970923	C3539976	Penicillins with extended spectrum combinations	antb	5.18
24970923	C3539976	Penicillins with extended spectrum combinations	orch	5.18
24970923	C3539961	Platelet aggregation inhibitor combinations excl. heparin	phsu	5.18
24970923	C3540740	Potassium supplement combinations	phsu	5.18
24970923	C3539182	Salt solution combinations	phsu	5.18
24970923	C3539181	Short-acting sulfonamide combinations	orch	5.18
24970923	C3539181	Short-acting sulfonamide combinations	phsu	5.18
24970923	C3539969	Specific immunoglobulin combinations	aapp	5.18
24970923	C3539969	Specific immunoglobulin combinations	imft	5.18
24970923	C3539969	Specific immunoglobulin combinations	phsu	5.18
24970923	C3539970	combination drugs used in erectile dysfunction	phsu	5.18
24970923	C3539978	expectorant combinations excluding combinations with cough suppressants	phsu	5.18
24970923	C3540724	expectorant combinations, excl. combinations with cough suppressants	phsu	5.18
24970923	C3540031	gonadotropin combinations	aapp	5.18
24970923	C3540031	gonadotropin combinations	horm	5.18
24970923	C3540031	gonadotropin combinations	phsu	5.18
24970923	C3539966	insulins and analogs for injection combinations, long-acting	phsu	5.18
24970923	C3539964	local opthalmologic anesthetic combinations	phsu	5.18
24970923	C3539955	lung surfactant combinations	phsu	5.18
24970923	C3539957	opium alkaloids and derivative combination cough suppressants	phsu	5.18
24970923	C3540030	other cough suppressant combinations in ATC	phsu	5.18
24970923	C3540721	other nasal preparation combinations in ATC	phsu	5.18
24970923	C3539971	otologic analgesic and anesthetic combinations	phsu	5.18
24970923	C3539954	topical antibiotic combinations	phsu	5.18
24970923	C3539962	vitamin D and analog combinations	phsu	5.18
24970923	C1561536	*Activity (kind of quantity)	idcn	3.56
24970923	C0205177	Active	ftcn	3.56
24970923	C0441655	Activities	acty	3.56
24970923	C3668946	Activity (animal life circumstance)	fndg	3.56
24970923	C1705242	Different	qlco	3.56
24970923	C0443199	Differential quality	qlco	3.56
24970923	C1280500	Effect	qlco	3.56
24970923	C2348382	Effect, Appearance	qlco	3.56
24970923	C4049939	FDA Establishment Activity Terminology	inpr	3.56
24970923	C0439167	Percent Activity	qnco	3.56
24970923	C4049938	Physical Activity Measurement	lbpr	3.56
24970923	C0700364	Appearance	qlco	3.54
24970923	C0233426	Personal appearance	orga	3.54
24970923	C0439645	Band form	spco	3.42
24970923	C0175723	Bands	medd	3.42
24970923	C1521913	Chromosome band	celc	3.42
24970923	C0205286	Mature	tmco	3.42
24970923	C1418943	PROC gene	gngm	3.42
24970923	C1168438	Protein C antigen measurement	lbpr	3.42
24970923	C1949480	protein C, human	aapp	3.42
24970923	C1949480	protein C, human	bacs	3.42
24970923	C1949480	protein C, human	phsu	3.42
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
24970923	C0034869	Records	inpr	16.59
24970923	C0000936	Visual Accommodation	clna	9.85
24970923	C2348236	Specimen at Room Temperature	qlco	5.18
24970923	C3167821	Temperature.ambient:Temperature:Point in time:Room:Quantitative	clna	5.18
24970923	C3853788	Record - QueryRequestLimit	qnco	3.98
24970923	C0456079	Disease classification level	clas	3.57
24970923	C1547707	Floor - story of building	geoa	3.57
24970923	C0205250	High	qlco	3.57
24970923	C2946261	Level	phsu	3.57
24970923	C0441889	Levels (qualifier value)	qlco	3.57
24970923	C2981153	Finding related to focusing	fndg	3.54
24970923	C1413365	CFTR gene	gngm	3.54
24970923	C1444783	Instability	fndg	3.54
24970923	C1947976	Correction (change)	ftcn	3.44
24970923	C1705565	Correction Report	inpr	3.44
24970923	C3252847	VX 809	orch	3.44
24970923	C3252847	VX 809	phsu	3.44
24970923	C0678420	Cocktail	food	3.42
24970923	C0021966	Iodides	inch	17.80
24970923	C0012634	Disease	dsyn	9.83
24970923	C0221138	Blood group antibody I	aapp	5.18
24970923	C0221138	Blood group antibody I	imft	5.18
24970923	C4049713	Borg Category-Ratio 10 Perceived Exertion Score 10	inpr	5.18
24970923	C0205198	Compound	qlco	5.18
24970923	C1706082	Compound (substance)	chem	5.18
24970923	C0205289	Maximal (qualifier value)	qlco	5.18
24970923	C0806909	Maximum	qnco	5.18
24970923	C2348205	Similarity	qlco	3.59
24970923	C1524063	Use of	ftcn	3.58
24970923	C0456079	Disease classification level	clas	3.56
24970923	C1547707	Floor - story of building	geoa	3.56
24970923	C2946261	Level	phsu	3.56
24970923	C0441889	Levels (qualifier value)	qlco	3.56
24970923	C1301820	Obtain	ftcn	3.55
24970923	C2698651	Optimum	qlco	3.55
24970923	C0277564	Acquired disease	dsyn	3.52
24970923	C1834645	Acquired disorder	fndg	3.52
24970923	C0348080	Condition	qlco	3.52
24970923	C3864998	Condition:Find:Pt:^Patient:Nom	clna	3.52
24970923	C1705253	Logical Condition	cnce	3.52
24970923	C3252847	VX 809	orch	3.43
24970923	C3252847	VX 809	phsu	3.43
24970923	C0542341	Function	ftcn	3.43
24970923	C0205245	Functional	ftcn	3.43
24970923	C2700217	Functional Relationship	cnce	3.43
24970923	C0439227	Hour	tmco	3.42
24970923	C1442770	24 Hours	tmco	3.44
24970923	C0439584	24 hour time frame	tmco	3.44
24970923	C3252847	VX 809	orch	3.44
24970923	C3252847	VX 809	phsu	3.44
24970923	C0456696	per 24 hours	tmco	3.44
24970923	C0917964	Colforsin	orch	32.99
24970923	C0917964	Colforsin	phsu	32.99
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
24970923	C0393003	potassium oxonate	orch	13.09
24970923	C0393003	potassium oxonate	phsu	13.09
24970923	C0754515	TERT protein, human	aapp	12.92
24970923	C0754515	TERT protein, human	enzy	12.92
24970923	C3838679	4+ Answer to question	fndg	7.11
24970923	C0007634	Cells	cell	5.18
24970923	C3282337	Cells [Chemical/Ingredient]	cell	5.18
24970923	C1707455	Comparison	acty	5.18
24970923	C2741958	VX-770	orch	3.75
24970923	C0369718	N not otherwise specified Antibody	aapp	3.68
24970923	C0369718	N not otherwise specified Antibody	imft	3.68
24970923	C0441922	N+ (tumor staging)	inpr	3.68
24970923	C3252847	VX 809	orch	3.61
24970923	C3252847	VX 809	phsu	3.61
24970923	C0205202	Corrected	qlco	3.56
24970923	C1948023	Stimulation (motivation)	npop	3.56
24970923	C1292856	Stimulation procedure	topp	3.56
24970923	C0450367	4/5	qnco	3.51
24970923	C3541881	Device Identifiers Domain	idcn	3.46
24970923	C3538902	SLC4A1 wt Allele	gngm	3.46
24970923	C1367342	TERT gene	gngm	3.46
24970923	C1705316	TERT wt Allele	gngm	3.46
24970923	C1413365	CFTR gene	gngm	3.43
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.32
24970923	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.32
24970923	C0039476	Temperature	qnco	19.21
24970923	C0040363	Togo	geoa	17.80
24970923	C0041260	Tryptophanase	aapp	17.80
24970923	C0041260	Tryptophanase	enzy	17.80
24970923	C0005903	Body Temperature	orga	16.05
24970923	C3658324	Polypharmacology	ocdi	12.88
24970923	C1413365	CFTR gene	gngm	7.24
24970923	C0175566	Open	spco	5.18
24970923	C1547282	Show	anim	5.18
24970923	C1883351	To	qlco	5.18
24970923	C2825142	Experimental Result	fndg	3.98
24970923	C1274040	Result	ftcn	3.98
24970923	C1546471	What subject filter - Result	idcn	3.98
24970923	C1705535	suggestion	idcn	3.98
24970923	C3640044	Cardiac Lead Function Indicator	cnce	3.56
24970923	C0205195	Combined	qlco	3.56
24970923	C1280500	Effect	qlco	3.56
24970923	C2348382	Effect, Appearance	qlco	3.56
24970923	C3811910	combination - answer to question	fndg	3.56
24970923	C1947911	combination of objects	phob	3.56
24970923	C1947976	Correction (change)	ftcn	3.55
24970923	C1705565	Correction Report	inpr	3.55
24970923	C0456079	Disease classification level	clas	3.55
24970923	C1547707	Floor - story of building	geoa	3.55
24970923	C2946261	Level	phsu	3.55
24970923	C0441889	Levels (qualifier value)	qlco	3.55
24970923	C0332272	Better	qlco	3.54
24970923	C3898777	Important	qlco	3.51
24970923	C0678723	Biologic Development	orgf	3.42
24970923	C1527148	Development	ftcn	3.42
24970923	C0205314	New	qlco	3.42
24970923	C2986495	Synergistic	qlco	3.42
24970923	C0243107	development aspects	phsf	3.42
25473543	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
25473543	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
25473543	C0039798	therapeutic aspects	ftcn	22.47
25473543	C3264621	ivacaftor	orch	12.88
25473543	C3264621	ivacaftor	phsu	12.88
25473543	C0010674	Cystic Fibrosis	dsyn	11.49
25473543	C0026882	Mutation	genf	9.91
25473543	C0030705	Patients	podg	6.57
25473543	C1705285	Mutation Abnormality	comd	3.60
25473543	C1413365	CFTR gene	gngm	3.58
25473543	C0087111	Therapeutic procedure	topp	3.54
25473543	C1363945	Therapy Object (animal model)	fndg	3.54
25473543	C0314622	Immune suppressor gene	gngm	3.43
25473543	C1552740	Entity Determiner - specific	inpr	3.42
25473543	C0442027	Oral	spco	3.42
25473543	C0205369	Specific qualifier value	qlco	3.42
25473543	C2348077	Date Fruit	food	27.26
25473543	C0282461	Phase 3 Clinical Trials	resa	22.57
25473543	C0009738	Congo	geoa	16.05
25473543	C0030705	Patients	podg	13.81
25473543	C0024115	Lung diseases	dsyn	8.34
25473543	C0011008	Date in time	tmco	5.18
25473543	C0445223	Related personal status	fndg	5.18
25473543	C0439849	Relationships	qlco	5.18
25473543	C1533716	Information	idcn	3.68
25473543	C0470187	Availability of	ftcn	3.57
25473543	C1554077	Excluded - Conformance Inclusion	idcn	3.55
25473543	C2828389	Exclusion	acty	3.55
25473543	C0439801	Limited (extensiveness)	ftcn	3.50
25473543	C4050251	Limited Lifting Ability	inpr	3.50
25473543	C2674459	Limited Walking Ability	fndg	3.50
25473543	C3542948	Limited component (foundation metadata concept)	inpr	3.50
25473543	C0814225	benefit	qnco	3.44
25473543	C4050466	Borg Category-Ratio 10 Perceived Exertion Score 5	inpr	3.43
25473543	C3811819	CFTR wt Allele	gngm	3.43
25473543	C0205082	Severe (severity modifier)	qlco	3.43
25473543	C4050465	Severe Extremity Pain	inpr	3.43
25473543	C0038990	Sweating	fndg	19.27
25473543	C0006560	C-reactive protein	aapp	16.26
25473543	C0006560	C-reactive protein	imft	16.26
25473543	C0026882	Mutation	genf	9.99
25473543	C0038984	Sweat	bdsu	9.81
25473543	C0001675	Adult	aggp	9.74
25473543	C1274040	Result	ftcn	6.96
25473543	C0024115	Lung diseases	dsyn	6.91
25473543	C0013832	Electrolytes	inch	6.83
25473543	C0013832	Electrolytes	phsu	6.83
25473543	C0024109	Lung	bpoc	6.63
25473543	C3273238	Regulatory Report	inpr	5.18
25473543	C0684224	Report (document)	inpr	5.18
25473543	C0700287	Reporting	hlca	5.18
25473543	C0679246	advanced disease	fndg	3.78
25473543	C3536863	Electrolyte [EPC]	phsu	3.68
25473543	C1705285	Mutation Abnormality	comd	3.68
25473543	C4048285	C-Reactive Protein, human	aapp	3.64
25473543	C4048285	C-Reactive Protein, human	imft	3.64
25473543	C2825142	Experimental Result	fndg	3.52
25473543	C1546471	What subject filter - Result	idcn	3.52
25473543	C0205179	Advanced phase	qlco	3.48
25473543	C1278908	Entire lung	bpoc	3.48
25473543	C0819757	Structure of parenchyma of lung	tisu	3.48
25473543	C0205210	Clinical	qlco	3.43
25473543	C1279919	Early	tmco	3.43
25473543	C1553058	Neuropsychologist - Clinical	prog	3.43
25473543	C0237412	Psychologist - Clinical	prog	3.43
25473543	C0497591	Social Worker - Clinical	prog	3.43
25473543	C0205449	Three	qnco	3.43
25473543	C0038990	Sweating	fndg	19.19
25473543	C0038984	Sweat	bdsu	9.73
25473543	C2347634	Population Mean	qnco	7.00
25473543	C2348143	Sample Mean	qnco	7.00
25473543	C0444504	Statistical mean	qnco	7.00
25473543	C1561566	FEV1 Adverse Event	fndg	5.18
25473543	C1441672	Observed	ftcn	5.18
25473543	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	5.18
25473543	C0439230	week	tmco	3.63
25473543	C0860861	cl- decreased	fndg	3.56
25473543	C0442805	Increase	ftcn	3.56
25473543	C0392756	Reduced	qlco	3.54
25473543	C0301630	Reduction (chemical)	npop	3.54
25473543	C0441610	Reduction - action	topp	3.54
25473543	C1516077	At	spco	3.48
25473543	C4049625	GATM wt Allele	gngm	3.48
25473543	C0428295	Cystic fibrosis sweat test	lbpr	3.44
25473543	C1304760	Sweat chloride level result	lbtr	3.44
25473543	C1532563	Millimole per Liter	qnco	3.68
25473543	C0043094	Weight Gain	fndg	27.26
25473543	C0282461	Phase 3 Clinical Trials	resa	22.57
25473543	C0038990	Sweating	fndg	19.21
25473543	C0037981	Spirometry	diap	16.07
25473543	C0038984	Sweat	bdsu	9.75
25473543	C0376315	Manufactured form	mnob	6.60
25473543	C0013832	Electrolytes	inch	6.59
25473543	C0013832	Electrolytes	phsu	6.59
25473543	C1518422	Negation	ftcn	5.18
25473543	C0884358	Performed	ftcn	5.18
25473543	C2911647	Weight Gain Adverse Event	fndg	5.18
25473543	C1707455	Comparison	acty	3.68
25473543	C2348205	Similarity	qlco	3.59
25473543	C0392756	Reduced	qlco	3.57
25473543	C0301630	Reduction (chemical)	npop	3.57
25473543	C0441610	Reduction - action	topp	3.57
25473543	C2986411	Improvement	cnce	3.55
25473543	C0684224	Report (document)	inpr	3.55
25473543	C0700287	Reporting	hlca	3.55
25473543	C1522492	Formation	ftcn	3.45
25473543	C0348078	Qualitative form	qlco	3.45
25473543	C3536863	Electrolyte [EPC]	phsu	3.44
27745802	C1314792	Etiology	ftcn	13.03
27745802	C0010674	Cystic Fibrosis	dsyn	11.49
27745802	C0015127	Etiology aspects	ftcn	9.88
27745802	C0001675	Adult	aggp	9.74
27745802	C1837655	Multifactorial	fndg	5.18
27745802	C3266069	Bone density below reference range	fndg	3.85
27745802	C1524003	Science of Etiology	cnce	3.57
27745802	C0033213	Problem	fndg	3.56
27745802	C3854081	Problem:Find:Pt:^Patient:Nom	clna	3.56
27745802	C0205214	Common (qualifier value)	qnco	3.43
27745802	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.43
27745802	C1522138	shared attribute	ftcn	3.43
27745802	C0009738	Congo	geoa	16.05
27745802	C0206243	Carrying	acty	14.64
27745802	C3264621	ivacaftor	orch	14.64
27745802	C3264621	ivacaftor	phsu	14.64
27745802	C0030705	Patients	podg	6.59
27745802	C0184511	Improved	qlco	5.18
27745802	C0369773	P Blood group antibodies	aapp	5.18
27745802	C0369773	P Blood group antibodies	imft	5.18
27745802	C2603361	P prime	clna	5.18
27745802	C1999230	Providing (action)	acty	5.18
27745802	C0557651	Room of building - Study	mnob	5.18
27745802	C2603343	Study	resa	5.18
27745802	C3887511	Evidence	idcn	3.68
27745802	C0205435	First (number)	qnco	3.50
27745802	C1279901	Firstly	qlco	3.50
27745802	C3811819	CFTR wt Allele	gngm	3.44
27745802	C0026882	Mutation	genf	9.94
27745802	C1705285	Mutation Abnormality	comd	3.63
27745802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
27745802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
27745802	C1448177	TNF protein, human	aapp	12.88
27745802	C1448177	TNF protein, human	bacs	12.88
27745802	C0029418	Osteoblasts	cell	9.73
27745802	C1947976	Correction (change)	ftcn	3.57
27745802	C1705565	Correction Report	inpr	3.57
27745802	C2827718	In Vitro Route of Administration	ftcn	3.55
27745802	C0021135	In Vitro [Publication Type]	inpr	3.55
27745802	C1533691	in vitro	qlco	3.55
27745802	C0681814	research study	resa	3.54
27745802	C1413365	CFTR gene	gngm	3.42
27745802	C0205225	Primary	qlco	3.42
27745802	C0439631	Primary operation	topp	3.42
27745802	C1948023	Stimulation (motivation)	npop	3.42
27745802	C0439612	True primary (qualifier value)	tmco	3.42
27745802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.06
27745802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.06
27745802	C0666364	TRANCE protein	aapp	38.68
27745802	C0666364	TRANCE protein	bacs	38.68
27745802	C0053933	bone resorption factor	aapp	13.09
27745802	C0666361	TNFSF11 protein, human	aapp	12.91
27745802	C0666361	TNFSF11 protein, human	bacs	12.91
27745802	C0033684	Proteins	aapp	6.61
27745802	C0033684	Proteins	bacs	6.61
27745802	C3156589	tumor necrosis factor (ligand) superfamily member 11 production	moft	3.63
27745802	C0033268	production	ocac	3.59
27745802	C1413365	CFTR gene	gngm	3.45
27745802	C0205216	Decreased	qnco	3.45
27745802	C0442797	Decreasing	qlco	3.45
27745802	C0522501	Massive	qlco	3.45
27745802	C3890560	Receptor Activator Nuclear KappaB Ligand Measurement	lbpr	3.45
27745802	C0392756	Reduced	qlco	3.45
27745802	C1367028	TNFSF11 gene	gngm	3.45
27745802	C1704863	TNFSF11 wt Allele	gngm	3.45
27745802	C0205164	Major	qlco	3.43
27745802	C0205082	Severe (severity modifier)	qlco	3.43
27745802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.16
27745802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.16
27745802	C0298973	Ataxia Telangiectasia Mutated Proteins	aapp	25.53
27745802	C0298973	Ataxia Telangiectasia Mutated Proteins	enzy	25.53
27745802	C0700325	Patient observation	hlca	16.30
27745802	C0085268	Bone remodeling	ortf	14.64
27745802	C0031843	physiological aspects	phsf	13.09
27745802	C0029432	Osteocytes	cell	13.00
27745802	C0302523	Observation in research	resa	9.99
27745802	C0031842	Physiology	bmod	9.94
27745802	C0391978	Bone Tissue	tisu	9.78
27745802	C1413365	CFTR gene	gngm	6.90
27745802	C1521997	Bone Remodelling Pathway	moft	5.18
27745802	C0205210	Clinical	qlco	5.18
27745802	C0184511	Improved	qlco	5.18
27745802	C1553058	Neuropsychologist - Clinical	prog	5.18
27745802	C0237412	Psychologist - Clinical	prog	5.18
27745802	C0497591	Social Worker - Clinical	prog	5.18
27745802	C0183683	Support, device	medd	5.18
27745802	C1521721	Supportive assistance	cnce	5.18
27745802	C1705535	suggestion	idcn	5.18
27745802	C0231542	Bone function	ortf	3.78
27745802	C0007613	Cell physiology	celf	3.75
27745802	C1325880	cellular process	celf	3.75
27745802	C3244290	Observations domain	ftcn	3.68
27745802	C1704666	Hyperlink	inpr	3.57
27745802	C1517892	Links List	inpr	3.57
27745802	C0222677	Cell of bone	cell	3.53
27745802	C1413336	CEL gene	gngm	3.48
27745802	C1948049	Cell (compartment)	spco	3.48
27745802	C1704653	Cell Device Component	medd	3.48
27745802	C0007634	Cells	cell	3.48
27745802	C1266908	Entire bone (organ)	bpoc	3.48
27745802	C1266909	Entire bony skeleton	bdsy	3.48
27745802	C1269647	Entire cell	cell	3.48
27745802	C0262950	Skeletal bone	bpoc	3.48
27745802	C1705285	Mutation Abnormality	comd	3.43
27745802	C0009738	Congo	geoa	16.08
27745802	C0005940	Bone Diseases	dsyn	6.83
27745802	C3539655	CDISC Findings Class	inpr	5.18
27745802	C1705117	Increment	qnco	5.18
27745802	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
27745802	C1882932	Representation (action)	acty	5.18
27745802	C2825408	Stair (equipment)	mnob	5.18
27745802	C1261552	Step (specific stage)	cnce	5.18
27745802	C3814463	Step Unit of Distance	qnco	5.18
27745802	C1704379	Treatment Step	ftcn	5.18
27745802	C2607943	findings aspects	ftcn	5.18
27745802	C3242274	new therapy	fndg	3.55
27745802	C0678723	Biologic Development	orgf	3.54
27745802	C1527148	Development	ftcn	3.54
27745802	C0439780	Forward	spco	3.54
27745802	C0243107	development aspects	phsf	3.54
27745802	C3245505	potential	qlco	3.54
27745802	C3811819	CFTR wt Allele	gngm	3.47
27745802	C0445223	Related personal status	fndg	3.47
27745802	C0439849	Relationships	qlco	3.47
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.53
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.53
27007499	C0010674	Cystic Fibrosis	dsyn	9.75
27007499	C0030705	Patients	podg	6.58
27007499	C1413365	CFTR gene	gngm	3.60
27007499	C0544885	Nonsense mutation	comd	3.57
27007499	C0439799	Channel	spco	3.54
27007499	C1706095	Channel Object	cnce	3.54
27007499	C2825142	Experimental Result	fndg	3.54
27007499	C1274040	Result	ftcn	3.54
27007499	C1546471	What subject filter - Result	idcn	3.54
27007499	C0033268	production	ocac	3.54
27007499	C0205214	Common (qualifier value)	qnco	3.42
27007499	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
27007499	C1522138	shared attribute	ftcn	3.42
27007499	C0087136	Unmarried	fndg	22.39
27007499	C0037179	Unmarried person	popg	22.39
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27007499	C0023376	Lesotho	geoa	16.22
27007499	C0033204	Probability	qnco	16.08
27007499	C2744579	ATP8A2 protein, human	aapp	13.01
27007499	C2744579	ATP8A2 protein, human	enzy	13.01
27007499	C0991556	Transdermal Patch	medd	6.70
27007499	C0596901	Membrane	celc	6.59
27007499	C0025255	Tissue membrane	tisu	6.59
27007499	C1305923	Polypeptides	aapp	6.58
27007499	C3842591	0%	fndg	5.18
27007499	C1547282	Show	anim	5.18
27007499	C3887647	Lymphotoxin-Alpha, human	aapp	3.60
27007499	C3887647	Lymphotoxin-Alpha, human	imft	3.60
27007499	C0230426	Structure of left thigh	bpoc	3.60
27007499	C1153410	channel activity	moft	3.57
27007499	C3890211	Low Mitosis-Karyorrhexis Index	qnco	3.56
27007499	C0205251	low	qlco	3.56
27007499	C1550472	low confidentiality	inpr	3.56
27007499	C4048187	low exposure	qlco	3.56
27007499	C1533128	Body tissue patch material	bodm	3.55
27007499	C0178602	Dosage	qnco	3.55
27007499	C0445403	Human patch material	bodm	3.55
27007499	C1707974	Patch - Extended Release Film	bodm	3.55
27007499	C0994894	Patch Dosage Form	medd	3.55
27007499	C1706366	Patch Dosing Unit	qnco	3.55
27007499	C0332461	Plaque (lesion)	fndg	3.55
27007499	C0522534	Saturated	phpr	3.55
27007499	C1305400	Surgical patch	medd	3.55
27007499	C0439799	Channel	spco	3.46
27007499	C1706095	Channel Object	cnce	3.46
27007499	C0175566	Open	spco	3.46
27007499	C0205171	Singular	qnco	3.46
27007499	C1706182	Membrane Device Component	mnob	3.43
27007499	C1413365	CFTR gene	gngm	3.42
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.14
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.14
27007499	C0010467	Curcumin	irda	25.71
27007499	C0010467	Curcumin	orch	25.71
27007499	C0010467	Curcumin	phsu	25.71
27007499	C0041714	United States Food and Drug Administration	hcro	25.69
27007499	C0012155	Diet	food	12.94
27007499	C1413365	CFTR gene	gngm	7.07
27007499	C2741958	VX-770	orch	3.68
27007499	C0205540	Approved	qlco	3.61
27007499	C0439799	Channel	spco	3.59
27007499	C1706095	Channel Object	cnce	3.59
27007499	C1948023	Stimulation (motivation)	npop	3.56
27007499	C0205448	Two	qnco	3.56
27007499	C1709060	Modulator Device Component	mnob	3.53
27007499	C0205198	Compound	qlco	3.48
27007499	C1706082	Compound (substance)	chem	3.48
27007499	C2699635	Dietary Route of Administration	ftcn	3.48
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27007499	C2744579	ATP8A2 protein, human	aapp	14.64
27007499	C2744579	ATP8A2 protein, human	enzy	14.64
27007499	C0023688	Ligands	chem	12.88
27007499	C0033414	Promotion (action)	acty	5.18
27007499	C1153410	channel activity	moft	3.56
27007499	C1709060	Modulator Device Component	mnob	3.56
27007499	C0205198	Compound	qlco	3.54
27007499	C1706082	Compound (substance)	chem	3.54
27007499	C1413365	CFTR gene	gngm	3.43
27007499	C1689985	Absence (morphologic abnormality)	anab	3.42
27007499	C0332197	Absent	ftcn	3.42
27007499	C0302891	Native (qualifier value)	ftcn	3.42
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
27007499	C0031715	Phosphorylation	moft	12.90
27007499	C2744579	ATP8A2 protein, human	aapp	12.89
27007499	C2744579	ATP8A2 protein, human	enzy	12.89
27007499	C0441655	Activities	acty	5.18
27007499	C2741958	VX-770	orch	3.64
27007499	C0439799	Channel	spco	3.59
27007499	C1706095	Channel Object	cnce	3.59
27007499	C1701901	Conditional	qlco	3.57
27007499	C0851827	Dependent - ability	qlco	3.57
27007499	C1948023	Stimulation (motivation)	npop	3.57
27007499	C3244310	dependent	ftcn	3.57
27007499	C1689985	Absence (morphologic abnormality)	anab	3.56
27007499	C0332197	Absent	ftcn	3.56
27007499	C1413365	CFTR gene	gngm	3.48
27007499	C1158886	Protein phosphorylation	moft	3.44
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
27007499	C0086982	Signal Transduction Pathways	moft	13.14
27007499	C0028630	Nucleotides	nnon	9.77
27007499	C1515655	in vivo	spco	5.18
27007499	C2587213	Control function	ftcn	3.58
27007499	C0439799	Channel	spco	3.58
27007499	C1706095	Channel Object	cnce	3.58
27007499	C1879547	Activation action	acty	3.47
27007499	C1413365	CFTR gene	gngm	3.47
27007499	C0439596	Cyclical	tmco	3.47
27007499	C1511572	event cycle	tmco	3.47
27007499	C0010467	Curcumin	irda	27.26
27007499	C0010467	Curcumin	orch	27.26
27007499	C0010467	Curcumin	phsu	27.26
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27007499	C0032729	Portugal	geoa	9.85
27007499	C0439799	Channel	spco	6.89
27007499	C1706095	Channel Object	cnce	6.89
27007499	C3842591	0%	fndg	5.18
27007499	C0587267	Closed	ftcn	5.18
27007499	C0015264	Exertion	orgf	5.18
27007499	C1435727	FABP6 protein, human	aapp	5.18
27007499	C1435727	FABP6 protein, human	bacs	5.18
27007499	C0175566	Open	spco	5.18
27007499	C1882151	Opening	spco	5.18
27007499	C2741958	VX-770	orch	3.75
27007499	C0994894	Patch Dosage Form	medd	3.68
27007499	C0442796	Additive	qlco	3.55
27007499	C1280500	Effect	qlco	3.55
27007499	C1550602	additive ingredient	sbst	3.55
27007499	C0442027	Oral	spco	3.54
27007499	C1413365	CFTR gene	gngm	3.42
27007499	C0449445	Approach	spco	3.40
27007499	C0332293	Treated with	topp	3.64
27007499	C1709060	Modulator Device Component	mnob	3.54
27007499	C0010467	Curcumin	irda	25.50
27007499	C0010467	Curcumin	orch	25.50
27007499	C0010467	Curcumin	phsu	25.50
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
27007499	C2741958	VX-770	orch	3.75
27007499	C0521116	Current (present time)	tmco	3.54
27007499	C1413365	CFTR gene	gngm	3.42
27007499	C1705150	FLT1 wt Allele	gngm	3.42
27007499	C0086597	Mediate	socb	3.42
27007499	C0127400	Mediator brand of benfluorex hydrochloride	orch	3.42
27007499	C0127400	Mediator brand of benfluorex hydrochloride	phsu	3.42
27007499	C1948023	Stimulation (motivation)	npop	3.42
27007499	C0221908	epithelial	qlco	3.42
27007499	C0872351	monolayer	clnd	3.42
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.13
27007499	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.13
27007499	C0040363	Togo	geoa	17.80
27007499	C0041260	Tryptophanase	aapp	17.80
27007499	C0041260	Tryptophanase	enzy	17.80
27007499	C0242391	Cell Membrane Proteins	aapp	9.77
27007499	C0242391	Cell Membrane Proteins	rcpt	9.77
27007499	C1413365	CFTR gene	gngm	7.06
27007499	C0442758	3/5	qnco	5.18
27007499	C1548802	Body Site Modifier - Lower	blor	5.18
27007499	C2003888	Lower (action)	acty	5.18
27007499	C0441994	Lower - spatial qualifier	spco	5.18
27007499	C1883351	To	qlco	5.18
27007499	C0542559	contextual factors	ftcn	5.18
27007499	C1318139	{Setting}	qnco	5.18
27007499	C3244092	expression level	qnco	3.98
27007499	C3146286	Due	idcn	3.68
27007499	C0678226	Due to	ftcn	3.68
27007499	C0521116	Current (present time)	tmco	3.61
27007499	C1883559	Wild Type	gngm	3.61
27007499	C0700321	Small	qnco	3.59
27007499	C0547044	Smaller	qlco	3.59
27007499	C0086597	Mediate	socb	3.56
27007499	C0127400	Mediator brand of benfluorex hydrochloride	orch	3.56
27007499	C0127400	Mediator brand of benfluorex hydrochloride	phsu	3.56
27007499	C1521840	Target	ftcn	3.55
27007499	C1948023	Stimulation (motivation)	npop	3.47
27007499	C1179841	Plasma membrane protein	aapp	3.46
27007499	C1179841	Plasma membrane protein	bacs	3.46
27007499	C0040363	Togo	geoa	17.80
27007499	C0041260	Tryptophanase	aapp	17.80
27007499	C0041260	Tryptophanase	enzy	17.80
27007499	C0009738	Congo	geoa	16.04
27007499	C0030705	Patients	podg	6.57
27007499	C0442805	Increase	ftcn	5.18
27007499	C1883351	To	qlco	5.18
27007499	C0336789	Combine	mnob	3.98
27007499	C1171362	protein expression	genf	3.60
27007499	C1948027	Couple (action)	ftcn	3.59
27007499	C0750591	consider	idcn	3.59
27007499	C0683525	treatment options	topp	3.56
27007499	C1709060	Modulator Device Component	mnob	3.52
27007499	C0684000	class differences	fndg	3.42
27007499	C3811819	CFTR wt Allele	gngm	3.42
27007499	C0441712	Mechanism (attribute)	ftcn	3.38
27007499	C1706376	Mechanism Component of Device	mnob	3.38
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
23440202	C0055363	Chloride Channels	aapp	19.20
23440202	C0055363	Chloride Channels	bacs	19.20
23440202	C0040452	Tooth root structure	bpoc	16.18
23440202	C3264621	ivacaftor	orch	14.64
23440202	C3264621	ivacaftor	phsu	14.64
23440202	C0026882	Mutation	genf	9.88
23440202	C0015127	Etiology aspects	ftcn	9.85
23440202	C0010674	Cystic Fibrosis	dsyn	9.77
23440202	C0012634	Disease	dsyn	9.74
23440202	C0016452	Food	food	9.73
23440202	C0030705	Patients	podg	6.71
23440202	C0242726	Plant Roots	plnt	6.71
23440202	C2347509	Physical Shift	phpr	5.18
23440202	C0333051	shift displacement	ftcn	5.18
23440202	C2741958	VX-770	orch	3.75
23440202	C3816499	Pathogenic	fndg	3.57
23440202	C0450254	Pathogenic organism	orgm	3.57
23440202	C1318154	Root body part	bpoc	3.56
23440202	C1705917	heirarchal root	idcn	3.56
23440202	C4036061	Drug-drug	fndg	3.56
23440202	C0681797	paradigm	resa	3.55
23440202	C0243067	defects aspect	ftcn	3.54
23440202	C1524003	Science of Etiology	cnce	3.54
23440202	C1947931	Direct (qualifier)	qlco	3.48
23440202	C0723712	Therapeutic brand of coal tar	orch	3.48
23440202	C0723712	Therapeutic brand of coal tar	phsu	3.48
23440202	C0087111	Therapeutic procedure	topp	3.48
23440202	C1413365	CFTR gene	gngm	3.47
23440202	C2945704	Conventional Treatment	topp	3.44
23440202	C0231220	Symptomatic	ftcn	3.43
23440202	C0001554	Administration occupational activities	ocac	3.42
23440202	C1533734	Administration procedure	topp	3.42
23440202	C1947919	Application (Document)	inpr	3.42
23440202	C3539080	Application Dosing Unit	qnco	3.42
23440202	C0185125	Application procedure	hlca	3.42
23440202	C4048755	Apply	ftcn	3.42
23440202	C0205540	Approved	qlco	3.42
23440202	C0205210	Clinical	qlco	3.42
23440202	C3540798	Food allergenic extracts	imft	3.42
23440202	C3540798	Food allergenic extracts	phsu	3.42
23440202	C1553058	Neuropsychologist - Clinical	prog	3.42
23440202	C0237412	Psychologist - Clinical	prog	3.42
23440202	C2347934	Regulatory Application	inpr	3.42
23440202	C0497591	Social Worker - Clinical	prog	3.42
23440202	C0542341	Function	ftcn	3.42
23440202	C0205245	Functional	ftcn	3.42
23440202	C2700217	Functional Relationship	cnce	3.42
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.98
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.98
23440202	C1524059	mechanism of action qualifier	ftcn	13.03
23440202	C0031843	physiological aspects	phsf	13.02
23440202	C2744579	ATP8A2 protein, human	aapp	12.90
23440202	C2744579	ATP8A2 protein, human	enzy	12.90
23440202	C0078433	methylphosphonothioic acid S-(2-(bis(1-methylethyl)amino)ethyl) O-ethyl ester	orch	12.88
23440202	C0078433	methylphosphonothioic acid S-(2-(bis(1-methylethyl)amino)ethyl) O-ethyl ester	phsu	12.88
23440202	C0026882	Mutation	genf	9.94
23440202	C0031327	Drug Kinetics	phsf	9.87
23440202	C0020291	Hydrolysis	npop	9.87
23440202	C0012634	Disease	dsyn	9.78
23440202	C1413365	CFTR gene	gngm	6.91
23440202	C0205198	Compound	qlco	5.18
23440202	C1706082	Compound (substance)	chem	5.18
23440202	C0184511	Improved	qlco	5.18
23440202	C0442805	Increase	ftcn	5.18
23440202	C0205217	Increased	qnco	5.18
23440202	C1518422	Negation	ftcn	5.18
23440202	C1720467	Only - dosing instruction fragment	inpr	5.18
23440202	C0205171	Singular	qnco	5.18
23440202	C1705285	Mutation Abnormality	comd	3.63
23440202	C0459205	Type of activity	inpr	3.62
23440202	C0332298	Controlled by	ftcn	3.61
23440202	C1148923	atp binding	moft	3.61
23440202	C1510699	ATP Hydrolysis	moft	3.60
23440202	C1167622	Binding (Molecular Function)	moft	3.56
23440202	C1145667	Binding action	acty	3.56
23440202	C0542341	Function	ftcn	3.56
23440202	C0700205	Function Axis	clas	3.56
23440202	C1705273	Mathematical Operator	inpr	3.56
23440202	C0205342	Responsive	ftcn	3.51
23440202	C0332281	Associated with	qlco	3.48
23440202	C0445392	Wild	inpr	3.43
23440202	C0441905	Venous stage VX	fndg	3.42
23440202	C0439799	Channel	spco	3.41
23440202	C1706095	Channel Object	cnce	3.41
23440202	C0040363	Togo	geoa	17.80
23440202	C0041260	Tryptophanase	aapp	17.80
23440202	C0041260	Tryptophanase	enzy	17.80
23440202	C1999230	Providing (action)	acty	5.18
23440202	C1883351	To	qlco	5.18
23440202	C0871935	theories	idcn	3.68
23440202	C2741958	VX-770	orch	3.57
23440202	C2741673	Account number:Identifier:Point in time:^Patient:Nominal	clna	3.54
23440202	C1554184	Dual	anim	3.54
23440202	C1280500	Effect	qlco	3.54
23440202	C2348382	Effect, Appearance	qlco	3.54
23440202	C2981730	Financial Account	inpr	3.54
23440202	C1706076	Unification process	qlco	3.50
23440202	C1548174	Unified - Type of Agreement	idcn	3.50
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.96
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.96
23440202	C2744579	ATP8A2 protein, human	aapp	12.89
23440202	C2744579	ATP8A2 protein, human	enzy	12.89
23440202	C2741958	VX-770	orch	7.27
23440202	C1280500	Effect	qlco	7.00
23440202	C1413365	CFTR gene	gngm	6.89
23440202	C2349975	Enhance (action)	acty	5.18
23440202	C2825142	Experimental Result	fndg	5.18
23440202	C0150312	Present	qnco	5.18
23440202	C1274040	Result	ftcn	5.18
23440202	C1546471	What subject filter - Result	idcn	5.18
23440202	C0439799	Channel	spco	3.63
23440202	C1706095	Channel Object	cnce	3.63
23440202	C2348382	Effect, Appearance	qlco	3.55
23440202	C1561536	*Activity (kind of quantity)	idcn	3.55
23440202	C0205177	Active	ftcn	3.55
23440202	C0441655	Activities	acty	3.55
23440202	C3668946	Activity (animal life circumstance)	fndg	3.55
23440202	C0449286	Degree or extent	qnco	3.55
23440202	C4049939	FDA Establishment Activity Terminology	inpr	3.55
23440202	C1704240	Magnitude	qnco	3.55
23440202	C0439167	Percent Activity	qnco	3.55
23440202	C4049938	Physical Activity Measurement	lbpr	3.55
23440202	C0332291	Independent of	ftcn	3.44
23440202	C2348205	Similarity	qlco	3.42
23440202	C0205359	Spontaneous	ftcn	3.42
23440202	C2700323	Wild Type Unspecified - zebrafish	fish	3.42
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
23440202	C2744579	ATP8A2 protein, human	aapp	14.64
23440202	C2744579	ATP8A2 protein, human	enzy	14.64
23440202	C0040223	Time	tmco	6.71
23440202	C0442805	Increase	ftcn	5.18
23440202	C0205217	Increased	qnco	5.18
23440202	C2741958	VX-770	orch	5.18
23440202	C0175566	Open	spco	3.55
23440202	C3541383	Time (foundation metadata concept)	tmco	3.55
23440202	C1701901	Conditional	qlco	3.50
23440202	C0851827	Dependent - ability	qlco	3.50
23440202	C3244310	dependent	ftcn	3.50
23440202	C1413365	CFTR gene	gngm	3.43
23440202	C2700323	Wild Type Unspecified - zebrafish	fish	3.43
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.96
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.96
23440202	C2744579	ATP8A2 protein, human	aapp	14.64
23440202	C2744579	ATP8A2 protein, human	enzy	14.64
23440202	C0078889	Accountability	idcn	12.95
23440202	C0022702	Kinetics	npop	9.78
23440202	C1413365	CFTR gene	gngm	6.89
23440202	C0441712	Mechanism (attribute)	ftcn	5.18
23440202	C1706376	Mechanism Component of Device	mnob	5.18
23440202	C0683607	allowing	socb	5.18
23440202	C1280500	Effect	qlco	3.63
23440202	C2348382	Effect, Appearance	qlco	3.63
23440202	C2584310	Shuffling	dora	3.55
23440202	C0332490	Round shape	spco	3.52
23440202	C1701901	Conditional	qlco	3.50
23440202	C0851827	Dependent - ability	qlco	3.50
23440202	C3845238	Reentry	fndg	3.50
23440202	C3244310	dependent	ftcn	3.50
23440202	C1510699	ATP Hydrolysis	moft	3.44
23440202	C1705242	Different	qlco	3.43
23440202	C1301808	Geographic state	geoa	3.43
23440202	C0175566	Open	spco	3.43
23440202	C0439064	Numerous	qnco	3.42
23440202	C1553874	Concept Status - Proposed	qlco	3.42
23440202	C3853906	Digital Model Attachment	inpr	3.42
23440202	C1578820	Edit Status - Proposed	qlco	3.42
23440202	C3161035	Model	inpr	3.42
23440202	C3714583	Model - style/design	cnce	3.42
23440202	C3274659	Model Number	inpr	3.42
23440202	C0750546	newly	idcn	3.42
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
23440202	C0700325	Patient observation	hlca	16.16
23440202	C0032930	Precipitating Factors	clna	16.02
23440202	C0302523	Observation in research	resa	9.86
23440202	C0020291	Hydrolysis	npop	9.73
23440202	C0332128	Examined	fndg	5.18
23440202	C1517331	Further	spco	5.18
23440202	C0683607	allowing	socb	5.18
23440202	C1413365	CFTR gene	gngm	3.68
23440202	C0596988	mutant	comd	3.68
23440202	C1280500	Effect	qlco	3.56
23440202	C2348382	Effect, Appearance	qlco	3.56
23440202	C1964257	Observation - diagnostic procedure	diap	3.55
23440202	C1710548	Unique	qlco	3.50
23440202	C2741958	VX-770	orch	3.46
23440202	C3541888	CDISC Events Class	clas	3.42
23440202	C1947931	Direct (qualifier)	qlco	3.42
23440202	C0439851	Direct type of relationship	qlco	3.42
23440202	C0441471	Event	evnt	3.42
23440202	C1444748	Triggered by	qlco	3.40
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
23440202	C0030013	Oxidative Phosphorylation	moft	16.40
23440202	C0242298	Fostering	dora	14.64
23440202	C0020291	Hydrolysis	npop	9.78
23440202	C0175566	Open	spco	7.22
23440202	C1511572	event cycle	tmco	7.07
23440202	C0040223	Time	tmco	6.71
23440202	C1511726	Data	idcn	5.18
23440202	C3714741	Data (eukaryote)	euka	5.18
23440202	C3245479	Data call receiving device	medd	5.18
23440202	C0344349	Fostered	famg	5.18
23440202	C0442805	Increase	ftcn	5.18
23440202	C0205217	Increased	qnco	5.18
23440202	C0184512	Stabilized (qualifier value)	qlco	5.18
23440202	C2741958	VX-770	orch	5.18
23440202	C1301808	Geographic state	geoa	3.63
23440202	C1442792	State	ftcn	3.63
23440202	C3148680	US State	geoa	3.63
23440202	C1880258	Decoupling Medical Device Problem	phpr	3.56
23440202	C3541383	Time (foundation metadata concept)	tmco	3.55
23440202	C1510699	ATP Hydrolysis	moft	3.53
23440202	C2737266	Post hydrolysis	tmco	3.43
23440202	C1413365	CFTR gene	gngm	3.43
23440202	C2700323	Wild Type Unspecified - zebrafish	fish	3.43
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
23440202	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
23440202	C0040363	Togo	geoa	17.80
23440202	C0041260	Tryptophanase	aapp	17.80
23440202	C0041260	Tryptophanase	enzy	17.80
23440202	C1524059	mechanism of action qualifier	ftcn	13.09
23440202	C0031843	physiological aspects	phsf	13.03
23440202	C0031327	Drug Kinetics	phsf	9.93
23440202	C2349975	Enhance (action)	acty	5.18
23440202	C1517331	Further	spco	5.18
23440202	C1883351	To	qlco	5.18
23440202	C0679199	strategy	menp	5.18
23440202	C1705535	suggestion	idcn	5.18
23440202	C0557651	Room of building - Study	mnob	3.68
23440202	C2603343	Study	resa	3.68
23440202	C0542341	Function	ftcn	3.57
23440202	C0700205	Function Axis	clas	3.57
23440202	C1705273	Mathematical Operator	inpr	3.57
23440202	C0521116	Current (present time)	tmco	3.50
23440202	C1705970	Electrical Current	npop	3.50
23440202	C1413365	CFTR gene	gngm	3.44
23440202	C0013227	Pharmaceutical Preparations	phsu	3.43
23440202	C1254351	Pharmacologic Substance	phsu	3.43
23440202	C1710548	Unique	qlco	3.43
24932877	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24932877	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24932877	C0040363	Togo	geoa	17.80
24932877	C0041260	Tryptophanase	aapp	17.80
24932877	C0041260	Tryptophanase	enzy	17.80
24932877	C2717881	Candidate Gene Identification	mbrt	9.88
24932877	C0010674	Cystic Fibrosis	dsyn	9.76
24932877	C1413365	CFTR gene	gngm	6.91
24932877	C1883351	To	qlco	5.18
24932877	C3274784	Commence	acty	3.98
24932877	C1706202	Search - action	acty	3.57
24932877	C1552603	search - EntityNameUse	inpr	3.57
24932877	C0243067	defects aspect	ftcn	3.55
24932877	C1880355	Discover	acty	3.55
24932877	C0087111	Therapeutic procedure	topp	3.44
24932877	C1527178	Basis - conceptual entity	ftcn	3.43
24932877	C0040363	Togo	geoa	17.80
24932877	C0041260	Tryptophanase	aapp	17.80
24932877	C0041260	Tryptophanase	enzy	17.80
24932877	C0597295	Protein Biosynthesis	moft	16.25
24932877	C0009738	Congo	geoa	16.07
24932877	C0031843	physiological aspects	phsf	14.64
24932877	C0021699	Integral Membrane Proteins	aapp	9.98
24932877	C0031330	Pharmacology	bmod	9.78
24932877	C0220781	Anabolism	biof	6.75
24932877	C2349975	Enhance (action)	acty	5.18
24932877	C0542341	Function	ftcn	5.18
24932877	C0700205	Function Axis	clas	5.18
24932877	C1705273	Mathematical Operator	inpr	5.18
24932877	C0359589	Provide (product)	food	5.18
24932877	C1999230	Providing (action)	acty	5.18
24932877	C1883351	To	qlco	5.18
24932877	C0947647	Manipulation procedure	topp	3.63
24932877	C0185111	Surgical Manipulation	topp	3.63
24932877	C1883254	Synthesis	acty	3.60
24932877	C0205464	pharmacological	ftcn	3.48
24932877	C3811819	CFTR wt Allele	gngm	3.46
24932877	C1704735	Regulator	cnce	3.46
24932877	C1704734	Regulator Device Component	mnob	3.46
24932877	C0182953	Regulators (device)	medd	3.46
24932877	C2752508	fully spanning the plasma membrane	celc	3.46
24932877	C1167322	integral to membrane	celc	3.46
24932877	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.28
24932877	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.28
24932877	C0040363	Togo	geoa	35.81
24932877	C0041260	Tryptophanase	aapp	35.81
24932877	C0041260	Tryptophanase	enzy	35.81
24932877	C0026882	Mutation	genf	30.30
24932877	C0242612	Codon, Nonsense	nusq	24.11
24932877	C0034754	Reading (activity)	dora	16.07
24932877	C0162847	protein folding	moft	13.14
24932877	C1883351	To	qlco	10.42
24932877	C1413365	CFTR gene	gngm	6.98
24932877	C0030705	Patients	podg	6.60
24932877	C2700399	Include (action)	acty	5.18
24932877	C0332257	Including (qualifier)	ftcn	5.18
24932877	C1552866	include - SetOperator	idcn	5.18
24932877	C0599896	trafficking	celf	5.18
24932877	C0185026	Plication	topp	3.61
24932877	C3687832	DRUGS	topp	3.60
24932877	C0013227	Pharmaceutical Preparations	phsu	3.60
24932877	C1709060	Modulator Device Component	mnob	3.59
24932877	C2347946	Relevance	qlco	3.59
24932877	C2698967	Canadian Cardiovascular Society Grading Scale Class I	fndg	3.53
24932877	C2698968	Canadian Cardiovascular Society Grading Scale Class II	fndg	3.53
24932877	C2698969	Canadian Cardiovascular Society Grading Scale Class III	fndg	3.53
24932877	C0441885	Class 1	clas	3.53
24932877	C0441886	Class 2	inpr	3.53
24932877	C0441887	Class 3	inpr	3.53
24932877	C0311448	Abnormal protein	aapp	3.51
24932877	C0311448	Abnormal protein	bacs	3.51
24932877	C0439799	Channel	spco	3.50
24932877	C1706095	Channel Object	cnce	3.50
24932877	C3845272	Stop Codon Mutation	fndg	3.50
24932877	C0205161	Abnormal	qlco	3.47
24932877	C2699333	Abnormal Reference Range	inpr	3.47
24932877	C2347472	Percent of Abnormal Cells	qnco	3.47
24932877	C1705179	Reading (datum presentation)	fndg	3.46
24932877	C0041714	United States Food and Drug Administration	hcro	25.58
24932877	C0026882	Mutation	genf	19.95
24932877	C0008976	Clinical Trials	resa	19.45
24932877	C0009738	Congo	geoa	17.80
24932877	C0040363	Togo	geoa	17.80
24932877	C0041260	Tryptophanase	aapp	17.80
24932877	C0041260	Tryptophanase	enzy	17.80
24932877	C3264621	ivacaftor	orch	14.64
24932877	C3264621	ivacaftor	phsu	14.64
24932877	C0023636	License	rnlw	13.14
24932877	C0001675	Adult	aggp	11.49
24932877	C0008059	Child	aggp	11.49
24932877	C1096775	Clinical Trial [Publication Type]	inpr	9.99
24932877	C0042153	utilization qualifier	ftcn	9.90
24932877	C2698969	Canadian Cardiovascular Society Grading Scale Class III	fndg	7.03
24932877	C0441887	Class 3	inpr	7.03
24932877	C1704689	Bearing Device Component	medd	5.18
24932877	C3811819	CFTR wt Allele	gngm	5.18
24932877	C0205229	Expanding	spco	5.18
24932877	C1435727	FABP6 protein, human	aapp	5.18
24932877	C1435727	FABP6 protein, human	bacs	5.18
24932877	C2700399	Include (action)	acty	5.18
24932877	C0332257	Including (qualifier)	ftcn	5.18
24932877	C1948052	Now (temporal qualifier)	tmco	5.18
24932877	C0680063	Offspring	famg	5.18
24932877	C0332185	Recent	tmco	5.18
24932877	C1883351	To	qlco	5.18
24932877	C1552866	include - SetOperator	idcn	5.18
24932877	C1550439	Entity Name Use - License	idcn	3.68
24932877	C0439234	year	tmco	3.68
24932877	C1705285	Mutation Abnormality	comd	3.61
24932877	C0457083	Usage	ftcn	3.59
24932877	C1947944	Use - dosing instruction imperative	inpr	3.59
24932877	C0205452	Six	qnco	3.50
24932877	C0439064	Numerous	qnco	3.47
24932877	C0443302	Several	qnco	3.47
24932877	C0597535	Success	socb	3.47
24932877	C1272703	Successful	qlco	3.47
24932877	C1524062	Additional	ftcn	3.46
24932877	C0026882	Mutation	genf	9.94
24932877	C0521116	Current (present time)	tmco	5.18
24932877	C0557651	Room of building - Study	mnob	3.98
24932877	C2603343	Study	resa	3.98
24932877	C0449445	Approach	spco	3.55
24932877	C1292724	Procedural approach	ftcn	3.55
24932877	C2698968	Canadian Cardiovascular Society Grading Scale Class II	fndg	3.53
24932877	C0441886	Class 2	inpr	3.53
24932877	C2698967	Canadian Cardiovascular Society Grading Scale Class I	fndg	3.45
24932877	C0441885	Class 1	clas	3.45
24932877	C1523987	Alternative	cnce	3.43
24932877	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.02
24932877	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.02
24932877	C0040363	Togo	geoa	35.81
24932877	C0041260	Tryptophanase	aapp	35.81
24932877	C0041260	Tryptophanase	enzy	35.81
24932877	C0039798	therapeutic aspects	ftcn	22.48
24932877	C0031843	physiological aspects	phsf	13.03
24932877	C1883351	To	qlco	10.42
24932877	C0026882	Mutation	genf	9.92
24932877	C1413365	CFTR gene	gngm	6.94
24932877	C0013162	Drug Combinations	phsu	6.60
24932877	C0700364	Appearance	qlco	5.18
24932877	C1514873	Requirement	ftcn	5.18
24932877	C1705285	Mutation Abnormality	comd	3.61
24932877	C3469597	Administration of medication	hlca	3.59
24932877	C0150270	Medication Management	hlca	3.59
24932877	C0542341	Function	ftcn	3.57
24932877	C0700205	Function Axis	clas	3.57
24932877	C1705273	Mathematical Operator	inpr	3.57
24932877	C1533734	Administration procedure	topp	3.55
24932877	C1705169	Biomaterial Treatment	cnce	3.55
24932877	C0087111	Therapeutic procedure	topp	3.55
24932877	C1522326	Treating	ftcn	3.55
24932877	C3538994	Treatment Epoch	resa	3.55
24932877	C3887704	treatment - ActInformationManagementReason	hlca	3.55
24932877	C0205214	Common (qualifier value)	qnco	3.47
24932877	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.47
24932877	C0205393	Most	qnco	3.47
24932877	C1522138	shared attribute	ftcn	3.47
24932877	C0205195	Combined	qlco	3.43
24932877	C3811910	combination - answer to question	fndg	3.43
24932877	C1947911	combination of objects	phob	3.43
24932877	C0022009	Ion Channel	aapp	16.06
24932877	C0022009	Ion Channel	bacs	16.06
24932877	C0026882	Mutation	genf	9.81
24932877	C0031330	Pharmacology	bmod	9.74
24932877	C0949216	Alternative Therapies	topp	6.73
24932877	C0085862	Independence	idcn	5.18
24932877	C1299583	Independently able	fndg	5.18
24932877	C1280477	Progress	ftcn	5.18
24932877	C1272688	status - In progress	ftcn	5.18
24932877	C0456387	Class	inpr	3.68
24932877	C1705943	Class (taxonomic)	clas	3.68
24932877	C0205179	Advanced phase	qlco	3.63
24932877	C0205170	Good	qlco	3.63
24932877	C3146287	Well	mnob	3.63
24932877	C0443264	Modulated	spco	3.55
24932877	C1705285	Mutation Abnormality	comd	3.50
24932877	C0439092	Less Than	qnco	3.48
24932877	C0547044	Smaller	qlco	3.48
24932877	C0017296	gene therapy	topp	3.44
24932877	C0205464	pharmacological	ftcn	3.43
24932877	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24932877	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24932877	C0008976	Clinical Trials	resa	19.36
24932877	C0009738	Congo	geoa	17.80
24932877	C0018724	Health Personnel	prog	11.49
24932877	C1096775	Clinical Trial [Publication Type]	inpr	9.90
24932877	C0030705	Patients	podg	6.74
24932877	C3811819	CFTR wt Allele	gngm	5.18
24932877	C1413365	CFTR gene	gngm	3.43
24932877	C1709060	Modulator Device Component	mnob	3.41
24932877	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.16
24932877	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.16
24932877	C0040363	Togo	geoa	35.81
24932877	C0041260	Tryptophanase	aapp	35.81
24932877	C0041260	Tryptophanase	enzy	35.81
24932877	C0008976	Clinical Trials	resa	19.24
24932877	C0220825	Evaluation	hlca	14.64
24932877	C0027552	Needs	qlco	14.64
24932877	C1883351	To	qlco	10.42
24932877	C0005532	biology (field)	bmod	9.87
24932877	C1413365	CFTR gene	gngm	7.09
24932877	C0014609	Epithelium	tisu	6.59
24932877	C0805586	Challenge	hlca	5.18
24932877	C2983310	Overcome	acty	5.18
24932877	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
24932877	C0392366	Tests (qualifier value)	inpr	5.18
24932877	C0683607	allowing	socb	5.18
24932877	C2349179	End Point	qlco	3.63
24932877	C1709060	Modulator Device Component	mnob	3.63
24932877	C0445223	Related personal status	fndg	3.55
24932877	C0439849	Relationships	qlco	3.55
24932877	C0439855	Complex	qlco	3.49
24932877	C1704241	complex (molecular entity)	chvs	3.49
24932877	C0205314	New	qlco	3.47
24932877	C0679622	literary novel	inpr	3.47
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26863533	C0009738	Congo	geoa	16.18
26863533	C0031453	Phenylalanine	aapp	16.05
26863533	C0031453	Phenylalanine	bacs	16.05
26863533	C0031453	Phenylalanine	phsu	16.05
26863533	C1511760	Deletion Mutation	genf	13.03
26863533	C0026882	Mutation	genf	9.86
26863533	C0030705	Patients	podg	6.71
26863533	C0392760	Affecting	ftcn	5.18
26863533	C1314939	Involvement with	ftcn	5.18
26863533	C4019252	Position of phenotypic abnormality	ftcn	3.68
26863533	C0733755	Positioning Attribute	spco	3.68
26863533	C1880274	Deletion (action)	acty	3.57
26863533	C1442161	Gene Deletion Abnormality	comd	3.57
26863533	C3842582	90%	fndg	3.56
26863533	C0439087	<90	qnco	3.56
26863533	C0439083	>90	qnco	3.56
26863533	C0332232	Approximate	qlco	3.56
26863533	C3811819	CFTR wt Allele	gngm	3.56
26863533	C1705285	Mutation Abnormality	comd	3.55
26863533	C0202174	blood phenylalanine measurement by Guthrie microbiologic assay	lbpr	3.44
26863533	C1413365	CFTR gene	gngm	3.43
26863533	C0205214	Common (qualifier value)	qnco	3.43
26863533	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.43
26863533	C0205393	Most	qnco	3.43
26863533	C1522138	shared attribute	ftcn	3.43
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
26863533	C0007603	Plasma membrane	celc	9.92
26863533	C1153420	chloride channel activity	moft	5.18
26863533	C0599896	trafficking	celf	3.56
26863533	C1413365	CFTR gene	gngm	3.43
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
26863533	C0040363	Togo	geoa	17.80
26863533	C0041260	Tryptophanase	aapp	17.80
26863533	C0041260	Tryptophanase	enzy	17.80
26863533	C0220825	Evaluation	hlca	12.88
26863533	C1328819	Small Molecule	orch	5.18
26863533	C1883254	Synthesis	acty	5.18
26863533	C1883351	To	qlco	5.18
26863533	C1153410	channel activity	moft	3.61
26863533	C0243071	Analog	chvs	3.51
26863533	C1413365	CFTR gene	gngm	3.43
26863533	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.43
26863533	C3715206	Eighteen	qnco	3.42
26863533	C0205314	New	qlco	3.42
26863533	C0679622	literary novel	inpr	3.42
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.27
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.27
26863533	C0040363	Togo	geoa	17.80
26863533	C0041260	Tryptophanase	aapp	17.80
26863533	C0041260	Tryptophanase	enzy	17.80
26863533	C0242625	Patch-Clamp Techniques	resa	14.64
26863533	C0005507	Biological Assay	lbpr	13.63
26863533	C1510438	Assay	lbpr	7.29
26863533	C0243073	assay qualifier	qlco	7.29
26863533	C0441655	Activities	acty	7.28
26863533	C1413365	CFTR gene	gngm	7.19
26863533	C0020517	Hypersensitivity	patf	6.62
26863533	C0444706	Measured	qlco	5.18
26863533	C3541902	Measured Tumor Identification	diap	5.18
26863533	C1883351	To	qlco	5.18
26863533	C1524063	Use of	ftcn	5.18
26863533	C1561536	*Activity (kind of quantity)	idcn	3.68
26863533	C0205177	Active	ftcn	3.68
26863533	C3668946	Activity (animal life circumstance)	fndg	3.68
26863533	C4049939	FDA Establishment Activity Terminology	inpr	3.68
26863533	C0439167	Percent Activity	qnco	3.68
26863533	C4049938	Physical Activity Measurement	lbpr	3.68
26863533	C0935616	Chamber (anatomical)	bpoc	3.48
26863533	C0179874	Chamber (physical object)	mnob	3.48
26863533	C0457555	Halide	inch	3.47
26863533	C0332324	Sensitive	ftcn	3.47
26863533	C0279023	chemosensitization/potentiation	topp	3.44
26863533	C0015272	Exhibits as Topic	inpr	16.59
26863533	C0023376	Lesotho	geoa	16.04
26863533	C0796361	Chromosome 7q	nusq	5.18
26863533	C1521610	Chromosome 7 Short Arm	nusq	3.63
26863533	C1553556	Maxillary right lateral incisor prosthesis	medd	3.63
26863533	C0279023	chemosensitization/potentiation	topp	3.55
26863533	C3842590	10%	fndg	3.50
26863533	C0205198	Compound	qlco	3.45
26863533	C1706082	Compound (substance)	chem	3.45
26863533	C1961136	Excellent (qualifier value)	qlco	3.43
26863533	C1548784	Excellent - Specimen Quality	qlco	3.43
26863533	C3887647	Lymphotoxin-Alpha, human	aapp	3.43
26863533	C3887647	Lymphotoxin-Alpha, human	imft	3.43
26863533	C1522609	Numerical value	qnco	3.43
26863533	C0230426	Structure of left thigh	bpoc	3.43
26863533	C0796361	Chromosome 7q	nusq	5.18
26863533	C0205198	Compound	qlco	3.98
26863533	C1706082	Compound (substance)	chem	3.98
26863533	C1547282	Show	anim	3.98
26863533	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.75
26863533	C1561536	*Activity (kind of quantity)	idcn	3.54
26863533	C0205177	Active	ftcn	3.54
26863533	C0441655	Activities	acty	3.54
26863533	C3668946	Activity (animal life circumstance)	fndg	3.54
26863533	C4049939	FDA Establishment Activity Terminology	inpr	3.54
26863533	C0439167	Percent Activity	qnco	3.54
26863533	C4049938	Physical Activity Measurement	lbpr	3.54
26863533	C0205314	New	qlco	3.48
26863533	C0679622	literary novel	inpr	3.48
26863533	C3842591	0%	fndg	3.42
26863533	C1522410	Highest	qlco	3.42
26863533	C0042295	Values	qlco	3.42
26863533	C0279023	chemosensitization/potentiation	topp	3.42
26863533	C3842591	0%	fndg	3.61
26863533	C3838679	4+ Answer to question	fndg	5.18
26863533	C3842591	0%	fndg	3.61
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
26863533	C1413365	CFTR gene	gngm	3.68
26863533	C1883559	Wild Type	gngm	3.45
26863533	C0450355	31	inpr	3.43
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.01
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.01
26863533	C0008203	Chlorides	inch	16.04
26863533	C1413365	CFTR gene	gngm	6.94
26863533	C3816745	1+	fndg	5.18
26863533	C2827734	1+ Score	qnco	5.18
26863533	C2981698	1+ Score, WHO	clas	5.18
26863533	C1561536	*Activity (kind of quantity)	idcn	3.63
26863533	C0205177	Active	ftcn	3.63
26863533	C0441655	Activities	acty	3.63
26863533	C3668946	Activity (animal life circumstance)	fndg	3.63
26863533	C1883712	Add - instruction imperative	ftcn	3.63
26863533	C4049939	FDA Establishment Activity Terminology	inpr	3.63
26863533	C0332287	In addition to	ftcn	3.63
26863533	C0439167	Percent Activity	qnco	3.63
26863533	C4049938	Physical Activity Measurement	lbpr	3.63
26863533	C0596988	mutant	comd	3.63
26863533	C4049713	Borg Category-Ratio 10 Perceived Exertion Score 10	inpr	3.48
26863533	C0205289	Maximal (qualifier value)	qlco	3.48
26863533	C0806909	Maximum	qnco	3.48
26863533	C0279023	chemosensitization/potentiation	topp	3.48
26863533	C0596019	Chloride Ion	elii	3.42
26863533	C0061202	Genistein	bacs	25.50
26863533	C0061202	Genistein	orch	25.50
26863533	C0061202	Genistein	phsu	25.50
26863533	C1880834	Fold in Medical Device Material	phpr	3.63
26863533	C0332462	Folded structure	spco	3.63
26863533	C0205250	High	qlco	3.54
26863533	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.44
26863533	C0205170	Good	qlco	3.42
26863533	C0205309	Known	qlco	3.42
26863533	C3146287	Well	mnob	3.42
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.97
26863533	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.97
26863533	C0039798	therapeutic aspects	ftcn	22.48
26863533	C3252847	VX 809	orch	7.56
26863533	C3252847	VX 809	phsu	7.56
26863533	C1413365	CFTR gene	gngm	6.90
26863533	C2349975	Enhance (action)	acty	5.18
26863533	C1533734	Administration procedure	topp	3.56
26863533	C1705169	Biomaterial Treatment	cnce	3.56
26863533	C1707455	Comparison	acty	3.56
26863533	C0439044	Living Alone	fndg	3.56
26863533	C0205171	Singular	qnco	3.56
26863533	C0087111	Therapeutic procedure	topp	3.56
26863533	C1522326	Treating	ftcn	3.56
26863533	C3538994	Treatment Epoch	resa	3.56
26863533	C0679994	alone - group size	grpa	3.56
26863533	C3887704	treatment - ActInformationManagementReason	hlca	3.56
26863533	C0205195	Combined	qlco	3.43
26863533	C0542341	Function	ftcn	3.43
26863533	C0205245	Functional	ftcn	3.43
26863533	C2700217	Functional Relationship	cnce	3.43
26863533	C3811910	combination - answer to question	fndg	3.43
26863533	C1947911	combination of objects	phob	3.43
26863533	C1383501	Cytoplasmic matrix	celc	16.09
26863533	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	13.09
26863533	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	13.09
26863533	C0004268	Attention	menp	12.89
26863533	C1547282	Show	anim	8.00
26863533	C1518422	Negation	ftcn	5.18
26863533	C0392747	Changing	ftcn	3.79
26863533	C1280519	Effectiveness	qlco	3.68
26863533	C1707887	Efficacy Study	resa	3.68
26863533	C0456079	Disease classification level	clas	3.63
26863533	C1547707	Floor - story of building	geoa	3.63
26863533	C2946261	Level	phsu	3.63
26863533	C0441889	Levels (qualifier value)	qlco	3.63
26863533	C0596402	cytotoxicity	comd	3.56
26863533	C1552615	Act Relationship Subset - maximum	qnco	3.50
26863533	C0806909	Maximum	qnco	3.50
26863533	C2826546	Maximum Value Derivation Technique	qnco	3.50
26863533	C1446561	Concentration measurement	qnco	3.43
26863533	C0086045	Mental concentration	menp	3.43
26863533	C0039798	therapeutic aspects	ftcn	22.35
26863533	C0010674	Cystic Fibrosis	dsyn	9.74
26863533	C0013217	pharmacotherapeutic	ftcn	9.74
26863533	C0013216	Pharmacotherapy	topp	6.59
26863533	C0872152	drug development	bmod	3.43
26863533	C0678723	Biologic Development	orgf	3.42
26863533	C1527148	Development	ftcn	3.42
26863533	C0087111	Therapeutic procedure	topp	3.42
26863533	C1363945	Therapy Object (animal model)	fndg	3.42
26863533	C0243107	development aspects	phsf	3.42
26863533	C3245505	potential	qlco	3.42
26097168	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
26097168	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
26097168	C0017337	Genes	gngm	16.22
26097168	C0031843	physiological aspects	phsf	13.02
26097168	C0010674	Cystic Fibrosis	dsyn	10.06
26097168	C0026882	Mutation	genf	9.90
26097168	C0015127	Etiology aspects	ftcn	9.86
26097168	C0311448	Abnormal protein	aapp	3.61
26097168	C0311448	Abnormal protein	bacs	3.61
26097168	C1527118	Protein Function	moft	3.61
26097168	C0815043	Protein, Organized by Function	aapp	3.61
26097168	C0332294	Resulting in	ftcn	3.61
26097168	C1413365	CFTR gene	gngm	3.58
26097168	C0205161	Abnormal	qlco	3.56
26097168	C2699333	Abnormal Reference Range	inpr	3.56
26097168	C0542341	Function	ftcn	3.56
26097168	C0700205	Function Axis	clas	3.56
26097168	C1705273	Mathematical Operator	inpr	3.56
26097168	C2347472	Percent of Abnormal Cells	qnco	3.56
26097168	C1524003	Science of Etiology	cnce	3.55
26097168	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.37
26097168	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.37
26097168	C0026882	Mutation	genf	9.86
26097168	C2699893	Molecular Targeted Therapy	topp	9.77
26097168	C0013216	Pharmacotherapy	topp	6.76
26097168	C1521840	Target	ftcn	5.18
26097168	C2986546	Target Lesion Identification	diap	5.18
26097168	C0872187	high throughput screening	diap	5.18
26097168	C0439064	Numerous	qnco	3.56
26097168	C2825142	Experimental Result	fndg	3.53
26097168	C1274040	Result	ftcn	3.53
26097168	C1546471	What subject filter - Result	idcn	3.53
26097168	C3854260	Advance	tmco	3.52
26097168	C0725066	Advance -- medical device	medd	3.52
26097168	C3898777	Important	qlco	3.42
26097168	C0332185	Recent	tmco	3.42
26097168	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.96
26097168	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.96
26097168	C0039798	therapeutic aspects	ftcn	22.48
26097168	C0282443	Review [Publication Type]	inpr	11.49
26097168	C0000936	Visual Accommodation	clna	9.86
26097168	C0010674	Cystic Fibrosis	dsyn	9.76
26097168	C0026882	Mutation	genf	9.73
26097168	C1413365	CFTR gene	gngm	6.89
26097168	C1552617	Act Class - review	idcn	5.18
26097168	C1999230	Providing (action)	acty	5.18
26097168	C2825142	Experimental Result	fndg	3.63
26097168	C1274040	Result	ftcn	3.63
26097168	C1546471	What subject filter - Result	idcn	3.63
26097168	C1280477	Progress	ftcn	3.56
26097168	C1272688	status - In progress	ftcn	3.56
26097168	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.56
26097168	C1533734	Administration procedure	topp	3.55
26097168	C1705169	Biomaterial Treatment	cnce	3.55
26097168	C0087111	Therapeutic procedure	topp	3.55
26097168	C1522326	Treating	ftcn	3.55
26097168	C3538994	Treatment Epoch	resa	3.55
26097168	C3887704	treatment - ActInformationManagementReason	hlca	3.55
26097168	C0439799	Channel	spco	3.55
26097168	C1706095	Channel Object	cnce	3.55
26097168	C2981153	Finding related to focusing	fndg	3.55
26097168	C0205087	Late	tmco	3.48
26097168	C0521116	Current (present time)	tmco	3.43
26097168	C1705970	Electrical Current	npop	3.43
26097168	C1705285	Mutation Abnormality	comd	3.42
26097168	C1709694	Processing (action)	acty	3.42
26097168	C1709060	Modulator Device Component	mnob	3.41
26097168	C0008976	Clinical Trials	resa	19.21
26097168	C1096775	Clinical Trial [Publication Type]	inpr	9.75
26097168	C3242274	new therapy	fndg	4.12
26097168	C1853126	MOLECULAR BASIS	idcn	3.61
26097168	C0442504	Place	spco	3.53
26097168	C1704765	Place - dosing instruction imperative	ftcn	3.53
26097168	C1882509	put - instruction imperative	acty	3.53
26097168	C2825142	Experimental Result	fndg	3.52
26097168	C1274040	Result	ftcn	3.52
26097168	C1546471	What subject filter - Result	idcn	3.52
26097168	C0205555	Special	qlco	3.48
26097168	C0205087	Late	tmco	3.40
26097168	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
26097168	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
26097168	C0016884	Future	tmco	6.59
26097168	C1709060	Modulator Device Component	mnob	3.63
26097168	C0439755	Directions	spco	3.56
26097168	C1413365	CFTR gene	gngm	3.50
26097168	C0205217	Increased	qnco	3.41
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
26648081	C0055363	Chloride Channels	aapp	19.39
26648081	C0055363	Chloride Channels	bacs	19.39
26648081	C0040363	Togo	geoa	17.80
26648081	C0041260	Tryptophanase	aapp	17.80
26648081	C0041260	Tryptophanase	enzy	17.80
26648081	C0007457	Caucasoid Race	popg	14.64
26648081	C0031843	physiological aspects	phsf	12.89
26648081	C0001721	Affect (mental function)	menp	11.49
26648081	C0015127	Etiology aspects	ftcn	9.86
26648081	C0026882	Mutation	genf	9.86
26648081	C0010674	Cystic Fibrosis	dsyn	9.76
26648081	C0043157	Caucasians	popg	5.18
26648081	C1550043	Container status - Identified	fndg	5.18
26648081	C0205396	Identified	qlco	5.18
26648081	C1517945	Loss	qnco	5.18
26648081	C0750554	MOSTLY	idcn	5.18
26648081	C0205393	Most	qnco	5.18
26648081	C1883351	To	qlco	5.18
26648081	C0679225	multiple pathologies	dsyn	3.70
26648081	C0681757	1980s	tmco	3.68
26648081	C0678941	Gene Mutant	gngm	3.57
26648081	C0596611	Gene Mutation	genf	3.57
26648081	C0205225	Primary	qlco	3.55
26648081	C0439631	Primary operation	topp	3.55
26648081	C1524003	Science of Etiology	cnce	3.55
26648081	C0439612	True primary (qualifier value)	tmco	3.55
26648081	C1705285	Mutation Abnormality	comd	3.55
26648081	C1413365	CFTR gene	gngm	3.55
26648081	C0205087	Late	tmco	3.50
26648081	C1705232	Death Related to Adverse Event	fndg	3.47
26648081	C1302234	Fatal	qlco	3.47
26648081	C0178784	Organ	bpoc	3.47
26648081	C0314627	Gene function	genf	3.44
26648081	C0314621	Operator gene	gngm	3.44
26648081	C2700640	Encode (action)	acty	3.42
26648081	C0542341	Function	ftcn	3.42
26648081	C0700205	Function Axis	clas	3.42
26648081	C1547699	MIME encoding	idcn	3.42
26648081	C1705273	Mathematical Operator	inpr	3.42
26648081	C2348077	Date Fruit	food	27.26
26648081	C0282111	Internet	mnob	17.80
26648081	C0026882	Mutation	genf	9.99
26648081	C0011008	Date in time	tmco	5.18
26648081	C1555015	HTTP	inpr	5.18
26648081	C1413365	CFTR gene	gngm	3.61
26648081	C1550043	Container status - Identified	fndg	3.56
26648081	C0205396	Identified	qlco	3.56
26648081	C0332232	Approximate	qlco	3.47
26648081	C0681760	2000s	tmco	3.44
26648081	C0325074	Genets	mamm	22.61
26648081	C3887642	Hippocampus Proper	bpoc	25.54
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
26648081	C1413365	CFTR gene	gngm	3.47
26648081	C0026565	Mortality Vital Statistics	qnco	19.36
26648081	C0026538	Morbidity - disease rate	qnco	19.20
26648081	C0009738	Congo	geoa	17.80
26648081	C0026566	Aspects of mortality statistics	qnco	9.90
26648081	C0036974	Shock	patf	9.88
26648081	C0015127	Etiology aspects	ftcn	9.86
26648081	C0035245	Respiratory physiology	ortf	6.60
26648081	C0332152	Before	tmco	5.18
26648081	C3811819	CFTR wt Allele	gngm	5.18
26648081	C1522538	Leading	ftcn	5.18
26648081	C0344329	Collapse (finding)	fndg	3.57
26648081	C0332521	Collapse (morphologic abnormality)	phpr	3.57
26648081	C1880118	Collapse of Medical Device or Device Component	phpr	3.57
26648081	C1546767	Specimen Source Codes - Respiratory	inpr	3.57
26648081	C0521346	respiratory	ftcn	3.57
26648081	C1524003	Science of Etiology	cnce	3.55
26648081	C0868945	deterioration	phpr	3.55
26648081	C0027361	Persons	popg	3.45
26648081	C0205214	Common (qualifier value)	qnco	3.43
26648081	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.43
26648081	C0205393	Most	qnco	3.43
26648081	C0205329	Progressive	ftcn	3.43
26648081	C0220880	morbidity aspects	inpr	3.43
26648081	C1522138	shared attribute	ftcn	3.43
26648081	C0023671	Life Expectancy	grpa	19.35
26648081	C0040363	Togo	geoa	17.80
26648081	C0041260	Tryptophanase	aapp	17.80
26648081	C0041260	Tryptophanase	enzy	17.80
26648081	C0009738	Congo	geoa	16.04
26648081	C0030705	Patients	podg	6.58
26648081	C0521116	Current (present time)	tmco	5.18
26648081	C0750572	Estimated	qnco	5.18
26648081	C1883351	To	qlco	5.18
26648081	C0439234	year	tmco	3.57
26648081	C3811819	CFTR wt Allele	gngm	3.42
26648081	C2939193	Median (qualifier value)	spco	3.42
26648081	C0876920	Median Statistical Measurement	qnco	3.42
26648081	C0549183	Midline (qualifier value)	spco	3.42
26648081	C2347635	Population Median	qnco	3.42
26648081	C2348144	Sample Median	qnco	3.42
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.00
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.00
26648081	C3178997	Endoplasmic Reticulum-Associated Degradation	moft	28.90
26648081	C0033105	Statistical Prevalence	qnco	22.34
26648081	C0009738	Congo	geoa	16.17
26648081	C0151526	Premature Birth	fndg	16.16
26648081	C1314792	Etiology	ftcn	14.64
26648081	C0038164	Staphylococcal Protein A	aapp	12.91
26648081	C0038164	Staphylococcal Protein A	imft	12.91
26648081	C0038164	Staphylococcal Protein A	irda	12.91
26648081	C0015127	Etiology aspects	ftcn	11.49
26648081	C0026882	Mutation	genf	9.92
26648081	C0011209	Obstetric Delivery	topp	9.85
26648081	C1413365	CFTR gene	gngm	6.93
26648081	C1524003	Science of Etiology	cnce	5.18
26648081	C1705285	Mutation Abnormality	comd	3.61
26648081	C3842584	70%	fndg	3.55
26648081	C2741673	Account number:Identifier:Point in time:^Patient:Nominal	clna	3.55
26648081	C3811819	CFTR wt Allele	gngm	3.55
26648081	C0868928	Case (situation)	ftcn	3.55
26648081	C1533148	Case unit dose	qnco	3.55
26648081	C1457869	Defect	ftcn	3.55
26648081	C2981730	Financial Account	inpr	3.55
26648081	C0332152	Before	tmco	3.55
26648081	C0205252	Immature	qlco	3.55
26648081	C1522538	Leading	ftcn	3.55
26648081	C1314680	Non-human parturition, function	orgf	3.54
26648081	C1705822	Transfer Technique	ftcn	3.54
26648081	C0205393	Most	qnco	3.47
26648081	C0699040	Cell surface	celc	3.44
26648081	C1709694	Processing (action)	acty	3.43
26648081	C0392756	Reduced	qlco	3.42
26648081	C0220900	Prevalence aspects	qnco	3.42
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26648081	C0009738	Congo	geoa	16.12
26648081	C0243041	Molecular Chaperones	aapp	9.87
26648081	C0243041	Molecular Chaperones	bacs	9.87
26648081	C0442805	Increase	ftcn	5.18
26648081	C0205217	Increased	qnco	5.18
26648081	C3272558	Chemical or Textual Reference to Actual Test or Parameter	inpr	3.56
26648081	C0220806	Chemicals	chem	3.56
26648081	C1704788	Definition	inpr	3.56
26648081	C3539106	Sufficiently defined concept definition status (core metadata concept)	inpr	3.56
26648081	C0441889	Levels (qualifier value)	qlco	3.55
26648081	C3811819	CFTR wt Allele	gngm	3.50
26648081	C0699040	Cell surface	celc	3.47
26648081	C1413365	CFTR gene	gngm	3.43
26648081	C0009738	Congo	geoa	32.39
26648081	C2348077	Date Fruit	food	27.26
26648081	C3852684	lumacaftor	orch	14.64
26648081	C3852684	lumacaftor	phsu	14.64
26648081	C3811819	CFTR wt Allele	gngm	7.00
26648081	C0011008	Date in time	tmco	5.18
26648081	C3252847	VX 809	orch	5.18
26648081	C3252847	VX 809	phsu	5.18
26648081	C0205549	Series	qnco	3.56
26648081	C2348044	Series - set of composite instances	inpr	3.56
26648081	C1704419	Effective	qlco	3.54
26648081	C1280519	Effectiveness	qlco	3.54
26648081	C0231220	Symptomatic	ftcn	3.54
26648081	C0031843	physiological aspects	phsf	13.01
26648081	C0010453	Anthropological Culture	idcn	13.01
26648081	C1564139	Mutant Proteins	aapp	9.76
26648081	C0184511	Improved	qlco	5.18
26648081	C3252847	VX 809	orch	3.75
26648081	C3252847	VX 809	phsu	3.75
26648081	C1527118	Protein Function	moft	3.58
26648081	C0815043	Protein, Organized by Function	aapp	3.58
26648081	C2827718	In Vitro Route of Administration	ftcn	3.56
26648081	C0021135	In Vitro [Publication Type]	inpr	3.56
26648081	C1533691	in vitro	qlco	3.56
26648081	C0542341	Function	ftcn	3.55
26648081	C0700205	Function Axis	clas	3.55
26648081	C1705273	Mathematical Operator	inpr	3.55
26648081	C0332232	Approximate	qlco	3.54
26648081	C0220814	Cultural aspects	ftcn	3.54
26648081	C0430400	Laboratory culture	lbpr	3.54
26648081	C2242979	Microbial culture (procedure)	lbpr	3.54
26648081	C1704459	Device Component System	mnob	3.51
26648081	C0449913	System	ftcn	3.51
26648081	C1553451	System - kit	mnob	3.51
26648081	C0596988	mutant	comd	3.43
26648081	C0039798	therapeutic aspects	ftcn	24.11
26648081	C0040710	Translating	ocac	17.80
26648081	C0019904	Homozygote	orga	9.85
26648081	C0035245	Respiratory physiology	ortf	6.72
26648081	C0030705	Patients	podg	6.70
26648081	C0205197	Complete	qlco	5.18
26648081	C1280500	Effect	qlco	5.18
26648081	C2348382	Effect, Appearance	qlco	5.18
26648081	C1518422	Negation	ftcn	5.18
26648081	C1720467	Only - dosing instruction fragment	inpr	5.18
26648081	C0205171	Singular	qnco	5.18
26648081	C0087111	Therapeutic procedure	topp	5.18
26648081	C1363945	Therapy Object (animal model)	fndg	5.18
26648081	C2986411	Improvement	cnce	3.68
26648081	C1441672	Observed	ftcn	3.54
26648081	C0205284	Marginal	spco	3.50
26648081	C1947914	Marginal (quality)	qlco	3.50
26648081	C1550517	Target Awareness - marginal	fndg	3.50
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.42
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.42
26648081	C0015272	Exhibits as Topic	inpr	17.80
26648081	C0032854	Poverty	grpa	16.12
26648081	C0031843	physiological aspects	phsf	14.64
26648081	C1413365	CFTR gene	gngm	7.35
26648081	C0542341	Function	ftcn	5.18
26648081	C0700205	Function Axis	clas	5.18
26648081	C1705273	Mathematical Operator	inpr	5.18
26648081	C1518422	Negation	ftcn	5.18
26648081	C0443289	Revealed	qlco	5.18
26648081	C0749075	STRUCTURAL Abnormalities	fndg	5.18
26648081	C2347098	Medical Product Stability	qlco	3.68
26648081	C0205360	Stable status	qlco	3.68
26648081	C0947630	Scientific Study	lbpr	3.63
26648081	C0699040	Cell surface	celc	3.61
26648081	C3810541	Adverse Event Emergency Room Visit	inbe	3.55
26648081	C3811131	Estrogen Receptor Measurement	lbpr	3.55
26648081	C1514918	Retrieval	hlca	3.55
26648081	C0597535	Success	socb	3.55
26648081	C1272703	Successful	qlco	3.55
26648081	C0439799	Channel	spco	3.50
26648081	C1706095	Channel Object	cnce	3.50
26648081	C0542537	Poor - grade value	qlco	3.50
26648081	C2700379	Poor - qualifier	qlco	3.50
26648081	C0205314	New	qlco	3.48
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.58
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.58
26648081	C0040363	Togo	geoa	35.81
26648081	C0041260	Tryptophanase	aapp	35.81
26648081	C0041260	Tryptophanase	enzy	35.81
26648081	C0233324	Term Birth	orgf	22.90
26648081	C0017337	Genes	gngm	16.17
26648081	C0009738	Congo	geoa	16.12
26648081	C0031843	physiological aspects	phsf	14.64
26648081	C1413365	CFTR gene	gngm	10.90
26648081	C1883351	To	qlco	10.42
26648081	C0015276	Existentialism	inpr	9.78
26648081	C0542341	Function	ftcn	7.30
26648081	C0031437	Phenotype	orga	6.83
26648081	C0700205	Function Axis	clas	5.18
26648081	C1517331	Further	spco	5.18
26648081	C1705273	Mathematical Operator	inpr	5.18
26648081	C0436331	Symptom aggravating factors	fndg	5.18
26648081	C1521840	Target	ftcn	5.18
26648081	C2826302	Reported Term	inpr	3.98
26648081	C1705313	Term (lexical)	idcn	3.98
26648081	C1515273	Term (temporal)	tmco	3.98
26648081	C1705535	suggestion	idcn	3.98
26648081	C0392747	Changing	ftcn	3.79
26648081	C1285572	Phenotype determination	lbpr	3.68
26648081	C0332452	defective	ftcn	3.68
26648081	C1516451	Chemical Modifier	chvf	3.63
26648081	C0205349	Modified By	qlco	3.63
26648081	C3542952	Modifier (core metadata concept)	inpr	3.63
26648081	C1514623	Qualifier (concept)	cnce	3.63
26648081	C1274040	Result	ftcn	3.61
26648081	C0231242	Complicated	ftcn	3.55
26648081	C3811819	CFTR wt Allele	gngm	3.50
26648081	C0205245	Functional	ftcn	3.47
26648081	C2700217	Functional Relationship	cnce	3.47
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26648081	C0040363	Togo	geoa	17.80
26648081	C0041260	Tryptophanase	aapp	17.80
26648081	C0041260	Tryptophanase	enzy	17.80
26648081	C0009738	Congo	geoa	16.05
26648081	C0162340	Comprehension	menp	14.64
26648081	C0007603	Plasma membrane	celc	9.90
26648081	C0005532	biology (field)	bmod	9.86
26648081	C0033684	Proteins	aapp	8.34
26648081	C0033684	Proteins	bacs	8.34
26648081	C1883351	To	qlco	5.18
26648081	C1516451	Chemical Modifier	chvf	3.98
26648081	C0205349	Modified By	qlco	3.98
26648081	C3542952	Modifier (core metadata concept)	inpr	3.98
26648081	C1514623	Qualifier (concept)	cnce	3.98
26648081	C0449432	Component object	mnob	3.56
26648081	C3811819	CFTR wt Allele	gngm	3.43
26648081	C0723712	Therapeutic brand of coal tar	orch	3.43
26648081	C0723712	Therapeutic brand of coal tar	phsu	3.43
26648081	C0087111	Therapeutic procedure	topp	3.43
26648081	C3810541	Adverse Event Emergency Room Visit	inbe	3.42
26648081	C1413365	CFTR gene	gngm	3.42
26648081	C3811131	Estrogen Receptor Measurement	lbpr	3.42
26648081	C0687676	Post	tmco	3.42
26648081	C1704687	Post Device Component	mnob	3.42
26648081	C0009738	Congo	geoa	16.12
26648081	C2718059	Precision Medicine	topp	13.04
26648081	C1272684	Accepted	qlco	5.18
26648081	C1548435	Referral status - Accepted	idcn	5.18
26648081	C0237401	Individual	humn	3.63
26648081	C0027361	Persons	popg	3.63
26648081	C0814225	benefit	qnco	3.55
26648081	C3811819	CFTR wt Allele	gngm	3.50
26648081	C0009738	Congo	geoa	32.48
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26648081	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26648081	C2718059	Precision Medicine	topp	13.07
26648081	C0162340	Comprehension	menp	13.05
26648081	C0683278	Mental Suffering	mobd	13.05
26648081	C0282443	Review [Publication Type]	inpr	11.49
26648081	C0005532	biology (field)	bmod	9.73
26648081	C0030705	Patients	podg	8.34
26648081	C3811819	CFTR wt Allele	gngm	7.09
26648081	C1552617	Act Class - review	idcn	5.18
26648081	C0723712	Therapeutic brand of coal tar	orch	3.63
26648081	C0723712	Therapeutic brand of coal tar	phsu	3.63
26648081	C0087111	Therapeutic procedure	topp	3.63
26648081	C0578671	Does move	fndg	3.56
26648081	C1269909	Moved from	ftcn	3.56
26648081	C1299988	Moved to	ftcn	3.56
26648081	C0560560	Moving	orgf	3.56
26648081	C2699029	Relocation of home or business	acty	3.56
26648081	C0439855	Complex	qlco	3.48
26648081	C1704241	complex (molecular entity)	chvs	3.48
26648081	C1413365	CFTR gene	gngm	3.42
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
25148434	C0026882	Mutation	genf	9.90
25148434	C0010674	Cystic Fibrosis	dsyn	9.81
25148434	C0030705	Patients	podg	6.77
25148434	C0332281	Associated with	qlco	3.64
25148434	C1836348	Severe disorder	fndg	3.64
25148434	C1705285	Mutation Abnormality	comd	3.59
25148434	C1413365	CFTR gene	gngm	3.55
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
25148434	C0055363	Chloride Channels	aapp	19.36
25148434	C0055363	Chloride Channels	bacs	19.36
25148434	C0525038	Amino Acid Substitution	genf	16.26
25148434	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	5.18
25148434	C2983310	Overcome	acty	5.18
25148434	C2827718	In Vitro Route of Administration	ftcn	3.64
25148434	C0021135	In Vitro [Publication Type]	inpr	3.64
25148434	C1533691	in vitro	qlco	3.64
25148434	C4050466	Borg Category-Ratio 10 Perceived Exertion Score 5	inpr	3.55
25148434	C1413365	CFTR gene	gngm	3.55
25148434	C1880022	Characterization	acty	3.55
25148434	C1457869	Defect	ftcn	3.55
25148434	C2825142	Experimental Result	fndg	3.55
25148434	C1274040	Result	ftcn	3.55
25148434	C0205082	Severe (severity modifier)	qlco	3.55
25148434	C4050465	Severe Extremity Pain	inpr	3.55
25148434	C1546471	What subject filter - Result	idcn	3.55
25148434	C0332157	Exposure to	clna	3.44
25148434	C0274281	Injury due to exposure to external cause	inpo	3.44
25148434	C0009924	Contrast Media	irda	14.64
25148434	C0031843	physiological aspects	phsf	13.09
25148434	C0038164	Staphylococcal Protein A	aapp	13.06
25148434	C0038164	Staphylococcal Protein A	imft	13.06
25148434	C0038164	Staphylococcal Protein A	irda	13.06
25148434	C0026882	Mutation	genf	9.92
25148434	C1979874	Contrast	qlco	5.18
25148434	C1457869	Defect	ftcn	5.18
25148434	C0599896	trafficking	celf	5.18
25148434	C0542341	Function	ftcn	3.63
25148434	C0700205	Function Axis	clas	3.63
25148434	C1705273	Mathematical Operator	inpr	3.63
25148434	C1705285	Mutation Abnormality	comd	3.61
25148434	C0332281	Associated with	qlco	3.61
25148434	C4050466	Borg Category-Ratio 10 Perceived Exertion Score 5	inpr	3.56
25148434	C0205082	Severe (severity modifier)	qlco	3.56
25148434	C4050465	Severe Extremity Pain	inpr	3.56
25148434	C0439799	Channel	spco	3.48
25148434	C1706095	Channel Object	cnce	3.48
25148434	C0221099	Impaired	ftcn	3.48
25148434	C0205214	Common (qualifier value)	qnco	3.47
25148434	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.47
25148434	C0205172	More	ftcn	3.47
25148434	C1522138	shared attribute	ftcn	3.47
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
25148434	C0008976	Clinical Trials	resa	19.45
25148434	C3264621	ivacaftor	orch	14.64
25148434	C3264621	ivacaftor	phsu	14.64
25148434	C1096775	Clinical Trial [Publication Type]	inpr	9.99
25148434	C0019904	Homozygote	orga	9.74
25148434	C1280500	Effect	qlco	7.14
25148434	C2348382	Effect, Appearance	qlco	7.14
25148434	C0035245	Respiratory physiology	ortf	6.76
25148434	C0030705	Patients	podg	6.59
25148434	C1704689	Bearing Device Component	medd	5.18
25148434	C2741958	VX-770	orch	5.18
25148434	C0205447	One	qnco	3.63
25148434	C1413365	CFTR gene	gngm	3.57
25148434	C1948062	Copy (object)	mnob	3.57
25148434	C0332185	Recent	tmco	3.47
25148434	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.44
25148434	C1705241	Delta (difference)	qnco	7.16
25148434	C1705242	Different	qlco	7.16
25148434	C0031437	Phenotype	orga	6.70
25148434	C0439799	Channel	spco	5.18
25148434	C1706095	Channel Object	cnce	5.18
25148434	C1518422	Negation	ftcn	5.18
25148434	C1272684	Accepted	qlco	3.55
25148434	C0443211	Established	qlco	3.55
25148434	C0449911	View	spco	3.55
25148434	C1280519	Effectiveness	qlco	3.44
25148434	C1707887	Efficacy Study	resa	3.44
25148434	C1521991	Molecular	qlco	3.42
25148434	C0205448	Two	qnco	3.42
25148434	C0596988	mutant	comd	3.42
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
25148434	C0031843	physiological aspects	phsf	14.64
25148434	C1511760	Deletion Mutation	genf	13.01
25148434	C0542341	Function	ftcn	5.18
25148434	C0700205	Function Axis	clas	5.18
25148434	C2827718	In Vitro Route of Administration	ftcn	5.18
25148434	C0021135	In Vitro [Publication Type]	inpr	5.18
25148434	C1705273	Mathematical Operator	inpr	5.18
25148434	C1533691	in vitro	qlco	5.18
25148434	C1547282	Show	anim	3.98
25148434	C1457869	Defect	ftcn	3.68
25148434	C0332185	Recent	tmco	3.68
25148434	C0332281	Associated with	qlco	3.56
25148434	C1880274	Deletion (action)	acty	3.55
25148434	C1442161	Gene Deletion Abnormality	comd	3.55
25148434	C1413365	CFTR gene	gngm	3.54
25148434	C0439799	Channel	spco	3.54
25148434	C1706095	Channel Object	cnce	3.54
25148434	C1444783	Instability	fndg	3.54
25148434	C1292748	Introduces	ftcn	3.52
25148434	C0678594	structure	spco	3.50
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
25148434	C3264621	ivacaftor	orch	12.89
25148434	C3264621	ivacaftor	phsu	12.89
25148434	C0031437	Phenotype	orga	6.79
25148434	C0442818	Raised	qlco	5.18
25148434	C0332149	Possible	qlco	3.82
25148434	C2362652	Possible diagnosis	qlco	3.82
25148434	C1705910	Possibly Related to Intervention	qlco	3.82
25148434	C1413365	CFTR gene	gngm	3.68
25148434	C1285572	Phenotype determination	lbpr	3.63
25148434	C1280519	Effectiveness	qlco	3.56
25148434	C1707887	Efficacy Study	resa	3.56
25148434	C0542299	Behavioral change	inbe	3.56
25148434	C0232040	Thermal reflex	ortf	3.51
25148434	C1524062	Additional	ftcn	3.48
25148434	C0596988	mutant	comd	3.48
25148434	C0205360	Stable status	qlco	3.42
25148434	C0205448	Two	qnco	3.42
25148434	C0439799	Channel	spco	3.40
25148434	C1706095	Channel Object	cnce	3.40
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
25148434	C1707455	Comparison	acty	5.18
25148434	C3854307	Presence (property)	qlco	5.18
25148434	C0150312	Present	qnco	5.18
25148434	C0392148	Providing presence (regime/therapy)	topp	5.18
25148434	C1689985	Absence (morphologic abnormality)	anab	3.57
25148434	C0332197	Absent	ftcn	3.57
25148434	C1413365	CFTR gene	gngm	3.56
25148434	C2347098	Medical Product Stability	qlco	3.56
25148434	C0205360	Stable status	qlco	3.56
25148434	C0597694	Xenopus oocyte	cell	3.45
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.14
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.14
25148434	C0015272	Exhibits as Topic	inpr	16.59
25148434	C1413365	CFTR gene	gngm	7.06
25148434	C1444783	Instability	fndg	3.68
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.42
25148434	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.42
25148434	C1413365	CFTR gene	gngm	7.35
25148434	C1518422	Negation	ftcn	5.18
25148434	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	4.12
25148434	C1444783	Instability	fndg	3.57
25148434	C0005903	Body Temperature	orga	32.79
25148434	C0086418	Homo sapiens	humn	28.71
25148434	C0039476	Temperature	qnco	19.40
25148434	C0040363	Togo	geoa	17.80
25148434	C0041260	Tryptophanase	aapp	17.80
25148434	C0041260	Tryptophanase	enzy	17.80
25148434	C0242821	Human body	humn	16.37
25148434	C0085732	Ability	orga	13.01
25148434	C0026882	Mutation	genf	9.99
25148434	C0030705	Patients	podg	8.34
25148434	C1704689	Bearing Device Component	medd	5.18
25148434	C1883351	To	qlco	5.18
25148434	C1705535	suggestion	idcn	5.18
25148434	C2825142	Experimental Result	fndg	3.98
25148434	C1274040	Result	ftcn	3.98
25148434	C1546471	What subject filter - Result	idcn	3.98
25148434	C0460148	Human body structure	anst	3.75
25148434	C1705285	Mutation Abnormality	comd	3.68
25148434	C3146286	Due	idcn	3.56
25148434	C0678226	Due to	ftcn	3.56
25148434	C1280519	Effectiveness	qlco	3.56
25148434	C1707887	Efficacy Study	resa	3.56
25148434	C0449719	Part	spco	3.56
25148434	C1709471	Part Dosing Unit	qnco	3.56
25148434	C0439799	Channel	spco	3.55
25148434	C1706095	Channel Object	cnce	3.55
25148434	C2741958	VX-770	orch	3.46
25148434	C1328819	Small Molecule	orch	3.44
25148434	C1444783	Instability	fndg	3.43
25148434	C0596988	mutant	comd	3.43
28611092	C0006037	City of Boston	geoa	24.11
28611092	C0039798	therapeutic aspects	ftcn	22.47
28611092	C0024443	Madagascar	geoa	14.64
28611092	C3264621	ivacaftor	orch	13.14
28611092	C3264621	ivacaftor	phsu	13.14
28611092	C3852684	lumacaftor	orch	12.90
28611092	C3852684	lumacaftor	phsu	12.90
28611092	C0010674	Cystic Fibrosis	dsyn	9.88
28611092	C1254351	Pharmacologic Substance	phsu	7.40
28611092	C1135440	Procedures involving the use of pharmaceuticals	topp	7.40
28611092	C2697524	Graph Node	cnce	7.04
28611092	C0230003	Vertex	blor	7.04
28611092	C0009429	Combined Modality Therapy	topp	6.79
28611092	C0521116	Current (present time)	tmco	5.18
28611092	C3264627	Kalydeco	phsu	5.18
28611092	C3887485	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1	fndg	5.18
28611092	C4033620	ORKAMBI	phsu	5.18
28611092	C0556895	Combination electrotherapy	topp	3.64
28611092	C1524063	Use of	ftcn	3.56
28611092	C1533734	Administration procedure	topp	3.55
28611092	C1705169	Biomaterial Treatment	cnce	3.55
28611092	C0087111	Therapeutic procedure	topp	3.55
28611092	C1522326	Treating	ftcn	3.55
28611092	C3538994	Treatment Epoch	resa	3.55
28611092	C3887704	treatment - ActInformationManagementReason	hlca	3.55
28611092	C0039798	therapeutic aspects	ftcn	24.11
28611092	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
28611092	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
28611092	C0030705	Patients	podg	20.96
28611092	C0026882	Mutation	genf	19.59
28611092	C0087111	Therapeutic procedure	topp	15.79
28611092	C0206243	Carrying	acty	14.64
28611092	C1522326	Treating	ftcn	10.42
28611092	C1292734	Treatment intent	ftcn	10.42
28611092	C1257890	Population Group	popg	9.94
28611092	C0019904	Homozygote	orga	9.86
28611092	C0032659	geographic population	qnco	6.79
28611092	C0033684	Proteins	aapp	6.75
28611092	C0033684	Proteins	bacs	6.75
28611092	C3264627	Kalydeco	phsu	5.18
28611092	C4033620	ORKAMBI	phsu	5.18
28611092	C1521840	Target	ftcn	5.18
28611092	C2986546	Target Lesion Identification	diap	5.18
28611092	C1363945	Therapy Object (animal model)	fndg	5.18
28611092	C1413365	CFTR gene	gngm	3.58
28611092	C0205447	One	qnco	3.56
28611092	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.48
28611092	C1552740	Entity Determiner - specific	inpr	3.48
28611092	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.48
28611092	C0205369	Specific qualifier value	qlco	3.48
28611092	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.48
28611092	C0205455	Nine	qnco	3.43
28611092	C1705285	Mutation Abnormality	comd	3.42
28611092	C1704735	Regulator	cnce	3.42
28611092	C1704734	Regulator Device Component	mnob	3.42
28611092	C0182953	Regulators (device)	medd	3.42
28611092	C3264621	ivacaftor	orch	39.70
28611092	C3264621	ivacaftor	phsu	39.70
28611092	C0010734	Cytidine Triphosphate	nnon	19.45
28611092	C0031330	Pharmacology	bmod	11.49
28611092	C0079107	chemical aspects	ftcn	9.74
28611092	C0007996	Science of Chemistry	ocdi	6.58
28611092	C0557651	Room of building - Study	mnob	5.18
28611092	C2603343	Study	resa	5.18
28611092	C0205464	pharmacological	ftcn	5.18
28611092	C1292474	Catheter tip specimen	sbst	3.68
28611092	C1420150	SLC25A1 gene	gngm	3.68
28611092	C2945675	metabolic effects	phsf	3.59
28611092	C1420488	STRA13 gene	gngm	3.50
28611092	C3889647	STRA13 wt Allele	gngm	3.50
28611092	C0201682	Chemical procedure	lbpr	3.43
28611092	C1706245	Precision - characteristic	qlco	3.43
28611092	C1547902	Precision - temporal	tmco	3.43
28611092	C0243071	Analog	chvs	3.42
28611092	C0205314	New	qlco	3.42
28611092	C0205448	Two	qnco	3.42
28611092	C0679622	literary novel	inpr	3.42
28611092	C0086418	Homo sapiens	humn	28.82
28611092	C3264621	ivacaftor	orch	13.14
28611092	C3264621	ivacaftor	phsu	13.14
28611092	C0870883	Metabolite	bacs	7.35
28611092	C2698672	Other Toxicity Studies: Metabolites	rnlw	7.35
28611092	C1412828	BSG gene	gngm	5.18
28611092	C2986885	BSG wt Allele	gngm	5.18
28611092	C1521801	Having administered	ftcn	5.18
28611092	C3815103	MRLN gene	gngm	5.18
28611092	C4082130	Prepared	fndg	5.18
28611092	C0585361	Twice a day	tmco	5.18
28611092	C0205164	Major	qlco	3.50
28611092	C0205082	Severe (severity modifier)	qlco	3.50
28611092	C3264621	ivacaftor	orch	39.87
28611092	C3264621	ivacaftor	phsu	39.87
28611092	C0031330	Pharmacology	bmod	19.63
28611092	C0010734	Cytidine Triphosphate	nnon	19.45
28611092	C1524059	mechanism of action qualifier	ftcn	12.90
28611092	C1547282	Show	anim	8.00
28611092	C0870883	Metabolite	bacs	7.26
28611092	C2698672	Other Toxicity Studies: Metabolites	rnlw	7.26
28611092	C1292474	Catheter tip specimen	sbst	3.68
28611092	C3815103	MRLN gene	gngm	3.68
28611092	C1420150	SLC25A1 gene	gngm	3.68
28611092	C2348205	Similarity	qlco	3.59
28611092	C0205163	Equal	qlco	3.57
28611092	C0439185	Equivalent Weight	qnco	3.57
28611092	C0332290	Consistent with	idcn	3.56
28611092	C3245505	potential	qlco	3.50
28611092	C1412828	BSG gene	gngm	3.50
28611092	C2986885	BSG wt Allele	gngm	3.50
28611092	C2827718	In Vitro Route of Administration	ftcn	3.50
28611092	C0021135	In Vitro [Publication Type]	inpr	3.50
28611092	C1533691	in vitro	qlco	3.50
28611092	C0205464	pharmacological	ftcn	3.47
28611092	C0683954	research results	fndg	3.42
28611092	C1552607	Act Relationship Subset - previous	tmco	3.42
28611092	C0205156	Previous	tmco	3.42
28611092	C0205198	Compound	qlco	3.40
28611092	C1706082	Compound (substance)	chem	3.40
28611092	C0010734	Cytidine Triphosphate	nnon	19.45
28611092	C0015272	Exhibits as Topic	inpr	16.59
28611092	C2827718	In Vitro Route of Administration	ftcn	5.18
28611092	C0021135	In Vitro [Publication Type]	inpr	5.18
28611092	C0392366	Tests (qualifier value)	inpr	5.18
28611092	C1533691	in vitro	qlco	5.18
28611092	C1292474	Catheter tip specimen	sbst	3.68
28611092	C1420150	SLC25A1 gene	gngm	3.68
28611092	C2347098	Medical Product Stability	qlco	3.63
28611092	C0205360	Stable status	qlco	3.63
28611092	C2349975	Enhance (action)	acty	3.48
28611092	C0522501	Massive	qlco	3.48
28611092	C0073187	Blood group antigen D	aapp	13.09
28611092	C0073187	Blood group antigen D	imft	13.09
28611092	C0011744	Deuterium	elii	12.88
28611092	C0022262	Isotopes	elii	6.58
28611092	C0332173	Daily	tmco	3.63
28611092	C1280500	Effect	qlco	3.54
28611092	C1158674	CTP metabolic process	moft	3.44
28611092	C0073187	Blood group antigen D	aapp	12.94
28611092	C0073187	Blood group antigen D	imft	12.94
28611092	C0740116	+2	qnco	5.18
28611092	C3833492	2+	fndg	5.18
28611092	C2827735	2+ Score	qnco	5.18
28611092	C2981700	2+ Score, WHO	clas	5.18
28611092	C1708601	K Prime	qnco	3.63
28611092	C0597277	Potassium Ion	elii	3.63
28611092	C0597277	Potassium Ion	phsu	3.63
28611092	C0332173	Daily	tmco	3.48
28611092	C0010762	Cytochrome P450	aapp	19.21
28611092	C0010762	Cytochrome P450	enzy	19.21
28611092	C0549177	Large	qnco	3.54
28611092	C1149063	cytochrome P450 activity	moft	3.44
28611092	C0086597	Mediate	socb	3.42
28611092	C0127400	Mediator brand of benfluorex hydrochloride	orch	3.42
28611092	C0127400	Mediator brand of benfluorex hydrochloride	phsu	3.42
28611092	C0030011	Oxidation	moft	3.42
28611092	C0010734	Cytidine Triphosphate	nnon	38.62
28611092	C0087136	Unmarried	fndg	22.39
28611092	C0037179	Unmarried person	popg	22.39
28611092	C0150097	Cross-Over Studies	resa	16.30
28611092	C3264621	ivacaftor	orch	13.14
28611092	C3264621	ivacaftor	phsu	13.14
28611092	C1708335	Healthy Volunteers	popg	9.92
28611092	C1292474	Catheter tip specimen	sbst	6.89
28611092	C1420150	SLC25A1 gene	gngm	6.89
28611092	C0678723	Biologic Development	orgf	5.18
28611092	C1527148	Development	ftcn	5.18
28611092	C1999230	Providing (action)	acty	5.18
28611092	C0243107	development aspects	phsf	5.18
28611092	C1516048	Assessed	acty	3.56
28611092	C0205452	Six	qnco	3.56
28611092	C1874451	Basis	phsu	3.55
28611092	C1527178	Basis - conceptual entity	ftcn	3.55
28611092	C1979963	Profile (lab procedure)	lbpr	3.55
28611092	C2003903	Profiling (action)	ftcn	3.55
28611092	C0178602	Dosage	qnco	3.47
28611092	C1114758	Dose number:Number:Point in time:^Patient:Quantitative	clna	3.47
28611092	C0205171	Singular	qnco	3.47
28611092	C0869039	Unit dose	qnco	3.47
28611092	C0201734	Pharmacokinetic study	resa	3.43
28611092	C3854260	Advance	tmco	3.41
28611092	C0725066	Advance -- medical device	medd	3.41
28611092	C1561607	Overall	qlco	9.78
28611092	C0282416	Overall Publication Type	inpr	9.78
28611092	C0332257	Including (qualifier)	ftcn	5.18
28611092	C1979963	Profile (lab procedure)	lbpr	3.63
28611092	C2003903	Profiling (action)	ftcn	3.63
28611092	C0010734	Cytidine Triphosphate	nnon	38.81
28611092	C1321605	Compliance behavior	inbe	17.80
28611092	C0018517	Half-Life	tmco	9.88
28611092	C1292474	Catheter tip specimen	sbst	7.08
28611092	C1420150	SLC25A1 gene	gngm	7.08
28611092	C0556983	Once daily	tmco	5.18
28611092	C1705535	suggestion	idcn	5.18
28611092	C0178602	Dosage	qnco	3.98
28611092	C1114758	Dose number:Number:Point in time:^Patient:Quantitative	clna	3.98
28611092	C2349975	Enhance (action)	acty	3.98
28611092	C0869039	Unit dose	qnco	3.98
28611092	C0456685	U/hour	qnco	3.44
28611092	C0040363	Togo	geoa	17.80
28611092	C0041260	Tryptophanase	aapp	17.80
28611092	C0041260	Tryptophanase	enzy	17.80
28611092	C0011744	Deuterium	elii	12.89
28611092	C0007589	Cell Differentiation process	celf	9.88
28611092	C0549178	Continuous	idcn	5.18
28611092	C1511726	Data	idcn	5.18
28611092	C3714741	Data (eukaryote)	euka	5.18
28611092	C3245479	Data call receiving device	medd	5.18
28611092	C1883351	To	qlco	5.18
28611092	C1883357	Together	qlco	3.68
28611092	C0304231	Therapeutic agent	mnob	3.58
28611092	C1611640	Therapeutic agent (substance)	phsu	3.58
28611092	C3687832	DRUGS	topp	3.57
28611092	C0013227	Pharmaceutical Preparations	phsu	3.57
28611092	C0205615	Well Differentiated	qlco	3.57
28611092	C1555721	Substitution - ActClass	idcn	3.55
28611092	C1706204	Substitution - change	acty	3.55
28611092	C0449445	Approach	spco	3.43
28611092	C0443348	Viable	qlco	3.43
28611092	C1292721	Has property	ftcn	3.42
28611092	C0205314	New	qlco	3.42
28611092	C0871161	Property (attribute)	qlco	3.42
28611092	C0679622	literary novel	inpr	3.42
28611092	C3244320	Create data operation	ftcn	3.40
28611092	C1706214	Creation	acty	3.40
27660821	C0010674	Cystic Fibrosis	dsyn	9.75
27660821	C0026882	Mutation	genf	9.73
27660821	C0376554	Knowledge	inpr	6.79
27660821	C0441712	Mechanism (attribute)	ftcn	3.68
27660821	C1706376	Mechanism Component of Device	mnob	3.68
27660821	C1299586	Has difficulty doing (qualifier value)	fndg	3.54
27660821	C3816499	Pathogenic	fndg	3.50
27660821	C0450254	Pathogenic organism	orgm	3.50
27660821	C2700116	Unusual	qlco	3.42
27660821	C0871968	categorizing	acty	3.42
27660821	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.42
27660821	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.42
27660821	C0009738	Congo	geoa	17.80
27660821	C0206243	Carrying	acty	13.01
27660821	C0026882	Mutation	genf	9.85
27660821	C3811819	CFTR wt Allele	gngm	5.18
27660821	C1511726	Data	idcn	5.18
27660821	C3714741	Data (eukaryote)	euka	5.18
27660821	C3245479	Data call receiving device	medd	5.18
27660821	C1457869	Defect	ftcn	5.18
27660821	C0150312	Present	qnco	5.18
27660821	C0449450	Presentation	idcn	5.18
27660821	C1998882	Sometimes	tmco	5.18
27660821	C2699424	Concern	idcn	3.98
27660821	C0868928	Case (situation)	ftcn	3.63
27660821	C1706256	Clinical Study Case	cnce	3.63
27660821	C1706255	Packaging Case	medd	3.63
27660821	C3714763	Point	spco	3.63
27660821	C2347617	Point Name	qnco	3.63
27660821	C1552961	point - UnitsOfMeasure	qnco	3.63
27660821	C1549735	Identifier type - Person number	idcn	3.56
27660821	C1455752	Person number	qnco	3.56
27660821	C1704258	Abnormality	fndg	3.55
27660821	C0439799	Channel	spco	3.55
27660821	C1706095	Channel Object	cnce	3.55
27660821	C0699809	Does carry	fndg	3.55
27660821	C0700321	Small	qnco	3.55
27660821	C1705285	Mutation Abnormality	comd	3.54
27660821	C0449234	Concept Attribute	idcn	3.52
27660821	C1882133	Object Attribute	qlco	3.52
27660821	C1704772	Protection Element Attribute	cnce	3.52
27660821	C1413365	CFTR gene	gngm	3.49
27660821	C0015272	Exhibits as Topic	inpr	16.18
27660821	C1314792	Etiology	ftcn	14.64
27660821	C0015127	Etiology aspects	ftcn	11.49
27660821	C0033684	Proteins	aapp	6.66
27660821	C0033684	Proteins	bacs	6.66
27660821	C1254042	Anatomical maturation	phsf	5.18
27660821	C0678723	Biologic Development	orgf	5.18
27660821	C0443211	Established	qlco	5.18
27660821	C0870861	Human maturation	phpr	5.18
27660821	C1955473	Others - Allergy	fndg	5.18
27660821	C1524003	Science of Etiology	cnce	5.18
27660821	C0332454	disrupted	qlco	5.18
27660821	C3539125	other medicated shampoos in ATC	phsu	5.18
27660821	C1547311	Patient Condition Code - Stable	inpr	3.68
27660821	C0205360	Stable status	qlco	3.68
27660821	C0243067	defects aspect	ftcn	3.68
27660821	C0587081	Laboratory test finding	fndg	3.58
27660821	C0231683	Gait normal	fndg	3.57
27660821	C2347086	Mean Percent of Normal	qnco	3.57
27660821	C0205307	Normal	qlco	3.57
27660821	C0439166	Percent normal	qnco	3.57
27660821	C0002085	Alleles	gngm	19.19
27660821	C0009738	Congo	geoa	16.04
27660821	C0205172	More	ftcn	5.18
27660821	C1999230	Providing (action)	acty	5.18
27660821	C2825142	Experimental Result	fndg	3.98
27660821	C1979963	Profile (lab procedure)	lbpr	3.98
27660821	C2003903	Profiling (action)	ftcn	3.98
27660821	C1274040	Result	ftcn	3.98
27660821	C1546471	What subject filter - Result	idcn	3.98
27660821	C0699748	Pathogenesis	patf	3.60
27660821	C0543483	pathogenic aspects	ftcn	3.60
27660821	C1521991	Molecular	qlco	3.46
27660821	C1571809	Visceral manipulation	topp	3.46
27660821	C3811819	CFTR wt Allele	gngm	3.42
27660821	C0521114	Infrequent	tmco	3.42
27660821	C0205447	One	qnco	3.42
27660821	C0522498	Rare	qlco	3.42
27660821	C1514917	Retinoic Acid Response Element	gngm	3.42
27660821	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27660821	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27660821	C0009738	Congo	geoa	16.08
27660821	C3852684	lumacaftor	orch	14.64
27660821	C3852684	lumacaftor	phsu	14.64
27660821	C3264621	ivacaftor	orch	13.08
27660821	C3264621	ivacaftor	phsu	13.08
27660821	C0031330	Pharmacology	bmod	9.74
27660821	C0086597	Mediate	socb	5.18
27660821	C1879547	Activation action	acty	3.55
27660821	C3811819	CFTR wt Allele	gngm	3.47
27660821	C0087111	Therapeutic procedure	topp	3.47
27660821	C1413365	CFTR gene	gngm	3.43
27660821	C0205464	pharmacological	ftcn	3.43
27660821	C0002085	Alleles	gngm	19.38
27660821	C0009738	Congo	geoa	16.08
27660821	C1880022	Characterization	acty	5.18
27660821	C0332183	Frequently	tmco	5.18
27660821	C1314939	Involvement with	ftcn	5.18
27660821	C4050225	Often - answer to question	inpr	5.18
27660821	C0449719	Part	spco	5.18
27660821	C1709471	Part Dosing Unit	qnco	5.18
27660821	C2360800	Number of patients	fndg	3.62
27660821	C3811819	CFTR wt Allele	gngm	3.47
27660821	C0521114	Infrequent	tmco	3.47
27660821	C0678226	Due to	ftcn	3.44
27660821	C0700321	Small	qnco	3.42
27660821	C0282461	Phase 3 Clinical Trials	resa	22.57
27660821	C0085123	Drug Costs	qnco	16.22
27660821	C1096117	Off-Label Use	inpo	13.18
27660821	C0018748	Health Services Accessibility	qlco	13.10
27660821	C1299586	Has difficulty doing (qualifier value)	fndg	7.44
27660821	C0030705	Patients	podg	6.71
27660821	C0017431	Genotype	orga	6.58
27660821	C0242299	Orphan child	popg	6.58
27660821	C1299351	Abnormally high	qlco	3.56
27660821	C0205250	High	qlco	3.56
27660821	C3889660	High Mitosis-Karyorrhexis Index	qnco	3.56
27660821	C0221099	Impaired	ftcn	3.56
27660821	C2700149	Value Above Reference Range	inpr	3.56
27660821	C3887512	high - ActExposureLevelCode	idcn	3.56
27660821	C0439801	Limited (extensiveness)	ftcn	3.54
27660821	C4050251	Limited Lifting Ability	inpr	3.54
27660821	C2674459	Limited Walking Ability	fndg	3.54
27660821	C3542948	Limited component (foundation metadata concept)	inpr	3.54
27660821	C1698594	Third Party	idcn	3.53
27660821	C3539931	Third Party Submitter	prog	3.53
27660821	C0205314	New	qlco	3.43
27660821	C1709510	Personalized	qlco	3.43
27660821	C0728475	ultra	medd	3.43
27660821	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27660821	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27660821	C0040363	Togo	geoa	17.80
27660821	C0041260	Tryptophanase	aapp	17.80
27660821	C0041260	Tryptophanase	enzy	17.80
27660821	C0026882	Mutation	genf	9.86
27660821	C0013919	Emblems	mnob	9.81
27660821	C0025118	Medicine	bmod	8.34
27660821	C0376315	Manufactured form	mnob	6.58
27660821	C0376554	Knowledge	inpr	6.58
27660821	C0332257	Including (qualifier)	ftcn	5.18
27660821	C0013227	Pharmaceutical Preparations	phsu	5.18
27660821	C0087111	Therapeutic procedure	topp	5.18
27660821	C1883351	To	qlco	5.18
27660821	C1522326	Treating	ftcn	5.18
27660821	C1292734	Treatment intent	ftcn	5.18
27660821	C1524063	Use of	ftcn	3.58
27660821	C0683521	patient condition	fndg	3.56
27660821	C1706245	Precision - characteristic	qlco	3.50
27660821	C1547902	Precision - temporal	tmco	3.50
27660821	C0805586	Challenge	hlca	3.44
27660821	C0348078	Qualitative form	qlco	3.43
27660821	C2700116	Unusual	qlco	3.43
27660821	C0470187	Availability of	ftcn	3.42
27660821	C1413365	CFTR gene	gngm	3.42
27660821	C0521114	Infrequent	tmco	3.42
27660821	C0522498	Rare	qlco	3.42
27660821	C1514917	Retinoic Acid Response Element	gngm	3.42
27660821	C1522427	best (quality)	qlco	3.42
27660821	C0441712	Mechanism (attribute)	ftcn	3.38
27660821	C1706376	Mechanism Component of Device	mnob	3.38
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
26976279	C0017337	Genes	gngm	16.22
26976279	C0021364	Male infertility	dsyn	14.64
26976279	C0267963	Exocrine pancreatic insufficiency	dsyn	11.49
26976279	C0030293	Pancreatic Insufficiency	dsyn	11.49
26976279	C0010674	Cystic Fibrosis	dsyn	10.06
26976279	C0012634	Disease	dsyn	9.94
26976279	C0026882	Mutation	genf	9.90
26976279	C0015127	Etiology aspects	ftcn	9.86
26976279	C0013832	Electrolytes	inch	6.71
26976279	C0013832	Electrolytes	phsu	6.71
26976279	C0011900	Diagnosis	fndg	5.18
26976279	C0348026	Diagnostic	ftcn	5.18
26976279	C1844383	Recurrent bacterial infection	fndg	5.18
26976279	C0430022	diagnostic procedure	diap	5.18
26976279	C0746102	Chronic lung disease	dsyn	3.62
26976279	C1413365	CFTR gene	gngm	3.58
26976279	C3536863	Electrolyte [EPC]	phsu	3.56
26976279	C0086045	Mental concentration	menp	3.56
26976279	C0700272	Increase in perspiration due to female physical maturation	fndg	3.55
26976279	C0518185	Increase in perspiration due to male physical maturation	fndg	3.55
26976279	C1524003	Science of Etiology	cnce	3.55
26976279	C3151529	Lethal	fndg	3.48
26976279	C1265828	Progressive inflammation	patf	3.45
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
26976279	C1457869	Defect	ftcn	3.68
26976279	C0087111	Therapeutic procedure	topp	3.68
26976279	C2948600	Aim	phsu	3.55
26976279	C1947946	Aim (idea)	idcn	3.55
26976279	C3540472	Ancestry-Informative Marker	ftcn	3.55
26976279	C3890193	CD5L wt Allele	gngm	3.55
26976279	C2744535	CD69 protein, human	aapp	3.55
26976279	C2744535	CD69 protein, human	imft	3.55
26976279	C3540471	CD69 wt Allele	gngm	3.55
26976279	C1413365	CFTR gene	gngm	3.50
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26976279	C0055363	Chloride Channels	aapp	19.31
26976279	C0055363	Chloride Channels	bacs	19.31
26976279	C0009738	Congo	geoa	16.16
26976279	C3264621	ivacaftor	orch	13.14
26976279	C3264621	ivacaftor	phsu	13.14
26976279	C0026882	Mutation	genf	9.73
26976279	C1704689	Bearing Device Component	medd	5.18
26976279	C1328819	Small Molecule	orch	5.18
26976279	C0175566	Open	spco	3.63
26976279	C1882151	Opening	spco	3.63
26976279	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.56
26976279	C3242455	HL7PublishingDomain <patient administration>	inpr	3.56
26976279	C3242279	healthcare operations <patient administration>	ocac	3.56
26976279	C0205540	Approved	qlco	3.55
26976279	C3811819	CFTR wt Allele	gngm	3.55
26976279	C0456387	Class	inpr	3.55
26976279	C1705943	Class (taxonomic)	clas	3.55
26976279	C1413365	CFTR gene	gngm	3.42
26976279	C0521114	Infrequent	tmco	3.42
26976279	C0522498	Rare	qlco	3.42
26976279	C1514917	Retinoic Acid Response Element	gngm	3.42
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
26976279	C0009738	Congo	geoa	16.18
26976279	C0175996	Protoplasm	celc	14.64
26976279	C3264621	ivacaftor	orch	14.64
26976279	C3264621	ivacaftor	phsu	14.64
26976279	C0030705	Patients	podg	6.72
26976279	C1947931	Direct (qualifier)	qlco	5.18
26976279	C1517001	Expected	inpr	5.18
26976279	C2827718	In Vitro Route of Administration	ftcn	5.18
26976279	C0021135	In Vitro [Publication Type]	inpr	5.18
26976279	C0178719	Intracellular	spco	5.18
26976279	C1328819	Small Molecule	orch	5.18
26976279	C1521840	Target	ftcn	5.18
26976279	C2986546	Target Lesion Identification	diap	5.18
26976279	C1533691	in vitro	qlco	5.18
26976279	C0599896	trafficking	celf	5.18
26976279	C0596988	mutant	comd	3.60
26976279	C0205195	Combined	qlco	3.59
26976279	C1704419	Effective	qlco	3.59
26976279	C1280519	Effectiveness	qlco	3.59
26976279	C3811910	combination - answer to question	fndg	3.59
26976279	C1947911	combination of objects	phob	3.59
26976279	C3811819	CFTR wt Allele	gngm	3.57
26976279	C0392366	Tests (qualifier value)	inpr	3.57
26976279	C0439092	Less Than	qnco	3.50
26976279	C1413365	CFTR gene	gngm	3.46
26976279	C0205214	Common (qualifier value)	qnco	3.46
26976279	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.46
26976279	C0205393	Most	qnco	3.46
26976279	C1522138	shared attribute	ftcn	3.46
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
26976279	C0040363	Togo	geoa	17.80
26976279	C0041260	Tryptophanase	aapp	17.80
26976279	C0041260	Tryptophanase	enzy	17.80
26976279	C1514873	Requirement	ftcn	5.18
26976279	C1883351	To	qlco	5.18
26976279	C0679199	strategy	menp	3.68
26976279	C1457869	Defect	ftcn	3.63
26976279	C0205314	New	qlco	3.50
26976279	C1413365	CFTR gene	gngm	3.48
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
26976279	C0015272	Exhibits as Topic	inpr	17.80
26976279	C0004391	Autophagy	celf	16.30
26976279	C0009738	Congo	geoa	16.04
26976279	C0242606	Oxidative Stress	comd	14.64
26976279	C0529334	transglutaminase 2	aapp	12.92
26976279	C0529334	transglutaminase 2	enzy	12.92
26976279	C0026882	Mutation	genf	9.94
26976279	C0021853	Intestines	bpoc	9.86
26976279	C0014597	Epithelial Cells	cell	6.74
26976279	C0018576	Disabled Persons	podg	6.66
26976279	C0030705	Patients	podg	6.58
26976279	C1704689	Bearing Device Component	medd	5.18
26976279	C0458827	Airway structure	bpoc	3.68
26976279	C0178987	Artificial Airways	medd	3.68
26976279	C1705285	Mutation Abnormality	comd	3.63
26976279	C1273342	Epithelial cell count (procedure)	lbpr	3.59
26976279	C1292984	Procedure on intestine	hlca	3.55
26976279	C1880351	Disabled	qlco	3.50
26976279	C1413365	CFTR gene	gngm	3.48
26976279	C1420714	TGM2 gene	gngm	3.46
26976279	C2256568	tissue transglutaminase activity	moft	3.46
26976279	C3811819	CFTR wt Allele	gngm	3.43
26976279	C0007634	Cells	cell	3.43
26976279	C0178539	Cellular	lbpr	3.43
26976279	C1998467	Impression	qlco	3.38
26976279	C4049863	Radiologic Impression	fndg	3.38
26976279	C0596764	impression (attitude)	inbe	3.38
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.00
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.00
26976279	C0206610	Mice, Inbred CFTR	mamm	28.67
26976279	C0030705	Patients	podg	20.25
26976279	C0019904	Homozygote	orga	19.62
26976279	C0008976	Clinical Trials	resa	19.34
26976279	C0004391	Autophagy	celf	16.30
26976279	C0010648	Cysteamine	orch	16.04
26976279	C0010648	Cysteamine	phsu	16.04
26976279	C0009738	Congo	geoa	16.04
26976279	C0038164	Staphylococcal Protein A	aapp	13.02
26976279	C0038164	Staphylococcal Protein A	imft	13.02
26976279	C0038164	Staphylococcal Protein A	irda	13.02
26976279	C0004340	Australia	geoa	13.01
26976279	C0028429	Nose	bpoc	12.93
26976279	C1096775	Clinical Trial [Publication Type]	inpr	9.88
26976279	C0007600	Cultured Cell Line	cell	9.75
26976279	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	6.93
26976279	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	6.93
26976279	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	6.93
26976279	C1413365	CFTR gene	gngm	6.92
26976279	C1516695	Collected	idcn	5.18
26976279	C1516698	Collection (action)	ftcn	5.18
26976279	C1314939	Involvement with	ftcn	5.18
26976279	C0184512	Stabilized (qualifier value)	qlco	5.18
26976279	C2348480	ex vivo	ftcn	3.72
26976279	C0007634	Cells	cell	3.61
26976279	C3282337	Cells [Chemical/Ingredient]	cell	3.61
26976279	C1515655	in vivo	spco	3.58
26976279	C2827718	In Vitro Route of Administration	ftcn	3.57
26976279	C0021135	In Vitro [Publication Type]	inpr	3.57
26976279	C1533691	in vitro	qlco	3.57
26976279	C0182953	Regulators (device)	medd	3.55
26976279	C1414316	EGR3 gene	gngm	3.54
26976279	C3890606	EGR3 wt Allele	gngm	3.54
26976279	C0205170	Good	qlco	3.54
26976279	C0473169	Pilot	prog	3.54
26976279	C3146287	Well	mnob	3.54
26976279	C0205225	Primary	qlco	3.47
26976279	C0439631	Primary operation	topp	3.47
26976279	C0439612	True primary (qualifier value)	tmco	3.47
26976279	C3811819	CFTR wt Allele	gngm	3.42
26976279	C1441547	Derivation	qlco	3.42
26976279	C3245521	Derived value	idcn	3.42
26976279	C1879547	Activation action	acty	3.42
26976279	C0542341	Function	ftcn	3.42
26976279	C0205245	Functional	ftcn	3.42
26976279	C2700217	Functional Relationship	cnce	3.42
26976279	C1260953	Suppressed	ftcn	3.42
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
26976279	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
26976279	C0009738	Congo	geoa	16.16
26976279	C0026882	Mutation	genf	9.94
26976279	C2584313	Discussion (communication)	socb	5.18
26976279	C1705285	Mutation Abnormality	comd	3.63
26976279	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.56
26976279	C3242455	HL7PublishingDomain <patient administration>	inpr	3.56
26976279	C3242279	healthcare operations <patient administration>	ocac	3.56
26976279	C1882115	Normalize	resa	3.55
26976279	C3811819	CFTR wt Allele	gngm	3.55
26976279	C3873748	Harness	mnob	3.52
26976279	C1413365	CFTR gene	gngm	3.48
26976279	C0302350	Therapeutic	ftcn	3.43
26976279	C0087111	Therapeutic procedure	topp	3.43
26976279	C0332452	defective	ftcn	3.43
28171547	C2718059	Precision Medicine	topp	12.92
28171547	C0010674	Cystic Fibrosis	dsyn	10.06
28171547	C1555307	promise	idcn	3.56
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
28171547	C0040363	Togo	geoa	17.80
28171547	C0041260	Tryptophanase	aapp	17.80
28171547	C0041260	Tryptophanase	enzy	17.80
28171547	C1314792	Etiology	ftcn	12.91
28171547	C0376636	Disease Management	hlca	9.81
28171547	C0015127	Etiology aspects	ftcn	9.76
28171547	C0033325	Forecast of outcome	hlca	6.90
28171547	C0035245	Respiratory physiology	ortf	6.76
28171547	C0441516	Demand (clinical)	topp	5.18
28171547	C1947931	Direct (qualifier)	qlco	5.18
28171547	C0699784	Economic demand	idcn	5.18
28171547	C1521840	Target	ftcn	5.18
28171547	C2986546	Target Lesion Identification	diap	5.18
28171547	C1883351	To	qlco	5.18
28171547	C1413365	CFTR gene	gngm	3.68
28171547	C0679006	Decision	menp	3.68
28171547	C0237942	Response Variability	qlco	3.68
28171547	C2825142	Experimental Result	fndg	3.56
28171547	C2986411	Improvement	cnce	3.56
28171547	C1274040	Result	ftcn	3.56
28171547	C1546471	What subject filter - Result	idcn	3.56
28171547	C3854260	Advance	tmco	3.52
28171547	C0725066	Advance -- medical device	medd	3.52
28171547	C0001554	Administration occupational activities	ocac	3.50
28171547	C3273539	Management Occupations	ocdi	3.50
28171547	C1273870	Management procedure	ocac	3.50
28171547	C0872152	drug development	bmod	3.45
28171547	C0332272	Better	qlco	3.44
28171547	C0332185	Recent	tmco	3.43
28171547	C0005615	Birth	orgf	19.22
28171547	C0009738	Congo	geoa	16.12
28171547	C1706279	Object Relationship	idcn	13.02
28171547	C0021853	Intestines	bpoc	9.90
28171547	C0521117	Severity of illness	qlco	7.11
28171547	C0030274	Pancreas	bpoc	6.83
28171547	C1516048	Assessed	acty	5.18
28171547	C1278931	Entire pancreas	bpoc	3.68
28171547	C1422675	SLC26A9 gene	gngm	3.63
28171547	C0521982	Response to treatment	clna	3.61
28171547	C1707789	Disease Relationship Object	cnce	3.60
28171547	C1708548	Intestinal Wall Tissue	tisu	3.59
28171547	C1880177	Contribution	acty	3.57
28171547	C3540605	CDISC Relationship Class	inpr	3.56
28171547	C1705630	Concept Relationship	idcn	3.56
28171547	C0439849	Relationships	qlco	3.56
28171547	C3811819	CFTR wt Allele	gngm	3.50
28171547	C1516451	Chemical Modifier	chvf	3.48
28171547	C0314603	Genetic	ftcn	3.48
28171547	C0205349	Modified By	qlco	3.48
28171547	C3542952	Modifier (core metadata concept)	inpr	3.48
28171547	C1514623	Qualifier (concept)	cnce	3.48
28171547	C0017296	gene therapy	topp	3.48
28171547	C1550722	Entity Name Part Qualifier - birth	inpr	3.45
28171547	C3245487	Name Given at Birth	inpr	3.45
28171547	C0458827	Airway structure	bpoc	3.43
28171547	C0178987	Artificial Airways	medd	3.43
28171547	C2983285	CDISC SEND Severity Terminology	inpr	3.43
28171547	C0439793	Severities	qlco	3.43
28171547	C0522510	With intensity	qlco	3.43
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28171547	C0026882	Mutation	genf	19.75
28171547	C3178895	Genes, Modifier	gngm	19.20
28171547	C0009738	Congo	geoa	16.04
28171547	C0004083	Mental association	menp	13.01
28171547	C0019904	Homozygote	orga	9.88
28171547	C1413365	CFTR gene	gngm	6.89
28171547	C0024115	Lung diseases	dsyn	6.60
28171547	C0024109	Lung	bpoc	6.58
28171547	C0238884	canadian	fndg	5.18
28171547	C1705285	Mutation Abnormality	comd	3.63
28171547	C1516048	Assessed	acty	3.59
28171547	C1511978	Disease Association	tmco	3.58
28171547	C0237401	Individual	humn	3.55
28171547	C0027361	Persons	popg	3.55
28171547	C0596306	Chemical Association	phpr	3.55
28171547	C0699792	Relationship by association	socb	3.55
28171547	C0439849	Relationships	qlco	3.55
28171547	C1880171	Consortium (group)	prog	3.51
28171547	C1513822	Consortium or Network	prog	3.51
28171547	C0205214	Common (qualifier value)	qnco	3.48
28171547	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.48
28171547	C1522138	shared attribute	ftcn	3.48
28171547	C0596611	Gene Mutation	genf	3.43
28171547	C1278908	Entire lung	bpoc	3.43
28171547	C1422675	SLC26A9 gene	gngm	3.43
28171547	C0819757	Structure of parenchyma of lung	tisu	3.43
28171547	C3811819	CFTR wt Allele	gngm	3.42
28171547	C1516451	Chemical Modifier	chvf	3.42
28171547	C3640168	French Catheter Gauge	qnco	3.42
28171547	C0376246	French language	lang	3.42
28171547	C0205349	Modified By	qlco	3.42
28171547	C3542952	Modifier (core metadata concept)	inpr	3.42
28171547	C1514623	Qualifier (concept)	cnce	3.42
28171547	C1556084	french race	popg	3.42
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
28171547	C0026882	Mutation	genf	9.99
28171547	C0017431	Genotype	orga	6.72
28171547	C0679651	directive therapy	topp	3.67
28171547	C0237942	Response Variability	qlco	3.62
28171547	C1555289	Assessed patient - therapy appropriate	fndg	3.60
28171547	C1422675	SLC26A9 gene	gngm	3.57
28171547	C0238884	canadian	fndg	3.57
28171547	C0449234	Concept Attribute	idcn	3.54
28171547	C1882133	Object Attribute	qlco	3.54
28171547	C1704772	Protection Element Attribute	cnce	3.54
28171547	C1413365	CFTR gene	gngm	3.48
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.97
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.97
28171547	C0039798	therapeutic aspects	ftcn	22.48
28171547	C0026339	Biological Models	resd	9.99
28171547	C1413365	CFTR gene	gngm	6.90
28171547	C1422675	SLC26A9 gene	gngm	5.18
28171547	C1547282	Show	anim	5.18
28171547	C3161035	Model	inpr	3.68
28171547	C0581601	Functional modification	topp	3.56
28171547	C1533734	Administration procedure	topp	3.55
28171547	C1705169	Biomaterial Treatment	cnce	3.55
28171547	C0087111	Therapeutic procedure	topp	3.55
28171547	C1522326	Treating	ftcn	3.55
28171547	C3538994	Treatment Epoch	resa	3.55
28171547	C3887704	treatment - ActInformationManagementReason	hlca	3.55
28171547	C0458827	Airway structure	bpoc	3.47
28171547	C0178987	Artificial Airways	medd	3.47
28171547	C0205225	Primary	qlco	3.47
28171547	C0439631	Primary operation	topp	3.47
28171547	C0439612	True primary (qualifier value)	tmco	3.47
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.54
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.54
28171547	C0026882	Mutation	genf	9.94
28171547	C0019904	Homozygote	orga	9.86
28171547	C0035245	Respiratory physiology	ortf	8.34
28171547	C0699040	Cell surface	celc	6.98
28171547	C0392747	Changing	ftcn	5.18
28171547	C0332268	Lacking	qlco	5.18
28171547	C1518422	Negation	ftcn	5.18
28171547	C0333118	Retained	ftcn	5.18
28171547	C1422675	SLC26A9 gene	gngm	5.18
28171547	C1547282	Show	anim	5.18
28171547	C1413365	CFTR gene	gngm	3.61
28171547	C0868928	Case (situation)	ftcn	3.57
28171547	C1706256	Clinical Study Case	cnce	3.57
28171547	C1706255	Packaging Case	medd	3.57
28171547	C0392752	Localized	spco	3.47
28171547	C3854321	Expression (foundation metadata concept)	idcn	3.42
28171547	C0185117	Expression procedure	topp	3.42
28171547	C0237401	Individual	humn	3.42
28171547	C0027361	Persons	popg	3.42
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28171547	C0040363	Togo	geoa	17.80
28171547	C0041260	Tryptophanase	aapp	17.80
28171547	C0041260	Tryptophanase	enzy	17.80
28171547	C0033204	Probability	qnco	16.17
28171547	C3264621	ivacaftor	orch	12.89
28171547	C3264621	ivacaftor	phsu	12.89
28171547	C0026882	Mutation	genf	9.99
28171547	C0030705	Patients	podg	6.58
28171547	C3540473	Abnormal Involuntary Movement Scale Questionnaire	inpr	5.18
28171547	C2948600	Aim	phsu	5.18
28171547	C1947946	Aim (idea)	idcn	5.18
28171547	C3540472	Ancestry-Informative Marker	ftcn	5.18
28171547	C3890193	CD5L wt Allele	gngm	5.18
28171547	C2744535	CD69 protein, human	aapp	5.18
28171547	C2744535	CD69 protein, human	imft	5.18
28171547	C3540471	CD69 wt Allele	gngm	5.18
28171547	C1422675	SLC26A9 gene	gngm	5.18
28171547	C1547282	Show	anim	5.18
28171547	C1883351	To	qlco	5.18
28171547	C0521982	Response to treatment	clna	3.65
28171547	C0237942	Response Variability	qlco	3.62
28171547	C0369773	P Blood group antibodies	aapp	3.50
28171547	C0369773	P Blood group antibodies	imft	3.50
28171547	C2603361	P prime	clna	3.50
28171547	C1413365	CFTR gene	gngm	3.43
28171547	C0439799	Channel	spco	3.43
28171547	C1706095	Channel Object	cnce	3.43
28171547	C0175566	Open	spco	3.43
28171547	C1882151	Opening	spco	3.43
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
28171547	C0039798	therapeutic aspects	ftcn	22.43
28171547	C0040363	Togo	geoa	17.80
28171547	C0041260	Tryptophanase	aapp	17.80
28171547	C0041260	Tryptophanase	enzy	17.80
28171547	C0019904	Homozygote	orga	9.77
28171547	C1522326	Treating	ftcn	7.36
28171547	C0392747	Changing	ftcn	5.18
28171547	C1422675	SLC26A9 gene	gngm	5.18
28171547	C1883351	To	qlco	5.18
28171547	C1413365	CFTR gene	gngm	3.68
28171547	C1704632	Disease Response	fndg	3.68
28171547	C2911692	Response (communication)	menp	3.68
28171547	C1706817	Response (statement)	inpr	3.68
28171547	C0871261	Response process	orga	3.68
28171547	C0007634	Cells	cell	3.60
28171547	C3282337	Cells [Chemical/Ingredient]	cell	3.60
28171547	C1533734	Administration procedure	topp	3.50
28171547	C1705169	Biomaterial Treatment	cnce	3.50
28171547	C0369773	P Blood group antibodies	aapp	3.50
28171547	C0369773	P Blood group antibodies	imft	3.50
28171547	C2603361	P prime	clna	3.50
28171547	C0205148	Surface	spco	3.50
28171547	C0087111	Therapeutic procedure	topp	3.50
28171547	C3538994	Treatment Epoch	resa	3.50
28171547	C3887704	treatment - ActInformationManagementReason	hlca	3.50
28171547	C0024496	Main Bronchus	bpoc	3.46
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.09
28171547	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.09
28171547	C0449738	Direction	spco	12.85
28171547	C1413365	CFTR gene	gngm	7.02
28171547	C1422675	SLC26A9 gene	gngm	6.95
28171547	C3539655	CDISC Findings Class	inpr	5.18
28171547	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
28171547	C2607943	findings aspects	ftcn	5.18
28171547	C0392747	Changing	ftcn	3.63
28171547	C3889737	Data Change Date	tmco	3.63
28171547	C3840684	Modification	inpr	3.63
28171547	C1554963	ResponseLevel - modification	ftcn	3.63
28171547	C0521982	Response to treatment	clna	3.56
28171547	C0205419	Variant	qlco	3.56
28171547	C0458827	Airway structure	bpoc	3.48
28171547	C0178987	Artificial Airways	medd	3.48
28171547	C0699040	Cell surface	celc	3.46
28171547	C0205214	Common (qualifier value)	qnco	3.43
28171547	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.43
28171547	C1522138	shared attribute	ftcn	3.43
28171547	C0439755	Directions	spco	3.39
27792891	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
27792891	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
27792891	C0010674	Cystic Fibrosis	dsyn	19.71
27792891	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	14.64
27792891	C3264621	ivacaftor	orch	14.64
27792891	C3264621	ivacaftor	phsu	14.64
27792891	C4033633	ivacaftor / lumacaftor	phsu	14.64
27792891	C0012634	Disease	dsyn	9.92
27792891	C0016059	Fibrosis	patf	9.77
27792891	C1561536	*Activity (kind of quantity)	idcn	5.18
27792891	C0205177	Active	ftcn	5.18
27792891	C0441655	Activities	acty	5.18
27792891	C3668946	Activity (animal life circumstance)	fndg	5.18
27792891	C1947931	Direct (qualifier)	qlco	5.18
27792891	C4049939	FDA Establishment Activity Terminology	inpr	5.18
27792891	C1054142	Iva <Plant>	plnt	5.18
27792891	C3264627	Kalydeco	phsu	5.18
27792891	C0443264	Modulated	spco	5.18
27792891	C0439167	Percent Activity	qnco	5.18
27792891	C4049938	Physical Activity Measurement	lbpr	5.18
27792891	C1718097	New medications	phsu	3.70
27792891	C0334054	cystic disease	dsyn	3.70
27792891	C4033620	ORKAMBI	phsu	3.68
27792891	C1301808	Geographic state	geoa	3.61
27792891	C1442792	State	ftcn	3.61
27792891	C3148680	US State	geoa	3.61
27792891	C1413365	CFTR gene	gngm	3.56
27792891	C0332452	defective	ftcn	3.56
27792891	C0599896	trafficking	celf	3.56
27792891	C0444503	Breakthrough	qlco	3.46
27792891	C0205448	Two	qnco	3.46
27792891	C0202264	Therapeutic drug monitoring assay	lbpr	4.12
27792891	C0521116	Current (present time)	tmco	3.68
27792891	C3687832	DRUGS	topp	3.68
27792891	C0013227	Pharmaceutical Preparations	phsu	3.68
27792891	C2987476	Exist	cnce	3.56
27792891	C0442824	Very	qlco	3.56
27792891	C2984081	Very Much	qlco	3.56
27792891	C3898777	Important	qlco	3.50
27792891	C0680864	expense	qnco	3.50
27792891	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	39.52
27792891	C0008562	High pressure liquid chromatography procedure	lbpr	16.25
27792891	C0009738	Congo	geoa	16.05
27792891	C0032105	Plasma	bdsu	12.90
27792891	C1054142	Iva <Plant>	plnt	10.68
27792891	C0025664	Methods aspects	inpr	9.94
27792891	C0038056	Sputum	bdsu	9.88
27792891	C0025663	Methods	inpr	6.79
27792891	C0040223	Time	tmco	6.63
27792891	C0030705	Patients	podg	6.59
27792891	C0205177	Active	ftcn	5.18
27792891	C3888249	Active License	qlco	5.18
27792891	C3834263	Inactive - answer to question	fndg	5.18
27792891	C3815103	MRLN gene	gngm	5.18
27792891	C3890554	Physical Inactivity	dora	5.18
27792891	C0557651	Room of building - Study	mnob	5.18
27792891	C0205254	Sedentary	qlco	5.18
27792891	C2603343	Study	resa	5.18
27792891	C3853793	active (HL7 RoleLink)	idcn	5.18
27792891	C1412828	BSG gene	gngm	3.63
27792891	C2986885	BSG wt Allele	gngm	3.63
27792891	C0449851	Techniques	ftcn	3.63
27792891	C1709793	Quantitation	qnco	3.59
27792891	C1511790	Detection	topp	3.57
27792891	C1497669	Luma (plant)	plnt	3.57
27792891	C3714762	Luma <moth>	euka	3.57
27792891	C0456962	Rapid	qlco	3.57
27792891	C1540016	TMEM43 gene	gngm	3.57
27792891	C0872318	Liquid Chromatography Mass Spectrometry	lbpr	3.53
27792891	C0205435	First (number)	qnco	3.48
27792891	C1279901	Firstly	qlco	3.48
27792891	C3541383	Time (foundation metadata concept)	tmco	3.48
27792891	C0178528	carboxylate	orch	3.48
27792891	C0205164	Major	qlco	3.47
27792891	C0870883	Metabolite	bacs	3.47
27792891	C2698672	Other Toxicity Studies: Metabolites	rnlw	3.47
27792891	C0205082	Severe (severity modifier)	qlco	3.47
27792891	C3811819	CFTR wt Allele	gngm	3.44
27792891	C1550098	Plasma, NOS (not otherwise specified)	bdsu	3.44
27792891	C0599638	Drinking Water	sbst	22.49
27792891	C0043047	Water	inch	19.34
27792891	C0043047	Water	phsu	19.34
27792891	C0050456	acetonitrile	orch	13.03
27792891	C3842591	0%	fndg	5.18
27792891	C3469601	Eluent	irda	5.18
27792891	C1550678	Water Specimen	inch	3.57
27792891	C0332529	Consistency	qlco	3.54
27792891	C0016576	formic acid	irda	13.14
27792891	C0016576	formic acid	orch	13.14
27792891	C0016576	formic acid	phsu	13.14
27792891	C0004268	Attention	menp	13.02
27792891	C3842591	0%	fndg	5.18
27792891	C3842585	60%	fndg	5.18
27792891	C1707520	Correlation	qlco	3.68
27792891	C0885348	Formicum acidum, formic acid, Homeopathic preparation	orch	3.68
27792891	C0231966	Alveolar gas volume	clna	3.56
27792891	C1446561	Concentration measurement	qnco	3.56
27792891	C3542016	Concept model range (foundation metadata concept)	inpr	3.56
27792891	C0086045	Mental concentration	menp	3.56
27792891	C1441672	Observed	ftcn	3.56
27792891	C1514721	Range	qnco	3.56
27792891	C2348147	Sample Range	qnco	3.56
27792891	C0205132	Linear	spco	3.50
27792891	C2826285	Flow Rate	qnco	3.43
27792891	C1524029	Mouse MIN NOS	neop	3.42
27792891	C0702093	Per Minute	tmco	3.42
27792891	C3813700	Percent per Minute	qnco	3.42
27792891	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	13.09
27792891	C0684010	Rabbi	prog	13.09
27792891	C3842591	0%	fndg	5.18
27792891	C1435727	FABP6 protein, human	aapp	5.18
27792891	C1435727	FABP6 protein, human	bacs	5.18
27792891	C0544357	human plasma	phsu	5.18
27792891	C1054142	Iva <Plant>	plnt	3.63
27792891	C2603358	R prime	clna	3.63
27792891	C0205090	Right	spco	3.63
27792891	C1880521	Enzyme Unit per Milliliter	qnco	3.58
27792891	C0439340	Kilounit per Liter	qnco	3.58
27792891	C2945590	Unit per Milliliter	qnco	3.58
27792891	C3842590	10%	fndg	3.55
27792891	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	13.08
27792891	C0684010	Rabbi	prog	13.08
27792891	C3842591	0%	fndg	5.18
27792891	C1435727	FABP6 protein, human	aapp	5.18
27792891	C1435727	FABP6 protein, human	bacs	5.18
27792891	C1054142	Iva <Plant>	plnt	3.61
27792891	C3815103	MRLN gene	gngm	3.61
27792891	C2603358	R prime	clna	3.61
27792891	C0205090	Right	spco	3.61
27792891	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	13.08
27792891	C0684010	Rabbi	prog	13.08
27792891	C3842591	0%	fndg	5.18
27792891	C1435727	FABP6 protein, human	aapp	5.18
27792891	C1435727	FABP6 protein, human	bacs	5.18
27792891	C1412828	BSG gene	gngm	3.61
27792891	C2986885	BSG wt Allele	gngm	3.61
27792891	C1054142	Iva <Plant>	plnt	3.61
27792891	C2603358	R prime	clna	3.61
27792891	C0205090	Right	spco	3.61
27792891	C0684010	Rabbi	prog	13.09
27792891	C3842591	0%	fndg	5.18
27792891	C1435727	FABP6 protein, human	aapp	5.18
27792891	C1435727	FABP6 protein, human	bacs	5.18
27792891	C1497669	Luma (plant)	plnt	3.63
27792891	C3714762	Luma <moth>	euka	3.63
27792891	C2603358	R prime	clna	3.63
27792891	C0205090	Right	spco	3.63
27792891	C1540016	TMEM43 gene	gngm	3.63
27792891	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	39.88
27792891	C0039798	therapeutic aspects	ftcn	22.51
27792891	C0040363	Togo	geoa	17.80
27792891	C0041260	Tryptophanase	aapp	17.80
27792891	C0041260	Tryptophanase	enzy	17.80
27792891	C0009738	Congo	geoa	16.05
27792891	C0004268	Attention	menp	13.03
27792891	C0032105	Plasma	bdsu	12.90
27792891	C1054142	Iva <Plant>	plnt	11.04
27792891	C0038056	Sputum	bdsu	9.88
27792891	C0005507	Biological Assay	lbpr	8.34
27792891	C0585327	Every twelve hours	tmco	7.10
27792891	C1497669	Luma (plant)	plnt	6.93
27792891	C3714762	Luma <moth>	euka	6.93
27792891	C1540016	TMEM43 gene	gngm	6.93
27792891	C0030705	Patients	podg	6.59
27792891	C1510438	Assay	lbpr	5.18
27792891	C3815103	MRLN gene	gngm	5.18
27792891	C4033620	ORKAMBI	phsu	5.18
27792891	C1709793	Quantitation	qnco	5.18
27792891	C1883351	To	qlco	5.18
27792891	C0243073	assay qualifier	qlco	5.18
27792891	C0087111	Therapeutic procedure	topp	3.59
27792891	C1363945	Therapy Object (animal model)	fndg	3.59
27792891	C1412828	BSG gene	gngm	3.57
27792891	C2986885	BSG wt Allele	gngm	3.57
27792891	C1446561	Concentration measurement	qnco	3.57
27792891	C0086045	Mental concentration	menp	3.57
27792891	C3264627	Kalydeco	phsu	3.45
27792891	C3811819	CFTR wt Allele	gngm	3.44
27792891	C1550098	Plasma, NOS (not otherwise specified)	bdsu	3.44
27792891	C0015272	Exhibits as Topic	inpr	16.59
27792891	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	12.89
27792891	C0030705	Patients	podg	6.83
27792891	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.68
27792891	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.68
27792891	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.68
27792891	C0683150	plasma concentration	qnco	3.59
27792891	C3264627	Kalydeco	phsu	3.50
27792891	C3842591	0%	fndg	3.43
27792891	C1054142	Iva <Plant>	plnt	3.43
27792891	C1880521	Enzyme Unit per Milliliter	qnco	3.50
27792891	C0439340	Kilounit per Liter	qnco	3.50
27792891	C2945590	Unit per Milliliter	qnco	3.50
27792891	C0439073	97	inpr	3.46
27792891	C0439082	>97	qnco	3.46
27792891	C1442467	5 Hours	tmco	3.68
27792891	C0178602	Dosage	qnco	3.68
27792891	C0687676	Post	tmco	3.68
27792891	C1704687	Post Device Component	mnob	3.68
27792891	C3842591	0%	fndg	5.18
27792891	C0683150	plasma concentration	qnco	3.72
27792891	C3815103	MRLN gene	gngm	3.68
27792891	C1412828	BSG gene	gngm	3.48
27792891	C2986885	BSG wt Allele	gngm	3.48
27792891	C3842591	0%	fndg	5.18
27792891	C1880521	Enzyme Unit per Milliliter	qnco	3.76
27792891	C0439340	Kilounit per Liter	qnco	3.76
27792891	C2945590	Unit per Milliliter	qnco	3.76
27792891	C3842586	50%	fndg	3.47
27792891	C3843766	<50	fndg	3.47
27792891	C1880521	Enzyme Unit per Milliliter	qnco	3.76
27792891	C0439340	Kilounit per Liter	qnco	3.76
27792891	C2945590	Unit per Milliliter	qnco	3.76
27792891	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	12.89
27792891	C0030705	Patients	podg	6.83
27792891	C3842591	0%	fndg	5.18
27792891	C0870432	Display - arrangement	ftcn	5.18
27792891	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.68
27792891	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.68
27792891	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.68
27792891	C0683150	plasma concentration	qnco	3.58
27792891	C4033620	ORKAMBI	phsu	3.50
27792891	C0442811	Very low	fndg	3.45
27792891	C1054142	Iva <Plant>	plnt	3.43
27792891	C3842591	0%	fndg	5.18
27792891	C3815103	MRLN gene	gngm	5.18
27792891	C1880521	Enzyme Unit per Milliliter	qnco	3.76
27792891	C0439340	Kilounit per Liter	qnco	3.76
27792891	C2945590	Unit per Milliliter	qnco	3.76
27792891	C1880521	Enzyme Unit per Milliliter	qnco	3.76
27792891	C0439340	Kilounit per Liter	qnco	3.76
27792891	C2945590	Unit per Milliliter	qnco	3.76
27792891	C3842591	0%	fndg	5.18
27792891	C0086045	Mental concentration	menp	3.68
27792891	C1412828	BSG gene	gngm	3.50
27792891	C2986885	BSG wt Allele	gngm	3.50
27792891	C0030705	Patients	podg	6.58
27792891	C1880521	Enzyme Unit per Milliliter	qnco	3.76
27792891	C0439340	Kilounit per Liter	qnco	3.76
27792891	C2945590	Unit per Milliliter	qnco	3.76
27792891	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.42
27792891	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.42
27792891	C3264627	Kalydeco	phsu	3.42
27792891	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.42
27792891	C3838679	4+ Answer to question	fndg	5.18
27792891	C1441672	Observed	ftcn	5.18
27792891	C0683150	plasma concentration	qnco	3.58
27792891	C1299351	Abnormally high	qlco	3.42
27792891	C0205250	High	qlco	3.42
27792891	C3889660	High Mitosis-Karyorrhexis Index	qnco	3.42
27792891	C1497669	Luma (plant)	plnt	3.42
27792891	C3714762	Luma <moth>	euka	3.42
27792891	C1540016	TMEM43 gene	gngm	3.42
27792891	C2700149	Value Above Reference Range	inpr	3.42
27792891	C3887512	high - ActExposureLevelCode	idcn	3.42
27792891	C1880521	Enzyme Unit per Milliliter	qnco	3.76
27792891	C0439340	Kilounit per Liter	qnco	3.76
27792891	C2945590	Unit per Milliliter	qnco	3.76
27792891	C1720825	Therapeutic Drug Monitoring	topp	12.92
27792891	C0032105	Plasma	bdsu	12.91
27792891	C0038056	Sputum	bdsu	11.49
27792891	C0025663	Methods	inpr	6.83
27792891	C0020517	Hypersensitivity	patf	6.58
27792891	C0205352	Simple	qlco	5.18
27792891	C3858758	reliable	inpr	5.18
27792891	C0449851	Techniques	ftcn	3.68
27792891	C0871511	Test Method	lbpr	3.68
27792891	C4033620	ORKAMBI	phsu	3.59
27792891	C0449445	Approach	spco	3.54
27792891	C0205314	New	qlco	3.50
27792891	C0679622	literary novel	inpr	3.50
27792891	C1550098	Plasma, NOS (not otherwise specified)	bdsu	3.45
27792891	C3264627	Kalydeco	phsu	3.42
27792891	C0332324	Sensitive	ftcn	3.42
27792891	C0031328	Pharmacokinetic aspects	ftcn	19.25
27792891	C0040363	Togo	geoa	17.80
27792891	C0041260	Tryptophanase	aapp	17.80
27792891	C0041260	Tryptophanase	enzy	17.80
27792891	C0018896	Helping Behavior	socb	14.64
27792891	C0010181	Cost Effectiveness	qnco	13.10
27792891	C1524024	analysis aspect	ftcn	13.09
27792891	C0381056	Platinol-Fluororuracil Regimen	topp	13.01
27792891	C0031327	Drug Kinetics	phsf	9.78
27792891	C0005507	Biological Assay	lbpr	6.59
27792891	C1269765	Assisted (qualifier value)	qlco	5.18
27792891	C0557034	Assisting (procedure)	hlca	5.18
27792891	C3176918	Clinical setting	spco	5.18
27792891	C0871685	Clinician	prog	5.18
27792891	C1883351	To	qlco	5.18
27792891	C0936012	Analysis	resa	3.63
27792891	C0002778	Analysis of substances	lbpr	3.63
27792891	C1875307	INTRODUCTION device	mnob	3.56
27792891	C1293116	Introduction procedure	hlca	3.56
27792891	C1880651	Fludarabine-Cyclophosphamide Regimen	topp	3.55
27792891	C0205172	More	ftcn	3.48
27792891	C1709518	Pharmacodynamic Study	resa	3.48
27792891	C0851347	Pharmacodynamics	biof	3.48
27792891	C0870450	drug dosages	qnco	3.44
27792891	C1510438	Assay	lbpr	3.43
27792891	C0243073	assay qualifier	qlco	3.43
27792891	C0444503	Breakthrough	qlco	3.42
27792891	C1280519	Effectiveness	qlco	3.38
27792891	C1707887	Efficacy Study	resa	3.38
28314539	C0016529	Forced expiratory volume function	ortf	19.41
28314539	C0023376	Lesotho	geoa	16.21
28314539	C0036043	Safety	hcpp	16.04
28314539	C4033633	ivacaftor / lumacaftor	phsu	12.90
28314539	C0030705	Patients	podg	6.71
28314539	C0024115	Lung diseases	dsyn	6.60
28314539	C0009429	Combined Modality Therapy	topp	6.59
28314539	C0024109	Lung	bpoc	6.58
28314539	C0439509	/40	tmco	5.18
28314539	C3842587	40%	qnco	5.18
28314539	C0439801	Limited (extensiveness)	ftcn	5.18
28314539	C4050251	Limited Lifting Ability	inpr	5.18
28314539	C2674459	Limited Walking Ability	fndg	5.18
28314539	C3542948	Limited component (foundation metadata concept)	inpr	5.18
28314539	C1306036	Forced expiratory volume procedure	diap	3.64
28314539	C3887647	Lymphotoxin-Alpha, human	aapp	3.59
28314539	C3887647	Lymphotoxin-Alpha, human	imft	3.59
28314539	C0439165	Percent (qualifier value)	qnco	3.59
28314539	C1882327	Percent of Predicted Value	qnco	3.59
28314539	C0230426	Structure of left thigh	bpoc	3.59
28314539	C1552115	Supernumerary maxillary right third molar	bpoc	3.59
28314539	C0681842	prediction	idcn	3.59
28314539	C1511726	Data	idcn	3.54
28314539	C3714741	Data (eukaryote)	euka	3.54
28314539	C3245479	Data call receiving device	medd	3.54
28314539	C1836348	Severe disorder	fndg	3.45
28314539	C0556895	Combination electrotherapy	topp	3.44
28314539	C4050466	Borg Category-Ratio 10 Perceived Exertion Score 5	inpr	3.43
28314539	C1278908	Entire lung	bpoc	3.43
28314539	C0205082	Severe (severity modifier)	qlco	3.43
28314539	C4050465	Severe Extremity Pain	inpr	3.43
28314539	C0819757	Structure of parenchyma of lung	tisu	3.43
28314539	C1705187	Safety Study	resa	3.42
28314539	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	13.09
28314539	C0392164	Pulmonary Cystic Fibrosis	dsyn	9.83
28314539	C2939193	Median (qualifier value)	spco	5.18
28314539	C0876920	Median Statistical Measurement	qnco	5.18
28314539	C0549183	Midline (qualifier value)	spco	5.18
28314539	C2347635	Population Median	qnco	5.18
28314539	C3273238	Regulatory Report	inpr	5.18
28314539	C0684224	Report (document)	inpr	5.18
28314539	C0700287	Reporting	hlca	5.18
28314539	C2348144	Sample Median	qnco	5.18
28314539	C1836348	Severe disorder	fndg	3.74
28314539	C0450355	31	inpr	3.68
28314539	C1054142	Iva <Plant>	plnt	3.63
28314539	C3242038	patient adverse event	inpr	3.54
28314539	C1416936	LUM gene	gngm	3.48
28314539	C0278329	prescribed	hlca	3.48
28314539	C0439568	Post-dose	tmco	3.43
28314539	C0205253	Immediate	tmco	3.42
28314539	C0445223	Related personal status	fndg	3.42
28314539	C0439849	Relationships	qlco	3.42
28314539	C1546767	Specimen Source Codes - Respiratory	inpr	3.42
28314539	C0205548	Stat (do immediately)	tmco	3.42
28314539	C0521346	respiratory	ftcn	3.42
28314539	C0023376	Lesotho	geoa	16.30
28314539	C0168634	BaseLine dental cement	bodm	12.93
28314539	C0030705	Patients	podg	8.34
28314539	C3842591	0%	fndg	5.18
28314539	C2939193	Median (qualifier value)	spco	5.18
28314539	C0876920	Median Statistical Measurement	qnco	5.18
28314539	C0549183	Midline (qualifier value)	spco	5.18
28314539	C2347635	Population Median	qnco	5.18
28314539	C2348144	Sample Median	qnco	5.18
28314539	C0596545	Experience	menp	3.98
28314539	C0237607	Practice Experience	menp	3.98
28314539	C0443172	Changed status	qnco	3.68
28314539	C0392747	Changing	ftcn	3.68
28314539	C1705241	Delta (difference)	qnco	3.68
28314539	C3887647	Lymphotoxin-Alpha, human	aapp	3.68
28314539	C3887647	Lymphotoxin-Alpha, human	imft	3.68
28314539	C0230426	Structure of left thigh	bpoc	3.68
28314539	C0439227	Hour	tmco	3.61
28314539	C1547039	*Relative	qnco	3.50
28314539	C0369773	P Blood group antibodies	aapp	3.50
28314539	C0369773	P Blood group antibodies	imft	3.50
28314539	C2603361	P prime	clna	3.50
28314539	C0205345	Relative	qlco	3.50
28314539	C0080103	Relative (related person)	famg	3.50
28314539	C1442488	Baseline	qnco	3.47
28314539	C0030705	Patients	podg	6.70
28314539	C1442770	24 Hours	tmco	3.64
28314539	C0439584	24 hour time frame	tmco	3.64
28314539	C0456696	per 24 hours	tmco	3.64
28314539	C0332177	Monthly (qualifier value)	tmco	3.55
28314539	C0521108	Recovering from	qlco	3.55
28314539	C0439231	month	tmco	3.55
28314539	C0439507	per month (qualifier value)	tmco	3.55
28314539	C0332152	Before	tmco	5.18
28314539	C0740175	Before values	qlco	5.18
28314539	C1441672	Observed	ftcn	5.18
28314539	C3669034	Pure Spanish horse breed (organism)	mamm	5.18
28314539	C2257086	photoreactivating enzyme activity	genf	5.18
28314539	C1705241	Delta (difference)	qnco	3.53
28314539	C1705242	Different	qlco	3.53
28314539	C2599594	post bronchodilator	tmco	3.46
28314539	C1704632	Disease Response	fndg	3.43
28314539	C2911692	Response (communication)	menp	3.43
28314539	C1706817	Response (statement)	inpr	3.43
28314539	C0871261	Response process	orga	3.43
28314539	C0014518	Toxic Epidermal Necrolysis	dsyn	16.30
28314539	C0205456	Ten	qnco	3.68
28314539	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	12.88
28314539	C0030705	Patients	podg	8.34
28314539	C0684224	Report (document)	inpr	5.18
28314539	C0700287	Reporting	hlca	5.18
28314539	C1519275	Grade 3 Severe Adverse Event	fndg	3.55
28314539	C2919019	Severe Adverse Event - CTCAE v4 Grade 3	fndg	3.55
28314539	C1442770	24 Hours	tmco	3.42
28314539	C0439584	24 hour time frame	tmco	3.42
28314539	C0456696	per 24 hours	tmco	3.42
28314539	C0589507	Cognitive function: initiation	menp	3.42
28314539	C1704686	Initiation	ftcn	3.42
28314539	C1054142	Iva <Plant>	plnt	3.42
28314539	C1416936	LUM gene	gngm	3.42
28314539	C1518422	Negation	ftcn	3.42
28314539	C0445223	Related personal status	fndg	3.42
28314539	C0439849	Relationships	qlco	3.42
28314539	C1546767	Specimen Source Codes - Respiratory	inpr	3.42
28314539	C1158830	Transcription Initiation	genf	3.42
28314539	C0521346	respiratory	ftcn	3.42
28314539	C0030705	Patients	podg	8.34
28314539	C0024109	Lung	bpoc	6.71
28314539	C3842586	50%	fndg	5.18
28314539	C3843766	<50	fndg	5.18
28314539	C0205454	Eight	qnco	5.18
28314539	C0205452	Six	qnco	5.18
28314539	C1457887	Symptoms	sosy	3.68
28314539	C0683368	Symptoms aspect	ftcn	3.68
28314539	C0332177	Monthly (qualifier value)	tmco	3.61
28314539	C0439231	month	tmco	3.61
28314539	C0439507	per month (qualifier value)	tmco	3.61
28314539	C2709248	Pulmonary (qualifier value)	qlco	3.56
28314539	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.56
28314539	C1522326	Treating	ftcn	3.56
28314539	C0205322	persistent	tmco	3.50
28314539	C0023376	Lesotho	geoa	16.30
28314539	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	12.92
28314539	C0030705	Patients	podg	6.60
28314539	C0439509	/40	tmco	5.18
28314539	C3842587	40%	qnco	5.18
28314539	C2825142	Experimental Result	fndg	3.98
28314539	C1274040	Result	ftcn	3.98
28314539	C1546471	What subject filter - Result	idcn	3.98
28314539	C3887647	Lymphotoxin-Alpha, human	aapp	3.68
28314539	C3887647	Lymphotoxin-Alpha, human	imft	3.68
28314539	C0230426	Structure of left thigh	bpoc	3.68
28314539	C1705413	Adverse Event Domain	inpr	3.63
28314539	C0877248	Adverse event	patf	3.63
28314539	C0205214	Common (qualifier value)	qnco	3.59
28314539	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.59
28314539	C1522138	shared attribute	ftcn	3.59
28314539	C1054142	Iva <Plant>	plnt	3.46
28314539	C1416936	LUM gene	gngm	3.46
28314539	C0445223	Related personal status	fndg	3.46
28314539	C0439849	Relationships	qlco	3.46
28314539	C1546767	Specimen Source Codes - Respiratory	inpr	3.46
28314539	C0521346	respiratory	ftcn	3.46
28314539	C0034866	Recommendation	idcn	5.18
28314539	C1516048	Assessed	acty	3.56
28314539	C1261322	Evaluation procedure	hlca	3.56
28314539	C1705413	Adverse Event Domain	inpr	3.46
28314539	C0877248	Adverse event	patf	3.46
28314539	C3810854	Close	fndg	3.43
28314539	C0587267	Closed	ftcn	3.43
28314539	C0040363	Togo	geoa	17.80
28314539	C0041260	Tryptophanase	aapp	17.80
28314539	C0041260	Tryptophanase	enzy	17.80
28314539	C0220825	Evaluation	hlca	14.64
28314539	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	12.89
28314539	C0030705	Patients	podg	6.71
28314539	C0024115	Lung diseases	dsyn	6.60
28314539	C0024109	Lung	bpoc	6.58
28314539	C1514873	Requirement	ftcn	5.18
28314539	C1883351	To	qlco	5.18
28314539	C0947630	Scientific Study	lbpr	3.63
28314539	C1280519	Effectiveness	qlco	3.56
28314539	C1707887	Efficacy Study	resa	3.56
28314539	C1517331	Further	spco	3.48
28314539	C1836348	Severe disorder	fndg	3.45
28314539	C1054142	Iva <Plant>	plnt	3.43
28314539	C1416936	LUM gene	gngm	3.43
28314539	C4050466	Borg Category-Ratio 10 Perceived Exertion Score 5	inpr	3.43
28314539	C1278908	Entire lung	bpoc	3.43
28314539	C0205082	Severe (severity modifier)	qlco	3.43
28314539	C4050465	Severe Extremity Pain	inpr	3.43
28314539	C0819757	Structure of parenchyma of lung	tisu	3.43
28529073	C0040363	Togo	geoa	17.80
28529073	C0041260	Tryptophanase	aapp	17.80
28529073	C0041260	Tryptophanase	enzy	17.80
28529073	C4033633	ivacaftor / lumacaftor	phsu	13.04
28529073	C0205263	Induce (action)	ftcn	5.18
28529073	C0684224	Report (document)	inpr	5.18
28529073	C0700287	Reporting	hlca	5.18
28529073	C1883351	To	qlco	5.18
28529073	C0205195	Combined	qlco	3.55
28529073	C3811910	combination - answer to question	fndg	3.55
28529073	C1947911	combination of objects	phob	3.55
28529073	C4048603	Drop - Unit of Volume	qnco	3.55
28529073	C2348338	Drop British	qnco	3.55
28529073	C1321095	Drop measurement	qnco	3.55
28529073	C1705648	Dropping	acty	3.55
28529073	C2347093	Medical Drop	qnco	3.55
28529073	C0205344	Absolute	qlco	3.42
28529073	C2347634	Population Mean	qnco	3.42
28529073	C2348143	Sample Mean	qnco	3.42
28529073	C0444504	Statistical mean	qnco	3.42
28529073	C0205178	acute	tmco	3.42
28529073	C0016529	Forced expiratory volume function	ortf	19.37
28529073	C1708335	Healthy Volunteers	popg	9.75
28529073	C1306036	Forced expiratory volume procedure	diap	3.60
28529073	C0001554	Administration occupational activities	ocac	3.55
28529073	C1533734	Administration procedure	topp	3.55
28529073	C1710548	Unique	qlco	3.42
28529073	C1882327	Percent of Predicted Value	qnco	3.42
28529073	C1552115	Supernumerary maxillary right third molar	bpoc	3.42
28529073	C0681842	prediction	idcn	3.42
28529073	C0040363	Togo	geoa	17.80
28529073	C0041260	Tryptophanase	aapp	17.80
28529073	C0041260	Tryptophanase	enzy	17.80
28529073	C0009738	Congo	geoa	16.12
28529073	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	13.01
28529073	C0030705	Patients	podg	6.83
28529073	C1516048	Assessed	acty	5.18
28529073	C1883351	To	qlco	5.18
28529073	C1561566	FEV1 Adverse Event	fndg	3.68
28529073	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.68
28529073	C1707811	Dose Modification	resa	3.56
28529073	C2948600	Aim	phsu	3.55
28529073	C1947946	Aim (idea)	idcn	3.55
28529073	C3540472	Ancestry-Informative Marker	ftcn	3.55
28529073	C3890193	CD5L wt Allele	gngm	3.55
28529073	C2744535	CD69 protein, human	aapp	3.55
28529073	C2744535	CD69 protein, human	imft	3.55
28529073	C3540471	CD69 wt Allele	gngm	3.55
28529073	C0205435	First (number)	qnco	3.54
28529073	C1279901	Firstly	qlco	3.54
28529073	C1054142	Iva <Plant>	plnt	3.54
28529073	C1416936	LUM gene	gngm	3.54
28529073	C3811819	CFTR wt Allele	gngm	3.50
28529073	C0205178	acute	tmco	3.50
28529073	C0150312	Present	qnco	3.43
28529073	C0449450	Presentation	idcn	3.43
28529073	C0557651	Room of building - Study	mnob	3.43
28529073	C2603343	Study	resa	3.43
28529073	C0030755	Pediatrics	bmod	9.74
28529073	C0030705	Patients	podg	6.58
28529073	C0332257	Including (qualifier)	ftcn	5.18
28529073	C0439175	% of total	qnco	3.55
28529073	C0439810	Total	qlco	3.55
28529073	C1521725	Pediatric	qlco	3.43
28529073	C0030705	Patients	podg	6.71
28529073	C0205319	Manifest	ftcn	3.63
28529073	C1280464	Manifestation of	qlco	3.63
28529073	C1709305	Occur (action)	acty	3.56
28529073	C1720467	Only - dosing instruction fragment	inpr	3.56
28529073	C0205171	Singular	qnco	3.56
28529073	C1546767	Specimen Source Codes - Respiratory	inpr	3.48
28529073	C0521346	respiratory	ftcn	3.48
28529073	C3842590	10%	fndg	5.18
28529073	C0205216	Decreased	qnco	5.18
28529073	C0442797	Decreasing	qlco	5.18
28529073	C1561566	FEV1 Adverse Event	fndg	5.18
28529073	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	5.18
28529073	C0392756	Reduced	qlco	5.18
28529073	C3816745	1+	fndg	5.18
28529073	C2827734	1+ Score	qnco	5.18
28529073	C2981698	1+ Score, WHO	clas	5.18
28529073	C3542016	Concept model range (foundation metadata concept)	inpr	5.18
28529073	C1514721	Range	qnco	5.18
28529073	C2348147	Sample Range	qnco	5.18
28529073	C0004048	Inspiration function	orgf	19.34
28529073	C0001927	Albuterol	orch	16.18
28529073	C0001927	Albuterol	phsu	16.18
28529073	C1561566	FEV1 Adverse Event	fndg	3.63
28529073	C0429706	Forced expiratory volume in 1 second finding	fndg	3.63
28529073	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.63
28529073	C1705211	Inhalation Dosing Unit	qnco	3.57
28529073	C0205535	Inhalation Route of Drug Administration	ftcn	3.57
28529073	C1880201	Curriculum Vitae	inpr	3.54
28529073	C1550028	Resume - Remote control command	idcn	3.54
28529073	C3242342	resume - DataOperation	ftcn	3.54
28529073	C1720467	Only - dosing instruction fragment	inpr	3.48
28529073	C0205171	Singular	qnco	3.48
28529073	C0001883	Airway Obstruction	dsyn	12.90
28529073	C1137094	Risk Reduction	inbe	9.89
28529073	C1561566	FEV1 Adverse Event	fndg	7.26
28529073	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	7.26
28529073	C0030705	Patients	podg	6.70
28529073	C0429706	Forced expiratory volume in 1 second finding	fndg	3.55
28529073	C0205172	More	ftcn	3.55
28529073	C3890211	Low Mitosis-Karyorrhexis Index	qnco	3.50
28529073	C0205251	low	qlco	3.50
28529073	C1550472	low confidentiality	inpr	3.50
28529073	C4048187	low exposure	qlco	3.50
28529073	C1546944	Event Seriousness - Significant	qlco	3.42
28529073	C0205309	Known	qlco	3.42
28529073	C0205343	Reversible	ftcn	3.42
28529073	C0750502	Significant	idcn	3.42
28529073	C0237881	Statistical Significance	qnco	3.42
24429096	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.42
24429096	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.42
24429096	C0008203	Chlorides	inch	16.30
24429096	C0033626	Protein Deficiency	dsyn	16.18
24429096	C0035820	Social Role	socb	13.00
24429096	C0010674	Cystic Fibrosis	dsyn	10.06
24429096	C0031847	physiopathological	ftcn	9.90
24429096	C0015127	Etiology aspects	ftcn	9.86
24429096	C0019868	Homeostasis	biof	9.73
24429096	C0024109	Lung	bpoc	8.34
24429096	C0024501	Maintenance	acty	6.55
24429096	C0439799	Channel	spco	5.18
24429096	C1706095	Channel Object	cnce	5.18
24429096	C0596019	Chloride Ion	elii	3.68
24429096	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.59
24429096	C3887504	Dysfunction	cnce	3.59
24429096	C0277785	Functional disorder	patf	3.59
24429096	C1524003	Science of Etiology	cnce	3.55
24429096	C1705810	Generic Role	cnce	3.54
24429096	C3871154	{Role}	inpr	3.54
24429096	C0221908	epithelial	qlco	3.50
24429096	C1413365	CFTR gene	gngm	3.49
24429096	C0872086	surface coating	bodm	3.43
24429096	C0458827	Airway structure	bpoc	3.42
24429096	C0178987	Artificial Airways	medd	3.42
24429096	C1304698	Liquid (finding)	fndg	3.42
24429096	C1546699	Liquid NOS - Specimen Source Codes	inpr	3.42
24429096	C1561501	Liquid Specimen	sbst	3.42
24429096	C0301571	Liquid diet	topp	3.42
24429096	C0302908	Liquid substance	sbst	3.42
24429096	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.08
24429096	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.08
24429096	C0031843	physiological aspects	phsf	14.64
24429096	C0026882	Mutation	genf	9.86
24429096	C0031437	Phenotype	orga	6.71
24429096	C1550043	Container status - Identified	fndg	5.18
24429096	C0542341	Function	ftcn	5.18
24429096	C0700205	Function Axis	clas	5.18
24429096	C0205396	Identified	qlco	5.18
24429096	C1705273	Mathematical Operator	inpr	5.18
24429096	C2347098	Medical Product Stability	qlco	5.18
24429096	C0205360	Stable status	qlco	5.18
24429096	C0599896	trafficking	celf	5.18
24429096	C3542417	CDISC SDTM Disease Outcome Terminology	inpr	3.60
24429096	C0679250	Disease Outcome	fndg	3.60
24429096	C0456387	Class	inpr	3.59
24429096	C1705943	Class (taxonomic)	clas	3.59
24429096	C4019422	Classes - encounter	hlca	3.59
24429096	C0439745	Grouped	spco	3.59
24429096	C1285572	Phenotype determination	lbpr	3.56
24429096	C1413365	CFTR gene	gngm	3.55
24429096	C1280500	Effect	qlco	3.54
24429096	C2348382	Effect, Appearance	qlco	3.54
24429096	C0681749	1900s	tmco	3.52
24429096	C1874451	Basis	phsu	3.42
24429096	C1527178	Basis - conceptual entity	ftcn	3.42
24429096	C0033268	production	ocac	3.42
24429096	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
24429096	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
24429096	C0008976	Clinical Trials	resa	19.52
24429096	C0023175	Lead	elii	13.02
24429096	C0023175	Lead	hops	13.02
24429096	C0031843	physiological aspects	phsf	12.89
24429096	C1096775	Clinical Trial [Publication Type]	inpr	10.06
24429096	C0010674	Cystic Fibrosis	dsyn	9.77
24429096	C1547282	Show	anim	3.98
24429096	C0439234	year	tmco	3.63
24429096	C3275067	Cardiac Lead Procedure	topp	3.56
24429096	C0205210	Clinical	qlco	3.56
24429096	C1947976	Correction (change)	ftcn	3.56
24429096	C1705565	Correction Report	inpr	3.56
24429096	C2348269	Dietary Lead	elii	3.56
24429096	C1522538	Leading	ftcn	3.56
24429096	C0181586	Leads (device)	medd	3.56
24429096	C1553058	Neuropsychologist - Clinical	prog	3.56
24429096	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.56
24429096	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.56
24429096	C0237412	Psychologist - Clinical	prog	3.56
24429096	C0497591	Social Worker - Clinical	prog	3.56
24429096	C0814225	benefit	qnco	3.56
24429096	C0237401	Individual	humn	3.53
24429096	C0027361	Persons	popg	3.53
24429096	C1444637	Past	tmco	3.48
24429096	C1413365	CFTR gene	gngm	3.43
24429096	C0542341	Function	ftcn	3.43
24429096	C0700205	Function Axis	clas	3.43
24429096	C1705273	Mathematical Operator	inpr	3.43
24429096	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
24429096	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
24429096	C0010674	Cystic Fibrosis	dsyn	9.87
24429096	C0026882	Mutation	genf	9.87
24429096	C0015127	Etiology aspects	ftcn	9.84
24429096	C3539655	CDISC Findings Class	inpr	5.18
24429096	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
24429096	C2607943	findings aspects	ftcn	5.18
24429096	C1457869	Defect	ftcn	3.63
24429096	C2349182	Correct (qualifier)	qlco	3.59
24429096	C0684000	class differences	fndg	3.56
24429096	C1705285	Mutation Abnormality	comd	3.56
24429096	C2983265	CDISC SEND Study Design Terminology	inpr	3.55
24429096	C1707689	Design	acty	3.55
24429096	C3495919	Enthesitis-Related Arthritis	dsyn	3.54
24429096	C0205314	New	qlco	3.54
24429096	C0087111	Therapeutic procedure	topp	3.54
24429096	C1524003	Science of Etiology	cnce	3.53
24429096	C1413365	CFTR gene	gngm	3.48
24429096	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
24429096	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
24429096	C0039798	therapeutic aspects	ftcn	22.48
24429096	C0008976	Clinical Trials	resa	19.18
24429096	C0040363	Togo	geoa	17.80
24429096	C0041260	Tryptophanase	aapp	17.80
24429096	C0041260	Tryptophanase	enzy	17.80
24429096	C1524024	analysis aspect	ftcn	13.02
24429096	C0026882	Mutation	genf	9.81
24429096	C0030705	Patients	podg	6.59
24429096	C1516048	Assessed	acty	5.18
24429096	C0449788	Count of entities	qnco	5.18
24429096	C0237753	Numbers	qnco	5.18
24429096	C0332148	Probable diagnosis	qlco	5.18
24429096	C0750492	Probably	idcn	5.18
24429096	C1883351	To	qlco	5.18
24429096	C0920631	patient registry	inpr	3.75
24429096	C0332307	Type - attribute	qlco	3.68
24429096	C0681686	geographic distribution	tmco	3.58
24429096	C1533734	Administration procedure	topp	3.56
24429096	C0936012	Analysis	resa	3.56
24429096	C0002778	Analysis of substances	lbpr	3.56
24429096	C1705169	Biomaterial Treatment	cnce	3.56
24429096	C1413365	CFTR gene	gngm	3.56
24429096	C0087111	Therapeutic procedure	topp	3.56
24429096	C1522326	Treating	ftcn	3.56
24429096	C3538994	Treatment Epoch	resa	3.56
24429096	C0814225	benefit	qnco	3.56
24429096	C3887704	treatment - ActInformationManagementReason	hlca	3.56
24429096	C2349182	Correct (qualifier)	qlco	3.53
24429096	C1705285	Mutation Abnormality	comd	3.50
24429096	C0470187	Availability of	ftcn	3.48
24429096	C0549178	Continuous	idcn	3.43
26903594	C0376558	Life	idcn	11.49
26903594	C0010674	Cystic Fibrosis	dsyn	10.06
26903594	C0019247	Hereditary Diseases	dsyn	8.34
26903594	C0392760	Affecting	ftcn	5.18
26903594	C1314939	Involvement with	ftcn	5.18
26903594	C0441636	Surgical shortening - action	topp	5.18
26903594	C0237401	Individual	humn	3.57
26903594	C0027361	Persons	popg	3.57
26903594	C3842584	70%	fndg	3.46
26903594	C0332232	Approximate	qlco	3.46
26903594	C0009738	Congo	geoa	32.38
26903594	C0031843	physiological aspects	phsf	13.00
26903594	C0005532	biology (field)	bmod	9.86
26903594	C0021699	Integral Membrane Proteins	aapp	9.74
26903594	C3811819	CFTR wt Allele	gngm	6.99
26903594	C0332185	Recent	tmco	5.18
26903594	C1457887	Symptoms	sosy	5.18
26903594	C0683368	Symptoms aspect	ftcn	5.18
26903594	C1522326	Treating	ftcn	5.18
26903594	C0220912	Aspects of signs	ftcn	3.68
26903594	C0220913	Manufactured sign	mnob	3.68
26903594	C0311392	Physical findings	fndg	3.68
26903594	C0087111	Therapeutic procedure	topp	3.68
26903594	C0015264	Exertion	orgf	3.59
26903594	C1527118	Protein Function	moft	3.56
26903594	C0815043	Protein, Organized by Function	aapp	3.56
26903594	C1457869	Defect	ftcn	3.55
26903594	C0678226	Due to	ftcn	3.55
26903594	C0205460	biological	qlco	3.55
26903594	C0542341	Function	ftcn	3.54
26903594	C0700205	Function Axis	clas	3.54
26903594	C1705273	Mathematical Operator	inpr	3.54
26903594	C0872152	drug development	bmod	3.53
26903594	C0522506	Downstream	spco	3.50
26903594	C0392756	Reduced	qlco	3.42
26903594	C1704735	Regulator	cnce	3.42
26903594	C1704734	Regulator Device Component	mnob	3.42
26903594	C0182953	Regulators (device)	medd	3.42
26903594	C2752508	fully spanning the plasma membrane	celc	3.42
26903594	C1167322	integral to membrane	celc	3.42
26903594	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	117.56
26903594	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	117.56
26903594	C0031843	physiological aspects	phsf	26.22
26903594	C0040363	Togo	geoa	17.80
26903594	C0041260	Tryptophanase	aapp	17.80
26903594	C0041260	Tryptophanase	enzy	17.80
26903594	C0009738	Congo	geoa	16.08
26903594	C1413365	CFTR gene	gngm	10.50
26903594	C1564139	Mutant Proteins	aapp	9.75
26903594	C0542341	Function	ftcn	7.18
26903594	C0700205	Function Axis	clas	7.18
26903594	C1705273	Mathematical Operator	inpr	7.18
26903594	C0007634	Cells	cell	5.18
26903594	C3282337	Cells [Chemical/Ingredient]	cell	5.18
26903594	C3844638	Either	fndg	5.18
26903594	C2349975	Enhance (action)	acty	5.18
26903594	C0205229	Expanding	spco	5.18
26903594	C2700399	Include (action)	acty	5.18
26903594	C0332257	Including (qualifier)	ftcn	5.18
26903594	C0442808	Increasing	ftcn	5.18
26903594	C0443264	Modulated	spco	5.18
26903594	C0087111	Therapeutic procedure	topp	5.18
26903594	C1883351	To	qlco	5.18
26903594	C1552866	include - SetOperator	idcn	5.18
26903594	C1171362	protein expression	genf	3.65
26903594	C3854321	Expression (foundation metadata concept)	idcn	3.60
26903594	C0185117	Expression procedure	topp	3.60
26903594	C0870781	Landscapes	spco	3.60
26903594	C0815043	Protein, Organized by Function	aapp	3.58
26903594	C1883559	Wild Type	gngm	3.49
26903594	C0872152	drug development	bmod	3.49
26903594	C3811819	CFTR wt Allele	gngm	3.46
26903594	C0521116	Current (present time)	tmco	3.46
26903594	C1705970	Electrical Current	npop	3.46
26903594	C0596988	mutant	comd	3.43
26903594	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.03
26903594	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.03
26903594	C2348077	Date Fruit	food	27.26
26903594	C0008976	Clinical Trials	resa	19.38
26903594	C0009738	Congo	geoa	16.05
26903594	C0220825	Evaluation	hlca	13.02
26903594	C1096775	Clinical Trial [Publication Type]	inpr	9.92
26903594	C1413365	CFTR gene	gngm	6.96
26903594	C0017431	Genotype	orga	6.77
26903594	C2346845	Approval (document)	inpr	5.18
26903594	C0205540	Approved	qlco	5.18
26903594	C0011008	Date in time	tmco	5.18
26903594	C2697909	Letter of Authorization	rnlw	5.18
26903594	C3242240	regulatory review	idcn	3.64
26903594	C1708698	Light Emitting Diode Device Component	mnob	3.57
26903594	C1709060	Modulator Device Component	mnob	3.56
26903594	C0237401	Individual	humn	3.54
26903594	C0027361	Persons	popg	3.54
26903594	C2947019	Pivot	food	3.50
26903594	C1709557	Pivot Device Component	medd	3.50
26903594	C1328819	Small Molecule	orch	3.48
26903594	C1552740	Entity Determiner - specific	inpr	3.47
26903594	C0205369	Specific qualifier value	qlco	3.47
26903594	C0596988	mutant	comd	3.47
26903594	C0205373	Systemic	ftcn	3.46
26903594	C0205448	Two	qnco	3.46
26903594	C3811819	CFTR wt Allele	gngm	3.44
26903594	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26903594	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26903594	C0040363	Togo	geoa	17.80
26903594	C0041260	Tryptophanase	aapp	17.80
26903594	C0041260	Tryptophanase	enzy	17.80
26903594	C0009738	Congo	geoa	16.03
26903594	C0012634	Disease	dsyn	9.73
26903594	C0043227	Work	ocac	8.34
26903594	C1709060	Modulator Device Component	mnob	6.94
26903594	C0017431	Genotype	orga	6.57
26903594	C1883351	To	qlco	5.18
26903594	C1998467	Impression	qlco	3.82
26903594	C4049863	Radiologic Impression	fndg	3.82
26903594	C0596764	impression (attitude)	inbe	3.82
26903594	C0456387	Class	inpr	3.55
26903594	C1705943	Class (taxonomic)	clas	3.55
26903594	C3854260	Advance	tmco	3.51
26903594	C0725066	Advance -- medical device	medd	3.51
26903594	C3242274	new therapy	fndg	3.43
26903594	C1413365	CFTR gene	gngm	3.42
26903594	C1880355	Discover	acty	3.42
26903594	C3811819	CFTR wt Allele	gngm	3.42
26903594	C1704419	Effective	qlco	3.42
26903594	C1280519	Effectiveness	qlco	3.42
26903594	C0205250	High	qlco	3.42
26903594	C1555307	promise	idcn	3.40
26903594	C0392747	Changing	ftcn	3.40
26903594	C0237401	Individual	humn	3.40
26903594	C0027361	Persons	popg	3.40
26903594	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.07
26903594	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.07
26903594	C0040363	Togo	geoa	17.80
26903594	C0041260	Tryptophanase	aapp	17.80
26903594	C0041260	Tryptophanase	enzy	17.80
26903594	C0001593	Adoption	socb	16.16
26903594	C0017431	Genotype	orga	13.48
26903594	C2936643	Standard of Care	topp	13.23
26903594	C0018017	objective (goal)	inpr	9.87
26903594	C0282443	Review [Publication Type]	inpr	9.74
26903594	C1552740	Entity Determiner - specific	inpr	7.13
26903594	C0205369	Specific qualifier value	qlco	7.13
26903594	C1709060	Modulator Device Component	mnob	7.07
26903594	C1413365	CFTR gene	gngm	7.00
26903594	C2983265	CDISC SEND Study Design Terminology	inpr	5.18
26903594	C0805586	Challenge	hlca	5.18
26903594	C1707689	Design	acty	5.18
26903594	C1883351	To	qlco	5.18
26903594	C0678723	Biologic Development	orgf	3.63
26903594	C1527148	Development	ftcn	3.63
26903594	C0243107	development aspects	phsf	3.63
26903594	C1707531	Created By	qlco	3.58
26903594	C1513396	Molecular Marker Activity	phsf	3.57
26903594	C1518601	Options	ftcn	3.55
26903594	C0205373	Systemic	ftcn	3.55
26903594	C0205540	Approved	qlco	3.54
26903594	C2363430	Early stage	tmco	3.53
26903594	C1517886	Limited stage (cancer stage)	clas	3.53
26903594	C0872152	drug development	bmod	3.48
26903594	C1879951	CDISC SDTM Trial Phase Terminology	inpr	3.47
26903594	C1710475	Trial Phase	clas	3.47
26903594	C0428295	Cystic fibrosis sweat test	lbpr	3.46
26903594	C1304760	Sweat chloride level result	lbtr	3.46
26903594	C1552617	Act Class - review	idcn	3.43
26903594	C0205087	Late	tmco	3.43
26903594	C1272684	Accepted	qlco	3.42
26903594	C0443211	Established	qlco	3.42
26903594	C0009738	Congo	geoa	17.80
26903594	C0040363	Togo	geoa	17.80
26903594	C0041260	Tryptophanase	aapp	17.80
26903594	C0041260	Tryptophanase	enzy	17.80
26903594	C0027552	Needs	qlco	14.64
26903594	C0678723	Biologic Development	orgf	6.93
26903594	C1527148	Development	ftcn	6.93
26903594	C0243107	development aspects	phsf	6.93
26903594	C0013216	Pharmacotherapy	topp	6.71
26903594	C3811819	CFTR wt Allele	gngm	5.18
26903594	C1874964	DELIVER (Dietary Supplement)	phsu	5.18
26903594	C0308779	DELIVER (veterinary product)	orch	5.18
26903594	C0308779	DELIVER (veterinary product)	phsu	5.18
26903594	C0578671	Does move	fndg	5.18
26903594	C1269909	Moved from	ftcn	5.18
26903594	C1299988	Moved to	ftcn	5.18
26903594	C0560560	Moving	orgf	5.18
26903594	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
26903594	C2699029	Relocation of home or business	acty	5.18
26903594	C1883351	To	qlco	5.18
26903594	C1705822	Transfer Technique	ftcn	5.18
26903594	C1280519	Effectiveness	qlco	3.82
26903594	C1707887	Efficacy Study	resa	3.82
26903594	C0204525	Individual psychotherapy	topp	3.58
26903594	C2698651	Optimum	qlco	3.48
26903594	C0205393	Most	qnco	3.42
26903594	C1555307	promise	idcn	3.40
25467948	C0087113	Treatment Effectiveness	qlco	19.36
25467948	C0030705	Patients	podg	6.71
25467948	C1292721	Has property	ftcn	3.68
25467948	C0871161	Property (attribute)	qlco	3.68
25467948	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.56
25467948	C1552740	Entity Determiner - specific	inpr	3.56
25467948	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.56
25467948	C0201734	Pharmacokinetic study	resa	3.56
25467948	C0205369	Specific qualifier value	qlco	3.56
25467948	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.56
25467948	C0725813	depend	medd	3.56
25467948	C1280519	Effectiveness	qlco	3.53
25467948	C1707887	Efficacy Study	resa	3.53
25467948	C1709518	Pharmacodynamic Study	resa	3.50
25467948	C0851347	Pharmacodynamics	biof	3.50
25467948	C3469597	Administration of medication	hlca	3.46
25467948	C3687832	DRUGS	topp	3.43
25467948	C0013227	Pharmaceutical Preparations	phsu	3.43
25467948	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25467948	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25467948	C0040363	Togo	geoa	17.80
25467948	C0041260	Tryptophanase	aapp	17.80
25467948	C0041260	Tryptophanase	enzy	17.80
25467948	C0011135	Defecation	orgf	13.04
25467948	C0032105	Plasma	bdsu	13.02
25467948	C0005507	Biological Assay	lbpr	8.34
25467948	C0079809	Measures	qnco	8.34
25467948	C2741958	VX-770	orch	7.06
25467948	C0029250	Organoids	tisu	6.58
25467948	C1510438	Assay	lbpr	5.18
25467948	C0205263	Induce (action)	ftcn	5.18
25467948	C0242485	Measurement	ftcn	5.18
25467948	C1441672	Observed	ftcn	5.18
25467948	C1883351	To	qlco	5.18
25467948	C0243073	assay qualifier	qlco	5.18
25467948	C0544357	human plasma	phsu	5.18
25467948	C0013018	Donor person	popg	3.68
25467948	C1527169	Encounter due to being a donor	fndg	3.68
25467948	C1550098	Plasma, NOS (not otherwise specified)	bdsu	3.56
25467948	C0441889	Levels (qualifier value)	qlco	3.54
25467948	C1705242	Different	qlco	3.50
25467948	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.44
25467948	C1413365	CFTR gene	gngm	3.43
25467948	C0439828	Variable (uniformity)	qlco	3.43
25467948	C0542341	Function	ftcn	3.42
25467948	C0205245	Functional	ftcn	3.42
25467948	C2700217	Functional Relationship	cnce	3.42
25467948	C0031328	Pharmacokinetic aspects	ftcn	19.45
25467948	C0040363	Togo	geoa	17.80
25467948	C0041260	Tryptophanase	aapp	17.80
25467948	C0041260	Tryptophanase	enzy	17.80
25467948	C0162340	Comprehension	menp	14.64
25467948	C0031327	Drug Kinetics	phsf	9.99
25467948	C0005507	Biological Assay	lbpr	8.34
25467948	C1510438	Assay	lbpr	5.18
25467948	C1269765	Assisted (qualifier value)	qlco	5.18
25467948	C1552861	Help document	inpr	5.18
25467948	C1883351	To	qlco	5.18
25467948	C0243073	assay qualifier	qlco	5.18
25467948	C0870071	modeling	resa	5.18
25467948	C0521982	Response to treatment	clna	3.60
25467948	C0237401	Individual	humn	3.50
25467948	C0027361	Persons	popg	3.50
25467948	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.43
25467948	C2827666	Variability	cnce	3.42
27475293	C0039798	therapeutic aspects	ftcn	22.48
27475293	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
27475293	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
27475293	C0009738	Congo	geoa	17.80
27475293	C0022326	Ivory Coast	geoa	16.09
27475293	C0026882	Mutation	genf	9.94
27475293	C0012634	Disease	dsyn	9.73
27475293	C0034037	Publishing	ocac	6.71
27475293	C0376554	Knowledge	inpr	6.70
27475293	C3811819	CFTR wt Allele	gngm	5.18
27475293	C0205229	Expanding	spco	5.18
27475293	C1705160	III (suffix)	qlco	5.18
27475293	C0332257	Including (qualifier)	ftcn	5.18
27475293	C0439070	Roman Numeral III	inpr	5.18
27475293	C0947630	Scientific Study	lbpr	3.68
27475293	C1704324	Scientific Publication	inpr	3.56
27475293	C0439508	per year	tmco	3.56
27475293	C0439234	year	tmco	3.56
27475293	C1533734	Administration procedure	topp	3.55
27475293	C1705169	Biomaterial Treatment	cnce	3.55
27475293	C0087111	Therapeutic procedure	topp	3.55
27475293	C1522326	Treating	ftcn	3.55
27475293	C3538994	Treatment Epoch	resa	3.55
27475293	C3887704	treatment - ActInformationManagementReason	hlca	3.55
27475293	C3273238	Regulatory Report	inpr	3.54
27475293	C0684224	Report (document)	inpr	3.54
27475293	C0700287	Reporting	hlca	3.54
27475293	C1413365	CFTR gene	gngm	3.48
27475293	C2698968	Canadian Cardiovascular Society Grading Scale Class II	fndg	3.45
27475293	C0441886	Class 2	inpr	3.45
27475293	C0017296	gene therapy	topp	3.44
27475293	C3245505	potential	qlco	3.42
27475293	C0205435	First (number)	qnco	3.42
27475293	C1279901	Firstly	qlco	3.42
27475293	C0450442	Agent	chvf	3.40
27475293	C0392747	Changing	ftcn	3.40
27475293	C1254351	Pharmacologic Substance	phsu	3.40
27475293	C1521826	Protocol Agent	inpr	3.40
27475293	C1280519	Effectiveness	qlco	3.38
27475293	C1707887	Efficacy Study	resa	3.38
27475293	C1547996	Diagnostic Service Section ID - Pulmonary Function	inpr	5.18
27475293	C0231921	Pulmonary function	ortf	5.18
27475293	C3160731	Pulmonary function (finding)	fndg	5.18
27475293	C3280118	Mild disorder	fndg	4.12
27475293	C1280500	Effect	qlco	3.55
27475293	C2348382	Effect, Appearance	qlco	3.55
27475293	C0470166	message	inpr	3.54
27475293	C0151317	Chronic infectious disease	dsyn	3.45
27475293	C1524063	Use of	ftcn	3.43
27475293	C2945704	Conventional Treatment	topp	3.42
27475293	C3898777	Important	qlco	3.42
27475293	C0442808	Increasing	ftcn	3.42
27475293	C0205191	chronic	tmco	3.42
28419121	C0036849	Set (Psychology)	menp	13.01
28419121	C3264621	ivacaftor	orch	12.88
28419121	C3264621	ivacaftor	phsu	12.88
28419121	C1708335	Healthy Volunteers	popg	9.89
28419121	C0038989	Sweat Glands	bpoc	9.89
28419121	C0026882	Mutation	genf	9.74
28419121	C1707455	Comparison	acty	5.18
28419121	C0392366	Tests (qualifier value)	inpr	5.18
28419121	C2349001	Human Study Subject	humn	3.59
28419121	C2697811	Investigative Subject	ftcn	3.59
28419121	C0681850	Study Subject	grup	3.59
28419121	C1706203	Subject - topic	idcn	3.59
28419121	C1550501	Subject -direct target	idcn	3.59
28419121	C0728893	+5	qnco	3.55
28419121	C0439084	>5	qnco	3.55
28419121	C2587213	Control function	ftcn	3.55
28419121	C1882979	Scientific Control	cnce	3.55
28419121	C1442518	Set scale	ftcn	3.55
28419121	C3274648	True Control Status	qlco	3.55
28419121	C0243148	control aspects	qlco	3.55
28419121	C1550141	control substance	sbst	3.55
28419121	C1705195	set (group)	cnce	3.55
28419121	C1280500	Effect	qlco	3.54
28419121	C1521828	Rate	qnco	3.52
28419121	C0871208	Rating (action)	acty	3.52
28419121	C3264627	Kalydeco	phsu	3.50
28419121	C3838680	3+ Answer to Question	fndg	3.48
28419121	C2827736	3+ Score	qnco	3.48
28419121	C2981702	3+ Score, WHO	clas	3.48
28419121	C0439086	<3 (qualifier value)	qnco	3.48
28419121	C1524062	Additional	ftcn	3.43
28419121	C1550043	Container status - Identified	fndg	3.43
28419121	C0205396	Identified	qlco	3.43
28419121	C1710548	Unique	qlco	3.43
28419121	C0444706	Measured	qlco	3.42
28419121	C3541902	Measured Tumor Identification	diap	3.42
28419121	C0442027	Oral	spco	3.42
28419121	C0470187	Availability of	ftcn	3.41
28419121	C0038990	Sweating	fndg	39.06
28419121	C0040363	Togo	geoa	35.81
28419121	C0041260	Tryptophanase	aapp	35.81
28419121	C0041260	Tryptophanase	enzy	35.81
28419121	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
28419121	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
28419121	C0600370	Methacholine	orch	20.95
28419121	C0600370	Methacholine	phsu	20.95
28419121	C0038984	Sweat	bdsu	20.02
28419121	C0001648	Adrenergic Agonists	phsu	19.45
28419121	C0009738	Congo	geoa	16.21
28419121	C1883351	To	qlco	10.42
28419121	C2349001	Human Study Subject	humn	5.18
28419121	C2697811	Investigative Subject	ftcn	5.18
28419121	C0681850	Study Subject	grup	5.18
28419121	C1706203	Subject - topic	idcn	5.18
28419121	C1550501	Subject -direct target	idcn	5.18
28419121	C1720154	Inject - dosing instruction imperative	ftcn	3.98
28419121	C2757025	Adrenergic Agonists [MoA]	moft	3.68
28419121	C3811819	CFTR wt Allele	gngm	3.59
28419121	C0369637	M NOS ANTIBODY	aapp	3.50
28419121	C0369637	M NOS ANTIBODY	imft	3.50
28419121	C0441923	M+ (tumor staging)	inpr	3.50
28419121	C1413365	CFTR gene	gngm	3.47
28419121	C1701901	Conditional	qlco	3.47
28419121	C0851827	Dependent - ability	qlco	3.47
28419121	C3244310	dependent	ftcn	3.47
28419121	C3264621	ivacaftor	orch	53.77
28419121	C3264621	ivacaftor	phsu	53.77
28419121	C0038990	Sweating	fndg	38.73
28419121	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28419121	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28419121	C0038984	Sweat	bdsu	19.70
28419121	C0040363	Togo	geoa	17.80
28419121	C0041260	Tryptophanase	aapp	17.80
28419121	C0041260	Tryptophanase	enzy	17.80
28419121	C0033204	Probability	qnco	16.16
28419121	C0750572	Estimated	qnco	5.18
28419121	C1883351	To	qlco	5.18
28419121	C0683607	allowing	socb	5.18
28419121	C3838680	3+ Answer to Question	fndg	3.57
28419121	C2827736	3+ Score	qnco	3.57
28419121	C2981702	3+ Score, WHO	clas	3.57
28419121	C0439086	<3 (qualifier value)	qnco	3.57
28419121	C1280500	Effect	qlco	3.57
28419121	C2348382	Effect, Appearance	qlco	3.57
28419121	C0022885	Laboratory Procedures	lbpr	3.57
28419121	C0392366	Tests (qualifier value)	inpr	3.57
28419121	C0470187	Availability of	ftcn	3.56
28419121	C0205234	Focal	spco	3.55
28419121	C1285542	Has focus	ftcn	3.55
28419121	C2349001	Human Study Subject	humn	3.55
28419121	C0442805	Increase	ftcn	3.55
28419121	C2697811	Investigative Subject	ftcn	3.55
28419121	C0175566	Open	spco	3.55
28419121	C0681850	Study Subject	grup	3.55
28419121	C1706203	Subject - topic	idcn	3.55
28419121	C1550501	Subject -direct target	idcn	3.55
28419121	C1515655	in vivo	spco	3.44
28419121	C0150108	Blinded	resa	3.43
28419121	C1413365	CFTR gene	gngm	3.42
28419121	C1880834	Fold in Medical Device Material	phpr	3.42
28419121	C0332462	Folded structure	spco	3.42
28419121	C1521828	Rate	qnco	3.40
28419121	C0871208	Rating (action)	acty	3.40
28419121	C0038990	Sweating	fndg	38.95
28419121	C0038984	Sweat	bdsu	19.91
28419121	C1521828	Rate	qnco	3.58
28419121	C0871208	Rating (action)	acty	3.58
28419121	C0205202	Corrected	qlco	3.57
28419121	C1517945	Loss	qnco	3.54
28419121	C0444706	Measured	qlco	3.47
28419121	C3541902	Measured Tumor Identification	diap	3.47
28419121	C0038990	Sweating	fndg	19.20
28419121	C0038984	Sweat	bdsu	9.74
28419121	C1517945	Loss	qnco	3.52
28419121	C3842591	0%	fndg	3.43
28419121	C0750572	Estimated	qnco	3.43
28419121	C3842591	0%	fndg	3.57
28419121	C0038990	Sweating	fndg	19.23
28419121	C3264621	ivacaftor	orch	14.64
28419121	C3264621	ivacaftor	phsu	14.64
28419121	C0031843	physiological aspects	phsf	13.02
28419121	C0027778	Netherlands	geoa	9.90
28419121	C0038984	Sweat	bdsu	9.76
28419121	C3838679	4+ Answer to question	fndg	5.18
28419121	C0442805	Increase	ftcn	5.18
28419121	C0205217	Increased	qnco	5.18
28419121	C1880834	Fold in Medical Device Material	phpr	3.59
28419121	C0332462	Folded structure	spco	3.59
28419121	C3892223	Per Nanoliter	qnco	3.59
28419121	C0560008	nanolitre	qnco	3.59
28419121	C0542341	Function	ftcn	3.56
28419121	C0700205	Function Axis	clas	3.56
28419121	C1705273	Mathematical Operator	inpr	3.56
28419121	C1510992	Average	qnco	3.45
28419121	C2825518	Average of Value Derivation Technique	qnco	3.45
28419121	C1521828	Rate	qnco	3.43
28419121	C0871208	Rating (action)	acty	3.43
28419121	C0750572	Estimated	qnco	3.43
28419121	C2700323	Wild Type Unspecified - zebrafish	fish	3.43
28419121	C3264621	ivacaftor	orch	13.02
28419121	C3264621	ivacaftor	phsu	13.02
28419121	C3264621	ivacaftor	orch	13.02
28419121	C3264621	ivacaftor	phsu	13.02
28419121	C0558058	Reflecting	menp	5.18
28419121	C0042295	Values	qlco	3.68
28419121	C0750572	Estimated	qnco	3.63
28419121	C1704243	Greater	qnco	3.50
28419121	C0549177	Large	qnco	3.50
28419121	C0442805	Increase	ftcn	3.48
28419121	C0205217	Increased	qnco	3.48
28419121	C1517945	Loss	qnco	3.48
28419121	C3264621	ivacaftor	orch	26.05
28419121	C3264621	ivacaftor	phsu	26.05
28419121	C0087136	Unmarried	fndg	22.49
28419121	C0037179	Unmarried person	popg	22.49
28419121	C0031843	physiological aspects	phsf	13.01
28419121	C1547282	Show	anim	3.98
28419121	C2349001	Human Study Subject	humn	3.60
28419121	C2697811	Investigative Subject	ftcn	3.60
28419121	C0681850	Study Subject	grup	3.60
28419121	C1706203	Subject - topic	idcn	3.60
28419121	C1550501	Subject -direct target	idcn	3.60
28419121	C1705938	Base - General Qualifier	idcn	3.57
28419121	C1527178	Basis - conceptual entity	ftcn	3.57
28419121	C0022885	Laboratory Procedures	lbpr	3.57
28419121	C0205171	Singular	qnco	3.57
28419121	C0392366	Tests (qualifier value)	inpr	3.57
28419121	C0542341	Function	ftcn	3.55
28419121	C0700205	Function Axis	clas	3.55
28419121	C1705273	Mathematical Operator	inpr	3.55
28419121	C0442751	Distance vision 6/9	fndg	3.45
28419121	C2700323	Wild Type Unspecified - zebrafish	fish	3.43
28419121	C3264621	ivacaftor	orch	13.05
28419121	C3264621	ivacaftor	phsu	13.05
28419121	C0442726	Detected (finding)	fndg	5.18
28419121	C1511790	Detection	topp	5.18
28419121	C1524031	Minimum	qlco	3.68
28419121	C1883002	Sequence Chromatogram	ftcn	3.68
28419121	C0442822	trace amount	qnco	3.68
28419121	C0039593	Testing	ftcn	3.54
28419121	C0392366	Tests (qualifier value)	inpr	3.54
28419121	C1720467	Only - dosing instruction fragment	inpr	3.50
28419121	C0205171	Singular	qnco	3.50
28419121	C2349001	Human Study Subject	humn	3.42
28419121	C2697811	Investigative Subject	ftcn	3.42
28419121	C0205341	Repeat	ftcn	3.42
28419121	C1705914	Repeat Object	cnce	3.42
28419121	C1547730	Repeat Pattern	tmco	3.42
28419121	C0681850	Study Subject	grup	3.42
28419121	C1706203	Subject - topic	idcn	3.42
28419121	C1550501	Subject -direct target	idcn	3.42
28419121	C0917903	Conclude Resin	bodm	27.26
28419121	C0917903	Conclude Resin	orch	27.26
28419121	C0015295	Exons	bacs	22.47
28419121	C0015295	Exons	nnon	22.47
28419121	C3264621	ivacaftor	orch	13.05
28419121	C3264621	ivacaftor	phsu	13.05
28419121	C1511760	Deletion Mutation	genf	13.01
28419121	C0032729	Portugal	geoa	9.92
28419121	C0449788	Count of entities	qnco	3.68
28419121	C0237753	Numbers	qnco	3.68
28419121	C0442027	Oral	spco	3.61
28419121	C0442805	Increase	ftcn	3.59
28419121	C0205217	Increased	qnco	3.59
28419121	C4054723	Influence	cnce	3.56
28419121	C3842590	10%	fndg	3.55
28419121	C1880274	Deletion (action)	acty	3.55
28419121	C1442161	Gene Deletion Abnormality	comd	3.55
28419121	C0439828	Variable (uniformity)	qlco	3.55
28419121	C0439799	Channel	spco	3.50
28419121	C1706095	Channel Object	cnce	3.50
28419121	C1515655	in vivo	spco	3.50
28419121	C1706089	Marked	qlco	3.43
28419121	C0522501	Massive	qlco	3.43
28419121	C1274040	Result	ftcn	3.41
24004658	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
24004658	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
24004658	C0017337	Genes	gngm	17.80
24004658	C0010674	Cystic Fibrosis	dsyn	10.06
24004658	C0012634	Disease	dsyn	9.99
24004658	C0026882	Mutation	genf	9.90
24004658	C0015127	Etiology aspects	ftcn	9.86
24004658	C0033684	Proteins	aapp	6.75
24004658	C0033684	Proteins	bacs	6.75
24004658	C2700640	Encode (action)	acty	5.18
24004658	C1413365	CFTR gene	gngm	3.58
24004658	C1524003	Science of Etiology	cnce	3.55
24004658	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.68
24004658	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.68
24004658	C0005367	Bicarbonates	inch	20.95
24004658	C0005367	Bicarbonates	phsu	20.95
24004658	C0008203	Chlorides	inch	17.80
24004658	C0162585	Ion Transport	celf	12.91
24004658	C0221908	epithelial	qlco	6.90
24004658	C2722820	Bicarbonate preparation	orch	5.18
24004658	C2722820	Bicarbonate preparation	phsu	5.18
24004658	C0439799	Channel	spco	5.18
24004658	C1706095	Channel Object	cnce	5.18
24004658	C0596019	Chloride Ion	elii	5.18
24004658	C0973231	bicarbonate ion	inch	5.18
24004658	C1321013	Hydration status	fndg	3.57
24004658	C1511545	Critical	qlco	3.55
24004658	C0231683	Gait normal	fndg	3.43
24004658	C2347086	Mean Percent of Normal	qnco	3.43
24004658	C0205307	Normal	qlco	3.43
24004658	C0439166	Percent normal	qnco	3.43
24004658	C0205148	Surface	spco	3.42
24004658	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.99
24004658	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.99
24004658	C0009738	Congo	geoa	16.08
24004658	C0018896	Helping Behavior	socb	14.64
24004658	C0031843	physiological aspects	phsf	13.01
24004658	C1564139	Mutant Proteins	aapp	9.75
24004658	C1269765	Assisted (qualifier value)	qlco	5.18
24004658	C0557034	Assisting (procedure)	hlca	5.18
24004658	C1521721	Supportive assistance	cnce	5.18
24004658	C0444503	Breakthrough	qlco	3.68
24004658	C1947933	care activity	acty	3.61
24004658	C0815043	Protein, Organized by Function	aapp	3.58
24004658	C0542341	Function	ftcn	3.55
24004658	C0700205	Function Axis	clas	3.55
24004658	C1705273	Mathematical Operator	inpr	3.55
24004658	C0205314	New	qlco	3.54
24004658	C1709305	Occur (action)	acty	3.54
24004658	C0302350	Therapeutic	ftcn	3.54
24004658	C0087111	Therapeutic procedure	topp	3.54
24004658	C0679622	literary novel	inpr	3.54
24004658	C0679199	strategy	menp	3.54
24004658	C0332185	Recent	tmco	3.50
24004658	C3811819	CFTR wt Allele	gngm	3.47
24004658	C0521116	Current (present time)	tmco	3.47
24004658	C1705970	Electrical Current	npop	3.47
24004658	C1413365	CFTR gene	gngm	3.43
24004658	C0596988	mutant	comd	3.43
24004658	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.16
24004658	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.16
24004658	C0008976	Clinical Trials	resa	19.52
24004658	C3264621	ivacaftor	orch	13.05
24004658	C3264621	ivacaftor	phsu	13.05
24004658	C1096775	Clinical Trial [Publication Type]	inpr	10.06
24004658	C0282443	Review [Publication Type]	inpr	9.88
24004658	C1413365	CFTR gene	gngm	7.09
24004658	C0678723	Biologic Development	orgf	5.18
24004658	C1527148	Development	ftcn	5.18
24004658	C0332257	Including (qualifier)	ftcn	5.18
24004658	C1328819	Small Molecule	orch	5.18
24004658	C1521840	Target	ftcn	5.18
24004658	C2986546	Target Lesion Identification	diap	5.18
24004658	C0243107	development aspects	phsf	5.18
24004658	C2825142	Experimental Result	fndg	3.59
24004658	C1274040	Result	ftcn	3.59
24004658	C1546471	What subject filter - Result	idcn	3.59
24004658	C1552617	Act Class - review	idcn	3.57
24004658	C0243067	defects aspect	ftcn	3.55
24004658	C2985434	Disease-causing Mutation	comd	3.45
24004658	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
24004658	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
24004658	C0040363	Togo	geoa	17.80
24004658	C0041260	Tryptophanase	aapp	17.80
24004658	C0041260	Tryptophanase	enzy	17.80
24004658	C0009738	Congo	geoa	16.04
24004658	C0010439	Cues	idcn	13.14
24004658	C0026882	Mutation	genf	9.99
24004658	C0007603	Plasma membrane	celc	9.92
24004658	C1257890	Population Group	popg	9.73
24004658	C0030705	Patients	podg	6.58
24004658	C0032659	geographic population	qnco	6.58
24004658	C0392752	Localized	spco	5.18
24004658	C1883351	To	qlco	5.18
24004658	C0231175	failed	ftcn	5.18
24004658	C1705285	Mutation Abnormality	comd	3.68
24004658	C1704632	Disease Response	fndg	3.59
24004658	C0175566	Open	spco	3.59
24004658	C2911692	Response (communication)	menp	3.59
24004658	C1706817	Response (statement)	inpr	3.59
24004658	C0871261	Response process	orga	3.59
24004658	C0205214	Common (qualifier value)	qnco	3.55
24004658	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.55
24004658	C1522138	shared attribute	ftcn	3.55
24004658	C0007634	Cells	cell	3.50
24004658	C0178539	Cellular	lbpr	3.50
24004658	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.42
24004658	C3811819	CFTR wt Allele	gngm	3.42
24004658	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.42
24004658	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.42
24004658	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.17
24004658	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.17
24004658	C0005910	Body Weight	orga	24.11
24004658	C0039798	therapeutic aspects	ftcn	22.56
24004658	C0026882	Mutation	genf	19.74
24004658	C0009738	Congo	geoa	17.80
24004658	C0030705	Patients	podg	13.35
24004658	C3264621	ivacaftor	orch	12.94
24004658	C3264621	ivacaftor	phsu	12.94
24004658	C1413365	CFTR gene	gngm	10.49
24004658	C0013109	Drama	inpr	9.70
24004658	C1705285	Mutation Abnormality	comd	7.05
24004658	C0005516	Biological Markers	clna	6.72
24004658	C0024115	Lung diseases	dsyn	6.69
24004658	C0035245	Respiratory physiology	ortf	6.62
24004658	C3811819	CFTR wt Allele	gngm	5.18
24004658	C1705104	Importance Weight	idcn	5.18
24004658	C1305866	Weighing patient	diap	5.18
24004658	C0043100	Weight	qnco	5.18
24004658	C0475311	Harbor	mnob	3.98
24004658	C2987124	Patient Reported Outcome	inpr	3.98
24004658	C1533734	Administration procedure	topp	3.63
24004658	C1705169	Biomaterial Treatment	cnce	3.63
24004658	C2347098	Medical Product Stability	qlco	3.63
24004658	C0205360	Stable status	qlco	3.63
24004658	C0087111	Therapeutic procedure	topp	3.63
24004658	C1522326	Treating	ftcn	3.63
24004658	C3538994	Treatment Epoch	resa	3.63
24004658	C3887704	treatment - ActInformationManagementReason	hlca	3.63
24004658	C1706408	Placebo Control	resa	3.62
24004658	C1707455	Comparison	acty	3.57
24004658	C2986411	Improvement	cnce	3.53
24004658	C0205214	Common (qualifier value)	qnco	3.42
24004658	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
24004658	C1948062	Copy (object)	mnob	3.42
24004658	C0205448	Two	qnco	3.42
24004658	C1522138	shared attribute	ftcn	3.42
24004658	C0009738	Congo	geoa	48.93
24004658	C0009462	Community	geoa	16.04
24004658	C0030705	Patients	podg	13.27
24004658	C0027627	Neoplasm Metastasis	neop	12.94
24004658	C3264621	ivacaftor	orch	12.89
24004658	C3264621	ivacaftor	phsu	12.89
24004658	C3811819	CFTR wt Allele	gngm	10.47
24004658	C1257890	Population Group	popg	9.92
24004658	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	6.93
24004658	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	6.93
24004658	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	6.93
24004658	C0032659	geographic population	qnco	6.77
24004658	C0243067	defects aspect	ftcn	3.63
24004658	C0679864	treatment success	qlco	3.58
24004658	C0680395	primary group	popg	3.57
24004658	C0233571	excitement emotion	menp	3.55
24004658	C0175668	Secondary to	tmco	3.48
24004658	C0205436	second (number)	qnco	3.48
24004658	C1524063	Use of	ftcn	3.46
24004658	C3146294	Generation (action)	acty	3.42
24004658	C1947933	care activity	acty	3.42
27990075	C0717758	Etanercept	aapp	28.74
27990075	C0717758	Etanercept	imft	28.74
27990075	C0717758	Etanercept	phsu	28.74
27990075	C0065374	Lisinopril	aapp	16.08
27990075	C0065374	Lisinopril	phsu	16.08
27990075	C3264621	ivacaftor	orch	13.14
27990075	C3264621	ivacaftor	phsu	13.14
27990075	C3852684	lumacaftor	orch	12.96
27990075	C3852684	lumacaftor	phsu	12.96
27990075	C0010674	Cystic Fibrosis	dsyn	11.49
27990075	C0018801	Heart failure	dsyn	11.49
27990075	C0004364	Autoimmune Diseases	dsyn	6.91
27990075	C3541950	Acute Myocardial Infarction by ECG Finding	fndg	5.18
27990075	C0155626	Acute myocardial infarction	dsyn	5.18
27990075	C0018802	Congestive heart failure	dsyn	5.18
27990075	C4033620	ORKAMBI	phsu	5.18
27990075	C0679225	multiple pathologies	dsyn	3.78
27990075	C0991536	Oral Solution	bodm	3.68
27990075	C0578998	On treatment for hypertension	hlca	3.60
27990075	C0443146	Autoimmune reaction	patf	3.48
27990075	C0439064	Numerous	qnco	3.48
25101884	C0010674	Cystic Fibrosis	dsyn	19.70
25101884	C0040363	Togo	geoa	17.80
25101884	C0040710	Translating	ocac	17.80
25101884	C0041260	Tryptophanase	aapp	17.80
25101884	C0041260	Tryptophanase	enzy	17.80
25101884	C0728866	Drug effect	ftcn	10.06
25101884	C0026882	Mutation	genf	9.73
25101884	C0087111	Therapeutic procedure	topp	7.61
25101884	C0030705	Patients	podg	6.70
25101884	C1880355	Discover	acty	5.18
25101884	C1883351	To	qlco	5.18
25101884	C1522326	Treating	ftcn	5.18
25101884	C1292734	Treatment intent	ftcn	5.18
25101884	C0202311	Aluminum measurement	lbpr	3.63
25101884	C0723712	Therapeutic brand of coal tar	orch	3.63
25101884	C0723712	Therapeutic brand of coal tar	phsu	3.63
25101884	C1522634	Question (inquiry)	inpr	3.59
25101884	C0205160	Negative	qlco	3.57
25101884	C3853545	Negative - answer	qlco	3.57
25101884	C2825491	Negative Charge	qlco	3.57
25101884	C1513916	Negative Finding	fndg	3.57
25101884	C2825415	Negative Number	cnce	3.57
25101884	C0233820	Insight	menp	3.56
25101884	C1446409	Positive	qlco	3.43
25101884	C2825490	Positive Charge	qlco	3.43
25101884	C1514241	Positive Finding	fndg	3.43
25101884	C3812269	Positive Number	cnce	3.43
25101884	C0439178	percent positive cells	qnco	3.43
25101884	C0205214	Common (qualifier value)	qnco	3.42
25101884	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
25101884	C1705285	Mutation Abnormality	comd	3.42
25101884	C1522138	shared attribute	ftcn	3.42
25101884	C0202311	Aluminum measurement	lbpr	3.63
25101884	C1706387	Issue (document)	inpr	5.18
25101884	C0033213	Problem	fndg	5.18
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
25101886	C0010674	Cystic Fibrosis	dsyn	10.06
25101886	C0026882	Mutation	genf	9.90
25101886	C0015127	Etiology aspects	ftcn	9.86
25101886	C1413365	CFTR gene	gngm	5.18
25101886	C1524003	Science of Etiology	cnce	3.55
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
25101886	C0039798	therapeutic aspects	ftcn	22.36
25101886	C0009738	Congo	geoa	16.05
25101886	C3264621	ivacaftor	orch	14.64
25101886	C3264621	ivacaftor	phsu	14.64
25101886	C3852684	lumacaftor	orch	14.64
25101886	C3852684	lumacaftor	phsu	14.64
25101886	C2349975	Enhance (action)	acty	5.18
25101886	C1999230	Providing (action)	acty	5.18
25101886	C3252847	VX 809	orch	5.18
25101886	C3252847	VX 809	phsu	5.18
25101886	C2741958	VX-770	orch	5.18
25101886	C1153410	channel activity	moft	5.18
25101886	C0750546	newly	idcn	5.18
25101886	C0599896	trafficking	celf	5.18
25101886	C1254042	Anatomical maturation	phsf	3.68
25101886	C0678723	Biologic Development	orgf	3.68
25101886	C0870861	Human maturation	phpr	3.68
25101886	C3854260	Advance	tmco	3.53
25101886	C0725066	Advance -- medical device	medd	3.53
25101886	C1413365	CFTR gene	gngm	3.50
25101886	C3811819	CFTR wt Allele	gngm	3.43
25101886	C3898777	Important	qlco	3.43
25101886	C0087111	Therapeutic procedure	topp	3.43
25101886	C1363945	Therapy Object (animal model)	fndg	3.43
25101886	C0087136	Unmarried	fndg	22.43
25101886	C0037179	Unmarried person	popg	22.43
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25101886	C0026882	Mutation	genf	19.91
25101886	C3850123	Clinical Effectiveness	qlco	19.33
25101886	C0040363	Togo	geoa	17.80
25101886	C0041260	Tryptophanase	aapp	17.80
25101886	C0041260	Tryptophanase	enzy	17.80
25101886	C0030705	Patients	podg	13.34
25101886	C0001721	Affect (mental function)	menp	11.49
25101886	C0205171	Singular	qnco	7.36
25101886	C1705285	Mutation Abnormality	comd	7.22
25101886	C1561536	*Activity (kind of quantity)	idcn	5.18
25101886	C0205177	Active	ftcn	5.18
25101886	C0441655	Activities	acty	5.18
25101886	C3668946	Activity (animal life circumstance)	fndg	5.18
25101886	C0439799	Channel	spco	5.18
25101886	C1706095	Channel Object	cnce	5.18
25101886	C4049939	FDA Establishment Activity Terminology	inpr	5.18
25101886	C1720467	Only - dosing instruction fragment	inpr	5.18
25101886	C0439167	Percent Activity	qnco	5.18
25101886	C4049938	Physical Activity Measurement	lbpr	5.18
25101886	C0087111	Therapeutic procedure	topp	5.18
25101886	C1883351	To	qlco	5.18
25101886	C1522326	Treating	ftcn	5.18
25101886	C1292734	Treatment intent	ftcn	5.18
25101886	C2741958	VX-770	orch	5.18
25101886	C0205198	Compound	qlco	3.68
25101886	C1706082	Compound (substance)	chem	3.68
25101886	C0205410	Sufficient	qlco	3.68
25101886	C1518422	Negation	ftcn	3.50
25101886	C1413365	CFTR gene	gngm	3.42
25101886	C0205214	Common (qualifier value)	qnco	3.42
25101886	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
25101886	C1522138	shared attribute	ftcn	3.42
25101886	C0700321	Small	qnco	3.42
25101886	C1515021	Subgroup	clas	3.42
25101886	C0039798	therapeutic aspects	ftcn	22.49
25101886	C0040363	Togo	geoa	17.80
25101886	C0041260	Tryptophanase	aapp	17.80
25101886	C0041260	Tryptophanase	enzy	17.80
25101886	C0030705	Patients	podg	6.74
25101886	C0332148	Probable diagnosis	qlco	5.18
25101886	C0750492	Probably	idcn	5.18
25101886	C1883351	To	qlco	5.18
25101886	C0814225	benefit	qnco	3.68
25101886	C1533734	Administration procedure	topp	3.57
25101886	C1705169	Biomaterial Treatment	cnce	3.57
25101886	C0087111	Therapeutic procedure	topp	3.57
25101886	C1522326	Treating	ftcn	3.57
25101886	C3538994	Treatment Epoch	resa	3.57
25101886	C3887704	treatment - ActInformationManagementReason	hlca	3.57
25101886	C0205210	Clinical	qlco	3.50
25101886	C1553058	Neuropsychologist - Clinical	prog	3.50
25101886	C0237412	Psychologist - Clinical	prog	3.50
25101886	C0497591	Social Worker - Clinical	prog	3.50
25101886	C0039798	therapeutic aspects	ftcn	22.36
25101886	C0087113	Treatment Effectiveness	qlco	19.37
25101886	C0013162	Drug Combinations	phsu	8.34
25101886	C1272684	Accepted	qlco	5.18
25101886	C0443211	Established	qlco	5.18
25101886	C2827718	In Vitro Route of Administration	ftcn	5.18
25101886	C0021135	In Vitro [Publication Type]	inpr	5.18
25101886	C1518422	Negation	ftcn	5.18
25101886	C1533691	in vitro	qlco	5.18
25101886	C1825598	IMPACT gene	gngm	3.56
25101886	C4049986	Impact	qlco	3.56
25101886	C0087111	Therapeutic procedure	topp	3.43
25101886	C1363945	Therapy Object (animal model)	fndg	3.43
25101886	C0205178	acute	tmco	3.43
25101886	C0205191	chronic	tmco	3.43
25101886	C0039798	therapeutic aspects	ftcn	22.47
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25101886	C0031843	physiological aspects	phsf	12.88
25101886	C0026882	Mutation	genf	9.74
25101886	C0008972	Clinical Research	resa	6.63
25101886	C0014597	Epithelial Cells	cell	6.59
25101886	C0150312	Present	qnco	5.18
25101886	C0205178	acute	tmco	5.18
25101886	C0332290	Consistent with	idcn	3.64
25101886	C0007634	Cells	cell	3.55
25101886	C3282337	Cells [Chemical/Ingredient]	cell	3.55
25101886	C0178693	human study	resa	3.55
25101886	C1533734	Administration procedure	topp	3.54
25101886	C1705169	Biomaterial Treatment	cnce	3.54
25101886	C0087111	Therapeutic procedure	topp	3.54
25101886	C1522326	Treating	ftcn	3.54
25101886	C3538994	Treatment Epoch	resa	3.54
25101886	C3887704	treatment - ActInformationManagementReason	hlca	3.54
25101886	C1273342	Epithelial cell count (procedure)	lbpr	3.44
25101886	C2741958	VX-770	orch	3.44
25101886	C1705285	Mutation Abnormality	comd	3.43
25101886	C1561611	Admission Level of Care Code - Improved	inpr	3.42
25101886	C0458827	Airway structure	bpoc	3.42
25101886	C0178987	Artificial Airways	medd	3.42
25101886	C0332272	Better	qlco	3.42
25101886	C1413365	CFTR gene	gngm	3.42
25101886	C0542341	Function	ftcn	3.42
25101886	C0700205	Function Axis	clas	3.42
25101886	C0184511	Improved	qlco	3.42
25101886	C1705273	Mathematical Operator	inpr	3.42
25101886	C0205225	Primary	qlco	3.42
25101886	C0439631	Primary operation	topp	3.42
25101886	C0439612	True primary (qualifier value)	tmco	3.42
25101886	C0205191	chronic	tmco	3.42
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
25101886	C0009924	Contrast Media	irda	14.64
25101886	C0010453	Anthropological Culture	idcn	13.09
25101886	C0015127	Etiology aspects	ftcn	10.28
25101886	C0019904	Homozygote	orga	9.78
25101886	C1979874	Contrast	qlco	5.18
25101886	C1524003	Science of Etiology	cnce	3.98
25101886	C0001554	Administration occupational activities	ocac	3.61
25101886	C1533734	Administration procedure	topp	3.61
25101886	C0443290	reversal action	ftcn	3.54
25101886	C2741958	VX-770	orch	3.50
25101886	C0205191	chronic	tmco	3.47
25101886	C1512045	Dose-dependent	qnco	3.43
25101886	C3252847	VX 809	orch	3.43
25101886	C3252847	VX 809	phsu	3.43
25101886	C1413365	CFTR gene	gngm	3.42
25101886	C1947976	Correction (change)	ftcn	3.42
25101886	C1705565	Correction Report	inpr	3.42
25101886	C0086597	Mediate	socb	3.42
25101886	C0127400	Mediator brand of benfluorex hydrochloride	orch	3.42
25101886	C0127400	Mediator brand of benfluorex hydrochloride	phsu	3.42
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25101886	C0031227	Personnel Turnover	qnco	12.96
25101886	C2825142	Experimental Result	fndg	5.18
25101886	C0442808	Increasing	ftcn	5.18
25101886	C0522501	Massive	qlco	5.18
25101886	C0558058	Reflecting	menp	5.18
25101886	C1274040	Result	ftcn	5.18
25101886	C2741958	VX-770	orch	5.18
25101886	C1546471	What subject filter - Result	idcn	5.18
25101886	C1521828	Rate	qnco	3.68
25101886	C0871208	Rating (action)	acty	3.68
25101886	C0243127	Biochemical turnover	ftcn	3.50
25101886	C0443331	Turnover technique	hlca	3.50
25101886	C1413365	CFTR gene	gngm	3.43
25101886	C0205202	Corrected	qlco	3.43
25101886	C0039798	therapeutic aspects	ftcn	22.53
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
25101886	C0031843	physiological aspects	phsf	14.64
25101886	C0542341	Function	ftcn	5.18
25101886	C0700205	Function Axis	clas	5.18
25101886	C1705273	Mathematical Operator	inpr	5.18
25101886	C0392756	Reduced	qlco	5.18
25101886	C1533734	Administration procedure	topp	3.60
25101886	C1705169	Biomaterial Treatment	cnce	3.60
25101886	C0441889	Levels (qualifier value)	qlco	3.60
25101886	C0087111	Therapeutic procedure	topp	3.60
25101886	C1522326	Treating	ftcn	3.60
25101886	C3538994	Treatment Epoch	resa	3.60
25101886	C3887704	treatment - ActInformationManagementReason	hlca	3.60
25101886	C2741958	VX-770	orch	3.49
25101886	C1883559	Wild Type	gngm	3.49
25101886	C1413365	CFTR gene	gngm	3.46
25101886	C0205286	Mature	tmco	3.46
25101886	C0205191	chronic	tmco	3.46
25101886	C0039798	therapeutic aspects	ftcn	22.48
25101886	C3539655	CDISC Findings Class	inpr	5.18
25101886	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
25101886	C0557651	Room of building - Study	mnob	5.18
25101886	C0947630	Scientific Study	lbpr	5.18
25101886	C2603343	Study	resa	5.18
25101886	C2607943	findings aspects	ftcn	5.18
25101886	C1280500	Effect	qlco	3.68
25101886	C0443303	short-term	tmco	3.64
25101886	C1882327	Percent of Predicted Value	qnco	3.57
25101886	C0681842	prediction	idcn	3.57
25101886	C1533734	Administration procedure	topp	3.55
25101886	C1705169	Biomaterial Treatment	cnce	3.55
25101886	C0087111	Therapeutic procedure	topp	3.55
25101886	C1522326	Treating	ftcn	3.55
25101886	C3538994	Treatment Epoch	resa	3.55
25101886	C3887704	treatment - ActInformationManagementReason	hlca	3.55
25101886	C4055646	Unexpected	inpr	3.50
25101886	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.44
25101886	C0205191	chronic	tmco	3.43
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.10
25101886	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.10
25101886	C0040363	Togo	geoa	17.80
25101886	C0041260	Tryptophanase	aapp	17.80
25101886	C0041260	Tryptophanase	enzy	17.80
25101886	C1413365	CFTR gene	gngm	7.03
25101886	C3687832	DRUGS	topp	5.18
25101886	C1518422	Negation	ftcn	5.18
25101886	C0013227	Pharmaceutical Preparations	phsu	5.18
25101886	C1883351	To	qlco	5.18
25101886	C0336789	Combine	mnob	3.98
25101886	C0443172	Changed status	qnco	3.59
25101886	C0392747	Changing	ftcn	3.59
25101886	C0521102	Interferes with	ftcn	3.57
25101886	C2347098	Medical Product Stability	qlco	3.57
25101886	C0205360	Stable status	qlco	3.57
25101886	C0678723	Biologic Development	orgf	3.56
25101886	C1527148	Development	ftcn	3.56
25101886	C0243107	development aspects	phsf	3.56
25101886	C0205314	New	qlco	3.43
25101886	C0205198	Compound	qlco	3.41
25101886	C1706082	Compound (substance)	chem	3.41
25101887	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
25101887	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
25101887	C0010674	Cystic Fibrosis	dsyn	19.93
25101887	C0003075	Anions	elii	12.89
25101887	C0026882	Mutation	genf	9.90
25101887	C0015127	Etiology aspects	ftcn	9.86
25101887	C0014609	Epithelium	tisu	6.56
25101887	C1413365	CFTR gene	gngm	5.18
25101887	C1704735	Regulator	cnce	3.61
25101887	C1704734	Regulator Device Component	mnob	3.61
25101887	C0182953	Regulators (device)	medd	3.61
25101887	C0596119	apical membrane	celc	3.58
25101887	C1524003	Science of Etiology	cnce	3.55
25101887	C2825142	Experimental Result	fndg	3.55
25101887	C1274040	Result	ftcn	3.55
25101887	C1546471	What subject filter - Result	idcn	3.55
25101887	C2752508	fully spanning the plasma membrane	celc	3.47
25101887	C1167322	integral to membrane	celc	3.47
25101887	C0392756	Reduced	qlco	3.43
25101887	C1327616	Cell secretion	celf	3.42
25101887	C0009738	Congo	geoa	16.05
25101887	C0206243	Carrying	acty	14.64
25101887	C3264621	ivacaftor	orch	14.64
25101887	C3264621	ivacaftor	phsu	14.64
25101887	C0026882	Mutation	genf	9.85
25101887	C1153410	channel activity	moft	5.18
25101887	C1547282	Show	anim	3.98
25101887	C0814225	benefit	qnco	3.63
25101887	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.58
25101887	C3242455	HL7PublishingDomain <patient administration>	inpr	3.58
25101887	C3242279	healthcare operations <patient administration>	ocac	3.58
25101887	C1705285	Mutation Abnormality	comd	3.54
25101887	C0205210	Clinical	qlco	3.48
25101887	C1553058	Neuropsychologist - Clinical	prog	3.48
25101887	C0237412	Psychologist - Clinical	prog	3.48
25101887	C0497591	Social Worker - Clinical	prog	3.48
25101887	C2741958	VX-770	orch	3.43
25101887	C3811819	CFTR wt Allele	gngm	3.43
25101887	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
25101887	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
25101887	C0009738	Congo	geoa	16.12
25101887	C0206243	Carrying	acty	14.64
25101887	C0031843	physiological aspects	phsf	14.64
25101887	C0026882	Mutation	genf	9.99
25101887	C0030705	Patients	podg	6.83
25101887	C0699809	Does carry	fndg	5.18
25101887	C0542341	Function	ftcn	5.18
25101887	C0700205	Function Axis	clas	5.18
25101887	C1705273	Mathematical Operator	inpr	5.18
25101887	C2347098	Medical Product Stability	qlco	5.18
25101887	C1709694	Processing (action)	acty	5.18
25101887	C0205360	Stable status	qlco	5.18
25101887	C1705285	Mutation Abnormality	comd	3.68
25101887	C0185026	Plication	topp	3.68
25101887	C1413365	CFTR gene	gngm	3.50
25101887	C3811819	CFTR wt Allele	gngm	3.50
25101887	C0008976	Clinical Trials	resa	19.52
25101887	C0009738	Congo	geoa	16.04
25101887	C3852684	lumacaftor	orch	14.64
25101887	C3852684	lumacaftor	phsu	14.64
25101887	C1096775	Clinical Trial [Publication Type]	inpr	10.06
25101887	C0019904	Homozygote	orga	9.73
25101887	C0035245	Respiratory physiology	ortf	6.62
25101887	C0030705	Patients	podg	6.58
25101887	C1444656	Indicated	fndg	5.18
25101887	C0439801	Limited (extensiveness)	ftcn	5.18
25101887	C4050251	Limited Lifting Ability	inpr	5.18
25101887	C2674459	Limited Walking Ability	fndg	5.18
25101887	C3542948	Limited component (foundation metadata concept)	inpr	5.18
25101887	C1547282	Show	anim	5.18
25101887	C2741958	VX-770	orch	5.18
25101887	C3252847	VX 809	orch	3.68
25101887	C3252847	VX 809	phsu	3.68
25101887	C1517586	Investigational	qlco	3.61
25101887	C3245491	investigational monitoring program	hlca	3.61
25101887	C0814225	benefit	qnco	3.56
25101887	C0947630	Scientific Study	lbpr	3.55
25101887	C2986411	Improvement	cnce	3.53
25101887	C0205195	Combined	qlco	3.48
25101887	C3811910	combination - answer to question	fndg	3.48
25101887	C1947911	combination of objects	phob	3.48
25101887	C0205210	Clinical	qlco	3.43
25101887	C1546944	Event Seriousness - Significant	qlco	3.43
25101887	C3714596	Little NOS	fndg	3.43
25101887	C1553058	Neuropsychologist - Clinical	prog	3.43
25101887	C0237412	Psychologist - Clinical	prog	3.43
25101887	C0750502	Significant	idcn	3.43
25101887	C0700321	Small	qnco	3.43
25101887	C2700395	Smallest	qnco	3.43
25101887	C0497591	Social Worker - Clinical	prog	3.43
25101887	C0237881	Statistical Significance	qnco	3.43
25101887	C3811819	CFTR wt Allele	gngm	3.42
25101887	C0078433	methylphosphonothioic acid S-(2-(bis(1-methylethyl)amino)ethyl) O-ethyl ester	orch	13.14
25101887	C0078433	methylphosphonothioic acid S-(2-(bis(1-methylethyl)amino)ethyl) O-ethyl ester	phsu	13.14
25101887	C1547282	Show	anim	5.18
25101887	C2741958	VX-770	orch	5.18
25101887	C0441905	Venous stage VX	fndg	3.68
25101887	C1280519	Effectiveness	qlco	3.55
25101887	C1707887	Efficacy Study	resa	3.55
25101887	C1517586	Investigational	qlco	3.50
25101887	C3245491	investigational monitoring program	hlca	3.50
25101887	C3252847	VX 809	orch	3.45
25101887	C3252847	VX 809	phsu	3.45
25101887	C1947976	Correction (change)	ftcn	3.43
25101887	C1705565	Correction Report	inpr	3.43
25101887	C0086418	Homo sapiens	humn	28.70
25101887	C0040363	Togo	geoa	17.80
25101887	C0041260	Tryptophanase	aapp	17.80
25101887	C0041260	Tryptophanase	enzy	17.80
25101887	C0023983	Longterm Effects	phpr	6.79
25101887	C0332128	Examined	fndg	5.18
25101887	C1883351	To	qlco	5.18
25101887	C3252847	VX 809	orch	5.18
25101887	C3252847	VX 809	phsu	5.18
25101887	C1282653	Entire respiratory epithelium	tisu	3.63
25101887	C0225385	Structure of respiratory epithelium	tisu	3.63
25101887	C0205195	Combined	qlco	3.59
25101887	C3811910	combination - answer to question	fndg	3.59
25101887	C1947911	combination of objects	phob	3.59
25101887	C0001554	Administration occupational activities	ocac	3.55
25101887	C1533734	Administration procedure	topp	3.55
25101887	C0205225	Primary	qlco	3.47
25101887	C0439631	Primary operation	topp	3.47
25101887	C0439612	True primary (qualifier value)	tmco	3.47
25101887	C2741958	VX-770	orch	3.45
25101887	C2826170	Immortalization	mbrt	3.43
25101887	C0439044	Living Alone	fndg	3.43
25101887	C0205171	Singular	qnco	3.43
25101887	C0679994	alone - group size	grpa	3.43
25101887	C0014239	Endoplasmic Reticulum	celc	45.77
25101887	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.99
25101887	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.99
25101887	C0031843	physiological aspects	phsf	14.64
25101887	C0013682	Efficiency	qnco	13.14
25101887	C1413365	CFTR gene	gngm	6.92
25101887	C0678227	Causing	ftcn	5.18
25101887	C0205216	Decreased	qnco	5.18
25101887	C0542341	Function	ftcn	5.18
25101887	C0700205	Function Axis	clas	5.18
25101887	C1705273	Mathematical Operator	inpr	5.18
25101887	C2741958	VX-770	orch	3.75
25101887	C1265608	Decreased density	fndg	3.74
25101887	C1185625	Anatomical compartments	inpr	3.61
25101887	C1382196	Compartments [PK]	npop	3.61
25101887	C0687676	Post	tmco	3.61
25101887	C1704687	Post Device Component	mnob	3.61
25101887	C2347098	Medical Product Stability	qlco	3.55
25101887	C0205360	Stable status	qlco	3.55
25101887	C0185026	Plication	topp	3.50
25101887	C0699040	Cell surface	celc	3.48
25101887	C0311400	Metabolic	ftcn	3.43
25101887	C1524026	Metabolic Process, Cellular	celf	3.43
25101887	C2707259	Metabolic:-:Point in time:^Patient:-	clna	3.43
25101887	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25101887	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25101887	C0038859	Suppressor Mutation	comd	13.02
25101887	C2945843	Site of	qlco	3.56
25101887	C1148916	nucleotide binding	moft	3.55
25101887	C1457869	Defect	ftcn	3.54
25101887	C0185026	Plication	topp	3.54
25101887	C1561503	Precision - second	idcn	3.54
25101887	C1705190	Second Suffix	qlco	3.54
25101887	C0565930	per second	qnco	3.54
25101887	C0205436	second (number)	qnco	3.54
25101887	C0457385	seconds	tmco	3.54
25101887	C2698172	Application Program Interface	inpr	3.54
25101887	C3541951	Concept model domain	inpr	3.54
25101887	C1880389	Domain (area of knowledge)	ftcn	3.54
25101887	C1708533	Interface Device Component	mnob	3.54
25101887	C1293130	Stabilization	topp	3.54
25101887	C1883221	Superkingdom (taxonomic category)	cnce	3.54
25101887	C4054723	Influence	cnce	3.51
25101887	C0309872	PREVENT (product)	phsu	3.51
25101887	C2741958	VX-770	orch	3.44
25101887	C1413365	CFTR gene	gngm	3.42
25101887	C0205263	Induce (action)	ftcn	3.42
25101887	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25101887	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25101887	C0009738	Congo	geoa	17.80
25101887	C0040363	Togo	geoa	17.80
25101887	C0041260	Tryptophanase	aapp	17.80
25101887	C0041260	Tryptophanase	enzy	17.80
25101887	C0004340	Australia	geoa	13.02
25101887	C0013682	Efficiency	qnco	13.01
25101887	C0027552	Needs	qlco	13.01
25101887	C0026882	Mutation	genf	9.85
25101887	C0009429	Combined Modality Therapy	topp	6.59
25101887	C3811819	CFTR wt Allele	gngm	5.18
25101887	C1883351	To	qlco	5.18
25101887	C1705535	suggestion	idcn	5.18
25101887	C0205170	Good	qlco	3.56
25101887	C0205448	Two	qnco	3.56
25101887	C3146287	Well	mnob	3.56
25101887	C0686904	Patient need for (contextual qualifier)	ftcn	3.55
25101887	C0814225	benefit	qnco	3.54
25101887	C0556895	Combination electrotherapy	topp	3.44
25101887	C2741958	VX-770	orch	3.43
25101887	C1413365	CFTR gene	gngm	3.42
25101887	C1947976	Correction (change)	ftcn	3.42
25101887	C1705565	Correction Report	inpr	3.42
25101887	C1517331	Further	spco	3.42
25101887	C2698650	Optimization	acty	3.42
25101887	C0392756	Reduced	qlco	3.42
25101887	C0205210	Clinical	qlco	3.42
25101887	C1553058	Neuropsychologist - Clinical	prog	3.42
25101887	C0237412	Psychologist - Clinical	prog	3.42
25101887	C0497591	Social Worker - Clinical	prog	3.42
25101887	C3854307	Presence (property)	qlco	3.42
25101887	C0150312	Present	qnco	3.42
25101887	C1709694	Processing (action)	acty	3.42
25101887	C0392148	Providing presence (regime/therapy)	topp	3.42
24771136	C0040363	Togo	geoa	17.80
24771136	C0041260	Tryptophanase	aapp	17.80
24771136	C0041260	Tryptophanase	enzy	17.80
24771136	C0010674	Cystic Fibrosis	dsyn	9.84
24771136	C0030705	Patients	podg	6.79
24771136	C0033684	Proteins	aapp	6.61
24771136	C0033684	Proteins	bacs	6.61
24771136	C1517001	Expected	inpr	5.18
24771136	C1718097	New medications	phsu	5.18
24771136	C1521840	Target	ftcn	5.18
24771136	C2986546	Target Lesion Identification	diap	5.18
24771136	C1883351	To	qlco	5.18
24771136	C0814225	benefit	qnco	5.18
24771136	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.85
24771136	C1457869	Defect	ftcn	3.60
24771136	C1527178	Basis - conceptual entity	ftcn	3.46
24771136	C1704735	Regulator	cnce	3.46
24771136	C1704734	Regulator Device Component	mnob	3.46
24771136	C0182953	Regulators (device)	medd	3.46
24771136	C0040363	Togo	geoa	54.24
24771136	C0041260	Tryptophanase	aapp	54.24
24771136	C0041260	Tryptophanase	enzy	54.24
24771136	C1883351	To	qlco	15.79
24771136	C0687133	Drug Interactions	moft	13.04
24771136	C0001688	aspects of adverse effects	ftcn	10.06
24771136	C0243092	Cellular Structures	celc	8.34
24771136	C0205108	Distal	spco	5.18
24771136	C0205224	Essential	qlco	5.18
24771136	C1292732	Investigates	ftcn	5.18
24771136	C0439861	Substance	sbst	5.18
24771136	C0879626	Adverse effects	patf	3.75
24771136	C4055445	Approved for Human Use Product	qlco	3.64
24771136	C1553874	Concept Status - Proposed	qlco	3.57
24771136	C1578820	Edit Status - Proposed	qlco	3.57
24771136	C0332149	Possible	qlco	3.43
24771136	C2362652	Possible diagnosis	qlco	3.43
24771136	C1705910	Possibly Related to Intervention	qlco	3.43
24771136	C0040363	Togo	geoa	17.80
24771136	C0041260	Tryptophanase	aapp	17.80
24771136	C0041260	Tryptophanase	enzy	17.80
24771136	C3264621	ivacaftor	orch	14.64
24771136	C3264621	ivacaftor	phsu	14.64
24771136	C3852684	lumacaftor	orch	14.64
24771136	C3852684	lumacaftor	phsu	14.64
24771136	C0728866	Drug effect	ftcn	9.92
24771136	C0031676	Phospholipids	bacs	9.78
24771136	C0031676	Phospholipids	orch	9.78
24771136	C0596901	Membrane	celc	6.79
24771136	C0025255	Tissue membrane	tisu	6.79
24771136	C1883351	To	qlco	5.18
24771136	C1273517	Used by	fndg	5.18
24771136	C3252847	VX 809	orch	3.75
24771136	C3252847	VX 809	phsu	3.75
24771136	C2741958	VX-770	orch	3.75
24771136	C1537058	small angle X ray scattering	lbpr	3.69
24771136	C4055445	Approved for Human Use Product	qlco	3.64
24771136	C1706182	Membrane Device Component	mnob	3.63
24771136	C0205540	Approved	qlco	3.57
24771136	C3853906	Digital Model Attachment	inpr	3.48
24771136	C3161035	Model	inpr	3.48
24771136	C3714583	Model - style/design	cnce	3.48
24771136	C3274659	Model Number	inpr	3.48
24771136	C0202177	Phospholipid measurement	lbpr	3.48
24771136	C0599746	synchrotron radiation	phpr	3.44
24771136	C1882932	Representation (action)	acty	3.43
24771136	C0205448	Two	qnco	3.43
24771136	C1721092	Unilamellar Vesicles	orch	19.20
24771136	C0031676	Phospholipids	bacs	9.81
24771136	C0031676	Phospholipids	orch	9.81
24771136	C0524865	Reconstructive Surgical Procedures	topp	6.69
24771136	C3687832	DRUGS	topp	5.18
24771136	C0205321	Penetration	ftcn	5.18
24771136	C0013227	Pharmaceutical Preparations	phsu	5.18
24771136	C0150312	Present	qnco	5.18
24771136	C3252847	VX 809	orch	5.18
24771136	C3252847	VX 809	phsu	5.18
24771136	C0332293	Treated with	topp	3.64
24771136	C2741958	VX-770	orch	3.64
24771136	C0020912	Optical Image Reconstruction	mcha	3.54
24771136	C0202177	Phospholipid measurement	lbpr	3.50
24771136	C0596488	electron density	mosq	3.43
24771136	C1979963	Profile (lab procedure)	lbpr	3.42
24771136	C2003903	Profiling (action)	ftcn	3.42
24771136	C0005758	Bulla	patf	12.96
24771136	C0004927	Behavior	inbe	8.34
24771136	C2707008	Behavior:-:Point in time:^Patient:-	clna	5.18
24771136	C0750492	Probably	idcn	5.18
24771136	C2741958	VX-770	orch	5.18
24771136	C3252847	VX 809	orch	3.75
24771136	C3252847	VX 809	phsu	3.75
24771136	C1704711	Distribution	ftcn	3.57
24771136	C1553872	Code System Type - Internal	qlco	3.56
24771136	C0205102	Internal	spco	3.56
24771136	C3273178	Leaflet	inpr	3.56
24771136	C1708664	Leaflet Device Component	mnob	3.56
24771136	C0332514	Asymmetry	spco	3.55
24771136	C3814530	Skin Vesicle	patf	3.50
24771136	C0333262	Vesicle (morphologic abnormality)	dsyn	3.50
24771136	C1622418	vesicle	celc	3.50
24771136	C1314792	Etiology	ftcn	14.64
24771136	C0015127	Etiology aspects	ftcn	11.49
24771136	C0016884	Future	tmco	6.63
24771136	C0596901	Membrane	celc	6.59
24771136	C0025255	Tissue membrane	tisu	6.59
24771136	C3687832	DRUGS	topp	5.18
24771136	C0013227	Pharmaceutical Preparations	phsu	5.18
24771136	C0750492	Probably	idcn	5.18
24771136	C1524003	Science of Etiology	cnce	5.18
24771136	C0872152	drug development	bmod	3.75
24771136	C2741673	Account number:Identifier:Point in time:^Patient:Nominal	clna	3.59
24771136	C2981730	Financial Account	inpr	3.59
24771136	C1292711	Part of	spco	3.59
24771136	C1883727	Taken	cnce	3.59
24771136	C0205321	Penetration	ftcn	3.56
24771136	C1706182	Membrane Device Component	mnob	3.44
24771136	C0441712	Mechanism (attribute)	ftcn	3.43
24771136	C0439690	Permeative	qlco	3.38
25447947	C0039798	therapeutic aspects	ftcn	22.35
25447947	C0376558	Life	idcn	9.99
25447947	C0012634	Disease	dsyn	9.87
25447947	C0001675	Adult	aggp	9.81
25447947	C0010674	Cystic Fibrosis	dsyn	9.74
25447947	C0008059	Child	aggp	9.74
25447947	C0038952	Continuance of life	acty	6.58
25447947	C0392747	Changing	ftcn	5.18
25447947	C0205214	Common (qualifier value)	qnco	3.68
25447947	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.68
25447947	C1522138	shared attribute	ftcn	3.68
25447947	C2981279	Decade	qnco	3.59
25447947	C0559758	Multisystem disorder	dsyn	3.59
25447947	C2986411	Improvement	cnce	3.51
25447947	C1706450	Legal Adult	humn	3.50
25447947	C1948052	Now (temporal qualifier)	tmco	3.50
25447947	C1517741	Last	qlco	3.48
25447947	C3151529	Lethal	fndg	3.43
25447947	C0680063	Offspring	famg	3.43
25447947	C0220921	survival aspects	ftcn	3.43
25447947	C1533734	Administration procedure	topp	3.42
25447947	C1705169	Biomaterial Treatment	cnce	3.42
25447947	C1546944	Event Seriousness - Significant	qlco	3.42
25447947	C0750502	Significant	idcn	3.42
25447947	C0237881	Statistical Significance	qnco	3.42
25447947	C0087111	Therapeutic procedure	topp	3.42
25447947	C1522326	Treating	ftcn	3.42
25447947	C3538994	Treatment Epoch	resa	3.42
25447947	C3887704	treatment - ActInformationManagementReason	hlca	3.42
25447947	C0282613	Developed Countries	qlco	14.64
25447947	C0008059	Child	aggp	11.49
25447947	C0010674	Cystic Fibrosis	dsyn	9.75
25447947	C0001675	Adult	aggp	9.73
25447947	C0680063	Offspring	famg	5.18
25447947	C2360800	Number of patients	fndg	3.60
25447947	C1706450	Legal Adult	humn	3.42
25447947	C0376558	Life	idcn	9.74
25447947	C0678226	Due to	ftcn	3.64
25447947	C1947933	care activity	acty	3.56
25447947	C2986411	Improvement	cnce	3.54
25447947	C1279919	Early	tmco	3.43
25447947	C0026565	Mortality Vital Statistics	qnco	20.95
25447947	C0026538	Morbidity - disease rate	qnco	19.20
25447947	C0037640	Somalia	geoa	17.80
25447947	C0026566	Aspects of mortality statistics	qnco	11.49
25447947	C0015127	Etiology aspects	ftcn	9.87
25447947	C0024109	Lung	bpoc	8.34
25447947	C0024115	Lung diseases	dsyn	8.34
25447947	C1521840	Target	ftcn	5.18
25447947	C0205234	Focal	spco	3.56
25447947	C1285542	Has focus	ftcn	3.56
25447947	C1524003	Science of Etiology	cnce	3.56
25447947	C0205314	New	qlco	3.43
25447947	C0205225	Primary	qlco	3.43
25447947	C0401925	Teaching principal	prog	3.43
25447947	C0087111	Therapeutic procedure	topp	3.43
25447947	C0220880	morbidity aspects	inpr	3.43
25447947	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
25447947	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
25447947	C0023981	Longitudinal Studies	resa	22.41
25447947	C0020792	Identification (Psychology)	menp	13.01
25447947	C0242481	Research Activities	resa	9.94
25447947	C0035168	research	resa	9.94
25447947	C0010674	Cystic Fibrosis	dsyn	9.84
25447947	C0000768	Congenital Abnormality	cgab	6.57
25447947	C1413365	CFTR gene	gngm	5.18
25447947	C3495919	Enthesitis-Related Arthritis	dsyn	3.56
25447947	C0205314	New	qlco	3.56
25447947	C0205396	Identified	qlco	3.55
25447947	C3846446	Prospective, NOS	fndg	3.49
25447947	C1880198	Cure (remedy)	cnce	3.43
25447947	C1737329	Dysmorphism	cgab	3.41
25447947	C0055363	Chloride Channels	aapp	19.52
25447947	C0055363	Chloride Channels	bacs	19.52
25447947	C0031843	physiological aspects	phsf	13.09
25447947	C0282443	Review [Publication Type]	inpr	11.49
25447947	C1552617	Act Class - review	idcn	5.18
25447947	C3854260	Advance	tmco	5.18
25447947	C0725066	Advance -- medical device	medd	5.18
25447947	C1706852	Article	inpr	5.18
25447947	C0017296	gene therapy	topp	5.18
25447947	C1513491	Most Recent	tmco	3.78
25447947	C0542341	Function	ftcn	3.63
25447947	C0700205	Function Axis	clas	3.63
25447947	C1705273	Mathematical Operator	inpr	3.63
25447947	C0243067	defects aspect	ftcn	3.55
25447947	C0230625	cell process structure	celc	3.43
25447947	C2349182	Correct (qualifier)	qlco	3.43
29073476	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
29073476	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
29073476	C0040452	Tooth root structure	bpoc	16.04
29073476	C1314792	Etiology	ftcn	13.02
29073476	C0010674	Cystic Fibrosis	dsyn	9.75
29073476	C0242481	Research Activities	resa	9.73
29073476	C0035168	research	resa	9.73
29073476	C0031847	physiopathological	ftcn	9.69
29073476	C0242726	Plant Roots	plnt	6.57
29073476	C1521840	Target	ftcn	5.18
29073476	C2986546	Target Lesion Identification	diap	5.18
29073476	C2981279	Decade	qnco	3.68
29073476	C0872152	drug development	bmod	3.62
29073476	C0444503	Breakthrough	qlco	3.54
29073476	C1444637	Past	tmco	3.50
29073476	C0205164	Major	qlco	3.42
29073476	C0205447	One	qnco	3.42
29073476	C0205082	Severe (severity modifier)	qlco	3.42
29073476	C1318154	Root body part	bpoc	3.42
29073476	C1705917	heirarchal root	idcn	3.42
29073476	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.38
29073476	C3887504	Dysfunction	cnce	3.38
29073476	C0277785	Functional disorder	patf	3.38
29073476	C0079613	Adoptive Immunotherapy	topp	25.67
29073476	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
29073476	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
29073476	C3264621	ivacaftor	orch	14.64
29073476	C3264621	ivacaftor	phsu	14.64
29073476	C1869853	SERPINA3 protein, human	aapp	13.05
29073476	C1869853	SERPINA3 protein, human	bacs	13.05
29073476	C0031843	physiological aspects	phsf	13.02
29073476	C0042153	utilization qualifier	ftcn	9.86
29073476	C3264627	Kalydeco	phsu	5.18
29073476	C4048375	Asthma Control Test Questionnaire	inpr	3.59
29073476	C0033414	Promotion (action)	acty	3.59
29073476	C3890007	SERPINA3 wt Allele	gngm	3.59
29073476	C0542341	Function	ftcn	3.56
29073476	C0700205	Function Axis	clas	3.56
29073476	C1705273	Mathematical Operator	inpr	3.56
29073476	C0205447	One	qnco	3.56
29073476	C0205540	Approved	qlco	3.55
29073476	C0205210	Clinical	qlco	3.55
29073476	C1553058	Neuropsychologist - Clinical	prog	3.55
29073476	C0237412	Psychologist - Clinical	prog	3.55
29073476	C0497591	Social Worker - Clinical	prog	3.55
29073476	C0457083	Usage	ftcn	3.55
29073476	C1947944	Use - dosing instruction imperative	inpr	3.55
29073476	C1413365	CFTR gene	gngm	3.43
29073476	C0205198	Compound	qlco	3.41
29073476	C1706082	Compound (substance)	chem	3.41
29073476	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
29073476	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
29073476	C0376525	Dimerization	npop	9.74
29073476	C1706388	Array Feature	cnce	5.18
29073476	C1521970	Characteristics	qlco	5.18
29073476	C2348519	Feature	qlco	5.18
29073476	C2346469	Image Feature	qlco	5.18
29073476	C0175566	Open	spco	5.18
29073476	C1882151	Opening	spco	5.18
29073476	C0947630	Scientific Study	lbpr	3.68
29073476	C0587267	Closed	ftcn	3.57
29073476	C3853906	Digital Model Attachment	inpr	3.56
29073476	C1708698	Light Emitting Diode Device Component	mnob	3.56
29073476	C3161035	Model	inpr	3.56
29073476	C3714583	Model - style/design	cnce	3.56
29073476	C3274659	Model Number	inpr	3.56
29073476	C1948027	Couple (action)	ftcn	3.55
29073476	C0332185	Recent	tmco	3.50
29073476	C1413365	CFTR gene	gngm	3.44
29073476	C1292780	Therapy-related myelodysplastic syndrome	neop	3.44
29073476	C3842459	Energetic	fndg	3.43
29073476	C1518456	Nucleosome Binding Domain	amas	3.43
29073476	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
29073476	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
29073476	C0026377	Molecular Conformation	spco	13.01
29073476	C2744579	ATP8A2 protein, human	aapp	12.96
29073476	C2744579	ATP8A2 protein, human	enzy	12.96
29073476	C3264621	ivacaftor	orch	12.90
29073476	C3264621	ivacaftor	phsu	12.90
29073476	C0376525	Dimerization	npop	9.74
29073476	C0043227	Work	ocac	6.72
29073476	C2349975	Enhance (action)	acty	5.18
29073476	C1547282	Show	anim	3.98
29073476	C0243071	Analog	chvs	3.68
29073476	C1705938	Base - General Qualifier	idcn	3.57
29073476	C1527178	Basis - conceptual entity	ftcn	3.57
29073476	C3853906	Digital Model Attachment	inpr	3.57
29073476	C3161035	Model	inpr	3.57
29073476	C3714583	Model - style/design	cnce	3.57
29073476	C3274659	Model Number	inpr	3.57
29073476	C0184512	Stabilized (qualifier value)	qlco	3.44
29073476	C1413365	CFTR gene	gngm	3.43
29073476	C1518456	Nucleosome Binding Domain	amas	3.43
29073476	C0439799	Channel	spco	3.42
29073476	C1706095	Channel Object	cnce	3.42
29073476	C0175566	Open	spco	3.42
29073476	C1292780	Therapy-related myelodysplastic syndrome	neop	3.42
29073476	C3264621	ivacaftor	orch	12.89
29073476	C3264621	ivacaftor	phsu	12.89
29073476	C1512612	Ideal	qlco	3.59
29073476	C0871003	omnipotence	inbe	3.56
29073476	C0475806	1/3 meter (distance vision finding)	fndg	3.43
29073476	C1706276	Near	qlco	3.43
29073476	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
29073476	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
29073476	C0033204	Probability	qnco	16.18
29073476	C1511253	Boost	ftcn	5.18
29073476	C1874596	Boost Nutrition Supplement	food	5.18
29073476	C2587213	Control function	ftcn	5.18
29073476	C3853906	Digital Model Attachment	inpr	5.18
29073476	C0522501	Massive	qlco	5.18
29073476	C3161035	Model	inpr	5.18
29073476	C3714583	Model - style/design	cnce	5.18
29073476	C3274659	Model Number	inpr	5.18
29073476	C1882979	Scientific Control	cnce	5.18
29073476	C3274648	True Control Status	qlco	5.18
29073476	C0243148	control aspects	qlco	5.18
29073476	C1550141	control substance	sbst	5.18
29073476	C0301641	Macromolecular alteration	moft	4.12
29073476	C3541888	CDISC Events Class	clas	3.61
29073476	C0441471	Event	evnt	3.61
29073476	C0449445	Approach	spco	3.59
29073476	C1292724	Procedural approach	ftcn	3.59
29073476	C0175566	Open	spco	3.56
29073476	C1521991	Molecular	qlco	3.47
29073476	C0439064	Numerous	qnco	3.45
29073476	C4054723	Influence	cnce	3.44
29073476	C1413365	CFTR gene	gngm	3.43
25755212	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
25755212	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
25755212	C3264621	ivacaftor	orch	13.05
25755212	C3264621	ivacaftor	phsu	13.05
25755212	C0010674	Cystic Fibrosis	dsyn	11.49
25755212	C1257890	Population Group	popg	11.49
25755212	C0008972	Clinical Research	resa	6.76
25755212	C0030705	Patients	podg	6.59
25755212	C1705428	Group Object	cnce	5.18
25755212	C0441833	Groups	idcn	5.18
25755212	C0687744	Social group	popg	5.18
25755212	C1552516	Specialty Group	hcro	5.18
25755212	C1705429	User Group	popg	5.18
25755212	C1547282	Show	anim	3.98
25755212	C0332293	Treated with	topp	3.72
25755212	C1413365	CFTR gene	gngm	3.68
25755212	C1274040	Result	ftcn	3.59
25755212	C1561611	Admission Level of Care Code - Improved	inpr	3.48
25755212	C0332272	Better	qlco	3.48
25755212	C0205210	Clinical	qlco	3.48
25755212	C0184511	Improved	qlco	3.48
25755212	C1553058	Neuropsychologist - Clinical	prog	3.48
25755212	C0237412	Psychologist - Clinical	prog	3.48
25755212	C0497591	Social Worker - Clinical	prog	3.48
25755212	C0282461	Phase 3 Clinical Trials	resa	22.40
25755212	C0162340	Comprehension	menp	14.64
25755212	C3264621	ivacaftor	orch	12.89
25755212	C3264621	ivacaftor	phsu	12.89
25755212	C0332272	Better	qlco	5.18
25755212	C0332128	Examined	fndg	3.68
25755212	C2986904	Respiratory Domain	idcn	3.68
25755212	C0556581	Retinol equivalents	qnco	3.68
25755212	C1518681	Outcome of Therapy	fndg	3.60
25755212	C1511726	Data	idcn	3.56
25755212	C3714741	Data (eukaryote)	euka	3.56
25755212	C3245479	Data call receiving device	medd	3.56
25755212	C0520511	Distributing	idcn	3.54
25755212	C1704711	Distribution	ftcn	3.54
25755212	C1561566	FEV1 Adverse Event	fndg	3.44
25755212	C0429706	Forced expiratory volume in 1 second finding	fndg	3.44
25755212	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.44
25755212	C0237401	Individual	humn	3.42
25755212	C0027361	Persons	popg	3.42
25755212	C0871261	Response process	orga	3.42
25755212	C0030705	Patients	podg	13.57
25755212	C1524024	analysis aspect	ftcn	13.01
25755212	C3264621	ivacaftor	orch	12.90
25755212	C3264621	ivacaftor	phsu	12.90
25755212	C0032042	Placebos	topp	8.34
25755212	C1706408	Placebo Control	resa	5.18
25755212	C1514756	Receive	qlco	5.18
25755212	C1696465	placebo	bodm	5.18
25755212	C1704632	Disease Response	fndg	3.63
25755212	C2911692	Response (communication)	menp	3.63
25755212	C1706817	Response (statement)	inpr	3.63
25755212	C0871261	Response process	orga	3.63
25755212	C1516050	Assignment - action	ftcn	3.59
25755212	C1552601	PersonNameUse - assigned	inpr	3.59
25755212	C0439230	week	tmco	3.57
25755212	C0936012	Analysis	resa	3.55
25755212	C0002778	Analysis of substances	lbpr	3.55
25755212	C1561566	FEV1 Adverse Event	fndg	3.53
25755212	C0429706	Forced expiratory volume in 1 second finding	fndg	3.53
25755212	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.53
25755212	C0369718	N not otherwise specified Antibody	aapp	3.50
25755212	C0369718	N not otherwise specified Antibody	imft	3.50
25755212	C0441922	N+ (tumor staging)	inpr	3.50
25755212	C0687676	Post	tmco	3.42
25755212	C1704687	Post Device Component	mnob	3.42
25755212	C0005910	Body Weight	orga	24.11
25755212	C0040363	Togo	geoa	17.80
25755212	C0041260	Tryptophanase	aapp	17.80
25755212	C0041260	Tryptophanase	enzy	17.80
25755212	C0220825	Evaluation	hlca	14.64
25755212	C0684010	Rabbi	prog	13.14
25755212	C1257890	Population Group	popg	11.49
25755212	C0024109	Lung	bpoc	6.66
25755212	C0428295	Cystic fibrosis sweat test	lbpr	5.18
25755212	C1704632	Disease Response	fndg	5.18
25755212	C1561566	FEV1 Adverse Event	fndg	5.18
25755212	C0429706	Forced expiratory volume in 1 second finding	fndg	5.18
25755212	C1705428	Group Object	cnce	5.18
25755212	C0441833	Groups	idcn	5.18
25755212	C1705104	Importance Weight	idcn	5.18
25755212	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	5.18
25755212	C2911692	Response (communication)	menp	5.18
25755212	C1706817	Response (statement)	inpr	5.18
25755212	C0871261	Response process	orga	5.18
25755212	C0687744	Social group	popg	5.18
25755212	C1552516	Specialty Group	hcro	5.18
25755212	C1304760	Sweat chloride level result	lbtr	5.18
25755212	C1552839	Table Rules - groups	inpr	5.18
25755212	C1883708	Then	tmco	5.18
25755212	C1883351	To	qlco	5.18
25755212	C1273517	Used by	fndg	5.18
25755212	C1705429	User Group	popg	5.18
25755212	C1305866	Weighing patient	diap	5.18
25755212	C0043100	Weight	qnco	5.18
25755212	C2603358	R prime	clna	3.68
25755212	C0205090	Right	spco	3.68
25755212	C2709248	Pulmonary (qualifier value)	qlco	3.50
25755212	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.50
25755212	C0027552	Needs	qlco	13.07
25755212	C1274040	Result	ftcn	5.18
25755212	C0449788	Count of entities	qnco	3.60
25755212	C0237753	Numbers	qnco	3.60
25755212	C0686904	Patient need for (contextual qualifier)	ftcn	3.60
25755212	C0087111	Therapeutic procedure	topp	3.60
25755212	C1522326	Treating	ftcn	3.60
25755212	C1292734	Treatment intent	ftcn	3.60
25755212	C0444686	Calculated (origins)	ftcn	3.57
25755212	C1443182	Calculated (procedure)	lbpr	3.57
25755212	C1441506	Calculation	acty	3.57
25755212	C1552740	Entity Determiner - specific	inpr	3.57
25755212	C0205369	Specific qualifier value	qlco	3.57
25755212	C0449864	Threshold	qlco	3.57
25755212	C0039798	therapeutic aspects	ftcn	22.43
25755212	C0684010	Rabbi	prog	13.14
25755212	C3264621	ivacaftor	orch	13.02
25755212	C3264621	ivacaftor	phsu	13.02
25755212	C0032042	Placebos	topp	8.34
25755212	C1522326	Treating	ftcn	7.10
25755212	C1274040	Result	ftcn	6.98
25755212	C0030705	Patients	podg	6.71
25755212	C0024109	Lung	bpoc	6.59
25755212	C1548802	Body Site Modifier - Lower	blor	5.18
25755212	C0428295	Cystic fibrosis sweat test	lbpr	5.18
25755212	C2003888	Lower (action)	acty	5.18
25755212	C0441994	Lower - spatial qualifier	spco	5.18
25755212	C1706408	Placebo Control	resa	5.18
25755212	C1304760	Sweat chloride level result	lbtr	5.18
25755212	C1696465	placebo	bodm	5.18
25755212	C1705241	Delta (difference)	qnco	3.68
25755212	C1705242	Different	qlco	3.68
25755212	C2603358	R prime	clna	3.68
25755212	C0205090	Right	spco	3.68
25755212	C0237881	Statistical Significance	qnco	3.61
25755212	C0439603	Frequencies (time pattern)	tmco	3.56
25755212	C3898838	How Often	inpr	3.56
25755212	C1561548	Kind of quantity - Frequency	qlco	3.56
25755212	C1441672	Observed	ftcn	3.56
25755212	C0871396	Spatial Frequency	qnco	3.56
25755212	C1705502	Statistical Frequency	qnco	3.56
25755212	C0376249	With frequency	qnco	3.56
25755212	C2986411	Improvement	cnce	3.53
25755212	C1533734	Administration procedure	topp	3.50
25755212	C1705169	Biomaterial Treatment	cnce	3.50
25755212	C0444598	Middle	spco	3.50
25755212	C0549183	Midline (qualifier value)	spco	3.50
25755212	C1552826	Table Cell Vertical Align - middle	inpr	3.50
25755212	C0087111	Therapeutic procedure	topp	3.50
25755212	C3538994	Treatment Epoch	resa	3.50
25755212	C1282910	Upper	spco	3.50
25755212	C3887704	treatment - ActInformationManagementReason	hlca	3.50
25755212	C1561566	FEV1 Adverse Event	fndg	3.46
25755212	C0429706	Forced expiratory volume in 1 second finding	fndg	3.46
25755212	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.46
25755212	C0237753	Numbers	qnco	3.43
25755212	C2709248	Pulmonary (qualifier value)	qlco	3.43
25755212	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.43
25755212	C3816745	1+	fndg	5.18
25755212	C2827734	1+ Score	qnco	5.18
25755212	C2981698	1+ Score, WHO	clas	5.18
25755212	C1561566	FEV1 Adverse Event	fndg	3.75
25755212	C0429706	Forced expiratory volume in 1 second finding	fndg	3.75
25755212	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.75
25755212	C1417750	NNT gene	gngm	3.54
25755212	C1882327	Percent of Predicted Value	qnco	3.48
25755212	C0681842	prediction	idcn	3.48
25755212	C2986411	Improvement	cnce	3.42
25755212	C0043094	Weight Gain	fndg	25.76
25755212	C0728893	+5	qnco	5.18
25755212	C0439084	>5	qnco	5.18
25755212	C2919042	U-90	orch	5.18
25755212	C2919042	U-90	phsu	5.18
25755212	C0040363	Togo	geoa	17.80
25755212	C0041260	Tryptophanase	aapp	17.80
25755212	C0041260	Tryptophanase	enzy	17.80
25755212	C0024109	Lung	bpoc	6.66
25755212	C3838680	3+ Answer to Question	fndg	5.18
25755212	C2827736	3+ Score	qnco	5.18
25755212	C2981702	3+ Score, WHO	clas	5.18
25755212	C0439086	<3 (qualifier value)	qnco	5.18
25755212	C0309872	PREVENT (product)	phsu	5.18
25755212	C1883351	To	qlco	5.18
25755212	C2709248	Pulmonary (qualifier value)	qlco	3.50
25755212	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.50
25755212	C0039798	therapeutic aspects	ftcn	22.49
25755212	C0040363	Togo	geoa	17.80
25755212	C0041260	Tryptophanase	aapp	17.80
25755212	C0041260	Tryptophanase	enzy	17.80
25755212	C1524024	analysis aspect	ftcn	14.64
25755212	C0030705	Patients	podg	13.59
25755212	C3264621	ivacaftor	orch	13.03
25755212	C3264621	ivacaftor	phsu	13.03
25755212	C0936012	Analysis	resa	5.18
25755212	C0002778	Analysis of substances	lbpr	5.18
25755212	C1883351	To	qlco	5.18
25755212	C0683325	clinical aspects	clna	5.18
25755212	C3245505	potential	qlco	5.18
25755212	C1705535	suggestion	idcn	5.18
25755212	C2348205	Similarity	qlco	3.64
25755212	C0087111	Therapeutic procedure	topp	3.57
25755212	C1363945	Therapy Object (animal model)	fndg	3.57
25755212	C0814225	benefit	qnco	3.57
25755212	C0680220	majority	socb	3.57
24855632	C0010674	Cystic Fibrosis	dsyn	23.12
24855632	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.41
24855632	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.41
24855632	C0055363	Chloride Channels	aapp	19.33
24855632	C0055363	Chloride Channels	bacs	19.33
24855632	C1314792	Etiology	ftcn	14.64
24855632	C0162340	Comprehension	menp	13.01
24855632	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	12.88
24855632	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	12.88
24855632	C0015127	Etiology aspects	ftcn	11.49
24855632	C0031847	physiopathological	ftcn	9.99
24855632	C0007603	Plasma membrane	celc	9.74
24855632	C1521991	Molecular	qlco	6.95
24855632	C1524003	Science of Etiology	cnce	5.18
24855632	C1521840	Target	ftcn	5.18
24855632	C2986546	Target Lesion Identification	diap	5.18
24855632	C3687832	DRUGS	topp	3.68
24855632	C0277785	Functional disorder	patf	3.68
24855632	C0013227	Pharmaceutical Preparations	phsu	3.68
24855632	C0243067	defects aspect	ftcn	3.54
24855632	C0205314	New	qlco	3.50
24855632	C0679622	literary novel	inpr	3.50
24855632	C1413365	CFTR gene	gngm	3.48
24855632	C0332272	Better	qlco	3.43
24855632	C0007634	Cells	cell	3.43
24855632	C0178539	Cellular	lbpr	3.43
24855632	C1879547	Activation action	acty	3.42
24855632	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24855632	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24855632	C0040363	Togo	geoa	17.80
24855632	C0041260	Tryptophanase	aapp	17.80
24855632	C0041260	Tryptophanase	enzy	17.80
24855632	C0085732	Ability	orga	14.64
24855632	C0019247	Hereditary Diseases	dsyn	6.59
24855632	C1299581	Able (finding)	fndg	5.18
24855632	C1550043	Container status - Identified	fndg	5.18
24855632	C3714578	Fix	phpr	5.18
24855632	C0205396	Identified	qlco	5.18
24855632	C1328819	Small Molecule	orch	5.18
24855632	C1883351	To	qlco	5.18
24855632	C0243067	defects aspect	ftcn	3.54
24855632	C0439659	Beginning	tmco	3.51
24855632	C0872187	high throughput screening	diap	3.46
24855632	C0301863	"""U"" lymphocyte"	cell	3.44
24855632	C1705938	Base - General Qualifier	idcn	3.42
24855632	C1527178	Basis - conceptual entity	ftcn	3.42
24855632	C1413365	CFTR gene	gngm	3.42
24855632	C0678227	Causing	ftcn	3.42
24855632	C1552740	Entity Determiner - specific	inpr	3.42
24855632	C0205369	Specific qualifier value	qlco	3.42
24855632	C3540763	VARIOUS DRUG CLASSES IN ATC	phsu	3.42
24855632	C0440102	Various patch test substance	irda	3.42
24855632	C0596988	mutant	comd	3.42
24855632	C3540765	various allergen extracts	imft	3.42
24855632	C3540765	various allergen extracts	phsu	3.42
24855632	C3540008	various antiinfectives and antiseptics for local oral treatment	phsu	3.42
24855632	C3540766	various antiseptic throat preparations	phsu	3.42
24855632	C3540762	various other agents for local oral treatment in ATC	phsu	3.42
24855632	C3540769	various other intestinal adsorbents in ATC	phsu	3.42
24855632	C3540761	various other nasal preparations in ATC	phsu	3.42
24855632	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
24855632	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
24855632	C0009738	Congo	geoa	16.04
24855632	C3264621	ivacaftor	orch	12.89
24855632	C3264621	ivacaftor	phsu	12.89
24855632	C0026882	Mutation	genf	9.73
24855632	C2349975	Enhance (action)	acty	5.18
24855632	C1153420	chloride channel activity	moft	3.81
24855632	C1554124	New type	inpr	3.57
24855632	C0678723	Biologic Development	orgf	3.55
24855632	C1527148	Development	ftcn	3.55
24855632	C0243107	development aspects	phsf	3.55
24855632	C2349182	Correct (qualifier)	qlco	3.50
24855632	C1413365	CFTR gene	gngm	3.47
24855632	C1328819	Small Molecule	orch	3.45
24855632	C0597535	Success	socb	3.43
24855632	C1272703	Successful	qlco	3.43
24855632	C3811819	CFTR wt Allele	gngm	3.42
24855632	C0678227	Causing	ftcn	3.42
24855632	C0205214	Common (qualifier value)	qnco	3.42
24855632	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
24855632	C1705285	Mutation Abnormality	comd	3.42
24855632	C1522138	shared attribute	ftcn	3.42
24855632	C0205198	Compound	qlco	3.41
24855632	C1706082	Compound (substance)	chem	3.41
24855632	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.46
24855632	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.46
24855632	C0040363	Togo	geoa	17.80
24855632	C0041260	Tryptophanase	aapp	17.80
24855632	C0041260	Tryptophanase	enzy	17.80
24855632	C0009738	Congo	geoa	16.21
24855632	C0023693	Light	npop	16.18
24855632	C1524059	mechanism of action qualifier	ftcn	13.01
24855632	C0031327	Drug Kinetics	phsf	9.86
24855632	C1883351	To	qlco	5.18
24855632	C0332281	Associated with	qlco	3.72
24855632	C1457887	Symptoms	sosy	3.68
24855632	C0683368	Symptoms aspect	ftcn	3.68
24855632	C0596988	mutant	comd	3.68
24855632	C0947630	Scientific Study	lbpr	3.63
24855632	C3811819	CFTR wt Allele	gngm	3.59
24855632	C1516084	Attempt	evnt	3.57
24855632	C1521840	Target	ftcn	3.57
24855632	C4050248	Borg Scale Rating of Perceived Exertion Score 11	inpr	3.56
24855632	C1881376	Light (qualifier)	qlco	3.56
24855632	C3842678	Light - subjective measurement	fndg	3.56
24855632	C1306462	Light color	ftcn	3.56
24855632	C1413365	CFTR gene	gngm	3.53
24855632	C0205234	Focal	spco	3.53
24855632	C1285542	Has focus	ftcn	3.53
24855632	C1517586	Investigational	qlco	3.53
24855632	C3245491	investigational monitoring program	hlca	3.53
24855632	C3245505	potential	qlco	3.53
24855632	C0205210	Clinical	qlco	3.50
24855632	C1553058	Neuropsychologist - Clinical	prog	3.50
24855632	C0237412	Psychologist - Clinical	prog	3.50
24855632	C0497591	Social Worker - Clinical	prog	3.50
24855632	C0332185	Recent	tmco	3.48
24855632	C0205314	New	qlco	3.43
24855632	C0040363	Togo	geoa	17.80
24855632	C0041260	Tryptophanase	aapp	17.80
24855632	C0041260	Tryptophanase	enzy	17.80
24855632	C1553874	Concept Status - Proposed	qlco	5.18
24855632	C1578820	Edit Status - Proposed	qlco	5.18
24855632	C1883351	To	qlco	5.18
24855632	C1947976	Correction (change)	ftcn	3.63
24855632	C1705565	Correction Report	inpr	3.63
24855632	C0449445	Approach	spco	3.61
24855632	C1299351	Abnormally high	qlco	3.48
24855632	C0205250	High	qlco	3.48
24855632	C3889660	High Mitosis-Karyorrhexis Index	qnco	3.48
24855632	C2700149	Value Above Reference Range	inpr	3.48
24855632	C3887512	high - ActExposureLevelCode	idcn	3.48
24855632	C3669471	Chicken laying egg for human food	bird	3.47
24855632	C1522408	Coating (film)	qlco	3.47
24855632	C0439064	Numerous	qnco	3.47
24855632	C0934502	anatomical layer	bpoc	3.47
24855632	C2826293	Clinical Significance	fndg	3.43
24855632	C1274040	Result	ftcn	3.43
24855632	C3540027	Adrenergic and dopaminergic agents combinations	phsu	3.42
24855632	C3539975	Aluminium antacid compound combinations	phsu	3.42
24855632	C3539963	Amide local anesthetic combinations	orch	3.42
24855632	C3539963	Amide local anesthetic combinations	phsu	3.42
24855632	C3539979	Antiinfective irrigating solution combinations	phsu	3.42
24855632	C3540722	Beta-lactamase sensitive penicillin combinations	antb	3.42
24855632	C3540722	Beta-lactamase sensitive penicillin combinations	orch	3.42
24855632	C3539977	Calcium antacid compound combinations	phsu	3.42
24855632	C3540720	Caries prophylactic agent combinations	phsu	3.42
24855632	C3539972	Combination solutions for parenteral nutrition	phsu	3.42
24855632	C0453882	Combinations (Undergarment)	mnob	3.42
24855632	C0205195	Combined	qlco	3.42
24855632	C3539968	Enema combinations	phsu	3.42
24855632	C3540026	Hepatitis vaccine combinations	aapp	3.42
24855632	C3540026	Hepatitis vaccine combinations	imft	3.42
24855632	C3540026	Hepatitis vaccine combinations	phsu	3.42
24855632	C3540723	Insulins and analogs for injection, fast-acting combinations	phsu	3.42
24855632	C3539974	Insulins and analogs for injection, intermediate-acting combinations	phsu	3.42
24855632	C3539967	Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations	phsu	3.42
24855632	C3540719	Intermediate-acting sulfonamide combinations	orch	3.42
24855632	C3540719	Intermediate-acting sulfonamide combinations	phsu	3.42
24855632	C3539965	Local hemostatic combinations	phsu	3.42
24855632	C3539959	Long-acting sulfonamide combinations	orch	3.42
24855632	C3539959	Long-acting sulfonamide combinations	phsu	3.42
24855632	C3539956	Magnesium antacid compound combinations	phsu	3.42
24855632	C3854036	Other anti-dementia drug combinations in ATC	phsu	3.42
24855632	C3539973	Other antifungal combinations for topical use in ATC	phsu	3.42
24855632	C3539960	Other intestinal adsorbent combinations in ATC	phsu	3.42
24855632	C3540028	Other irrigating solution combinations in ATC	phsu	3.42
24855632	C3539976	Penicillins with extended spectrum combinations	antb	3.42
24855632	C3539976	Penicillins with extended spectrum combinations	orch	3.42
24855632	C3539961	Platelet aggregation inhibitor combinations excl. heparin	phsu	3.42
24855632	C3540740	Potassium supplement combinations	phsu	3.42
24855632	C3539182	Salt solution combinations	phsu	3.42
24855632	C3539181	Short-acting sulfonamide combinations	orch	3.42
24855632	C3539181	Short-acting sulfonamide combinations	phsu	3.42
24855632	C3539969	Specific immunoglobulin combinations	aapp	3.42
24855632	C3539969	Specific immunoglobulin combinations	imft	3.42
24855632	C3539969	Specific immunoglobulin combinations	phsu	3.42
24855632	C3811910	combination - answer to question	fndg	3.42
24855632	C3539970	combination drugs used in erectile dysfunction	phsu	3.42
24855632	C1947911	combination of objects	phob	3.42
24855632	C3539978	expectorant combinations excluding combinations with cough suppressants	phsu	3.42
24855632	C3540724	expectorant combinations, excl. combinations with cough suppressants	phsu	3.42
24855632	C3540031	gonadotropin combinations	aapp	3.42
24855632	C3540031	gonadotropin combinations	horm	3.42
24855632	C3540031	gonadotropin combinations	phsu	3.42
24855632	C3539966	insulins and analogs for injection combinations, long-acting	phsu	3.42
24855632	C3539964	local opthalmologic anesthetic combinations	phsu	3.42
24855632	C3539955	lung surfactant combinations	phsu	3.42
24855632	C3539957	opium alkaloids and derivative combination cough suppressants	phsu	3.42
24855632	C3540030	other cough suppressant combinations in ATC	phsu	3.42
24855632	C3540721	other nasal preparation combinations in ATC	phsu	3.42
24855632	C3539971	otologic analgesic and anesthetic combinations	phsu	3.42
24855632	C3539954	topical antibiotic combinations	phsu	3.42
24855632	C3539962	vitamin D and analog combinations	phsu	3.42
24855632	C3245505	potential	qlco	3.40
24855632	C0009738	Congo	geoa	16.03
24855632	C0016884	Future	tmco	6.57
24855632	C0030705	Patients	podg	6.57
24855632	C0348078	Qualitative form	qlco	5.18
24855632	C0332479	Shapes	spco	5.18
24855632	C0522512	With shape	spco	5.18
24855632	C0233820	Insight	menp	3.68
24855632	C1301820	Obtain	ftcn	3.57
24855632	C0947630	Scientific Study	lbpr	3.57
24855632	C0678723	Biologic Development	orgf	3.54
24855632	C1527148	Development	ftcn	3.54
24855632	C0243107	development aspects	phsf	3.54
24855632	C0441712	Mechanism (attribute)	ftcn	3.45
24855632	C1706376	Mechanism Component of Device	mnob	3.45
24855632	C3811819	CFTR wt Allele	gngm	3.42
24855632	C0723712	Therapeutic brand of coal tar	orch	3.42
24855632	C0723712	Therapeutic brand of coal tar	phsu	3.42
24855632	C0087111	Therapeutic procedure	topp	3.42
24855632	C0680220	majority	socb	3.42
24855632	C0814230	veterans alcoholism screening test (VAST)	inpr	3.42
22942289	C0079613	Adoptive Immunotherapy	topp	25.65
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
22942289	C1869853	SERPINA3 protein, human	aapp	13.03
22942289	C1869853	SERPINA3 protein, human	bacs	13.03
22942289	C0014609	Epithelium	tisu	6.56
22942289	C1413365	CFTR gene	gngm	5.18
22942289	C0596119	apical membrane	celc	3.59
22942289	C4048375	Asthma Control Test Questionnaire	inpr	3.57
22942289	C0439799	Channel	spco	3.57
22942289	C1706095	Channel Object	cnce	3.57
22942289	C3890007	SERPINA3 wt Allele	gngm	3.57
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.53
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.53
22942289	C0017337	Genes	gngm	16.04
22942289	C0023175	Lead	elii	13.02
22942289	C0023175	Lead	hops	13.02
22942289	C0031847	physiopathological	ftcn	9.99
22942289	C0026882	Mutation	genf	9.85
22942289	C0010674	Cystic Fibrosis	dsyn	9.74
22942289	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.68
22942289	C3887504	Dysfunction	cnce	3.68
22942289	C0277785	Functional disorder	patf	3.68
22942289	C2985434	Disease-causing Mutation	comd	3.58
22942289	C3275067	Cardiac Lead Procedure	topp	3.56
22942289	C2348269	Dietary Lead	elii	3.56
22942289	C1522538	Leading	ftcn	3.56
22942289	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.56
22942289	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.56
22942289	C0868928	Case (situation)	ftcn	3.54
22942289	C1706256	Clinical Study Case	cnce	3.54
22942289	C1705285	Mutation Abnormality	comd	3.54
22942289	C1706255	Packaging Case	medd	3.54
22942289	C0439799	Channel	spco	3.50
22942289	C1706095	Channel Object	cnce	3.50
22942289	C0040363	Togo	geoa	17.80
22942289	C0041260	Tryptophanase	aapp	17.80
22942289	C0041260	Tryptophanase	enzy	17.80
22942289	C3264621	ivacaftor	orch	14.64
22942289	C3264621	ivacaftor	phsu	14.64
22942289	C0043240	Wound Healing	orgf	13.01
22942289	C0026882	Mutation	genf	9.99
22942289	C0030705	Patients	podg	8.34
22942289	C0035245	Respiratory physiology	ortf	6.62
22942289	C1704689	Bearing Device Component	medd	5.18
22942289	C1328819	Small Molecule	orch	5.18
22942289	C1883351	To	qlco	5.18
22942289	C2741958	VX-770	orch	5.18
22942289	C1704666	Hyperlink	inpr	3.98
22942289	C1517892	Links List	inpr	3.98
22942289	C1547282	Show	anim	3.98
22942289	C1705285	Mutation Abnormality	comd	3.68
22942289	C0332185	Recent	tmco	3.68
22942289	C1280519	Effectiveness	qlco	3.56
22942289	C1707887	Efficacy Study	resa	3.56
22942289	C0439799	Channel	spco	3.55
22942289	C1706095	Channel Object	cnce	3.55
22942289	C1457869	Defect	ftcn	3.55
22942289	C0374711	Surgical repair	topp	3.55
22942289	C1524059	mechanism of action qualifier	ftcn	13.08
22942289	C0031327	Drug Kinetics	phsf	9.92
22942289	C1522508	Details	qlco	5.18
22942289	C1518422	Negation	ftcn	5.18
22942289	C0443289	Revealed	qlco	5.18
22942289	C0947630	Scientific Study	lbpr	5.18
22942289	C1561567	detail - Response Level	ftcn	5.18
22942289	C2741958	VX-770	orch	3.44
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
22942289	C0031715	Phosphorylation	moft	13.05
22942289	C0020291	Hydrolysis	npop	11.49
22942289	C0851285	Regulation	gora	9.90
22942289	C1148923	atp binding	moft	5.18
22942289	C1153410	channel activity	moft	3.75
22942289	C1158886	Protein phosphorylation	moft	3.59
22942289	C1413365	CFTR gene	gngm	3.48
22942289	C0392747	Changing	ftcn	5.18
22942289	C0205447	One	qnco	5.18
22942289	C2741958	VX-770	orch	5.18
22942289	C3541888	CDISC Events Class	clas	3.56
22942289	C0441471	Event	evnt	3.56
22942289	C0311400	Metabolic	ftcn	3.56
22942289	C1524026	Metabolic Process, Cellular	celf	3.56
22942289	C2707259	Metabolic:-:Point in time:^Patient:-	clna	3.56
22942289	C0205172	More	ftcn	3.56
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
22942289	C1704459	Device Component System	mnob	7.45
22942289	C0449913	System	ftcn	7.45
22942289	C1553451	System - kit	mnob	7.45
22942289	C0562342	Empowered	menp	5.18
22942289	C1171285	Enabling	menp	5.18
22942289	C0332128	Examined	fndg	5.18
22942289	C0557651	Room of building - Study	mnob	5.18
22942289	C2603343	Study	resa	5.18
22942289	C1524063	Use of	ftcn	5.18
22942289	C1561536	*Activity (kind of quantity)	idcn	3.63
22942289	C0205177	Active	ftcn	3.63
22942289	C0441655	Activities	acty	3.63
22942289	C3668946	Activity (animal life circumstance)	fndg	3.63
22942289	C4049939	FDA Establishment Activity Terminology	inpr	3.63
22942289	C0439167	Percent Activity	qnco	3.63
22942289	C4049938	Physical Activity Measurement	lbpr	3.63
22942289	C0683951	control variable	qnco	3.60
22942289	C2741958	VX-770	orch	3.53
22942289	C0597302	protein reconstitution	moft	3.44
22942289	C0205309	Known	qlco	3.43
22942289	C1704735	Regulator	cnce	3.43
22942289	C0220905	regulatory	rnlw	3.43
22942289	C1413365	CFTR gene	gngm	3.42
22942289	C1998793	Purifying	ftcn	3.42
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
22942289	C0023768	Lipid Bilayers	celc	16.22
22942289	C0072422	proteoliposomes	orch	13.05
22942289	C0683901	Airplanes	mnob	12.96
22942289	C0005507	Biological Assay	lbpr	6.77
22942289	C1413365	CFTR gene	gngm	5.18
22942289	C1524063	Use of	ftcn	5.18
22942289	C0557651	Room of building - Study	mnob	3.98
22942289	C2603343	Study	resa	3.98
22942289	C1510438	Assay	lbpr	3.61
22942289	C0243073	assay qualifier	qlco	3.61
22942289	C0686907	Consequence of	ftcn	3.57
22942289	C0444660	Anatomic Plane	spco	3.50
22942289	C1049866	Planes Grapsidae	euka	3.50
22942289	C1705938	Base - General Qualifier	idcn	3.47
22942289	C1527178	Basis - conceptual entity	ftcn	3.47
22942289	C2348693	Flux	npop	3.47
22942289	C0205314	New	qlco	3.47
22942289	C0679622	literary novel	inpr	3.47
22942289	C2741958	VX-770	orch	3.45
22942289	C1704675	Interaction	ftcn	3.43
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.40
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.40
22942289	C0031678	Phosphoric Monoester Hydrolases	aapp	17.80
22942289	C0031678	Phosphoric Monoester Hydrolases	enzy	17.80
22942289	C0031727	Phosphotransferases	aapp	13.14
22942289	C0031727	Phosphotransferases	enzy	13.14
22942289	C2744579	ATP8A2 protein, human	aapp	13.01
22942289	C2744579	ATP8A2 protein, human	enzy	13.01
22942289	C0026410	Mongolia	geoa	13.01
22942289	C0150312	Present	qnco	7.45
22942289	C1689898	% bound (qualifier value)	qnco	5.18
22942289	C1167622	Binding (Molecular Function)	moft	5.18
22942289	C1145667	Binding action	acty	5.18
22942289	C2349209	Bound (value)	cnce	5.18
22942289	C0332297	Bounded by	spco	5.18
22942289	C1998793	Purifying	ftcn	5.18
22942289	C2741958	VX-770	orch	5.18
22942289	C1705535	suggestion	idcn	3.98
22942289	C1413365	CFTR gene	gngm	3.68
22942289	C1947931	Direct (qualifier)	qlco	3.56
22942289	C2346927	Magnesium Cation	elii	3.55
22942289	C2346927	Magnesium Cation	phsu	3.55
22942289	C1960952	Milligram percent	qnco	3.55
22942289	C3854307	Presence (property)	qlco	3.55
22942289	C0392148	Providing presence (regime/therapy)	topp	3.55
22942289	C0439269	mg/dL	qnco	3.55
22942289	C0332281	Associated with	qlco	3.50
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
22942289	C2744579	ATP8A2 protein, human	aapp	12.88
22942289	C2744579	ATP8A2 protein, human	enzy	12.88
22942289	C0026410	Mongolia	geoa	12.88
22942289	C2349975	Enhance (action)	acty	5.18
22942289	C0150312	Present	qnco	5.18
22942289	C2741958	VX-770	orch	5.18
22942289	C1153410	channel activity	moft	3.61
22942289	C1413365	CFTR gene	gngm	3.54
22942289	C1998793	Purifying	ftcn	3.43
22942289	C1689985	Absence (morphologic abnormality)	anab	3.42
22942289	C0332197	Absent	ftcn	3.42
22942289	C2346927	Magnesium Cation	elii	3.42
22942289	C2346927	Magnesium Cation	phsu	3.42
22942289	C1960952	Milligram percent	qnco	3.42
22942289	C0439269	mg/dL	qnco	3.42
22942289	C0596988	mutant	comd	3.42
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
22942289	C2744579	ATP8A2 protein, human	aapp	12.88
22942289	C2744579	ATP8A2 protein, human	enzy	12.88
22942289	C0015127	Etiology aspects	ftcn	11.49
22942289	C3539655	CDISC Findings Class	inpr	5.18
22942289	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
22942289	C1524003	Science of Etiology	cnce	5.18
22942289	C2741958	VX-770	orch	5.18
22942289	C2607943	findings aspects	ftcn	5.18
22942289	C1705535	suggestion	idcn	5.18
22942289	C0175566	Open	spco	3.54
22942289	C1882151	Opening	spco	3.54
22942289	C1413365	CFTR gene	gngm	3.42
22942289	C0439799	Channel	spco	3.42
22942289	C1706095	Channel Object	cnce	3.42
22942289	C0085862	Independence	idcn	3.42
22942289	C1299583	Independently able	fndg	3.42
22942289	C0441712	Mechanism (attribute)	ftcn	3.42
22942289	C1706376	Mechanism Component of Device	mnob	3.42
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
22942289	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
22942289	C0036849	Set (Psychology)	menp	14.64
22942289	C0043227	Work	ocac	8.34
22942289	C0016884	Future	tmco	6.57
22942289	C0086597	Mediate	socb	5.18
22942289	C1442518	Set scale	ftcn	5.18
22942289	C1524063	Use of	ftcn	5.18
22942289	C1705195	set (group)	cnce	5.18
22942289	C2741958	VX-770	orch	3.61
22942289	C2347609	Chemical Probe	chvf	3.56
22942289	C3536729	Probe Device Component	mnob	3.56
22942289	C0182400	Probes	medd	3.56
22942289	C1704681	probe gene fragment	gngm	3.56
22942289	C0205390	Phase	tmco	3.54
22942289	C1306673	Stage	qlco	3.54
22942289	C1300072	Tumor stage	clna	3.54
22942289	C1413365	CFTR gene	gngm	3.50
22942289	C1292721	Has property	ftcn	3.42
22942289	C0871161	Property (attribute)	qlco	3.42
22942289	C0947630	Scientific Study	lbpr	3.42
22942289	C0678594	structure	spco	3.42
24392786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
24392786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
24392786	C0010674	Cystic Fibrosis	dsyn	19.93
24392786	C0055363	Chloride Channels	aapp	19.52
24392786	C0055363	Chloride Channels	bacs	19.52
24392786	C0017337	Genes	gngm	17.80
24392786	C0015127	Etiology aspects	ftcn	9.86
24392786	C0019247	Hereditary Diseases	dsyn	8.34
24392786	C1413365	CFTR gene	gngm	5.18
24392786	C2700640	Encode (action)	acty	5.18
24392786	C1704735	Regulator	cnce	3.61
24392786	C1704734	Regulator Device Component	mnob	3.61
24392786	C0182953	Regulators (device)	medd	3.61
24392786	C0243067	defects aspect	ftcn	3.59
24392786	C1524003	Science of Etiology	cnce	3.55
24392786	C0221908	epithelial	qlco	3.48
24392786	C2752508	fully spanning the plasma membrane	celc	3.47
24392786	C1167322	integral to membrane	celc	3.47
24392786	C0007603	Plasma membrane	celc	11.49
24392786	C0026882	Mutation	genf	9.94
24392786	C0033684	Proteins	aapp	8.34
24392786	C0033684	Proteins	bacs	8.34
24392786	C3161472	Cellular Membrane	celc	5.18
24392786	C1518422	Negation	ftcn	5.18
24392786	C2584321	Reaching	orgf	5.18
24392786	C1705285	Mutation Abnormality	comd	3.63
24392786	C0205214	Common (qualifier value)	qnco	3.48
24392786	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.48
24392786	C0205393	Most	qnco	3.48
24392786	C1522138	shared attribute	ftcn	3.48
24392786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
24392786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
24392786	C0055363	Chloride Channels	aapp	19.45
24392786	C0055363	Chloride Channels	bacs	19.45
24392786	C0031843	physiological aspects	phsf	13.08
24392786	C0036576	Genetic Selection	genf	9.74
24392786	C1880355	Discover	acty	5.18
24392786	C0234402	Stimulus	phpr	3.63
24392786	C0542341	Function	ftcn	3.61
24392786	C0700205	Function Axis	clas	3.61
24392786	C1705273	Mathematical Operator	inpr	3.61
24392786	C1709060	Modulator Device Component	mnob	3.59
24392786	C0332157	Exposure to	clna	3.59
24392786	C0274281	Injury due to exposure to external cause	inpo	3.59
24392786	C1708698	Light Emitting Diode Device Component	mnob	3.57
24392786	C1706202	Search - action	acty	3.57
24392786	C1552603	search - EntityNameUse	inpr	3.57
24392786	C1413365	CFTR gene	gngm	3.48
24392786	C3272558	Chemical or Textual Reference to Actual Test or Parameter	inpr	3.48
24392786	C0220806	Chemicals	chem	3.48
24392786	C0205228	Exogenous	ftcn	3.48
24392786	C0205101	Extrinsic	spco	3.48
24392786	C0728938	Partial	qnco	3.47
24392786	C1550516	Target Awareness - partial	idcn	3.47
24392786	C1707391	Choose (action)	acty	3.43
24392786	C1449035	SPRR2A protein, human	aapp	13.24
24392786	C1449035	SPRR2A protein, human	bacs	13.24
24392786	C0078433	methylphosphonothioic acid S-(2-(bis(1-methylethyl)amino)ethyl) O-ethyl ester	orch	13.14
24392786	C0078433	methylphosphonothioic acid S-(2-(bis(1-methylethyl)amino)ethyl) O-ethyl ester	phsu	13.14
24392786	C2714138	cyclopropanecarboxamide	orch	12.89
24392786	C3852684	lumacaftor	orch	12.89
24392786	C3852684	lumacaftor	phsu	12.89
24392786	C0740116	+2	qnco	5.18
24392786	C3833492	2+	fndg	5.18
24392786	C2827735	2+ Score	qnco	5.18
24392786	C2981700	2+ Score, WHO	clas	5.18
24392786	C2349182	Correct (qualifier)	qlco	5.18
24392786	C1708698	Light Emitting Diode Device Component	mnob	5.18
24392786	C1153420	chloride channel activity	moft	5.18
24392786	C2697524	Graph Node	cnce	3.68
24392786	C0441905	Venous stage VX	fndg	3.68
24392786	C0230003	Vertex	blor	3.68
24392786	C0599896	trafficking	celf	3.59
24392786	C0243072	derivatives	chvs	3.56
24392786	C0442758	3/5	qnco	3.51
24392786	C3838680	3+ Answer to Question	fndg	14.95
24392786	C2827736	3+ Score	qnco	14.95
24392786	C2981702	3+ Score, WHO	clas	14.95
24392786	C0439086	<3 (qualifier value)	qnco	14.95
24392786	C0913771	trifluoromethylpyridine	orch	12.96
24392786	C0071037	picolinamide	irda	12.88
24392786	C0071037	picolinamide	orch	12.88
24392786	C0728893	+5	qnco	5.18
24392786	C0439084	>5	qnco	5.18
24392786	C1552116	Supernumerary maxillary right second molar	bpoc	5.18
24392786	C3811385	BAG3 wt Allele	gngm	3.68
24392786	C3540495	Body Image Scale	inpr	3.68
24392786	C0556985	Twice weekly	tmco	3.68
24392786	C2247301	biphenyl synthase activity	moft	3.68
24392786	C1561536	*Activity (kind of quantity)	idcn	3.54
24392786	C0205177	Active	ftcn	3.54
24392786	C0441655	Activities	acty	3.54
24392786	C3668946	Activity (animal life circumstance)	fndg	3.54
24392786	C4049939	FDA Establishment Activity Terminology	inpr	3.54
24392786	C0439167	Percent Activity	qnco	3.54
24392786	C4049938	Physical Activity Measurement	lbpr	3.54
24392786	C0700307	hydroxyl group	inch	3.46
24392786	C1550043	Container status - Identified	fndg	3.42
24392786	C0205396	Identified	qlco	3.42
24392786	C0205549	Series	qnco	3.42
24392786	C2348044	Series - set of composite instances	inpr	3.42
24392786	C2348205	Similarity	qlco	3.42
24392786	C0243072	derivatives	chvs	3.42
24392786	C0016094	File (record)	ocac	12.89
24392786	C0205198	Compound	qlco	7.09
24392786	C1706082	Compound (substance)	chem	7.09
24392786	C1516365	Cellular Assay	resa	4.12
24392786	C1705938	Base - General Qualifier	idcn	3.57
24392786	C1527178	Basis - conceptual entity	ftcn	3.57
24392786	C0337143	Scaffold	mnob	3.57
24392786	C0205549	Series	qnco	3.56
24392786	C2348044	Series - set of composite instances	inpr	3.56
24392786	C1561536	*Activity (kind of quantity)	idcn	3.55
24392786	C0205177	Active	ftcn	3.55
24392786	C0441655	Activities	acty	3.55
24392786	C3668946	Activity (animal life circumstance)	fndg	3.55
24392786	C0205229	Expanding	spco	3.55
24392786	C4049939	FDA Establishment Activity Terminology	inpr	3.55
24392786	C0439167	Percent Activity	qnco	3.55
24392786	C4049938	Physical Activity Measurement	lbpr	3.55
24392786	C0205451	Five	qnco	3.43
24392786	C0439282	Nanomole/liter	qnco	3.43
24392786	C1999230	Providing (action)	acty	3.43
24392786	C3245505	potential	qlco	3.36
24298579	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.56
24298579	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.56
24298579	C0026882	Mutation	genf	19.71
24298579	C0017337	Genes	gngm	16.09
24298579	C0010674	Cystic Fibrosis	dsyn	10.06
24298579	C0012634	Disease	dsyn	9.86
24298579	C0033684	Proteins	aapp	8.34
24298579	C0033684	Proteins	bacs	8.34
24298579	C0019247	Hereditary Diseases	dsyn	6.73
24298579	C0596019	Chloride Ion	elii	3.64
24298579	C1413365	CFTR gene	gngm	3.63
24298579	C1704735	Regulator	cnce	3.61
24298579	C1704734	Regulator Device Component	mnob	3.61
24298579	C0182953	Regulators (device)	medd	3.61
24298579	C1519624	Transmembrane Transport	celf	3.61
24298579	C0007634	Cells	cell	3.56
24298579	C0178539	Cellular	lbpr	3.56
24298579	C1314939	Involvement with	ftcn	3.56
24298579	C2700640	Encode (action)	acty	3.48
24298579	C1547699	MIME encoding	idcn	3.48
24298579	C0205207	Cystic	qlco	3.47
24298579	C0678226	Due to	ftcn	3.44
24298579	C0205404	Serious	qlco	3.42
24298579	C3264621	ivacaftor	orch	13.14
24298579	C3264621	ivacaftor	phsu	13.14
24298579	C0038164	Staphylococcal Protein A	aapp	13.03
24298579	C0038164	Staphylococcal Protein A	imft	13.03
24298579	C0038164	Staphylococcal Protein A	irda	13.03
24298579	C0036576	Genetic Selection	genf	9.79
24298579	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.56
24298579	C1552738	described	idcn	3.54
24298579	C1707391	Choose (action)	acty	3.49
24298579	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
24298579	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
24298579	C0010674	Cystic Fibrosis	dsyn	19.87
24298579	C0206243	Carrying	acty	14.64
24298579	C0023636	License	rnlw	13.00
24298579	C0242373	Licensing	gora	13.00
24298579	C0026882	Mutation	genf	9.94
24298579	C0030705	Patients	podg	6.71
24298579	C0699809	Does carry	fndg	5.18
24298579	C1948052	Now (temporal qualifier)	tmco	5.18
24298579	C0580836	Old	tmco	3.98
24298579	C1705285	Mutation Abnormality	comd	3.63
24298579	C0868928	Case (situation)	ftcn	3.56
24298579	C1706256	Clinical Study Case	cnce	3.56
24298579	C1706255	Packaging Case	medd	3.56
24298579	C0728893	+5	qnco	3.55
24298579	C0439084	>5	qnco	3.55
24298579	C1510829	Age-Years	tmco	3.55
24298579	C1548573	Licensed - Location characteristic ID	inpr	3.54
24298579	C3889832	Licensed as Wholesale Drug Distributor or Third Party Logistics Provider	qlco	3.54
24298579	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.53
24298579	C3242455	HL7PublishingDomain <patient administration>	inpr	3.53
24298579	C3242279	healthcare operations <patient administration>	ocac	3.53
24298579	C1413365	CFTR gene	gngm	3.48
24298579	C0009933	Controlled Clinical Trials as Topic	resa	22.51
24298579	C0206243	Carrying	acty	14.64
24298579	C0936233	Controlled Clinical Trial [Publication Type]	inpr	13.05
24298579	C3264621	ivacaftor	orch	12.89
24298579	C3264621	ivacaftor	phsu	12.89
24298579	C0032042	Placebos	topp	6.59
24298579	C0030705	Patients	podg	6.58
24298579	C0699809	Does carry	fndg	5.18
24298579	C0205448	Two	qnco	3.68
24298579	C0439787	Out (direction)	spco	3.57
24298579	C0849355	Removed	qlco	3.57
24298579	C0542559	contextual factors	ftcn	3.57
24298579	C1318139	{Setting}	qnco	3.57
24298579	C0439175	% of total	qnco	3.55
24298579	C0439810	Total	qlco	3.55
24298579	C1706408	Placebo Control	resa	3.43
24298579	C1696465	placebo	bodm	3.43
24298579	C0003237	Antibiotics, Antitubercular	antb	22.36
24298579	C0039798	therapeutic aspects	ftcn	22.35
24298579	C0008976	Clinical Trials	resa	19.29
24298579	C0003232	Antibiotics	antb	16.05
24298579	C0085639	Falls	fndg	12.98
24298579	C0019993	Hospitalization	hlca	12.89
24298579	C0024109	Lung	bpoc	6.59
24298579	C1524063	Use of	ftcn	3.61
24298579	C0439603	Frequencies (time pattern)	tmco	3.56
24298579	C3898838	How Often	inpr	3.56
24298579	C1561548	Kind of quantity - Frequency	qlco	3.56
24298579	C0871396	Spatial Frequency	qnco	3.56
24298579	C1705502	Statistical Frequency	qnco	3.56
24298579	C0376249	With frequency	qnco	3.56
24298579	C1825598	IMPACT gene	gngm	3.55
24298579	C4049986	Impact	qlco	3.55
24298579	C0205447	One	qnco	3.55
24298579	C0205448	Two	qnco	3.55
24298579	C0439230	week	tmco	3.55
24298579	C0238715	Autumn	tmco	3.52
24298579	C3540706	Antibiotic throat preparations	antb	3.43
24298579	C3540707	Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	antb	3.43
24298579	C3540704	Antibiotics for systemic use	antb	3.43
24298579	C3540708	Antibiotics, Gynecological	antb	3.43
24298579	C3540710	Antibiotics, ophthalmologic	antb	3.43
24298579	C3540705	Antifungal Antibiotics, Topical	antb	3.43
24298579	C0348016	Intravenous	spco	3.43
24298579	C2709248	Pulmonary (qualifier value)	qlco	3.43
24298579	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.43
24298579	C3540709	antibiotics, intestinal	antb	3.43
24298579	C1533734	Administration procedure	topp	3.42
24298579	C1705169	Biomaterial Treatment	cnce	3.42
24298579	C0449788	Count of entities	qnco	3.42
24298579	C0205435	First (number)	qnco	3.42
24298579	C1279901	Firstly	qlco	3.42
24298579	C0237753	Numbers	qnco	3.42
24298579	C0087111	Therapeutic procedure	topp	3.42
24298579	C1522326	Treating	ftcn	3.42
24298579	C3538994	Treatment Epoch	resa	3.42
24298579	C3887704	treatment - ActInformationManagementReason	hlca	3.42
24298579	C0043094	Weight Gain	fndg	25.67
24298579	C0008976	Clinical Trials	resa	19.75
24298579	C0242821	Human body	humn	16.16
24298579	C3264621	ivacaftor	orch	12.89
24298579	C3264621	ivacaftor	phsu	12.89
24298579	C1510992	Average	qnco	7.00
24298579	C2825518	Average of Value Derivation Technique	qnco	7.00
24298579	C0332174	Weekly	tmco	3.68
24298579	C0439230	week	tmco	3.68
24298579	C2983587	Average Body Weight Gain	fndg	3.58
24298579	C1883712	Add - instruction imperative	ftcn	3.56
24298579	C0332287	In addition to	ftcn	3.56
24298579	C1268086	Body structure	anst	3.54
24298579	C0460148	Human body structure	anst	3.54
24298579	C1561611	Admission Level of Care Code - Improved	inpr	3.43
24298579	C0332272	Better	qlco	3.43
24298579	C1561566	FEV1 Adverse Event	fndg	3.43
24298579	C0429706	Forced expiratory volume in 1 second finding	fndg	3.43
24298579	C0184511	Improved	qlco	3.43
24298579	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.43
24298579	C3842590	10%	fndg	3.43
24298579	C1300561	Unit/kilogram	qnco	3.58
24298579	C0439508	per year	tmco	3.43
24298579	C0439234	year	tmco	3.43
24298579	C0008976	Clinical Trials	resa	19.75
24298579	C3264621	ivacaftor	orch	13.02
24298579	C3264621	ivacaftor	phsu	13.02
24298579	C0041912	Upper Respiratory Infections	dsyn	10.16
24298579	C1257890	Population Group	popg	9.87
24298579	C0205172	More	ftcn	6.89
24298579	C0024109	Lung	bpoc	6.58
24298579	C2362652	Possible diagnosis	qlco	5.18
24298579	C0581381	Recurrent upper respiratory tract infection	dsyn	3.85
24298579	C1705428	Group Object	cnce	3.56
24298579	C0441833	Groups	idcn	3.56
24298579	C1709305	Occur (action)	acty	3.56
24298579	C0687744	Social group	popg	3.56
24298579	C1552516	Specialty Group	hcro	3.56
24298579	C1552839	Table Rules - groups	inpr	3.56
24298579	C1705429	User Group	popg	3.56
24298579	C0868928	Case (situation)	ftcn	3.55
24298579	C1533148	Case unit dose	qnco	3.55
24298579	C1879778	Bacterial Contamination of Medical Device	phpr	3.45
24298579	C2709248	Pulmonary (qualifier value)	qlco	3.42
24298579	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.42
24298579	C0443252	Long-term	tmco	3.42
24298579	C0035647	Risk	idcn	19.32
24298579	C0022173	Isoenzymes	aapp	12.92
24298579	C0022173	Isoenzymes	enzy	12.92
24298579	C0030705	Patients	podg	6.74
24298579	C2826232	Dose Adjustment	hlca	5.18
24298579	C0948807	Hepatic impairment	dsyn	5.18
24298579	C3898767	Inducer	sbst	3.98
24298579	C3819037	Cytochrome P450 3A Inhibitors [MoA]	moft	3.74
24298579	C2698778	Pharmacokinetics: Drug Interactions	rnlw	3.45
24298579	C1514756	Receive	qlco	3.43
24298579	C0439064	Numerous	qnco	3.43
24298579	C0032961	Pregnancy	orgf	16.21
24298579	C3264621	ivacaftor	orch	14.64
24298579	C3264621	ivacaftor	phsu	14.64
24298579	C1550718	Entity Name Part Type - given	idcn	5.18
24298579	C1442162	GIVEN	cnce	5.18
24298579	C1947971	Give - dosing instruction imperative	ftcn	5.18
24298579	C3244317	Given name	inpr	5.18
24298579	C3484365	Pregnancy:History:Point in time:^Patient:Ordinal	clna	3.59
24298579	C1689985	Absence (morphologic abnormality)	anab	3.57
24298579	C0332197	Absent	ftcn	3.57
24298579	C1511726	Data	idcn	3.44
24298579	C3714741	Data (eukaryote)	euka	3.44
24298579	C3245479	Data call receiving device	medd	3.44
24298579	C0040363	Togo	geoa	17.80
24298579	C0041260	Tryptophanase	aapp	17.80
24298579	C0041260	Tryptophanase	enzy	17.80
24298579	C0687133	Drug Interactions	moft	12.90
24298579	C3264621	ivacaftor	orch	12.89
24298579	C3264621	ivacaftor	phsu	12.89
24298579	C0332149	Possible	qlco	7.09
24298579	C2362652	Possible diagnosis	qlco	7.09
24298579	C1705910	Possibly Related to Intervention	qlco	7.09
24298579	C1883351	To	qlco	5.18
24298579	C0348754	Toxic liver disease	dsyn	4.02
24298579	C3245512	HL7PublishingSubSection <practice>	inpr	3.63
24298579	C0237607	Practice Experience	menp	3.63
24298579	C0332167	High risk of	qlco	3.60
24298579	C0582147	At risk of infection	fndg	3.56
24298579	C0560184	Ability to balance	fndg	3.55
24298579	C0179199	Balance, device	medd	3.55
24298579	C0205415	Balanced - adjective	ftcn	3.55
24298579	C0014653	Equilibrium	orgf	3.55
24298579	C0442805	Increase	ftcn	3.55
24298579	C0205217	Increased	qnco	3.55
24298579	C1518422	Negation	ftcn	3.50
24298579	C0678226	Due to	ftcn	3.44
24298579	C0814225	benefit	qnco	3.43
25103957	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.03
25103957	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.03
25103957	C0039798	therapeutic aspects	ftcn	22.48
25103957	C0026882	Mutation	genf	19.78
25103957	C3264621	ivacaftor	orch	13.14
25103957	C3264621	ivacaftor	phsu	13.14
25103957	C0041703	United States	geoa	13.03
25103957	C0010674	Cystic Fibrosis	dsyn	9.76
25103957	C1413365	CFTR gene	gngm	6.96
25103957	C0030705	Patients	podg	6.70
25103957	C0205447	One	qnco	3.59
25103957	C0205540	Approved	qlco	3.57
25103957	C1533734	Administration procedure	topp	3.55
25103957	C1705169	Biomaterial Treatment	cnce	3.55
25103957	C0087111	Therapeutic procedure	topp	3.55
25103957	C1522326	Treating	ftcn	3.55
25103957	C3538994	Treatment Epoch	resa	3.55
25103957	C3887704	treatment - ActInformationManagementReason	hlca	3.55
25103957	C0205454	Eight	qnco	3.45
25103957	C1705285	Mutation Abnormality	comd	3.42
25103957	C0242643	P-Glycoprotein	aapp	30.42
25103957	C0242643	P-Glycoprotein	bacs	30.42
25103957	C0069906	P-Glycoproteins	aapp	30.42
25103957	C0069906	P-Glycoproteins	bacs	30.42
25103957	C0057223	Cytochrome P-450 CYP2D6	aapp	27.26
25103957	C0057223	Cytochrome P-450 CYP2D6	enzy	27.26
25103957	C0040363	Togo	geoa	17.80
25103957	C0041260	Tryptophanase	aapp	17.80
25103957	C0041260	Tryptophanase	enzy	17.80
25103957	C0897385	CYP2C8 protein, human	aapp	14.64
25103957	C0897385	CYP2C8 protein, human	enzy	14.64
25103957	C3264621	ivacaftor	orch	13.01
25103957	C3264621	ivacaftor	phsu	13.01
25103957	C0018790	Cardiac Arrest	dsyn	10.18
25103957	C0004927	Behavior	inbe	7.13
25103957	C1332830	CYP2D6 gene	gngm	5.18
25103957	C3814396	CYP3A Gene Locus	gngm	5.18
25103957	C3887685	Cytochrome P450 2D6, human	aapp	5.18
25103957	C3887685	Cytochrome P450 2D6, human	enzy	5.18
25103957	C0870883	Metabolite	bacs	5.18
25103957	C2698672	Other Toxicity Studies: Metabolites	rnlw	5.18
25103957	C1883351	To	qlco	5.18
25103957	C3245505	potential	qlco	5.18
25103957	C1706084	(City) Block	geoa	3.87
25103957	C0237477	Arrested progression	tmco	3.87
25103957	C2828370	Block (unit of measure)	qnco	3.87
25103957	C1533157	Block Specimens	sbst	3.87
25103957	C3811660	Block Unit of Distance	qnco	3.87
25103957	C0332206	Blocking	ftcn	3.87
25103957	C0392351	Law enforcement arrest	gora	3.87
25103957	C0233660	Mental blocking	mobd	3.87
25103957	C0028778	Obstruction	patf	3.87
25103957	C0521111	Retarded	qlco	3.87
25103957	C0205549	Series	qnco	3.55
25103957	C2348044	Series - set of composite instances	inpr	3.55
25103957	C0678723	Biologic Development	orgf	3.54
25103957	C1527148	Development	ftcn	3.54
25103957	C1279919	Early	tmco	3.54
25103957	C1444656	Indicated	fndg	3.54
25103957	C0243107	development aspects	phsf	3.54
25103957	C2827718	In Vitro Route of Administration	ftcn	3.45
25103957	C0021135	In Vitro [Publication Type]	inpr	3.45
25103957	C1533691	in vitro	qlco	3.45
25103957	C0681814	research study	resa	3.43
25103957	C0057223	Cytochrome P-450 CYP2D6	aapp	27.26
25103957	C0057223	Cytochrome P-450 CYP2D6	enzy	27.26
25103957	C1382144	Cytochrome P-450 CYP2C8	aapp	25.51
25103957	C1382144	Cytochrome P-450 CYP2C8	enzy	25.51
25103957	C0012265	Digoxin	orch	24.11
25103957	C0012265	Digoxin	phsu	24.11
25103957	C0026056	Midazolam	orch	17.80
25103957	C0026056	Midazolam	phsu	17.80
25103957	C0040363	Togo	geoa	17.80
25103957	C0041260	Tryptophanase	aapp	17.80
25103957	C0041260	Tryptophanase	enzy	17.80
25103957	C0011685	Desipramine	orch	14.64
25103957	C0011685	Desipramine	phsu	14.64
25103957	C0220825	Evaluation	hlca	14.64
25103957	C0289313	rosiglitazone	orch	14.64
25103957	C0289313	rosiglitazone	phsu	14.64
25103957	C0687133	Drug Interactions	moft	12.92
25103957	C3264621	ivacaftor	orch	12.90
25103957	C3264621	ivacaftor	phsu	12.90
25103957	C0004927	Behavior	inbe	7.13
25103957	C0008972	Clinical Research	resa	6.59
25103957	C0020517	Hypersensitivity	patf	6.59
25103957	C1332830	CYP2D6 gene	gngm	5.18
25103957	C3814396	CYP3A Gene Locus	gngm	5.18
25103957	C3887685	Cytochrome P450 2D6, human	aapp	5.18
25103957	C3887685	Cytochrome P450 2D6, human	enzy	5.18
25103957	C1883351	To	qlco	5.18
25103957	C0369773	P Blood group antibodies	aapp	3.68
25103957	C0369773	P Blood group antibodies	imft	3.68
25103957	C2603361	P prime	clna	3.68
25103957	C3811116	RNF130 wt Allele	gngm	3.68
25103957	C1705938	Base - General Qualifier	idcn	3.57
25103957	C1527178	Basis - conceptual entity	ftcn	3.57
25103957	C1280500	Effect	qlco	3.57
25103957	C2348382	Effect, Appearance	qlco	3.57
25103957	C2985404	Clinical Series	resa	3.56
25103957	C0205549	Series	qnco	3.54
25103957	C2348044	Series - set of composite instances	inpr	3.54
25103957	C2825142	Experimental Result	fndg	3.54
25103957	C1274040	Result	ftcn	3.54
25103957	C1546471	What subject filter - Result	idcn	3.54
25103957	C3891814	Substrate	sbst	3.53
25103957	C1710236	Substrate Device Component	mnob	3.53
25103957	C1413873	CYP2C8 gene	gngm	3.43
25103957	C0332324	Sensitive	ftcn	3.43
25103957	C0947630	Scientific Study	lbpr	3.42
25103957	C0009906	Combined Oral Contraceptives	phsu	27.26
25103957	C0012133	Didanosine	nnon	19.27
25103957	C0012133	Didanosine	phsu	19.27
25103957	C0040363	Togo	geoa	17.80
25103957	C0041260	Tryptophanase	aapp	17.80
25103957	C0041260	Tryptophanase	enzy	17.80
25103957	C0009738	Congo	geoa	16.04
25103957	C0220825	Evaluation	hlca	14.64
25103957	C3264621	ivacaftor	orch	12.90
25103957	C3264621	ivacaftor	phsu	12.90
25103957	C0004927	Behavior	inbe	7.13
25103957	C0030705	Patients	podg	6.58
25103957	C1883351	To	qlco	5.18
25103957	C0750591	consider	idcn	5.18
25103957	C0557651	Room of building - Study	mnob	3.68
25103957	C2603343	Study	resa	3.68
25103957	C1883712	Add - instruction imperative	ftcn	3.63
25103957	C0332287	In addition to	ftcn	3.63
25103957	C1280500	Effect	qlco	3.57
25103957	C2348382	Effect, Appearance	qlco	3.57
25103957	C3811819	CFTR wt Allele	gngm	3.43
25103957	C3898777	Important	qlco	3.43
25103957	C0057223	Cytochrome P-450 CYP2D6	aapp	27.26
25103957	C0057223	Cytochrome P-450 CYP2D6	enzy	27.26
25103957	C1382144	Cytochrome P-450 CYP2C8	aapp	25.52
25103957	C1382144	Cytochrome P-450 CYP2C8	enzy	25.52
25103957	C3264621	ivacaftor	orch	14.64
25103957	C3264621	ivacaftor	phsu	14.64
25103957	C1332830	CYP2D6 gene	gngm	5.18
25103957	C3887685	Cytochrome P450 2D6, human	aapp	5.18
25103957	C3887685	Cytochrome P450 2D6, human	enzy	5.18
25103957	C2825142	Experimental Result	fndg	3.98
25103957	C1274040	Result	ftcn	3.98
25103957	C1546471	What subject filter - Result	idcn	3.98
25103957	C0369773	P Blood group antibodies	aapp	3.68
25103957	C0369773	P Blood group antibodies	imft	3.68
25103957	C2603361	P prime	clna	3.68
25103957	C3811116	RNF130 wt Allele	gngm	3.68
25103957	C1280500	Effect	qlco	3.57
25103957	C2348382	Effect, Appearance	qlco	3.57
25103957	C1999216	Inhibitor	qlco	3.56
25103957	C1413873	CYP2C8 gene	gngm	3.44
25103957	C3814396	CYP3A Gene Locus	gngm	3.43
25103957	C1762617	Weak	qlco	3.43
25103957	C3714552	Weakness	sosy	3.43
25103957	C0015011	Ethinyl Estradiol	horm	22.37
25103957	C0015011	Ethinyl Estradiol	orch	22.37
25103957	C0015011	Ethinyl Estradiol	phsu	22.37
25103957	C0028356	Norethindrone	horm	19.27
25103957	C0028356	Norethindrone	orch	19.27
25103957	C0028356	Norethindrone	phsu	19.27
25103957	C3264621	ivacaftor	orch	13.14
25103957	C3264621	ivacaftor	phsu	13.14
25103957	C0015127	Etiology aspects	ftcn	10.28
25103957	C1524003	Science of Etiology	cnce	3.98
25103957	C0332157	Exposure to	clna	3.68
25103957	C0274281	Injury due to exposure to external cause	inpo	3.68
25103957	C0442805	Increase	ftcn	3.55
25103957	C0205217	Increased	qnco	3.55
25103957	C1546944	Event Seriousness - Significant	qlco	3.42
25103957	C1518422	Negation	ftcn	3.42
25103957	C0750502	Significant	idcn	3.42
25103957	C0237881	Statistical Significance	qnco	3.42
25103957	C0043031	Warfarin	hops	24.11
25103957	C0043031	Warfarin	orch	24.11
25103957	C0043031	Warfarin	phsu	24.11
25103957	C0039798	therapeutic aspects	ftcn	22.51
25103957	C3264621	ivacaftor	orch	14.64
25103957	C3264621	ivacaftor	phsu	14.64
25103957	C3814396	CYP3A Gene Locus	gngm	5.18
25103957	C0034866	Recommendation	idcn	5.18
25103957	C1516647	Clinical Trials, Monitoring	resa	3.68
25103957	C1283169	Monitoring - action	hlca	3.68
25103957	C0369773	P Blood group antibodies	aapp	3.68
25103957	C0369773	P Blood group antibodies	imft	3.68
25103957	C2603361	P prime	clna	3.68
25103957	C0150369	Preventive monitoring	hlca	3.68
25103957	C3811116	RNF130 wt Allele	gngm	3.68
25103957	C3899735	CYP2C9 Substrate	sbst	3.60
25103957	C1533734	Administration procedure	topp	3.59
25103957	C1705169	Biomaterial Treatment	cnce	3.59
25103957	C0087111	Therapeutic procedure	topp	3.59
25103957	C1522326	Treating	ftcn	3.59
25103957	C3538994	Treatment Epoch	resa	3.59
25103957	C1273517	Used by	fndg	3.59
25103957	C3887704	treatment - ActInformationManagementReason	hlca	3.59
25103957	C1705938	Base - General Qualifier	idcn	3.57
25103957	C1527178	Basis - conceptual entity	ftcn	3.57
25103957	C3687832	DRUGS	topp	3.55
25103957	C0013227	Pharmaceutical Preparations	phsu	3.55
25103957	C2825142	Experimental Result	fndg	3.54
25103957	C1274040	Result	ftcn	3.54
25103957	C1546471	What subject filter - Result	idcn	3.54
25103957	C1548787	Appropriate	qlco	3.50
25103957	C3889681	Narrow Therapeutic Index	qnco	3.47
25103957	C0521115	Simultaneous	tmco	3.44
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	118.25
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	118.25
25330774	C1413365	CFTR gene	gngm	14.97
25330774	C0031715	Phosphorylation	moft	12.89
25330774	C0026882	Mutation	genf	9.91
25330774	C0010674	Cystic Fibrosis	dsyn	9.79
25330774	C0220781	Anabolism	biof	6.58
25330774	C0699040	Cell surface	celc	5.18
25330774	C0439801	Limited (extensiveness)	ftcn	5.18
25330774	C1705285	Mutation Abnormality	comd	3.60
25330774	C1660003	protein maturation	celf	3.58
25330774	C1254042	Anatomical maturation	phsf	3.55
25330774	C0678723	Biologic Development	orgf	3.55
25330774	C0870861	Human maturation	phpr	3.55
25330774	C3854321	Expression (foundation metadata concept)	idcn	3.55
25330774	C0185117	Expression procedure	topp	3.55
25330774	C0678227	Causing	ftcn	3.46
25330774	C0205164	Major	qlco	3.46
25330774	C0205082	Severe (severity modifier)	qlco	3.46
25330774	C3810841	Biosynthetic	fndg	3.43
25330774	C0439799	Channel	spco	3.42
25330774	C1706095	Channel Object	cnce	3.42
25330774	C1701901	Conditional	qlco	3.42
25330774	C0851827	Dependent - ability	qlco	3.42
25330774	C1158886	Protein phosphorylation	moft	3.42
25330774	C3244310	dependent	ftcn	3.42
25330774	C0009264	Cold Temperature	npop	22.57
25330774	C0007585	Cell Culture Techniques	lbpr	16.37
25330774	C0012634	Disease	dsyn	9.90
25330774	C0334070	Maturation defect	acab	5.18
25330774	C0348080	Condition	qlco	3.59
25330774	C3864998	Condition:Find:Pt:^Patient:Nom	clna	3.59
25330774	C1705253	Logical Condition	cnce	3.59
25330774	C0205198	Compound	qlco	3.58
25330774	C1706082	Compound (substance)	chem	3.58
25330774	C1328819	Small Molecule	orch	3.50
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25330774	C0033204	Probability	qnco	16.17
25330774	C0332282	Following	tmco	5.18
25330774	C0231290	Status post	tmco	5.18
25330774	C2741958	VX-770	orch	5.18
25330774	C0205198	Compound	qlco	3.56
25330774	C1706082	Compound (substance)	chem	3.56
25330774	C2349975	Enhance (action)	acty	3.56
25330774	C0175566	Open	spco	3.55
25330774	C0728938	Partial	qnco	3.50
25330774	C1550516	Target Awareness - partial	idcn	3.50
25330774	C1413365	CFTR gene	gngm	3.43
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.09
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.09
25330774	C1153410	channel activity	moft	3.58
25330774	C0439092	Less Than	qnco	3.57
25330774	C3854307	Presence (property)	qlco	3.55
25330774	C0150312	Present	qnco	3.55
25330774	C0392148	Providing presence (regime/therapy)	topp	3.55
25330774	C2700323	Wild Type Unspecified - zebrafish	fish	3.54
25330774	C2741958	VX-770	orch	3.45
25330774	C1413365	CFTR gene	gngm	3.42
25330774	C0031715	Phosphorylation	moft	12.93
25330774	C0684010	Rabbi	prog	12.93
25330774	C0851285	Regulation	gora	9.77
25330774	C0557651	Room of building - Study	mnob	5.18
25330774	C2603343	Study	resa	5.18
25330774	C3541951	Concept model domain	inpr	3.61
25330774	C1880389	Domain (area of knowledge)	ftcn	3.61
25330774	C1883221	Superkingdom (taxonomic category)	cnce	3.61
25330774	C1280500	Effect	qlco	3.57
25330774	C1158886	Protein phosphorylation	moft	3.47
25330774	C2603358	R prime	clna	3.47
25330774	C0205090	Right	spco	3.47
25330774	C0010531	Cyclic AMP-Dependent Protein Kinases	aapp	28.69
25330774	C0010531	Cyclic AMP-Dependent Protein Kinases	enzy	28.69
25330774	C0684010	Rabbi	prog	25.93
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
25330774	C0040363	Togo	geoa	17.80
25330774	C0041260	Tryptophanase	aapp	17.80
25330774	C0041260	Tryptophanase	enzy	17.80
25330774	C0031715	Phosphorylation	moft	12.88
25330774	C3541951	Concept model domain	inpr	7.01
25330774	C1880389	Domain (area of knowledge)	ftcn	7.01
25330774	C1883221	Superkingdom (taxonomic category)	cnce	7.01
25330774	C2603358	R prime	clna	6.90
25330774	C0205090	Right	spco	6.90
25330774	C1707455	Comparison	acty	5.18
25330774	C1883351	To	qlco	5.18
25330774	C1413365	CFTR gene	gngm	3.68
25330774	C0243067	defects aspect	ftcn	3.56
25330774	C2347794	Study Site Status	qlco	3.55
25330774	C0449438	Status	qlco	3.54
25330774	C2700323	Wild Type Unspecified - zebrafish	fish	3.43
25330774	C1519063	Phosphorylation Site	amas	3.43
25330774	C1158886	Protein phosphorylation	moft	3.42
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
25330774	C0039676	5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase	aapp	19.34
25330774	C0039676	5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase	enzy	19.34
25330774	C0031715	Phosphorylation	moft	13.02
25330774	C1547282	Show	anim	5.18
25330774	C1413365	CFTR gene	gngm	3.57
25330774	C3539704	MTR wt Allele	gngm	3.57
25330774	C2349943	Ms. - Title	cnce	3.57
25330774	C0392756	Reduced	qlco	3.57
25330774	C1420404	SRM gene	gngm	3.57
25330774	C1420406	SRMS gene	gngm	3.57
25330774	C1158886	Protein phosphorylation	moft	3.56
25330774	C1709793	Quantitation	qnco	3.54
25330774	C0523888	Serine measurement	lbpr	3.43
25330774	C0039798	therapeutic aspects	ftcn	22.49
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25330774	C0079411	Generations	tmco	16.18
25330774	C0004015	Aspartic Acid	aapp	13.10
25330774	C0004015	Aspartic Acid	bacs	13.10
25330774	C0031843	physiological aspects	phsf	13.01
25330774	C0036720	Serine	aapp	12.90
25330774	C0036720	Serine	bacs	12.90
25330774	C0036720	Serine	phsu	12.90
25330774	C0031330	Pharmacology	bmod	9.73
25330774	C1515974	Anatomic Site	blor	5.18
25330774	C0392747	Changing	ftcn	5.18
25330774	C2349975	Enhance (action)	acty	5.18
25330774	C0334070	Maturation defect	acab	5.18
25330774	C1518422	Negation	ftcn	5.18
25330774	C0205145	Site	spco	5.18
25330774	C2825164	Study Site	spco	5.18
25330774	C2741958	VX-770	orch	5.18
25330774	C3252847	VX 809	orch	3.75
25330774	C3252847	VX 809	phsu	3.75
25330774	C4048238	Aspartic Acid Measurement	lbpr	3.64
25330774	C1533734	Administration procedure	topp	3.57
25330774	C1705169	Biomaterial Treatment	cnce	3.57
25330774	C0087111	Therapeutic procedure	topp	3.57
25330774	C1522326	Treating	ftcn	3.57
25330774	C3538994	Treatment Epoch	resa	3.57
25330774	C3887704	treatment - ActInformationManagementReason	hlca	3.57
25330774	C3146294	Generation (action)	acty	3.56
25330774	C0542341	Function	ftcn	3.55
25330774	C0700205	Function Axis	clas	3.55
25330774	C1705273	Mathematical Operator	inpr	3.55
25330774	C0523888	Serine measurement	lbpr	3.44
25330774	C1413365	CFTR gene	gngm	3.42
25330774	C0439799	Channel	spco	3.42
25330774	C1706095	Channel Object	cnce	3.42
25330774	C0205464	pharmacological	ftcn	3.42
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25330774	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25330774	C0031715	Phosphorylation	moft	13.01
25330774	C3539655	CDISC Findings Class	inpr	5.18
25330774	C0699040	Cell surface	celc	5.18
25330774	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
25330774	C0183683	Support, device	medd	5.18
25330774	C1521721	Supportive assistance	cnce	5.18
25330774	C0178566	concept	idcn	5.18
25330774	C2607943	findings aspects	ftcn	5.18
25330774	C1153410	channel activity	moft	3.59
25330774	C2741673	Account number:Identifier:Point in time:^Patient:Nominal	clna	3.55
25330774	C0392747	Changing	ftcn	3.55
25330774	C2981730	Financial Account	inpr	3.55
25330774	C1158886	Protein phosphorylation	moft	3.55
25330774	C1413365	CFTR gene	gngm	3.43
25330774	C0332452	defective	ftcn	3.43
26245207	C0040363	Togo	geoa	35.81
26245207	C0041260	Tryptophanase	aapp	35.81
26245207	C0041260	Tryptophanase	enzy	35.81
26245207	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
26245207	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
26245207	C0055363	Chloride Channels	aapp	19.52
26245207	C0055363	Chloride Channels	bacs	19.52
26245207	C0031843	physiological aspects	phsf	13.09
26245207	C0010674	Cystic Fibrosis	dsyn	11.49
26245207	C1883351	To	qlco	10.42
26245207	C0013218	Combination Drug Therapy	topp	9.95
26245207	C0026882	Mutation	genf	9.87
26245207	C0015127	Etiology aspects	ftcn	9.84
26245207	C1413365	CFTR gene	gngm	5.18
26245207	C2700399	Include (action)	acty	5.18
26245207	C0332257	Including (qualifier)	ftcn	5.18
26245207	C1552866	include - SetOperator	idcn	5.18
26245207	C0230625	cell process structure	celc	3.96
26245207	C0542341	Function	ftcn	3.63
26245207	C0700205	Function Axis	clas	3.63
26245207	C1705273	Mathematical Operator	inpr	3.63
26245207	C1705285	Mutation Abnormality	comd	3.56
26245207	C1524003	Science of Etiology	cnce	3.53
26245207	C0678723	Biologic Development	orgf	3.43
26245207	C1527148	Development	ftcn	3.43
26245207	C0243107	development aspects	phsf	3.43
26245207	C1449035	SPRR2A protein, human	aapp	40.36
26245207	C1449035	SPRR2A protein, human	bacs	40.36
26245207	C0053225	Benzoic Acid	orch	24.11
26245207	C0053225	Benzoic Acid	phsu	24.11
26245207	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
26245207	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
26245207	C0008976	Clinical Trials	resa	20.95
26245207	C0740116	+2	qnco	15.79
26245207	C3833492	2+	fndg	15.79
26245207	C2827735	2+ Score	qnco	15.79
26245207	C2981700	2+ Score, WHO	clas	15.79
26245207	C3816745	1+	fndg	15.70
26245207	C2827734	1+ Score	qnco	15.70
26245207	C2981698	1+ Score, WHO	clas	15.70
26245207	C3264621	ivacaftor	orch	14.64
26245207	C3264621	ivacaftor	phsu	14.64
26245207	C0393003	potassium oxonate	orch	13.09
26245207	C0393003	potassium oxonate	phsu	13.09
26245207	C0220825	Evaluation	hlca	13.02
26245207	C0754515	TERT protein, human	aapp	12.92
26245207	C0754515	TERT protein, human	enzy	12.92
26245207	C1096775	Clinical Trial [Publication Type]	inpr	11.49
26245207	C3838680	3+ Answer to Question	fndg	10.90
26245207	C2827736	3+ Score	qnco	10.90
26245207	C2981702	3+ Score, WHO	clas	10.90
26245207	C0439086	<3 (qualifier value)	qnco	10.90
26245207	C0684224	Report (document)	inpr	7.44
26245207	C0700287	Reporting	hlca	7.44
26245207	C3838679	4+ Answer to question	fndg	7.11
26245207	C0442758	3/5	qnco	7.07
26245207	C0009429	Combined Modality Therapy	topp	6.72
26245207	C1161334	Benzoicum acidum, benzoic acid, Homeopathic preparation	orch	5.18
26245207	C1161334	Benzoicum acidum, benzoic acid, Homeopathic preparation	phsu	5.18
26245207	C0332257	Including (qualifier)	ftcn	5.18
26245207	C0369718	N not otherwise specified Antibody	aapp	5.18
26245207	C0369718	N not otherwise specified Antibody	imft	5.18
26245207	C0441922	N+ (tumor staging)	inpr	5.18
26245207	C0332185	Recent	tmco	3.68
26245207	C0700307	hydroxyl group	inch	3.63
26245207	C2347098	Medical Product Stability	qlco	3.61
26245207	C0205360	Stable status	qlco	3.61
26245207	C0556895	Combination electrotherapy	topp	3.56
26245207	C1880177	Contribution	acty	3.54
26245207	C1280519	Effectiveness	qlco	3.54
26245207	C1707887	Efficacy Study	resa	3.54
26245207	C4054480	Modest Extremity Pain	inpr	3.54
26245207	C0450367	4/5	qnco	3.51
26245207	C1442450	1 Hour	tmco	3.47
26245207	C0205540	Approved	qlco	3.47
26245207	C1413365	CFTR gene	gngm	3.47
26245207	C0007634	Cells	cell	3.47
26245207	C0178539	Cellular	lbpr	3.47
26245207	C0885445	indol	orch	3.47
26245207	C3541881	Device Identifiers Domain	idcn	3.46
26245207	C3538902	SLC4A1 wt Allele	gngm	3.46
26245207	C1367342	TERT gene	gngm	3.46
26245207	C1705316	TERT wt Allele	gngm	3.46
26245207	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
26245207	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
26245207	C0020792	Identification (Psychology)	menp	14.64
26245207	C0205396	Identified	qlco	5.18
26245207	C1518422	Negation	ftcn	5.18
26245207	C3273238	Regulatory Report	inpr	5.18
26245207	C0684224	Report (document)	inpr	5.18
26245207	C0700287	Reporting	hlca	5.18
26245207	C3266814	Action	acty	3.68
26245207	C0441472	Clinical action	ftcn	3.68
26245207	C1880022	Characterization	acty	3.59
26245207	C1413365	CFTR gene	gngm	3.56
26245207	C0521102	Interferes with	ftcn	3.56
26245207	C2347098	Medical Product Stability	qlco	3.56
26245207	C0205360	Stable status	qlco	3.56
26245207	C0022266	Isoxazoles	orch	13.09
26245207	C0034325	Pyrroles	orch	12.94
26245207	C0072662	pyrazole	orch	12.94
26245207	C1550043	Container status - Identified	fndg	5.18
26245207	C0205396	Identified	qlco	5.18
26245207	C0332257	Including (qualifier)	ftcn	5.18
26245207	C1518422	Negation	ftcn	5.18
26245207	C0872187	high throughput screening	diap	3.81
26245207	C0556570	Activity analysis	topp	3.75
26245207	C3266814	Action	acty	3.68
26245207	C0441472	Clinical action	ftcn	3.68
26245207	C0678594	structure	spco	3.63
26245207	C0456387	Class	inpr	3.57
26245207	C1705943	Class (taxonomic)	clas	3.57
26245207	C4019422	Classes - encounter	hlca	3.57
26245207	C3489010	Pyrrole	phsu	3.48
26245207	C0439064	Numerous	qnco	3.44
26245207	C0443302	Several	qnco	3.44
26245207	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.96
26245207	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.96
26245207	C0086418	Homo sapiens	humn	28.66
26245207	C0010453	Anthropological Culture	idcn	13.01
26245207	C1413365	CFTR gene	gngm	6.89
26245207	C1518422	Negation	ftcn	5.18
26245207	C0205198	Compound	qlco	3.59
26245207	C1706082	Compound (substance)	chem	3.59
26245207	C0312860	Neutrophil migration, function	celf	3.57
26245207	C3890923	Nuclear Medicine Study File	inpr	3.57
26245207	C3842586	50%	fndg	3.55
26245207	C3843766	<50	fndg	3.55
26245207	C3890233	Exposure as Collected Domain	idcn	3.55
26245207	C1280519	Effectiveness	qlco	3.54
26245207	C1707887	Efficacy Study	resa	3.54
26245207	C0205225	Primary	qlco	3.54
26245207	C0439631	Primary operation	topp	3.54
26245207	C0439612	True primary (qualifier value)	tmco	3.54
26245207	C0205393	Most	qnco	3.48
26245207	C0599333	Epithelium of bronchus	bpoc	3.43
26245207	C0279023	chemosensitization/potentiation	topp	3.42
26245207	C0007634	Cells	cell	3.42
26245207	C3282337	Cells [Chemical/Ingredient]	cell	3.42
26245207	C0439860	Heterologous	qlco	3.42
26245207	C3245505	potential	qlco	3.41
26245207	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
26245207	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
26245207	C1879547	Activation action	acty	5.18
26245207	C1883559	Wild Type	gngm	5.18
26245207	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.72
26245207	C1413365	CFTR gene	gngm	3.68
26245207	C3264621	ivacaftor	orch	13.02
26245207	C3264621	ivacaftor	phsu	13.02
26245207	C0010674	Cystic Fibrosis	dsyn	11.49
26245207	C0026882	Mutation	genf	9.87
26245207	C0035139	Surgical Replantation	topp	9.87
26245207	C0015127	Etiology aspects	ftcn	9.84
26245207	C0009429	Combined Modality Therapy	topp	6.62
26245207	C1518422	Negation	ftcn	5.18
26245207	C3266814	Action	acty	3.57
26245207	C0441472	Clinical action	ftcn	3.57
26245207	C0521102	Interferes with	ftcn	3.57
26245207	C1561611	Admission Level of Care Code - Improved	inpr	3.56
26245207	C0332272	Better	qlco	3.56
26245207	C1280519	Effectiveness	qlco	3.56
26245207	C1707887	Efficacy Study	resa	3.56
26245207	C0184511	Improved	qlco	3.56
26245207	C1705285	Mutation Abnormality	comd	3.56
26245207	C0559956	Replacement	ftcn	3.56
26245207	C1555302	Replacement - supply	hlca	3.56
26245207	C1524003	Science of Etiology	cnce	3.53
26245207	C0556895	Combination electrotherapy	topp	3.46
27894875	C0920321	Phase I Clinical Trials	resa	22.49
27894875	C0087136	Unmarried	fndg	22.34
27894875	C0037179	Unmarried person	popg	22.34
27894875	C0016529	Forced expiratory volume function	ortf	19.34
27894875	C0037981	Spirometry	diap	16.05
27894875	C3264621	ivacaftor	orch	14.64
27894875	C3264621	ivacaftor	phsu	14.64
27894875	C3852684	lumacaftor	orch	13.05
27894875	C3852684	lumacaftor	phsu	13.05
27894875	C0282443	Review [Publication Type]	inpr	9.88
27894875	C1708335	Healthy Volunteers	popg	9.73
27894875	C1709323	Open Label Study	resa	7.01
27894875	C1514756	Receive	qlco	5.18
27894875	C1547282	Show	anim	3.98
27894875	C1306036	Forced expiratory volume procedure	diap	3.57
27894875	C1552617	Act Class - review	idcn	3.57
27894875	C1292426	4 Hours	tmco	3.56
27894875	C0439165	Percent (qualifier value)	qnco	3.54
27894875	C1882327	Percent of Predicted Value	qnco	3.54
27894875	C1552115	Supernumerary maxillary right third molar	bpoc	3.54
27894875	C0040704	Transient Population Group	popg	3.54
27894875	C0205374	Transitory	tmco	3.54
27894875	C0681842	prediction	idcn	3.54
27894875	C3469597	Administration of medication	hlca	3.46
27894875	C0150270	Medication Management	hlca	3.46
27894875	C0205195	Combined	qlco	3.45
27894875	C3811910	combination - answer to question	fndg	3.45
27894875	C1947911	combination of objects	phob	3.45
27894875	C1511726	Data	idcn	3.44
27894875	C3714741	Data (eukaryote)	euka	3.44
27894875	C3245479	Data call receiving device	medd	3.44
27894875	C0439559	Phase 1	tmco	3.42
27894875	C3810851	Center of town	fndg	3.42
27894875	C0205099	Central	spco	3.42
27894875	C0201734	Pharmacokinetic study	resa	3.42
27894875	C0205171	Singular	qnco	3.42
27894875	C0079613	Adoptive Immunotherapy	topp	51.27
27894875	C1869853	SERPINA3 protein, human	aapp	25.89
27894875	C1869853	SERPINA3 protein, human	bacs	25.89
27894875	C3179385	Bronchodilator Effect	phsf	19.34
27894875	C0006280	Bronchodilator Agents	phsu	19.32
27894875	C0040363	Togo	geoa	17.80
27894875	C0041260	Tryptophanase	aapp	17.80
27894875	C0041260	Tryptophanase	enzy	17.80
27894875	C0220825	Evaluation	hlca	14.64
27894875	C0168634	BaseLine dental cement	bodm	12.93
27894875	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	12.89
27894875	C0086715	Normal Range	qnco	10.06
27894875	C1708335	Healthy Volunteers	popg	9.76
27894875	C1704632	Disease Response	fndg	7.00
27894875	C2911692	Response (communication)	menp	7.00
27894875	C1706817	Response (statement)	inpr	7.00
27894875	C0871261	Response process	orga	7.00
27894875	C4048375	Asthma Control Test Questionnaire	inpr	6.85
27894875	C3890007	SERPINA3 wt Allele	gngm	6.85
27894875	C1516048	Assessed	acty	5.18
27894875	C1883351	To	qlco	5.18
27894875	C0557651	Room of building - Study	mnob	3.98
27894875	C2603343	Study	resa	3.98
27894875	C0599755	cohort	popg	3.55
27894875	C1442488	Baseline	qnco	3.47
27894875	C1524062	Additional	ftcn	3.43
27894875	C0205166	Long	qlco	3.43
27894875	C1706317	Long Variable	qlco	3.43
27894875	C1806781	Short	qnco	3.43
27894875	C2350002	Short Value	qnco	3.43
27894875	C1282927	Shortened	qlco	3.43
27894875	C0001554	Administration occupational activities	ocac	3.42
27894875	C1533734	Administration procedure	topp	3.42
27894875	C1054142	Iva <Plant>	plnt	3.42
27894875	C1416936	LUM gene	gngm	3.42
27894875	C0396059	Vocal cord dysfunction familial	cgab	12.90
27894875	C0332282	Following	tmco	10.42
27894875	C0231290	Status post	tmco	10.42
27894875	C0001554	Administration occupational activities	ocac	7.18
27894875	C1533734	Administration procedure	topp	7.18
27894875	C0332161	Attenuated by (contextual qualifier)	qlco	5.18
27894875	C0599946	Attenuation	acty	5.18
27894875	C1555029	Reverse	ftcn	3.98
27894875	C1292426	4 Hours	tmco	3.59
27894875	C1441672	Observed	ftcn	3.59
27894875	C0006280	Bronchodilator Agents	phsu	20.95
27894875	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	12.89
27894875	C0205170	Good	qlco	3.68
27894875	C3146287	Well	mnob	3.68
27894875	C0001554	Administration occupational activities	ocac	3.55
27894875	C1533734	Administration procedure	topp	3.55
27894875	C1054142	Iva <Plant>	plnt	3.43
27894875	C1416936	LUM gene	gngm	3.43
27894875	C0521115	Simultaneous	tmco	3.43
27894875	C0396059	Vocal cord dysfunction familial	cgab	13.02
27894875	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	12.89
27894875	C1708335	Healthy Volunteers	popg	9.95
27894875	C0009429	Combined Modality Therapy	topp	6.60
27894875	C1511726	Data	idcn	5.18
27894875	C3714741	Data (eukaryote)	euka	5.18
27894875	C3245479	Data call receiving device	medd	5.18
27894875	C0332282	Following	tmco	5.18
27894875	C1547282	Show	anim	5.18
27894875	C0231290	Status post	tmco	5.18
27894875	C1441672	Observed	ftcn	3.57
27894875	C0001554	Administration occupational activities	ocac	3.55
27894875	C1533734	Administration procedure	topp	3.55
27894875	C0556895	Combination electrotherapy	topp	3.45
27894875	C0040704	Transient Population Group	popg	3.43
27894875	C0205374	Transitory	tmco	3.43
27894875	C1054142	Iva <Plant>	plnt	3.43
27894875	C1416936	LUM gene	gngm	3.43
23890012	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.57
23890012	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.57
23890012	C0014239	Endoplasmic Reticulum	celc	22.51
23890012	C0010674	Cystic Fibrosis	dsyn	10.06
23890012	C0026882	Mutation	genf	9.87
23890012	C0015127	Etiology aspects	ftcn	9.84
23890012	C0750554	MOSTLY	idcn	5.18
23890012	C0205393	Most	qnco	5.18
23890012	C1705285	Mutation Abnormality	comd	3.56
23890012	C1524003	Science of Etiology	cnce	3.53
23890012	C0678226	Due to	ftcn	3.45
23890012	C0337094	Exit	spco	3.44
23890012	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
23890012	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
23890012	C0008976	Clinical Trials	resa	19.41
23890012	C1524059	mechanism of action qualifier	ftcn	13.10
23890012	C1096775	Clinical Trial [Publication Type]	inpr	9.95
23890012	C0031327	Drug Kinetics	phsf	9.95
23890012	C0332185	Recent	tmco	5.18
23890012	C1328819	Small Molecule	orch	5.18
23890012	C3252847	VX 809	orch	3.75
23890012	C3252847	VX 809	phsu	3.75
23890012	C1744691	establishment and maintenance of localization	biof	3.63
23890012	C0475264	localization	ftcn	3.63
23890012	C0439673	Unknown	qlco	3.55
23890012	C1413365	CFTR gene	gngm	3.48
23890012	C0009264	Cold Temperature	npop	24.11
23890012	C0040363	Togo	geoa	17.80
23890012	C0041260	Tryptophanase	aapp	17.80
23890012	C0041260	Tryptophanase	enzy	17.80
23890012	C0442796	Additive	qlco	5.18
23890012	C1516048	Assessed	acty	5.18
23890012	C1883351	To	qlco	5.18
23890012	C3252847	VX 809	orch	5.18
23890012	C3252847	VX 809	phsu	5.18
23890012	C1550602	additive ingredient	sbst	5.18
23890012	C2986495	Synergistic	qlco	3.55
23890012	C1413365	CFTR gene	gngm	3.42
23890012	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
23890012	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
23890012	C0040363	Togo	geoa	17.80
23890012	C0041260	Tryptophanase	aapp	17.80
23890012	C0041260	Tryptophanase	enzy	17.80
23890012	C0009429	Combined Modality Therapy	topp	6.59
23890012	C1883351	To	qlco	5.18
23890012	C1547282	Show	anim	3.98
23890012	C1883712	Add - instruction imperative	ftcn	3.57
23890012	C2348003	Agent Administration	hlca	3.55
23890012	C0450442	Agent	chvf	3.52
23890012	C1254351	Pharmacologic Substance	phsu	3.52
23890012	C1521826	Protocol Agent	inpr	3.52
23890012	C1704537	Osteopathic Combined Method	topp	3.44
23890012	C0205195	Combined	qlco	3.43
23890012	C3540763	VARIOUS DRUG CLASSES IN ATC	phsu	3.43
23890012	C0440102	Various patch test substance	irda	3.43
23890012	C3540765	various allergen extracts	imft	3.43
23890012	C3540765	various allergen extracts	phsu	3.43
23890012	C3540008	various antiinfectives and antiseptics for local oral treatment	phsu	3.43
23890012	C3540766	various antiseptic throat preparations	phsu	3.43
23890012	C3540762	various other agents for local oral treatment in ATC	phsu	3.43
23890012	C3540769	various other intestinal adsorbents in ATC	phsu	3.43
23890012	C3540761	various other nasal preparations in ATC	phsu	3.43
23890012	C1413365	CFTR gene	gngm	3.42
23890012	C1947976	Correction (change)	ftcn	3.42
23890012	C1705565	Correction Report	inpr	3.42
23890012	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.16
23890012	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.16
23890012	C1155874	Cell Cycle Checkpoints	celf	12.86
23890012	C0026377	Molecular Conformation	spco	12.84
23890012	C0033972	Psychotherapy, Multiple	topp	9.77
23890012	C1413365	CFTR gene	gngm	7.09
23890012	C1517586	Investigational	qlco	5.18
23890012	C1705535	suggestion	idcn	3.98
23890012	C2698172	Application Program Interface	inpr	3.68
23890012	C1511726	Data	idcn	3.68
23890012	C3714741	Data (eukaryote)	euka	3.68
23890012	C3245479	Data call receiving device	medd	3.68
23890012	C1708533	Interface Device Component	mnob	3.68
23890012	C3889426	Content Type Requirement	ftcn	3.57
23890012	C1514873	Requirement	ftcn	3.57
23890012	C1524057	Compatible	qlco	3.55
23890012	C0332290	Consistent with	idcn	3.55
23890012	C1710028	Scope	cnce	3.55
23890012	C0205198	Compound	qlco	3.51
23890012	C1706082	Compound (substance)	chem	3.51
23890012	C0870071	modeling	resa	3.50
23890012	C3252847	VX 809	orch	3.44
23890012	C3252847	VX 809	phsu	3.44
23890012	C1167622	Binding (Molecular Function)	moft	3.42
23890012	C1145667	Binding action	acty	3.42
23890012	C1947976	Correction (change)	ftcn	3.42
23890012	C1705565	Correction Report	inpr	3.42
23890012	C1517331	Further	spco	3.42
23890012	C2986495	Synergistic	qlco	3.42
23890012	C0007634	Cells	cell	3.42
23890012	C0178539	Cellular	lbpr	3.42
23890012	C0205145	Site	spco	3.42
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.41
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.41
28001373	C0010674	Cystic Fibrosis	dsyn	10.06
28001373	C0026882	Mutation	genf	9.85
28001373	C0012634	Disease	dsyn	9.78
28001373	C1413365	CFTR gene	gngm	3.48
28001373	C2825142	Experimental Result	fndg	3.42
28001373	C1274040	Result	ftcn	3.42
28001373	C1546471	What subject filter - Result	idcn	3.42
28001373	C0033105	Statistical Prevalence	qnco	22.35
28001373	C1511760	Deletion Mutation	genf	13.03
28001373	C0026882	Mutation	genf	9.94
28001373	C0033684	Proteins	aapp	6.72
28001373	C0033684	Proteins	bacs	6.72
28001373	C0332454	disrupted	qlco	5.18
28001373	C1705285	Mutation Abnormality	comd	3.63
28001373	C0243083	associated disease	patf	3.62
28001373	C1880274	Deletion (action)	acty	3.57
28001373	C1442161	Gene Deletion Abnormality	comd	3.57
28001373	C0599896	trafficking	celf	3.57
28001373	C0205393	Most	qnco	3.48
28001373	C0220900	Prevalence aspects	qnco	3.43
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
28001373	C0007603	Plasma membrane	celc	11.49
28001373	C1413365	CFTR gene	gngm	3.57
28001373	C0599896	trafficking	celf	3.57
28001373	C2986411	Improvement	cnce	3.54
28001373	C1328819	Small Molecule	orch	3.50
28001373	C4049706	Borg Category-Ratio 10 Perceived Exertion Score 3	inpr	3.44
28001373	C0205081	Moderate (severity modifier)	qlco	3.44
28001373	C4049705	Moderate Extremity Pain	inpr	3.44
28001373	C1881878	Moderation	qlco	3.44
28001373	C0887882	Transport Vesicles	celc	25.65
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
28001373	C1413365	CFTR gene	gngm	5.18
28001373	C0521116	Current (present time)	tmco	5.18
28001373	C0442805	Increase	ftcn	5.18
28001373	C0205309	Known	qlco	5.18
28001373	C1518422	Negation	ftcn	5.18
28001373	C0456079	Disease classification level	clas	3.59
28001373	C1547707	Floor - story of building	geoa	3.59
28001373	C2946261	Level	phsu	3.59
28001373	C0441889	Levels (qualifier value)	qlco	3.59
28001373	C1167622	Binding (Molecular Function)	moft	3.57
28001373	C1145667	Binding action	acty	3.57
28001373	C1947931	Direct (qualifier)	qlco	3.57
28001373	C0439851	Direct type of relationship	qlco	3.57
28001373	C1561611	Admission Level of Care Code - Improved	inpr	3.54
28001373	C0332272	Better	qlco	3.54
28001373	C0184511	Improved	qlco	3.54
28001373	C1708715	Loading Technique	acty	3.54
28001373	C0599896	trafficking	celf	3.54
28001373	C0009264	Cold Temperature	npop	24.11
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
28001373	C0040363	Togo	geoa	17.80
28001373	C0041260	Tryptophanase	aapp	17.80
28001373	C0041260	Tryptophanase	enzy	17.80
28001373	C0027627	Neoplasm Metastasis	neop	12.96
28001373	C0012634	Disease	dsyn	11.49
28001373	C0026882	Mutation	genf	9.99
28001373	C0348080	Condition	qlco	5.18
28001373	C3864998	Condition:Find:Pt:^Patient:Nom	clna	5.18
28001373	C1705253	Logical Condition	cnce	5.18
28001373	C1883351	To	qlco	5.18
28001373	C1524063	Use of	ftcn	5.18
28001373	C0599896	trafficking	celf	5.18
28001373	C1705285	Mutation Abnormality	comd	3.68
28001373	C3252847	VX 809	orch	3.68
28001373	C3252847	VX 809	phsu	3.68
28001373	C1947976	Correction (change)	ftcn	3.63
28001373	C1705565	Correction Report	inpr	3.63
28001373	C1521761	Factor	ftcn	3.63
28001373	C2827422	Mathematical Factor	cnce	3.63
28001373	C0567416	Molecule	sbst	3.61
28001373	C1254545	time measurements	lbpr	3.61
28001373	C0242485	Measurement	ftcn	3.56
28001373	C1522508	Details	qlco	3.55
28001373	C0175668	Secondary to	tmco	3.50
28001373	C0205436	second (number)	qnco	3.50
28001373	C1413365	CFTR gene	gngm	3.48
28001373	C1825598	IMPACT gene	gngm	3.48
28001373	C4049986	Impact	qlco	3.48
28001373	C1550177	Real Time	tmco	3.46
28001373	C0237400	Actual	qlco	3.43
28001373	C3272377	Real Data Type	inpr	3.43
28001373	C3272558	Chemical or Textual Reference to Actual Test or Parameter	inpr	3.43
28001373	C0220806	Chemicals	chem	3.43
28001373	C0678659	biochemical mechanism	moft	3.42
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
28001373	C1561611	Admission Level of Care Code - Improved	inpr	5.18
28001373	C0332272	Better	qlco	5.18
28001373	C0184511	Improved	qlco	5.18
28001373	C1883559	Wild Type	gngm	3.58
28001373	C1413365	CFTR gene	gngm	3.57
28001373	C0599896	trafficking	celf	3.57
28001373	C3842590	10%	fndg	3.55
28001373	C0332232	Approximate	qlco	3.55
28001373	C0441889	Levels (qualifier value)	qlco	3.55
28001373	C0009264	Cold Temperature	npop	22.68
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
28001373	C0026882	Mutation	genf	9.99
28001373	C0007603	Plasma membrane	celc	9.88
28001373	C0442805	Increase	ftcn	5.18
28001373	C0205217	Increased	qnco	5.18
28001373	C1561536	*Activity (kind of quantity)	idcn	3.68
28001373	C0205177	Active	ftcn	3.68
28001373	C0441655	Activities	acty	3.68
28001373	C3668946	Activity (animal life circumstance)	fndg	3.68
28001373	C4049939	FDA Establishment Activity Terminology	inpr	3.68
28001373	C1705285	Mutation Abnormality	comd	3.68
28001373	C0439167	Percent Activity	qnco	3.68
28001373	C4049938	Physical Activity Measurement	lbpr	3.68
28001373	C1265611	Quantity	qnco	3.57
28001373	C0205195	Combined	qlco	3.56
28001373	C3811910	combination - answer to question	fndg	3.56
28001373	C1947911	combination of objects	phob	3.56
28001373	C2986495	Synergistic	qlco	3.50
28001373	C3844638	Either	fndg	3.48
28001373	C3252847	VX 809	orch	3.46
28001373	C3252847	VX 809	phsu	3.46
28001373	C1413365	CFTR gene	gngm	3.44
28001373	C0439509	/40	tmco	3.42
28001373	C3842587	40%	qnco	3.42
28001373	C3828842	Nearly	qlco	3.42
28001373	C0005758	Bulla	patf	14.64
28001373	C0333262	Vesicle (morphologic abnormality)	dsyn	7.25
28001373	C0392747	Changing	ftcn	5.18
28001373	C2584321	Reaching	orgf	5.18
28001373	C0445247	Same	qlco	5.18
28001373	C3814530	Skin Vesicle	patf	5.18
28001373	C0205148	Surface	spco	5.18
28001373	C1622418	vesicle	celc	5.18
28001373	C0449788	Count of entities	qnco	3.57
28001373	C0237753	Numbers	qnco	3.57
28001373	C1265611	Quantity	qnco	3.57
28001373	C0439799	Channel	spco	3.44
28001373	C1706095	Channel Object	cnce	3.44
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
28001373	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
28001373	C0026882	Mutation	genf	11.49
28001373	C1167622	Binding (Molecular Function)	moft	7.02
28001373	C1145667	Binding action	acty	7.02
28001373	C0021730	Interferometry	lbpr	6.83
28001373	C0025255	Tissue membrane	tisu	6.83
28001373	C1947931	Direct (qualifier)	qlco	5.18
28001373	C0439851	Direct type of relationship	qlco	5.18
28001373	C1705285	Mutation Abnormality	comd	5.18
28001373	C1524063	Use of	ftcn	5.18
28001373	C1709305	Occur (action)	acty	3.57
28001373	C0242485	Measurement	ftcn	3.56
28001373	C0302891	Native (qualifier value)	ftcn	3.50
28001373	C3252847	VX 809	orch	3.46
28001373	C3252847	VX 809	phsu	3.46
28001373	C1413365	CFTR gene	gngm	3.44
28001373	C0439816	Tightness sensation quality	qlco	3.44
28001373	C0453911	Tights	mnob	3.44
28001373	C0005456	Binding Sites	rcpt	14.64
28001373	C0026882	Mutation	genf	9.88
28001373	C0376315	Manufactured form	mnob	6.72
28001373	C0682969	Ligand Binding Domain	amas	5.18
28001373	C1518422	Negation	ftcn	5.18
28001373	C2945640	compromise	fndg	3.98
28001373	C0042295	Values	qlco	3.68
28001373	C1301820	Obtain	ftcn	3.59
28001373	C0439799	Channel	spco	3.57
28001373	C1706095	Channel Object	cnce	3.57
28001373	C2349975	Enhance (action)	acty	3.57
28001373	C1522492	Formation	ftcn	3.57
28001373	C0348078	Qualitative form	qlco	3.57
28001373	C2348205	Similarity	qlco	3.50
29046368	C0023175	Lead	elii	13.01
29046368	C0023175	Lead	hops	13.01
29046368	C0010674	Cystic Fibrosis	dsyn	11.49
29046368	C0031847	physiopathological	ftcn	9.86
29046368	C0600260	Lung Diseases, Obstructive	dsyn	9.79
29046368	C1283798	Entire respiratory tract	bpoc	5.18
29046368	C0035237	Respiratory System	bdsy	5.18
29046368	C0282335	Respiratory tract structure	bpoc	5.18
29046368	C0151317	Chronic infectious disease	dsyn	3.58
29046368	C0277785	Functional disorder	patf	3.55
29046368	C0678723	Biologic Development	orgf	3.55
29046368	C3275067	Cardiac Lead Procedure	topp	3.55
29046368	C1527148	Development	ftcn	3.55
29046368	C2348269	Dietary Lead	elii	3.55
29046368	C1522538	Leading	ftcn	3.55
29046368	C0181586	Leads (device)	medd	3.55
29046368	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.55
29046368	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.55
29046368	C0243107	development aspects	phsf	3.55
29046368	C0039798	therapeutic aspects	ftcn	22.51
29046368	C0376636	Disease Management	hlca	9.89
29046368	C0231220	Symptomatic	ftcn	3.43
29046368	C0279516	Anti-Bacterial Agents	antb	16.12
29046368	C0024117	Chronic Obstructive Airway Disease	dsyn	14.64
29046368	C0010674	Cystic Fibrosis	dsyn	11.49
29046368	C0030664	Pathology	bmod	9.99
29046368	C0087111	Therapeutic procedure	topp	3.68
29046368	C1512806	Intake	ftcn	3.56
29046368	C0205423	Certain (qualifier value)	qlco	3.50
29046368	C1704787	Definitely Related to Intervention	qlco	3.50
29046368	C3687832	DRUGS	topp	3.43
29046368	C0013227	Pharmaceutical Preparations	phsu	3.43
29046368	C0000854	Process of absorption	npop	13.14
29046368	C0687133	Drug Interactions	moft	13.07
29046368	C0023175	Lead	elii	13.02
29046368	C0023175	Lead	hops	13.02
29046368	C2347023	Biological Absorption	phpr	3.68
29046368	C2825050	Energy Absorption	phpr	3.68
29046368	C2347080	Material Absorption	phpr	3.68
29046368	C2698776	Pharmacokinetics: Absorption	bmod	3.68
29046368	C3275067	Cardiac Lead Procedure	topp	3.56
29046368	C2348269	Dietary Lead	elii	3.56
29046368	C1522538	Leading	ftcn	3.56
29046368	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.56
29046368	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.56
29046368	C0205420	Concurrent	tmco	3.50
29046368	C1548968	Service Request Relationship - Simultaneous	idcn	3.50
29046368	C0521115	Simultaneous	tmco	3.50
29046368	C0040363	Togo	geoa	35.81
29046368	C0041260	Tryptophanase	aapp	35.81
29046368	C0041260	Tryptophanase	enzy	35.81
29046368	C0003237	Antibiotics, Antitubercular	antb	22.51
29046368	C0026907	Mycobacteriaceae	bact	20.95
29046368	C0140575	Rifabutin	antb	17.80
29046368	C0140575	Rifabutin	orch	17.80
29046368	C0035608	Rifampin	antb	17.80
29046368	C0035608	Rifampin	orch	17.80
29046368	C0003232	Antibiotics	antb	16.21
29046368	C0015576	Family	famg	13.14
29046368	C3264621	ivacaftor	orch	13.14
29046368	C3264621	ivacaftor	phsu	13.14
29046368	C0035609	Rifamycins	antb	12.96
29046368	C0035609	Rifamycins	orch	12.96
29046368	C3852684	lumacaftor	orch	12.96
29046368	C3852684	lumacaftor	phsu	12.96
29046368	C0073371	rifamycin SV	antb	12.96
29046368	C0073371	rifamycin SV	orch	12.96
29046368	C0014003	Employment	qlco	11.49
29046368	C0087111	Therapeutic procedure	topp	10.42
29046368	C1883351	To	qlco	10.42
29046368	C1522326	Treating	ftcn	10.42
29046368	C1292734	Treatment intent	ftcn	10.42
29046368	C0031330	Pharmacology	bmod	9.81
29046368	C0030705	Patients	podg	6.83
29046368	C0557351	Employed	fndg	5.18
29046368	C1707959	Example	cnce	5.18
29046368	C2697524	Graph Node	cnce	5.18
29046368	C0230003	Vertex	blor	5.18
29046368	C1704727	Family (taxonomic)	cnce	3.68
29046368	C0013227	Pharmaceutical Preparations	phsu	3.68
29046368	C1254351	Pharmacologic Substance	phsu	3.68
29046368	C3540706	Antibiotic throat preparations	antb	3.59
29046368	C3540707	Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	antb	3.59
29046368	C3540704	Antibiotics for systemic use	antb	3.59
29046368	C3540708	Antibiotics, Gynecological	antb	3.59
29046368	C3540710	Antibiotics, ophthalmologic	antb	3.59
29046368	C3540705	Antifungal Antibiotics, Topical	antb	3.59
29046368	C1273517	Used by	fndg	3.59
29046368	C3540709	antibiotics, intestinal	antb	3.59
29046368	C4033620	ORKAMBI	phsu	3.50
29046368	C0205464	pharmacological	ftcn	3.50
29046368	C0017296	gene therapy	topp	7.27
29046368	C0081786	Microbial Biofilms	bact	6.72
29046368	C0004611	Bacteria	bact	5.18
29046368	C3463902	Bacteria <stick insect genus>	euka	5.18
29046368	C4038931	Bacteria present	fndg	5.18
29046368	C2347473	Percent of Bacteria	qnco	5.18
29046368	C0150312	Present	qnco	5.18
29046368	C0449450	Presentation	idcn	5.18
29046368	C1510439	bacteria aspects	ftcn	5.18
29046368	C2699424	Concern	idcn	3.98
29046368	C1706912	BARRIER	medd	3.55
29046368	C1517499	Gene Transfer	mbrt	3.45
29046368	C0458827	Airway structure	bpoc	3.44
29046368	C0178987	Artificial Airways	medd	3.44
29046368	C1524062	Additional	ftcn	3.43
29046368	C0040363	Togo	geoa	17.80
29046368	C0041260	Tryptophanase	aapp	17.80
29046368	C0041260	Tryptophanase	enzy	17.80
29046368	C1112870	Aerosol Dose Form	bodm	12.90
29046368	C0001712	Aerosols	mnob	12.90
29046368	C1450054	Artificial nanoparticles	mnob	12.90
29046368	C2983310	Overcome	acty	5.18
29046368	C1883351	To	qlco	5.18
29046368	C0205321	Penetration	ftcn	3.55
29046368	C0001554	Administration occupational activities	ocac	3.54
29046368	C1533734	Administration procedure	topp	3.54
29046368	C0683607	allowing	socb	3.44
29046368	C0007634	Cells	cell	3.43
29046368	C0178539	Cellular	lbpr	3.43
29046368	C0302350	Therapeutic	ftcn	3.43
29046368	C0087111	Therapeutic procedure	topp	3.43
29046368	C0205198	Compound	qlco	3.41
29046368	C1706082	Compound (substance)	chem	3.41
29046368	C1112870	Aerosol Dose Form	bodm	13.01
29046368	C0001712	Aerosols	mnob	13.01
29046368	C0282443	Review [Publication Type]	inpr	11.49
29046368	C1552617	Act Class - review	idcn	5.18
29046368	C1706912	BARRIER	medd	3.63
29046368	C1283798	Entire respiratory tract	bpoc	3.61
29046368	C0035237	Respiratory System	bdsy	3.61
29046368	C0282335	Respiratory tract structure	bpoc	3.61
29046368	C2937289	Adapt (substance)	orch	3.56
29046368	C0678723	Biologic Development	orgf	3.55
29046368	C1527148	Development	ftcn	3.55
29046368	C0205234	Focal	spco	3.55
29046368	C1285542	Has focus	ftcn	3.55
29046368	C0243107	development aspects	phsf	3.55
29046368	C0524527	Drug Formulation Process	resa	3.52
29046368	C0439064	Numerous	qnco	3.50
29046368	C0521116	Current (present time)	tmco	5.18
29046368	C1705822	Transfer Technique	ftcn	5.18
29046368	C0524527	Drug Formulation Process	resa	3.98
29046368	C1883708	Then	tmco	3.68
29046368	C0185125	Application procedure	hlca	3.57
29046368	C0205210	Clinical	qlco	3.57
29046368	C1553058	Neuropsychologist - Clinical	prog	3.57
29046368	C0237412	Psychologist - Clinical	prog	3.57
29046368	C0497591	Social Worker - Clinical	prog	3.57
29046368	C1273517	Used by	fndg	3.57
29046368	C0205177	Active	ftcn	3.56
29046368	C3888249	Active License	qlco	3.56
29046368	C0567416	Molecule	sbst	3.56
29046368	C3853793	active (HL7 RoleLink)	idcn	3.56
29046368	C0725813	depend	medd	3.53
29046368	C0040363	Togo	geoa	17.80
29046368	C0041260	Tryptophanase	aapp	17.80
29046368	C0041260	Tryptophanase	enzy	17.80
29046368	C0279516	Anti-Bacterial Agents	antb	16.17
29046368	C0218063	Ensure (product)	food	13.44
29046368	C0013682	Efficiency	qnco	13.14
29046368	C0040669	Transfection	mbrt	13.14
29046368	C0687133	Drug Interactions	moft	13.07
29046368	C1883351	To	qlco	5.18
29046368	C1561536	*Activity (kind of quantity)	idcn	3.55
29046368	C0205177	Active	ftcn	3.55
29046368	C0441655	Activities	acty	3.55
29046368	C3668946	Activity (animal life circumstance)	fndg	3.55
29046368	C4049939	FDA Establishment Activity Terminology	inpr	3.55
29046368	C0205234	Focal	spco	3.55
29046368	C1285542	Has focus	ftcn	3.55
29046368	C0439167	Percent Activity	qnco	3.55
29046368	C4049938	Physical Activity Measurement	lbpr	3.55
29046368	C0332149	Possible	qlco	3.43
29046368	C2362652	Possible diagnosis	qlco	3.43
29046368	C1705910	Possibly Related to Intervention	qlco	3.43
29046368	C1540850	Transferring (function)	acty	3.43
29046368	C1830404	Transferring:-:Point in time:^Patient:-	clna	3.43
29046368	C0449445	Approach	spco	3.43
29046368	C0205314	New	qlco	3.43
29046368	C1292724	Procedural approach	ftcn	3.43
29046368	C0302350	Therapeutic	ftcn	3.43
29046368	C0087111	Therapeutic procedure	topp	3.43
26556432	C0079613	Adoptive Immunotherapy	topp	25.60
26556432	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
26556432	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
26556432	C0040363	Togo	geoa	17.80
26556432	C0041260	Tryptophanase	aapp	17.80
26556432	C0041260	Tryptophanase	enzy	17.80
26556432	C3264621	ivacaftor	orch	13.14
26556432	C3264621	ivacaftor	phsu	13.14
26556432	C0031843	physiological aspects	phsf	13.06
26556432	C1869853	SERPINA3 protein, human	aapp	12.98
26556432	C1869853	SERPINA3 protein, human	bacs	12.98
26556432	C0010674	Cystic Fibrosis	dsyn	9.99
26556432	C0042153	utilization qualifier	ftcn	9.88
26556432	C0031336	Pharmacy (field)	bmod	8.34
26556432	C0205435	First (number)	qnco	7.30
26556432	C1279901	Firstly	qlco	7.30
26556432	C1135440	Procedures involving the use of pharmaceuticals	topp	5.18
26556432	C1883351	To	qlco	5.18
26556432	C0542341	Function	ftcn	3.60
26556432	C0700205	Function Axis	clas	3.60
26556432	C1705273	Mathematical Operator	inpr	3.60
26556432	C1413365	CFTR gene	gngm	3.58
26556432	C0205540	Approved	qlco	3.57
26556432	C0205210	Clinical	qlco	3.57
26556432	C1553058	Neuropsychologist - Clinical	prog	3.57
26556432	C0237412	Psychologist - Clinical	prog	3.57
26556432	C0497591	Social Worker - Clinical	prog	3.57
26556432	C0457083	Usage	ftcn	3.57
26556432	C1947944	Use - dosing instruction imperative	inpr	3.57
26556432	C4048375	Asthma Control Test Questionnaire	inpr	3.52
26556432	C3890007	SERPINA3 wt Allele	gngm	3.52
26556432	C0205314	New	qlco	3.47
26556432	C0679622	literary novel	inpr	3.47
26556432	C0456079	Disease classification level	clas	3.43
26556432	C1547707	Floor - story of building	geoa	3.43
26556432	C2946261	Level	phsu	3.43
26556432	C0441889	Levels (qualifier value)	qlco	3.43
26556432	C1521991	Molecular	qlco	3.43
26556432	C0087136	Unmarried	fndg	22.35
26556432	C0037179	Unmarried person	popg	22.35
26556432	C0030705	Patients	podg	13.40
26556432	C0030755	Pediatrics	bmod	9.87
26556432	C0001675	Adult	aggp	9.78
26556432	C0027362	Human Age Group	aggp	6.76
26556432	C0237876	Sharing (Social Behavior)	socb	5.18
26556432	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.63
26556432	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.63
26556432	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.63
26556432	C2348001	Age Cohort	popg	3.61
26556432	C0205450	Four	qnco	3.56
26556432	C1521725	Pediatric	qlco	3.56
26556432	C0596545	Experience	menp	3.55
26556432	C0237607	Practice Experience	menp	3.55
26556432	C1706450	Legal Adult	humn	3.48
26556432	C0205447	One	qnco	3.48
26556432	C3810851	Center of town	fndg	3.42
26556432	C0205099	Central	spco	3.42
26556432	C0205451	Five	qnco	3.42
26556432	C0205171	Singular	qnco	3.42
26556432	C0030705	Patients	podg	8.34
26556432	C0018684	Health	idcn	6.59
26556432	C0439655	Subjective observation (qualifier value)	qlco	5.18
26556432	C2979880	Subjective:Finding:Point in time:^Patient:Narrative	inpr	5.18
26556432	C2986412	Objective Improvement	cnce	3.59
26556432	C2986411	Improvement	cnce	3.53
26556432	C3839803	Health objective	inpr	3.46
26556432	C0005893	Body mass index procedure	diap	20.95
26556432	C0030705	Patients	podg	8.34
26556432	C0429706	Forced expiratory volume in 1 second finding	fndg	7.13
26556432	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	7.13
26556432	C0024115	Lung diseases	dsyn	6.91
26556432	C1305855	Body mass index	clna	5.18
26556432	C2986411	Improvement	cnce	3.57
26556432	C1272684	Accepted	qlco	3.48
26556432	C0443211	Established	qlco	3.48
26556432	C1546944	Event Seriousness - Significant	qlco	3.44
26556432	C0750502	Significant	idcn	3.44
26556432	C0237881	Statistical Significance	qnco	3.44
26556432	C1561566	FEV1 Adverse Event	fndg	3.42
26556432	C1720467	Only - dosing instruction fragment	inpr	3.68
26556432	C0205171	Singular	qnco	3.68
26556432	C0947630	Scientific Study	lbpr	3.63
26556432	C1704243	Greater	qnco	3.48
26556432	C0549177	Large	qnco	3.48
26556432	C0039798	therapeutic aspects	ftcn	22.56
26556432	C0040363	Togo	geoa	17.80
26556432	C0041260	Tryptophanase	aapp	17.80
26556432	C0041260	Tryptophanase	enzy	17.80
26556432	C0031843	physiological aspects	phsf	14.64
26556432	C3264621	ivacaftor	orch	12.94
26556432	C3264621	ivacaftor	phsu	12.94
26556432	C1257890	Population Group	popg	9.99
26556432	C0439659	Beginning	tmco	7.10
26556432	C0024109	Lung	bpoc	6.83
26556432	C0032659	geographic population	qnco	6.83
26556432	C0030705	Patients	podg	6.66
26556432	C0542341	Function	ftcn	5.18
26556432	C0700205	Function Axis	clas	5.18
26556432	C1705273	Mathematical Operator	inpr	5.18
26556432	C1883351	To	qlco	5.18
26556432	C1278908	Entire lung	bpoc	3.68
26556432	C0819757	Structure of parenchyma of lung	tisu	3.68
26556432	C0087111	Therapeutic procedure	topp	3.63
26556432	C1363945	Therapy Object (animal model)	fndg	3.63
26556432	C2986411	Improvement	cnce	3.55
26556432	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.50
26556432	C0231683	Gait normal	fndg	3.50
26556432	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.50
26556432	C2347086	Mean Percent of Normal	qnco	3.50
26556432	C0205307	Normal	qlco	3.50
26556432	C0439166	Percent normal	qnco	3.50
26556432	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.50
26556432	C1561566	FEV1 Adverse Event	fndg	3.43
26556432	C0429706	Forced expiratory volume in 1 second finding	fndg	3.43
26556432	C2347634	Population Mean	qnco	3.43
26556432	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.43
26556432	C2348143	Sample Mean	qnco	3.43
26556432	C0444504	Statistical mean	qnco	3.43
26556432	C0040363	Togo	geoa	17.80
26556432	C0041260	Tryptophanase	aapp	17.80
26556432	C0041260	Tryptophanase	enzy	17.80
26556432	C0009924	Contrast Media	irda	14.64
26556432	C3264621	ivacaftor	orch	14.64
26556432	C3264621	ivacaftor	phsu	14.64
26556432	C0235063	Respiratory Depression	patf	11.49
26556432	C0035245	Respiratory physiology	ortf	8.34
26556432	C0030705	Patients	podg	6.71
26556432	C0024115	Lung diseases	dsyn	6.60
26556432	C1979874	Contrast	qlco	5.18
26556432	C3687625	Demonstrates	acty	5.18
26556432	C1517001	Expected	inpr	5.18
26556432	C1883351	To	qlco	5.18
26556432	C0150093	case series	resa	5.18
26556432	C2825142	Experimental Result	fndg	3.56
26556432	C0205250	High	qlco	3.56
26556432	C0237820	Recovery - action	acty	3.56
26556432	C2004454	Recovery - healing process	orgf	3.56
26556432	C1274040	Result	ftcn	3.56
26556432	C1546471	What subject filter - Result	idcn	3.56
26556432	C1555688	recovery - adjustment	qnco	3.56
26556432	C1272684	Accepted	qlco	3.43
26556432	C0443211	Established	qlco	3.43
26556432	C0150093	case series	resa	5.18
26556432	C1561566	FEV1 Adverse Event	fndg	3.63
26556432	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.63
26556432	C1561611	Admission Level of Care Code - Improved	inpr	3.59
26556432	C0332272	Better	qlco	3.59
26556432	C0184511	Improved	qlco	3.59
26556432	C2347634	Population Mean	qnco	3.48
26556432	C2348143	Sample Mean	qnco	3.48
26556432	C0444504	Statistical mean	qnco	3.48
26556432	C0039798	therapeutic aspects	ftcn	22.61
26556432	C0087084	Third-Party Payers	hcro	19.24
26556432	C0041703	United States	geoa	14.64
26556432	C3264621	ivacaftor	orch	13.14
26556432	C3264621	ivacaftor	phsu	13.14
26556432	C0030705	Patients	podg	6.72
26556432	C0439508	per year	tmco	5.18
26556432	C0439234	year	tmco	5.18
26556432	C4050363	Comprehensive Score for Financial Toxicity	inpr	3.98
26556432	C0220812	Cost aspects	ftcn	3.98
26556432	C0010186	Financial cost	qnco	3.98
26556432	C0087111	Therapeutic procedure	topp	3.68
26556432	C1363945	Therapy Object (animal model)	fndg	3.68
26556432	C0680864	expense	qnco	3.59
26556432	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.57
26556432	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.57
26556432	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.57
26556432	C0332152	Before	tmco	3.55
26556432	C2826257	Prior Medication Usage	evnt	3.55
26556432	C0680281	authorization	socb	3.55
26556432	C0205403	Extreme	qlco	3.50
26556432	C0086388	Health Care	hlca	9.73
26556432	C0376554	Knowledge	inpr	8.34
26556432	C0030705	Patients	podg	6.57
26556432	C0596545	Experience	menp	3.57
26556432	C0237607	Practice Experience	menp	3.57
26556432	C0237876	Sharing (Social Behavior)	socb	3.57
26556432	C3827682	Useful	qlco	3.57
26556432	C1522138	shared attribute	ftcn	3.57
26556432	C0871685	Clinician	prog	3.44
29045347	C0149521	Pancreatitis, Chronic	dsyn	12.91
29045347	C3264621	ivacaftor	orch	12.90
29045347	C3264621	ivacaftor	phsu	12.90
29045347	C0010674	Cystic Fibrosis	dsyn	9.75
29045347	C0030705	Patients	podg	6.70
29045347	C0439673	Unknown	qlco	5.18
29045347	C1280500	Effect	qlco	3.57
29045347	C2348382	Effect, Appearance	qlco	3.57
29045347	C0035363	Retrospective Studies	resa	22.47
29045347	C0009738	Congo	geoa	16.04
29045347	C3264621	ivacaftor	orch	14.64
29045347	C3264621	ivacaftor	phsu	14.64
29045347	C0004927	Behavior	inbe	7.13
29045347	C1096776	Multicenter Study	resa	6.73
29045347	C0030705	Patients	podg	6.58
29045347	C1515187	Take	hlca	3.98
29045347	C3887021	History of pancreatitis	fndg	3.65
29045347	C1514923	Retrospective	qlco	3.55
29045347	C2945760	Recurrent	tmco	3.43
29045347	C3811819	CFTR wt Allele	gngm	3.42
29045347	C0039798	therapeutic aspects	ftcn	22.35
29045347	C0029921	Outpatients	podg	9.87
29045347	C0030305	Pancreatitis	dsyn	9.75
29045347	C0030705	Patients	podg	6.58
29045347	C0332189	Episode of	tmco	3.64
29045347	C4082119	Three months	tmco	3.58
29045347	C1874451	Basis	phsu	3.56
29045347	C1527178	Basis - conceptual entity	ftcn	3.56
29045347	C1273870	Management procedure	ocac	3.56
29045347	C1549405	Patient Class - Outpatient	clas	3.56
29045347	C1548439	Referral category - Outpatient	idcn	3.56
29045347	C0205447	One	qnco	3.55
29045347	C1963198	Pancreatitis Adverse Event	fndg	3.44
29045347	C1720467	Only - dosing instruction fragment	inpr	3.43
29045347	C0205171	Singular	qnco	3.43
29045347	C0205452	Six	qnco	3.43
29045347	C0205435	First (number)	qnco	3.42
29045347	C1279901	Firstly	qlco	3.42
29045347	C0087111	Therapeutic procedure	topp	3.42
29045347	C1363945	Therapy Object (animal model)	fndg	3.42
29045347	C0039798	therapeutic aspects	ftcn	22.36
29045347	C0149521	Pancreatitis, Chronic	dsyn	13.09
29045347	C3264621	ivacaftor	orch	12.89
29045347	C3264621	ivacaftor	phsu	12.89
29045347	C0030705	Patients	podg	6.72
29045347	C1708385	Hospitalization Required	fndg	5.18
29045347	C0205449	Three	qnco	5.18
29045347	C0439231	month	tmco	3.56
29045347	C0087111	Therapeutic procedure	topp	3.43
29045347	C1363945	Therapy Object (animal model)	fndg	3.43
29045347	C0205458	Twelve	qnco	3.43
29045347	C0009738	Congo	geoa	16.12
29045347	C0149521	Pancreatitis, Chronic	dsyn	13.04
29045347	C3264621	ivacaftor	orch	12.90
29045347	C3264621	ivacaftor	phsu	12.90
29045347	C0030705	Patients	podg	6.83
29045347	C1524063	Use of	ftcn	3.64
29045347	C0332281	Associated with	qlco	3.61
29045347	C1521828	Rate	qnco	3.57
29045347	C0871208	Rating (action)	acty	3.57
29045347	C0439603	Frequencies (time pattern)	tmco	3.56
29045347	C3898838	How Often	inpr	3.56
29045347	C1561548	Kind of quantity - Frequency	qlco	3.56
29045347	C0392756	Reduced	qlco	3.56
29045347	C0871396	Spatial Frequency	qnco	3.56
29045347	C1705502	Statistical Frequency	qnco	3.56
29045347	C0376249	With frequency	qnco	3.56
29045347	C3811819	CFTR wt Allele	gngm	3.50
21967060	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.31
21967060	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.31
21967060	C0009738	Congo	geoa	17.80
21967060	C0001883	Airway Obstruction	dsyn	13.10
21967060	C0009450	Communicable Diseases	dsyn	11.49
21967060	C0010674	Cystic Fibrosis	dsyn	11.49
21967060	C0015127	Etiology aspects	ftcn	11.49
21967060	C0026882	Mutation	genf	9.87
21967060	C3714514	Infection	patf	8.34
21967060	C1413365	CFTR gene	gngm	7.23
21967060	C0019247	Hereditary Diseases	dsyn	6.91
21967060	C3811819	CFTR wt Allele	gngm	5.18
21967060	C1524003	Science of Etiology	cnce	5.18
21967060	C1265823	Recurrent inflammation	patf	3.78
21967060	C0332152	Before	tmco	3.57
21967060	C1522538	Leading	ftcn	3.57
21967060	C0458827	Airway structure	bpoc	3.48
21967060	C0178987	Artificial Airways	medd	3.48
21967060	C1705232	Death Related to Adverse Event	fndg	3.48
21967060	C1302234	Fatal	qlco	3.48
21967060	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
21967060	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
21967060	C0022009	Ion Channel	aapp	16.16
21967060	C0022009	Ion Channel	bacs	16.16
21967060	C0009738	Congo	geoa	16.05
21967060	C0031843	physiological aspects	phsf	13.01
21967060	C0851285	Regulation	gora	9.72
21967060	C0024109	Lung	bpoc	6.59
21967060	C0014609	Epithelium	tisu	6.57
21967060	C0458827	Airway structure	bpoc	5.18
21967060	C0178987	Artificial Airways	medd	5.18
21967060	C0205132	Linear	spco	5.18
21967060	C0028778	Obstruction	patf	3.56
21967060	C1882136	Obstruction within Medical Device	phpr	3.56
21967060	C1413365	CFTR gene	gngm	3.55
21967060	C0542341	Function	ftcn	3.55
21967060	C0700205	Function Axis	clas	3.55
21967060	C1517945	Loss	qnco	3.55
21967060	C1705273	Mathematical Operator	inpr	3.55
21967060	C1704666	Hyperlink	inpr	3.52
21967060	C1517892	Links List	inpr	3.52
21967060	C3811819	CFTR wt Allele	gngm	3.43
21967060	C2709248	Pulmonary (qualifier value)	qlco	3.43
21967060	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.43
21967060	C0596019	Chloride Ion	elii	3.42
21967060	C1282864	Entire lumen of body system	bsoj	3.42
21967060	C1301906	Lumen	qlco	3.42
21967060	C0524461	Structure of lumen of body system	bsoj	3.42
21967060	C1551056	Units Of Measure - lumen	qnco	3.42
21967060	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
21967060	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
21967060	C0023185	Learning	menp	14.64
21967060	C0028630	Nucleotides	nnon	11.49
21967060	C1883559	Wild Type	gngm	5.18
21967060	C0850293	electrophysiological studies	diap	5.18
21967060	C1853126	MOLECULAR BASIS	idcn	3.61
21967060	C1158897	regulation of phosphorylation	celf	3.58
21967060	C0205393	Most	qnco	3.56
21967060	C0333052	Version	ftcn	3.56
21967060	C2607870	Version (morphologic abnormality)	spco	3.56
21967060	C1153410	channel activity	moft	3.43
21967060	C1701901	Conditional	qlco	3.42
21967060	C0851827	Dependent - ability	qlco	3.42
21967060	C0231683	Gait normal	fndg	3.42
21967060	C2347086	Mean Percent of Normal	qnco	3.42
21967060	C0205307	Normal	qlco	3.42
21967060	C0439166	Percent normal	qnco	3.42
21967060	C3244310	dependent	ftcn	3.42
21967060	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
21967060	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
21967060	C0014239	Endoplasmic Reticulum	celc	22.51
21967060	C0009738	Congo	geoa	16.08
21967060	C1314792	Etiology	ftcn	14.64
21967060	C0015127	Etiology aspects	ftcn	11.49
21967060	C0026882	Mutation	genf	9.92
21967060	C0033684	Proteins	aapp	6.72
21967060	C0033684	Proteins	bacs	6.72
21967060	C1524003	Science of Etiology	cnce	5.18
21967060	C1413365	CFTR gene	gngm	3.68
21967060	C1705285	Mutation Abnormality	comd	3.61
21967060	C3810541	Adverse Event Emergency Room Visit	inbe	3.55
21967060	C3811131	Estrogen Receptor Measurement	lbpr	3.55
21967060	C0333118	Retained	ftcn	3.55
21967060	C3811819	CFTR wt Allele	gngm	3.47
21967060	C0678227	Causing	ftcn	3.47
21967060	C0205164	Major	qlco	3.47
21967060	C0205082	Severe (severity modifier)	qlco	3.47
21967060	C0007585	Cell Culture Techniques	lbpr	16.27
21967060	C0035280	Retention (Psychology)	menp	16.18
21967060	C0031843	physiological aspects	phsf	13.01
21967060	C0205202	Corrected	qlco	5.18
21967060	C1547282	Show	anim	3.98
21967060	C0205148	Surface	spco	3.57
21967060	C0333117	Retention of content	ftcn	3.56
21967060	C1753315	cellular entity retention	celf	3.56
21967060	C1947919	Application (Document)	inpr	3.54
21967060	C3539080	Application Dosing Unit	qnco	3.54
21967060	C0185125	Application procedure	hlca	3.54
21967060	C4048755	Apply	ftcn	3.54
21967060	C0542341	Function	ftcn	3.54
21967060	C0700205	Function Axis	clas	3.54
21967060	C1705273	Mathematical Operator	inpr	3.54
21967060	C2347934	Regulatory Application	inpr	3.54
21967060	C0332185	Recent	tmco	3.46
21967060	C0947630	Scientific Study	lbpr	3.46
21967060	C1328819	Small Molecule	orch	3.44
21967060	C3810541	Adverse Event Emergency Room Visit	inbe	3.43
21967060	C3811131	Estrogen Receptor Measurement	lbpr	3.43
21967060	C0392747	Changing	ftcn	3.42
21967060	C0439799	Channel	spco	3.42
21967060	C1706095	Channel Object	cnce	3.42
21967060	C0205164	Major	qlco	3.42
21967060	C0205082	Severe (severity modifier)	qlco	3.42
21967060	C0596988	mutant	comd	3.42
21967060	C1709060	Modulator Device Component	mnob	3.40
21967060	C0205423	Certain (qualifier value)	qlco	3.38
21967060	C0439543	Certainties	qlco	3.38
21967060	C0008976	Clinical Trials	resa	38.89
21967060	C0039798	therapeutic aspects	ftcn	22.35
21967060	C0009738	Congo	geoa	16.04
21967060	C1096775	Clinical Trial [Publication Type]	inpr	9.88
21967060	C0205198	Compound	qlco	5.18
21967060	C1706082	Compound (substance)	chem	5.18
21967060	C1328819	Small Molecule	orch	5.18
21967060	C0205448	Two	qnco	5.18
21967060	C3252847	VX 809	orch	5.18
21967060	C3252847	VX 809	phsu	5.18
21967060	C2741958	VX-770	orch	5.18
21967060	C1516635	Clinical Treatment	topp	3.57
21967060	C1533734	Administration procedure	topp	3.42
21967060	C1705169	Biomaterial Treatment	cnce	3.42
21967060	C3811819	CFTR wt Allele	gngm	3.42
21967060	C0087111	Therapeutic procedure	topp	3.42
21967060	C1522326	Treating	ftcn	3.42
21967060	C3538994	Treatment Epoch	resa	3.42
21967060	C3887704	treatment - ActInformationManagementReason	hlca	3.42
21967060	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.49
21967060	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.49
21967060	C0043309	Roentgen Rays	npop	16.37
21967060	C1962945	Radiographic imaging procedure	diap	13.22
21967060	C0034571	roentgenographic	ftcn	13.22
21967060	C0152244	Bone Cysts, Aneurysmal	dsyn	13.03
21967060	C0026344	Models, Molecular	inpr	9.76
21967060	C0033684	Proteins	aapp	8.34
21967060	C0033684	Proteins	bacs	8.34
21967060	C0686817	Prokaryote	orgm	6.66
21967060	C1705938	Base - General Qualifier	idcn	5.18
21967060	C1527178	Basis - conceptual entity	ftcn	5.18
21967060	C1552857	chapter	idcn	5.18
21967060	C0043299	Diagnostic radiologic examination	diap	3.75
21967060	C1306645	Plain x-ray	diap	3.75
21967060	C3891450	Radiography Study File	inpr	3.75
21967060	C1148923	atp binding	moft	3.75
21967060	C1413365	CFTR gene	gngm	3.63
21967060	C0450240	Cassette (physical object)	medd	3.63
21967060	C1706210	Cassette Device Component	mnob	3.63
21967060	C1880355	Discover	acty	3.63
21967060	C3890225	Active Breathing Coordinator-Mediated Radiation Therapy	topp	3.57
21967060	C0678594	structure	spco	3.57
21967060	C0449255	Context	fndg	3.55
21967060	C0542559	contextual factors	ftcn	3.55
21967060	C1883559	Wild Type	gngm	3.53
21967060	C0332185	Recent	tmco	3.50
21967060	C1720294	On (qualifier value)	inpr	3.48
21967060	C1720176	Upon - dosing instruction fragment	ftcn	3.48
21967060	C0040363	Togo	geoa	17.80
21967060	C0041260	Tryptophanase	aapp	17.80
21967060	C0041260	Tryptophanase	enzy	17.80
21967060	C0026882	Mutation	genf	9.86
21967060	C0015127	Etiology aspects	ftcn	9.83
21967060	C0243067	defects aspect	ftcn	7.70
21967060	C2347609	Chemical Probe	chvf	5.18
21967060	C2584313	Discussion (communication)	socb	5.18
21967060	C3536729	Probe Device Component	mnob	5.18
21967060	C0182400	Probes	medd	5.18
21967060	C0581602	Structural modification	topp	5.18
21967060	C1883351	To	qlco	5.18
21967060	C1704681	probe gene fragment	gngm	5.18
21967060	C2349182	Correct (qualifier)	qlco	3.59
21967060	C1514873	Requirement	ftcn	3.59
21967060	C1527118	Protein Function	moft	3.58
21967060	C0815043	Protein, Organized by Function	aapp	3.58
21967060	C0923800	Structural anatomical relation	cnce	3.58
21967060	C0205214	Common (qualifier value)	qnco	3.55
21967060	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.55
21967060	C1705285	Mutation Abnormality	comd	3.55
21967060	C1555307	promise	idcn	3.55
21967060	C1522138	shared attribute	ftcn	3.55
21967060	C1524003	Science of Etiology	cnce	3.52
21967060	C1521991	Molecular	qlco	3.50
21967060	C1328819	Small Molecule	orch	3.45
21967060	C1883559	Wild Type	gngm	3.45
21967060	C1709060	Modulator Device Component	mnob	3.41
27703398	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27703398	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27703398	C0010674	Cystic Fibrosis	dsyn	10.06
27703398	C0015127	Etiology aspects	ftcn	9.94
27703398	C0012634	Disease	dsyn	9.91
27703398	C0026882	Mutation	genf	9.86
27703398	C1413365	CFTR gene	gngm	6.92
27703398	C1524003	Science of Etiology	cnce	3.63
27703398	C0596611	Gene Mutation	genf	3.58
27703398	C0205214	Common (qualifier value)	qnco	3.46
27703398	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.46
27703398	C0205393	Most	qnco	3.46
27703398	C1522138	shared attribute	ftcn	3.46
27703398	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27703398	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27703398	C0055363	Chloride Channels	aapp	19.52
27703398	C0055363	Chloride Channels	bacs	19.52
27703398	C0031843	physiological aspects	phsf	14.64
27703398	C0035150	Reproduction	orgf	12.96
27703398	C0021853	Intestines	bpoc	11.49
27703398	C0026882	Mutation	genf	11.49
27703398	C0018517	Half-Life	tmco	9.95
27703398	C0220781	Anabolism	biof	8.34
27703398	C0030274	Pancreas	bpoc	8.34
27703398	C0458827	Airway structure	bpoc	5.18
27703398	C0178987	Artificial Airways	medd	5.18
27703398	C1278931	Entire pancreas	bpoc	5.18
27703398	C0542341	Function	ftcn	5.18
27703398	C0700205	Function Axis	clas	5.18
27703398	C1708548	Intestinal Wall Tissue	tisu	5.18
27703398	C1705273	Mathematical Operator	inpr	5.18
27703398	C1709694	Processing (action)	acty	5.18
27703398	C1883254	Synthesis	acty	5.18
27703398	C0392747	Changing	ftcn	3.79
27703398	C1185740	Tract	bpoc	3.68
27703398	C1167182	Apical plasma membrane	celc	3.58
27703398	C0221908	epithelial	qlco	3.54
27703398	C1542147	Main	qlco	3.48
27703398	C0205225	Primary	qlco	3.48
27703398	C1413365	CFTR gene	gngm	3.44
27703398	C0009738	Congo	geoa	16.04
27703398	C0024115	Lung diseases	dsyn	6.91
27703398	C1280464	Manifestation of	qlco	3.59
27703398	C3811819	CFTR wt Allele	gngm	3.43
27703398	C1511545	Critical	qlco	3.43
27703398	C0205393	Most	qnco	3.43
27703398	C0001883	Airway Obstruction	dsyn	13.10
27703398	C0023175	Lead	elii	13.01
27703398	C0023175	Lead	hops	13.01
27703398	C0009450	Communicable Diseases	dsyn	11.49
27703398	C0021368	Inflammation	patf	11.49
27703398	C3714514	Infection	patf	8.34
27703398	C1880022	Characterization	acty	3.57
27703398	C3275067	Cardiac Lead Procedure	topp	3.55
27703398	C2348269	Dietary Lead	elii	3.55
27703398	C1522538	Leading	ftcn	3.55
27703398	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.55
27703398	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.55
27703398	C0040300	Body tissue	tisu	3.43
27703398	C1705232	Death Related to Adverse Event	fndg	3.43
27703398	C1948029	Destruction (action)	acty	3.43
27703398	C1261381	Destructive procedure (surgical)	topp	3.43
27703398	C1302234	Fatal	qlco	3.43
27703398	C1547928	Tissue Specimen Code	inpr	3.43
27703398	C0023671	Life Expectancy	grpa	19.38
27703398	C0009738	Congo	geoa	17.80
27703398	C0162340	Comprehension	menp	13.01
27703398	C0031847	physiopathological	ftcn	9.86
27703398	C0242479	Interdisciplinary Studies	ocac	9.78
27703398	C0030705	Patients	podg	6.59
27703398	C3811819	CFTR wt Allele	gngm	5.18
27703398	C0392756	Reduced	qlco	5.18
27703398	C0496675	medical care	fndg	3.75
27703398	C0277785	Functional disorder	patf	3.55
27703398	C3854260	Advance	tmco	3.52
27703398	C0725066	Advance -- medical device	medd	3.52
27703398	C1279919	Early	tmco	3.42
27703398	C1704243	Greater	qnco	3.42
27703398	C0549177	Large	qnco	3.42
27703398	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.97
27703398	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.97
27703398	C0031843	physiological aspects	phsf	13.03
27703398	C0282443	Review [Publication Type]	inpr	11.49
27703398	C0031330	Pharmacology	bmod	9.73
27703398	C1413365	CFTR gene	gngm	6.90
27703398	C1552617	Act Class - review	idcn	5.18
27703398	C3854321	Expression (foundation metadata concept)	idcn	5.18
27703398	C0185117	Expression procedure	topp	5.18
27703398	C2948600	Aim	phsu	3.59
27703398	C1947946	Aim (idea)	idcn	3.59
27703398	C3540472	Ancestry-Informative Marker	ftcn	3.59
27703398	C3890193	CD5L wt Allele	gngm	3.59
27703398	C2744535	CD69 protein, human	aapp	3.59
27703398	C2744535	CD69 protein, human	imft	3.59
27703398	C3540471	CD69 wt Allele	gngm	3.59
27703398	C0542341	Function	ftcn	3.57
27703398	C0700205	Function Axis	clas	3.57
27703398	C1705273	Mathematical Operator	inpr	3.57
27703398	C0678723	Biologic Development	orgf	3.54
27703398	C1527148	Development	ftcn	3.54
27703398	C0243107	development aspects	phsf	3.54
27703398	C1705285	Mutation Abnormality	comd	3.44
27703398	C0521116	Current (present time)	tmco	3.42
27703398	C1705970	Electrical Current	npop	3.42
27703398	C0205464	pharmacological	ftcn	3.42
27703398	C1709060	Modulator Device Component	mnob	3.40
27703398	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27703398	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27703398	C0015576	Family	famg	13.02
27703398	C0030705	Patients	podg	6.59
27703398	C1709630	Preclinical	qlco	5.18
27703398	C1516634	research clinical testing	resa	5.18
27703398	C0470187	Availability of	ftcn	3.57
27703398	C1704727	Family (taxonomic)	cnce	3.56
27703398	C4033620	ORKAMBI	phsu	3.50
27703398	C3264627	Kalydeco	phsu	3.48
27703398	C1720467	Only - dosing instruction fragment	inpr	3.48
27703398	C0205171	Singular	qnco	3.48
27703398	C0521116	Current (present time)	tmco	3.44
27703398	C1413365	CFTR gene	gngm	3.43
27703398	C1709060	Modulator Device Component	mnob	3.41
27703398	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27703398	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27703398	C0009738	Congo	geoa	17.80
27703398	C2718059	Precision Medicine	topp	14.64
27703398	C0031843	physiological aspects	phsf	12.88
27703398	C2936405	Drug Repositioning	topp	10.06
27703398	C0282443	Review [Publication Type]	inpr	9.88
27703398	C3811819	CFTR wt Allele	gngm	5.18
27703398	C1882932	Representation (action)	acty	5.18
27703398	C1552617	Act Class - review	idcn	3.57
27703398	C1522508	Details	qlco	3.57
27703398	C0679199	strategy	menp	3.54
27703398	C1413365	CFTR gene	gngm	3.42
27703398	C0542341	Function	ftcn	3.42
27703398	C0700205	Function Axis	clas	3.42
27703398	C1705273	Mathematical Operator	inpr	3.42
27703398	C0205393	Most	qnco	3.42
27703398	C1555307	promise	idcn	3.40
29079142	C0023175	Lead	elii	13.02
29079142	C0023175	Lead	hops	13.02
29079142	C3264621	ivacaftor	orch	12.94
29079142	C3264621	ivacaftor	phsu	12.94
29079142	C0042153	utilization qualifier	ftcn	9.94
29079142	C0013109	Drama	inpr	9.81
29079142	C0010674	Cystic Fibrosis	dsyn	9.75
29079142	C0026882	Mutation	genf	9.73
29079142	C0018684	Health	idcn	6.71
29079142	C0030705	Patients	podg	6.70
29079142	C0457083	Usage	ftcn	3.63
29079142	C1947944	Use - dosing instruction imperative	inpr	3.63
29079142	C3275067	Cardiac Lead Procedure	topp	3.56
29079142	C2348269	Dietary Lead	elii	3.56
29079142	C1522538	Leading	ftcn	3.56
29079142	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.56
29079142	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.56
29079142	C2986411	Improvement	cnce	3.53
29079142	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
29079142	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
29079142	C3264621	ivacaftor	orch	12.91
29079142	C3264621	ivacaftor	phsu	12.91
29079142	C0026882	Mutation	genf	9.73
29079142	C0013109	Drama	inpr	9.69
29079142	C0332282	Following	tmco	5.18
29079142	C3273238	Regulatory Report	inpr	5.18
29079142	C0684224	Report (document)	inpr	5.18
29079142	C0700287	Reporting	hlca	5.18
29079142	C0231290	Status post	tmco	5.18
29079142	C2349954	Withdraw (activity)	acty	3.59
29079142	C2825032	Withdrawal (dysfunction)	mobd	3.59
29079142	C3812880	Withdrawal - birth control	fndg	3.59
29079142	C4049634	Withdrawal Scale (BASC-2)	inpr	3.59
29079142	C1550608	Instance	idcn	3.52
29079142	C0237401	Individual	humn	3.51
29079142	C0027361	Persons	popg	3.51
29079142	C0205210	Clinical	qlco	3.43
29079142	C0205451	Five	qnco	3.43
29079142	C1553058	Neuropsychologist - Clinical	prog	3.43
29079142	C0237412	Psychologist - Clinical	prog	3.43
29079142	C0497591	Social Worker - Clinical	prog	3.43
29079142	C1413365	CFTR gene	gngm	3.42
29079142	C1705285	Mutation Abnormality	comd	3.42
29079142	C0205449	Three	qnco	3.42
29079142	C0871549	Withholding Treatment	hlca	13.14
29079142	C0035245	Respiratory physiology	ortf	6.91
29079142	C0030705	Patients	podg	6.63
29079142	C0868928	Case (situation)	ftcn	5.18
29079142	C1706256	Clinical Study Case	cnce	5.18
29079142	C1706255	Packaging Case	medd	5.18
29079142	C0456962	Rapid	qlco	5.18
29079142	C1457887	Symptoms	sosy	5.18
29079142	C0683368	Symptoms aspect	ftcn	5.18
29079142	C1457868	Worse	fndg	3.56
29079142	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.48
29079142	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.48
29079142	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.48
29079142	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
29079142	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
29079142	C0537670	Oprelvekin	aapp	14.64
29079142	C0537670	Oprelvekin	imft	14.64
29079142	C0537670	Oprelvekin	phsu	14.64
29079142	C0004448	Awareness	menp	13.02
29079142	C0016884	Future	tmco	6.57
29079142	C0700287	Reporting	hlca	5.18
29079142	C1552002	inform	ocac	5.18
29079142	C0205210	Clinical	qlco	3.68
29079142	C1553058	Neuropsychologist - Clinical	prog	3.68
29079142	C0237607	Practice Experience	menp	3.68
29079142	C0237412	Psychologist - Clinical	prog	3.68
29079142	C0497591	Social Worker - Clinical	prog	3.68
29079142	C3641234	CDISC Trial Design Class	inpr	3.55
29079142	C1882365	Phenomenon	phpr	3.43
29079142	C0205177	Active	ftcn	3.42
29079142	C3888249	Active License	qlco	3.42
29079142	C1413365	CFTR gene	gngm	3.42
29079142	C0205250	High	qlco	3.42
29079142	C3853793	active (HL7 RoleLink)	idcn	3.42
29079142	C1709060	Modulator Device Component	mnob	3.40
25477137	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	48.50
25477137	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	48.50
25477137	C0040363	Togo	geoa	17.80
25477137	C0041260	Tryptophanase	aapp	17.80
25477137	C0041260	Tryptophanase	enzy	17.80
25477137	C1413365	CFTR gene	gngm	10.42
25477137	C0010674	Cystic Fibrosis	dsyn	9.77
25477137	C0740116	+2	qnco	5.18
25477137	C3833492	2+	fndg	5.18
25477137	C2827735	2+ Score	qnco	5.18
25477137	C2981700	2+ Score, WHO	clas	5.18
25477137	C0684224	Report (document)	inpr	5.18
25477137	C0700287	Reporting	hlca	5.18
25477137	C1883351	To	qlco	5.18
25477137	C0553702	ca increase	fndg	3.62
25477137	C1948027	Couple (action)	ftcn	3.56
25477137	C0542341	Function	ftcn	3.56
25477137	C0205245	Functional	ftcn	3.56
25477137	C2700217	Functional Relationship	cnce	3.56
25477137	C0439799	Channel	spco	3.55
25477137	C1706095	Channel Object	cnce	3.55
25477137	C0445223	Related personal status	fndg	3.55
25477137	C0439849	Relationships	qlco	3.55
25477137	C0040704	Transient Population Group	popg	3.55
25477137	C0205374	Transitory	tmco	3.55
25477137	C3245505	potential	qlco	3.55
25477137	C0597357	receptor	aapp	3.55
25477137	C0597357	receptor	rcpt	3.55
25477137	C0007634	Cells	cell	3.43
25477137	C3282337	Cells [Chemical/Ingredient]	cell	3.43
25477137	C0108303	TRPV Cation Channels	aapp	22.36
25477137	C0108303	TRPV Cation Channels	rcpt	22.36
25477137	C0015576	Family	famg	14.64
25477137	C0035204	Respiration Disorders	dsyn	8.34
25477137	C0439799	Channel	spco	5.18
25477137	C1706095	Channel Object	cnce	5.18
25477137	C1704727	Family (taxonomic)	cnce	5.18
25477137	C1521840	Target	ftcn	3.57
25477137	C2986546	Target Lesion Identification	diap	3.57
25477137	C1552738	described	idcn	3.57
25477137	C0680022	member	popg	3.54
25477137	C0040704	Transient Population Group	popg	3.42
25477137	C0205374	Transitory	tmco	3.42
25477137	C3245505	potential	qlco	3.42
25477137	C3887642	Hippocampus Proper	bpoc	51.32
25477137	C0009738	Congo	geoa	16.04
25477137	C0019868	Homeostasis	biof	11.49
25477137	C0740116	+2	qnco	10.42
25477137	C3833492	2+	fndg	10.42
25477137	C2827735	2+ Score	qnco	10.42
25477137	C2981700	2+ Score, WHO	clas	10.42
25477137	C0597298	Protein Isoforms	aapp	9.92
25477137	C0036576	Genetic Selection	genf	9.81
25477137	C1879547	Activation action	acty	5.18
25477137	C1414243	TRPV5 gene	gngm	5.18
25477137	C1422342	TRPV6 gene	gngm	5.18
25477137	C2986601	Transient Receptor Potential Cation Channel Subfamily V Member 6	aapp	5.18
25477137	C2986601	Transient Receptor Potential Cation Channel Subfamily V Member 6	bacs	5.18
25477137	C0543488	Interested	menp	3.57
25477137	C0449255	Context	fndg	3.55
25477137	C0542559	contextual factors	ftcn	3.55
25477137	C1707391	Choose (action)	acty	3.51
25477137	C1552740	Entity Determiner - specific	inpr	3.47
25477137	C0205369	Specific qualifier value	qlco	3.47
25477137	C0205448	Two	qnco	3.47
25477137	C0205250	High	qlco	3.44
25477137	C3811819	CFTR wt Allele	gngm	3.43
25477137	C0009738	Congo	geoa	32.33
25477137	C0086418	Homo sapiens	humn	28.69
25477137	C3887642	Hippocampus Proper	bpoc	27.26
25477137	C3811819	CFTR wt Allele	gngm	6.94
25477137	C0740116	+2	qnco	5.18
25477137	C3833492	2+	fndg	5.18
25477137	C2827735	2+ Score	qnco	5.18
25477137	C2981700	2+ Score, WHO	clas	5.18
25477137	C1292732	Investigates	ftcn	5.18
25477137	C0682523	human cell line	cell	3.69
25477137	C0205132	Linear	spco	3.59
25477137	C1314939	Involvement with	ftcn	3.56
25477137	C1711178	Bronchial Epithelial Cell	cell	3.49
25477137	C0205039	Bronchial	bpoc	3.45
25477137	C1442216	Bronchial system	bpoc	3.45
25477137	C1518422	Negation	ftcn	3.45
25477137	C0221908	epithelial	qlco	3.45
25477137	C0439799	Channel	spco	3.41
25477137	C1706095	Channel Object	cnce	3.41
25477137	C0086418	Homo sapiens	humn	57.68
25477137	C0009738	Congo	geoa	32.32
25477137	C0014597	Epithelial Cells	cell	13.60
25477137	C0007600	Cultured Cell Line	cell	10.06
25477137	C0427861	Human cells	lbtr	7.29
25477137	C1273342	Epithelial cell count (procedure)	lbpr	7.25
25477137	C0458827	Airway structure	bpoc	7.19
25477137	C0178987	Artificial Airways	medd	7.19
25477137	C0221908	epithelial	qlco	7.19
25477137	C3811819	CFTR wt Allele	gngm	6.94
25477137	C1273517	Used by	fndg	5.18
25477137	C0237401	Individual	humn	3.59
25477137	C0027361	Persons	popg	3.59
25477137	C1518422	Negation	ftcn	3.48
25477137	C0205225	Primary	qlco	3.46
25477137	C0439631	Primary operation	topp	3.46
25477137	C0439612	True primary (qualifier value)	tmco	3.46
25477137	C1548221	Bed Status - Isolated	idcn	3.42
25477137	C0205409	Isolated	ftcn	3.42
25477137	C0009738	Congo	geoa	66.38
25477137	C3887642	Hippocampus Proper	bpoc	25.76
25477137	C3811819	CFTR wt Allele	gngm	14.38
25477137	C0007634	Cells	cell	10.94
25477137	C3282337	Cells [Chemical/Ingredient]	cell	10.94
25477137	C1518422	Negation	ftcn	6.99
25477137	C0740116	+2	qnco	5.18
25477137	C3833492	2+	fndg	5.18
25477137	C2827735	2+ Score	qnco	5.18
25477137	C2981700	2+ Score, WHO	clas	5.18
25477137	C4055637	Significantly high	qnco	4.12
25477137	C0439799	Channel	spco	3.98
25477137	C1706095	Channel Object	cnce	3.98
25477137	C1547282	Show	anim	3.98
25477137	C0205447	One	qnco	3.59
25477137	C1707455	Comparison	acty	3.59
25477137	C0237401	Individual	humn	3.41
25477137	C0027361	Persons	popg	3.41
25477137	C1099354	RNA, Small Interfering	bacs	19.27
25477137	C1099354	RNA, Small Interfering	nnon	19.27
25477137	C0908152	TRPV6 channel	aapp	12.90
25477137	C0908152	TRPV6 channel	bacs	12.90
25477137	C0036576	Genetic Selection	genf	9.69
25477137	C0740116	+2	qnco	5.18
25477137	C3833492	2+	fndg	5.18
25477137	C2827735	2+ Score	qnco	5.18
25477137	C2981700	2+ Score, WHO	clas	5.18
25477137	C0750554	MOSTLY	idcn	5.18
25477137	C0205393	Most	qnco	5.18
25477137	C0443289	Revealed	qlco	5.18
25477137	C1422342	TRPV6 gene	gngm	5.18
25477137	C2986601	Transient Receptor Potential Cation Channel Subfamily V Member 6	aapp	5.18
25477137	C2986601	Transient Receptor Potential Cation Channel Subfamily V Member 6	bacs	5.18
25477137	C1524063	Use of	ftcn	5.18
25477137	C2825142	Experimental Result	fndg	3.98
25477137	C1274040	Result	ftcn	3.98
25477137	C1546471	What subject filter - Result	idcn	3.98
25477137	C0679199	strategy	menp	3.68
25477137	C0553702	ca increase	fndg	3.58
25477137	C1314939	Involvement with	ftcn	3.55
25477137	C1999216	Inhibitor	qlco	3.54
25477137	C2247226	sulfur oxygenase reductase activity	moft	3.42
25477137	C1707391	Choose (action)	acty	3.38
25477137	C0089795	1-Phosphatidylinositol-4,5-bisphosphate phosphodiesterase	aapp	25.66
25477137	C0089795	1-Phosphatidylinositol-4,5-bisphosphate phosphodiesterase	enzy	25.66
25477137	C0908152	TRPV6 channel	aapp	13.22
25477137	C0908152	TRPV6 channel	bacs	13.22
25477137	C0851285	Regulation	gora	9.86
25477137	C1704259	Biochemical Pathway	moft	3.55
25477137	C1705987	Pathway (interactions)	cnce	3.55
25477137	C0086418	Homo sapiens	humn	28.83
25477137	C3887642	Hippocampus Proper	bpoc	27.26
25477137	C0009738	Congo	geoa	16.07
25477137	C0740116	+2	qnco	5.18
25477137	C3833492	2+	fndg	5.18
25477137	C2827735	2+ Score	qnco	5.18
25477137	C2981700	2+ Score, WHO	clas	5.18
25477137	C0444706	Measured	qlco	5.18
25477137	C3541902	Measured Tumor Identification	diap	5.18
25477137	C1620102	U 73122	orch	5.18
25477137	C1620102	U 73122	phsu	5.18
25477137	C1711178	Bronchial Epithelial Cell	cell	3.63
25477137	C3811819	CFTR wt Allele	gngm	3.46
25477137	C1518422	Negation	ftcn	3.46
25477137	C0205370	Unspecified	qlco	3.43
25477137	C1999216	Inhibitor	qlco	3.42
25477137	C3854307	Presence (property)	qlco	3.42
25477137	C0150312	Present	qnco	3.42
25477137	C0392148	Providing presence (regime/therapy)	topp	3.42
25477137	C3887642	Hippocampus Proper	bpoc	25.76
25477137	C0442805	Increase	ftcn	7.53
25477137	C0740116	+2	qnco	5.18
25477137	C3833492	2+	fndg	5.18
25477137	C2827735	2+ Score	qnco	5.18
25477137	C2981700	2+ Score, WHO	clas	5.18
25477137	C1620102	U 73122	orch	5.18
25477137	C1620102	U 73122	phsu	5.18
25477137	C0205217	Increased	qnco	3.59
25477137	C3854307	Presence (property)	qlco	3.55
25477137	C0150312	Present	qnco	3.55
25477137	C0392148	Providing presence (regime/therapy)	topp	3.55
25477137	C0392756	Reduced	qlco	3.55
25477137	C2247226	sulfur oxygenase reductase activity	moft	3.55
25477137	C3887642	Hippocampus Proper	bpoc	25.52
25477137	C0009738	Congo	geoa	16.04
25477137	C3463820	Inhibition	acty	13.01
25477137	C0021467	Psychological inhibition	menp	13.01
25477137	C0740116	+2	qnco	5.18
25477137	C3833492	2+	fndg	5.18
25477137	C2827735	2+ Score	qnco	5.18
25477137	C2981700	2+ Score, WHO	clas	5.18
25477137	C1620102	U 73122	orch	5.18
25477137	C1620102	U 73122	phsu	5.18
25477137	C1280500	Effect	qlco	3.57
25477137	C2348382	Effect, Appearance	qlco	3.57
25477137	C0021469	Metabolic Inhibition	moft	3.55
25477137	C1628982	Percent inhibition	qnco	3.55
25477137	C0301863	"""U"" lymphocyte"	cell	3.44
25477137	C3811819	CFTR wt Allele	gngm	3.43
25477137	C0070798	Phosphatidylinositol 4,5-Diphosphate	bacs	28.71
25477137	C0070798	Phosphatidylinositol 4,5-Diphosphate	orch	28.71
25477137	C0009738	Congo	geoa	16.18
25477137	C0023175	Lead	elii	13.01
25477137	C0023175	Lead	hops	13.01
25477137	C2825142	Experimental Result	fndg	3.98
25477137	C1274040	Result	ftcn	3.98
25477137	C1547282	Show	anim	3.98
25477137	C1546471	What subject filter - Result	idcn	3.98
25477137	C1704259	Biochemical Pathway	moft	3.63
25477137	C1705987	Pathway (interactions)	cnce	3.63
25477137	C3811819	CFTR wt Allele	gngm	3.57
25477137	C0007634	Cells	cell	3.57
25477137	C3282337	Cells [Chemical/Ingredient]	cell	3.57
25477137	C1561536	*Activity (kind of quantity)	idcn	3.55
25477137	C0205177	Active	ftcn	3.55
25477137	C0441655	Activities	acty	3.55
25477137	C3668946	Activity (animal life circumstance)	fndg	3.55
25477137	C3275067	Cardiac Lead Procedure	topp	3.55
25477137	C2348269	Dietary Lead	elii	3.55
25477137	C4049939	FDA Establishment Activity Terminology	inpr	3.55
25477137	C0442805	Increase	ftcn	3.55
25477137	C1522538	Leading	ftcn	3.55
25477137	C0181586	Leads (device)	medd	3.55
25477137	C0439167	Percent Activity	qnco	3.55
25477137	C4049938	Physical Activity Measurement	lbpr	3.55
25477137	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.55
25477137	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.55
25477137	C1422342	TRPV6 gene	gngm	3.55
25477137	C2986601	Transient Receptor Potential Cation Channel Subfamily V Member 6	aapp	3.55
25477137	C2986601	Transient Receptor Potential Cation Channel Subfamily V Member 6	bacs	3.55
25477137	C3538724	Proximal Interphalangeal Joint 2	bpoc	3.48
25477137	C0070798	Phosphatidylinositol 4,5-Diphosphate	bacs	28.71
25477137	C0070798	Phosphatidylinositol 4,5-Diphosphate	orch	28.71
25477137	C0597298	Protein Isoforms	aapp	9.94
25477137	C0851285	Regulation	gora	9.88
25477137	C1704259	Biochemical Pathway	moft	3.63
25477137	C1705987	Pathway (interactions)	cnce	3.63
25477137	C1327622	Regulation of biological process	biof	3.57
25477137	C1552740	Entity Determiner - specific	inpr	3.48
25477137	C3538724	Proximal Interphalangeal Joint 2	bpoc	3.48
25477137	C0205369	Specific qualifier value	qlco	3.48
25477137	C1422342	TRPV6 gene	gngm	3.44
25477137	C2986601	Transient Receptor Potential Cation Channel Subfamily V Member 6	aapp	3.44
25477137	C2986601	Transient Receptor Potential Cation Channel Subfamily V Member 6	bacs	3.44
25477137	C0009738	Congo	geoa	16.12
25477137	C0020985	Immunoblotting	lbpr	12.94
25477137	C0443289	Revealed	qlco	5.18
25477137	C0007634	Cells	cell	3.68
25477137	C3282337	Cells [Chemical/Ingredient]	cell	3.68
25477137	C0681814	research study	resa	3.63
25477137	C3842584	70%	fndg	3.59
25477137	C0205216	Decreased	qnco	3.59
25477137	C0442797	Decreasing	qlco	3.59
25477137	C0392756	Reduced	qlco	3.59
25477137	C3854321	Expression (foundation metadata concept)	idcn	3.56
25477137	C0185117	Expression procedure	topp	3.56
25477137	C3811819	CFTR wt Allele	gngm	3.50
25477137	C0033727	Protons	elii	39.00
25477137	C0009264	Cold Temperature	npop	22.37
25477137	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25477137	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25477137	C0009738	Congo	geoa	16.16
25477137	C0564385	/hour	qnco	7.28
25477137	C0369286	H NOS Antibodies	aapp	7.28
25477137	C0369286	H NOS Antibodies	imft	7.28
25477137	C0441932	Hepatic Involvement	clas	7.28
25477137	C0033684	Proteins	aapp	6.58
25477137	C0033684	Proteins	bacs	6.58
25477137	C1518422	Negation	ftcn	5.18
25477137	C1882115	Normalize	resa	5.18
25477137	C1561536	*Activity (kind of quantity)	idcn	3.63
25477137	C0205177	Active	ftcn	3.63
25477137	C0441655	Activities	acty	3.63
25477137	C3668946	Activity (animal life circumstance)	fndg	3.63
25477137	C4049939	FDA Establishment Activity Terminology	inpr	3.63
25477137	C0439167	Percent Activity	qnco	3.63
25477137	C4049938	Physical Activity Measurement	lbpr	3.63
25477137	C1522326	Treating	ftcn	3.57
25477137	C3252847	VX 809	orch	3.57
25477137	C3252847	VX 809	phsu	3.57
25477137	C0428479	Protein level - finding	lbtr	3.56
25477137	C3244092	expression level	qnco	3.56
25477137	C3842590	10%	fndg	3.54
25477137	C3811819	CFTR wt Allele	gngm	3.54
25477137	C0007634	Cells	cell	3.54
25477137	C3282337	Cells [Chemical/Ingredient]	cell	3.54
25477137	C0456079	Disease classification level	clas	3.54
25477137	C1547707	Floor - story of building	geoa	3.54
25477137	C2946261	Level	phsu	3.54
25477137	C0441889	Levels (qualifier value)	qlco	3.54
25477137	C1422342	TRPV6 gene	gngm	3.48
25477137	C2986601	Transient Receptor Potential Cation Channel Subfamily V Member 6	aapp	3.48
25477137	C2986601	Transient Receptor Potential Cation Channel Subfamily V Member 6	bacs	3.48
25477137	C1171362	protein expression	genf	3.44
25477137	C1413365	CFTR gene	gngm	3.42
25477137	C3854321	Expression (foundation metadata concept)	idcn	3.42
25477137	C0185117	Expression procedure	topp	3.42
25477137	C0086418	Homo sapiens	humn	28.66
25477137	C3887642	Hippocampus Proper	bpoc	25.50
25477137	C0009738	Congo	geoa	16.04
25477137	C0019868	Homeostasis	biof	9.86
25477137	C0740116	+2	qnco	5.18
25477137	C3833492	2+	fndg	5.18
25477137	C2827735	2+ Score	qnco	5.18
25477137	C2981700	2+ Score, WHO	clas	5.18
25477137	C0443289	Revealed	qlco	5.18
25477137	C0557651	Room of building - Study	mnob	5.18
25477137	C2603343	Study	resa	5.18
25477137	C1422342	TRPV6 gene	gngm	5.18
25477137	C2986601	Transient Receptor Potential Cation Channel Subfamily V Member 6	aapp	5.18
25477137	C2986601	Transient Receptor Potential Cation Channel Subfamily V Member 6	bacs	5.18
25477137	C1711178	Bronchial Epithelial Cell	cell	3.44
25477137	C0335083	Actor	prog	3.42
25477137	C3811819	CFTR wt Allele	gngm	3.42
25477137	C1511545	Critical	qlco	3.42
27394157	C3264621	ivacaftor	orch	26.64
27394157	C3264621	ivacaftor	phsu	26.64
27394157	C3852684	lumacaftor	orch	26.35
27394157	C3852684	lumacaftor	phsu	26.35
27394157	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
27394157	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
27394157	C0039798	therapeutic aspects	ftcn	22.61
27394157	C0040363	Togo	geoa	17.80
27394157	C0041260	Tryptophanase	aapp	17.80
27394157	C0041260	Tryptophanase	enzy	17.80
27394157	C0001792	Elderly (population group)	popg	12.94
27394157	C0039225	Tablet Dosage Form	bodm	9.94
27394157	C0015127	Etiology aspects	ftcn	9.86
27394157	C0019904	Homozygote	orga	9.85
27394157	C0010674	Cystic Fibrosis	dsyn	9.76
27394157	C0026882	Mutation	genf	9.73
27394157	C0030705	Patients	podg	8.34
27394157	C0087111	Therapeutic procedure	topp	7.70
27394157	C0205540	Approved	qlco	5.18
27394157	C1413365	CFTR gene	gngm	5.18
27394157	C2700400	Contain (action)	acty	5.18
27394157	C0332256	Containing (qualifier)	ftcn	5.18
27394157	C1883351	To	qlco	5.18
27394157	C1522326	Treating	ftcn	5.18
27394157	C1292734	Treatment intent	ftcn	5.18
27394157	C1363945	Therapy Object (animal model)	fndg	3.68
27394157	C1705223	Tablet Dosing Unit	qnco	3.63
27394157	C1524003	Science of Etiology	cnce	3.55
27394157	C0205435	First (number)	qnco	3.50
27394157	C1279901	Firstly	qlco	3.50
27394157	C4033620	ORKAMBI	phsu	3.50
27394157	C0001779	Age	orga	3.48
27394157	C0178602	Dosage	qnco	3.48
27394157	C1114758	Dose number:Number:Point in time:^Patient:Quantitative	clna	3.48
27394157	C3714578	Fix	phpr	3.48
27394157	C2827483	Fixed Specimen	bdsu	3.48
27394157	C0443218	Fixed behavior	qlco	3.48
27394157	C1999167	Old age	popg	3.48
27394157	C0869039	Unit dose	qnco	3.48
27394157	C0205214	Common (qualifier value)	qnco	3.42
27394157	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
27394157	C1705285	Mutation Abnormality	comd	3.42
27394157	C1704735	Regulator	cnce	3.42
27394157	C1704734	Regulator Device Component	mnob	3.42
27394157	C0182953	Regulators (device)	medd	3.42
27394157	C1522138	shared attribute	ftcn	3.42
27394157	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27394157	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27394157	C0033204	Probability	qnco	16.25
27394157	C3264621	ivacaftor	orch	14.64
27394157	C3264621	ivacaftor	phsu	14.64
27394157	C3852684	lumacaftor	orch	13.14
27394157	C3852684	lumacaftor	phsu	13.14
27394157	C0005528	Biological Transport	celf	9.86
27394157	C0184511	Improved	qlco	5.18
27394157	C0442805	Increase	ftcn	5.18
27394157	C0205217	Increased	qnco	5.18
27394157	C1159591	chloride transport	celf	3.68
27394157	C0439799	Channel	spco	3.63
27394157	C1706095	Channel Object	cnce	3.63
27394157	C0175566	Open	spco	3.63
27394157	C1709694	Processing (action)	acty	3.56
27394157	C3495449	Mobility aid	medd	3.55
27394157	C1317949	transport (device)	mnob	3.55
27394157	C0699040	Cell surface	celc	3.45
27394157	C1413365	CFTR gene	gngm	3.43
27394157	C0016529	Forced expiratory volume function	ortf	19.41
27394157	C0008976	Clinical Trials	resa	19.28
27394157	C2936643	Standard of Care	topp	14.64
27394157	C0031843	physiological aspects	phsf	14.64
27394157	C3264621	ivacaftor	orch	12.92
27394157	C3264621	ivacaftor	phsu	12.92
27394157	C3852684	lumacaftor	orch	12.92
27394157	C3852684	lumacaftor	phsu	12.92
27394157	C0005528	Biological Transport	celf	11.49
27394157	C1257890	Population Group	popg	9.73
27394157	C0024109	Lung	bpoc	8.34
27394157	C0032042	Placebos	topp	6.60
27394157	C0030705	Patients	podg	6.57
27394157	C0032659	geographic population	qnco	6.57
27394157	C1278908	Entire lung	bpoc	5.18
27394157	C0542341	Function	ftcn	5.18
27394157	C0700205	Function Axis	clas	5.18
27394157	C1521801	Having administered	ftcn	5.18
27394157	C1705273	Mathematical Operator	inpr	5.18
27394157	C3495449	Mobility aid	medd	5.18
27394157	C1882327	Percent of Predicted Value	qnco	5.18
27394157	C0819757	Structure of parenchyma of lung	tisu	5.18
27394157	C3840880	Traffic	fndg	5.18
27394157	C0681842	prediction	idcn	5.18
27394157	C1317949	transport (device)	mnob	5.18
27394157	C3875154	Relative to	idcn	3.72
27394157	C1306036	Forced expiratory volume procedure	diap	3.64
27394157	C0332281	Associated with	qlco	3.57
27394157	C0444706	Measured	qlco	3.57
27394157	C3541902	Measured Tumor Identification	diap	3.57
27394157	C0439165	Percent (qualifier value)	qnco	3.57
27394157	C0237881	Statistical Significance	qnco	3.57
27394157	C2986411	Improvement	cnce	3.54
27394157	C0332287	In addition to	ftcn	3.45
27394157	C1706408	Placebo Control	resa	3.45
27394157	C1696465	placebo	bodm	3.45
27394157	C0205195	Combined	qlco	3.43
27394157	C3811910	combination - answer to question	fndg	3.43
27394157	C1947911	combination of objects	phob	3.43
27394157	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.42
27394157	C0205540	Approved	qlco	3.42
27394157	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.42
27394157	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.42
27394157	C0205448	Two	qnco	3.42
27394157	C0332174	Weekly	tmco	3.42
27394157	C0439230	week	tmco	3.42
27394157	C0005893	Body mass index procedure	diap	19.49
27394157	C0008976	Clinical Trials	resa	19.45
27394157	C3264621	ivacaftor	orch	13.08
27394157	C3264621	ivacaftor	phsu	13.08
27394157	C3852684	lumacaftor	orch	12.93
27394157	C3852684	lumacaftor	phsu	12.93
27394157	C0005528	Biological Transport	celf	11.49
27394157	C0037090	Signs and Symptoms, Respiratory	sosy	11.49
27394157	C0024109	Lung	bpoc	6.58
27394157	C3495449	Mobility aid	medd	5.18
27394157	C1518422	Negation	ftcn	5.18
27394157	C1317949	transport (device)	mnob	5.18
27394157	C1305855	Body mass index	clna	3.72
27394157	C0205447	One	qnco	3.50
27394157	C0332287	In addition to	ftcn	3.47
27394157	C1561611	Admission Level of Care Code - Improved	inpr	3.46
27394157	C0332272	Better	qlco	3.46
27394157	C0184511	Improved	qlco	3.46
27394157	C0439792	Extent	spco	3.42
27394157	C2709248	Pulmonary (qualifier value)	qlco	3.42
27394157	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.42
27394157	C0392756	Reduced	qlco	3.42
27394157	C0876919	Meaning	idcn	3.38
27394157	C3264621	ivacaftor	orch	13.09
27394157	C3264621	ivacaftor	phsu	13.09
27394157	C3852684	lumacaftor	orch	12.94
27394157	C3852684	lumacaftor	phsu	12.94
27394157	C1280477	Progress	ftcn	5.18
27394157	C1999230	Providing (action)	acty	5.18
27394157	C1272688	status - In progress	ftcn	5.18
27394157	C0231448	Extension	ftcn	3.55
27394157	C1880641	Telephone Extension Number	cnce	3.55
27394157	C0814225	benefit	qnco	3.54
27394157	C0332287	In addition to	ftcn	3.48
27394157	C1516635	Clinical Treatment	topp	3.43
27394157	C0549178	Continuous	idcn	3.42
27394157	C0947630	Scientific Study	lbpr	3.42
27394157	C1517331	Further	spco	3.42
27394157	C3264621	ivacaftor	orch	13.08
27394157	C3264621	ivacaftor	phsu	13.08
27394157	C3852684	lumacaftor	orch	12.93
27394157	C3852684	lumacaftor	phsu	12.93
27394157	C0349590	Nature	idcn	6.60
27394157	C1546767	Specimen Source Codes - Respiratory	inpr	5.18
27394157	C0521346	respiratory	ftcn	5.18
27394157	C1705413	Adverse Event Domain	inpr	3.68
27394157	C0877248	Adverse event	patf	3.68
27394157	C1979963	Profile (lab procedure)	lbpr	3.63
27394157	C2003903	Profiling (action)	ftcn	3.63
27394157	C0521362	gastrointestinal	spco	3.59
27394157	C1879533	Acceptable	qlco	3.48
27394157	C3539083	Acceptable (foundation metadata concept)	qlco	3.48
27394157	C3274448	Tolerability Study	resa	3.48
27394157	C0205214	Common (qualifier value)	qnco	3.47
27394157	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.47
27394157	C0332287	In addition to	ftcn	3.47
27394157	C0205393	Most	qnco	3.47
27394157	C1522138	shared attribute	ftcn	3.47
27394157	C1262865	Natures	ftcn	3.45
27394157	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27394157	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27394157	C0040363	Togo	geoa	17.80
27394157	C0041260	Tryptophanase	aapp	17.80
27394157	C0041260	Tryptophanase	enzy	17.80
27394157	C3264621	ivacaftor	orch	13.14
27394157	C3264621	ivacaftor	phsu	13.14
27394157	C3852684	lumacaftor	orch	12.96
27394157	C3852684	lumacaftor	phsu	12.96
27394157	C0010674	Cystic Fibrosis	dsyn	11.49
27394157	C0019904	Homozygote	orga	9.86
27394157	C0026882	Mutation	genf	9.74
27394157	C0030705	Patients	podg	6.60
27394157	C0205229	Expanding	spco	5.18
27394157	C1883351	To	qlco	5.18
27394157	C0683525	treatment options	topp	5.18
27394157	C0470187	Availability of	ftcn	3.59
27394157	C0442504	Place	spco	3.55
27394157	C1704765	Place - dosing instruction imperative	ftcn	3.55
27394157	C1882509	put - instruction imperative	acty	3.55
27394157	C1413365	CFTR gene	gngm	3.43
27394157	C0205210	Clinical	qlco	3.43
27394157	C3245512	HL7PublishingSubSection <practice>	inpr	3.43
27394157	C1705285	Mutation Abnormality	comd	3.43
27394157	C1553058	Neuropsychologist - Clinical	prog	3.43
27394157	C0237607	Practice Experience	menp	3.43
27394157	C0237412	Psychologist - Clinical	prog	3.43
27394157	C0497591	Social Worker - Clinical	prog	3.43
27394157	C1706245	Precision - characteristic	qlco	3.38
27394157	C1547902	Precision - temporal	tmco	3.38
28122735	C0033809	Pseudomonas aeruginosa	bact	24.11
28122735	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28122735	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28122735	C0026687	Mucociliary Clearance	clna	13.10
28122735	C0003075	Anions	elii	12.88
28122735	C0007292	Carrier Proteins	aapp	9.74
28122735	C0007292	Carrier Proteins	bacs	9.74
28122735	C0024109	Lung	bpoc	6.83
28122735	C1690016	% volume (qualifier value)	qlco	5.18
28122735	C0439799	Channel	spco	5.18
28122735	C1706095	Channel Object	cnce	5.18
28122735	C1522240	Process	phpr	5.18
28122735	C1962990	Pseudomonas aeruginosa (antigen)	imft	5.18
28122735	C0456962	Rapid	qlco	5.18
28122735	C0449468	Volume	qnco	5.18
28122735	C1705102	Volume (publication)	inpr	5.18
28122735	C2700258	Volume Measurement	lbpr	5.18
28122735	C1184743	bony process	bpoc	5.18
28122735	C1278908	Entire lung	bpoc	3.68
28122735	C0450254	Pathogenic organism	orgm	3.68
28122735	C0819757	Structure of parenchyma of lung	tisu	3.68
28122735	C0849355	Removed	qlco	3.57
28122735	C1555710	Act Class - Attestable unit	inpr	3.55
28122735	C0486616	Composition	clna	3.55
28122735	C1701901	Conditional	qlco	3.54
28122735	C0851827	Dependent - ability	qlco	3.54
28122735	C3244310	dependent	ftcn	3.54
28122735	C3898900	Healthy	qlco	3.50
28122735	C1304698	Liquid (finding)	fndg	3.43
28122735	C1546699	Liquid NOS - Specimen Source Codes	inpr	3.43
28122735	C1561501	Liquid Specimen	sbst	3.43
28122735	C0301571	Liquid diet	topp	3.43
28122735	C0302908	Liquid substance	sbst	3.43
28122735	C0205148	Surface	spco	3.43
28122735	C1561536	*Activity (kind of quantity)	idcn	3.42
28122735	C0205177	Active	ftcn	3.42
28122735	C0441655	Activities	acty	3.42
28122735	C3668946	Activity (animal life circumstance)	fndg	3.42
28122735	C1413365	CFTR gene	gngm	3.42
28122735	C4049939	FDA Establishment Activity Terminology	inpr	3.42
28122735	C0439167	Percent Activity	qnco	3.42
28122735	C4049938	Physical Activity Measurement	lbpr	3.42
28122735	C0449788	Count of entities	qnco	3.42
28122735	C0237753	Numbers	qnco	3.42
28122735	C0040363	Togo	geoa	35.81
28122735	C0041260	Tryptophanase	aapp	35.81
28122735	C0041260	Tryptophanase	enzy	35.81
28122735	C0015422	Eyelash	bpoc	20.95
28122735	C0008778	Cilia	celc	14.64
28122735	C1883351	To	qlco	10.42
28122735	C0005889	Body Fluids	bdsu	6.66
28122735	C0024109	Lung	bpoc	6.59
28122735	C2963144	Clear	qlco	5.18
28122735	C0562342	Empowered	menp	5.18
28122735	C1171285	Enabling	menp	5.18
28122735	C0205224	Essential	qlco	5.18
28122735	C1709157	Negative Surgical Margin	fndg	5.18
28122735	C3669471	Chicken laying egg for human food	bird	3.68
28122735	C1522408	Coating (film)	qlco	3.68
28122735	C0934502	anatomical layer	bpoc	3.68
28122735	C0450254	Pathogenic organism	orgm	3.54
28122735	C0444611	Fluid behavior	qlco	3.50
28122735	C0302908	Liquid substance	sbst	3.50
28122735	C1704353	fluid - substance	sbst	3.50
28122735	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
28122735	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
28122735	C0036536	Process of secretion	biof	20.95
28122735	C0042789	Vision	orgf	20.95
28122735	C0026687	Mucociliary Clearance	clna	13.10
28122735	C0010674	Cystic Fibrosis	dsyn	11.49
28122735	C0026882	Mutation	genf	9.87
28122735	C0036537	Bodily secretions	bdsu	8.34
28122735	C1413365	CFTR gene	gngm	6.93
28122735	C1705501	Chemical Formula	inpr	5.18
28122735	C0596019	Chloride Ion	elii	5.18
28122735	C0442797	Decreasing	qlco	5.18
28122735	C0489829	Mathematical formula	inpr	5.18
28122735	C1947903	See	acty	5.18
28122735	C1527021	Text	inpr	5.18
28122735	C3541382	Text (foundation metadata concept)	inpr	5.18
28122735	C1554111	Text - MDFAttributeType	inpr	5.18
28122735	C1705606	Text Line	inpr	5.18
28122735	C0449971	Volume of fluid used	qnco	3.68
28122735	C0596611	Gene Mutation	genf	3.60
28122735	C0205148	Surface	spco	3.47
28122735	C0004611	Bacteria	bact	3.44
28122735	C3463902	Bacteria <stick insect genus>	euka	3.44
28122735	C4038931	Bacteria present	fndg	3.44
28122735	C2347473	Percent of Bacteria	qnco	3.44
28122735	C1510439	bacteria aspects	ftcn	3.44
28122735	C0009738	Congo	geoa	17.80
28122735	C0023175	Lead	elii	13.03
28122735	C0023175	Lead	hops	13.03
28122735	C3811819	CFTR wt Allele	gngm	5.18
28122735	C0369773	P Blood group antibodies	aapp	5.18
28122735	C0369773	P Blood group antibodies	imft	5.18
28122735	C2603361	P prime	clna	5.18
28122735	C0450254	Pathogenic organism	orgm	3.68
28122735	C1264606	Persistent infection	dsyn	3.64
28122735	C3275067	Cardiac Lead Procedure	topp	3.57
28122735	C2348269	Dietary Lead	elii	3.57
28122735	C1522538	Leading	ftcn	3.57
28122735	C0181586	Leads (device)	medd	3.57
28122735	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.57
28122735	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.57
28122735	C0009738	Congo	geoa	16.04
28122735	C0015127	Etiology aspects	ftcn	9.86
28122735	C0035245	Respiratory physiology	ortf	6.60
28122735	C1555024	Patient Deceased	fndg	3.56
28122735	C1524003	Science of Etiology	cnce	3.55
28122735	C3811819	CFTR wt Allele	gngm	3.43
28122735	C0392756	Reduced	qlco	3.43
28122735	C0040363	Togo	geoa	17.80
28122735	C0041260	Tryptophanase	aapp	17.80
28122735	C0041260	Tryptophanase	enzy	17.80
28122735	C0004927	Behavior	inbe	7.13
28122735	C0557651	Room of building - Study	mnob	5.18
28122735	C0947630	Scientific Study	lbpr	5.18
28122735	C2603343	Study	resa	5.18
28122735	C1883351	To	qlco	5.18
28122735	C1955473	Others - Allergy	fndg	3.68
28122735	C3539125	other medicated shampoos in ATC	phsu	3.68
28122735	C1280500	Effect	qlco	3.57
28122735	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
28122735	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
28122735	C0036536	Process of secretion	biof	20.95
28122735	C0004340	Australia	geoa	13.01
28122735	C0036537	Bodily secretions	bdsu	8.34
28122735	C0301872	Immune response	ortf	7.17
28122735	C0596019	Chloride Ion	elii	3.63
28122735	C0205170	Good	qlco	3.54
28122735	C1167395	Host (organism)	orgm	3.54
28122735	C0439662	Immune	ftcn	3.54
28122735	C3146287	Well	mnob	3.54
28122735	C1413365	CFTR gene	gngm	3.48
28122735	C1883559	Wild Type	gngm	3.46
28122735	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
28122735	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
28122735	C3463820	Inhibition	acty	12.94
28122735	C1136170	Virulence Factors	bacs	11.49
28122735	C1136170	Virulence Factors	hops	11.49
28122735	C1136170	Virulence Factors	orch	11.49
28122735	C0947630	Scientific Study	lbpr	5.18
28122735	C1521761	Factor	ftcn	3.63
28122735	C2827422	Mathematical Factor	cnce	3.63
28122735	C1327616	Cell secretion	celf	3.59
28122735	C1413365	CFTR gene	gngm	3.48
28122735	C1519751	Ubiquitination	moft	27.26
28122735	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
28122735	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
28122735	C0009738	Congo	geoa	17.80
28122735	C0206431	Antigen Presentation	celf	16.37
28122735	C0032214	Play	dora	14.64
28122735	C0035820	Social Role	socb	13.02
28122735	C0003321	Antigens, Bacterial	imft	10.06
28122735	C0035245	Respiratory physiology	ortf	6.76
28122735	C0699900	Catabolism	orgf	6.72
28122735	C3811819	CFTR wt Allele	gngm	5.18
28122735	C0600138	Does play	fndg	5.18
28122735	C0205263	Induce (action)	ftcn	5.18
28122735	C0449450	Presentation	idcn	3.63
28122735	C0332281	Associated with	qlco	3.61
28122735	C0243125	degradation aspects	ftcn	3.57
28122735	C1705810	Generic Role	cnce	3.56
28122735	C0392756	Reduced	qlco	3.56
28122735	C3871154	{Role}	inpr	3.56
28122735	C0521009	Bacterial	qlco	3.48
28122735	C1413365	CFTR gene	gngm	3.44
28122735	C2700323	Wild Type Unspecified - zebrafish	fish	3.44
28122735	C0521026	Viral	ftcn	3.43
28122735	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.97
28122735	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.97
28122735	C0009738	Congo	geoa	16.18
28122735	C0019904	Homozygote	orga	9.86
28122735	C0026882	Mutation	genf	9.74
28122735	C1413365	CFTR gene	gngm	6.90
28122735	C0030705	Patients	podg	6.72
28122735	C0699900	Catabolism	orgf	6.71
28122735	C2349975	Enhance (action)	acty	5.18
28122735	C0013227	Pharmaceutical Preparations	phsu	5.18
28122735	C1254351	Pharmacologic Substance	phsu	5.18
28122735	C0392756	Reduced	qlco	5.18
28122735	C0598333	drug efficacy	qlco	5.18
28122735	C4033620	ORKAMBI	phsu	3.59
28122735	C0205540	Approved	qlco	3.57
28122735	C3811819	CFTR wt Allele	gngm	3.57
28122735	C0243125	degradation aspects	ftcn	3.56
28122735	C1705285	Mutation Abnormality	comd	3.43
28122735	C0282443	Review [Publication Type]	inpr	11.49
28122735	C0376683	Lectures	inpr	9.86
28122735	C0005532	biology (field)	bmod	9.77
28122735	C1552617	Act Class - review	idcn	5.18
28122735	C0556656	Meetings	acty	3.61
28122735	C3812881	Author	prog	3.57
28122735	C1550718	Entity Name Part Type - given	idcn	3.57
28122735	C1442162	GIVEN	cnce	3.57
28122735	C1947971	Give - dosing instruction imperative	ftcn	3.57
28122735	C3244317	Given name	inpr	3.57
28122735	C1705938	Base - General Qualifier	idcn	3.55
28122735	C1527178	Basis - conceptual entity	ftcn	3.55
28122735	C1551910	Dawson Language	lang	3.52
28122735	C1517586	Investigational	qlco	3.47
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.45
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.45
23788656	C0031843	physiological aspects	phsf	13.01
23788656	C0010674	Cystic Fibrosis	dsyn	10.06
23788656	C0026882	Mutation	genf	9.86
23788656	C0015127	Etiology aspects	ftcn	9.83
23788656	C0439799	Channel	spco	3.59
23788656	C1706095	Channel Object	cnce	3.59
23788656	C0542341	Function	ftcn	3.55
23788656	C0700205	Function Axis	clas	3.55
23788656	C1517945	Loss	qnco	3.55
23788656	C1705273	Mathematical Operator	inpr	3.55
23788656	C1413365	CFTR gene	gngm	3.52
23788656	C1524003	Science of Etiology	cnce	3.52
23788656	C0596019	Chloride Ion	elii	3.45
23788656	C0086418	Homo sapiens	humn	28.65
23788656	C3887642	Hippocampus Proper	bpoc	25.50
23788656	C0039798	therapeutic aspects	ftcn	22.61
23788656	C0040363	Togo	geoa	17.80
23788656	C0041260	Tryptophanase	aapp	17.80
23788656	C0041260	Tryptophanase	enzy	17.80
23788656	C0009738	Congo	geoa	16.12
23788656	C0031437	Phenotype	orga	6.62
23788656	C1705053	Screen Device Component	mnob	5.18
23788656	C1305399	Screening - procedure intent	ftcn	5.18
23788656	C0220908	Screening procedure	hlca	5.18
23788656	C1883351	To	qlco	5.18
23788656	C1413447	CLCA1 gene	gngm	3.98
23788656	C1707135	CLCA2 wt Allele	gngm	3.98
23788656	C0087111	Therapeutic procedure	topp	3.68
23788656	C1363945	Therapy Object (animal model)	fndg	3.68
23788656	C3811819	CFTR wt Allele	gngm	3.50
23788656	C1299351	Abnormally high	qlco	3.47
23788656	C1705938	Base - General Qualifier	idcn	3.47
23788656	C1527178	Basis - conceptual entity	ftcn	3.47
23788656	C0205250	High	qlco	3.47
23788656	C3889660	High Mitosis-Karyorrhexis Index	qnco	3.47
23788656	C1285572	Phenotype determination	lbpr	3.47
23788656	C2700149	Value Above Reference Range	inpr	3.47
23788656	C3887512	high - ActExposureLevelCode	idcn	3.47
23788656	C1328819	Small Molecule	orch	3.42
23788656	C1879547	Activation action	acty	3.42
23788656	C0458827	Airway structure	bpoc	3.42
23788656	C0178987	Artificial Airways	medd	3.42
23788656	C0596019	Chloride Ion	elii	3.42
23788656	C0221908	epithelial	qlco	3.42
23788656	C0439799	Channel	spco	3.40
23788656	C1706095	Channel Object	cnce	3.40
23788656	C0079613	Adoptive Immunotherapy	topp	25.58
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
23788656	C0072662	pyrazole	orch	13.09
23788656	C1869853	SERPINA3 protein, human	aapp	12.96
23788656	C1869853	SERPINA3 protein, human	bacs	12.96
23788656	C0443289	Revealed	qlco	5.18
23788656	C1413365	CFTR gene	gngm	3.68
23788656	C1328819	Small Molecule	orch	3.68
23788656	C4050014	Unknown GENC	geoa	3.68
23788656	C0220909	Aspects of disease screening	ftcn	3.59
23788656	C1710031	Disease Screening	diap	3.59
23788656	C0220908	Screening procedure	hlca	3.59
23788656	C1710477	Trial Screening	resa	3.59
23788656	C1698960	research subject screening	inpr	3.59
23788656	C1879547	Activation action	acty	3.50
23788656	C4048375	Asthma Control Test Questionnaire	inpr	3.50
23788656	C3890007	SERPINA3 wt Allele	gngm	3.50
23788656	C1883254	Synthesis	acty	3.47
23788656	C1413447	CLCA1 gene	gngm	3.46
23788656	C1707135	CLCA2 wt Allele	gngm	3.46
23788656	C0596019	Chloride Ion	elii	3.46
23788656	C1518422	Negation	ftcn	3.46
23788656	C0086418	Homo sapiens	humn	28.78
23788656	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	26.25
23788656	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	26.25
23788656	C0079613	Adoptive Immunotherapy	topp	25.58
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
23788656	C0010453	Anthropological Culture	idcn	13.00
23788656	C1869853	SERPINA3 protein, human	aapp	12.96
23788656	C1869853	SERPINA3 protein, human	bacs	12.96
23788656	C0175996	Protoplasm	celc	12.94
23788656	C0549177	Large	qnco	5.18
23788656	C4050014	Unknown GENC	geoa	3.68
23788656	C1711178	Bronchial Epithelial Cell	cell	3.55
23788656	C1689985	Absence (morphologic abnormality)	anab	3.54
23788656	C0332197	Absent	ftcn	3.54
23788656	C2987634	Agonist	phsu	3.54
23788656	C0205225	Primary	qlco	3.54
23788656	C0439631	Primary operation	topp	3.54
23788656	C0439612	True primary (qualifier value)	tmco	3.54
23788656	C0521116	Current (present time)	tmco	3.54
23788656	C4048375	Asthma Control Test Questionnaire	inpr	3.50
23788656	C3890007	SERPINA3 wt Allele	gngm	3.50
23788656	C0442808	Increasing	ftcn	3.48
23788656	C0178719	Intracellular	spco	3.48
23788656	C1882881	Rat Thyroid Gland	bpoc	3.43
23788656	C1413365	CFTR gene	gngm	3.42
23788656	C0007634	Cells	cell	3.42
23788656	C3282337	Cells [Chemical/Ingredient]	cell	3.42
23788656	C0596019	Chloride Ion	elii	3.42
23788656	C0325045	Martes pennanti	mamm	3.42
23788656	C0443318	Sustained	ftcn	3.42
23788656	C0079613	Adoptive Immunotherapy	topp	25.58
23788656	C1869853	SERPINA3 protein, human	aapp	12.96
23788656	C1869853	SERPINA3 protein, human	bacs	12.96
23788656	C4050014	Unknown GENC	geoa	3.68
23788656	C0521116	Current (present time)	tmco	3.61
23788656	C4048375	Asthma Control Test Questionnaire	inpr	3.50
23788656	C1269647	Entire cell	cell	3.50
23788656	C3890007	SERPINA3 wt Allele	gngm	3.50
23788656	C0205132	Linear	spco	3.47
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.02
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.02
23788656	C0079613	Adoptive Immunotherapy	topp	25.53
23788656	C0009264	Cold Temperature	npop	22.39
23788656	C0009738	Congo	geoa	16.09
23788656	C0917964	Colforsin	orch	16.05
23788656	C0917964	Colforsin	phsu	16.05
23788656	C1869853	SERPINA3 protein, human	aapp	12.91
23788656	C1869853	SERPINA3 protein, human	bacs	12.91
23788656	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	12.89
23788656	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	12.89
23788656	C0019904	Homozygote	orga	9.78
23788656	C0007634	Cells	cell	7.26
23788656	C3282337	Cells [Chemical/Ingredient]	cell	7.26
23788656	C1413365	CFTR gene	gngm	6.94
23788656	C0030705	Patients	podg	6.79
23788656	C1547282	Show	anim	3.98
23788656	C1415484	HBE1 gene	gngm	3.63
23788656	C2827566	HBE1 wt Allele	gngm	3.63
23788656	C3844844	Hb E	fndg	3.63
23788656	C0521116	Current (present time)	tmco	3.59
23788656	C0442796	Additive	qlco	3.57
23788656	C1280500	Effect	qlco	3.57
23788656	C1550602	additive ingredient	sbst	3.57
23788656	C1689985	Absence (morphologic abnormality)	anab	3.55
23788656	C0332197	Absent	ftcn	3.55
23788656	C3811819	CFTR wt Allele	gngm	3.48
23788656	C1705150	FLT1 wt Allele	gngm	3.45
23788656	C1879547	Activation action	acty	3.45
23788656	C4048375	Asthma Control Test Questionnaire	inpr	3.45
23788656	C0596019	Chloride Ion	elii	3.45
23788656	C3890007	SERPINA3 wt Allele	gngm	3.45
23788656	C4050014	Unknown GENC	geoa	3.45
23788656	C2987634	Agonist	phsu	3.42
23788656	C0061202	Genistein	bacs	27.26
23788656	C0061202	Genistein	orch	27.26
23788656	C0061202	Genistein	phsu	27.26
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
23788656	C0009924	Contrast Media	irda	14.64
23788656	C0393003	potassium oxonate	orch	13.09
23788656	C0393003	potassium oxonate	phsu	13.09
23788656	C0754515	TERT protein, human	aapp	12.92
23788656	C0754515	TERT protein, human	enzy	12.92
23788656	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	12.88
23788656	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	12.88
23788656	C3838679	4+ Answer to question	fndg	7.11
23788656	C1979874	Contrast	qlco	5.18
23788656	C3714596	Little NOS	fndg	5.18
23788656	C0700321	Small	qnco	5.18
23788656	C2700395	Smallest	qnco	5.18
23788656	C2741958	VX-770	orch	5.18
23788656	C0369718	N not otherwise specified Antibody	aapp	3.68
23788656	C0369718	N not otherwise specified Antibody	imft	3.68
23788656	C0441922	N+ (tumor staging)	inpr	3.68
23788656	C0521116	Current (present time)	tmco	3.54
23788656	C1705970	Electrical Current	npop	3.54
23788656	C0450367	4/5	qnco	3.51
23788656	C3541881	Device Identifiers Domain	idcn	3.46
23788656	C3538902	SLC4A1 wt Allele	gngm	3.46
23788656	C1367342	TERT gene	gngm	3.46
23788656	C1705316	TERT wt Allele	gngm	3.46
23788656	C1689985	Absence (morphologic abnormality)	anab	3.42
23788656	C0332197	Absent	ftcn	3.42
23788656	C2987634	Agonist	phsu	3.42
23788656	C1413365	CFTR gene	gngm	3.42
23788656	C0596019	Chloride Ion	elii	3.42
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.21
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.21
23788656	C0079613	Adoptive Immunotherapy	topp	25.58
23788656	C0009738	Congo	geoa	16.16
23788656	C0917964	Colforsin	orch	16.07
23788656	C0917964	Colforsin	phsu	16.07
23788656	C0027430	Nasal Polyps	dsyn	13.04
23788656	C1869853	SERPINA3 protein, human	aapp	12.96
23788656	C1869853	SERPINA3 protein, human	bacs	12.96
23788656	C0019425	Heterozygote	orga	9.77
23788656	C1413365	CFTR gene	gngm	7.14
23788656	C0030705	Patients	podg	6.76
23788656	C0014597	Epithelial Cells	cell	6.73
23788656	C1547282	Show	anim	3.98
23788656	C0007634	Cells	cell	3.68
23788656	C3282337	Cells [Chemical/Ingredient]	cell	3.68
23788656	C4050014	Unknown GENC	geoa	3.68
23788656	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.60
23788656	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.60
23788656	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.60
23788656	C1273342	Epithelial cell count (procedure)	lbpr	3.58
23788656	C0521116	Current (present time)	tmco	3.55
23788656	C1705970	Electrical Current	npop	3.55
23788656	C3811819	CFTR wt Allele	gngm	3.55
23788656	C4048375	Asthma Control Test Questionnaire	inpr	3.50
23788656	C1705150	FLT1 wt Allele	gngm	3.50
23788656	C3890007	SERPINA3 wt Allele	gngm	3.50
23788656	C0596019	Chloride Ion	elii	3.43
23788656	C3714596	Little NOS	fndg	3.43
23788656	C0700321	Small	qnco	3.43
23788656	C2700395	Smallest	qnco	3.43
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.07
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.07
23788656	C0079613	Adoptive Immunotherapy	topp	25.58
23788656	C1869853	SERPINA3 protein, human	aapp	12.96
23788656	C1869853	SERPINA3 protein, human	bacs	12.96
23788656	C0072662	pyrazole	orch	12.93
23788656	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	12.88
23788656	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	12.88
23788656	C1879547	Activation action	acty	7.23
23788656	C1413365	CFTR gene	gngm	7.00
23788656	C1550043	Container status - Identified	fndg	5.18
23788656	C0205396	Identified	qlco	5.18
23788656	C1883559	Wild Type	gngm	5.18
23788656	C4050014	Unknown GENC	geoa	3.68
23788656	C1710548	Unique	qlco	3.55
23788656	C4048375	Asthma Control Test Questionnaire	inpr	3.50
23788656	C3890007	SERPINA3 wt Allele	gngm	3.50
23788656	C0332152	Before	tmco	3.43
23788656	C2826257	Prior Medication Usage	evnt	3.43
23788656	C1689985	Absence (morphologic abnormality)	anab	3.42
23788656	C0332197	Absent	ftcn	3.42
23788656	C2987634	Agonist	phsu	3.42
23788656	C0205198	Compound	qlco	3.41
23788656	C1706082	Compound (substance)	chem	3.41
23788656	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	26.00
23788656	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	26.00
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
23788656	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
23788656	C0009738	Congo	geoa	16.04
23788656	C0359589	Provide (product)	food	5.18
23788656	C1999230	Providing (action)	acty	5.18
23788656	C0702240	Elevation	spco	3.68
23788656	C0439775	Elevation procedure	topp	3.68
23788656	C1879547	Activation action	acty	3.59
23788656	C1704788	Definition	inpr	3.59
23788656	C3539106	Sufficiently defined concept definition status (core metadata concept)	inpr	3.59
23788656	C1689985	Absence (morphologic abnormality)	anab	3.55
23788656	C0332197	Absent	ftcn	3.55
23788656	C1705242	Different	qlco	3.55
23788656	C0679199	strategy	menp	3.55
23788656	C0683465	novel AODU treatment method	topp	3.45
23788656	C3642222	Unit Per Centiliter	qnco	3.43
23788656	C3811819	CFTR wt Allele	gngm	3.43
23788656	C1948023	Stimulation (motivation)	npop	3.43
23788656	C1292856	Stimulation procedure	topp	3.43
23788656	C1413365	CFTR gene	gngm	3.42
23788656	C0442808	Increasing	ftcn	3.42
28371569	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
28371569	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
28371569	C3264621	ivacaftor	orch	13.14
28371569	C3264621	ivacaftor	phsu	13.14
28371569	C0026882	Mutation	genf	9.86
28371569	C0332257	Including (qualifier)	ftcn	5.18
28371569	C2698969	Canadian Cardiovascular Society Grading Scale Class III	fndg	3.58
28371569	C0441887	Class 3	inpr	3.58
28371569	C0205540	Approved	qlco	3.55
28371569	C1413365	CFTR gene	gngm	3.55
28371569	C0521114	Infrequent	tmco	3.52
28371569	C0522498	Rare	qlco	3.52
28371569	C1514917	Retinoic Acid Response Element	gngm	3.52
28371569	C0026882	Mutation	genf	23.12
28371569	C3264621	ivacaftor	orch	13.05
28371569	C3264621	ivacaftor	phsu	13.05
28371569	C3898777	Important	qlco	5.18
28371569	C0596545	Experience	menp	3.59
28371569	C0237607	Practice Experience	menp	3.59
28371569	C0588446	Informing patient	hlca	3.58
28371569	C0747307	patient report	fndg	3.58
28371569	C0549178	Continuous	idcn	3.43
28371569	C0522498	Rare	qlco	3.43
28371569	C0039798	therapeutic aspects	ftcn	22.47
28371569	C3850123	Clinical Effectiveness	qlco	20.95
28371569	C0018270	Growth	orgf	14.64
28371569	C0086409	Hispanics	popg	12.88
28371569	C3264621	ivacaftor	orch	12.88
28371569	C3264621	ivacaftor	phsu	12.88
28371569	C0009450	Communicable Diseases	dsyn	9.78
28371569	C0030755	Pediatrics	bmod	9.73
28371569	C0035245	Respiratory physiology	ortf	8.34
28371569	C3714514	Infection	patf	6.63
28371569	C0030705	Patients	podg	6.58
28371569	C2911660	Growth action	acty	5.18
28371569	C0332257	Including (qualifier)	ftcn	5.18
28371569	C1621966	Tissue Growth	ortf	5.18
28371569	C0150093	case series	resa	5.18
28371569	C0220844	growth aspects	phsf	5.18
28371569	C3262866	Airway status	fndg	3.78
28371569	C3262865	Airway status:Finding:Point in time:^Patient:Nominal	clna	3.78
28371569	C0517627	Infection status	fndg	3.75
28371569	C0087111	Therapeutic procedure	topp	3.54
28371569	C1363945	Therapy Object (animal model)	fndg	3.54
28371569	C0458827	Airway structure	bpoc	3.48
28371569	C0178987	Artificial Airways	medd	3.48
28371569	C0439231	month	tmco	3.44
28371569	C0205450	Four	qnco	3.42
28371569	C1521725	Pediatric	qlco	3.42
28371569	C0018270	Growth	orgf	14.64
28371569	C3264621	ivacaftor	orch	14.64
28371569	C3264621	ivacaftor	phsu	14.64
28371569	C0030705	Patients	podg	13.57
28371569	C0035245	Respiratory physiology	ortf	6.62
28371569	C2911660	Growth action	acty	5.18
28371569	C1621966	Tissue Growth	ortf	5.18
28371569	C0220844	growth aspects	phsf	5.18
28371569	C2986411	Improvement	cnce	3.53
28371569	C1280519	Effectiveness	qlco	3.49
28371569	C1707887	Efficacy Study	resa	3.49
28371569	C4054166	Positive Pseudomonas Culture	lbtr	3.44
28371569	C0332152	Before	tmco	3.42
28371569	C2826257	Prior Medication Usage	evnt	3.42
28371569	C0205449	Three	qnco	3.42
28371569	C0205191	chronic	tmco	3.42
28371569	C1517331	Further	spco	3.42
28371569	C0205250	High	qlco	3.42
28371569	C0018270	Growth	orgf	14.64
28371569	C0038452	Strikes, Employee	ocac	12.88
28371569	C0009450	Communicable Diseases	dsyn	9.73
28371569	C0035245	Respiratory physiology	ortf	6.60
28371569	C0030705	Patients	podg	6.59
28371569	C3714514	Infection	patf	6.58
28371569	C2911660	Growth action	acty	5.18
28371569	C1621966	Tissue Growth	ortf	5.18
28371569	C0220844	growth aspects	phsf	5.18
28371569	C0443172	Changed status	qnco	3.58
28371569	C3242344	modify status	ftcn	3.58
28371569	C2348205	Similarity	qlco	3.57
28371569	C2986411	Improvement	cnce	3.52
28371569	C0458827	Airway structure	bpoc	3.42
28371569	C0178987	Artificial Airways	medd	3.42
28371569	C0205172	More	ftcn	3.42
28371569	C0115342	E39	orch	3.68
28371569	C0115342	E39	phsu	3.68
28371569	C0031082	Periodicals	inpr	6.76
27334259	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.59
27334259	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.59
27334259	C0026882	Mutation	genf	9.91
27334259	C0010674	Cystic Fibrosis	dsyn	9.76
27334259	C1413365	CFTR gene	gngm	3.66
27334259	C0805586	Challenge	hlca	3.55
27334259	C0798503	Challenge:Type:Point in time:^Patient:Nominal	clna	3.55
27334259	C0237401	Individual	humn	3.55
27334259	C0027361	Persons	popg	3.55
27334259	C3274764	Proficiency Testing Challenge	cnce	3.55
27334259	C3687832	DRUGS	topp	3.54
27334259	C0443264	Modulated	spco	3.54
27334259	C0013227	Pharmaceutical Preparations	phsu	3.54
27334259	C0814225	benefit	qnco	3.54
27334259	C3827829	Time-Consuming	qlco	3.53
27334259	C2349001	Human Study Subject	humn	3.52
27334259	C2697811	Investigative Subject	ftcn	3.52
27334259	C0681850	Study Subject	grup	3.52
27334259	C1706203	Subject - topic	idcn	3.52
27334259	C1550501	Subject -direct target	idcn	3.52
27334259	C0521114	Infrequent	tmco	3.46
27334259	C0522498	Rare	qlco	3.46
27334259	C1704735	Regulator	cnce	3.46
27334259	C1704734	Regulator Device Component	mnob	3.46
27334259	C0182953	Regulators (device)	medd	3.46
27334259	C1514917	Retinoic Acid Response Element	gngm	3.46
27334259	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.36
27334259	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.36
27334259	C0009738	Congo	geoa	17.80
27334259	C3852684	lumacaftor	orch	14.64
27334259	C3852684	lumacaftor	phsu	14.64
27334259	C0010453	Anthropological Culture	idcn	13.14
27334259	C0031843	physiological aspects	phsf	13.14
27334259	C3264621	ivacaftor	orch	12.96
27334259	C3264621	ivacaftor	phsu	12.96
27334259	C1413365	CFTR gene	gngm	10.68
27334259	C0026882	Mutation	genf	9.74
27334259	C0029250	Organoids	tisu	6.66
27334259	C3811819	CFTR wt Allele	gngm	5.18
27334259	C0557651	Room of building - Study	mnob	3.98
27334259	C2603343	Study	resa	3.98
27334259	C0542341	Function	ftcn	3.68
27334259	C0700205	Function Axis	clas	3.68
27334259	C3264627	Kalydeco	phsu	3.68
27334259	C1705273	Mathematical Operator	inpr	3.68
27334259	C3252847	VX 809	orch	3.68
27334259	C3252847	VX 809	phsu	3.68
27334259	C0683154	drug response	orgf	3.68
27334259	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.65
27334259	C2741958	VX-770	orch	3.65
27334259	C0736241	Epithelium of rectum	bpoc	3.57
27334259	C3542016	Concept model range (foundation metadata concept)	inpr	3.55
27334259	C1514721	Range	qnco	3.55
27334259	C2348147	Sample Range	qnco	3.55
27334259	C1441547	Derivation	qlco	3.55
27334259	C3245521	Derived value	idcn	3.55
27334259	C2349001	Human Study Subject	humn	3.52
27334259	C2697811	Investigative Subject	ftcn	3.52
27334259	C0681850	Study Subject	grup	3.52
27334259	C1706203	Subject - topic	idcn	3.52
27334259	C1550501	Subject -direct target	idcn	3.52
27334259	C0205448	Two	qnco	3.44
27334259	C0332464	Widening	spco	3.43
27334259	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.09
27334259	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.09
27334259	C0039798	therapeutic aspects	ftcn	22.36
27334259	C0031843	physiological aspects	phsf	13.09
27334259	C0026882	Mutation	genf	9.99
27334259	C1413365	CFTR gene	gngm	7.02
27334259	C4042916	Genetic Background	orga	6.74
27334259	C1441672	Observed	ftcn	5.18
27334259	C0683154	drug response	orgf	3.75
27334259	C1705285	Mutation Abnormality	comd	3.68
27334259	C0542341	Function	ftcn	3.63
27334259	C0700205	Function Axis	clas	3.63
27334259	C1705273	Mathematical Operator	inpr	3.63
27334259	C0725813	depend	medd	3.55
27334259	C1609982	Residual	qlco	3.48
27334259	C0087111	Therapeutic procedure	topp	3.44
27334259	C1363945	Therapy Object (animal model)	fndg	3.44
27334259	C2349001	Human Study Subject	humn	3.41
27334259	C2697811	Investigative Subject	ftcn	3.41
27334259	C0681850	Study Subject	grup	3.41
27334259	C1706203	Subject - topic	idcn	3.41
27334259	C1550501	Subject -direct target	idcn	3.41
27334259	C0040363	Togo	geoa	35.81
27334259	C0041260	Tryptophanase	aapp	35.81
27334259	C0041260	Tryptophanase	enzy	35.81
27334259	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
27334259	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
27334259	C0008976	Clinical Trials	resa	19.36
27334259	C0009738	Congo	geoa	16.05
27334259	C0206243	Carrying	acty	14.64
27334259	C1883351	To	qlco	10.42
27334259	C0013217	pharmacotherapeutic	ftcn	9.95
27334259	C0026882	Mutation	genf	9.94
27334259	C1096775	Clinical Trial [Publication Type]	inpr	9.90
27334259	C1511726	Data	idcn	7.17
27334259	C3714741	Data (eukaryote)	euka	7.17
27334259	C3245479	Data call receiving device	medd	7.17
27334259	C0013216	Pharmacotherapy	topp	6.79
27334259	C0034037	Publishing	ocac	6.71
27334259	C0030705	Patients	podg	6.59
27334259	C0029250	Organoids	tisu	6.58
27334259	C2741958	VX-770	orch	5.18
27334259	C0683607	allowing	socb	5.18
27334259	C1709630	Preclinical	qlco	3.57
27334259	C0683154	drug response	orgf	3.57
27334259	C1707520	Correlation	qlco	3.56
27334259	C1274040	Result	ftcn	3.56
27334259	C1704324	Scientific Publication	inpr	3.56
27334259	C3245505	potential	qlco	3.56
27334259	C1413365	CFTR gene	gngm	3.48
27334259	C0521114	Infrequent	tmco	3.48
27334259	C0522498	Rare	qlco	3.48
27334259	C1514917	Retinoic Acid Response Element	gngm	3.48
27334259	C3252847	VX 809	orch	3.45
27334259	C3252847	VX 809	phsu	3.45
27334259	C2827718	In Vitro Route of Administration	ftcn	3.44
27334259	C0021135	In Vitro [Publication Type]	inpr	3.44
27334259	C1533691	in vitro	qlco	3.44
27334259	C3811819	CFTR wt Allele	gngm	3.43
27334259	C0205052	rectal	spco	3.42
27334259	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
27334259	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
27334259	C0039798	therapeutic aspects	ftcn	22.35
27334259	C3264621	ivacaftor	orch	14.64
27334259	C3264621	ivacaftor	phsu	14.64
27334259	C1547282	Show	anim	8.00
27334259	C2349001	Human Study Subject	humn	7.31
27334259	C2697811	Investigative Subject	ftcn	7.31
27334259	C0681850	Study Subject	grup	7.31
27334259	C1706203	Subject - topic	idcn	7.31
27334259	C1550501	Subject -direct target	idcn	7.31
27334259	C0017431	Genotype	orga	6.77
27334259	C2827718	In Vitro Route of Administration	ftcn	5.18
27334259	C0021135	In Vitro [Publication Type]	inpr	5.18
27334259	C1533691	in vitro	qlco	5.18
27334259	C1515655	in vivo	spco	5.18
27334259	C0521982	Response to treatment	clna	3.75
27334259	C0683154	drug response	orgf	3.64
27334259	C0556981	% proof	qnco	3.59
27334259	C0205447	One	qnco	3.50
27334259	C0205448	Two	qnco	3.48
27334259	C1413365	CFTR gene	gngm	3.47
27334259	C0521114	Infrequent	tmco	3.47
27334259	C0522498	Rare	qlco	3.47
27334259	C1514917	Retinoic Acid Response Element	gngm	3.47
27334259	C1707391	Choose (action)	acty	3.45
27334259	C0205210	Clinical	qlco	3.44
27334259	C1553058	Neuropsychologist - Clinical	prog	3.44
27334259	C0237412	Psychologist - Clinical	prog	3.44
27334259	C0497591	Social Worker - Clinical	prog	3.44
27334259	C0439801	Limited (extensiveness)	ftcn	3.43
27334259	C4050251	Limited Lifting Ability	inpr	3.43
27334259	C2674459	Limited Walking Ability	fndg	3.43
27334259	C3542948	Limited component (foundation metadata concept)	inpr	3.43
27334259	C0087111	Therapeutic procedure	topp	3.43
27334259	C1363945	Therapy Object (animal model)	fndg	3.43
27334259	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.31
27334259	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.31
27334259	C0039798	therapeutic aspects	ftcn	22.48
27334259	C0031843	physiological aspects	phsf	12.89
27334259	C1413365	CFTR gene	gngm	10.63
27334259	C0026882	Mutation	genf	9.99
27334259	C0029250	Organoids	tisu	6.77
27334259	C0030705	Patients	podg	6.62
27334259	C1511726	Data	idcn	5.18
27334259	C3714741	Data (eukaryote)	euka	5.18
27334259	C3245479	Data call receiving device	medd	5.18
27334259	C1705535	suggestion	idcn	5.18
27334259	C1705285	Mutation Abnormality	comd	3.68
27334259	C3827682	Useful	qlco	3.57
27334259	C1533734	Administration procedure	topp	3.56
27334259	C1705169	Biomaterial Treatment	cnce	3.56
27334259	C0087111	Therapeutic procedure	topp	3.56
27334259	C1522326	Treating	ftcn	3.56
27334259	C3538994	Treatment Epoch	resa	3.56
27334259	C0814225	benefit	qnco	3.56
27334259	C3887704	treatment - ActInformationManagementReason	hlca	3.56
27334259	C0242485	Measurement	ftcn	3.55
27334259	C0940836	functional measurement	diap	3.54
27334259	C2349182	Correct (qualifier)	qlco	3.53
27334259	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.47
27334259	C1441547	Derivation	qlco	3.47
27334259	C3245521	Derived value	idcn	3.47
27334259	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.47
27334259	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.47
27334259	C0205052	rectal	spco	3.47
27334259	C2827718	In Vitro Route of Administration	ftcn	3.44
27334259	C0021135	In Vitro [Publication Type]	inpr	3.44
27334259	C1533691	in vitro	qlco	3.44
27334259	C0542341	Function	ftcn	3.42
27334259	C0700205	Function Axis	clas	3.42
27334259	C1705273	Mathematical Operator	inpr	3.42
27334259	C2349001	Human Study Subject	humn	3.42
27334259	C2697811	Investigative Subject	ftcn	3.42
27334259	C0681850	Study Subject	grup	3.42
27334259	C1706203	Subject - topic	idcn	3.42
27334259	C1550501	Subject -direct target	idcn	3.42
27626100	C0027552	Needs	qlco	13.02
27626100	C0015127	Etiology aspects	ftcn	9.85
27626100	C0009429	Combined Modality Therapy	topp	6.83
27626100	C0683465	novel AODU treatment method	topp	3.70
27626100	C0556895	Combination electrotherapy	topp	3.68
27626100	C0876973	Infectious disease of lung	dsyn	3.59
27626100	C0521009	Bacterial	qlco	3.57
27626100	C0686904	Patient need for (contextual qualifier)	ftcn	3.56
27626100	C1524003	Science of Etiology	cnce	3.54
27626100	C0205195	Combined	qlco	3.47
27626100	C0205314	New	qlco	3.47
27626100	C3811910	combination - answer to question	fndg	3.47
27626100	C1947911	combination of objects	phob	3.47
27626100	C0679622	literary novel	inpr	3.47
27626100	C0033809	Pseudomonas aeruginosa	bact	22.68
27626100	C0032535	Polymyxin B	aapp	22.37
27626100	C0032535	Polymyxin B	antb	22.37
27626100	C0040363	Togo	geoa	17.80
27626100	C0041260	Tryptophanase	aapp	17.80
27626100	C0041260	Tryptophanase	enzy	17.80
27626100	C0279516	Anti-Bacterial Agents	antb	16.16
27626100	C3264621	ivacaftor	orch	14.64
27626100	C3264621	ivacaftor	phsu	14.64
27626100	C4033633	ivacaftor / lumacaftor	phsu	14.64
27626100	C0392164	Pulmonary Cystic Fibrosis	dsyn	11.49
27626100	C0010674	Cystic Fibrosis	dsyn	9.75
27626100	C0013162	Drug Combinations	phsu	6.72
27626100	C1292732	Investigates	ftcn	5.18
27626100	C4033620	ORKAMBI	phsu	5.18
27626100	C0557651	Room of building - Study	mnob	5.18
27626100	C2603343	Study	resa	5.18
27626100	C1883351	To	qlco	5.18
27626100	C2948600	Aim	phsu	3.98
27626100	C1947946	Aim (idea)	idcn	3.98
27626100	C3540472	Ancestry-Informative Marker	ftcn	3.98
27626100	C3890193	CD5L wt Allele	gngm	3.98
27626100	C2744535	CD69 protein, human	aapp	3.98
27626100	C2744535	CD69 protein, human	imft	3.98
27626100	C3540471	CD69 wt Allele	gngm	3.98
27626100	C1962990	Pseudomonas aeruginosa (antigen)	imft	3.75
27626100	C0450254	Pathogenic organism	orgm	3.59
27626100	C1561536	*Activity (kind of quantity)	idcn	3.55
27626100	C0205177	Active	ftcn	3.55
27626100	C0441655	Activities	acty	3.55
27626100	C3668946	Activity (animal life circumstance)	fndg	3.55
27626100	C4049939	FDA Establishment Activity Terminology	inpr	3.55
27626100	C0439167	Percent Activity	qnco	3.55
27626100	C4049938	Physical Activity Measurement	lbpr	3.55
27626100	C0205160	Negative	qlco	3.48
27626100	C3853545	Negative - answer	qlco	3.48
27626100	C2825491	Negative Charge	qlco	3.48
27626100	C1513916	Negative Finding	fndg	3.48
27626100	C2825415	Negative Number	cnce	3.48
27626100	C0439208	gram	qnco	3.48
27626100	C2986495	Synergistic	qlco	3.42
27626100	C3264627	Kalydeco	phsu	3.42
27626100	C0032539	Polymyxins	aapp	38.66
27626100	C0032539	Polymyxins	antb	38.66
27626100	C0032535	Polymyxin B	aapp	22.36
27626100	C0032535	Polymyxin B	antb	22.36
27626100	C3852684	lumacaftor	orch	14.64
27626100	C3852684	lumacaftor	phsu	14.64
27626100	C3264621	ivacaftor	orch	13.05
27626100	C3264621	ivacaftor	phsu	13.05
27626100	C0162388	Killing	socb	12.88
27626100	C0005507	Biological Assay	lbpr	6.66
27626100	C0040223	Time	tmco	6.57
27626100	C1516048	Assessed	acty	5.18
27626100	C1524063	Use of	ftcn	5.18
27626100	C0205195	Combined	qlco	3.59
27626100	C1561536	*Activity (kind of quantity)	idcn	3.54
27626100	C0205177	Active	ftcn	3.54
27626100	C0441655	Activities	acty	3.54
27626100	C3668946	Activity (animal life circumstance)	fndg	3.54
27626100	C4049939	FDA Establishment Activity Terminology	inpr	3.54
27626100	C0439167	Percent Activity	qnco	3.54
27626100	C4049938	Physical Activity Measurement	lbpr	3.54
27626100	C1510438	Assay	lbpr	3.51
27626100	C0243073	assay qualifier	qlco	3.51
27626100	C2827757	Antimicrobial Resistance Result	lbtr	3.48
27626100	C1514892	Resistance Process	phsf	3.48
27626100	C0332325	Resistant (qualifier value)	ftcn	3.48
27626100	C1550464	resistant - Observation Interpretation Susceptibility	idcn	3.48
27626100	C2827718	In Vitro Route of Administration	ftcn	3.44
27626100	C0021135	In Vitro [Publication Type]	inpr	3.44
27626100	C1533691	in vitro	qlco	3.44
27626100	C2986495	Synergistic	qlco	3.42
27626100	C2827758	Antimicrobial Susceptibility Result	lbtr	3.42
27626100	C0441833	Groups	idcn	3.42
27626100	C1999270	Laboratory Order Panels	inpr	3.42
27626100	C3537156	Panel Device Component	mnob	3.42
27626100	C0220898	Predisposition	orga	3.42
27626100	C0681205	Sacrifice	idcn	3.42
27626100	C0441463	Static	qlco	3.42
27626100	C0231204	Susceptible	ftcn	3.42
27626100	C3541383	Time (foundation metadata concept)	tmco	3.42
27626100	C1550555	kill - ActRelationshipJoin	ftcn	3.42
27626100	C0009738	Congo	geoa	16.16
27626100	C0024109	Lung	bpoc	6.70
27626100	C0030705	Patients	podg	6.70
27626100	C3811819	CFTR wt Allele	gngm	3.55
27626100	C1875400	ISOLATE COMPOUND	phsu	3.55
27626100	C1764827	Isolate - microorganism	bacs	3.55
27626100	C0032535	Polymyxin B	aapp	22.68
27626100	C0032535	Polymyxin B	antb	22.68
27626100	C0032539	Polymyxins	aapp	19.34
27626100	C0032539	Polymyxins	antb	19.34
27626100	C3264621	ivacaftor	orch	14.64
27626100	C3264621	ivacaftor	phsu	14.64
27626100	C3852684	lumacaftor	orch	14.64
27626100	C3852684	lumacaftor	phsu	14.64
27626100	C1875400	ISOLATE COMPOUND	phsu	5.18
27626100	C1764827	Isolate - microorganism	bacs	5.18
27626100	C1273517	Used by	fndg	5.18
27626100	C3242229	ineffective	idcn	5.18
27626100	C0439268	Microgram per Milliliter	qnco	3.65
27626100	C2827757	Antimicrobial Resistance Result	lbtr	3.57
27626100	C1514892	Resistance Process	phsf	3.57
27626100	C0332325	Resistant (qualifier value)	ftcn	3.57
27626100	C1550464	resistant - Observation Interpretation Susceptibility	idcn	3.57
27626100	C2732473	Ductal Carcinoma In Situ with Microinvasion	neop	3.46
27626100	C0427978	Minimum Inhibitory Concentration measurement	lbpr	3.46
27626100	C0281162	cisplatin/ifosfamide/mitomycin protocol	topp	3.46
27626100	C3264621	ivacaftor	orch	26.56
27626100	C3264621	ivacaftor	phsu	26.56
27626100	C0032535	Polymyxin B	aapp	22.36
27626100	C0032535	Polymyxin B	antb	22.36
27626100	C0032539	Polymyxins	aapp	19.20
27626100	C0032539	Polymyxins	antb	19.20
27626100	C0439268	Microgram per Milliliter	qnco	15.10
27626100	C0162388	Killing	socb	14.64
27626100	C3852684	lumacaftor	orch	13.08
27626100	C3852684	lumacaftor	phsu	13.08
27626100	C0205195	Combined	qlco	7.17
27626100	C0870432	Display - arrangement	ftcn	5.18
27626100	C2986495	Synergistic	qlco	5.18
27626100	C1883357	Together	qlco	5.18
27626100	C1273517	Used by	fndg	5.18
27626100	C1561536	*Activity (kind of quantity)	idcn	3.56
27626100	C0205177	Active	ftcn	3.56
27626100	C0441655	Activities	acty	3.56
27626100	C3668946	Activity (animal life circumstance)	fndg	3.56
27626100	C4049939	FDA Establishment Activity Terminology	inpr	3.56
27626100	C0439167	Percent Activity	qnco	3.56
27626100	C4049938	Physical Activity Measurement	lbpr	3.56
27626100	C3811910	combination - answer to question	fndg	3.54
27626100	C1947911	combination of objects	phob	3.54
27626100	C0740116	+2	qnco	3.48
27626100	C3833492	2+	fndg	3.48
27626100	C2827735	2+ Score	qnco	3.48
27626100	C2981700	2+ Score, WHO	clas	3.48
27626100	C2827757	Antimicrobial Resistance Result	lbtr	3.43
27626100	C1514892	Resistance Process	phsf	3.43
27626100	C0332325	Resistant (qualifier value)	ftcn	3.43
27626100	C1550464	resistant - Observation Interpretation Susceptibility	idcn	3.43
27626100	C0086045	Mental concentration	menp	3.42
27626100	C2347946	Relevance	qlco	3.42
27626100	C0033727	Protons	elii	19.34
27626100	C0004618	Bacterial Count Measurement	lbpr	5.18
27626100	C0439361	cfu/mL	qnco	5.18
27626100	C1764827	Isolate - microorganism	bacs	3.63
27626100	C0564385	/hour	qnco	3.57
27626100	C0369286	H NOS Antibodies	aapp	3.57
27626100	C0369286	H NOS Antibodies	imft	3.57
27626100	C0441932	Hepatic Involvement	clas	3.57
27626100	C3817553	100%	qnco	3.55
27626100	C0547047	Decrease	qnco	3.55
27626100	C1880834	Fold in Medical Device Material	phpr	3.55
27626100	C0332462	Folded structure	spco	3.55
27626100	C0392756	Reduced	qlco	3.55
27626100	C0279516	Anti-Bacterial Agents	antb	16.18
27626100	C3540027	Adrenergic and dopaminergic agents combinations	phsu	5.18
27626100	C3539975	Aluminium antacid compound combinations	phsu	5.18
27626100	C3539963	Amide local anesthetic combinations	orch	5.18
27626100	C3539963	Amide local anesthetic combinations	phsu	5.18
27626100	C3539979	Antiinfective irrigating solution combinations	phsu	5.18
27626100	C3540722	Beta-lactamase sensitive penicillin combinations	antb	5.18
27626100	C3540722	Beta-lactamase sensitive penicillin combinations	orch	5.18
27626100	C3539977	Calcium antacid compound combinations	phsu	5.18
27626100	C3540720	Caries prophylactic agent combinations	phsu	5.18
27626100	C3539972	Combination solutions for parenteral nutrition	phsu	5.18
27626100	C0453882	Combinations (Undergarment)	mnob	5.18
27626100	C0870432	Display - arrangement	ftcn	5.18
27626100	C3539968	Enema combinations	phsu	5.18
27626100	C3540026	Hepatitis vaccine combinations	aapp	5.18
27626100	C3540026	Hepatitis vaccine combinations	imft	5.18
27626100	C3540026	Hepatitis vaccine combinations	phsu	5.18
27626100	C3540723	Insulins and analogs for injection, fast-acting combinations	phsu	5.18
27626100	C3539974	Insulins and analogs for injection, intermediate-acting combinations	phsu	5.18
27626100	C3539967	Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations	phsu	5.18
27626100	C3540719	Intermediate-acting sulfonamide combinations	orch	5.18
27626100	C3540719	Intermediate-acting sulfonamide combinations	phsu	5.18
27626100	C3539965	Local hemostatic combinations	phsu	5.18
27626100	C3539959	Long-acting sulfonamide combinations	orch	5.18
27626100	C3539959	Long-acting sulfonamide combinations	phsu	5.18
27626100	C3539956	Magnesium antacid compound combinations	phsu	5.18
27626100	C3854036	Other anti-dementia drug combinations in ATC	phsu	5.18
27626100	C3539973	Other antifungal combinations for topical use in ATC	phsu	5.18
27626100	C3539960	Other intestinal adsorbent combinations in ATC	phsu	5.18
27626100	C3540028	Other irrigating solution combinations in ATC	phsu	5.18
27626100	C3539976	Penicillins with extended spectrum combinations	antb	5.18
27626100	C3539976	Penicillins with extended spectrum combinations	orch	5.18
27626100	C3539961	Platelet aggregation inhibitor combinations excl. heparin	phsu	5.18
27626100	C3540740	Potassium supplement combinations	phsu	5.18
27626100	C3539182	Salt solution combinations	phsu	5.18
27626100	C3539181	Short-acting sulfonamide combinations	orch	5.18
27626100	C3539181	Short-acting sulfonamide combinations	phsu	5.18
27626100	C3539969	Specific immunoglobulin combinations	aapp	5.18
27626100	C3539969	Specific immunoglobulin combinations	imft	5.18
27626100	C3539969	Specific immunoglobulin combinations	phsu	5.18
27626100	C3539970	combination drugs used in erectile dysfunction	phsu	5.18
27626100	C3539978	expectorant combinations excluding combinations with cough suppressants	phsu	5.18
27626100	C3540724	expectorant combinations, excl. combinations with cough suppressants	phsu	5.18
27626100	C3540031	gonadotropin combinations	aapp	5.18
27626100	C3540031	gonadotropin combinations	horm	5.18
27626100	C3540031	gonadotropin combinations	phsu	5.18
27626100	C3539966	insulins and analogs for injection combinations, long-acting	phsu	5.18
27626100	C3539964	local opthalmologic anesthetic combinations	phsu	5.18
27626100	C3539955	lung surfactant combinations	phsu	5.18
27626100	C3539957	opium alkaloids and derivative combination cough suppressants	phsu	5.18
27626100	C3540030	other cough suppressant combinations in ATC	phsu	5.18
27626100	C3540721	other nasal preparation combinations in ATC	phsu	5.18
27626100	C3539971	otologic analgesic and anesthetic combinations	phsu	5.18
27626100	C3539954	topical antibiotic combinations	phsu	5.18
27626100	C3539962	vitamin D and analog combinations	phsu	5.18
27626100	C1561536	*Activity (kind of quantity)	idcn	3.56
27626100	C0205177	Active	ftcn	3.56
27626100	C0441655	Activities	acty	3.56
27626100	C3668946	Activity (animal life circumstance)	fndg	3.56
27626100	C4049939	FDA Establishment Activity Terminology	inpr	3.56
27626100	C0439167	Percent Activity	qnco	3.56
27626100	C4049938	Physical Activity Measurement	lbpr	3.56
27626100	C1961136	Excellent (qualifier value)	qlco	3.43
27626100	C1548784	Excellent - Specimen Quality	qlco	3.43
27626100	C0009738	Congo	geoa	16.04
27626100	C0038056	Sputum	bdsu	9.78
27626100	C0012634	Disease	dsyn	9.72
27626100	C0005507	Biological Assay	lbpr	6.79
27626100	C0009458	Communications Media	inpr	6.63
27626100	C1510438	Assay	lbpr	3.63
27626100	C0243073	assay qualifier	qlco	3.63
27626100	C0439536	Medium	qnco	3.48
27626100	C1705217	Medium (Substance)	sbst	3.48
27626100	C3244283	medium exposure	qlco	3.48
27626100	C3811819	CFTR wt Allele	gngm	3.43
27626100	C2347946	Relevance	qlco	3.43
27626100	C0348080	Condition	qlco	3.41
27626100	C3864998	Condition:Find:Pt:^Patient:Nom	clna	3.41
27626100	C1705253	Logical Condition	cnce	3.41
27626100	C0032535	Polymyxin B	aapp	24.11
27626100	C0032535	Polymyxin B	antb	24.11
27626100	C3852684	lumacaftor	orch	12.90
27626100	C3852684	lumacaftor	phsu	12.90
27626100	C0439044	Living Alone	fndg	5.18
27626100	C0205171	Singular	qnco	5.18
27626100	C0679994	alone - group size	grpa	5.18
27626100	C1547282	Show	anim	3.98
27626100	C0205195	Combined	qlco	3.57
27626100	C3811910	combination - answer to question	fndg	3.57
27626100	C1947911	combination of objects	phob	3.57
27626100	C0442796	Additive	qlco	3.52
27626100	C1550602	additive ingredient	sbst	3.52
27626100	C1524059	mechanism of action qualifier	ftcn	13.05
27626100	C1136254	Microbicides	phsu	12.88
27626100	C0369773	P Blood group antibodies	aapp	5.18
27626100	C0369773	P Blood group antibodies	imft	5.18
27626100	C2603361	P prime	clna	5.18
27626100	C3540027	Adrenergic and dopaminergic agents combinations	phsu	3.42
27626100	C3539975	Aluminium antacid compound combinations	phsu	3.42
27626100	C3539963	Amide local anesthetic combinations	orch	3.42
27626100	C3539963	Amide local anesthetic combinations	phsu	3.42
27626100	C3539979	Antiinfective irrigating solution combinations	phsu	3.42
27626100	C3540722	Beta-lactamase sensitive penicillin combinations	antb	3.42
27626100	C3540722	Beta-lactamase sensitive penicillin combinations	orch	3.42
27626100	C3539977	Calcium antacid compound combinations	phsu	3.42
27626100	C3540720	Caries prophylactic agent combinations	phsu	3.42
27626100	C3539972	Combination solutions for parenteral nutrition	phsu	3.42
27626100	C0453882	Combinations (Undergarment)	mnob	3.42
27626100	C3539968	Enema combinations	phsu	3.42
27626100	C3540026	Hepatitis vaccine combinations	aapp	3.42
27626100	C3540026	Hepatitis vaccine combinations	imft	3.42
27626100	C3540026	Hepatitis vaccine combinations	phsu	3.42
27626100	C3540723	Insulins and analogs for injection, fast-acting combinations	phsu	3.42
27626100	C3539974	Insulins and analogs for injection, intermediate-acting combinations	phsu	3.42
27626100	C3539967	Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations	phsu	3.42
27626100	C3540719	Intermediate-acting sulfonamide combinations	orch	3.42
27626100	C3540719	Intermediate-acting sulfonamide combinations	phsu	3.42
27626100	C3539965	Local hemostatic combinations	phsu	3.42
27626100	C3539959	Long-acting sulfonamide combinations	orch	3.42
27626100	C3539959	Long-acting sulfonamide combinations	phsu	3.42
27626100	C3539956	Magnesium antacid compound combinations	phsu	3.42
27626100	C3854036	Other anti-dementia drug combinations in ATC	phsu	3.42
27626100	C3539973	Other antifungal combinations for topical use in ATC	phsu	3.42
27626100	C3539960	Other intestinal adsorbent combinations in ATC	phsu	3.42
27626100	C3540028	Other irrigating solution combinations in ATC	phsu	3.42
27626100	C3539976	Penicillins with extended spectrum combinations	antb	3.42
27626100	C3539976	Penicillins with extended spectrum combinations	orch	3.42
27626100	C3539961	Platelet aggregation inhibitor combinations excl. heparin	phsu	3.42
27626100	C3540740	Potassium supplement combinations	phsu	3.42
27626100	C3539182	Salt solution combinations	phsu	3.42
27626100	C3539181	Short-acting sulfonamide combinations	orch	3.42
27626100	C3539181	Short-acting sulfonamide combinations	phsu	3.42
27626100	C3539969	Specific immunoglobulin combinations	aapp	3.42
27626100	C3539969	Specific immunoglobulin combinations	imft	3.42
27626100	C3539969	Specific immunoglobulin combinations	phsu	3.42
27626100	C3539970	combination drugs used in erectile dysfunction	phsu	3.42
27626100	C3539978	expectorant combinations excluding combinations with cough suppressants	phsu	3.42
27626100	C3540724	expectorant combinations, excl. combinations with cough suppressants	phsu	3.42
27626100	C3540031	gonadotropin combinations	aapp	3.42
27626100	C3540031	gonadotropin combinations	horm	3.42
27626100	C3540031	gonadotropin combinations	phsu	3.42
27626100	C3539966	insulins and analogs for injection combinations, long-acting	phsu	3.42
27626100	C3539964	local opthalmologic anesthetic combinations	phsu	3.42
27626100	C3539955	lung surfactant combinations	phsu	3.42
27626100	C3539957	opium alkaloids and derivative combination cough suppressants	phsu	3.42
27626100	C3540030	other cough suppressant combinations in ATC	phsu	3.42
27626100	C3540721	other nasal preparation combinations in ATC	phsu	3.42
27626100	C3539971	otologic analgesic and anesthetic combinations	phsu	3.42
27626100	C3245505	potential	qlco	3.42
27626100	C3539954	topical antibiotic combinations	phsu	3.42
27626100	C3539962	vitamin D and analog combinations	phsu	3.42
27626100	C0025664	Methods aspects	inpr	9.99
27626100	C0025663	Methods	inpr	6.83
27626100	C1292732	Investigates	ftcn	5.18
27626100	C1524063	Use of	ftcn	5.18
27626100	C0449851	Techniques	ftcn	3.68
27626100	C1705242	Different	qlco	3.50
27626100	C0039798	therapeutic aspects	ftcn	22.48
27626100	C0030685	Patient Discharge	hlca	19.33
27626100	C1383501	Cytoplasmic matrix	celc	16.05
27626100	C0120285	Green Fluorescent Proteins	aapp	12.89
27626100	C0120285	Green Fluorescent Proteins	irda	12.89
27626100	C0205263	Induce (action)	ftcn	5.18
27626100	C0439180	% release (qualifier value)	qnco	3.56
27626100	C1533734	Administration procedure	topp	3.56
27626100	C1705169	Biomaterial Treatment	cnce	3.56
27626100	C0680255	Discharge (release)	hlca	3.56
27626100	C1963578	Release (procedure)	topp	3.56
27626100	C1283071	Release - action (qualifier value)	ftcn	3.56
27626100	C0391871	Released (action)	ftcn	3.56
27626100	C0087111	Therapeutic procedure	topp	3.56
27626100	C1522326	Treating	ftcn	3.56
27626100	C3538994	Treatment Epoch	resa	3.56
27626100	C3887704	treatment - ActInformationManagementReason	hlca	3.56
27626100	C3540027	Adrenergic and dopaminergic agents combinations	phsu	3.43
27626100	C3539975	Aluminium antacid compound combinations	phsu	3.43
27626100	C3539963	Amide local anesthetic combinations	orch	3.43
27626100	C3539963	Amide local anesthetic combinations	phsu	3.43
27626100	C3539979	Antiinfective irrigating solution combinations	phsu	3.43
27626100	C3540722	Beta-lactamase sensitive penicillin combinations	antb	3.43
27626100	C3540722	Beta-lactamase sensitive penicillin combinations	orch	3.43
27626100	C3539977	Calcium antacid compound combinations	phsu	3.43
27626100	C3540720	Caries prophylactic agent combinations	phsu	3.43
27626100	C3539972	Combination solutions for parenteral nutrition	phsu	3.43
27626100	C0453882	Combinations (Undergarment)	mnob	3.43
27626100	C3539968	Enema combinations	phsu	3.43
27626100	C3540026	Hepatitis vaccine combinations	aapp	3.43
27626100	C3540026	Hepatitis vaccine combinations	imft	3.43
27626100	C3540026	Hepatitis vaccine combinations	phsu	3.43
27626100	C3540723	Insulins and analogs for injection, fast-acting combinations	phsu	3.43
27626100	C3539974	Insulins and analogs for injection, intermediate-acting combinations	phsu	3.43
27626100	C3539967	Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations	phsu	3.43
27626100	C3540719	Intermediate-acting sulfonamide combinations	orch	3.43
27626100	C3540719	Intermediate-acting sulfonamide combinations	phsu	3.43
27626100	C3539965	Local hemostatic combinations	phsu	3.43
27626100	C3539959	Long-acting sulfonamide combinations	orch	3.43
27626100	C3539959	Long-acting sulfonamide combinations	phsu	3.43
27626100	C3539956	Magnesium antacid compound combinations	phsu	3.43
27626100	C3854036	Other anti-dementia drug combinations in ATC	phsu	3.43
27626100	C3539973	Other antifungal combinations for topical use in ATC	phsu	3.43
27626100	C3539960	Other intestinal adsorbent combinations in ATC	phsu	3.43
27626100	C3540028	Other irrigating solution combinations in ATC	phsu	3.43
27626100	C3539976	Penicillins with extended spectrum combinations	antb	3.43
27626100	C3539976	Penicillins with extended spectrum combinations	orch	3.43
27626100	C3539961	Platelet aggregation inhibitor combinations excl. heparin	phsu	3.43
27626100	C3540740	Potassium supplement combinations	phsu	3.43
27626100	C3539182	Salt solution combinations	phsu	3.43
27626100	C3539181	Short-acting sulfonamide combinations	orch	3.43
27626100	C3539181	Short-acting sulfonamide combinations	phsu	3.43
27626100	C3539969	Specific immunoglobulin combinations	aapp	3.43
27626100	C3539969	Specific immunoglobulin combinations	imft	3.43
27626100	C3539969	Specific immunoglobulin combinations	phsu	3.43
27626100	C3539970	combination drugs used in erectile dysfunction	phsu	3.43
27626100	C3539978	expectorant combinations excluding combinations with cough suppressants	phsu	3.43
27626100	C3540724	expectorant combinations, excl. combinations with cough suppressants	phsu	3.43
27626100	C3540031	gonadotropin combinations	aapp	3.43
27626100	C3540031	gonadotropin combinations	horm	3.43
27626100	C3540031	gonadotropin combinations	phsu	3.43
27626100	C3539966	insulins and analogs for injection combinations, long-acting	phsu	3.43
27626100	C3539964	local opthalmologic anesthetic combinations	phsu	3.43
27626100	C3539955	lung surfactant combinations	phsu	3.43
27626100	C3539957	opium alkaloids and derivative combination cough suppressants	phsu	3.43
27626100	C3540030	other cough suppressant combinations in ATC	phsu	3.43
27626100	C3540721	other nasal preparation combinations in ATC	phsu	3.43
27626100	C3539971	otologic analgesic and anesthetic combinations	phsu	3.43
27626100	C3539954	topical antibiotic combinations	phsu	3.43
27626100	C3539962	vitamin D and analog combinations	phsu	3.43
27626100	C0068828	nitrocefin	antb	12.89
27626100	C0068828	nitrocefin	irda	12.89
27626100	C0068828	nitrocefin	orch	12.89
27626100	C0007603	Plasma membrane	celc	9.96
27626100	C0005507	Biological Assay	lbpr	6.58
27626100	C0205101	Extrinsic	spco	5.18
27626100	C1547282	Show	anim	3.98
27626100	C0301863	"""U"" lymphocyte"	cell	3.74
27626100	C1883709	Damage	ftcn	3.59
27626100	C0010957	Tissue damage	inpo	3.59
27626100	C1561536	*Activity (kind of quantity)	idcn	3.55
27626100	C0205177	Active	ftcn	3.55
27626100	C0441655	Activities	acty	3.55
27626100	C3668946	Activity (animal life circumstance)	fndg	3.55
27626100	C4049939	FDA Establishment Activity Terminology	inpr	3.55
27626100	C0439167	Percent Activity	qnco	3.55
27626100	C4049938	Physical Activity Measurement	lbpr	3.55
27626100	C0205102	Internal	spco	3.46
27626100	C0205160	Negative	qlco	3.46
27626100	C3853545	Negative - answer	qlco	3.46
27626100	C2825491	Negative Charge	qlco	3.46
27626100	C1513916	Negative Finding	fndg	3.46
27626100	C2825415	Negative Number	cnce	3.46
27626100	C0439208	gram	qnco	3.46
27626100	C1510438	Assay	lbpr	3.43
27626100	C0243073	assay qualifier	qlco	3.43
27626100	C0034606	Radionuclide Imaging	diap	14.64
27626100	C0013852	Electrons	qnco	13.09
27626100	C0242781	disease transmission	patf	9.94
27626100	C0040722	disease transmission qualifier	idcn	9.94
27626100	C3540027	Adrenergic and dopaminergic agents combinations	phsu	5.18
27626100	C3539975	Aluminium antacid compound combinations	phsu	5.18
27626100	C3539963	Amide local anesthetic combinations	orch	5.18
27626100	C3539963	Amide local anesthetic combinations	phsu	5.18
27626100	C3539979	Antiinfective irrigating solution combinations	phsu	5.18
27626100	C3540722	Beta-lactamase sensitive penicillin combinations	antb	5.18
27626100	C3540722	Beta-lactamase sensitive penicillin combinations	orch	5.18
27626100	C3539977	Calcium antacid compound combinations	phsu	5.18
27626100	C3540720	Caries prophylactic agent combinations	phsu	5.18
27626100	C3539972	Combination solutions for parenteral nutrition	phsu	5.18
27626100	C0453882	Combinations (Undergarment)	mnob	5.18
27626100	C3539968	Enema combinations	phsu	5.18
27626100	C3540026	Hepatitis vaccine combinations	aapp	5.18
27626100	C3540026	Hepatitis vaccine combinations	imft	5.18
27626100	C3540026	Hepatitis vaccine combinations	phsu	5.18
27626100	C3540723	Insulins and analogs for injection, fast-acting combinations	phsu	5.18
27626100	C3539974	Insulins and analogs for injection, intermediate-acting combinations	phsu	5.18
27626100	C3539967	Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations	phsu	5.18
27626100	C3540719	Intermediate-acting sulfonamide combinations	orch	5.18
27626100	C3540719	Intermediate-acting sulfonamide combinations	phsu	5.18
27626100	C3539965	Local hemostatic combinations	phsu	5.18
27626100	C3539959	Long-acting sulfonamide combinations	orch	5.18
27626100	C3539959	Long-acting sulfonamide combinations	phsu	5.18
27626100	C3539956	Magnesium antacid compound combinations	phsu	5.18
27626100	C3854036	Other anti-dementia drug combinations in ATC	phsu	5.18
27626100	C3539973	Other antifungal combinations for topical use in ATC	phsu	5.18
27626100	C3539960	Other intestinal adsorbent combinations in ATC	phsu	5.18
27626100	C3540028	Other irrigating solution combinations in ATC	phsu	5.18
27626100	C3539976	Penicillins with extended spectrum combinations	antb	5.18
27626100	C3539976	Penicillins with extended spectrum combinations	orch	5.18
27626100	C3539961	Platelet aggregation inhibitor combinations excl. heparin	phsu	5.18
27626100	C3540740	Potassium supplement combinations	phsu	5.18
27626100	C0443289	Revealed	qlco	5.18
27626100	C3539182	Salt solution combinations	phsu	5.18
27626100	C0441633	Scanning	diap	5.18
27626100	C3539181	Short-acting sulfonamide combinations	orch	5.18
27626100	C3539181	Short-acting sulfonamide combinations	phsu	5.18
27626100	C3539969	Specific immunoglobulin combinations	aapp	5.18
27626100	C3539969	Specific immunoglobulin combinations	imft	5.18
27626100	C3539969	Specific immunoglobulin combinations	phsu	5.18
27626100	C3539970	combination drugs used in erectile dysfunction	phsu	5.18
27626100	C3539978	expectorant combinations excluding combinations with cough suppressants	phsu	5.18
27626100	C3540724	expectorant combinations, excl. combinations with cough suppressants	phsu	5.18
27626100	C3540031	gonadotropin combinations	aapp	5.18
27626100	C3540031	gonadotropin combinations	horm	5.18
27626100	C3540031	gonadotropin combinations	phsu	5.18
27626100	C3539966	insulins and analogs for injection combinations, long-acting	phsu	5.18
27626100	C3539964	local opthalmologic anesthetic combinations	phsu	5.18
27626100	C3539955	lung surfactant combinations	phsu	5.18
27626100	C3539957	opium alkaloids and derivative combination cough suppressants	phsu	5.18
27626100	C3540030	other cough suppressant combinations in ATC	phsu	5.18
27626100	C3540721	other nasal preparation combinations in ATC	phsu	5.18
27626100	C3539971	otologic analgesic and anesthetic combinations	phsu	5.18
27626100	C3539954	topical antibiotic combinations	phsu	5.18
27626100	C3539962	vitamin D and analog combinations	phsu	5.18
27626100	C3463986	Electron <bird>	bird	3.63
27626100	C1521797	transmission process	npop	3.63
27626100	C1883709	Damage	ftcn	3.56
27626100	C0010957	Tissue damage	inpo	3.56
27626100	C0240341	Micrographia	fndg	3.52
27626100	C0596928	micrography	lbpr	3.52
27626100	C1167331	outer membrane	celc	3.46
27626100	C0036919	Seychelles	geoa	13.14
27626100	C0301863	"""U"" lymphocyte"	cell	3.74
27626100	C0205198	Compound	qlco	3.42
27626100	C1706082	Compound (substance)	chem	3.42
27626100	C1280500	Effect	qlco	3.42
27626100	C2348382	Effect, Appearance	qlco	3.42
27626100	C0086418	Homo sapiens	humn	28.70
27626100	C0082329	DNA Topoisomerase IV	aapp	19.38
27626100	C0082329	DNA Topoisomerase IV	enzy	19.38
27626100	C0949782	DNA Gyrase	aapp	19.21
27626100	C0949782	DNA Gyrase	enzy	19.21
27626100	C0040363	Togo	geoa	17.80
27626100	C0041260	Tryptophanase	aapp	17.80
27626100	C0041260	Tryptophanase	enzy	17.80
27626100	C3264621	ivacaftor	orch	13.14
27626100	C3264621	ivacaftor	phsu	13.14
27626100	C1883351	To	qlco	5.18
27626100	C1547282	Show	anim	3.98
27626100	C0441729	Type 1	clas	3.68
27626100	C1336767	Topoisomerase	aapp	3.58
27626100	C1336767	Topoisomerase	enzy	3.58
27626100	C2257142	topoisomerase activity	genf	3.58
27626100	C1999216	Inhibitor	qlco	3.54
27626100	C0441730	Type 2	clas	3.50
27626100	C3844638	Either	fndg	3.47
27626100	C1280500	Effect	qlco	3.43
27626100	C2348382	Effect, Appearance	qlco	3.43
27626100	C0521009	Bacterial	qlco	3.42
27626100	C1762617	Weak	qlco	3.42
27626100	C3714552	Weakness	sosy	3.42
27626100	C0040363	Togo	geoa	17.80
27626100	C0041260	Tryptophanase	aapp	17.80
27626100	C0041260	Tryptophanase	enzy	17.80
27626100	C0085732	Ability	orga	14.64
27626100	C3852684	lumacaftor	orch	13.14
27626100	C3852684	lumacaftor	phsu	13.14
27626100	C0162772	Reactive Oxygen Species	bacs	9.77
27626100	C0162772	Reactive Oxygen Species	elii	9.77
27626100	C0870432	Display - arrangement	ftcn	5.18
27626100	C0442805	Increase	ftcn	5.18
27626100	C1883351	To	qlco	5.18
27626100	C0033268	production	ocac	3.54
27626100	C0007634	Cells	cell	3.42
27626100	C0178539	Cellular	lbpr	3.42
27626100	C1883709	Damage	ftcn	3.40
27626100	C0010957	Tissue damage	inpo	3.40
27626100	C0032535	Polymyxin B	aapp	22.39
27626100	C0032535	Polymyxin B	antb	22.39
27626100	C0032539	Polymyxins	aapp	19.19
27626100	C0032539	Polymyxins	antb	19.19
27626100	C0015272	Exhibits as Topic	inpr	16.59
27626100	C3264627	Kalydeco	phsu	5.18
27626100	C4033620	ORKAMBI	phsu	5.18
27626100	C1706244	Summary (document)	inpr	5.18
27626100	C1552616	summary - ActRelationshipSubset	inpr	5.18
27626100	C0205195	Combined	qlco	3.56
27626100	C3811910	combination - answer to question	fndg	3.56
27626100	C1947911	combination of objects	phob	3.56
27626100	C1561536	*Activity (kind of quantity)	idcn	3.55
27626100	C0205177	Active	ftcn	3.55
27626100	C0441655	Activities	acty	3.55
27626100	C3668946	Activity (animal life circumstance)	fndg	3.55
27626100	C4049939	FDA Establishment Activity Terminology	inpr	3.55
27626100	C0439167	Percent Activity	qnco	3.55
27626100	C4049938	Physical Activity Measurement	lbpr	3.55
27626100	C2827757	Antimicrobial Resistance Result	lbtr	3.42
27626100	C0205250	High	qlco	3.42
27626100	C1514892	Resistance Process	phsf	3.42
27626100	C0332325	Resistant (qualifier value)	ftcn	3.42
27626100	C2986495	Synergistic	qlco	3.42
27626100	C1550464	resistant - Observation Interpretation Susceptibility	idcn	3.42
27626100	C0009738	Congo	geoa	32.31
27626100	C3811819	CFTR wt Allele	gngm	6.93
27626100	C1764827	Isolate - microorganism	bacs	3.61
27626100	C3827682	Useful	qlco	3.54
27626100	C0876973	Infectious disease of lung	dsyn	3.43
26840186	C0242612	Codon, Nonsense	nusq	24.11
26840186	C0012634	Disease	dsyn	20.39
26840186	C0002085	Alleles	gngm	19.45
26840186	C0151526	Premature Birth	fndg	16.05
26840186	C0597295	Protein Biosynthesis	moft	16.05
26840186	C0206243	Carrying	acty	14.64
26840186	C0040712	Language Translations	inpr	12.90
26840186	C0015127	Etiology aspects	ftcn	11.49
26840186	C0678227	Causing	ftcn	5.18
26840186	C0699809	Does carry	fndg	5.18
26840186	C1524003	Science of Etiology	cnce	5.18
26840186	C3640044	Cardiac Lead Function Indicator	cnce	3.58
26840186	C1880019	Cessation	acty	3.57
26840186	C1517945	Loss	qnco	3.56
26840186	C3845876	Consequent	fndg	3.50
26840186	C1519614	Genetic Translation Process	genf	3.44
26840186	C0205252	Immature	qlco	3.44
26840186	C2930764	ataluren	orch	14.64
26840186	C2930764	ataluren	phsu	14.64
26840186	C3484370	Programs	ftcn	11.49
26840186	C2728259	Program	phsu	5.18
26840186	C1709697	Program - framework of goals	cnce	5.18
26840186	C0450442	Agent	chvf	3.68
26840186	C1254351	Pharmacologic Substance	phsu	3.68
26840186	C1521826	Protocol Agent	inpr	3.68
26840186	C0332185	Recent	tmco	3.68
26840186	C0872187	high throughput screening	diap	3.64
26840186	C0205314	New	qlco	3.50
26840186	C0679622	literary novel	inpr	3.50
26840186	C0040363	Togo	geoa	17.80
26840186	C0041260	Tryptophanase	aapp	17.80
26840186	C0041260	Tryptophanase	enzy	17.80
26840186	C2930764	ataluren	orch	13.14
26840186	C2930764	ataluren	phsu	13.14
26840186	C0010674	Cystic Fibrosis	dsyn	9.79
26840186	C1883351	To	qlco	5.18
26840186	C1547282	Show	anim	3.98
26840186	C0935763	Bioavailable	qlco	3.68
26840186	C1704419	Effective	qlco	3.57
26840186	C1280519	Effectiveness	qlco	3.57
26840186	C0442027	Oral	spco	3.50
26840186	C0036043	Safety	hcpp	17.80
26840186	C2930764	ataluren	orch	12.90
26840186	C2930764	ataluren	phsu	12.90
26840186	C1272684	Accepted	qlco	5.18
26840186	C0443211	Established	qlco	5.18
26840186	C1705187	Safety Study	resa	5.18
26840186	C0441766	Stage level 1	inpr	3.75
26840186	C0947630	Scientific Study	lbpr	3.68
26840186	C2348331	Dose Regimen	topp	3.60
26840186	C0034384	Quantitative Evaluation	qnco	12.91
26840186	C0010200	Coughing	sosy	12.89
26840186	C1547282	Show	anim	3.98
26840186	C0151574	Decreased coughing	fndg	3.58
26840186	C0683954	research results	fndg	3.58
26840186	C0392756	Reduced	qlco	3.55
26840186	C0301630	Reduction (chemical)	npop	3.55
26840186	C0441610	Reduction - action	topp	3.55
26840186	C2986411	Improvement	cnce	3.53
26840186	C1547996	Diagnostic Service Section ID - Pulmonary Function	inpr	3.46
26840186	C0231921	Pulmonary function	ortf	3.46
26840186	C3160731	Pulmonary function (finding)	fndg	3.46
26840186	C4054480	Modest Extremity Pain	inpr	3.43
26840186	C1516048	Assessed	acty	3.43
26840186	C1961131	Cough Adverse Event	fndg	3.43
26840186	C1261322	Evaluation procedure	hlca	3.43
26840186	C0392762	Quantitative	qnco	3.43
26840186	C1806781	Short	qnco	3.43
26840186	C2350002	Short Value	qnco	3.43
26840186	C1282927	Shortened	qlco	3.43
26840186	C0028429	Nose	bpoc	25.97
26840186	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
26840186	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
26840186	C2986411	Improvement	cnce	3.56
26840186	C0221908	epithelial	qlco	3.47
26840186	C1705241	Delta (difference)	qnco	3.43
26840186	C1705242	Different	qlco	3.43
26840186	C3245505	potential	qlco	3.43
26840186	C0282461	Phase 3 Clinical Trials	resa	24.11
26840186	C0004048	Inspiration function	orgf	19.34
26840186	C0040341	Tobramycin	antb	19.34
26840186	C0040341	Tobramycin	orch	19.34
26840186	C0030705	Patients	podg	6.74
26840186	C1280500	Effect	qlco	5.18
26840186	C2348382	Effect, Appearance	qlco	5.18
26840186	C1518422	Negation	ftcn	5.18
26840186	C0332293	Treated with	topp	3.64
26840186	C1441672	Observed	ftcn	3.59
26840186	C1705211	Inhalation Dosing Unit	qnco	3.57
26840186	C0205535	Inhalation Route of Drug Administration	ftcn	3.57
26840186	C0282461	Phase 3 Clinical Trials	resa	22.64
26840186	C0332282	Following	tmco	5.18
26840186	C0231290	Status post	tmco	5.18
26840186	C1514241	Positive Finding	fndg	4.12
26840186	C0521116	Current (present time)	tmco	3.50
26840186	C1706408	Placebo Control	resa	3.47
26840186	C1280519	Effectiveness	qlco	3.45
26840186	C1707887	Efficacy Study	resa	3.45
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.52
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.52
27413118	C0055363	Chloride Channels	aapp	19.45
27413118	C0055363	Chloride Channels	bacs	19.45
27413118	C0031843	physiological aspects	phsf	13.00
27413118	C0031715	Phosphorylation	moft	12.96
27413118	C2744579	ATP8A2 protein, human	aapp	12.93
27413118	C2744579	ATP8A2 protein, human	enzy	12.93
27413118	C0010674	Cystic Fibrosis	dsyn	10.06
27413118	C0026882	Mutation	genf	9.84
27413118	C0015127	Etiology aspects	ftcn	9.82
27413118	C2700640	Encode (action)	acty	5.18
27413118	C1547699	MIME encoding	idcn	5.18
27413118	C1879547	Activation action	acty	3.68
27413118	C1413365	CFTR gene	gngm	3.59
27413118	C0596611	Gene Mutation	genf	3.55
27413118	C0314627	Gene function	genf	3.55
27413118	C0314621	Operator gene	gngm	3.55
27413118	C0542341	Function	ftcn	3.53
27413118	C0700205	Function Axis	clas	3.53
27413118	C1517945	Loss	qnco	3.53
27413118	C1705273	Mathematical Operator	inpr	3.53
27413118	C1524003	Science of Etiology	cnce	3.51
27413118	C1158886	Protein phosphorylation	moft	3.50
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27413118	C0040363	Togo	geoa	17.80
27413118	C0041260	Tryptophanase	aapp	17.80
27413118	C0041260	Tryptophanase	enzy	17.80
27413118	C0033204	Probability	qnco	16.18
27413118	C3264621	ivacaftor	orch	14.64
27413118	C3264621	ivacaftor	phsu	14.64
27413118	C0393003	potassium oxonate	orch	13.09
27413118	C0393003	potassium oxonate	phsu	13.09
27413118	C0754515	TERT protein, human	aapp	12.92
27413118	C0754515	TERT protein, human	enzy	12.92
27413118	C3838679	4+ Answer to question	fndg	7.11
27413118	C0175566	Open	spco	7.07
27413118	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	5.18
27413118	C0442805	Increase	ftcn	5.18
27413118	C0205217	Increased	qnco	5.18
27413118	C1948052	Now (temporal qualifier)	tmco	5.18
27413118	C1883351	To	qlco	5.18
27413118	C2741958	VX-770	orch	5.18
27413118	C0309049	favor	orch	5.18
27413118	C0309049	favor	phsu	5.18
27413118	C0309049	favor	vita	5.18
27413118	C0333051	shift displacement	ftcn	5.18
27413118	C1705535	suggestion	idcn	3.98
27413118	C0301641	Macromolecular alteration	moft	3.72
27413118	C0369718	N not otherwise specified Antibody	aapp	3.68
27413118	C0369718	N not otherwise specified Antibody	imft	3.68
27413118	C0441922	N+ (tumor staging)	inpr	3.68
27413118	C2827597	Computer Configuration	cnce	3.63
27413118	C0947630	Scientific Study	lbpr	3.63
27413118	C0449830	With configuration	spco	3.63
27413118	C0442592	Clinic	hcro	3.59
27413118	C0442592	Clinic	mnob	3.59
27413118	C1273517	Used by	fndg	3.59
27413118	C0450367	4/5	qnco	3.51
27413118	C1552607	Act Relationship Subset - previous	tmco	3.48
27413118	C0439799	Channel	spco	3.48
27413118	C1706095	Channel Object	cnce	3.48
27413118	C0205156	Previous	tmco	3.48
27413118	C3541881	Device Identifiers Domain	idcn	3.46
27413118	C3538902	SLC4A1 wt Allele	gngm	3.46
27413118	C1367342	TERT gene	gngm	3.46
27413118	C1705316	TERT wt Allele	gngm	3.46
27413118	C1413365	CFTR gene	gngm	3.43
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.99
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.99
27413118	C0220795	Benzoate	orch	20.95
27413118	C0220795	Benzoate	phsu	20.95
27413118	C0005058	Benzoates	orch	20.95
27413118	C0040363	Togo	geoa	17.80
27413118	C0041260	Tryptophanase	aapp	17.80
27413118	C0041260	Tryptophanase	enzy	17.80
27413118	C0008203	Chlorides	inch	16.09
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	orch	14.64
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	phsu	14.64
27413118	C0013126	Intrinsic drive	menp	10.28
27413118	C0441712	Mechanism (attribute)	ftcn	7.07
27413118	C1706376	Mechanism Component of Device	mnob	7.07
27413118	C1413365	CFTR gene	gngm	6.92
27413118	C1510699	ATP Hydrolysis	moft	5.18
27413118	C2349975	Enhance (action)	acty	5.18
27413118	C1417808	NPPB gene	gngm	5.18
27413118	C0684224	Report (document)	inpr	5.18
27413118	C0700287	Reporting	hlca	5.18
27413118	C1883351	To	qlco	5.18
27413118	C0870261	channel blockers	phsu	3.75
27413118	C0332185	Recent	tmco	3.68
27413118	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.65
27413118	C1710548	Unique	qlco	3.59
27413118	C1561536	*Activity (kind of quantity)	idcn	3.56
27413118	C0205177	Active	ftcn	3.56
27413118	C0441655	Activities	acty	3.56
27413118	C3668946	Activity (animal life circumstance)	fndg	3.56
27413118	C4049939	FDA Establishment Activity Terminology	inpr	3.56
27413118	C0439167	Percent Activity	qnco	3.56
27413118	C4049938	Physical Activity Measurement	lbpr	3.56
27413118	C3838680	3+ Answer to Question	fndg	3.50
27413118	C2827736	3+ Score	qnco	3.50
27413118	C2981702	3+ Score, WHO	clas	3.50
27413118	C0439086	<3 (qualifier value)	qnco	3.50
27413118	C0596019	Chloride Ion	elii	3.48
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27413118	C0035920	Rubella	dsyn	16.12
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	orch	14.64
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	phsu	14.64
27413118	C0026882	Mutation	genf	9.91
27413118	C0442805	Increase	ftcn	5.18
27413118	C0205217	Increased	qnco	5.18
27413118	C1417808	NPPB gene	gngm	5.18
27413118	C1705285	Mutation Abnormality	comd	3.60
27413118	C1561536	*Activity (kind of quantity)	idcn	3.55
27413118	C0205177	Active	ftcn	3.55
27413118	C0441655	Activities	acty	3.55
27413118	C3668946	Activity (animal life circumstance)	fndg	3.55
27413118	C4049939	FDA Establishment Activity Terminology	inpr	3.55
27413118	C0439167	Percent Activity	qnco	3.55
27413118	C4049938	Physical Activity Measurement	lbpr	3.55
27413118	C0332281	Associated with	qlco	3.46
27413118	C0205214	Common (qualifier value)	qnco	3.46
27413118	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.46
27413118	C1522138	shared attribute	ftcn	3.46
27413118	C1413365	CFTR gene	gngm	3.43
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	orch	12.89
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	phsu	12.89
27413118	C1517331	Further	spco	5.18
27413118	C1292732	Investigates	ftcn	5.18
27413118	C0441712	Mechanism (attribute)	ftcn	3.56
27413118	C1706376	Mechanism Component of Device	mnob	3.56
27413118	C1704675	Interaction	ftcn	3.55
27413118	C2741958	VX-770	orch	3.44
27413118	C1413365	CFTR gene	gngm	3.43
27413118	C1280500	Effect	qlco	3.43
27413118	C1417808	NPPB gene	gngm	3.43
27413118	C0205170	Good	qlco	3.42
27413118	C3146287	Well	mnob	3.42
27413118	C1516048	Assessed	acty	3.41
27413118	C0557651	Room of building - Study	mnob	3.40
27413118	C2603343	Study	resa	3.40
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	orch	14.64
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	phsu	14.64
27413118	C1561536	*Activity (kind of quantity)	idcn	5.18
27413118	C0205177	Active	ftcn	5.18
27413118	C0441655	Activities	acty	5.18
27413118	C3668946	Activity (animal life circumstance)	fndg	5.18
27413118	C4049939	FDA Establishment Activity Terminology	inpr	5.18
27413118	C1517331	Further	spco	5.18
27413118	C0442805	Increase	ftcn	5.18
27413118	C0205217	Increased	qnco	5.18
27413118	C1417808	NPPB gene	gngm	5.18
27413118	C0439167	Percent Activity	qnco	5.18
27413118	C4049938	Physical Activity Measurement	lbpr	5.18
27413118	C1413365	CFTR gene	gngm	3.68
27413118	C2741958	VX-770	orch	3.64
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
27413118	C0005456	Binding Sites	rcpt	13.14
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	orch	13.01
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	phsu	13.01
27413118	C1524024	analysis aspect	ftcn	13.01
27413118	C0687133	Drug Interactions	moft	12.93
27413118	C0031330	Pharmacology	bmod	9.81
27413118	C1511726	Data	idcn	5.18
27413118	C3714741	Data (eukaryote)	euka	5.18
27413118	C3245479	Data call receiving device	medd	5.18
27413118	C1314939	Involvement with	ftcn	5.18
27413118	C0183683	Support, device	medd	5.18
27413118	C1521721	Supportive assistance	cnce	5.18
27413118	C1705535	suggestion	idcn	5.18
27413118	C0441712	Mechanism (attribute)	ftcn	3.68
27413118	C1706376	Mechanism Component of Device	mnob	3.68
27413118	C0599739	synergism	moft	3.68
27413118	C2741958	VX-770	orch	3.61
27413118	C0678226	Due to	ftcn	3.58
27413118	C0332291	Independent of	ftcn	3.57
27413118	C1413365	CFTR gene	gngm	3.56
27413118	C0936012	Analysis	resa	3.55
27413118	C0002778	Analysis of substances	lbpr	3.55
27413118	C0441472	Clinical action	ftcn	3.55
27413118	C1417808	NPPB gene	gngm	3.55
27413118	C1518422	Negation	ftcn	3.55
27413118	C0392762	Quantitative	qnco	3.55
27413118	C1701901	Conditional	qlco	3.50
27413118	C0851827	Dependent - ability	qlco	3.50
27413118	C3244310	dependent	ftcn	3.50
27413118	C0205464	pharmacological	ftcn	3.50
27413118	C0205448	Two	qnco	3.47
27413118	C0700325	Patient observation	hlca	16.18
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	orch	13.05
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	phsu	13.05
27413118	C0302523	Observation in research	resa	9.88
27413118	C0020291	Hydrolysis	npop	9.73
27413118	C0040223	Time	tmco	6.69
27413118	C1517331	Further	spco	5.18
27413118	C2741958	VX-770	orch	3.64
27413118	C1417808	NPPB gene	gngm	3.59
27413118	C1282927	Shortened	qlco	3.59
27413118	C1512612	Ideal	qlco	3.59
27413118	C1964257	Observation - diagnostic procedure	diap	3.57
27413118	C0439590	Prolonged	tmco	3.57
27413118	C1521721	Supportive assistance	cnce	3.57
27413118	C0175566	Open	spco	3.54
27413118	C3541383	Time (foundation metadata concept)	tmco	3.54
27413118	C1636779	% deficient	qnco	3.42
27413118	C0011155	Deficiency	ftcn	3.42
27413118	C3244297	locked	ftcn	3.42
27413118	C0596988	mutant	comd	3.42
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	orch	12.90
27413118	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	phsu	12.90
27413118	C0205197	Complete	qlco	5.18
27413118	C3840786	Greatly	fndg	5.18
27413118	C0849355	Removed	qlco	5.18
27413118	C1148916	nucleotide binding	moft	3.68
27413118	C2741958	VX-770	orch	3.64
27413118	C1883712	Add - instruction imperative	ftcn	3.63
27413118	C0332287	In addition to	ftcn	3.63
27413118	C3541951	Concept model domain	inpr	3.61
27413118	C1880389	Domain (area of knowledge)	ftcn	3.61
27413118	C1883221	Superkingdom (taxonomic category)	cnce	3.61
27413118	C0205216	Decreased	qnco	3.57
27413118	C1280519	Effectiveness	qlco	3.57
27413118	C1518422	Negation	ftcn	3.57
27413118	C0596988	mutant	comd	3.57
27413118	C1561503	Precision - second	idcn	3.47
27413118	C1705190	Second Suffix	qlco	3.47
27413118	C0565930	per second	qnco	3.47
27413118	C0205436	second (number)	qnco	3.47
27413118	C0457385	seconds	tmco	3.47
27413118	C1417808	NPPB gene	gngm	3.44
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.97
27413118	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.97
27413118	C1524059	mechanism of action qualifier	ftcn	12.94
27413118	C0162340	Comprehension	menp	12.88
27413118	C0031327	Drug Kinetics	phsf	9.79
27413118	C1413365	CFTR gene	gngm	6.90
27413118	C0205197	Complete	qlco	5.18
27413118	C3853530	Data operation - complete	ftcn	5.18
27413118	C1285553	Interprets	ftcn	5.18
27413118	C0205172	More	ftcn	5.18
27413118	C1518422	Negation	ftcn	5.18
27413118	C1720467	Only - dosing instruction fragment	inpr	5.18
27413118	C0443289	Revealed	qlco	5.18
27413118	C0205171	Singular	qnco	5.18
27413118	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.72
27413118	C0439780	Forward	spco	3.55
27413118	C0233820	Insight	menp	3.55
27413118	C2825142	Experimental Result	fndg	3.51
27413118	C1274040	Result	ftcn	3.51
27413118	C1546471	What subject filter - Result	idcn	3.51
27413118	C1705242	Different	qlco	3.48
27413118	C0534010	One-Step dentin bonding system	bodm	3.45
27413118	C0534010	One-Step dentin bonding system	orch	3.45
27413118	C0521116	Current (present time)	tmco	3.42
27413118	C1705970	Electrical Current	npop	3.42
26417173	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
26417173	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
26417173	C1269683	Major Depressive Disorder	mobd	14.64
26417173	C3885614	brexpiprazole	orch	14.64
26417173	C3885614	brexpiprazole	phsu	14.64
26417173	C3264621	ivacaftor	orch	13.14
26417173	C3264621	ivacaftor	phsu	13.14
26417173	C3852684	lumacaftor	orch	12.96
26417173	C3852684	lumacaftor	phsu	12.96
26417173	C0010674	Cystic Fibrosis	dsyn	11.49
26417173	C0036341	Schizophrenia	mobd	11.49
26417173	C0041696	Unipolar Depression	mobd	11.49
26417173	C0026882	Mutation	genf	9.94
26417173	C0264716	Chronic heart failure	dsyn	5.18
26417173	C0018802	Congestive heart failure	dsyn	5.18
26417173	C4033616	Entresto	phsu	5.18
26417173	C1314939	Involvement with	ftcn	5.18
26417173	C4033620	ORKAMBI	phsu	5.18
26417173	C4033609	Rexulti	phsu	5.18
26417173	C4033631	sacubitril / valsartan	phsu	3.75
26417173	C1413365	CFTR gene	gngm	3.48
26417173	C1552740	Entity Determiner - specific	inpr	3.48
26417173	C0205369	Specific qualifier value	qlco	3.48
19846789	C0010531	Cyclic AMP-Dependent Protein Kinases	aapp	28.72
19846789	C0010531	Cyclic AMP-Dependent Protein Kinases	enzy	28.72
19846789	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
19846789	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
19846789	C0017337	Genes	gngm	17.80
19846789	C0037494	Sodium Chloride	bacs	16.21
19846789	C0037494	Sodium Chloride	inch	16.21
19846789	C0037494	Sodium Chloride	phsu	16.21
19846789	C0206136	Sodium Chloride, Dietary	food	13.05
19846789	C0003075	Anions	elii	12.92
19846789	C0010674	Cystic Fibrosis	dsyn	10.06
19846789	C0026882	Mutation	genf	9.90
19846789	C0015127	Etiology aspects	ftcn	9.86
19846789	C0024109	Lung	bpoc	8.34
19846789	C0019247	Hereditary Diseases	dsyn	6.91
19846789	C0036140	Salts	chvs	6.74
19846789	C1413365	CFTR gene	gngm	5.18
19846789	C2700640	Encode (action)	acty	5.18
19846789	C1278908	Entire lung	bpoc	5.18
19846789	C0332257	Including (qualifier)	ftcn	5.18
19846789	C1547699	MIME encoding	idcn	5.18
19846789	C0819757	Structure of parenchyma of lung	tisu	5.18
19846789	C1159569	fluid transport	celf	3.61
19846789	C0439799	Channel	spco	3.59
19846789	C1706095	Channel Object	cnce	3.59
19846789	C1314939	Involvement with	ftcn	3.59
19846789	C1524003	Science of Etiology	cnce	3.55
19846789	C1705232	Death Related to Adverse Event	fndg	3.48
19846789	C1302234	Fatal	qlco	3.48
19846789	C1879547	Activation action	acty	3.45
19846789	C0221908	epithelial	qlco	3.45
19846789	C0439064	Numerous	qnco	3.43
19846789	C0178784	Organ	bpoc	3.43
19846789	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
19846789	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
19846789	C0009738	Congo	geoa	16.12
19846789	C0026882	Mutation	genf	9.99
19846789	C3844638	Either	fndg	5.18
19846789	C0699040	Cell surface	celc	3.61
19846789	C0449788	Count of entities	qnco	3.57
19846789	C0237753	Numbers	qnco	3.57
19846789	C0439799	Channel	spco	3.56
19846789	C1706095	Channel Object	cnce	3.56
19846789	C3811819	CFTR wt Allele	gngm	3.50
19846789	C1413365	CFTR gene	gngm	3.44
19846789	C1532633	Kilounit per Kilogram	qnco	5.18
19846789	C2608091	Unit/gram	qnco	5.18
19846789	C0031843	physiological aspects	phsf	13.14
19846789	C0026882	Mutation	genf	9.99
19846789	C0220781	Anabolism	biof	8.34
19846789	C1883254	Synthesis	acty	5.18
19846789	C0542341	Function	ftcn	3.68
19846789	C0700205	Function Axis	clas	3.68
19846789	C1705273	Mathematical Operator	inpr	3.68
19846789	C0439799	Channel	spco	3.50
19846789	C1706095	Channel Object	cnce	3.50
19846789	C1709694	Processing (action)	acty	3.50
19846789	C1532633	Kilounit per Kilogram	qnco	5.18
19846789	C2608091	Unit/gram	qnco	5.18
19846789	C0026882	Mutation	genf	9.99
19846789	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
19846789	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
19846789	C1413365	CFTR gene	gngm	5.18
19846789	C0521116	Current (present time)	tmco	5.18
19846789	C1521840	Target	ftcn	5.18
19846789	C2986546	Target Lesion Identification	diap	5.18
19846789	C0087111	Therapeutic procedure	topp	3.68
19846789	C0205540	Approved	qlco	3.50
19846789	C0039798	therapeutic aspects	ftcn	22.48
19846789	C0009738	Congo	geoa	16.05
19846789	C1524059	mechanism of action qualifier	ftcn	13.01
19846789	C0031330	Pharmacology	bmod	9.86
19846789	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.57
19846789	C1533734	Administration procedure	topp	3.56
19846789	C1705169	Biomaterial Treatment	cnce	3.56
19846789	C0087111	Therapeutic procedure	topp	3.56
19846789	C1522326	Treating	ftcn	3.56
19846789	C3538994	Treatment Epoch	resa	3.56
19846789	C3887704	treatment - ActInformationManagementReason	hlca	3.56
19846789	C2827718	In Vitro Route of Administration	ftcn	3.44
19846789	C0021135	In Vitro [Publication Type]	inpr	3.44
19846789	C2741958	VX-770	orch	3.44
19846789	C1533691	in vitro	qlco	3.44
19846789	C3811819	CFTR wt Allele	gngm	3.43
19846789	C0935763	Bioavailable	qlco	3.42
19846789	C0678723	Biologic Development	orgf	3.42
19846789	C0205210	Clinical	qlco	3.42
19846789	C1527148	Development	ftcn	3.42
19846789	C1553058	Neuropsychologist - Clinical	prog	3.42
19846789	C0442027	Oral	spco	3.42
19846789	C0237412	Psychologist - Clinical	prog	3.42
19846789	C0497591	Social Worker - Clinical	prog	3.42
19846789	C0243107	development aspects	phsf	3.42
19846789	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
19846789	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
19846789	C0026882	Mutation	genf	20.00
19846789	C0033204	Probability	qnco	16.21
19846789	C1705285	Mutation Abnormality	comd	7.31
19846789	C0439799	Channel	spco	3.59
19846789	C1706095	Channel Object	cnce	3.59
19846789	C0175566	Open	spco	3.59
19846789	C0369773	P Blood group antibodies	aapp	3.57
19846789	C0369773	P Blood group antibodies	imft	3.57
19846789	C2603361	P prime	clna	3.57
19846789	C1709694	Processing (action)	acty	3.48
19846789	C2741958	VX-770	orch	3.46
19846789	C1413365	CFTR gene	gngm	3.45
19846789	C0007634	Cells	cell	3.45
19846789	C3282337	Cells [Chemical/Ingredient]	cell	3.45
19846789	C0442805	Increase	ftcn	3.45
19846789	C0205217	Increased	qnco	3.45
19846789	C1514798	Recombinants	orgm	3.45
19846789	C0086418	Homo sapiens	humn	57.77
19846789	C0009738	Congo	geoa	49.35
19846789	C0002085	Alleles	gngm	38.72
19846789	C0026882	Mutation	genf	19.83
19846789	C0036536	Process of secretion	biof	19.32
19846789	C0206243	Carrying	acty	14.64
19846789	C3811819	CFTR wt Allele	gngm	10.90
19846789	C1705285	Mutation Abnormality	comd	7.14
19846789	C0599333	Epithelium of bronchus	bpoc	7.03
19846789	C0036537	Bodily secretions	bdsu	6.70
19846789	C0014609	Epithelium	tisu	6.56
19846789	C3642222	Unit Per Centiliter	qnco	3.74
19846789	C1548221	Bed Status - Isolated	idcn	3.59
19846789	C0205409	Isolated	ftcn	3.59
19846789	C1511332	Bronchial Secretion	bdsu	3.57
19846789	C0237401	Individual	humn	3.55
19846789	C0027361	Persons	popg	3.55
19846789	C1441672	Observed	ftcn	3.55
19846789	C2741958	VX-770	orch	3.48
19846789	C0442805	Increase	ftcn	3.46
19846789	C0205217	Increased	qnco	3.46
19846789	C1709694	Processing (action)	acty	3.43
19846789	C0205447	One	qnco	3.42
19846789	C3842590	10%	fndg	3.42
19846789	C3842586	50%	fndg	3.42
19846789	C3843766	<50	fndg	3.42
19846789	C0332232	Approximate	qlco	3.42
19846789	C1880834	Fold in Medical Device Material	phpr	3.42
19846789	C0332462	Folded structure	spco	3.42
19846789	C0015422	Eyelash	bpoc	19.45
19846789	C0040363	Togo	geoa	17.80
19846789	C0041260	Tryptophanase	aapp	17.80
19846789	C0041260	Tryptophanase	enzy	17.80
19846789	C0008778	Cilia	celc	13.14
19846789	C0000854	Process of absorption	npop	13.14
19846789	C0010453	Anthropological Culture	idcn	13.02
19846789	C0011175	Dehydration	dsyn	13.02
19846789	C0005889	Body Fluids	bdsu	6.66
19846789	C0309872	PREVENT (product)	phsu	5.18
19846789	C1883351	To	qlco	5.18
19846789	C2347023	Biological Absorption	phpr	3.68
19846789	C2825050	Energy Absorption	phpr	3.68
19846789	C2347080	Material Absorption	phpr	3.68
19846789	C2698776	Pharmacokinetics: Absorption	bmod	3.68
19846789	C1546968	No Application Type	idcn	3.60
19846789	C1272460	Not Applicable	qlco	3.60
19846789	C4049872	Package Type Not Applicable	ftcn	3.60
19846789	C0597484	Sodium Cation	elii	3.60
19846789	C0868443	beatings nos	socb	3.56
19846789	C0221908	epithelial	qlco	3.56
19846789	C0444611	Fluid behavior	qlco	3.50
19846789	C0442805	Increase	ftcn	3.50
19846789	C0205217	Increased	qnco	3.50
19846789	C0302908	Liquid substance	sbst	3.50
19846789	C1704353	fluid - substance	sbst	3.50
19846789	C2741958	VX-770	orch	3.49
19846789	C0442802	Excessive	qlco	3.46
19846789	C0392756	Reduced	qlco	3.46
19846789	C0205111	Apical	spco	3.43
19846789	C0205148	Surface	spco	3.43
19846789	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
19846789	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
19846789	C0009738	Congo	geoa	16.04
19846789	C0031843	physiological aspects	phsf	13.09
19846789	C0014597	Epithelial Cells	cell	6.60
19846789	C1512571	Hypothesis	idcn	5.18
19846789	C0183683	Support, device	medd	5.18
19846789	C1521721	Supportive assistance	cnce	5.18
19846789	C2825142	Experimental Result	fndg	3.98
19846789	C1274040	Result	ftcn	3.98
19846789	C1546471	What subject filter - Result	idcn	3.98
19846789	C1254351	Pharmacologic Substance	phsu	3.84
19846789	C0542341	Function	ftcn	3.63
19846789	C0700205	Function Axis	clas	3.63
19846789	C1705273	Mathematical Operator	inpr	3.63
19846789	C3826168	Human physiology	bmod	3.57
19846789	C1413365	CFTR gene	gngm	3.48
19846789	C0442805	Increase	ftcn	3.48
19846789	C0458827	Airway structure	bpoc	3.42
19846789	C0178987	Artificial Airways	medd	3.42
19846789	C3811819	CFTR wt Allele	gngm	3.42
26894479	C2718059	Precision Medicine	topp	13.22
26894479	C0030705	Patients	podg	6.71
26894479	C0237607	Practice Experience	menp	5.18
26894479	C1514468	product	enty	5.18
26894479	C1555307	promise	idcn	5.18
26894479	C0679006	Decision	menp	3.68
26894479	C0205476	Medical	ftcn	3.68
26894479	C0199168	Medical service	hlca	3.68
26894479	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.56
26894479	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.56
26894479	C0237401	Individual	humn	3.56
26894479	C0027361	Persons	popg	3.56
26894479	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.56
26894479	C0402883	tailor	prog	3.56
26894479	C0039798	therapeutic aspects	ftcn	22.56
26894479	C0008203	Chlorides	inch	16.05
26894479	C0010674	Cystic Fibrosis	dsyn	10.06
26894479	C0026882	Mutation	genf	9.78
26894479	C0019247	Hereditary Diseases	dsyn	6.76
26894479	C0015282	Exocrine Glands	bpoc	6.62
26894479	C1552740	Entity Determiner - specific	inpr	3.63
26894479	C0205369	Specific qualifier value	qlco	3.63
26894479	C0087111	Therapeutic procedure	topp	3.63
26894479	C1363945	Therapy Object (animal model)	fndg	3.63
26894479	C1159589	bicarbonate transport	celf	3.61
26894479	C0268026	Chloride disorder	patf	3.60
26894479	C1707959	Example	cnce	3.54
26894479	C1705285	Mutation Abnormality	comd	3.48
26894479	C0872152	drug development	bmod	3.44
26894479	C0596019	Chloride Ion	elii	3.43
26894479	C0439660	Hereditary	ftcn	3.43
26894479	C1880202	Customize	acty	3.42
26894479	C0205435	First (number)	qnco	3.42
26894479	C1279901	Firstly	qlco	3.42
26894479	C0597535	Success	socb	3.42
26894479	C1272703	Successful	qlco	3.42
26894479	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.26
26894479	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.26
26894479	C0597295	Protein Biosynthesis	moft	17.80
26894479	C0034754	Reading (activity)	dora	16.17
26894479	C0040712	Language Translations	inpr	14.64
26894479	C1413365	CFTR gene	gngm	10.58
26894479	C0699040	Cell surface	celc	10.42
26894479	C1254042	Anatomical maturation	phsf	5.18
26894479	C0678723	Biologic Development	orgf	5.18
26894479	C3844638	Either	fndg	5.18
26894479	C1519614	Genetic Translation Process	genf	5.18
26894479	C0870861	Human maturation	phpr	5.18
26894479	C0442805	Increase	ftcn	5.18
26894479	C0185026	Plication	topp	5.18
26894479	C0033414	Promotion (action)	acty	5.18
26894479	C1561536	*Activity (kind of quantity)	idcn	3.57
26894479	C0205177	Active	ftcn	3.57
26894479	C0441655	Activities	acty	3.57
26894479	C3668946	Activity (animal life circumstance)	fndg	3.57
26894479	C4049939	FDA Establishment Activity Terminology	inpr	3.57
26894479	C0439167	Percent Activity	qnco	3.57
26894479	C4049938	Physical Activity Measurement	lbpr	3.57
26894479	C0596988	mutant	comd	3.57
26894479	C0599896	trafficking	celf	3.57
26894479	C0456387	Class	inpr	3.56
26894479	C1705943	Class (taxonomic)	clas	3.56
26894479	C4019422	Classes - encounter	hlca	3.56
26894479	C1705179	Reading (datum presentation)	fndg	3.55
26894479	C0544885	Nonsense mutation	comd	3.45
26894479	C0205448	Two	qnco	3.43
26894479	C1709060	Modulator Device Component	mnob	3.41
26894479	C0039798	therapeutic aspects	ftcn	22.48
26894479	C0206243	Carrying	acty	14.64
26894479	C3264621	ivacaftor	orch	13.14
26894479	C3264621	ivacaftor	phsu	13.14
26894479	C3852684	lumacaftor	orch	13.14
26894479	C3852684	lumacaftor	phsu	13.14
26894479	C0010674	Cystic Fibrosis	dsyn	11.49
26894479	C0017480	Germany	geoa	9.90
26894479	C0026882	Mutation	genf	9.86
26894479	C0699809	Does carry	fndg	5.18
26894479	C0205540	Approved	qlco	3.59
26894479	C1533734	Administration procedure	topp	3.56
26894479	C1705169	Biomaterial Treatment	cnce	3.56
26894479	C0087111	Therapeutic procedure	topp	3.56
26894479	C1522326	Treating	ftcn	3.56
26894479	C3538994	Treatment Epoch	resa	3.56
26894479	C3887704	treatment - ActInformationManagementReason	hlca	3.56
26894479	C1705285	Mutation Abnormality	comd	3.55
26894479	C0027361	Persons	popg	3.43
26894479	C0019904	Homozygote	orga	9.86
26894479	C0026882	Mutation	genf	9.73
26894479	C0205214	Common (qualifier value)	qnco	3.42
26894479	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
26894479	C1705285	Mutation Abnormality	comd	3.42
26894479	C1522138	shared attribute	ftcn	3.42
26894479	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.14
26894479	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.14
26894479	C0040363	Togo	geoa	35.81
26894479	C0041260	Tryptophanase	aapp	35.81
26894479	C0041260	Tryptophanase	enzy	35.81
26894479	C0008976	Clinical Trials	resa	20.95
26894479	C0017404	Genetics, Population	ocdi	16.21
26894479	C0001072	Achievement	bhvr	13.01
26894479	C1096775	Clinical Trial [Publication Type]	inpr	11.49
26894479	C0010674	Cystic Fibrosis	dsyn	11.49
26894479	C0017480	Germany	geoa	11.49
26894479	C1413365	CFTR gene	gngm	10.46
26894479	C1883351	To	qlco	10.42
26894479	C0002424	Ambulatory Care Facilities	hcro	9.74
26894479	C0002424	Ambulatory Care Facilities	mnob	9.74
26894479	C0026882	Mutation	genf	9.74
26894479	C0242481	Research Activities	resa	9.73
26894479	C0035168	research	resa	9.73
26894479	C0005507	Biological Assay	lbpr	8.34
26894479	C1516048	Assessed	acty	5.18
26894479	C0359589	Provide (product)	food	5.18
26894479	C1999230	Providing (action)	acty	5.18
26894479	C3273238	Regulatory Report	inpr	5.18
26894479	C0684224	Report (document)	inpr	5.18
26894479	C0700287	Reporting	hlca	5.18
26894479	C3826168	Human physiology	bmod	3.60
26894479	C0814812	overview	inpr	3.55
26894479	C1709060	Modulator Device Component	mnob	3.53
26894479	C0442592	Clinic	hcro	3.43
26894479	C0442592	Clinic	mnob	3.43
26894479	C1527178	Basis - conceptual entity	ftcn	3.43
26894479	C1457869	Defect	ftcn	3.43
26894479	C0205164	Major	qlco	3.42
26894479	C1709630	Preclinical	qlco	3.42
26894479	C0205082	Severe (severity modifier)	qlco	3.42
26894479	C1883357	Together	qlco	3.42
26894479	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
26894479	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
26894479	C3852684	lumacaftor	orch	13.03
26894479	C3852684	lumacaftor	phsu	13.03
26894479	C3264621	ivacaftor	orch	12.88
26894479	C3264621	ivacaftor	phsu	12.88
26894479	C0805586	Challenge	hlca	5.18
26894479	C1999230	Providing (action)	acty	5.18
26894479	C1519814	Update	tmco	3.57
26894479	C1533716	Information	idcn	3.54
26894479	C0679199	strategy	menp	3.54
26894479	C2985533	Bench-to-Bedside	clas	3.44
26894479	C0332173	Daily	tmco	3.44
26894479	C3245512	HL7PublishingSubSection <practice>	inpr	3.44
26894479	C0237607	Practice Experience	menp	3.44
26894479	C1524063	Use of	ftcn	3.44
26894479	C0678723	Biologic Development	orgf	3.42
26894479	C1413365	CFTR gene	gngm	3.42
26894479	C1527148	Development	ftcn	3.42
26894479	C0205314	New	qlco	3.42
26894479	C0243107	development aspects	phsf	3.42
26894479	C0679622	literary novel	inpr	3.42
26894479	C1709060	Modulator Device Component	mnob	3.40
27168400	C0014239	Endoplasmic Reticulum	celc	24.11
27168400	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.53
27168400	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.53
27168400	C0031453	Phenylalanine	aapp	16.05
27168400	C0031453	Phenylalanine	bacs	16.05
27168400	C0031453	Phenylalanine	phsu	16.05
27168400	C1511760	Deletion Mutation	genf	13.03
27168400	C0026882	Mutation	genf	9.91
27168400	C0010674	Cystic Fibrosis	dsyn	9.78
27168400	C0205214	Common (qualifier value)	qnco	7.03
27168400	C3245511	Common Specifications in HL7 V3 Publishing	inpr	7.03
27168400	C1522138	shared attribute	ftcn	7.03
27168400	C0699900	Catabolism	orgf	6.70
27168400	C0014609	Epithelium	tisu	6.56
27168400	C3810541	Adverse Event Emergency Room Visit	inbe	5.18
27168400	C3811131	Estrogen Receptor Measurement	lbpr	5.18
27168400	C1413365	CFTR gene	gngm	3.60
27168400	C1167182	Apical plasma membrane	celc	3.60
27168400	C1705285	Mutation Abnormality	comd	3.60
27168400	C1880274	Deletion (action)	acty	3.57
27168400	C1442161	Gene Deletion Abnormality	comd	3.57
27168400	C0439799	Channel	spco	3.54
27168400	C1706095	Channel Object	cnce	3.54
27168400	C0243125	degradation aspects	ftcn	3.54
27168400	C1457869	Defect	ftcn	3.54
27168400	C2825142	Experimental Result	fndg	3.54
27168400	C3854321	Expression (foundation metadata concept)	idcn	3.54
27168400	C0185117	Expression procedure	topp	3.54
27168400	C0542341	Function	ftcn	3.54
27168400	C0205245	Functional	ftcn	3.54
27168400	C2700217	Functional Relationship	cnce	3.54
27168400	C1274040	Result	ftcn	3.54
27168400	C1546471	What subject filter - Result	idcn	3.54
27168400	C0449234	Concept Attribute	idcn	3.51
27168400	C1882133	Object Attribute	qlco	3.51
27168400	C1704772	Protection Element Attribute	cnce	3.51
27168400	C0678227	Causing	ftcn	3.46
27168400	C0205393	Most	qnco	3.46
27168400	C0202174	blood phenylalanine measurement by Guthrie microbiologic assay	lbpr	3.44
27168400	C1327616	Cell secretion	celf	3.42
27168400	C0036025	Saccharomyces cerevisiae	fngs	39.01
27168400	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
27168400	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
27168400	C0242738	ATP-Binding Cassette Transporters	aapp	17.80
27168400	C0242738	ATP-Binding Cassette Transporters	bacs	17.80
27168400	C0043392	Yeast, Dried	food	16.08
27168400	C0031453	Phenylalanine	aapp	16.05
27168400	C0031453	Phenylalanine	bacs	16.05
27168400	C0031453	Phenylalanine	phsu	16.05
27168400	C1511760	Deletion Mutation	genf	13.02
27168400	C0028951	Oligomycins	antb	12.92
27168400	C0028951	Oligomycins	orch	12.92
27168400	C0043393	Yeasts	fngs	9.77
27168400	C0678921	Phenocopy	orga	5.18
27168400	C0243067	defects aspect	ftcn	5.18
27168400	C0599896	trafficking	celf	5.18
27168400	C2945710	resistance genes	gngm	3.67
27168400	C0185026	Plication	topp	3.63
27168400	C1880274	Deletion (action)	acty	3.56
27168400	C1442161	Gene Deletion Abnormality	comd	3.56
27168400	C1413365	CFTR gene	gngm	3.48
27168400	C0717551	Candida albicans extract	imft	3.46
27168400	C0717551	Candida albicans extract	phsu	3.46
27168400	C4049929	Yeast Present	lbtr	3.46
27168400	C0202174	blood phenylalanine measurement by Guthrie microbiologic assay	lbpr	3.43
27168400	C3178895	Genes, Modifier	gngm	19.36
27168400	C0036025	Saccharomyces cerevisiae	fngs	19.21
27168400	C0597295	Protein Biosynthesis	moft	17.80
27168400	C0043392	Yeast, Dried	food	16.05
27168400	C0005495	Origin of Life	npop	16.04
27168400	C0040712	Language Translations	inpr	14.64
27168400	C1524024	analysis aspect	ftcn	13.01
27168400	C0028951	Oligomycins	antb	12.90
27168400	C0028951	Oligomycins	orch	12.90
27168400	C0017428	Genome	gngm	9.77
27168400	C0043393	Yeasts	fngs	9.75
27168400	C0220781	Anabolism	biof	6.58
27168400	C1550043	Container status - Identified	fndg	5.18
27168400	C1519614	Genetic Translation Process	genf	5.18
27168400	C0205396	Identified	qlco	5.18
27168400	C1292208	U- phenotype	fndg	3.69
27168400	C0332325	Resistant (qualifier value)	ftcn	3.60
27168400	C0936012	Analysis	resa	3.55
27168400	C0002778	Analysis of substances	lbpr	3.55
27168400	C2338314	Genome - anatomical entity	cnce	3.47
27168400	C0332464	Widening	spco	3.47
27168400	C1749524	mRNA processing	genf	3.45
27168400	C0717551	Candida albicans extract	imft	3.44
27168400	C0717551	Candida albicans extract	phsu	3.44
27168400	C4049929	Yeast Present	lbtr	3.44
27168400	C0439064	Numerous	qnco	3.43
27168400	C0443302	Several	qnco	3.43
27168400	C0086418	Homo sapiens	humn	28.70
27168400	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27168400	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27168400	C0598496	Gene Silencing	genf	16.17
27168400	C0009738	Congo	geoa	16.08
27168400	C0030266	Panama	geoa	12.88
27168400	C2349975	Enhance (action)	acty	5.18
27168400	C0599333	Epithelium of bronchus	bpoc	3.65
27168400	C3854321	Expression (foundation metadata concept)	idcn	3.54
27168400	C0185117	Expression procedure	topp	3.54
27168400	C3811819	CFTR wt Allele	gngm	3.47
27168400	C0205111	Apical	spco	3.42
27168400	C1413365	CFTR gene	gngm	3.42
27168400	C0542341	Function	ftcn	3.42
27168400	C0205245	Functional	ftcn	3.42
27168400	C2700217	Functional Relationship	cnce	3.42
27168400	C4049155	Infusion pump Alert priority PM	fndg	3.42
27168400	C0035553	Ribosomes	celc	22.35
27168400	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27168400	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27168400	C0935572	Stalking (behavior)	mobd	16.04
27168400	C0013682	Efficiency	qnco	13.14
27168400	C0031843	physiological aspects	phsf	13.03
27168400	C0030266	Panama	geoa	12.96
27168400	C0026377	Molecular Conformation	spco	12.85
27168400	C0205217	Increased	qnco	10.42
27168400	C0332161	Attenuated by (contextual qualifier)	qlco	5.18
27168400	C0599946	Attenuation	acty	5.18
27168400	C0442805	Increase	ftcn	5.18
27168400	C0178587	density	qnco	3.68
27168400	C1521828	Rate	qnco	3.63
27168400	C0871208	Rating (action)	acty	3.63
27168400	C1880834	Fold in Medical Device Material	phpr	3.57
27168400	C0332462	Folded structure	spco	3.57
27168400	C0542341	Function	ftcn	3.57
27168400	C0700205	Function Axis	clas	3.57
27168400	C0205319	Manifest	ftcn	3.57
27168400	C1705273	Mathematical Operator	inpr	3.57
27168400	C1705248	Component (part)	cnce	3.55
27168400	C0449432	Component object	mnob	3.55
27168400	C2347098	Medical Product Stability	qlco	3.55
27168400	C0205360	Stable status	qlco	3.55
27168400	C1157562	translational elongation	genf	3.53
27168400	C4049155	Infusion pump Alert priority PM	fndg	3.50
27168400	C0185026	Plication	topp	3.50
27168400	C1419629	RPL12 gene	gngm	3.45
27168400	C0596988	mutant	comd	3.44
27168400	C2700372	Plant stalk	plnt	3.43
27168400	C1947953	Stalk - anatomical structure	anst	3.43
27168400	C1413365	CFTR gene	gngm	3.42
27168400	C0086418	Homo sapiens	humn	28.69
27168400	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
27168400	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
27168400	C3852684	lumacaftor	orch	14.64
27168400	C3852684	lumacaftor	phsu	14.64
27168400	C0031843	physiological aspects	phsf	13.00
27168400	C3252847	VX 809	orch	5.18
27168400	C3252847	VX 809	phsu	5.18
27168400	C0013227	Pharmaceutical Preparations	phsu	3.68
27168400	C1254351	Pharmacologic Substance	phsu	3.68
27168400	C0599333	Epithelium of bronchus	bpoc	3.60
27168400	C0205195	Combined	qlco	3.56
27168400	C3811910	combination - answer to question	fndg	3.56
27168400	C1947911	combination of objects	phob	3.56
27168400	C0542341	Function	ftcn	3.54
27168400	C0700205	Function Axis	clas	3.54
27168400	C1705273	Mathematical Operator	inpr	3.54
27168400	C1413365	CFTR gene	gngm	3.45
27168400	C0205225	Primary	qlco	3.45
27168400	C0439631	Primary operation	topp	3.45
27168400	C0439612	True primary (qualifier value)	tmco	3.45
27168400	C1419629	RPL12 gene	gngm	3.43
27168400	C1883559	Wild Type	gngm	3.43
27168400	C3842586	50%	fndg	3.42
27168400	C3843766	<50	fndg	3.42
27168400	C0439799	Channel	spco	3.42
27168400	C1706095	Channel Object	cnce	3.42
27168400	C0596988	mutant	comd	3.42
27168400	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.96
27168400	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.96
27168400	C0935572	Stalking (behavior)	mobd	32.47
27168400	C0035553	Ribosomes	celc	22.43
27168400	C0700325	Patient observation	hlca	17.80
27168400	C0013682	Efficiency	qnco	13.01
27168400	C0031843	physiological aspects	phsf	12.89
27168400	C0302523	Observation in research	resa	11.49
27168400	C0035552	Ribosomal Proteins	aapp	9.75
27168400	C0035552	Ribosomal Proteins	bacs	9.75
27168400	C2700372	Plant stalk	plnt	7.09
27168400	C1947953	Stalk - anatomical structure	anst	7.09
27168400	C1413365	CFTR gene	gngm	6.88
27168400	C0185026	Plication	topp	6.88
27168400	C0031437	Phenotype	orga	6.71
27168400	C1517945	Loss	qnco	5.18
27168400	C0443264	Modulated	spco	5.18
27168400	C1964257	Observation - diagnostic procedure	diap	5.18
27168400	C1705535	suggestion	idcn	5.18
27168400	C2825142	Experimental Result	fndg	3.98
27168400	C1274040	Result	ftcn	3.98
27168400	C1546471	What subject filter - Result	idcn	3.98
27168400	C1285572	Phenotype determination	lbpr	3.55
27168400	C1521840	Target	ftcn	3.54
27168400	C2986546	Target Lesion Identification	diap	3.54
27168400	C0858952	silence	mobd	3.52
27168400	C0542341	Function	ftcn	3.43
27168400	C0700205	Function Axis	clas	3.43
27168400	C1705273	Mathematical Operator	inpr	3.43
27168400	C0596988	mutant	comd	3.43
27168400	C1947976	Correction (change)	ftcn	3.42
27168400	C1705565	Correction Report	inpr	3.42
27168400	C1457869	Defect	ftcn	3.42
27168400	C0302350	Therapeutic	ftcn	3.42
27168400	C0087111	Therapeutic procedure	topp	3.42
27168400	C3245505	potential	qlco	3.42
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.69
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.69
26336913	C0004135	Ataxia Telangiectasia	dsyn	22.40
26336913	C0597295	Protein Biosynthesis	moft	17.80
26336913	C0031843	physiological aspects	phsf	14.64
26336913	C1519323	Silent Mutation	genf	13.22
26336913	C1511760	Deletion Mutation	genf	13.03
26336913	C0001721	Affect (mental function)	menp	11.49
26336913	C1413365	CFTR gene	gngm	11.02
26336913	C0012634	Disease	dsyn	9.86
26336913	C0031437	Phenotype	orga	6.71
26336913	C0542341	Function	ftcn	5.18
26336913	C0700205	Function Axis	clas	5.18
26336913	C1705273	Mathematical Operator	inpr	5.18
26336913	C0678594	structure	spco	5.18
26336913	C1880274	Deletion (action)	acty	3.57
26336913	C1442161	Gene Deletion Abnormality	comd	3.57
26336913	C0392747	Changing	ftcn	3.55
26336913	C1880177	Contribution	acty	3.55
26336913	C1285572	Phenotype determination	lbpr	3.55
26336913	C0596988	mutant	comd	3.54
26336913	C3540695	Anatomical Therapeutic Chemical (ATC)-classification system	inpr	3.48
26336913	C0243083	associated disease	patf	3.44
26336913	C0332183	Frequently	tmco	3.42
26336913	C0205393	Most	qnco	3.42
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
26336913	C3687832	DRUGS	topp	3.61
26336913	C0013227	Pharmaceutical Preparations	phsu	3.61
26336913	C1413365	CFTR gene	gngm	3.56
26336913	C2349182	Correct (qualifier)	qlco	3.56
26336913	C1328819	Small Molecule	orch	3.50
26336913	C0004135	Ataxia Telangiectasia	dsyn	22.39
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
26336913	C0040363	Togo	geoa	17.80
26336913	C0041260	Tryptophanase	aapp	17.80
26336913	C0041260	Tryptophanase	enzy	17.80
26336913	C0005495	Origin of Life	npop	16.22
26336913	C0162340	Comprehension	menp	14.64
26336913	C3852684	lumacaftor	orch	14.64
26336913	C3852684	lumacaftor	phsu	14.64
26336913	C0031843	physiological aspects	phsf	14.64
26336913	C1519323	Silent Mutation	genf	12.92
26336913	C0220781	Anabolism	biof	6.76
26336913	C0936012	Analysis	resa	5.18
26336913	C0542341	Function	ftcn	5.18
26336913	C0700205	Function Axis	clas	5.18
26336913	C1705273	Mathematical Operator	inpr	5.18
26336913	C1883351	To	qlco	5.18
26336913	C3252847	VX 809	orch	5.18
26336913	C3252847	VX 809	phsu	5.18
26336913	C0450373	4a serotype	inpr	3.68
26336913	C1553636	Maxillary right second premolar abutment	medd	3.68
26336913	C0441712	Mechanism (attribute)	ftcn	3.68
26336913	C0686907	Consequence of	ftcn	3.59
26336913	C1280500	Effect	qlco	3.55
26336913	C2348382	Effect, Appearance	qlco	3.55
26336913	C1947976	Correction (change)	ftcn	3.50
26336913	C1705565	Correction Report	inpr	3.50
26336913	C3540695	Anatomical Therapeutic Chemical (ATC)-classification system	inpr	3.46
26336913	C1413365	CFTR gene	gngm	3.46
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
26336913	C0184512	Stabilized (qualifier value)	qlco	5.18
26336913	C1947976	Correction (change)	ftcn	3.68
26336913	C1705565	Correction Report	inpr	3.68
26336913	C0205474	Biochemical	ftcn	3.57
26336913	C0542341	Function	ftcn	3.50
26336913	C0205245	Functional	ftcn	3.50
26336913	C2700217	Functional Relationship	cnce	3.50
26336913	C0439645	Band form	spco	3.46
26336913	C0175723	Bands	medd	3.46
26336913	C1413365	CFTR gene	gngm	3.46
26336913	C1521913	Chromosome band	celc	3.46
26336913	C0917964	Colforsin	orch	16.15
26336913	C0917964	Colforsin	phsu	16.15
26336913	C0066447	methylxanthine	orch	13.00
26336913	C0066447	methylxanthine	phsu	13.00
26336913	C0205419	Variant	qlco	3.56
26336913	C1269647	Entire cell	cell	3.55
26336913	C3854307	Presence (property)	qlco	3.55
26336913	C0150312	Present	qnco	3.55
26336913	C0392148	Providing presence (regime/therapy)	topp	3.55
26336913	C1879547	Activation action	acty	3.54
26336913	C0332152	Before	tmco	3.54
26336913	C0521116	Current (present time)	tmco	3.54
26336913	C1522538	Leading	ftcn	3.54
26336913	C3536939	Methylxanthine [EPC]	phsu	3.54
26336913	C1547311	Patient Condition Code - Stable	inpr	3.54
26336913	C0205360	Stable status	qlco	3.54
26336913	C3252847	VX 809	orch	3.48
26336913	C3252847	VX 809	phsu	3.48
26336913	C0205202	Corrected	qlco	3.46
26336913	C0242624	Whole-Cell Recording	resa	13.06
26336913	C3252847	VX 809	orch	7.06
26336913	C3252847	VX 809	phsu	7.06
26336913	C1705535	suggestion	idcn	3.98
26336913	C1293130	Stabilization	topp	3.56
26336913	C0521116	Current (present time)	tmco	3.54
26336913	C1708698	Light Emitting Diode Device Component	mnob	3.54
26336913	C0205359	Spontaneous	ftcn	3.54
26336913	C0750563	omit	idcn	3.54
26336913	C0039798	therapeutic aspects	ftcn	45.24
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.54
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.54
26336913	C0004135	Ataxia Telangiectasia	dsyn	22.39
26336913	C0000096	1-Methyl-3-isobutylxanthine	orch	22.34
26336913	C0000096	1-Methyl-3-isobutylxanthine	phsu	22.34
26336913	C0917964	Colforsin	orch	16.03
26336913	C0917964	Colforsin	phsu	16.03
26336913	C1533734	Administration procedure	topp	7.17
26336913	C1705169	Biomaterial Treatment	cnce	7.17
26336913	C0087111	Therapeutic procedure	topp	7.17
26336913	C1522326	Treating	ftcn	7.17
26336913	C3538994	Treatment Epoch	resa	7.17
26336913	C3887704	treatment - ActInformationManagementReason	hlca	7.17
26336913	C3252847	VX 809	orch	7.14
26336913	C3252847	VX 809	phsu	7.14
26336913	C0439044	Living Alone	fndg	5.18
26336913	C0205171	Singular	qnco	5.18
26336913	C0679994	alone - group size	grpa	5.18
26336913	C1413365	CFTR gene	gngm	3.61
26336913	C0205195	Combined	qlco	3.61
26336913	C3811910	combination - answer to question	fndg	3.61
26336913	C1947911	combination of objects	phob	3.61
26336913	C2349975	Enhance (action)	acty	3.57
26336913	C1707455	Comparison	acty	3.56
26336913	C0521116	Current (present time)	tmco	3.54
26336913	C2825142	Experimental Result	fndg	3.54
26336913	C1274040	Result	ftcn	3.54
26336913	C1546471	What subject filter - Result	idcn	3.54
26336913	C3540695	Anatomical Therapeutic Chemical (ATC)-classification system	inpr	3.47
26336913	C0301863	"""U"" lymphocyte"	cell	3.46
26336913	C3841722	2 - High	fndg	3.42
26336913	C1879547	Activation action	acty	3.42
26336913	C1880834	Fold in Medical Device Material	phpr	3.42
26336913	C0332462	Folded structure	spco	3.42
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.26
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.26
26336913	C0004135	Ataxia Telangiectasia	dsyn	45.11
26336913	C0079613	Adoptive Immunotherapy	topp	25.59
26336913	C1869853	SERPINA3 protein, human	aapp	12.98
26336913	C1869853	SERPINA3 protein, human	bacs	12.98
26336913	C3252847	VX 809	orch	7.47
26336913	C3252847	VX 809	phsu	7.47
26336913	C1413365	CFTR gene	gngm	7.19
26336913	C3540695	Anatomical Therapeutic Chemical (ATC)-classification system	inpr	7.04
26336913	C1280500	Effect	qlco	7.01
26336913	C2348382	Effect, Appearance	qlco	7.01
26336913	C0442796	Additive	qlco	3.56
26336913	C1550602	additive ingredient	sbst	3.56
26336913	C0332268	Lacking	qlco	3.55
26336913	C0392747	Changing	ftcn	3.54
26336913	C3889737	Data Change Date	tmco	3.54
26336913	C4048375	Asthma Control Test Questionnaire	inpr	3.51
26336913	C3890007	SERPINA3 wt Allele	gngm	3.51
26336913	C0205195	Combined	qlco	3.43
26336913	C3811910	combination - answer to question	fndg	3.43
26336913	C1947911	combination of objects	phob	3.43
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
26336913	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
26336913	C0026377	Molecular Conformation	spco	14.64
26336913	C1519323	Silent Mutation	genf	14.64
26336913	C0033684	Proteins	aapp	6.59
26336913	C0033684	Proteins	bacs	6.59
26336913	C1552740	Entity Determiner - specific	inpr	5.18
26336913	C3887511	Evidence	idcn	5.18
26336913	C1999230	Providing (action)	acty	5.18
26336913	C0205369	Specific qualifier value	qlco	5.18
26336913	C1705535	suggestion	idcn	5.18
26336913	C2825142	Experimental Result	fndg	3.98
26336913	C1274040	Result	ftcn	3.98
26336913	C1546471	What subject filter - Result	idcn	3.98
26336913	C0392747	Changing	ftcn	3.79
26336913	C0237865	Propensity to adverse reactions to drug	orga	3.61
26336913	C3252847	VX 809	orch	3.61
26336913	C3252847	VX 809	phsu	3.61
26336913	C1167622	Binding (Molecular Function)	moft	3.57
26336913	C1145667	Binding action	acty	3.57
26336913	C1413365	CFTR gene	gngm	3.56
27707539	C0242612	Codon, Nonsense	nusq	22.49
27707539	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
27707539	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
27707539	C0002085	Alleles	gngm	19.19
27707539	C0009738	Congo	geoa	16.04
27707539	C0017337	Genes	gngm	16.03
27707539	C0015127	Etiology aspects	ftcn	9.85
27707539	C0033684	Proteins	aapp	6.77
27707539	C0033684	Proteins	bacs	6.77
27707539	C1524003	Science of Etiology	cnce	3.54
27707539	C0205300	Non-functional	ftcn	3.47
27707539	C1704735	Regulator	cnce	3.47
27707539	C1704734	Regulator Device Component	mnob	3.47
27707539	C0182953	Regulators (device)	medd	3.47
27707539	C1413365	CFTR gene	gngm	3.46
27707539	C3811819	CFTR wt Allele	gngm	3.42
27707539	C0678227	Causing	ftcn	3.42
27707539	C2825142	Experimental Result	fndg	3.42
27707539	C1274040	Result	ftcn	3.42
27707539	C1546471	What subject filter - Result	idcn	3.42
27707539	C0040363	Togo	geoa	17.80
27707539	C0041260	Tryptophanase	aapp	17.80
27707539	C0041260	Tryptophanase	enzy	17.80
27707539	C0002556	Aminoglycosides	orch	9.99
27707539	C0002556	Aminoglycosides	phsu	9.99
27707539	C0205263	Induce (action)	ftcn	5.18
27707539	C0205309	Known	qlco	5.18
27707539	C1883351	To	qlco	5.18
27707539	C0003233	Antibiotics, Aminoglycoside	antb	3.68
27707539	C0003233	Antibiotics, Aminoglycoside	orch	3.68
27707539	C1749527	translational readthrough	genf	3.64
27707539	C0450442	Agent	chvf	3.63
27707539	C0449445	Approach	spco	3.63
27707539	C1254351	Pharmacologic Substance	phsu	3.63
27707539	C1521826	Protocol Agent	inpr	3.63
27707539	C0205314	New	qlco	3.50
27707539	C0679622	literary novel	inpr	3.50
27707539	C0302350	Therapeutic	ftcn	3.48
27707539	C0087111	Therapeutic procedure	topp	3.48
27707539	C3245505	potential	qlco	3.48
27707539	C4048286	Coagulation Factor V, Human	aapp	3.42
27707539	C4048286	Coagulation Factor V, Human	bacs	3.42
27707539	C0724584	coagulation factor IX, human	aapp	3.42
27707539	C0724584	coagulation factor IX, human	bacs	3.42
27707539	C0724584	coagulation factor IX, human	phsu	3.42
27707539	C4048712	factor IX complex	aapp	3.42
27707539	C4048712	factor IX complex	bacs	3.42
27707539	C4048712	factor IX complex	phsu	3.42
27707539	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.21
27707539	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.21
27707539	C0015272	Exhibits as Topic	inpr	17.80
27707539	C0026882	Mutation	genf	9.91
27707539	C1413365	CFTR gene	gngm	7.14
27707539	C1710548	Unique	qlco	5.18
27707539	C4048286	Coagulation Factor V, Human	aapp	3.98
27707539	C4048286	Coagulation Factor V, Human	bacs	3.98
27707539	C0724584	coagulation factor IX, human	aapp	3.98
27707539	C0724584	coagulation factor IX, human	bacs	3.98
27707539	C0724584	coagulation factor IX, human	phsu	3.98
27707539	C4048712	factor IX complex	aapp	3.98
27707539	C4048712	factor IX complex	bacs	3.98
27707539	C4048712	factor IX complex	phsu	3.98
27707539	C1561536	*Activity (kind of quantity)	idcn	3.68
27707539	C0205177	Active	ftcn	3.68
27707539	C0441655	Activities	acty	3.68
27707539	C3668946	Activity (animal life circumstance)	fndg	3.68
27707539	C4049939	FDA Establishment Activity Terminology	inpr	3.68
27707539	C0439167	Percent Activity	qnco	3.68
27707539	C4049938	Physical Activity Measurement	lbpr	3.68
27707539	C1705285	Mutation Abnormality	comd	3.60
27707539	C1301808	Geographic state	geoa	3.56
27707539	C1442792	State	ftcn	3.56
27707539	C3148680	US State	geoa	3.56
27707539	C0728938	Partial	qnco	3.50
27707539	C1550516	Target Awareness - partial	idcn	3.50
27707539	C1707271	Carboxy-Terminal Amino Acid	amas	3.49
27707539	C0009738	Congo	geoa	16.18
27707539	C3264621	ivacaftor	orch	13.14
27707539	C3264621	ivacaftor	phsu	13.14
27707539	C0026882	Mutation	genf	9.99
27707539	C0030705	Patients	podg	6.71
27707539	C2741958	VX-770	orch	5.18
27707539	C0205540	Approved	qlco	3.56
27707539	C3811819	CFTR wt Allele	gngm	3.56
27707539	C1522326	Treating	ftcn	3.56
27707539	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.17
27707539	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.17
27707539	C3264621	ivacaftor	orch	26.27
27707539	C3264621	ivacaftor	phsu	26.27
27707539	C0009738	Congo	geoa	16.05
27707539	C0026882	Mutation	genf	9.99
27707539	C2349975	Enhance (action)	acty	7.53
27707539	C1413365	CFTR gene	gngm	7.10
27707539	C0030705	Patients	podg	6.59
27707539	C0332282	Following	tmco	5.18
27707539	C1517331	Further	spco	5.18
27707539	C2827718	In Vitro Route of Administration	ftcn	5.18
27707539	C0021135	In Vitro [Publication Type]	inpr	5.18
27707539	C0231290	Status post	tmco	5.18
27707539	C1533691	in vitro	qlco	5.18
27707539	C1552607	Act Relationship Subset - previous	tmco	3.57
27707539	C1705938	Base - General Qualifier	idcn	3.57
27707539	C1527178	Basis - conceptual entity	ftcn	3.57
27707539	C0205156	Previous	tmco	3.57
27707539	C0947630	Scientific Study	lbpr	3.57
27707539	C1561536	*Activity (kind of quantity)	idcn	3.56
27707539	C0205177	Active	ftcn	3.56
27707539	C0441655	Activities	acty	3.56
27707539	C3668946	Activity (animal life circumstance)	fndg	3.56
27707539	C1280500	Effect	qlco	3.56
27707539	C2348382	Effect, Appearance	qlco	3.56
27707539	C4049939	FDA Establishment Activity Terminology	inpr	3.56
27707539	C0439167	Percent Activity	qnco	3.56
27707539	C4049938	Physical Activity Measurement	lbpr	3.56
27707539	C4048286	Coagulation Factor V, Human	aapp	3.50
27707539	C4048286	Coagulation Factor V, Human	bacs	3.50
27707539	C0724584	coagulation factor IX, human	aapp	3.50
27707539	C0724584	coagulation factor IX, human	bacs	3.50
27707539	C0724584	coagulation factor IX, human	phsu	3.50
27707539	C4048712	factor IX complex	aapp	3.50
27707539	C4048712	factor IX complex	bacs	3.50
27707539	C4048712	factor IX complex	phsu	3.50
27707539	C3811819	CFTR wt Allele	gngm	3.43
27707539	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.07
27707539	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.07
27707539	C0052009	antibiotic G 418	antb	13.14
27707539	C0052009	antibiotic G 418	orch	13.14
27707539	C3264621	ivacaftor	orch	12.88
27707539	C3264621	ivacaftor	phsu	12.88
27707539	C0002556	Aminoglycosides	orch	9.81
27707539	C0002556	Aminoglycosides	phsu	9.81
27707539	C1413365	CFTR gene	gngm	7.00
27707539	C1517331	Further	spco	5.18
27707539	C2349975	Enhance (action)	acty	3.59
27707539	C0007634	Cells	cell	3.56
27707539	C3282337	Cells [Chemical/Ingredient]	cell	3.56
27707539	C1707455	Comparison	acty	3.56
27707539	C0474395	Behavior showing increased motor activity	fndg	3.56
27707539	C3536835	Aminoglycoside [EPC]	phsu	3.50
27707539	C0003233	Antibiotics, Aminoglycoside	antb	3.50
27707539	C0003233	Antibiotics, Aminoglycoside	orch	3.50
27707539	C0301863	"""U"" lymphocyte"	cell	3.42
27707539	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27707539	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27707539	C0031843	physiological aspects	phsf	13.01
27707539	C3264621	ivacaftor	orch	12.88
27707539	C3264621	ivacaftor	phsu	12.88
27707539	C0028429	Nose	bpoc	12.88
27707539	C0019904	Homozygote	orga	9.73
27707539	C0030705	Patients	podg	6.57
27707539	C1547282	Show	anim	3.98
27707539	C0542341	Function	ftcn	3.54
27707539	C0700205	Function Axis	clas	3.54
27707539	C1705273	Mathematical Operator	inpr	3.54
27707539	C0301863	"""U"" lymphocyte"	cell	3.54
27707539	C0221908	epithelial	qlco	3.54
27707539	C1561611	Admission Level of Care Code - Improved	inpr	3.42
27707539	C0332272	Better	qlco	3.42
27707539	C1413365	CFTR gene	gngm	3.42
27707539	C0184511	Improved	qlco	3.42
27707539	C3854307	Presence (property)	qlco	3.42
27707539	C0150312	Present	qnco	3.42
27707539	C0392148	Providing presence (regime/therapy)	topp	3.42
27707539	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.42
27707539	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.42
27707539	C0205225	Primary	qlco	3.42
27707539	C0439631	Primary operation	topp	3.42
27707539	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.42
27707539	C0439612	True primary (qualifier value)	tmco	3.42
27707539	C0021641	Insulin	aapp	22.43
27707539	C0021641	Insulin	horm	22.43
27707539	C0021641	Insulin	phsu	22.43
27707539	C3264621	ivacaftor	orch	12.89
27707539	C3264621	ivacaftor	phsu	12.89
27707539	C0024109	Lung	bpoc	6.58
27707539	C1561566	FEV1 Adverse Event	fndg	5.18
27707539	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	5.18
27707539	C3889426	Content Type Requirement	ftcn	3.68
27707539	C1514873	Requirement	ftcn	3.68
27707539	C1547311	Patient Condition Code - Stable	inpr	3.59
27707539	C0205360	Stable status	qlco	3.59
27707539	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.57
27707539	C3242455	HL7PublishingDomain <patient administration>	inpr	3.57
27707539	C3242279	healthcare operations <patient administration>	ocac	3.57
27707539	C2986411	Improvement	cnce	3.55
27707539	C3714501	Insulin Drug Class	horm	3.50
27707539	C3714501	Insulin Drug Class	phsu	3.50
27707539	C1579433	Insulin [EPC]	phsu	3.50
27707539	C1533581	Recombinant Insulin	aapp	3.50
27707539	C1533581	Recombinant Insulin	horm	3.50
27707539	C1533581	Recombinant Insulin	phsu	3.50
27707539	C1546944	Event Seriousness - Significant	qlco	3.43
27707539	C0439603	Frequencies (time pattern)	tmco	3.43
27707539	C3898838	How Often	inpr	3.43
27707539	C1561548	Kind of quantity - Frequency	qlco	3.43
27707539	C2709248	Pulmonary (qualifier value)	qlco	3.43
27707539	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.43
27707539	C0750502	Significant	idcn	3.43
27707539	C0871396	Spatial Frequency	qnco	3.43
27707539	C1705502	Statistical Frequency	qnco	3.43
27707539	C0237881	Statistical Significance	qnco	3.43
27707539	C0376249	With frequency	qnco	3.43
27707539	C0445247	Same	qlco	3.42
27707539	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27707539	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27707539	C3264621	ivacaftor	orch	14.64
27707539	C3264621	ivacaftor	phsu	14.64
27707539	C0027552	Needs	qlco	13.02
27707539	C0026882	Mutation	genf	9.73
27707539	C1705535	suggestion	idcn	8.28
27707539	C0947630	Scientific Study	lbpr	7.23
27707539	C0030705	Patients	podg	6.59
27707539	C0033085	Biologic Preservation	lbpr	6.58
27707539	C0332257	Including (qualifier)	ftcn	5.18
27707539	C1537044	protein activity	moft	3.56
27707539	C0686904	Patient need for (contextual qualifier)	ftcn	3.56
27707539	C0814225	benefit	qnco	3.56
27707539	C1883712	Add - instruction imperative	ftcn	3.55
27707539	C0332287	In addition to	ftcn	3.55
27707539	C3854321	Expression (foundation metadata concept)	idcn	3.54
27707539	C0185117	Expression procedure	topp	3.54
27707539	C4049706	Borg Category-Ratio 10 Perceived Exertion Score 3	inpr	3.43
27707539	C0205210	Clinical	qlco	3.43
27707539	C1517331	Further	spco	3.43
27707539	C0205081	Moderate (severity modifier)	qlco	3.43
27707539	C4049705	Moderate Extremity Pain	inpr	3.43
27707539	C1881878	Moderation	qlco	3.43
27707539	C1553058	Neuropsychologist - Clinical	prog	3.43
27707539	C0237412	Psychologist - Clinical	prog	3.43
27707539	C0497591	Social Worker - Clinical	prog	3.43
27707539	C1413365	CFTR gene	gngm	3.42
27707539	C1705285	Mutation Abnormality	comd	3.42
27707539	C1609982	Residual	qlco	3.42
27707539	C1948023	Stimulation (motivation)	npop	3.42
27707539	C0450442	Agent	chvf	3.41
27707539	C1254351	Pharmacologic Substance	phsu	3.41
27707539	C1521826	Protocol Agent	inpr	3.41
27707539	C1280519	Effectiveness	qlco	3.38
27707539	C1707887	Efficacy Study	resa	3.38
25698453	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.18
25698453	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.18
25698453	C3264621	ivacaftor	orch	13.14
25698453	C3264621	ivacaftor	phsu	13.14
25698453	C0010674	Cystic Fibrosis	dsyn	9.76
25698453	C1413365	CFTR gene	gngm	7.11
25698453	C0184511	Improved	qlco	5.18
25698453	C0442805	Increase	ftcn	5.18
25698453	C0205217	Increased	qnco	5.18
25698453	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.75
25698453	C1561536	*Activity (kind of quantity)	idcn	3.68
25698453	C0205177	Active	ftcn	3.68
25698453	C0441655	Activities	acty	3.68
25698453	C3668946	Activity (animal life circumstance)	fndg	3.68
25698453	C4049939	FDA Establishment Activity Terminology	inpr	3.68
25698453	C0439167	Percent Activity	qnco	3.68
25698453	C4049938	Physical Activity Measurement	lbpr	3.68
25698453	C0205447	One	qnco	3.63
25698453	C1948062	Copy (object)	mnob	3.57
25698453	C1547647	Patient Outcome	idcn	3.55
25698453	C0205314	New	qlco	3.48
25698453	C0679622	literary novel	inpr	3.48
25698453	C0205210	Clinical	qlco	3.43
25698453	C1553058	Neuropsychologist - Clinical	prog	3.43
25698453	C0237412	Psychologist - Clinical	prog	3.43
25698453	C0497591	Social Worker - Clinical	prog	3.43
25698453	C0009738	Congo	geoa	32.33
25698453	C0005910	Body Weight	orga	24.11
25698453	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
25698453	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
25698453	C0008976	Clinical Trials	resa	19.52
25698453	C3264621	ivacaftor	orch	13.01
25698453	C3264621	ivacaftor	phsu	13.01
25698453	C1096775	Clinical Trial [Publication Type]	inpr	10.06
25698453	C0001675	Adult	aggp	9.74
25698453	C3811819	CFTR wt Allele	gngm	6.95
25698453	C0035245	Respiratory physiology	ortf	6.62
25698453	C0024109	Lung	bpoc	6.59
25698453	C3816745	1+	fndg	5.18
25698453	C2827734	1+ Score	qnco	5.18
25698453	C2981698	1+ Score, WHO	clas	5.18
25698453	C1705104	Importance Weight	idcn	5.18
25698453	C1305866	Weighing patient	diap	5.18
25698453	C0043100	Weight	qnco	5.18
25698453	C1547282	Show	anim	3.98
25698453	C0683465	novel AODU treatment method	topp	3.78
25698453	C2986411	Improvement	cnce	3.56
25698453	C2346845	Approval (document)	inpr	3.55
25698453	C0205540	Approved	qlco	3.55
25698453	C0332152	Before	tmco	3.55
25698453	C1522538	Leading	ftcn	3.55
25698453	C2697909	Letter of Authorization	rnlw	3.55
25698453	C1413365	CFTR gene	gngm	3.50
25698453	C2709248	Pulmonary (qualifier value)	qlco	3.43
25698453	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.43
25698453	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.00
25698453	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.00
25698453	C0026882	Mutation	genf	30.07
25698453	C3264621	ivacaftor	orch	26.56
25698453	C3264621	ivacaftor	phsu	26.56
25698453	C0055363	Chloride Channels	aapp	19.21
25698453	C0055363	Chloride Channels	bacs	19.21
25698453	C1413365	CFTR gene	gngm	6.93
25698453	C0030705	Patients	podg	6.72
25698453	C0740116	+2	qnco	5.18
25698453	C3833492	2+	fndg	5.18
25698453	C2827735	2+ Score	qnco	5.18
25698453	C2981700	2+ Score, WHO	clas	5.18
25698453	C1547282	Show	anim	3.98
25698453	C1705535	suggestion	idcn	3.98
25698453	C2827718	In Vitro Route of Administration	ftcn	3.75
25698453	C0021135	In Vitro [Publication Type]	inpr	3.75
25698453	C1533691	in vitro	qlco	3.75
25698453	C0557651	Room of building - Study	mnob	3.59
25698453	C0947630	Scientific Study	lbpr	3.59
25698453	C2603343	Study	resa	3.59
25698453	C0814225	benefit	qnco	3.59
25698453	C2986411	Improvement	cnce	3.51
25698453	C1518422	Negation	ftcn	3.47
25698453	C3476289	Opening time	fndg	3.44
25698453	C1546944	Event Seriousness - Significant	qlco	3.42
25698453	C0750502	Significant	idcn	3.42
25698453	C0237881	Statistical Significance	qnco	3.42
25698453	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.19
25698453	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.19
25698453	C3264621	ivacaftor	orch	12.89
25698453	C3264621	ivacaftor	phsu	12.89
25698453	C0026882	Mutation	genf	9.92
25698453	C1413365	CFTR gene	gngm	7.11
25698453	C0740116	+2	qnco	5.18
25698453	C3833492	2+	fndg	5.18
25698453	C2827735	2+ Score	qnco	5.18
25698453	C2981700	2+ Score, WHO	clas	5.18
25698453	C3838680	3+ Answer to Question	fndg	5.18
25698453	C2827736	3+ Score	qnco	5.18
25698453	C2981702	3+ Score, WHO	clas	5.18
25698453	C0439086	<3 (qualifier value)	qnco	5.18
25698453	C3687625	Demonstrates	acty	5.18
25698453	C1705285	Mutation Abnormality	comd	3.61
25698453	C1704632	Disease Response	fndg	3.55
25698453	C2911692	Response (communication)	menp	3.55
25698453	C1706817	Response (statement)	inpr	3.55
25698453	C0871261	Response process	orga	3.55
25698453	C0205214	Common (qualifier value)	qnco	3.47
25698453	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.47
25698453	C1522138	shared attribute	ftcn	3.47
25698453	C2827718	In Vitro Route of Administration	ftcn	3.45
25698453	C0021135	In Vitro [Publication Type]	inpr	3.45
25698453	C1533691	in vitro	qlco	3.45
25698453	C0008976	Clinical Trials	resa	42.15
25698453	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25698453	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25698453	C0009738	Congo	geoa	16.04
25698453	C0030705	Patients	podg	13.49
25698453	C0035820	Social Role	socb	13.03
25698453	C3264621	ivacaftor	orch	12.90
25698453	C3264621	ivacaftor	phsu	12.90
25698453	C1096775	Clinical Trial [Publication Type]	inpr	11.49
25698453	C0024115	Lung diseases	dsyn	6.60
25698453	C3838679	4+ Answer to question	fndg	5.18
25698453	C2700399	Include (action)	acty	5.18
25698453	C0332257	Including (qualifier)	ftcn	5.18
25698453	C1518422	Negation	ftcn	5.18
25698453	C1552866	include - SetOperator	idcn	5.18
25698453	C1705535	suggestion	idcn	3.98
25698453	C1705810	Generic Role	cnce	3.57
25698453	C3871154	{Role}	inpr	3.57
25698453	C4050419	Borg Category-Ratio 10 Perceived Exertion Score 7	inpr	3.44
25698453	C3641272	Very severe	qlco	3.44
25698453	C1413365	CFTR gene	gngm	3.43
25698453	C3811819	CFTR wt Allele	gngm	3.42
25698453	C0580836	Old	tmco	3.41
25698453	C0039798	therapeutic aspects	ftcn	22.48
25698453	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25698453	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25698453	C0009738	Congo	geoa	16.04
25698453	C0001792	Elderly (population group)	popg	14.64
25698453	C3264621	ivacaftor	orch	14.64
25698453	C3264621	ivacaftor	phsu	14.64
25698453	C0041703	United States	geoa	13.07
25698453	C0001779	Age	orga	5.18
25698453	C1999167	Old age	popg	5.18
25698453	C0439093	Greater Than	qnco	3.61
25698453	C0205540	Approved	qlco	3.56
25698453	C1533734	Administration procedure	topp	3.55
25698453	C1705169	Biomaterial Treatment	cnce	3.55
25698453	C1948062	Copy (object)	mnob	3.55
25698453	C0087111	Therapeutic procedure	topp	3.55
25698453	C1522326	Treating	ftcn	3.55
25698453	C3538994	Treatment Epoch	resa	3.55
25698453	C3887704	treatment - ActInformationManagementReason	hlca	3.55
25698453	C0580836	Old	tmco	3.43
25698453	C0439234	year	tmco	3.43
25698453	C1413365	CFTR gene	gngm	3.43
25698453	C3811819	CFTR wt Allele	gngm	3.43
25698453	C2349001	Human Study Subject	humn	3.41
25698453	C2697811	Investigative Subject	ftcn	3.41
25698453	C0681850	Study Subject	grup	3.41
25698453	C1706203	Subject - topic	idcn	3.41
25698453	C1550501	Subject -direct target	idcn	3.41
25698453	C0009738	Congo	geoa	16.04
25698453	C3264621	ivacaftor	orch	12.89
25698453	C3264621	ivacaftor	phsu	12.89
25698453	C0024115	Lung diseases	dsyn	6.91
25698453	C0030705	Patients	podg	6.70
25698453	C0024109	Lung	bpoc	6.63
25698453	C0017431	Genotype	orga	6.58
25698453	C0868928	Case (situation)	ftcn	5.18
25698453	C1706256	Clinical Study Case	cnce	5.18
25698453	C1706255	Packaging Case	medd	5.18
25698453	C0150312	Present	qnco	5.18
25698453	C0449450	Presentation	idcn	5.18
25698453	C0679246	advanced disease	fndg	3.78
25698453	C1527144	Therapeutic Effect	clna	3.59
25698453	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.54
25698453	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.54
25698453	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.54
25698453	C0205179	Advanced phase	qlco	3.48
25698453	C1278908	Entire lung	bpoc	3.48
25698453	C0819757	Structure of parenchyma of lung	tisu	3.48
25698453	C3811819	CFTR wt Allele	gngm	3.42
25512598	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.81
25512598	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.81
25512598	C2744579	ATP8A2 protein, human	aapp	12.94
25512598	C2744579	ATP8A2 protein, human	enzy	12.94
25512598	C0015127	Etiology aspects	ftcn	9.82
25512598	C0022023	Ions	elii	9.76
25512598	C0439799	Channel	spco	7.09
25512598	C1706095	Channel Object	cnce	7.09
25512598	C1413365	CFTR gene	gngm	3.88
25512598	C0449261	Reversibility	tmco	3.68
25512598	C1521802	Closure	resa	3.63
25512598	C0185003	Reparative closure	topp	3.63
25512598	C1514557	Protein Kinase Protein Phosphorylation	moft	3.60
25512598	C1710548	Unique	qlco	3.59
25512598	C1510699	ATP Hydrolysis	moft	3.57
25512598	C0699756	Intimate (qualifier value)	qlco	3.54
25512598	C2584308	Intimate relationships	socb	3.54
25512598	C1314939	Involvement with	ftcn	3.54
25512598	C1524003	Science of Etiology	cnce	3.51
25512598	C0205288	Microscopic	qlco	3.50
25512598	C1701901	Conditional	qlco	3.48
25512598	C2587213	Control function	ftcn	3.48
25512598	C2239193	Controlling (action)	phpr	3.48
25512598	C0851827	Dependent - ability	qlco	3.48
25512598	C3244310	dependent	ftcn	3.48
25512598	C1700702	Iontophoresis Route of Drug Administration	ftcn	3.45
25512598	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
25512598	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
25512598	C0004083	Mental association	menp	14.64
25512598	C0086168	Dissociation	mobd	6.70
25512598	C0596306	Chemical Association	phpr	5.18
25512598	C0699792	Relationship by association	socb	5.18
25512598	C0439849	Relationships	qlco	5.18
25512598	C1705535	suggestion	idcn	5.18
25512598	C1519623	Transmembrane Domain	amas	3.69
25512598	C0947630	Scientific Study	lbpr	3.63
25512598	C1706388	Array Feature	cnce	3.59
25512598	C1521970	Characteristics	qlco	3.59
25512598	C2348519	Feature	qlco	3.59
25512598	C2346469	Image Feature	qlco	3.59
25512598	C0587267	Closed	ftcn	3.57
25512598	C1948027	Couple (action)	ftcn	3.56
25512598	C1413365	CFTR gene	gngm	3.48
25512598	C3853906	Digital Model Attachment	inpr	3.48
25512598	C3161035	Model	inpr	3.48
25512598	C3714583	Model - style/design	cnce	3.48
25512598	C3274659	Model Number	inpr	3.48
25512598	C0332185	Recent	tmco	3.48
25512598	C1148916	nucleotide binding	moft	3.44
25512598	C3842459	Energetic	fndg	3.43
25512598	C0175566	Open	spco	3.43
25512598	C1882151	Opening	spco	3.43
25512598	C0205448	Two	qnco	3.42
25512598	C3541951	Concept model domain	inpr	3.40
25512598	C1880389	Domain (area of knowledge)	ftcn	3.40
25512598	C1883221	Superkingdom (taxonomic category)	cnce	3.40
25512598	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25512598	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25512598	C0033204	Probability	qnco	16.16
25512598	C1521828	Rate	qnco	7.40
25512598	C0871208	Rating (action)	acty	7.40
25512598	C0175566	Open	spco	7.09
25512598	C0442797	Decreasing	qlco	5.18
25512598	C0442805	Increase	ftcn	5.18
25512598	C0442808	Increasing	ftcn	5.18
25512598	C0150312	Present	qnco	5.18
25512598	C3848573	nitrate ion	elii	3.56
25512598	C3848573	nitrate ion	phsu	3.56
25512598	C0587267	Closed	ftcn	3.50
25512598	C1882151	Opening	spco	3.50
25512598	C1883559	Wild Type	gngm	3.44
25512598	C1413365	CFTR gene	gngm	3.42
25512598	C0031715	Phosphorylation	moft	26.26
25512598	C0028125	Nitrates	chvs	17.80
25512598	C2744579	ATP8A2 protein, human	aapp	12.93
25512598	C2744579	ATP8A2 protein, human	enzy	12.93
25512598	C0001721	Affect (mental function)	menp	11.49
25512598	C1158886	Protein phosphorylation	moft	7.23
25512598	C1701901	Conditional	qlco	6.98
25512598	C0851827	Dependent - ability	qlco	6.98
25512598	C3244310	dependent	ftcn	6.98
25512598	C1561536	*Activity (kind of quantity)	idcn	5.18
25512598	C0205177	Active	ftcn	5.18
25512598	C0441655	Activities	acty	5.18
25512598	C3668946	Activity (animal life circumstance)	fndg	5.18
25512598	C4049939	FDA Establishment Activity Terminology	inpr	5.18
25512598	C1518422	Negation	ftcn	5.18
25512598	C0699857	Nitrate	inch	5.18
25512598	C0439167	Percent Activity	qnco	5.18
25512598	C4049938	Physical Activity Measurement	lbpr	5.18
25512598	C1280500	Effect	qlco	3.61
25512598	C1261552	Step (specific stage)	cnce	3.61
25512598	C3814463	Step Unit of Distance	qnco	3.61
25512598	C2827421	Construct	clas	3.57
25512598	C0205397	seen	qlco	3.57
25512598	C0205280	Identical	qlco	3.47
25512598	C3828842	Nearly	qlco	3.47
25512598	C3541951	Concept model domain	inpr	3.43
25512598	C1880389	Domain (area of knowledge)	ftcn	3.43
25512598	C1704735	Regulator	cnce	3.43
25512598	C1883221	Superkingdom (taxonomic category)	cnce	3.43
25512598	C0220905	regulatory	rnlw	3.43
25512598	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
25512598	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
25512598	C0028125	Nitrates	chvs	16.05
25512598	C0393003	potassium oxonate	orch	13.09
25512598	C0393003	potassium oxonate	phsu	13.09
25512598	C0754515	TERT protein, human	aapp	12.92
25512598	C0754515	TERT protein, human	enzy	12.92
25512598	C3838679	4+ Answer to question	fndg	7.11
25512598	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.75
25512598	C0369718	N not otherwise specified Antibody	aapp	3.68
25512598	C0369718	N not otherwise specified Antibody	imft	3.68
25512598	C0441922	N+ (tumor staging)	inpr	3.68
25512598	C0442592	Clinic	hcro	3.59
25512598	C0442592	Clinic	mnob	3.59
25512598	C1273517	Used by	fndg	3.59
25512598	C1280500	Effect	qlco	3.57
25512598	C2348205	Similarity	qlco	3.55
25512598	C0450367	4/5	qnco	3.51
25512598	C1413365	CFTR gene	gngm	3.50
25512598	C3541881	Device Identifiers Domain	idcn	3.46
25512598	C3538902	SLC4A1 wt Allele	gngm	3.46
25512598	C1367342	TERT gene	gngm	3.46
25512598	C1705316	TERT wt Allele	gngm	3.46
25512598	C2741958	VX-770	orch	3.44
25512598	C0699857	Nitrate	inch	3.44
25512598	C3245505	potential	qlco	3.41
25512598	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25512598	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25512598	C0087136	Unmarried	fndg	22.35
25512598	C0037179	Unmarried person	popg	22.35
25512598	C0011100	Deceleration	npop	16.17
25512598	C0022702	Kinetics	npop	9.73
25512598	C0032729	Portugal	geoa	9.73
25512598	C2700399	Include (action)	acty	5.18
25512598	C0332257	Including (qualifier)	ftcn	5.18
25512598	C1552866	include - SetOperator	idcn	5.18
25512598	C1280500	Effect	qlco	3.54
25512598	C0279023	chemosensitization/potentiation	topp	3.54
25512598	C0243083	associated disease	patf	3.43
25512598	C0587267	Closed	ftcn	3.43
25512598	C1521828	Rate	qnco	3.43
25512598	C0871208	Rating (action)	acty	3.43
25512598	C1413365	CFTR gene	gngm	3.42
25512598	C0439799	Channel	spco	3.42
25512598	C1706095	Channel Object	cnce	3.42
25512598	C2825046	Kinetics (discipline)	ocdi	3.42
25512598	C0205171	Singular	qnco	3.42
25512598	C2700323	Wild Type Unspecified - zebrafish	fish	3.42
25512598	C0442027	Oral	spco	3.42
25512598	C0596988	mutant	comd	3.42
25512598	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25512598	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25512598	C0028125	Nitrates	chvs	17.80
25512598	C0376525	Dimerization	npop	9.87
25512598	C0442805	Increase	ftcn	5.18
25512598	C0205217	Increased	qnco	5.18
25512598	C0699857	Nitrate	inch	5.18
25512598	C2741958	VX-770	orch	5.18
25512598	C1280500	Effect	qlco	3.68
25512598	C1883712	Add - instruction imperative	ftcn	3.63
25512598	C0332287	In addition to	ftcn	3.63
25512598	C0332291	Independent of	ftcn	3.61
25512598	C1518456	Nucleosome Binding Domain	amas	3.56
25512598	C1561536	*Activity (kind of quantity)	idcn	3.54
25512598	C0205177	Active	ftcn	3.54
25512598	C0441655	Activities	acty	3.54
25512598	C3668946	Activity (animal life circumstance)	fndg	3.54
25512598	C4049939	FDA Establishment Activity Terminology	inpr	3.54
25512598	C0439167	Percent Activity	qnco	3.54
25512598	C4049938	Physical Activity Measurement	lbpr	3.54
25512598	C1413365	CFTR gene	gngm	3.42
25512598	C2827421	Construct	clas	3.42
25512598	C0332268	Lacking	qlco	3.42
25512598	C0028125	Nitrates	chvs	17.80
25512598	C0010834	Cytoplasm	celc	13.02
25512598	C0699857	Nitrate	inch	5.18
25512598	C2741958	VX-770	orch	5.18
25512598	C1704419	Effective	qlco	3.68
25512598	C1280519	Effectiveness	qlco	3.68
25512598	C3821273	side of membrane	tisu	3.60
25512598	C2945843	Site of	qlco	3.56
25512598	C0521449	Cytoplasmic	blor	3.56
25512598	C0441987	Side	spco	3.56
25512598	C0441712	Mechanism (attribute)	ftcn	3.55
25512598	C1706376	Mechanism Component of Device	mnob	3.55
25512598	C3266814	Action	acty	3.55
25512598	C4048755	Apply	ftcn	3.55
25512598	C0441472	Clinical action	ftcn	3.55
25512598	C0086597	Mediate	socb	3.55
25512598	C0127400	Mediator brand of benfluorex hydrochloride	orch	3.55
25512598	C0127400	Mediator brand of benfluorex hydrochloride	phsu	3.55
25512598	C0443299	Separate	qlco	3.55
25512598	C0205448	Two	qnco	3.55
25512598	C0205214	Common (qualifier value)	qnco	3.43
25512598	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.43
25512598	C0443264	Modulated	spco	3.43
25512598	C1522138	shared attribute	ftcn	3.43
27773592	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.39
27773592	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.39
27773592	C0040363	Togo	geoa	17.80
27773592	C0041260	Tryptophanase	aapp	17.80
27773592	C0041260	Tryptophanase	enzy	17.80
27773592	C3264621	ivacaftor	orch	13.14
27773592	C3264621	ivacaftor	phsu	13.14
27773592	C0026882	Mutation	genf	9.94
27773592	C1413365	CFTR gene	gngm	7.31
27773592	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	5.18
27773592	C2349975	Enhance (action)	acty	5.18
27773592	C0442805	Increase	ftcn	5.18
27773592	C1883351	To	qlco	5.18
27773592	C1153410	channel activity	moft	3.78
27773592	C0679830	patient assessment	hlca	3.68
27773592	C1159591	chloride transport	celf	3.61
27773592	C1705242	Different	qlco	3.48
27773592	C1947931	Direct (qualifier)	qlco	3.43
27773592	C0010101	Correlation Study	inpr	13.07
27773592	C0010101	Correlation Study	resa	13.07
27773592	C3264621	ivacaftor	orch	13.05
27773592	C3264621	ivacaftor	phsu	13.05
27773592	C1524024	analysis aspect	ftcn	13.04
27773592	C0168634	BaseLine dental cement	bodm	13.03
27773592	C0684224	Report (document)	inpr	5.18
27773592	C0700287	Reporting	hlca	5.18
27773592	C0237401	Individual	humn	3.98
27773592	C0027361	Persons	popg	3.98
27773592	C0332293	Treated with	topp	3.72
27773592	C0936012	Analysis	resa	3.58
27773592	C0002778	Analysis of substances	lbpr	3.58
27773592	C1442488	Baseline	qnco	3.57
27773592	C0392756	Reduced	qlco	3.56
27773592	C0301630	Reduction (chemical)	npop	3.56
27773592	C0441610	Reduction - action	topp	3.56
27773592	C0428295	Cystic fibrosis sweat test	lbpr	3.49
27773592	C1552607	Act Relationship Subset - previous	tmco	3.47
27773592	C0205156	Previous	tmco	3.47
27773592	C0443172	Changed status	qnco	3.43
27773592	C0392747	Changing	ftcn	3.43
27773592	C1705241	Delta (difference)	qnco	3.43
27773592	C1524024	analysis aspect	ftcn	26.03
27773592	C0040363	Togo	geoa	17.80
27773592	C0041260	Tryptophanase	aapp	17.80
27773592	C0041260	Tryptophanase	enzy	17.80
27773592	C0009738	Congo	geoa	16.08
27773592	C0220825	Evaluation	hlca	14.64
27773592	C3264621	ivacaftor	orch	13.05
27773592	C3264621	ivacaftor	phsu	13.05
27773592	C0026882	Mutation	genf	9.92
27773592	C0018017	objective (goal)	inpr	9.86
27773592	C0936012	Analysis	resa	6.99
27773592	C0002778	Analysis of substances	lbpr	6.99
27773592	C0030705	Patients	podg	6.71
27773592	C1883351	To	qlco	5.18
27773592	C1552738	described	idcn	5.18
27773592	C0332293	Treated with	topp	3.72
27773592	C1552607	Act Relationship Subset - previous	tmco	3.57
27773592	C0205229	Expanding	spco	3.57
27773592	C0205156	Previous	tmco	3.57
27773592	C0443172	Changed status	qnco	3.55
27773592	C0392747	Changing	ftcn	3.55
27773592	C1707520	Correlation	qlco	3.55
27773592	C1705241	Delta (difference)	qnco	3.55
27773592	C0439064	Numerous	qnco	3.55
27773592	C0599755	cohort	popg	3.55
27773592	C1571702	Objective observation	qlco	3.55
27773592	C0205344	Absolute	qlco	3.50
27773592	C0428295	Cystic fibrosis sweat test	lbpr	3.47
27773592	C3811819	CFTR wt Allele	gngm	3.47
27773592	C0678227	Causing	ftcn	3.47
27773592	C1705242	Different	qlco	3.47
27773592	C0687676	Post	tmco	3.42
27773592	C1704687	Post Device Component	mnob	3.42
27773592	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
27773592	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
27773592	C0008976	Clinical Trials	resa	19.36
27773592	C0040363	Togo	geoa	17.80
27773592	C0041260	Tryptophanase	aapp	17.80
27773592	C0041260	Tryptophanase	enzy	17.80
27773592	C1524024	analysis aspect	ftcn	12.89
27773592	C0018017	objective (goal)	inpr	9.87
27773592	C0042153	utilization qualifier	ftcn	9.74
27773592	C0005516	Biological Markers	clna	6.71
27773592	C1269765	Assisted (qualifier value)	qlco	5.18
27773592	C1552861	Help document	inpr	5.18
27773592	C1883351	To	qlco	5.18
27773592	C1571704	Act Mood - Goal	idcn	3.56
27773592	C1522609	Numerical value	qnco	3.55
27773592	C1413365	CFTR gene	gngm	3.48
27773592	C1709060	Modulator Device Component	mnob	3.48
27773592	C0428295	Cystic fibrosis sweat test	lbpr	3.45
27773592	C1304760	Sweat chloride level result	lbtr	3.45
27773592	C0936012	Analysis	resa	3.43
27773592	C0002778	Analysis of substances	lbpr	3.43
27773592	C1709518	Pharmacodynamic Study	resa	3.43
27773592	C0851347	Pharmacodynamics	biof	3.43
27773592	C0457083	Usage	ftcn	3.43
27773592	C1947944	Use - dosing instruction imperative	inpr	3.43
27773592	C3245505	potential	qlco	3.43
27773592	C0030705	Patients	podg	6.72
27773592	C1518422	Negation	ftcn	5.18
27773592	C0557651	Room of building - Study	mnob	3.68
27773592	C2603343	Study	resa	3.68
27773592	C1707520	Correlation	qlco	3.57
27773592	C0237401	Individual	humn	3.57
27773592	C0027361	Persons	popg	3.57
27773592	C0301630	Reduction (chemical)	npop	3.56
27773592	C0441610	Reduction - action	topp	3.56
27773592	C2986411	Improvement	cnce	3.54
27773592	C1550718	Entity Name Part Type - given	idcn	3.50
27773592	C1442162	GIVEN	cnce	3.50
27773592	C1947971	Give - dosing instruction imperative	ftcn	3.50
27773592	C3244317	Given name	inpr	3.50
27773592	C0428295	Cystic fibrosis sweat test	lbpr	3.49
27773592	C0205344	Absolute	qlco	3.44
27773592	C0023376	Lesotho	geoa	16.30
27773592	C0428295	Cystic fibrosis sweat test	lbpr	6.93
27773592	C3842591	0%	fndg	5.18
27773592	C0205195	Combined	qlco	5.18
27773592	C1441672	Observed	ftcn	5.18
27773592	C0443172	Changed status	qnco	3.68
27773592	C0392747	Changing	ftcn	3.68
27773592	C3887647	Lymphotoxin-Alpha, human	aapp	3.68
27773592	C3887647	Lymphotoxin-Alpha, human	imft	3.68
27773592	C0230426	Structure of left thigh	bpoc	3.68
27773592	C0681873	research data	resa	3.58
27773592	C1707520	Correlation	qlco	3.54
27773592	C0369773	P Blood group antibodies	aapp	3.50
27773592	C0369773	P Blood group antibodies	imft	3.50
27773592	C2603361	P prime	clna	3.50
27773592	C0814896	significance level	resa	3.44
27773592	C0237881	Statistical Significance	qnco	3.44
27773592	C1304760	Sweat chloride level result	lbtr	3.44
27773592	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
27773592	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
27773592	C0039798	therapeutic aspects	ftcn	22.35
27773592	C0040363	Togo	geoa	17.80
27773592	C0041260	Tryptophanase	aapp	17.80
27773592	C0041260	Tryptophanase	enzy	17.80
27773592	C3264621	ivacaftor	orch	14.64
27773592	C3264621	ivacaftor	phsu	14.64
27773592	C1257890	Population Group	popg	9.81
27773592	C0443172	Changed status	qnco	7.03
27773592	C0392747	Changing	ftcn	7.03
27773592	C0005516	Biological Markers	clna	6.70
27773592	C0032659	geographic population	qnco	6.66
27773592	C0035245	Respiratory physiology	ortf	6.59
27773592	C0700364	Appearance	qlco	5.18
27773592	C0428295	Cystic fibrosis sweat test	lbpr	5.18
27773592	C1883351	To	qlco	5.18
27773592	C1874451	Basis	phsu	3.68
27773592	C1527178	Basis - conceptual entity	ftcn	3.68
27773592	C1705241	Delta (difference)	qnco	3.59
27773592	C1704632	Disease Response	fndg	3.59
27773592	C2911692	Response (communication)	menp	3.59
27773592	C1706817	Response (statement)	inpr	3.59
27773592	C0871261	Response process	orga	3.59
27773592	C0814225	benefit	qnco	3.59
27773592	C0237401	Individual	humn	3.55
27773592	C0027361	Persons	popg	3.55
27773592	C0279023	chemosensitization/potentiation	topp	3.55
27773592	C1533734	Administration procedure	topp	3.43
27773592	C1705169	Biomaterial Treatment	cnce	3.43
27773592	C0087111	Therapeutic procedure	topp	3.43
27773592	C1522326	Treating	ftcn	3.43
27773592	C3538994	Treatment Epoch	resa	3.43
27773592	C0681842	prediction	idcn	3.43
27773592	C3887704	treatment - ActInformationManagementReason	hlca	3.43
27773592	C1709518	Pharmacodynamic Study	resa	3.42
27773592	C0851347	Pharmacodynamics	biof	3.42
27773592	C0681890	predictive	qlco	3.42
27821435	C0040363	Togo	geoa	35.81
27821435	C0041260	Tryptophanase	aapp	35.81
27821435	C0041260	Tryptophanase	enzy	35.81
27821435	C0041714	United States Food and Drug Administration	hcro	25.75
27821435	C3494303	Databases, Pharmaceutical	inpr	25.73
27821435	C0031328	Pharmacokinetic aspects	ftcn	20.95
27821435	C0043038	Washington state	geoa	19.23
27821435	C0687133	Drug Interactions	moft	13.02
27821435	C1524024	analysis aspect	ftcn	12.89
27821435	C0005528	Biological Transport	celf	11.49
27821435	C0031327	Drug Kinetics	phsf	11.49
27821435	C1883351	To	qlco	10.42
27821435	C0041740	Universities	mnob	9.76
27821435	C0041740	Universities	orgt	9.76
27821435	C0282443	Review [Publication Type]	inpr	9.74
27821435	C3495449	Mobility aid	medd	5.18
27821435	C1524063	Use of	ftcn	5.18
27821435	C0683140	drug metabolism	moft	5.18
27821435	C1317949	transport (device)	mnob	5.18
27821435	C3539655	CDISC Findings Class	inpr	3.68
27821435	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	3.68
27821435	C2607943	findings aspects	ftcn	3.68
27821435	C1511726	Data	idcn	3.61
27821435	C3714741	Data (eukaryote)	euka	3.61
27821435	C3245479	Data call receiving device	medd	3.61
27821435	C3845700	New Drug Available	fndg	3.60
27821435	C3274571	Clinical Study Follow-up	hlca	3.59
27821435	C1704685	Follow-Up Report	inpr	3.59
27821435	C0589120	Follow-up status	fndg	3.59
27821435	C1522577	follow-up	hlca	3.59
27821435	C2948600	Aim	phsu	3.55
27821435	C1947946	Aim (idea)	idcn	3.55
27821435	C3540472	Ancestry-Informative Marker	ftcn	3.55
27821435	C3890193	CD5L wt Allele	gngm	3.55
27821435	C2744535	CD69 protein, human	aapp	3.55
27821435	C2744535	CD69 protein, human	imft	3.55
27821435	C3540471	CD69 wt Allele	gngm	3.55
27821435	C0205540	Approved	qlco	3.55
27821435	C1546944	Event Seriousness - Significant	qlco	3.50
27821435	C0750502	Significant	idcn	3.50
27821435	C0237881	Statistical Significance	qnco	3.50
27821435	C1704675	Interaction	ftcn	3.46
27821435	C1552607	Act Relationship Subset - previous	tmco	3.43
27821435	C0936012	Analysis	resa	3.43
27821435	C0002778	Analysis of substances	lbpr	3.43
27821435	C0150312	Present	qnco	3.43
27821435	C0449450	Presentation	idcn	3.43
27821435	C0205156	Previous	tmco	3.43
27821435	C0185125	Application procedure	hlca	3.42
27821435	C0040363	Togo	geoa	17.80
27821435	C0041260	Tryptophanase	aapp	17.80
27821435	C0041260	Tryptophanase	enzy	17.80
27821435	C0596902	Membrane Transport Proteins	aapp	14.64
27821435	C0596902	Membrane Transport Proteins	bacs	14.64
27821435	C0150312	Present	qnco	5.18
27821435	C1883351	To	qlco	5.18
27821435	C3854146	Transporter device	medd	5.18
27821435	C3891814	Substrate	sbst	3.98
27821435	C1710236	Substrate Device Component	mnob	3.98
27821435	C2827718	In Vitro Route of Administration	ftcn	3.75
27821435	C0021135	In Vitro [Publication Type]	inpr	3.75
27821435	C1533691	in vitro	qlco	3.75
27821435	C0680220	majority	socb	3.55
27821435	C3898767	Inducer	sbst	3.51
27821435	C0919438	Enzyme Inhibitor Drugs	phsu	3.44
27821435	C1521991	Molecular	qlco	3.42
27821435	C0205314	New	qlco	3.42
27821435	C0205447	One	qnco	3.42
27821435	C1551338	Entity	enty	3.40
27821435	C0012133	Didanosine	nnon	19.37
27821435	C0012133	Didanosine	phsu	19.37
27821435	C0376690	Area Under Curve	qnco	16.24
27821435	C0557651	Room of building - Study	mnob	5.18
27821435	C0947630	Scientific Study	lbpr	5.18
27821435	C2603343	Study	resa	5.18
27821435	C1704675	Interaction	ftcn	3.58
27821435	C1515655	in vivo	spco	3.48
27821435	C0870432	Display - arrangement	ftcn	3.47
27821435	C1446409	Positive	qlco	3.47
27821435	C2825490	Positive Charge	qlco	3.47
27821435	C1514241	Positive Finding	fndg	3.47
27821435	C3812269	Positive Number	cnce	3.47
27821435	C0439178	percent positive cells	qnco	3.47
27821435	C0205210	Clinical	qlco	3.46
27821435	C1553058	Neuropsychologist - Clinical	prog	3.46
27821435	C0237412	Psychologist - Clinical	prog	3.46
27821435	C0497591	Social Worker - Clinical	prog	3.46
27821435	C0456603	Ratio	qnco	3.42
27821435	C1547037	data type - ratio	inpr	3.42
27821435	C3463820	Inhibition	acty	13.03
27821435	C0021467	Psychological inhibition	menp	13.03
27821435	C3842591	0%	fndg	3.68
27821435	C0021469	Metabolic Inhibition	moft	3.57
27821435	C1628982	Percent inhibition	qnco	3.57
27821435	C0205263	Induce (action)	ftcn	3.57
27821435	C0857127	Induction procedure	topp	3.57
27821435	C0012133	Didanosine	nnon	19.37
27821435	C0012133	Didanosine	phsu	19.37
27821435	C0040363	Togo	geoa	17.80
27821435	C0041260	Tryptophanase	aapp	17.80
27821435	C0041260	Tryptophanase	enzy	17.80
27821435	C0376690	Area Under Curve	qnco	16.23
27821435	C1832021	isavuconazole	phsu	14.64
27821435	C0257190	ivabradine	orch	14.64
27821435	C0257190	ivabradine	phsu	14.64
27821435	C2985393	Neuromuscular Electrical Stimulation	topp	11.48
27821435	C0020517	Hypersensitivity	patf	6.59
27821435	C0033262	Prodrugs	chvf	6.58
27821435	C4049146	Cobimetinib	phsu	5.18
27821435	C1883351	To	qlco	5.18
27821435	C1547282	Show	anim	3.98
27821435	C0456603	Ratio	qnco	3.61
27821435	C1547037	data type - ratio	inpr	3.61
27821435	C3687832	DRUGS	topp	3.57
27821435	C0013227	Pharmaceutical Preparations	phsu	3.57
27821435	C0442821	Strong	qlco	3.57
27821435	C0750591	consider	idcn	3.57
27821435	C0243077	inhibitors	chvf	3.57
27821435	C0680681	victim	popg	3.57
27821435	C0870883	Metabolite	bacs	3.55
27821435	C3891814	Substrate	sbst	3.54
27821435	C1710236	Substrate Device Component	mnob	3.54
27821435	C0205449	Three	qnco	3.50
27821435	C0205210	Clinical	qlco	3.46
27821435	C1553058	Neuropsychologist - Clinical	prog	3.46
27821435	C0205447	One	qnco	3.46
27821435	C1446409	Positive	qlco	3.46
27821435	C2825490	Positive Charge	qlco	3.46
27821435	C1514241	Positive Finding	fndg	3.46
27821435	C3812269	Positive Number	cnce	3.46
27821435	C0237412	Psychologist - Clinical	prog	3.46
27821435	C0497591	Social Worker - Clinical	prog	3.46
27821435	C0439178	percent positive cells	qnco	3.46
27821435	C4018470	isavuconazonium sulfate	phsu	3.44
27821435	C3814396	CYP3A Gene Locus	gngm	3.44
27821435	C0332324	Sensitive	ftcn	3.44
27821435	C0205177	Active	ftcn	3.42
27821435	C3888249	Active License	qlco	3.42
27821435	C3853793	active (HL7 RoleLink)	idcn	3.42
27821435	C0596902	Membrane Transport Proteins	aapp	14.64
27821435	C0596902	Membrane Transport Proteins	bacs	14.64
27821435	C3463820	Inhibition	acty	13.14
27821435	C0021467	Psychological inhibition	menp	13.14
27821435	C0014445	enzymology	ftcn	11.49
27821435	C0014442	Enzymes	enzy	8.34
27821435	C0014442	Enzymes	orch	8.34
27821435	C1547282	Show	anim	8.00
27821435	C2985393	Neuromuscular Electrical Stimulation	topp	7.40
27821435	C1446409	Positive	qlco	7.04
27821435	C2825490	Positive Charge	qlco	7.04
27821435	C1514241	Positive Finding	fndg	7.04
27821435	C3812269	Positive Number	cnce	7.04
27821435	C0439178	percent positive cells	qnco	7.04
27821435	C3540048	ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS	enzy	5.18
27821435	C3540048	ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS	phsu	5.18
27821435	C3540772	Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	enzy	5.18
27821435	C3540772	Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	phsu	5.18
27821435	C3542456	Enzymes for ALIMENTARY TRACT AND METABOLISM	enzy	5.18
27821435	C3542456	Enzymes for ALIMENTARY TRACT AND METABOLISM	phsu	5.18
27821435	C3541394	Enzymes, antithrombotic	enzy	5.18
27821435	C3541394	Enzymes, antithrombotic	phsu	5.18
27821435	C3540017	Enzymes, hematological	enzy	5.18
27821435	C3540017	Enzymes, hematological	phsu	5.18
27821435	C3540790	Enzymes, peripheral vasodilators	enzy	5.18
27821435	C3540790	Enzymes, peripheral vasodilators	phsu	5.18
27821435	C1314939	Involvement with	ftcn	5.18
27821435	C0205263	Induce (action)	ftcn	3.68
27821435	C0857127	Induction procedure	topp	3.68
27821435	C0021469	Metabolic Inhibition	moft	3.68
27821435	C1628982	Percent inhibition	qnco	3.68
27821435	C1704675	Interaction	ftcn	3.53
27821435	C0205455	Nine	qnco	3.50
27821435	C0205449	Three	qnco	3.50
27821435	C3852684	lumacaftor	orch	14.64
27821435	C3852684	lumacaftor	phsu	14.64
27821435	C3463820	Inhibition	acty	12.89
27821435	C0021467	Psychological inhibition	menp	12.89
27821435	C0205263	Induce (action)	ftcn	5.18
27821435	C0857127	Induction procedure	topp	5.18
27821435	C2962189	Cytochrome P450 2D6 Inhibitor [EPC]	phsu	3.60
27821435	C1441672	Observed	ftcn	3.59
27821435	C3273719	rolapitant	phsu	3.59
27821435	C3898767	Inducer	sbst	3.56
27821435	C0443172	Changed status	qnco	3.55
27821435	C0392747	Changing	ftcn	3.55
27821435	C1299394	Most significant	qlco	3.45
27821435	C4049706	Borg Category-Ratio 10 Perceived Exertion Score 3	inpr	3.43
27821435	C3814396	CYP3A Gene Locus	gngm	3.43
27821435	C0205081	Moderate (severity modifier)	qlco	3.43
27821435	C4049705	Moderate Extremity Pain	inpr	3.43
27821435	C1881878	Moderation	qlco	3.43
27821435	C0442821	Strong	qlco	3.43
27821435	C0021469	Metabolic Inhibition	moft	3.43
27821435	C1628982	Percent inhibition	qnco	3.43
27821435	C0031328	Pharmacokinetic aspects	ftcn	19.23
27821435	C0040363	Togo	geoa	17.80
27821435	C0041260	Tryptophanase	aapp	17.80
27821435	C0041260	Tryptophanase	enzy	17.80
27821435	C0031325	Pharmacogenetics	bmod	16.12
27821435	C0537670	Oprelvekin	aapp	14.64
27821435	C0537670	Oprelvekin	imft	14.64
27821435	C0537670	Oprelvekin	phsu	14.64
27821435	C0031327	Drug Kinetics	phsf	9.77
27821435	C0700287	Reporting	hlca	5.18
27821435	C1883351	To	qlco	5.18
27821435	C1552002	inform	ocac	5.18
27821435	C2985393	Neuromuscular Electrical Stimulation	topp	3.68
27821435	C0034866	Recommendation	idcn	3.68
27821435	C0947630	Scientific Study	lbpr	3.68
27821435	C0679083	simulation	resa	3.60
27821435	C0205452	Six	qnco	3.59
27821435	C1273517	Used by	fndg	3.59
27821435	C0205454	Eight	qnco	3.50
27821435	C0178602	Dosage	qnco	3.48
27821435	C1114758	Dose number:Number:Point in time:^Patient:Quantitative	clna	3.48
27821435	C0869039	Unit dose	qnco	3.48
27821435	C1705938	Base - General Qualifier	idcn	3.46
27821435	C1527178	Basis - conceptual entity	ftcn	3.46
27821435	C0040363	Togo	geoa	17.80
27821435	C0041260	Tryptophanase	aapp	17.80
27821435	C0041260	Tryptophanase	enzy	17.80
27821435	C1565489	Renal Insufficiency	dsyn	16.21
27821435	C0220825	Evaluation	hlca	14.64
27821435	C0027712	Nephrology Speciality	bmod	13.04
27821435	C1257890	Population Group	popg	9.74
27821435	C0032659	geographic population	qnco	6.58
27821435	C0183683	Support, device	medd	5.18
27821435	C1521721	Supportive assistance	cnce	5.18
27821435	C1883351	To	qlco	5.18
27821435	C3469597	Administration of medication	hlca	3.59
27821435	C0150270	Medication Management	hlca	3.59
27821435	C1280500	Effect	qlco	3.57
27821435	C0221099	Impaired	ftcn	3.55
27821435	C0684336	Impaired health	patf	3.55
27821435	C0205054	Hepatic	blor	3.44
27821435	C3687832	DRUGS	topp	3.43
27821435	C1552740	Entity Determiner - specific	inpr	3.43
27821435	C0013227	Pharmaceutical Preparations	phsu	3.43
27821435	C0205369	Specific qualifier value	qlco	3.43
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
23664284	C1413365	CFTR gene	gngm	10.42
23664284	C0010674	Cystic Fibrosis	dsyn	10.06
23664284	C0026882	Mutation	genf	9.73
23664284	C0265388	Autosomal recessive hereditary disorder	dsyn	3.64
23664284	C0678226	Due to	ftcn	3.44
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
23664284	C0055363	Chloride Channels	aapp	20.95
23664284	C0055363	Chloride Channels	bacs	20.95
23664284	C2327105	Surface of epithelial cell	celc	3.61
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.98
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.98
23664284	C0007465	Cause of Death	fndg	22.61
23664284	C0023175	Lead	elii	13.02
23664284	C0023175	Lead	hops	13.02
23664284	C0031843	physiological aspects	phsf	13.01
23664284	C0024115	Lung diseases	dsyn	8.34
23664284	C1522538	Leading	ftcn	7.02
23664284	C4050444	Cause of death:Find:Pt:^Patient:Nom	clna	3.68
23664284	C1836348	Severe disorder	fndg	3.61
23664284	C1527118	Protein Function	moft	3.57
23664284	C0815043	Protein, Organized by Function	aapp	3.57
23664284	C3275067	Cardiac Lead Procedure	topp	3.56
23664284	C2348269	Dietary Lead	elii	3.56
23664284	C0181586	Leads (device)	medd	3.56
23664284	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.56
23664284	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.56
23664284	C0542341	Function	ftcn	3.55
23664284	C0700205	Function Axis	clas	3.55
23664284	C1705273	Mathematical Operator	inpr	3.55
23664284	C0332152	Before	tmco	3.43
23664284	C1413365	CFTR gene	gngm	3.42
23664284	C0332452	defective	ftcn	3.42
23664284	C0231220	Symptomatic	ftcn	5.18
23664284	C2827774	Current Therapy	topp	3.72
23664284	C0011129	Dedications	acty	12.85
23664284	C0010674	Cystic Fibrosis	dsyn	9.75
23664284	C1611835	Specialist	prog	8.34
23664284	C0038952	Continuance of life	acty	6.83
23664284	C1561611	Admission Level of Care Code - Improved	inpr	5.18
23664284	C0332272	Better	qlco	5.18
23664284	C0087009	Hospital specialist	prog	5.18
23664284	C0184511	Improved	qlco	5.18
23664284	C2348234	Specialist Physician	prog	5.18
23664284	C2939193	Median (qualifier value)	spco	3.68
23664284	C0876920	Median Statistical Measurement	qnco	3.68
23664284	C0549183	Midline (qualifier value)	spco	3.68
23664284	C2347635	Population Median	qnco	3.68
23664284	C2348144	Sample Median	qnco	3.68
23664284	C0220921	survival aspects	ftcn	3.68
23664284	C1947933	care activity	acty	3.55
23664284	C0205099	Central	spco	3.42
23664284	C1552235	Holistic	prog	3.42
23664284	C1546180	Age at death	fndg	3.68
23664284	C0439234	year	tmco	3.68
23664284	C3843708	29+	fndg	3.50
23664284	C1510992	Average	qnco	3.43
23664284	C2825518	Average of Value Derivation Technique	qnco	3.43
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
23664284	C0567416	Molecule	sbst	3.63
23664284	C0678723	Biologic Development	orgf	3.59
23664284	C2349182	Correct (qualifier)	qlco	3.59
23664284	C1527148	Development	ftcn	3.59
23664284	C0243107	development aspects	phsf	3.59
23664284	C2948600	Aim	phsu	3.55
23664284	C1947946	Aim (idea)	idcn	3.55
23664284	C3540472	Ancestry-Informative Marker	ftcn	3.55
23664284	C3890193	CD5L wt Allele	gngm	3.55
23664284	C2744535	CD69 protein, human	aapp	3.55
23664284	C2744535	CD69 protein, human	imft	3.55
23664284	C3540471	CD69 wt Allele	gngm	3.55
23664284	C0683243	innovativeness	menp	3.43
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
23664284	C0031847	physiopathological	ftcn	9.74
23664284	C0017431	Genotype	orga	6.72
23664284	C0087111	Therapeutic procedure	topp	5.18
23664284	C1547052	*Type - Kind of quantity	qnco	3.56
23664284	C0332307	Type - attribute	qlco	3.56
23664284	C0725813	depend	medd	3.54
23664284	C1413365	CFTR gene	gngm	3.43
23664284	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.43
23664284	C3887504	Dysfunction	cnce	3.43
23664284	C0277785	Functional disorder	patf	3.43
23664284	C0041703	United States	geoa	14.64
23664284	C3264621	ivacaftor	orch	14.64
23664284	C3264621	ivacaftor	phsu	14.64
23664284	C0015176	Europe	geoa	6.74
23664284	C0567416	Molecule	sbst	3.68
23664284	C0205540	Approved	qlco	3.59
23664284	C0205435	First (number)	qnco	3.50
23664284	C1279901	Firstly	qlco	3.50
23664284	C0008976	Clinical Trials	resa	20.95
23664284	C3264621	ivacaftor	orch	13.05
23664284	C3264621	ivacaftor	phsu	13.05
23664284	C0052080	antineoplaston A10	orch	12.92
23664284	C0052080	antineoplaston A10	phsu	12.92
23664284	C0008059	Child	aggp	11.49
23664284	C1096775	Clinical Trial [Publication Type]	inpr	11.49
23664284	C0001675	Adult	aggp	9.99
23664284	C0680063	Offspring	famg	5.18
23664284	C0439508	per year	tmco	5.18
23664284	C0439234	year	tmco	5.18
23664284	C0332293	Treated with	topp	3.72
23664284	C1314677	Maintaining (action)	ftcn	3.59
23664284	C2986411	Improvement	cnce	3.56
23664284	C1561566	FEV1 Adverse Event	fndg	3.43
23664284	C0429706	Forced expiratory volume in 1 second finding	fndg	3.43
23664284	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.43
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.98
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.98
23664284	C3264621	ivacaftor	orch	13.03
23664284	C3264621	ivacaftor	phsu	13.03
23664284	C0030705	Patients	podg	6.59
23664284	C0449445	Approach	spco	3.68
23664284	C0205540	Approved	qlco	3.59
23664284	C1720467	Only - dosing instruction fragment	inpr	3.59
23664284	C0205171	Singular	qnco	3.59
23664284	C0150312	Present	qnco	3.57
23664284	C0449450	Presentation	idcn	3.57
23664284	C1549488	Amount type - Percentage	idcn	3.56
23664284	C1561533	Money or percentage indicator - Percentage	idcn	3.56
23664284	C0439165	Percent (qualifier value)	qnco	3.56
23664284	C0679199	strategy	menp	3.55
23664284	C2349099	Valid	qlco	3.50
23664284	C0872285	therapeutic protein	phsu	3.44
23664284	C0700321	Small	qnco	3.43
23664284	C1413365	CFTR gene	gngm	3.42
23664284	C0302350	Therapeutic	ftcn	3.42
23664284	C0087111	Therapeutic procedure	topp	3.42
23664284	C2349182	Correct (qualifier)	qlco	3.40
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
23664284	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
23664284	C0220825	Evaluation	hlca	13.05
23664284	C0567416	Molecule	sbst	5.18
23664284	C1521840	Target	ftcn	5.18
23664284	C1261322	Evaluation procedure	hlca	3.59
23664284	C0243067	defects aspect	ftcn	3.55
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
27103391	C0010674	Cystic Fibrosis	dsyn	9.95
27103391	C0026882	Mutation	genf	9.78
27103391	C0599896	trafficking	celf	5.18
27103391	C0087111	Therapeutic procedure	topp	3.61
27103391	C0243067	defects aspect	ftcn	3.54
27103391	C1413365	CFTR gene	gngm	3.51
27103391	C1328819	Small Molecule	orch	3.50
27103391	C1552740	Entity Determiner - specific	inpr	3.48
27103391	C1705285	Mutation Abnormality	comd	3.48
27103391	C0205369	Specific qualifier value	qlco	3.48
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27103391	C0031330	Pharmacology	bmod	9.73
27103391	C1518601	Options	ftcn	3.54
27103391	C1413365	CFTR gene	gngm	3.42
27103391	C1947976	Correction (change)	ftcn	3.42
27103391	C1705565	Correction Report	inpr	3.42
27103391	C0205464	pharmacological	ftcn	3.42
27103391	C0039798	therapeutic aspects	ftcn	22.49
27103391	C0596988	mutant	comd	5.18
27103391	C0599896	trafficking	celf	5.18
27103391	C0557651	Room of building - Study	mnob	3.98
27103391	C2603343	Study	resa	3.98
27103391	C0439673	Unknown	qlco	3.68
27103391	C1947976	Correction (change)	ftcn	3.59
27103391	C1705565	Correction Report	inpr	3.59
27103391	C1533734	Administration procedure	topp	3.57
27103391	C1705169	Biomaterial Treatment	cnce	3.57
27103391	C0087111	Therapeutic procedure	topp	3.57
27103391	C1522326	Treating	ftcn	3.57
27103391	C3538994	Treatment Epoch	resa	3.57
27103391	C0814225	benefit	qnco	3.57
27103391	C3887704	treatment - ActInformationManagementReason	hlca	3.57
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27103391	C0557651	Room of building - Study	mnob	3.98
27103391	C2603343	Study	resa	3.98
27103391	C1947976	Correction (change)	ftcn	3.55
27103391	C1705565	Correction Report	inpr	3.55
27103391	C1413365	CFTR gene	gngm	3.42
27103391	C0185026	Plication	topp	3.42
27103391	C0596988	mutant	comd	3.42
27103391	C0369773	P Blood group antibodies	aapp	5.18
27103391	C0369773	P Blood group antibodies	imft	5.18
27103391	C2603361	P prime	clna	5.18
27103391	C0369773	P Blood group antibodies	aapp	5.18
27103391	C0369773	P Blood group antibodies	imft	5.18
27103391	C2603361	P prime	clna	5.18
27103391	C0086418	Homo sapiens	humn	28.65
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27103391	C0009738	Congo	geoa	16.04
27103391	C0021853	Intestines	bpoc	9.73
27103391	C0005507	Biological Assay	lbpr	6.70
27103391	C0029250	Organoids	tisu	6.57
27103391	C1524063	Use of	ftcn	5.18
27103391	C3252847	VX 809	orch	5.18
27103391	C3252847	VX 809	phsu	5.18
27103391	C3889128	BBS9 wt Allele	gngm	3.68
27103391	C1510438	Assay	lbpr	3.54
27103391	C0243073	assay qualifier	qlco	3.54
27103391	C0456879	TNM certainty factor C1	fndg	3.50
27103391	C1413365	CFTR gene	gngm	3.42
27103391	C3811819	CFTR wt Allele	gngm	3.42
27103391	C0542341	Function	ftcn	3.42
27103391	C0205245	Functional	ftcn	3.42
27103391	C2700217	Functional Relationship	cnce	3.42
27103391	C1292984	Procedure on intestine	hlca	3.42
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27103391	C0031843	physiological aspects	phsf	13.01
27103391	C0542341	Function	ftcn	3.55
27103391	C0700205	Function Axis	clas	3.55
27103391	C1705273	Mathematical Operator	inpr	3.55
27103391	C1413365	CFTR gene	gngm	3.43
27103391	C0369773	P Blood group antibodies	aapp	5.18
27103391	C0369773	P Blood group antibodies	imft	5.18
27103391	C2603361	P prime	clna	5.18
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
27103391	C1609982	Residual	qlco	5.18
27103391	C0205263	Induce (action)	ftcn	3.64
27103391	C0332281	Associated with	qlco	3.64
27103391	C1413365	CFTR gene	gngm	3.57
27103391	C2346866	Assortment	cnce	3.55
27103391	C2349975	Enhance (action)	acty	3.55
27103391	C1883525	Variety (taxon)	cnce	3.55
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27103391	C1947976	Correction (change)	ftcn	3.61
27103391	C1705565	Correction Report	inpr	3.61
27103391	C1527180	Dominant	ftcn	3.56
27103391	C3252847	VX 809	orch	3.50
27103391	C3252847	VX 809	phsu	3.50
27103391	C0205263	Induce (action)	ftcn	3.47
27103391	C1413365	CFTR gene	gngm	3.43
27103391	C0205393	Most	qnco	3.43
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27103391	C1947976	Correction (change)	ftcn	3.57
27103391	C1705565	Correction Report	inpr	3.57
27103391	C1413365	CFTR gene	gngm	3.44
27103391	C1539216	CYTL1 gene	gngm	5.18
27103391	C0302945	Carbon-14	elii	5.18
27103391	C0302945	Carbon-14	irda	5.18
27103391	C1947967	Call (Instruction)	ftcn	3.98
27103391	C0679006	Decision	menp	3.98
27103391	C1522410	Highest	qlco	3.55
27103391	C1515021	Subgroup	clas	3.43
27103391	C1079230	Subgroup A Nepoviruses	virs	3.43
27103391	C0205198	Compound	qlco	3.41
27103391	C1706082	Compound (substance)	chem	3.41
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.97
27103391	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.97
27103391	C0039798	therapeutic aspects	ftcn	22.48
27103391	C0026882	Mutation	genf	9.74
27103391	C1413365	CFTR gene	gngm	6.90
27103391	C1511726	Data	idcn	5.18
27103391	C3714741	Data (eukaryote)	euka	5.18
27103391	C3245479	Data call receiving device	medd	5.18
27103391	C0183683	Support, device	medd	5.18
27103391	C1521721	Supportive assistance	cnce	5.18
27103391	C0596988	mutant	comd	5.18
27103391	C0599896	trafficking	celf	5.18
27103391	C1947976	Correction (change)	ftcn	3.56
27103391	C1705565	Correction Report	inpr	3.56
27103391	C1533734	Administration procedure	topp	3.55
27103391	C0678723	Biologic Development	orgf	3.55
27103391	C1705169	Biomaterial Treatment	cnce	3.55
27103391	C1527148	Development	ftcn	3.55
27103391	C0087111	Therapeutic procedure	topp	3.55
27103391	C1522326	Treating	ftcn	3.55
27103391	C3538994	Treatment Epoch	resa	3.55
27103391	C0243107	development aspects	phsf	3.55
27103391	C3887704	treatment - ActInformationManagementReason	hlca	3.55
27103391	C1705242	Different	qlco	3.43
27103391	C1552740	Entity Determiner - specific	inpr	3.43
27103391	C1705285	Mutation Abnormality	comd	3.43
27103391	C2698651	Optimum	qlco	3.43
27103391	C0205369	Specific qualifier value	qlco	3.43
27103391	C0205198	Compound	qlco	3.41
27103391	C1706082	Compound (substance)	chem	3.41
27103391	C1555307	promise	idcn	3.41
29079713	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.52
29079713	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.52
29079713	C0055363	Chloride Channels	aapp	19.42
29079713	C0055363	Chloride Channels	bacs	19.42
29079713	C0001480	Adenosine Triphosphate	bacs	19.26
29079713	C0001480	Adenosine Triphosphate	nnon	19.26
29079713	C0001480	Adenosine Triphosphate	phsu	19.26
29079713	C0031843	physiological aspects	phsf	13.00
29079713	C0031715	Phosphorylation	moft	12.96
29079713	C1720983	Channelopathies	dsyn	11.49
29079713	C0010674	Cystic Fibrosis	dsyn	10.06
29079713	C0026882	Mutation	genf	9.84
29079713	C0015127	Etiology aspects	ftcn	9.82
29079713	C2700640	Encode (action)	acty	5.18
29079713	C1879547	Activation action	acty	3.68
29079713	C1413365	CFTR gene	gngm	3.59
29079713	C0596611	Gene Mutation	genf	3.55
29079713	C0314627	Gene function	genf	3.55
29079713	C0314621	Operator gene	gngm	3.55
29079713	C0542341	Function	ftcn	3.53
29079713	C0700205	Function Axis	clas	3.53
29079713	C1517945	Loss	qnco	3.53
29079713	C1705273	Mathematical Operator	inpr	3.53
29079713	C1524003	Science of Etiology	cnce	3.51
29079713	C1158886	Protein phosphorylation	moft	3.50
29079713	C0041714	United States Food and Drug Administration	hcro	25.55
29079713	C0039798	therapeutic aspects	ftcn	22.47
29079713	C0009738	Congo	geoa	16.04
29079713	C3264621	ivacaftor	orch	13.14
29079713	C3264621	ivacaftor	phsu	13.14
29079713	C0205435	First (number)	qnco	5.18
29079713	C1279901	Firstly	qlco	5.18
29079713	C2741958	VX-770	orch	5.18
29079713	C0872187	high throughput screening	diap	3.81
29079713	C0439234	year	tmco	3.63
29079713	C0013227	Pharmaceutical Preparations	phsu	3.61
29079713	C1254351	Pharmacologic Substance	phsu	3.61
29079713	C0087111	Therapeutic procedure	topp	3.54
29079713	C1363945	Therapy Object (animal model)	fndg	3.54
29079713	C1947967	Call (Instruction)	ftcn	3.48
29079713	C0679006	Decision	menp	3.48
29079713	C1444637	Past	tmco	3.48
29079713	C0205540	Approved	qlco	3.42
29079713	C3811819	CFTR wt Allele	gngm	3.42
29079713	C0015272	Exhibits as Topic	inpr	17.80
29079713	C0040363	Togo	geoa	17.80
29079713	C0041260	Tryptophanase	aapp	17.80
29079713	C0041260	Tryptophanase	enzy	17.80
29079713	C0072662	pyrazole	orch	12.96
29079713	C3264621	ivacaftor	orch	12.89
29079713	C3264621	ivacaftor	phsu	12.89
29079713	C0026882	Mutation	genf	9.99
29079713	C0034234	Pyrans	orch	9.78
29079713	C0740116	+2	qnco	5.18
29079713	C0728893	+5	qnco	5.18
29079713	C3833492	2+	fndg	5.18
29079713	C2827735	2+ Score	qnco	5.18
29079713	C2981700	2+ Score, WHO	clas	5.18
29079713	C0439084	>5	qnco	5.18
29079713	C0369718	N not otherwise specified Antibody	aapp	5.18
29079713	C0369718	N not otherwise specified Antibody	imft	5.18
29079713	C0441922	N+ (tumor staging)	inpr	5.18
29079713	C1883351	To	qlco	5.18
29079713	C1547282	Show	anim	3.98
29079713	C0442758	3/5	qnco	3.78
29079713	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.68
29079713	C1705285	Mutation Abnormality	comd	3.68
29079713	C1280519	Effectiveness	qlco	3.56
29079713	C1707887	Efficacy Study	resa	3.56
29079713	C0441712	Mechanism (attribute)	ftcn	3.56
29079713	C1706376	Mechanism Component of Device	mnob	3.56
29079713	C3838680	3+ Answer to Question	fndg	3.50
29079713	C2827736	3+ Score	qnco	3.50
29079713	C2981702	3+ Score, WHO	clas	3.50
29079713	C0439086	<3 (qualifier value)	qnco	3.50
29079713	C1442467	5 Hours	tmco	3.47
29079713	C0205172	More	ftcn	3.47
29079713	C0332185	Recent	tmco	3.47
29079713	C0205250	High	qlco	3.43
29079713	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
29079713	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
29079713	C1280519	Effectiveness	qlco	5.18
29079713	C1707887	Efficacy Study	resa	5.18
29079713	C0243095	Finding	fndg	5.18
29079713	C2741958	VX-770	orch	5.18
29079713	C3245505	potential	qlco	3.72
29079713	C1705241	Delta (difference)	qnco	3.54
29079713	C1705242	Different	qlco	3.54
29079713	C1413365	CFTR gene	gngm	3.42
29079713	C2348205	Similarity	qlco	3.42
29079713	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
29079713	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
29079713	C0087136	Unmarried	fndg	22.34
29079713	C0037179	Unmarried person	popg	22.34
29079713	C0022702	Kinetics	npop	9.73
29079713	C0237876	Sharing (Social Behavior)	socb	5.18
29079713	C1280500	Effect	qlco	3.54
29079713	C1883559	Wild Type	gngm	3.43
29079713	C1413365	CFTR gene	gngm	3.42
29079713	C0439799	Channel	spco	3.42
29079713	C1706095	Channel Object	cnce	3.42
29079713	C2825046	Kinetics (discipline)	ocdi	3.42
29079713	C2348205	Similarity	qlco	3.42
29079713	C0205171	Singular	qnco	3.42
29079713	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
29079713	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
29079713	C0376525	Dimerization	npop	9.86
29079713	C1510699	ATP Hydrolysis	moft	5.18
29079713	C0441472	Clinical action	ftcn	5.18
29079713	C0587267	Closed	ftcn	5.18
29079713	C2587213	Control function	ftcn	5.18
29079713	C2239193	Controlling (action)	phpr	5.18
29079713	C1261552	Step (specific stage)	cnce	3.68
29079713	C3814463	Step Unit of Distance	qnco	3.68
29079713	C0175566	Open	spco	3.63
29079713	C1882151	Opening	spco	3.63
29079713	C0332291	Independent of	ftcn	3.58
29079713	C1148916	nucleotide binding	moft	3.58
29079713	C3541951	Concept model domain	inpr	3.55
29079713	C1880389	Domain (area of knowledge)	ftcn	3.55
29079713	C1883221	Superkingdom (taxonomic category)	cnce	3.55
29079713	C1511545	Critical	qlco	3.50
29079713	C1413365	CFTR gene	gngm	3.48
29079713	C0001480	Adenosine Triphosphate	bacs	19.58
29079713	C0001480	Adenosine Triphosphate	nnon	19.58
29079713	C0001480	Adenosine Triphosphate	phsu	19.58
29079713	C0034760	Reagents	irda	13.09
29079713	C2744579	ATP8A2 protein, human	aapp	12.92
29079713	C2744579	ATP8A2 protein, human	enzy	12.92
29079713	C0069851	oxytocin, 1-desamino-(O-Et-Tyr)(2)-	aapp	12.92
29079713	C0043227	Work	ocac	8.34
29079713	C0205145	Site	spco	7.16
29079713	C0205448	Two	qnco	7.07
29079713	C3887511	Evidence	idcn	5.18
29079713	C0332148	Probable diagnosis	qlco	5.18
29079713	C0750492	Probably	idcn	5.18
29079713	C1999230	Providing (action)	acty	5.18
29079713	C2741958	VX-770	orch	5.18
29079713	C4048755	Apply	ftcn	3.98
29079713	C1879355	Apply (instruction)	ftcn	3.98
29079713	C1632850	apply - action	ftcn	3.98
29079713	C1515974	Anatomic Site	blor	3.56
29079713	C1705242	Different	qlco	3.56
29079713	C0445247	Same	qlco	3.56
29079713	C2825164	Study Site	spco	3.56
29079713	C0740116	+2	qnco	3.50
29079713	C3833492	2+	fndg	3.50
29079713	C2827735	2+ Score	qnco	3.50
29079713	C2981700	2+ Score, WHO	clas	3.50
29079713	C1883357	Together	qlco	3.48
29079713	C1299351	Abnormally high	qlco	3.45
29079713	C1510827	Affinity	npop	3.45
29079713	C0243071	Analog	chvs	3.45
29079713	C0205250	High	qlco	3.45
29079713	C3889660	High Mitosis-Karyorrhexis Index	qnco	3.45
29079713	C2700149	Value Above Reference Range	inpr	3.45
29079713	C3887512	high - ActExposureLevelCode	idcn	3.45
29079713	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
29079713	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
29079713	C0033204	Probability	qnco	16.04
29079713	C1301808	Geographic state	geoa	10.62
29079713	C1442792	State	ftcn	10.62
29079713	C3148680	US State	geoa	10.62
29079713	C1510827	Affinity	npop	7.15
29079713	C1167622	Binding (Molecular Function)	moft	7.14
29079713	C1145667	Binding action	acty	7.14
29079713	C1701901	Conditional	qlco	7.00
29079713	C0851827	Dependent - ability	qlco	7.00
29079713	C3244310	dependent	ftcn	7.00
29079713	C0175566	Open	spco	6.89
29079713	C1413365	CFTR gene	gngm	5.18
29079713	C0243095	Finding	fndg	5.18
29079713	C1705535	suggestion	idcn	3.98
29079713	C0587267	Closed	ftcn	3.68
29079713	C0443264	Modulated	spco	3.68
29079713	C0332290	Consistent with	idcn	3.61
29079713	C0678749	drug binding	phsf	3.57
29079713	C0205250	High	qlco	3.55
29079713	C1290955	drug dependent	fndg	3.44
29079713	C0441712	Mechanism (attribute)	ftcn	3.43
29079713	C1706376	Mechanism Component of Device	mnob	3.43
29079713	C0750489	apparent	idcn	3.43
29079713	C0439658	classic behavior	qlco	3.43
29079713	C0439858	classical example	qlco	3.43
29079713	C0439799	Channel	spco	3.42
29079713	C1706095	Channel Object	cnce	3.42
29079713	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
29079713	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
29079713	C0040363	Togo	geoa	17.80
29079713	C0041260	Tryptophanase	aapp	17.80
29079713	C0041260	Tryptophanase	enzy	17.80
29079713	C1883351	To	qlco	5.18
29079713	C2825142	Experimental Result	fndg	3.98
29079713	C1167622	Binding (Molecular Function)	moft	3.68
29079713	C1145667	Binding action	acty	3.68
29079713	C0220865	kinetic characteristics	ftcn	3.63
29079713	C1948027	Couple (action)	ftcn	3.55
29079713	C3853906	Digital Model Attachment	inpr	3.46
29079713	C0205450	Four	qnco	3.46
29079713	C1301808	Geographic state	geoa	3.46
29079713	C3161035	Model	inpr	3.46
29079713	C3714583	Model - style/design	cnce	3.46
29079713	C3274659	Model Number	inpr	3.46
29079713	C0205352	Simple	qlco	3.46
29079713	C1442792	State	ftcn	3.46
29079713	C3148680	US State	geoa	3.46
29079713	C1413365	CFTR gene	gngm	3.43
29079713	C3842459	Energetic	fndg	3.43
25584290	C0282686	Respiratory System Agents	phsu	14.64
25584290	C0021289	Infant, Newborn	aggp	12.89
25584290	C0010674	Cystic Fibrosis	dsyn	10.06
25584290	C0025345	Menstruation Disturbances	patf	9.75
25584290	C0012634	Disease	dsyn	9.74
25584290	C0700597	Adulthood	tmco	5.18
25584290	C0392760	Affecting	ftcn	5.18
25584290	C1269561	Entire respiratory system	bdsy	5.18
25584290	C1314939	Involvement with	ftcn	5.18
25584290	C3541375	RESPIRATORY SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS	irda	5.18
25584290	C0035237	Respiratory System	bdsy	5.18
25584290	C0425442	Respiratory System Finding	fndg	5.18
25584290	C0449450	Presentation	idcn	3.55
25584290	C0935562	neonatal period	tmco	3.45
25584290	C2939425	Neonatal (qualifier value)	tmco	3.43
25584290	C2239178	Newborn (finding)	fndg	3.43
25584290	C0017362	Genes, Regulator	gngm	19.42
25584290	C0009738	Congo	geoa	16.08
25584290	C0026882	Mutation	genf	9.90
25584290	C0015127	Etiology aspects	ftcn	9.86
25584290	C1705285	Mutation Abnormality	comd	3.59
25584290	C1524003	Science of Etiology	cnce	3.55
25584290	C3811819	CFTR wt Allele	gngm	3.46
25584290	C2752508	fully spanning the plasma membrane	celc	3.46
25584290	C1167322	integral to membrane	celc	3.46
25584290	C0026882	Mutation	genf	9.94
25584290	C0205397	seen	qlco	5.18
25584290	C1705285	Mutation Abnormality	comd	3.63
25584290	C0205214	Common (qualifier value)	qnco	3.48
25584290	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.48
25584290	C0205393	Most	qnco	3.48
25584290	C1522138	shared attribute	ftcn	3.48
25584290	C0003237	Antibiotics, Antitubercular	antb	24.11
25584290	C0039798	therapeutic aspects	ftcn	22.36
25584290	C0006280	Bronchodilator Agents	phsu	19.20
25584290	C0003232	Antibiotics	antb	17.80
25584290	C0003209	Anti-Inflammatory Agents	phsu	14.64
25584290	C0006736	Calculi	bdsu	9.87
25584290	C0376636	Disease Management	hlca	9.87
25584290	C1515999	Anti-inflammatory effect	qlco	5.18
25584290	C3540706	Antibiotic throat preparations	antb	5.18
25584290	C3540707	Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	antb	5.18
25584290	C3540704	Antibiotics for systemic use	antb	5.18
25584290	C3540708	Antibiotics, Gynecological	antb	5.18
25584290	C3540710	Antibiotics, ophthalmologic	antb	5.18
25584290	C3540705	Antifungal Antibiotics, Topical	antb	5.18
25584290	C3540709	antibiotics, intestinal	antb	5.18
25584290	C0026698	mucolytic agents	phsu	5.18
25584290	C0001554	Administration occupational activities	ocac	3.56
25584290	C1879655	Corner Minus	lbpr	3.56
25584290	C1879656	Corner Plus	lbpr	3.56
25584290	C3273539	Management Occupations	ocdi	3.56
25584290	C1273870	Management procedure	ocac	3.56
25584290	C1521721	Supportive assistance	cnce	3.43
25584290	C0087111	Therapeutic procedure	topp	3.43
25584290	C1363945	Therapy Object (animal model)	fndg	3.43
25584290	C0041714	United States Food and Drug Administration	hcro	25.63
25584290	C0026882	Mutation	genf	19.84
25584290	C0206243	Carrying	acty	14.64
25584290	C3264621	ivacaftor	orch	14.64
25584290	C3264621	ivacaftor	phsu	14.64
25584290	C0030705	Patients	podg	8.34
25584290	C1705285	Mutation Abnormality	comd	7.14
25584290	C0013227	Pharmaceutical Preparations	phsu	3.61
25584290	C1254351	Pharmacologic Substance	phsu	3.61
25584290	C1552740	Entity Determiner - specific	inpr	3.47
25584290	C0205369	Specific qualifier value	qlco	3.47
25584290	C0205540	Approved	qlco	3.43
25584290	C3829466	January	qlco	3.43
25584290	C0332185	Recent	tmco	3.43
25584290	C1998602	Meal (occasion for eating)	dora	19.40
25584290	C0026410	Mongolia	geoa	12.88
25584290	C0030705	Patients	podg	6.74
25584290	C0439234	year	tmco	3.68
25584290	C0205540	Approved	qlco	3.59
25584290	C0580836	Old	tmco	3.51
25584290	C0205452	Six	qnco	3.50
25584290	C2700400	Contain (action)	acty	3.48
25584290	C0332256	Containing (qualifier)	ftcn	3.48
25584290	C1708004	FAT wt Allele	gngm	3.48
25584290	C0424612	Obese build	orga	3.48
25584290	C0585361	Twice a day	tmco	3.44
25584290	C2348070	Daily Dose	qnco	3.43
25584290	C2346927	Magnesium Cation	elii	3.42
25584290	C2346927	Magnesium Cation	phsu	3.42
25584290	C1960952	Milligram percent	qnco	3.42
25584290	C0086960	Schedule (document type)	inpr	3.42
25584290	C1948050	Twice (Numerical Qualifier)	qnco	3.42
25584290	C1720725	Twice - dosing instruction fragment	inpr	3.42
25584290	C0439269	mg/dL	qnco	3.42
25584290	C0178602	Dosage	qnco	3.40
25584290	C1114758	Dose number:Number:Point in time:^Patient:Quantitative	clna	3.40
25584290	C0869039	Unit dose	qnco	3.40
25584290	C0043094	Weight Gain	fndg	27.26
25584290	C0012634	Disease	dsyn	9.75
25584290	C0035245	Respiratory physiology	ortf	8.34
25584290	C0184511	Improved	qlco	5.18
25584290	C0332257	Including (qualifier)	ftcn	5.18
25584290	C2911647	Weight Gain Adverse Event	fndg	5.18
25584290	C1879746	Aspect (characteristic)	qlco	3.54
25584290	C1547011	Aspect - Kind of quantity	qnco	3.54
25584290	C0012833	Dizziness	sosy	17.80
25584290	C0018681	Headache	sosy	17.80
25584290	C0042571	Vertigo	sosy	17.80
25584290	C0011991	Diarrhea	sosy	14.64
25584290	C0036588	Self	idcn	13.14
25584290	C0015230	Exanthema	sosy	11.49
25584290	C0001688	aspects of adverse effects	ftcn	9.88
25584290	C0041912	Upper Respiratory Infections	dsyn	9.77
25584290	C1963091	Diarrhea Adverse Event	fndg	5.18
25584290	C1963093	Dizziness Adverse Event	fndg	5.18
25584290	C2945599	Mild (qualifier value)	qlco	5.18
25584290	C0221512	Stomach ache	sosy	5.18
25584290	C0235309	Upset stomach	sosy	5.18
25584290	C0439801	Limited (extensiveness)	ftcn	3.68
25584290	C1551994	subscriber - self	inpr	3.68
25584290	C0879626	Adverse effects	patf	3.58
25584290	C0085104	Drug Delivery Systems	medd	19.58
25584290	C0013227	Pharmaceutical Preparations	phsu	6.88
25584290	C0030705	Patients	podg	6.71
25584290	C0025118	Medicine	bmod	6.57
25584290	C0087111	Therapeutic procedure	topp	5.18
25584290	C1522326	Treating	ftcn	5.18
25584290	C1292734	Treatment intent	ftcn	5.18
25584290	C1707959	Example	cnce	3.54
25584290	C1552740	Entity Determiner - specific	inpr	3.43
25584290	C0314603	Genetic	ftcn	3.43
25584290	C1998591	Makeup	mnob	3.43
25584290	C0205369	Specific qualifier value	qlco	3.43
25584290	C0017296	gene therapy	topp	3.43
25584290	C1961136	Excellent (qualifier value)	qlco	3.42
25584290	C1548784	Excellent - Specimen Quality	qlco	3.42
25584290	C1254351	Pharmacologic Substance	phsu	3.42
25584290	C1555307	promise	idcn	3.42
28611235	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.41
28611235	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.41
28611235	C0055363	Chloride Channels	aapp	19.36
28611235	C0055363	Chloride Channels	bacs	19.36
28611235	C0031843	physiological aspects	phsf	13.01
28611235	C0010674	Cystic Fibrosis	dsyn	9.88
28611235	C0678941	Gene Mutant	gngm	3.56
28611235	C0596611	Gene Mutation	genf	3.56
28611235	C2825142	Experimental Result	fndg	3.55
28611235	C0542341	Function	ftcn	3.55
28611235	C0700205	Function Axis	clas	3.55
28611235	C0221099	Impaired	ftcn	3.55
28611235	C1705273	Mathematical Operator	inpr	3.55
28611235	C1274040	Result	ftcn	3.55
28611235	C1546471	What subject filter - Result	idcn	3.55
28611235	C1413365	CFTR gene	gngm	3.48
28611235	C0444930	End	spco	3.42
28611235	C0205319	Manifest	ftcn	3.42
28611235	C1280464	Manifestation of	qlco	3.42
28611235	C0439064	Numerous	qnco	3.42
28611235	C0178784	Organ	bpoc	3.42
28611235	C2746065	Stop (qualifier value)	tmco	3.42
28611235	C0015259	Exercise	dora	19.33
28611235	C0009738	Congo	geoa	16.05
28611235	C3264621	ivacaftor	orch	12.90
28611235	C3264621	ivacaftor	phsu	12.90
28611235	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	5.18
28611235	C0439673	Unknown	qlco	5.18
28611235	C1280500	Effect	qlco	3.57
28611235	C2348382	Effect, Appearance	qlco	3.57
28611235	C1516240	Capacity	qnco	3.56
28611235	C1522704	Exercise Pain Management	topp	3.56
28611235	C3811819	CFTR wt Allele	gngm	3.43
28611235	C0087136	Unmarried	fndg	22.48
28611235	C0037179	Unmarried person	popg	22.48
28611235	C0013072	Double-Blind Method	resa	17.80
28611235	C0150097	Cross-Over Studies	resa	16.21
28611235	C0009738	Congo	geoa	16.08
28611235	C3264621	ivacaftor	orch	12.89
28611235	C3264621	ivacaftor	phsu	12.89
28611235	C0030705	Patients	podg	6.76
28611235	C1706408	Placebo Control	resa	5.18
28611235	C3810851	Center of town	fndg	3.56
28611235	C0205099	Central	spco	3.56
28611235	C0205171	Singular	qnco	3.56
28611235	C3811819	CFTR wt Allele	gngm	3.46
28611235	C0724000	Twenties	aggp	3.46
28611235	C3715212	Twenty	qnco	3.46
28611235	C0332173	Daily	tmco	3.43
28611235	C0439228	day	tmco	3.43
28611235	C0439505	per day	tmco	3.43
28611235	C2959886	Cardiopulmonary Exercise Test	diap	32.78
28611235	C0005893	Body mass index procedure	diap	20.95
28611235	C0684010	Rabbi	prog	13.14
28611235	C0168634	BaseLine dental cement	bodm	12.89
28611235	C0012634	Disease	dsyn	9.73
28611235	C0035245	Respiratory physiology	ortf	8.34
28611235	C0439828	Variable (uniformity)	qlco	7.32
28611235	C0030055	Oxygen Consumption	clna	6.91
28611235	C0018684	Health	idcn	6.83
28611235	C0079809	Measures	qnco	6.58
28611235	C1305855	Body mass index	clna	5.18
28611235	C0428295	Cystic fibrosis sweat test	lbpr	5.18
28611235	C0444706	Measured	qlco	5.18
28611235	C3541902	Measured Tumor Identification	diap	5.18
28611235	C2347946	Relevance	qlco	5.18
28611235	C1304760	Sweat chloride level result	lbtr	5.18
28611235	C1305742	Oxygen consumption measurement	diap	3.75
28611235	C2603358	R prime	clna	3.68
28611235	C1274040	Result	ftcn	3.68
28611235	C0205090	Right	spco	3.68
28611235	C0518906	health & life quality	inpr	3.63
28611235	C0443172	Changed status	qnco	3.56
28611235	C0392747	Changing	ftcn	3.56
28611235	C1705241	Delta (difference)	qnco	3.56
28611235	C0205225	Primary	qlco	3.50
28611235	C0439631	Primary operation	topp	3.50
28611235	C0439612	True primary (qualifier value)	tmco	3.50
28611235	C4049713	Borg Category-Ratio 10 Perceived Exertion Score 10	inpr	3.48
28611235	C0205289	Maximal (qualifier value)	qlco	3.48
28611235	C0806909	Maximum	qnco	3.48
28611235	C0205463	Physiological	ftcn	3.46
28611235	C1549488	Amount type - Percentage	idcn	3.43
28611235	C1442488	Baseline	qnco	3.43
28611235	C0332257	Including (qualifier)	ftcn	3.43
28611235	C1561533	Money or percentage indicator - Percentage	idcn	3.43
28611235	C0439165	Percent (qualifier value)	qnco	3.43
28611235	C1552740	Entity Determiner - specific	inpr	3.42
28611235	C1879489	Measures (attribute)	ftcn	3.42
28611235	C0445223	Related personal status	fndg	3.42
28611235	C0439849	Relationships	qlco	3.42
28611235	C0205369	Specific qualifier value	qlco	3.42
28611235	C0042491	Environmental air flow	phpr	13.14
28611235	C0035203	Respiration	phsf	13.14
28611235	C0032042	Placebos	topp	6.74
28611235	C2346711	About The Same	qlco	5.18
28611235	C0442739	No status change	fndg	5.18
28611235	C2945579	Ventilation, function (observable entity)	phsf	3.68
28611235	C1707455	Comparison	acty	3.59
28611235	C1706408	Placebo Control	resa	3.59
28611235	C1696465	placebo	bodm	3.59
28611235	C0040223	Time	tmco	6.83
28611235	C2347634	Population Mean	qnco	3.68
28611235	C2348143	Sample Mean	qnco	3.68
28611235	C0444504	Statistical mean	qnco	3.68
28611235	C3541383	Time (foundation metadata concept)	tmco	3.68
28611235	C0008107	Chile	geoa	13.14
28611235	C3842591	0%	fndg	3.68
28611235	C3259781	Coagulation Index Measurement	lbpr	3.68
28611235	C3816745	1+	fndg	5.18
28611235	C2827734	1+ Score	qnco	5.18
28611235	C2981698	1+ Score, WHO	clas	5.18
28611235	C3842591	0%	fndg	3.68
28611235	C0369773	P Blood group antibodies	aapp	3.68
28611235	C0369773	P Blood group antibodies	imft	3.68
28611235	C2603361	P prime	clna	3.68
28611235	C0442805	Increase	ftcn	5.18
28611235	C0205217	Increased	qnco	5.18
28611235	C3542016	Concept model range (foundation metadata concept)	inpr	3.68
28611235	C1514721	Range	qnco	3.68
28611235	C2348147	Sample Range	qnco	3.68
28611235	C0382778	U-18	orch	13.24
28611235	C0382778	U-18	phsu	13.24
28611235	C0023376	Lesotho	geoa	16.30
28611235	C3816745	1+	fndg	5.18
28611235	C2827734	1+ Score	qnco	5.18
28611235	C2981698	1+ Score, WHO	clas	5.18
28611235	C3887647	Lymphotoxin-Alpha, human	aapp	3.68
28611235	C3887647	Lymphotoxin-Alpha, human	imft	3.68
28611235	C0230426	Structure of left thigh	bpoc	3.68
28611235	C3842591	0%	fndg	3.50
28611235	C0369773	P Blood group antibodies	aapp	3.50
28611235	C0369773	P Blood group antibodies	imft	3.50
28611235	C2603361	P prime	clna	3.50
28611235	C3842591	0%	fndg	3.68
28611235	C3542016	Concept model range (foundation metadata concept)	inpr	3.68
28611235	C1514721	Range	qnco	3.68
28611235	C2348147	Sample Range	qnco	3.68
28611235	C0428295	Cystic fibrosis sweat test	lbpr	5.18
28611235	C0205216	Decreased	qnco	5.18
28611235	C0442797	Decreasing	qlco	5.18
28611235	C0392756	Reduced	qlco	5.18
28611235	C1304760	Sweat chloride level result	lbtr	5.18
28611235	C2347634	Population Mean	qnco	3.68
28611235	C2348143	Sample Mean	qnco	3.68
28611235	C0444504	Statistical mean	qnco	3.68
28611235	C3842591	0%	fndg	3.48
28611235	C0369773	P Blood group antibodies	aapp	3.48
28611235	C0369773	P Blood group antibodies	imft	3.48
28611235	C2603361	P prime	clna	3.48
28611235	C0450382	55	inpr	3.68
28611235	C3542016	Concept model range (foundation metadata concept)	inpr	3.68
28611235	C1514721	Range	qnco	3.68
28611235	C2348147	Sample Range	qnco	3.68
28611235	C0382778	U-18	orch	13.24
28611235	C0382778	U-18	phsu	13.24
28611235	C0023376	Lesotho	geoa	16.30
28611235	C3816745	1+	fndg	5.18
28611235	C2827734	1+ Score	qnco	5.18
28611235	C2981698	1+ Score, WHO	clas	5.18
28611235	C3887647	Lymphotoxin-Alpha, human	aapp	3.68
28611235	C3887647	Lymphotoxin-Alpha, human	imft	3.68
28611235	C0230426	Structure of left thigh	bpoc	3.68
28611235	C2985216	Unit per Millimole	qnco	3.51
28611235	C3842591	0%	fndg	3.50
28611235	C0369773	P Blood group antibodies	aapp	3.50
28611235	C0369773	P Blood group antibodies	imft	3.50
28611235	C2603361	P prime	clna	3.50
28611235	C0684010	Rabbi	prog	12.89
28611235	C0442805	Increase	ftcn	5.18
28611235	C0205217	Increased	qnco	5.18
28611235	C0439175	% of total	qnco	3.68
28611235	C0439810	Total	qlco	3.68
28611235	C3541951	Concept model domain	inpr	3.52
28611235	C1880389	Domain (area of knowledge)	ftcn	3.52
28611235	C1883221	Superkingdom (taxonomic category)	cnce	3.52
28611235	C1561536	*Activity (kind of quantity)	idcn	3.42
28611235	C0205177	Active	ftcn	3.42
28611235	C0441655	Activities	acty	3.42
28611235	C3668946	Activity (animal life circumstance)	fndg	3.42
28611235	C1705938	Base - General Qualifier	idcn	3.42
28611235	C1527178	Basis - conceptual entity	ftcn	3.42
28611235	C4049939	FDA Establishment Activity Terminology	inpr	3.42
28611235	C0439167	Percent Activity	qnco	3.42
28611235	C4049938	Physical Activity Measurement	lbpr	3.42
28611235	C2603358	R prime	clna	3.42
28611235	C0205090	Right	spco	3.42
28611235	C0860888	Tomography, Spiral Computed	diap	27.26
28611235	C0009738	Congo	geoa	16.08
28611235	C0037981	Spirometry	diap	16.04
28611235	C1848934	SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME	dsyn	14.64
28611235	C0079809	Measures	qnco	6.77
28611235	C0439175	% of total	qnco	5.18
28611235	C1561536	*Activity (kind of quantity)	idcn	5.18
28611235	C0205177	Active	ftcn	5.18
28611235	C0441655	Activities	acty	5.18
28611235	C3668946	Activity (animal life circumstance)	fndg	5.18
28611235	C1705938	Base - General Qualifier	idcn	5.18
28611235	C1527178	Basis - conceptual entity	ftcn	5.18
28611235	C0205216	Decreased	qnco	5.18
28611235	C0442797	Decreasing	qlco	5.18
28611235	C1517001	Expected	inpr	5.18
28611235	C4049939	FDA Establishment Activity Terminology	inpr	5.18
28611235	C0442805	Increase	ftcn	5.18
28611235	C0205217	Increased	qnco	5.18
28611235	C0439167	Percent Activity	qnco	5.18
28611235	C4049938	Physical Activity Measurement	lbpr	5.18
28611235	C0392756	Reduced	qlco	5.18
28611235	C1419875	SCT gene	gngm	5.18
28611235	C0439810	Total	qlco	5.18
28611235	C1879489	Measures (attribute)	ftcn	3.61
28611235	C1518681	Outcome of Therapy	fndg	3.59
28611235	C3811819	CFTR wt Allele	gngm	3.47
28611235	C1552740	Entity Determiner - specific	inpr	3.47
28611235	C0518214	Perceived quality of life	sosy	3.47
28611235	C0205369	Specific qualifier value	qlco	3.47
28611235	C1446409	Positive	qlco	3.43
28611235	C2825490	Positive Charge	qlco	3.43
28611235	C1514241	Positive Finding	fndg	3.43
28611235	C3812269	Positive Number	cnce	3.43
28611235	C0439178	percent positive cells	qnco	3.43
28611235	C0015259	Exercise	dora	19.32
28611235	C0009247	Cohort Studies	qnco	19.21
28611235	C0037981	Spirometry	diap	16.05
28611235	C0042469	Venezuela	geoa	13.02
28611235	C3264621	ivacaftor	orch	12.88
28611235	C3264621	ivacaftor	phsu	12.88
28611235	C0035245	Respiratory physiology	ortf	6.91
28611235	C0443172	Changed status	qnco	6.90
28611235	C0392747	Changing	ftcn	6.90
28611235	C0332257	Including (qualifier)	ftcn	5.18
28611235	C1518422	Negation	ftcn	5.18
28611235	C1705535	suggestion	idcn	5.18
28611235	C0449381	Observation parameter	fndg	3.68
28611235	C1831738	exercise intervention	topp	3.56
28611235	C1705366	Driver Device Component	mnob	3.56
28611235	C0684312	Drivers of Vehicles	popg	3.56
28611235	C0332268	Lacking	qlco	3.56
28611235	C1556026	Other Service Providers - Driver	prog	3.56
28611235	C3714652	Ventricular Premature Complex by ECG Finding	fndg	3.56
28611235	C1516240	Capacity	qnco	3.55
28611235	C1522704	Exercise Pain Management	topp	3.55
28611235	C0439511	times/day	qnco	3.53
28611235	C1705241	Delta (difference)	qnco	3.43
28611235	C0205396	Identified	qlco	3.43
28611235	C2986411	Improvement	cnce	3.43
28611235	C1446409	Positive	qlco	3.43
28611235	C2825490	Positive Charge	qlco	3.43
28611235	C1514241	Positive Finding	fndg	3.43
28611235	C3812269	Positive Number	cnce	3.43
28611235	C0230463	Sole of Foot	blor	3.43
28611235	C0439178	percent positive cells	qnco	3.43
28611235	C0183441	Spirometer (device)	medd	3.43
28611235	C1705202	Spirometer Device Component	mnob	3.43
28611235	C0220825	Evaluation	hlca	13.01
28611235	C0040223	Time	tmco	8.34
28611235	C3541383	Time (foundation metadata concept)	tmco	5.18
28611235	C1552578	Act Class - investigation	inpr	3.55
28611235	C1261322	Evaluation procedure	hlca	3.55
28611235	C0680215	psychosocial interdependence	socb	3.52
28611235	C1441672	Observed	ftcn	3.42
28611235	C1948053	Period (temporal qualifier)	tmco	3.42
28611235	C0439590	Prolonged	tmco	3.42
28611235	C0439531	per period (qualifier value)	tmco	3.42
28611235	C3245505	potential	qlco	3.42
28611235	C3639994	Discordant	cnce	3.38
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.58
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.58
23924900	C0010674	Cystic Fibrosis	dsyn	10.06
23924900	C1413365	CFTR gene	gngm	7.51
23924900	C0019247	Hereditary Diseases	dsyn	6.91
23924900	C0033684	Proteins	aapp	6.75
23924900	C0033684	Proteins	bacs	6.75
23924900	C0024109	Lung	bpoc	6.70
23924900	C0332281	Associated with	qlco	3.58
23924900	C0458827	Airway structure	bpoc	3.55
23924900	C0178987	Artificial Airways	medd	3.55
23924900	C1278908	Entire lung	bpoc	3.55
23924900	C1321013	Hydration status	fndg	3.55
23924900	C1517945	Loss	qnco	3.55
23924900	C0819757	Structure of parenchyma of lung	tisu	3.55
23924900	C0332452	defective	ftcn	3.55
23924900	C1705232	Death Related to Adverse Event	fndg	3.48
23924900	C1302234	Fatal	qlco	3.48
23924900	C0678226	Due to	ftcn	3.44
23924900	C1159591	chloride transport	celf	3.44
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
23924900	C3541951	Concept model domain	inpr	10.99
23924900	C1880389	Domain (area of knowledge)	ftcn	10.99
23924900	C1883221	Superkingdom (taxonomic category)	cnce	10.99
23924900	C0205448	Two	qnco	6.97
23924900	C0596901	Membrane	celc	6.77
23924900	C0025255	Tissue membrane	tisu	6.77
23924900	C1705415	Communication Contact	idcn	5.18
23924900	C0332158	Contact with	ftcn	5.18
23924900	C4036459	Contacts	hlca	5.18
23924900	C2700400	Contain (action)	acty	5.18
23924900	C0332256	Containing (qualifier)	ftcn	5.18
23924900	C3812666	Personal Contact	acty	5.18
23924900	C0337611	contact person	popg	5.18
23924900	C1706853	Assembly (construction)	acty	3.68
23924900	C1879748	Assembly (group of parts)	mnob	3.68
23924900	C1413365	CFTR gene	gngm	3.68
23924900	C1704735	Regulator	cnce	3.68
23924900	C1148916	nucleotide binding	moft	3.68
23924900	C0220905	regulatory	rnlw	3.68
23924900	C1706182	Membrane Device Component	mnob	3.61
23924900	C1711300	Span - parameter	cnce	3.58
23924900	C2700613	Span Distance	qnco	3.58
23924900	C0439799	Channel	spco	3.50
23924900	C1706095	Channel Object	cnce	3.50
23924900	C0439064	Numerous	qnco	3.50
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
23924900	C0009738	Congo	geoa	16.08
23924900	C0151526	Premature Birth	fndg	16.05
23924900	C0026882	Mutation	genf	9.91
23924900	C0699900	Catabolism	orgf	6.71
23924900	C1705285	Mutation Abnormality	comd	3.60
23924900	C2825142	Experimental Result	fndg	3.59
23924900	C1709305	Occur (action)	acty	3.59
23924900	C2745955	Occurrence	tmco	3.59
23924900	C1274040	Result	ftcn	3.59
23924900	C1546471	What subject filter - Result	idcn	3.59
23924900	C0243125	degradation aspects	ftcn	3.56
23924900	C3811819	CFTR wt Allele	gngm	3.46
23924900	C0678227	Causing	ftcn	3.46
23924900	C0205214	Common (qualifier value)	qnco	3.46
23924900	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.46
23924900	C0205393	Most	qnco	3.46
23924900	C1522138	shared attribute	ftcn	3.46
23924900	C1413365	CFTR gene	gngm	3.43
23924900	C0205252	Immature	qlco	3.43
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.19
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.19
23924900	C0031843	physiological aspects	phsf	13.03
23924900	C1413365	CFTR gene	gngm	10.51
23924900	C0019904	Homozygote	orga	9.88
23924900	C3252847	VX 809	orch	3.75
23924900	C3252847	VX 809	phsu	3.75
23924900	C0542341	Function	ftcn	3.57
23924900	C0700205	Function Axis	clas	3.57
23924900	C1705273	Mathematical Operator	inpr	3.57
23924900	C1517586	Investigational	qlco	3.48
23924900	C3245491	investigational monitoring program	hlca	3.48
23924900	C0027361	Persons	popg	3.44
23924900	C0040363	Togo	geoa	35.81
23924900	C0041260	Tryptophanase	aapp	35.81
23924900	C0041260	Tryptophanase	enzy	35.81
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
23924900	C0009738	Congo	geoa	17.80
23924900	C1524059	mechanism of action qualifier	ftcn	13.09
23924900	C1883351	To	qlco	10.42
23924900	C0031327	Drug Kinetics	phsf	9.93
23924900	C3811819	CFTR wt Allele	gngm	5.18
23924900	C0205340	Repaired	ftcn	5.18
23924900	C0087111	Therapeutic procedure	topp	5.18
23924900	C1522326	Treating	ftcn	5.18
23924900	C1292734	Treatment intent	ftcn	5.18
23924900	C1457869	Defect	ftcn	3.68
23924900	C1413365	CFTR gene	gngm	3.57
23924900	C2603362	S prime	clna	3.57
23924900	C0565930	per second	qnco	3.57
23924900	C0185026	Plication	topp	3.50
23924900	C3252847	VX 809	orch	3.45
23924900	C3252847	VX 809	phsu	3.45
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.97
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.97
23924900	C0599155	Missense Mutation	genf	13.10
23924900	C0031843	physiological aspects	phsf	13.02
23924900	C0376315	Manufactured form	mnob	8.34
23924900	C1413365	CFTR gene	gngm	6.90
23924900	C2700400	Contain (action)	acty	5.18
23924900	C0332256	Containing (qualifier)	ftcn	5.18
23924900	C1522492	Formation	ftcn	5.18
23924900	C0348078	Qualitative form	qlco	5.18
23924900	C0184512	Stabilized (qualifier value)	qlco	5.18
23924900	C3252847	VX 809	orch	3.75
23924900	C3252847	VX 809	phsu	3.75
23924900	C0542341	Function	ftcn	3.56
23924900	C0700205	Function Axis	clas	3.56
23924900	C1705273	Mathematical Operator	inpr	3.56
23924900	C3541951	Concept model domain	inpr	3.55
23924900	C1880389	Domain (area of knowledge)	ftcn	3.55
23924900	C0205088	End-stage	qlco	3.55
23924900	C1883221	Superkingdom (taxonomic category)	cnce	3.55
23924900	C1705315	Terminal (end postition)	spco	3.55
23924900	C1705314	Terminal Device Component	mnob	3.55
23924900	C1720467	Only - dosing instruction fragment	inpr	3.50
23924900	C0205171	Singular	qnco	3.50
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
23924900	C0040363	Togo	geoa	17.80
23924900	C0041260	Tryptophanase	aapp	17.80
23924900	C0041260	Tryptophanase	enzy	17.80
23924900	C0700364	Appearance	qlco	5.18
23924900	C1260953	Suppressed	ftcn	5.18
23924900	C1883351	To	qlco	5.18
23924900	C3541951	Concept model domain	inpr	3.63
23924900	C1880389	Domain (area of knowledge)	ftcn	3.63
23924900	C1883221	Superkingdom (taxonomic category)	cnce	3.63
23924900	C3266814	Action	acty	3.56
23924900	C0441472	Clinical action	ftcn	3.56
23924900	C0243067	defects aspect	ftcn	3.56
23924900	C1704675	Interaction	ftcn	3.52
23924900	C3252847	VX 809	orch	3.46
23924900	C3252847	VX 809	phsu	3.46
23924900	C1413365	CFTR gene	gngm	3.43
23924900	C0185026	Plication	topp	3.43
23924900	C2349975	Enhance (action)	acty	3.41
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.56
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.56
23924900	C0085732	Ability	orga	13.02
23924900	C0026882	Mutation	genf	9.90
23924900	C2349975	Enhance (action)	acty	5.18
23924900	C1413365	CFTR gene	gngm	3.63
23924900	C0205195	Combined	qlco	3.59
23924900	C1704675	Interaction	ftcn	3.56
23924900	C2349182	Correct (qualifier)	qlco	3.48
23924900	C3252847	VX 809	orch	3.46
23924900	C3252847	VX 809	phsu	3.46
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.32
23924900	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.32
23924900	C0031843	physiological aspects	phsf	13.03
23924900	C1413365	CFTR gene	gngm	10.64
23924900	C1511726	Data	idcn	5.18
23924900	C3714741	Data (eukaryote)	euka	5.18
23924900	C3245479	Data call receiving device	medd	5.18
23924900	C2349975	Enhance (action)	acty	5.18
23924900	C1517331	Further	spco	5.18
23924900	C1260953	Suppressed	ftcn	5.18
23924900	C1705535	suggestion	idcn	5.18
23924900	C1524063	Use of	ftcn	3.61
23924900	C0542341	Function	ftcn	3.57
23924900	C0700205	Function Axis	clas	3.57
23924900	C1705273	Mathematical Operator	inpr	3.57
23924900	C0243067	defects aspect	ftcn	3.56
23924900	C0205195	Combined	qlco	3.55
23924900	C3811910	combination - answer to question	fndg	3.55
23924900	C1947911	combination of objects	phob	3.55
23924900	C3252847	VX 809	orch	3.46
23924900	C3252847	VX 809	phsu	3.46
23924900	C0027361	Persons	popg	3.44
23924900	C0522506	Downstream	spco	3.43
23924900	C0185026	Plication	topp	3.43
23924900	C1524062	Additional	ftcn	3.42
28602538	C0282461	Phase 3 Clinical Trials	resa	22.49
28602538	C0268575	Isovaleryl-CoA dehydrogenase deficiency	dsyn	12.88
28602538	C0025353	mental health	menp	9.95
28602538	C1518422	Negation	ftcn	5.18
28602538	C0557651	Room of building - Study	mnob	3.68
28602538	C2603343	Study	resa	3.68
28602538	C0587720	Mental health counselor	prog	3.64
28602538	C0879626	Adverse effects	patf	3.59
28602538	C1546960	Patient Outcome - Worsening	idcn	3.57
28602538	C1457868	Worse	fndg	3.57
28602538	C0332271	Worsening pattern	qlco	3.57
28602538	C0205214	Common (qualifier value)	qnco	3.55
28602538	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.55
28602538	C0684224	Report (document)	inpr	3.55
28602538	C0700287	Reporting	hlca	3.55
28602538	C1522138	shared attribute	ftcn	3.55
28602538	C0231448	Extension	ftcn	3.50
28602538	C1880641	Telephone Extension Number	cnce	3.50
28602538	C1054142	Iva <Plant>	plnt	3.42
28602538	C1416936	LUM gene	gngm	3.42
28602538	C0011570	Mental Depression	mobd	14.64
28602538	C0011581	Depressive disorder	mobd	11.49
28602538	C0042153	utilization qualifier	ftcn	9.88
28602538	C0001588	Adolescents, Female	aggp	9.76
28602538	C0003467	Anxiety	mobd	9.75
28602538	C0205653	Adolescent (age group)	aggp	9.74
28602538	C0003469	Anxiety Disorders	mobd	6.59
28602538	C0030705	Patients	podg	6.58
28602538	C0344315	Depressed mood	fndg	5.18
28602538	C4049644	Depression Scale (BASC-2)	inpr	5.18
28602538	C0460137	Depression motion	ftcn	5.18
28602538	C1705535	suggestion	idcn	5.18
28602538	C0332281	Associated with	qlco	3.64
28602538	C1546960	Patient Outcome - Worsening	idcn	3.57
28602538	C0457083	Usage	ftcn	3.57
28602538	C1947944	Use - dosing instruction imperative	inpr	3.57
28602538	C1457868	Worse	fndg	3.57
28602538	C0332271	Worsening pattern	qlco	3.57
28602538	C0868928	Case (situation)	ftcn	3.55
28602538	C1533148	Case unit dose	qnco	3.55
28602538	C0150905	patient is female	orga	3.45
28602538	C4050613	Anxiety Scale (BASC-2)	inpr	3.44
28602538	C0205451	Five	qnco	3.43
28602538	C0424000	Feeling suicidal (finding)	fndg	20.95
28602538	C0038663	Suicide attempt	fndg	19.45
28602538	C0030705	Patients	podg	6.83
28602538	C0205448	Two	qnco	5.18
28602538	C0596545	Experience	menp	3.98
28602538	C0237607	Practice Experience	menp	3.98
28602538	C0748061	psychiatric hospitalization	mobd	3.62
28602538	C2825142	Experimental Result	fndg	3.54
28602538	C1274040	Result	ftcn	3.54
28602538	C1546471	What subject filter - Result	idcn	3.54
28602538	C0205451	Five	qnco	3.50
28602538	C0205449	Three	qnco	3.47
28602538	C1881534	Make - Instruction Imperative	ftcn	3.44
25727661	C0040363	Togo	geoa	17.80
25727661	C0041260	Tryptophanase	aapp	17.80
25727661	C0041260	Tryptophanase	enzy	17.80
25727661	C0017337	Genes	gngm	16.04
25727661	C0020792	Identification (Psychology)	menp	12.88
25727661	C0010674	Cystic Fibrosis	dsyn	9.74
25727661	C0030705	Patients	podg	6.74
25727661	C0439659	Beginning	tmco	5.18
25727661	C1880355	Discover	acty	5.18
25727661	C1883351	To	qlco	5.18
25727661	C0814225	benefit	qnco	3.59
25727661	C0439234	year	tmco	3.54
25727661	C3715062	Twenty Five	qnco	3.43
25727661	C0205396	Identified	qlco	3.42
25727661	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
25727661	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
25727661	C0040363	Togo	geoa	17.80
25727661	C0041260	Tryptophanase	aapp	17.80
25727661	C0041260	Tryptophanase	enzy	17.80
25727661	C0005532	biology (field)	bmod	9.74
25727661	C1881534	Make - Instruction Imperative	ftcn	7.04
25727661	C0376554	Knowledge	inpr	6.71
25727661	C0578671	Does move	fndg	5.18
25727661	C0439780	Forward	spco	5.18
25727661	C0442808	Increasing	ftcn	5.18
25727661	C1269909	Moved from	ftcn	5.18
25727661	C1299988	Moved to	ftcn	5.18
25727661	C0560560	Moving	orgf	5.18
25727661	C2699029	Relocation of home or business	acty	5.18
25727661	C1883351	To	qlco	5.18
25727661	C1705117	Increment	qnco	3.68
25727661	C1280477	Progress	ftcn	3.68
25727661	C2825408	Stair (equipment)	mnob	3.68
25727661	C1261552	Step (specific stage)	cnce	3.68
25727661	C3814463	Step Unit of Distance	qnco	3.68
25727661	C1704379	Treatment Step	ftcn	3.68
25727661	C1272688	status - In progress	ftcn	3.68
25727661	C1718097	New medications	phsu	3.64
25727661	C0679199	strategy	menp	3.63
25727661	C1705178	Order (action)	acty	3.59
25727661	C1705176	Order (arrangement)	qlco	3.59
25727661	C1705175	Order (document)	inpr	3.59
25727661	C1705177	Order (taxonomic)	clas	3.59
25727661	C1882348	Permutation	qlco	3.59
25727661	C3889825	Sequence of Planned Assessment Schedule	inpr	3.59
25727661	C1705053	Screen Device Component	mnob	3.57
25727661	C1305399	Screening - procedure intent	ftcn	3.57
25727661	C0220908	Screening procedure	hlca	3.57
25727661	C3898777	Important	qlco	3.50
25727661	C0449851	Techniques	ftcn	3.50
25727661	C0302350	Therapeutic	ftcn	3.48
25727661	C0087111	Therapeutic procedure	topp	3.48
25727661	C1413365	CFTR gene	gngm	3.43
25727661	C0009738	Congo	geoa	16.05
25727661	C0030705	Patients	podg	6.59
25727661	C1704243	Greater	qnco	5.18
25727661	C0549177	Large	qnco	5.18
25727661	C0332148	Probable diagnosis	qlco	5.18
25727661	C0750492	Probably	idcn	5.18
25727661	C0470187	Availability of	ftcn	3.57
25727661	C0441833	Groups	idcn	3.57
25727661	C1999270	Laboratory Order Panels	inpr	3.57
25727661	C3537156	Panel Device Component	mnob	3.57
25727661	C0439234	year	tmco	3.56
25727661	C0205314	New	qlco	3.50
25727661	C3811819	CFTR wt Allele	gngm	3.44
25727661	C0567416	Molecule	sbst	3.44
25727661	C0175860	Natural History	ocdi	13.07
25727661	C0012634	Disease	dsyn	9.88
25727661	C0443172	Changed status	qnco	3.56
25727661	C0392747	Changing	ftcn	3.56
25727661	C1705241	Delta (difference)	qnco	3.56
25727661	C0036572	Seizures	sosy	17.80
25727661	C0040363	Togo	geoa	17.80
25727661	C0041260	Tryptophanase	aapp	17.80
25727661	C0041260	Tryptophanase	enzy	17.80
25727661	C0009738	Congo	geoa	16.30
25727661	C2718059	Precision Medicine	topp	12.90
25727661	C4042916	Genetic Background	orga	6.60
25727661	C2349186	Fit (action)	acty	5.18
25727661	C1883351	To	qlco	5.18
25727661	C2948600	Aim	phsu	3.98
25727661	C1947946	Aim (idea)	idcn	3.98
25727661	C3540472	Ancestry-Informative Marker	ftcn	3.98
25727661	C3890193	CD5L wt Allele	gngm	3.98
25727661	C2744535	CD69 protein, human	aapp	3.98
25727661	C2744535	CD69 protein, human	imft	3.98
25727661	C3540471	CD69 wt Allele	gngm	3.98
25727661	C3811819	CFTR wt Allele	gngm	3.68
25727661	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.58
25727661	C3242455	HL7PublishingDomain <patient administration>	inpr	3.58
25727661	C3242279	healthcare operations <patient administration>	ocac	3.58
25727661	C1707959	Example	cnce	3.54
25727661	C0680240	agreement	socb	3.43
25727661	C1947967	Call (Instruction)	ftcn	3.40
25727661	C0679006	Decision	menp	3.40
25727661	C0008976	Clinical Trials	resa	19.45
25727661	C0009738	Congo	geoa	16.05
25727661	C3264621	ivacaftor	orch	12.89
25727661	C3264621	ivacaftor	phsu	12.89
25727661	C1096775	Clinical Trial [Publication Type]	inpr	9.99
25727661	C0439801	Limited (extensiveness)	ftcn	5.18
25727661	C4050251	Limited Lifting Ability	inpr	5.18
25727661	C2674459	Limited Walking Ability	fndg	5.18
25727661	C3542948	Limited component (foundation metadata concept)	inpr	5.18
25727661	C2360800	Number of patients	fndg	3.65
25727661	C1718097	New medications	phsu	3.59
25727661	C0549178	Continuous	idcn	3.47
25727661	C3811819	CFTR wt Allele	gngm	3.43
25727661	C1548635	eligible	idcn	3.43
25727661	C0087111	Therapeutic procedure	topp	7.05
25727661	C0205447	One	qnco	5.18
25727661	C0549255	Excitation	acty	3.98
25727661	C0449445	Approach	spco	3.61
25727661	C0231220	Symptomatic	ftcn	3.55
25727661	C0205314	New	qlco	3.47
25727661	C0302350	Therapeutic	ftcn	3.47
25727661	C1555307	promise	idcn	3.44
25727661	C1518422	Negation	ftcn	3.42
25727661	C1719958	Push - dosing instruction imperative	ftcn	3.42
25727661	C0441987	Side	spco	3.42
25727661	C0008976	Clinical Trials	resa	20.95
25727661	C0004048	Inspiration function	orgf	19.33
25727661	C0040363	Togo	geoa	17.80
25727661	C0041260	Tryptophanase	aapp	17.80
25727661	C0041260	Tryptophanase	enzy	17.80
25727661	C0085732	Ability	orga	13.10
25727661	C0003209	Anti-Inflammatory Agents	phsu	13.07
25727661	C1096775	Clinical Trial [Publication Type]	inpr	11.49
25727661	C0026727	Mucous body substance	bdsu	11.49
25727661	C0376558	Life	idcn	9.99
25727661	C0030705	Patients	podg	6.66
25727661	C1546714	Specimen Source Codes - Mucus	inpr	5.18
25727661	C1883351	To	qlco	5.18
25727661	C1524063	Use of	ftcn	5.18
25727661	C2753459	mucus layer	bdsu	5.18
25727661	C2948600	Aim	phsu	3.98
25727661	C1947946	Aim (idea)	idcn	3.98
25727661	C3540472	Ancestry-Informative Marker	ftcn	3.98
25727661	C3890193	CD5L wt Allele	gngm	3.98
25727661	C2744535	CD69 protein, human	aapp	3.98
25727661	C2744535	CD69 protein, human	imft	3.98
25727661	C3540471	CD69 wt Allele	gngm	3.98
25727661	C0567416	Molecule	sbst	3.68
25727661	C1299581	Able (finding)	fndg	3.64
25727661	C2986411	Improvement	cnce	3.63
25727661	C1515999	Anti-inflammatory effect	qlco	3.61
25727661	C0199779	Administration of antibiotic	topp	3.60
25727661	C1292721	Has property	ftcn	3.56
25727661	C0871161	Property (attribute)	qlco	3.56
25727661	C1881534	Make - Instruction Imperative	ftcn	3.53
25727661	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.50
25727661	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.50
25727661	C0205314	New	qlco	3.50
25727661	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.50
25727661	C0009738	Congo	geoa	32.29
25727661	C0040363	Togo	geoa	17.80
25727661	C0041260	Tryptophanase	aapp	17.80
25727661	C0041260	Tryptophanase	enzy	17.80
25727661	C0021270	Infant	aggp	9.74
25727661	C0004927	Behavior	inbe	8.34
25727661	C3811819	CFTR wt Allele	gngm	6.90
25727661	C2983265	CDISC SEND Study Design Terminology	inpr	5.18
25727661	C1707689	Design	acty	5.18
25727661	C1883351	To	qlco	5.18
25727661	C0534010	One-Step dentin bonding system	bodm	3.68
25727661	C0534010	One-Step dentin bonding system	orch	3.68
25727661	C0814861	prevention trial	resa	3.59
25727661	C1947933	care activity	acty	3.57
25727661	C0205117	Adjacent	spco	3.46
25727661	C0332282	Following	tmco	3.46
25727661	C3898777	Important	qlco	3.46
25727661	C1883708	Then	tmco	3.46
25727661	C1279919	Early	tmco	3.43
25727661	C0027617	Neonatal Screening	diap	25.58
25727661	C3484370	Programs	ftcn	9.92
25727661	C0542341	Function	ftcn	5.18
25727661	C0205245	Functional	ftcn	5.18
25727661	C2700217	Functional Relationship	cnce	5.18
25727661	C1709305	Occur (action)	acty	5.18
25727661	C0557651	Room of building - Study	mnob	5.18
25727661	C0749075	STRUCTURAL Abnormalities	fndg	5.18
25727661	C0947630	Scientific Study	lbpr	5.18
25727661	C2603343	Study	resa	5.18
25727661	C0439816	Tightness sensation quality	qlco	5.18
25727661	C0453911	Tights	mnob	5.18
25727661	C0599755	cohort	popg	5.18
25727661	C1881534	Make - Instruction Imperative	ftcn	3.98
25727661	C1547282	Show	anim	3.98
25727661	C1279919	Early	tmco	3.68
25727661	C0442824	Very	qlco	3.68
25727661	C2984081	Very Much	qlco	3.68
25727661	C2728259	Program	phsu	3.61
25727661	C1709697	Program - framework of goals	cnce	3.61
25727661	C0678793	therapeutic index	qnco	3.61
25727661	C2828363	Implanted Medical Device (finding)	fndg	3.57
25727661	C0021102	Implants	medd	3.57
25727661	C1705313	Term (lexical)	idcn	3.57
22914736	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
22914736	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
22914736	C0013232	Drugs, Orphan	phsu	17.80
22914736	C3264621	ivacaftor	orch	14.64
22914736	C3264621	ivacaftor	phsu	14.64
22914736	C0026882	Mutation	genf	9.94
22914736	C0010674	Cystic Fibrosis	dsyn	9.88
22914736	C0392760	Affecting	ftcn	5.18
22914736	C0205540	Approved	qlco	5.18
22914736	C1314939	Involvement with	ftcn	5.18
22914736	C0332185	Recent	tmco	5.18
22914736	C1705285	Mutation Abnormality	comd	3.63
22914736	C1521840	Target	ftcn	3.57
22914736	C2986546	Target Lesion Identification	diap	3.57
22914736	C1720467	Only - dosing instruction fragment	inpr	3.54
22914736	C0205171	Singular	qnco	3.54
22914736	C1413365	CFTR gene	gngm	3.48
22914736	C0009738	Congo	geoa	16.04
22914736	C0376636	Disease Management	hlca	9.73
22914736	C1555307	promise	idcn	3.55
22914736	C3495919	Enthesitis-Related Arthritis	dsyn	3.54
22914736	C0087111	Therapeutic procedure	topp	3.42
22914736	C0001554	Administration occupational activities	ocac	3.42
22914736	C3811819	CFTR wt Allele	gngm	3.42
22914736	C3273539	Management Occupations	ocdi	3.42
22914736	C1273870	Management procedure	ocac	3.42
22914736	C0205314	New	qlco	3.42
22914736	C1706050	Guide Device Component	mnob	3.40
22914736	C0302614	Guide device	medd	3.40
22914736	C0181090	Professional guide	prog	3.40
22914736	C0282461	Phase 3 Clinical Trials	resa	24.11
22914736	C0016529	Forced expiratory volume function	ortf	19.25
22914736	C0004268	Attention	menp	13.03
22914736	C0168634	BaseLine dental cement	bodm	12.90
22914736	C0024109	Lung	bpoc	6.59
22914736	C3816745	1+	fndg	5.18
22914736	C2827734	1+ Score	qnco	5.18
22914736	C2981698	1+ Score, WHO	clas	5.18
22914736	C2983587	Average Body Weight Gain	fndg	5.18
22914736	C1561566	FEV1 Adverse Event	fndg	3.64
22914736	C0429706	Forced expiratory volume in 1 second finding	fndg	3.64
22914736	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.64
22914736	C1446561	Concentration measurement	qnco	3.57
22914736	C0086045	Mental concentration	menp	3.57
22914736	C0301630	Reduction (chemical)	npop	3.57
22914736	C0441610	Reduction - action	topp	3.57
22914736	C2986411	Improvement	cnce	3.52
22914736	C0428295	Cystic fibrosis sweat test	lbpr	3.48
22914736	C1306036	Forced expiratory volume procedure	diap	3.48
22914736	C1304760	Sweat chloride level result	lbtr	3.48
22914736	C1442488	Baseline	qnco	3.44
22914736	C2709248	Pulmonary (qualifier value)	qlco	3.44
22914736	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.44
22914736	C1546944	Event Seriousness - Significant	qlco	3.43
22914736	C0750502	Significant	idcn	3.43
22914736	C0237881	Statistical Significance	qnco	3.43
22914736	C0202311	Aluminum measurement	lbpr	3.68
22914736	C0009738	Congo	geoa	17.80
22914736	C0026882	Mutation	genf	9.99
22914736	C0030705	Patients	podg	6.59
22914736	C3811819	CFTR wt Allele	gngm	5.18
22914736	C1705285	Mutation Abnormality	comd	3.68
22914736	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.61
22914736	C1414400	EXOG gene	gngm	3.68
22914736	C0013232	Drugs, Orphan	phsu	16.10
22914736	C3264621	ivacaftor	orch	13.14
22914736	C3264621	ivacaftor	phsu	13.14
22914736	C0026882	Mutation	genf	9.77
22914736	C0013216	Pharmacotherapy	topp	6.80
22914736	C0242299	Orphan child	popg	6.61
22914736	C0205540	Approved	qlco	5.18
22914736	C0205314	New	qlco	5.18
22914736	C0332185	Recent	tmco	5.18
22914736	C0679622	literary novel	inpr	5.18
22914736	C0087111	Therapeutic procedure	topp	3.60
22914736	C0441835	Group A	clas	3.60
22914736	C0814225	benefit	qnco	3.54
22914736	C1705285	Mutation Abnormality	comd	3.46
22914736	C1706050	Guide Device Component	mnob	3.44
22914736	C0302614	Guide device	medd	3.44
22914736	C0181090	Professional guide	prog	3.44
22914736	C3699655	Disease category	qnco	3.43
22914736	C1272684	Accepted	qlco	3.42
22914736	C0205210	Clinical	qlco	3.42
22914736	C0443211	Established	qlco	3.42
22914736	C1553058	Neuropsychologist - Clinical	prog	3.42
22914736	C0237412	Psychologist - Clinical	prog	3.42
22914736	C0497591	Social Worker - Clinical	prog	3.42
22914736	C1880198	Cure (remedy)	cnce	5.18
22914736	C1518422	Negation	ftcn	5.18
22914736	C0079613	Adoptive Immunotherapy	topp	27.26
22914736	C0040363	Togo	geoa	17.80
22914736	C0041260	Tryptophanase	aapp	17.80
22914736	C0041260	Tryptophanase	enzy	17.80
22914736	C0023376	Lesotho	geoa	16.07
22914736	C0013232	Drugs, Orphan	phsu	16.06
22914736	C0920627	Orphan Diseases	dsyn	14.64
22914736	C1869853	SERPINA3 protein, human	aapp	14.64
22914736	C1869853	SERPINA3 protein, human	bacs	14.64
22914736	C1257890	Population Group	popg	9.90
22914736	C0031336	Pharmacy (field)	bmod	6.83
22914736	C0030705	Patients	podg	6.79
22914736	C0032659	geographic population	qnco	6.74
22914736	C0392760	Affecting	ftcn	5.18
22914736	C4048375	Asthma Control Test Questionnaire	inpr	5.18
22914736	C1314939	Involvement with	ftcn	5.18
22914736	C3890007	SERPINA3 wt Allele	gngm	5.18
22914736	C1883351	To	qlco	5.18
22914736	C0683757	Company (organization)	mnob	3.68
22914736	C0683757	Company (organization)	orgt	3.68
22914736	C1135440	Procedures involving the use of pharmaceuticals	topp	3.68
22914736	C3687832	DRUGS	topp	3.57
22914736	C0205172	More	ftcn	3.57
22914736	C0013227	Pharmaceutical Preparations	phsu	3.57
22914736	C0814225	benefit	qnco	3.55
22914736	C3887647	Lymphotoxin-Alpha, human	aapp	3.45
22914736	C3887647	Lymphotoxin-Alpha, human	imft	3.45
22914736	C0230426	Structure of left thigh	bpoc	3.45
22914736	C0233324	Term Birth	orgf	22.33
22914736	C3850123	Clinical Effectiveness	qlco	19.34
22914736	C0162326	DNA Sequence	nusq	16.05
22914736	C0015316	Expenditures	qnco	14.64
22914736	C0036849	Set (Psychology)	menp	14.64
22914736	C0549178	Continuous	idcn	5.18
22914736	C3687832	DRUGS	topp	5.18
22914736	C0013227	Pharmaceutical Preparations	phsu	5.18
22914736	C1442518	Set scale	ftcn	5.18
22914736	C1705195	set (group)	cnce	5.18
22914736	C1521798	trend	tmco	5.18
22914736	C1882265	Practice-Based Research Collaborative in Evidence-Based Dentistry	hcro	3.54
22914736	C0150600	Advice	hlca	3.42
22914736	C1706089	Marked	qlco	3.42
22914736	C0522501	Massive	qlco	3.42
22914736	C1959633	Spatial guidance for medical procedure	topp	3.42
22914736	C3854153	guidance - Measure Attribute	clna	3.42
22914736	C0332181	Annual	tmco	3.42
22914736	C0010186	Financial cost	qnco	3.42
22914736	C2826302	Reported Term	inpr	3.40
22914736	C1705313	Term (lexical)	idcn	3.40
22914736	C1515273	Term (temporal)	tmco	3.40
22914736	C0009738	Congo	geoa	16.05
22914736	C0887950	Genomics	bmod	16.05
22914736	C3264621	ivacaftor	orch	12.89
22914736	C3264621	ivacaftor	phsu	12.89
22914736	C0030351	Paper	mnob	11.49
22914736	C0031847	physiopathological	ftcn	9.87
22914736	C0017428	Genome	gngm	9.74
22914736	C0012634	Disease	dsyn	9.74
22914736	C0080045	Prices	qnco	8.34
22914736	C3163633	Elevated	qlco	5.18
22914736	C0205250	High	qlco	5.18
22914736	C1547566	Paper Authorization	idcn	5.18
22914736	C3714763	Point	spco	5.18
22914736	C2347617	Point Name	qnco	5.18
22914736	C1999230	Providing (action)	acty	5.18
22914736	C1552961	point - UnitsOfMeasure	qnco	5.18
22914736	C0277785	Functional disorder	patf	3.56
22914736	C0087111	Therapeutic procedure	topp	3.56
22914736	C0814225	benefit	qnco	3.55
22914736	C3811819	CFTR wt Allele	gngm	3.43
28546419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
28546419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
28546419	C0162340	Comprehension	menp	14.64
28546419	C1524059	mechanism of action qualifier	ftcn	13.08
28546419	C0031327	Drug Kinetics	phsf	9.92
28546419	C1413365	CFTR gene	gngm	5.18
28546419	C0233820	Insight	menp	3.54
28546419	C3893721	molecular function regulator	moft	3.44
28546419	C2698650	Optimization	acty	3.43
28546419	C0723712	Therapeutic brand of coal tar	orch	3.43
28546419	C0723712	Therapeutic brand of coal tar	phsu	3.43
28546419	C0087111	Therapeutic procedure	topp	3.43
28546419	C1709060	Modulator Device Component	mnob	3.42
28546419	C0441712	Mechanism (attribute)	ftcn	3.42
28546419	C0205198	Compound	qlco	3.40
28546419	C1706082	Compound (substance)	chem	3.40
28546419	C1706701	Acquisition (action)	acty	3.40
28546419	C1301820	Obtain	ftcn	3.40
28546419	C0086418	Homo sapiens	humn	28.65
28546419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28546419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28546419	C1148916	nucleotide binding	moft	3.56
28546419	C1167622	Binding (Molecular Function)	moft	3.55
28546419	C1145667	Binding action	acty	3.55
28546419	C3541951	Concept model domain	inpr	3.54
28546419	C1880389	Domain (area of knowledge)	ftcn	3.54
28546419	C1883221	Superkingdom (taxonomic category)	cnce	3.54
28546419	C3252847	VX 809	orch	3.45
28546419	C3252847	VX 809	phsu	3.45
28546419	C1947931	Direct (qualifier)	qlco	3.43
28546419	C0439851	Direct type of relationship	qlco	3.43
28546419	C1413365	CFTR gene	gngm	3.42
28546419	C0205435	First (number)	qnco	3.42
28546419	C1279901	Firstly	qlco	3.42
28546419	C0018882	Helix (Snails)	euka	45.68
28546419	C0024485	Magnetic Resonance Imaging	diap	16.16
28546419	C0028580	Nuclear Magnetic Resonance	npop	13.01
28546419	C1017315	Helice	euka	7.61
28546419	C0229304	Helix of ear	bpoc	7.61
28546419	C1705682	Molecular helix	anst	7.61
28546419	C1704821	Protein Helix	spco	7.61
28546419	C1704972	Genomic Orientation	spco	5.18
28546419	C3810647	L1CAM wt Allele	gngm	5.18
28546419	C1704973	Nucleic Acid Strand	nnon	5.18
28546419	C1419029	PSMD11 gene	gngm	5.18
28546419	C1419033	PSMD3 gene	gngm	5.18
28546419	C1419037	PSMD6 gene	gngm	5.18
28546419	C1419699	RPS10 gene	gngm	5.18
28546419	C1335643	RPS3 gene	gngm	5.18
28546419	C1419753	RPS9 gene	gngm	5.18
28546419	C1179706	S3 (sacral segmental innervation)	blor	5.18
28546419	C1861421	SA17 gene	gngm	5.18
28546419	C3812877	Testicular Cancer Serum Markers Test Result S3	lbtr	5.18
28546419	C3272558	Chemical or Textual Reference to Actual Test or Parameter	inpr	3.57
28546419	C0220806	Chemicals	chem	3.57
28546419	C1441672	Observed	ftcn	3.57
28546419	C2347509	Physical Shift	phpr	3.57
28546419	C0333051	shift displacement	ftcn	3.57
28546419	C0332453	Disruption	ftcn	3.56
28546419	C0205148	Surface	spco	3.55
28546419	C0443172	Changed status	qnco	3.55
28546419	C0392747	Changing	ftcn	3.55
28546419	C0444669	Core	spco	3.55
28546419	C1706352	Core Device Component	medd	3.55
28546419	C3274653	Core Specimen	bdsu	3.55
28546419	C1705241	Delta (difference)	qnco	3.55
28546419	C1882467	Processor Core	mnob	3.55
28546419	C1167518	viral nucleocapsid location	celc	3.55
28546419	C1707271	Carboxy-Terminal Amino Acid	amas	3.53
28546419	C1883073	Electromagnetic Spectrum	qnco	3.52
28546419	C1709915	Residue	cnce	3.52
28546419	C1882936	Residue after Decontamination Medical Device Problem	evnt	3.52
28546419	C2827424	Spectrum	cnce	3.52
28546419	C3252847	VX 809	orch	3.44
28546419	C3252847	VX 809	phsu	3.44
28546419	C1704675	Interaction	ftcn	3.43
28546419	C1167622	Binding (Molecular Function)	moft	3.42
28546419	C1145667	Binding action	acty	3.42
28546419	C0039476	Temperature	qnco	19.38
28546419	C0040363	Togo	geoa	17.80
28546419	C0041260	Tryptophanase	aapp	17.80
28546419	C0041260	Tryptophanase	enzy	17.80
28546419	C0005903	Body Temperature	orga	16.23
28546419	C0599882	Melting	npop	16.23
28546419	C0023175	Lead	elii	13.01
28546419	C0023175	Lead	hops	13.01
28546419	C0026377	Molecular Conformation	spco	12.89
28546419	C0333051	shift displacement	ftcn	7.46
28546419	C3252847	VX 809	orch	7.03
28546419	C3252847	VX 809	phsu	7.03
28546419	C1947931	Direct (qualifier)	qlco	5.18
28546419	C0439851	Direct type of relationship	qlco	5.18
28546419	C1883351	To	qlco	5.18
28546419	C3714763	Point	spco	3.98
28546419	C2347617	Point Name	qnco	3.98
28546419	C1552961	point - UnitsOfMeasure	qnco	3.98
28546419	C0014653	Equilibrium	orgf	3.63
28546419	C1704675	Interaction	ftcn	3.63
28546419	C1547026	Kind of quantity - Equilibrium	qnco	3.63
28546419	C1167622	Binding (Molecular Function)	moft	3.56
28546419	C1145667	Binding action	acty	3.56
28546419	C3275067	Cardiac Lead Procedure	topp	3.55
28546419	C2348269	Dietary Lead	elii	3.55
28546419	C1546944	Event Seriousness - Significant	qlco	3.55
28546419	C1522538	Leading	ftcn	3.55
28546419	C0181586	Leads (device)	medd	3.55
28546419	C0205160	Negative	qlco	3.55
28546419	C3853545	Negative - answer	qlco	3.55
28546419	C2825491	Negative Charge	qlco	3.55
28546419	C1513916	Negative Finding	fndg	3.55
28546419	C2825415	Negative Number	cnce	3.55
28546419	C2347509	Physical Shift	phpr	3.55
28546419	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.55
28546419	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.55
28546419	C0750502	Significant	idcn	3.55
28546419	C0237881	Statistical Significance	qnco	3.55
28546419	C0005456	Binding Sites	rcpt	13.22
28546419	C0010101	Correlation Study	inpr	13.02
28546419	C0010101	Correlation Study	resa	13.02
28546419	C2698172	Application Program Interface	inpr	7.09
28546419	C1708533	Interface Device Component	mnob	7.09
28546419	C1167622	Binding (Molecular Function)	moft	7.06
28546419	C1145667	Binding action	acty	7.06
28546419	C1947931	Direct (qualifier)	qlco	6.94
28546419	C0439851	Direct type of relationship	qlco	6.94
28546419	C1515974	Anatomic Site	blor	5.18
28546419	C0450429	Location	spco	5.18
28546419	C0359589	Provide (product)	food	5.18
28546419	C1999230	Providing (action)	acty	5.18
28546419	C3875149	Direct site	idcn	3.78
28546419	C0682969	Ligand Binding Domain	amas	3.75
28546419	C3887511	Evidence	idcn	3.57
28546419	C3495389	Chemical analysis	lbpr	3.56
28546419	C0243074	Chemical analysis aspects	ftcn	3.56
28546419	C1689985	Absence (morphologic abnormality)	anab	3.55
28546419	C0332197	Absent	ftcn	3.55
28546419	C1280500	Effect	qlco	3.55
28546419	C3147236	ERVW-3 gene	gngm	3.50
28546419	C1948027	Couple (action)	ftcn	3.44
28546419	C1171285	Enabling	menp	3.43
28546419	C3845720	Shift change	fndg	3.42
28546419	C3272558	Chemical or Textual Reference to Actual Test or Parameter	inpr	3.42
28546419	C0220806	Chemicals	chem	3.42
28546419	C1707520	Correlation	qlco	3.42
28546419	C1548610	Inter	tmco	3.42
28546419	C0205103	Intermediate	spco	3.42
28546419	C1709915	Residue	cnce	3.42
28546419	C1882936	Residue after Decontamination Medical Device Problem	evnt	3.42
28546419	C0024485	Magnetic Resonance Imaging	diap	16.09
28546419	C0028580	Nuclear Magnetic Resonance	npop	12.94
28546419	C2744539	THBD protein, human	aapp	12.94
28546419	C2744539	THBD protein, human	bacs	12.94
28546419	C1167622	Binding (Molecular Function)	moft	7.21
28546419	C1145667	Binding action	acty	7.21
28546419	C1709908	Reported By	grup	3.72
28546419	C0202311	Aluminum measurement	lbpr	3.63
28546419	C1511726	Data	idcn	3.63
28546419	C3714741	Data (eukaryote)	euka	3.63
28546419	C3245479	Data call receiving device	medd	3.63
28546419	C0333051	shift displacement	ftcn	3.63
28546419	C2348205	Similarity	qlco	3.57
28546419	C0205160	Negative	qlco	3.48
28546419	C3853545	Negative - answer	qlco	3.48
28546419	C2825491	Negative Charge	qlco	3.48
28546419	C1513916	Negative Finding	fndg	3.48
28546419	C2825415	Negative Number	cnce	3.48
28546419	C3540468	THBD wt Allele	gngm	3.48
28546419	C0442824	Very	qlco	3.44
28546419	C2984081	Very Much	qlco	3.44
28546419	C1554184	Dual	anim	3.42
28546419	C1524059	mechanism of action qualifier	ftcn	12.91
28546419	C0031327	Drug Kinetics	phsf	9.76
28546419	C0237876	Sharing (Social Behavior)	socb	5.18
28546419	C1705535	suggestion	idcn	3.98
28546419	C0205198	Compound	qlco	3.63
28546419	C1706082	Compound (substance)	chem	3.63
28546419	C1879746	Aspect (characteristic)	qlco	3.52
28546419	C1547011	Aspect - Kind of quantity	qnco	3.52
28546419	C0205448	Two	qnco	3.50
28546419	C0035820	Social Role	socb	13.01
28546419	C0026377	Molecular Conformation	spco	13.01
28546419	C0596901	Membrane	celc	6.58
28546419	C0025255	Tissue membrane	tisu	6.58
28546419	C0443264	Modulated	spco	5.18
28546419	C1547282	Show	anim	3.98
28546419	C0947630	Scientific Study	lbpr	3.68
28546419	C0202311	Aluminum measurement	lbpr	3.63
28546419	C1705810	Generic Role	cnce	3.55
28546419	C3871154	{Role}	inpr	3.55
28546419	C1552607	Act Relationship Subset - previous	tmco	3.50
28546419	C0205156	Previous	tmco	3.50
28546419	C3252847	VX 809	orch	3.45
28546419	C3252847	VX 809	phsu	3.45
28546419	C3898777	Important	qlco	3.43
28546419	C3541951	Concept model domain	inpr	3.42
28546419	C1880389	Domain (area of knowledge)	ftcn	3.42
28546419	C0205435	First (number)	qnco	3.42
28546419	C1279901	Firstly	qlco	3.42
28546419	C1706182	Membrane Device Component	mnob	3.42
28546419	C1883221	Superkingdom (taxonomic category)	cnce	3.42
28546419	C1711300	Span - parameter	cnce	3.40
28546419	C2700613	Span Distance	qnco	3.40
28546419	C0022646	Kidney	bpoc	9.78
28546419	C0202311	Aluminum measurement	lbpr	3.63
28546419	C1427479	KCTD11 gene	gngm	3.48
28546419	C1419338	REN gene	gngm	3.48
28546419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
28546419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
28546419	C0026377	Molecular Conformation	spco	12.86
28546419	C0359589	Provide (product)	food	5.18
28546419	C1999230	Providing (action)	acty	5.18
28546419	C0233820	Insight	menp	3.57
28546419	C1513371	Mode	ftcn	3.55
28546419	C2347637	Population Mode	qnco	3.55
28546419	C2348146	Sample Mode	qnco	3.55
28546419	C1705738	Statistical Mode	qnco	3.55
28546419	C1413365	CFTR gene	gngm	3.45
28546419	C3252847	VX 809	orch	3.44
28546419	C3252847	VX 809	phsu	3.44
28546419	C3826426	Dynamics	npop	3.44
28546419	C1524062	Additional	ftcn	3.42
28546419	C1167622	Binding (Molecular Function)	moft	3.42
28546419	C1145667	Binding action	acty	3.42
25707701	C3264621	ivacaftor	orch	13.14
25707701	C3264621	ivacaftor	phsu	13.14
25707701	C0010674	Cystic Fibrosis	dsyn	11.49
25707701	C0026882	Mutation	genf	9.91
25707701	C0033684	Proteins	aapp	6.61
25707701	C0033684	Proteins	bacs	6.61
25707701	C0030705	Patients	podg	6.59
25707701	C1704689	Bearing Device Component	medd	5.18
25707701	C0184511	Improved	qlco	5.18
25707701	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.91
25707701	C1547996	Diagnostic Service Section ID - Pulmonary Function	inpr	3.61
25707701	C0231921	Pulmonary function	ortf	3.61
25707701	C3160731	Pulmonary function (finding)	fndg	3.61
25707701	C1705285	Mutation Abnormality	comd	3.60
25707701	C1704735	Regulator	cnce	3.46
25707701	C1704734	Regulator Device Component	mnob	3.46
25707701	C0182953	Regulators (device)	medd	3.46
25707701	C0205314	New	qlco	3.45
25707701	C0679622	literary novel	inpr	3.45
25707701	C0032120	Plasma Proteins	aapp	20.18
25707701	C0032120	Plasma Proteins	bacs	20.18
25707701	C0009738	Congo	geoa	16.12
25707701	C3264621	ivacaftor	orch	14.64
25707701	C3264621	ivacaftor	phsu	14.64
25707701	C3245499	Colombia	geoa	13.14
25707701	C0004268	Attention	menp	13.09
25707701	C0005456	Binding Sites	rcpt	13.03
25707701	C0036825	Serum Proteins	aapp	9.88
25707701	C0036825	Serum Proteins	bacs	9.88
25707701	C1689898	% bound (qualifier value)	qnco	5.18
25707701	C0439073	97	inpr	5.18
25707701	C0439082	>97	qnco	5.18
25707701	C1167622	Binding (Molecular Function)	moft	5.18
25707701	C1145667	Binding action	acty	5.18
25707701	C2349209	Bound (value)	cnce	5.18
25707701	C0332297	Bounded by	spco	5.18
25707701	C1435727	FABP6 protein, human	aapp	5.18
25707701	C1435727	FABP6 protein, human	bacs	5.18
25707701	C0205250	High	qlco	5.18
25707701	C1825598	IMPACT gene	gngm	5.18
25707701	C4049986	Impact	qlco	5.18
25707701	C0678756	drug concentration	qnco	3.75
25707701	C0678752	free drug	qnco	3.75
25707701	C3687832	DRUGS	topp	3.68
25707701	C1521801	Having administered	ftcn	3.68
25707701	C0013227	Pharmaceutical Preparations	phsu	3.68
25707701	C1446561	Concentration measurement	qnco	3.63
25707701	C1880497	Empty (qualifier)	qlco	3.63
25707701	C1996904	Free (available (qualifier))	qlco	3.63
25707701	C0332296	Free of (attribute)	ftcn	3.63
25707701	C0086045	Mental concentration	menp	3.63
25707701	C0332149	Possible	qlco	3.59
25707701	C2362652	Possible diagnosis	qlco	3.59
25707701	C1705910	Possibly Related to Intervention	qlco	3.59
25707701	C0445247	Same	qlco	3.54
25707701	C3811819	CFTR wt Allele	gngm	3.50
25707701	C0442821	Strong	qlco	3.50
25707701	C0023175	Lead	elii	13.03
25707701	C0023175	Lead	hops	13.03
25707701	C3264621	ivacaftor	orch	12.89
25707701	C3264621	ivacaftor	phsu	12.89
25707701	C0541749	Does turn (finding)	fndg	3.68
25707701	C1709743	Protein Turn	spco	3.68
25707701	C1274040	Result	ftcn	3.63
25707701	C3275067	Cardiac Lead Procedure	topp	3.57
25707701	C0443172	Changed status	qnco	3.57
25707701	C0392747	Changing	ftcn	3.57
25707701	C2348269	Dietary Lead	elii	3.57
25707701	C1522538	Leading	ftcn	3.57
25707701	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.57
25707701	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.57
25707701	C1280519	Effectiveness	qlco	3.55
25707701	C1707887	Efficacy Study	resa	3.55
25707701	C0302350	Therapeutic	ftcn	3.50
25707701	C0087111	Therapeutic procedure	topp	3.50
25707701	C1515655	in vivo	spco	3.44
25707701	C0016352	Fluorometry	lbpr	16.05
25707701	C0009738	Congo	geoa	16.04
25707701	C0597731	Surface Plasmon Resonance	mbrt	14.64
25707701	C3245499	Colombia	geoa	13.14
25707701	C3264621	ivacaftor	orch	12.89
25707701	C3264621	ivacaftor	phsu	12.89
25707701	C0017968	Glycoproteins	aapp	9.94
25707701	C0017968	Glycoproteins	bacs	9.94
25707701	C0012725	Psychologic Displacement	menp	9.86
25707701	C0036576	Genetic Selection	genf	9.69
25707701	C0079809	Measures	qnco	8.34
25707701	C1167622	Binding (Molecular Function)	moft	6.95
25707701	C1145667	Binding action	acty	6.95
25707701	C0001128	Acids	chem	6.79
25707701	C0005507	Biological Assay	lbpr	6.75
25707701	C1707455	Comparison	acty	5.18
25707701	C0242485	Measurement	ftcn	5.18
25707701	C1524063	Use of	ftcn	5.18
25707701	C0205474	Biochemical	ftcn	3.68
25707701	C1521801	Having administered	ftcn	3.68
25707701	C0557651	Room of building - Study	mnob	3.68
25707701	C2603343	Study	resa	3.68
25707701	C0202406	Lysergic acid diethylamide measurement	lbpr	3.63
25707701	C1510438	Assay	lbpr	3.59
25707701	C0243073	assay qualifier	qlco	3.59
25707701	C1510827	Affinity	npop	3.56
25707701	C3687832	DRUGS	topp	3.55
25707701	C0013227	Pharmaceutical Preparations	phsu	3.55
25707701	C2347509	Physical Shift	phpr	3.55
25707701	C0456080	Qualitative Displacement	qlco	3.55
25707701	C0012727	Spatial Displacement	spco	3.55
25707701	C0304925	Albumin Human, USP	aapp	3.48
25707701	C0304925	Albumin Human, USP	phsu	3.48
25707701	C3537198	Human Serum Albumin [EPC]	phsu	3.48
25707701	C0449996	Probe location	spco	3.46
25707701	C3811819	CFTR wt Allele	gngm	3.43
25707701	C1707391	Choose (action)	acty	3.38
25707701	C0012093	Dicloxacillin	antb	30.42
25707701	C0012093	Dicloxacillin	orch	30.42
25707701	C0065180	Loratadine	orch	30.42
25707701	C0065180	Loratadine	phsu	30.42
25707701	C3264621	ivacaftor	orch	26.05
25707701	C3264621	ivacaftor	phsu	26.05
25707701	C0029297	Orosomucoid	aapp	20.95
25707701	C0029297	Orosomucoid	bacs	20.95
25707701	C0020740	Ibuprofen	orch	17.80
25707701	C0020740	Ibuprofen	phsu	17.80
25707701	C0028978	Omeprazole	orch	17.80
25707701	C0028978	Omeprazole	phsu	17.80
25707701	C0040363	Togo	geoa	17.80
25707701	C0041260	Tryptophanase	aapp	17.80
25707701	C0041260	Tryptophanase	enzy	17.80
25707701	C0298130	montelukast	orch	14.64
25707701	C0298130	montelukast	phsu	14.64
25707701	C0687133	Drug Interactions	moft	13.13
25707701	C0005456	Binding Sites	rcpt	13.05
25707701	C0085732	Ability	orga	13.02
25707701	C1883351	To	qlco	5.18
25707701	C1517001	Expected	inpr	3.59
25707701	C0332285	Within	spco	3.43
25707701	C0233324	Term Birth	orgf	22.44
25707701	C3494273	Molecular Docking Simulation	mbrt	13.08
25707701	C0687133	Drug Interactions	moft	12.91
25707701	C0032120	Plasma Proteins	aapp	9.74
25707701	C0032120	Plasma Proteins	bacs	9.74
25707701	C0036825	Serum Proteins	aapp	9.74
25707701	C0036825	Serum Proteins	bacs	9.74
25707701	C1285553	Interprets	ftcn	3.55
25707701	C0750502	Significant	idcn	3.54
25707701	C0237881	Statistical Significance	qnco	3.54
25707701	C2826302	Reported Term	inpr	3.52
25707701	C1705313	Term (lexical)	idcn	3.52
25707701	C1515273	Term (temporal)	tmco	3.52
25707701	C0009738	Congo	geoa	16.12
25707701	C3245499	Colombia	geoa	13.14
25707701	C0687133	Drug Interactions	moft	12.90
25707701	C3264621	ivacaftor	orch	12.88
25707701	C3264621	ivacaftor	phsu	12.88
25707701	C0032120	Plasma Proteins	aapp	9.74
25707701	C0032120	Plasma Proteins	bacs	9.74
25707701	C0036825	Serum Proteins	aapp	9.74
25707701	C0036825	Serum Proteins	bacs	9.74
25707701	C0359589	Provide (product)	food	5.18
25707701	C1999230	Providing (action)	acty	5.18
25707701	C0681828	in vitro study	resa	5.18
25707701	C3687832	DRUGS	topp	3.68
25707701	C1521801	Having administered	ftcn	3.68
25707701	C0013227	Pharmaceutical Preparations	phsu	3.68
25707701	C0233820	Insight	menp	3.54
25707701	C3811819	CFTR wt Allele	gngm	3.50
25707701	C0039798	therapeutic aspects	ftcn	22.61
25707701	C3850123	Clinical Effectiveness	qlco	19.41
25707701	C0008976	Clinical Trials	resa	19.23
25707701	C0040363	Togo	geoa	17.80
25707701	C0041260	Tryptophanase	aapp	17.80
25707701	C0041260	Tryptophanase	enzy	17.80
25707701	C3264621	ivacaftor	orch	12.90
25707701	C3264621	ivacaftor	phsu	12.90
25707701	C1096775	Clinical Trial [Publication Type]	inpr	9.77
25707701	C0016884	Future	tmco	6.59
25707701	C3540473	Abnormal Involuntary Movement Scale Questionnaire	inpr	5.18
25707701	C2948600	Aim	phsu	5.18
25707701	C1947946	Aim (idea)	idcn	5.18
25707701	C3540472	Ancestry-Informative Marker	ftcn	5.18
25707701	C3890193	CD5L wt Allele	gngm	5.18
25707701	C2744535	CD69 protein, human	aapp	5.18
25707701	C2744535	CD69 protein, human	imft	5.18
25707701	C3540471	CD69 wt Allele	gngm	5.18
25707701	C1511726	Data	idcn	5.18
25707701	C3714741	Data (eukaryote)	euka	5.18
25707701	C3245479	Data call receiving device	medd	5.18
25707701	C1883351	To	qlco	5.18
25707701	C0678791	effective drug concentration	qnco	3.81
25707701	C1533734	Administration procedure	topp	3.68
25707701	C1705169	Biomaterial Treatment	cnce	3.68
25707701	C0087111	Therapeutic procedure	topp	3.68
25707701	C1522326	Treating	ftcn	3.68
25707701	C3538994	Treatment Epoch	resa	3.68
25707701	C3887704	treatment - ActInformationManagementReason	hlca	3.68
25707701	C1880497	Empty (qualifier)	qlco	3.61
25707701	C1996904	Free (available (qualifier))	qlco	3.61
25707701	C0332296	Free of (attribute)	ftcn	3.61
25707701	C3827682	Useful	qlco	3.56
25707701	C0344191	Cerebellar decompression injury	dsyn	3.50
26092729	C0271093	Stargardt's disease	fndg	13.22
26092729	C0376315	Manufactured form	mnob	6.70
26092729	C1412063	ABCA4 gene	gngm	3.75
26092729	C1522492	Formation	ftcn	3.54
26092729	C0348078	Qualitative form	qlco	3.54
26092729	C4015286	MACULAR DEGENERATION, EARLY-ONSET	dsyn	3.47
26092729	C0205214	Common (qualifier value)	qnco	3.42
26092729	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
26092729	C0205393	Most	qnco	3.42
26092729	C1522138	shared attribute	ftcn	3.42
26092729	C0271093	Stargardt's disease	fndg	13.10
26092729	C0026882	Mutation	genf	9.88
26092729	C1412063	ABCA4 gene	gngm	7.08
26092729	C0332281	Associated with	qlco	3.64
26092729	C0086282	Family member	famg	3.56
26092729	C1148923	atp binding	moft	3.44
26092729	C0450240	Cassette (physical object)	medd	3.42
26092729	C1706210	Cassette Device Component	mnob	3.42
26092729	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
26092729	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
26092729	C0017337	Genes	gngm	16.25
26092729	C0242738	ATP-Binding Cassette Transporters	aapp	16.15
26092729	C0242738	ATP-Binding Cassette Transporters	bacs	16.15
26092729	C0010674	Cystic Fibrosis	dsyn	9.95
26092729	C0017446	Geographic Locations	geoa	6.97
26092729	C0205147	regional	spco	6.97
26092729	C1413365	CFTR gene	gngm	5.18
26092729	C0332128	Examined	fndg	5.18
26092729	C0332281	Associated with	qlco	3.64
26092729	C2985434	Disease-causing Mutation	comd	3.57
26092729	C1299351	Abnormally high	qlco	3.55
26092729	C0205250	High	qlco	3.55
26092729	C3889660	High Mitosis-Karyorrhexis Index	qnco	3.55
26092729	C1709305	Occur (action)	acty	3.55
26092729	C2745955	Occurrence	tmco	3.55
26092729	C2348205	Similarity	qlco	3.55
26092729	C2700149	Value Above Reference Range	inpr	3.55
26092729	C3887512	high - ActExposureLevelCode	idcn	3.55
26092729	C1412063	ABCA4 gene	gngm	3.42
26092729	C0205448	Two	qnco	3.42
26092729	C0018847	Heat Shock Protein 27	aapp	19.21
26092729	C0018847	Heat Shock Protein 27	bacs	19.21
26092729	C1547282	Show	anim	10.42
26092729	C0034378	quality control	ftcn	9.99
26092729	C0243041	Molecular Chaperones	aapp	9.73
26092729	C0243041	Molecular Chaperones	bacs	9.73
26092729	C0597561	temperature sensitive mutant	comd	3.76
26092729	C1561524	Quality Control Specimen	ftcn	3.68
26092729	C1610034	Specimen Source Codes - Quality Control	inpr	3.68
26092729	C0441712	Mechanism (attribute)	ftcn	3.61
26092729	C1706376	Mechanism Component of Device	mnob	3.61
26092729	C1704675	Interaction	ftcn	3.54
26092729	C0007634	Cells	cell	3.47
26092729	C0178539	Cellular	lbpr	3.47
26092729	C1709694	Processing (action)	acty	3.47
26092729	C1333928	HSPB1 gene	gngm	3.44
26092729	C1708296	HSPB1 wt Allele	gngm	3.44
26092729	C0442821	Strong	qlco	3.42
26092729	C1564139	Mutant Proteins	aapp	11.49
26092729	C1167059	Aggresome	celc	3.57
26092729	C1881707	Medical Device Material Degradation	phpr	3.57
26092729	C0010674	Cystic Fibrosis	dsyn	11.49
26092729	C3252847	VX 809	orch	5.18
26092729	C3252847	VX 809	phsu	5.18
26092729	C0237455	Test Administration	edac	3.65
26092729	C0205198	Compound	qlco	3.59
26092729	C1706082	Compound (substance)	chem	3.59
26092729	C1167622	Binding (Molecular Function)	moft	3.57
26092729	C1145667	Binding action	acty	3.57
26092729	C3854321	Expression (foundation metadata concept)	idcn	3.55
26092729	C0185117	Expression procedure	topp	3.55
26092729	C1709694	Processing (action)	acty	3.55
26092729	C0205314	New	qlco	3.48
26092729	C0679622	literary novel	inpr	3.48
26092729	C0699040	Cell surface	celc	3.45
26092729	C1333895	HDAC6 gene	gngm	3.44
26092729	C0969119	histone deacetylase 6	aapp	3.44
26092729	C0969119	histone deacetylase 6	enzy	3.44
26092729	C1412063	ABCA4 gene	gngm	3.43
26092729	C0596988	mutant	comd	3.43
26092729	C0039798	therapeutic aspects	ftcn	24.11
26092729	C0271093	Stargardt's disease	fndg	14.64
26092729	C1412063	ABCA4 gene	gngm	5.18
26092729	C1533734	Administration procedure	topp	5.18
26092729	C1705169	Biomaterial Treatment	cnce	5.18
26092729	C0521116	Current (present time)	tmco	5.18
26092729	C1511726	Data	idcn	5.18
26092729	C3714741	Data (eukaryote)	euka	5.18
26092729	C3245479	Data call receiving device	medd	5.18
26092729	C0087111	Therapeutic procedure	topp	5.18
26092729	C1522326	Treating	ftcn	5.18
26092729	C3538994	Treatment Epoch	resa	5.18
26092729	C3252847	VX 809	orch	5.18
26092729	C3252847	VX 809	phsu	5.18
26092729	C1705535	suggestion	idcn	5.18
26092729	C3887704	treatment - ActInformationManagementReason	hlca	5.18
26092729	C3242274	new therapy	fndg	3.61
24832698	C0039798	therapeutic aspects	ftcn	22.48
24832698	C0031268	Pet Animal	anim	16.09
24832698	C0033684	Proteins	aapp	8.34
24832698	C0033684	Proteins	bacs	8.34
24832698	C0025118	Medicine	bmod	6.79
24832698	C0335343	Companions	popg	6.63
24832698	C0870883	Metabolite	bacs	5.18
24832698	C2698672	Other Toxicity Studies: Metabolites	rnlw	5.18
24832698	C0086143	Diagnostic tests	diap	3.75
24832698	C0430022	diagnostic procedure	diap	3.75
24832698	C0013227	Pharmaceutical Preparations	phsu	3.63
24832698	C1513380	Molecular Analysis	mbrt	3.59
24832698	C1533734	Administration procedure	topp	3.56
24832698	C0449445	Approach	spco	3.56
24832698	C1705169	Biomaterial Treatment	cnce	3.56
24832698	C0205543	Referring	ftcn	3.56
24832698	C0087111	Therapeutic procedure	topp	3.56
24832698	C1522326	Treating	ftcn	3.56
24832698	C3538994	Treatment Epoch	resa	3.56
24832698	C0402883	tailor	prog	3.56
24832698	C3887704	treatment - ActInformationManagementReason	hlca	3.56
24832698	C1705938	Base - General Qualifier	idcn	3.55
24832698	C1527178	Basis - conceptual entity	ftcn	3.55
24832698	C0682323	Partner in relationship	famg	3.48
24832698	C0237401	Individual	humn	3.43
24832698	C0027361	Persons	popg	3.43
24832698	C0678236	Rare Diseases	dsyn	13.10
24832698	C0030705	Patients	podg	6.71
24832698	C3538928	Usual	qlco	5.18
24832698	C3888388	Usually	inpr	5.18
24832698	C0332183	Frequently	tmco	3.57
24832698	C4050225	Often - answer to question	inpr	3.57
24832698	C4048755	Apply	ftcn	3.55
24832698	C1879355	Apply (instruction)	ftcn	3.55
24832698	C0700321	Small	qnco	3.55
24832698	C1632850	apply - action	ftcn	3.55
24832698	C1515021	Subgroup	clas	3.52
24832698	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	48.50
24832698	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	48.50
24832698	C0010674	Cystic Fibrosis	dsyn	19.94
24832698	C3264621	ivacaftor	orch	14.64
24832698	C3264621	ivacaftor	phsu	14.64
24832698	C1413365	CFTR gene	gngm	10.42
24832698	C0030705	Patients	podg	6.58
24832698	C0369773	P Blood group antibodies	aapp	5.18
24832698	C0369773	P Blood group antibodies	imft	5.18
24832698	C2603361	P prime	clna	5.18
24832698	C1707959	Example	cnce	3.68
24832698	C2347946	Relevance	qlco	3.54
24832698	C1522427	best (quality)	qlco	3.50
24832698	C0678941	Gene Mutant	gngm	3.68
24832698	C0596611	Gene Mutation	genf	3.68
24832698	C0085123	Drug Costs	qnco	16.21
24832698	C0018696	Health Care Systems	hcro	11.49
24832698	C4036058	Too high	fndg	5.18
24832698	C1881534	Make - Instruction Imperative	ftcn	3.98
24832698	C0443252	Long-term	tmco	3.45
24832698	C0040363	Togo	geoa	35.81
24832698	C0041260	Tryptophanase	aapp	35.81
24832698	C0041260	Tryptophanase	enzy	35.81
24832698	C0025320	Menopause	phsf	19.22
24832698	C0008943	Climacteric	orgf	16.07
24832698	C0027552	Needs	qlco	14.64
24832698	C1883351	To	qlco	10.42
24832698	C0037455	Societies	orgt	9.99
24832698	C0025118	Medicine	bmod	6.83
24832698	C2700401	Deny (action)	acty	5.18
24832698	C0243095	Finding	fndg	5.18
24832698	C1881534	Make - Instruction Imperative	ftcn	5.18
24832698	C1518422	Negation	ftcn	5.18
24832698	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
24832698	C0013227	Pharmaceutical Preparations	phsu	3.68
24832698	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.56
24832698	C3242455	HL7PublishingDomain <patient administration>	inpr	3.56
24832698	C3242279	healthcare operations <patient administration>	ocac	3.56
24832698	C0814630	affordability	qnco	3.52
24832698	C1705178	Order (action)	acty	3.45
24832698	C1705176	Order (arrangement)	qlco	3.45
24832698	C1705175	Order (document)	inpr	3.45
24832698	C1705177	Order (taxonomic)	clas	3.45
24832698	C1882348	Permutation	qlco	3.45
24832698	C3889825	Sequence of Planned Assessment Schedule	inpr	3.45
26416827	C1855073	Mortality, Premature	fndg	24.11
26416827	C0026538	Morbidity - disease rate	qnco	19.45
26416827	C1314792	Etiology	ftcn	14.64
26416827	C0015127	Etiology aspects	ftcn	11.49
26416827	C0010674	Cystic Fibrosis	dsyn	10.06
26416827	C0019247	Hereditary Diseases	dsyn	8.34
26416827	C1524003	Science of Etiology	cnce	5.18
26416827	C0220880	morbidity aspects	inpr	3.68
26416827	C1709770	Pulmonary Dysfunction	fndg	3.61
26416827	C0205393	Most	qnco	3.56
26416827	C0009738	Congo	geoa	16.03
26416827	C0038164	Staphylococcal Protein A	aapp	12.90
26416827	C0038164	Staphylococcal Protein A	imft	12.90
26416827	C0038164	Staphylococcal Protein A	irda	12.90
26416827	C0031847	physiopathological	ftcn	9.69
26416827	C1704735	Regulator	cnce	6.88
26416827	C1704734	Regulator Device Component	mnob	6.88
26416827	C0182953	Regulators (device)	medd	6.88
26416827	C1552738	described	idcn	5.18
26416827	C0596611	Gene Mutation	genf	3.55
26416827	C2825142	Experimental Result	fndg	3.55
26416827	C1274040	Result	ftcn	3.55
26416827	C1546471	What subject filter - Result	idcn	3.55
26416827	C3811819	CFTR wt Allele	gngm	3.42
26416827	C3828842	Nearly	qlco	3.42
26416827	C2752508	fully spanning the plasma membrane	celc	3.42
26416827	C1167322	integral to membrane	celc	3.42
26416827	C0681760	2000s	tmco	3.40
26416827	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.38
26416827	C3887504	Dysfunction	cnce	3.38
26416827	C0277785	Functional disorder	patf	3.38
26416827	C0001480	Adenosine Triphosphate	bacs	19.26
26416827	C0001480	Adenosine Triphosphate	nnon	19.26
26416827	C0001480	Adenosine Triphosphate	phsu	19.26
26416827	C0003075	Anions	elii	12.92
26416827	C0033684	Proteins	aapp	8.34
26416827	C0033684	Proteins	bacs	8.34
26416827	C0150312	Present	qnco	5.18
26416827	C0449450	Presentation	idcn	5.18
26416827	C2327105	Surface of epithelial cell	celc	3.65
26416827	C0439799	Channel	spco	3.60
26416827	C1706095	Channel Object	cnce	3.60
26416827	C1167622	Binding (Molecular Function)	moft	3.46
26416827	C1145667	Binding action	acty	3.46
26416827	C0005367	Bicarbonates	inch	19.24
26416827	C0005367	Bicarbonates	phsu	19.24
26416827	C0008203	Chlorides	inch	16.08
26416827	C0031843	physiological aspects	phsf	12.89
26416827	C0003075	Anions	elii	12.89
26416827	C0026882	Mutation	genf	9.74
26416827	C1159591	chloride transport	celf	3.70
26416827	C1159589	bicarbonate transport	celf	3.68
26416827	C1517945	Loss	qnco	3.56
26416827	C2825142	Experimental Result	fndg	3.55
26416827	C1274040	Result	ftcn	3.55
26416827	C1546471	What subject filter - Result	idcn	3.55
26416827	C0332197	Absent	ftcn	3.47
26416827	C2699517	Absent Adverse Event	fndg	3.47
26416827	C2722820	Bicarbonate preparation	orch	3.47
26416827	C2722820	Bicarbonate preparation	phsu	3.47
26416827	C0596019	Chloride Ion	elii	3.47
26416827	C0973231	bicarbonate ion	inch	3.47
26416827	C0542341	Function	ftcn	3.43
26416827	C0700205	Function Axis	clas	3.43
26416827	C1705273	Mathematical Operator	inpr	3.43
26416827	C0439799	Channel	spco	3.42
26416827	C1706095	Channel Object	cnce	3.42
26416827	C0205216	Decreased	qnco	3.42
26416827	C0442797	Decreasing	qlco	3.42
26416827	C0392756	Reduced	qlco	3.42
26416827	C0037494	Sodium Chloride	bacs	16.25
26416827	C0037494	Sodium Chloride	inch	16.25
26416827	C0037494	Sodium Chloride	phsu	16.25
26416827	C0206136	Sodium Chloride, Dietary	food	13.09
26416827	C0023175	Lead	elii	13.03
26416827	C0023175	Lead	hops	13.03
26416827	C0009450	Communicable Diseases	dsyn	11.49
26416827	C0021368	Inflammation	patf	9.88
26416827	C3714514	Infection	patf	8.34
26416827	C0036140	Salts	chvs	6.79
26416827	C0036537	Bodily secretions	bdsu	6.72
26416827	C1159571	water transport	celf	3.59
26416827	C3275067	Cardiac Lead Procedure	topp	3.57
26416827	C2348269	Dietary Lead	elii	3.57
26416827	C1522538	Leading	ftcn	3.57
26416827	C0181586	Leads (device)	medd	3.57
26416827	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.57
26416827	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.57
26416827	C0205400	Thickened	fndg	3.57
26416827	C0205161	Abnormal	qlco	3.48
26416827	C2699333	Abnormal Reference Range	inpr	3.48
26416827	C0332282	Following	tmco	3.48
26416827	C2347472	Percent of Abnormal Cells	qnco	3.48
26416827	C2327105	Surface of epithelial cell	celc	3.47
26416827	C0392760	Affecting	ftcn	3.44
26416827	C1314939	Involvement with	ftcn	3.44
26416827	C0178784	Organ	bpoc	3.44
26416827	C0040363	Togo	geoa	17.80
26416827	C0041260	Tryptophanase	aapp	17.80
26416827	C0041260	Tryptophanase	enzy	17.80
26416827	C0009738	Congo	geoa	16.07
26416827	C0087111	Therapeutic procedure	topp	10.42
26416827	C0220912	Aspects of signs	ftcn	5.18
26416827	C0220913	Manufactured sign	mnob	5.18
26416827	C0311392	Physical findings	fndg	5.18
26416827	C0723712	Therapeutic brand of coal tar	orch	5.18
26416827	C0723712	Therapeutic brand of coal tar	phsu	5.18
26416827	C1883351	To	qlco	5.18
26416827	C1522326	Treating	ftcn	5.18
26416827	C1292734	Treatment intent	ftcn	5.18
26416827	C0439234	year	tmco	3.63
26416827	C1457887	Symptoms	sosy	3.59
26416827	C0683368	Symptoms aspect	ftcn	3.59
26416827	C3842589	20%	fndg	3.48
26416827	C1517741	Last	qlco	3.48
26416827	C3811819	CFTR wt Allele	gngm	3.45
26416827	C0039798	therapeutic aspects	ftcn	22.56
26416827	C0009738	Congo	geoa	16.05
26416827	C3264621	ivacaftor	orch	14.64
26416827	C3264621	ivacaftor	phsu	14.64
26416827	C0376649	Addresses (publication format)	inpr	8.34
26416827	C1442065	Address	spco	5.18
26416827	C0013227	Pharmaceutical Preparations	phsu	3.63
26416827	C1254351	Pharmacologic Substance	phsu	3.63
26416827	C0087111	Therapeutic procedure	topp	3.63
26416827	C1363945	Therapy Object (animal model)	fndg	3.63
26416827	C1457869	Defect	ftcn	3.56
26416827	C1328819	Small Molecule	orch	3.53
26416827	C0205540	Approved	qlco	3.48
26416827	C0205435	First (number)	qnco	3.48
26416827	C1279901	Firstly	qlco	3.48
26416827	C1527178	Basis - conceptual entity	ftcn	3.43
26416827	C3811819	CFTR wt Allele	gngm	3.43
26416827	C0005367	Bicarbonates	inch	19.19
26416827	C0005367	Bicarbonates	phsu	19.19
26416827	C0008203	Chlorides	inch	16.04
26416827	C3264621	ivacaftor	orch	13.14
26416827	C3264621	ivacaftor	phsu	13.14
26416827	C0439799	Channel	spco	5.18
26416827	C1706095	Channel Object	cnce	5.18
26416827	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.62
26416827	C0150312	Present	qnco	3.55
26416827	C0449450	Presentation	idcn	3.55
26416827	C0332452	defective	ftcn	3.55
26416827	C2327105	Surface of epithelial cell	celc	3.48
26416827	C2722820	Bicarbonate preparation	orch	3.42
26416827	C2722820	Bicarbonate preparation	phsu	3.42
26416827	C0596019	Chloride Ion	elii	3.42
26416827	C0973231	bicarbonate ion	inch	3.42
26416827	C0009738	Congo	geoa	17.80
26416827	C0206243	Carrying	acty	13.00
26416827	C0026882	Mutation	genf	9.88
26416827	C1257890	Population Group	popg	9.85
26416827	C0030705	Patients	podg	6.70
26416827	C0032659	geographic population	qnco	6.70
26416827	C3811819	CFTR wt Allele	gngm	5.18
26416827	C1720467	Only - dosing instruction fragment	inpr	5.18
26416827	C0205171	Singular	qnco	5.18
26416827	C3842590	10%	fndg	3.57
26416827	C0205540	Approved	qlco	3.57
26416827	C0332232	Approximate	qlco	3.54
26416827	C0699809	Does carry	fndg	3.54
26416827	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
26416827	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
26416827	C0009738	Congo	geoa	17.80
26416827	C0026882	Mutation	genf	9.92
26416827	C0019904	Homozygote	orga	9.76
26416827	C0030705	Patients	podg	6.71
26416827	C3811819	CFTR wt Allele	gngm	5.18
26416827	C1705285	Mutation Abnormality	comd	3.61
26416827	C0150312	Present	qnco	3.59
26416827	C0449450	Presentation	idcn	3.59
26416827	C3842586	50%	fndg	3.56
26416827	C3843766	<50	fndg	3.56
26416827	C0332232	Approximate	qlco	3.56
26416827	C1413365	CFTR gene	gngm	3.47
26416827	C0205214	Common (qualifier value)	qnco	3.47
26416827	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.47
26416827	C0205393	Most	qnco	3.47
26416827	C1522138	shared attribute	ftcn	3.47
26416827	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.09
26416827	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.09
26416827	C0026882	Mutation	genf	9.99
26416827	C1413365	CFTR gene	gngm	7.02
26416827	C0014597	Epithelial Cells	cell	6.74
26416827	C1947976	Correction (change)	ftcn	5.18
26416827	C1705565	Correction Report	inpr	5.18
26416827	C0279023	chemosensitization/potentiation	topp	5.18
26416827	C1705285	Mutation Abnormality	comd	3.68
26416827	C1293130	Stabilization	topp	3.57
26416827	C1513112	Membrane Protein Traffic	moft	3.56
26416827	C0439799	Channel	spco	3.55
26416827	C1706095	Channel Object	cnce	3.55
26416827	C2825142	Experimental Result	fndg	3.55
26416827	C0439064	Numerous	qnco	3.55
26416827	C1274040	Result	ftcn	3.55
26416827	C1546471	What subject filter - Result	idcn	3.55
26416827	C0243067	defects aspect	ftcn	3.55
26416827	C0008976	Clinical Trials	resa	38.62
26416827	C0009738	Congo	geoa	16.05
26416827	C3264621	ivacaftor	orch	14.64
26416827	C3264621	ivacaftor	phsu	14.64
26416827	C3852684	lumacaftor	orch	14.64
26416827	C3852684	lumacaftor	phsu	14.64
26416827	C0282443	Review [Publication Type]	inpr	11.49
26416827	C1096775	Clinical Trial [Publication Type]	inpr	9.74
26416827	C0030705	Patients	podg	6.72
26416827	C1552617	Act Class - review	idcn	5.18
26416827	C1706852	Article	inpr	5.18
26416827	C2827718	In Vitro Route of Administration	ftcn	5.18
26416827	C0021135	In Vitro [Publication Type]	inpr	5.18
26416827	C1533691	in vitro	qlco	5.18
26416827	C1516606	Clinical Data	inpr	3.56
26416827	C1511726	Data	idcn	3.54
26416827	C3714741	Data (eukaryote)	euka	3.54
26416827	C3245479	Data call receiving device	medd	3.54
26416827	C3811819	CFTR wt Allele	gngm	3.44
26416827	C1524063	Use of	ftcn	3.43
26416827	C3245505	potential	qlco	3.42
27976892	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
27976892	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
27976892	C0004391	Autophagy	celf	16.30
27976892	C0549249	Depressed Level of Consciousness	fndg	16.12
27976892	C0026882	Mutation	genf	9.92
27976892	C0010674	Cystic Fibrosis	dsyn	9.92
27976892	C1705285	Mutation Abnormality	comd	3.61
27976892	C0588446	Informing patient	hlca	3.60
27976892	C0344315	Depressed mood	fndg	3.50
27976892	C1413365	CFTR gene	gngm	3.47
27976892	C0205214	Common (qualifier value)	qnco	3.47
27976892	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.47
27976892	C1522138	shared attribute	ftcn	3.47
27976892	C0010648	Cysteamine	orch	16.25
27976892	C0010648	Cysteamine	phsu	16.25
27976892	C0004391	Autophagy	celf	16.04
27976892	C0005532	biology (field)	bmod	9.73
27976892	C0220781	Anabolism	biof	8.34
27976892	C0015684	Fatty Acids	orch	6.69
27976892	C0301869	Immunostimulating conjugate (antigen)	imft	5.18
27976892	C1314939	Involvement with	ftcn	5.18
27976892	C3273238	Regulatory Report	inpr	5.18
27976892	C0684224	Report (document)	inpr	5.18
27976892	C0700287	Reporting	hlca	5.18
27976892	C1883254	Synthesis	acty	5.18
27976892	C1880022	Characterization	acty	3.54
27976892	C0205314	New	qlco	3.42
27976892	C0439611	Preliminary	tmco	3.42
27976892	C0205549	Series	qnco	3.42
27976892	C2348044	Series - set of composite instances	inpr	3.42
27976892	C0205460	biological	qlco	3.42
27976892	C0679622	literary novel	inpr	3.42
27976892	C0012968	Docosahexaenoic Acids	bacs	19.25
27976892	C0012968	Docosahexaenoic Acids	orch	19.25
27976892	C0012968	Docosahexaenoic Acids	phsu	19.25
27976892	C0010648	Cysteamine	orch	16.18
27976892	C0010648	Cysteamine	phsu	16.18
27976892	C1704666	Hyperlink	inpr	3.98
27976892	C1517892	Links List	inpr	3.98
27976892	C1551338	Entity	enty	3.63
27976892	C0205435	First (number)	qnco	3.59
27976892	C1279901	Firstly	qlco	3.59
27976892	C1883254	Synthesis	acty	3.59
27976892	C1521991	Molecular	qlco	3.50
27976892	C0556150	docosahexaenoic acid	orch	3.48
27976892	C0556150	docosahexaenoic acid	phsu	3.48
27976892	C0086418	Homo sapiens	humn	28.65
27976892	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
27976892	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
27976892	C0004391	Autophagy	celf	16.15
27976892	C0019904	Homozygote	orga	9.72
27976892	C0086045	Mental concentration	menp	3.68
27976892	C0332294	Resulting in	ftcn	3.42
27976892	C1879547	Activation action	acty	3.41
27976892	C1413365	CFTR gene	gngm	3.41
27976892	C0301869	Immunostimulating conjugate (antigen)	imft	3.41
27976892	C0205225	Primary	qlco	3.41
27976892	C0439631	Primary operation	topp	3.41
27976892	C0439612	True primary (qualifier value)	tmco	3.41
27976892	C1711178	Bronchial Epithelial Cell	cell	3.41
27976892	C0008203	Chlorides	inch	16.16
27976892	C3264621	ivacaftor	orch	13.14
27976892	C3264621	ivacaftor	phsu	13.14
27976892	C3852684	lumacaftor	orch	13.14
27976892	C3852684	lumacaftor	phsu	13.14
27976892	C0005507	Biological Assay	lbpr	6.58
27976892	C1547282	Show	anim	3.98
27976892	C0442796	Additive	qlco	3.68
27976892	C1280500	Effect	qlco	3.68
27976892	C2348382	Effect, Appearance	qlco	3.68
27976892	C0301869	Immunostimulating conjugate (antigen)	imft	3.68
27976892	C1550602	additive ingredient	sbst	3.68
27976892	C0205195	Combined	qlco	3.59
27976892	C1273517	Used by	fndg	3.59
27976892	C3811910	combination - answer to question	fndg	3.59
27976892	C1947911	combination of objects	phob	3.59
27976892	C0442805	Increase	ftcn	3.57
27976892	C0444706	Measured	qlco	3.57
27976892	C3541902	Measured Tumor Identification	diap	3.57
27976892	C0596019	Chloride Ion	elii	3.54
27976892	C0521116	Current (present time)	tmco	3.54
27976892	C1705970	Electrical Current	npop	3.54
27976892	C1510438	Assay	lbpr	3.42
27976892	C0542341	Function	ftcn	3.42
27976892	C0205245	Functional	ftcn	3.42
27976892	C2700217	Functional Relationship	cnce	3.42
27976892	C0243073	assay qualifier	qlco	3.42
27976892	C0012771	Disulfides	chvs	19.32
27976892	C0040363	Togo	geoa	17.80
27976892	C0041260	Tryptophanase	aapp	17.80
27976892	C0041260	Tryptophanase	enzy	17.80
27976892	C0038734	Sulfhydryl Compounds	orch	9.90
27976892	C0376315	Manufactured form	mnob	6.70
27976892	C1706701	Acquisition (action)	acty	5.18
27976892	C1301820	Obtain	ftcn	5.18
27976892	C1705178	Order (action)	acty	5.18
27976892	C1705176	Order (arrangement)	qlco	5.18
27976892	C1705175	Order (document)	inpr	5.18
27976892	C1705177	Order (taxonomic)	clas	5.18
27976892	C1882348	Permutation	qlco	5.18
27976892	C3889825	Sequence of Planned Assessment Schedule	inpr	5.18
27976892	C1883351	To	qlco	5.18
27976892	C1522492	Formation	ftcn	3.55
27976892	C0348078	Qualitative form	qlco	3.55
27976892	C0301869	Immunostimulating conjugate (antigen)	imft	3.43
27976892	C0205172	More	ftcn	3.42
27976892	C0442027	Oral	spco	3.42
27976892	C1547311	Patient Condition Code - Stable	inpr	3.42
27976892	C0205360	Stable status	qlco	3.42
27976892	C0034721	Rattus	mamm	30.42
27976892	C0034693	Rattus norvegicus	mamm	30.42
27976892	C0026809	Mus	mamm	28.66
27976892	C0012984	Canis familiaris	mamm	27.26
27976892	C0011209	Obstetric Delivery	topp	9.85
27976892	C0301869	Immunostimulating conjugate (antigen)	imft	7.05
27976892	C1280551	Dog family	mamm	5.18
27976892	C0683607	allowing	socb	5.18
27976892	C0678226	Due to	ftcn	3.63
27976892	C0935763	Bioavailable	qlco	3.56
27976892	C1314680	Non-human parturition, function	orgf	3.54
27976892	C1705822	Transfer Technique	ftcn	3.54
27976892	C0025914	House mice	mamm	3.43
27976892	C0025929	Laboratory mice	mamm	3.43
27976892	C0442027	Oral	spco	3.43
27976892	C0205177	Active	ftcn	3.42
27976892	C3888249	Active License	qlco	3.42
27976892	C0443318	Sustained	ftcn	3.42
27976892	C3853793	active (HL7 RoleLink)	idcn	3.42
27976892	C0205460	biological	qlco	3.42
24598717	C0010674	Cystic Fibrosis	dsyn	10.06
24598717	C0012634	Disease	dsyn	9.73
24598717	C0376558	Life	idcn	9.73
24598717	C0026882	Mutation	genf	9.73
24598717	C1413365	CFTR gene	gngm	5.18
24598717	C4019053	Arising	dora	3.54
24598717	C0332284	Arising in	qlco	3.54
24598717	C0686907	Consequence of	ftcn	3.43
24598717	C0441636	Surgical shortening - action	topp	3.42
24598717	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.54
24598717	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.54
24598717	C0009738	Congo	geoa	32.31
24598717	C0021699	Integral Membrane Proteins	aapp	9.98
24598717	C1413365	CFTR gene	gngm	7.47
24598717	C3811819	CFTR wt Allele	gngm	6.93
24598717	C0243067	defects aspect	ftcn	5.18
24598717	C0678226	Due to	ftcn	3.56
24598717	C1552740	Entity Determiner - specific	inpr	3.56
24598717	C0205369	Specific qualifier value	qlco	3.56
24598717	C0723712	Therapeutic brand of coal tar	orch	3.56
24598717	C0723712	Therapeutic brand of coal tar	phsu	3.56
24598717	C0087111	Therapeutic procedure	topp	3.56
24598717	C0205419	Variant	qlco	3.56
24598717	C1704735	Regulator	cnce	3.46
24598717	C1704734	Regulator Device Component	mnob	3.46
24598717	C0182953	Regulators (device)	medd	3.46
24598717	C1521840	Target	ftcn	3.46
24598717	C2986546	Target Lesion Identification	diap	3.46
24598717	C0205314	New	qlco	3.43
24598717	C0679622	literary novel	inpr	3.43
24598717	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.43
24598717	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.43
24598717	C0009738	Congo	geoa	16.18
24598717	C3264621	ivacaftor	orch	13.14
24598717	C3264621	ivacaftor	phsu	13.14
24598717	C0031843	physiological aspects	phsf	13.09
24598717	C1413365	CFTR gene	gngm	10.75
24598717	C0030705	Patients	podg	6.72
24598717	C0013227	Pharmaceutical Preparations	phsu	5.18
24598717	C1254351	Pharmacologic Substance	phsu	5.18
24598717	C0542341	Function	ftcn	3.63
24598717	C0700205	Function Axis	clas	3.63
24598717	C1705273	Mathematical Operator	inpr	3.63
24598717	C0205419	Variant	qlco	3.63
24598717	C3811819	CFTR wt Allele	gngm	3.57
24598717	C1444656	Indicated	fndg	3.57
24598717	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
24598717	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
24598717	C3264621	ivacaftor	orch	12.90
24598717	C3264621	ivacaftor	phsu	12.90
24598717	C0017431	Genotype	orga	6.71
24598717	C2825142	Experimental Result	fndg	5.18
24598717	C1999230	Providing (action)	acty	5.18
24598717	C1274040	Result	ftcn	5.18
24598717	C1546471	What subject filter - Result	idcn	5.18
24598717	C0034866	Recommendation	idcn	3.57
24598717	C1705938	Base - General Qualifier	idcn	3.56
24598717	C1527178	Basis - conceptual entity	ftcn	3.56
24598717	C1413365	CFTR gene	gngm	3.56
24598717	C0302350	Therapeutic	ftcn	3.44
24598717	C0087111	Therapeutic procedure	topp	3.44
19747007	C0039798	therapeutic aspects	ftcn	22.48
19747007	C0010674	Cystic Fibrosis	dsyn	9.76
19747007	C0008972	Clinical Research	resa	8.34
19747007	C0521116	Current (present time)	tmco	5.18
19747007	C0449788	Count of entities	qnco	3.56
19747007	C0237753	Numbers	qnco	3.56
19747007	C1533734	Administration procedure	topp	3.55
19747007	C1705169	Biomaterial Treatment	cnce	3.55
19747007	C0087111	Therapeutic procedure	topp	3.55
19747007	C1522326	Treating	ftcn	3.55
19747007	C3538994	Treatment Epoch	resa	3.55
19747007	C3887704	treatment - ActInformationManagementReason	hlca	3.55
19747007	C3687832	DRUGS	topp	3.43
19747007	C0013227	Pharmaceutical Preparations	phsu	3.43
19747007	C3245505	potential	qlco	3.43
19747007	C0008809	Ciprofloxacin	orch	42.15
19747007	C0008809	Ciprofloxacin	phsu	42.15
19747007	C0040341	Tobramycin	antb	39.21
19747007	C0040341	Tobramycin	orch	39.21
19747007	C0282386	Levofloxacin	antb	24.11
19747007	C0282386	Levofloxacin	orch	24.11
19747007	C0009316	Colistin	aapp	22.35
19747007	C0009316	Colistin	antb	22.35
19747007	C0004048	Inspiration function	orgf	20.95
19747007	C0002499	Amikacin	antb	17.80
19747007	C0002499	Amikacin	orch	17.80
19747007	C0279516	Anti-Bacterial Agents	antb	16.05
19747007	C0016610	Fosfomycin	antb	12.90
19747007	C0016610	Fosfomycin	orch	12.90
19747007	C0011209	Obstetric Delivery	topp	9.90
19747007	C3853847	Dry Powder Inhaler	bodm	9.79
19747007	C1967611	Dry Powder Inhaler (device)	medd	9.79
19747007	C2700399	Include (action)	acty	5.18
19747007	C0332257	Including (qualifier)	ftcn	5.18
19747007	C1705211	Inhalation Dosing Unit	qnco	5.18
19747007	C0205535	Inhalation Route of Drug Administration	ftcn	5.18
19747007	C1552866	include - SetOperator	idcn	5.18
19747007	C1314680	Non-human parturition, function	orgf	3.59
19747007	C1705822	Transfer Technique	ftcn	3.59
19747007	C0449788	Count of entities	qnco	3.57
19747007	C0237753	Numbers	qnco	3.57
19747007	C0524527	Drug Formulation Process	resa	3.55
19747007	C0557651	Room of building - Study	mnob	3.55
19747007	C1306673	Stage	qlco	3.55
19747007	C2603343	Study	resa	3.55
19747007	C3540763	VARIOUS DRUG CLASSES IN ATC	phsu	3.55
19747007	C0440102	Various patch test substance	irda	3.55
19747007	C0333052	Version	ftcn	3.55
19747007	C3540765	various allergen extracts	imft	3.55
19747007	C3540765	various allergen extracts	phsu	3.55
19747007	C3540008	various antiinfectives and antiseptics for local oral treatment	phsu	3.55
19747007	C3540766	various antiseptic throat preparations	phsu	3.55
19747007	C3540762	various other agents for local oral treatment in ATC	phsu	3.55
19747007	C3540769	various other intestinal adsorbents in ATC	phsu	3.55
19747007	C3540761	various other nasal preparations in ATC	phsu	3.55
19747007	C0418992	Dry powder inhaler administration	topp	3.48
19747007	C1659427	Nebulization	topp	3.44
19747007	C0074554	Simvastatin	orch	27.26
19747007	C0074554	Simvastatin	phsu	27.26
19747007	C0012968	Docosahexaenoic Acids	bacs	20.95
19747007	C0012968	Docosahexaenoic Acids	orch	20.95
19747007	C0012968	Docosahexaenoic Acids	phsu	20.95
19747007	C0020336	Hydroxychloroquine	orch	20.95
19747007	C0020336	Hydroxychloroquine	phsu	20.95
19747007	C0025677	Methotrexate	orch	20.95
19747007	C0025677	Methotrexate	phsu	20.95
19747007	C0002191	alpha 1-Antitrypsin	aapp	20.95
19747007	C0002191	alpha 1-Antitrypsin	bacs	20.95
19747007	C0002191	alpha 1-Antitrypsin	phsu	20.95
19747007	C1318700	Phosphodiesterase 5 inhibitor	phsu	19.41
19747007	C0001047	Acetylcysteine	aapp	16.30
19747007	C0001047	Acetylcysteine	phsu	16.30
19747007	C0017817	Glutathione	aapp	14.64
19747007	C0017817	Glutathione	bacs	14.64
19747007	C0071097	pioglitazone	orch	14.64
19747007	C0071097	pioglitazone	phsu	14.64
19747007	C0003209	Anti-Inflammatory Agents	phsu	12.91
19747007	C0201856	Alpha-1-antitrypsin measurement	lbpr	5.18
19747007	C0549178	Continuous	idcn	5.18
19747007	C0332257	Including (qualifier)	ftcn	5.18
19747007	C0795657	alpha 1-proteinase inhibitor, human	aapp	5.18
19747007	C0795657	alpha 1-proteinase inhibitor, human	imft	5.18
19747007	C0795657	alpha 1-proteinase inhibitor, human	phsu	5.18
19747007	C0556150	docosahexaenoic acid	orch	5.18
19747007	C0556150	docosahexaenoic acid	phsu	5.18
19747007	C2267138	Phosphodiesterase 5 Inhibitors [MoA]	moft	3.64
19747007	C2983596	Clinical Trial Agent	chvf	3.57
19747007	C0442027	Oral	spco	3.50
19747007	C1515999	Anti-inflammatory effect	qlco	3.44
19747007	C0529793	sildenafil	orch	3.43
19747007	C0529793	sildenafil	phsu	3.43
19747007	C0009738	Congo	geoa	32.32
19747007	C0039798	therapeutic aspects	ftcn	22.48
19747007	C0055363	Chloride Channels	aapp	20.95
19747007	C0055363	Chloride Channels	bacs	20.95
19747007	C0037492	Sodium Channel	aapp	19.31
19747007	C0037492	Sodium Channel	bacs	19.31
19747007	C0022009	Ion Channel	aapp	16.10
19747007	C0022009	Ion Channel	bacs	16.10
19747007	C1311572	Moli1901	aapp	14.64
19747007	C0058815	duramycin	aapp	14.64
19747007	C0058815	duramycin	antb	14.64
19747007	C3811819	CFTR wt Allele	gngm	6.94
19747007	C0008972	Clinical Research	resa	6.73
19747007	C1879547	Activation action	acty	5.18
19747007	C0332270	Alternating	ftcn	5.18
19747007	C1523987	Alternative	cnce	5.18
19747007	C1998014	Denufosol	nnon	5.18
19747007	C1998014	Denufosol	phsu	5.18
19747007	C0597535	Success	socb	5.18
19747007	C1272703	Successful	qlco	5.18
19747007	C3853838	activate - Data Operation	ftcn	5.18
19747007	C1515877	activate biological process	ftcn	5.18
19747007	C0231491	Antagonist muscle action	ortf	3.63
19747007	C1704735	Regulator	cnce	3.61
19747007	C1704734	Regulator Device Component	mnob	3.61
19747007	C0182953	Regulators (device)	medd	3.61
19747007	C0205563	Clinical stage finding	tmco	3.57
19747007	C0450442	Agent	chvf	3.57
19747007	C1254351	Pharmacologic Substance	phsu	3.57
19747007	C1521826	Protocol Agent	inpr	3.57
19747007	C1533734	Administration procedure	topp	3.56
19747007	C1705169	Biomaterial Treatment	cnce	3.56
19747007	C0087111	Therapeutic procedure	topp	3.56
19747007	C1522326	Treating	ftcn	3.56
19747007	C3538994	Treatment Epoch	resa	3.56
19747007	C3887704	treatment - ActInformationManagementReason	hlca	3.56
19747007	C0683312	Categories	inpr	3.55
19747007	C3889287	Digital Content Category	clas	3.55
19747007	C1948052	Now (temporal qualifier)	tmco	3.55
19747007	C0557651	Room of building - Study	mnob	3.55
19747007	C1306673	Stage	qlco	3.55
19747007	C2603343	Study	resa	3.55
19747007	C1518422	Negation	ftcn	3.47
19747007	C2752508	fully spanning the plasma membrane	celc	3.47
19747007	C1167322	integral to membrane	celc	3.47
19747007	C0443264	Modulated	spco	3.46
19747007	C0304231	Therapeutic agent	mnob	3.45
19747007	C1611640	Therapeutic agent (substance)	phsu	3.45
19747007	C0205314	New	qlco	3.43
19747007	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
19747007	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
19747007	C0023981	Longitudinal Studies	resa	22.42
19747007	C0009738	Congo	geoa	17.80
19747007	C0017337	Genes	gngm	16.04
19747007	C2930764	ataluren	orch	14.64
19747007	C2930764	ataluren	phsu	14.64
19747007	C0031847	physiopathological	ftcn	9.76
19747007	C0008972	Clinical Research	resa	8.34
19747007	C0017296	gene therapy	topp	7.62
19747007	C3811819	CFTR wt Allele	gngm	5.18
19747007	C0549178	Continuous	idcn	5.18
19747007	C3252847	VX 809	orch	5.18
19747007	C3252847	VX 809	phsu	5.18
19747007	C2741958	VX-770	orch	5.18
19747007	C0549255	Excitation	acty	3.98
19747007	C1413365	CFTR gene	gngm	3.68
19747007	C1517499	Gene Transfer	mbrt	3.64
19747007	C1269765	Assisted (qualifier value)	qlco	3.59
19747007	C2349182	Correct (qualifier)	qlco	3.59
19747007	C3844638	Either	fndg	3.59
19747007	C1552861	Help document	inpr	3.59
19747007	C0450442	Agent	chvf	3.55
19747007	C1254351	Pharmacologic Substance	phsu	3.55
19747007	C1521826	Protocol Agent	inpr	3.55
19747007	C1947976	Correction (change)	ftcn	3.55
19747007	C1705565	Correction Report	inpr	3.55
19747007	C3846446	Prospective, NOS	fndg	3.50
19747007	C3242274	new therapy	fndg	3.46
19747007	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.45
19747007	C3887504	Dysfunction	cnce	3.45
19747007	C0277785	Functional disorder	patf	3.45
19747007	C1280500	Effect	qlco	3.42
19747007	C2348382	Effect, Appearance	qlco	3.42
19747007	C0009738	Congo	geoa	32.60
19747007	C0220825	Evaluation	hlca	13.03
19747007	C0282443	Review [Publication Type]	inpr	11.49
19747007	C0242481	Research Activities	resa	9.90
19747007	C0035168	research	resa	9.90
19747007	C0015450	Face	blor	9.86
19747007	C3811819	CFTR wt Allele	gngm	7.22
19747007	C3245505	potential	qlco	6.89
19747007	C0008972	Clinical Research	resa	6.79
19747007	C1552617	Act Class - review	idcn	5.18
19747007	C1706852	Article	inpr	5.18
19747007	C0521116	Current (present time)	tmco	5.18
19747007	C0805586	Challenge	hlca	3.57
19747007	C0871489	teams	grup	3.57
19747007	C1281591	Entire face	bpoc	3.55
19747007	C1280519	Effectiveness	qlco	3.55
19747007	C1707887	Efficacy Study	resa	3.55
19747007	C3469597	Administration of medication	hlca	3.54
19747007	C0150270	Medication Management	hlca	3.54
19747007	C3242274	new therapy	fndg	3.44
19747007	C0205210	Clinical	qlco	3.44
19747007	C1553058	Neuropsychologist - Clinical	prog	3.44
19747007	C0237412	Psychologist - Clinical	prog	3.44
19747007	C0497591	Social Worker - Clinical	prog	3.44
19747007	C1516048	Assessed	acty	3.42
26968770	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
26968770	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
26968770	C0031843	physiological aspects	phsf	13.14
26968770	C0332185	Recent	tmco	7.01
26968770	C0205210	Clinical	qlco	6.95
26968770	C1553058	Neuropsychologist - Clinical	prog	6.95
26968770	C0237412	Psychologist - Clinical	prog	6.95
26968770	C0497591	Social Worker - Clinical	prog	6.95
26968770	C0443264	Modulated	spco	5.18
26968770	C1518422	Negation	ftcn	5.18
26968770	C1547282	Show	anim	3.98
26968770	C1261322	Evaluation procedure	hlca	3.68
26968770	C0542341	Function	ftcn	3.68
26968770	C0700205	Function Axis	clas	3.68
26968770	C1705273	Mathematical Operator	inpr	3.68
26968770	C0441712	Mechanism (attribute)	ftcn	3.68
26968770	C1706376	Mechanism Component of Device	mnob	3.68
26968770	C0332290	Consistent with	idcn	3.64
26968770	C0814225	benefit	qnco	3.63
26968770	C0087111	Therapeutic procedure	topp	3.61
26968770	C0205195	Combined	qlco	3.59
26968770	C1273517	Used by	fndg	3.59
26968770	C3811910	combination - answer to question	fndg	3.59
26968770	C1947911	combination of objects	phob	3.59
26968770	C1413365	CFTR gene	gngm	3.50
26968770	C1521991	Molecular	qlco	3.50
26968770	C1546944	Event Seriousness - Significant	qlco	3.48
26968770	C0750502	Significant	idcn	3.48
26968770	C0237881	Statistical Significance	qnco	3.48
26968770	C0205540	Approved	qlco	3.47
26968770	C2825142	Experimental Result	fndg	3.42
26968770	C1274040	Result	ftcn	3.42
26968770	C1546471	What subject filter - Result	idcn	3.42
26968770	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26968770	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26968770	C0920367	Tomography, Optical Coherence	diap	19.37
26968770	C0040363	Togo	geoa	17.80
26968770	C0041260	Tryptophanase	aapp	17.80
26968770	C0041260	Tryptophanase	enzy	17.80
26968770	C0026687	Mucociliary Clearance	clna	14.64
26968770	C1524059	mechanism of action qualifier	ftcn	13.08
26968770	C0014003	Employment	qlco	11.49
26968770	C0031327	Drug Kinetics	phsf	9.92
26968770	C0000936	Visual Accommodation	clna	9.88
26968770	C1516048	Assessed	acty	5.18
26968770	C0557351	Employed	fndg	5.18
26968770	C1883351	To	qlco	5.18
26968770	C1280500	Effect	qlco	3.57
26968770	C2981153	Finding related to focusing	fndg	3.57
26968770	C1413365	CFTR gene	gngm	3.42
26968770	C1704970	Means	cnce	3.42
26968770	C3811161	Micro (prefix)	cnce	3.42
26968770	C4049106	Microbiology - Laboratory Class	inpr	3.42
26968770	C0085672	Microbiology procedure	lbpr	3.42
26968770	C0205314	New	qlco	3.42
26968770	C1553035	Unit Of Measure Prefix - micro	qnco	3.42
26968770	C0679622	literary novel	inpr	3.42
26968770	C1709060	Modulator Device Component	mnob	3.40
26968770	C0086418	Homo sapiens	humn	28.66
26968770	C0039798	therapeutic aspects	ftcn	22.49
26968770	C0015422	Eyelash	bpoc	19.34
26968770	C0162585	Ion Transport	celf	13.22
26968770	C0026687	Mucociliary Clearance	clna	13.22
26968770	C3264621	ivacaftor	orch	13.03
26968770	C3264621	ivacaftor	phsu	13.03
26968770	C0026882	Mutation	genf	9.99
26968770	C0042784	Viscosity	npop	9.85
26968770	C0458827	Airway structure	bpoc	6.93
26968770	C0178987	Artificial Airways	medd	6.93
26968770	C0030705	Patients	podg	6.58
26968770	C0441712	Mechanism (attribute)	ftcn	3.68
26968770	C1706376	Mechanism Component of Device	mnob	3.68
26968770	C1705285	Mutation Abnormality	comd	3.68
26968770	C0439603	Frequencies (time pattern)	tmco	3.63
26968770	C3898838	How Often	inpr	3.63
26968770	C1561548	Kind of quantity - Frequency	qlco	3.63
26968770	C1521828	Rate	qnco	3.63
26968770	C0871208	Rating (action)	acty	3.63
26968770	C0871396	Spatial Frequency	qnco	3.63
26968770	C1705502	Statistical Frequency	qnco	3.63
26968770	C0376249	With frequency	qnco	3.63
26968770	C0205125	Depth	spco	3.61
26968770	C1288305	Entire eyelash	bpoc	3.57
26968770	C1272684	Accepted	qlco	3.57
26968770	C1533734	Administration procedure	topp	3.57
26968770	C1705169	Biomaterial Treatment	cnce	3.57
26968770	C3539655	CDISC Findings Class	inpr	3.57
26968770	C0443211	Established	qlco	3.57
26968770	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	3.57
26968770	C0087111	Therapeutic procedure	topp	3.57
26968770	C1522326	Treating	ftcn	3.57
26968770	C3538994	Treatment Epoch	resa	3.57
26968770	C2607943	findings aspects	ftcn	3.57
26968770	C3887704	treatment - ActInformationManagementReason	hlca	3.57
26968770	C0872351	monolayer	clnd	3.55
26968770	C1547055	*Viscosity	qnco	3.54
26968770	C0391802	Blood viscosity examination	lbpr	3.54
26968770	C1710548	Unique	qlco	3.50
26968770	C0442805	Increase	ftcn	3.48
26968770	C0205217	Increased	qnco	3.48
26968770	C1304698	Liquid (finding)	fndg	3.47
26968770	C1546699	Liquid NOS - Specimen Source Codes	inpr	3.47
26968770	C1561501	Liquid Specimen	sbst	3.47
26968770	C0301571	Liquid diet	topp	3.47
26968770	C0302908	Liquid substance	sbst	3.47
26968770	C0205148	Surface	spco	3.47
26968770	C0332287	In addition to	ftcn	3.44
26968770	C2753459	mucus layer	bdsu	3.43
26968770	C0205225	Primary	qlco	3.42
26968770	C0439631	Primary operation	topp	3.42
26968770	C0439612	True primary (qualifier value)	tmco	3.42
26968770	C0205216	Decreased	qnco	3.42
26968770	C0442797	Decreasing	qlco	3.42
26968770	C1704419	Effective	qlco	3.42
26968770	C1280519	Effectiveness	qlco	3.42
26968770	C0392756	Reduced	qlco	3.42
26968770	C3264621	ivacaftor	orch	13.05
26968770	C3264621	ivacaftor	phsu	13.05
26968770	C0042784	Viscosity	npop	9.99
26968770	C0026727	Mucous body substance	bdsu	9.81
26968770	C0030705	Patients	podg	6.72
26968770	C2349179	End Point	qlco	5.18
26968770	C1314939	Involvement with	ftcn	5.18
26968770	C0332293	Treated with	topp	3.72
26968770	C1547055	*Viscosity	qnco	3.68
26968770	C0391802	Blood viscosity examination	lbpr	3.68
26968770	C0441712	Mechanism (attribute)	ftcn	3.68
26968770	C1706376	Mechanism Component of Device	mnob	3.68
26968770	C0332290	Consistent with	idcn	3.64
26968770	C1441672	Observed	ftcn	3.57
26968770	C0205314	New	qlco	3.50
26968770	C1546714	Specimen Source Codes - Mucus	inpr	3.50
26968770	C0679622	literary novel	inpr	3.50
26968770	C2753459	mucus layer	bdsu	3.50
26968770	C0814225	benefit	qnco	3.44
26968770	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
26968770	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
26968770	C0031843	physiological aspects	phsf	14.64
26968770	C0030705	Patients	podg	6.72
26968770	C0231242	Complicated	ftcn	5.18
26968770	C0542341	Function	ftcn	5.18
26968770	C0700205	Function Axis	clas	5.18
26968770	C1705273	Mathematical Operator	inpr	5.18
26968770	C0205172	More	ftcn	5.18
26968770	C0872351	monolayer	clnd	5.18
26968770	C3854321	Expression (foundation metadata concept)	idcn	3.68
26968770	C0185117	Expression procedure	topp	3.68
26968770	C0205198	Compound	qlco	3.57
26968770	C1441547	Derivation	qlco	3.57
26968770	C3245521	Derived value	idcn	3.57
26968770	C1280500	Effect	qlco	3.57
26968770	C1413365	CFTR gene	gngm	3.50
26968770	C0162585	Ion Transport	celf	26.12
26968770	C0011923	Diagnostic Imaging	diap	9.73
26968770	C0037088	Signs and Symptoms	sosy	8.34
26968770	C0443211	Established	qlco	5.18
26968770	C2825141	Experimental Finding	fndg	5.18
26968770	C0243095	Finding	fndg	5.18
26968770	C0439044	Living Alone	fndg	5.18
26968770	C1518422	Negation	ftcn	5.18
26968770	C0557651	Room of building - Study	mnob	5.18
26968770	C0947630	Scientific Study	lbpr	5.18
26968770	C0205171	Singular	qnco	5.18
26968770	C2603343	Study	resa	5.18
26968770	C0679994	alone - group size	grpa	5.18
26968770	C0814225	benefit	qnco	3.68
26968770	C0940836	functional measurement	diap	3.56
26968770	C1704666	Hyperlink	inpr	3.55
26968770	C1517892	Links List	inpr	3.55
26968770	C0242485	Measurement	ftcn	3.54
26968770	C0205210	Clinical	qlco	3.50
26968770	C1553058	Neuropsychologist - Clinical	prog	3.50
26968770	C0237412	Psychologist - Clinical	prog	3.50
26968770	C0497591	Social Worker - Clinical	prog	3.50
26968770	C2827718	In Vitro Route of Administration	ftcn	3.44
26968770	C0021135	In Vitro [Publication Type]	inpr	3.44
26968770	C1533691	in vitro	qlco	3.44
26968770	C1517324	Functional Imaging	diap	3.44
26968770	C1511726	Data	idcn	3.42
26968770	C3714741	Data (eukaryote)	euka	3.42
26968770	C3245479	Data call receiving device	medd	3.42
26968770	C0079595	Imaging Techniques	diap	3.42
26968770	C0336789	Combine	mnob	3.40
26968770	C0015272	Exhibits as Topic	inpr	17.80
26968770	C0040808	Treatment Protocols	topp	16.18
26968770	C3264621	ivacaftor	orch	14.64
26968770	C3264621	ivacaftor	phsu	14.64
26968770	C0026687	Mucociliary Clearance	clna	13.22
26968770	C0042784	Viscosity	npop	9.92
26968770	C0026727	Mucous body substance	bdsu	9.77
26968770	C0443211	Established	qlco	5.18
26968770	C1720467	Only - dosing instruction fragment	inpr	5.18
26968770	C0205171	Singular	qnco	5.18
26968770	C0007634	Cells	cell	3.68
26968770	C3282337	Cells [Chemical/Ingredient]	cell	3.68
26968770	C1547055	*Viscosity	qnco	3.61
26968770	C0391802	Blood viscosity examination	lbpr	3.61
26968770	C1524062	Additional	ftcn	3.57
26968770	C2945654	Regimen - CHV concept	inpr	3.57
26968770	C0442805	Increase	ftcn	3.48
26968770	C0205217	Increased	qnco	3.48
26968770	C0205216	Decreased	qnco	3.47
26968770	C0442797	Decreasing	qlco	3.47
26968770	C1704419	Effective	qlco	3.47
26968770	C1280519	Effectiveness	qlco	3.47
26968770	C0392756	Reduced	qlco	3.47
26968770	C1546714	Specimen Source Codes - Mucus	inpr	3.47
26968770	C2753459	mucus layer	bdsu	3.47
26968770	C0008976	Clinical Trials	resa	19.38
26968770	C0019638	Histology	bmod	12.89
26968770	C0005528	Biological Transport	celf	11.49
26968770	C0022023	Ions	elii	11.49
26968770	C2827718	In Vitro Route of Administration	ftcn	10.42
26968770	C0021135	In Vitro [Publication Type]	inpr	10.42
26968770	C1533691	in vitro	qlco	10.42
26968770	C1096775	Clinical Trial [Publication Type]	inpr	9.92
26968770	C0035245	Respiratory physiology	ortf	6.76
26968770	C0428295	Cystic fibrosis sweat test	lbpr	5.18
26968770	C1517331	Further	spco	5.18
26968770	C1700702	Iontophoresis Route of Drug Administration	ftcn	5.18
26968770	C3495449	Mobility aid	medd	5.18
26968770	C1547282	Show	anim	5.18
26968770	C1304760	Sweat chloride level result	lbtr	5.18
26968770	C1317949	transport (device)	mnob	5.18
26968770	C0443172	Changed status	qnco	3.59
26968770	C0392747	Changing	ftcn	3.59
26968770	C1441672	Observed	ftcn	3.56
26968770	C0814225	benefit	qnco	3.56
26968770	C2986411	Improvement	cnce	3.55
26968770	C0542341	Function	ftcn	3.43
26968770	C0205245	Functional	ftcn	3.43
26968770	C2700217	Functional Relationship	cnce	3.43
26968770	C1513264	Microanatomic Structure	anst	3.43
26968770	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
26968770	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
26968770	C3850123	Clinical Effectiveness	qlco	19.25
26968770	C0162340	Comprehension	menp	13.02
26968770	C0005532	biology (field)	bmod	9.99
26968770	C0443289	Revealed	qlco	5.18
26968770	C1517324	Functional Imaging	diap	3.75
26968770	C1825598	IMPACT gene	gngm	3.68
26968770	C4049986	Impact	qlco	3.68
26968770	C0233820	Insight	menp	3.57
26968770	C1413365	CFTR gene	gngm	3.50
26968770	C0683465	novel AODU treatment method	topp	3.46
26403534	C0010674	Cystic Fibrosis	dsyn	10.06
26403534	C0012634	Disease	dsyn	9.85
26403534	C0376558	Life	idcn	9.73
26403534	C1257890	Population Group	popg	9.73
26403534	C0032659	geographic population	qnco	6.58
26403534	C0205214	Common (qualifier value)	qnco	3.68
26403534	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.68
26403534	C1522138	shared attribute	ftcn	3.68
26403534	C0205393	Most	qnco	3.50
26403534	C1535514	European race	popg	3.42
26403534	C0439801	Limited (extensiveness)	ftcn	3.42
26403534	C0239307	ethnic european	popg	3.42
26403534	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.42
26403534	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.42
26403534	C0040363	Togo	geoa	17.80
26403534	C0041260	Tryptophanase	aapp	17.80
26403534	C0041260	Tryptophanase	enzy	17.80
26403534	C0008203	Chlorides	inch	16.04
26403534	C0010674	Cystic Fibrosis	dsyn	9.76
26403534	C0014597	Epithelial Cells	cell	6.79
26403534	C0439799	Channel	spco	5.18
26403534	C1706095	Channel Object	cnce	5.18
26403534	C1883351	To	qlco	5.18
26403534	C1272684	Accepted	qlco	3.68
26403534	C0443211	Established	qlco	3.68
26403534	C0205170	Good	qlco	3.68
26403534	C3146287	Well	mnob	3.68
26403534	C1273342	Epithelial cell count (procedure)	lbpr	3.64
26403534	C0596611	Gene Mutation	genf	3.56
26403534	C1874451	Basis	phsu	3.55
26403534	C1527178	Basis - conceptual entity	ftcn	3.55
26403534	C0919279	A Codes	clas	3.55
26403534	C1413365	CFTR gene	gngm	3.49
26403534	C0596119	apical membrane	celc	3.44
26403534	C0314603	Genetic	ftcn	3.43
26403534	C0017296	gene therapy	topp	3.43
26403534	C0596019	Chloride Ion	elii	3.42
26403534	C0040363	Togo	geoa	17.80
26403534	C0041260	Tryptophanase	aapp	17.80
26403534	C0041260	Tryptophanase	enzy	17.80
26403534	C0392209	Nutritional status	fndg	14.64
26403534	C0010674	Cystic Fibrosis	dsyn	9.75
26403534	C0024501	Maintenance	acty	8.34
26403534	C0036537	Bodily secretions	bdsu	6.79
26403534	C1269765	Assisted (qualifier value)	qlco	5.18
26403534	C1552861	Help document	inpr	5.18
26403534	C0876973	Infectious disease of lung	dsyn	5.18
26403534	C1883351	To	qlco	5.18
26403534	C0449445	Approach	spco	3.55
26403534	C2828008	Burden	idcn	3.55
26403534	C1292724	Procedural approach	ftcn	3.55
26403534	C0425452	No obstruction of airway	fndg	3.53
26403534	C0332173	Daily	tmco	3.42
26403534	C0439539	Heavy sensation quality	qlco	3.42
26403534	C1521721	Supportive assistance	cnce	3.42
26403534	C0087111	Therapeutic procedure	topp	3.42
26403534	C1947933	care activity	acty	3.42
26403534	C0439858	classical example	qlco	3.42
26403534	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26403534	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26403534	C3264621	ivacaftor	orch	14.64
26403534	C3264621	ivacaftor	phsu	14.64
26403534	C0031843	physiological aspects	phsf	13.01
26403534	C0242373	Licensing	gora	13.01
26403534	C2718059	Precision Medicine	topp	12.91
26403534	C0010674	Cystic Fibrosis	dsyn	9.84
26403534	C0017431	Genotype	orga	6.63
26403534	C0030705	Patients	podg	6.58
26403534	C0184511	Improved	qlco	5.18
26403534	C1521840	Target	ftcn	5.18
26403534	C2986546	Target Lesion Identification	diap	5.18
26403534	C1457869	Defect	ftcn	3.68
26403534	C0723712	Therapeutic brand of coal tar	orch	3.63
26403534	C0723712	Therapeutic brand of coal tar	phsu	3.63
26403534	C0087111	Therapeutic procedure	topp	3.63
26403534	C1328819	Small Molecule	orch	3.57
26403534	C3495919	Enthesitis-Related Arthritis	dsyn	3.55
26403534	C0542341	Function	ftcn	3.55
26403534	C0700205	Function Axis	clas	3.55
26403534	C1705273	Mathematical Operator	inpr	3.55
26403534	C3889833	Structured Product Labeling Licensing Terminology	inpr	3.54
26403534	C0439659	Beginning	tmco	3.51
26403534	C1552740	Entity Determiner - specific	inpr	3.48
26403534	C0205369	Specific qualifier value	qlco	3.48
26403534	C0205314	New	qlco	3.43
26403534	C1413365	CFTR gene	gngm	3.42
26403534	C1515021	Subgroup	clas	3.42
26403534	C1079230	Subgroup A Nepoviruses	virs	3.42
26403534	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	92.26
26403534	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	92.26
26403534	C0026882	Mutation	genf	30.40
26403534	C0031843	physiological aspects	phsf	26.31
26403534	C0040363	Togo	geoa	17.80
26403534	C0041260	Tryptophanase	aapp	17.80
26403534	C0041260	Tryptophanase	enzy	17.80
26403534	C0022326	Ivory Coast	geoa	16.09
26403534	C0034754	Reading (activity)	dora	16.09
26403534	C1413365	CFTR gene	gngm	14.25
26403534	C0040649	Transcription, Genetic	genf	13.05
26403534	C0175996	Protoplasm	celc	12.90
26403534	C0282443	Review [Publication Type]	inpr	11.49
26403534	C0542341	Function	ftcn	7.28
26403534	C0700205	Function Axis	clas	7.28
26403534	C1705273	Mathematical Operator	inpr	7.28
26403534	C1552617	Act Class - review	idcn	5.18
26403534	C0442808	Increasing	ftcn	5.18
26403534	C0425382	Personal status - Adopted	fndg	5.18
26403534	C0033414	Promotion (action)	acty	5.18
26403534	C0521108	Recovering from	qlco	5.18
26403534	C2004454	Recovery - healing process	orgf	5.18
26403534	C1883351	To	qlco	5.18
26403534	C3854321	Expression (foundation metadata concept)	idcn	3.68
26403534	C0185117	Expression procedure	topp	3.68
26403534	C0205148	Surface	spco	3.68
26403534	C2327105	Surface of epithelial cell	celc	3.65
26403534	C2698969	Canadian Cardiovascular Society Grading Scale Class III	fndg	3.64
26403534	C0441887	Class 3	inpr	3.64
26403534	C0449445	Approach	spco	3.61
26403534	C1292724	Procedural approach	ftcn	3.61
26403534	C0450442	Agent	chvf	3.59
26403534	C1254351	Pharmacologic Substance	phsu	3.59
26403534	C1521826	Protocol Agent	inpr	3.59
26403534	C1709694	Processing (action)	acty	3.57
26403534	C0332454	disrupted	qlco	3.57
26403534	C0205111	Apical	spco	3.55
26403534	C2698967	Canadian Cardiovascular Society Grading Scale Class I	fndg	3.53
26403534	C2698968	Canadian Cardiovascular Society Grading Scale Class II	fndg	3.53
26403534	C0441885	Class 1	clas	3.53
26403534	C0441886	Class 2	inpr	3.53
26403534	C0033268	production	ocac	3.50
26403534	C1705179	Reading (datum presentation)	fndg	3.48
26403534	C1542147	Main	qlco	3.47
26403534	C0205225	Primary	qlco	3.47
26403534	C1521840	Target	ftcn	3.47
26403534	C0205449	Three	qnco	3.47
26403534	C0178719	Intracellular	spco	3.44
26403534	C0010674	Cystic Fibrosis	dsyn	11.49
26403534	C0016884	Future	tmco	6.58
26403534	C0678723	Biologic Development	orgf	3.55
26403534	C1527148	Development	ftcn	3.55
26403534	C0243107	development aspects	phsf	3.55
26403534	C1555307	promise	idcn	3.55
26403534	C0449445	Approach	spco	3.43
26403534	C1517331	Further	spco	3.43
26403534	C1704243	Greater	qnco	3.43
26403534	C0549177	Large	qnco	3.43
26403534	C1292724	Procedural approach	ftcn	3.43
26403534	C0302350	Therapeutic	ftcn	3.43
26403534	C0087111	Therapeutic procedure	topp	3.43
26403534	C0679199	strategy	menp	3.43
24520399	C0038990	Sweating	fndg	38.72
24520399	C0009738	Congo	geoa	32.39
24520399	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24520399	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24520399	C0036536	Process of secretion	biof	19.31
24520399	C0040363	Togo	geoa	17.80
24520399	C0041260	Tryptophanase	aapp	17.80
24520399	C0041260	Tryptophanase	enzy	17.80
24520399	C0206243	Carrying	acty	14.64
24520399	C3264621	ivacaftor	orch	12.89
24520399	C3264621	ivacaftor	phsu	12.89
24520399	C0026882	Mutation	genf	9.94
24520399	C0038984	Sweat	bdsu	9.73
24520399	C3811819	CFTR wt Allele	gngm	7.01
24520399	C0205447	One	qnco	6.97
24520399	C2349001	Human Study Subject	humn	6.96
24520399	C2697811	Investigative Subject	ftcn	6.96
24520399	C0681850	Study Subject	grup	6.96
24520399	C1706203	Subject - topic	idcn	6.96
24520399	C1550501	Subject -direct target	idcn	6.96
24520399	C0036537	Bodily secretions	bdsu	6.69
24520399	C0184511	Improved	qlco	5.18
24520399	C3264627	Kalydeco	phsu	5.18
24520399	C1883351	To	qlco	5.18
24520399	C2741958	VX-770	orch	5.18
24520399	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.44
24520399	C0449770	Measured from	qnco	3.43
24520399	C1413365	CFTR gene	gngm	3.43
24520399	C1701901	Conditional	qlco	3.43
24520399	C0851827	Dependent - ability	qlco	3.43
24520399	C3244310	dependent	ftcn	3.43
24520399	C0442027	Oral	spco	3.42
24520399	C1550043	Container status - Identified	fndg	3.42
24520399	C1285092	Gland	bpoc	3.42
24520399	C0205396	Identified	qlco	3.42
24520399	C3264621	ivacaftor	orch	44.63
24520399	C3264621	ivacaftor	phsu	44.63
24520399	C0012634	Disease	dsyn	9.74
24520399	C3838680	3+ Answer to Question	fndg	7.70
24520399	C2827736	3+ Score	qnco	7.70
24520399	C2981702	3+ Score, WHO	clas	7.70
24520399	C0439086	<3 (qualifier value)	qnco	7.70
24520399	C1720467	Only - dosing instruction fragment	inpr	7.70
24520399	C0205171	Singular	qnco	7.70
24520399	C0392366	Tests (qualifier value)	inpr	7.47
24520399	C2349001	Human Study Subject	humn	3.59
24520399	C2697811	Investigative Subject	ftcn	3.59
24520399	C0681850	Study Subject	grup	3.59
24520399	C1706203	Subject - topic	idcn	3.59
24520399	C1550501	Subject -direct target	idcn	3.59
24520399	C0022885	Laboratory Procedures	lbpr	3.56
24520399	C0205448	Two	qnco	3.48
24520399	C0450316	1/5	qnco	3.46
24520399	C0348080	Condition	qlco	3.43
24520399	C3864998	Condition:Find:Pt:^Patient:Nom	clna	3.43
24520399	C1705253	Logical Condition	cnce	3.43
24520399	C3264621	ivacaftor	orch	29.46
24520399	C3264621	ivacaftor	phsu	29.46
24520399	C1293928	Total measurement	qnco	3.56
24520399	C0449788	Count of entities	qnco	3.55
24520399	C0237753	Numbers	qnco	3.55
24520399	C1285092	Gland	bpoc	3.43
24520399	C0040223	Time	tmco	6.83
24520399	C2986479	Healthy Control	qlco	5.18
24520399	C0392366	Tests (qualifier value)	inpr	5.18
24520399	C1285092	Gland	bpoc	3.68
24520399	C1632851	Times	qnco	3.68
24520399	C3838679	4+ Answer to question	fndg	3.50
24520399	C0038990	Sweating	fndg	59.28
24520399	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.12
24520399	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.12
24520399	C0038984	Sweat	bdsu	30.44
24520399	C0034826	Muscarinic Acetylcholine Receptor	aapp	24.11
24520399	C0034826	Muscarinic Acetylcholine Receptor	rcpt	24.11
24520399	C0021966	Iodides	inch	17.80
24520399	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	14.64
24520399	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	14.64
24520399	C1413365	CFTR gene	gngm	7.04
24520399	C0332206	Blocking	ftcn	5.18
24520399	C0221138	Blood group antibody I	aapp	5.18
24520399	C0221138	Blood group antibody I	imft	5.18
24520399	C3163633	Elevated	qlco	5.18
24520399	C1285092	Gland	bpoc	5.18
24520399	C0205250	High	qlco	5.18
24520399	C0444706	Measured	qlco	5.18
24520399	C3541902	Measured Tumor Identification	diap	5.18
24520399	C0233660	Mental blocking	mobd	5.18
24520399	C1701901	Conditional	qlco	3.68
24520399	C0851827	Dependent - ability	qlco	3.68
24520399	C0085862	Independence	idcn	3.68
24520399	C1299583	Independently able	fndg	3.68
24520399	C3244310	dependent	ftcn	3.68
24520399	C0678420	Cocktail	food	3.55
24520399	C1948023	Stimulation (motivation)	npop	3.55
24520399	C0599756	adrenergic	ftcn	3.55
24520399	C0369637	M NOS ANTIBODY	aapp	3.50
24520399	C0369637	M NOS ANTIBODY	imft	3.50
24520399	C0441923	M+ (tumor staging)	inpr	3.50
24520399	C0038990	Sweating	fndg	19.45
24520399	C0009738	Congo	geoa	16.12
24520399	C3264621	ivacaftor	orch	13.09
24520399	C3264621	ivacaftor	phsu	13.09
24520399	C0038984	Sweat	bdsu	9.99
24520399	C1285092	Gland	bpoc	7.33
24520399	C3828842	Nearly	qlco	5.18
24520399	C0022885	Laboratory Procedures	lbpr	3.68
24520399	C0392366	Tests (qualifier value)	inpr	3.68
24520399	C2349001	Human Study Subject	humn	3.63
24520399	C2697811	Investigative Subject	ftcn	3.63
24520399	C0681850	Study Subject	grup	3.63
24520399	C1706203	Subject - topic	idcn	3.63
24520399	C1550501	Subject -direct target	idcn	3.63
24520399	C0430179	Sweat test	lbpr	3.60
24520399	C0728893	+5	qnco	3.50
24520399	C3842590	10%	fndg	3.50
24520399	C0439084	>5	qnco	3.50
24520399	C3811819	CFTR wt Allele	gngm	3.50
24520399	C0332197	Absent	ftcn	3.48
24520399	C2699517	Absent Adverse Event	fndg	3.48
24520399	C1720467	Only - dosing instruction fragment	inpr	3.47
24520399	C0205171	Singular	qnco	3.47
24520399	C0369637	M NOS ANTIBODY	aapp	3.43
24520399	C0369637	M NOS ANTIBODY	imft	3.43
24520399	C0441923	M+ (tumor staging)	inpr	3.43
24520399	C0038990	Sweating	fndg	38.87
24520399	C0038984	Sweat	bdsu	19.84
24520399	C0009924	Contrast Media	irda	14.64
24520399	C3264621	ivacaftor	orch	12.96
24520399	C3264621	ivacaftor	phsu	12.96
24520399	C0012634	Disease	dsyn	9.99
24520399	C1285092	Gland	bpoc	7.24
24520399	C2349001	Human Study Subject	humn	7.18
24520399	C2697811	Investigative Subject	ftcn	7.18
24520399	C0681850	Study Subject	grup	7.18
24520399	C1706203	Subject - topic	idcn	7.18
24520399	C1550501	Subject -direct target	idcn	7.18
24520399	C1979874	Contrast	qlco	5.18
24520399	C0348080	Condition	qlco	3.68
24520399	C3864998	Condition:Find:Pt:^Patient:Nom	clna	3.68
24520399	C1705253	Logical Condition	cnce	3.68
24520399	C3838680	3+ Answer to Question	fndg	3.57
24520399	C2827736	3+ Score	qnco	3.57
24520399	C2981702	3+ Score, WHO	clas	3.57
24520399	C0439086	<3 (qualifier value)	qnco	3.57
24520399	C1548610	Inter	tmco	3.55
24520399	C0205103	Intermediate	spco	3.55
24520399	C0549177	Large	qnco	3.55
24520399	C3842591	0%	fndg	3.55
24520399	C1610540	Kind of quantity - Ratios	qnco	3.55
24520399	C0369637	M NOS ANTIBODY	aapp	3.55
24520399	C0369637	M NOS ANTIBODY	imft	3.55
24520399	C0441923	M+ (tumor staging)	inpr	3.55
24520399	C0456603	Ratio	qnco	3.55
24520399	C0442750	Distance vision 6/6	fndg	3.53
24520399	C1705241	Delta (difference)	qnco	3.52
24520399	C1705242	Different	qlco	3.52
24520399	C3842591	0%	fndg	3.54
24520399	C1510992	Average	qnco	3.54
24520399	C2825518	Average of Value Derivation Technique	qnco	3.54
24520399	C0456603	Ratio	qnco	3.54
24520399	C2700323	Wild Type Unspecified - zebrafish	fish	3.54
24520399	C1547037	data type - ratio	inpr	3.54
24520399	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24520399	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24520399	C0038990	Sweating	fndg	19.40
24520399	C0031843	physiological aspects	phsf	12.89
24520399	C0015127	Etiology aspects	ftcn	11.49
24520399	C0038984	Sweat	bdsu	9.94
24520399	C1524003	Science of Etiology	cnce	5.18
24520399	C1521828	Rate	qnco	3.59
24520399	C0871208	Rating (action)	acty	3.59
24520399	C1517945	Loss	qnco	3.58
24520399	C1278296	Sweat volume	clna	3.50
24520399	C1548802	Body Site Modifier - Lower	blor	3.48
24520399	C2003888	Lower (action)	acty	3.48
24520399	C0441994	Lower - spatial qualifier	spco	3.48
24520399	C1413365	CFTR gene	gngm	3.43
24520399	C0542341	Function	ftcn	3.43
24520399	C0700205	Function Axis	clas	3.43
24520399	C1704243	Greater	qnco	3.43
24520399	C0549177	Large	qnco	3.43
24520399	C1705273	Mathematical Operator	inpr	3.43
24520399	C0038990	Sweating	fndg	19.38
24520399	C0038984	Sweat	bdsu	9.92
24520399	C0369637	M NOS ANTIBODY	aapp	7.05
24520399	C0369637	M NOS ANTIBODY	imft	7.05
24520399	C0441923	M+ (tumor staging)	inpr	7.05
24520399	C2349001	Human Study Subject	humn	5.18
24520399	C2697811	Investigative Subject	ftcn	5.18
24520399	C0681850	Study Subject	grup	5.18
24520399	C1706203	Subject - topic	idcn	5.18
24520399	C1550501	Subject -direct target	idcn	5.18
24520399	C1517945	Loss	qnco	3.98
24520399	C1521828	Rate	qnco	3.58
24520399	C0871208	Rating (action)	acty	3.58
24520399	C1285092	Gland	bpoc	3.56
24520399	C1610540	Kind of quantity - Ratios	qnco	3.55
24520399	C0444706	Measured	qlco	3.55
24520399	C0449770	Measured from	qnco	3.55
24520399	C0456603	Ratio	qnco	3.55
24520399	C0392756	Reduced	qlco	3.55
24520399	C1522410	Highest	qlco	3.47
24520399	C0087136	Unmarried	fndg	22.48
24520399	C0037179	Unmarried person	popg	22.48
24520399	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
24520399	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
24520399	C3264621	ivacaftor	orch	12.96
24520399	C3264621	ivacaftor	phsu	12.96
24520399	C0031843	physiological aspects	phsf	12.90
24520399	C0750572	Estimated	qnco	7.17
24520399	C3816745	1+	fndg	5.18
24520399	C2827734	1+ Score	qnco	5.18
24520399	C2981698	1+ Score, WHO	clas	5.18
24520399	C1947971	Give - dosing instruction imperative	ftcn	3.98
24520399	C1610540	Kind of quantity - Ratios	qnco	3.63
24520399	C0456603	Ratio	qnco	3.63
24520399	C1517945	Loss	qnco	3.59
24520399	C2349182	Correct (qualifier)	qlco	3.59
24520399	C1273517	Used by	fndg	3.59
24520399	C0439799	Channel	spco	3.56
24520399	C1706095	Channel Object	cnce	3.56
24520399	C1511726	Data	idcn	3.56
24520399	C3714741	Data (eukaryote)	euka	3.56
24520399	C3245479	Data call receiving device	medd	3.56
24520399	C0205171	Singular	qnco	3.56
24520399	C0369637	M NOS ANTIBODY	aapp	3.48
24520399	C0369637	M NOS ANTIBODY	imft	3.48
24520399	C0441923	M+ (tumor staging)	inpr	3.48
24520399	C1527428	Remaining	qlco	3.48
24520399	C1413365	CFTR gene	gngm	3.44
24520399	C0542341	Function	ftcn	3.44
24520399	C0700205	Function Axis	clas	3.44
24520399	C1705273	Mathematical Operator	inpr	3.44
24520399	C1510992	Average	qnco	3.55
24520399	C2825518	Average of Value Derivation Technique	qnco	3.55
24520399	C2700323	Wild Type Unspecified - zebrafish	fish	3.55
24520399	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
24520399	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
24520399	C0087136	Unmarried	fndg	22.40
24520399	C0037179	Unmarried person	popg	22.40
24520399	C1524024	analysis aspect	ftcn	13.14
24520399	C0750572	Estimated	qnco	5.18
24520399	C1705535	suggestion	idcn	5.18
24520399	C0936012	Analysis	resa	3.68
24520399	C0002778	Analysis of substances	lbpr	3.68
24520399	C1511726	Data	idcn	3.63
24520399	C3714741	Data (eukaryote)	euka	3.63
24520399	C3245479	Data call receiving device	medd	3.63
24520399	C0814225	benefit	qnco	3.63
24520399	C0935587	level of functioning	qlco	3.59
24520399	C0680240	agreement	socb	3.59
24520399	C1413365	CFTR gene	gngm	3.55
24520399	C3890211	Low Mitosis-Karyorrhexis Index	qnco	3.55
24520399	C0205251	low	qlco	3.55
24520399	C1550472	low confidentiality	inpr	3.55
24520399	C4048187	low exposure	qlco	3.55
24520399	C1519595	Transcript	nnon	3.50
24520399	C0439799	Channel	spco	3.48
24520399	C1706095	Channel Object	cnce	3.48
24520399	C0205210	Clinical	qlco	3.48
24520399	C1546944	Event Seriousness - Significant	qlco	3.48
24520399	C1553058	Neuropsychologist - Clinical	prog	3.48
24520399	C0237412	Psychologist - Clinical	prog	3.48
24520399	C0750502	Significant	idcn	3.48
24520399	C0205171	Singular	qnco	3.48
24520399	C0497591	Social Worker - Clinical	prog	3.48
24520399	C0237881	Statistical Significance	qnco	3.48
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
25274064	C0055363	Chloride Channels	aapp	19.39
25274064	C0055363	Chloride Channels	bacs	19.39
25274064	C0025252	Membrane Proteins	aapp	10.09
25274064	C0025252	Membrane Proteins	bacs	10.09
25274064	C1148923	atp binding	moft	3.58
25274064	C0450240	Cassette (physical object)	medd	3.55
25274064	C1706210	Cassette Device Component	mnob	3.55
25274064	C1883220	Superfamily	cnce	3.55
25274064	C1413365	CFTR gene	gngm	3.55
25274064	C0443238	Integral	qnco	3.48
25274064	C0599638	Drinking Water	sbst	24.11
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25274064	C0043047	Water	inch	20.95
25274064	C0043047	Water	phsu	20.95
25274064	C0037494	Sodium Chloride	bacs	16.05
25274064	C0037494	Sodium Chloride	inch	16.05
25274064	C0037494	Sodium Chloride	phsu	16.05
25274064	C0206136	Sodium Chloride, Dietary	food	12.89
25274064	C0005528	Biological Transport	celf	11.49
25274064	C0015127	Etiology aspects	ftcn	11.49
25274064	C0010674	Cystic Fibrosis	dsyn	9.92
25274064	C0026882	Mutation	genf	9.86
25274064	C0033684	Proteins	aapp	8.34
25274064	C0033684	Proteins	bacs	8.34
25274064	C1413365	CFTR gene	gngm	6.92
25274064	C0036140	Salts	chvs	6.59
25274064	C3495449	Mobility aid	medd	5.18
25274064	C1524003	Science of Etiology	cnce	5.18
25274064	C3669221	Transports (Activity)	acty	5.18
25274064	C1550678	Water Specimen	inch	5.18
25274064	C1317949	transport (device)	mnob	5.18
25274064	C0596611	Gene Mutation	genf	3.58
25274064	C0332452	defective	ftcn	3.57
25274064	C0040300	Body tissue	tisu	3.44
25274064	C3540763	VARIOUS DRUG CLASSES IN ATC	phsu	3.44
25274064	C0440102	Various patch test substance	irda	3.44
25274064	C3540765	various allergen extracts	imft	3.44
25274064	C3540765	various allergen extracts	phsu	3.44
25274064	C3540008	various antiinfectives and antiseptics for local oral treatment	phsu	3.44
25274064	C3540766	various antiseptic throat preparations	phsu	3.44
25274064	C3540762	various other agents for local oral treatment in ATC	phsu	3.44
25274064	C3540769	various other intestinal adsorbents in ATC	phsu	3.44
25274064	C3540761	various other nasal preparations in ATC	phsu	3.44
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.40
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.40
25274064	C0040363	Togo	geoa	17.80
25274064	C0041260	Tryptophanase	aapp	17.80
25274064	C0041260	Tryptophanase	enzy	17.80
25274064	C1257739	NIH 3T3 Cells	cell	16.26
25274064	C0206243	Carrying	acty	14.64
25274064	C0025255	Tissue membrane	tisu	13.59
25274064	C0026377	Molecular Conformation	spco	13.02
25274064	C1413365	CFTR gene	gngm	10.72
25274064	C0026882	Mutation	genf	9.99
25274064	C0596901	Membrane	celc	8.34
25274064	C4048755	Apply	ftcn	5.18
25274064	C1292732	Investigates	ftcn	5.18
25274064	C1706182	Membrane Device Component	mnob	5.18
25274064	C1660735	SAXS	lbpr	5.18
25274064	C1883351	To	qlco	5.18
25274064	C1537058	small angle X ray scattering	lbpr	5.18
25274064	C1705285	Mutation Abnormality	comd	3.68
25274064	C1883559	Wild Type	gngm	3.61
25274064	C0449851	Techniques	ftcn	3.57
25274064	C3541890	Extracted Lead	fndg	3.55
25274064	C0185115	Extraction	topp	3.55
25274064	C1979928	Microsomal	qlco	3.44
25274064	C0028377	Normal Statistical Distribution	qnco	19.32
25274064	C0040363	Togo	geoa	17.80
25274064	C0041260	Tryptophanase	aapp	17.80
25274064	C0041260	Tryptophanase	enzy	17.80
25274064	C0023768	Lipid Bilayers	celc	16.12
25274064	C0596488	electron density	mosq	7.05
25274064	C0025255	Tissue membrane	tisu	6.58
25274064	C1883351	To	qlco	5.18
25274064	C0444686	Calculated (origins)	ftcn	3.56
25274064	C1443182	Calculated (procedure)	lbpr	3.56
25274064	C1441506	Calculation	acty	3.56
25274064	C1511726	Data	idcn	3.56
25274064	C3714741	Data (eukaryote)	euka	3.56
25274064	C3245479	Data call receiving device	medd	3.56
25274064	C1660735	SAXS	lbpr	3.56
25274064	C1979963	Profile (lab procedure)	lbpr	3.55
25274064	C2003903	Profiling (action)	ftcn	3.55
25274064	C0205549	Series	qnco	3.55
25274064	C2348044	Series - set of composite instances	inpr	3.55
25274064	C0222041	Shell - Animal skin appendage	bpoc	3.55
25274064	C0026377	Molecular Conformation	spco	13.01
25274064	C0026029	Microsomes	celc	12.89
25274064	C2700400	Contain (action)	acty	5.18
25274064	C0332256	Containing (qualifier)	ftcn	5.18
25274064	C1511726	Data	idcn	5.18
25274064	C3714741	Data (eukaryote)	euka	5.18
25274064	C3245479	Data call receiving device	medd	5.18
25274064	C0230770	Endoplasmic reticulum, membrane	celc	3.76
25274064	C0205101	Extrinsic	spco	3.55
25274064	C1704322	Orientation (spatial)	spco	3.55
25274064	C1961028	Oriented to place	fndg	3.55
25274064	C0439787	Out (direction)	spco	3.55
25274064	C0849355	Removed	qlco	3.55
25274064	C1167317	vesicle membrane	celc	3.55
25274064	C0750554	MOSTLY	idcn	3.47
25274064	C0205393	Most	qnco	3.47
25274064	C0031715	Phosphorylation	moft	13.14
25274064	C0392747	Changing	ftcn	7.43
25274064	C1979963	Profile (lab procedure)	lbpr	7.05
25274064	C2003903	Profiling (action)	ftcn	7.05
25274064	C0443172	Changed status	qnco	5.18
25274064	C1705241	Delta (difference)	qnco	5.18
25274064	C3160734	Dephosphorylation	moft	5.18
25274064	C1518422	Negation	ftcn	5.18
25274064	C1158884	Protein dephosphorylation	moft	5.18
25274064	C1158886	Protein phosphorylation	moft	3.68
25274064	C3889737	Data Change Date	tmco	3.54
25274064	C3840684	Modification	inpr	3.54
25274064	C1554963	ResponseLevel - modification	ftcn	3.54
25274064	C0596488	electron density	mosq	3.50
25274064	C1546944	Event Seriousness - Significant	qlco	3.42
25274064	C0205102	Internal	spco	3.42
25274064	C0441987	Side	spco	3.42
25274064	C0750502	Significant	idcn	3.42
25274064	C0237881	Statistical Significance	qnco	3.42
25274064	C0917903	Conclude Resin	bodm	27.26
25274064	C0917903	Conclude Resin	orch	27.26
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
25274064	C0026029	Microsomes	celc	12.89
25274064	C1413365	CFTR gene	gngm	5.18
25274064	C0750554	MOSTLY	idcn	5.18
25274064	C0205393	Most	qnco	5.18
25274064	C1180347	Protein complex	aapp	3.59
25274064	C1180347	Protein complex	bacs	3.59
25274064	C1523872	protein complex location	celc	3.59
25274064	C0332281	Associated with	qlco	3.43
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25274064	C0038164	Staphylococcal Protein A	aapp	12.90
25274064	C0038164	Staphylococcal Protein A	imft	12.90
25274064	C0038164	Staphylococcal Protein A	irda	12.90
25274064	C0026029	Microsomes	celc	12.88
25274064	C0025255	Tissue membrane	tisu	8.34
25274064	C1705242	Different	qlco	7.02
25274064	C1705535	suggestion	idcn	3.98
25274064	C1979963	Profile (lab procedure)	lbpr	3.54
25274064	C2003903	Profiling (action)	ftcn	3.54
25274064	C0205197	Complete	qlco	3.44
25274064	C2700323	Wild Type Unspecified - zebrafish	fish	3.44
25274064	C1413365	CFTR gene	gngm	3.42
25274064	C0596488	electron density	mosq	3.41
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.68
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.68
25274064	C0039798	therapeutic aspects	ftcn	22.48
25274064	C0009264	Cold Temperature	npop	22.38
25274064	C0026377	Molecular Conformation	spco	13.03
25274064	C2700323	Wild Type Unspecified - zebrafish	fish	5.18
25274064	C0332294	Resulting in	ftcn	3.64
25274064	C1533734	Administration procedure	topp	3.55
25274064	C1705169	Biomaterial Treatment	cnce	3.55
25274064	C0087111	Therapeutic procedure	topp	3.55
25274064	C1522326	Treating	ftcn	3.55
25274064	C3538994	Treatment Epoch	resa	3.55
25274064	C3887704	treatment - ActInformationManagementReason	hlca	3.55
25274064	C0301863	"""U"" lymphocyte"	cell	3.44
25274064	C0039798	therapeutic aspects	ftcn	22.48
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25274064	C0026377	Molecular Conformation	spco	13.14
25274064	C0013850	Electronic	mnob	9.73
25274064	C0596901	Membrane	celc	6.58
25274064	C0025255	Tissue membrane	tisu	6.58
25274064	C0392747	Changing	ftcn	5.18
25274064	C0205197	Complete	qlco	5.18
25274064	C1518422	Negation	ftcn	5.18
25274064	C0521108	Recovering from	qlco	5.18
25274064	C2004454	Recovery - healing process	orgf	5.18
25274064	C1533734	Administration procedure	topp	3.55
25274064	C1705169	Biomaterial Treatment	cnce	3.55
25274064	C0087111	Therapeutic procedure	topp	3.55
25274064	C1522326	Treating	ftcn	3.55
25274064	C3538994	Treatment Epoch	resa	3.55
25274064	C3887704	treatment - ActInformationManagementReason	hlca	3.55
25274064	C1979963	Profile (lab procedure)	lbpr	3.55
25274064	C2003903	Profiling (action)	ftcn	3.55
25274064	C2700323	Wild Type Unspecified - zebrafish	fish	3.50
25274064	C3252847	VX 809	orch	3.45
25274064	C3252847	VX 809	phsu	3.45
25274064	C1547561	Authorization Mode - Electronic	idcn	3.42
25274064	C1413365	CFTR gene	gngm	3.42
25274064	C1706182	Membrane Device Component	mnob	3.42
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
25274064	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
25274064	C0012634	Disease	dsyn	9.94
25274064	C0031330	Pharmacology	bmod	9.81
25274064	C0014406	Environment	spco	9.74
25274064	C0376554	Knowledge	inpr	8.34
25274064	C0596901	Membrane	celc	6.57
25274064	C2700400	Contain (action)	acty	5.18
25274064	C0332256	Containing (qualifier)	ftcn	5.18
25274064	C0348080	Condition	qlco	3.63
25274064	C3864998	Condition:Find:Pt:^Patient:Nom	clna	3.63
25274064	C1705253	Logical Condition	cnce	3.63
25274064	C1705242	Different	qlco	3.57
25274064	C0542341	Function	ftcn	3.57
25274064	C0205245	Functional	ftcn	3.57
25274064	C2700217	Functional Relationship	cnce	3.57
25274064	C1413365	CFTR gene	gngm	3.56
25274064	C3273238	Regulatory Report	inpr	3.54
25274064	C0684224	Report (document)	inpr	3.54
25274064	C0700287	Reporting	hlca	3.54
25274064	C0205464	pharmacological	ftcn	3.50
25274064	C0302891	Native (qualifier value)	ftcn	3.43
25274064	C1947931	Direct (qualifier)	qlco	3.42
25274064	C0439851	Direct type of relationship	qlco	3.42
25274064	C0205435	First (number)	qnco	3.42
25274064	C1279901	Firstly	qlco	3.42
25274064	C0242485	Measurement	ftcn	3.42
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
27214033	C0031453	Phenylalanine	aapp	16.17
27214033	C0031453	Phenylalanine	bacs	16.17
27214033	C0031453	Phenylalanine	phsu	16.17
27214033	C1314792	Etiology	ftcn	14.64
27214033	C1511760	Deletion Mutation	genf	13.01
27214033	C0023175	Lead	elii	13.01
27214033	C0023175	Lead	hops	13.01
27214033	C0015127	Etiology aspects	ftcn	11.49
27214033	C0033684	Proteins	aapp	6.79
27214033	C0033684	Proteins	bacs	6.79
27214033	C1524003	Science of Etiology	cnce	5.18
27214033	C0185026	Plication	topp	3.68
27214033	C4019252	Position of phenotypic abnormality	ftcn	3.68
27214033	C0733755	Positioning Attribute	spco	3.68
27214033	C0243067	defects aspect	ftcn	3.68
27214033	C3275067	Cardiac Lead Procedure	topp	3.55
27214033	C1880274	Deletion (action)	acty	3.55
27214033	C2348269	Dietary Lead	elii	3.55
27214033	C1442161	Gene Deletion Abnormality	comd	3.55
27214033	C1522538	Leading	ftcn	3.55
27214033	C0181586	Leads (device)	medd	3.55
27214033	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.55
27214033	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.55
27214033	C0202174	blood phenylalanine measurement by Guthrie microbiologic assay	lbpr	3.55
27214033	C0678941	Gene Mutant	gngm	3.55
27214033	C0596611	Gene Mutation	genf	3.55
27214033	C0542341	Function	ftcn	3.50
27214033	C0205245	Functional	ftcn	3.50
27214033	C2700217	Functional Relationship	cnce	3.50
27214033	C0439064	Numerous	qnco	3.50
27214033	C1704735	Regulator	cnce	3.48
27214033	C1704734	Regulator Device Component	mnob	3.48
27214033	C0182953	Regulators (device)	medd	3.48
27214033	C1413365	CFTR gene	gngm	3.46
27214033	C0205214	Common (qualifier value)	qnco	3.42
27214033	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
27214033	C0205393	Most	qnco	3.42
27214033	C1522138	shared attribute	ftcn	3.42
27214033	C0087136	Unmarried	fndg	22.48
27214033	C0037179	Unmarried person	popg	22.48
27214033	C0021267	Industry	ocac	8.34
27214033	C1510747	Academia (organization)	orgt	5.18
27214033	C0814225	benefit	qnco	3.63
27214033	C0205171	Singular	qnco	3.56
27214033	C1546944	Event Seriousness - Significant	qlco	3.48
27214033	C0750502	Significant	idcn	3.48
27214033	C0237881	Statistical Significance	qnco	3.48
27214033	C0302350	Therapeutic	ftcn	3.48
27214033	C0087111	Therapeutic procedure	topp	3.48
27214033	C0349674	Intellectual scale	inpr	3.43
27214033	C0549177	Large	qnco	3.43
27214033	C3536777	Scale Device Component	mnob	3.43
27214033	C1947916	Scaling	acty	3.43
27214033	C0175659	Weight measurement scales	medd	3.43
27214033	C0015264	Exertion	orgf	3.41
27214033	C0013162	Drug Combinations	phsu	6.79
27214033	C1261322	Evaluation procedure	hlca	5.18
27214033	C2003864	Concentrate (activity)	acty	3.57
27214033	C1880310	Dialysate Concentrate	mnob	3.57
27214033	C0041714	United States Food and Drug Administration	hcro	25.50
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
27214033	C0005495	Origin of Life	npop	16.25
27214033	C0031843	physiological aspects	phsf	14.64
27214033	C0026882	Mutation	genf	9.88
27214033	C0015127	Etiology aspects	ftcn	9.85
27214033	C0010674	Cystic Fibrosis	dsyn	9.74
27214033	C0220781	Anabolism	biof	6.79
27214033	C0542341	Function	ftcn	5.18
27214033	C0700205	Function Axis	clas	5.18
27214033	C0184511	Improved	qlco	5.18
27214033	C1705273	Mathematical Operator	inpr	5.18
27214033	C3252847	VX 809	orch	5.18
27214033	C3252847	VX 809	phsu	5.18
27214033	C2741958	VX-770	orch	5.18
27214033	C4033620	ORKAMBI	phsu	3.68
27214033	C1254351	Pharmacologic Substance	phsu	3.68
27214033	C1135440	Procedures involving the use of pharmaceuticals	topp	3.68
27214033	C1705285	Mutation Abnormality	comd	3.57
27214033	C0205195	Combined	qlco	3.56
27214033	C3811910	combination - answer to question	fndg	3.56
27214033	C1947911	combination of objects	phob	3.56
27214033	C3469597	Administration of medication	hlca	3.56
27214033	C0150270	Medication Management	hlca	3.56
27214033	C1524003	Science of Etiology	cnce	3.54
27214033	C2697524	Graph Node	cnce	3.50
27214033	C0230003	Vertex	blor	3.50
27214033	C1413365	CFTR gene	gngm	3.48
27214033	C0205540	Approved	qlco	3.42
27214033	C0205435	First (number)	qnco	3.42
27214033	C1279901	Firstly	qlco	3.42
27214033	C0008976	Clinical Trials	resa	20.95
27214033	C1096775	Clinical Trial [Publication Type]	inpr	11.49
27214033	C0205195	Combined	qlco	5.18
27214033	C3811910	combination - answer to question	fndg	5.18
27214033	C1947911	combination of objects	phob	5.18
27214033	C1547282	Show	anim	3.98
27214033	C0814225	benefit	qnco	3.61
27214033	C4054480	Modest Extremity Pain	inpr	3.47
27214033	C1720467	Only - dosing instruction fragment	inpr	3.47
27214033	C0205171	Singular	qnco	3.47
27214033	C0302350	Therapeutic	ftcn	3.47
27214033	C0087111	Therapeutic procedure	topp	3.47
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.46
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.46
27214033	C4033620	ORKAMBI	phsu	3.63
27214033	C2741958	VX-770	orch	3.55
27214033	C1413365	CFTR gene	gngm	3.54
27214033	C0086597	Mediate	socb	3.54
27214033	C0127400	Mediator brand of benfluorex hydrochloride	orch	3.54
27214033	C0127400	Mediator brand of benfluorex hydrochloride	phsu	3.54
27214033	C0449234	Concept Attribute	idcn	3.51
27214033	C1882133	Object Attribute	qlco	3.51
27214033	C1704772	Protection Element Attribute	cnce	3.51
27214033	C1280519	Effectiveness	qlco	3.48
27214033	C1707887	Efficacy Study	resa	3.48
27214033	C3890211	Low Mitosis-Karyorrhexis Index	qnco	3.48
27214033	C0205251	low	qlco	3.48
27214033	C1550472	low confidentiality	inpr	3.48
27214033	C4048187	low exposure	qlco	3.48
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27214033	C0014239	Endoplasmic Reticulum	celc	22.36
27214033	C0018517	Half-Life	tmco	9.88
27214033	C0376315	Manufactured form	mnob	6.58
27214033	C0439645	Band form	spco	5.18
27214033	C0175723	Bands	medd	5.18
27214033	C1521913	Chromosome band	celc	5.18
27214033	C3273238	Regulatory Report	inpr	5.18
27214033	C0684224	Report (document)	inpr	5.18
27214033	C0700287	Reporting	hlca	5.18
27214033	C0450373	4a serotype	inpr	3.68
27214033	C1553636	Maxillary right second premolar abutment	medd	3.68
27214033	C0442808	Increasing	ftcn	3.59
27214033	C1555029	Reverse	ftcn	3.55
27214033	C1280500	Effect	qlco	3.55
27214033	C0205160	Negative	qlco	3.55
27214033	C3853545	Negative - answer	qlco	3.55
27214033	C2825491	Negative Charge	qlco	3.55
27214033	C1513916	Negative Finding	fndg	3.55
27214033	C2825415	Negative Number	cnce	3.55
27214033	C2741958	VX-770	orch	3.45
27214033	C1413365	CFTR gene	gngm	3.44
27214033	C1522492	Formation	ftcn	3.42
27214033	C0348078	Qualitative form	qlco	3.42
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.96
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.96
27214033	C0018517	Half-Life	tmco	19.75
27214033	C0205171	Singular	qnco	7.22
27214033	C1413365	CFTR gene	gngm	6.89
27214033	C0442805	Increase	ftcn	5.18
27214033	C0205217	Increased	qnco	5.18
27214033	C0439044	Living Alone	fndg	5.18
27214033	C0679994	alone - group size	grpa	5.18
27214033	C0450373	4a serotype	inpr	3.68
27214033	C1553636	Maxillary right second premolar abutment	medd	3.68
27214033	C0150312	Present	qnco	3.56
27214033	C0449450	Presentation	idcn	3.56
27214033	C1280500	Effect	qlco	3.55
27214033	C0242485	Measurement	ftcn	3.43
27214033	C2945599	Mild (qualifier value)	qlco	3.42
27214033	C0547040	Minimal	qlco	3.42
27214033	C1524031	Minimum	qlco	3.42
27214033	C1720467	Only - dosing instruction fragment	inpr	3.42
27214033	C0439645	Band form	spco	3.42
27214033	C0175723	Bands	medd	3.42
27214033	C1521913	Chromosome band	celc	3.42
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27214033	C0023175	Lead	elii	13.03
27214033	C0023175	Lead	hops	13.03
27214033	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	12.88
27214033	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	12.88
27214033	C3252847	VX 809	orch	7.09
27214033	C3252847	VX 809	phsu	7.09
27214033	C0521116	Current (present time)	tmco	5.18
27214033	C1511726	Data	idcn	5.18
27214033	C3714741	Data (eukaryote)	euka	5.18
27214033	C3245479	Data call receiving device	medd	5.18
27214033	C1547282	Show	anim	5.18
27214033	C0311403	inhibited	qlco	5.18
27214033	C2741958	VX-770	orch	3.76
27214033	C0450373	4a serotype	inpr	3.68
27214033	C1553636	Maxillary right second premolar abutment	medd	3.68
27214033	C3275067	Cardiac Lead Procedure	topp	3.57
27214033	C2348269	Dietary Lead	elii	3.57
27214033	C1435727	FABP6 protein, human	aapp	3.57
27214033	C1435727	FABP6 protein, human	bacs	3.57
27214033	C1522538	Leading	ftcn	3.57
27214033	C0181586	Leads (device)	medd	3.57
27214033	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.57
27214033	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.57
27214033	C1707455	Comparison	acty	3.56
27214033	C0439044	Living Alone	fndg	3.56
27214033	C0205171	Singular	qnco	3.56
27214033	C0679994	alone - group size	grpa	3.56
27214033	C1293130	Stabilization	topp	3.55
27214033	C0442805	Increase	ftcn	3.54
27214033	C0205420	Concurrent	tmco	3.43
27214033	C1548968	Service Request Relationship - Simultaneous	idcn	3.43
27214033	C0521115	Simultaneous	tmco	3.43
27214033	C0439645	Band form	spco	3.42
27214033	C0175723	Bands	medd	3.42
27214033	C1413365	CFTR gene	gngm	3.42
27214033	C1521913	Chromosome band	celc	3.42
27214033	C0740116	+2	qnco	3.42
27214033	C3833492	2+	fndg	3.42
27214033	C2827735	2+ Score	qnco	3.42
27214033	C2981700	2+ Score, WHO	clas	3.42
27214033	C1879547	Activation action	acty	3.42
27214033	C1880834	Fold in Medical Device Material	phpr	3.42
27214033	C0332462	Folded structure	spco	3.42
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.10
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.10
27214033	C0004135	Ataxia Telangiectasia	dsyn	22.38
27214033	C1413365	CFTR gene	gngm	7.03
27214033	C0392760	Affecting	ftcn	5.18
27214033	C1314939	Involvement with	ftcn	5.18
27214033	C1545588	Protection	fndg	3.63
27214033	C1280500	Effect	qlco	3.55
27214033	C0205160	Negative	qlco	3.55
27214033	C3853545	Negative - answer	qlco	3.55
27214033	C2825491	Negative Charge	qlco	3.55
27214033	C1513916	Negative Finding	fndg	3.55
27214033	C2825415	Negative Number	cnce	3.55
27214033	C1552740	Entity Determiner - specific	inpr	3.54
27214033	C0205369	Specific qualifier value	qlco	3.54
27214033	C0450373	4a serotype	inpr	3.48
27214033	C1553636	Maxillary right second premolar abutment	medd	3.48
27214033	C3540695	Anatomical Therapeutic Chemical (ATC)-classification system	inpr	3.45
27214033	C1547311	Patient Condition Code - Stable	inpr	3.45
27214033	C0205360	Stable status	qlco	3.45
27214033	C0205419	Variant	qlco	3.45
27214033	C2741958	VX-770	orch	3.45
27214033	C0302891	Native (qualifier value)	ftcn	3.42
27214033	C0871468	Synonym	cnce	3.41
27214033	C3541381	Synonym (core metadata concept)	inpr	3.41
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27214033	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27214033	C3810541	Adverse Event Emergency Room Visit	inbe	5.18
27214033	C3811131	Estrogen Receptor Measurement	lbpr	5.18
27214033	C0947630	Scientific Study	lbpr	5.18
27214033	C1293130	Stabilization	topp	3.55
27214033	C0542341	Function	ftcn	3.43
27214033	C0205245	Functional	ftcn	3.43
27214033	C2700217	Functional Relationship	cnce	3.43
27214033	C4033620	ORKAMBI	phsu	3.43
27214033	C0439645	Band form	spco	3.42
27214033	C0175723	Bands	medd	3.42
27214033	C1413365	CFTR gene	gngm	3.42
27214033	C1521913	Chromosome band	celc	3.42
28231890	C0001721	Affect (mental function)	menp	11.49
28231890	C0267963	Exocrine pancreatic insufficiency	dsyn	11.49
28231890	C0010674	Cystic Fibrosis	dsyn	9.88
28231890	C0021270	Infant	aggp	9.86
28231890	C3842583	80%	fndg	3.55
28231890	C0205172	More	ftcn	3.55
28231890	C0267963	Exocrine pancreatic insufficiency	dsyn	10.06
28231890	C0030293	Pancreatic Insufficiency	dsyn	10.06
28231890	C2033024	pancreatic functions fecal elastase (lab test)	lbpr	3.58
28231890	C0011900	Diagnosis	fndg	3.55
28231890	C0441889	Levels (qualifier value)	qlco	3.55
28231890	C3890211	Low Mitosis-Karyorrhexis Index	qnco	3.55
28231890	C0205251	low	qlco	3.55
28231890	C1550472	low confidentiality	inpr	3.55
28231890	C4048187	low exposure	qlco	3.55
28231890	C0039798	therapeutic aspects	ftcn	22.56
28231890	C0040363	Togo	geoa	17.80
28231890	C0041260	Tryptophanase	aapp	17.80
28231890	C0041260	Tryptophanase	enzy	17.80
28231890	C0006777	Energy Intake	qnco	16.37
28231890	C0392209	Nutritional status	fndg	13.22
28231890	C0024501	Maintenance	acty	8.34
28231890	C0014442	Enzymes	enzy	6.63
28231890	C0014442	Enzymes	orch	6.63
28231890	C1883351	To	qlco	5.18
28231890	C0851683	Pancreatic Therapy	topp	3.78
28231890	C1533734	Administration procedure	topp	3.63
28231890	C1705169	Biomaterial Treatment	cnce	3.63
28231890	C0087111	Therapeutic procedure	topp	3.63
28231890	C1522326	Treating	ftcn	3.63
28231890	C3538994	Treatment Epoch	resa	3.63
28231890	C3887704	treatment - ActInformationManagementReason	hlca	3.63
28231890	C0920330	Pancreatic enzyme	aapp	3.53
28231890	C0920330	Pancreatic enzyme	enzy	3.53
28231890	C0920330	Pancreatic enzyme	phsu	3.53
28231890	C0205170	Good	qlco	3.48
28231890	C2698651	Optimum	qlco	3.48
28231890	C0039798	therapeutic aspects	ftcn	22.48
28231890	C0032105	Plasma	bdsu	13.03
28231890	C0014445	enzymology	ftcn	9.87
28231890	C0014442	Enzymes	enzy	6.71
28231890	C0014442	Enzymes	orch	6.71
28231890	C0556111	Fat soluble vitamin supplementation	phsu	4.12
28231890	C0332281	Associated with	qlco	3.61
28231890	C0920330	Pancreatic enzyme	aapp	3.61
28231890	C0920330	Pancreatic enzyme	enzy	3.61
28231890	C0920330	Pancreatic enzyme	phsu	3.61
28231890	C0851683	Pancreatic Therapy	topp	3.60
28231890	C2937289	Adapt (substance)	orch	3.57
28231890	C0441889	Levels (qualifier value)	qlco	3.57
28231890	C1550098	Plasma, NOS (not otherwise specified)	bdsu	3.57
28231890	C1533734	Administration procedure	topp	3.56
28231890	C1705169	Biomaterial Treatment	cnce	3.56
28231890	C3540048	ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS	enzy	3.56
28231890	C3540048	ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS	phsu	3.56
28231890	C3540772	Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	enzy	3.56
28231890	C3540772	Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	phsu	3.56
28231890	C3542456	Enzymes for ALIMENTARY TRACT AND METABOLISM	enzy	3.56
28231890	C3542456	Enzymes for ALIMENTARY TRACT AND METABOLISM	phsu	3.56
28231890	C3541394	Enzymes, antithrombotic	enzy	3.56
28231890	C3541394	Enzymes, antithrombotic	phsu	3.56
28231890	C3540017	Enzymes, hematological	enzy	3.56
28231890	C3540017	Enzymes, hematological	phsu	3.56
28231890	C3540790	Enzymes, peripheral vasodilators	enzy	3.56
28231890	C3540790	Enzymes, peripheral vasodilators	phsu	3.56
28231890	C0087111	Therapeutic procedure	topp	3.56
28231890	C1522326	Treating	ftcn	3.56
28231890	C3538994	Treatment Epoch	resa	3.56
28231890	C3887704	treatment - ActInformationManagementReason	hlca	3.56
28231890	C0376520	Dietary Iron	inch	13.14
28231890	C0302583	Iron	bacs	13.14
28231890	C0302583	Iron	elii	13.14
28231890	C0302583	Iron	phsu	13.14
28231890	C0045143	2',5'-oligoadenylate	nnon	12.89
28231890	C0045143	2',5'-oligoadenylate	phsu	12.89
28231890	C0028953	Oligonucleotides	nnon	12.89
28231890	C0013879	Elements	elii	6.58
28231890	C0205214	Common (qualifier value)	qnco	5.18
28231890	C3245511	Common Specifications in HL7 V3 Publishing	inpr	5.18
28231890	C1522138	shared attribute	ftcn	5.18
28231890	C1166521	Ferrum metallicum, Homeopathic preparation	phsu	3.68
28231890	C3714701	Iron Drug Class	phsu	3.68
28231890	C0235950	Zinc deficiency	dsyn	3.58
28231890	C1705248	Component (part)	cnce	3.43
28231890	C3812827	Study Element	cnce	3.43
28231890	C0021853	Intestines	bpoc	19.63
28231890	C0005367	Bicarbonates	inch	19.19
28231890	C0005367	Bicarbonates	phsu	19.19
28231890	C0030685	Patient Discharge	hlca	19.19
28231890	C0031843	physiological aspects	phsf	14.64
28231890	C0030274	Pancreas	bpoc	8.34
28231890	C4048290	pH	qnco	6.79
28231890	C1278931	Entire pancreas	bpoc	5.18
28231890	C0542341	Function	ftcn	5.18
28231890	C0700205	Function Axis	clas	5.18
28231890	C1705273	Mathematical Operator	inpr	5.18
28231890	C0920330	Pancreatic enzyme	aapp	5.18
28231890	C0920330	Pancreatic enzyme	enzy	5.18
28231890	C0920330	Pancreatic enzyme	phsu	5.18
28231890	C4049686	Infusion pump Alert priority PH	fndg	3.63
28231890	C0450407	ph+	fndg	3.63
28231890	C0450408	ph++	fndg	3.63
28231890	C0450409	ph+++	fndg	3.63
28231890	C2698651	Optimum	qlco	3.55
28231890	C3890211	Low Mitosis-Karyorrhexis Index	qnco	3.54
28231890	C0205251	low	qlco	3.54
28231890	C1550472	low confidentiality	inpr	3.54
28231890	C4048187	low exposure	qlco	3.54
28231890	C0442115	Intraluminal	spco	3.48
28231890	C1292984	Procedure on intestine	hlca	3.48
28231890	C1518422	Negation	ftcn	3.43
28231890	C0205107	Proximal	spco	3.43
28231890	C0439180	% release (qualifier value)	qnco	3.42
28231890	C1689985	Absence (morphologic abnormality)	anab	3.42
28231890	C0332197	Absent	ftcn	3.42
28231890	C2722820	Bicarbonate preparation	orch	3.42
28231890	C2722820	Bicarbonate preparation	phsu	3.42
28231890	C0680255	Discharge (release)	hlca	3.42
28231890	C1963578	Release (procedure)	topp	3.42
28231890	C1283071	Release - action (qualifier value)	ftcn	3.42
28231890	C0391871	Released (action)	ftcn	3.42
28231890	C0973231	bicarbonate ion	inch	3.42
28231890	C0358591	Proton Pump Inhibitors	phsu	16.10
28231890	C1524063	Use of	ftcn	3.59
28231890	C1562632	Hoover technique	topp	3.55
28231890	C1384478	Proton Pump Inhibitors [MoA]	moft	3.48
28231890	C3540020	Proton pump inhibitors for peptic ulcer and GORD	phsu	3.48
28231890	C0920330	Pancreatic enzyme	aapp	3.45
28231890	C0920330	Pancreatic enzyme	enzy	3.45
28231890	C0920330	Pancreatic enzyme	phsu	3.45
28231890	C0043094	Weight Gain	fndg	25.69
28231890	C3264621	ivacaftor	orch	12.89
28231890	C3264621	ivacaftor	phsu	12.89
28231890	C0021853	Intestines	bpoc	9.78
28231890	C0026882	Mutation	genf	9.74
28231890	C4048290	pH	qnco	6.79
28231890	C0030705	Patients	podg	6.71
28231890	C0683607	allowing	socb	5.18
28231890	C4049686	Infusion pump Alert priority PH	fndg	3.63
28231890	C0450407	ph+	fndg	3.63
28231890	C0450408	ph++	fndg	3.63
28231890	C0450409	ph+++	fndg	3.63
28231890	C2911647	Weight Gain Adverse Event	fndg	3.61
28231890	C2348205	Similarity	qlco	3.59
28231890	C3242274	new therapy	fndg	3.57
28231890	C1292984	Procedure on intestine	hlca	3.48
28231890	C2587213	Control function	ftcn	3.43
28231890	C1882979	Scientific Control	cnce	3.43
28231890	C3274648	True Control Status	qlco	3.43
28231890	C0243148	control aspects	qlco	3.43
28231890	C1550141	control substance	sbst	3.43
28231890	C1705285	Mutation Abnormality	comd	3.43
28231890	C0023671	Life Expectancy	grpa	19.21
28231890	C0009738	Congo	geoa	17.80
28231890	C0011849	Diabetes Mellitus	dsyn	13.14
28231890	C1527396	Fibrocystic Disease of Pancreas	dsyn	9.99
28231890	C0022131	Islets of Langerhans	bpoc	9.88
28231890	C0012634	Disease	dsyn	9.85
28231890	C0030705	Patients	podg	6.58
28231890	C3811819	CFTR wt Allele	gngm	5.18
28231890	C0011847	Diabetes	dsyn	3.68
28231890	C0332294	Resulting in	ftcn	3.57
28231890	C1948029	Destruction (action)	acty	3.54
28231890	C1261381	Destructive procedure (surgical)	topp	3.54
28231890	C0441592	Surgical lengthening - action	topp	3.54
28231890	C0220784	anatomic	qlco	3.54
28231890	C0205314	New	qlco	3.54
28231890	C0309049	favor	orch	3.53
28231890	C0309049	favor	phsu	3.53
28231890	C0309049	favor	vita	3.53
28231890	C1879746	Aspect (characteristic)	qlco	3.51
28231890	C1547011	Aspect - Kind of quantity	qnco	3.51
28231890	C0750573	emergent	idcn	3.48
28231890	C0011849	Diabetes Mellitus	dsyn	14.64
28231890	C0001721	Affect (mental function)	menp	11.49
28231890	C0439234	year	tmco	7.11
28231890	C0030705	Patients	podg	6.71
28231890	C0011847	Diabetes	dsyn	5.18
28231890	C0521116	Current (present time)	tmco	3.68
28231890	C2825407	Half	qnco	3.57
28231890	C0205437	Third	qnco	3.56
28231890	C3842589	20%	fndg	3.50
28231890	C3842588	30%	fndg	3.44
28231890	C0026538	Morbidity - disease rate	qnco	19.20
28231890	C0026565	Mortality Vital Statistics	qnco	19.20
28231890	C0271650	Impaired glucose tolerance	dsyn	16.17
28231890	C0011849	Diabetes Mellitus	dsyn	13.07
28231890	C0960756	factor A	orch	13.04
28231890	C0010674	Cystic Fibrosis	dsyn	9.96
28231890	C0026566	Aspects of mortality statistics	qnco	9.74
28231890	C0439234	year	tmco	3.68
28231890	C0699749	disease stage	diap	3.62
28231890	C0011847	Diabetes	dsyn	3.60
28231890	C0445223	Related personal status	fndg	3.60
28231890	C0439849	Relationships	qlco	3.60
28231890	C1880022	Characterization	acty	3.54
28231890	C0205166	Long	qlco	3.54
28231890	C1706317	Long Variable	qlco	3.54
28231890	C0205390	Phase	tmco	3.54
28231890	C1709630	Preclinical	qlco	3.54
28231890	C2584321	Reaching	orgf	3.54
28231890	C3842590	10%	fndg	3.50
28231890	C0205164	Major	qlco	3.43
28231890	C0205082	Severe (severity modifier)	qlco	3.43
28231890	C0220880	morbidity aspects	inpr	3.43
28231890	C0061355	Glucagon-Like Peptide 1	aapp	20.95
28231890	C0021655	Insulin Resistance	patf	17.80
28231890	C0031847	physiopathological	ftcn	11.49
28231890	C0336789	Combine	mnob	5.18
28231890	C0277785	Functional disorder	patf	5.18
28231890	C3539624	GATA-Type Zinc Finger Protein 1	aapp	5.18
28231890	C3539624	GATA-Type Zinc Finger Protein 1	bacs	5.18
28231890	C4049994	Insulin Resistance Measurement	lbpr	5.18
28231890	C1999257	ZGLP1 gene	gngm	5.18
28231890	C3539623	ZGLP1 wt Allele	gngm	5.18
28231890	C0175668	Secondary to	tmco	3.64
28231890	C0332268	Lacking	qlco	3.56
28231890	C0547047	Decrease	qnco	3.54
28231890	C0392756	Reduced	qlco	3.54
28231890	C0151317	Chronic infectious disease	dsyn	3.48
28231890	C1256369	insulin secretion	celf	3.46
28231890	C0033268	production	ocac	3.42
28231890	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
28231890	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
28231890	C0021641	Insulin	aapp	22.35
28231890	C0021641	Insulin	horm	22.35
28231890	C0021641	Insulin	phsu	22.35
28231890	C0008209	Chlorine	elii	13.02
28231890	C0008209	Chlorine	hops	13.02
28231890	C0030274	Pancreas	bpoc	6.70
28231890	C1413365	CFTR gene	gngm	5.18
28231890	C1256369	insulin secretion	celf	5.18
28231890	C0596897	membrane activity	celf	3.56
28231890	C0332152	Before	tmco	3.56
28231890	C0439799	Channel	spco	3.56
28231890	C1706095	Channel Object	cnce	3.56
28231890	C0596019	Chloride Ion	elii	3.56
28231890	C2348260	Dietary Chlorine	elii	3.56
28231890	C1554210	Act Relationship Type - occurrence	idcn	3.54
28231890	C0205462	Histologic	ftcn	3.54
28231890	C0221198	Lesion	fndg	3.54
28231890	C2745955	Occurrence	tmco	3.54
28231890	C0392756	Reduced	qlco	3.54
28231890	C0243132	occurrence characteristics	ftcn	3.54
28231890	C0725813	depend	medd	3.53
28231890	C0699040	Cell surface	celc	3.45
28231890	C3714501	Insulin Drug Class	horm	3.42
28231890	C3714501	Insulin Drug Class	phsu	3.42
28231890	C1579433	Insulin [EPC]	phsu	3.42
28231890	C1533581	Recombinant Insulin	aapp	3.42
28231890	C1533581	Recombinant Insulin	horm	3.42
28231890	C1533581	Recombinant Insulin	phsu	3.42
28231890	C0392209	Nutritional status	fndg	14.64
28231890	C0011849	Diabetes Mellitus	dsyn	12.89
28231890	C0035245	Respiratory physiology	ortf	6.62
28231890	C1279919	Early	tmco	5.18
28231890	C0442824	Very	qlco	5.18
28231890	C2984081	Very Much	qlco	5.18
28231890	C1706701	Acquisition (action)	acty	3.98
28231890	C0439659	Beginning	tmco	3.98
28231890	C1301820	Obtain	ftcn	3.98
28231890	C0439834	Slow	qlco	3.59
28231890	C0683607	allowing	socb	3.59
28231890	C0205390	Phase	tmco	3.56
28231890	C1306673	Stage	qlco	3.56
28231890	C1300072	Tumor stage	clna	3.56
28231890	C0580545	Blood glucose normal	fndg	3.50
28231890	C0745343	insulin treatment	topp	3.46
28231890	C0011847	Diabetes	dsyn	3.43
28231890	C0029161	Oral Glucose Tolerance Test	diap	19.31
28231890	C0009738	Congo	geoa	16.17
28231890	C0011849	Diabetes Mellitus	dsyn	12.89
28231890	C0376315	Manufactured form	mnob	6.71
28231890	C0220909	Aspects of disease screening	ftcn	5.18
28231890	C1710031	Disease Screening	diap	5.18
28231890	C1550718	Entity Name Part Type - given	idcn	5.18
28231890	C1442162	GIVEN	cnce	5.18
28231890	C1947971	Give - dosing instruction imperative	ftcn	5.18
28231890	C3244317	Given name	inpr	5.18
28231890	C0220908	Screening procedure	hlca	5.18
28231890	C1710477	Trial Screening	resa	5.18
28231890	C1698960	research subject screening	inpr	5.18
28231890	C1510829	Age-Years	tmco	3.60
28231890	C0205390	Phase	tmco	3.56
28231890	C0332152	Before	tmco	3.55
28231890	C1705850	Before - dosing instruction fragment	inpr	3.55
28231890	C4050466	Borg Category-Ratio 10 Perceived Exertion Score 5	inpr	3.55
28231890	C3811819	CFTR wt Allele	gngm	3.55
28231890	C0348078	Qualitative form	qlco	3.55
28231890	C0205082	Severe (severity modifier)	qlco	3.55
28231890	C4050465	Severe Extremity Pain	inpr	3.55
28231890	C0332181	Annual	tmco	3.54
28231890	C0034866	Recommendation	idcn	3.54
28231890	C3842590	10%	fndg	3.43
28231890	C3816734	Absence of Signs or Symptoms	fndg	3.43
28231890	C0011847	Diabetes	dsyn	3.43
28231890	C0443304	Silent	qlco	3.43
28231890	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
28231890	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
28231890	C0040363	Togo	geoa	17.80
28231890	C0041260	Tryptophanase	aapp	17.80
28231890	C0041260	Tryptophanase	enzy	17.80
28231890	C0206132	Age of Onset	qnco	16.18
28231890	C0009738	Congo	geoa	16.05
28231890	C0085732	Ability	orga	14.64
28231890	C0011849	Diabetes Mellitus	dsyn	12.90
28231890	C0439834	Slow	qlco	7.05
28231890	C0035245	Respiratory physiology	ortf	6.62
28231890	C1299581	Able (finding)	fndg	5.18
28231890	C1413365	CFTR gene	gngm	5.18
28231890	C0309872	PREVENT (product)	phsu	5.18
28231890	C1521840	Target	ftcn	5.18
28231890	C2986546	Target Lesion Identification	diap	5.18
28231890	C1883351	To	qlco	5.18
28231890	C1547282	Show	anim	3.98
28231890	C1880177	Contribution	acty	3.59
28231890	C1280519	Effectiveness	qlco	3.57
28231890	C1707887	Efficacy Study	resa	3.57
28231890	C0332162	Onset of (contextual qualifier)	qlco	3.57
28231890	C0087111	Therapeutic procedure	topp	3.56
28231890	C0011847	Diabetes	dsyn	3.44
28231890	C3811819	CFTR wt Allele	gngm	3.43
28231890	C0205314	New	qlco	3.43
26335956	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
26335956	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
26335956	C0010674	Cystic Fibrosis	dsyn	19.64
26335956	C0040363	Togo	geoa	17.80
26335956	C0041260	Tryptophanase	aapp	17.80
26335956	C0041260	Tryptophanase	enzy	17.80
26335956	C0034380	Quality of life	idcn	14.64
26335956	C0087111	Therapeutic procedure	topp	10.42
26335956	C0242481	Research Activities	resa	9.73
26335956	C0035168	research	resa	9.73
26335956	C1521840	Target	ftcn	7.45
26335956	C0033684	Proteins	aapp	6.75
26335956	C0033684	Proteins	bacs	6.75
26335956	C0030705	Patients	podg	6.71
26335956	C0518214	Perceived quality of life	sosy	5.18
26335956	C1554078	Replace - HL7UpdateMode	idcn	5.18
26335956	C0559956	Replacement	ftcn	5.18
26335956	C1883351	To	qlco	5.18
26335956	C1550208	Health Outcomes	inpr	3.75
26335956	C3687832	DRUGS	topp	3.68
26335956	C0013227	Pharmaceutical Preparations	phsu	3.68
26335956	C0439234	year	tmco	3.68
26335956	C1518422	Negation	ftcn	3.60
26335956	C0456369	Proven findings	qlco	3.60
26335956	C2986815	Robust	qlco	3.60
26335956	C1413365	CFTR gene	gngm	3.58
26335956	C0678723	Biologic Development	orgf	3.57
26335956	C1527148	Development	ftcn	3.57
26335956	C0243107	development aspects	phsf	3.57
26335956	C2986546	Target Lesion Identification	diap	3.55
26335956	C0332185	Recent	tmco	3.50
26335956	C1561611	Admission Level of Care Code - Improved	inpr	3.48
26335956	C0332272	Better	qlco	3.48
26335956	C0184511	Improved	qlco	3.48
26335956	C0205164	Major	qlco	3.42
26335956	C0205082	Severe (severity modifier)	qlco	3.42
26335956	C0041714	United States Food and Drug Administration	hcro	27.26
26335956	C3264621	ivacaftor	orch	26.61
26335956	C3264621	ivacaftor	phsu	26.61
26335956	C0009738	Congo	geoa	16.12
26335956	C3852684	lumacaftor	orch	12.93
26335956	C3852684	lumacaftor	phsu	12.93
26335956	C1257890	Population Group	popg	9.99
26335956	C0019904	Homozygote	orga	9.88
26335956	C0009429	Combined Modality Therapy	topp	8.34
26335956	C0032659	geographic population	qnco	6.83
26335956	C0556895	Combination electrotherapy	topp	5.18
26335956	C1720467	Only - dosing instruction fragment	inpr	5.18
26335956	C2584321	Reaching	orgf	5.18
26335956	C0205171	Singular	qnco	5.18
26335956	C1517331	Further	spco	3.68
26335956	C2360800	Number of patients	fndg	3.64
26335956	C1551357	intended - ParticipationSignature	fndg	3.57
26335956	C1283828	intent	qlco	3.57
26335956	C0332232	Approximate	qlco	3.55
26335956	C1444656	Indicated	fndg	3.55
26335956	C3811819	CFTR wt Allele	gngm	3.50
26335956	C0205540	Approved	qlco	3.47
26335956	C0332185	Recent	tmco	3.47
26335956	C1704243	Greater	qnco	3.43
26335956	C0549177	Large	qnco	3.43
26335956	C0205393	Most	qnco	3.43
26335956	C0079411	Generations	tmco	16.17
26335956	C0282443	Review [Publication Type]	inpr	11.49
26335956	C1552617	Act Class - review	idcn	5.18
26335956	C0723712	Therapeutic brand of coal tar	orch	5.18
26335956	C0723712	Therapeutic brand of coal tar	phsu	5.18
26335956	C0087111	Therapeutic procedure	topp	5.18
26335956	C0557651	Room of building - Study	mnob	3.98
26335956	C2603343	Study	resa	3.98
26335956	C0470187	Availability of	ftcn	3.68
26335956	C3146294	Generation (action)	acty	3.55
26335956	C0521116	Current (present time)	tmco	3.50
26335956	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.44
26335956	C0205117	Adjacent	spco	3.43
26335956	C0332282	Following	tmco	3.43
26335956	C1883708	Then	tmco	3.43
28694231	C0040363	Togo	geoa	17.80
28694231	C0041260	Tryptophanase	aapp	17.80
28694231	C0041260	Tryptophanase	enzy	17.80
28694231	C1136254	Microbicides	phsu	12.89
28694231	C2936405	Drug Repositioning	topp	9.90
28694231	C0025663	Methods	inpr	6.83
28694231	C0205217	Increased	qnco	5.18
28694231	C1883351	To	qlco	5.18
28694231	C0449851	Techniques	ftcn	3.68
28694231	C0871511	Test Method	lbpr	3.68
28694231	C0205314	New	qlco	3.50
28694231	C0679622	literary novel	inpr	3.50
28694231	C4036061	Drug-drug	fndg	3.43
28694231	C1518422	Negation	ftcn	3.43
28694231	C2827757	Antimicrobial Resistance Result	lbtr	3.42
28694231	C0333668	Depletion	ftcn	3.42
28694231	C1514892	Resistance Process	phsf	3.42
28694231	C0332325	Resistant (qualifier value)	ftcn	3.42
28694231	C1521840	Target	ftcn	3.42
28694231	C1550464	resistant - Observation Interpretation Susceptibility	idcn	3.42
28694231	C0450254	Pathogenic organism	orgm	3.40
28694231	C0038172	Staphylococcus aureus	bact	24.11
28694231	C0042313	Vancomycin	aapp	14.64
28694231	C0042313	Vancomycin	antb	14.64
28694231	C3264621	ivacaftor	orch	12.89
28694231	C3264621	ivacaftor	phsu	12.89
28694231	C1706852	Article	inpr	5.18
28694231	C0332257	Including (qualifier)	ftcn	5.18
28694231	C1318973	Staphylococcus aureus infection	dsyn	5.18
28694231	C0456178	Microbiology subtype strains	qlco	3.63
28694231	C0080194	Muscle strain	inpo	3.63
28694231	C1271650	Antimicrobial activity	lbtr	3.59
28694231	C2827757	Antimicrobial Resistance Result	lbtr	3.48
28694231	C1514892	Resistance Process	phsf	3.48
28694231	C0332325	Resistant (qualifier value)	ftcn	3.48
28694231	C1550464	resistant - Observation Interpretation Susceptibility	idcn	3.48
28694231	C3245505	potential	qlco	3.37
28694231	C0026809	Mus	mamm	28.78
28694231	C0039866	Thigh structure	blor	13.01
28694231	C0001272	Action Potentials	celf	12.97
28694231	C3264621	ivacaftor	orch	12.89
28694231	C3264621	ivacaftor	phsu	12.89
28694231	C1515655	in vivo	spco	5.18
28694231	C1167779	neutropenic infection	dsyn	3.56
28694231	C3853906	Digital Model Attachment	inpr	3.54
28694231	C1281586	Entire thigh	bpoc	3.54
28694231	C3161035	Model	inpr	3.54
28694231	C3714583	Model - style/design	cnce	3.54
28694231	C3274659	Model Number	inpr	3.54
28694231	C1136254	Microbicides	phsu	26.04
28694231	C0039798	therapeutic aspects	ftcn	22.34
28694231	C3264621	ivacaftor	orch	12.90
28694231	C3264621	ivacaftor	phsu	12.90
28694231	C0038160	Staphylococcal Infections	dsyn	12.89
28694231	C0183683	Support, device	medd	5.18
28694231	C1521721	Supportive assistance	cnce	5.18
28694231	C1883727	Taken	cnce	5.18
28694231	C1883357	Together	qlco	5.18
28694231	C2825142	Experimental Result	fndg	3.98
28694231	C1274040	Result	ftcn	3.98
28694231	C1546471	What subject filter - Result	idcn	3.98
28694231	C3245505	potential	qlco	3.57
28694231	C2348003	Agent Administration	hlca	3.56
28694231	C1533734	Administration procedure	topp	3.42
28694231	C1705169	Biomaterial Treatment	cnce	3.42
28694231	C0087111	Therapeutic procedure	topp	3.42
28694231	C1522326	Treating	ftcn	3.42
28694231	C3538994	Treatment Epoch	resa	3.42
28694231	C3887704	treatment - ActInformationManagementReason	hlca	3.42
23616732	C0079613	Adoptive Immunotherapy	topp	25.59
23616732	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.42
23616732	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.42
23616732	C0040363	Togo	geoa	17.80
23616732	C0041260	Tryptophanase	aapp	17.80
23616732	C0041260	Tryptophanase	enzy	17.80
23616732	C3264621	ivacaftor	orch	13.14
23616732	C3264621	ivacaftor	phsu	13.14
23616732	C1869853	SERPINA3 protein, human	aapp	12.98
23616732	C1869853	SERPINA3 protein, human	bacs	12.98
23616732	C1561536	*Activity (kind of quantity)	idcn	5.18
23616732	C0205177	Active	ftcn	5.18
23616732	C0441655	Activities	acty	5.18
23616732	C3668946	Activity (animal life circumstance)	fndg	5.18
23616732	C0439799	Channel	spco	5.18
23616732	C1706095	Channel Object	cnce	5.18
23616732	C4049939	FDA Establishment Activity Terminology	inpr	5.18
23616732	C0439167	Percent Activity	qnco	5.18
23616732	C4049938	Physical Activity Measurement	lbpr	5.18
23616732	C1883351	To	qlco	5.18
23616732	C0392747	Changing	ftcn	3.79
23616732	C0304231	Therapeutic agent	mnob	3.75
23616732	C1611640	Therapeutic agent (substance)	phsu	3.75
23616732	C4048375	Asthma Control Test Questionnaire	inpr	3.51
23616732	C3890007	SERPINA3 wt Allele	gngm	3.51
23616732	C1413365	CFTR gene	gngm	3.49
23616732	C0205314	New	qlco	3.48
23616732	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
23616732	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
23616732	C0042153	utilization qualifier	ftcn	9.90
23616732	C0026882	Mutation	genf	9.85
23616732	C0010674	Cystic Fibrosis	dsyn	9.79
23616732	C1413365	CFTR gene	gngm	6.89
23616732	C0030705	Patients	podg	6.63
23616732	C0439234	year	tmco	3.63
23616732	C0205540	Approved	qlco	3.59
23616732	C0457083	Usage	ftcn	3.59
23616732	C1947944	Use - dosing instruction imperative	inpr	3.59
23616732	C0678941	Gene Mutant	gngm	3.56
23616732	C0596611	Gene Mutation	genf	3.56
23616732	C1705285	Mutation Abnormality	comd	3.54
23616732	C0580836	Old	tmco	3.54
23616732	C0010674	Cystic Fibrosis	dsyn	19.78
23616732	C0000768	Congenital Abnormality	cgab	7.06
23616732	C1521840	Target	ftcn	5.18
23616732	C2986546	Target Lesion Identification	diap	5.18
23616732	C1737329	Dysmorphism	cgab	3.91
23616732	C0332281	Associated with	qlco	3.64
23616732	C1254351	Pharmacologic Substance	phsu	3.58
23616732	C0678226	Due to	ftcn	3.56
23616732	C1522326	Treating	ftcn	3.56
23616732	C0521116	Current (present time)	tmco	3.42
23616732	C1705970	Electrical Current	npop	3.42
23616732	C0003237	Antibiotics, Antitubercular	antb	24.11
23616732	C0039798	therapeutic aspects	ftcn	22.35
23616732	C0004048	Inspiration function	orgf	19.25
23616732	C0003232	Antibiotics	antb	17.80
23616732	C0003209	Anti-Inflammatory Agents	phsu	14.64
23616732	C0243192	agonists	phsu	9.94
23616732	C0001688	aspects of adverse effects	ftcn	9.92
23616732	C0010674	Cystic Fibrosis	dsyn	9.76
23616732	C1533734	Administration procedure	topp	6.89
23616732	C3540718	ANTIINFLAMMATORY AGENTS, OPHTHALMOLOGIC	phsu	5.18
23616732	C3540717	ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS	irda	5.18
23616732	C3540717	ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS	phsu	5.18
23616732	C3540706	Antibiotic throat preparations	antb	5.18
23616732	C3540707	Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	antb	5.18
23616732	C3540704	Antibiotics for systemic use	antb	5.18
23616732	C3540708	Antibiotics, Gynecological	antb	5.18
23616732	C3540710	Antibiotics, ophthalmologic	antb	5.18
23616732	C3540705	Antifungal Antibiotics, Topical	antb	5.18
23616732	C0521116	Current (present time)	tmco	5.18
23616732	C3540709	antibiotics, intestinal	antb	5.18
23616732	C2987634	Agonist	phsu	3.63
23616732	C2004068	Beta (qualifier)	qlco	3.63
23616732	C0439096	Beta greek letter	inpr	3.63
23616732	C0330390	Beta plant	plnt	3.63
23616732	C0879626	Adverse effects	patf	3.61
23616732	C0332281	Associated with	qlco	3.61
23616732	C0450442	Agent	chvf	3.59
23616732	C1254351	Pharmacologic Substance	phsu	3.59
23616732	C1521826	Protocol Agent	inpr	3.59
23616732	C0439603	Frequencies (time pattern)	tmco	3.55
23616732	C3898838	How Often	inpr	3.55
23616732	C1561548	Kind of quantity - Frequency	qlco	3.55
23616732	C0871396	Spatial Frequency	qnco	3.55
23616732	C1705502	Statistical Frequency	qnco	3.55
23616732	C0376249	With frequency	qnco	3.55
23616732	C0332287	In addition to	ftcn	3.47
23616732	C1705169	Biomaterial Treatment	cnce	3.43
23616732	C0087111	Therapeutic procedure	topp	3.43
23616732	C1522326	Treating	ftcn	3.43
23616732	C3538994	Treatment Epoch	resa	3.43
23616732	C3887704	treatment - ActInformationManagementReason	hlca	3.43
23616732	C0001554	Administration occupational activities	ocac	3.42
23616732	C3264621	ivacaftor	orch	12.92
23616732	C3264621	ivacaftor	phsu	12.92
23616732	C0683525	treatment options	topp	3.68
23616732	C2348331	Dose Regimen	topp	3.63
23616732	C3831015	Convenient	qlco	3.47
23616732	C0205172	More	ftcn	3.47
23616732	C0442027	Oral	spco	3.46
23616732	C0687133	Drug Interactions	moft	13.11
23616732	C0332281	Associated with	qlco	3.55
23616732	C1546944	Event Seriousness - Significant	qlco	3.55
23616732	C0750502	Significant	idcn	3.55
23616732	C0237881	Statistical Significance	qnco	3.55
22723294	C0023671	Life Expectancy	grpa	19.36
22723294	C0010674	Cystic Fibrosis	dsyn	9.76
22723294	C0038952	Continuance of life	acty	6.79
22723294	C1561611	Admission Level of Care Code - Improved	inpr	5.18
22723294	C0449445	Approach	spco	5.18
22723294	C0332272	Better	qlco	5.18
22723294	C0184511	Improved	qlco	5.18
22723294	C1948052	Now (temporal qualifier)	tmco	5.18
22723294	C0439234	year	tmco	3.68
22723294	C0220921	survival aspects	ftcn	3.63
22723294	C3840862	75+ years	fndg	3.59
22723294	C0439509	/40	tmco	3.50
22723294	C3842587	40%	qnco	3.50
22723294	C2939193	Median (qualifier value)	spco	3.48
22723294	C0876920	Median Statistical Measurement	qnco	3.48
22723294	C0549183	Midline (qualifier value)	spco	3.48
22723294	C1882327	Percent of Predicted Value	qnco	3.48
22723294	C2347635	Population Median	qnco	3.48
22723294	C2348144	Sample Median	qnco	3.48
22723294	C0681842	prediction	idcn	3.48
22723294	C2986411	Improvement	cnce	5.18
22723294	C1522326	Treating	ftcn	5.18
22723294	C2825142	Experimental Result	fndg	3.98
22723294	C1274040	Result	ftcn	3.98
22723294	C1546471	What subject filter - Result	idcn	3.98
22723294	C0205319	Manifest	ftcn	3.63
22723294	C1280464	Manifestation of	qlco	3.63
22723294	C0087111	Therapeutic procedure	topp	3.59
22723294	C0444930	End	spco	3.48
22723294	C0178784	Organ	bpoc	3.48
22723294	C2746065	Stop (qualifier value)	tmco	3.48
22723294	C0040363	Togo	geoa	54.24
22723294	C0041260	Tryptophanase	aapp	54.24
22723294	C0041260	Tryptophanase	enzy	54.24
22723294	C0009738	Congo	geoa	32.28
22723294	C1883351	To	qlco	15.79
22723294	C0016617	Foundations	orgt	13.09
22723294	C0282116	Collaboration	socb	13.03
22723294	C0010674	Cystic Fibrosis	dsyn	10.06
22723294	C0015264	Exertion	orgf	7.53
22723294	C0013227	Pharmaceutical Preparations	phsu	7.49
22723294	C3811819	CFTR wt Allele	gngm	6.90
22723294	C1272684	Accepted	qlco	5.18
22723294	C3687832	DRUGS	topp	5.18
22723294	C1880355	Discover	acty	5.18
22723294	C0443211	Established	qlco	5.18
22723294	C0183683	Support, device	medd	5.18
22723294	C1521721	Supportive assistance	cnce	5.18
22723294	C1521840	Target	ftcn	5.18
22723294	C2986546	Target Lesion Identification	diap	5.18
22723294	C0424093	Initiative	menp	3.56
22723294	C0243067	defects aspect	ftcn	3.54
22723294	C2363430	Early stage	tmco	3.53
22723294	C0005515	Biological Factors	bacs	3.44
22723294	C0683757	Company (organization)	mnob	3.44
22723294	C0683757	Company (organization)	orgt	3.44
22723294	C0205314	New	qlco	3.44
22723294	C1704735	Regulator	cnce	3.42
22723294	C1704734	Regulator Device Component	mnob	3.42
22723294	C0182953	Regulators (device)	medd	3.42
22723294	C2752508	fully spanning the plasma membrane	celc	3.42
22723294	C1167322	integral to membrane	celc	3.42
22723294	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
22723294	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
22723294	C0026882	Mutation	genf	9.94
22723294	C0013175	Drug Evaluation	resa	9.77
22723294	C1521840	Target	ftcn	5.18
22723294	C0678723	Biologic Development	orgf	3.57
22723294	C1527148	Development	ftcn	3.57
22723294	C1708698	Light Emitting Diode Device Component	mnob	3.57
22723294	C0243107	development aspects	phsf	3.57
22723294	C0039593	Testing	ftcn	3.55
22723294	C0392366	Tests (qualifier value)	inpr	3.55
22723294	C1413365	CFTR gene	gngm	3.48
22723294	C1552740	Entity Determiner - specific	inpr	3.48
22723294	C0205369	Specific qualifier value	qlco	3.48
22723294	C0205314	New	qlco	3.42
22723294	C0679622	literary novel	inpr	3.42
22723294	C0041714	United States Food and Drug Administration	hcro	25.68
22723294	C0009738	Congo	geoa	17.80
22723294	C3264621	ivacaftor	orch	14.64
22723294	C3264621	ivacaftor	phsu	14.64
22723294	C0026882	Mutation	genf	9.94
22723294	C0030705	Patients	podg	6.57
22723294	C3811819	CFTR wt Allele	gngm	5.18
22723294	C0332185	Recent	tmco	5.18
22723294	C1705285	Mutation Abnormality	comd	3.63
22723294	C0013227	Pharmaceutical Preparations	phsu	3.63
22723294	C1254351	Pharmacologic Substance	phsu	3.63
22723294	C0205540	Approved	qlco	3.59
22723294	C0205447	One	qnco	3.48
22723294	C0332232	Approximate	qlco	3.42
22723294	C0242612	Codon, Nonsense	nusq	24.11
22723294	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
22723294	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
22723294	C0008976	Clinical Trials	resa	20.95
22723294	C0009738	Congo	geoa	17.80
22723294	C1096775	Clinical Trial [Publication Type]	inpr	11.49
22723294	C0030705	Patients	podg	6.59
22723294	C3811819	CFTR wt Allele	gngm	5.18
22723294	C1521840	Target	ftcn	5.18
22723294	C1413365	CFTR gene	gngm	3.68
22723294	C3687832	DRUGS	topp	3.68
22723294	C0013227	Pharmaceutical Preparations	phsu	3.68
22723294	C1706839	Applicable	qlco	3.56
22723294	C1272460	Not Applicable	qlco	3.56
22723294	C3842582	90%	fndg	3.43
22723294	C0439087	<90	qnco	3.43
22723294	C0439083	>90	qnco	3.43
22723294	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
22723294	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
22723294	C0009738	Congo	geoa	16.05
22723294	C0028429	Nose	bpoc	13.09
22723294	C0005516	Biological Markers	clna	6.83
22723294	C0023983	Longterm Effects	phpr	6.78
22723294	C0428295	Cystic fibrosis sweat test	lbpr	5.18
22723294	C1304760	Sweat chloride level result	lbtr	5.18
22723294	C1705535	suggestion	idcn	5.18
22723294	C1705241	Delta (difference)	qnco	3.63
22723294	C1705242	Different	qlco	3.63
22723294	C3245505	potential	qlco	3.63
22723294	C0439673	Unknown	qlco	3.57
22723294	C1825598	IMPACT gene	gngm	3.56
22723294	C4049986	Impact	qlco	3.56
22723294	C1413365	CFTR gene	gngm	3.50
22723294	C0439234	year	tmco	3.44
22723294	C3811819	CFTR wt Allele	gngm	3.43
22723294	C0205210	Clinical	qlco	3.43
22723294	C3687832	DRUGS	topp	3.43
22723294	C1553058	Neuropsychologist - Clinical	prog	3.43
22723294	C0013227	Pharmaceutical Preparations	phsu	3.43
22723294	C0237412	Psychologist - Clinical	prog	3.43
22723294	C0497591	Social Worker - Clinical	prog	3.43
22723294	C1274040	Result	ftcn	3.41
22723294	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
22723294	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
22723294	C0009738	Congo	geoa	16.05
22723294	C0017313	patient care	hlca	9.89
22723294	C1882932	Representation (action)	acty	5.18
22723294	C0872152	drug development	bmod	3.60
22723294	C1554098	HL7 Committee ID In RIM - Patient Care	inpr	3.58
22723294	C3853617	Patient care - patient profile query reason	hlca	3.58
22723294	C2347129	Milestone	cnce	3.56
22723294	C1413365	CFTR gene	gngm	3.43
22723294	C3811819	CFTR wt Allele	gngm	3.43
22723294	C3898777	Important	qlco	3.43
22723294	C1521840	Target	ftcn	3.43
26823392	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
26823392	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
26823392	C0005532	biology (field)	bmod	11.49
26823392	C0026882	Mutation	genf	9.87
26823392	C0031437	Phenotype	orga	6.83
26823392	C1413365	CFTR gene	gngm	5.18
26823392	C0205460	biological	qlco	5.18
26823392	C1552738	described	idcn	5.18
26823392	C3542016	Concept model range (foundation metadata concept)	inpr	3.56
26823392	C1514721	Range	qnco	3.56
26823392	C2348147	Sample Range	qnco	3.56
26823392	C0681760	2000s	tmco	3.53
26823392	C0542341	Function	ftcn	3.50
26823392	C0205245	Functional	ftcn	3.50
26823392	C2700217	Functional Relationship	cnce	3.50
26823392	C1413336	CEL gene	gngm	3.43
26823392	C1948049	Cell (compartment)	spco	3.43
26823392	C1704653	Cell Device Component	medd	3.43
26823392	C0007634	Cells	cell	3.43
26823392	C1269647	Entire cell	cell	3.43
26823392	C1521991	Molecular	qlco	3.43
26823392	C0003075	Anions	elii	13.02
26823392	C0023175	Lead	elii	13.02
26823392	C0023175	Lead	hops	13.02
26823392	C0010674	Cystic Fibrosis	dsyn	10.06
26823392	C0015127	Etiology aspects	ftcn	9.94
26823392	C0026882	Mutation	genf	9.87
26823392	C0014609	Epithelium	tisu	6.56
26823392	C3805925	Variable disease severity	fndg	5.18
26823392	C1524003	Science of Etiology	cnce	3.63
26823392	C1167182	Apical plasma membrane	celc	3.60
26823392	C3275067	Cardiac Lead Procedure	topp	3.56
26823392	C2348269	Dietary Lead	elii	3.56
26823392	C1522538	Leading	ftcn	3.56
26823392	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.56
26823392	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.56
26823392	C1327616	Cell secretion	celf	3.42
26823392	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.07
26823392	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.07
26823392	C0012655	Disease susceptibility	clna	13.03
26823392	C0026882	Mutation	genf	11.49
26823392	C0013217	pharmacotherapeutic	ftcn	9.75
26823392	C0005532	biology (field)	bmod	9.74
26823392	C1413365	CFTR gene	gngm	7.00
26823392	C0031437	Phenotype	orga	6.64
26823392	C0013216	Pharmacotherapy	topp	6.59
26823392	C1547045	*Susceptibility	qnco	3.57
26823392	C0220898	Predisposition	orga	3.57
26823392	C1264642	Susceptibility (property) (qualifier value)	ftcn	3.57
26823392	C0243067	defects aspect	ftcn	3.55
26823392	C1705938	Base - General Qualifier	idcn	3.54
26823392	C1527178	Basis - conceptual entity	ftcn	3.54
26823392	C1521991	Molecular	qlco	3.54
26823392	C0596988	mutant	comd	3.54
26823392	C0439855	Complex	qlco	3.48
26823392	C1285572	Phenotype determination	lbpr	3.48
26823392	C1704241	complex (molecular entity)	chvs	3.48
26823392	C1554668	Pharmacist - Pharmacotherapy	prog	3.44
26823392	C0439799	Channel	spco	3.43
26823392	C1706095	Channel Object	cnce	3.43
26823392	C0087136	Unmarried	fndg	22.43
26823392	C0037179	Unmarried person	popg	22.43
26823392	C1521750	Combination Chemotherapy	topp	9.93
26823392	C0013218	Combination Drug Therapy	topp	9.93
26823392	C0376649	Addresses (publication format)	inpr	7.13
26823392	C1442065	Address	spco	3.98
26823392	C0243067	defects aspect	ftcn	3.68
26823392	C1707478	Conclusion	idcn	3.57
26823392	C1708698	Light Emitting Diode Device Component	mnob	3.57
26823392	C0205171	Singular	qnco	3.50
26823392	C1532633	Kilounit per Kilogram	qnco	5.18
26823392	C2608091	Unit/gram	qnco	5.18
26823392	C3850123	Clinical Effectiveness	qlco	19.21
26823392	C0597295	Protein Biosynthesis	moft	17.80
26823392	C0040712	Language Translations	inpr	14.64
26823392	C0040649	Transcription, Genetic	genf	14.64
26823392	C1519614	Genetic Translation Process	genf	5.18
26823392	C0185026	Plication	topp	5.18
26823392	C1547282	Show	anim	5.18
26823392	C0814225	benefit	qnco	3.54
26823392	C1561611	Admission Level of Care Code - Improved	inpr	3.42
26823392	C0470187	Availability of	ftcn	3.42
26823392	C0332272	Better	qlco	3.42
26823392	C0184511	Improved	qlco	3.42
26823392	C3890211	Low Mitosis-Karyorrhexis Index	qnco	3.42
26823392	C0205251	low	qlco	3.42
26823392	C1550472	low confidentiality	inpr	3.42
26823392	C4048187	low exposure	qlco	3.42
26823392	C0282461	Phase 3 Clinical Trials	resa	22.77
26823392	C0009738	Congo	geoa	16.05
26823392	C3264621	ivacaftor	orch	14.64
26823392	C3264621	ivacaftor	phsu	14.64
26823392	C3852684	lumacaftor	orch	14.64
26823392	C3852684	lumacaftor	phsu	14.64
26823392	C1511760	Deletion Mutation	genf	13.03
26823392	C0026882	Mutation	genf	9.94
26823392	C0030705	Patients	podg	6.59
26823392	C0336789	Combine	mnob	3.98
26823392	C0475311	Harbor	mnob	3.98
26823392	C1705285	Mutation Abnormality	comd	3.63
26823392	C1880274	Deletion (action)	acty	3.57
26823392	C1442161	Gene Deletion Abnormality	comd	3.57
26823392	C0185026	Plication	topp	3.50
26823392	C1280519	Effectiveness	qlco	3.50
26823392	C1707887	Efficacy Study	resa	3.50
26823392	C0205214	Common (qualifier value)	qnco	3.48
26823392	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.48
26823392	C0205393	Most	qnco	3.48
26823392	C1522138	shared attribute	ftcn	3.48
26823392	C0332185	Recent	tmco	3.46
26823392	C1709915	Residue	cnce	3.44
26823392	C1882936	Residue after Decontamination Medical Device Problem	evnt	3.44
26823392	C3811819	CFTR wt Allele	gngm	3.43
26823392	C0456369	Proven findings	qlco	3.43
26823392	C0013162	Drug Combinations	phsu	8.34
26823392	C0332185	Recent	tmco	5.18
26823392	C0205540	Approved	qlco	3.57
26823392	C0041703	United States	geoa	14.64
26823392	C0041714	United States Food and Drug Administration	hcro	25.75
26823392	C0019904	Homozygote	orga	9.90
26823392	C0030705	Patients	podg	6.58
26823392	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
26823392	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
26823392	C0002085	Alleles	gngm	19.40
26823392	C0005532	biology (field)	bmod	11.49
26823392	C0026882	Mutation	genf	9.88
26823392	C0015127	Etiology aspects	ftcn	9.85
26823392	C0162429	Malnutrition	dsyn	9.73
26823392	C1623416	deficiency aspects	qlco	9.73
26823392	C1999230	Providing (action)	acty	5.18
26823392	C0443289	Revealed	qlco	5.18
26823392	C0205460	biological	qlco	5.18
26823392	C0243067	defects aspect	ftcn	3.68
26823392	C0521114	Infrequent	tmco	3.57
26823392	C0439962	Mixture	sbst	3.57
26823392	C0522498	Rare	qlco	3.57
26823392	C1514917	Retinoic Acid Response Element	gngm	3.57
26823392	C0947630	Scientific Study	lbpr	3.55
26823392	C1524003	Science of Etiology	cnce	3.54
26823392	C0542341	Function	ftcn	3.50
26823392	C0205245	Functional	ftcn	3.50
26823392	C2700217	Functional Relationship	cnce	3.50
26823392	C0205314	New	qlco	3.50
26823392	C1413365	CFTR gene	gngm	3.48
26823392	C1705242	Different	qlco	3.48
26823392	C0301863	"""U"" lymphocyte"	cell	3.44
26823392	C0678594	structure	spco	3.42
26823392	C0011155	Deficiency	ftcn	3.42
26823392	C0009738	Congo	geoa	32.35
26823392	C0002085	Alleles	gngm	19.20
26823392	C0036849	Set (Psychology)	menp	12.88
26823392	C3811819	CFTR wt Allele	gngm	6.97
26823392	C0030705	Patients	podg	6.83
26823392	C3540469	AICDA wt Allele	gngm	5.18
26823392	C1269765	Assisted (qualifier value)	qlco	5.18
26823392	C1704788	Definition	inpr	5.18
26823392	C0449435	Manufactured aid	mnob	5.18
26823392	C3539106	Sufficiently defined concept definition status (core metadata concept)	inpr	5.18
26823392	C0243067	defects aspect	ftcn	3.56
26823392	C2983265	CDISC SEND Study Design Terminology	inpr	3.54
26823392	C1707689	Design	acty	3.54
26823392	C0808232	Therapeutic Intervention	topp	3.44
26823392	C0087111	Therapeutic procedure	topp	3.44
26823392	C1527178	Basis - conceptual entity	ftcn	3.43
26823392	C3542921	CDISC Interventions Class	clas	3.42
26823392	C1273869	Intervention regimes	hlca	3.42
26823392	C2979881	Interventions:Finding:Point in time:^Patient:Narrative	clna	3.42
26823392	C0886296	Nursing interventions	hlca	3.42
26823392	C0683312	Categories	inpr	3.42
26823392	C1442518	Set scale	ftcn	3.42
26823392	C1705195	set (group)	cnce	3.42
26823392	C2348767	Therapeutic Efficacy	qlco	3.41
26823392	C1280519	Effectiveness	qlco	3.38
26823392	C1707887	Efficacy Study	resa	3.38
28012258	C1959616	Phosphatidylcholines	bacs	22.43
28012258	C1959616	Phosphatidylcholines	orch	22.43
28012258	C1959616	Phosphatidylcholines	phsu	22.43
28012258	C0001480	Adenosine Triphosphate	bacs	19.45
28012258	C0001480	Adenosine Triphosphate	nnon	19.45
28012258	C0001480	Adenosine Triphosphate	phsu	19.45
28012258	C0036536	Process of secretion	biof	19.45
28012258	C0242738	ATP-Binding Cassette Transporters	aapp	17.80
28012258	C0242738	ATP-Binding Cassette Transporters	bacs	17.80
28012258	C0227525	Hepatocyte	cell	9.86
28012258	C1412071	ABCB4 gene	gngm	7.70
28012258	C0036537	Bodily secretions	bdsu	6.83
28012258	C0596901	Membrane	celc	6.70
28012258	C0025255	Tissue membrane	tisu	6.70
28012258	C0086597	Mediate	socb	5.18
28012258	C1167622	Binding (Molecular Function)	moft	3.61
28012258	C1145667	Binding action	acty	3.61
28012258	C0450240	Cassette (physical object)	medd	3.61
28012258	C1706210	Cassette Device Component	mnob	3.61
28012258	C1706182	Membrane Device Component	mnob	3.55
28012258	C0678236	Rare Diseases	dsyn	14.64
28012258	C0268312	Progressive intrahepatic cholestasis (disorder)	dsyn	13.22
28012258	C0023911	Transplantation of liver	topp	12.92
28012258	C0016977	Gall Bladder Diseases	dsyn	9.77
28012258	C0040733	transplantation aspects	ftcn	9.73
28012258	C1412071	ABCB4 gene	gngm	6.92
28012258	C0040732	Transplantation	topp	6.58
28012258	C0332257	Including (qualifier)	ftcn	5.18
28012258	C0441731	Type 3	clas	3.63
28012258	C0678941	Gene Mutant	gngm	3.58
28012258	C1273518	Responsible to	fndg	3.56
28012258	C0205419	Variant	qlco	3.55
28012258	C3151529	Lethal	fndg	3.55
28012258	C0266258	Congenital absence of liver	cgab	3.47
28012258	C1689985	Absence (morphologic abnormality)	anab	3.42
28012258	C0332197	Absent	ftcn	3.42
28012258	C1514562	Protein Domain	amas	19.28
28012258	C0242738	ATP-Binding Cassette Transporters	aapp	16.18
28012258	C0242738	ATP-Binding Cassette Transporters	bacs	16.18
28012258	C1280500	Effect	qlco	5.18
28012258	C2348382	Effect, Appearance	qlco	5.18
28012258	C1292732	Investigates	ftcn	5.18
28012258	C0557651	Room of building - Study	mnob	5.18
28012258	C2603343	Study	resa	5.18
28012258	C1148923	atp binding	moft	3.64
28012258	C1314939	Involvement with	ftcn	3.57
28012258	C2984318	ABC Transporter Pathway	ftcn	3.56
28012258	C0205250	High	qlco	3.54
28012258	C2982691	Reside	acty	3.54
28012258	C1412071	ABCB4 gene	gngm	3.43
28012258	C3845273	Missense	fndg	3.43
28012258	C0205419	Variant	qlco	3.43
28012258	C3245505	potential	qlco	3.43
28012258	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.38
28012258	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.38
28012258	C1514562	Protein Domain	amas	19.17
28012258	C0021966	Iodides	inch	17.80
28012258	C1314792	Etiology	ftcn	12.89
28012258	C1413365	CFTR gene	gngm	11.34
28012258	C0026882	Mutation	genf	9.73
28012258	C0221138	Blood group antibody I	aapp	5.18
28012258	C0221138	Blood group antibody I	imft	5.18
28012258	C3811819	CFTR wt Allele	gngm	5.18
28012258	C1412071	ABCB4 gene	gngm	3.59
28012258	C1550043	Container status - Identified	fndg	3.59
28012258	C0205396	Identified	qlco	3.59
28012258	C0205449	Three	qnco	3.59
28012258	C0205419	Variant	qlco	3.54
28012258	C1334043	Homologous Gene	gngm	3.54
28012258	C0205451	Five	qnco	3.42
28012258	C0040363	Togo	geoa	17.80
28012258	C0041260	Tryptophanase	aapp	17.80
28012258	C0041260	Tryptophanase	enzy	17.80
28012258	C0031843	physiological aspects	phsf	14.64
28012258	C3264621	ivacaftor	orch	13.05
28012258	C3264621	ivacaftor	phsu	13.05
28012258	C0542341	Function	ftcn	5.18
28012258	C0700205	Function Axis	clas	5.18
28012258	C3264627	Kalydeco	phsu	5.18
28012258	C1705273	Mathematical Operator	inpr	5.18
28012258	C1883351	To	qlco	5.18
28012258	C2741958	VX-770	orch	5.18
28012258	C0332452	defective	ftcn	5.18
28012258	C1547282	Show	anim	3.98
28012258	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.68
28012258	C0205202	Corrected	qlco	3.59
28012258	C0205540	Approved	qlco	3.47
28012258	C0031843	physiological aspects	phsf	13.14
28012258	C2744579	ATP8A2 protein, human	aapp	12.92
28012258	C2744579	ATP8A2 protein, human	enzy	12.92
28012258	C0376525	Dimerization	npop	9.91
28012258	C0028630	Nucleotides	nnon	9.76
28012258	C1412071	ABCB4 gene	gngm	7.02
28012258	C1148923	atp binding	moft	6.98
28012258	C1882327	Percent of Predicted Value	qnco	5.18
28012258	C0332454	disrupted	qlco	5.18
28012258	C0681842	prediction	idcn	5.18
28012258	C0542341	Function	ftcn	3.68
28012258	C0700205	Function Axis	clas	3.68
28012258	C1705273	Mathematical Operator	inpr	3.68
28012258	C0205419	Variant	qlco	3.63
28012258	C0870071	modeling	resa	3.60
28012258	C1704675	Interaction	ftcn	3.52
28012258	C0450363	Three-dimensional	spco	3.49
28012258	C0205451	Five	qnco	3.48
28012258	C1148916	nucleotide binding	moft	3.48
28012258	C0678594	structure	spco	3.46
28012258	C3541951	Concept model domain	inpr	3.46
28012258	C1880389	Domain (area of knowledge)	ftcn	3.46
28012258	C0205263	Induce (action)	ftcn	3.46
28012258	C1883221	Superkingdom (taxonomic category)	cnce	3.46
28012258	C1511545	Critical	qlco	3.42
28012258	C0036536	Process of secretion	biof	19.25
28012258	C0034341	Pyruvate Carboxylase Deficiency Disease	dsyn	19.25
28012258	C0031995	Pitcairn Island	geoa	16.09
28012258	C0007603	Plasma membrane	celc	9.92
28012258	C0036537	Bodily secretions	bdsu	6.63
28012258	C0205216	Decreased	qnco	5.18
28012258	C0442797	Decreasing	qlco	5.18
28012258	C1522240	Process	phpr	5.18
28012258	C0392756	Reduced	qlco	5.18
28012258	C0681842	prediction	idcn	5.18
28012258	C1547282	Show	anim	3.98
28012258	C0596988	mutant	comd	3.68
28012258	C1561536	*Activity (kind of quantity)	idcn	3.63
28012258	C0205177	Active	ftcn	3.63
28012258	C0441655	Activities	acty	3.63
28012258	C3668946	Activity (animal life circumstance)	fndg	3.63
28012258	C4049939	FDA Establishment Activity Terminology	inpr	3.63
28012258	C0439167	Percent Activity	qnco	3.63
28012258	C4049938	Physical Activity Measurement	lbpr	3.63
28012258	C0521093	Confirmed by	qlco	3.59
28012258	C1521840	Target	ftcn	3.56
28012258	C1413336	CEL gene	gngm	3.55
28012258	C1948049	Cell (compartment)	spco	3.55
28012258	C1704653	Cell Device Component	medd	3.55
28012258	C0007634	Cells	cell	3.55
28012258	C1269647	Entire cell	cell	3.55
28012258	C3854321	Expression (foundation metadata concept)	idcn	3.55
28012258	C0185117	Expression procedure	topp	3.55
28012258	C3161035	Model	inpr	3.55
28012258	C1412071	ABCB4 gene	gngm	3.50
28012258	C3810569	KRT17 wt Allele	gngm	3.48
28012258	C0540463	PODXL protein, human	aapp	3.48
28012258	C0540463	PODXL protein, human	bacs	3.48
28012258	C3811118	PODXL wt Allele	gngm	3.48
28012258	C3540812	PROC wt Allele	gngm	3.48
28012258	C0036536	Process of secretion	biof	19.20
28012258	C0034341	Pyruvate Carboxylase Deficiency Disease	dsyn	19.20
28012258	C0031995	Pitcairn Island	geoa	16.04
28012258	C3264621	ivacaftor	orch	14.64
28012258	C3264621	ivacaftor	phsu	14.64
28012258	C0036537	Bodily secretions	bdsu	6.58
28012258	C2741958	VX-770	orch	5.18
28012258	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.61
28012258	C0600115	molecular modeling	inpr	3.58
28012258	C0600115	molecular modeling	resa	3.58
28012258	C1853126	MOLECULAR BASIS	idcn	3.57
28012258	C1561536	*Activity (kind of quantity)	idcn	3.55
28012258	C0205177	Active	ftcn	3.55
28012258	C0441655	Activities	acty	3.55
28012258	C3668946	Activity (animal life circumstance)	fndg	3.55
28012258	C4049939	FDA Establishment Activity Terminology	inpr	3.55
28012258	C0439167	Percent Activity	qnco	3.55
28012258	C4049938	Physical Activity Measurement	lbpr	3.55
28012258	C1874451	Basis	phsu	3.55
28012258	C1527178	Basis - conceptual entity	ftcn	3.55
28012258	C0870071	modeling	resa	3.55
28012258	C3810569	KRT17 wt Allele	gngm	3.43
28012258	C0540463	PODXL protein, human	aapp	3.43
28012258	C0540463	PODXL protein, human	bacs	3.43
28012258	C3811118	PODXL wt Allele	gngm	3.43
28012258	C3540812	PROC wt Allele	gngm	3.43
28012258	C0596988	mutant	comd	3.43
26515683	C0004048	Inspiration function	orgf	19.20
26515683	C0032285	Pneumonia	dsyn	9.90
26515683	C3714636	Pneumonitis	dsyn	9.90
26515683	C0441712	Mechanism (attribute)	ftcn	5.18
26515683	C1706376	Mechanism Component of Device	mnob	5.18
26515683	C0332685	Thermal injury	inpo	3.45
26515683	C1705211	Inhalation Dosing Unit	qnco	3.43
26515683	C0205535	Inhalation Route of Drug Administration	ftcn	3.43
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
26515683	C0039476	Temperature	qnco	19.45
26515683	C0005903	Body Temperature	orga	16.30
26515683	C0010674	Cystic Fibrosis	dsyn	10.06
26515683	C0032285	Pneumonia	dsyn	9.95
26515683	C3714636	Pneumonitis	dsyn	9.95
26515683	C0026882	Mutation	genf	9.90
26515683	C0015127	Etiology aspects	ftcn	9.86
26515683	C0020517	Hypersensitivity	patf	6.83
26515683	C1413365	CFTR gene	gngm	5.18
26515683	C0332324	Sensitive	ftcn	3.68
26515683	C3854321	Expression (foundation metadata concept)	idcn	3.57
26515683	C0185117	Expression procedure	topp	3.57
26515683	C1524003	Science of Etiology	cnce	3.55
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
26515683	C0032285	Pneumonia	dsyn	9.90
26515683	C3714636	Pneumonitis	dsyn	9.90
26515683	C1413365	CFTR gene	gngm	5.18
26515683	C1292732	Investigates	ftcn	5.18
26515683	C0018837	Heat (physical force)	npop	3.55
26515683	C0205263	Induce (action)	ftcn	3.55
26515683	C1314939	Involvement with	ftcn	3.55
26515683	C0034721	Rattus	mamm	28.67
26515683	C0034693	Rattus norvegicus	mamm	28.67
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
26515683	C0004048	Inspiration function	orgf	19.34
26515683	C4048755	Apply	ftcn	5.18
26515683	C1514559	Protein Overexpression	genf	5.18
26515683	C1515655	in vivo	spco	5.18
26515683	C0203597	hyperthermia treatment	topp	3.61
26515683	C1705211	Inhalation Dosing Unit	qnco	3.57
26515683	C0205535	Inhalation Route of Drug Administration	ftcn	3.57
26515683	C1413365	CFTR gene	gngm	3.50
26515683	C0018837	Heat (physical force)	npop	3.44
26515683	C0007634	Cells	cell	3.43
26515683	C3282337	Cells [Chemical/Ingredient]	cell	3.43
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
26515683	C1565860	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human	aapp	12.94
26515683	C1565860	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human	enzy	12.94
26515683	C0015127	Etiology aspects	ftcn	10.28
26515683	C2827718	In Vitro Route of Administration	ftcn	5.18
26515683	C0021135	In Vitro [Publication Type]	inpr	5.18
26515683	C1533691	in vitro	qlco	5.18
26515683	C1515655	in vivo	spco	5.18
26515683	C2363430	Early stage	tmco	4.12
26515683	C1524003	Science of Etiology	cnce	3.98
26515683	C0203597	hyperthermia treatment	topp	3.75
26515683	C0442805	Increase	ftcn	3.57
26515683	C0392756	Reduced	qlco	3.57
26515683	C0301630	Reduction (chemical)	npop	3.57
26515683	C0441610	Reduction - action	topp	3.57
26515683	C1705323	PTGS2 wt Allele	gngm	3.48
26515683	C1413365	CFTR gene	gngm	3.44
26515683	C1546944	Event Seriousness - Significant	qlco	3.44
26515683	C0750502	Significant	idcn	3.44
26515683	C0237881	Statistical Significance	qnco	3.44
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.13
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.13
26515683	C0012472	Dinoprostone	horm	22.56
26515683	C0012472	Dinoprostone	orch	22.56
26515683	C0012472	Dinoprostone	phsu	22.56
26515683	C3813211	Prostaglandin E2	orch	22.56
26515683	C1565860	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human	aapp	13.00
26515683	C1565860	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human	enzy	13.00
26515683	C3849574	EPHB2 protein, human	aapp	12.89
26515683	C3849574	EPHB2 protein, human	enzy	12.89
26515683	C0026882	Mutation	genf	9.77
26515683	C1413365	CFTR gene	gngm	7.06
26515683	C3252847	VX 809	orch	5.18
26515683	C3252847	VX 809	phsu	5.18
26515683	C3538990	Prostaglandin E2 Measurement	lbpr	3.63
26515683	C1879547	Activation action	acty	3.56
26515683	C0007634	Cells	cell	3.56
26515683	C3282337	Cells [Chemical/Ingredient]	cell	3.56
26515683	C0442726	Detected (finding)	fndg	3.56
26515683	C1511790	Detection	topp	3.56
26515683	C0018837	Heat (physical force)	npop	3.56
26515683	C1514559	Protein Overexpression	genf	3.56
26515683	C1522326	Treating	ftcn	3.56
26515683	C1705323	PTGS2 wt Allele	gngm	3.53
26515683	C1555029	Reverse	ftcn	3.53
26515683	C1705285	Mutation Abnormality	comd	3.47
26515683	C0684224	Report (document)	inpr	3.47
26515683	C0700287	Reporting	hlca	3.47
26515683	C1150587	JUN kinase activity	moft	3.43
26515683	C1367731	MAPK8 gene	gngm	3.43
26515683	C1705632	MAPK8 wt Allele	gngm	3.43
26515683	C3849574	EPHB2 protein, human	aapp	25.97
26515683	C3849574	EPHB2 protein, human	enzy	25.97
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
26515683	C3463820	Inhibition	acty	13.08
26515683	C0021467	Psychological inhibition	menp	13.08
26515683	C1150587	JUN kinase activity	moft	6.94
26515683	C1367731	MAPK8 gene	gngm	6.94
26515683	C1705632	MAPK8 wt Allele	gngm	6.94
26515683	C1555029	Reverse	ftcn	3.98
26515683	C1547282	Show	anim	3.98
26515683	C1999216	Inhibitor	qlco	3.63
26515683	C0021469	Metabolic Inhibition	moft	3.61
26515683	C1628982	Percent inhibition	qnco	3.61
26515683	C1879547	Activation action	acty	3.59
26515683	C1280500	Effect	qlco	3.56
26515683	C2348382	Effect, Appearance	qlco	3.56
26515683	C1413365	CFTR gene	gngm	3.45
26515683	C0018837	Heat (physical force)	npop	3.45
26515683	C0205263	Induce (action)	ftcn	3.45
26515683	C0079633	Interleukin-8	aapp	22.68
26515683	C0079633	Interleukin-8	imft	22.68
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
26515683	C1565860	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human	aapp	14.64
26515683	C1565860	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human	enzy	14.64
26515683	C1698756	CXCL8 protein, human	aapp	13.22
26515683	C1698756	CXCL8 protein, human	bacs	13.22
26515683	C3849574	EPHB2 protein, human	aapp	13.14
26515683	C3849574	EPHB2 protein, human	enzy	13.14
26515683	C3463820	Inhibition	acty	13.01
26515683	C0021467	Psychological inhibition	menp	13.01
26515683	C1705323	PTGS2 wt Allele	gngm	5.18
26515683	C0203597	hyperthermia treatment	topp	3.64
26515683	C0205217	Increased	qnco	3.57
26515683	C0021469	Metabolic Inhibition	moft	3.55
26515683	C1628982	Percent inhibition	qnco	3.55
26515683	C1413365	CFTR gene	gngm	3.50
26515683	C1150587	JUN kinase activity	moft	3.50
26515683	C1367731	MAPK8 gene	gngm	3.50
26515683	C1705632	MAPK8 wt Allele	gngm	3.50
26515683	C0010467	Curcumin	irda	25.51
26515683	C0010467	Curcumin	orch	25.51
26515683	C0010467	Curcumin	phsu	25.51
26515683	C0039798	therapeutic aspects	ftcn	22.48
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
26515683	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
26515683	C0079633	Interleukin-8	aapp	22.36
26515683	C0079633	Interleukin-8	imft	22.36
26515683	C0012472	Dinoprostone	horm	22.34
26515683	C0012472	Dinoprostone	orch	22.34
26515683	C0012472	Dinoprostone	phsu	22.34
26515683	C3813211	Prostaglandin E2	orch	22.34
26515683	C1698756	CXCL8 protein, human	aapp	12.89
26515683	C1698756	CXCL8 protein, human	bacs	12.89
26515683	C1565860	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human	aapp	12.89
26515683	C1565860	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human	enzy	12.89
26515683	C0751982	Neutrophil Infiltration	phsf	11.49
26515683	C0333361	Acute inflammation	fndg	5.18
26515683	C2827718	In Vitro Route of Administration	ftcn	5.18
26515683	C0021135	In Vitro [Publication Type]	inpr	5.18
26515683	C1533691	in vitro	qlco	5.18
26515683	C1555029	Reverse	ftcn	3.98
26515683	C0205198	Compound	qlco	3.63
26515683	C1706082	Compound (substance)	chem	3.63
26515683	C3854321	Expression (foundation metadata concept)	idcn	3.61
26515683	C0185117	Expression procedure	topp	3.61
26515683	C0010957	Tissue damage	inpo	3.61
26515683	C1533734	Administration procedure	topp	3.56
26515683	C1705169	Biomaterial Treatment	cnce	3.56
26515683	C0087111	Therapeutic procedure	topp	3.56
26515683	C1522326	Treating	ftcn	3.56
26515683	C3538994	Treatment Epoch	resa	3.56
26515683	C3887704	treatment - ActInformationManagementReason	hlca	3.56
26515683	C0442805	Increase	ftcn	3.54
26515683	C0205217	Increased	qnco	3.54
26515683	C0205296	Natural	ftcn	3.48
26515683	C0359916	Phenolics	orch	3.48
26515683	C0359916	Phenolics	phsu	3.48
26515683	C1413365	CFTR gene	gngm	3.47
26515683	C2349975	Enhance (action)	acty	3.47
26515683	C1515655	in vivo	spco	3.46
26515683	C0458827	Airway structure	bpoc	3.43
26515683	C0178987	Artificial Airways	medd	3.43
26515683	C1705323	PTGS2 wt Allele	gngm	3.43
26515683	C0018837	Heat (physical force)	npop	3.42
26515683	C0205263	Induce (action)	ftcn	3.42
26515683	C3538990	Prostaglandin E2 Measurement	lbpr	3.42
26515683	C0010467	Curcumin	irda	25.51
26515683	C0010467	Curcumin	orch	25.51
26515683	C0010467	Curcumin	phsu	25.51
26515683	C0079633	Interleukin-8	aapp	22.49
26515683	C0079633	Interleukin-8	imft	22.49
26515683	C0012472	Dinoprostone	horm	22.47
26515683	C0012472	Dinoprostone	orch	22.47
26515683	C0012472	Dinoprostone	phsu	22.47
26515683	C3813211	Prostaglandin E2	orch	22.47
26515683	C0004048	Inspiration function	orgf	19.25
26515683	C1698756	CXCL8 protein, human	aapp	13.03
26515683	C1698756	CXCL8 protein, human	bacs	13.03
26515683	C1565860	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human	aapp	13.03
26515683	C1565860	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human	enzy	13.03
26515683	C0032285	Pneumonia	dsyn	9.96
26515683	C3714636	Pneumonitis	dsyn	9.96
26515683	C0851285	Regulation	gora	9.76
26515683	C0443289	Revealed	qlco	5.18
26515683	C2825142	Experimental Result	fndg	3.98
26515683	C1274040	Result	ftcn	3.98
26515683	C1546471	What subject filter - Result	idcn	3.98
26515683	C0332685	Thermal injury	inpo	3.78
26515683	C0745334	Inhalation injury	inpo	3.75
26515683	C1511437	CFTR Pathway	moft	3.74
26515683	C1705323	PTGS2 wt Allele	gngm	3.57
26515683	C3245505	potential	qlco	3.56
26515683	C1879547	Activation action	acty	3.54
26515683	C0332152	Before	tmco	3.54
26515683	C1522538	Leading	ftcn	3.54
26515683	C3538990	Prostaglandin E2 Measurement	lbpr	3.54
26515683	C1705211	Inhalation Dosing Unit	qnco	3.48
26515683	C0205535	Inhalation Route of Drug Administration	ftcn	3.48
26515683	C0018837	Heat (physical force)	npop	3.46
26515683	C0205263	Induce (action)	ftcn	3.46
26515683	C0302350	Therapeutic	ftcn	3.43
26515683	C0087111	Therapeutic procedure	topp	3.43
25487078	C0018684	Health	idcn	6.58
25487078	C1881534	Make - Instruction Imperative	ftcn	3.98
25487078	C0013227	Pharmaceutical Preparations	phsu	3.68
25487078	C1880177	Contribution	acty	3.55
25487078	C1272745	Improving (qualifier value)	qlco	3.43
25487078	C0040363	Togo	geoa	17.80
25487078	C0041260	Tryptophanase	aapp	17.80
25487078	C0041260	Tryptophanase	enzy	17.80
25487078	C0016820	Funds	qnco	11.49
25487078	C0021162	Income	qnco	9.77
25487078	C0080045	Prices	qnco	6.60
25487078	C1883351	To	qlco	5.18
25487078	C0454664	Country	geoa	3.61
25487078	C0013227	Pharmaceutical Preparations	phsu	3.61
25487078	C1299351	Abnormally high	qlco	3.47
25487078	C0205250	High	qlco	3.47
25487078	C3889660	High Mitosis-Karyorrhexis Index	qnco	3.47
25487078	C0205314	New	qlco	3.47
25487078	C2700149	Value Above Reference Range	inpr	3.47
25487078	C3887512	high - ActExposureLevelCode	idcn	3.47
25487078	C0040363	Togo	geoa	17.80
25487078	C0041260	Tryptophanase	aapp	17.80
25487078	C0041260	Tryptophanase	enzy	17.80
25487078	C0042153	utilization qualifier	ftcn	11.49
25487078	C1883351	To	qlco	5.18
25487078	C0457083	Usage	ftcn	5.18
25487078	C1947944	Use - dosing instruction imperative	inpr	5.18
25487078	C0920595	model development	inpr	3.58
25487078	C0205314	New	qlco	3.43
25487078	C0040363	Togo	geoa	35.81
25487078	C0041260	Tryptophanase	aapp	35.81
25487078	C0041260	Tryptophanase	enzy	35.81
25487078	C0015316	Expenditures	qnco	13.03
25487078	C0282443	Review [Publication Type]	inpr	11.49
25487078	C0018017	objective (goal)	inpr	11.49
25487078	C0042153	utilization qualifier	ftcn	11.49
25487078	C1883351	To	qlco	10.42
25487078	C0085970	Case Histories	inpr	6.76
25487078	C1552617	Act Class - review	idcn	5.18
25487078	C1571702	Objective observation	qlco	5.18
25487078	C1273803	Health Authority	hcro	3.45
25487078	C0205314	New	qlco	3.44
25487078	C0013227	Pharmaceutical Preparations	phsu	3.44
25487078	C0040363	Togo	geoa	17.80
25487078	C0041260	Tryptophanase	aapp	17.80
25487078	C0041260	Tryptophanase	enzy	17.80
25487078	C0042153	utilization qualifier	ftcn	11.49
25487078	C1883351	To	qlco	5.18
25487078	C0457083	Usage	ftcn	5.18
25487078	C1947944	Use - dosing instruction imperative	inpr	5.18
25487078	C3161035	Model	inpr	3.68
25487078	C0085970	Case Histories	inpr	6.76
25487078	C0805586	Challenge	hlca	5.18
25487078	C0449788	Count of entities	qnco	3.57
25487078	C0237753	Numbers	qnco	3.57
25487078	C1550043	Container status - Identified	fndg	3.56
25487078	C0205396	Identified	qlco	3.56
25487078	C1706387	Issue (document)	inpr	3.42
25487078	C0033213	Problem	fndg	3.42
25487078	C0011849	Diabetes Mellitus	dsyn	14.64
25487078	C0220847	Hepatitis C virus	virs	14.64
25487078	C0920627	Orphan Diseases	dsyn	14.64
25487078	C0080045	Prices	qnco	6.70
25487078	C0011847	Diabetes	dsyn	5.18
25487078	C0332257	Including (qualifier)	ftcn	5.18
25487078	C0027651	Neoplasms	neop	3.59
25487078	C0278627	oncology field	bmod	3.59
25487078	C0205397	seen	qlco	3.59
25487078	C0449788	Count of entities	qnco	3.55
25487078	C0237753	Numbers	qnco	3.55
25487078	C0683243	innovativeness	menp	3.52
25487078	C3890211	Low Mitosis-Karyorrhexis Index	qnco	3.43
25487078	C0205314	New	qlco	3.43
25487078	C0013227	Pharmaceutical Preparations	phsu	3.43
25487078	C0205251	low	qlco	3.43
25487078	C1550472	low confidentiality	inpr	3.43
25487078	C4048187	low exposure	qlco	3.43
25487078	C0442808	Increasing	ftcn	3.42
25487078	C1272683	Request - action	ftcn	3.42
25487078	C0920627	Orphan Diseases	dsyn	13.03
25487078	C0015316	Expenditures	qnco	12.88
25487078	C0013175	Drug Evaluation	resa	10.06
25487078	C3161035	Model	inpr	7.24
25487078	C0031336	Pharmacy (field)	bmod	6.58
25487078	C0347985	During values	tmco	5.18
25487078	C0332257	Including (qualifier)	ftcn	5.18
25487078	C0439064	Numerous	qnco	3.68
25487078	C0243161	criteria	inpr	3.68
25487078	C0729762	Drug values	phsu	3.58
25487078	C3853906	Digital Model Attachment	inpr	3.57
25487078	C3714583	Model - style/design	cnce	3.57
25487078	C3274659	Model Number	inpr	3.57
25487078	C0332152	Before	tmco	3.55
25487078	C0740175	Before values	qlco	3.55
25487078	C3810851	Center of town	fndg	3.55
25487078	C0205099	Central	spco	3.55
25487078	C3669034	Pure Spanish horse breed (organism)	mamm	3.55
25487078	C0205449	Three	qnco	3.55
25487078	C2257086	photoreactivating enzyme activity	genf	3.55
25487078	C0687676	Post	tmco	3.50
25487078	C1704687	Post Device Component	mnob	3.50
25487078	C1553874	Concept Status - Proposed	qlco	3.48
25487078	C1511545	Critical	qlco	3.48
25487078	C1578820	Edit Status - Proposed	qlco	3.48
25487078	C1135440	Procedures involving the use of pharmaceuticals	topp	3.42
25487078	C0302167	capping	celf	3.42
25487078	C0175671	Universal	qlco	12.94
25487078	C0173021	Universal varnish	bodm	12.94
25487078	C0173021	Universal varnish	orch	12.94
25487078	C1257890	Population Group	popg	9.94
25487078	C0018696	Health Care Systems	hcro	9.75
25487078	C1707478	Conclusion	idcn	5.18
25487078	C1314939	Involvement with	ftcn	5.18
25487078	C3161035	Model	inpr	3.68
25487078	C0444454	Access	spco	3.63
25487078	C1705428	Group Object	cnce	3.63
25487078	C0441833	Groups	idcn	3.63
25487078	C1554204	Role Class - access	ftcn	3.63
25487078	C0687744	Social group	popg	3.63
25487078	C1552516	Specialty Group	hcro	3.63
25487078	C1552839	Table Rules - groups	inpr	3.63
25487078	C1705429	User Group	popg	3.63
25487078	C1511545	Critical	qlco	3.55
25487078	C1553874	Concept Status - Proposed	qlco	3.50
25487078	C1578820	Edit Status - Proposed	qlco	3.50
25487078	C1552870	Universal - VocabularyDomainQualifier	inpr	3.48
25487078	C2349975	Enhance (action)	acty	3.45
25487078	C0237935	Trust (Social Behavior)	inbe	13.03
25487078	C1257890	Population Group	popg	11.49
25487078	C1269765	Assisted (qualifier value)	qlco	5.18
25487078	C1705428	Group Object	cnce	5.18
25487078	C0441833	Groups	idcn	5.18
25487078	C1552861	Help document	inpr	5.18
25487078	C3161035	Model	inpr	5.18
25487078	C0687744	Social group	popg	5.18
25487078	C1552516	Specialty Group	hcro	5.18
25487078	C1552839	Table Rules - groups	inpr	5.18
25487078	C1705429	User Group	popg	5.18
25487078	C0870392	debate	acty	5.18
25487078	C3245466	ObservationValue - trust	idcn	3.57
28667089	C0026882	Mutation	genf	19.74
28667089	C3264621	ivacaftor	orch	14.64
28667089	C3264621	ivacaftor	phsu	14.64
28667089	C0030705	Patients	podg	13.52
28667089	C3852684	lumacaftor	orch	12.89
28667089	C3852684	lumacaftor	phsu	12.89
28667089	C4033620	ORKAMBI	phsu	10.42
28667089	C0010674	Cystic Fibrosis	dsyn	9.81
28667089	C0009429	Combined Modality Therapy	topp	6.76
28667089	C1704689	Bearing Device Component	medd	5.18
28667089	C1518422	Negation	ftcn	5.18
28667089	C1882327	Percent of Predicted Value	qnco	5.18
28667089	C0684224	Report (document)	inpr	5.18
28667089	C0700287	Reporting	hlca	5.18
28667089	C0087111	Therapeutic procedure	topp	5.18
28667089	C1522326	Treating	ftcn	5.18
28667089	C1292734	Treatment intent	ftcn	5.18
28667089	C0681842	prediction	idcn	5.18
28667089	C1705285	Mutation Abnormality	comd	3.61
28667089	C0556895	Combination electrotherapy	topp	3.61
28667089	C0205540	Approved	qlco	3.59
28667089	C1280519	Effectiveness	qlco	3.54
28667089	C1707887	Efficacy Study	resa	3.54
28667089	C0205164	Major	qlco	3.47
28667089	C0205082	Severe (severity modifier)	qlco	3.47
28667089	C2348205	Similarity	qlco	3.42
28667089	C0449445	Approach	spco	3.42
28667089	C0750484	Confirmation	idcn	3.42
28667089	C0521093	Confirmed by	qlco	3.42
28667089	C0599755	cohort	popg	3.42
28667089	C0521114	Infrequent	tmco	3.40
28667089	C0522498	Rare	qlco	3.40
28667089	C1514917	Retinoic Acid Response Element	gngm	3.40
28667089	C0026882	Mutation	genf	9.99
28667089	C0030705	Patients	podg	8.34
28667089	C1704689	Bearing Device Component	medd	5.18
28667089	C1705285	Mutation Abnormality	comd	3.68
28667089	C0521114	Infrequent	tmco	3.50
28667089	C0522498	Rare	qlco	3.50
28667089	C1514917	Retinoic Acid Response Element	gngm	3.50
28667089	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28667089	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28667089	C0040363	Togo	geoa	17.80
28667089	C0041260	Tryptophanase	aapp	17.80
28667089	C0041260	Tryptophanase	enzy	17.80
28667089	C0031843	physiological aspects	phsf	12.89
28667089	C0033684	Proteins	aapp	6.66
28667089	C0033684	Proteins	bacs	6.66
28667089	C0678227	Causing	ftcn	5.18
28667089	C1704632	Disease Response	fndg	5.18
28667089	C0439267	Gram per Deciliter	qnco	5.18
28667089	C2911692	Response (communication)	menp	5.18
28667089	C1706817	Response (statement)	inpr	5.18
28667089	C0871261	Response process	orga	5.18
28667089	C1883351	To	qlco	5.18
28667089	C0750558	Unlikely	cnce	5.18
28667089	C1710571	Unlikely Related to Intervention	qlco	5.18
28667089	C4033620	ORKAMBI	phsu	3.68
28667089	C1435727	FABP6 protein, human	aapp	3.61
28667089	C1435727	FABP6 protein, human	bacs	3.61
28667089	C2348205	Similarity	qlco	3.55
28667089	C2986815	Robust	qlco	3.50
28667089	C1413365	CFTR gene	gngm	3.42
28667089	C0392747	Changing	ftcn	3.42
28667089	C0439799	Channel	spco	3.42
28667089	C1706095	Channel Object	cnce	3.42
28667089	C0542341	Function	ftcn	3.42
28667089	C0700205	Function Axis	clas	3.42
28667089	C1705273	Mathematical Operator	inpr	3.42
28667089	C3264621	ivacaftor	orch	14.64
28667089	C3264621	ivacaftor	phsu	14.64
28667089	C3852684	lumacaftor	orch	13.05
28667089	C3852684	lumacaftor	phsu	13.05
28667089	C0026882	Mutation	genf	11.49
28667089	C0026193	Minor (person)	popg	6.72
28667089	C0030705	Patients	podg	6.58
28667089	C0205195	Combined	qlco	5.18
28667089	C0750484	Confirmation	idcn	5.18
28667089	C0521093	Confirmed by	qlco	5.18
28667089	C0205202	Corrected	qlco	5.18
28667089	C1705285	Mutation Abnormality	comd	5.18
28667089	C3811910	combination - answer to question	fndg	5.18
28667089	C1947911	combination of objects	phob	5.18
28667089	C0205474	Biochemical	ftcn	3.60
28667089	C0947630	Scientific Study	lbpr	3.60
28667089	C1708698	Light Emitting Diode Device Component	mnob	3.57
28667089	C0205165	Minor (value)	qlco	3.57
28667089	C1704632	Disease Response	fndg	3.55
28667089	C2911692	Response (communication)	menp	3.55
28667089	C1706817	Response (statement)	inpr	3.55
28667089	C0871261	Response process	orga	3.55
28667089	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.42
28667089	C0040300	Body tissue	tisu	3.42
28667089	C1441547	Derivation	qlco	3.42
28667089	C3245521	Derived value	idcn	3.42
28667089	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.42
28667089	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.42
28667089	C1547928	Tissue Specimen Code	inpr	3.42
28667089	C3658200	Clustered Regularly Interspaced Short Palindromic Repeats	nnon	25.53
28667089	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
28667089	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
28667089	C0002684	Electronic Amplifiers	mnob	9.81
28667089	C0026882	Mutation	genf	9.78
28667089	C1704689	Bearing Device Component	medd	5.18
28667089	C0205198	Compound	qlco	5.18
28667089	C1706082	Compound (substance)	chem	5.18
28667089	C1704632	Disease Response	fndg	5.18
28667089	C0205217	Increased	qnco	5.18
28667089	C4033620	ORKAMBI	phsu	5.18
28667089	C2911692	Response (communication)	menp	5.18
28667089	C1706817	Response (statement)	inpr	5.18
28667089	C0871261	Response process	orga	5.18
28667089	C1547282	Show	anim	3.98
28667089	C0947630	Scientific Study	lbpr	3.63
28667089	C0700221	Intravascular line	medd	3.59
28667089	C1550648	Line Specimen	sbst	3.59
28667089	C1552960	Line Unit of Length	qnco	3.59
28667089	C0205132	Linear	spco	3.59
28667089	C1704419	Effective	qlco	3.59
28667089	C1280519	Effectiveness	qlco	3.59
28667089	C0441889	Levels (qualifier value)	qlco	3.55
28667089	C3888061	Amplifier	mnob	3.50
28667089	C1706099	Amplifier Device Component	medd	3.50
28667089	C1711178	Bronchial Epithelial Cell	cell	3.49
28667089	C0562342	Empowered	menp	3.48
28667089	C1705285	Mutation Abnormality	comd	3.48
28667089	C0442808	Increasing	ftcn	3.45
28667089	C0868955	editing	ocac	3.43
28667089	C0205252	Immature	qlco	3.43
28667089	C0009738	Congo	geoa	16.08
28667089	C0010453	Anthropological Culture	idcn	13.01
28667089	C0028429	Nose	bpoc	13.01
28667089	C0026882	Mutation	genf	9.92
28667089	C0002684	Electronic Amplifiers	mnob	9.81
28667089	C0030705	Patients	podg	6.71
28667089	C0040300	Body tissue	tisu	5.18
28667089	C1280500	Effect	qlco	5.18
28667089	C2348382	Effect, Appearance	qlco	5.18
28667089	C0475311	Harbor	mnob	3.98
28667089	C1999230	Providing (action)	acty	3.98
28667089	C4033620	ORKAMBI	phsu	3.68
28667089	C1705285	Mutation Abnormality	comd	3.61
28667089	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.55
28667089	C1441547	Derivation	qlco	3.55
28667089	C3245521	Derived value	idcn	3.55
28667089	C3887511	Evidence	idcn	3.55
28667089	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.55
28667089	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.55
28667089	C3888061	Amplifier	mnob	3.50
28667089	C1706099	Amplifier Device Component	medd	3.50
28667089	C0205217	Increased	qnco	3.48
28667089	C3811819	CFTR wt Allele	gngm	3.47
28667089	C0678227	Causing	ftcn	3.47
28667089	C0521114	Infrequent	tmco	3.47
28667089	C0522498	Rare	qlco	3.47
28667089	C1514917	Retinoic Acid Response Element	gngm	3.47
28667089	C1280519	Effectiveness	qlco	3.43
28667089	C1707887	Efficacy Study	resa	3.43
28667089	C0205435	First (number)	qnco	3.43
28667089	C1279901	Firstly	qlco	3.43
28667089	C3658200	Clustered Regularly Interspaced Short Palindromic Repeats	nnon	25.51
28667089	C0040363	Togo	geoa	17.80
28667089	C0041260	Tryptophanase	aapp	17.80
28667089	C0041260	Tryptophanase	enzy	17.80
28667089	C0009738	Congo	geoa	16.09
28667089	C0026882	Mutation	genf	9.94
28667089	C0030705	Patients	podg	6.59
28667089	C0332257	Including (qualifier)	ftcn	5.18
28667089	C1180138	Principal tissue	tisu	5.18
28667089	C1979963	Profile (lab procedure)	lbpr	5.18
28667089	C2003903	Profiling (action)	ftcn	5.18
28667089	C1883351	To	qlco	5.18
28667089	C1524063	Use of	ftcn	5.18
28667089	C0449445	Approach	spco	3.63
28667089	C1522647	Developmental Therapeutics Program	resa	3.58
28667089	C0556496	Developmental therapy	topp	3.58
28667089	C1706214	Creation	acty	3.55
28667089	C0441513	Surgical construction	topp	3.55
28667089	C1709060	Modulator Device Component	mnob	3.54
28667089	C3811819	CFTR wt Allele	gngm	3.48
28667089	C0521114	Infrequent	tmco	3.48
28667089	C0439064	Numerous	qnco	3.48
28667089	C0522498	Rare	qlco	3.48
28667089	C1514917	Retinoic Acid Response Element	gngm	3.48
28667089	C1883357	Together	qlco	3.44
28667089	C1519941	Validation	resa	3.44
28667089	C0007634	Cells	cell	3.43
28667089	C3282337	Cells [Chemical/Ingredient]	cell	3.43
28667089	C0868955	editing	ocac	3.41
26041577	C0055363	Chloride Channels	aapp	19.20
26041577	C0055363	Chloride Channels	bacs	19.20
26041577	C0596901	Membrane	celc	6.57
26041577	C0025255	Tissue membrane	tisu	6.57
26041577	C1704735	Regulator	cnce	3.60
26041577	C1704734	Regulator Device Component	mnob	3.60
26041577	C0182953	Regulators (device)	medd	3.60
26041577	C1313906	Epithelial cells present	fndg	3.58
26041577	C0205207	Cystic	qlco	3.46
26041577	C2752508	fully spanning the plasma membrane	celc	3.46
26041577	C1167322	integral to membrane	celc	3.46
26041577	C1706182	Membrane Device Component	mnob	3.42
26041577	C0010674	Cystic Fibrosis	dsyn	10.06
26041577	C0026882	Mutation	genf	9.99
26041577	C0015127	Etiology aspects	ftcn	9.94
26041577	C0392760	Affecting	ftcn	5.18
26041577	C1413365	CFTR gene	gngm	5.18
26041577	C1314939	Involvement with	ftcn	5.18
26041577	C1836348	Severe disorder	fndg	3.68
26041577	C1524003	Science of Etiology	cnce	3.63
26041577	C0439064	Numerous	qnco	3.47
26041577	C0178784	Organ	bpoc	3.47
26041577	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
26041577	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
26041577	C0009738	Congo	geoa	16.08
26041577	C0026882	Mutation	genf	9.92
26041577	C1561536	*Activity (kind of quantity)	idcn	5.18
26041577	C0205177	Active	ftcn	5.18
26041577	C0441655	Activities	acty	5.18
26041577	C3668946	Activity (animal life circumstance)	fndg	5.18
26041577	C4049939	FDA Establishment Activity Terminology	inpr	5.18
26041577	C0439167	Percent Activity	qnco	5.18
26041577	C4049938	Physical Activity Measurement	lbpr	5.18
26041577	C1709694	Processing (action)	acty	5.18
26041577	C1705285	Mutation Abnormality	comd	3.61
26041577	C3811819	CFTR wt Allele	gngm	3.47
26041577	C0205214	Common (qualifier value)	qnco	3.47
26041577	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.47
26041577	C0205393	Most	qnco	3.47
26041577	C1522138	shared attribute	ftcn	3.47
26041577	C0015127	Etiology aspects	ftcn	11.49
26041577	C0026882	Mutation	genf	11.49
26041577	C1720467	Only - dosing instruction fragment	inpr	5.18
26041577	C1524003	Science of Etiology	cnce	5.18
26041577	C0205171	Singular	qnco	5.18
26041577	C1457869	Defect	ftcn	3.68
26041577	C1947967	Call (Instruction)	ftcn	3.98
26041577	C0679006	Decision	menp	3.98
26041577	C1709694	Processing (action)	acty	3.68
26041577	C0243067	defects aspect	ftcn	3.68
26041577	C1328819	Small Molecule	orch	3.64
26041577	C1521840	Target	ftcn	3.57
26041577	C2700399	Include (action)	acty	5.18
26041577	C0332257	Including (qualifier)	ftcn	5.18
26041577	C1882932	Representation (action)	acty	5.18
26041577	C1552866	include - SetOperator	idcn	5.18
26041577	C2983595	Class of Trial Agent	clas	3.67
26041577	C0567416	Molecule	sbst	3.57
26041577	C1561536	*Activity (kind of quantity)	idcn	3.44
26041577	C0205177	Active	ftcn	3.44
26041577	C0441655	Activities	acty	3.44
26041577	C3668946	Activity (animal life circumstance)	fndg	3.44
26041577	C1554184	Dual	anim	3.44
26041577	C4049939	FDA Establishment Activity Terminology	inpr	3.44
26041577	C0439167	Percent Activity	qnco	3.44
26041577	C4049938	Physical Activity Measurement	lbpr	3.44
26041577	C0543488	Interested	menp	3.43
26041577	C0040363	Togo	geoa	35.81
26041577	C0041260	Tryptophanase	aapp	35.81
26041577	C0041260	Tryptophanase	enzy	35.81
26041577	C1883351	To	qlco	10.42
26041577	C0872147	DNA Library	gngm	9.87
26041577	C0872147	DNA Library	nnon	9.87
26041577	C0023621	Libraries	mnob	9.87
26041577	C0023621	Libraries	orgt	9.87
26041577	C0751608	cDNA Library	gngm	9.87
26041577	C0751608	cDNA Library	nnon	9.87
26041577	C1561536	*Activity (kind of quantity)	idcn	6.91
26041577	C0205177	Active	ftcn	6.91
26041577	C0441655	Activities	acty	6.91
26041577	C3668946	Activity (animal life circumstance)	fndg	6.91
26041577	C4049939	FDA Establishment Activity Terminology	inpr	6.91
26041577	C0439167	Percent Activity	qnco	6.91
26041577	C4049938	Physical Activity Measurement	lbpr	6.91
26041577	C2948600	Aim	phsu	5.18
26041577	C1947946	Aim (idea)	idcn	5.18
26041577	C3540472	Ancestry-Informative Marker	ftcn	5.18
26041577	C3890193	CD5L wt Allele	gngm	5.18
26041577	C2744535	CD69 protein, human	aapp	5.18
26041577	C2744535	CD69 protein, human	imft	5.18
26041577	C3540471	CD69 wt Allele	gngm	5.18
26041577	C0443211	Established	qlco	5.18
26041577	C1948052	Now (temporal qualifier)	tmco	5.18
26041577	C1705178	Order (action)	acty	5.18
26041577	C1705176	Order (arrangement)	qlco	5.18
26041577	C1705175	Order (document)	inpr	5.18
26041577	C1705177	Order (taxonomic)	clas	5.18
26041577	C1882348	Permutation	qlco	5.18
26041577	C1999230	Providing (action)	acty	5.18
26041577	C3889825	Sequence of Planned Assessment Schedule	inpr	5.18
26041577	C1883254	Synthesis	acty	5.18
26041577	C2983265	CDISC SEND Study Design Terminology	inpr	3.98
26041577	C1707689	Design	acty	3.98
26041577	C0392360	Indication of (contextual qualifier)	idcn	3.56
26041577	C1979963	Profile (lab procedure)	lbpr	3.56
26041577	C2003903	Profiling (action)	ftcn	3.56
26041577	C1279901	Firstly	qlco	3.50
26041577	C1555582	Initial (abbreviation)	idcn	3.50
26041577	C1705685	Initial Usage	ftcn	3.50
26041577	C0205265	Initially	tmco	3.50
26041577	C0596316	chemical group	chvs	3.46
26041577	C0205314	New	qlco	3.43
26041577	C0679622	literary novel	inpr	3.43
26041577	C0205198	Compound	qlco	3.41
26041577	C1706082	Compound (substance)	chem	3.41
26041577	C3537219	SERPINA1 wt Allele	gngm	3.41
26041577	C0005507	Biological Assay	lbpr	6.83
26041577	C1524063	Use of	ftcn	5.18
26041577	C1510438	Assay	lbpr	3.68
26041577	C0243073	assay qualifier	qlco	3.68
26041577	C0205198	Compound	qlco	3.63
26041577	C1706082	Compound (substance)	chem	3.63
26041577	C0392366	Tests (qualifier value)	inpr	3.59
26041577	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.56
26041577	C0542341	Function	ftcn	3.50
26041577	C0205245	Functional	ftcn	3.50
26041577	C2700217	Functional Relationship	cnce	3.50
26041577	C0205314	New	qlco	3.50
26041577	C1550043	Container status - Identified	fndg	5.18
26041577	C0205396	Identified	qlco	5.18
26041577	C0450373	4a serotype	inpr	3.68
26041577	C1553636	Maxillary right second premolar abutment	medd	3.68
26041577	C0205198	Compound	qlco	3.63
26041577	C1706082	Compound (substance)	chem	3.63
26041577	C3252847	VX 809	orch	3.59
26041577	C3252847	VX 809	phsu	3.59
26041577	C1561611	Admission Level of Care Code - Improved	inpr	3.57
26041577	C0332272	Better	qlco	3.57
26041577	C1880022	Characterization	acty	3.57
26041577	C1280519	Effectiveness	qlco	3.57
26041577	C1707887	Efficacy Study	resa	3.57
26041577	C0184511	Improved	qlco	3.57
26041577	C0205195	Combined	qlco	3.55
26041577	C1706089	Marked	qlco	3.50
26041577	C0522501	Massive	qlco	3.50
26041577	C3537219	SERPINA1 wt Allele	gngm	3.50
26041577	C0205177	Active	ftcn	3.48
26041577	C3888249	Active License	qlco	3.48
26041577	C1554184	Dual	anim	3.48
26041577	C3853793	active (HL7 RoleLink)	idcn	3.48
26041577	C0005456	Binding Sites	rcpt	13.05
26041577	C1516769	Computational Technique	resa	5.18
26041577	C0442726	Detected (finding)	fndg	5.18
26041577	C1511790	Detection	topp	5.18
26041577	C0682969	Ligand Binding Domain	amas	3.59
26041577	C1148916	nucleotide binding	moft	3.50
26041577	C3541951	Concept model domain	inpr	3.47
26041577	C1880389	Domain (area of knowledge)	ftcn	3.47
26041577	C1883221	Superkingdom (taxonomic category)	cnce	3.47
26041577	C0332149	Possible	qlco	3.43
26041577	C2362652	Possible diagnosis	qlco	3.43
26041577	C1705910	Possibly Related to Intervention	qlco	3.43
26041577	C3537219	SERPINA1 wt Allele	gngm	3.41
26041577	C0220781	Anabolism	biof	6.71
26041577	C1947931	Direct (qualifier)	qlco	5.18
26041577	C0439851	Direct type of relationship	qlco	5.18
26041577	C2825142	Experimental Result	fndg	3.98
26041577	C1274040	Result	ftcn	3.98
26041577	C1546471	What subject filter - Result	idcn	3.98
26041577	C1561536	*Activity (kind of quantity)	idcn	3.63
26041577	C0205177	Active	ftcn	3.63
26041577	C0441655	Activities	acty	3.63
26041577	C3668946	Activity (animal life circumstance)	fndg	3.63
26041577	C4049939	FDA Establishment Activity Terminology	inpr	3.63
26041577	C0439167	Percent Activity	qnco	3.63
26041577	C4049938	Physical Activity Measurement	lbpr	3.63
26041577	C1883254	Synthesis	acty	3.56
26041577	C1561611	Admission Level of Care Code - Improved	inpr	3.48
26041577	C0332272	Better	qlco	3.48
26041577	C0184511	Improved	qlco	3.48
26041577	C2362652	Possible diagnosis	qlco	3.48
26041577	C0205314	New	qlco	3.43
26041577	C0243071	Analog	chvs	3.41
28346090	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.57
28346090	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.57
28346090	C0087136	Unmarried	fndg	22.35
28346090	C0037179	Unmarried person	popg	22.35
28346090	C0055363	Chloride Channels	aapp	19.36
28346090	C0055363	Chloride Channels	bacs	19.36
28346090	C0031453	Phenylalanine	aapp	16.04
28346090	C0031453	Phenylalanine	bacs	16.04
28346090	C0031453	Phenylalanine	phsu	16.04
28346090	C1511760	Deletion Mutation	genf	13.01
28346090	C0015127	Etiology aspects	ftcn	9.86
28346090	C0010674	Cystic Fibrosis	dsyn	9.75
28346090	C0014609	Epithelium	tisu	6.58
28346090	C0024109	Lung	bpoc	6.58
28346090	C1413365	CFTR gene	gngm	5.18
28346090	C1880274	Deletion (action)	acty	3.55
28346090	C1442161	Gene Deletion Abnormality	comd	3.55
28346090	C4019252	Position of phenotypic abnormality	ftcn	3.55
28346090	C0733755	Positioning Attribute	spco	3.55
28346090	C1524003	Science of Etiology	cnce	3.55
28346090	C1278908	Entire lung	bpoc	3.43
28346090	C0819757	Structure of parenchyma of lung	tisu	3.43
28346090	C0205214	Common (qualifier value)	qnco	3.42
28346090	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
28346090	C0205393	Most	qnco	3.42
28346090	C1709915	Residue	cnce	3.42
28346090	C1882936	Residue after Decontamination Medical Device Problem	evnt	3.42
28346090	C0205171	Singular	qnco	3.42
28346090	C0202174	blood phenylalanine measurement by Guthrie microbiologic assay	lbpr	3.42
28346090	C1522138	shared attribute	ftcn	3.42
28346090	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.25
28346090	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.25
28346090	C0162847	protein folding	moft	13.04
28346090	C0011209	Obstetric Delivery	topp	9.87
28346090	C0699900	Catabolism	orgf	6.71
28346090	C1305923	Polypeptides	aapp	6.71
28346090	C0686907	Consequence of	ftcn	5.18
28346090	C2945640	compromise	fndg	3.98
28346090	C0332294	Resulting in	ftcn	3.59
28346090	C1314680	Non-human parturition, function	orgf	3.56
28346090	C1705822	Transfer Technique	ftcn	3.56
28346090	C1413365	CFTR gene	gngm	3.55
28346090	C0185026	Plication	topp	3.55
28346090	C0243125	degradation aspects	ftcn	3.55
28346090	C0699040	Cell surface	celc	3.46
28346090	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28346090	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28346090	C1314792	Etiology	ftcn	14.64
28346090	C0015127	Etiology aspects	ftcn	11.49
28346090	C0026727	Mucous body substance	bdsu	9.88
28346090	C0010674	Cystic Fibrosis	dsyn	9.77
28346090	C1524003	Science of Etiology	cnce	5.18
28346090	C0332281	Associated with	qlco	3.64
28346090	C4055506	Accumulation	fndg	3.57
28346090	C1546714	Specimen Source Codes - Mucus	inpr	3.57
28346090	C2753459	mucus layer	bdsu	3.57
28346090	C3854307	Presence (property)	qlco	3.55
28346090	C0150312	Present	qnco	3.55
28346090	C0392148	Providing presence (regime/therapy)	topp	3.55
28346090	C0232217	Cardiac conduction	ortf	3.52
28346090	C0457405	Conduction Phenomenon	npop	3.52
28346090	C0596019	Chloride Ion	elii	3.50
28346090	C0221099	Impaired	ftcn	3.47
28346090	C1413365	CFTR gene	gngm	3.43
28346090	C0205216	Decreased	qnco	3.43
28346090	C0442797	Decreasing	qlco	3.43
28346090	C0392756	Reduced	qlco	3.43
28346090	C0205148	Surface	spco	3.43
28346090	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28346090	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28346090	C0243041	Molecular Chaperones	aapp	19.77
28346090	C0243041	Molecular Chaperones	bacs	19.77
28346090	C0040363	Togo	geoa	17.80
28346090	C0041260	Tryptophanase	aapp	17.80
28346090	C0041260	Tryptophanase	enzy	17.80
28346090	C0243044	HSP90 Heat-Shock Proteins	aapp	16.04
28346090	C0243044	HSP90 Heat-Shock Proteins	bacs	16.04
28346090	C0032214	Play	dora	14.64
28346090	C0035820	Social Role	socb	13.00
28346090	C3245499	Colombia	geoa	12.93
28346090	C0039869	Thinking, function	menp	11.49
28346090	C0699900	Catabolism	orgf	8.34
28346090	C0600138	Does play	fndg	5.18
28346090	C1883351	To	qlco	5.18
28346090	C0243125	degradation aspects	ftcn	5.18
28346090	C1412886	AHSA1 gene	gngm	3.61
28346090	C1705810	Generic Role	cnce	3.54
28346090	C3871154	{Role}	inpr	3.54
28346090	C3887537	Partner	popg	3.47
28346090	C0682323	Partner in relationship	famg	3.47
28346090	C1825534	HSP90AA1 gene	gngm	3.43
28346090	C3273507	HSP90AA1 wt Allele	gngm	3.43
28346090	C1636779	% deficient	qnco	3.42
28346090	C1413365	CFTR gene	gngm	3.42
28346090	C0011155	Deficiency	ftcn	3.42
28346090	C0185026	Plication	topp	3.42
28346090	C1521840	Target	ftcn	3.42
28346090	C0040363	Togo	geoa	35.81
28346090	C0041260	Tryptophanase	aapp	35.81
28346090	C0041260	Tryptophanase	enzy	35.81
28346090	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
28346090	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
28346090	C0018790	Cardiac Arrest	dsyn	20.48
28346090	C0243044	HSP90 Heat-Shock Proteins	aapp	16.08
28346090	C0243044	HSP90 Heat-Shock Proteins	bacs	16.08
28346090	C0597304	Proteolysis	moft	13.03
28346090	C1883351	To	qlco	10.42
28346090	C0031330	Pharmacology	bmod	9.81
28346090	C0243041	Molecular Chaperones	aapp	9.77
28346090	C0243041	Molecular Chaperones	bacs	9.77
28346090	C1706084	(City) Block	geoa	7.79
28346090	C0237477	Arrested progression	tmco	7.79
28346090	C2828370	Block (unit of measure)	qnco	7.79
28346090	C1533157	Block Specimens	sbst	7.79
28346090	C3811660	Block Unit of Distance	qnco	7.79
28346090	C0332206	Blocking	ftcn	7.79
28346090	C0392351	Law enforcement arrest	gora	7.79
28346090	C0233660	Mental blocking	mobd	7.79
28346090	C0028778	Obstruction	patf	7.79
28346090	C0521111	Retarded	qlco	7.79
28346090	C0220781	Anabolism	biof	6.76
28346090	C0700364	Appearance	qlco	5.18
28346090	C1153420	chloride channel activity	moft	3.81
28346090	C0947647	Manipulation procedure	topp	3.68
28346090	C0185111	Surgical Manipulation	topp	3.68
28346090	C1522492	Formation	ftcn	3.60
28346090	C0439634	Formations	spco	3.60
28346090	C0205464	pharmacological	ftcn	3.50
28346090	C1609982	Residual	qlco	3.47
28346090	C1412886	AHSA1 gene	gngm	3.46
28346090	C0439855	Complex	qlco	3.46
28346090	C1825534	HSP90AA1 gene	gngm	3.46
28346090	C3273507	HSP90AA1 wt Allele	gngm	3.46
28346090	C1704241	complex (molecular entity)	chvs	3.46
28346090	C1413365	CFTR gene	gngm	3.44
28346090	C0243044	HSP90 Heat-Shock Proteins	aapp	16.04
28346090	C0243044	HSP90 Heat-Shock Proteins	bacs	16.04
28346090	C1450269	Luminescent Measurements	lbpr	13.11
28346090	C2003941	Alpha	inpr	5.18
28346090	C2350010	Alpha Value	qlco	5.18
28346090	C0439095	Greek letter alpha (qualifier value)	inpr	5.18
28346090	C1705053	Screen Device Component	mnob	3.98
28346090	C1305399	Screening - procedure intent	ftcn	3.98
28346090	C0220908	Screening procedure	hlca	3.98
28346090	C0243077	inhibitors	chvf	3.55
28346090	C1516698	Collection (action)	ftcn	3.54
28346090	C1704814	Item Collection	idcn	3.54
28346090	C1881065	Homogeneity	qlco	3.46
28346090	C1514583	Proximity	spco	3.46
28346090	C0220806	Chemicals	chem	3.44
28346090	C1412886	AHSA1 gene	gngm	3.42
28346090	C0439855	Complex	qlco	3.42
28346090	C1825534	HSP90AA1 gene	gngm	3.42
28346090	C3273507	HSP90AA1 wt Allele	gngm	3.42
28346090	C1704241	complex (molecular entity)	chvs	3.42
28346090	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.23
28346090	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.23
28346090	C0040363	Togo	geoa	17.80
28346090	C0041260	Tryptophanase	aapp	17.80
28346090	C0041260	Tryptophanase	enzy	17.80
28346090	C0007585	Cell Culture Techniques	lbpr	16.06
28346090	C0085732	Ability	orga	14.64
28346090	C1564139	Mutant Proteins	aapp	10.06
28346090	C1550043	Container status - Identified	fndg	5.18
28346090	C0205396	Identified	qlco	5.18
28346090	C0392366	Tests (qualifier value)	inpr	5.18
28346090	C1883351	To	qlco	5.18
28346090	C1547282	Show	anim	3.98
28346090	C1153420	chloride channel activity	moft	3.64
28346090	C2825142	Experimental Result	fndg	3.63
28346090	C0567416	Molecule	sbst	3.63
28346090	C1274040	Result	ftcn	3.63
28346090	C1546471	What subject filter - Result	idcn	3.63
28346090	C1555307	promise	idcn	3.48
28346090	C0205448	Two	qnco	3.48
28346090	C1413365	CFTR gene	gngm	3.47
28346090	C0596988	mutant	comd	3.47
28346090	C0040363	Togo	geoa	17.80
28346090	C0041260	Tryptophanase	aapp	17.80
28346090	C0041260	Tryptophanase	enzy	17.80
28346090	C0010674	Cystic Fibrosis	dsyn	9.84
28346090	C0030705	Patients	podg	6.79
28346090	C1517331	Further	spco	5.18
28346090	C0087111	Therapeutic procedure	topp	5.18
28346090	C1883351	To	qlco	5.18
28346090	C1522326	Treating	ftcn	5.18
28346090	C1292734	Treatment intent	ftcn	5.18
28346090	C3252847	VX 809	orch	3.75
28346090	C3252847	VX 809	phsu	3.75
28346090	C0567416	Molecule	sbst	3.68
28346090	C0303231	Lead compound	chvs	3.61
28346090	C1704419	Effective	qlco	3.57
28346090	C1280519	Effectiveness	qlco	3.57
28346090	C0013227	Pharmaceutical Preparations	phsu	3.57
28346090	C1254351	Pharmacologic Substance	phsu	3.57
28346090	C0205448	Two	qnco	3.50
28346090	C0205195	Combined	qlco	3.44
28346090	C0205393	Most	qnco	3.44
28346090	C3811910	combination - answer to question	fndg	3.44
28346090	C1947911	combination of objects	phob	3.44
26793709	C0023175	Lead	elii	13.03
26793709	C0023175	Lead	hops	13.03
26793709	C0010674	Cystic Fibrosis	dsyn	11.49
26793709	C0035243	Respiratory Tract Infections	dsyn	10.06
26793709	C1547996	Diagnostic Service Section ID - Pulmonary Function	inpr	5.18
26793709	C0231921	Pulmonary function	ortf	5.18
26793709	C3160731	Pulmonary function (finding)	fndg	5.18
26793709	C0151317	Chronic infectious disease	dsyn	3.78
26793709	C1155266	inflammatory response	patf	3.75
26793709	C1546767	Specimen Source Codes - Respiratory	inpr	3.63
26793709	C0521346	respiratory	ftcn	3.63
26793709	C3275067	Cardiac Lead Procedure	topp	3.57
26793709	C0547047	Decrease	qnco	3.57
26793709	C2348269	Dietary Lead	elii	3.57
26793709	C0442801	Exaggerated	qlco	3.57
26793709	C2825142	Experimental Result	fndg	3.57
26793709	C1522538	Leading	ftcn	3.57
26793709	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.57
26793709	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.57
26793709	C0392756	Reduced	qlco	3.57
26793709	C1274040	Result	ftcn	3.57
26793709	C1546471	What subject filter - Result	idcn	3.57
26793709	C0205318	Uncontrolled	qlco	3.48
26793709	C0205191	chronic	tmco	3.48
26793709	C3540587	Interleukin-33	aapp	19.21
26793709	C0009738	Congo	geoa	16.04
26793709	C1667752	IL33 protein, human	aapp	12.91
26793709	C1667752	IL33 protein, human	bacs	12.91
26793709	C3891560	Alarmins	aapp	12.89
26793709	C3891560	Alarmins	bacs	12.89
26793709	C0024109	Lung	bpoc	6.58
26793709	C0030705	Patients	podg	6.58
26793709	C1552738	described	idcn	5.18
26793709	C3854307	Presence (property)	qlco	3.55
26793709	C0150312	Present	qnco	3.55
26793709	C0392148	Providing presence (regime/therapy)	topp	3.55
26793709	C2248030	interleukin-33 receptor binding	moft	3.44
26793709	C3811819	CFTR wt Allele	gngm	3.43
26793709	C1278908	Entire lung	bpoc	3.43
26793709	C0819757	Structure of parenchyma of lung	tisu	3.43
26793709	C3540587	Interleukin-33	aapp	19.21
26793709	C1667752	IL33 protein, human	aapp	12.91
26793709	C1667752	IL33 protein, human	bacs	12.91
26793709	C0085423	Gram-Negative Bacterial Infections	dsyn	11.49
26793709	C0014609	Epithelium	tisu	6.58
26793709	C0332282	Following	tmco	5.18
26793709	C0231290	Status post	tmco	5.18
26793709	C1710082	Signal	phpr	3.98
26793709	C0439673	Unknown	qlco	3.68
26793709	C3854321	Expression (foundation metadata concept)	idcn	3.55
26793709	C0185117	Expression procedure	topp	3.55
26793709	C0521116	Current (present time)	tmco	3.50
26793709	C2248030	interleukin-33 receptor binding	moft	3.44
26793709	C0458827	Airway structure	bpoc	3.42
26793709	C0178987	Artificial Airways	medd	3.42
26793709	C3540587	Interleukin-33	aapp	19.31
26793709	C0040363	Togo	geoa	17.80
26793709	C0041260	Tryptophanase	aapp	17.80
26793709	C0041260	Tryptophanase	enzy	17.80
26793709	C0009738	Congo	geoa	16.04
26793709	C1667752	IL33 protein, human	aapp	13.00
26793709	C1667752	IL33 protein, human	bacs	13.00
26793709	C0018017	objective (goal)	inpr	11.49
26793709	C0014597	Epithelial Cells	cell	6.60
26793709	C1571702	Objective observation	qlco	5.18
26793709	C1883351	To	qlco	5.18
26793709	C3854321	Expression (foundation metadata concept)	idcn	3.63
26793709	C0185117	Expression procedure	topp	3.63
26793709	C0332152	Before	tmco	3.57
26793709	C0442805	Increase	ftcn	3.57
26793709	C1522538	Leading	ftcn	3.57
26793709	C1704259	Biochemical Pathway	moft	3.55
26793709	C1705987	Pathway (interactions)	cnce	3.55
26793709	C2248030	interleukin-33 receptor binding	moft	3.53
26793709	C1273342	Epithelial cell count (procedure)	lbpr	3.44
26793709	C0458827	Airway structure	bpoc	3.42
26793709	C0178987	Artificial Airways	medd	3.42
26793709	C3811819	CFTR wt Allele	gngm	3.42
26793709	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
26793709	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
26793709	C0033809	Pseudomonas aeruginosa	bact	24.11
26793709	C0009219	Coding	ocac	22.47
26793709	C3540587	Interleukin-33	aapp	19.38
26793709	C0040363	Togo	geoa	17.80
26793709	C0041260	Tryptophanase	aapp	17.80
26793709	C0041260	Tryptophanase	enzy	17.80
26793709	C0009738	Congo	geoa	16.12
26793709	C0031453	Phenylalanine	aapp	16.05
26793709	C0031453	Phenylalanine	bacs	16.05
26793709	C0031453	Phenylalanine	phsu	16.05
26793709	C1667752	IL33 protein, human	aapp	13.07
26793709	C1667752	IL33 protein, human	bacs	13.07
26793709	C1511760	Deletion Mutation	genf	13.02
26793709	C0887940	Gene Order	moft	6.73
26793709	C1634625	% live	qlco	5.18
26793709	C1413365	CFTR gene	gngm	5.18
26793709	C0332157	Exposure to	clna	5.18
26793709	C0274281	Injury due to exposure to external cause	inpo	5.18
26793709	C1548795	Live - Specimen Condition	qlco	5.18
26793709	C0150312	Present	qnco	5.18
26793709	C1962990	Pseudomonas aeruginosa (antigen)	imft	5.18
26793709	C2982691	Reside	acty	5.18
26793709	C1883351	To	qlco	5.18
26793709	C2247729	toll-like receptor 5 signaling pathway	moft	4.19
26793709	C0318602	Avian enteric calicivirus	virs	3.68
26793709	C2248030	interleukin-33 receptor binding	moft	3.61
26793709	C1880274	Deletion (action)	acty	3.56
26793709	C1442161	Gene Deletion Abnormality	comd	3.56
26793709	C4050311	Coding Subtest (WAIS-IV)	inpr	3.55
26793709	C4050310	Coding Subtest (WISC-V)	inpr	3.55
26793709	C3811819	CFTR wt Allele	gngm	3.50
26793709	C0202174	blood phenylalanine measurement by Guthrie microbiologic assay	lbpr	3.43
26793709	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26793709	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26793709	C0162493	Transcriptional Activation	genf	14.64
26793709	C0041904	Up-Regulation (Physiology)	moft	14.64
26793709	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	5.18
26793709	C3252847	VX 809	orch	5.18
26793709	C3252847	VX 809	phsu	5.18
26793709	C2741958	VX-770	orch	5.18
26793709	C0332152	Before	tmco	3.68
26793709	C0740175	Before values	qlco	3.68
26793709	C3669034	Pure Spanish horse breed (organism)	mamm	3.68
26793709	C1439852	incubated	lbpr	3.68
26793709	C2257086	photoreactivating enzyme activity	genf	3.68
26793709	C0318602	Avian enteric calicivirus	virs	3.55
26793709	C1413365	CFTR gene	gngm	3.43
26793709	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
26793709	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
26793709	C0079633	Interleukin-8	aapp	22.36
26793709	C0079633	Interleukin-8	imft	22.36
26793709	C1698756	CXCL8 protein, human	aapp	12.89
26793709	C1698756	CXCL8 protein, human	bacs	12.89
26793709	C0009450	Communicable Diseases	dsyn	11.49
26793709	C3714514	Infection	patf	8.34
26793709	C3854321	Expression (foundation metadata concept)	idcn	3.54
26793709	C0185117	Expression procedure	topp	3.54
26793709	C1413365	CFTR gene	gngm	3.43
26793709	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.43
26793709	C0205216	Decreased	qnco	3.42
26793709	C0442797	Decreasing	qlco	3.42
26793709	C1704632	Disease Response	fndg	3.42
26793709	C0392756	Reduced	qlco	3.42
26793709	C2911692	Response (communication)	menp	3.42
26793709	C1706817	Response (statement)	inpr	3.42
26793709	C0871261	Response process	orga	3.42
26793709	C3540587	Interleukin-33	aapp	19.31
26793709	C1449702	Protein Kinase Inhibitors	aapp	16.42
26793709	C1449702	Protein Kinase Inhibitors	phsu	16.42
26793709	C1667752	IL33 protein, human	aapp	13.00
26793709	C1667752	IL33 protein, human	bacs	13.00
26793709	C0009450	Communicable Diseases	dsyn	9.88
26793709	C3714514	Infection	patf	6.72
26793709	C0013879	Elements	elii	6.71
26793709	C0332282	Following	tmco	5.18
26793709	C1547282	Show	anim	5.18
26793709	C0231290	Status post	tmco	5.18
26793709	C1521840	Target	ftcn	5.18
26793709	C2986546	Target Lesion Identification	diap	5.18
26793709	C1524063	Use of	ftcn	5.18
26793709	C2757016	Protein Kinase Inhibitors [MoA]	moft	3.81
26793709	C3540756	Protein kinase inhibitors, antineoplastic drugs	phsu	3.81
26793709	C3854321	Expression (foundation metadata concept)	idcn	3.63
26793709	C0185117	Expression procedure	topp	3.63
26793709	C1704259	Biochemical Pathway	moft	3.59
26793709	C1705987	Pathway (interactions)	cnce	3.59
26793709	C2248030	interleukin-33 receptor binding	moft	3.53
26793709	C1705242	Different	qlco	3.47
26793709	C1817393	Toll-Like Receptor Signaling Pathway	moft	3.46
26793709	C1150604	MAP kinase kinase activity	moft	3.45
26793709	C1456385	MAP2K2 gene	gngm	3.45
26793709	C3811164	MAP2K2 wt Allele	gngm	3.45
26793709	C1334477	MAP3K7 gene	gngm	3.45
26793709	C1708802	MAP3K7 wt Allele	gngm	3.45
26793709	C1417830	NR2C2 gene	gngm	3.45
26793709	C3812805	NR2C2 wt Allele	gngm	3.45
26793709	C0522506	Downstream	spco	3.43
26793709	C3540587	Interleukin-33	aapp	19.21
26793709	C0009738	Congo	geoa	16.04
26793709	C1667752	IL33 protein, human	aapp	12.90
26793709	C1667752	IL33 protein, human	bacs	12.90
26793709	C0009450	Communicable Diseases	dsyn	9.74
26793709	C0014597	Epithelial Cells	cell	6.59
26793709	C3714514	Infection	patf	6.58
26793709	C3539655	CDISC Findings Class	inpr	5.18
26793709	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
26793709	C1882932	Representation (action)	acty	5.18
26793709	C2607943	findings aspects	ftcn	5.18
26793709	C1155286	response to bacterium	orgf	3.60
26793709	C1880022	Characterization	acty	3.55
26793709	C3854321	Expression (foundation metadata concept)	idcn	3.54
26793709	C0185117	Expression procedure	topp	3.54
26793709	C1273342	Epithelial cell count (procedure)	lbpr	3.44
26793709	C2248030	interleukin-33 receptor binding	moft	3.44
26793709	C0205435	First (number)	qnco	3.43
26793709	C1279901	Firstly	qlco	3.43
26793709	C0458827	Airway structure	bpoc	3.42
26793709	C0178987	Artificial Airways	medd	3.42
26793709	C3811819	CFTR wt Allele	gngm	3.42
26793709	C1710082	Signal	phpr	3.41
26545902	C0010674	Cystic Fibrosis	dsyn	10.06
26545902	C0012634	Disease	dsyn	9.94
26545902	C0026882	Mutation	genf	9.90
26545902	C0015127	Etiology aspects	ftcn	9.86
26545902	C0376558	Life	idcn	9.78
26545902	C0019247	Hereditary Diseases	dsyn	8.34
26545902	C0004623	Bacterial Infections	dsyn	6.74
26545902	C1413365	CFTR gene	gngm	5.18
26545902	C0522569	Severe inflammation	fndg	5.18
26545902	C0151317	Chronic infectious disease	dsyn	3.58
26545902	C1524003	Science of Etiology	cnce	3.55
26545902	C0458827	Airway structure	bpoc	3.55
26545902	C0178987	Artificial Airways	medd	3.55
26545902	C0521009	Bacterial	qlco	3.55
26545902	C1880022	Characterization	acty	3.55
26545902	C0205191	chronic	tmco	3.55
26545902	C0439801	Limited (extensiveness)	ftcn	3.48
26545902	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
26545902	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
26545902	C0039798	therapeutic aspects	ftcn	22.35
26545902	C0009738	Congo	geoa	16.04
26545902	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	13.14
26545902	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	13.14
26545902	C0175996	Protoplasm	celc	12.96
26545902	C0205250	High	qlco	5.18
26545902	C1254351	Pharmacologic Substance	phsu	3.84
26545902	C0596988	mutant	comd	3.68
26545902	C3276433	Decreased mental alertness	fndg	3.59
26545902	C1524063	Use of	ftcn	3.54
26545902	C1413365	CFTR gene	gngm	3.50
26545902	C0178719	Intracellular	spco	3.50
26545902	C1155589	cAMP-mediated signaling	moft	3.45
26545902	C1533734	Administration procedure	topp	3.42
26545902	C1705169	Biomaterial Treatment	cnce	3.42
26545902	C3811819	CFTR wt Allele	gngm	3.42
26545902	C0087111	Therapeutic procedure	topp	3.42
26545902	C1522326	Treating	ftcn	3.42
26545902	C3538994	Treatment Epoch	resa	3.42
26545902	C3887704	treatment - ActInformationManagementReason	hlca	3.42
26545902	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
26545902	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
26545902	C0031638	Phosphodiesterase Inhibitors	phsu	17.80
26545902	C3463820	Inhibition	acty	12.94
26545902	C1413365	CFTR gene	gngm	5.18
26545902	C2827718	In Vitro Route of Administration	ftcn	5.18
26545902	C0021135	In Vitro [Publication Type]	inpr	5.18
26545902	C1656262	Phosphodiesterase Inhibitors [MoA]	moft	5.18
26545902	C3539996	Phosphodiesterase inhibitors, cardiac stimulant	phsu	5.18
26545902	C1533691	in vitro	qlco	5.18
26545902	C1515655	in vivo	spco	5.18
26545902	C1158044	cAMP catabolic process	moft	3.75
26545902	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26545902	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26545902	C0036536	Process of secretion	biof	19.31
26545902	C0040363	Togo	geoa	17.80
26545902	C0041260	Tryptophanase	aapp	17.80
26545902	C0041260	Tryptophanase	enzy	17.80
26545902	C0009738	Congo	geoa	16.08
26545902	C0004096	Asthma	dsyn	16.07
26545902	C0206243	Carrying	acty	14.64
26545902	C0030705	Patients	podg	13.58
26545902	C0024117	Chronic Obstructive Airway Disease	dsyn	13.03
26545902	C3463820	Inhibition	acty	13.02
26545902	C0021467	Psychological inhibition	menp	13.02
26545902	C0015127	Etiology aspects	ftcn	11.49
26545902	C0022023	Ions	elii	9.73
26545902	C0017431	Genotype	orga	6.77
26545902	C0036537	Bodily secretions	bdsu	6.70
26545902	C0013227	Pharmaceutical Preparations	phsu	5.18
26545902	C1254351	Pharmacologic Substance	phsu	5.18
26545902	C1524003	Science of Etiology	cnce	5.18
26545902	C1883351	To	qlco	5.18
26545902	C1547282	Show	anim	3.98
26545902	C1548221	Bed Status - Isolated	idcn	3.59
26545902	C3537072	Bronchodilation	ortf	3.59
26545902	C1371299	Bronchodilation [PE]	ortf	3.59
26545902	C0205409	Isolated	ftcn	3.59
26545902	C0021469	Metabolic Inhibition	moft	3.56
26545902	C1628982	Percent inhibition	qnco	3.56
26545902	C3811819	CFTR wt Allele	gngm	3.47
26545902	C2984299	Asthma Pathway	ftcn	3.45
26545902	C1711178	Bronchial Epithelial Cell	cell	3.44
26545902	C1744162	RPL 554	orch	3.43
26545902	C1413365	CFTR gene	gngm	3.42
26545902	C1701901	Conditional	qlco	3.42
26545902	C0851827	Dependent - ability	qlco	3.42
26545902	C1700702	Iontophoresis Route of Drug Administration	ftcn	3.42
26545902	C3244310	dependent	ftcn	3.42
26545902	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
26545902	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
26545902	C0013162	Drug Combinations	phsu	6.60
26545902	C1517331	Further	spco	5.18
26545902	C1705535	suggestion	idcn	3.98
26545902	C1561536	*Activity (kind of quantity)	idcn	3.60
26545902	C0205177	Active	ftcn	3.60
26545902	C0441655	Activities	acty	3.60
26545902	C3668946	Activity (animal life circumstance)	fndg	3.60
26545902	C4049939	FDA Establishment Activity Terminology	inpr	3.60
26545902	C0439167	Percent Activity	qnco	3.60
26545902	C4049938	Physical Activity Measurement	lbpr	3.60
26545902	C2741958	VX-770	orch	3.59
26545902	C0442805	Increase	ftcn	3.55
26545902	C0205217	Increased	qnco	3.55
26545902	C0814225	benefit	qnco	3.55
26545902	C1413365	CFTR gene	gngm	3.46
26545902	C0205263	Induce (action)	ftcn	3.46
26545902	C1744162	RPL 554	orch	3.46
26545902	C1524062	Additional	ftcn	3.42
26545902	C0086418	Homo sapiens	humn	28.66
26545902	C0015422	Eyelash	bpoc	19.38
26545902	C0008778	Cilia	celc	13.07
26545902	C0439603	Frequencies (time pattern)	tmco	3.55
26545902	C3898838	How Often	inpr	3.55
26545902	C1561548	Kind of quantity - Frequency	qlco	3.55
26545902	C0871396	Spatial Frequency	qnco	3.55
26545902	C1705502	Statistical Frequency	qnco	3.55
26545902	C0376249	With frequency	qnco	3.55
26545902	C0442805	Increase	ftcn	3.46
26545902	C0205217	Increased	qnco	3.46
26545902	C1744162	RPL 554	orch	3.46
26545902	C1711178	Bronchial Epithelial Cell	cell	3.44
26545902	C0205225	Primary	qlco	3.42
26545902	C0439631	Primary operation	topp	3.42
26545902	C0439612	True primary (qualifier value)	tmco	3.42
26545902	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26545902	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26545902	C0015422	Eyelash	bpoc	19.33
26545902	C0009738	Congo	geoa	16.04
26545902	C0026687	Mucociliary Clearance	clna	13.05
26545902	C0442805	Increase	ftcn	5.18
26545902	C1999230	Providing (action)	acty	5.18
26545902	C1744162	RPL 554	orch	5.18
26545902	C2825142	Experimental Result	fndg	3.98
26545902	C1274040	Result	ftcn	3.98
26545902	C1546471	What subject filter - Result	idcn	3.98
26545902	C0439603	Frequencies (time pattern)	tmco	3.61
26545902	C3898838	How Often	inpr	3.61
26545902	C1561548	Kind of quantity - Frequency	qlco	3.61
26545902	C0871396	Spatial Frequency	qnco	3.61
26545902	C1705502	Statistical Frequency	qnco	3.61
26545902	C0376249	With frequency	qnco	3.61
26545902	C1288305	Entire eyelash	bpoc	3.55
26545902	C1518601	Options	ftcn	3.55
26545902	C1550456	option - ActMoodPredicate	idcn	3.55
26545902	C0442808	Increasing	ftcn	3.47
26545902	C1413365	CFTR gene	gngm	3.43
26545902	C3811819	CFTR wt Allele	gngm	3.43
26545902	C0205314	New	qlco	3.43
26545902	C1948023	Stimulation (motivation)	npop	3.43
26545902	C1292856	Stimulation procedure	topp	3.43
26545902	C0302350	Therapeutic	ftcn	3.43
26545902	C0087111	Therapeutic procedure	topp	3.43
26545902	C0679622	literary novel	inpr	3.43
27393775	C0033105	Statistical Prevalence	qnco	22.43
27393775	C0026538	Morbidity - disease rate	qnco	19.34
27393775	C1384901	Cystic Disease Of Lung	dsyn	12.93
27393775	C0010674	Cystic Fibrosis	dsyn	11.49
27393775	C0392164	Pulmonary Cystic Fibrosis	dsyn	9.79
27393775	C0012634	Disease	dsyn	9.74
27393775	C0016059	Fibrosis	patf	9.74
27393775	C0030705	Patients	podg	6.59
27393775	C0149516	Chronic sinusitis	dsyn	3.75
27393775	C2741673	Account number:Identifier:Point in time:^Patient:Nominal	clna	3.57
27393775	C1546944	Event Seriousness - Significant	qlco	3.57
27393775	C2981730	Financial Account	inpr	3.57
27393775	C0750502	Significant	idcn	3.57
27393775	C0237881	Statistical Significance	qnco	3.57
27393775	C0220880	morbidity aspects	inpr	3.57
27393775	C1880177	Contribution	acty	3.55
27393775	C0220900	Prevalence aspects	qnco	3.51
27393775	C0546483	Lung cyst	dsyn	3.47
27393775	C0205250	High	qlco	3.44
27393775	C0010278	Craniosynostosis	cgab	38.64
27393775	C0010278	Craniosynostosis	dsyn	38.64
27393775	C0033105	Statistical Prevalence	qnco	22.49
27393775	C0017362	Genes, Regulator	gngm	19.21
27393775	C0009738	Congo	geoa	17.80
27393775	C0026882	Mutation	genf	9.85
27393775	C0010674	Cystic Fibrosis	dsyn	9.74
27393775	C0031847	physiopathological	ftcn	9.74
27393775	C0030705	Patients	podg	6.72
27393775	C3811819	CFTR wt Allele	gngm	5.18
27393775	C1705535	suggestion	idcn	3.98
27393775	C0442805	Increase	ftcn	3.57
27393775	C0205217	Increased	qnco	3.57
27393775	C1709305	Occur (action)	acty	3.57
27393775	C2745955	Occurrence	tmco	3.57
27393775	C0220900	Prevalence aspects	qnco	3.57
27393775	C0596611	Gene Mutation	genf	3.56
27393775	C1880177	Contribution	acty	3.56
27393775	C0277785	Functional disorder	patf	3.43
27393775	C1704735	Regulator	cnce	3.42
27393775	C1704734	Regulator Device Component	mnob	3.42
27393775	C0182953	Regulators (device)	medd	3.42
27393775	C2752508	fully spanning the plasma membrane	celc	3.42
27393775	C1167322	integral to membrane	celc	3.42
27393775	C0009738	Congo	geoa	32.29
27393775	C0027341	Nail-Patella Syndrome	cgab	26.25
27393775	C0027341	Nail-Patella Syndrome	dsyn	26.25
27393775	C0033105	Statistical Prevalence	qnco	22.49
27393775	C0014467	eosinophil	cell	19.19
27393775	C0162574	Glycosylation End Products, Advanced	bacs	14.64
27393775	C0162574	Glycosylation End Products, Advanced	orch	14.64
27393775	C0030705	Patients	podg	13.51
27393775	C0027430	Nasal Polyps	dsyn	13.22
27393775	C1836075	NPS gene	gngm	7.22
27393775	C3538803	Neuropathic Pain Scale Questionnaire	inpr	7.22
27393775	C0442805	Increase	ftcn	7.01
27393775	C0205217	Increased	qnco	7.01
27393775	C3811819	CFTR wt Allele	gngm	6.90
27393775	C0013879	Elements	elii	6.70
27393775	C0001779	Age	orga	5.18
27393775	C1709305	Occur (action)	acty	3.57
27393775	C2745955	Occurrence	tmco	3.57
27393775	C0220900	Prevalence aspects	qnco	3.57
27393775	C0700364	Appearance	qlco	3.55
27393775	C0233426	Personal appearance	orga	3.55
27393775	C0200638	Eosinophil count procedure	lbpr	3.42
27393775	C0205172	More	ftcn	3.42
27393775	C0746885	neutrophilic	celf	3.42
27393775	C1707455	Comparison	acty	3.42
27393775	C1285092	Gland	bpoc	3.42
27393775	C0225353	Glandular	qlco	3.42
27393775	C1515025	Submucosal Route of Drug Administration	ftcn	3.42
27393775	C0065827	Measles Virus Nucleoprotein	aapp	12.96
27393775	C0065827	Measles Virus Nucleoprotein	bacs	12.96
27393775	C0017712	topical glucocorticoid	orch	7.53
27393775	C0017712	topical glucocorticoid	phsu	7.53
27393775	C0442118	Intranasal approach	spco	6.99
27393775	C3887511	Evidence	idcn	5.18
27393775	C2700399	Include (action)	acty	5.18
27393775	C0332257	Including (qualifier)	ftcn	5.18
27393775	C1552866	include - SetOperator	idcn	5.18
27393775	C0456389	size	spco	3.68
27393775	C0022100	Irrigation	topp	3.63
27393775	C0445115	Normal saline	inch	3.53
27393775	C0445115	Normal saline	phsu	3.53
27393775	C1706141	PNP wt Allele	gngm	3.50
27393775	C3887659	Purine Nucleoside Phosphorylase, human	aapp	3.50
27393775	C3887659	Purine Nucleoside Phosphorylase, human	enzy	3.50
27393775	C0679624	medical treatment method	topp	3.46
27393775	C0009738	Congo	geoa	32.40
27393775	C0010278	Craniosynostosis	cgab	19.45
27393775	C0010278	Craniosynostosis	dsyn	19.45
27393775	C0004048	Inspiration function	orgf	19.25
27393775	C0036085	Saline Solution, Hypertonic	inch	13.22
27393775	C0036085	Saline Solution, Hypertonic	phsu	13.22
27393775	C0026698	mucolytic agents	phsu	7.20
27393775	C3811819	CFTR wt Allele	gngm	7.02
27393775	C0024115	Lung diseases	dsyn	6.91
27393775	C2986486	Chemoprevention Study	resa	3.58
27393775	C1521826	Protocol Agent	inpr	3.58
27393775	C3889645	Clinical Trial Final Report	inpr	3.56
27393775	C3536808	Mucolytic [EPC]	phsu	3.56
27393775	C0684224	Report (document)	inpr	3.56
27393775	C0700287	Reporting	hlca	3.56
27393775	C0557651	Room of building - Study	mnob	3.53
27393775	C2603343	Study	resa	3.53
27393775	C1524063	Use of	ftcn	3.46
27393775	C0009738	Congo	geoa	32.29
27393775	C0010278	Craniosynostosis	cgab	19.34
27393775	C0010278	Craniosynostosis	dsyn	19.34
27393775	C1518422	Negation	ftcn	10.42
27393775	C0042153	utilization qualifier	ftcn	9.86
27393775	C3811819	CFTR wt Allele	gngm	6.90
27393775	C0024115	Lung diseases	dsyn	6.60
27393775	C3887511	Evidence	idcn	5.18
27393775	C0183683	Support, device	medd	5.18
27393775	C1521721	Supportive assistance	cnce	5.18
27393775	C0026698	mucolytic agents	phsu	3.68
27393775	C3161471	Treatment Study	resa	3.60
27393775	C0457083	Usage	ftcn	3.55
27393775	C1947944	Use - dosing instruction imperative	inpr	3.55
27393775	C0086418	Homo sapiens	humn	28.71
27393775	C0039798	therapeutic aspects	ftcn	22.38
27393775	C0011522	Deoxyribonucleases	aapp	16.25
27393775	C0011522	Deoxyribonucleases	enzy	16.25
27393775	C0011522	Deoxyribonucleases	phsu	16.25
27393775	C1135662	Dornase Alfa	aapp	13.11
27393775	C1135662	Dornase Alfa	enzy	13.11
27393775	C1135662	Dornase Alfa	phsu	13.11
27393775	C0332282	Following	tmco	5.18
27393775	C1547282	Show	anim	5.18
27393775	C0231290	Status post	tmco	5.18
27393775	C0748725	sinus surgery	topp	5.18
27393775	C1555307	promise	idcn	3.59
27393775	C1514798	Recombinants	orgm	3.48
27393775	C2979938	nebulized - CHV concept	ftcn	3.46
27393775	C1549541	nebulized Administration Method	ftcn	3.46
27393775	C1549531	nebulized body site	blor	3.46
27393775	C1533734	Administration procedure	topp	3.45
27393775	C1705169	Biomaterial Treatment	cnce	3.45
27393775	C0087111	Therapeutic procedure	topp	3.45
27393775	C1522326	Treating	ftcn	3.45
27393775	C3538994	Treatment Epoch	resa	3.45
27393775	C3887704	treatment - ActInformationManagementReason	hlca	3.45
27393775	C0026727	Mucous body substance	bdsu	9.91
27393775	C1269765	Assisted (qualifier value)	qlco	5.18
27393775	C1552861	Help document	inpr	5.18
27393775	C2700399	Include (action)	acty	5.18
27393775	C0332257	Including (qualifier)	ftcn	5.18
27393775	C0309872	PREVENT (product)	phsu	5.18
27393775	C1325881	biofilm formation	celf	5.18
27393775	C1552866	include - SetOperator	idcn	5.18
27393775	C0087111	Therapeutic procedure	topp	3.68
27393775	C1546714	Specimen Source Codes - Mucus	inpr	3.60
27393775	C2753459	mucus layer	bdsu	3.60
27393775	C1883712	Add - instruction imperative	ftcn	3.57
27393775	C0332287	In addition to	ftcn	3.57
27393775	C0456370	Unproven	qlco	3.50
27393775	C0974718	BABY SHAMPOO	mnob	3.48
27393775	C0445115	Normal saline	inch	3.48
27393775	C0445115	Normal saline	phsu	3.48
27393775	C0205168	Thin (qualifier value)	qlco	3.46
27393775	C0010278	Craniosynostosis	cgab	19.34
27393775	C0010278	Craniosynostosis	dsyn	19.34
27393775	C0009738	Congo	geoa	17.80
27393775	C0040363	Togo	geoa	17.80
27393775	C0041260	Tryptophanase	aapp	17.80
27393775	C0041260	Tryptophanase	enzy	17.80
27393775	C1524063	Use of	ftcn	7.20
27393775	C0442027	Oral	spco	6.89
27393775	C0030705	Patients	podg	6.59
27393775	C3811819	CFTR wt Allele	gngm	5.18
27393775	C1511726	Data	idcn	5.18
27393775	C3714741	Data (eukaryote)	euka	5.18
27393775	C3245479	Data call receiving device	medd	5.18
27393775	C0183683	Support, device	medd	5.18
27393775	C1521721	Supportive assistance	cnce	5.18
27393775	C1883351	To	qlco	5.18
27393775	C0445550	Low dose	qnco	3.44
27393775	C1708745	Low-Dose Treatment	resa	3.44
27393775	C0003240	Macrolide Antibiotics	antb	3.44
27393775	C0003240	Macrolide Antibiotics	orch	3.44
27393775	C0362063	Other prophylactic chemotherapy	fndg	3.44
27393775	C0040341	Tobramycin	antb	20.95
27393775	C0040341	Tobramycin	orch	20.95
27393775	C0010453	Anthropological Culture	idcn	13.44
27393775	C0030705	Patients	podg	6.59
27393775	C0110462	Colistimethate sodium	aapp	5.18
27393775	C0110462	Colistimethate sodium	antb	5.18
27393775	C0332282	Following	tmco	5.18
27393775	C0332257	Including (qualifier)	ftcn	5.18
27393775	C0231290	Status post	tmco	5.18
27393775	C0748725	sinus surgery	topp	5.18
27393775	C0220814	Cultural aspects	ftcn	3.98
27393775	C0430400	Laboratory culture	lbpr	3.98
27393775	C2242979	Microbial culture (procedure)	lbpr	3.98
27393775	C0004611	Bacteria	bact	3.68
27393775	C3463902	Bacteria <stick insect genus>	euka	3.68
27393775	C4038931	Bacteria present	fndg	3.68
27393775	C2347473	Percent of Bacteria	qnco	3.68
27393775	C1510439	bacteria aspects	ftcn	3.68
27393775	C1261291	Irrigation of maxillary antrum	topp	3.64
27393775	C0189160	Irrigation of nasal sinus	topp	3.61
27393775	C1521801	Having administered	ftcn	3.56
27393775	C0183683	Support, device	medd	3.54
27393775	C1521721	Supportive assistance	cnce	3.54
27393775	C2827758	Antimicrobial Susceptibility Result	lbtr	3.50
27393775	C0220898	Predisposition	orga	3.50
27393775	C0231204	Susceptible	ftcn	3.50
27393775	C3653723	ANTIBIOTICS FOR TOPICAL USE	phsu	3.47
27393775	C0040363	Togo	geoa	35.81
27393775	C0041260	Tryptophanase	aapp	35.81
27393775	C0041260	Tryptophanase	enzy	35.81
27393775	C0038895	Surgical aspects	ftcn	22.61
27393775	C0024947	Maxilla	bpoc	22.40
27393775	C0003237	Antibiotics, Antitubercular	antb	22.35
27393775	C0037884	Sphenoid bone structure	bpoc	16.25
27393775	C0041928	Uranium	elii	16.17
27393775	C0032790	Postoperative Period	tmco	16.08
27393775	C0003232	Antibiotics	antb	16.04
27393775	C0009738	Congo	geoa	16.04
27393775	C0218063	Ensure (product)	food	14.64
27393775	C0015028	Ethmoid sinus structure	bsoj	14.64
27393775	C1274039	General surgery specialty	bmod	13.14
27393775	C0010453	Anthropological Culture	idcn	12.89
27393775	C0449738	Direction	spco	12.85
27393775	C1883351	To	qlco	10.42
27393775	C2350442	Nasal Lavage	hlca	9.96
27393775	C0030471	Nasal sinus	bsoj	9.73
27393775	C0016169	pathologic fistula	anab	9.73
27393775	C2700399	Include (action)	acty	5.18
27393775	C0332257	Including (qualifier)	ftcn	5.18
27393775	C0302144	Mucus retention	patf	5.18
27393775	C0309872	PREVENT (product)	phsu	5.18
27393775	C1552866	include - SetOperator	idcn	5.18
27393775	C3853799	Allopathic & Osteopathic Physicians - Surgery	prog	3.68
27393775	C0543467	Operative Surgical Procedures	hlca	3.68
27393775	C0038894	Surgery specialty	bmod	3.68
27393775	C1524063	Use of	ftcn	3.58
27393775	C0443157	Bony	ftcn	3.55
27393775	C0175566	Open	spco	3.55
27393775	C0205357	Smooth	qlco	3.55
27393775	C1948044	Smoothing (statistical technique)	resa	3.55
27393775	C0521009	Bacterial	qlco	3.50
27393775	C0205231	Extensive	qlco	3.50
27393775	C0205123	Coronal	spco	3.48
27393775	C0332173	Daily	tmco	3.46
27393775	C1515089	Surgical Management	hlca	3.44
27393775	C3540706	Antibiotic throat preparations	antb	3.42
27393775	C3540707	Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	antb	3.42
27393775	C3540704	Antibiotics for systemic use	antb	3.42
27393775	C3540708	Antibiotics, Gynecological	antb	3.42
27393775	C3540710	Antibiotics, ophthalmologic	antb	3.42
27393775	C3540705	Antifungal Antibiotics, Topical	antb	3.42
27393775	C1548787	Appropriate	qlco	3.42
27393775	C0220814	Cultural aspects	ftcn	3.42
27393775	C0430400	Laboratory culture	lbpr	3.42
27393775	C2242979	Microbial culture (procedure)	lbpr	3.42
27393775	C0332237	Topical surface	spco	3.42
27393775	C3540709	antibiotics, intestinal	antb	3.42
27393775	C3811819	CFTR wt Allele	gngm	3.42
27393775	C1305231	Sinus - general anatomical term	bsoj	3.42
27393775	C0439755	Directions	spco	3.38
27393775	C0009738	Congo	geoa	32.33
27393775	C3264621	ivacaftor	orch	29.46
27393775	C3264621	ivacaftor	phsu	29.46
27393775	C0010278	Craniosynostosis	cgab	19.20
27393775	C0010278	Craniosynostosis	dsyn	19.20
27393775	C3852684	lumacaftor	orch	13.05
27393775	C3852684	lumacaftor	phsu	13.05
27393775	C3811819	CFTR wt Allele	gngm	6.95
27393775	C0332257	Including (qualifier)	ftcn	5.18
27393775	C2985566	Targeted Therapy	topp	3.72
27393775	C0205195	Combined	qlco	3.59
27393775	C1511726	Data	idcn	3.57
27393775	C3714741	Data (eukaryote)	euka	3.57
27393775	C3245479	Data call receiving device	medd	3.57
27393775	C1825598	IMPACT gene	gngm	3.56
27393775	C4049986	Impact	qlco	3.56
25441013	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
25441013	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
25441013	C1257739	NIH 3T3 Cells	cell	16.08
25441013	C0034428	Quinolones	orch	13.07
25441013	C0026882	Mutation	genf	9.94
25441013	C1524063	Use of	ftcn	5.18
25441013	C1880355	Discover	acty	3.98
25441013	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.75
25441013	C1705285	Mutation Abnormality	comd	3.63
25441013	C0872187	high throughput screening	diap	3.62
25441013	C1413365	CFTR gene	gngm	3.48
25441013	C0205314	New	qlco	3.48
25441013	C0679622	literary novel	inpr	3.48
25441013	C0041714	United States Food and Drug Administration	hcro	25.65
25441013	C0040363	Togo	geoa	17.80
25441013	C0041260	Tryptophanase	aapp	17.80
25441013	C0041260	Tryptophanase	enzy	17.80
25441013	C0009738	Congo	geoa	16.04
25441013	C0206243	Carrying	acty	14.64
25441013	C0220825	Evaluation	hlca	14.64
25441013	C3264621	ivacaftor	orch	14.64
25441013	C3264621	ivacaftor	phsu	14.64
25441013	C0038477	Structure-Activity Relationship	qlco	13.18
25441013	C0008003	Chemistry, Pharmaceutical	bmod	13.14
25441013	C0393003	potassium oxonate	orch	13.09
25441013	C0393003	potassium oxonate	phsu	13.09
25441013	C0020792	Identification (Psychology)	menp	13.01
25441013	C0754515	TERT protein, human	aapp	12.92
25441013	C0754515	TERT protein, human	enzy	12.92
25441013	C0036576	Genetic Selection	genf	10.06
25441013	C0026882	Mutation	genf	9.99
25441013	C3838679	4+ Answer to question	fndg	7.11
25441013	C0013230	Investigational New Drugs	phsu	6.91
25441013	C1883351	To	qlco	5.18
25441013	C2741958	VX-770	orch	5.18
25441013	C0580836	Old	tmco	3.98
25441013	C1707391	Choose (action)	acty	3.75
25441013	C3245505	potential	qlco	3.72
25441013	C1292721	Has property	ftcn	3.68
25441013	C1705285	Mutation Abnormality	comd	3.68
25441013	C0871161	Property (attribute)	qlco	3.68
25441013	C0947630	Scientific Study	lbpr	3.60
25441013	C0205540	Approved	qlco	3.57
25441013	C0205396	Identified	qlco	3.55
25441013	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.54
25441013	C3242455	HL7PublishingDomain <patient administration>	inpr	3.54
25441013	C3242279	healthcare operations <patient administration>	ocac	3.54
25441013	C2825142	Experimental Result	fndg	3.52
25441013	C1274040	Result	ftcn	3.52
25441013	C1546471	What subject filter - Result	idcn	3.52
25441013	C0450367	4/5	qnco	3.51
25441013	C0201734	Pharmacokinetic study	resa	3.50
25441013	C0205231	Extensive	qlco	3.47
25441013	C3541881	Device Identifiers Domain	idcn	3.46
25441013	C3538902	SLC4A1 wt Allele	gngm	3.46
25441013	C1367342	TERT gene	gngm	3.46
25441013	C1705316	TERT wt Allele	gngm	3.46
25441013	C1510829	Age-Years	tmco	3.43
25441013	C3811819	CFTR wt Allele	gngm	3.42
25441013	C1854293	Iterations	fndg	3.41
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
25825526	C0017337	Genes	gngm	17.80
25825526	C0010674	Cystic Fibrosis	dsyn	10.06
25825526	C0026882	Mutation	genf	9.90
25825526	C0015127	Etiology aspects	ftcn	9.86
25825526	C3899988	Autosomal Recessive Disorder	dsyn	5.18
25825526	C1413365	CFTR gene	gngm	5.18
25825526	C2700640	Encode (action)	acty	5.18
25825526	C1547699	MIME encoding	idcn	5.18
25825526	C1524003	Science of Etiology	cnce	3.55
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.56
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.56
25825526	C0014239	Endoplasmic Reticulum	celc	22.53
25825526	C0015272	Exhibits as Topic	inpr	17.80
25825526	C0009738	Congo	geoa	16.07
25825526	C1314792	Etiology	ftcn	12.93
25825526	C0185026	Plication	topp	5.18
25825526	C0243067	defects aspect	ftcn	5.18
25825526	C0599896	trafficking	celf	5.18
25825526	C1413365	CFTR gene	gngm	3.63
25825526	C0596988	mutant	comd	3.60
25825526	C3824143	proteasome complex disassembly	moft	3.60
25825526	C1521840	Target	ftcn	3.57
25825526	C0333118	Retained	ftcn	3.56
25825526	C3811819	CFTR wt Allele	gngm	3.46
25825526	C0205214	Common (qualifier value)	qnco	3.46
25825526	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.46
25825526	C0205393	Most	qnco	3.46
25825526	C1522138	shared attribute	ftcn	3.46
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
25825526	C1099354	RNA, Small Interfering	bacs	19.21
25825526	C1099354	RNA, Small Interfering	nnon	19.21
25825526	C0014241	Endoribonucleases	aapp	19.19
25825526	C0014241	Endoribonucleases	enzy	19.19
25825526	C0040363	Togo	geoa	17.80
25825526	C0041260	Tryptophanase	aapp	17.80
25825526	C0041260	Tryptophanase	enzy	17.80
25825526	C0086982	Signal Transduction Pathways	moft	14.64
25825526	C0031727	Phosphotransferases	aapp	13.08
25825526	C0031727	Phosphotransferases	enzy	13.08
25825526	C0872147	DNA Library	gngm	9.85
25825526	C0872147	DNA Library	nnon	9.85
25825526	C0023621	Libraries	mnob	9.85
25825526	C0023621	Libraries	orgt	9.85
25825526	C0751608	cDNA Library	gngm	9.85
25825526	C0751608	cDNA Library	nnon	9.85
25825526	C1883351	To	qlco	5.18
25825526	C1705053	Screen Device Component	mnob	3.98
25825526	C1305399	Screening - procedure intent	ftcn	3.98
25825526	C0220908	Screening procedure	hlca	3.98
25825526	C1335962	Signaling Protein	aapp	3.72
25825526	C1335962	Signaling Protein	bacs	3.72
25825526	C1413365	CFTR gene	gngm	3.56
25825526	C1314939	Involvement with	ftcn	3.56
25825526	C0332281	Associated with	qlco	3.48
25825526	C1705242	Different	qlco	3.47
25825526	C1521840	Target	ftcn	3.47
25825526	C2986546	Target Lesion Identification	diap	3.47
25825526	C4082130	Prepared	fndg	3.42
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25825526	C1527757	FGFR1 protein, human	aapp	14.64
25825526	C1527757	FGFR1 protein, human	enzy	14.64
25825526	C1527757	FGFR1 protein, human	rcpt	14.64
25825526	C1550043	Container status - Identified	fndg	5.18
25825526	C1704723	FGFR1 wt Allele	gngm	5.18
25825526	C0205396	Identified	qlco	5.18
25825526	C0332257	Including (qualifier)	ftcn	5.18
25825526	C2954564	Suppressor	phsu	3.52
25825526	C1710252	Suppressor Device Component	mnob	3.52
25825526	C3842589	20%	fndg	3.42
25825526	C1254042	Anatomical maturation	phsf	3.42
25825526	C0678723	Biologic Development	orgf	3.42
25825526	C1413365	CFTR gene	gngm	3.42
25825526	C0870861	Human maturation	phpr	3.42
25825526	C0205314	New	qlco	3.42
25825526	C0679622	literary novel	inpr	3.42
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.12
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.12
25825526	C2930586	Short Hairpin RNA	nnon	19.25
25825526	C0014441	Enzyme-Linked Immunosorbent Assay	lbpr	17.80
25825526	C0020985	Immunoblotting	lbpr	13.03
25825526	C0444706	Measured	qlco	7.47
25825526	C0449770	Measured from	qnco	7.47
25825526	C1413365	CFTR gene	gngm	7.05
25825526	C0005507	Biological Assay	lbpr	6.77
25825526	C0020517	Hypersensitivity	patf	6.77
25825526	C0332282	Following	tmco	5.18
25825526	C0231290	Status post	tmco	5.18
25825526	C1510438	Assay	lbpr	3.61
25825526	C0332324	Sensitive	ftcn	3.61
25825526	C0243073	assay qualifier	qlco	3.61
25825526	C1153410	channel activity	moft	3.61
25825526	C1265611	Quantity	qnco	3.55
25825526	C0086597	Mediate	socb	3.48
25825526	C0127400	Mediator brand of benfluorex hydrochloride	orch	3.48
25825526	C0127400	Mediator brand of benfluorex hydrochloride	phsu	3.48
25825526	C0439645	Band form	spco	3.47
25825526	C0175723	Bands	medd	3.47
25825526	C1521913	Chromosome band	celc	3.47
25825526	C0457555	Halide	inch	3.47
25825526	C0205286	Mature	tmco	3.44
25825526	C0205148	Surface	spco	3.43
25825526	C0082529	Mitogen-Activated Protein Kinase 3	aapp	28.91
25825526	C0082529	Mitogen-Activated Protein Kinase 3	enzy	28.91
25825526	C0164786	Proto-Oncogene Proteins c-akt	aapp	27.26
25825526	C0164786	Proto-Oncogene Proteins c-akt	enzy	27.26
25825526	C0060369	Fibroblast Growth Factor Receptors	aapp	22.90
25825526	C0060369	Fibroblast Growth Factor Receptors	rcpt	22.90
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
25825526	C0540129	FRS2 protein, human	aapp	14.64
25825526	C0540129	FRS2 protein, human	bacs	14.64
25825526	C0035820	Social Role	socb	13.02
25825526	C0812228	AKT1 gene	gngm	5.18
25825526	C1333578	FRS2 gene	gngm	5.18
25825526	C1517331	Further	spco	5.18
25825526	C0599896	trafficking	celf	5.18
25825526	C1150619	FGFR activity	moft	3.98
25825526	C1335962	Signaling Protein	aapp	3.72
25825526	C1335962	Signaling Protein	bacs	3.72
25825526	C1413365	CFTR gene	gngm	3.68
25825526	C1705810	Generic Role	cnce	3.56
25825526	C3871154	{Role}	inpr	3.56
25825526	C0522506	Downstream	spco	3.48
25825526	C1155389	fibroblast growth factor receptor signaling pathway	moft	3.46
25825526	C0206610	Mice, Inbred CFTR	mamm	28.79
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
25825526	C0020885	ileum	bpoc	16.16
25825526	C0538431	SU 5402	orch	14.64
25825526	C0538431	SU 5402	phsu	14.64
25825526	C3463820	Inhibition	acty	13.05
25825526	C0021467	Psychological inhibition	menp	13.05
25825526	C1527757	FGFR1 protein, human	aapp	12.91
25825526	C1527757	FGFR1 protein, human	enzy	12.91
25825526	C1527757	FGFR1 protein, human	rcpt	12.91
25825526	C0021853	Intestines	bpoc	9.88
25825526	C0019904	Homozygote	orga	9.85
25825526	C0029250	Organoids	tisu	6.72
25825526	C0699819	Gut	bpoc	3.68
25825526	C0021469	Metabolic Inhibition	moft	3.59
25825526	C1628982	Percent inhibition	qnco	3.59
25825526	C1521801	Having administered	ftcn	3.57
25825526	C1292984	Procedure on intestine	hlca	3.57
25825526	C1413365	CFTR gene	gngm	3.55
25825526	C2986815	Robust	qlco	3.55
25825526	C1278923	Entire ileum	bpoc	3.54
25825526	C3146294	Generation (action)	acty	3.54
25825526	C2825142	Experimental Result	fndg	3.52
25825526	C1274040	Result	ftcn	3.52
25825526	C1546471	What subject filter - Result	idcn	3.52
25825526	C0445542	Mini	orga	3.50
25825526	C1704723	FGFR1 wt Allele	gngm	3.45
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
25825526	C0538431	SU 5402	orch	12.91
25825526	C0538431	SU 5402	phsu	12.91
25825526	C0205198	Compound	qlco	3.98
25825526	C1706082	Compound (substance)	chem	3.98
25825526	C1705535	suggestion	idcn	3.98
25825526	C0205195	Combined	qlco	3.59
25825526	C3811910	combination - answer to question	fndg	3.59
25825526	C1947911	combination of objects	phob	3.59
25825526	C1705242	Different	qlco	3.57
25825526	C0441712	Mechanism (attribute)	ftcn	3.57
25825526	C3242339	operate	ftcn	3.57
25825526	C0087111	Therapeutic procedure	topp	3.56
25825526	C0442796	Additive	qlco	3.54
25825526	C1413365	CFTR gene	gngm	3.54
25825526	C2349975	Enhance (action)	acty	3.54
25825526	C2985765	Enhancement Description	inpr	3.54
25825526	C1708698	Light Emitting Diode Device Component	mnob	3.54
25825526	C1627358	Refractive surgery enhancement	topp	3.54
25825526	C1550602	additive ingredient	sbst	3.54
25825526	C3252847	VX 809	orch	3.46
25825526	C3252847	VX 809	phsu	3.46
25825526	C0007634	Cells	cell	3.43
25825526	C3282337	Cells [Chemical/Ingredient]	cell	3.43
25825526	C0086418	Homo sapiens	humn	28.65
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
25825526	C0243041	Molecular Chaperones	aapp	19.56
25825526	C0243041	Molecular Chaperones	bacs	19.56
25825526	C0538431	SU 5402	orch	13.05
25825526	C0538431	SU 5402	phsu	13.05
25825526	C1524024	analysis aspect	ftcn	13.00
25825526	C0030705	Patients	podg	6.70
25825526	C3841811	Transplant	fndg	6.70
25825526	C0040732	Transplantation	topp	6.70
25825526	C0332835	Transplanted tissue	tisu	6.70
25825526	C1550043	Container status - Identified	fndg	5.18
25825526	C1280500	Effect	qlco	5.18
25825526	C2348382	Effect, Appearance	qlco	5.18
25825526	C0205396	Identified	qlco	5.18
25825526	C0332293	Treated with	topp	3.72
25825526	C0681814	research study	resa	3.68
25825526	C1514559	Protein Overexpression	genf	3.57
25825526	C3854321	Expression (foundation metadata concept)	idcn	3.56
25825526	C0185117	Expression procedure	topp	3.56
25825526	C1413365	CFTR gene	gngm	3.55
25825526	C0936012	Analysis	resa	3.54
25825526	C0002778	Analysis of substances	lbpr	3.54
25825526	C1512335	Harvest Procedure	hlca	3.52
25825526	C0392747	Changing	ftcn	3.43
25825526	C0301863	"""U"" lymphocyte"	cell	3.42
25825526	C1510941	Array	spco	3.42
25825526	C0205039	Bronchial	bpoc	3.42
25825526	C1442216	Bronchial system	bpoc	3.42
25825526	C0221908	epithelial	qlco	3.42
25825526	C0060369	Fibroblast Growth Factor Receptors	aapp	22.90
25825526	C0060369	Fibroblast Growth Factor Receptors	rcpt	22.90
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
25825526	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
25825526	C0039798	therapeutic aspects	ftcn	22.35
25825526	C0009738	Congo	geoa	16.04
25825526	C0243041	Molecular Chaperones	aapp	9.94
25825526	C0243041	Molecular Chaperones	bacs	9.94
25825526	C0087111	Therapeutic procedure	topp	6.88
25825526	C2587213	Control function	ftcn	5.18
25825526	C1882979	Scientific Control	cnce	5.18
25825526	C3274648	True Control Status	qlco	5.18
25825526	C0243148	control aspects	qlco	5.18
25825526	C1550141	control substance	sbst	5.18
25825526	C1155389	fibroblast growth factor receptor signaling pathway	moft	5.18
25825526	C1705535	suggestion	idcn	5.18
25825526	C1150619	FGFR activity	moft	3.98
25825526	C1254042	Anatomical maturation	phsf	3.63
25825526	C0678723	Biologic Development	orgf	3.63
25825526	C0870861	Human maturation	phpr	3.63
25825526	C3898777	Important	qlco	3.57
25825526	C0808232	Therapeutic Intervention	topp	3.57
25825526	C0237403	treatments and procedures	topp	3.56
25825526	C1521840	Target	ftcn	3.54
25825526	C2986546	Target Lesion Identification	diap	3.54
25825526	C1552740	Entity Determiner - specific	inpr	3.50
25825526	C0205369	Specific qualifier value	qlco	3.50
25825526	C1413365	CFTR gene	gngm	3.48
25825526	C1533734	Administration procedure	topp	3.42
25825526	C1705169	Biomaterial Treatment	cnce	3.42
25825526	C3811819	CFTR wt Allele	gngm	3.42
25825526	C0302350	Therapeutic	ftcn	3.42
25825526	C1522326	Treating	ftcn	3.42
25825526	C3538994	Treatment Epoch	resa	3.42
25825526	C3887704	treatment - ActInformationManagementReason	hlca	3.42
25083129	C0039798	therapeutic aspects	ftcn	22.35
25083129	C0079870	Mutagenesis, Site-Directed	genf	16.06
25083129	C0023175	Lead	elii	13.02
25083129	C0023175	Lead	hops	13.02
25083129	C0010674	Cystic Fibrosis	dsyn	11.49
25083129	C0012634	Disease	dsyn	11.49
25083129	C0015127	Etiology aspects	ftcn	11.49
25083129	C0026882	Mutation	genf	9.73
25083129	C0037176	Single-Gene Defects	dsyn	6.78
25083129	C0033684	Proteins	aapp	6.71
25083129	C0033684	Proteins	bacs	6.71
25083129	C1524003	Science of Etiology	cnce	5.18
25083129	C1881534	Make - Instruction Imperative	ftcn	3.98
25083129	C3275067	Cardiac Lead Procedure	topp	3.56
25083129	C2348269	Dietary Lead	elii	3.56
25083129	C1522538	Leading	ftcn	3.56
25083129	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.56
25083129	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.56
25083129	C0332452	defective	ftcn	3.56
25083129	C2985566	Targeted Therapy	topp	3.44
25083129	C1512612	Ideal	qlco	3.42
25083129	C1705285	Mutation Abnormality	comd	3.42
25083129	C0087111	Therapeutic procedure	topp	3.42
25083129	C1363945	Therapy Object (animal model)	fndg	3.42
25083129	C0041714	United States Food and Drug Administration	hcro	25.54
25083129	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
25083129	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
25083129	C3264621	ivacaftor	orch	14.64
25083129	C3264621	ivacaftor	phsu	14.64
25083129	C0521116	Current (present time)	tmco	5.18
25083129	C1955473	Others - Allergy	fndg	5.18
25083129	C3539125	other medicated shampoos in ATC	phsu	5.18
25083129	C1516451	Chemical Modifier	chvf	3.60
25083129	C0205349	Modified By	qlco	3.60
25083129	C3542952	Modifier (core metadata concept)	inpr	3.60
25083129	C1514623	Qualifier (concept)	cnce	3.60
25083129	C0678723	Biologic Development	orgf	3.59
25083129	C1527148	Development	ftcn	3.59
25083129	C0243107	development aspects	phsf	3.59
25083129	C0205540	Approved	qlco	3.46
25083129	C1413365	CFTR gene	gngm	3.46
25083129	C1720467	Only - dosing instruction fragment	inpr	3.46
25083129	C0205171	Singular	qnco	3.46
27252987	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.41
27252987	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.41
27252987	C0017362	Genes, Regulator	gngm	19.52
27252987	C0376558	Life	idcn	11.49
27252987	C0010674	Cystic Fibrosis	dsyn	10.06
27252987	C0026882	Mutation	genf	9.90
27252987	C0031847	physiopathological	ftcn	9.85
27252987	C0015127	Etiology aspects	ftcn	9.85
27252987	C0019247	Hereditary Diseases	dsyn	8.34
27252987	C0441636	Surgical shortening - action	topp	5.18
27252987	C0678226	Due to	ftcn	3.59
27252987	C1517945	Loss	qnco	3.57
27252987	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.54
27252987	C3887504	Dysfunction	cnce	3.54
27252987	C0277785	Functional disorder	patf	3.54
27252987	C1524003	Science of Etiology	cnce	3.54
27252987	C1413365	CFTR gene	gngm	3.48
27252987	C1153410	channel activity	moft	3.43
27252987	C0033105	Statistical Prevalence	qnco	22.35
27252987	C0002085	Alleles	gngm	19.32
27252987	C0009738	Congo	geoa	16.16
27252987	C0206243	Carrying	acty	14.64
27252987	C0026882	Mutation	genf	9.94
27252987	C0030705	Patients	podg	6.70
27252987	C1705285	Mutation Abnormality	comd	3.63
27252987	C0205447	One	qnco	3.55
27252987	C3842582	90%	fndg	3.55
27252987	C0439087	<90	qnco	3.55
27252987	C0439083	>90	qnco	3.55
27252987	C0332232	Approximate	qlco	3.55
27252987	C3811819	CFTR wt Allele	gngm	3.55
27252987	C0205393	Most	qnco	3.48
27252987	C0220900	Prevalence aspects	qnco	3.43
27252987	C0009738	Congo	geoa	32.39
27252987	C0162340	Comprehension	menp	13.05
27252987	C3811819	CFTR wt Allele	gngm	7.01
27252987	C1280477	Progress	ftcn	3.68
27252987	C0205448	Two	qnco	3.68
27252987	C1272688	status - In progress	ftcn	3.68
27252987	C2981279	Decade	qnco	3.63
27252987	C0699748	Pathogenesis	patf	3.57
27252987	C0543483	pathogenic aspects	ftcn	3.57
27252987	C2712145	Actual Effective Human Development	fndg	3.56
27252987	C1881534	Make - Instruction Imperative	ftcn	3.55
27252987	C0087111	Therapeutic procedure	topp	3.54
27252987	C1546944	Event Seriousness - Significant	qlco	3.50
27252987	C1444637	Past	tmco	3.50
27252987	C0750502	Significant	idcn	3.50
27252987	C0237881	Statistical Significance	qnco	3.50
27252987	C0205449	Three	qnco	3.50
27252987	C0009738	Congo	geoa	32.35
27252987	C3264621	ivacaftor	orch	13.14
27252987	C3264621	ivacaftor	phsu	13.14
27252987	C3852684	lumacaftor	orch	12.96
27252987	C3852684	lumacaftor	phsu	12.96
27252987	C2718059	Precision Medicine	topp	12.91
27252987	C0376636	Disease Management	hlca	11.49
27252987	C3811819	CFTR wt Allele	gngm	6.96
27252987	C0001554	Administration occupational activities	ocac	5.18
27252987	C3273539	Management Occupations	ocdi	5.18
27252987	C1273870	Management procedure	ocac	5.18
27252987	C0522501	Massive	qlco	5.18
27252987	C1947933	care activity	acty	3.68
27252987	C2346845	Approval (document)	inpr	3.56
27252987	C0205540	Approved	qlco	3.56
27252987	C2697909	Letter of Authorization	rnlw	3.56
27252987	C2347129	Milestone	cnce	3.55
27252987	C2983568	Developmental Milestone	cnce	3.55
27252987	C2986894	Developmental Milestone Domain	idcn	3.55
27252987	C4033620	ORKAMBI	phsu	3.43
27252987	C0723712	Therapeutic brand of coal tar	orch	3.43
27252987	C0723712	Therapeutic brand of coal tar	phsu	3.43
27252987	C0087111	Therapeutic procedure	topp	3.43
27252987	C1522647	Developmental Therapeutics Program	resa	3.42
27252987	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27252987	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27252987	C0040363	Togo	geoa	17.80
27252987	C0041260	Tryptophanase	aapp	17.80
27252987	C0041260	Tryptophanase	enzy	17.80
27252987	C0009738	Congo	geoa	16.12
27252987	C0449738	Direction	spco	13.00
27252987	C4033633	ivacaftor / lumacaftor	phsu	12.89
27252987	C0282443	Review [Publication Type]	inpr	11.49
27252987	C0019904	Homozygote	orga	9.86
27252987	C0026882	Mutation	genf	9.74
27252987	C0030705	Patients	podg	6.83
27252987	C0016884	Future	tmco	6.57
27252987	C1552617	Act Class - review	idcn	5.18
27252987	C1706852	Article	inpr	5.18
27252987	C0392360	Indication of (contextual qualifier)	idcn	5.18
27252987	C1280477	Progress	ftcn	5.18
27252987	C2699007	Rationale	idcn	5.18
27252987	C0087111	Therapeutic procedure	topp	5.18
27252987	C1883351	To	qlco	5.18
27252987	C1522326	Treating	ftcn	5.18
27252987	C1292734	Treatment intent	ftcn	5.18
27252987	C1272688	status - In progress	ftcn	5.18
27252987	C3811819	CFTR wt Allele	gngm	3.50
27252987	C1413365	CFTR gene	gngm	3.43
27252987	C1705285	Mutation Abnormality	comd	3.43
27252987	C0678723	Biologic Development	orgf	3.42
27252987	C0205195	Combined	qlco	3.42
27252987	C1527148	Development	ftcn	3.42
27252987	C3811910	combination - answer to question	fndg	3.42
27252987	C1947911	combination of objects	phob	3.42
27252987	C0243107	development aspects	phsf	3.42
25438972	C0010674	Cystic Fibrosis	dsyn	19.61
25438972	C0013117	Dreams	menp	16.16
25438972	C0085537	Caregiver	prog	14.64
25438972	C0031831	Physicians	prog	14.64
25438972	C0035173	Research Personnel	prog	11.49
25438972	C0013217	pharmacotherapeutic	ftcn	9.88
25438972	C0013216	Pharmacotherapy	topp	6.73
25438972	C0030705	Patients	podg	6.58
25438972	C1825644	KCNIP3 gene	gngm	3.54
25438972	C0443252	Long-term	tmco	3.44
25438972	C1709510	Personalized	qlco	3.42
25438972	C0039798	therapeutic aspects	ftcn	22.36
25438972	C0040363	Togo	geoa	17.80
25438972	C0041260	Tryptophanase	aapp	17.80
25438972	C0041260	Tryptophanase	enzy	17.80
25438972	C0392347	Hope (emotion)	menp	11.49
25438972	C0887933	Fictional Works	inpr	6.71
25438972	C0541749	Does turn (finding)	fndg	5.18
25438972	C1883351	To	qlco	5.18
25438972	C3258203	Study year	tmco	3.65
25438972	C1533734	Administration procedure	topp	3.43
25438972	C1705169	Biomaterial Treatment	cnce	3.43
25438972	C1709510	Personalized	qlco	3.43
25438972	C0087111	Therapeutic procedure	topp	3.43
25438972	C1522326	Treating	ftcn	3.43
25438972	C3538994	Treatment Epoch	resa	3.43
25438972	C3887704	treatment - ActInformationManagementReason	hlca	3.43
25438972	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25438972	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25438972	C0040363	Togo	geoa	17.80
25438972	C0041260	Tryptophanase	aapp	17.80
25438972	C0041260	Tryptophanase	enzy	17.80
25438972	C0009738	Congo	geoa	16.17
25438972	C0027552	Needs	qlco	14.64
25438972	C0026882	Mutation	genf	9.73
25438972	C0205314	New	qlco	7.09
25438972	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
25438972	C1883351	To	qlco	5.18
25438972	C0087111	Therapeutic procedure	topp	3.68
25438972	C3811819	CFTR wt Allele	gngm	3.55
25438972	C3495919	Enthesitis-Related Arthritis	dsyn	3.55
25438972	C1533716	Information	idcn	3.55
25438972	C1527178	Basis - conceptual entity	ftcn	3.42
25438972	C1413365	CFTR gene	gngm	3.42
25438972	C0456387	Class	inpr	3.42
25438972	C1705943	Class (taxonomic)	clas	3.42
25438972	C4019422	Classes - encounter	hlca	3.42
25438972	C0004268	Attention	menp	14.64
25438972	C0220825	Evaluation	hlca	13.03
25438972	C1546466	Problems - What subject filter	idcn	5.18
25438972	C1704243	Greater	qnco	3.57
25438972	C1314939	Involvement with	ftcn	3.57
25438972	C1706387	Issue (document)	inpr	3.57
25438972	C0033213	Problem	fndg	3.57
25438972	C1947933	care activity	acty	3.57
25438972	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25438972	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25438972	C0040363	Togo	geoa	17.80
25438972	C0041260	Tryptophanase	aapp	17.80
25438972	C0041260	Tryptophanase	enzy	17.80
25438972	C0009738	Congo	geoa	16.04
25438972	C0026882	Mutation	genf	9.73
25438972	C0030705	Patients	podg	6.70
25438972	C0470187	Availability of	ftcn	5.18
25438972	C0456387	Class	inpr	5.18
25438972	C1705943	Class (taxonomic)	clas	5.18
25438972	C4019422	Classes - encounter	hlca	5.18
25438972	C3687832	DRUGS	topp	5.18
25438972	C0013227	Pharmaceutical Preparations	phsu	5.18
25438972	C0087111	Therapeutic procedure	topp	5.18
25438972	C1883351	To	qlco	5.18
25438972	C1522326	Treating	ftcn	5.18
25438972	C1292734	Treatment intent	ftcn	5.18
25438972	C0557651	Room of building - Study	mnob	3.98
25438972	C2603343	Study	resa	3.98
25438972	C1718097	New medications	phsu	3.93
25438972	C2741958	VX-770	orch	3.75
25438972	C2698969	Canadian Cardiovascular Society Grading Scale Class III	fndg	3.44
25438972	C0441887	Class 3	inpr	3.44
25438972	C1413365	CFTR gene	gngm	3.42
25438972	C3811819	CFTR wt Allele	gngm	3.42
25438972	C0039798	therapeutic aspects	ftcn	22.35
25438972	C2827718	In Vitro Route of Administration	ftcn	5.18
25438972	C0021135	In Vitro [Publication Type]	inpr	5.18
25438972	C1704324	Scientific Publication	inpr	5.18
25438972	C1533691	in vitro	qlco	5.18
25438972	C1515655	in vivo	spco	5.18
25438972	C1533716	Information	idcn	3.55
25438972	C1948059	Constant (qualifier)	qlco	3.43
25438972	C0087111	Therapeutic procedure	topp	3.43
25438972	C1363945	Therapy Object (animal model)	fndg	3.43
25438972	C0392347	Hope (emotion)	menp	11.49
25438972	C0442808	Increasing	ftcn	5.18
25438972	C0027552	Needs	qlco	13.07
25438972	C0036397	Science	ocdi	6.63
25438972	C0018684	Health	idcn	6.61
25438972	C0332268	Lacking	qlco	5.18
25438972	C0686904	Patient need for (contextual qualifier)	ftcn	3.60
25438972	C1955348	Patient Information	inpr	3.60
25438972	C2598117	Patient Information:-:Point in time:^Patient:-	clna	3.60
25438972	C2700280	World	popg	3.48
25438972	C0332173	Daily	tmco	3.46
25438972	C0445223	Related personal status	fndg	3.46
25438972	C0439849	Relationships	qlco	3.46
25438972	C0871222	reality	idcn	3.44
25438972	C0039798	therapeutic aspects	ftcn	92.87
25438972	C0040363	Togo	geoa	73.37
25438972	C0041260	Tryptophanase	aapp	73.37
25438972	C0041260	Tryptophanase	enzy	73.37
25438972	C0023981	Longitudinal Studies	resa	22.41
25438972	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
25438972	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
25438972	C1883351	To	qlco	21.36
25438972	C0008976	Clinical Trials	resa	19.52
25438972	C0009738	Congo	geoa	16.05
25438972	C0087111	Therapeutic procedure	topp	14.85
25438972	C0220825	Evaluation	hlca	14.64
25438972	C1096775	Clinical Trial [Publication Type]	inpr	10.06
25438972	C0013175	Drug Evaluation	resa	9.90
25438972	C0026882	Mutation	genf	9.78
25438972	C0033213	Problem	fndg	7.53
25438972	C1718097	New medications	phsu	7.53
25438972	C1883073	Electromagnetic Spectrum	qnco	7.31
25438972	C2827424	Spectrum	cnce	7.31
25438972	C1533734	Administration procedure	topp	7.28
25438972	C1705169	Biomaterial Treatment	cnce	7.28
25438972	C1522326	Treating	ftcn	7.28
25438972	C3538994	Treatment Epoch	resa	7.28
25438972	C3887704	treatment - ActInformationManagementReason	hlca	7.28
25438972	C3687832	DRUGS	topp	7.22
25438972	C0013227	Pharmaceutical Preparations	phsu	7.22
25438972	C1363945	Therapy Object (animal model)	fndg	7.22
25438972	C1689985	Absence (morphologic abnormality)	anab	7.16
25438972	C0332197	Absent	ftcn	7.16
25438972	C3854321	Expression (foundation metadata concept)	idcn	6.97
25438972	C0185117	Expression procedure	topp	6.97
25438972	C0205170	Good	qlco	6.90
25438972	C0030705	Patients	podg	6.74
25438972	C0013216	Pharmacotherapy	topp	6.74
25438972	C0008963	Markers, Clinical	qlco	6.62
25438972	C0936012	Analysis	resa	5.18
25438972	C1706912	BARRIER	medd	5.18
25438972	C4055223	Clinical Response	fndg	5.18
25438972	C0205108	Distal	spco	5.18
25438972	C0010186	Financial cost	qnco	5.18
25438972	C0022885	Laboratory Procedures	lbpr	5.18
25438972	C0449295	Limitation	ftcn	5.18
25438972	C2983310	Overcome	acty	5.18
25438972	C0456984	Test Result	fndg	5.18
25438972	C0039593	Testing	ftcn	5.18
25438972	C0392366	Tests (qualifier value)	inpr	5.18
25438972	C1273517	Used by	fndg	5.18
25438972	C0683154	drug response	orgf	5.18
25438972	C1706387	Issue (document)	inpr	3.98
25438972	C1547282	Show	anim	3.98
25438972	C1704632	Disease Response	fndg	3.68
25438972	C2911692	Response (communication)	menp	3.68
25438972	C1706817	Response (statement)	inpr	3.68
25438972	C0871261	Response process	orga	3.68
25438972	C0580836	Old	tmco	3.63
25438972	C3854081	Problem:Find:Pt:^Patient:Nom	clna	3.63
25438972	C0332464	Widening	spco	3.63
25438972	C1842176	Clinical variability	fndg	3.60
25438972	C3242274	new therapy	fndg	3.58
25438972	C0445223	Related personal status	fndg	3.57
25438972	C0439849	Relationships	qlco	3.57
25438972	C0205314	New	qlco	3.55
25438972	C0814225	benefit	qnco	3.55
25438972	C2827718	In Vitro Route of Administration	ftcn	3.53
25438972	C0021135	In Vitro [Publication Type]	inpr	3.53
25438972	C2741958	VX-770	orch	3.53
25438972	C1533691	in vitro	qlco	3.53
25438972	C1413365	CFTR gene	gngm	3.48
25438972	C3898777	Important	qlco	3.48
25438972	C0205393	Most	qnco	3.48
25438972	C0205452	Six	qnco	3.48
25438972	C0439234	year	tmco	3.48
25438972	C3811819	CFTR wt Allele	gngm	3.43
25438972	C0009738	Congo	geoa	16.04
25438972	C0013217	pharmacotherapeutic	ftcn	9.99
25438972	C1518422	Negation	ftcn	7.70
25438972	C0887933	Fictional Works	inpr	6.83
25438972	C0013216	Pharmacotherapy	topp	6.83
25438972	C0030705	Patients	podg	6.58
25438972	C0871222	reality	idcn	3.55
25438972	C1709510	Personalized	qlco	3.47
25438972	C3811819	CFTR wt Allele	gngm	3.43
24309546	C0010674	Cystic Fibrosis	dsyn	9.74
24309546	C0150312	Present	qnco	5.18
24309546	C0449450	Presentation	idcn	5.18
24309546	C3854260	Advance	tmco	3.51
24309546	C0725066	Advance -- medical device	medd	3.51
24309546	C0332185	Recent	tmco	3.42
24309546	C0302350	Therapeutic	ftcn	3.42
24309546	C0087111	Therapeutic procedure	topp	3.42
24309546	C1947933	care activity	acty	3.42
24309546	C0079613	Adoptive Immunotherapy	topp	27.26
24309546	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
24309546	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
24309546	C0039798	therapeutic aspects	ftcn	22.36
24309546	C0003237	Antibiotics, Antitubercular	antb	22.35
24309546	C0004048	Inspiration function	orgf	19.19
24309546	C0003232	Antibiotics	antb	16.04
24309546	C1869853	SERPINA3 protein, human	aapp	14.64
24309546	C1869853	SERPINA3 protein, human	bacs	14.64
24309546	C0034380	Quality of life	idcn	13.14
24309546	C0011682	Desiccation	npop	12.88
24309546	C0012634	Disease	dsyn	9.88
24309546	C0032861	Powder dose form	bodm	9.73
24309546	C0087111	Therapeutic procedure	topp	7.08
24309546	C0033684	Proteins	aapp	6.57
24309546	C0033684	Proteins	bacs	6.57
24309546	C4048375	Asthma Control Test Questionnaire	inpr	5.18
24309546	C2699424	Concern	idcn	5.18
24309546	C0567416	Molecule	sbst	5.18
24309546	C3890007	SERPINA3 wt Allele	gngm	5.18
24309546	C0518214	Perceived quality of life	sosy	3.68
24309546	C0678723	Biologic Development	orgf	3.54
24309546	C1527148	Development	ftcn	3.54
24309546	C0456079	Disease classification level	clas	3.54
24309546	C1547707	Floor - story of building	geoa	3.54
24309546	C2946261	Level	phsu	3.54
24309546	C0441889	Levels (qualifier value)	qlco	3.54
24309546	C0441712	Mechanism (attribute)	ftcn	3.54
24309546	C0332452	defective	ftcn	3.54
24309546	C0243107	development aspects	phsf	3.54
24309546	C2986411	Improvement	cnce	3.54
24309546	C1709060	Modulator Device Component	mnob	3.51
24309546	C1413365	CFTR gene	gngm	3.47
24309546	C1533734	Administration procedure	topp	3.44
24309546	C1705169	Biomaterial Treatment	cnce	3.44
24309546	C0231220	Symptomatic	ftcn	3.44
24309546	C1522326	Treating	ftcn	3.44
24309546	C3538994	Treatment Epoch	resa	3.44
24309546	C3887704	treatment - ActInformationManagementReason	hlca	3.44
24309546	C1561611	Admission Level of Care Code - Improved	inpr	3.43
24309546	C0332272	Better	qlco	3.43
24309546	C0184511	Improved	qlco	3.43
24309546	C0683243	innovativeness	menp	3.43
24309546	C3540706	Antibiotic throat preparations	antb	3.42
24309546	C3540707	Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	antb	3.42
24309546	C3540704	Antibiotics for systemic use	antb	3.42
24309546	C3540708	Antibiotics, Gynecological	antb	3.42
24309546	C3540710	Antibiotics, ophthalmologic	antb	3.42
24309546	C3540705	Antifungal Antibiotics, Topical	antb	3.42
24309546	C0205222	Dry	qlco	3.42
24309546	C1512080	Dryness (characteristic)	qlco	3.42
24309546	C3540709	antibiotics, intestinal	antb	3.42
24309546	C1382110	powder physical state	sbst	3.42
24309546	C0005615	Birth	orgf	19.36
24309546	C0023671	Life Expectancy	grpa	19.35
24309546	C0040363	Togo	geoa	17.80
24309546	C0041260	Tryptophanase	aapp	17.80
24309546	C0041260	Tryptophanase	enzy	17.80
24309546	C0010674	Cystic Fibrosis	dsyn	9.75
24309546	C0030705	Patients	podg	6.58
24309546	C0750572	Estimated	qnco	5.18
24309546	C1948052	Now (temporal qualifier)	tmco	5.18
24309546	C1883351	To	qlco	5.18
24309546	C0439234	year	tmco	3.63
24309546	C0681760	2000s	tmco	3.55
24309546	C3842586	50%	fndg	3.48
24309546	C3843766	<50	fndg	3.48
24309546	C0332232	Approximate	qlco	3.48
24309546	C0011198	Delaware	geoa	19.22
24309546	C0023031	Lanthanum	elii	16.07
24309546	C0056167	cyclophosphamide/methotrexate/prednisone/vincristine protocol	topp	12.91
24309546	C0017480	Germany	geoa	9.76
24309546	C0010674	Cystic Fibrosis	dsyn	9.75
24309546	C0029246	Organization administrative structures	orgt	6.70
24309546	C0038952	Continuance of life	acty	6.59
24309546	C2986411	Improvement	cnce	3.57
24309546	C1519441	Specialized Center Grant	hcro	3.56
24309546	C1705938	Base - General Qualifier	idcn	3.56
24309546	C1527178	Basis - conceptual entity	ftcn	3.56
24309546	C0439539	Heavy sensation quality	qlco	3.56
24309546	C0231220	Symptomatic	ftcn	3.56
24309546	C0087111	Therapeutic procedure	topp	3.56
24309546	C1301820	Obtain	ftcn	3.55
24309546	C1552679	Organization Name	inpr	3.55
24309546	C1300196	Organized	ftcn	3.55
24309546	C0029237	Physiologic Organization	phsf	3.55
24309546	C1522486	Professional Organization or Group	prog	3.55
24309546	C1947933	care activity	acty	3.55
24309546	C0220885	organizational	qlco	3.55
24309546	C1456376	COMP gene	gngm	3.45
24309546	C3715143	Cartilage Oligomeric Matrix Protein Measurement	lbpr	3.45
24309546	C3810851	Center of town	fndg	3.45
24309546	C0205099	Central	spco	3.45
24309546	C3541240	Device Events Domain	idcn	3.45
24309546	C0230347	Left upper arm structure	bpoc	3.45
24309546	C2346906	Lupus Anticoagulant Antibody	aapp	3.45
24309546	C2346906	Lupus Anticoagulant Antibody	imft	3.45
24309546	C0220921	survival aspects	ftcn	3.44
24309546	C0003237	Antibiotics, Antitubercular	antb	22.56
24309546	C0004048	Inspiration function	orgf	19.25
24309546	C0003232	Antibiotics	antb	16.25
24309546	C0011682	Desiccation	npop	14.64
24309546	C0032861	Powder dose form	bodm	9.78
24309546	C0040223	Time	tmco	6.71
24309546	C0030705	Patients	podg	6.58
24309546	C0205222	Dry	qlco	5.18
24309546	C1512080	Dryness (characteristic)	qlco	5.18
24309546	C1947933	care activity	acty	5.18
24309546	C0556974	hours/day	tmco	3.75
24309546	C3540706	Antibiotic throat preparations	antb	3.63
24309546	C3540707	Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	antb	3.63
24309546	C3540704	Antibiotics for systemic use	antb	3.63
24309546	C3540708	Antibiotics, Gynecological	antb	3.63
24309546	C3540710	Antibiotics, ophthalmologic	antb	3.63
24309546	C3540705	Antifungal Antibiotics, Topical	antb	3.63
24309546	C3540709	antibiotics, intestinal	antb	3.63
24309546	C3541383	Time (foundation metadata concept)	tmco	3.55
24309546	C2347840	Commit Operation	mcha	3.52
24309546	C0205448	Two	qnco	3.48
24309546	C1382110	powder physical state	sbst	3.48
24309546	C1546944	Event Seriousness - Significant	qlco	3.43
24309546	C0750502	Significant	idcn	3.43
24309546	C0237881	Statistical Significance	qnco	3.43
24309546	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
24309546	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
24309546	C0079870	Mutagenesis, Site-Directed	genf	16.17
24309546	C0683607	allowing	socb	10.42
24309546	C0031330	Pharmacology	bmod	9.81
24309546	C0012634	Disease	dsyn	9.73
24309546	C0449445	Approach	spco	7.25
24309546	C0567416	Molecule	sbst	5.18
24309546	C1547052	*Type - Kind of quantity	qnco	3.54
24309546	C0332307	Type - attribute	qlco	3.54
24309546	C0680240	agreement	socb	3.54
24309546	C1709060	Modulator Device Component	mnob	3.54
24309546	C0205464	pharmacological	ftcn	3.50
24309546	C1413365	CFTR gene	gngm	3.44
24309546	C1552740	Entity Determiner - specific	inpr	3.42
24309546	C0205172	More	ftcn	3.42
24309546	C0205369	Specific qualifier value	qlco	3.42
24309546	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.99
24309546	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.99
24309546	C3264621	ivacaftor	orch	13.14
24309546	C3264621	ivacaftor	phsu	13.14
24309546	C0031843	physiological aspects	phsf	13.01
24309546	C0026882	Mutation	genf	9.99
24309546	C0030705	Patients	podg	6.59
24309546	C3264627	Kalydeco	phsu	5.18
24309546	C1705285	Mutation Abnormality	comd	3.68
24309546	C1527118	Protein Function	moft	3.58
24309546	C0815043	Protein, Organized by Function	aapp	3.58
24309546	C0470187	Availability of	ftcn	3.57
24309546	C0699040	Cell surface	celc	3.57
24309546	C0542341	Function	ftcn	3.55
24309546	C0700205	Function Axis	clas	3.55
24309546	C1705273	Mathematical Operator	inpr	3.55
24309546	C1948052	Now (temporal qualifier)	tmco	3.44
24309546	C1413365	CFTR gene	gngm	3.43
24309546	C0040363	Togo	geoa	17.80
24309546	C0041260	Tryptophanase	aapp	17.80
24309546	C0041260	Tryptophanase	enzy	17.80
24309546	C0030705	Patients	podg	13.24
24309546	C3852684	lumacaftor	orch	13.14
24309546	C3852684	lumacaftor	phsu	13.14
24309546	C0004083	Mental association	menp	13.05
24309546	C3264621	ivacaftor	orch	13.03
24309546	C3264621	ivacaftor	phsu	13.03
24309546	C0026882	Mutation	genf	9.99
24309546	C1883351	To	qlco	5.18
24309546	C1705285	Mutation Abnormality	comd	3.68
24309546	C0596306	Chemical Association	phpr	3.59
24309546	C0699792	Relationship by association	socb	3.59
24309546	C0439849	Relationships	qlco	3.59
24309546	C0392366	Tests (qualifier value)	inpr	3.59
24309546	C0150312	Present	qnco	3.54
24309546	C0449450	Presentation	idcn	3.54
24309546	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24309546	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24309546	C2930764	ataluren	orch	14.64
24309546	C2930764	ataluren	phsu	14.64
24309546	C0036658	Esthesia	ortf	12.96
24309546	C0038164	Staphylococcal Protein A	aapp	12.90
24309546	C0038164	Staphylococcal Protein A	imft	12.90
24309546	C0038164	Staphylococcal Protein A	irda	12.90
24309546	C0026882	Mutation	genf	9.99
24309546	C0030705	Patients	podg	6.72
24309546	C0683607	allowing	socb	5.18
24309546	C1705285	Mutation Abnormality	comd	3.68
24309546	C0033268	production	ocac	3.55
24309546	C1882932	Representation (action)	acty	3.51
24309546	C3858838	therapeutic class	inpr	3.44
24309546	C1413365	CFTR gene	gngm	3.42
24309546	C0542341	Function	ftcn	3.42
24309546	C0205245	Functional	ftcn	3.42
24309546	C2700217	Functional Relationship	cnce	3.42
24309546	C0205314	New	qlco	3.42
24309546	C0205437	Third	qnco	3.42
24309546	C0010674	Cystic Fibrosis	dsyn	9.75
24309546	C0750528	presently	idcn	5.18
24309546	C0231220	Symptomatic	ftcn	3.54
24309546	C0087111	Therapeutic procedure	topp	3.54
24309546	C0439064	Numerous	qnco	3.42
24309546	C1947933	care activity	acty	3.42
24309546	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
24309546	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
24309546	C3264621	ivacaftor	orch	13.05
24309546	C3264621	ivacaftor	phsu	13.05
24309546	C1882932	Representation (action)	acty	5.18
24309546	C0310367	Today	antb	5.18
24309546	C0310367	Today	orch	5.18
24309546	C0750526	Today (temporal qualifier)	tmco	5.18
24309546	C0442824	Very	qlco	5.18
24309546	C2984081	Very Much	qlco	5.18
24309546	C1555307	promise	idcn	3.98
24309546	C0332293	Treated with	topp	3.72
24309546	C0678723	Biologic Development	orgf	3.56
24309546	C1527148	Development	ftcn	3.56
24309546	C0243107	development aspects	phsf	3.56
24309546	C0470187	Availability of	ftcn	3.55
24309546	C0302350	Therapeutic	ftcn	3.50
24309546	C0087111	Therapeutic procedure	topp	3.50
24309546	C2360800	Number of patients	fndg	3.47
24309546	C1413365	CFTR gene	gngm	3.43
24309546	C0443288	Restricted	ftcn	3.42
24309546	C1709060	Modulator Device Component	mnob	3.41
24309546	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
24309546	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
24309546	C0039798	therapeutic aspects	ftcn	22.35
24309546	C1722730	First Step	bodm	13.04
24309546	C0017431	Genotype	orga	6.83
24309546	C0750492	Probably	idcn	5.18
24309546	C1882932	Representation (action)	acty	5.18
24309546	C1704379	Treatment Step	ftcn	3.57
24309546	C1413365	CFTR gene	gngm	3.50
24309546	C1533734	Administration procedure	topp	3.42
24309546	C1705169	Biomaterial Treatment	cnce	3.42
24309546	C0205435	First (number)	qnco	3.42
24309546	C1279901	Firstly	qlco	3.42
24309546	C1709510	Personalized	qlco	3.42
24309546	C0087111	Therapeutic procedure	topp	3.42
24309546	C1522326	Treating	ftcn	3.42
24309546	C3538994	Treatment Epoch	resa	3.42
24309546	C3887704	treatment - ActInformationManagementReason	hlca	3.42
25447681	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.66
25447681	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.66
25447681	C0008203	Chlorides	inch	16.04
25447681	C3264621	ivacaftor	orch	13.14
25447681	C3264621	ivacaftor	phsu	13.14
25447681	C0010674	Cystic Fibrosis	dsyn	9.76
25447681	C0033684	Proteins	aapp	8.34
25447681	C0033684	Proteins	bacs	8.34
25447681	C1413365	CFTR gene	gngm	7.58
25447681	C0000768	Congenital Abnormality	cgab	6.71
25447681	C1521840	Target	ftcn	5.18
25447681	C2986546	Target Lesion Identification	diap	5.18
25447681	C1254351	Pharmacologic Substance	phsu	3.68
25447681	C1737329	Dysmorphism	cgab	3.56
25447681	C0205314	New	qlco	3.47
25447681	C0442027	Oral	spco	3.47
25447681	C0679622	literary novel	inpr	3.47
25447681	C0596019	Chloride Ion	elii	3.42
25447681	C0205217	Increased	qnco	3.40
25447681	C0021966	Iodides	inch	17.80
25447681	C0009738	Congo	geoa	16.05
25447681	C0162521	Exercise Tolerance	clna	14.64
25447681	C0037090	Signs and Symptoms, Respiratory	sosy	11.49
25447681	C0026882	Mutation	genf	9.86
25447681	C0035245	Respiratory physiology	ortf	8.34
25447681	C0221138	Blood group antibody I	aapp	5.18
25447681	C0221138	Blood group antibody I	imft	5.18
25447681	C0449381	Observation parameter	fndg	3.68
25447681	C0205447	One	qnco	3.63
25447681	C1948062	Copy (object)	mnob	3.55
25447681	C1705285	Mutation Abnormality	comd	3.55
25447681	C2986411	Improvement	cnce	3.54
25447681	C0237401	Individual	humn	3.54
25447681	C0027361	Persons	popg	3.54
25447681	C1521739	Nutritional	qlco	3.50
25447681	C2707262	Nutritional:-:Point in time:^Patient:-	clna	3.50
25447681	C0428295	Cystic fibrosis sweat test	lbpr	3.48
25447681	C1304760	Sweat chloride level result	lbtr	3.48
25447681	C3811819	CFTR wt Allele	gngm	3.44
25447681	C3264621	ivacaftor	orch	13.01
25447681	C3264621	ivacaftor	phsu	13.01
25447681	C0429886	Walking distance	fndg	3.68
25447681	C0439230	week	tmco	3.55
25447681	C1548602	Initiate (source type)	idcn	3.52
25447681	C1704686	Initiation	ftcn	3.52
25447681	C1524029	Mouse MIN NOS	neop	3.47
25447681	C0702093	Per Minute	tmco	3.47
25447681	C3813700	Percent per Minute	qnco	3.47
25447681	C3889645	Clinical Trial Final Report	inpr	5.18
25447681	C0205463	Physiological	ftcn	5.18
25447681	C0684224	Report (document)	inpr	5.18
25447681	C0700287	Reporting	hlca	5.18
25447681	C1522508	Details	qlco	3.98
25447681	C1561567	detail - Response Level	ftcn	3.98
25447681	C0441712	Mechanism (attribute)	ftcn	3.68
25447681	C0445254	Sensory (qualifier value)	qlco	3.43
25447681	C2986411	Improvement	cnce	3.41
25447681	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
25447681	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
25447681	C2959886	Cardiopulmonary Exercise Test	diap	16.14
25447681	C0009738	Congo	geoa	16.04
25447681	C1527303	Chronic Airflow Obstruction	dsyn	14.64
25447681	C3264621	ivacaftor	orch	12.90
25447681	C3264621	ivacaftor	phsu	12.90
25447681	C0086582	Males	orga	9.85
25447681	C0017431	Genotype	orga	6.62
25447681	C3842591	0%	fndg	5.18
25447681	C3815113	Forced Expiratory Volume in 1 Second to Forced Vital Capacity Ratio Measurement	lbpr	5.18
25447681	C0884358	Performed	ftcn	5.18
25447681	C0802741	Volume at 1.0 s post forced expiration/Vital capacity.forced:Volume Ratio:Point in time:Respiratory system:Quantitative	clna	5.18
25447681	C0332152	Before	tmco	3.60
25447681	C0740175	Before values	qlco	3.60
25447681	C3669034	Pure Spanish horse breed (organism)	mamm	3.60
25447681	C2257086	photoreactivating enzyme activity	genf	3.60
25447681	C0589507	Cognitive function: initiation	menp	3.57
25447681	C1704686	Initiation	ftcn	3.57
25447681	C0687676	Post	tmco	3.57
25447681	C1704687	Post Device Component	mnob	3.57
25447681	C1158830	Transcription Initiation	genf	3.57
25447681	C1706180	Male Gender, Self Report	qlco	3.54
25447681	C1706428	Male Phenotype	qlco	3.54
25447681	C1706429	Male, Self-Reported	orga	3.54
25447681	C1413365	CFTR gene	gngm	3.47
25447681	C1522508	Details	qlco	3.46
25447681	C3811819	CFTR wt Allele	gngm	3.42
25447681	C0580836	Old	tmco	3.42
25447681	C0439508	per year	tmco	3.42
25447681	C0439234	year	tmco	3.42
25447681	C0015259	Exercise	dora	19.45
25447681	C3264621	ivacaftor	orch	14.64
25447681	C3264621	ivacaftor	phsu	14.64
25447681	C2986411	Improvement	cnce	7.14
25447681	C0231807	Dyspnea on exertion	sosy	5.18
25447681	C0332282	Following	tmco	5.18
25447681	C0231290	Status post	tmco	5.18
25447681	C1516240	Capacity	qnco	3.68
25447681	C1522704	Exercise Pain Management	topp	3.68
25447681	C0449399	Borg scale	inpr	3.58
25447681	C0547043	Up	spco	3.58
25447681	C1546944	Event Seriousness - Significant	qlco	3.56
25447681	C0750502	Significant	idcn	3.56
25447681	C0237881	Statistical Significance	qnco	3.56
25447681	C0439148	Unit	qnco	3.55
25447681	C3853603	Unit - NCI Thesaurus Property	ftcn	3.55
25447681	C1519795	Unit of Measure	qnco	3.55
25447681	C1561566	FEV1 Adverse Event	fndg	3.44
25447681	C0429706	Forced expiratory volume in 1 second finding	fndg	3.44
25447681	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.44
25447681	C0015259	Exercise	dora	20.95
25447681	C0040363	Togo	geoa	17.80
25447681	C0041260	Tryptophanase	aapp	17.80
25447681	C0041260	Tryptophanase	enzy	17.80
25447681	C2986411	Improvement	cnce	7.37
25447681	C1522704	Exercise Pain Management	topp	5.18
25447681	C0332257	Including (qualifier)	ftcn	5.18
25447681	C1883351	To	qlco	5.18
25447681	C0449719	Part	spco	3.56
25447681	C1709471	Part Dosing Unit	qnco	3.56
25447681	C0596130	attribution	menp	3.56
25447681	C1515926	Alteration	idcn	3.52
25447681	C0517967	Respiratory pattern	fndg	3.48
25447681	C4054987	Favorable Response	fndg	3.44
25447681	C1532633	Kilounit per Kilogram	qnco	5.18
25447681	C2608091	Unit/gram	qnco	5.18
25447681	C0040210	Tidal Volume	lbtr	30.42
25447681	C0004048	Inspiration function	orgf	19.40
25447681	C0035203	Respiration	phsf	13.09
25447681	C0442805	Increase	ftcn	5.18
25447681	C0205217	Increased	qnco	5.18
25447681	C0429704	Dynamic lung volume	fndg	3.76
25447681	C0439603	Frequencies (time pattern)	tmco	3.63
25447681	C3898838	How Often	inpr	3.63
25447681	C1561548	Kind of quantity - Frequency	qlco	3.63
25447681	C0871396	Spatial Frequency	qnco	3.63
25447681	C1705502	Statistical Frequency	qnco	3.63
25447681	C0376249	With frequency	qnco	3.63
25447681	C1160636	respiratory gaseous exchange in organisms	biof	3.63
25447681	C0392756	Reduced	qlco	3.48
25447681	C3242339	operate	ftcn	3.44
25447681	C1532633	Kilounit per Kilogram	qnco	5.18
25447681	C2608091	Unit/gram	qnco	5.18
25447681	C0021613	Inspiratory Reserve Volume	fndg	30.42
25447681	C0021610	Inspiratory Capacity	orga	27.26
25447681	C0802663	Capacity.inspiratory:Volume:Point in time:Respiratory system:Quantitative	clna	5.18
25447681	C0442805	Increase	ftcn	5.18
25447681	C0205217	Increased	qnco	5.18
25447681	C0547047	Decrease	qnco	3.55
25447681	C0442797	Decreasing	qlco	3.55
25447681	C0729333	Dynamic	ftcn	3.55
25447681	C0443254	Mechanical Methods	ftcn	3.55
25447681	C0392756	Reduced	qlco	3.55
25447681	C2986806	Quantitative Constraint	ocac	3.52
25447681	C0443288	Restricted	ftcn	3.52
21602569	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
21602569	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
21602569	C0015127	Etiology aspects	ftcn	19.69
21602569	C0017337	Genes	gngm	16.22
21602569	C0031843	physiological aspects	phsf	12.88
21602569	C0010674	Cystic Fibrosis	dsyn	10.06
21602569	C0026882	Mutation	genf	9.90
21602569	C1524003	Science of Etiology	cnce	7.00
21602569	C2327105	Surface of epithelial cell	celc	3.65
21602569	C1413365	CFTR gene	gngm	3.58
21602569	C0205111	Apical	spco	3.55
21602569	C1517945	Loss	qnco	3.54
21602569	C0439799	Channel	spco	3.42
21602569	C1706095	Channel Object	cnce	3.42
21602569	C0542341	Function	ftcn	3.42
21602569	C0700205	Function Axis	clas	3.42
21602569	C1705273	Mathematical Operator	inpr	3.42
21602569	C1704735	Regulator	cnce	3.42
21602569	C1704734	Regulator Device Component	mnob	3.42
21602569	C0182953	Regulators (device)	medd	3.42
21602569	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
21602569	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
21602569	C0014239	Endoplasmic Reticulum	celc	22.53
21602569	C0009738	Congo	geoa	16.08
21602569	C0026882	Mutation	genf	9.92
21602569	C1881707	Medical Device Material Degradation	phpr	5.18
21602569	C1413365	CFTR gene	gngm	3.68
21602569	C1705285	Mutation Abnormality	comd	3.61
21602569	C0333118	Retained	ftcn	3.56
21602569	C3811819	CFTR wt Allele	gngm	3.47
21602569	C0678227	Causing	ftcn	3.47
21602569	C0205164	Major	qlco	3.47
21602569	C0205082	Severe (severity modifier)	qlco	3.47
21602569	C0014239	Endoplasmic Reticulum	celc	22.68
21602569	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
21602569	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
21602569	C0055363	Chloride Channels	aapp	19.21
21602569	C0055363	Chloride Channels	bacs	19.21
21602569	C0015272	Exhibits as Topic	inpr	17.80
21602569	C0040363	Togo	geoa	17.80
21602569	C0041260	Tryptophanase	aapp	17.80
21602569	C0041260	Tryptophanase	enzy	17.80
21602569	C0035280	Retention (Psychology)	menp	16.25
21602569	C0031843	physiological aspects	phsf	13.01
21602569	C0038164	Staphylococcal Protein A	aapp	12.91
21602569	C0038164	Staphylococcal Protein A	imft	12.91
21602569	C0038164	Staphylococcal Protein A	irda	12.91
21602569	C0032105	Plasma	bdsu	12.89
21602569	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	12.88
21602569	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	12.88
21602569	C0007603	Plasma membrane	celc	9.77
21602569	C0851285	Regulation	gora	9.73
21602569	C1550043	Container status - Identified	fndg	5.18
21602569	C0870509	Escape (mental process)	menp	5.18
21602569	C1880554	Escape Medical Device Problem	evnt	5.18
21602569	C0205396	Identified	qlco	5.18
21602569	C1883351	To	qlco	5.18
21602569	C1524063	Use of	ftcn	5.18
21602569	C0683607	allowing	socb	5.18
21602569	C0599896	trafficking	celf	5.18
21602569	C0333117	Retention of content	ftcn	3.63
21602569	C1753315	cellular entity retention	celf	3.63
21602569	C1513112	Membrane Protein Traffic	moft	3.60
21602569	C1705053	Screen Device Component	mnob	3.59
21602569	C1305399	Screening - procedure intent	ftcn	3.59
21602569	C0220908	Screening procedure	hlca	3.59
21602569	C1264633	Fraction of	qnco	3.59
21602569	C0205198	Compound	qlco	3.57
21602569	C1706082	Compound (substance)	chem	3.57
21602569	C1457869	Defect	ftcn	3.57
21602569	C3840880	Traffic	fndg	3.56
21602569	C0542341	Function	ftcn	3.54
21602569	C0700205	Function Axis	clas	3.54
21602569	C1705273	Mathematical Operator	inpr	3.54
21602569	C1328819	Small Molecule	orch	3.49
21602569	C1299351	Abnormally high	qlco	3.48
21602569	C0205250	High	qlco	3.48
21602569	C3889660	High Mitosis-Karyorrhexis Index	qnco	3.48
21602569	C2700149	Value Above Reference Range	inpr	3.48
21602569	C3887512	high - ActExposureLevelCode	idcn	3.48
21602569	C1413365	CFTR gene	gngm	3.44
21602569	C1550098	Plasma, NOS (not otherwise specified)	bdsu	3.43
21602569	C0596988	mutant	comd	3.43
21602569	C0728938	Partial	qnco	3.42
21602569	C1550516	Target Awareness - partial	idcn	3.42
21602569	C0033625	Protein Conformation	spco	16.05
21602569	C1564139	Mutant Proteins	aapp	9.92
21602569	C0220781	Anabolism	biof	6.58
21602569	C1167622	Binding (Molecular Function)	moft	5.18
21602569	C1145667	Binding action	acty	5.18
21602569	C1512571	Hypothesis	idcn	5.18
21602569	C0871157	Prompting	ftcn	5.18
21602569	C1947931	Direct (qualifier)	qlco	3.56
21602569	C1515021	Subgroup	clas	3.55
21602569	C1457869	Defect	ftcn	3.54
21602569	C1561611	Admission Level of Care Code - Improved	inpr	3.42
21602569	C0332272	Better	qlco	3.42
21602569	C3810841	Biosynthetic	fndg	3.42
21602569	C0184511	Improved	qlco	3.42
21602569	C0205263	Induce (action)	ftcn	3.42
21602569	C0205198	Compound	qlco	3.41
21602569	C1706082	Compound (substance)	chem	3.41
21602569	C0026377	Molecular Conformation	spco	13.01
21602569	C0597304	Proteolysis	moft	12.94
21602569	C0220825	Evaluation	hlca	12.87
21602569	C1564139	Mutant Proteins	aapp	9.74
21602569	C0557651	Room of building - Study	mnob	5.18
21602569	C0947630	Scientific Study	lbpr	5.18
21602569	C2603343	Study	resa	5.18
21602569	C0392366	Tests (qualifier value)	inpr	5.18
21602569	C0868946	digest	phsf	3.63
21602569	C0686907	Consequence of	ftcn	3.57
21602569	C1512571	Hypothesis	idcn	3.56
21602569	C0449255	Context	fndg	3.54
21602569	C0542559	contextual factors	ftcn	3.54
21602569	C0439801	Limited (extensiveness)	ftcn	3.48
21602569	C4050251	Limited Lifting Ability	inpr	3.48
21602569	C2674459	Limited Walking Ability	fndg	3.48
21602569	C3542948	Limited component (foundation metadata concept)	inpr	3.48
21602569	C1947941	Proteolytic Enzyme	enzy	3.48
21602569	C1148916	nucleotide binding	moft	3.44
21602569	C1947931	Direct (qualifier)	qlco	3.43
21602569	C0205198	Compound	qlco	3.43
21602569	C1706082	Compound (substance)	chem	3.43
21602569	C3541951	Concept model domain	inpr	3.42
21602569	C1880389	Domain (area of knowledge)	ftcn	3.42
21602569	C1883221	Superkingdom (taxonomic category)	cnce	3.42
21602569	C0443225	Full	qlco	3.42
21602569	C1444754	Length	qnco	3.42
21602569	C1706316	Length of Trial	resa	3.42
21602569	C1869391	CFcor-325	orch	5.18
21602569	C0150312	Present	qnco	5.18
21602569	C2698977	Capability	qlco	3.56
21602569	C1333134	Compact Pattern	fndg	3.52
21602569	C0026377	Molecular Conformation	spco	12.87
21602569	C1869391	CFcor-325	orch	5.18
21602569	C1280500	Effect	qlco	3.54
21602569	C2348382	Effect, Appearance	qlco	3.54
21602569	C3843057	Second half	fndg	3.42
21602569	C3830527	Detectable	clna	3.42
21602569	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.56
21602569	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.56
21602569	C0038976	Svalbard	geoa	17.80
21602569	C0030946	Endopeptidases	aapp	16.05
21602569	C0030946	Endopeptidases	enzy	16.05
21602569	C0030946	Endopeptidases	phsu	16.05
21602569	C0004793	Base Sequence	nusq	16.04
21602569	C0162326	DNA Sequence	nusq	16.04
21602569	C0162327	RNA Sequence	nusq	16.04
21602569	C1962945	Radiographic imaging procedure	diap	14.64
21602569	C0684010	Rabbi	prog	13.14
21602569	C0012655	Disease susceptibility	clna	13.02
21602569	C0003765	Arginine	aapp	12.89
21602569	C0003765	Arginine	bacs	12.89
21602569	C0003765	Arginine	phsu	12.89
21602569	C0033684	Proteins	aapp	6.79
21602569	C0033684	Proteins	bacs	6.79
21602569	C1707455	Comparison	acty	5.18
21602569	C1707968	Extended Release Dosage Form	bodm	5.18
21602569	C2603358	R prime	clna	3.68
21602569	C0205090	Right	spco	3.68
21602569	C1413365	CFTR gene	gngm	3.63
21602569	C1547045	*Susceptibility	qnco	3.56
21602569	C0220898	Predisposition	orga	3.56
21602569	C1264642	Susceptibility (property) (qualifier value)	ftcn	3.56
21602569	C0547070	Ablation	topp	3.55
21602569	C1261381	Destructive procedure (surgical)	topp	3.55
21602569	C0443225	Full	qlco	3.48
21602569	C1444754	Length	qnco	3.48
21602569	C1706316	Length of Trial	resa	3.48
21602569	C0392747	Changing	ftcn	3.43
21602569	C3889737	Data Change Date	tmco	3.43
21602569	C1947941	Proteolytic Enzyme	enzy	3.43
21602569	C0523503	Arginine measurement	lbpr	3.43
21602569	C3541881	Device Identifiers Domain	idcn	3.43
21602569	C3538902	SLC4A1 wt Allele	gngm	3.43
21602569	C1519249	Sequence	ftcn	3.43
21602569	C3853789	Sequence - TransmissionRelationshipTypeCode	inpr	3.43
21602569	C1273869	Intervention regimes	hlca	5.18
21602569	C0886296	Nursing interventions	hlca	5.18
21602569	C1948041	Surgical and medical procedures	topp	5.18
21602569	C1947976	Correction (change)	ftcn	3.54
21602569	C1705565	Correction Report	inpr	3.54
21602569	C1457869	Defect	ftcn	3.54
21602569	C1708698	Light Emitting Diode Device Component	mnob	3.54
21602569	C0728938	Partial	qnco	3.54
21602569	C1709694	Processing (action)	acty	3.54
21602569	C1550516	Target Awareness - partial	idcn	3.54
21602569	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
21602569	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
21602569	C3542921	CDISC Interventions Class	clas	5.18
21602569	C1273869	Intervention regimes	hlca	5.18
21602569	C2979881	Interventions:Finding:Point in time:^Patient:Narrative	clna	5.18
21602569	C0886296	Nursing interventions	hlca	5.18
21602569	C1883559	Wild Type	gngm	3.75
21602569	C1883357	Together	qlco	3.68
21602569	C1413365	CFTR gene	gngm	3.57
21602569	C1709694	Processing (action)	acty	3.57
21602569	C0475806	1/3 meter (distance vision finding)	fndg	3.48
21602569	C1706276	Near	qlco	3.48
21602569	C0026377	Molecular Conformation	spco	12.89
21602569	C1457869	Defect	ftcn	7.00
21602569	C1879547	Activation action	acty	3.54
21602569	C3542921	CDISC Interventions Class	clas	3.42
21602569	C0439799	Channel	spco	3.42
21602569	C1706095	Channel Object	cnce	3.42
21602569	C0205195	Combined	qlco	3.42
21602569	C1273869	Intervention regimes	hlca	3.42
21602569	C2979881	Interventions:Finding:Point in time:^Patient:Narrative	clna	3.42
21602569	C0886296	Nursing interventions	hlca	3.42
21602569	C2741958	VX-770	orch	5.18
21602569	C1879547	Activation action	acty	3.61
21602569	C1883712	Add - instruction imperative	ftcn	3.55
21602569	C0205202	Corrected	qlco	3.55
21602569	C0332287	In addition to	ftcn	3.55
21602569	C0439799	Channel	spco	3.47
21602569	C1706095	Channel Object	cnce	3.47
21602569	C1457869	Defect	ftcn	3.47
27417354	C0040363	Togo	geoa	17.80
27417354	C0041260	Tryptophanase	aapp	17.80
27417354	C0041260	Tryptophanase	enzy	17.80
27417354	C0023260	Legislation, Pharmacy	rnlw	13.14
27417354	C0008059	Child	aggp	11.49
27417354	C0030755	Pediatrics	bmod	9.77
27417354	C0031336	Pharmacy (field)	bmod	6.72
27417354	C0680063	Offspring	famg	5.18
27417354	C1883351	To	qlco	5.18
27417354	C0814225	benefit	qnco	5.18
27417354	C0205172	More	ftcn	3.57
27417354	C1135440	Procedures involving the use of pharmaceuticals	topp	3.57
27417354	C1280477	Progress	ftcn	3.57
27417354	C1272688	status - In progress	ftcn	3.57
27417354	C1535514	European race	popg	3.47
27417354	C1521725	Pediatric	qlco	3.47
27417354	C0239307	ethnic european	popg	3.47
27417354	C0678236	Rare Diseases	dsyn	14.64
27417354	C0242481	Research Activities	resa	11.49
27417354	C0023252	Statutes and Laws	rnlw	11.49
27417354	C0035168	research	resa	11.49
27417354	C0600657	Legislation (documents)	inpr	8.34
27417354	C2699424	Concern	idcn	5.18
27417354	C1883709	Damage	ftcn	5.18
27417354	C0442818	Raised	qlco	5.18
27417354	C0010957	Tissue damage	inpo	5.18
27417354	C0872152	drug development	bmod	3.75
27417354	C0026882	Mutation	genf	20.39
27417354	C0010674	Cystic Fibrosis	dsyn	19.64
27417354	C2930764	ataluren	orch	14.64
27417354	C2930764	ataluren	phsu	14.64
27417354	C3852684	lumacaftor	orch	13.05
27417354	C3852684	lumacaftor	phsu	13.05
27417354	C0035820	Social Role	socb	13.01
27417354	C3264621	ivacaftor	orch	12.88
27417354	C3264621	ivacaftor	phsu	12.88
27417354	C0030755	Pediatrics	bmod	9.73
27417354	C0013227	Pharmaceutical Preparations	phsu	7.03
27417354	C2584313	Discussion (communication)	socb	5.18
27417354	C0205454	Eight	qnco	5.18
27417354	C0205087	Late	tmco	5.18
27417354	C1705285	Mutation Abnormality	comd	3.68
27417354	C2598133	Medications:-:Point in time:^Patient:-	clna	3.59
27417354	C0802604	Medications:Presence or Identity:Duration of the study:^Patient:Nominal	clna	3.59
27417354	C1550329	Patient Class	clas	3.56
27417354	C1705810	Generic Role	cnce	3.55
27417354	C3871154	{Role}	inpr	3.55
27417354	C2699414	Committee	grup	3.54
27417354	C1881704	Medical Device Break	phpr	3.45
27417354	C0205448	Two	qnco	3.45
27417354	C3245505	potential	qlco	3.45
27417354	C0237463	Agencies	orgt	3.42
27417354	C1535514	European race	popg	3.42
27417354	C0205435	First (number)	qnco	3.42
27417354	C1279901	Firstly	qlco	3.42
27417354	C0239307	ethnic european	popg	3.42
27417354	C0678723	Biologic Development	orgf	3.42
27417354	C1527148	Development	ftcn	3.42
27417354	C1521725	Pediatric	qlco	3.42
27417354	C0243107	development aspects	phsf	3.42
27417354	C0041703	United States	geoa	14.64
27417354	C3264621	ivacaftor	orch	13.14
27417354	C3264621	ivacaftor	phsu	13.14
27417354	C0015179	European Union	orgt	12.90
27417354	C0205540	Approved	qlco	5.18
27417354	C4082120	Six months	tmco	5.18
27417354	C1279919	Early	tmco	3.68
27417354	C0205087	Late	tmco	3.57
27417354	C3665627	Ehrlich units per deciliter (qualifier value)	qnco	3.44
27417354	C0993637	Published Database	inpr	6.73
27417354	C2697663	Image Registration	mcha	3.68
27417354	C1514821	Registration	hlca	3.68
27417354	C1553384	registration - ActClass	inpr	3.68
27417354	C0242356	Databases	inpr	3.58
27417354	C0445247	Same	qlco	3.56
27417354	C0030755	Pediatrics	bmod	19.61
27417354	C0282111	Internet	mnob	16.21
27417354	C0009738	Congo	geoa	16.04
27417354	C0270724	Infantile Neuroaxonal Dystrophy	dsyn	13.03
27417354	C0015179	European Union	orgt	12.92
27417354	C0013175	Drug Evaluation	resa	9.82
27417354	C1418587	PIP gene	gngm	7.18
27417354	C0279391	mercaptopurine/methotrexate/vincristine	topp	7.18
27417354	C1521725	Pediatric	qlco	6.92
27417354	C0936012	Analysis	resa	5.18
27417354	C1707455	Comparison	acty	5.18
27417354	C1301732	Planned	ftcn	3.57
27417354	C0599880	Treatment Plan	inpr	3.57
27417354	C0745732	List	cnce	3.55
27417354	C3272378	Sequence Data Type	inpr	3.55
27417354	C3665627	Ehrlich units per deciliter (qualifier value)	qnco	3.46
27417354	C3811819	CFTR wt Allele	gngm	3.42
27417354	C0947630	Scientific Study	lbpr	3.42
27417354	C1419208	RAB3D gene	gngm	3.68
27417354	C0040363	Togo	geoa	17.80
27417354	C0041260	Tryptophanase	aapp	17.80
27417354	C0041260	Tryptophanase	enzy	17.80
27417354	C3264621	ivacaftor	orch	12.94
27417354	C3264621	ivacaftor	phsu	12.94
27417354	C0700364	Appearance	qlco	5.18
27417354	C1518422	Negation	ftcn	5.18
27417354	C0558058	Reflecting	menp	5.18
27417354	C1272689	Started	qlco	5.18
27417354	C1883351	To	qlco	5.18
27417354	C0947630	Scientific Study	lbpr	3.63
27417354	C2363670	developers	medd	3.63
27417354	C0557651	Room of building - Study	mnob	3.54
27417354	C2603343	Study	resa	3.54
27417354	C1418587	PIP gene	gngm	3.48
27417354	C1301732	Planned	ftcn	3.48
27417354	C0279391	mercaptopurine/methotrexate/vincristine	topp	3.48
27417354	C0450348	23	qnco	3.42
27417354	C0332177	Monthly (qualifier value)	tmco	3.42
27417354	C0439231	month	tmco	3.42
27417354	C0439507	per month (qualifier value)	tmco	3.42
27417354	C0580836	Old	tmco	3.40
27417354	C0680727	Mediation	socb	16.04
27417354	C0040223	Time	tmco	6.70
27417354	C0332232	Approximate	qlco	3.68
27417354	C3541383	Time (foundation metadata concept)	tmco	3.54
27417354	C0439175	% of total	qnco	3.42
27417354	C0521116	Current (present time)	tmco	3.42
27417354	C1705970	Electrical Current	npop	3.42
27417354	C1418587	PIP gene	gngm	3.42
27417354	C0439810	Total	qlco	3.42
27417354	C0333052	Version	ftcn	3.42
27417354	C2607870	Version (morphologic abnormality)	spco	3.42
27417354	C0279391	mercaptopurine/methotrexate/vincristine	topp	3.42
27417354	C0439234	year	tmco	3.63
27417354	C0030755	Pediatrics	bmod	9.93
27417354	C0012634	Disease	dsyn	9.75
27417354	C0683757	Company (organization)	mnob	5.18
27417354	C0683757	Company (organization)	orgt	5.18
27417354	C3687832	DRUGS	topp	3.57
27417354	C0013227	Pharmaceutical Preparations	phsu	3.57
27417354	C0679381	Pediatric Disorder	dsyn	3.48
27417354	C1532633	Kilounit per Kilogram	qnco	5.18
27417354	C2608091	Unit/gram	qnco	5.18
27417354	C0009738	Congo	geoa	17.80
27417354	C0085122	Workload	qnco	13.01
27417354	C0030705	Patients	podg	6.58
27417354	C3811819	CFTR wt Allele	gngm	5.18
27417354	C1882932	Representation (action)	acty	5.18
27417354	C1418587	PIP gene	gngm	3.98
27417354	C0279391	mercaptopurine/methotrexate/vincristine	topp	3.98
27417354	C1548633	Referral reason - Work Load	idcn	3.55
27417354	C0814225	benefit	qnco	3.55
27417354	C0940824	Additional procedure	hlca	3.43
27417354	C1524062	Additional	ftcn	3.43
27417354	C2945599	Mild (qualifier value)	qlco	3.43
27417354	C0547040	Minimal	qlco	3.43
27417354	C1524031	Minimum	qlco	3.43
27417354	C0036043	Safety	hcpp	16.05
27417354	C1518422	Negation	ftcn	5.18
27417354	C0680826	bureaucracy	idcn	3.68
27417354	C1718097	New medications	phsu	3.59
27417354	C0456962	Rapid	qlco	3.59
27417354	C1514821	Registration	hlca	3.59
27417354	C1524062	Additional	ftcn	3.57
27417354	C0332149	Possible	qlco	3.56
27417354	C2362652	Possible diagnosis	qlco	3.56
27417354	C1705910	Possibly Related to Intervention	qlco	3.56
27417354	C0181113	Hamper	mnob	3.54
27417354	C0679381	Pediatric Disorder	dsyn	3.45
27417354	C1705187	Safety Study	resa	3.43
27417354	C2945640	compromise	fndg	3.41
23922647	C0384156	epithelial sodium channel	aapp	24.11
23922647	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.55
23922647	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.55
23922647	C0028429	Nose	bpoc	13.08
23922647	C0005516	Biological Markers	clna	6.69
23922647	C1561536	*Activity (kind of quantity)	idcn	5.18
23922647	C0205177	Active	ftcn	5.18
23922647	C0441655	Activities	acty	5.18
23922647	C3668946	Activity (animal life circumstance)	fndg	5.18
23922647	C4049939	FDA Establishment Activity Terminology	inpr	5.18
23922647	C0439167	Percent Activity	qnco	5.18
23922647	C4049938	Physical Activity Measurement	lbpr	5.18
23922647	C3540429	epithelial sodium channel activity	moft	5.18
23922647	C1413365	CFTR gene	gngm	3.62
23922647	C1705241	Delta (difference)	qnco	3.61
23922647	C1705242	Different	qlco	3.61
23922647	C3245505	potential	qlco	3.61
23922647	C1273517	Used by	fndg	3.54
23922647	C0282460	Phase 2 Clinical Trials	resa	22.49
23922647	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.46
23922647	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.46
23922647	C0040363	Togo	geoa	17.80
23922647	C0041260	Tryptophanase	aapp	17.80
23922647	C0041260	Tryptophanase	enzy	17.80
23922647	C0008203	Chlorides	inch	16.07
23922647	C0220825	Evaluation	hlca	14.64
23922647	C0027627	Neoplasm Metastasis	neop	13.00
23922647	C1524024	analysis aspect	ftcn	13.00
23922647	C0068515	neodymium pyrocatechin disulfonate	orch	12.90
23922647	C0025664	Methods aspects	inpr	11.49
23922647	C0025663	Methods	inpr	8.34
23922647	C0442726	Detected (finding)	fndg	5.18
23922647	C3891454	Dosing Days to Detection	tmco	5.18
23922647	C0449851	Techniques	ftcn	5.18
23922647	C1883351	To	qlco	5.18
23922647	C1159690	sodium ion transport	celf	3.64
23922647	C0443172	Changed status	qnco	3.59
23922647	C0392747	Changing	ftcn	3.59
23922647	C0936012	Analysis	resa	3.54
23922647	C0002778	Analysis of substances	lbpr	3.54
23922647	C1705938	Base - General Qualifier	idcn	3.54
23922647	C1527178	Basis - conceptual entity	ftcn	3.54
23922647	C1413365	CFTR gene	gngm	3.54
23922647	C1709060	Modulator Device Component	mnob	3.54
23922647	C0175668	Secondary to	tmco	3.54
23922647	C0205436	second (number)	qnco	3.54
23922647	C0596019	Chloride Ion	elii	3.45
23922647	C3539725	SMPD1 wt Allele	gngm	3.44
23922647	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
23922647	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
23922647	C0034656	Randomization	resa	17.80
23922647	C0040363	Togo	geoa	17.80
23922647	C0041260	Tryptophanase	aapp	17.80
23922647	C0041260	Tryptophanase	enzy	17.80
23922647	C0009738	Congo	geoa	16.04
23922647	C3264621	ivacaftor	orch	14.64
23922647	C3264621	ivacaftor	phsu	14.64
23922647	C0026882	Mutation	genf	9.94
23922647	C0032042	Placebos	topp	6.70
23922647	C1514756	Receive	qlco	5.18
23922647	C3815594	Subject is Randomized	fndg	5.18
23922647	C1883351	To	qlco	5.18
23922647	C0178602	Dosage	qnco	3.68
23922647	C2741958	VX-770	orch	3.64
23922647	C1705285	Mutation Abnormality	comd	3.63
23922647	C0205309	Known	qlco	3.57
23922647	C1706408	Placebo Control	resa	3.54
23922647	C1696465	placebo	bodm	3.54
23922647	C2349001	Human Study Subject	humn	3.52
23922647	C2697811	Investigative Subject	ftcn	3.52
23922647	C0681850	Study Subject	grup	3.52
23922647	C1706203	Subject - topic	idcn	3.52
23922647	C1550501	Subject -direct target	idcn	3.52
23922647	C0205450	Four	qnco	3.50
23922647	C3264627	Kalydeco	phsu	3.50
23922647	C1413365	CFTR gene	gngm	3.48
23922647	C3845350	At least daily	fndg	3.45
23922647	C3816447	Thirty Nine	qnco	3.45
23922647	C3811819	CFTR wt Allele	gngm	3.43
23922647	C0585361	Twice a day	tmco	3.43
23922647	C0087136	Unmarried	fndg	22.48
23922647	C0037179	Unmarried person	popg	22.48
23922647	C0035173	Research Personnel	prog	9.87
23922647	C1511726	Data	idcn	5.18
23922647	C3714741	Data (eukaryote)	euka	5.18
23922647	C3245479	Data call receiving device	medd	5.18
23922647	C3640651	Blinded Treatment Epoch	resa	3.62
23922647	C1516050	Assignment - action	ftcn	3.57
23922647	C0936012	Analysis	resa	3.56
23922647	C0205171	Singular	qnco	3.56
23922647	C0040363	Togo	geoa	35.81
23922647	C0041260	Tryptophanase	aapp	35.81
23922647	C0041260	Tryptophanase	enzy	35.81
23922647	C0008203	Chlorides	inch	16.07
23922647	C0206243	Carrying	acty	14.64
23922647	C0595944	Anterior nares	bsoj	10.68
23922647	C1883351	To	qlco	10.42
23922647	C0205393	Most	qnco	6.89
23922647	C0740116	+2	qnco	5.18
23922647	C3816745	1+	fndg	5.18
23922647	C2827734	1+ Score	qnco	5.18
23922647	C2981698	1+ Score, WHO	clas	5.18
23922647	C3833492	2+	fndg	5.18
23922647	C2827735	2+ Score	qnco	5.18
23922647	C2981700	2+ Score, WHO	clas	5.18
23922647	C3838680	3+ Answer to Question	fndg	5.18
23922647	C2827736	3+ Score	qnco	5.18
23922647	C2981702	3+ Score, WHO	clas	5.18
23922647	C0439086	<3 (qualifier value)	qnco	5.18
23922647	C0449445	Approach	spco	5.18
23922647	C1707455	Comparison	acty	5.18
23922647	C0699809	Does carry	fndg	5.18
23922647	C0439780	Forward	spco	5.18
23922647	C1709793	Quantitation	qnco	5.18
23922647	C1522427	best (quality)	qlco	5.18
23922647	C1159690	sodium ion transport	celf	5.18
23922647	C3900047	Analysis Method	resa	3.72
23922647	C0443172	Changed status	qnco	3.59
23922647	C0392747	Changing	ftcn	3.59
23922647	C1510992	Average	qnco	3.56
23922647	C2825518	Average of Value Derivation Technique	qnco	3.56
23922647	C0205449	Three	qnco	3.48
23922647	C0596019	Chloride Ion	elii	3.45
23922647	C0220909	Aspects of disease screening	ftcn	3.43
23922647	C1710031	Disease Screening	diap	3.43
23922647	C0220908	Screening procedure	hlca	3.43
23922647	C1710477	Trial Screening	resa	3.43
23922647	C1698960	research subject screening	inpr	3.43
23922647	C1512346	Patient Visit	hlca	3.42
23922647	C0545082	Visit	bhvr	3.42
23922647	C2826704	Visit Name	inpr	3.42
23922647	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.27
23922647	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.27
23922647	C0008203	Chlorides	inch	16.04
23922647	C0022245	Isoproterenol	orch	16.04
23922647	C0022245	Isoproterenol	phsu	16.04
23922647	C0002502	Amiloride	orch	14.64
23922647	C0002502	Amiloride	phsu	14.64
23922647	C0068515	neodymium pyrocatechin disulfonate	orch	13.14
23922647	C0162585	Ion Transport	celf	12.92
23922647	C1705241	Delta (difference)	qnco	10.79
23922647	C1561536	*Activity (kind of quantity)	idcn	7.40
23922647	C0205177	Active	ftcn	7.40
23922647	C0441655	Activities	acty	7.40
23922647	C3668946	Activity (animal life circumstance)	fndg	7.40
23922647	C4049939	FDA Establishment Activity Terminology	inpr	7.40
23922647	C0439167	Percent Activity	qnco	7.40
23922647	C4049938	Physical Activity Measurement	lbpr	7.40
23922647	C1413365	CFTR gene	gngm	7.19
23922647	C0443172	Changed status	qnco	7.17
23922647	C0392747	Changing	ftcn	7.17
23922647	C0332257	Including (qualifier)	ftcn	5.18
23922647	C3539725	SMPD1 wt Allele	gngm	3.68
23922647	C0449381	Observation parameter	fndg	3.56
23922647	C0242485	Measurement	ftcn	3.55
23922647	C3538806	Axial R	spco	3.50
23922647	C0205112	Basal	spco	3.50
23922647	C0439097	Delta - greek letter	inpr	3.50
23922647	C3146239	Delta <Insecta>	euka	3.50
23922647	C3815527	Delta-Like Protein 1, human	aapp	3.50
23922647	C0444706	Measured	qlco	3.50
23922647	C0449770	Measured from	qnco	3.50
23922647	C1875730	RINGER'S	orch	3.50
23922647	C1875730	RINGER'S	phsu	3.50
23922647	C3540585	YY1 wt Allele	gngm	3.50
23922647	C0919414	Arabic numeral 0	qnco	3.42
23922647	C0596019	Chloride Ion	elii	3.42
23922647	C0332287	In addition to	ftcn	3.42
23922647	C0008203	Chlorides	inch	17.80
23922647	C0206243	Carrying	acty	14.64
23922647	C0205393	Most	qnco	10.45
23922647	C0595944	Anterior nares	bsoj	7.14
23922647	C1510992	Average	qnco	5.18
23922647	C2825518	Average of Value Derivation Technique	qnco	5.18
23922647	C0596019	Chloride Ion	elii	5.18
23922647	C0699809	Does carry	fndg	5.18
23922647	C0439780	Forward	spco	5.18
23922647	C1159690	sodium ion transport	celf	5.18
23922647	C0332324	Sensitive	ftcn	3.64
23922647	C0439092	Less Than	qnco	3.50
23922647	C0547044	Smaller	qlco	3.50
23922647	C0443172	Changed status	qnco	3.44
23922647	C0392747	Changing	ftcn	3.44
23922647	C0220909	Aspects of disease screening	ftcn	3.43
23922647	C1710031	Disease Screening	diap	3.43
23922647	C1512346	Patient Visit	hlca	3.43
23922647	C0220908	Screening procedure	hlca	3.43
23922647	C1710477	Trial Screening	resa	3.43
23922647	C0545082	Visit	bhvr	3.43
23922647	C2826704	Visit Name	inpr	3.43
23922647	C1698960	research subject screening	inpr	3.43
23922647	C0068515	neodymium pyrocatechin disulfonate	orch	12.96
23922647	C0595944	Anterior nares	bsoj	5.18
23922647	C1516048	Assessed	acty	5.18
23922647	C0685682	Single naris	cgab	5.18
23922647	C0947630	Scientific Study	lbpr	3.68
23922647	C1705938	Base - General Qualifier	idcn	3.57
23922647	C1527178	Basis - conceptual entity	ftcn	3.57
23922647	C3539655	CDISC Findings Class	inpr	3.57
23922647	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	3.57
23922647	C2607943	findings aspects	ftcn	3.57
23922647	C3539725	SMPD1 wt Allele	gngm	3.50
23922647	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
23922647	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
23922647	C0026837	Muscle Rigidity	sosy	19.22
23922647	C0038136	Standardization	resa	9.99
23922647	C0443172	Changed status	qnco	7.17
23922647	C0392747	Changing	ftcn	7.17
23922647	C1561536	*Activity (kind of quantity)	idcn	7.02
23922647	C0205177	Active	ftcn	7.02
23922647	C0441655	Activities	acty	7.02
23922647	C3668946	Activity (animal life circumstance)	fndg	7.02
23922647	C4049939	FDA Establishment Activity Terminology	inpr	7.02
23922647	C0439167	Percent Activity	qnco	7.02
23922647	C4049938	Physical Activity Measurement	lbpr	7.02
23922647	C0032042	Placebos	topp	6.58
23922647	C0205172	More	ftcn	5.18
23922647	C0150312	Present	qnco	5.18
23922647	C0332281	Associated with	qlco	3.64
23922647	C0442726	Detected (finding)	fndg	3.64
23922647	C1511790	Detection	topp	3.64
23922647	C1705241	Delta (difference)	qnco	3.57
23922647	C0205170	Good	qlco	3.57
23922647	C1514863	Reproducibility	qlco	3.55
23922647	C0424790	Rigor - Temperature-associated observation	sosy	3.45
23922647	C1413365	CFTR gene	gngm	3.43
23922647	C2349001	Human Study Subject	humn	3.42
23922647	C2697811	Investigative Subject	ftcn	3.42
23922647	C1706408	Placebo Control	resa	3.42
23922647	C0681850	Study Subject	grup	3.42
23922647	C1706203	Subject - topic	idcn	3.42
23922647	C1550501	Subject -direct target	idcn	3.42
23922647	C1522326	Treating	ftcn	3.42
23922647	C1696465	placebo	bodm	3.42
23922647	C0428679	Minute volume	fndg	3.63
23922647	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
23922647	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
23922647	C0005507	Biological Assay	lbpr	6.71
23922647	C0750484	Confirmation	idcn	5.18
23922647	C0521093	Confirmed by	qlco	5.18
23922647	C0443264	Modulated	spco	3.68
23922647	C1510438	Assay	lbpr	3.56
23922647	C0243073	assay qualifier	qlco	3.56
23922647	C2986411	Improvement	cnce	3.52
23922647	C1413365	CFTR gene	gngm	3.50
23922647	C1159591	chloride transport	celf	3.44
23922647	C1514863	Reproducibility	qlco	3.43
23922647	C1704632	Disease Response	fndg	3.42
23922647	C2911692	Response (communication)	menp	3.42
23922647	C1706817	Response (statement)	inpr	3.42
23922647	C0871261	Response process	orga	3.42
23922647	C0442726	Detected (finding)	fndg	3.40
23922647	C3891454	Dosing Days to Detection	tmco	3.40
27662106	C0027552	Needs	qlco	14.64
27662106	C0004268	Attention	menp	13.09
27662106	C3852684	lumacaftor	orch	12.96
27662106	C3852684	lumacaftor	phsu	12.96
27662106	C0013162	Drug Combinations	phsu	6.75
27662106	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
27662106	C0360363	Azole antifungal	orch	4.12
27662106	C0360363	Azole antifungal	phsu	4.12
27662106	C1709060	Modulator Device Component	mnob	3.63
27662106	C1413365	CFTR gene	gngm	3.50
27662106	C0278329	prescribed	hlca	3.50
27662106	C0085971	Case management (procedure)	hlca	16.07
27662106	C0009738	Congo	geoa	16.04
27662106	C0031323	Pharmacist	prog	14.64
27662106	C1999230	Providing (action)	acty	5.18
27662106	C3511493	Interaction complexity	topp	3.56
27662106	C0392360	Indication of (contextual qualifier)	idcn	3.55
27662106	C2699007	Rationale	idcn	3.55
27662106	C0260120	Pharmacologist	prog	3.54
27662106	C1292711	Part of	spco	3.44
27662106	C0442821	Strong	qlco	3.43
27662106	C3811819	CFTR wt Allele	gngm	3.42
27662106	C0205547	Routine	qlco	3.42
27662106	C1947933	care activity	acty	3.42
27662106	C0031082	Periodicals	inpr	6.76
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.51
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.51
23835419	C0018790	Cardiac Arrest	dsyn	10.18
23835419	C0026882	Mutation	genf	9.94
23835419	C0015127	Etiology aspects	ftcn	9.86
23835419	C0010674	Cystic Fibrosis	dsyn	9.76
23835419	C0185026	Plication	topp	5.18
23835419	C1706084	(City) Block	geoa	3.87
23835419	C0237477	Arrested progression	tmco	3.87
23835419	C2828370	Block (unit of measure)	qnco	3.87
23835419	C1533157	Block Specimens	sbst	3.87
23835419	C3811660	Block Unit of Distance	qnco	3.87
23835419	C0332206	Blocking	ftcn	3.87
23835419	C0392351	Law enforcement arrest	gora	3.87
23835419	C0233660	Mental blocking	mobd	3.87
23835419	C0028778	Obstruction	patf	3.87
23835419	C0521111	Retarded	qlco	3.87
23835419	C1413365	CFTR gene	gngm	3.59
23835419	C0599896	trafficking	celf	3.59
23835419	C1524003	Science of Etiology	cnce	3.55
23835419	C1709694	Processing (action)	acty	3.48
23835419	C1542147	Main	qlco	3.43
23835419	C0205225	Primary	qlco	3.43
23835419	C0039798	therapeutic aspects	ftcn	22.56
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
23835419	C0040363	Togo	geoa	17.80
23835419	C0041260	Tryptophanase	aapp	17.80
23835419	C0041260	Tryptophanase	enzy	17.80
23835419	C0009738	Congo	geoa	16.09
23835419	C0043240	Wound Healing	orgf	14.64
23835419	C0374711	Surgical repair	topp	5.18
23835419	C1883351	To	qlco	5.18
23835419	C0087111	Therapeutic procedure	topp	3.63
23835419	C1363945	Therapy Object (animal model)	fndg	3.63
23835419	C0596988	mutant	comd	3.63
23835419	C1413365	CFTR gene	gngm	3.48
23835419	C3811819	CFTR wt Allele	gngm	3.48
23835419	C1709694	Processing (action)	acty	3.48
23835419	C3245505	potential	qlco	3.48
23835419	C0242643	P-Glycoprotein	aapp	28.68
23835419	C0242643	P-Glycoprotein	bacs	28.68
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.71
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.71
23835419	C0337514	Sister	famg	19.25
23835419	C3661486	Drug Rescue	resa	9.90
23835419	C0441712	Mechanism (attribute)	ftcn	3.55
23835419	C1706376	Mechanism Component of Device	mnob	3.55
23835419	C0205340	Repaired	ftcn	3.55
23835419	C0596988	mutant	comd	3.55
23835419	C1709694	Processing (action)	acty	3.43
23835419	C0018882	Helix (Snails)	euka	22.36
23835419	C0040363	Togo	geoa	17.80
23835419	C0041260	Tryptophanase	aapp	17.80
23835419	C0041260	Tryptophanase	enzy	17.80
23835419	C0003765	Arginine	aapp	12.96
23835419	C0003765	Arginine	bacs	12.96
23835419	C0003765	Arginine	phsu	12.96
23835419	C0020276	Hydrogen Bonding	npop	12.91
23835419	C3661486	Drug Rescue	resa	11.49
23835419	C0033414	Promotion (action)	acty	5.18
23835419	C1292780	Therapy-related myelodysplastic syndrome	neop	5.18
23835419	C1883351	To	qlco	5.18
23835419	C2954564	Suppressor	phsu	3.63
23835419	C1710252	Suppressor Device Component	mnob	3.63
23835419	C0184967	Insertion of pack (procedure)	topp	3.56
23835419	C2828395	Packing (action)	acty	3.56
23835419	C1289829	Packing material	medd	3.56
23835419	C1550043	Container status - Identified	fndg	3.55
23835419	C0205396	Identified	qlco	3.55
23835419	C3811116	RNF130 wt Allele	gngm	3.55
23835419	C1519623	Transmembrane Domain	amas	3.54
23835419	C1709915	Residue	cnce	3.53
23835419	C1882936	Residue after Decontamination Medical Device Problem	evnt	3.53
23835419	C0523503	Arginine measurement	lbpr	3.50
23835419	C0205117	Adjacent	spco	3.43
23835419	C1017315	Helice	euka	3.43
23835419	C0229304	Helix of ear	bpoc	3.43
23835419	C1705682	Molecular helix	anst	3.43
23835419	C1704821	Protein Helix	spco	3.43
23835419	C2752508	fully spanning the plasma membrane	celc	3.43
23835419	C1167322	integral to membrane	celc	3.43
23835419	C1522492	Formation	ftcn	3.43
23835419	C0205431	Formed	ftcn	3.43
23835419	C0441635	Anatomical segmentation	spco	3.41
23835419	C0040363	Togo	geoa	35.81
23835419	C0041260	Tryptophanase	aapp	35.81
23835419	C0041260	Tryptophanase	enzy	35.81
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
23835419	C0022885	Laboratory Procedures	lbpr	10.42
23835419	C0456984	Test Result	fndg	10.42
23835419	C0039593	Testing	ftcn	10.42
23835419	C0392366	Tests (qualifier value)	inpr	10.42
23835419	C1883351	To	qlco	10.42
23835419	C3661486	Drug Rescue	resa	9.90
23835419	C0596988	mutant	comd	7.40
23835419	C1273517	Used by	fndg	5.18
23835419	C3252847	VX 809	orch	3.75
23835419	C3252847	VX 809	phsu	3.75
23835419	C1292780	Therapy-related myelodysplastic syndrome	neop	3.57
23835419	C0441712	Mechanism (attribute)	ftcn	3.55
23835419	C1706376	Mechanism Component of Device	mnob	3.55
23835419	C0205340	Repaired	ftcn	3.55
23835419	C1413365	CFTR gene	gngm	3.50
23835419	C1706395	Protein Truncation Abnormality	comd	3.50
23835419	C2348077	Date Fruit	food	25.67
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
23835419	C3252847	VX 809	orch	3.75
23835419	C3252847	VX 809	phsu	3.75
23835419	C0814225	benefit	qnco	3.63
23835419	C1707391	Choose (action)	acty	3.59
23835419	C1550043	Container status - Identified	fndg	3.59
23835419	C0011008	Date in time	tmco	3.59
23835419	C1552740	Entity Determiner - specific	inpr	3.59
23835419	C0205396	Identified	qlco	3.59
23835419	C0557651	Room of building - Study	mnob	3.59
23835419	C0205369	Specific qualifier value	qlco	3.59
23835419	C2603343	Study	resa	3.59
23835419	C0205210	Clinical	qlco	3.48
23835419	C1704419	Effective	qlco	3.48
23835419	C1280519	Effectiveness	qlco	3.48
23835419	C0439801	Limited (extensiveness)	ftcn	3.48
23835419	C4050251	Limited Lifting Ability	inpr	3.48
23835419	C2674459	Limited Walking Ability	fndg	3.48
23835419	C3542948	Limited component (foundation metadata concept)	inpr	3.48
23835419	C0205393	Most	qnco	3.48
23835419	C1553058	Neuropsychologist - Clinical	prog	3.48
23835419	C0237412	Psychologist - Clinical	prog	3.48
23835419	C0497591	Social Worker - Clinical	prog	3.48
23835419	C1413365	CFTR gene	gngm	3.45
23835419	C0040363	Togo	geoa	17.80
23835419	C0041260	Tryptophanase	aapp	17.80
23835419	C0041260	Tryptophanase	enzy	17.80
23835419	C0020792	Identification (Psychology)	menp	13.01
23835419	C1269765	Assisted (qualifier value)	qlco	5.18
23835419	C1552861	Help document	inpr	5.18
23835419	C1883351	To	qlco	5.18
23835419	C0205396	Identified	qlco	3.54
23835419	C3252847	VX 809	orch	3.44
23835419	C3252847	VX 809	phsu	3.44
23835419	C1561611	Admission Level of Care Code - Improved	inpr	3.43
23835419	C0332272	Better	qlco	3.43
23835419	C0205210	Clinical	qlco	3.43
23835419	C0184511	Improved	qlco	3.43
23835419	C1553058	Neuropsychologist - Clinical	prog	3.43
23835419	C0237412	Psychologist - Clinical	prog	3.43
23835419	C0497591	Social Worker - Clinical	prog	3.43
23835419	C0814225	benefit	qnco	3.43
23835419	C3541951	Concept model domain	inpr	3.42
23835419	C1880389	Domain (area of knowledge)	ftcn	3.42
23835419	C1883221	Superkingdom (taxonomic category)	cnce	3.42
23835419	C1521840	Target	ftcn	3.42
23835419	C2986546	Target Lesion Identification	diap	3.42
23835419	C0684010	Rabbi	prog	12.96
23835419	C0332268	Lacking	qlco	5.18
23835419	C0150312	Present	qnco	5.18
23835419	C3541951	Concept model domain	inpr	3.63
23835419	C1880389	Domain (area of knowledge)	ftcn	3.63
23835419	C1883221	Superkingdom (taxonomic category)	cnce	3.63
23835419	C0596988	mutant	comd	3.60
23835419	C2603358	R prime	clna	3.50
23835419	C0205090	Right	spco	3.50
23835419	C3252847	VX 809	orch	3.49
23835419	C3252847	VX 809	phsu	3.49
23835419	C1706395	Protein Truncation Abnormality	comd	3.46
23835419	C1305923	Polypeptides	aapp	6.72
23835419	C0442805	Increase	ftcn	5.18
23835419	C0205217	Increased	qnco	5.18
23835419	C1720467	Only - dosing instruction fragment	inpr	5.18
23835419	C0205171	Singular	qnco	5.18
23835419	C3252847	VX 809	orch	5.18
23835419	C3252847	VX 809	phsu	5.18
23835419	C3541951	Concept model domain	inpr	3.63
23835419	C1880389	Domain (area of knowledge)	ftcn	3.63
23835419	C1883221	Superkingdom (taxonomic category)	cnce	3.63
23835419	C2347098	Medical Product Stability	qlco	3.57
23835419	C0443299	Separate	qlco	3.57
23835419	C0205360	Stable status	qlco	3.57
23835419	C1527428	Remaining	qlco	3.50
23835419	C0003765	Arginine	aapp	12.89
23835419	C0003765	Arginine	bacs	12.89
23835419	C0003765	Arginine	phsu	12.89
23835419	C0079866	Mutagenesis Process	moft	9.86
23835419	C3146302	Mutagenesis Procedure	lbpr	3.55
23835419	C0523503	Arginine measurement	lbpr	3.42
23835419	C0884358	Performed	ftcn	3.42
23835419	C1883708	Then	tmco	3.42
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.31
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.31
23835419	C0003765	Arginine	aapp	14.64
23835419	C0003765	Arginine	bacs	14.64
23835419	C0003765	Arginine	phsu	14.64
23835419	C0015450	Face	blor	9.99
23835419	C1413365	CFTR gene	gngm	7.23
23835419	C0523503	Arginine measurement	lbpr	5.18
23835419	C2825142	Experimental Result	fndg	3.98
23835419	C0033414	Promotion (action)	acty	3.98
23835419	C1274040	Result	ftcn	3.98
23835419	C1547282	Show	anim	3.98
23835419	C1546471	What subject filter - Result	idcn	3.98
23835419	C0023779	Lipids	orch	3.68
23835419	C1511806	Developmental Process	ortf	3.58
23835419	C1705242	Different	qlco	3.57
23835419	C0599956	aqueous	qlco	3.50
23835419	C3811116	RNF130 wt Allele	gngm	3.44
23835419	C0596988	mutant	comd	3.43
23835419	C0005456	Binding Sites	rcpt	13.14
23835419	C3661486	Drug Rescue	resa	9.90
23835419	C2700400	Contain (action)	acty	5.18
23835419	C0332256	Containing (qualifier)	ftcn	5.18
23835419	C0441712	Mechanism (attribute)	ftcn	5.18
23835419	C1706376	Mechanism Component of Device	mnob	5.18
23835419	C1705535	suggestion	idcn	5.18
23835419	C2825142	Experimental Result	fndg	3.98
23835419	C1274040	Result	ftcn	3.98
23835419	C1546471	What subject filter - Result	idcn	3.98
23835419	C0682969	Ligand Binding Domain	amas	3.68
23835419	C3811116	RNF130 wt Allele	gngm	3.55
23835419	C3252847	VX 809	orch	3.50
23835419	C3252847	VX 809	phsu	3.50
23835419	C0079613	Adoptive Immunotherapy	topp	25.64
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
23835419	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
23835419	C0040363	Togo	geoa	17.80
23835419	C0041260	Tryptophanase	aapp	17.80
23835419	C0041260	Tryptophanase	enzy	17.80
23835419	C1869853	SERPINA3 protein, human	aapp	13.02
23835419	C1869853	SERPINA3 protein, human	bacs	13.02
23835419	C0175671	Universal	qlco	13.02
23835419	C0173021	Universal varnish	bodm	13.02
23835419	C0173021	Universal varnish	orch	13.02
23835419	C3273238	Regulatory Report	inpr	5.18
23835419	C0684224	Report (document)	inpr	5.18
23835419	C0700287	Reporting	hlca	5.18
23835419	C1883351	To	qlco	5.18
23835419	C0596988	mutant	comd	3.63
23835419	C4048375	Asthma Control Test Questionnaire	inpr	3.56
23835419	C3890007	SERPINA3 wt Allele	gngm	3.56
23835419	C2954564	Suppressor	phsu	3.56
23835419	C1710252	Suppressor Device Component	mnob	3.56
23835419	C1552870	Universal - VocabularyDomainQualifier	inpr	3.56
23835419	C1413365	CFTR gene	gngm	3.48
23835419	C1709694	Processing (action)	acty	3.48
28845852	C0020125	Human Genome Project	resa	20.95
28845852	C1721101	Biosynthetic Pathways	moft	14.64
28845852	C0023636	License	rnlw	13.44
28845852	C0039421	Technology	ocdi	8.34
28845852	C0018684	Health	idcn	6.83
28845852	C0016884	Future	tmco	6.74
28845852	C0024501	Maintenance	acty	6.71
28845852	C1999230	Providing (action)	acty	5.18
28845852	C0329040	Trachinotus falcatus	fish	3.98
28845852	C0814036	chromosome map	inpr	3.98
28845852	C0199171	Medical procedure	hlca	3.72
28845852	C3813622	Overall Well Being	inpr	3.68
28845852	C1947931	Direct (qualifier)	qlco	3.55
28845852	C0439851	Direct type of relationship	qlco	3.55
28845852	C1709510	Personalized	qlco	3.48
28845852	C0025118	Medicine	bmod	6.72
28845852	C1709510	Personalized	qlco	5.18
28845852	C1456501	Preventive intent	qlco	3.68
28845852	C0445202	Prophylactic behavior	ftcn	3.68
28845852	C0814184	4P's	inpr	3.57
28845852	C3540473	Abnormal Involuntary Movement Scale Questionnaire	inpr	3.57
28845852	C2948600	Aim	phsu	3.57
28845852	C1947946	Aim (idea)	idcn	3.57
28845852	C3540472	Ancestry-Informative Marker	ftcn	3.57
28845852	C3890193	CD5L wt Allele	gngm	3.57
28845852	C2744535	CD69 protein, human	aapp	3.57
28845852	C2744535	CD69 protein, human	imft	3.57
28845852	C3540471	CD69 wt Allele	gngm	3.57
28845852	C1521758	Chromosome 4 Short Arm	nusq	3.57
28845852	C1552219	Maxillary right second premolar prosthesis	medd	3.57
28845852	C0013227	Pharmaceutical Preparations	phsu	3.57
28845852	C0558058	Reflecting	menp	3.57
28845852	C0679199	strategy	menp	3.57
28845852	C0681890	predictive	qlco	3.50
28845852	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28845852	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28845852	C0009013	Clone Cells	cell	9.86
28845852	C0009015	Cloning	resa	9.86
28845852	C0010674	Cystic Fibrosis	dsyn	9.76
28845852	C1524063	Use of	ftcn	7.62
28845852	C1413365	CFTR gene	gngm	6.92
28845852	C1301820	Obtain	ftcn	5.18
28845852	C2825142	Experimental Result	fndg	3.98
28845852	C1274040	Result	ftcn	3.98
28845852	C1546471	What subject filter - Result	idcn	3.98
28845852	C0679199	strategy	menp	3.68
28845852	C3539073	In the Field	spco	3.64
28845852	C0521982	Response to treatment	clna	3.61
28845852	C0598888	gene cloning	lbpr	3.58
28845852	C0598888	gene cloning	mbrt	3.58
28845852	C3264627	Kalydeco	phsu	3.44
28845852	C0521114	Infrequent	tmco	3.43
28845852	C0522498	Rare	qlco	3.43
28845852	C1514917	Retinoic Acid Response Element	gngm	3.43
28845852	C0030699	Patient Participation	hlca	16.05
28845852	C0035820	Social Role	socb	13.01
28845852	C0018017	objective (goal)	inpr	9.94
28845852	C0013919	Emblems	mnob	9.76
28845852	C0025118	Medicine	bmod	6.63
28845852	C1707959	Example	cnce	3.68
28845852	C1705810	Generic Role	cnce	3.54
28845852	C3871154	{Role}	inpr	3.54
28845852	C1539372	EXOSC10 gene	gngm	3.48
28845852	C3264627	Kalydeco	phsu	3.48
28845852	C0013227	Pharmaceutical Preparations	phsu	3.48
28845852	C0205177	Active	ftcn	3.42
28845852	C3888249	Active License	qlco	3.42
28845852	C3853793	active (HL7 RoleLink)	idcn	3.42
28845852	C0030699	Patient Participation	hlca	17.80
28845852	C0018759	Health Status	qlco	16.05
28845852	C0018684	Health	idcn	6.58
28845852	C0030705	Patients	podg	6.58
28845852	C1511726	Data	idcn	3.68
28845852	C3714741	Data (eukaryote)	euka	3.68
28845852	C3245479	Data call receiving device	medd	3.68
28845852	C1552740	Entity Determiner - specific	inpr	3.54
28845852	C0205369	Specific qualifier value	qlco	3.54
28845852	C1513392	Molecular Fingerprint of Tumor	clna	3.45
28845852	C0449437	Patient status	fndg	3.44
28845852	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.42
28845852	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.42
28845852	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.42
28845852	C0012634	Disease	dsyn	11.49
28845852	C0018684	Health	idcn	8.34
28845852	C0024501	Maintenance	acty	6.71
28845852	C0348080	Condition	qlco	5.18
28845852	C3864998	Condition:Find:Pt:^Patient:Nom	clna	5.18
28845852	C1705253	Logical Condition	cnce	5.18
28845852	C1456501	Preventive intent	qlco	5.18
28845852	C0445202	Prophylactic behavior	ftcn	5.18
28845852	C0808232	Therapeutic Intervention	topp	5.18
28845852	C0087111	Therapeutic procedure	topp	5.18
28845852	C1513392	Molecular Fingerprint of Tumor	clna	4.12
28845852	C0032074	Cognitive function: planning	menp	3.59
28845852	C1880177	Contribution	acty	3.59
28845852	C1301732	Planned	ftcn	3.59
28845852	C2948600	Aim	phsu	3.55
28845852	C1947946	Aim (idea)	idcn	3.55
28845852	C3540472	Ancestry-Informative Marker	ftcn	3.55
28845852	C3890193	CD5L wt Allele	gngm	3.55
28845852	C2744535	CD69 protein, human	aapp	3.55
28845852	C2744535	CD69 protein, human	imft	3.55
28845852	C3540471	CD69 wt Allele	gngm	3.55
28845852	C0015576	Family	famg	14.64
28845852	C0018724	Health Personnel	prog	11.49
28845852	C0035173	Research Personnel	prog	11.49
28845852	C0025118	Medicine	bmod	6.59
28845852	C3812891	All of the Time	inpr	5.18
28845852	C2003902	Always (frequency)	tmco	5.18
28845852	C2349182	Correct (qualifier)	qlco	5.18
28845852	C1704727	Family (taxonomic)	cnce	5.18
28845852	C0750591	consider	idcn	5.18
28845852	C1881534	Make - Instruction Imperative	ftcn	3.98
28845852	C0596545	Experience	menp	3.68
28845852	C1705483	Pathname	inpr	3.63
28845852	C0919386	Pathology procedure	lbpr	3.63
28845852	C0815172	patient characteristics	clna	3.60
28845852	C1708476	Implementation	acty	3.56
28845852	C0679646	Participant	popg	3.56
28845852	C1306597	Psychiatric problem	mobd	3.50
28845852	C0205486	Psychologic	ftcn	3.50
28845852	C1548787	Appropriate	qlco	3.48
28845852	C0302350	Therapeutic	ftcn	3.48
28845852	C0087111	Therapeutic procedure	topp	3.48
28845852	C1539372	EXOSC10 gene	gngm	3.43
28845852	C1704419	Effective	qlco	3.43
28845852	C1280519	Effectiveness	qlco	3.43
28845852	C0013227	Pharmaceutical Preparations	phsu	3.43
28845852	C0040363	Togo	geoa	17.80
28845852	C0041260	Tryptophanase	aapp	17.80
28845852	C0041260	Tryptophanase	enzy	17.80
28845852	C0085537	Caregiver	prog	14.64
28845852	C0678236	Rare Diseases	dsyn	13.05
28845852	C0015450	Face	blor	9.86
28845852	C0030705	Patients	podg	6.63
28845852	C1299351	Abnormally high	qlco	5.18
28845852	C0332152	Before	tmco	5.18
28845852	C1705850	Before - dosing instruction fragment	inpr	5.18
28845852	C0332183	Frequently	tmco	5.18
28845852	C0205250	High	qlco	5.18
28845852	C3889660	High Mitosis-Karyorrhexis Index	qnco	5.18
28845852	C1518422	Negation	ftcn	5.18
28845852	C2003901	Never (frequency)	tmco	5.18
28845852	C4050225	Often - answer to question	inpr	5.18
28845852	C1720467	Only - dosing instruction fragment	inpr	5.18
28845852	C0205171	Singular	qnco	5.18
28845852	C1883351	To	qlco	5.18
28845852	C2700149	Value Above Reference Range	inpr	5.18
28845852	C0750591	consider	idcn	5.18
28845852	C3887512	high - ActExposureLevelCode	idcn	5.18
28845852	C0302113	Fragility	comd	3.63
28845852	C1706387	Issue (document)	inpr	3.63
28845852	C0033213	Problem	fndg	3.63
28845852	C1710548	Unique	qlco	3.59
28845852	C0178566	concept	idcn	3.57
28845852	C1281591	Entire face	bpoc	3.55
28845852	C1521738	Field	cnce	3.55
28845852	C0440042	Field's stain	irda	3.55
28845852	C2349184	Force Field	cnce	3.55
28845852	C3539073	In the Field	spco	3.55
28845852	C2346620	Knowledge Field	cnce	3.55
28845852	C0332218	Difficult (qualifier value)	qlco	3.50
28845852	C1299586	Has difficulty doing (qualifier value)	fndg	3.50
28845852	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.48
28845852	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.48
28845852	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.48
28845852	C1524063	Use of	ftcn	3.47
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
26183966	C0055363	Chloride Channels	aapp	19.52
26183966	C0055363	Chloride Channels	bacs	19.52
26183966	C0010674	Cystic Fibrosis	dsyn	10.06
26183966	C0026882	Mutation	genf	9.90
26183966	C0015127	Etiology aspects	ftcn	9.86
26183966	C1524003	Science of Etiology	cnce	3.55
26183966	C1413365	CFTR gene	gngm	3.48
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
26183966	C0009738	Congo	geoa	16.08
26183966	C0031453	Phenylalanine	aapp	16.05
26183966	C0031453	Phenylalanine	bacs	16.05
26183966	C0031453	Phenylalanine	phsu	16.05
26183966	C1511760	Deletion Mutation	genf	13.02
26183966	C0026882	Mutation	genf	9.92
26183966	C1413365	CFTR gene	gngm	5.18
26183966	C0599896	trafficking	celf	5.18
26183966	C1705285	Mutation Abnormality	comd	3.61
26183966	C1880274	Deletion (action)	acty	3.56
26183966	C1442161	Gene Deletion Abnormality	comd	3.56
26183966	C3811819	CFTR wt Allele	gngm	3.47
26183966	C0332183	Frequently	tmco	3.47
26183966	C0205393	Most	qnco	3.47
26183966	C0202174	blood phenylalanine measurement by Guthrie microbiologic assay	lbpr	3.43
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.51
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.51
26183966	C1413365	CFTR gene	gngm	7.14
26183966	C1882932	Representation (action)	acty	5.18
26183966	C1521840	Target	ftcn	5.18
26183966	C2986546	Target Lesion Identification	diap	5.18
26183966	C0013227	Pharmaceutical Preparations	phsu	3.68
26183966	C1254351	Pharmacologic Substance	phsu	3.68
26183966	C0205202	Corrected	qlco	3.57
26183966	C1947931	Direct (qualifier)	qlco	3.57
26183966	C1561536	*Activity (kind of quantity)	idcn	3.54
26183966	C0205177	Active	ftcn	3.54
26183966	C0441655	Activities	acty	3.54
26183966	C3668946	Activity (animal life circumstance)	fndg	3.54
26183966	C3854321	Expression (foundation metadata concept)	idcn	3.54
26183966	C0185117	Expression procedure	topp	3.54
26183966	C4049939	FDA Establishment Activity Terminology	inpr	3.54
26183966	C0443264	Modulated	spco	3.54
26183966	C0439167	Percent Activity	qnco	3.54
26183966	C4049938	Physical Activity Measurement	lbpr	3.54
26183966	C0596988	mutant	comd	3.50
26183966	C3245505	potential	qlco	3.50
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.99
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.99
26183966	C1099354	RNA, Small Interfering	bacs	19.23
26183966	C1099354	RNA, Small Interfering	nnon	19.23
26183966	C0040363	Togo	geoa	17.80
26183966	C0041260	Tryptophanase	aapp	17.80
26183966	C0041260	Tryptophanase	enzy	17.80
26183966	C0220825	Evaluation	hlca	14.64
26183966	C0872147	DNA Library	gngm	9.76
26183966	C0872147	DNA Library	nnon	9.76
26183966	C0023621	Libraries	mnob	9.76
26183966	C0023621	Libraries	orgt	9.76
26183966	C0751608	cDNA Library	gngm	9.76
26183966	C0751608	cDNA Library	nnon	9.76
26183966	C1413365	CFTR gene	gngm	6.92
26183966	C1883351	To	qlco	5.18
26183966	C1705053	Screen Device Component	mnob	3.98
26183966	C1305399	Screening - procedure intent	ftcn	3.98
26183966	C0220908	Screening procedure	hlca	3.98
26183966	C0205309	Known	qlco	3.46
26183966	C1521840	Target	ftcn	3.46
26183966	C0332149	Possible	qlco	3.43
26183966	C2362652	Possible diagnosis	qlco	3.43
26183966	C1705910	Possibly Related to Intervention	qlco	3.43
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
26183966	C3463820	Inhibition	acty	14.64
26183966	C0021467	Psychological inhibition	menp	14.64
26183966	C1524024	analysis aspect	ftcn	14.64
26183966	C0038164	Staphylococcal Protein A	aapp	12.93
26183966	C0038164	Staphylococcal Protein A	imft	12.93
26183966	C0038164	Staphylococcal Protein A	irda	12.93
26183966	C0728866	Drug effect	ftcn	9.87
26183966	C0013230	Investigational New Drugs	phsu	6.59
26183966	C0936012	Analysis	resa	5.18
26183966	C0002778	Analysis of substances	lbpr	5.18
26183966	C1550043	Container status - Identified	fndg	5.18
26183966	C0870432	Display - arrangement	ftcn	5.18
26183966	C0205396	Identified	qlco	5.18
26183966	C0021469	Metabolic Inhibition	moft	5.18
26183966	C1628982	Percent inhibition	qnco	5.18
26183966	C0033414	Promotion (action)	acty	3.98
26183966	C1419426	RNF5 gene	gngm	3.57
26183966	C0301283	Drug additive	bodm	3.56
26183966	C0728867	Drug effect disorder	patf	3.56
26183966	C1411996	Pharmacological drug effects	biof	3.56
26183966	C0442796	Additive	qlco	3.54
26183966	C1280500	Effect	qlco	3.54
26183966	C2348382	Effect, Appearance	qlco	3.54
26183966	C1550602	additive ingredient	sbst	3.54
26183966	C1413365	CFTR gene	gngm	3.47
26183966	C1546944	Event Seriousness - Significant	qlco	3.47
26183966	C0750502	Significant	idcn	3.47
26183966	C0237881	Statistical Significance	qnco	3.47
26183966	C3252847	VX 809	orch	3.43
26183966	C3252847	VX 809	phsu	3.43
26183966	C1517586	Investigational	qlco	3.42
26183966	C3245491	investigational monitoring program	hlca	3.42
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.96
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.96
26183966	C0024523	Malabsorption Syndrome	dsyn	14.64
26183966	C0003069	Animals, Transgenic	anim	12.91
26183966	C0021853	Intestines	bpoc	9.73
26183966	C1413365	CFTR gene	gngm	6.89
26183966	C0014597	Epithelial Cells	cell	6.60
26183966	C3714745	Malabsorption	fndg	5.18
26183966	C0442805	Increase	ftcn	3.57
26183966	C1708698	Light Emitting Diode Device Component	mnob	3.57
26183966	C1561536	*Activity (kind of quantity)	idcn	3.55
26183966	C0205177	Active	ftcn	3.55
26183966	C0441655	Activities	acty	3.55
26183966	C3668946	Activity (animal life circumstance)	fndg	3.55
26183966	C4049939	FDA Establishment Activity Terminology	inpr	3.55
26183966	C1517945	Loss	qnco	3.55
26183966	C0439167	Percent Activity	qnco	3.55
26183966	C4049938	Physical Activity Measurement	lbpr	3.55
26183966	C1273342	Epithelial cell count (procedure)	lbpr	3.44
26183966	C1292984	Procedure on intestine	hlca	3.42
26183966	C1419426	RNF5 gene	gngm	3.42
26183966	C0086418	Homo sapiens	humn	28.79
26183966	C0009738	Congo	geoa	17.80
26183966	C3811819	CFTR wt Allele	gngm	5.18
26183966	C0150312	Present	qnco	5.18
26183966	C1419426	RNF5 gene	gngm	5.18
26183966	C1883712	Add - instruction imperative	ftcn	3.63
26183966	C0332287	In addition to	ftcn	3.63
26183966	C0599333	Epithelium of bronchus	bpoc	3.59
26183966	C0030705	Patients	podg	6.79
26183966	C2587213	Control function	ftcn	3.63
26183966	C1882979	Scientific Control	cnce	3.63
26183966	C3274648	True Control Status	qlco	3.63
26183966	C0243148	control aspects	qlco	3.63
26183966	C1550141	control substance	sbst	3.63
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.27
26183966	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.27
26183966	C0040363	Togo	geoa	17.80
26183966	C0041260	Tryptophanase	aapp	17.80
26183966	C0041260	Tryptophanase	enzy	17.80
26183966	C1564139	Mutant Proteins	aapp	10.09
26183966	C1883351	To	qlco	5.18
26183966	C2825142	Experimental Result	fndg	3.98
26183966	C1274040	Result	ftcn	3.98
26183966	C1546471	What subject filter - Result	idcn	3.98
26183966	C0695347	Modality	idcn	3.68
26183966	C1419426	RNF5 gene	gngm	3.57
26183966	C0302350	Therapeutic	ftcn	3.50
26183966	C0087111	Therapeutic procedure	topp	3.50
26183966	C1413365	CFTR gene	gngm	3.48
26183966	C0596988	mutant	comd	3.48
26183966	C1521840	Target	ftcn	3.44
26183966	C2986546	Target Lesion Identification	diap	3.44
26406363	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	48.50
26406363	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	48.50
26406363	C0033105	Statistical Prevalence	qnco	22.31
26406363	C1511760	Deletion Mutation	genf	13.01
26406363	C1413365	CFTR gene	gngm	10.42
26406363	C0016059	Fibrosis	patf	9.73
26406363	C0002520	Amino Acids	aapp	6.74
26406363	C0002520	Amino Acids	bacs	6.74
26406363	C0002520	Amino Acids	phsu	6.74
26406363	C2917660	Amino Acid [EPC]	phsu	3.59
26406363	C0449597	Form of cyst	spco	3.59
26406363	C1880274	Deletion (action)	acty	3.55
26406363	C1442161	Gene Deletion Abnormality	comd	3.55
26406363	C0205393	Most	qnco	3.42
26406363	C0220900	Prevalence aspects	qnco	3.38
26406363	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.09
26406363	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.09
26406363	C0039798	therapeutic aspects	ftcn	22.48
26406363	C0019904	Homozygote	orga	9.88
26406363	C0026882	Mutation	genf	9.75
26406363	C1413365	CFTR gene	gngm	7.02
26406363	C1269765	Assisted (qualifier value)	qlco	5.18
26406363	C0336789	Combine	mnob	5.18
26406363	C1552861	Help document	inpr	5.18
26406363	C0442805	Increase	ftcn	5.18
26406363	C0205217	Increased	qnco	5.18
26406363	C1153410	channel activity	moft	3.75
26406363	C1880834	Fold in Medical Device Material	phpr	3.68
26406363	C0332462	Folded structure	spco	3.68
26406363	C1533734	Administration procedure	topp	3.55
26406363	C1705169	Biomaterial Treatment	cnce	3.55
26406363	C0087111	Therapeutic procedure	topp	3.55
26406363	C1522326	Treating	ftcn	3.55
26406363	C3538994	Treatment Epoch	resa	3.55
26406363	C3887704	treatment - ActInformationManagementReason	hlca	3.55
26406363	C3272558	Chemical or Textual Reference to Actual Test or Parameter	inpr	3.50
26406363	C0220806	Chemicals	chem	3.50
26406363	C1705285	Mutation Abnormality	comd	3.44
26406363	C0205540	Approved	qlco	3.43
26406363	C0332185	Recent	tmco	3.43
26406363	C0237401	Individual	humn	3.41
26406363	C0027361	Persons	popg	3.41
26410278	C0242821	Human body	humn	17.80
26410278	C0035150	Reproduction	orgf	13.05
26410278	C0010674	Cystic Fibrosis	dsyn	10.06
26410278	C0026882	Mutation	genf	10.06
26410278	C0030286	Pancreatic Diseases	dsyn	6.73
26410278	C1268086	Body structure	anst	5.18
26410278	C0040300	Body tissue	tisu	5.18
26410278	C0460148	Human body structure	anst	5.18
26410278	C0332257	Including (qualifier)	ftcn	5.18
26410278	C0750591	consider	idcn	5.18
26410278	C1314939	Involvement with	ftcn	3.59
26410278	C1260922	Abnormal breathing	fndg	3.57
26410278	C0459424	Abnormal result	fndg	3.57
26410278	C0007613	Cell physiology	celf	3.56
26410278	C0009738	Congo	geoa	17.80
26410278	C0683278	Mental Suffering	mobd	14.64
26410278	C3264621	ivacaftor	orch	14.64
26410278	C3264621	ivacaftor	phsu	14.64
26410278	C1314792	Etiology	ftcn	13.03
26410278	C0086582	Males	orga	11.49
26410278	C0162429	Malnutrition	dsyn	9.94
26410278	C0015127	Etiology aspects	ftcn	9.88
26410278	C0015780	Female	orga	9.86
26410278	C0086287	Females	popg	9.86
26410278	C3811819	CFTR wt Allele	gngm	5.18
26410278	C1837655	Multifactorial	fndg	5.18
26410278	C1521840	Target	ftcn	5.18
26410278	C2986546	Target Lesion Identification	diap	5.18
26410278	C0278048	Fertility problem	fndg	4.12
26410278	C2987487	Deficit	qlco	3.63
26410278	C1561611	Admission Level of Care Code - Improved	inpr	3.59
26410278	C0332272	Better	qlco	3.59
26410278	C0184511	Improved	qlco	3.59
26410278	C0087111	Therapeutic procedure	topp	3.59
26410278	C0547043	Up	spco	3.59
26410278	C3842586	50%	fndg	3.55
26410278	C3843766	<50	fndg	3.55
26410278	C0205463	Physiological	ftcn	3.48
26410278	C0009738	Congo	geoa	17.80
26410278	C0282443	Review [Publication Type]	inpr	11.49
26410278	C0015895	Fertility	orgf	9.73
26410278	C1257890	Population Group	popg	9.73
26410278	C1552617	Act Class - review	idcn	5.18
26410278	C3811819	CFTR wt Allele	gngm	5.18
26410278	C0456962	Rapid	qlco	5.18
26410278	C0750591	consider	idcn	5.18
26410278	C3887511	Evidence	idcn	3.61
26410278	C1882536	Radiation Field	blor	3.60
26410278	C1521738	Field	cnce	3.57
26410278	C0440042	Field's stain	irda	3.57
26410278	C2349184	Force Field	cnce	3.57
26410278	C3539073	In the Field	spco	3.57
26410278	C2346620	Knowledge Field	cnce	3.57
26410278	C0441712	Mechanism (attribute)	ftcn	3.57
26410278	C1825598	IMPACT gene	gngm	3.55
26410278	C4049986	Impact	qlco	3.55
26410278	C0678812	systemic administration	topp	3.47
26410278	C0237400	Actual	qlco	3.47
26410278	C0470187	Availability of	ftcn	3.47
26410278	C3272377	Real Data Type	inpr	3.47
26410278	C2700280	World	popg	3.47
26410278	C0205373	Systemic	ftcn	3.44
26410278	C2986895	Fertility Domain	idcn	3.42
26410278	C1705428	Group Object	cnce	3.42
26410278	C0441833	Groups	idcn	3.42
26410278	C0200069	Infertility study	diap	3.42
26410278	C0687744	Social group	popg	3.42
26410278	C1552516	Specialty Group	hcro	3.42
26410278	C1705429	User Group	popg	3.42
23276841	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.35
23276841	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.35
23276841	C0008203	Chlorides	inch	17.80
23276841	C0017337	Genes	gngm	16.22
23276841	C0376558	Life	idcn	11.49
23276841	C0010674	Cystic Fibrosis	dsyn	10.06
23276841	C0026882	Mutation	genf	9.90
23276841	C0015127	Etiology aspects	ftcn	9.86
23276841	C0022023	Ions	elii	9.85
23276841	C0019247	Hereditary Diseases	dsyn	8.34
23276841	C1413365	CFTR gene	gngm	7.28
23276841	C0439799	Channel	spco	5.18
23276841	C1706095	Channel Object	cnce	5.18
23276841	C0596019	Chloride Ion	elii	5.18
23276841	C0441636	Surgical shortening - action	topp	5.18
23276841	C1704735	Regulator	cnce	3.68
23276841	C1704734	Regulator Device Component	mnob	3.68
23276841	C0182953	Regulators (device)	medd	3.68
23276841	C1159571	water transport	celf	3.57
23276841	C1524003	Science of Etiology	cnce	3.55
23276841	C2700640	Encode (action)	acty	3.54
23276841	C1700702	Iontophoresis Route of Drug Administration	ftcn	3.54
23276841	C2327105	Surface of epithelial cell	celc	3.47
23276841	C0041714	United States Food and Drug Administration	hcro	27.26
23276841	C0039798	therapeutic aspects	ftcn	22.47
23276841	C0009738	Congo	geoa	16.04
23276841	C3264621	ivacaftor	orch	13.14
23276841	C3264621	ivacaftor	phsu	13.14
23276841	C0026882	Mutation	genf	9.73
23276841	C0013227	Pharmaceutical Preparations	phsu	5.18
23276841	C1254351	Pharmacologic Substance	phsu	5.18
23276841	C0332185	Recent	tmco	5.18
23276841	C1882932	Representation (action)	acty	5.18
23276841	C0205540	Approved	qlco	3.59
23276841	C1552740	Entity Determiner - specific	inpr	3.55
23276841	C0205369	Specific qualifier value	qlco	3.55
23276841	C0087111	Therapeutic procedure	topp	3.55
23276841	C1363945	Therapy Object (animal model)	fndg	3.55
23276841	C3811819	CFTR wt Allele	gngm	3.42
23276841	C0205435	First (number)	qnco	3.42
23276841	C1279901	Firstly	qlco	3.42
23276841	C1705285	Mutation Abnormality	comd	3.42
23276841	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.03
23276841	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.03
23276841	C0009738	Congo	geoa	17.80
23276841	C0031843	physiological aspects	phsf	13.03
23276841	C0026882	Mutation	genf	9.99
23276841	C1413365	CFTR gene	gngm	6.95
23276841	C0030705	Patients	podg	6.59
23276841	C3811819	CFTR wt Allele	gngm	5.18
23276841	C0184511	Improved	qlco	5.18
23276841	C1705285	Mutation Abnormality	comd	3.68
23276841	C1709060	Modulator Device Component	mnob	3.63
23276841	C0542341	Function	ftcn	3.57
23276841	C0700205	Function Axis	clas	3.57
23276841	C1705273	Mathematical Operator	inpr	3.57
23276841	C0439799	Channel	spco	3.48
23276841	C1706095	Channel Object	cnce	3.48
23276841	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
23276841	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
23276841	C0008976	Clinical Trials	resa	20.95
23276841	C0040363	Togo	geoa	17.80
23276841	C0041260	Tryptophanase	aapp	17.80
23276841	C0041260	Tryptophanase	enzy	17.80
23276841	C3264621	ivacaftor	orch	12.94
23276841	C3264621	ivacaftor	phsu	12.94
23276841	C0031843	physiological aspects	phsf	12.89
23276841	C1096775	Clinical Trial [Publication Type]	inpr	11.49
23276841	C0036576	Genetic Selection	genf	9.94
23276841	C0079809	Measures	qnco	6.71
23276841	C1561566	FEV1 Adverse Event	fndg	5.18
23276841	C0429706	Forced expiratory volume in 1 second finding	fndg	5.18
23276841	C0884358	Performed	ftcn	5.18
23276841	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	5.18
23276841	C0183683	Support, device	medd	5.18
23276841	C1521721	Supportive assistance	cnce	5.18
23276841	C1883351	To	qlco	5.18
23276841	C0678790	dose-response relationship	biof	3.64
23276841	C1707391	Choose (action)	acty	3.63
23276841	C0547047	Decrease	qnco	3.57
23276841	C0392756	Reduced	qlco	3.57
23276841	C0242485	Measurement	ftcn	3.56
23276841	C0428295	Cystic fibrosis sweat test	lbpr	3.48
23276841	C1304760	Sweat chloride level result	lbtr	3.48
23276841	C0178602	Dosage	qnco	3.48
23276841	C1114758	Dose number:Number:Point in time:^Patient:Quantitative	clna	3.48
23276841	C0869039	Unit dose	qnco	3.48
23276841	C1413365	CFTR gene	gngm	3.43
23276841	C0542341	Function	ftcn	3.43
23276841	C0700205	Function Axis	clas	3.43
23276841	C1705273	Mathematical Operator	inpr	3.43
23276841	C2986411	Improvement	cnce	3.43
23276841	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
23276841	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
23276841	C1706279	Object Relationship	idcn	13.02
23276841	C0428295	Cystic fibrosis sweat test	lbpr	5.18
23276841	C1304760	Sweat chloride level result	lbtr	5.18
23276841	C1521840	Target	ftcn	5.18
23276841	C2986546	Target Lesion Identification	diap	5.18
23276841	C1413365	CFTR gene	gngm	3.68
23276841	C0872152	drug development	bmod	3.62
23276841	C0678723	Biologic Development	orgf	3.57
23276841	C1527148	Development	ftcn	3.57
23276841	C1519941	Validation	resa	3.57
23276841	C0243107	development aspects	phsf	3.57
23276841	C3540605	CDISC Relationship Class	inpr	3.56
23276841	C1705630	Concept Relationship	idcn	3.56
23276841	C0439849	Relationships	qlco	3.56
23276841	C0332452	defective	ftcn	3.50
23276841	C1718097	New medications	phsu	3.48
23276841	C1561566	FEV1 Adverse Event	fndg	3.46
23276841	C0429706	Forced expiratory volume in 1 second finding	fndg	3.46
23276841	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.46
23276841	C0205314	New	qlco	3.44
23276841	C0282461	Phase 3 Clinical Trials	resa	22.90
23276841	C0038990	Sweating	fndg	19.21
23276841	C0038984	Sweat	bdsu	9.75
23276841	C3843787	10 - 12	fndg	3.68
23276841	C1561566	FEV1 Adverse Event	fndg	3.68
23276841	C0429706	Forced expiratory volume in 1 second finding	fndg	3.68
23276841	C1532563	Millimole per Liter	qnco	3.68
23276841	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.68
23276841	C0860861	cl- decreased	fndg	3.62
23276841	C1546944	Event Seriousness - Significant	qlco	3.57
23276841	C0392756	Reduced	qlco	3.57
23276841	C0301630	Reduction (chemical)	npop	3.57
23276841	C0441610	Reduction - action	topp	3.57
23276841	C0750502	Significant	idcn	3.57
23276841	C0237881	Statistical Significance	qnco	3.57
23276841	C3264622	ivacaftor 150 MG	clnd	3.55
23276841	C2825142	Experimental Result	fndg	3.54
23276841	C2986411	Improvement	cnce	3.54
23276841	C1274040	Result	ftcn	3.54
23276841	C1546471	What subject filter - Result	idcn	3.54
23276841	C0428295	Cystic fibrosis sweat test	lbpr	3.48
23276841	C1304760	Sweat chloride level result	lbtr	3.48
23276841	C3842586	50%	fndg	3.47
23276841	C3843766	<50	fndg	3.47
23276841	C0332232	Approximate	qlco	3.47
23276841	C0040363	Togo	geoa	17.80
23276841	C0041260	Tryptophanase	aapp	17.80
23276841	C0041260	Tryptophanase	enzy	17.80
23276841	C1561566	FEV1 Adverse Event	fndg	7.29
23276841	C0429706	Forced expiratory volume in 1 second finding	fndg	7.29
23276841	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	7.29
23276841	C2986411	Improvement	cnce	7.19
23276841	C0428295	Cystic fibrosis sweat test	lbpr	7.09
23276841	C1304760	Sweat chloride level result	lbtr	7.09
23276841	C0700364	Appearance	qlco	5.18
23276841	C1518422	Negation	ftcn	5.18
23276841	C1883351	To	qlco	5.18
23276841	C0750489	apparent	idcn	5.18
23276841	C0547047	Decrease	qnco	3.56
23276841	C0456079	Disease classification level	clas	3.56
23276841	C1547707	Floor - story of building	geoa	3.56
23276841	C2946261	Level	phsu	3.56
23276841	C0441889	Levels (qualifier value)	qlco	3.56
23276841	C0392756	Reduced	qlco	3.56
23276841	C0449864	Threshold	qlco	3.56
23276841	C0443172	Changed status	qnco	3.43
23276841	C0392747	Changing	ftcn	3.43
23276841	C1705241	Delta (difference)	qnco	3.43
23276841	C0009738	Congo	geoa	16.09
23276841	C0014406	Environment	spco	11.49
23276841	C0314603	Genetic	ftcn	5.18
23276841	C0443264	Modulated	spco	5.18
23276841	C0205463	Physiological	ftcn	5.18
23276841	C0332148	Probable diagnosis	qlco	5.18
23276841	C0750492	Probably	idcn	5.18
23276841	C0017296	gene therapy	topp	5.18
23276841	C0521117	Severity of illness	qlco	3.75
23276841	C2986411	Improvement	cnce	3.56
23276841	C0600116	Does speak	fndg	3.55
23276841	C0449822	Multiplicity	qnco	3.55
23276841	C1547187	Speak - language ability	idcn	3.55
23276841	C0234856	Speaking (activity)	dora	3.55
23276841	C0332268	Lacking	qlco	3.55
23276841	C1521761	Factor	ftcn	3.52
23276841	C2827422	Mathematical Factor	cnce	3.52
23276841	C3811819	CFTR wt Allele	gngm	3.48
23276841	C1561566	FEV1 Adverse Event	fndg	3.46
23276841	C0429706	Forced expiratory volume in 1 second finding	fndg	3.46
23276841	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.46
23276841	C0428295	Cystic fibrosis sweat test	lbpr	3.44
23276841	C1304760	Sweat chloride level result	lbtr	3.44
23276841	C1707520	Correlation	qlco	3.42
23276841	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
23276841	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
23276841	C0087130	Uncertainty	fndg	19.36
23276841	C0027552	Needs	qlco	14.64
23276841	C0013175	Drug Evaluation	resa	9.92
23276841	C0016884	Future	tmco	6.58
23276841	C2741673	Account number:Identifier:Point in time:^Patient:Nominal	clna	5.18
23276841	C0428295	Cystic fibrosis sweat test	lbpr	5.18
23276841	C2981730	Financial Account	inpr	5.18
23276841	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
23276841	C1304760	Sweat chloride level result	lbtr	5.18
23276841	C1524063	Use of	ftcn	5.18
23276841	C2349179	End Point	qlco	3.69
23276841	C1515187	Take	hlca	3.64
23276841	C0242485	Measurement	ftcn	3.63
23276841	C1413365	CFTR gene	gngm	3.56
23276841	C0332452	defective	ftcn	3.56
23276841	C1947931	Direct (qualifier)	qlco	3.53
23276841	C0439851	Direct type of relationship	qlco	3.53
23276841	C1272684	Accepted	qlco	3.48
23276841	C0205210	Clinical	qlco	3.48
23276841	C0443211	Established	qlco	3.48
23276841	C1553058	Neuropsychologist - Clinical	prog	3.48
23276841	C0237412	Psychologist - Clinical	prog	3.48
23276841	C0497591	Social Worker - Clinical	prog	3.48
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.58
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.58
26581802	C0026565	Mortality Vital Statistics	qnco	20.95
26581802	C0026538	Morbidity - disease rate	qnco	19.34
26581802	C0017337	Genes	gngm	17.80
26581802	C0026566	Aspects of mortality statistics	qnco	11.49
26581802	C0010674	Cystic Fibrosis	dsyn	10.06
26581802	C0026882	Mutation	genf	9.90
26581802	C0015127	Etiology aspects	ftcn	9.86
26581802	C1413365	CFTR gene	gngm	7.51
26581802	C0033684	Proteins	aapp	6.75
26581802	C0033684	Proteins	bacs	6.75
26581802	C3899988	Autosomal Recessive Disorder	dsyn	5.18
26581802	C2700640	Encode (action)	acty	5.18
26581802	C1547699	MIME encoding	idcn	5.18
26581802	C0332152	Before	tmco	3.57
26581802	C1546944	Event Seriousness - Significant	qlco	3.57
26581802	C1522538	Leading	ftcn	3.57
26581802	C0750502	Significant	idcn	3.57
26581802	C0237881	Statistical Significance	qnco	3.57
26581802	C0220880	morbidity aspects	inpr	3.57
26581802	C1524003	Science of Etiology	cnce	3.55
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
26581802	C0005367	Bicarbonates	inch	19.19
26581802	C0005367	Bicarbonates	phsu	19.19
26581802	C0008203	Chlorides	inch	17.80
26581802	C0022009	Ion Channel	aapp	16.19
26581802	C0022009	Ion Channel	bacs	16.19
26581802	C0014597	Epithelial Cells	cell	6.60
26581802	C0596019	Chloride Ion	elii	5.18
26581802	C1413365	CFTR gene	gngm	3.68
26581802	C2722820	Bicarbonate preparation	orch	3.42
26581802	C2722820	Bicarbonate preparation	phsu	3.42
26581802	C0973231	bicarbonate ion	inch	3.42
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.14
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.14
26581802	C0007603	Plasma membrane	celc	11.49
26581802	C0026882	Mutation	genf	9.92
26581802	C1413365	CFTR gene	gngm	7.06
26581802	C0332294	Resulting in	ftcn	3.64
26581802	C1705285	Mutation Abnormality	comd	3.61
26581802	C2945599	Mild (qualifier value)	qlco	3.57
26581802	C0547040	Minimal	qlco	3.57
26581802	C1524031	Minimum	qlco	3.57
26581802	C0205214	Common (qualifier value)	qnco	3.47
26581802	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.47
26581802	C0205393	Most	qnco	3.47
26581802	C1522138	shared attribute	ftcn	3.47
26581802	C0040363	Togo	geoa	35.81
26581802	C0041260	Tryptophanase	aapp	35.81
26581802	C0041260	Tryptophanase	enzy	35.81
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
26581802	C1883351	To	qlco	10.42
26581802	C0018017	objective (goal)	inpr	9.99
26581802	C1521721	Supportive assistance	cnce	5.18
26581802	C0087111	Therapeutic procedure	topp	5.18
26581802	C2827774	Current Therapy	topp	3.81
26581802	C1561536	*Activity (kind of quantity)	idcn	3.68
26581802	C1571704	Act Mood - Goal	idcn	3.68
26581802	C0205177	Active	ftcn	3.68
26581802	C0441655	Activities	acty	3.68
26581802	C3668946	Activity (animal life circumstance)	fndg	3.68
26581802	C4049939	FDA Establishment Activity Terminology	inpr	3.68
26581802	C0439167	Percent Activity	qnco	3.68
26581802	C4049938	Physical Activity Measurement	lbpr	3.68
26581802	C1413365	CFTR gene	gngm	3.50
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26581802	C3852684	lumacaftor	orch	12.91
26581802	C3852684	lumacaftor	phsu	12.91
26581802	C0007603	Plasma membrane	celc	9.75
26581802	C0442805	Increase	ftcn	5.18
26581802	C0205217	Increased	qnco	5.18
26581802	C1328819	Small Molecule	orch	5.18
26581802	C0596545	Experience	menp	3.59
26581802	C0237607	Practice Experience	menp	3.59
26581802	C0441889	Levels (qualifier value)	qlco	3.55
26581802	C1413365	CFTR gene	gngm	3.42
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26581802	C3264621	ivacaftor	orch	14.64
26581802	C3264621	ivacaftor	phsu	14.64
26581802	C3852684	lumacaftor	orch	13.03
26581802	C3852684	lumacaftor	phsu	13.03
26581802	C0019904	Homozygote	orga	9.87
26581802	C0026882	Mutation	genf	9.74
26581802	C0079809	Measures	qnco	6.74
26581802	C0030705	Patients	podg	6.74
26581802	C0184511	Improved	qlco	5.18
26581802	C1274040	Result	ftcn	3.68
26581802	C0242485	Measurement	ftcn	3.59
26581802	C1879489	Measures (attribute)	ftcn	3.59
26581802	C1709060	Modulator Device Component	mnob	3.55
26581802	C0205210	Clinical	qlco	3.50
26581802	C1553058	Neuropsychologist - Clinical	prog	3.50
26581802	C0237412	Psychologist - Clinical	prog	3.50
26581802	C0497591	Social Worker - Clinical	prog	3.50
26581802	C0205195	Combined	qlco	3.44
26581802	C3811910	combination - answer to question	fndg	3.44
26581802	C1947911	combination of objects	phob	3.44
26581802	C1705285	Mutation Abnormality	comd	3.43
26581802	C1413365	CFTR gene	gngm	3.43
26581802	C0243067	defects aspect	ftcn	3.43
26581802	C0039798	therapeutic aspects	ftcn	22.35
26581802	C0009738	Congo	geoa	17.80
26581802	C3852684	lumacaftor	orch	13.14
26581802	C3852684	lumacaftor	phsu	13.14
26581802	C0000769	teratologic	ftcn	9.73
26581802	C0000768	Congenital Abnormality	cgab	6.57
26581802	C3811819	CFTR wt Allele	gngm	5.18
26581802	C1882932	Representation (action)	acty	5.18
26581802	C0441478	Surgical advancement - action	ftcn	3.54
26581802	C1533734	Administration procedure	topp	3.42
26581802	C0205474	Biochemical	ftcn	3.42
26581802	C1705169	Biomaterial Treatment	cnce	3.42
26581802	C1546944	Event Seriousness - Significant	qlco	3.42
26581802	C0750502	Significant	idcn	3.42
26581802	C0237881	Statistical Significance	qnco	3.42
26581802	C0087111	Therapeutic procedure	topp	3.42
26581802	C1522326	Treating	ftcn	3.42
26581802	C3538994	Treatment Epoch	resa	3.42
26581802	C3887704	treatment - ActInformationManagementReason	hlca	3.42
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.97
26581802	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.97
26581802	C0026882	Mutation	genf	9.74
26581802	C1413365	CFTR gene	gngm	6.90
26581802	C0449445	Approach	spco	5.18
26581802	C1999230	Providing (action)	acty	5.18
26581802	C2827774	Current Therapy	topp	3.62
26581802	C0087111	Therapeutic procedure	topp	3.56
26581802	C0678723	Biologic Development	orgf	3.55
26581802	C1527148	Development	ftcn	3.55
26581802	C0243107	development aspects	phsf	3.55
26581802	C1517331	Further	spco	3.43
26581802	C1709060	Modulator Device Component	mnob	3.41
23276843	C0039798	therapeutic aspects	ftcn	22.61
23276843	C0162696	Drug Approval	gora	19.42
23276843	C0008976	Clinical Trials	resa	19.40
23276843	C1314792	Etiology	ftcn	13.09
23276843	C3264621	ivacaftor	orch	12.88
23276843	C3264621	ivacaftor	phsu	12.88
23276843	C0392347	Hope (emotion)	menp	11.49
23276843	C0010674	Cystic Fibrosis	dsyn	10.06
23276843	C0015127	Etiology aspects	ftcn	9.94
23276843	C0470187	Availability of	ftcn	5.18
23276843	C0332283	Followed by	tmco	5.18
23276843	C3264627	Kalydeco	phsu	5.18
23276843	C1521840	Target	ftcn	5.18
23276843	C2986546	Target Lesion Identification	diap	5.18
23276843	C1457869	Defect	ftcn	3.68
23276843	C0087111	Therapeutic procedure	topp	3.68
23276843	C1363945	Therapy Object (animal model)	fndg	3.68
23276843	C1524003	Science of Etiology	cnce	3.63
23276843	C0205435	First (number)	qnco	3.50
23276843	C1279901	Firstly	qlco	3.50
23276843	C0597535	Success	socb	3.50
23276843	C1272703	Successful	qlco	3.50
23276843	C1704243	Greater	qnco	3.43
23276843	C0549177	Large	qnco	3.43
23276843	C0233571	excitement emotion	menp	3.43
23276843	C0009738	Congo	geoa	32.26
23276843	C0026192	Minority Groups	popg	25.92
23276843	C0211067	PAVe protocol 1	topp	14.64
23276843	C3264621	ivacaftor	orch	13.05
23276843	C3264621	ivacaftor	phsu	13.05
23276843	C0814225	benefit	qnco	7.43
23276843	C3811819	CFTR wt Allele	gngm	6.88
23276843	C0030705	Patients	podg	6.83
23276843	C0521116	Current (present time)	tmco	5.18
23276843	C0013227	Pharmaceutical Preparations	phsu	5.18
23276843	C1254351	Pharmacologic Substance	phsu	5.18
23276843	C1704259	Biochemical Pathway	moft	3.68
23276843	C1705987	Pathway (interactions)	cnce	3.68
23276843	C1272684	Accepted	qlco	3.59
23276843	C0443211	Established	qlco	3.59
23276843	C0678723	Biologic Development	orgf	3.50
23276843	C0458003	Developmental (qualifier value)	qlco	3.50
23276843	C0205172	More	ftcn	3.50
23276843	C0679993	small groups	grpa	3.43
23276843	C1704735	Regulator	cnce	3.42
23276843	C1704734	Regulator Device Component	mnob	3.42
23276843	C0182953	Regulators (device)	medd	3.42
23276843	C2752508	fully spanning the plasma membrane	celc	3.42
23276843	C1167322	integral to membrane	celc	3.42
23276843	C0205210	Clinical	qlco	3.42
23276843	C1553058	Neuropsychologist - Clinical	prog	3.42
23276843	C0237412	Psychologist - Clinical	prog	3.42
23276843	C0700321	Small	qnco	3.42
23276843	C0497591	Social Worker - Clinical	prog	3.42
23276843	C1709060	Modulator Device Component	mnob	3.40
23276843	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
23276843	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
23276843	C0009738	Congo	geoa	16.09
23276843	C0035173	Research Personnel	prog	11.49
23276843	C1136080	Innovative Therapies	topp	6.93
23276843	C0439064	Numerous	qnco	5.18
23276843	C1709060	Modulator Device Component	mnob	3.59
23276843	C1413365	CFTR gene	gngm	3.48
23276843	C3811819	CFTR wt Allele	gngm	3.48
23276843	C1292732	Investigates	ftcn	3.48
23276843	C0040363	Togo	geoa	35.81
23276843	C0041260	Tryptophanase	aapp	35.81
23276843	C0041260	Tryptophanase	enzy	35.81
23276843	C0009738	Congo	geoa	32.40
23276843	C0016617	Foundations	orgt	26.03
23276843	C0010674	Cystic Fibrosis	dsyn	19.71
23276843	C0220825	Evaluation	hlca	13.00
23276843	C0282443	Review [Publication Type]	inpr	11.49
23276843	C0042153	utilization qualifier	ftcn	11.49
23276843	C0087111	Therapeutic procedure	topp	10.56
23276843	C1883351	To	qlco	10.42
23276843	C3811819	CFTR wt Allele	gngm	7.02
23276843	C0024115	Lung diseases	dsyn	6.91
23276843	C0376658	Catalogs	inpr	6.71
23276843	C1552617	Act Class - review	idcn	5.18
23276843	C2584313	Discussion (communication)	socb	5.18
23276843	C1710360	Technology Platform	resd	5.18
23276843	C0457083	Usage	ftcn	5.18
23276843	C1947944	Use - dosing instruction imperative	inpr	5.18
23276843	C1555307	promise	idcn	5.18
23276843	C1947933	care activity	acty	3.68
23276843	C2346866	Assortment	cnce	3.56
23276843	C1883525	Variety (taxon)	cnce	3.56
23276843	C0205309	Known	qlco	3.54
23276843	C0723712	Therapeutic brand of coal tar	orch	3.54
23276843	C0723712	Therapeutic brand of coal tar	phsu	3.54
23276843	C1261322	Evaluation procedure	hlca	3.54
23276843	C0521116	Current (present time)	tmco	3.43
23276843	C0183683	Support, device	medd	3.42
23276843	C1521721	Supportive assistance	cnce	3.42
23276843	C0009738	Congo	geoa	17.80
23276843	C0001883	Airway Obstruction	dsyn	12.89
23276843	C0009450	Communicable Diseases	dsyn	11.49
23276843	C0021368	Inflammation	patf	11.49
23276843	C0031847	physiopathological	ftcn	9.74
23276843	C3714514	Infection	patf	8.34
23276843	C1511572	event cycle	tmco	7.21
23276843	C0033684	Proteins	aapp	6.79
23276843	C0033684	Proteins	bacs	6.79
23276843	C0000768	Congenital Abnormality	cgab	6.71
23276843	C0024115	Lung diseases	dsyn	6.67
23276843	C3811819	CFTR wt Allele	gngm	5.18
23276843	C1955473	Others - Allergy	fndg	5.18
23276843	C1521840	Target	ftcn	5.18
23276843	C2986546	Target Lesion Identification	diap	5.18
23276843	C3539125	other medicated shampoos in ATC	phsu	5.18
23276843	C2948600	Aim	phsu	3.98
23276843	C1947946	Aim (idea)	idcn	3.98
23276843	C3540472	Ancestry-Informative Marker	ftcn	3.98
23276843	C3890193	CD5L wt Allele	gngm	3.98
23276843	C2744535	CD69 protein, human	aapp	3.98
23276843	C2744535	CD69 protein, human	imft	3.98
23276843	C3540471	CD69 wt Allele	gngm	3.98
23276843	C0449445	Approach	spco	3.57
23276843	C1521970	Characteristics	qlco	3.57
23276843	C1292724	Procedural approach	ftcn	3.57
23276843	C1947931	Direct (qualifier)	qlco	3.56
23276843	C1737329	Dysmorphism	cgab	3.56
23276843	C0449432	Component object	mnob	3.54
23276843	C0678226	Due to	ftcn	3.48
23276843	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.43
23276843	C3887504	Dysfunction	cnce	3.43
23276843	C0277785	Functional disorder	patf	3.43
23276843	C0237401	Individual	humn	3.42
23276843	C0027361	Persons	popg	3.42
23276843	C0040363	Togo	geoa	17.80
23276843	C0041260	Tryptophanase	aapp	17.80
23276843	C0041260	Tryptophanase	enzy	17.80
23276843	C0022877	Laboratory	mnob	9.74
23276843	C0022877	Laboratory	orgt	9.74
23276843	C0079809	Measures	qnco	8.34
23276843	C0205314	New	qlco	6.90
23276843	C2584313	Discussion (communication)	socb	5.18
23276843	C1280500	Effect	qlco	5.18
23276843	C1522154	Informed	qlco	5.18
23276843	C0242485	Measurement	ftcn	5.18
23276843	C1883351	To	qlco	5.18
23276843	C1273517	Used by	fndg	5.18
23276843	C1274040	Result	ftcn	3.98
23276843	C1518422	Negation	ftcn	3.68
23276843	C1720467	Only - dosing instruction fragment	inpr	3.68
23276843	C0205171	Singular	qnco	3.68
23276843	C3146298	Indication	idcn	3.58
23276843	C1268649	New finding since previous mammogram	fndg	3.57
23276843	C0587081	Laboratory test finding	fndg	3.56
23276843	C1522647	Developmental Therapeutics Program	resa	3.56
23276843	C0679622	literary novel	inpr	3.43
23276843	C3244292	Laboratory domain	ftcn	3.43
23276843	C0040363	Togo	geoa	17.80
23276843	C0041260	Tryptophanase	aapp	17.80
23276843	C0041260	Tryptophanase	enzy	17.80
23276843	C0009738	Congo	geoa	16.04
23276843	C0392347	Hope (emotion)	menp	11.49
23276843	C0282443	Review [Publication Type]	inpr	11.49
23276843	C0087111	Therapeutic procedure	topp	10.55
23276843	C0237428	Optimism	menp	9.88
23276843	C0015219	Biological Evolution	genf	9.85
23276843	C0332185	Recent	tmco	7.00
23276843	C0678723	Biologic Development	orgf	5.18
23276843	C1527148	Development	ftcn	5.18
23276843	C1704362	Reviewing	qlco	5.18
23276843	C1883351	To	qlco	5.18
23276843	C0679106	anticipation	menp	5.18
23276843	C0243107	development aspects	phsf	5.18
23276843	C0439234	year	tmco	3.63
23276843	C1707059	Pre-release version of a computer program	cnce	3.57
23276843	C1280477	Progress	ftcn	3.55
23276843	C1272688	status - In progress	ftcn	3.55
23276843	C3146294	Generation (action)	acty	3.55
23276843	C3264627	Kalydeco	phsu	3.55
23276843	C0597535	Success	socb	3.55
23276843	C0558058	Reflecting	menp	3.54
23276843	C0723712	Therapeutic brand of coal tar	orch	3.54
23276843	C0723712	Therapeutic brand of coal tar	phsu	3.54
23276843	C1444637	Past	tmco	3.48
23276843	C3811819	CFTR wt Allele	gngm	3.43
23276843	C0521116	Current (present time)	tmco	3.43
25148205	C3264621	ivacaftor	orch	13.14
25148205	C3264621	ivacaftor	phsu	13.14
25148205	C0033684	Proteins	aapp	6.57
25148205	C0033684	Proteins	bacs	6.57
25148205	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.63
25148205	C0935763	Bioavailable	qlco	3.42
25148205	C0442027	Oral	spco	3.42
25148205	C0026882	Mutation	genf	20.02
25148205	C0206243	Carrying	acty	14.64
25148205	C0010674	Cystic Fibrosis	dsyn	11.49
25148205	C0042153	utilization qualifier	ftcn	9.88
25148205	C0699809	Does carry	fndg	5.18
25148205	C1521840	Target	ftcn	5.18
25148205	C2986546	Target Lesion Identification	diap	5.18
25148205	C0304231	Therapeutic agent	mnob	3.75
25148205	C1611640	Therapeutic agent (substance)	phsu	3.75
25148205	C1705285	Mutation Abnormality	comd	3.68
25148205	C0205210	Clinical	qlco	3.57
25148205	C1553058	Neuropsychologist - Clinical	prog	3.57
25148205	C0237412	Psychologist - Clinical	prog	3.57
25148205	C1514821	Registration	hlca	3.57
25148205	C0497591	Social Worker - Clinical	prog	3.57
25148205	C0457083	Usage	ftcn	3.57
25148205	C1947944	Use - dosing instruction imperative	inpr	3.57
25148205	C1457869	Defect	ftcn	3.56
25148205	C0205435	First (number)	qnco	3.48
25148205	C1279901	Firstly	qlco	3.48
25148205	C1552740	Entity Determiner - specific	inpr	3.47
25148205	C0205369	Specific qualifier value	qlco	3.47
25148205	C0521114	Infrequent	tmco	3.44
25148205	C0522498	Rare	qlco	3.44
25148205	C1514917	Retinoic Acid Response Element	gngm	3.44
25148205	C1527178	Basis - conceptual entity	ftcn	3.43
25148205	C0027361	Persons	popg	3.43
25148205	C0206243	Carrying	acty	29.46
25148205	C0026882	Mutation	genf	20.04
25148205	C0008976	Clinical Trials	resa	19.52
25148205	C0040363	Togo	geoa	17.80
25148205	C0041260	Tryptophanase	aapp	17.80
25148205	C0041260	Tryptophanase	enzy	17.80
25148205	C0699809	Does carry	fndg	10.42
25148205	C1096775	Clinical Trial [Publication Type]	inpr	10.06
25148205	C0010674	Cystic Fibrosis	dsyn	9.77
25148205	C0814225	benefit	qnco	7.35
25148205	C0040223	Time	tmco	6.74
25148205	C0700364	Appearance	qlco	5.18
25148205	C0332290	Consistent with	idcn	5.18
25148205	C1883351	To	qlco	5.18
25148205	C1547282	Show	anim	3.98
25148205	C1705285	Mutation Abnormality	comd	3.68
25148205	C0443318	Sustained	ftcn	3.59
25148205	C3541383	Time (foundation metadata concept)	tmco	3.59
25148205	C0205397	seen	qlco	3.59
25148205	C0027361	Persons	popg	3.56
25148205	C2348205	Similarity	qlco	3.50
25148205	C0205210	Clinical	qlco	3.48
25148205	C1553058	Neuropsychologist - Clinical	prog	3.48
25148205	C0237412	Psychologist - Clinical	prog	3.48
25148205	C0497591	Social Worker - Clinical	prog	3.48
25148205	C0521114	Infrequent	tmco	3.45
25148205	C0522498	Rare	qlco	3.45
25148205	C1514917	Retinoic Acid Response Element	gngm	3.45
25148205	C1998467	Impression	qlco	3.43
25148205	C4049863	Radiologic Impression	fndg	3.43
25148205	C0596764	impression (attitude)	inbe	3.43
25148205	C0001792	Elderly (population group)	popg	14.64
25148205	C3264621	ivacaftor	orch	13.14
25148205	C3264621	ivacaftor	phsu	13.14
25148205	C0008059	Child	aggp	9.90
25148205	C0376558	Life	idcn	9.87
25148205	C0001675	Adult	aggp	9.74
25148205	C0030705	Patients	podg	6.59
25148205	C0001779	Age	orga	5.18
25148205	C1521801	Having administered	ftcn	5.18
25148205	C1518422	Negation	ftcn	5.18
25148205	C1999167	Old age	popg	5.18
25148205	C0442027	Oral	spco	5.18
25148205	C0585361	Twice a day	tmco	3.61
25148205	C2348070	Daily Dose	qnco	3.60
25148205	C0680063	Offspring	famg	3.59
25148205	C0439234	year	tmco	3.59
25148205	C0178602	Dosage	qnco	3.56
25148205	C1114758	Dose number:Number:Point in time:^Patient:Quantitative	clna	3.56
25148205	C1948050	Twice (Numerical Qualifier)	qnco	3.56
25148205	C1720725	Twice - dosing instruction fragment	inpr	3.56
25148205	C0869039	Unit dose	qnco	3.56
25148205	C1706450	Legal Adult	humn	3.43
25148205	C0040363	Togo	geoa	17.80
25148205	C0041260	Tryptophanase	aapp	17.80
25148205	C0041260	Tryptophanase	enzy	17.80
25148205	C0700364	Appearance	qlco	5.18
25148205	C1883351	To	qlco	5.18
25148205	C0205170	Good	qlco	3.68
25148205	C3146287	Well	mnob	3.68
25148205	C3840750	Potential adverse drug interaction	fndg	3.66
25148205	C3814396	CYP3A Gene Locus	gngm	3.57
25148205	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
25148205	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
25148205	C0026882	Mutation	genf	19.93
25148205	C3264621	ivacaftor	orch	13.14
25148205	C3264621	ivacaftor	phsu	13.14
25148205	C1705285	Mutation Abnormality	comd	7.24
25148205	C0030705	Patients	podg	6.59
25148205	C0521116	Current (present time)	tmco	5.18
25148205	C1413365	CFTR gene	gngm	3.47
25148205	C0205195	Combined	qlco	3.45
25148205	C3811910	combination - answer to question	fndg	3.45
25148205	C1947911	combination of objects	phob	3.45
25148205	C0205214	Common (qualifier value)	qnco	3.42
25148205	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
25148205	C0205393	Most	qnco	3.42
25148205	C1522138	shared attribute	ftcn	3.42
25990958	C0077678	ubiquitin-protein ligase	aapp	16.17
25990958	C0077678	ubiquitin-protein ligase	enzy	16.17
25990958	C1155874	Cell Cycle Checkpoints	celf	13.07
25990958	C0529134	ST13 protein, human	aapp	12.94
25990958	C0529134	ST13 protein, human	bacs	12.94
25990958	C0242391	Cell Membrane Proteins	aapp	9.91
25990958	C0242391	Cell Membrane Proteins	rcpt	9.91
25990958	C0034378	quality control	ftcn	9.79
25990958	C0033684	Proteins	aapp	6.61
25990958	C0033684	Proteins	bacs	6.61
25990958	C1314939	Involvement with	ftcn	5.18
25990958	C0441712	Mechanism (attribute)	ftcn	5.18
25990958	C1706376	Mechanism Component of Device	mnob	5.18
25990958	C0849355	Removed	qlco	5.18
25990958	C1883720	Removing (action)	acty	5.18
25990958	C3244314	operate <remove>	ftcn	5.18
25990958	C0600596	DNA Microarray Chip	resd	3.61
25990958	C1418270	PARK2 gene	gngm	3.55
25990958	C0596260	Carboxyl Group	orch	3.55
25990958	C0205088	End-stage	qlco	3.49
25990958	C1705315	Terminal (end postition)	spco	3.49
25990958	C1705314	Terminal Device Component	mnob	3.49
25990958	C1561524	Quality Control Specimen	ftcn	3.49
25990958	C1610034	Specimen Source Codes - Quality Control	inpr	3.49
25990958	C1337104	ST13 gene	gngm	3.48
25990958	C0205100	Peripheral	spco	3.46
25990958	C1880834	Fold in Medical Device Material	phpr	3.42
25990958	C0332462	Folded structure	spco	3.42
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.51
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.51
25990958	C0007603	Plasma membrane	celc	9.85
25990958	C0010674	Cystic Fibrosis	dsyn	9.75
25990958	C2349209	Bound (value)	cnce	5.18
25990958	C0332257	Including (qualifier)	ftcn	5.18
25990958	C1549649	Limit - Amount class	idcn	5.18
25990958	C0439801	Limited (extensiveness)	ftcn	5.18
25990958	C0333118	Retained	ftcn	5.18
25990958	C3252847	VX 809	orch	5.18
25990958	C3252847	VX 809	phsu	5.18
25990958	C1704735	Regulator	cnce	3.63
25990958	C1704734	Regulator Device Component	mnob	3.63
25990958	C0182953	Regulators (device)	medd	3.63
25990958	C1413365	CFTR gene	gngm	3.59
25990958	C0542341	Function	ftcn	3.59
25990958	C0205245	Functional	ftcn	3.59
25990958	C2700217	Functional Relationship	cnce	3.59
25990958	C0598333	drug efficacy	qlco	3.56
25990958	C0596988	mutant	comd	3.53
25990958	C0599896	trafficking	celf	3.53
25990958	C0728938	Partial	qnco	3.50
25990958	C1550516	Target Awareness - partial	idcn	3.50
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
25990958	C1155874	Cell Cycle Checkpoints	celf	13.01
25990958	C0014597	Epithelial Cells	cell	6.60
25990958	C0024109	Lung	bpoc	6.58
25990958	C1292732	Investigates	ftcn	5.18
25990958	C1413365	CFTR gene	gngm	3.68
25990958	C3252847	VX 809	orch	3.64
25990958	C3252847	VX 809	phsu	3.64
25990958	C0332157	Exposure to	clna	3.57
25990958	C1273342	Epithelial cell count (procedure)	lbpr	3.44
25990958	C1278908	Entire lung	bpoc	3.42
25990958	C0819757	Structure of parenchyma of lung	tisu	3.42
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
25990958	C0033625	Protein Conformation	spco	16.19
25990958	C0026377	Molecular Conformation	spco	13.01
25990958	C4019011	Exchange (clinical)	clna	5.18
25990958	C0449719	Part	spco	5.18
25990958	C0678640	degree of relationship - exchange	socb	5.18
25990958	C2584321	Reaching	orgf	3.98
25990958	C1413365	CFTR gene	gngm	3.68
25990958	C1521761	Factor	ftcn	3.63
25990958	C2827422	Mathematical Factor	cnce	3.63
25990958	C1704735	Regulator	cnce	3.63
25990958	C0220905	regulatory	rnlw	3.63
25990958	C0699040	Cell surface	celc	3.57
25990958	C1546968	No Application Type	idcn	3.50
25990958	C1272460	Not Applicable	qlco	3.50
25990958	C4049872	Package Type Not Applicable	ftcn	3.50
25990958	C0597484	Sodium Cation	elii	3.50
25990958	C1179132	Scaffold protein	aapp	3.44
25990958	C1179132	Scaffold protein	bacs	3.44
25990958	C3252847	VX 809	orch	3.44
25990958	C3252847	VX 809	phsu	3.44
25990958	C1420236	SLC9A3R1 gene	gngm	3.42
25990958	C0337143	Scaffold	mnob	3.42
25990958	C0007634	Cells	cell	3.42
25990958	C3282337	Cells [Chemical/Ingredient]	cell	3.42
25990958	C1522326	Treating	ftcn	3.42
25990958	C1956036	PDZ Domains	spco	25.52
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
25990958	C0010853	Cytoskeleton	celc	19.19
25990958	C0032930	Precipitating Factors	clna	16.59
25990958	C0059973	ezrin	aapp	12.88
25990958	C0059973	ezrin	bacs	12.88
25990958	C1420236	SLC9A3R1 gene	gngm	7.22
25990958	C0033414	Promotion (action)	acty	3.98
25990958	C1444748	Triggered by	qlco	3.98
25990958	C1413365	CFTR gene	gngm	3.56
25990958	C1879547	Activation action	acty	3.55
25990958	C0332157	Exposure to	clna	3.54
25990958	C0274281	Injury due to exposure to external cause	inpo	3.54
25990958	C1704675	Interaction	ftcn	3.54
25990958	C0001239	Actin-Binding Protein	aapp	3.45
25990958	C0001239	Actin-Binding Protein	bacs	3.45
25990958	C1419227	RAC1 gene	gngm	3.42
25990958	C3274857	RAC1 wt Allele	gngm	3.42
25990958	C1704735	Regulator	cnce	3.42
25990958	C1704734	Regulator Device Component	mnob	3.42
25990958	C0182953	Regulators (device)	medd	3.42
25990958	C1561503	Precision - second	idcn	3.42
25990958	C1705190	Second Suffix	qlco	3.42
25990958	C0565930	per second	qnco	3.42
25990958	C0205436	second (number)	qnco	3.42
25990958	C0457385	seconds	tmco	3.42
25990958	C1706710	Adapter Device Component	mnob	3.42
25990958	C1421450	EZR gene	gngm	3.42
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
25990958	C3828842	Nearly	qlco	5.18
25990958	C0205174	Triplicate	qnco	3.98
25990958	C1167622	Binding (Molecular Function)	moft	3.57
25990958	C1145667	Binding action	acty	3.57
25990958	C1413365	CFTR gene	gngm	3.57
25990958	C2949735	Recruitment	acty	3.57
25990958	C1280519	Effectiveness	qlco	3.56
25990958	C1707887	Efficacy Study	resa	3.56
25990958	C1419227	RAC1 gene	gngm	3.50
25990958	C3274857	RAC1 wt Allele	gngm	3.50
25990958	C3252847	VX 809	orch	3.46
25990958	C3252847	VX 809	phsu	3.46
25990958	C0600596	DNA Microarray Chip	resd	3.44
25990958	C0458827	Airway structure	bpoc	3.43
25990958	C0178987	Artificial Airways	medd	3.43
25990958	C0007634	Cells	cell	3.43
25990958	C3282337	Cells [Chemical/Ingredient]	cell	3.43
25990958	C1420236	SLC9A3R1 gene	gngm	3.43
25990958	C0175668	Secondary to	tmco	3.42
25990958	C0059973	ezrin	aapp	25.93
25990958	C0059973	ezrin	bacs	25.93
25990958	C1280519	Effectiveness	qlco	7.22
25990958	C1707887	Efficacy Study	resa	7.22
25990958	C0442805	Increase	ftcn	7.16
25990958	C1421450	EZR gene	gngm	6.89
25990958	C1518422	Negation	ftcn	5.18
25990958	C0309872	PREVENT (product)	phsu	3.98
25990958	C1879547	Activation action	acty	3.68
25990958	C1149245	actin binding	moft	3.59
25990958	C1514873	Requirement	ftcn	3.57
25990958	C3541951	Concept model domain	inpr	3.55
25990958	C1880389	Domain (area of knowledge)	ftcn	3.55
25990958	C1883221	Superkingdom (taxonomic category)	cnce	3.55
25990958	C0521102	Interferes with	ftcn	3.55
25990958	C1419227	RAC1 gene	gngm	3.50
25990958	C3274857	RAC1 wt Allele	gngm	3.50
25990958	C3252847	VX 809	orch	3.44
25990958	C3252847	VX 809	phsu	3.44
25990958	C1704675	Interaction	ftcn	3.42
25990958	C1420236	SLC9A3R1 gene	gngm	3.42
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.09
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.09
25990958	C0025979	Microfilaments	celc	24.11
25990958	C0040363	Togo	geoa	17.80
25990958	C0041260	Tryptophanase	aapp	17.80
25990958	C0041260	Tryptophanase	enzy	17.80
25990958	C0032930	Precipitating Factors	clna	16.59
25990958	C0085732	Ability	orga	13.14
25990958	C0037083	Signal Transduction	celf	13.14
25990958	C0059973	ezrin	aapp	12.90
25990958	C0059973	ezrin	bacs	12.90
25990958	C0007603	Plasma membrane	celc	9.76
25990958	C1413365	CFTR gene	gngm	7.02
25990958	C1167622	Binding (Molecular Function)	moft	5.18
25990958	C1145667	Binding action	acty	5.18
25990958	C0184512	Stabilized (qualifier value)	qlco	5.18
25990958	C1883351	To	qlco	5.18
25990958	C1947931	Direct (qualifier)	qlco	3.98
25990958	C0439851	Direct type of relationship	qlco	3.98
25990958	C1444748	Triggered by	qlco	3.98
25990958	C1299581	Able (finding)	fndg	3.68
25990958	C3537152	biological signaling	biof	3.68
25990958	C0301641	Macromolecular alteration	moft	3.61
25990958	C1293132	Anchoring procedure	topp	3.57
25990958	C0205263	Induce (action)	ftcn	3.57
25990958	C0857127	Induction procedure	topp	3.57
25990958	C1624581	anchoring activity	moft	3.57
25990958	C1419227	RAC1 gene	gngm	3.50
25990958	C3274857	RAC1 wt Allele	gngm	3.50
25990958	C1883708	Then	tmco	3.50
25990958	C1879547	Activation action	acty	3.44
25990958	C1421450	EZR gene	gngm	3.44
25990958	C1420236	SLC9A3R1 gene	gngm	3.43
25990958	C0039798	therapeutic aspects	ftcn	22.51
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25990958	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25990958	C0040363	Togo	geoa	17.80
25990958	C0041260	Tryptophanase	aapp	17.80
25990958	C0041260	Tryptophanase	enzy	17.80
25990958	C0009738	Congo	geoa	16.07
25990958	C1999230	Providing (action)	acty	5.18
25990958	C1883351	To	qlco	5.18
25990958	C1521840	Target	ftcn	3.63
25990958	C2986546	Target Lesion Identification	diap	3.63
25990958	C1533734	Administration procedure	topp	3.59
25990958	C1705169	Biomaterial Treatment	cnce	3.59
25990958	C0087111	Therapeutic procedure	topp	3.59
25990958	C1522326	Treating	ftcn	3.59
25990958	C3538994	Treatment Epoch	resa	3.59
25990958	C3887704	treatment - ActInformationManagementReason	hlca	3.59
25990958	C0233820	Insight	menp	3.54
25990958	C0205314	New	qlco	3.50
25990958	C3811819	CFTR wt Allele	gngm	3.45
25990958	C0699040	Cell surface	celc	3.44
25990958	C1413365	CFTR gene	gngm	3.42
25990958	C1293130	Stabilization	topp	3.42
24726831	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.42
24726831	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.42
24726831	C0026377	Molecular Conformation	spco	12.84
24726831	C0010674	Cystic Fibrosis	dsyn	10.06
24726831	C0026882	Mutation	genf	9.94
24726831	C0678227	Causing	ftcn	7.05
24726831	C0392756	Reduced	qlco	5.18
24726831	C1705285	Mutation Abnormality	comd	3.63
24726831	C3854321	Expression (foundation metadata concept)	idcn	3.54
24726831	C0185117	Expression procedure	topp	3.54
24726831	C1254042	Anatomical maturation	phsf	3.54
24726831	C0678723	Biologic Development	orgf	3.54
24726831	C0870861	Human maturation	phpr	3.54
24726831	C1413365	CFTR gene	gngm	3.49
24726831	C0205214	Common (qualifier value)	qnco	3.48
24726831	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.48
24726831	C0205393	Most	qnco	3.48
24726831	C1522138	shared attribute	ftcn	3.48
24726831	C1182809	Surface of epithelium	blor	3.45
24726831	C0542341	Function	ftcn	3.42
24726831	C0205245	Functional	ftcn	3.42
24726831	C2700217	Functional Relationship	cnce	3.42
24726831	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
24726831	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
24726831	C0040363	Togo	geoa	17.80
24726831	C0041260	Tryptophanase	aapp	17.80
24726831	C0041260	Tryptophanase	enzy	17.80
24726831	C1254042	Anatomical maturation	phsf	5.18
24726831	C3889128	BBS9 wt Allele	gngm	5.18
24726831	C0678723	Biologic Development	orgf	5.18
24726831	C0439780	Forward	spco	5.18
24726831	C0870861	Human maturation	phpr	5.18
24726831	C0332257	Including (qualifier)	ftcn	5.18
24726831	C1883351	To	qlco	5.18
24726831	C3252847	VX 809	orch	5.18
24726831	C3252847	VX 809	phsu	5.18
24726831	C1547282	Show	anim	3.98
24726831	C0699040	Cell surface	celc	3.61
24726831	C0205198	Compound	qlco	3.59
24726831	C1706082	Compound (substance)	chem	3.59
24726831	C1413365	CFTR gene	gngm	3.57
24726831	C0599896	trafficking	celf	3.56
24726831	C0035820	Social Role	socb	13.02
24726831	C0220781	Anabolism	biof	6.66
24726831	C1547282	Show	anim	5.18
24726831	C3266814	Action	acty	3.68
24726831	C1706853	Assembly (construction)	acty	3.68
24726831	C1879748	Assembly (group of parts)	mnob	3.68
24726831	C0441472	Clinical action	ftcn	3.68
24726831	C1948052	Now (temporal qualifier)	tmco	3.68
24726831	C1705810	Generic Role	cnce	3.56
24726831	C3871154	{Role}	inpr	3.56
24726831	C0205198	Compound	qlco	3.54
24726831	C1706082	Compound (substance)	chem	3.54
24726831	C1524062	Additional	ftcn	3.50
24726831	C3810841	Biosynthetic	fndg	3.50
24726831	C1272745	Improving (qualifier value)	qlco	3.43
24726831	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
24726831	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
24726831	C1167622	Binding (Molecular Function)	moft	5.18
24726831	C1145667	Binding action	acty	5.18
24726831	C1547282	Show	anim	5.18
24726831	C0205198	Compound	qlco	3.98
24726831	C1706082	Compound (substance)	chem	3.98
24726831	C0947630	Scientific Study	lbpr	3.68
24726831	C1413365	CFTR gene	gngm	3.54
24726831	C0439799	Channel	spco	3.54
24726831	C1706095	Channel Object	cnce	3.54
24726831	C1947931	Direct (qualifier)	qlco	3.54
24726831	C0443225	Full	qlco	3.54
24726831	C1444754	Length	qnco	3.54
24726831	C1706316	Length of Trial	resa	3.54
24726831	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
24726831	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
24726831	C0040363	Togo	geoa	17.80
24726831	C0041260	Tryptophanase	aapp	17.80
24726831	C0041260	Tryptophanase	enzy	17.80
24726831	C0007585	Cell Culture Techniques	lbpr	16.37
24726831	C0031843	physiological aspects	phsf	14.64
24726831	C0010453	Anthropological Culture	idcn	13.09
24726831	C0005507	Biological Assay	lbpr	6.73
24726831	C1456348	Confirm	qlco	5.18
24726831	C0750484	Confirmation	idcn	5.18
24726831	C0521093	Confirmed by	qlco	5.18
24726831	C2349975	Enhance (action)	acty	5.18
24726831	C0542341	Function	ftcn	5.18
24726831	C0700205	Function Axis	clas	5.18
24726831	C1705273	Mathematical Operator	inpr	5.18
24726831	C0185026	Plication	topp	5.18
24726831	C1883351	To	qlco	5.18
24726831	C0301863	"""U"" lymphocyte"	cell	3.75
24726831	C0220814	Cultural aspects	ftcn	3.63
24726831	C0430400	Laboratory culture	lbpr	3.63
24726831	C2242979	Microbial culture (procedure)	lbpr	3.63
24726831	C0332287	In addition to	ftcn	3.62
24726831	C0205198	Compound	qlco	3.59
24726831	C1706082	Compound (substance)	chem	3.59
24726831	C1510438	Assay	lbpr	3.58
24726831	C0243073	assay qualifier	qlco	3.58
24726831	C1167622	Binding (Molecular Function)	moft	3.55
24726831	C1145667	Binding action	acty	3.55
24726831	C1413365	CFTR gene	gngm	3.55
24726831	C1280500	Effect	qlco	3.55
24726831	C2348382	Effect, Appearance	qlco	3.55
24726831	C0443225	Full	qlco	3.55
24726831	C1444754	Length	qnco	3.55
24726831	C1706316	Length of Trial	resa	3.55
24726831	C1709483	Patient Base	qnco	3.48
24726831	C0205423	Certain (qualifier value)	qlco	3.48
24726831	C1704787	Definitely Related to Intervention	qlco	3.48
24726831	C0040300	Body tissue	tisu	3.47
24726831	C1547928	Tissue Specimen Code	inpr	3.47
24726831	C0699040	Cell surface	celc	3.44
24726831	C0728938	Partial	qnco	3.42
24726831	C1550516	Target Awareness - partial	idcn	3.42
24726831	C0537670	Oprelvekin	aapp	14.64
24726831	C0537670	Oprelvekin	imft	14.64
24726831	C0537670	Oprelvekin	phsu	14.64
24726831	C3539655	CDISC Findings Class	inpr	5.18
24726831	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
24726831	C0700287	Reporting	hlca	5.18
24726831	C2607943	findings aspects	ftcn	5.18
24726831	C1552002	inform	ocac	5.18
24726831	C2348767	Therapeutic Efficacy	qlco	3.75
24726831	C0678723	Biologic Development	orgf	3.56
24726831	C1527148	Development	ftcn	3.56
24726831	C0243107	development aspects	phsf	3.56
24726831	C1561611	Admission Level of Care Code - Improved	inpr	3.48
24726831	C0332272	Better	qlco	3.48
24726831	C0184511	Improved	qlco	3.48
24726831	C1523987	Alternative	cnce	3.43
24726831	C0205198	Compound	qlco	3.41
24726831	C1706082	Compound (substance)	chem	3.41
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
24106801	C0008677	Bronchitis, Chronic	dsyn	17.80
24106801	C1314792	Etiology	ftcn	13.08
24106801	C0026687	Mucociliary Clearance	clna	13.07
24106801	C0015127	Etiology aspects	ftcn	9.92
24106801	C0031847	physiopathological	ftcn	9.91
24106801	C0439661	Acquired (qualifier value)	tmco	5.18
24106801	C3245488	Acquired Name	inpr	5.18
24106801	C0332281	Associated with	qlco	3.61
24106801	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.60
24106801	C3887504	Dysfunction	cnce	3.60
24106801	C0277785	Functional disorder	patf	3.60
24106801	C1413365	CFTR gene	gngm	3.58
24106801	C0205421	Deferred	tmco	3.56
24106801	C3272602	Delayed Testing	qlco	3.56
24106801	C0239059	Cigarette smoke (substance)	hops	3.50
24106801	C0700219	Cigarette smoking behavior	inbe	3.50
24106801	C2936609	Phosphodiesterase 4 Inhibitors	phsu	19.49
24106801	C0008677	Bronchitis, Chronic	dsyn	17.80
24106801	C0965618	Roflumilast	orch	13.14
24106801	C0965618	Roflumilast	phsu	13.14
24106801	C0035245	Respiratory physiology	ortf	6.79
24106801	C0030705	Patients	podg	6.59
24106801	C0184511	Improved	qlco	5.18
24106801	C3537247	Phosphodiesterase 4 Inhibitor [EPC]	phsu	3.72
24106801	C4049968	Phosphodiesterase 4 inhibitor	phsu	3.72
24106801	C0205540	Approved	qlco	3.46
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
24106801	C0814225	benefit	qnco	3.68
24106801	C0449719	Part	spco	3.59
24106801	C1709471	Part Dosing Unit	qnco	3.59
24106801	C0445223	Related personal status	fndg	3.59
24106801	C0439849	Relationships	qlco	3.59
24106801	C1879547	Activation action	acty	3.57
24106801	C0302350	Therapeutic	ftcn	3.50
24106801	C0087111	Therapeutic procedure	topp	3.50
24106801	C1413365	CFTR gene	gngm	3.44
24106801	C0086418	Homo sapiens	humn	28.83
24106801	C0039798	therapeutic aspects	ftcn	22.49
24106801	C3536832	Air	inch	16.26
24106801	C3536832	Air	phsu	16.26
24106801	C0001861	Air (substance)	sbst	16.26
24106801	C0965618	Roflumilast	orch	13.03
24106801	C0965618	Roflumilast	phsu	13.03
24106801	C0301863	"""U"" lymphocyte"	cell	3.71
24106801	C1413097	CALU gene	gngm	3.68
24106801	C0872351	monolayer	clnd	3.68
24106801	C1551331	Transportation Services; Ambulance; Air	hcro	3.64
24106801	C1551331	Transportation Services; Ambulance; Air	mnob	3.64
24106801	C0239059	Cigarette smoke (substance)	hops	3.61
24106801	C0024496	Main Bronchus	bpoc	3.60
24106801	C0221908	epithelial	qlco	3.60
24106801	C1533734	Administration procedure	topp	3.57
24106801	C1705169	Biomaterial Treatment	cnce	3.57
24106801	C0087111	Therapeutic procedure	topp	3.57
24106801	C1522326	Treating	ftcn	3.57
24106801	C3538994	Treatment Epoch	resa	3.57
24106801	C3887704	treatment - ActInformationManagementReason	hlca	3.57
24106801	C0332157	Exposure to	clna	3.56
24106801	C0444667	Whole	qnco	3.56
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
24106801	C0162585	Ion Transport	celf	13.11
24106801	C0179874	Chamber (physical object)	mnob	3.56
24106801	C0392747	Changing	ftcn	3.56
24106801	C3889737	Data Change Date	tmco	3.56
24106801	C0444706	Measured	qlco	3.56
24106801	C3541902	Measured Tumor Identification	diap	3.56
24106801	C1413365	CFTR gene	gngm	3.46
24106801	C1701901	Conditional	qlco	3.46
24106801	C0851827	Dependent - ability	qlco	3.46
24106801	C3244310	dependent	ftcn	3.46
24106801	C0242842	Microscopy, Confocal	lbpr	16.26
24106801	C0458827	Airway structure	bpoc	3.61
24106801	C0178987	Artificial Airways	medd	3.61
24106801	C1304698	Liquid (finding)	fndg	3.61
24106801	C1546699	Liquid NOS - Specimen Source Codes	inpr	3.61
24106801	C1561501	Liquid Specimen	sbst	3.61
24106801	C0301571	Liquid diet	topp	3.61
24106801	C0302908	Liquid substance	sbst	3.61
24106801	C0205148	Surface	spco	3.61
24106801	C0026809	Mus	mamm	28.66
24106801	C0030695	Patient Monitoring	hlca	10.28
24106801	C0021849	Intestinal Secretions	bdsu	9.87
24106801	C0021853	Intestines	bpoc	9.73
24106801	C0005889	Body Fluids	bdsu	6.58
24106801	C2348480	ex vivo	ftcn	5.18
24106801	C0181904	Biomedical Monitors	medd	3.98
24106801	C1704646	Monitor Device Component	mnob	3.98
24106801	C1521743	Monitor, occupation	prog	3.98
24106801	C0596972	Monitoring Device	medd	3.98
24106801	C0150369	Preventive monitoring	hlca	3.98
24106801	C2263233	body fluid secretion	celf	3.57
24106801	C0444611	Fluid behavior	qlco	3.42
24106801	C0302908	Liquid substance	sbst	3.42
24106801	C1292984	Procedure on intestine	hlca	3.42
24106801	C1704353	fluid - substance	sbst	3.42
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24106801	C0965618	Roflumilast	orch	13.14
24106801	C0965618	Roflumilast	phsu	13.14
24106801	C1879547	Activation action	acty	5.18
24106801	C1159585	anion transport	celf	3.57
24106801	C1704419	Effective	qlco	3.54
24106801	C1280519	Effectiveness	qlco	3.54
24106801	C2347813	Cmax	qnco	3.53
24106801	C0007634	Cells	cell	3.43
24106801	C1268443	Normal cell	cell	3.43
24106801	C1413365	CFTR gene	gngm	3.42
24106801	C1701901	Conditional	qlco	3.42
24106801	C0851827	Dependent - ability	qlco	3.42
24106801	C1415484	HBE1 gene	gngm	3.42
24106801	C2827566	HBE1 wt Allele	gngm	3.42
24106801	C2825407	Half	qnco	3.42
24106801	C3844844	Hb E	fndg	3.42
24106801	C3244310	dependent	ftcn	3.42
24106801	C0312860	Neutrophil migration, function	celf	3.63
24106801	C3890923	Nuclear Medicine Study File	inpr	3.63
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
24106801	C0965618	Roflumilast	orch	12.88
24106801	C0965618	Roflumilast	phsu	12.88
24106801	C0728893	+5	qnco	5.18
24106801	C0439084	>5	qnco	5.18
24106801	C1561536	*Activity (kind of quantity)	idcn	3.54
24106801	C0205177	Active	ftcn	3.54
24106801	C0441655	Activities	acty	3.54
24106801	C3668946	Activity (animal life circumstance)	fndg	3.54
24106801	C4049939	FDA Establishment Activity Terminology	inpr	3.54
24106801	C0439167	Percent Activity	qnco	3.54
24106801	C4049938	Physical Activity Measurement	lbpr	3.54
24106801	C0301863	"""U"" lymphocyte"	cell	3.42
24106801	C1413365	CFTR gene	gngm	3.42
24106801	C0332157	Exposure to	clna	3.42
24106801	C1415484	HBE1 gene	gngm	3.42
24106801	C2827566	HBE1 wt Allele	gngm	3.42
24106801	C3844844	Hb E	fndg	3.42
24106801	C0740116	+2	qnco	5.18
24106801	C3833492	2+	fndg	5.18
24106801	C2827735	2+ Score	qnco	5.18
24106801	C2981700	2+ Score, WHO	clas	5.18
24106801	C3842591	0%	fndg	3.61
24106801	C0023376	Lesotho	geoa	16.30
24106801	C0740116	+2	qnco	5.18
24106801	C3842591	0%	fndg	5.18
24106801	C3833492	2+	fndg	5.18
24106801	C2827735	2+ Score	qnco	5.18
24106801	C2981700	2+ Score, WHO	clas	5.18
24106801	C2587213	Control function	ftcn	5.18
24106801	C1882979	Scientific Control	cnce	5.18
24106801	C3274648	True Control Status	qlco	5.18
24106801	C0243148	control aspects	qlco	5.18
24106801	C1550141	control substance	sbst	5.18
24106801	C3887647	Lymphotoxin-Alpha, human	aapp	3.68
24106801	C3887647	Lymphotoxin-Alpha, human	imft	3.68
24106801	C0230426	Structure of left thigh	bpoc	3.68
24106801	C0369773	P Blood group antibodies	aapp	3.50
24106801	C0369773	P Blood group antibodies	imft	3.50
24106801	C2603361	P prime	clna	3.50
24106801	C0039798	therapeutic aspects	ftcn	22.48
24106801	C0009738	Congo	geoa	16.17
24106801	C3264621	ivacaftor	orch	12.91
24106801	C3264621	ivacaftor	phsu	12.91
24106801	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.75
24106801	C0442796	Additive	qlco	3.59
24106801	C1550602	additive ingredient	sbst	3.59
24106801	C1533734	Administration procedure	topp	3.55
24106801	C0205540	Approved	qlco	3.55
24106801	C1705169	Biomaterial Treatment	cnce	3.55
24106801	C3811819	CFTR wt Allele	gngm	3.55
24106801	C0087111	Therapeutic procedure	topp	3.55
24106801	C1522326	Treating	ftcn	3.55
24106801	C3538994	Treatment Epoch	resa	3.55
24106801	C3887704	treatment - ActInformationManagementReason	hlca	3.55
24106801	C1552740	Entity Determiner - specific	inpr	3.48
24106801	C0205369	Specific qualifier value	qlco	3.48
24106801	C0965618	Roflumilast	orch	13.14
24106801	C0965618	Roflumilast	phsu	13.14
24106801	C1561611	Admission Level of Care Code - Improved	inpr	5.18
24106801	C0332272	Better	qlco	5.18
24106801	C0184511	Improved	qlco	5.18
24106801	C0332157	Exposure to	clna	3.59
24106801	C0205125	Depth	spco	3.55
24106801	C1412582	ASL gene	gngm	3.42
24106801	C3891302	Arterial Spin Labeling Magnetic Resonance Imaging	diap	3.42
24106801	C0333668	Depletion	ftcn	3.42
24106801	C1415484	HBE1 gene	gngm	3.42
24106801	C2827566	HBE1 wt Allele	gngm	3.42
24106801	C3844844	Hb E	fndg	3.42
24106801	C0872351	monolayer	clnd	3.42
24106801	C3842591	0%	fndg	3.61
24106801	C0023376	Lesotho	geoa	16.30
24106801	C3842591	0%	fndg	7.31
24106801	C2587213	Control function	ftcn	5.18
24106801	C1882979	Scientific Control	cnce	5.18
24106801	C3274648	True Control Status	qlco	5.18
24106801	C0243148	control aspects	qlco	5.18
24106801	C1550141	control substance	sbst	5.18
24106801	C3887647	Lymphotoxin-Alpha, human	aapp	3.68
24106801	C3887647	Lymphotoxin-Alpha, human	imft	3.68
24106801	C0230426	Structure of left thigh	bpoc	3.68
24106801	C0369773	P Blood group antibodies	aapp	3.50
24106801	C0369773	P Blood group antibodies	imft	3.50
24106801	C2603361	P prime	clna	3.50
24106801	C3536832	Air	inch	16.30
24106801	C3536832	Air	phsu	16.30
24106801	C0001861	Air (substance)	sbst	16.30
24106801	C2587213	Control function	ftcn	5.18
24106801	C1441672	Observed	ftcn	5.18
24106801	C1882979	Scientific Control	cnce	5.18
24106801	C3274648	True Control Status	qlco	5.18
24106801	C0243148	control aspects	qlco	5.18
24106801	C1550141	control substance	sbst	5.18
24106801	C1551331	Transportation Services; Ambulance; Air	hcro	3.68
24106801	C1551331	Transportation Services; Ambulance; Air	mnob	3.68
24106801	C0026809	Mus	mamm	57.73
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
24106801	C0011682	Desiccation	npop	12.96
24106801	C0965618	Roflumilast	orch	12.88
24106801	C0965618	Roflumilast	phsu	12.88
24106801	C0021853	Intestines	bpoc	9.99
24106801	C0442808	Increasing	ftcn	5.18
24106801	C0205381	Moist	qlco	5.18
24106801	C1708548	Intestinal Wall Tissue	tisu	3.68
24106801	C0456603	Ratio	qnco	3.68
24106801	C1547037	data type - ratio	inpr	3.68
24106801	C1301886	Diameter (qualifier value)	qnco	3.55
24106801	C1879547	Activation action	acty	3.54
24106801	C0205222	Dry	qlco	3.50
24106801	C1512080	Dryness (characteristic)	qlco	3.50
24106801	C2263233	body fluid secretion	celf	3.43
24106801	C1413365	CFTR gene	gngm	3.42
24106801	C1701901	Conditional	qlco	3.42
24106801	C0851827	Dependent - ability	qlco	3.42
24106801	C0205263	Induce (action)	ftcn	3.42
24106801	C3244310	dependent	ftcn	3.42
24106801	C0441635	Anatomical segmentation	spco	3.41
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24106801	C0001455	Cyclic AMP	bacs	19.22
24106801	C0001455	Cyclic AMP	nnon	19.22
24106801	C0001455	Cyclic AMP	phsu	19.22
24106801	C0965618	Roflumilast	orch	13.14
24106801	C0965618	Roflumilast	phsu	13.14
24106801	C1879547	Activation action	acty	5.18
24106801	C1555029	Reverse	ftcn	5.18
24106801	C3853838	activate - Data Operation	ftcn	5.18
24106801	C1515877	activate biological process	ftcn	5.18
24106801	C0332294	Resulting in	ftcn	3.61
24106801	C1159585	anion transport	celf	3.59
24106801	C1412582	ASL gene	gngm	3.56
24106801	C3891302	Arterial Spin Labeling Magnetic Resonance Imaging	diap	3.56
24106801	C0205125	Depth	spco	3.56
24106801	C1280500	Effect	qlco	3.56
24106801	C0205217	Increased	qnco	3.56
24106801	C1280750	Entire intestinal epithelium	tisu	3.55
24106801	C0226890	Structure of intestinal epithelium	tisu	3.55
24106801	C0458827	Airway structure	bpoc	3.43
24106801	C0178987	Artificial Airways	medd	3.43
24106801	C1413365	CFTR gene	gngm	3.43
24106801	C0086597	Mediate	socb	3.43
24106801	C0127400	Mediator brand of benfluorex hydrochloride	orch	3.43
24106801	C0127400	Mediator brand of benfluorex hydrochloride	phsu	3.43
24106801	C1704259	Biochemical Pathway	moft	3.42
24106801	C1701901	Conditional	qlco	3.42
24106801	C0851827	Dependent - ability	qlco	3.42
24106801	C1705987	Pathway (interactions)	cnce	3.42
24106801	C3244310	dependent	ftcn	3.42
24106801	C0965618	Roflumilast	orch	26.34
24106801	C0965618	Roflumilast	phsu	26.34
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24106801	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24106801	C0008677	Bronchitis, Chronic	dsyn	16.21
24106801	C0024117	Chronic Obstructive Airway Disease	dsyn	12.98
24106801	C0015127	Etiology aspects	ftcn	9.86
24106801	C0030705	Patients	podg	6.71
24106801	C0267436	Non-infective diarrhea	dsyn	5.18
24106801	C0814225	benefit	qnco	5.18
24106801	C1524003	Science of Etiology	cnce	3.55
24106801	C1879547	Activation action	acty	3.43
24106801	C1413365	CFTR gene	gngm	3.43
27490265	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.00
27490265	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.00
27490265	C0031843	physiological aspects	phsf	13.02
27490265	C0010674	Cystic Fibrosis	dsyn	10.06
27490265	C0015127	Etiology aspects	ftcn	9.86
27490265	C0019247	Hereditary Diseases	dsyn	6.91
27490265	C1527118	Protein Function	moft	3.60
27490265	C0815043	Protein, Organized by Function	aapp	3.60
27490265	C0392756	Reduced	qlco	3.59
27490265	C0542341	Function	ftcn	3.56
27490265	C0700205	Function Axis	clas	3.56
27490265	C1705273	Mathematical Operator	inpr	3.56
27490265	C1524003	Science of Etiology	cnce	3.55
27490265	C0441748	Autosomal recessive inheritance	genf	3.50
27490265	C0332197	Absent	ftcn	3.43
27490265	C2699517	Absent Adverse Event	fndg	3.43
27490265	C1413365	CFTR gene	gngm	3.43
27490265	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.46
27490265	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.46
27490265	C0009738	Congo	geoa	17.80
27490265	C3811819	CFTR wt Allele	gngm	5.18
27490265	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.58
27490265	C3242455	HL7PublishingDomain <patient administration>	inpr	3.58
27490265	C3242279	healthcare operations <patient administration>	ocac	3.58
27490265	C0686907	Consequence of	ftcn	3.54
27490265	C1413365	CFTR gene	gngm	3.54
27490265	C0522506	Downstream	spco	3.54
27490265	C0444930	End	spco	3.54
27490265	C0205234	Focal	spco	3.54
27490265	C1285542	Has focus	ftcn	3.54
27490265	C0178784	Organ	bpoc	3.54
27490265	C2746065	Stop (qualifier value)	tmco	3.54
27490265	C0332452	defective	ftcn	3.54
27490265	C0009738	Congo	geoa	32.44
27490265	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27490265	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27490265	C1314792	Etiology	ftcn	14.64
27490265	C0162340	Comprehension	menp	12.88
27490265	C0017398	Science of genetics	bmod	12.88
27490265	C0017399	genetic aspects	ftcn	12.88
27490265	C0015127	Etiology aspects	ftcn	11.49
27490265	C0031847	physiopathological	ftcn	9.90
27490265	C2717881	Candidate Gene Identification	mbrt	9.89
27490265	C3811819	CFTR wt Allele	gngm	7.06
27490265	C1413365	CFTR gene	gngm	6.92
27490265	C1524003	Science of Etiology	cnce	5.18
27490265	C0277785	Functional disorder	patf	3.59
27490265	C1880355	Discover	acty	3.55
27490265	C3854260	Advance	tmco	3.51
27490265	C0725066	Advance -- medical device	medd	3.51
27490265	C0314603	Genetic	ftcn	3.42
27490265	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.46
27490265	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.46
27490265	C0079870	Mutagenesis, Site-Directed	genf	16.17
27490265	C0009738	Congo	geoa	16.07
27490265	C0030705	Patients	podg	6.74
27490265	C1707391	Choose (action)	acty	5.18
27490265	C0332185	Recent	tmco	5.18
27490265	C2985439	De novo mutation	comd	3.55
27490265	C2985566	Targeted Therapy	topp	3.54
27490265	C0678723	Biologic Development	orgf	3.54
27490265	C1413365	CFTR gene	gngm	3.54
27490265	C1527148	Development	ftcn	3.54
27490265	C1552740	Entity Determiner - specific	inpr	3.54
27490265	C1708698	Light Emitting Diode Device Component	mnob	3.54
27490265	C0205314	New	qlco	3.54
27490265	C0205369	Specific qualifier value	qlco	3.54
27490265	C1521840	Target	ftcn	3.54
27490265	C0243107	development aspects	phsf	3.54
27490265	C1881345	LED Therapy	topp	3.54
27490265	C3242274	new therapy	fndg	3.54
27490265	C3811819	CFTR wt Allele	gngm	3.45
27490265	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.04
27490265	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.04
27490265	C0009738	Congo	geoa	17.80
27490265	C0015127	Etiology aspects	ftcn	11.49
27490265	C0282443	Review [Publication Type]	inpr	11.49
27490265	C1413365	CFTR gene	gngm	10.54
27490265	C0026882	Mutation	genf	9.99
27490265	C0010674	Cystic Fibrosis	dsyn	9.84
27490265	C0013216	Pharmacotherapy	topp	6.80
27490265	C1552617	Act Class - review	idcn	5.18
27490265	C3811819	CFTR wt Allele	gngm	5.18
27490265	C2584313	Discussion (communication)	socb	5.18
27490265	C0332257	Including (qualifier)	ftcn	5.18
27490265	C1524003	Science of Etiology	cnce	5.18
27490265	C0017296	gene therapy	topp	5.18
27490265	C1947933	care activity	acty	3.63
27490265	C1517495	Gene Feature	gngm	3.58
27490265	C1521970	Characteristics	qlco	3.55
27490265	C1880177	Contribution	acty	3.54
27490265	C3495919	Enthesitis-Related Arthritis	dsyn	3.54
27490265	C0205314	New	qlco	3.54
27490265	C2985439	De novo mutation	comd	3.49
27490265	C1552740	Entity Determiner - specific	inpr	3.46
27490265	C0205369	Specific qualifier value	qlco	3.46
25027379	C0014239	Endoplasmic Reticulum	celc	22.41
25027379	C0040363	Togo	geoa	17.80
25027379	C0041260	Tryptophanase	aapp	17.80
25027379	C0041260	Tryptophanase	enzy	17.80
25027379	C1159342	Secretory Pathway	celf	14.64
25027379	C0026377	Molecular Conformation	spco	12.87
25027379	C0034378	quality control	ftcn	9.96
25027379	C1880834	Fold in Medical Device Material	phpr	6.95
25027379	C0332462	Folded structure	spco	6.95
25027379	C0033684	Proteins	aapp	6.79
25027379	C0033684	Proteins	bacs	6.79
25027379	C0309872	PREVENT (product)	phsu	5.18
25027379	C1883351	To	qlco	5.18
25027379	C1561524	Quality Control Specimen	ftcn	3.65
25027379	C1610034	Specimen Source Codes - Quality Control	inpr	3.65
25027379	C0680582	control system	rnlw	3.65
25027379	C1704459	Device Component System	mnob	3.60
25027379	C0332306	Quality	qlco	3.60
25027379	C0449913	System	ftcn	3.60
25027379	C1553451	System - kit	mnob	3.60
25027379	C1709694	Processing (action)	acty	3.56
25027379	C0599155	Missense Mutation	genf	13.24
25027379	C0152244	Bone Cysts, Aneurysmal	dsyn	13.01
25027379	C0023175	Lead	elii	13.01
25027379	C0023175	Lead	hops	13.01
25027379	C0031437	Phenotype	orga	6.79
25027379	C0033684	Proteins	aapp	6.71
25027379	C0033684	Proteins	bacs	6.71
25027379	C3890225	Active Breathing Coordinator-Mediated Radiation Therapy	topp	3.55
25027379	C3275067	Cardiac Lead Procedure	topp	3.55
25027379	C2348269	Dietary Lead	elii	3.55
25027379	C1522538	Leading	ftcn	3.55
25027379	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.55
25027379	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.55
25027379	C0243083	associated disease	patf	3.53
25027379	C0037640	Somalia	geoa	16.08
25027379	C1292208	U- phenotype	fndg	3.74
25027379	C2828102	Pharmacological Chaperone	chvf	3.65
25027379	C1328819	Small Molecule	orch	3.64
25027379	C0205202	Corrected	qlco	3.57
25027379	C1552740	Entity Determiner - specific	inpr	3.48
25027379	C0205369	Specific qualifier value	qlco	3.48
25027379	C1947967	Call (Instruction)	ftcn	3.44
25027379	C0679006	Decision	menp	3.44
25027379	C0039798	therapeutic aspects	ftcn	22.35
25027379	C0008372	Intrahepatic Cholestasis	dsyn	17.80
25027379	C0040363	Togo	geoa	17.80
25027379	C0041260	Tryptophanase	aapp	17.80
25027379	C0041260	Tryptophanase	enzy	17.80
25027379	C0010674	Cystic Fibrosis	dsyn	11.49
25027379	C0012634	Disease	dsyn	9.74
25027379	C1517001	Expected	inpr	5.18
25027379	C0175566	Open	spco	5.18
25027379	C1883351	To	qlco	5.18
25027379	C0220909	Aspects of disease screening	ftcn	3.56
25027379	C1710031	Disease Screening	diap	3.56
25027379	C0220908	Screening procedure	hlca	3.56
25027379	C1710477	Trial Screening	resa	3.56
25027379	C1698960	research subject screening	inpr	3.56
25027379	C0185026	Plication	topp	3.43
25027379	C1533734	Administration procedure	topp	3.43
25027379	C1705169	Biomaterial Treatment	cnce	3.43
25027379	C0087111	Therapeutic procedure	topp	3.43
25027379	C1522326	Treating	ftcn	3.43
25027379	C3538994	Treatment Epoch	resa	3.43
25027379	C3887704	treatment - ActInformationManagementReason	hlca	3.43
25266997	C0007457	Caucasoid Race	popg	12.88
25266997	C0010674	Cystic Fibrosis	dsyn	10.06
25266997	C0376558	Life	idcn	9.73
25266997	C0019247	Hereditary Diseases	dsyn	6.71
25266997	C0043157	Caucasians	popg	3.42
25266997	C0205214	Common (qualifier value)	qnco	3.42
25266997	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
25266997	C0205393	Most	qnco	3.42
25266997	C0441636	Surgical shortening - action	topp	3.42
25266997	C1522138	shared attribute	ftcn	3.42
25266997	C0009738	Congo	geoa	17.80
25266997	C0015544	Failure to Thrive	dsyn	11.49
25266997	C0012634	Disease	dsyn	9.94
25266997	C3811819	CFTR wt Allele	gngm	5.18
25266997	C3887638	Failure to thrive in infant	dsyn	5.18
25266997	C2315100	Pediatric failure to thrive	dsyn	5.18
25266997	C0876973	Infectious disease of lung	dsyn	3.75
25266997	C0333133	Mucus cast	acab	3.61
25266997	C0264220	Chronic disease of respiratory system	dsyn	3.60
25266997	C0264219	Acute respiratory disease	dsyn	3.59
25266997	C0011900	Diagnosis	fndg	3.54
25266997	C1457887	Symptoms	sosy	3.54
25266997	C0683368	Symptoms aspect	ftcn	3.54
25266997	C0205178	acute	tmco	3.54
25266997	C0205191	chronic	tmco	3.54
25266997	C0439064	Numerous	qnco	3.48
25266997	C0178784	Organ	bpoc	3.48
25266997	C0205322	persistent	tmco	3.48
25266997	C0458827	Airway structure	bpoc	3.43
25266997	C0178987	Artificial Airways	medd	3.43
25266997	C0009738	Congo	geoa	16.16
25266997	C0021699	Integral Membrane Proteins	aapp	9.86
25266997	C0031847	physiopathological	ftcn	9.85
25266997	C0014609	Epithelium	tisu	6.57
25266997	C0439799	Channel	spco	5.18
25266997	C1706095	Channel Object	cnce	5.18
25266997	C0086597	Mediate	socb	5.18
25266997	C0231217	Multiple symptoms	sosy	5.18
25266997	C1159585	anion transport	celf	3.64
25266997	C3811819	CFTR wt Allele	gngm	3.54
25266997	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.54
25266997	C3887504	Dysfunction	cnce	3.54
25266997	C0277785	Functional disorder	patf	3.54
25266997	C1704735	Regulator	cnce	3.54
25266997	C1704734	Regulator Device Component	mnob	3.54
25266997	C0182953	Regulators (device)	medd	3.54
25266997	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
25266997	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
25266997	C1704338	diagnosis aspect	qlco	22.35
25266997	C0038990	Sweating	fndg	19.32
25266997	C0009738	Congo	geoa	16.04
25266997	C0038984	Sweat	bdsu	9.86
25266997	C0031847	physiopathological	ftcn	9.75
25266997	C0022885	Laboratory Procedures	lbpr	5.18
25266997	C0456984	Test Result	fndg	5.18
25266997	C0039593	Testing	ftcn	5.18
25266997	C0392366	Tests (qualifier value)	inpr	5.18
25266997	C0556981	% proof	qnco	3.57
25266997	C0596019	Chloride Ion	elii	3.55
25266997	C1947967	Call (Instruction)	ftcn	3.52
25266997	C0679006	Decision	menp	3.52
25266997	C1413365	CFTR gene	gngm	3.44
25266997	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.44
25266997	C3887504	Dysfunction	cnce	3.44
25266997	C0277785	Functional disorder	patf	3.44
25266997	C3811819	CFTR wt Allele	gngm	3.43
25266997	C0439544	Definite	qlco	3.43
25266997	C1704787	Definitely Related to Intervention	qlco	3.43
25266997	C0011900	Diagnosis	fndg	3.43
25266997	C1704656	Diagnosis Study	resa	3.43
25266997	C0003237	Antibiotics, Antitubercular	antb	24.11
25266997	C0003232	Antibiotics	antb	17.80
25266997	C0040363	Togo	geoa	17.80
25266997	C0041260	Tryptophanase	aapp	17.80
25266997	C0041260	Tryptophanase	enzy	17.80
25266997	C0009738	Congo	geoa	16.04
25266997	C0013216	Pharmacotherapy	topp	8.34
25266997	C0024115	Lung diseases	dsyn	6.63
25266997	C2948600	Aim	phsu	5.18
25266997	C1947946	Aim (idea)	idcn	5.18
25266997	C3540472	Ancestry-Informative Marker	ftcn	5.18
25266997	C3540706	Antibiotic throat preparations	antb	5.18
25266997	C3540707	Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	antb	5.18
25266997	C3540704	Antibiotics for systemic use	antb	5.18
25266997	C3540708	Antibiotics, Gynecological	antb	5.18
25266997	C3540710	Antibiotics, ophthalmologic	antb	5.18
25266997	C3540705	Antifungal Antibiotics, Topical	antb	5.18
25266997	C3890193	CD5L wt Allele	gngm	5.18
25266997	C2744535	CD69 protein, human	aapp	5.18
25266997	C2744535	CD69 protein, human	imft	5.18
25266997	C3540471	CD69 wt Allele	gngm	5.18
25266997	C0332257	Including (qualifier)	ftcn	5.18
25266997	C1883351	To	qlco	5.18
25266997	C3540709	antibiotics, intestinal	antb	5.18
25266997	C0026698	mucolytic agents	phsu	5.18
25266997	C1457887	Symptoms	sosy	3.55
25266997	C0683368	Symptoms aspect	ftcn	3.55
25266997	C3811819	CFTR wt Allele	gngm	3.43
25266997	C0040363	Togo	geoa	35.81
25266997	C0041260	Tryptophanase	aapp	35.81
25266997	C0041260	Tryptophanase	enzy	35.81
25266997	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
25266997	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
25266997	C0008976	Clinical Trials	resa	19.41
25266997	C0009738	Congo	geoa	16.23
25266997	C0002424	Ambulatory Care Facilities	hcro	11.49
25266997	C0002424	Ambulatory Care Facilities	mnob	11.49
25266997	C1883351	To	qlco	10.42
25266997	C1096775	Clinical Trial [Publication Type]	inpr	9.95
25266997	C0442592	Clinic	hcro	5.18
25266997	C0442592	Clinic	mnob	5.18
25266997	C0443264	Modulated	spco	5.18
25266997	C2584321	Reaching	orgf	5.18
25266997	C1272689	Started	qlco	5.18
25266997	C3242274	new therapy	fndg	4.12
25266997	C1413365	CFTR gene	gngm	3.68
25266997	C1955473	Others - Allergy	fndg	3.68
25266997	C3539125	other medicated shampoos in ATC	phsu	3.68
25266997	C3811819	CFTR wt Allele	gngm	3.61
25266997	C0678723	Biologic Development	orgf	3.59
25266997	C1527148	Development	ftcn	3.59
25266997	C0243107	development aspects	phsf	3.59
25266997	C0439064	Numerous	qnco	3.50
25266997	C0443302	Several	qnco	3.50
25266997	C0332452	defective	ftcn	3.50
25266997	C1527178	Basis - conceptual entity	ftcn	3.47
25266997	C1457869	Defect	ftcn	3.47
25266997	C0009738	Congo	geoa	16.23
25266997	C0026882	Mutation	genf	11.49
25266997	C1552740	Entity Determiner - specific	inpr	5.18
25266997	C1705285	Mutation Abnormality	comd	5.18
25266997	C0205369	Specific qualifier value	qlco	5.18
25266997	C1521840	Target	ftcn	5.18
25266997	C3811819	CFTR wt Allele	gngm	3.61
25266997	C0683465	novel AODU treatment method	topp	3.56
25266997	C1527178	Basis - conceptual entity	ftcn	3.47
25266997	C1457869	Defect	ftcn	3.47
25266997	C0040363	Togo	geoa	17.80
25266997	C0041260	Tryptophanase	aapp	17.80
25266997	C0041260	Tryptophanase	enzy	17.80
25266997	C0004340	Australia	geoa	13.01
25266997	C0012634	Disease	dsyn	9.99
25266997	C0005532	biology (field)	bmod	9.81
25266997	C1516048	Assessed	acty	5.18
25266997	C0332218	Difficult (qualifier value)	qlco	5.18
25266997	C1299586	Has difficulty doing (qualifier value)	fndg	5.18
25266997	C1883351	To	qlco	5.18
25266997	C1704259	Biochemical Pathway	moft	3.68
25266997	C1705987	Pathway (interactions)	cnce	3.68
25266997	C1516998	Exogenous Factors	ftcn	3.59
25266997	C3172256	Number of birth	fndg	3.56
25266997	C0205170	Good	qlco	3.55
25266997	C3146287	Well	mnob	3.55
25266997	C1705242	Different	qlco	3.54
25266997	C0549177	Large	qnco	3.54
25266997	C4054723	Influence	cnce	3.51
25266997	C0205460	biological	qlco	3.50
25266997	C0009738	Congo	geoa	16.05
25266997	C0037640	Somalia	geoa	16.04
25266997	C0030705	Patients	podg	6.58
25266997	C1710548	Unique	qlco	5.18
25266997	C2348480	ex vivo	ftcn	5.18
25266997	C0521117	Severity of illness	qlco	3.60
25266997	C0278372	Functional assessment	diap	3.59
25266997	C0679830	patient assessment	hlca	3.58
25266997	C2347489	Person Observer	grup	3.57
25266997	C0027361	Persons	popg	3.57
25266997	C0542341	Function	ftcn	3.55
25266997	C0205245	Functional	ftcn	3.55
25266997	C2700217	Functional Relationship	cnce	3.55
25266997	C0011900	Diagnosis	fndg	3.45
25266997	C3811819	CFTR wt Allele	gngm	3.44
25266997	C0040300	Body tissue	tisu	3.43
25266997	C0040363	Togo	geoa	17.80
25266997	C0041260	Tryptophanase	aapp	17.80
25266997	C0041260	Tryptophanase	enzy	17.80
25266997	C0009738	Congo	geoa	16.12
25266997	C1516048	Assessed	acty	10.42
25266997	C0030705	Patients	podg	6.83
25266997	C1316572	Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}	clna	5.18
25266997	C1261322	Evaluation procedure	hlca	5.18
25266997	C1317574	Note (document)	inpr	5.18
25266997	C0087111	Therapeutic procedure	topp	5.18
25266997	C1883351	To	qlco	5.18
25266997	C1522326	Treating	ftcn	5.18
25266997	C1292734	Treatment intent	ftcn	5.18
25266997	C0683154	drug response	orgf	5.18
25266997	C1705178	Order (action)	acty	3.59
25266997	C1705176	Order (arrangement)	qlco	3.59
25266997	C1705175	Order (document)	inpr	3.59
25266997	C1705177	Order (taxonomic)	clas	3.59
25266997	C1882348	Permutation	qlco	3.59
25266997	C3889825	Sequence of Planned Assessment Schedule	inpr	3.59
25266997	C3811819	CFTR wt Allele	gngm	3.50
25266997	C0039798	therapeutic aspects	ftcn	22.48
25266997	C0012634	Disease	dsyn	20.09
25266997	C0009738	Congo	geoa	16.05
25266997	C1518422	Negation	ftcn	5.18
25266997	C1533734	Administration procedure	topp	3.56
25266997	C1705169	Biomaterial Treatment	cnce	3.56
25266997	C0087111	Therapeutic procedure	topp	3.56
25266997	C1522326	Treating	ftcn	3.56
25266997	C3538994	Treatment Epoch	resa	3.56
25266997	C3887704	treatment - ActInformationManagementReason	hlca	3.56
25266997	C0332219	Easy	qlco	3.55
25266997	C0439855	Complex	qlco	3.50
25266997	C1704241	complex (molecular entity)	chvs	3.50
25266997	C0205393	Most	qnco	3.45
25266997	C3811819	CFTR wt Allele	gngm	3.43
25266997	C1709510	Personalized	qlco	3.43
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
24945463	C0034851	Conditions, Recessive Genetic	biof	20.95
24945463	C0022009	Ion Channel	aapp	16.32
24945463	C0022009	Ion Channel	bacs	16.32
24945463	C0003075	Anions	elii	12.92
24945463	C0032105	Plasma	bdsu	12.92
24945463	C0010674	Cystic Fibrosis	dsyn	10.06
24945463	C0026882	Mutation	genf	9.90
24945463	C0015127	Etiology aspects	ftcn	9.86
24945463	C0007603	Plasma membrane	celc	9.79
24945463	C1413365	CFTR gene	gngm	5.18
24945463	C0439799	Channel	spco	3.60
24945463	C1706095	Channel Object	cnce	3.60
24945463	C1524003	Science of Etiology	cnce	3.55
24945463	C0392752	Localized	spco	3.46
24945463	C1550098	Plasma, NOS (not otherwise specified)	bdsu	3.46
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.11
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.11
24945463	C0031453	Phenylalanine	aapp	16.07
24945463	C0031453	Phenylalanine	bacs	16.07
24945463	C0031453	Phenylalanine	phsu	16.07
24945463	C1314792	Etiology	ftcn	14.64
24945463	C1511760	Deletion Mutation	genf	13.05
24945463	C0015127	Etiology aspects	ftcn	11.49
24945463	C0026882	Mutation	genf	9.86
24945463	C1413365	CFTR gene	gngm	7.03
24945463	C1524003	Science of Etiology	cnce	5.18
24945463	C0332294	Resulting in	ftcn	3.72
24945463	C1709915	Residue	cnce	3.68
24945463	C1882936	Residue after Decontamination Medical Device Problem	evnt	3.68
24945463	C1179841	Plasma membrane protein	aapp	3.62
24945463	C1179841	Plasma membrane protein	bacs	3.62
24945463	C1880274	Deletion (action)	acty	3.59
24945463	C1442161	Gene Deletion Abnormality	comd	3.59
24945463	C3714596	Little NOS	fndg	3.59
24945463	C0700321	Small	qnco	3.59
24945463	C2700395	Smallest	qnco	3.59
24945463	C1705285	Mutation Abnormality	comd	3.55
24945463	C0202174	blood phenylalanine measurement by Guthrie microbiologic assay	lbpr	3.45
24945463	C0205214	Common (qualifier value)	qnco	3.43
24945463	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.43
24945463	C0205393	Most	qnco	3.43
24945463	C1522138	shared attribute	ftcn	3.43
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.54
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.54
24945463	C0009738	Congo	geoa	16.05
24945463	C0019904	Homozygote	orga	9.90
24945463	C0030705	Patients	podg	6.59
24945463	C1547282	Show	anim	5.18
24945463	C3252847	VX 809	orch	3.68
24945463	C3252847	VX 809	phsu	3.68
24945463	C1413365	CFTR gene	gngm	3.61
24945463	C1555307	promise	idcn	3.56
24945463	C3811819	CFTR wt Allele	gngm	3.43
24945463	C1522326	Treating	ftcn	3.43
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.96
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.96
24945463	C0007603	Plasma membrane	celc	11.49
24945463	C2350440	Protein Stability	qlco	9.87
24945463	C1564139	Mutant Proteins	aapp	9.74
24945463	C2349975	Enhance (action)	acty	3.98
24945463	C0750502	Significant	idcn	3.55
24945463	C0237881	Statistical Significance	qnco	3.55
24945463	C2347098	Medical Product Stability	qlco	3.54
24945463	C0205360	Stable status	qlco	3.54
24945463	C0872079	protein protein interaction	moft	3.48
24945463	C1413365	CFTR gene	gngm	3.42
24945463	C0439799	Channel	spco	3.42
24945463	C1706095	Channel Object	cnce	3.42
24945463	C0596988	mutant	comd	3.42
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
24945463	C0007603	Plasma membrane	celc	11.49
24945463	C3252847	VX 809	orch	5.18
24945463	C3252847	VX 809	phsu	5.18
24945463	C2347098	Medical Product Stability	qlco	3.56
24945463	C0205360	Stable status	qlco	3.56
24945463	C1413365	CFTR gene	gngm	3.43
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.34
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.34
24945463	C0297119	sodium-hydrogen exchanger regulatory factor	aapp	13.16
24945463	C1413365	CFTR gene	gngm	7.27
24945463	C0005507	Biological Assay	lbpr	6.75
24945463	C0442805	Increase	ftcn	5.18
24945463	C0205217	Increased	qnco	5.18
24945463	C1420236	SLC9A3R1 gene	gngm	5.18
24945463	C1524063	Use of	ftcn	5.18
24945463	C3252847	VX 809	orch	5.18
24945463	C3252847	VX 809	phsu	5.18
24945463	C1510827	Affinity	npop	3.68
24945463	C1883559	Wild Type	gngm	3.61
24945463	C1510438	Assay	lbpr	3.59
24945463	C0243073	assay qualifier	qlco	3.59
24945463	C1707455	Comparison	acty	3.56
24945463	C0205169	Bad	qlco	3.54
24945463	C1167622	Binding (Molecular Function)	moft	3.50
24945463	C1145667	Binding action	acty	3.50
24945463	C1705938	Base - General Qualifier	idcn	3.48
24945463	C1527178	Basis - conceptual entity	ftcn	3.48
24945463	C0679932	competition	socb	3.48
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.99
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.99
24945463	C0917903	Conclude Resin	bodm	27.26
24945463	C0917903	Conclude Resin	orch	27.26
24945463	C0013682	Efficiency	qnco	12.88
24945463	C1413365	CFTR gene	gngm	6.92
24945463	C1704675	Interaction	ftcn	3.61
24945463	C1521761	Factor	ftcn	3.54
24945463	C1420236	SLC9A3R1 gene	gngm	3.47
24945463	C0184512	Stabilized (qualifier value)	qlco	3.47
24945463	C0542341	Function	ftcn	3.42
24945463	C0205245	Functional	ftcn	3.42
24945463	C2700217	Functional Relationship	cnce	3.42
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.06
24945463	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.06
24945463	C0040363	Togo	geoa	17.80
24945463	C0041260	Tryptophanase	aapp	17.80
24945463	C0041260	Tryptophanase	enzy	17.80
24945463	C0079411	Generations	tmco	16.03
24945463	C0016617	Foundations	orgt	12.94
24945463	C0007603	Plasma membrane	celc	9.74
24945463	C1413365	CFTR gene	gngm	6.98
24945463	C0220781	Anabolism	biof	6.58
24945463	C1883351	To	qlco	5.18
24945463	C1705535	suggestion	idcn	5.18
24945463	C2825142	Experimental Result	fndg	3.98
24945463	C1274040	Result	ftcn	3.98
24945463	C1546471	What subject filter - Result	idcn	3.98
24945463	C3898777	Important	qlco	3.49
24945463	C2246374	macromolecular complex	celc	3.45
24945463	C1522492	Formation	ftcn	3.43
24945463	C0439634	Formations	spco	3.43
24945463	C2712145	Actual Effective Human Development	fndg	3.42
24945463	C0184512	Stabilized (qualifier value)	qlco	3.42
24945463	C0596988	mutant	comd	3.42
24945463	C1705938	Base - General Qualifier	idcn	3.42
24945463	C1527178	Basis - conceptual entity	ftcn	3.42
24945463	C3146294	Generation (action)	acty	3.42
24945463	C0205314	New	qlco	3.42
24945463	C0723712	Therapeutic brand of coal tar	orch	3.42
24945463	C0723712	Therapeutic brand of coal tar	phsu	3.42
24945463	C0087111	Therapeutic procedure	topp	3.42
28769592	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
28769592	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
28769592	C0041703	United States	geoa	12.88
28769592	C0001721	Affect (mental function)	menp	11.49
28769592	C0012634	Disease	dsyn	11.49
28769592	C0010674	Cystic Fibrosis	dsyn	10.06
28769592	C0026882	Mutation	genf	9.88
28769592	C0025252	Membrane Proteins	aapp	9.86
28769592	C0025252	Membrane Proteins	bacs	9.86
28769592	C0015127	Etiology aspects	ftcn	9.85
28769592	C1705285	Mutation Abnormality	comd	3.57
28769592	C0027361	Persons	popg	3.54
28769592	C1524003	Science of Etiology	cnce	3.54
28769592	C1413365	CFTR gene	gngm	3.46
28769592	C3842588	30%	fndg	3.42
28769592	C0221908	epithelial	qlco	3.42
28769592	C0011900	Diagnosis	fndg	5.18
28769592	C0439508	per year	tmco	5.18
28769592	C0439234	year	tmco	5.18
28769592	C0868928	Case (situation)	ftcn	3.63
28769592	C1533148	Case unit dose	qnco	3.63
28769592	C0205314	New	qlco	3.48
28769592	C0006280	Bronchodilator Agents	phsu	20.95
28769592	C0009738	Congo	geoa	17.80
28769592	C0036085	Saline Solution, Hypertonic	inch	14.64
28769592	C0036085	Saline Solution, Hypertonic	phsu	14.64
28769592	C3811819	CFTR wt Allele	gngm	5.18
28769592	C0251564	Pulmozyme	aapp	5.18
28769592	C0251564	Pulmozyme	enzy	5.18
28769592	C0251564	Pulmozyme	phsu	5.18
28769592	C1522326	Treating	ftcn	5.18
28769592	C0920330	Pancreatic enzyme	aapp	3.64
28769592	C0920330	Pancreatic enzyme	enzy	3.64
28769592	C0920330	Pancreatic enzyme	phsu	3.64
28769592	C0041714	United States Food and Drug Administration	hcro	27.26
28769592	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
28769592	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
28769592	C3264621	ivacaftor	orch	13.14
28769592	C3264621	ivacaftor	phsu	13.14
28769592	C3852684	lumacaftor	orch	12.96
28769592	C3852684	lumacaftor	phsu	12.96
28769592	C0013162	Drug Combinations	phsu	8.34
28769592	C0043227	Work	ocac	6.72
28769592	C0033684	Proteins	aapp	6.57
28769592	C0033684	Proteins	bacs	6.57
28769592	C0205540	Approved	qlco	5.18
28769592	C4033620	ORKAMBI	phsu	5.18
28769592	C3829447	July	qlco	3.68
28769592	C1280500	Effect	qlco	3.54
28769592	C1413365	CFTR gene	gngm	3.47
28769592	C0332452	defective	ftcn	3.42
28769592	C1555029	Reverse	ftcn	3.42
28769592	C0013404	Dyspnea	sosy	13.05
28769592	C0042784	Viscosity	npop	9.87
28769592	C0026727	Mucous body substance	bdsu	9.74
28769592	C0036537	Bodily secretions	bdsu	6.59
28769592	C1515933	Alveolus	bpoc	5.18
28769592	C0547047	Decrease	qnco	5.18
28769592	C0392756	Reduced	qlco	5.18
28769592	C0026698	mucolytic agents	phsu	5.18
28769592	C0332294	Resulting in	ftcn	3.72
28769592	C4033620	ORKAMBI	phsu	3.68
28769592	C0333229	Accumulation of fluid	ftcn	3.60
28769592	C1547055	*Viscosity	qnco	3.56
28769592	C0391802	Blood viscosity examination	lbpr	3.56
28769592	C0332152	Before	tmco	3.55
28769592	C1522538	Leading	ftcn	3.55
28769592	C0439708	Mucous Appearance	qlco	3.43
28769592	C2753459	mucus layer	bdsu	3.43
28769592	C0449450	Presentation	idcn	5.18
28769592	C0743559	error	qlco	3.53
28769592	C0009738	Congo	geoa	32.27
28769592	C0039798	therapeutic aspects	ftcn	22.49
28769592	C0004048	Inspiration function	orgf	19.19
28769592	C0033131	Primary Care Physicians	prog	16.26
28769592	C0003232	Antibiotics	antb	16.16
28769592	C0013404	Dyspnea	sosy	14.64
28769592	C0015780	Female	orga	9.87
28769592	C0086287	Females	popg	9.87
28769592	C0449450	Presentation	idcn	7.46
28769592	C3811819	CFTR wt Allele	gngm	6.89
28769592	C0043210	Woman	popg	6.71
28769592	C4049785	Increased Respiratory Secretion	phpr	5.18
28769592	C1372558	Increased Respiratory Secretions [PE]	ortf	5.18
28769592	C0150312	Present	qnco	5.18
28769592	C0332185	Recent	tmco	5.18
28769592	C0184666	Hospital admission	hlca	3.62
28769592	C1442457	2 Weeks	tmco	3.61
28769592	C0338237	Antibiotic therapy	topp	3.57
28769592	C0868928	Case (situation)	ftcn	3.57
28769592	C1706256	Clinical Study Case	cnce	3.57
28769592	C4033620	ORKAMBI	phsu	3.57
28769592	C1706255	Packaging Case	medd	3.57
28769592	C1272689	Started	qlco	3.57
28769592	C0087111	Therapeutic procedure	topp	3.57
28769592	C1363945	Therapy Object (animal model)	fndg	3.57
28769592	C1406915	breathing therapy	hlca	3.56
28769592	C1705498	Female Phenotype	qlco	3.56
28769592	C1705497	Female, Self-Report	qlco	3.56
28769592	C0348016	Intravenous	spco	3.43
28769592	C0332239	Young	tmco	3.43
28769592	C0040363	Togo	geoa	35.81
28769592	C0041260	Tryptophanase	aapp	35.81
28769592	C0041260	Tryptophanase	enzy	35.81
28769592	C0003237	Antibiotics, Antitubercular	antb	22.61
28769592	C0039798	therapeutic aspects	ftcn	22.35
28769592	C0003232	Antibiotics	antb	16.30
28769592	C0004448	Awareness	menp	14.64
28769592	C0019993	Hospitalization	hlca	13.14
28769592	C0162425	Intention - mental process	menp	11.49
28769592	C1883351	To	qlco	10.42
28769592	C0021562	inpatient	podg	9.81
28769592	C0039401	Educational process of instructing	edac	8.34
28769592	C0030705	Patients	podg	8.34
28769592	C1550453	Act Mood - intent	ftcn	5.18
28769592	C0868928	Case (situation)	ftcn	5.18
28769592	C1706256	Clinical Study Case	cnce	5.18
28769592	C1706255	Packaging Case	medd	5.18
28769592	C1283828	intent	qlco	5.18
28769592	C0587569	Physician service	hlca	3.75
28769592	C3540706	Antibiotic throat preparations	antb	3.68
28769592	C3540707	Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	antb	3.68
28769592	C3540704	Antibiotics for systemic use	antb	3.68
28769592	C3540708	Antibiotics, Gynecological	antb	3.68
28769592	C3540710	Antibiotics, ophthalmologic	antb	3.68
28769592	C3540705	Antifungal Antibiotics, Topical	antb	3.68
28769592	C3540709	antibiotics, intestinal	antb	3.68
28769592	C0871685	Clinician	prog	3.54
28769592	C1549404	Patient Class - Inpatient	idcn	3.50
28769592	C1548438	Referral category - Inpatient	idcn	3.50
28769592	C0879626	Adverse effects	patf	3.43
28769592	C1518681	Outcome of Therapy	fndg	3.43
28769592	C4033620	ORKAMBI	phsu	3.42
28769592	C1979963	Profile (lab procedure)	lbpr	3.42
28769592	C2003903	Profiling (action)	ftcn	3.42
28769592	C0441987	Side	spco	3.42
28769592	C0087111	Therapeutic procedure	topp	3.42
28769592	C1363945	Therapy Object (animal model)	fndg	3.42
27614011	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
27614011	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
27614011	C0017337	Genes	gngm	16.22
27614011	C0010674	Cystic Fibrosis	dsyn	10.06
27614011	C0026882	Mutation	genf	9.90
27614011	C0015127	Etiology aspects	ftcn	9.86
27614011	C1413365	CFTR gene	gngm	3.58
27614011	C1524003	Science of Etiology	cnce	3.55
27614011	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27614011	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27614011	C0031453	Phenylalanine	aapp	16.05
27614011	C0031453	Phenylalanine	bacs	16.05
27614011	C0031453	Phenylalanine	phsu	16.05
27614011	C1511760	Deletion Mutation	genf	13.03
27614011	C0031843	physiological aspects	phsf	12.90
27614011	C0026882	Mutation	genf	9.94
27614011	C0014609	Epithelium	tisu	8.34
27614011	C0033684	Proteins	aapp	6.66
27614011	C0033684	Proteins	bacs	6.66
27614011	C0678227	Causing	ftcn	5.18
27614011	C0332454	disrupted	qlco	5.18
27614011	C1706853	Assembly (construction)	acty	3.68
27614011	C1879748	Assembly (group of parts)	mnob	3.68
27614011	C1705285	Mutation Abnormality	comd	3.63
27614011	C1880274	Deletion (action)	acty	3.57
27614011	C1442161	Gene Deletion Abnormality	comd	3.57
27614011	C1517945	Loss	qnco	3.57
27614011	C0205372	Tertiary	qnco	3.50
27614011	C0205214	Common (qualifier value)	qnco	3.48
27614011	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.48
27614011	C0205393	Most	qnco	3.48
27614011	C1522138	shared attribute	ftcn	3.48
27614011	C1413365	CFTR gene	gngm	3.44
27614011	C0542341	Function	ftcn	3.44
27614011	C0700205	Function Axis	clas	3.44
27614011	C1705273	Mathematical Operator	inpr	3.44
27614011	C0202174	blood phenylalanine measurement by Guthrie microbiologic assay	lbpr	3.44
27614011	C0040363	Togo	geoa	17.80
27614011	C0041260	Tryptophanase	aapp	17.80
27614011	C0041260	Tryptophanase	enzy	17.80
27614011	C0009738	Congo	geoa	16.17
27614011	C3264621	ivacaftor	orch	14.64
27614011	C3264621	ivacaftor	phsu	14.64
27614011	C3852684	lumacaftor	orch	13.14
27614011	C3852684	lumacaftor	phsu	13.14
27614011	C0019904	Homozygote	orga	9.87
27614011	C0026882	Mutation	genf	9.74
27614011	C1883351	To	qlco	5.18
27614011	C3252847	VX 809	orch	5.18
27614011	C3252847	VX 809	phsu	5.18
27614011	C2741958	VX-770	orch	5.18
27614011	C1547282	Show	anim	3.98
27614011	C0567416	Molecule	sbst	3.61
27614011	C1153410	channel activity	moft	3.57
27614011	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.56
27614011	C3242455	HL7PublishingDomain <patient administration>	inpr	3.56
27614011	C3242279	healthcare operations <patient administration>	ocac	3.56
27614011	C0205540	Approved	qlco	3.55
27614011	C3811819	CFTR wt Allele	gngm	3.55
27614011	C1883357	Together	qlco	3.54
27614011	C0441885	Class 1	clas	3.50
27614011	C1705285	Mutation Abnormality	comd	3.43
27614011	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
27614011	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
27614011	C0040363	Togo	geoa	17.80
27614011	C0041260	Tryptophanase	aapp	17.80
27614011	C0041260	Tryptophanase	enzy	17.80
27614011	C0037791	Specificity	qnco	16.18
27614011	C0039869	Thinking, function	menp	11.49
27614011	C1413365	CFTR gene	gngm	5.18
27614011	C1883351	To	qlco	5.18
27614011	C1167622	Binding (Molecular Function)	moft	3.57
27614011	C1145667	Binding action	acty	3.57
27614011	C1947931	Direct (qualifier)	qlco	3.57
27614011	C0439851	Direct type of relationship	qlco	3.57
27614011	C1511884	Diagnostic Specificity	qnco	3.56
27614011	C1709060	Modulator Device Component	mnob	3.41
27614011	C0015272	Exhibits as Topic	inpr	17.80
27614011	C0040363	Togo	geoa	17.80
27614011	C0041260	Tryptophanase	aapp	17.80
27614011	C0041260	Tryptophanase	enzy	17.80
27614011	C1883351	To	qlco	5.18
27614011	C1547282	Show	anim	3.98
27614011	C0441655	Activities	acty	3.68
27614011	C1709060	Modulator Device Component	mnob	3.61
27614011	C1328819	Small Molecule	orch	3.50
27614011	C0040363	Togo	geoa	17.80
27614011	C0041260	Tryptophanase	aapp	17.80
27614011	C0041260	Tryptophanase	enzy	17.80
27614011	C0301363	5-Trimethoxyamphetamine	orch	5.18
27614011	C0301363	5-Trimethoxyamphetamine	phsu	5.18
27614011	C0086597	Mediate	socb	5.18
27614011	C0871157	Prompting	ftcn	5.18
27614011	C1519522	Tissue Microarray	resd	5.18
27614011	C1883351	To	qlco	5.18
27614011	C2266866	Binding Activity [MoA]	moft	3.58
27614011	C1947931	Direct (qualifier)	qlco	3.43
27614011	C0439851	Direct type of relationship	qlco	3.43
27614011	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
27614011	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
27614011	C0023828	Liposomes	orch	16.18
27614011	C0003075	Anions	elii	12.89
27614011	C0031676	Phospholipids	bacs	9.88
27614011	C0031676	Phospholipids	orch	9.88
27614011	C0301363	5-Trimethoxyamphetamine	orch	5.18
27614011	C0301363	5-Trimethoxyamphetamine	phsu	5.18
27614011	C0150312	Present	qnco	5.18
27614011	C1519522	Tissue Microarray	resd	5.18
27614011	C2741958	VX-770	orch	3.64
27614011	C0202177	Phospholipid measurement	lbpr	3.57
27614011	C1413365	CFTR gene	gngm	3.56
27614011	C1704419	Effective	qlco	3.56
27614011	C1280519	Effectiveness	qlco	3.56
27614011	C0086597	Mediate	socb	3.56
27614011	C0127400	Mediator brand of benfluorex hydrochloride	orch	3.56
27614011	C0127400	Mediator brand of benfluorex hydrochloride	phsu	3.56
27614011	C1998793	Purifying	ftcn	3.56
27614011	C2700323	Wild Type Unspecified - zebrafish	fish	3.56
27614011	C2349975	Enhance (action)	acty	3.41
27614011	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27614011	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27614011	C0684010	Rabbi	prog	12.96
27614011	C3541951	Concept model domain	inpr	7.57
27614011	C1880389	Domain (area of knowledge)	ftcn	7.57
27614011	C1883221	Superkingdom (taxonomic category)	cnce	7.57
27614011	C0301363	5-Trimethoxyamphetamine	orch	5.18
27614011	C0301363	5-Trimethoxyamphetamine	phsu	5.18
27614011	C0332268	Lacking	qlco	5.18
27614011	C1519522	Tissue Microarray	resd	5.18
27614011	C3252847	VX 809	orch	5.18
27614011	C3252847	VX 809	phsu	5.18
27614011	C1148916	nucleotide binding	moft	3.68
27614011	C1704419	Effective	qlco	3.59
27614011	C1280519	Effectiveness	qlco	3.59
27614011	C3854321	Expression (foundation metadata concept)	idcn	3.56
27614011	C0185117	Expression procedure	topp	3.56
27614011	C2603358	R prime	clna	3.50
27614011	C1704735	Regulator	cnce	3.50
27614011	C0205090	Right	spco	3.50
27614011	C0220905	regulatory	rnlw	3.50
27614011	C1561503	Precision - second	idcn	3.47
27614011	C1705190	Second Suffix	qlco	3.47
27614011	C0565930	per second	qnco	3.47
27614011	C0205436	second (number)	qnco	3.47
27614011	C0457385	seconds	tmco	3.47
27614011	C0184512	Stabilized (qualifier value)	qlco	3.45
27614011	C1413365	CFTR gene	gngm	3.43
27614011	C0542341	Function	ftcn	3.43
27614011	C0205245	Functional	ftcn	3.43
27614011	C2700217	Functional Relationship	cnce	3.43
27614011	C3541951	Concept model domain	inpr	7.33
27614011	C1880389	Domain (area of knowledge)	ftcn	7.33
27614011	C1883221	Superkingdom (taxonomic category)	cnce	7.33
27614011	C0596901	Membrane	celc	6.77
27614011	C0025255	Tissue membrane	tisu	6.77
27614011	C3252847	VX 809	orch	3.64
27614011	C3252847	VX 809	phsu	3.64
27614011	C1706182	Membrane Device Component	mnob	3.61
27614011	C1711300	Span - parameter	cnce	3.58
27614011	C2700613	Span Distance	qnco	3.58
27614011	C0301363	5-Trimethoxyamphetamine	orch	3.57
27614011	C0301363	5-Trimethoxyamphetamine	phsu	3.57
27614011	C1167622	Binding (Molecular Function)	moft	3.57
27614011	C1145667	Binding action	acty	3.57
27614011	C1441672	Observed	ftcn	3.57
27614011	C0184512	Stabilized (qualifier value)	qlco	3.57
27614011	C1519522	Tissue Microarray	resd	3.57
27614011	C2700395	Smallest	qnco	3.50
27614011	C0205435	First (number)	qnco	3.47
27614011	C1279901	Firstly	qlco	3.47
27614011	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.60
27614011	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.60
27614011	C0040363	Togo	geoa	17.80
27614011	C0041260	Tryptophanase	aapp	17.80
27614011	C0041260	Tryptophanase	enzy	17.80
27614011	C1413365	CFTR gene	gngm	7.53
27614011	C0301363	5-Trimethoxyamphetamine	orch	5.18
27614011	C0301363	5-Trimethoxyamphetamine	phsu	5.18
27614011	C1167622	Binding (Molecular Function)	moft	5.18
27614011	C1145667	Binding action	acty	5.18
27614011	C3539655	CDISC Findings Class	inpr	5.18
27614011	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
27614011	C0237876	Sharing (Social Behavior)	socb	5.18
27614011	C0184512	Stabilized (qualifier value)	qlco	5.18
27614011	C0183683	Support, device	medd	5.18
27614011	C1521721	Supportive assistance	cnce	5.18
27614011	C1519522	Tissue Microarray	resd	5.18
27614011	C1883351	To	qlco	5.18
27614011	C3252847	VX 809	orch	5.18
27614011	C3252847	VX 809	phsu	5.18
27614011	C2607943	findings aspects	ftcn	5.18
27614011	C1883357	Together	qlco	3.68
27614011	C0220807	Chemical Structure	inpr	3.59
27614011	C1947931	Direct (qualifier)	qlco	3.59
27614011	C0441712	Mechanism (attribute)	ftcn	3.56
27614011	C2741958	VX-770	orch	3.46
27614011	C2348205	Similarity	qlco	3.43
27328319	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
27328319	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
27328319	C0055363	Chloride Channels	aapp	20.95
27328319	C0055363	Chloride Channels	bacs	20.95
27328319	C0010674	Cystic Fibrosis	dsyn	9.92
27328319	C0376525	Dimerization	npop	9.85
27328319	C0028630	Nucleotides	nnon	9.73
27328319	C0030705	Patients	podg	6.71
27328319	C1413365	CFTR gene	gngm	5.18
27328319	C0332282	Following	tmco	5.18
27328319	C0175566	Open	spco	5.18
27328319	C1325742	Pore	celc	5.18
27328319	C0231290	Status post	tmco	5.18
27328319	C0332453	Disruption	ftcn	3.68
27328319	C3810854	Close	fndg	3.63
27328319	C0587267	Closed	ftcn	3.63
27328319	C1705285	Mutation Abnormality	comd	3.56
27328319	C1510699	ATP Hydrolysis	moft	3.53
27328319	C0596448	dimer	chvs	3.50
27328319	C1148923	atp binding	moft	3.43
27328319	C1511625	Cytoplasmic Domain	celc	3.42
27328319	C0205263	Induce (action)	ftcn	3.42
27328319	C0205448	Two	qnco	3.42
27328319	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27328319	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27328319	C0009738	Congo	geoa	16.18
27328319	C3264621	ivacaftor	orch	13.05
27328319	C3264621	ivacaftor	phsu	13.05
27328319	C2744579	ATP8A2 protein, human	aapp	12.89
27328319	C2744579	ATP8A2 protein, human	enzy	12.89
27328319	C0441712	Mechanism (attribute)	ftcn	5.18
27328319	C1706376	Mechanism Component of Device	mnob	5.18
27328319	C1720467	Only - dosing instruction fragment	inpr	5.18
27328319	C0205171	Singular	qnco	5.18
27328319	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.68
27328319	C1948023	Stimulation (motivation)	npop	3.59
27328319	C3811819	CFTR wt Allele	gngm	3.56
27328319	C0205423	Certain (qualifier value)	qlco	3.56
27328319	C1704787	Definitely Related to Intervention	qlco	3.56
27328319	C0521114	Infrequent	tmco	3.56
27328319	C0175566	Open	spco	3.56
27328319	C0522498	Rare	qlco	3.56
27328319	C1514917	Retinoic Acid Response Element	gngm	3.56
27328319	C0596988	mutant	comd	3.56
27328319	C0205540	Approved	qlco	3.47
27328319	C1883559	Wild Type	gngm	3.46
27328319	C1413365	CFTR gene	gngm	3.43
27328319	C0205359	Spontaneous	ftcn	3.43
27328319	C0026597	Motion	npop	9.99
27328319	C0687704	Motions	ftcn	9.99
27328319	C1521991	Molecular	qlco	3.50
27328319	C0205359	Spontaneous	ftcn	3.50
27328319	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
27328319	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
27328319	C0087136	Unmarried	fndg	22.43
27328319	C0037179	Unmarried person	popg	22.43
27328319	C0439799	Channel	spco	5.18
27328319	C1706095	Channel Object	cnce	5.18
27328319	C1413365	CFTR gene	gngm	3.68
27328319	C1948027	Couple (action)	ftcn	3.57
27328319	C2698172	Application Program Interface	inpr	3.54
27328319	C1708533	Interface Device Component	mnob	3.54
27328319	C0205171	Singular	qnco	3.50
27328319	C3842459	Energetic	fndg	3.44
27328319	C0332248	Spontaneously closed	ftcn	3.43
27328319	C0175566	Open	spco	3.42
27328319	C1882151	Opening	spco	3.42
27328319	C1325742	Pore	celc	3.42
27328319	C0596448	dimer	chvs	3.42
27328319	C1709915	Residue	cnce	3.42
27328319	C1882936	Residue after Decontamination Medical Device Problem	evnt	3.42
27328319	C2744579	ATP8A2 protein, human	aapp	13.05
27328319	C2744579	ATP8A2 protein, human	enzy	13.05
27328319	C0376525	Dimerization	npop	9.88
27328319	C1709305	Occur (action)	acty	5.18
27328319	C2745955	Occurrence	tmco	5.18
27328319	C1547282	Show	anim	5.18
27328319	C0175566	Open	spco	3.68
27328319	C1948027	Couple (action)	ftcn	3.57
27328319	C1518456	Nucleosome Binding Domain	amas	3.57
27328319	C0205359	Spontaneous	ftcn	3.50
27328319	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27328319	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27328319	C0026377	Molecular Conformation	spco	13.09
27328319	C1325742	Pore	celc	7.00
27328319	C0003737	Architecture as Topic	ocdi	6.79
27328319	C0587267	Closed	ftcn	5.18
27328319	C2347098	Medical Product Stability	qlco	5.18
27328319	C1518422	Negation	ftcn	5.18
27328319	C0175566	Open	spco	5.18
27328319	C0205360	Stable status	qlco	5.18
27328319	C0392747	Changing	ftcn	3.79
27328319	C1319208	Ability to make coordinated movements	fndg	3.70
27328319	C0205102	Internal	spco	3.57
27328319	C0439674	Intrinsic origin	ftcn	3.57
27328319	C0678594	structure	spco	3.48
27328319	C1518456	Nucleosome Binding Domain	amas	3.46
27328319	C1413365	CFTR gene	gngm	3.44
27328319	C0026882	Mutation	genf	19.92
27328319	C0009738	Congo	geoa	16.05
27328319	C2744579	ATP8A2 protein, human	aapp	12.91
27328319	C2744579	ATP8A2 protein, human	enzy	12.91
27328319	C0031715	Phosphorylation	moft	12.90
27328319	C0162340	Comprehension	menp	12.89
27328319	C0013126	Intrinsic drive	menp	10.28
27328319	C0920474	drug mechanism	patf	4.12
27328319	C1999230	Providing (action)	acty	3.98
27328319	C1561536	*Activity (kind of quantity)	idcn	3.68
27328319	C0205177	Active	ftcn	3.68
27328319	C0441655	Activities	acty	3.68
27328319	C3668946	Activity (animal life circumstance)	fndg	3.68
27328319	C4049939	FDA Establishment Activity Terminology	inpr	3.68
27328319	C0439167	Percent Activity	qnco	3.68
27328319	C4049938	Physical Activity Measurement	lbpr	3.68
27328319	C0205359	Spontaneous	ftcn	3.68
27328319	C3687832	DRUGS	topp	3.59
27328319	C0013227	Pharmaceutical Preparations	phsu	3.59
27328319	C1280500	Effect	qlco	3.57
27328319	C0233820	Insight	menp	3.56
27328319	C1707520	Correlation	qlco	3.44
27328319	C1158886	Protein phosphorylation	moft	3.44
27328319	C3811819	CFTR wt Allele	gngm	3.43
27328319	C1705285	Mutation Abnormality	comd	3.43
24412276	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.51
24412276	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.51
24412276	C0018790	Cardiac Arrest	dsyn	10.18
24412276	C0026882	Mutation	genf	9.94
24412276	C0015127	Etiology aspects	ftcn	9.86
24412276	C0010674	Cystic Fibrosis	dsyn	9.76
24412276	C0185026	Plication	topp	5.18
24412276	C1706084	(City) Block	geoa	3.87
24412276	C0237477	Arrested progression	tmco	3.87
24412276	C2828370	Block (unit of measure)	qnco	3.87
24412276	C1533157	Block Specimens	sbst	3.87
24412276	C3811660	Block Unit of Distance	qnco	3.87
24412276	C0332206	Blocking	ftcn	3.87
24412276	C0392351	Law enforcement arrest	gora	3.87
24412276	C0233660	Mental blocking	mobd	3.87
24412276	C0028778	Obstruction	patf	3.87
24412276	C0521111	Retarded	qlco	3.87
24412276	C1413365	CFTR gene	gngm	3.59
24412276	C0599896	trafficking	celf	3.59
24412276	C1524003	Science of Etiology	cnce	3.55
24412276	C1709694	Processing (action)	acty	3.48
24412276	C1542147	Main	qlco	3.43
24412276	C0205225	Primary	qlco	3.43
24412276	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
24412276	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
24412276	C0043240	Wound Healing	orgf	13.02
24412276	C0162340	Comprehension	menp	13.01
24412276	C0026882	Mutation	genf	9.88
24412276	C0015127	Etiology aspects	ftcn	9.85
24412276	C1709694	Processing (action)	acty	3.57
24412276	C0374711	Surgical repair	topp	3.56
24412276	C1524003	Science of Etiology	cnce	3.54
24412276	C1413365	CFTR gene	gngm	3.43
24412276	C0596988	mutant	comd	3.43
24412276	C0441712	Mechanism (attribute)	ftcn	3.42
24412276	C0282642	Helix-Turn-Helix Motifs	spco	28.70
24412276	C0040363	Togo	geoa	17.80
24412276	C0041260	Tryptophanase	aapp	17.80
24412276	C0041260	Tryptophanase	enzy	17.80
24412276	C0020276	Hydrogen Bonding	npop	13.03
24412276	C0026882	Mutation	genf	9.86
24412276	C1550024	Lock - Remote control command	idcn	5.18
24412276	C1704783	Lock Component of Device	mnob	5.18
24412276	C0441712	Mechanism (attribute)	ftcn	5.18
24412276	C1706376	Mechanism Component of Device	mnob	5.18
24412276	C3273659	TPM3 wt Allele	gngm	5.18
24412276	C1883351	To	qlco	5.18
24412276	C1705535	suggestion	idcn	3.98
24412276	C2752508	fully spanning the plasma membrane	celc	3.63
24412276	C1167322	integral to membrane	celc	3.63
24412276	C0441635	Anatomical segmentation	spco	3.59
24412276	C1708096	Fragment	qlco	3.55
24412276	C0332255	Fragment of (qualifier value)	ftcn	3.55
24412276	C0486805	Fragments	bdsu	3.55
24412276	C1705285	Mutation Abnormality	comd	3.55
24412276	C1709694	Processing (action)	acty	3.55
24412276	C0947630	Scientific Study	lbpr	3.55
24412276	C3838679	4+ Answer to question	fndg	3.54
24412276	C0302891	Native (qualifier value)	ftcn	3.54
24412276	C1518422	Negation	ftcn	3.54
24412276	C1883357	Together	qlco	3.54
24412276	C1552607	Act Relationship Subset - previous	tmco	3.42
24412276	C0205156	Previous	tmco	3.42
24412276	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.56
24412276	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.56
24412276	C0040363	Togo	geoa	17.80
24412276	C0041260	Tryptophanase	aapp	17.80
24412276	C0041260	Tryptophanase	enzy	17.80
24412276	C0884358	Performed	ftcn	5.18
24412276	C1883351	To	qlco	5.18
24412276	C0796357	mutation analysis	lbpr	3.96
24412276	C1413365	CFTR gene	gngm	3.63
24412276	C0022885	Laboratory Procedures	lbpr	3.56
24412276	C0456984	Test Result	fndg	3.56
24412276	C0039593	Testing	ftcn	3.56
24412276	C0392366	Tests (qualifier value)	inpr	3.56
24412276	C1704675	Interaction	ftcn	3.53
24412276	C0443225	Full	qlco	3.48
24412276	C1444754	Length	qnco	3.48
24412276	C1706316	Length of Trial	resa	3.48
24412276	C0020276	Hydrogen Bonding	npop	13.08
24412276	C0026882	Mutation	genf	9.99
24412276	C0015127	Etiology aspects	ftcn	9.85
24412276	C0392360	Indication of (contextual qualifier)	idcn	5.18
24412276	C0205286	Mature	tmco	5.18
24412276	C2699007	Rationale	idcn	5.18
24412276	C1457869	Defect	ftcn	3.68
24412276	C1705285	Mutation Abnormality	comd	3.68
24412276	C0596988	mutant	comd	3.63
24412276	C1524003	Science of Etiology	cnce	3.54
24412276	C1709694	Processing (action)	acty	3.50
24412276	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
24412276	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
24412276	C0026882	Mutation	genf	9.84
24412276	C0002520	Amino Acids	aapp	6.58
24412276	C0002520	Amino Acids	bacs	6.58
24412276	C0002520	Amino Acids	phsu	6.58
24412276	C3273238	Regulatory Report	inpr	5.18
24412276	C0684224	Report (document)	inpr	5.18
24412276	C0700287	Reporting	hlca	5.18
24412276	C3539946	Amino Acids, I.V. solution additive	aapp	3.43
24412276	C3539946	Amino Acids, I.V. solution additive	phsu	3.43
24412276	C3539947	Antifibrinolytic amino acids	aapp	3.43
24412276	C3539947	Antifibrinolytic amino acids	phsu	3.43
24412276	C1254042	Anatomical maturation	phsf	3.42
24412276	C0678723	Biologic Development	orgf	3.42
24412276	C0332206	Blocking	ftcn	3.42
24412276	C1413365	CFTR gene	gngm	3.42
24412276	C1706211	Charge (electrical)	orga	3.42
24412276	C0870861	Human maturation	phpr	3.42
24412276	C0028778	Obstruction	patf	3.42
24412276	C1720467	Only - dosing instruction fragment	inpr	3.42
24412276	C0205082	Severe (severity modifier)	qlco	3.42
24412276	C0205171	Singular	qnco	3.42
24412276	C0026882	Mutation	genf	9.99
24412276	C1518422	Negation	ftcn	5.18
24412276	C1547282	Show	anim	3.98
24412276	C1254042	Anatomical maturation	phsf	3.68
24412276	C0678723	Biologic Development	orgf	3.68
24412276	C0870861	Human maturation	phpr	3.68
24412276	C1705285	Mutation Abnormality	comd	3.68
24412276	C1707455	Comparison	acty	3.59
24412276	C0439509	/40	tmco	3.50
24412276	C3842587	40%	qnco	3.50
24412276	C0031453	Phenylalanine	aapp	17.80
24412276	C0031453	Phenylalanine	bacs	17.80
24412276	C0031453	Phenylalanine	phsu	17.80
24412276	C0023401	Leucine	aapp	14.64
24412276	C0023401	Leucine	bacs	14.64
24412276	C0023401	Leucine	phsu	14.64
24412276	C0026882	Mutation	genf	9.88
24412276	C0428209	Leucine measurement	lbpr	5.18
24412276	C0202174	blood phenylalanine measurement by Guthrie microbiologic assay	lbpr	5.18
24412276	C1280500	Effect	qlco	3.68
24412276	C2348382	Effect, Appearance	qlco	3.68
24412276	C1709915	Residue	cnce	3.59
24412276	C1882936	Residue after Decontamination Medical Device Problem	evnt	3.59
24412276	C1705285	Mutation Abnormality	comd	3.57
24412276	C3714596	Little NOS	fndg	3.50
24412276	C0700321	Small	qnco	3.50
24412276	C2700395	Smallest	qnco	3.50
24412276	C0549177	Large	qnco	3.48
24412276	C0813984	nonpolar	qnco	3.48
24412276	C0026882	Mutation	genf	9.99
24412276	C1518422	Negation	ftcn	5.18
24412276	C0205166	Long	qlco	3.98
24412276	C1706317	Long Variable	qlco	3.98
24412276	C1705285	Mutation Abnormality	comd	3.68
24412276	C3842586	50%	fndg	3.57
24412276	C3843766	<50	fndg	3.57
24412276	C1254042	Anatomical maturation	phsf	3.57
24412276	C0678723	Biologic Development	orgf	3.57
24412276	C0870861	Human maturation	phpr	3.57
24412276	C3854307	Presence (property)	qlco	3.55
24412276	C0150312	Present	qnco	3.55
24412276	C0392148	Providing presence (regime/therapy)	topp	3.55
24412276	C1547282	Show	anim	3.54
24412276	C3252847	VX 809	orch	3.44
24412276	C3252847	VX 809	phsu	3.44
24412276	C0020276	Hydrogen Bonding	npop	13.14
24412276	C2744539	THBD protein, human	aapp	12.89
24412276	C2744539	THBD protein, human	bacs	12.89
24412276	C0018790	Cardiac Arrest	dsyn	10.18
24412276	C0598629	Hydrophobicity	qlco	9.74
24412276	C0441635	Anatomical segmentation	spco	5.18
24412276	C1522492	Formation	ftcn	5.18
24412276	C0205431	Formed	ftcn	5.18
24412276	C1705535	suggestion	idcn	5.18
24412276	C2825142	Experimental Result	fndg	3.98
24412276	C1274040	Result	ftcn	3.98
24412276	C1546471	What subject filter - Result	idcn	3.98
24412276	C1706084	(City) Block	geoa	3.87
24412276	C0237477	Arrested progression	tmco	3.87
24412276	C2828370	Block (unit of measure)	qnco	3.87
24412276	C1533157	Block Specimens	sbst	3.87
24412276	C3811660	Block Unit of Distance	qnco	3.87
24412276	C0332206	Blocking	ftcn	3.87
24412276	C0392351	Law enforcement arrest	gora	3.87
24412276	C0233660	Mental blocking	mobd	3.87
24412276	C0028778	Obstruction	patf	3.87
24412276	C0521111	Retarded	qlco	3.87
24412276	C1254042	Anatomical maturation	phsf	3.59
24412276	C0678723	Biologic Development	orgf	3.59
24412276	C0870861	Human maturation	phpr	3.59
24412276	C0302891	Native (qualifier value)	ftcn	3.47
24412276	C1518422	Negation	ftcn	3.47
24412276	C0332454	disrupted	qlco	3.45
24412276	C3540468	THBD wt Allele	gngm	3.43
24412276	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
24412276	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
24412276	C0012771	Disulfides	chvs	19.45
24412276	C1524024	analysis aspect	ftcn	13.03
24412276	C0010654	Cysteine	aapp	12.90
24412276	C0010654	Cysteine	bacs	12.90
24412276	C0018790	Cardiac Arrest	dsyn	10.18
24412276	C0026882	Mutation	genf	9.99
24412276	C2827755	Antimicrobial Intermediate Susceptibility Result	lbtr	5.18
24412276	C0332220	Cross-linking	ftcn	5.18
24412276	C1880834	Fold in Medical Device Material	phpr	5.18
24412276	C0332462	Folded structure	spco	5.18
24412276	C0205103	Intermediate	spco	5.18
24412276	C3889971	Intermediate Mitosis-Karyorrhexis Index	qnco	5.18
24412276	C1550465	Observation Interpretation - intermediate	lbtr	5.18
24412276	C1705535	suggestion	idcn	5.18
24412276	C1706084	(City) Block	geoa	3.87
24412276	C0237477	Arrested progression	tmco	3.87
24412276	C2828370	Block (unit of measure)	qnco	3.87
24412276	C1533157	Block Specimens	sbst	3.87
24412276	C3811660	Block Unit of Distance	qnco	3.87
24412276	C0332206	Blocking	ftcn	3.87
24412276	C0392351	Law enforcement arrest	gora	3.87
24412276	C0233660	Mental blocking	mobd	3.87
24412276	C0028778	Obstruction	patf	3.87
24412276	C0521111	Retarded	qlco	3.87
24412276	C1705285	Mutation Abnormality	comd	3.68
24412276	C0936012	Analysis	resa	3.57
24412276	C0002778	Analysis of substances	lbpr	3.57
24412276	C1254042	Anatomical maturation	phsf	3.57
24412276	C0678723	Biologic Development	orgf	3.57
24412276	C0870861	Human maturation	phpr	3.57
24412276	C1413365	CFTR gene	gngm	3.44
24412276	C3887583	CD40 Ligand, human	aapp	3.42
24412276	C3887583	CD40 Ligand, human	imft	3.42
24412276	C1706005	CD40LG wt Allele	gngm	3.42
24412276	C0184047	Trap medical device	medd	3.42
24412276	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
24412276	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
24412276	C0015450	Face	blor	10.28
24412276	C0026882	Mutation	genf	9.94
24412276	C0598629	Hydrophobicity	qlco	9.81
24412276	C0475370	Hydrophilicity	qlco	9.78
24412276	C1705535	suggestion	idcn	5.18
24412276	C2828102	Pharmacological Chaperone	chvf	4.12
24412276	C1281591	Entire face	bpoc	3.98
24412276	C2825142	Experimental Result	fndg	3.98
24412276	C1274040	Result	ftcn	3.98
24412276	C1546471	What subject filter - Result	idcn	3.98
24412276	C1413365	CFTR gene	gngm	3.68
24412276	C1709694	Processing (action)	acty	3.48
24412276	C0205170	Good	qlco	3.44
25395018	C2959886	Cardiopulmonary Exercise Test	diap	16.42
25395018	C0010674	Cystic Fibrosis	dsyn	11.49
25395018	C0030705	Patients	podg	6.70
25395018	C1516615	Clinical Management	hlca	3.58
25395018	C0010674	Cystic Fibrosis	dsyn	9.75
25395018	C0037455	Societies	orgt	9.73
25395018	C0025663	Methods	inpr	6.70
25395018	C0030705	Patients	podg	6.58
25395018	C1706385	Device Evaluation Method	hlca	3.56
25395018	C2911685	Evaluation Method	resa	3.56
25395018	C0543488	Interested	menp	3.56
25395018	C1517741	Last	qlco	3.55
25395018	C0439234	year	tmco	3.55
25395018	C0449851	Techniques	ftcn	3.54
25395018	C0871511	Test Method	lbpr	3.54
25395018	C1261322	Evaluation procedure	hlca	3.44
25395018	C1516634	research clinical testing	resa	3.44
25395018	C0679830	patient assessment	hlca	3.44
25395018	C1708476	Implementation	acty	3.43
25395018	C0205210	Clinical	qlco	3.42
25395018	C1535514	European race	popg	3.42
25395018	C0332257	Including (qualifier)	ftcn	3.42
25395018	C1553058	Neuropsychologist - Clinical	prog	3.42
25395018	C0237412	Psychologist - Clinical	prog	3.42
25395018	C0497591	Social Worker - Clinical	prog	3.42
25395018	C0239307	ethnic european	popg	3.42
25395018	C0015259	Exercise	dora	19.34
25395018	C2959886	Cardiopulmonary Exercise Test	diap	16.08
25395018	C0015127	Etiology aspects	ftcn	11.49
25395018	C0282443	Review [Publication Type]	inpr	11.49
25395018	C0030755	Pediatrics	bmod	9.81
25395018	C1552617	Act Class - review	idcn	5.18
25395018	C0439792	Extent	spco	5.18
25395018	C1524003	Science of Etiology	cnce	5.18
25395018	C1516048	Assessed	acty	3.98
25395018	C1524063	Use of	ftcn	3.58
25395018	C1522704	Exercise Pain Management	topp	3.57
25395018	C0449295	Limitation	ftcn	3.57
25395018	C2603362	S prime	clna	3.57
25395018	C0565930	per second	qnco	3.57
25395018	C1521725	Pediatric	qlco	3.50
25395018	C0521116	Current (present time)	tmco	3.42
25395018	C1705970	Electrical Current	npop	3.42
25395018	C0459471	Interpretation Process	inpr	5.18
25395018	C3173575	Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal	clna	5.18
25395018	C1999230	Providing (action)	acty	5.18
25395018	C1707959	Example	cnce	3.52
25395018	C0444706	Measured	qlco	3.43
25395018	C3541902	Measured Tumor Identification	diap	3.43
25395018	C0449381	Observation parameter	fndg	3.43
25395018	C0015259	Exercise	dora	20.95
25395018	C0162521	Exercise Tolerance	clna	13.11
25395018	C0162340	Comprehension	menp	13.02
25395018	C0035173	Research Personnel	prog	11.49
25395018	C0042153	utilization qualifier	ftcn	11.49
25395018	C0242481	Research Activities	resa	9.87
25395018	C0035168	research	resa	9.87
25395018	C0022702	Kinetics	npop	9.76
25395018	C0220781	Anabolism	biof	6.71
25395018	C0026845	Muscle	tisu	6.61
25395018	C0043227	Work	ocac	6.58
25395018	C3854260	Advance	tmco	5.18
25395018	C0725066	Advance -- medical device	medd	5.18
25395018	C1550043	Container status - Identified	fndg	5.18
25395018	C1522704	Exercise Pain Management	topp	5.18
25395018	C0332282	Following	tmco	5.18
25395018	C0205396	Identified	qlco	5.18
25395018	C1305742	Oxygen consumption measurement	diap	5.18
25395018	C0429627	Oxygen uptake	fndg	5.18
25395018	C0231290	Status post	tmco	5.18
25395018	C2584313	Discussion (communication)	socb	3.98
25395018	C1704632	Disease Response	fndg	3.59
25395018	C2911692	Response (communication)	menp	3.59
25395018	C1706817	Response (statement)	inpr	3.59
25395018	C0871261	Response process	orga	3.59
25395018	C3887460	Cardiovascular	blor	3.56
25395018	C0007226	Cardiovascular system	bdsy	3.56
25395018	C0205172	More	ftcn	3.56
25395018	C2827396	Scientific Equipment	mnob	3.56
25395018	C1546767	Specimen Source Codes - Respiratory	inpr	3.56
25395018	C0336791	Tool, device (physical object)	mnob	3.56
25395018	C0521346	respiratory	ftcn	3.56
25395018	C1883254	Synthesis	acty	3.55
25395018	C0449295	Limitation	ftcn	3.46
25395018	C0442025	Muscular	spco	3.46
25395018	C2825046	Kinetics (discipline)	ocdi	3.45
25395018	C1511545	Critical	qlco	3.43
25395018	C0332185	Recent	tmco	3.43
25395018	C0015259	Exercise	dora	20.95
25395018	C1522704	Exercise Pain Management	topp	5.18
25395018	C0588464	Exercise on prescription	topp	3.58
25395018	C0449788	Count of entities	qnco	3.57
25395018	C0237753	Numbers	qnco	3.57
25395018	C1947919	Application (Document)	inpr	3.56
25395018	C3539080	Application Dosing Unit	qnco	3.56
25395018	C0185125	Application procedure	hlca	3.56
25395018	C4048755	Apply	ftcn	3.56
25395018	C2347934	Regulatory Application	inpr	3.56
25395018	C0582205	Utilities (organization)	orgt	3.55
25395018	C3669222	Utility (animal life circumstance)	ftcn	3.55
25395018	C1881534	Make - Instruction Imperative	ftcn	3.52
25395018	C0808232	Therapeutic Intervention	topp	3.46
25395018	C0087111	Therapeutic procedure	topp	3.46
25395018	C0034866	Recommendation	idcn	3.44
23199563	C0040363	Togo	geoa	17.80
23199563	C0041260	Tryptophanase	aapp	17.80
23199563	C0041260	Tryptophanase	enzy	17.80
23199563	C0027552	Needs	qlco	14.64
23199563	C0024109	Lung	bpoc	13.41
23199563	C0010674	Cystic Fibrosis	dsyn	11.49
23199563	C0030705	Patients	podg	6.72
23199563	C0033085	Biologic Preservation	lbpr	6.63
23199563	C0024115	Lung diseases	dsyn	6.62
23199563	C0243095	Finding	fndg	5.18
23199563	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
23199563	C1883351	To	qlco	5.18
23199563	C0679252	cure of disease	fndg	3.60
23199563	C0443288	Restricted	ftcn	3.57
23199563	C1880198	Cure (remedy)	cnce	3.56
23199563	C0814225	benefit	qnco	3.56
23199563	C0205170	Good	qlco	3.48
23199563	C3146287	Well	mnob	3.48
23199563	C0449445	Approach	spco	3.43
23199563	C0443225	Full	qlco	3.43
23199563	C2709248	Pulmonary (qualifier value)	qlco	3.43
23199563	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.43
23199563	C0026882	Mutation	genf	19.70
23199563	C0064716	lead chloride	hops	13.04
23199563	C0064716	lead chloride	inch	13.04
23199563	C0013153	Drug Administration Routes	ftcn	9.94
23199563	C0031330	Pharmacology	bmod	9.85
23199563	C0014597	Epithelial Cells	cell	6.91
23199563	C0521116	Current (present time)	tmco	5.18
23199563	C2349182	Correct (qualifier)	qlco	3.98
23199563	C1273342	Epithelial cell count (procedure)	lbpr	3.75
23199563	C1879941	CDISC SDTM Route of Administration Terminology	inpr	3.63
23199563	C0449444	Route	spco	3.63
23199563	C1546767	Specimen Source Codes - Respiratory	inpr	3.63
23199563	C0521346	respiratory	ftcn	3.63
23199563	C0441712	Mechanism (attribute)	ftcn	3.56
23199563	C1706376	Mechanism Component of Device	mnob	3.56
23199563	C0221099	Impaired	ftcn	3.55
23199563	C0684336	Impaired health	patf	3.55
23199563	C0449445	Approach	spco	3.54
23199563	C1552740	Entity Determiner - specific	inpr	3.54
23199563	C1705285	Mutation Abnormality	comd	3.54
23199563	C0205369	Specific qualifier value	qlco	3.54
23199563	C0205464	pharmacological	ftcn	3.54
23199563	C2948600	Aim	phsu	3.51
23199563	C1947946	Aim (idea)	idcn	3.51
23199563	C3540472	Ancestry-Informative Marker	ftcn	3.51
23199563	C3890193	CD5L wt Allele	gngm	3.51
23199563	C2744535	CD69 protein, human	aapp	3.51
23199563	C2744535	CD69 protein, human	imft	3.51
23199563	C3540471	CD69 wt Allele	gngm	3.51
23199563	C0205393	Most	qnco	3.48
23199563	C1555307	promise	idcn	3.45
23199563	C2959886	Cardiopulmonary Exercise Test	diap	17.80
23199563	C0009738	Congo	geoa	16.18
23199563	C3854019	Gentamicin	antb	14.64
23199563	C3854019	Gentamicin	orch	14.64
23199563	C0546866	Gentamicin Sulfate (USP)	antb	14.64
23199563	C0546866	Gentamicin Sulfate (USP)	orch	14.64
23199563	C1321596	Miglustat	orch	14.64
23199563	C1321596	Miglustat	phsu	14.64
23199563	C3264621	ivacaftor	orch	14.64
23199563	C3264621	ivacaftor	phsu	14.64
23199563	C3852684	lumacaftor	orch	14.64
23199563	C3852684	lumacaftor	phsu	14.64
23199563	C0030705	Patients	podg	6.72
23199563	C1869204	PTC 124	orch	5.18
23199563	C3252847	VX 809	orch	5.18
23199563	C3252847	VX 809	phsu	5.18
23199563	C2741958	VX-770	orch	5.18
23199563	C3687832	DRUGS	topp	3.63
23199563	C0013227	Pharmaceutical Preparations	phsu	3.63
23199563	C3811819	CFTR wt Allele	gngm	3.57
23199563	C1292732	Investigates	ftcn	3.57
23199563	C1444637	Past	tmco	3.50
23199563	C0036536	Process of secretion	biof	19.40
23199563	C0040363	Togo	geoa	17.80
23199563	C0041260	Tryptophanase	aapp	17.80
23199563	C0041260	Tryptophanase	enzy	17.80
23199563	C0008203	Chlorides	inch	16.09
23199563	C0028429	Nose	bpoc	12.89
23199563	C0036537	Bodily secretions	bdsu	6.79
23199563	C0034037	Publishing	ocac	6.63
23199563	C1516048	Assessed	acty	5.18
23199563	C1883351	To	qlco	5.18
23199563	C0450442	Agent	chvf	3.68
23199563	C1254351	Pharmacologic Substance	phsu	3.68
23199563	C1521826	Protocol Agent	inpr	3.68
23199563	C0947630	Scientific Study	lbpr	3.63
23199563	C1515655	in vivo	spco	3.58
23199563	C1704419	Effective	qlco	3.50
23199563	C1280519	Effectiveness	qlco	3.50
23199563	C0439175	% of total	qnco	3.48
23199563	C0596019	Chloride Ion	elii	3.48
23199563	C1704324	Scientific Publication	inpr	3.48
23199563	C0439810	Total	qlco	3.48
23199563	C1705241	Delta (difference)	qnco	3.42
23199563	C1705242	Different	qlco	3.42
23199563	C0242485	Measurement	ftcn	3.42
23199563	C3245505	potential	qlco	3.42
23199563	C0671954	CD3EAP protein, human	aapp	14.64
23199563	C0671954	CD3EAP protein, human	bacs	14.64
23199563	C0282443	Review [Publication Type]	inpr	9.99
23199563	C2699127	Cast Present Or Absent (lab procedure)	lbpr	5.18
23199563	C0302143	Casts body substance	bdsu	5.18
23199563	C1511545	Critical	qlco	5.18
23199563	C0179686	Orthopedic Cast	medd	5.18
23199563	C4048266	Urine Casts	bdsu	5.18
23199563	C1552617	Act Class - review	idcn	3.68
23199563	C0233426	Personal appearance	orga	3.57
23199563	C0947630	Scientific Study	lbpr	3.57
23199563	C0150312	Present	qnco	3.50
23199563	C0449450	Presentation	idcn	3.50
23199563	C0008976	Clinical Trials	resa	19.18
23199563	C0028429	Nose	bpoc	12.89
23199563	C2584313	Discussion (communication)	socb	3.98
23199563	C0449381	Observation parameter	fndg	3.55
23199563	C0449295	Limitation	ftcn	3.55
23199563	C0442809	Inconsistent	qlco	3.54
23199563	C0750489	apparent	idcn	3.48
23199563	C1274040	Result	ftcn	3.43
23199563	C1705241	Delta (difference)	qnco	3.42
23199563	C1705242	Different	qlco	3.42
23199563	C0242485	Measurement	ftcn	3.42
23199563	C0332149	Possible	qlco	3.42
23199563	C2362652	Possible diagnosis	qlco	3.42
23199563	C1705910	Possibly Related to Intervention	qlco	3.42
23199563	C3245505	potential	qlco	3.42
23199563	C0009738	Congo	geoa	32.39
23199563	C0206243	Carrying	acty	13.05
23199563	C3264621	ivacaftor	orch	12.94
23199563	C3264621	ivacaftor	phsu	12.94
23199563	C0026882	Mutation	genf	11.49
23199563	C0740116	+2	qnco	7.06
23199563	C3833492	2+	fndg	7.06
23199563	C2827735	2+ Score	qnco	7.06
23199563	C2981700	2+ Score, WHO	clas	7.06
23199563	C3811819	CFTR wt Allele	gngm	7.01
23199563	C0030705	Patients	podg	6.71
23199563	C0205170	Good	qlco	5.18
23199563	C1705285	Mutation Abnormality	comd	5.18
23199563	C1521840	Target	ftcn	5.18
23199563	C3146287	Well	mnob	5.18
23199563	C0947630	Scientific Study	lbpr	3.63
23199563	C0699809	Does carry	fndg	3.59
23199563	C1880198	Cure (remedy)	cnce	3.56
23199563	C3640168	French Catheter Gauge	qnco	3.55
23199563	C0376246	French language	lang	3.55
23199563	C2347129	Milestone	cnce	3.55
23199563	C1556084	french race	popg	3.55
23199563	C0205166	Long	qlco	3.43
23199563	C1706317	Long Variable	qlco	3.43
23199563	C0442650	Road	mnob	3.43
23199563	C0036043	Safety	hcpp	16.05
23199563	C0027552	Needs	qlco	14.64
23199563	C0080045	Prices	qnco	6.71
23199563	C0030705	Patients	podg	6.59
23199563	C1881534	Make - Instruction Imperative	ftcn	5.18
23199563	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
23199563	C1280519	Effectiveness	qlco	3.63
23199563	C1707887	Efficacy Study	resa	3.63
23199563	C0680994	drug price	qnco	3.58
23199563	C1511726	Data	idcn	3.57
23199563	C3714741	Data (eukaryote)	euka	3.57
23199563	C3245479	Data call receiving device	medd	3.57
23199563	C0443252	Long-term	tmco	3.53
23199563	C0746467	medication current	fndg	3.45
23199563	C1517331	Further	spco	3.44
23199563	C1705187	Safety Study	resa	3.44
23199563	C1535514	European race	popg	3.43
23199563	C0239307	ethnic european	popg	3.43
23199563	C0521116	Current (present time)	tmco	3.43
23199563	C1705970	Electrical Current	npop	3.43
27895116	C0010674	Cystic Fibrosis	dsyn	19.99
27895116	C1314792	Etiology	ftcn	14.64
27895116	C0015127	Etiology aspects	ftcn	11.49
27895116	C0026882	Mutation	genf	9.90
27895116	C1524003	Science of Etiology	cnce	5.18
27895116	C1705285	Mutation Abnormality	comd	3.59
27895116	C0205214	Common (qualifier value)	qnco	3.45
27895116	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.45
27895116	C0205439	Fifth	qnco	3.45
27895116	C1704735	Regulator	cnce	3.45
27895116	C1704734	Regulator Device Component	mnob	3.45
27895116	C0182953	Regulators (device)	medd	3.45
27895116	C2752508	fully spanning the plasma membrane	celc	3.45
27895116	C1167322	integral to membrane	celc	3.45
27895116	C1522138	shared attribute	ftcn	3.45
27895116	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
27895116	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
27895116	C0040363	Togo	geoa	17.80
27895116	C0041260	Tryptophanase	aapp	17.80
27895116	C0041260	Tryptophanase	enzy	17.80
27895116	C0034754	Reading (activity)	dora	16.04
27895116	C0597295	Protein Biosynthesis	moft	16.03
27895116	C0027552	Needs	qlco	13.01
27895116	C0040712	Language Translations	inpr	12.88
27895116	C0026882	Mutation	genf	9.73
27895116	C1292732	Investigates	ftcn	5.18
27895116	C1883351	To	qlco	5.18
27895116	C1413365	CFTR gene	gngm	3.57
27895116	C1273517	Used by	fndg	3.57
27895116	C0686904	Patient need for (contextual qualifier)	ftcn	3.55
27895116	C0582205	Utilities (organization)	orgt	3.54
27895116	C3669222	Utility (animal life circumstance)	ftcn	3.54
27895116	C1328819	Small Molecule	orch	3.43
27895116	C1705179	Reading (datum presentation)	fndg	3.43
27895116	C0679199	strategy	menp	3.42
27895116	C0542341	Function	ftcn	3.42
27895116	C0205245	Functional	ftcn	3.42
27895116	C2700217	Functional Relationship	cnce	3.42
27895116	C1519614	Genetic Translation Process	genf	3.42
27895116	C1704444	Multiplicative Product	qnco	3.42
27895116	C1705285	Mutation Abnormality	comd	3.42
27895116	C1514468	product	enty	3.42
27895116	C0332257	Including (qualifier)	ftcn	5.18
27895116	C3252847	VX 809	orch	5.18
27895116	C3252847	VX 809	phsu	5.18
27895116	C2741958	VX-770	orch	5.18
27895116	C0474395	Behavior showing increased motor activity	fndg	3.78
27895116	C1704459	Device Component System	mnob	3.59
27895116	C0449913	System	ftcn	3.59
27895116	C1553451	System - kit	mnob	3.59
27895116	C0205423	Certain (qualifier value)	qlco	3.50
27895116	C1704787	Definitely Related to Intervention	qlco	3.50
27895116	C1413336	CEL gene	gngm	3.48
27895116	C1948049	Cell (compartment)	spco	3.48
27895116	C1704653	Cell Device Component	medd	3.48
27895116	C0007634	Cells	cell	3.48
27895116	C1269647	Entire cell	cell	3.48
27895116	C0040363	Togo	geoa	17.80
27895116	C0041260	Tryptophanase	aapp	17.80
27895116	C0041260	Tryptophanase	enzy	17.80
27895116	C1518478	Nutraceuticals	food	13.01
27895116	C1883351	To	qlco	5.18
27895116	C1328819	Small Molecule	orch	3.68
27895116	C1705053	Screen Device Component	mnob	3.63
27895116	C1305399	Screening - procedure intent	ftcn	3.63
27895116	C0220908	Screening procedure	hlca	3.63
27895116	C1272695	Done (qualifier value)	qlco	3.59
27895116	C0542341	Function	ftcn	3.50
27895116	C0205245	Functional	ftcn	3.50
27895116	C2700217	Functional Relationship	cnce	3.50
27895116	C0205314	New	qlco	3.50
27895116	C0679622	literary novel	inpr	3.50
27895116	C1883254	Synthesis	acty	3.47
27895116	C1280519	Effectiveness	qlco	3.43
27895116	C1707887	Efficacy Study	resa	3.43
27895116	C1704243	Greater	qnco	3.43
27895116	C0007634	Cells	cell	3.43
27895116	C3282337	Cells [Chemical/Ingredient]	cell	3.43
27895116	C3687832	DRUGS	topp	3.43
27895116	C0013227	Pharmaceutical Preparations	phsu	3.43
27895116	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.53
27895116	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.53
27895116	C0031959	piperidine	orch	12.93
27895116	C0031957	piperazine	orch	12.88
27895116	C0031957	piperazine	phsu	12.88
27895116	C0036576	Genetic Selection	genf	9.83
27895116	C1550043	Container status - Identified	fndg	3.64
27895116	C0205396	Identified	qlco	3.64
27895116	C0456387	Class	inpr	3.61
27895116	C1705943	Class (taxonomic)	clas	3.61
27895116	C4019422	Classes - encounter	hlca	3.61
27895116	C1413365	CFTR gene	gngm	3.60
27895116	C1280519	Effectiveness	qlco	3.54
27895116	C1707887	Efficacy Study	resa	3.54
27895116	C0337143	Scaffold	mnob	3.54
27895116	C1707391	Choose (action)	acty	3.52
27895116	C0205202	Corrected	qlco	3.46
27895116	C1955473	Others - Allergy	fndg	3.46
27895116	C3539125	other medicated shampoos in ATC	phsu	3.46
27895116	C0547043	Up	spco	3.43
27895116	C3252847	VX 809	orch	3.43
27895116	C3252847	VX 809	phsu	3.43
27895116	C0439093	Greater Than	qnco	3.43
27895116	C1880834	Fold in Medical Device Material	phpr	3.42
27895116	C0332462	Folded structure	spco	3.42
27895116	C0079613	Adoptive Immunotherapy	topp	26.06
27895116	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
27895116	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
27895116	C0040363	Togo	geoa	17.80
27895116	C0041260	Tryptophanase	aapp	17.80
27895116	C0041260	Tryptophanase	enzy	17.80
27895116	C1869853	SERPINA3 protein, human	aapp	13.44
27895116	C1869853	SERPINA3 protein, human	bacs	13.44
27895116	C0031843	physiological aspects	phsf	12.88
27895116	C2741958	VX-770	orch	10.67
27895116	C0442805	Increase	ftcn	5.18
27895116	C1883351	To	qlco	5.18
27895116	C4048375	Asthma Control Test Questionnaire	inpr	3.98
27895116	C3890007	SERPINA3 wt Allele	gngm	3.98
27895116	C0337143	Scaffold	mnob	3.60
27895116	C1550043	Container status - Identified	fndg	3.59
27895116	C1280519	Effectiveness	qlco	3.59
27895116	C1707887	Efficacy Study	resa	3.59
27895116	C0205396	Identified	qlco	3.59
27895116	C1883559	Wild Type	gngm	3.59
27895116	C1413365	CFTR gene	gngm	3.55
27895116	C1880834	Fold in Medical Device Material	phpr	3.53
27895116	C0332462	Folded structure	spco	3.53
27895116	C0597978	phenylsulfonamide	orch	3.50
27895116	C0205314	New	qlco	3.46
27895116	C0679622	literary novel	inpr	3.46
27895116	C1153410	channel activity	moft	3.42
27895116	C0542341	Function	ftcn	3.42
27895116	C0700205	Function Axis	clas	3.42
27895116	C0439044	Living Alone	fndg	3.42
27895116	C1705273	Mathematical Operator	inpr	3.42
27895116	C0205171	Singular	qnco	3.42
27895116	C0679994	alone - group size	grpa	3.42
27895116	C1882115	Normalize	resa	3.40
27895116	C0010453	Anthropological Culture	idcn	13.03
27895116	C0028429	Nose	bpoc	13.03
27895116	C0040461	Toothbrushing	topp	13.00
27895116	C0019904	Homozygote	orga	9.77
27895116	C3540027	Adrenergic and dopaminergic agents combinations	phsu	3.68
27895116	C3539975	Aluminium antacid compound combinations	phsu	3.68
27895116	C3539963	Amide local anesthetic combinations	orch	3.68
27895116	C3539963	Amide local anesthetic combinations	phsu	3.68
27895116	C3539979	Antiinfective irrigating solution combinations	phsu	3.68
27895116	C3540722	Beta-lactamase sensitive penicillin combinations	antb	3.68
27895116	C3540722	Beta-lactamase sensitive penicillin combinations	orch	3.68
27895116	C3539977	Calcium antacid compound combinations	phsu	3.68
27895116	C3540720	Caries prophylactic agent combinations	phsu	3.68
27895116	C3539972	Combination solutions for parenteral nutrition	phsu	3.68
27895116	C0453882	Combinations (Undergarment)	mnob	3.68
27895116	C3539968	Enema combinations	phsu	3.68
27895116	C3540026	Hepatitis vaccine combinations	aapp	3.68
27895116	C3540026	Hepatitis vaccine combinations	imft	3.68
27895116	C3540026	Hepatitis vaccine combinations	phsu	3.68
27895116	C3540723	Insulins and analogs for injection, fast-acting combinations	phsu	3.68
27895116	C3539974	Insulins and analogs for injection, intermediate-acting combinations	phsu	3.68
27895116	C3539967	Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations	phsu	3.68
27895116	C3540719	Intermediate-acting sulfonamide combinations	orch	3.68
27895116	C3540719	Intermediate-acting sulfonamide combinations	phsu	3.68
27895116	C3539965	Local hemostatic combinations	phsu	3.68
27895116	C3539959	Long-acting sulfonamide combinations	orch	3.68
27895116	C3539959	Long-acting sulfonamide combinations	phsu	3.68
27895116	C3539956	Magnesium antacid compound combinations	phsu	3.68
27895116	C3854036	Other anti-dementia drug combinations in ATC	phsu	3.68
27895116	C3539973	Other antifungal combinations for topical use in ATC	phsu	3.68
27895116	C3539960	Other intestinal adsorbent combinations in ATC	phsu	3.68
27895116	C3540028	Other irrigating solution combinations in ATC	phsu	3.68
27895116	C3539976	Penicillins with extended spectrum combinations	antb	3.68
27895116	C3539976	Penicillins with extended spectrum combinations	orch	3.68
27895116	C3539961	Platelet aggregation inhibitor combinations excl. heparin	phsu	3.68
27895116	C3540740	Potassium supplement combinations	phsu	3.68
27895116	C3539182	Salt solution combinations	phsu	3.68
27895116	C3539181	Short-acting sulfonamide combinations	orch	3.68
27895116	C3539181	Short-acting sulfonamide combinations	phsu	3.68
27895116	C3539969	Specific immunoglobulin combinations	aapp	3.68
27895116	C3539969	Specific immunoglobulin combinations	imft	3.68
27895116	C3539969	Specific immunoglobulin combinations	phsu	3.68
27895116	C3539970	combination drugs used in erectile dysfunction	phsu	3.68
27895116	C3539978	expectorant combinations excluding combinations with cough suppressants	phsu	3.68
27895116	C3540724	expectorant combinations, excl. combinations with cough suppressants	phsu	3.68
27895116	C3540031	gonadotropin combinations	aapp	3.68
27895116	C3540031	gonadotropin combinations	horm	3.68
27895116	C3540031	gonadotropin combinations	phsu	3.68
27895116	C3539966	insulins and analogs for injection combinations, long-acting	phsu	3.68
27895116	C3539964	local opthalmologic anesthetic combinations	phsu	3.68
27895116	C3539955	lung surfactant combinations	phsu	3.68
27895116	C3539957	opium alkaloids and derivative combination cough suppressants	phsu	3.68
27895116	C3540030	other cough suppressant combinations in ATC	phsu	3.68
27895116	C3540721	other nasal preparation combinations in ATC	phsu	3.68
27895116	C3539971	otologic analgesic and anesthetic combinations	phsu	3.68
27895116	C3539954	topical antibiotic combinations	phsu	3.68
27895116	C3539962	vitamin D and analog combinations	phsu	3.68
27895116	C0007634	Cells	cell	3.63
27895116	C3282337	Cells [Chemical/Ingredient]	cell	3.63
27895116	C2349001	Human Study Subject	humn	3.61
27895116	C2697811	Investigative Subject	ftcn	3.61
27895116	C0681850	Study Subject	grup	3.61
27895116	C1706203	Subject - topic	idcn	3.61
27895116	C1550501	Subject -direct target	idcn	3.61
27895116	C3146294	Generation (action)	acty	3.57
27895116	C0205225	Primary	qlco	3.57
27895116	C0439631	Primary operation	topp	3.57
27895116	C0392366	Tests (qualifier value)	inpr	3.57
27895116	C0439612	True primary (qualifier value)	tmco	3.57
27895116	C0443165	hair brushing activity	dora	3.54
27895116	C3828338	Reprogram	acty	3.48
27895116	C0205447	One	qnco	3.47
27895116	C0008203	Chlorides	inch	32.37
27895116	C0019904	Homozygote	orga	9.74
27895116	C0596019	Chloride Ion	elii	6.99
27895116	C1518422	Negation	ftcn	5.18
27895116	C0427850	Presence of cells	lbtr	3.62
27895116	C0205397	seen	qlco	3.59
27895116	C3854307	Presence (property)	qlco	3.55
27895116	C0150312	Present	qnco	3.55
27895116	C0392148	Providing presence (regime/therapy)	topp	3.55
27895116	C0442805	Increase	ftcn	3.48
27895116	C0205217	Increased	qnco	3.48
27895116	C2986815	Robust	qlco	3.48
27895116	C0007634	Cells	cell	3.43
27895116	C3282337	Cells [Chemical/Ingredient]	cell	3.43
27895116	C0205411	Adequate	qlco	3.42
27895116	C0441889	Levels (qualifier value)	qlco	3.42
27895116	C0205410	Sufficient	qlco	3.42
27895116	C1519595	Transcript	nnon	3.42
27895116	C0027552	Needs	qlco	13.03
27895116	C0026882	Mutation	genf	9.87
27895116	C0015127	Etiology aspects	ftcn	9.84
27895116	C0010674	Cystic Fibrosis	dsyn	9.77
27895116	C2349001	Human Study Subject	humn	7.84
27895116	C2697811	Investigative Subject	ftcn	5.18
27895116	C0681850	Study Subject	grup	5.18
27895116	C1706203	Subject - topic	idcn	5.18
27895116	C1550501	Subject -direct target	idcn	5.18
27895116	C0178693	human study	resa	3.75
27895116	C3540027	Adrenergic and dopaminergic agents combinations	phsu	3.68
27895116	C3539975	Aluminium antacid compound combinations	phsu	3.68
27895116	C3539963	Amide local anesthetic combinations	orch	3.68
27895116	C3539963	Amide local anesthetic combinations	phsu	3.68
27895116	C3539979	Antiinfective irrigating solution combinations	phsu	3.68
27895116	C3540722	Beta-lactamase sensitive penicillin combinations	antb	3.68
27895116	C3540722	Beta-lactamase sensitive penicillin combinations	orch	3.68
27895116	C3539977	Calcium antacid compound combinations	phsu	3.68
27895116	C3540720	Caries prophylactic agent combinations	phsu	3.68
27895116	C3539972	Combination solutions for parenteral nutrition	phsu	3.68
27895116	C0453882	Combinations (Undergarment)	mnob	3.68
27895116	C3539968	Enema combinations	phsu	3.68
27895116	C3540026	Hepatitis vaccine combinations	aapp	3.68
27895116	C3540026	Hepatitis vaccine combinations	imft	3.68
27895116	C3540026	Hepatitis vaccine combinations	phsu	3.68
27895116	C3540723	Insulins and analogs for injection, fast-acting combinations	phsu	3.68
27895116	C3539974	Insulins and analogs for injection, intermediate-acting combinations	phsu	3.68
27895116	C3539967	Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations	phsu	3.68
27895116	C3540719	Intermediate-acting sulfonamide combinations	orch	3.68
27895116	C3540719	Intermediate-acting sulfonamide combinations	phsu	3.68
27895116	C3539965	Local hemostatic combinations	phsu	3.68
27895116	C3539959	Long-acting sulfonamide combinations	orch	3.68
27895116	C3539959	Long-acting sulfonamide combinations	phsu	3.68
27895116	C3539956	Magnesium antacid compound combinations	phsu	3.68
27895116	C3854036	Other anti-dementia drug combinations in ATC	phsu	3.68
27895116	C3539973	Other antifungal combinations for topical use in ATC	phsu	3.68
27895116	C3539960	Other intestinal adsorbent combinations in ATC	phsu	3.68
27895116	C3540028	Other irrigating solution combinations in ATC	phsu	3.68
27895116	C3539976	Penicillins with extended spectrum combinations	antb	3.68
27895116	C3539976	Penicillins with extended spectrum combinations	orch	3.68
27895116	C3539961	Platelet aggregation inhibitor combinations excl. heparin	phsu	3.68
27895116	C3540740	Potassium supplement combinations	phsu	3.68
27895116	C3539182	Salt solution combinations	phsu	3.68
27895116	C0947630	Scientific Study	lbpr	3.68
27895116	C3539181	Short-acting sulfonamide combinations	orch	3.68
27895116	C3539181	Short-acting sulfonamide combinations	phsu	3.68
27895116	C3539969	Specific immunoglobulin combinations	aapp	3.68
27895116	C3539969	Specific immunoglobulin combinations	imft	3.68
27895116	C3539969	Specific immunoglobulin combinations	phsu	3.68
27895116	C3539970	combination drugs used in erectile dysfunction	phsu	3.68
27895116	C3539978	expectorant combinations excluding combinations with cough suppressants	phsu	3.68
27895116	C3540724	expectorant combinations, excl. combinations with cough suppressants	phsu	3.68
27895116	C3540031	gonadotropin combinations	aapp	3.68
27895116	C3540031	gonadotropin combinations	horm	3.68
27895116	C3540031	gonadotropin combinations	phsu	3.68
27895116	C3539966	insulins and analogs for injection combinations, long-acting	phsu	3.68
27895116	C3539964	local opthalmologic anesthetic combinations	phsu	3.68
27895116	C3539955	lung surfactant combinations	phsu	3.68
27895116	C3539957	opium alkaloids and derivative combination cough suppressants	phsu	3.68
27895116	C3540030	other cough suppressant combinations in ATC	phsu	3.68
27895116	C3540721	other nasal preparation combinations in ATC	phsu	3.68
27895116	C3539971	otologic analgesic and anesthetic combinations	phsu	3.68
27895116	C3539954	topical antibiotic combinations	phsu	3.68
27895116	C3539962	vitamin D and analog combinations	phsu	3.68
27895116	C0427861	Human cells	lbtr	3.64
27895116	C2348767	Therapeutic Efficacy	qlco	3.61
27895116	C0686904	Patient need for (contextual qualifier)	ftcn	3.57
27895116	C1705285	Mutation Abnormality	comd	3.56
27895116	C1511726	Data	idcn	3.55
27895116	C3714741	Data (eukaryote)	euka	3.55
27895116	C3245479	Data call receiving device	medd	3.55
27895116	C1524003	Science of Etiology	cnce	3.53
27895116	C1524062	Additional	ftcn	3.50
27895116	C0205447	One	qnco	3.48
27895116	C0007634	Cells	cell	3.43
27895116	C3282337	Cells [Chemical/Ingredient]	cell	3.43
27895116	C0205160	Negative	qlco	3.43
27895116	C3853545	Negative - answer	qlco	3.43
27895116	C2825491	Negative Charge	qlco	3.43
27895116	C1513916	Negative Finding	fndg	3.43
27895116	C2825415	Negative Number	cnce	3.43
26167629	C0086418	Homo sapiens	humn	28.78
26167629	C0016977	Gall Bladder Diseases	dsyn	9.77
26167629	C2985574	Study Condition	qlco	3.60
26167629	C0557651	Room of building - Study	mnob	3.56
26167629	C2603343	Study	resa	3.56
26167629	C1707494	Constrain	cnce	3.54
26167629	C0332268	Lacking	qlco	3.54
26167629	C0205225	Primary	qlco	3.54
26167629	C0439631	Primary operation	topp	3.54
26167629	C0439612	True primary (qualifier value)	tmco	3.54
26167629	C3686472	Biliary epithelial cell	cell	3.51
26167629	C3275124	Biliary System Disorder	dsyn	3.46
26167629	C0521378	biliary	ftcn	3.43
26167629	C3658289	Human Induced Pluripotent Stem Cells	cell	12.92
26167629	C0229671	Serum	bdsu	12.88
26167629	C0449738	Direction	spco	12.84
26167629	C0007589	Cell Differentiation process	celf	9.72
26167629	C0150312	Present	qnco	5.18
26167629	C0449450	Presentation	idcn	5.18
26167629	C3686472	Biliary epithelial cell	cell	3.61
26167629	C0007634	Cells	cell	3.61
26167629	C3282337	Cells [Chemical/Ingredient]	cell	3.61
26167629	C1507394	Clinical trial protocol document	inpr	3.53
26167629	C1522729	Library Protocol	inpr	3.53
26167629	C3715209	Protocol - answer to question	fndg	3.53
26167629	C0442711	Protocols documentation	inpr	3.53
26167629	C2348563	Study Protocol	inpr	3.53
26167629	C2945687	Differentiation	ftcn	3.42
26167629	C0442799	Efficient	qlco	3.42
26167629	C1880497	Empty (qualifier)	qlco	3.42
26167629	C1996904	Free (available (qualifier))	qlco	3.42
26167629	C0332296	Free of (attribute)	ftcn	3.42
26167629	C1511938	Histopathologic Grade differentiation	clna	3.42
26167629	C1546774	Specimen Source Codes - Serum	inpr	3.42
26167629	C1550100	Specimen Type - Serum	bdsu	3.42
26167629	C0439755	Directions	spco	3.37
26167629	C0037659	Somatostatin	aapp	24.11
26167629	C0037659	Somatostatin	horm	24.11
26167629	C0037659	Somatostatin	phsu	24.11
26167629	C0036534	Secretin	aapp	16.05
26167629	C0036534	Secretin	horm	16.05
26167629	C0036534	Secretin	phsu	16.05
26167629	C0040671	Psychological Transfer	menp	14.64
26167629	C0005390	Bile Acids	bacs	11.49
26167629	C0005390	Bile Acids	orch	11.49
26167629	C0523530	Bile acid measurement	lbpr	5.18
26167629	C0332257	Including (qualifier)	ftcn	5.18
26167629	C1881011	Recombinant Somatostatin	aapp	5.18
26167629	C1881011	Recombinant Somatostatin	phsu	5.18
26167629	C1522575	Recombinant Vascular Endothelial Growth Factor	aapp	5.18
26167629	C1522575	Recombinant Vascular Endothelial Growth Factor	phsu	5.18
26167629	C1547282	Show	anim	5.18
26167629	C1705822	Transfer Technique	ftcn	5.18
26167629	C1149888	alkaline phosphatase activity	moft	5.18
26167629	C1324645	gamma-glutamyltransferase activity	moft	3.81
26167629	C1704939	ABCB1 wt Allele	gngm	3.68
26167629	C1861502	COLCHICINE RESISTANCE	dsyn	3.68
26167629	C1521970	Characteristics	qlco	3.57
26167629	C0871261	Response process	orga	3.57
26167629	C0542341	Function	ftcn	3.44
26167629	C0205245	Functional	ftcn	3.44
26167629	C2700217	Functional Relationship	cnce	3.44
26167629	C0205463	Physiological	ftcn	3.44
26167629	C2752584	secretin activity	moft	3.44
26167629	C3686472	Biliary epithelial cell	cell	3.42
26167629	C0085280	Alagille Syndrome	cgab	19.20
26167629	C0158683	Polycystic liver disease	cgab	14.64
26167629	C0158683	Polycystic liver disease	dsyn	14.64
26167629	C0042153	utilization qualifier	ftcn	11.49
26167629	C0010674	Cystic Fibrosis	dsyn	9.81
26167629	C0457083	Usage	ftcn	5.18
26167629	C1947944	Use - dosing instruction imperative	inpr	5.18
26167629	C1704939	ABCB1 wt Allele	gngm	3.54
26167629	C1861502	COLCHICINE RESISTANCE	dsyn	3.54
26167629	C0332281	Associated with	qlco	3.47
26167629	C1515654	In Vitro Model	resa	3.44
26167629	C1706388	Array Feature	cnce	3.40
26167629	C1521970	Characteristics	qlco	3.40
26167629	C2348519	Feature	qlco	3.40
26167629	C2346469	Image Feature	qlco	3.40
26167629	C0009738	Congo	geoa	32.31
26167629	C0040363	Togo	geoa	17.80
26167629	C0041260	Tryptophanase	aapp	17.80
26167629	C0041260	Tryptophanase	enzy	17.80
26167629	C0042523	Verapamil	orch	16.04
26167629	C0042523	Verapamil	phsu	16.04
26167629	C0028833	Octreotide	aapp	14.64
26167629	C0028833	Octreotide	horm	14.64
26167629	C0028833	Octreotide	phsu	14.64
26167629	C0158683	Polycystic liver disease	cgab	12.96
26167629	C0158683	Polycystic liver disease	dsyn	12.96
26167629	C0042153	utilization qualifier	ftcn	11.49
26167629	C0728866	Drug effect	ftcn	9.92
26167629	C0012634	Disease	dsyn	9.74
26167629	C3811819	CFTR wt Allele	gngm	6.93
26167629	C0030705	Patients	podg	6.71
26167629	C0031437	Phenotype	orga	6.71
26167629	C0013230	Investigational New Drugs	phsu	6.67
26167629	C1704939	ABCB1 wt Allele	gngm	5.18
26167629	C1861502	COLCHICINE RESISTANCE	dsyn	5.18
26167629	C2827718	In Vitro Route of Administration	ftcn	5.18
26167629	C0021135	In Vitro [Publication Type]	inpr	5.18
26167629	C1547282	Show	anim	5.18
26167629	C1883351	To	qlco	5.18
26167629	C0457083	Usage	ftcn	5.18
26167629	C1947944	Use - dosing instruction imperative	inpr	5.18
26167629	C1533691	in vitro	qlco	5.18
26167629	C3146294	Generation (action)	acty	3.57
26167629	C3898900	Healthy	qlco	3.57
26167629	C1285572	Phenotype determination	lbpr	3.55
26167629	C0237401	Individual	humn	3.54
26167629	C0027361	Persons	popg	3.54
26167629	C0304229	Experimental drug	phsu	3.51
26167629	C0013206	Drug Evaluation, Preclinical	resa	11.49
26167629	C0007589	Cell Differentiation process	celf	9.81
26167629	C0012634	Disease	dsyn	9.81
26167629	C0005532	biology (field)	bmod	9.74
26167629	C2587213	Control function	ftcn	5.18
26167629	C2239193	Controlling (action)	phpr	5.18
26167629	C0373483	Drug screen (procedure)	lbpr	5.18
26167629	C0678723	Biologic Development	orgf	3.68
26167629	C1507394	Clinical trial protocol document	inpr	3.68
26167629	C1527148	Development	ftcn	3.68
26167629	C1522729	Library Protocol	inpr	3.68
26167629	C3715209	Protocol - answer to question	fndg	3.68
26167629	C0442711	Protocols documentation	inpr	3.68
26167629	C2348563	Study Protocol	inpr	3.68
26167629	C0243107	development aspects	phsf	3.68
26167629	C0870071	modeling	resa	3.68
26167629	C0557651	Room of building - Study	mnob	3.56
26167629	C2603343	Study	resa	3.56
26167629	C2945687	Differentiation	ftcn	3.50
26167629	C1511938	Histopathologic Grade differentiation	clna	3.50
26167629	C0521378	biliary	ftcn	3.50
26167629	C0441712	Mechanism (attribute)	ftcn	3.43
26167629	C0205460	biological	qlco	3.43
26744656	C0010674	Cystic Fibrosis	dsyn	10.06
26744656	C0030705	Patients	podg	6.71
26744656	C0392760	Affecting	ftcn	5.18
26744656	C0458827	Airway structure	bpoc	5.18
26744656	C0178987	Artificial Airways	medd	5.18
26744656	C1314939	Involvement with	ftcn	5.18
26744656	C0559758	Multisystem disorder	dsyn	5.18
26744656	C3826980	Multi-Drug Resistant Organism	orgm	3.81
26744656	C3540763	VARIOUS DRUG CLASSES IN ATC	phsu	3.47
26744656	C0440102	Various patch test substance	irda	3.47
26744656	C3540765	various allergen extracts	imft	3.47
26744656	C3540765	various allergen extracts	phsu	3.47
26744656	C3540008	various antiinfectives and antiseptics for local oral treatment	phsu	3.47
26744656	C3540766	various antiseptic throat preparations	phsu	3.47
26744656	C3540762	various other agents for local oral treatment in ATC	phsu	3.47
26744656	C3540769	various other intestinal adsorbents in ATC	phsu	3.47
26744656	C3540761	various other nasal preparations in ATC	phsu	3.47
26744656	C0239998	Recurrent infections	fndg	3.46
26744656	C0231203	predisposed	ftcn	3.43
26744656	C0026926	Mycobacterium tuberculosis	bact	25.83
26744656	C0009738	Congo	geoa	16.04
26744656	C0009450	Communicable Diseases	dsyn	11.49
26744656	C3714514	Infection	patf	8.34
26744656	C0030705	Patients	podg	6.58
26744656	C0522498	Rare	qlco	5.18
26744656	C0750591	consider	idcn	5.18
26744656	C0205397	seen	qlco	5.18
26744656	C0450254	Pathogenic organism	orgm	3.55
26744656	C3811819	CFTR wt Allele	gngm	3.43
26744656	C3245505	potential	qlco	3.43
26744656	C0041296	Tuberculosis	dsyn	19.22
26744656	C0009738	Congo	geoa	16.04
26744656	C3264621	ivacaftor	orch	12.88
26744656	C3264621	ivacaftor	phsu	12.88
26744656	C3273238	Regulatory Report	inpr	5.18
26744656	C0684224	Report (document)	inpr	5.18
26744656	C0700287	Reporting	hlca	5.18
26744656	C0332299	Suggestive of	ftcn	3.72
26744656	C0809949	Admission activity	hlca	3.59
26744656	C0184666	Hospital admission	hlca	3.59
26744656	C1457887	Symptoms	sosy	3.59
26744656	C0683368	Symptoms aspect	ftcn	3.59
26744656	C0549206	Patient currently pregnant	fndg	3.56
26744656	C3811819	CFTR wt Allele	gngm	3.42
26744656	C0580836	Old	tmco	3.42
26744656	C0439508	per year	tmco	3.42
26744656	C0439234	year	tmco	3.42
26744656	C0039798	therapeutic aspects	ftcn	22.36
26744656	C0024109	Lung	bpoc	6.57
26744656	C0205160	Negative	qlco	5.18
26744656	C3853545	Negative - answer	qlco	5.18
26744656	C2825491	Negative Charge	qlco	5.18
26744656	C1513916	Negative Finding	fndg	5.18
26744656	C2825415	Negative Number	cnce	5.18
26744656	C0750591	consider	idcn	5.18
26744656	C4082120	Six months	tmco	3.61
26744656	C0523174	Microbial culture of sputum	lbpr	3.58
26744656	C0580690	TB chemotherapy	topp	3.58
26744656	C1880198	Cure (remedy)	cnce	3.56
26744656	C0439234	year	tmco	3.54
26744656	C0332152	Before	tmco	3.44
26744656	C1533734	Administration procedure	topp	3.43
26744656	C1705169	Biomaterial Treatment	cnce	3.43
26744656	C0087111	Therapeutic procedure	topp	3.43
26744656	C1522326	Treating	ftcn	3.43
26744656	C3538994	Treatment Epoch	resa	3.43
26744656	C3887704	treatment - ActInformationManagementReason	hlca	3.43
26744656	C0809949	Admission activity	hlca	3.42
26744656	C0521116	Current (present time)	tmco	3.42
26744656	C1705970	Electrical Current	npop	3.42
26744656	C0184666	Hospital admission	hlca	3.42
26744656	C0205449	Three	qnco	3.42
26744656	C0205197	Complete	qlco	3.42
26744656	C0205450	Four	qnco	3.42
26744656	C2709248	Pulmonary (qualifier value)	qlco	3.42
26744656	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.42
26744656	C3854010	completed - RoleLinkStatus	idcn	3.42
26744656	C0040363	Togo	geoa	17.80
26744656	C0041260	Tryptophanase	aapp	17.80
26744656	C0041260	Tryptophanase	enzy	17.80
26744656	C0009450	Communicable Diseases	dsyn	9.99
26744656	C2987481	Emotional Strain	menp	7.25
26744656	C0456178	Microbiology subtype strains	qlco	7.25
26744656	C0080194	Muscle strain	inpo	7.25
26744656	C1518614	Organism Strain	orgm	7.25
26744656	C3714514	Infection	patf	6.83
26744656	C0678227	Causing	ftcn	5.18
26744656	C0443289	Revealed	qlco	5.18
26744656	C1883351	To	qlco	5.18
26744656	C1285573	Genotype determination	lbpr	3.75
26744656	C1705242	Different	qlco	3.57
26744656	C1552607	Act Relationship Subset - previous	tmco	3.50
26744656	C0521116	Current (present time)	tmco	3.50
26744656	C1705970	Electrical Current	npop	3.50
26744656	C0205156	Previous	tmco	3.50
26744656	C0041296	Tuberculosis	dsyn	19.19
26744656	C0032961	Pregnancy	orgf	16.18
26744656	C0040808	Treatment Protocols	topp	16.16
26744656	C0011209	Obstetric Delivery	topp	11.49
26744656	C1561611	Admission Level of Care Code - Improved	inpr	5.18
26744656	C0332272	Better	qlco	5.18
26744656	C0184511	Improved	qlco	5.18
26744656	C0522501	Massive	qlco	5.18
26744656	C1314680	Non-human parturition, function	orgf	5.18
26744656	C1705822	Transfer Technique	ftcn	5.18
26744656	C0683521	patient condition	fndg	5.18
26744656	C1514756	Receive	qlco	3.98
26744656	C0205260	Culminating	qlco	3.56
26744656	C3484365	Pregnancy:History:Point in time:^Patient:Ordinal	clna	3.56
26744656	C2945654	Regimen - CHV concept	inpr	3.54
26744656	C0205435	First (number)	qnco	3.42
26744656	C1279901	Firstly	qlco	3.42
26744656	C0700221	Intravascular line	medd	3.42
26744656	C1550648	Line Specimen	sbst	3.42
26744656	C1552960	Line Unit of Length	qnco	3.42
26744656	C0205132	Linear	spco	3.42
26744656	C0205455	Nine	qnco	3.42
26744656	C0439231	month	tmco	3.42
26744656	C0009738	Congo	geoa	16.12
26744656	C0376554	Knowledge	inpr	8.34
26744656	C0030705	Patients	podg	6.83
26744656	C0007320	Case Reports Publication Type	inpr	6.71
26744656	C0085973	Case Study	inpr	6.71
26744656	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.68
26744656	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.68
26744656	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.68
26744656	C3853626	Case report:Find:Pt:{Setting}:Doc:{Author Type}	clna	3.56
26744656	C3811819	CFTR wt Allele	gngm	3.50
26744656	C0275965	Reactivation tuberculosis	dsyn	3.44
26744656	C1720467	Only - dosing instruction fragment	inpr	3.42
26744656	C0205171	Singular	qnco	3.42
28539217	C0039798	therapeutic aspects	ftcn	22.34
28539217	C0010674	Cystic Fibrosis	dsyn	9.74
28539217	C0012634	Disease	dsyn	9.73
28539217	C0087111	Therapeutic procedure	topp	6.88
28539217	C3495919	Enthesitis-Related Arthritis	dsyn	3.54
28539217	C0750573	emergent	idcn	3.49
28539217	C1533734	Administration procedure	topp	3.42
28539217	C1705169	Biomaterial Treatment	cnce	3.42
28539217	C0205393	Most	qnco	3.42
28539217	C1522326	Treating	ftcn	3.42
28539217	C3538994	Treatment Epoch	resa	3.42
28539217	C3887704	treatment - ActInformationManagementReason	hlca	3.42
28539217	C0392747	Changing	ftcn	3.40
28539217	C0009738	Congo	geoa	16.07
28539217	C0162340	Comprehension	menp	13.01
28539217	C0031843	physiological aspects	phsf	13.01
28539217	C0030351	Paper	mnob	9.94
28539217	C0376636	Disease Management	hlca	9.90
28539217	C0031842	Physiology	bmod	9.85
28539217	C0376554	Knowledge	inpr	6.58
28539217	C0205397	seen	qlco	5.18
28539217	C0439508	per year	tmco	3.68
28539217	C0439234	year	tmco	3.68
28539217	C0001554	Administration occupational activities	ocac	3.59
28539217	C3273539	Management Occupations	ocdi	3.59
28539217	C1273870	Management procedure	ocac	3.59
28539217	C0702116	Consolidation	qlco	3.55
28539217	C3854260	Advance	tmco	3.54
28539217	C0725066	Advance -- medical device	medd	3.54
28539217	C1517741	Last	qlco	3.50
28539217	C0205388	Few	qnco	3.45
28539217	C3811819	CFTR wt Allele	gngm	3.45
27875677	C3264621	ivacaftor	orch	26.61
27875677	C3264621	ivacaftor	phsu	26.61
27875677	C3852684	lumacaftor	orch	12.93
27875677	C3852684	lumacaftor	phsu	12.93
27875677	C2718059	Precision Medicine	topp	12.91
27875677	C0015127	Etiology aspects	ftcn	9.86
27875677	C0010674	Cystic Fibrosis	dsyn	9.75
27875677	C0013162	Drug Combinations	phsu	6.66
27875677	C1521840	Target	ftcn	5.18
27875677	C2986546	Target Lesion Identification	diap	5.18
27875677	C0723712	Therapeutic brand of coal tar	orch	3.63
27875677	C0723712	Therapeutic brand of coal tar	phsu	3.63
27875677	C0087111	Therapeutic procedure	topp	3.63
27875677	C0150593	game	dora	3.57
27875677	C3495919	Enthesitis-Related Arthritis	dsyn	3.55
27875677	C1524003	Science of Etiology	cnce	3.55
27875677	C0681774	hail	npop	3.54
27875677	C0205314	New	qlco	3.48
27875677	C0314603	Genetic	ftcn	3.42
27875677	C0017296	gene therapy	topp	3.42
27875677	C3178752	Fertility Effect	phsf	16.21
27875677	C0015780	Female	orga	9.74
27875677	C0086287	Females	popg	9.74
27875677	C0035245	Respiratory physiology	ortf	8.34
27875677	C0043210	Woman	popg	6.59
27875677	C3687832	DRUGS	topp	5.18
27875677	C1518422	Negation	ftcn	5.18
27875677	C0013227	Pharmaceutical Preparations	phsu	5.18
27875677	C0557651	Room of building - Study	mnob	3.98
27875677	C2603343	Study	resa	3.98
27875677	C1280500	Effect	qlco	3.56
27875677	C1955260	Female fertility	clna	3.46
27875677	C1705498	Female Phenotype	qlco	3.43
27875677	C1705497	Female, Self-Report	qlco	3.43
27875677	C0032961	Pregnancy	orgf	16.30
27875677	C3264621	ivacaftor	orch	12.89
27875677	C3264621	ivacaftor	phsu	12.89
27875677	C0007320	Case Reports Publication Type	inpr	8.34
27875677	C0085973	Case Study	inpr	8.34
27875677	C0043210	Woman	popg	6.59
27875677	C3853626	Case report:Find:Pt:{Setting}:Doc:{Author Type}	clna	5.18
27875677	C3484365	Pregnancy:History:Point in time:^Patient:Ordinal	clna	3.68
27875677	C0596545	Experience	menp	3.56
27875677	C0237607	Practice Experience	menp	3.56
27875677	C0205447	One	qnco	3.43
27875677	C0009586	Comprehensive Health Care	hlca	19.89
27875677	C0035150	Reproduction	orgf	13.01
27875677	C0242667	Reproductive Health	bmod	9.88
27875677	C2362326	Sexual Health	orga	9.87
27875677	C0036864	Sex Behavior	bhvr	9.85
27875677	C0010674	Cystic Fibrosis	dsyn	9.77
27875677	C0043210	Woman	popg	6.71
27875677	C0449450	Presentation	idcn	5.18
27875677	C0445223	Related personal status	fndg	3.54
27875677	C0439849	Relationships	qlco	3.54
26701662	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
26701662	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
26701662	C0070683	phenylhydrazone	orch	13.09
26701662	C0562342	Empowered	menp	5.18
26701662	C1171285	Enabling	menp	5.18
26701662	C0678594	structure	spco	3.68
26701662	C1513375	Moderate Exercise	dora	3.64
26701662	C3833417	Moderate activity	fndg	3.64
26701662	C1549885	RDR - Message structure	inpr	3.63
26701662	C3889386	SLC1A5 wt Allele	gngm	3.63
26701662	C0678723	Biologic Development	orgf	3.52
26701662	C1527148	Development	ftcn	3.52
26701662	C0243107	development aspects	phsf	3.52
26701662	C0205352	Simple	qlco	3.50
26701662	C1413365	CFTR gene	gngm	3.48
26701662	C0456387	Class	inpr	3.42
26701662	C1705943	Class (taxonomic)	clas	3.42
26701662	C1948023	Stimulation (motivation)	npop	3.42
26701662	C0016849	Furaldehyde	bacs	13.00
26701662	C0016849	Furaldehyde	hops	13.00
26701662	C0016849	Furaldehyde	irda	13.00
26701662	C0016849	Furaldehyde	orch	13.00
26701662	C0031479	phenylhydrazine	orch	13.00
26701662	C0031479	phenylhydrazine	phsu	13.00
26701662	C0070683	phenylhydrazone	orch	12.89
26701662	C1883254	Synthesis	acty	5.18
26701662	C0449788	Count of entities	qnco	3.56
26701662	C0237753	Numbers	qnco	3.56
26701662	C0243072	derivatives	chvs	3.54
26701662	C0034251	pyridine	irda	13.09
26701662	C0034251	pyridine	orch	13.09
26701662	C0034255	Pyridines	orch	9.94
26701662	C0243072	derivatives	chvs	7.31
26701662	C4082130	Prepared	fndg	5.18
26701662	C3539113	Hydrazides for tuberculosis treatment	orch	3.68
26701662	C3539113	Hydrazides for tuberculosis treatment	phsu	3.68
26701662	C0443286	Reaction	ftcn	3.68
26701662	C0682951	hydrazides	orch	3.68
26701662	C0599532	Thiophene	orch	3.63
26701662	C0599532	Thiophene	phsu	3.63
26701662	C0445247	Same	qlco	3.50
26701662	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
26701662	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
26701662	C0010674	Cystic Fibrosis	dsyn	9.78
26701662	C2587213	Control function	ftcn	5.18
26701662	C1882979	Scientific Control	cnce	5.18
26701662	C3274648	True Control Status	qlco	5.18
26701662	C1524063	Use of	ftcn	5.18
26701662	C3252847	VX 809	orch	5.18
26701662	C3252847	VX 809	phsu	5.18
26701662	C0243148	control aspects	qlco	5.18
26701662	C1550141	control substance	sbst	5.18
26701662	C0205198	Compound	qlco	3.98
26701662	C1706082	Compound (substance)	chem	3.98
26701662	C0450373	4a serotype	inpr	3.68
26701662	C1553636	Maxillary right second premolar abutment	medd	3.68
26701662	C1413365	CFTR gene	gngm	3.56
26701662	C0392366	Tests (qualifier value)	inpr	3.56
26701662	C1711178	Bronchial Epithelial Cell	cell	3.49
26701662	C0700221	Intravascular line	medd	3.45
26701662	C1550648	Line Specimen	sbst	3.45
26701662	C1552960	Line Unit of Length	qnco	3.45
26701662	C0205132	Linear	spco	3.45
26701662	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
26701662	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
26701662	C0450366	3c	inpr	5.18
26701662	C4071834	5D	tmco	5.18
26701662	C0392366	Tests (qualifier value)	inpr	3.56
26701662	C1413365	CFTR gene	gngm	3.55
26701662	C0543488	Interested	menp	3.55
26701662	C0205198	Compound	qlco	3.53
26701662	C1706082	Compound (substance)	chem	3.53
26701662	C0740116	+2	qnco	3.48
26701662	C3833492	2+	fndg	3.48
26701662	C2827735	2+ Score	qnco	3.48
26701662	C2981700	2+ Score, WHO	clas	3.48
26701662	C3842589	20%	fndg	3.48
26701662	C4071834	5D	tmco	5.18
26701662	C0450366	3c	inpr	3.68
26701662	C3252847	VX 809	orch	3.61
26701662	C3252847	VX 809	phsu	3.61
26701662	C1521801	Having administered	ftcn	3.56
26701662	C1883357	Together	qlco	3.56
26701662	C0442796	Additive	qlco	3.50
26701662	C1550602	additive ingredient	sbst	3.50
26701662	C3266814	Action	acty	3.43
26701662	C0441472	Clinical action	ftcn	3.43
26701662	C1547307	Satisfactory - Patient Condition Code	inpr	3.43
26701662	C0205410	Sufficient	qlco	3.43
26701662	C0205451	Five	qnco	5.18
26701662	C0205379	Visible	qlco	3.68
26701662	C2983265	CDISC SEND Study Design Terminology	inpr	3.63
26701662	C1707689	Design	acty	3.63
26701662	C0185027	Imbrication (procedure)	topp	3.57
26701662	C1549885	RDR - Message structure	inpr	3.57
26701662	C3889386	SLC1A5 wt Allele	gngm	3.57
26701662	C0678594	structure	spco	3.57
26701662	C1272684	Accepted	qlco	3.50
26701662	C0443211	Established	qlco	3.50
26701662	C0205099	Central	spco	3.48
26701662	C1879652	Central Minus	lbpr	3.48
26701662	C0237876	Sharing (Social Behavior)	socb	3.48
26701662	C1522138	shared attribute	ftcn	3.48
26701662	C4071834	5D	tmco	3.44
26701662	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26701662	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26701662	C0543488	Interested	menp	3.59
26701662	C1706202	Search - action	acty	3.54
26701662	C1552603	search - EntityNameUse	inpr	3.54
26701662	C1413365	CFTR gene	gngm	3.42
26701662	C0205314	New	qlco	3.42
26227551	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.42
26227551	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.42
26227551	C0010674	Cystic Fibrosis	dsyn	10.06
26227551	C0031847	physiopathological	ftcn	9.85
26227551	C0015127	Etiology aspects	ftcn	9.85
26227551	C0019247	Hereditary Diseases	dsyn	6.91
26227551	C1517945	Loss	qnco	3.57
26227551	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.54
26227551	C3887504	Dysfunction	cnce	3.54
26227551	C0277785	Functional disorder	patf	3.54
26227551	C1524003	Science of Etiology	cnce	3.54
26227551	C1413365	CFTR gene	gngm	3.49
26227551	C3151529	Lethal	fndg	3.48
26227551	C0439799	Channel	spco	3.42
26227551	C1706095	Channel Object	cnce	3.42
26227551	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26227551	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26227551	C0033105	Statistical Prevalence	qnco	22.31
26227551	C0026882	Mutation	genf	9.85
26227551	C0033684	Proteins	aapp	8.34
26227551	C0033684	Proteins	bacs	8.34
26227551	C1413365	CFTR gene	gngm	6.90
26227551	C2700640	Encode (action)	acty	5.18
26227551	C1709694	Processing (action)	acty	5.18
26227551	C0332452	defective	ftcn	3.59
26227551	C0678941	Gene Mutant	gngm	3.56
26227551	C0596611	Gene Mutation	genf	3.56
26227551	C1705285	Mutation Abnormality	comd	3.54
26227551	C0185026	Plication	topp	3.45
26227551	C0205393	Most	qnco	3.42
26227551	C0220900	Prevalence aspects	qnco	3.38
26227551	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
26227551	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
26227551	C0040363	Togo	geoa	17.80
26227551	C0041260	Tryptophanase	aapp	17.80
26227551	C0041260	Tryptophanase	enzy	17.80
26227551	C0031843	physiological aspects	phsf	13.14
26227551	C0205217	Increased	qnco	5.18
26227551	C0185026	Plication	topp	5.18
26227551	C0684224	Report (document)	inpr	5.18
26227551	C0700287	Reporting	hlca	5.18
26227551	C1883351	To	qlco	5.18
26227551	C3252847	VX 809	orch	3.75
26227551	C3252847	VX 809	phsu	3.75
26227551	C0542341	Function	ftcn	3.68
26227551	C0700205	Function Axis	clas	3.68
26227551	C1705273	Mathematical Operator	inpr	3.68
26227551	C1413365	CFTR gene	gngm	3.57
26227551	C0599896	trafficking	celf	3.57
26227551	C0439799	Channel	spco	3.50
26227551	C1706095	Channel Object	cnce	3.50
26227551	C0162340	Comprehension	menp	14.64
26227551	C1524059	mechanism of action qualifier	ftcn	13.08
26227551	C0031327	Drug Kinetics	phsf	9.92
26227551	C0205169	Bad	qlco	5.18
26227551	C3252847	VX 809	orch	3.44
26227551	C3252847	VX 809	phsu	3.44
26227551	C0040363	Togo	geoa	35.81
26227551	C0041260	Tryptophanase	aapp	35.81
26227551	C0041260	Tryptophanase	enzy	35.81
26227551	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
26227551	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
26227551	C0002078	Alkynes	orch	12.96
26227551	C3252847	VX 809	orch	10.58
26227551	C3252847	VX 809	phsu	10.58
26227551	C1883351	To	qlco	10.42
26227551	C1257890	Population Group	popg	9.99
26227551	C3266814	Action	acty	5.18
26227551	C1167622	Binding (Molecular Function)	moft	5.18
26227551	C1145667	Binding action	acty	5.18
26227551	C0441472	Clinical action	ftcn	5.18
26227551	C0015264	Exertion	orgf	5.18
26227551	C3154893	Possess	idcn	5.18
26227551	C0850310	Possessed	mobd	5.18
26227551	C1706817	Response (statement)	inpr	5.18
26227551	C0333118	Retained	ftcn	5.18
26227551	C0557651	Room of building - Study	mnob	5.18
26227551	C2603343	Study	resa	5.18
26227551	C1883254	Synthesis	acty	5.18
26227551	C1663627	ALK protein, human	aapp	3.68
26227551	C1663627	ALK protein, human	enzy	3.68
26227551	C1705428	Group Object	cnce	3.68
26227551	C0441833	Groups	idcn	3.68
26227551	C1522634	Question (inquiry)	inpr	3.68
26227551	C0687744	Social group	popg	3.68
26227551	C1552516	Specialty Group	hcro	3.68
26227551	C1705429	User Group	popg	3.68
26227551	C0243072	derivatives	chvs	3.61
26227551	C1413365	CFTR gene	gngm	3.57
26227551	C0441712	Mechanism (attribute)	ftcn	3.56
26227551	C1706376	Mechanism Component of Device	mnob	3.56
26227551	C1516240	Capacity	qnco	3.55
26227551	C0205448	Two	qnco	3.47
26227551	C1947931	Direct (qualifier)	qlco	3.44
26227551	C1705178	Order (action)	acty	3.44
26227551	C1705176	Order (arrangement)	qlco	3.44
26227551	C1705175	Order (document)	inpr	3.44
26227551	C1705177	Order (taxonomic)	clas	3.44
26227551	C1882348	Permutation	qlco	3.44
26227551	C3889825	Sequence of Planned Assessment Schedule	inpr	3.44
26227551	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
26227551	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
26227551	C2936295	Click Chemistry	resa	16.30
26227551	C0021966	Iodides	inch	16.08
26227551	C1167622	Binding (Molecular Function)	moft	5.18
26227551	C1145667	Binding action	acty	5.18
26227551	C1413365	CFTR gene	gngm	5.18
26227551	C2347872	Cuprous	elii	5.18
26227551	C3887511	Evidence	idcn	5.18
26227551	C1999230	Providing (action)	acty	5.18
26227551	C1524063	Use of	ftcn	5.18
26227551	C1177210	cupric cation	inch	5.18
26227551	C1177210	cupric cation	phsu	5.18
26227551	C2827718	In Vitro Route of Administration	ftcn	3.75
26227551	C0021135	In Vitro [Publication Type]	inpr	3.75
26227551	C1533691	in vitro	qlco	3.75
26227551	C0243072	derivatives	chvs	3.63
26227551	C0007634	Cells	cell	3.59
26227551	C3282337	Cells [Chemical/Ingredient]	cell	3.59
26227551	C3252847	VX 809	orch	3.53
26227551	C3252847	VX 809	phsu	3.53
26227551	C1947931	Direct (qualifier)	qlco	3.48
26227551	C0221138	Blood group antibody I	aapp	3.47
26227551	C0221138	Blood group antibody I	imft	3.47
26227551	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.46
26227551	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.46
26227551	C0009738	Congo	geoa	17.80
26227551	C0040363	Togo	geoa	17.80
26227551	C0041260	Tryptophanase	aapp	17.80
26227551	C0041260	Tryptophanase	enzy	17.80
26227551	C1524059	mechanism of action qualifier	ftcn	13.03
26227551	C0031327	Drug Kinetics	phsf	9.87
26227551	C3539655	CDISC Findings Class	inpr	5.18
26227551	C3811819	CFTR wt Allele	gngm	5.18
26227551	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
26227551	C1883351	To	qlco	5.18
26227551	C2607943	findings aspects	ftcn	5.18
26227551	C2983265	CDISC SEND Study Design Terminology	inpr	3.55
26227551	C1707689	Design	acty	3.55
26227551	C1413365	CFTR gene	gngm	3.54
26227551	C1880177	Contribution	acty	3.54
26227551	C0723712	Therapeutic brand of coal tar	orch	3.43
26227551	C0723712	Therapeutic brand of coal tar	phsu	3.43
26227551	C0087111	Therapeutic procedure	topp	3.43
26227551	C3245505	potential	qlco	3.37
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
26171232	C0017337	Genes	gngm	17.80
26171232	C0007457	Caucasoid Race	popg	12.88
26171232	C0010674	Cystic Fibrosis	dsyn	10.06
26171232	C0026882	Mutation	genf	9.90
26171232	C0015127	Etiology aspects	ftcn	9.86
26171232	C0012634	Disease	dsyn	9.85
26171232	C0033684	Proteins	aapp	6.75
26171232	C0033684	Proteins	bacs	6.75
26171232	C2700640	Encode (action)	acty	5.18
26171232	C1547699	MIME encoding	idcn	5.18
26171232	C1413365	CFTR gene	gngm	3.58
26171232	C1524003	Science of Etiology	cnce	3.55
26171232	C0441748	Autosomal recessive inheritance	genf	3.44
26171232	C0043157	Caucasians	popg	3.42
26171232	C0205214	Common (qualifier value)	qnco	3.42
26171232	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
26171232	C0205393	Most	qnco	3.42
26171232	C1522138	shared attribute	ftcn	3.42
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.51
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.51
26171232	C0023175	Lead	elii	13.05
26171232	C0023175	Lead	hops	13.05
26171232	C0007603	Plasma membrane	celc	11.49
26171232	C0026882	Mutation	genf	9.94
26171232	C0221099	Impaired	ftcn	5.18
26171232	C0599896	trafficking	celf	5.18
26171232	C1705285	Mutation Abnormality	comd	3.63
26171232	C1413365	CFTR gene	gngm	3.59
26171232	C3275067	Cardiac Lead Procedure	topp	3.59
26171232	C2348269	Dietary Lead	elii	3.59
26171232	C1522538	Leading	ftcn	3.59
26171232	C0181586	Leads (device)	medd	3.59
26171232	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.59
26171232	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.59
26171232	C0205214	Common (qualifier value)	qnco	3.48
26171232	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.48
26171232	C0205393	Most	qnco	3.48
26171232	C1522138	shared attribute	ftcn	3.48
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.01
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.01
26171232	C0282461	Phase 3 Clinical Trials	resa	22.59
26171232	C1096780	Clinical Trial, Phase III (publication)	inpr	13.13
26171232	C1096780	Clinical Trial, Phase III (publication)	resa	13.13
26171232	C1413365	CFTR gene	gngm	6.94
26171232	C0443264	Modulated	spco	5.18
26171232	C3252847	VX 809	orch	5.18
26171232	C3252847	VX 809	phsu	5.18
26171232	C0087111	Therapeutic procedure	topp	3.68
26171232	C1457869	Defect	ftcn	3.63
26171232	C1527178	Basis - conceptual entity	ftcn	3.48
26171232	C3840880	Traffic	fndg	3.43
26171232	C1869391	CFcor-325	orch	5.18
26171232	C0332185	Recent	tmco	5.18
26171232	C3252847	VX 809	orch	5.18
26171232	C3252847	VX 809	phsu	5.18
26171232	C1547282	Show	anim	3.98
26171232	C0450373	4a serotype	inpr	3.68
26171232	C1553636	Maxillary right second premolar abutment	medd	3.68
26171232	C0205448	Two	qnco	3.63
26171232	C0205198	Compound	qlco	3.50
26171232	C1706082	Compound (substance)	chem	3.50
26171232	C0442796	Additive	qlco	3.48
26171232	C1550602	additive ingredient	sbst	3.48
26171232	C0040363	Togo	geoa	17.80
26171232	C0041260	Tryptophanase	aapp	17.80
26171232	C0041260	Tryptophanase	enzy	17.80
26171232	C0005495	Origin of Life	npop	16.30
26171232	C0220781	Anabolism	biof	6.83
26171232	C1709694	Processing (action)	acty	5.18
26171232	C1883351	To	qlco	5.18
26171232	C2948600	Aim	phsu	3.98
26171232	C1947946	Aim (idea)	idcn	3.98
26171232	C3540472	Ancestry-Informative Marker	ftcn	3.98
26171232	C3890193	CD5L wt Allele	gngm	3.98
26171232	C2744535	CD69 protein, human	aapp	3.98
26171232	C2744535	CD69 protein, human	imft	3.98
26171232	C3540471	CD69 wt Allele	gngm	3.98
26171232	C1280500	Effect	qlco	3.57
26171232	C1413336	CEL gene	gngm	3.56
26171232	C1948049	Cell (compartment)	spco	3.56
26171232	C1704653	Cell Device Component	medd	3.56
26171232	C0007634	Cells	cell	3.56
26171232	C1269647	Entire cell	cell	3.56
26171232	C1552740	Entity Determiner - specific	inpr	3.56
26171232	C2825142	Experimental Result	fndg	3.56
26171232	C1274040	Result	ftcn	3.56
26171232	C0205369	Specific qualifier value	qlco	3.56
26171232	C1546471	What subject filter - Result	idcn	3.56
26171232	C1521761	Factor	ftcn	3.53
26171232	C2827422	Mathematical Factor	cnce	3.53
26171232	C1279919	Early	tmco	3.50
26171232	C1705242	Different	qlco	3.43
26171232	C0443199	Differential quality	qlco	3.43
26171232	C0205198	Compound	qlco	3.41
26171232	C1706082	Compound (substance)	chem	3.41
26171232	C0021966	Iodides	inch	16.12
26171232	C0013682	Efficiency	qnco	13.01
26171232	C0010674	Cystic Fibrosis	dsyn	9.81
26171232	C0021270	Infant	aggp	9.77
26171232	C0022646	Kidney	bpoc	9.77
26171232	C0007634	Cells	cell	7.23
26171232	C0205435	First (number)	qnco	5.18
26171232	C1279901	Firstly	qlco	5.18
26171232	C1512333	Hamster Cell Line	cell	3.70
26171232	C0449445	Approach	spco	3.68
26171232	C1292724	Procedural approach	ftcn	3.68
26171232	C3282337	Cells [Chemical/Ingredient]	cell	3.63
26171232	C0935616	Chamber (anatomical)	bpoc	3.63
26171232	C0179874	Chamber (physical object)	mnob	3.63
26171232	C0221908	epithelial	qlco	3.61
26171232	C0178539	Cellular	lbpr	3.56
26171232	C1707455	Comparison	acty	3.56
26171232	C1705242	Different	qlco	3.56
26171232	C3161035	Model	inpr	3.56
26171232	C0542341	Function	ftcn	3.50
26171232	C0205245	Functional	ftcn	3.50
26171232	C2700217	Functional Relationship	cnce	3.50
26171232	C3811161	Micro (prefix)	cnce	3.48
26171232	C4049106	Microbiology - Laboratory Class	inpr	3.48
26171232	C0085672	Microbiology procedure	lbpr	3.48
26171232	C0205225	Primary	qlco	3.48
26171232	C0439631	Primary operation	topp	3.48
26171232	C1546767	Specimen Source Codes - Respiratory	inpr	3.48
26171232	C0439612	True primary (qualifier value)	tmco	3.48
26171232	C1553035	Unit Of Measure Prefix - micro	qnco	3.48
26171232	C0521346	respiratory	ftcn	3.48
26171232	C0205039	Bronchial	bpoc	3.47
26171232	C1442216	Bronchial system	bpoc	3.47
26171232	C0227665	Both kidneys	bpoc	3.46
26171232	C1278978	Entire kidney	bpoc	3.46
26171232	C1514845	Renal Tissue	tisu	3.46
26171232	C0205449	Three	qnco	3.42
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26171232	C0040363	Togo	geoa	17.80
26171232	C0041260	Tryptophanase	aapp	17.80
26171232	C0041260	Tryptophanase	enzy	17.80
26171232	C0232117	Pulse Rate	clna	16.12
26171232	C0005495	Origin of Life	npop	16.04
26171232	C0021069	Immunoprecipitation	lbpr	14.64
26171232	C0033263	Product Labeling	ocac	13.14
26171232	C0025664	Methods aspects	inpr	9.99
26171232	C0025663	Methods	inpr	6.83
26171232	C0220781	Anabolism	biof	6.58
26171232	C1883351	To	qlco	5.18
26171232	C1273517	Used by	fndg	5.18
26171232	C0205117	Adjacent	spco	3.68
26171232	C0332282	Following	tmco	3.68
26171232	C2827499	Labeling Activity	gora	3.68
26171232	C3829356	Labeling, Not Otherwise Specified	acty	3.68
26171232	C1947902	Medical Product Labeling	mnob	3.68
26171232	C0449851	Techniques	ftcn	3.68
26171232	C1883708	Then	tmco	3.68
26171232	C1167624	psychosocial labeling	menp	3.68
26171232	C1825598	IMPACT gene	gngm	3.55
26171232	C4049986	Impact	qlco	3.55
26171232	C0205474	Biochemical	ftcn	3.50
26171232	C0311400	Metabolic	ftcn	3.50
26171232	C1524026	Metabolic Process, Cellular	celf	3.50
26171232	C2707259	Metabolic:-:Point in time:^Patient:-	clna	3.50
26171232	C0391850	Physiologic pulse	phsf	3.50
26171232	C1947910	Pulse phenomenon	phpr	3.50
26171232	C1413365	CFTR gene	gngm	3.43
26171232	C1709694	Processing (action)	acty	3.43
26171232	C0013682	Efficiency	qnco	13.01
26171232	C0205449	Three	qnco	7.00
26171232	C0443289	Revealed	qlco	5.18
26171232	C0392366	Tests (qualifier value)	inpr	5.18
26171232	C3252847	VX 809	orch	5.18
26171232	C3252847	VX 809	phsu	5.18
26171232	C0558024	Functional behavioral assessment	hlca	3.72
26171232	C1280519	Effectiveness	qlco	3.63
26171232	C1707887	Efficacy Study	resa	3.63
26171232	C0007634	Cells	cell	3.55
26171232	C0178539	Cellular	lbpr	3.55
26171232	C1314677	Maintaining (action)	ftcn	3.55
26171232	C3161035	Model	inpr	3.55
26171232	C1547039	*Relative	qnco	3.55
26171232	C0205345	Relative	qlco	3.55
26171232	C0080103	Relative (related person)	famg	3.55
26171232	C0205393	Most	qnco	3.48
26171232	C0205198	Compound	qlco	3.40
26171232	C1706082	Compound (substance)	chem	3.40
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
26171232	C1571455	C3 protein, human	aapp	13.05
26171232	C1571455	C3 protein, human	bacs	13.05
26171232	C0376315	Manufactured form	mnob	6.77
26171232	C1280500	Effect	qlco	5.18
26171232	C2348382	Effect, Appearance	qlco	5.18
26171232	C1518422	Negation	ftcn	5.18
26171232	C1547282	Show	anim	5.18
26171232	C0184512	Stabilized (qualifier value)	qlco	5.18
26171232	C3252847	VX 809	orch	5.18
26171232	C3252847	VX 809	phsu	5.18
26171232	C1511726	Data	idcn	3.68
26171232	C3714741	Data (eukaryote)	euka	3.68
26171232	C3245479	Data call receiving device	medd	3.68
26171232	C1522492	Formation	ftcn	3.61
26171232	C0348078	Qualitative form	qlco	3.61
26171232	C1441672	Observed	ftcn	3.59
26171232	C0205474	Biochemical	ftcn	3.50
26171232	C1413365	CFTR gene	gngm	3.47
26171232	C0205252	Immature	qlco	3.47
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
26171232	C1571455	C3 protein, human	aapp	13.14
26171232	C1571455	C3 protein, human	bacs	13.14
26171232	C0442805	Increase	ftcn	5.18
26171232	C3252847	VX 809	orch	3.75
26171232	C3252847	VX 809	phsu	3.75
26171232	C4055506	Accumulation	fndg	3.57
26171232	C1413365	CFTR gene	gngm	3.44
26171232	C0205252	Immature	qlco	3.44
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26171232	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26171232	C0005495	Origin of Life	npop	16.04
26171232	C0442805	Increase	ftcn	7.36
26171232	C0205217	Increased	qnco	7.36
26171232	C0220781	Anabolism	biof	6.58
26171232	C0376315	Manufactured form	mnob	6.58
26171232	C1511726	Data	idcn	5.18
26171232	C3714741	Data (eukaryote)	euka	5.18
26171232	C3245479	Data call receiving device	medd	5.18
26171232	C0205263	Induce (action)	ftcn	5.18
26171232	C3252847	VX 809	orch	5.18
26171232	C3252847	VX 809	phsu	5.18
26171232	C1705535	suggestion	idcn	5.18
26171232	C1280519	Effectiveness	qlco	3.68
26171232	C1707887	Efficacy Study	resa	3.68
26171232	C2363430	Early stage	tmco	3.58
26171232	C1517886	Limited stage (cancer stage)	clas	3.58
26171232	C2347098	Medical Product Stability	qlco	3.55
26171232	C0205360	Stable status	qlco	3.55
26171232	C1413365	CFTR gene	gngm	3.42
26171232	C1522492	Formation	ftcn	3.42
26171232	C0205252	Immature	qlco	3.42
26171232	C0348078	Qualitative form	qlco	3.42
25182267	C0007457	Caucasoid Race	popg	12.89
25182267	C0010674	Cystic Fibrosis	dsyn	10.06
25182267	C0012634	Disease	dsyn	9.86
25182267	C1257890	Population Group	popg	9.74
25182267	C0032659	geographic population	qnco	6.58
25182267	C0439660	Hereditary	ftcn	5.18
25182267	C0205447	One	qnco	3.56
25182267	C0205214	Common (qualifier value)	qnco	3.43
25182267	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.43
25182267	C1522138	shared attribute	ftcn	3.43
25182267	C0043157	Caucasians	popg	3.43
25182267	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25182267	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25182267	C0002085	Alleles	gngm	19.21
25182267	C0012634	Disease	dsyn	11.49
25182267	C0026882	Mutation	genf	9.86
25182267	C1413365	CFTR gene	gngm	6.92
25182267	C2700640	Encode (action)	acty	5.18
25182267	C1547699	MIME encoding	idcn	5.18
25182267	C1704735	Regulator	cnce	3.63
25182267	C1704734	Regulator Device Component	mnob	3.63
25182267	C0182953	Regulators (device)	medd	3.63
25182267	C0596611	Gene Mutation	genf	3.58
25182267	C0150312	Present	qnco	3.57
25182267	C0449450	Presentation	idcn	3.57
25182267	C2752508	fully spanning the plasma membrane	celc	3.48
25182267	C1167322	integral to membrane	celc	3.48
25182267	C3816499	Pathogenic	fndg	3.43
25182267	C0450254	Pathogenic organism	orgm	3.43
25182267	C0242656	Disease Progression	patf	13.03
25182267	C0010674	Cystic Fibrosis	dsyn	10.06
25182267	C0012634	Disease	dsyn	9.85
25182267	C0019425	Heterozygote	orga	9.73
25182267	C0449259	Clinical course	tmco	3.44
25182267	C0205210	Clinical	qlco	3.42
25182267	C1553058	Neuropsychologist - Clinical	prog	3.42
25182267	C0439064	Numerous	qnco	3.42
25182267	C0178784	Organ	bpoc	3.42
25182267	C0237412	Psychologist - Clinical	prog	3.42
25182267	C0497591	Social Worker - Clinical	prog	3.42
25182267	C1145670	Respiratory Failure	dsyn	9.95
25182267	C0024109	Lung	bpoc	6.59
25182267	C0678226	Due to	ftcn	3.64
25182267	C0681679	disease mortality	qnco	3.58
25182267	C0332152	Before	tmco	3.57
25182267	C1522538	Leading	ftcn	3.57
25182267	C0205329	Progressive	ftcn	3.57
25182267	C0443172	Changed status	qnco	3.56
25182267	C0392747	Changing	ftcn	3.56
25182267	C1299351	Abnormally high	qlco	3.55
25182267	C0205250	High	qlco	3.55
25182267	C3889660	High Mitosis-Karyorrhexis Index	qnco	3.55
25182267	C2700149	Value Above Reference Range	inpr	3.55
25182267	C3887512	high - ActExposureLevelCode	idcn	3.55
25182267	C0024117	Chronic Obstructive Airway Disease	dsyn	14.64
25182267	C0037633	Solutions	sbst	6.79
25182267	C1521840	Target	ftcn	3.55
25182267	C2986546	Target Lesion Identification	diap	3.55
25182267	C1704419	Effective	qlco	3.48
25182267	C1280519	Effectiveness	qlco	3.48
25182267	C0302350	Therapeutic	ftcn	3.48
25182267	C0087111	Therapeutic procedure	topp	3.48
25182267	C0205225	Primary	qlco	3.43
25182267	C0439631	Primary operation	topp	3.43
25182267	C1706202	Search - action	acty	3.43
25182267	C0439612	True primary (qualifier value)	tmco	3.43
25182267	C1552603	search - EntityNameUse	inpr	3.43
25182267	C0039798	therapeutic aspects	ftcn	22.49
25182267	C0010674	Cystic Fibrosis	dsyn	9.79
25182267	C0242481	Research Activities	resa	9.74
25182267	C0035168	research	resa	9.74
25182267	C0596473	Early Diagnosis	diap	8.34
25182267	C0439234	year	tmco	3.68
25182267	C1533734	Administration procedure	topp	3.57
25182267	C1705169	Biomaterial Treatment	cnce	3.57
25182267	C0087111	Therapeutic procedure	topp	3.57
25182267	C1522326	Treating	ftcn	3.57
25182267	C3538994	Treatment Epoch	resa	3.57
25182267	C3887704	treatment - ActInformationManagementReason	hlca	3.57
25182267	C1280477	Progress	ftcn	3.55
25182267	C1272688	status - In progress	ftcn	3.55
25182267	C0332185	Recent	tmco	3.50
25182267	C1546944	Event Seriousness - Significant	qlco	3.43
25182267	C0750502	Significant	idcn	3.43
25182267	C0237881	Statistical Significance	qnco	3.43
25182267	C0015127	Etiology aspects	ftcn	19.81
25182267	C0021368	Inflammation	patf	11.49
25182267	C0010674	Cystic Fibrosis	dsyn	9.86
25182267	C0026727	Mucous body substance	bdsu	9.74
25182267	C1524003	Science of Etiology	cnce	7.11
25182267	C0004623	Bacterial Infections	dsyn	6.79
25182267	C0024115	Lung diseases	dsyn	6.72
25182267	C0033684	Proteins	aapp	6.66
25182267	C0033684	Proteins	bacs	6.66
25182267	C1704444	Multiplicative Product	qnco	3.68
25182267	C1514468	product	enty	3.68
25182267	C0205234	Focal	spco	3.63
25182267	C1285542	Has focus	ftcn	3.63
25182267	C0028778	Obstruction	patf	3.56
25182267	C1882136	Obstruction within Medical Device	phpr	3.56
25182267	C1413365	CFTR gene	gngm	3.55
25182267	C1542147	Main	qlco	3.54
25182267	C1518422	Negation	ftcn	3.54
25182267	C1720467	Only - dosing instruction fragment	inpr	3.54
25182267	C0205225	Primary	qlco	3.54
25182267	C0205171	Singular	qnco	3.54
25182267	C1457887	Symptoms	sosy	3.54
25182267	C0683368	Symptoms aspect	ftcn	3.54
25182267	C1947976	Correction (change)	ftcn	3.54
25182267	C1705565	Correction Report	inpr	3.54
25182267	C0332452	defective	ftcn	3.54
25182267	C0679199	strategy	menp	3.48
25182267	C0678226	Due to	ftcn	3.46
25182267	C0205314	New	qlco	3.45
25182267	C1546714	Specimen Source Codes - Mucus	inpr	3.43
25182267	C0205400	Thickened	fndg	3.43
25182267	C2753459	mucus layer	bdsu	3.43
25182267	C0017431	Genotype	orga	6.83
25182267	C0030705	Patients	podg	6.74
25182267	C1869204	PTC 124	orch	5.18
25182267	C1551357	intended - ParticipationSignature	fndg	3.59
25182267	C1283828	intent	qlco	3.59
25182267	C0723712	Therapeutic brand of coal tar	orch	3.56
25182267	C0723712	Therapeutic brand of coal tar	phsu	3.56
25182267	C0087111	Therapeutic procedure	topp	3.56
25182267	C1552740	Entity Determiner - specific	inpr	3.50
25182267	C0205369	Specific qualifier value	qlco	3.50
25182267	C2741958	VX-770	orch	3.46
25182267	C0041703	United States	geoa	14.64
25182267	C1318228	Market	geoa	3.63
25182267	C1535514	European race	popg	3.48
25182267	C0205476	Medical	ftcn	3.48
25182267	C0199168	Medical service	hlca	3.48
25182267	C0239307	ethnic european	popg	3.48
25182267	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.35
25182267	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.35
25182267	C0079613	Adoptive Immunotherapy	topp	25.62
25182267	C0031843	physiological aspects	phsf	13.08
25182267	C0035696	RNA, Messenger	bacs	13.01
25182267	C0035696	RNA, Messenger	nnon	13.01
25182267	C1869853	SERPINA3 protein, human	aapp	13.01
25182267	C1869853	SERPINA3 protein, human	bacs	13.01
25182267	C1413365	CFTR gene	gngm	7.04
25182267	C0443264	Modulated	spco	5.18
25182267	C1527118	Protein Function	moft	3.68
25182267	C0815043	Protein, Organized by Function	aapp	3.68
25182267	C0542341	Function	ftcn	3.61
25182267	C0700205	Function Axis	clas	3.61
25182267	C1705273	Mathematical Operator	inpr	3.61
25182267	C0205161	Abnormal	qlco	3.54
25182267	C2699333	Abnormal Reference Range	inpr	3.54
25182267	C4048375	Asthma Control Test Questionnaire	inpr	3.54
25182267	C0456079	Disease classification level	clas	3.54
25182267	C1547707	Floor - story of building	geoa	3.54
25182267	C2946261	Level	phsu	3.54
25182267	C0441889	Levels (qualifier value)	qlco	3.54
25182267	C2347472	Percent of Abnormal Cells	qnco	3.54
25182267	C3890007	SERPINA3 wt Allele	gngm	3.54
25182267	C0332452	defective	ftcn	3.47
25182267	C0040363	Togo	geoa	35.81
25182267	C0041260	Tryptophanase	aapp	35.81
25182267	C0041260	Tryptophanase	enzy	35.81
25182267	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25182267	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25182267	C0013682	Efficiency	qnco	13.01
25182267	C0037645	Gene Therapy, Somatic	topp	12.93
25182267	C1883351	To	qlco	10.42
25182267	C0011209	Obstetric Delivery	topp	9.74
25182267	C0024501	Maintenance	acty	8.34
25182267	C0037633	Solutions	sbst	6.83
25182267	C0040223	Time	tmco	6.63
25182267	C0442805	Increase	ftcn	5.18
25182267	C1705178	Order (action)	acty	5.18
25182267	C1705176	Order (arrangement)	qlco	5.18
25182267	C1705175	Order (document)	inpr	5.18
25182267	C1705177	Order (taxonomic)	clas	5.18
25182267	C1882348	Permutation	qlco	5.18
25182267	C3889825	Sequence of Planned Assessment Schedule	inpr	5.18
25182267	C0007634	Cells	cell	3.63
25182267	C3282337	Cells [Chemical/Ingredient]	cell	3.63
25182267	C0402112	Scientist	prog	3.63
25182267	C3539073	In the Field	spco	3.62
25182267	C3854321	Expression (foundation metadata concept)	idcn	3.55
25182267	C0185117	Expression procedure	topp	3.55
25182267	C1283798	Entire respiratory tract	bpoc	3.53
25182267	C0035237	Respiratory System	bdsy	3.53
25182267	C0282335	Respiratory tract structure	bpoc	3.53
25182267	C0205314	New	qlco	3.50
25182267	C0445247	Same	qlco	3.48
25182267	C3541383	Time (foundation metadata concept)	tmco	3.48
25182267	C0221284	Leptocyte	cell	3.45
25182267	C3272919	Target Cell Count	lbpr	3.45
25182267	C2939170	target cells (lab result)	lbtr	3.45
25182267	C1413365	CFTR gene	gngm	3.43
25182267	C0205202	Corrected	qlco	3.43
25182267	C1314680	Non-human parturition, function	orgf	3.43
25182267	C1705822	Transfer Technique	ftcn	3.43
25182267	C0282443	Review [Publication Type]	inpr	11.49
25182267	C1552617	Act Class - review	idcn	5.18
25182267	C0205563	Clinical stage finding	tmco	5.18
25182267	C2584313	Discussion (communication)	socb	5.18
25182267	C1280477	Progress	ftcn	5.18
25182267	C1272688	status - In progress	ftcn	5.18
25182267	C1522647	Developmental Therapeutics Program	resa	3.55
25182267	C0556496	Developmental therapy	topp	3.55
25182267	C0205390	Phase	tmco	3.55
25182267	C1709630	Preclinical	qlco	3.55
25182267	C1306673	Stage	qlco	3.55
25182267	C1300072	Tumor stage	clna	3.55
27081574	C0040363	Togo	geoa	17.80
27081574	C0041260	Tryptophanase	aapp	17.80
27081574	C0041260	Tryptophanase	enzy	17.80
27081574	C0015576	Family	famg	14.64
27081574	C0012634	Disease	dsyn	9.99
27081574	C0392347	Hope (emotion)	menp	9.88
27081574	C0010674	Cystic Fibrosis	dsyn	9.76
27081574	C0030705	Patients	podg	6.59
27081574	C1704727	Family (taxonomic)	cnce	5.18
27081574	C0087111	Therapeutic procedure	topp	5.18
27081574	C1883351	To	qlco	5.18
27081574	C1522326	Treating	ftcn	5.18
27081574	C1292734	Treatment intent	ftcn	5.18
27081574	C2700205	FDA Approval	inpr	3.58
27081574	C1457869	Defect	ftcn	3.55
27081574	C1550718	Entity Name Part Type - given	idcn	3.44
27081574	C1442162	GIVEN	cnce	3.44
27081574	C1947971	Give - dosing instruction imperative	ftcn	3.44
27081574	C3244317	Given name	inpr	3.44
27081574	C1527178	Basis - conceptual entity	ftcn	3.43
27081574	C3687832	DRUGS	topp	3.42
27081574	C0013227	Pharmaceutical Preparations	phsu	3.42
27081574	C0332185	Recent	tmco	3.42
27081574	C0205448	Two	qnco	3.42
27081574	C0016617	Foundations	orgt	13.09
27081574	C0220825	Evaluation	hlca	13.01
27081574	C0010674	Cystic Fibrosis	dsyn	10.06
27081574	C0013175	Drug Evaluation	resa	9.87
27081574	C0021953	Investments	mnob	9.86
27081574	C1261322	Evaluation procedure	hlca	7.15
27081574	C4033620	ORKAMBI	phsu	5.18
27081574	C0439234	year	tmco	5.18
27081574	C1516634	research clinical testing	resa	3.57
27081574	C3264627	Kalydeco	phsu	3.55
27081574	C0033268	production	ocac	3.55
27081574	C2825142	Experimental Result	fndg	3.52
27081574	C1274040	Result	ftcn	3.52
27081574	C1546471	What subject filter - Result	idcn	3.52
27081574	C1709630	Preclinical	qlco	3.44
27081574	C0259849	Synthetic drug	phsu	3.44
27081574	C2350008	Financial (qualifier)	qlco	3.42
27081574	C2697524	Graph Node	cnce	3.42
27081574	C0439539	Heavy sensation quality	qlco	3.42
27081574	C1254351	Pharmacologic Substance	phsu	3.42
27081574	C1135440	Procedures involving the use of pharmaceuticals	topp	3.42
27081574	C0230003	Vertex	blor	3.42
27081574	C3853790	What subject filter - Financial	idcn	3.42
27081574	C0376243	financial	qnco	3.42
27081574	C0332152	Before	tmco	3.42
27081574	C0740175	Before values	qlco	3.42
27081574	C1883310	One Thousand	qnco	3.42
27081574	C3669034	Pure Spanish horse breed (organism)	mamm	3.42
27081574	C1883254	Synthesis	acty	3.42
27081574	C2257086	photoreactivating enzyme activity	genf	3.42
27081574	C0039798	therapeutic aspects	ftcn	22.48
27081574	C0009738	Congo	geoa	16.05
27081574	C0205198	Compound	qlco	3.98
27081574	C1706082	Compound (substance)	chem	3.98
27081574	C0304231	Therapeutic agent	mnob	3.64
27081574	C1611640	Therapeutic agent (substance)	phsu	3.64
27081574	C1553874	Concept Status - Proposed	qlco	3.57
27081574	C1578820	Edit Status - Proposed	qlco	3.57
27081574	C1533734	Administration procedure	topp	3.56
27081574	C1705169	Biomaterial Treatment	cnce	3.56
27081574	C0087111	Therapeutic procedure	topp	3.56
27081574	C1522326	Treating	ftcn	3.56
27081574	C3538994	Treatment Epoch	resa	3.56
27081574	C3887704	treatment - ActInformationManagementReason	hlca	3.56
27081574	C0597535	Success	socb	3.55
27081574	C3811819	CFTR wt Allele	gngm	3.43
27081574	C0037910	Spices	food	16.07
27081574	C0013231	Drugs, Non-Prescription	phsu	6.62
27081574	C0018684	Health	idcn	6.58
27081574	C1316572	Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}	clna	5.18
27081574	C1317574	Note (document)	inpr	5.18
27081574	C1698986	Storage	ftcn	5.18
27081574	C0557778	Supermarket	mnob	5.18
27081574	C1709305	Occur (action)	acty	3.98
27081574	C2745955	Occurrence	tmco	3.98
27081574	C0150312	Present	qnco	3.59
27081574	C0449450	Presentation	idcn	3.59
27081574	C0439064	Numerous	qnco	3.57
27081574	C0443302	Several	qnco	3.57
27081574	C0920297	food preparation	ocac	3.56
27081574	C0205198	Compound	qlco	3.42
27081574	C1706082	Compound (substance)	chem	3.42
27081574	C0010467	Curcumin	irda	27.26
27081574	C0010467	Curcumin	orch	27.26
27081574	C0010467	Curcumin	phsu	27.26
27081574	C0061202	Genistein	bacs	27.26
27081574	C0061202	Genistein	orch	27.26
27081574	C0061202	Genistein	phsu	27.26
27081574	C0009738	Congo	geoa	17.80
27081574	C0220825	Evaluation	hlca	14.64
27081574	C0073096	resveratrol	orch	14.64
27081574	C0073096	resveratrol	phsu	14.64
27081574	C0282443	Review [Publication Type]	inpr	9.99
27081574	C0042153	utilization qualifier	ftcn	9.74
27081574	C0036397	Science	ocdi	6.58
27081574	C3811819	CFTR wt Allele	gngm	5.18
27081574	C0205198	Compound	qlco	3.98
27081574	C1706082	Compound (substance)	chem	3.98
27081574	C1552617	Act Class - review	idcn	3.68
27081574	C0233426	Personal appearance	orga	3.59
27081574	C0205449	Three	qnco	3.59
27081574	C0304231	Therapeutic agent	mnob	3.57
27081574	C1611640	Therapeutic agent (substance)	phsu	3.57
27081574	C0183683	Support, device	medd	3.55
27081574	C1521721	Supportive assistance	cnce	3.55
27081574	C1806781	Short	qnco	3.50
27081574	C2350002	Short Value	qnco	3.50
27081574	C1282927	Shortened	qlco	3.50
27081574	C0457083	Usage	ftcn	3.43
27081574	C1947944	Use - dosing instruction imperative	inpr	3.43
27081574	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.43
27081574	C3242455	HL7PublishingDomain <patient administration>	inpr	3.43
27081574	C3242279	healthcare operations <patient administration>	ocac	3.43
27160424	C0039798	therapeutic aspects	ftcn	22.47
27160424	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27160424	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27160424	C0206243	Carrying	acty	14.64
27160424	C3264621	ivacaftor	orch	12.94
27160424	C3264621	ivacaftor	phsu	12.94
27160424	C0026882	Mutation	genf	11.49
27160424	C0010674	Cystic Fibrosis	dsyn	9.88
27160424	C1521840	Target	ftcn	5.18
27160424	C2986546	Target Lesion Identification	diap	5.18
27160424	C2741958	VX-770	orch	3.75
27160424	C0205447	One	qnco	3.59
27160424	C1533734	Administration procedure	topp	3.55
27160424	C0205540	Approved	qlco	3.55
27160424	C1705169	Biomaterial Treatment	cnce	3.55
27160424	C0087111	Therapeutic procedure	topp	3.55
27160424	C1522326	Treating	ftcn	3.55
27160424	C3538994	Treatment Epoch	resa	3.55
27160424	C3887704	treatment - ActInformationManagementReason	hlca	3.55
27160424	C2349001	Human Study Subject	humn	3.52
27160424	C2697811	Investigative Subject	ftcn	3.52
27160424	C0681850	Study Subject	grup	3.52
27160424	C1706203	Subject - topic	idcn	3.52
27160424	C1550501	Subject -direct target	idcn	3.52
27160424	C3264627	Kalydeco	phsu	3.48
27160424	C1413365	CFTR gene	gngm	3.44
27160424	C0332452	defective	ftcn	3.44
27160424	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
27160424	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
27160424	C0027552	Needs	qlco	13.00
27160424	C0005516	Biological Markers	clna	6.79
27160424	C1518422	Negation	ftcn	5.18
27160424	C1882115	Normalize	resa	5.18
27160424	C2827774	Current Therapy	topp	3.78
27160424	C0686904	Patient need for (contextual qualifier)	ftcn	3.54
27160424	C1413365	CFTR gene	gngm	3.48
27160424	C1701901	Conditional	qlco	3.48
27160424	C0851827	Dependent - ability	qlco	3.48
27160424	C3244310	dependent	ftcn	3.48
27160424	C2712145	Actual Effective Human Development	fndg	3.43
27160424	C0679199	strategy	menp	3.42
27160424	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.96
27160424	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.96
27160424	C0010467	Curcumin	irda	27.26
27160424	C0010467	Curcumin	orch	27.26
27160424	C0010467	Curcumin	phsu	27.26
27160424	C0061202	Genistein	bacs	27.26
27160424	C0061202	Genistein	orch	27.26
27160424	C0061202	Genistein	phsu	27.26
27160424	C0040363	Togo	geoa	17.80
27160424	C0041260	Tryptophanase	aapp	17.80
27160424	C0041260	Tryptophanase	enzy	17.80
27160424	C1413365	CFTR gene	gngm	6.88
27160424	C0005507	Biological Assay	lbpr	6.70
27160424	C0029250	Organoids	tisu	6.58
27160424	C3853906	Digital Model Attachment	inpr	5.18
27160424	C3161035	Model	inpr	5.18
27160424	C3714583	Model - style/design	cnce	5.18
27160424	C3274659	Model Number	inpr	5.18
27160424	C0332185	Recent	tmco	5.18
27160424	C1883351	To	qlco	5.18
27160424	C1273517	Used by	fndg	5.18
27160424	C1880311	Food Component	chvf	3.55
27160424	C1510438	Assay	lbpr	3.54
27160424	C0243073	assay qualifier	qlco	3.54
27160424	C1704675	Interaction	ftcn	3.54
27160424	C2741958	VX-770	orch	3.48
27160424	C1272684	Accepted	qlco	3.42
27160424	C0443211	Established	qlco	3.42
27160424	C0542341	Function	ftcn	3.42
27160424	C0205245	Functional	ftcn	3.42
27160424	C2700217	Functional Relationship	cnce	3.42
27160424	C0205296	Natural	ftcn	3.42
27160424	C0205225	Primary	qlco	3.42
27160424	C0439631	Primary operation	topp	3.42
27160424	C0439612	True primary (qualifier value)	tmco	3.42
27160424	C0279023	chemosensitization/potentiation	topp	3.42
27160424	C0205052	rectal	spco	3.42
27160424	C1516240	Capacity	qnco	3.40
27160424	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	92.40
27160424	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	92.40
27160424	C0061202	Genistein	bacs	27.26
27160424	C0061202	Genistein	orch	27.26
27160424	C0061202	Genistein	phsu	27.26
27160424	C0010467	Curcumin	irda	25.50
27160424	C0010467	Curcumin	orch	25.50
27160424	C0010467	Curcumin	phsu	25.50
27160424	C0917964	Colforsin	orch	16.04
27160424	C0917964	Colforsin	phsu	16.04
27160424	C1413365	CFTR gene	gngm	14.39
27160424	C0012634	Disease	dsyn	11.49
27160424	C0029250	Organoids	tisu	6.57
27160424	C0348080	Condition	qlco	5.18
27160424	C3864998	Condition:Find:Pt:^Patient:Nom	clna	5.18
27160424	C1444656	Indicated	fndg	5.18
27160424	C1705253	Logical Condition	cnce	5.18
27160424	C0332251	Predominate	qlco	5.18
27160424	C1515655	in vivo	spco	5.18
27160424	C0086045	Mental concentration	menp	3.68
27160424	C2825142	Experimental Result	fndg	3.63
27160424	C1274040	Result	ftcn	3.63
27160424	C1546471	What subject filter - Result	idcn	3.63
27160424	C1879547	Activation action	acty	3.56
27160424	C2984009	Suboptimal	qlco	3.56
27160424	C0235437	Dependent edema	fndg	3.56
27160424	C3540027	Adrenergic and dopaminergic agents combinations	phsu	3.55
27160424	C3539975	Aluminium antacid compound combinations	phsu	3.55
27160424	C3539963	Amide local anesthetic combinations	orch	3.55
27160424	C3539963	Amide local anesthetic combinations	phsu	3.55
27160424	C3539979	Antiinfective irrigating solution combinations	phsu	3.55
27160424	C3540722	Beta-lactamase sensitive penicillin combinations	antb	3.55
27160424	C3540722	Beta-lactamase sensitive penicillin combinations	orch	3.55
27160424	C3539977	Calcium antacid compound combinations	phsu	3.55
27160424	C3540720	Caries prophylactic agent combinations	phsu	3.55
27160424	C3539972	Combination solutions for parenteral nutrition	phsu	3.55
27160424	C0453882	Combinations (Undergarment)	mnob	3.55
27160424	C3539968	Enema combinations	phsu	3.55
27160424	C3540026	Hepatitis vaccine combinations	aapp	3.55
27160424	C3540026	Hepatitis vaccine combinations	imft	3.55
27160424	C3540026	Hepatitis vaccine combinations	phsu	3.55
27160424	C3540723	Insulins and analogs for injection, fast-acting combinations	phsu	3.55
27160424	C3539974	Insulins and analogs for injection, intermediate-acting combinations	phsu	3.55
27160424	C3539967	Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations	phsu	3.55
27160424	C3540719	Intermediate-acting sulfonamide combinations	orch	3.55
27160424	C3540719	Intermediate-acting sulfonamide combinations	phsu	3.55
27160424	C3539965	Local hemostatic combinations	phsu	3.55
27160424	C3539959	Long-acting sulfonamide combinations	orch	3.55
27160424	C3539959	Long-acting sulfonamide combinations	phsu	3.55
27160424	C3539956	Magnesium antacid compound combinations	phsu	3.55
27160424	C3854036	Other anti-dementia drug combinations in ATC	phsu	3.55
27160424	C3539973	Other antifungal combinations for topical use in ATC	phsu	3.55
27160424	C3539960	Other intestinal adsorbent combinations in ATC	phsu	3.55
27160424	C3540028	Other irrigating solution combinations in ATC	phsu	3.55
27160424	C3539976	Penicillins with extended spectrum combinations	antb	3.55
27160424	C3539976	Penicillins with extended spectrum combinations	orch	3.55
27160424	C3539961	Platelet aggregation inhibitor combinations excl. heparin	phsu	3.55
27160424	C3540740	Potassium supplement combinations	phsu	3.55
27160424	C3539182	Salt solution combinations	phsu	3.55
27160424	C3539181	Short-acting sulfonamide combinations	orch	3.55
27160424	C3539181	Short-acting sulfonamide combinations	phsu	3.55
27160424	C3539969	Specific immunoglobulin combinations	aapp	3.55
27160424	C3539969	Specific immunoglobulin combinations	imft	3.55
27160424	C3539969	Specific immunoglobulin combinations	phsu	3.55
27160424	C3539970	combination drugs used in erectile dysfunction	phsu	3.55
27160424	C3539978	expectorant combinations excluding combinations with cough suppressants	phsu	3.55
27160424	C3540724	expectorant combinations, excl. combinations with cough suppressants	phsu	3.55
27160424	C3540031	gonadotropin combinations	aapp	3.55
27160424	C3540031	gonadotropin combinations	horm	3.55
27160424	C3540031	gonadotropin combinations	phsu	3.55
27160424	C3539966	insulins and analogs for injection combinations, long-acting	phsu	3.55
27160424	C3539964	local opthalmologic anesthetic combinations	phsu	3.55
27160424	C3539955	lung surfactant combinations	phsu	3.55
27160424	C3539957	opium alkaloids and derivative combination cough suppressants	phsu	3.55
27160424	C3540030	other cough suppressant combinations in ATC	phsu	3.55
27160424	C3540721	other nasal preparation combinations in ATC	phsu	3.55
27160424	C3539971	otologic analgesic and anesthetic combinations	phsu	3.55
27160424	C3539954	topical antibiotic combinations	phsu	3.55
27160424	C3539962	vitamin D and analog combinations	phsu	3.55
27160424	C0205198	Compound	qlco	3.48
27160424	C1706082	Compound (substance)	chem	3.48
27160424	C2741958	VX-770	orch	3.45
27160424	C0332149	Possible	qlco	3.43
27160424	C2362652	Possible diagnosis	qlco	3.43
27160424	C1705910	Possibly Related to Intervention	qlco	3.43
27160424	C0205263	Induce (action)	ftcn	3.42
27160424	C0205340	Repaired	ftcn	3.42
27160424	C0061202	Genistein	bacs	25.76
27160424	C0061202	Genistein	orch	25.76
27160424	C0061202	Genistein	phsu	25.76
27160424	C0010467	Curcumin	irda	25.50
27160424	C0010467	Curcumin	orch	25.50
27160424	C0010467	Curcumin	phsu	25.50
27160424	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.53
27160424	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.53
27160424	C0917964	Colforsin	orch	16.04
27160424	C0917964	Colforsin	phsu	16.04
27160424	C0013604	Edema	fndg	9.85
27160424	C0019904	Homozygote	orga	9.73
27160424	C0029250	Organoids	tisu	6.57
27160424	C3252847	VX 809	orch	3.65
27160424	C3252847	VX 809	phsu	3.65
27160424	C0332293	Treated with	topp	3.64
27160424	C2741958	VX-770	orch	3.64
27160424	C1413365	CFTR gene	gngm	3.60
27160424	C0038999	Swelling	fndg	3.54
27160424	C2349975	Enhance (action)	acty	3.42
27160424	C0205263	Induce (action)	ftcn	3.42
27160424	C0009738	Congo	geoa	32.33
27160424	C0061202	Genistein	bacs	27.26
27160424	C0061202	Genistein	orch	27.26
27160424	C0061202	Genistein	phsu	27.26
27160424	C0010467	Curcumin	irda	25.67
27160424	C0010467	Curcumin	orch	25.67
27160424	C0010467	Curcumin	phsu	25.67
27160424	C0039798	therapeutic aspects	ftcn	22.49
27160424	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
27160424	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
27160424	C3811819	CFTR wt Allele	gngm	6.95
27160424	C0183683	Support, device	medd	5.18
27160424	C1521721	Supportive assistance	cnce	5.18
27160424	C2741958	VX-770	orch	5.18
27160424	C2825142	Experimental Result	fndg	3.98
27160424	C1274040	Result	ftcn	3.98
27160424	C1546471	What subject filter - Result	idcn	3.98
27160424	C3540027	Adrenergic and dopaminergic agents combinations	phsu	3.68
27160424	C3539975	Aluminium antacid compound combinations	phsu	3.68
27160424	C3539963	Amide local anesthetic combinations	orch	3.68
27160424	C3539963	Amide local anesthetic combinations	phsu	3.68
27160424	C3539979	Antiinfective irrigating solution combinations	phsu	3.68
27160424	C3540722	Beta-lactamase sensitive penicillin combinations	antb	3.68
27160424	C3540722	Beta-lactamase sensitive penicillin combinations	orch	3.68
27160424	C3539977	Calcium antacid compound combinations	phsu	3.68
27160424	C3540720	Caries prophylactic agent combinations	phsu	3.68
27160424	C3539972	Combination solutions for parenteral nutrition	phsu	3.68
27160424	C0453882	Combinations (Undergarment)	mnob	3.68
27160424	C3539968	Enema combinations	phsu	3.68
27160424	C3540026	Hepatitis vaccine combinations	aapp	3.68
27160424	C3540026	Hepatitis vaccine combinations	imft	3.68
27160424	C3540026	Hepatitis vaccine combinations	phsu	3.68
27160424	C3540723	Insulins and analogs for injection, fast-acting combinations	phsu	3.68
27160424	C3539974	Insulins and analogs for injection, intermediate-acting combinations	phsu	3.68
27160424	C3539967	Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations	phsu	3.68
27160424	C3540719	Intermediate-acting sulfonamide combinations	orch	3.68
27160424	C3540719	Intermediate-acting sulfonamide combinations	phsu	3.68
27160424	C3539965	Local hemostatic combinations	phsu	3.68
27160424	C3539959	Long-acting sulfonamide combinations	orch	3.68
27160424	C3539959	Long-acting sulfonamide combinations	phsu	3.68
27160424	C3539956	Magnesium antacid compound combinations	phsu	3.68
27160424	C3854036	Other anti-dementia drug combinations in ATC	phsu	3.68
27160424	C3539973	Other antifungal combinations for topical use in ATC	phsu	3.68
27160424	C3539960	Other intestinal adsorbent combinations in ATC	phsu	3.68
27160424	C3540028	Other irrigating solution combinations in ATC	phsu	3.68
27160424	C3539976	Penicillins with extended spectrum combinations	antb	3.68
27160424	C3539976	Penicillins with extended spectrum combinations	orch	3.68
27160424	C3539961	Platelet aggregation inhibitor combinations excl. heparin	phsu	3.68
27160424	C3540740	Potassium supplement combinations	phsu	3.68
27160424	C3539182	Salt solution combinations	phsu	3.68
27160424	C3539181	Short-acting sulfonamide combinations	orch	3.68
27160424	C3539181	Short-acting sulfonamide combinations	phsu	3.68
27160424	C3539969	Specific immunoglobulin combinations	aapp	3.68
27160424	C3539969	Specific immunoglobulin combinations	imft	3.68
27160424	C3539969	Specific immunoglobulin combinations	phsu	3.68
27160424	C3539970	combination drugs used in erectile dysfunction	phsu	3.68
27160424	C3539978	expectorant combinations excluding combinations with cough suppressants	phsu	3.68
27160424	C3540724	expectorant combinations, excl. combinations with cough suppressants	phsu	3.68
27160424	C3540031	gonadotropin combinations	aapp	3.68
27160424	C3540031	gonadotropin combinations	horm	3.68
27160424	C3540031	gonadotropin combinations	phsu	3.68
27160424	C3539966	insulins and analogs for injection combinations, long-acting	phsu	3.68
27160424	C3539964	local opthalmologic anesthetic combinations	phsu	3.68
27160424	C3539955	lung surfactant combinations	phsu	3.68
27160424	C3539957	opium alkaloids and derivative combination cough suppressants	phsu	3.68
27160424	C3540030	other cough suppressant combinations in ATC	phsu	3.68
27160424	C3540721	other nasal preparation combinations in ATC	phsu	3.68
27160424	C3539971	otologic analgesic and anesthetic combinations	phsu	3.68
27160424	C3539954	topical antibiotic combinations	phsu	3.68
27160424	C3539962	vitamin D and analog combinations	phsu	3.68
27160424	C0007634	Cells	cell	3.63
27160424	C3282337	Cells [Chemical/Ingredient]	cell	3.63
27160424	C1524063	Use of	ftcn	3.61
27160424	C2263233	body fluid secretion	celf	3.58
27160424	C1533734	Administration procedure	topp	3.57
27160424	C1705169	Biomaterial Treatment	cnce	3.57
27160424	C0087111	Therapeutic procedure	topp	3.57
27160424	C1522326	Treating	ftcn	3.57
27160424	C3538994	Treatment Epoch	resa	3.57
27160424	C3887704	treatment - ActInformationManagementReason	hlca	3.57
27160424	C1413365	CFTR gene	gngm	3.55
27160424	C1701901	Conditional	qlco	3.55
27160424	C0851827	Dependent - ability	qlco	3.55
27160424	C3244310	dependent	ftcn	3.55
27160424	C0205174	Triplicate	qnco	3.50
27160424	C0205225	Primary	qlco	3.48
27160424	C0439631	Primary operation	topp	3.48
27160424	C0439612	True primary (qualifier value)	tmco	3.48
27160424	C1705765	Double Value Type	qlco	3.45
27160424	C1705764	Doubling	acty	3.45
27160424	C0205173	Duplicate	ftcn	3.45
27160424	C0439064	Numerous	qnco	3.43
27288428	C0039798	therapeutic aspects	ftcn	22.36
27288428	C3264621	ivacaftor	orch	12.90
27288428	C3264621	ivacaftor	phsu	12.90
27288428	C0282443	Review [Publication Type]	inpr	11.49
27288428	C0010674	Cystic Fibrosis	dsyn	9.74
27288428	C0030755	Pediatrics	bmod	9.73
27288428	C0030705	Patients	podg	6.69
27288428	C1709940	Reviewed	qlco	5.18
27288428	C1825598	IMPACT gene	gngm	3.57
27288428	C4049986	Impact	qlco	3.57
27288428	C1533734	Administration procedure	topp	3.43
27288428	C1705169	Biomaterial Treatment	cnce	3.43
27288428	C0087111	Therapeutic procedure	topp	3.43
27288428	C1522326	Treating	ftcn	3.43
27288428	C3538994	Treatment Epoch	resa	3.43
27288428	C3887704	treatment - ActInformationManagementReason	hlca	3.43
27288428	C0001779	Age	orga	3.42
27288428	C1521725	Pediatric	qlco	3.42
27288428	C0240966	Scottish race	popg	3.42
27288428	C0005893	Body mass index procedure	diap	20.95
27288428	C0038990	Sweating	fndg	19.20
27288428	C0038984	Sweat	bdsu	9.74
27288428	C0034037	Publishing	ocac	6.58
27288428	C1305855	Body mass index	clna	5.18
27288428	C1441672	Observed	ftcn	5.18
27288428	C0860861	cl- decreased	fndg	3.60
27288428	C0392756	Reduced	qlco	3.56
27288428	C0301630	Reduction (chemical)	npop	3.56
27288428	C0441610	Reduction - action	topp	3.56
27288428	C2986411	Improvement	cnce	3.52
27288428	C0428295	Cystic fibrosis sweat test	lbpr	3.46
27288428	C1304760	Sweat chloride level result	lbtr	3.46
27288428	C0237881	Statistical Significance	qnco	3.45
27288428	C1511726	Data	idcn	3.43
27288428	C3714741	Data (eukaryote)	euka	3.43
27288428	C3245479	Data call receiving device	medd	3.43
27288428	C1561566	FEV1 Adverse Event	fndg	3.43
27288428	C0429706	Forced expiratory volume in 1 second finding	fndg	3.43
27288428	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	3.43
27288428	C1704324	Scientific Publication	inpr	3.43
27288428	C0003237	Antibiotics, Antitubercular	antb	45.17
27288428	C0003232	Antibiotics	antb	32.48
27288428	C3540706	Antibiotic throat preparations	antb	7.10
27288428	C3540707	Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	antb	7.10
27288428	C3540704	Antibiotics for systemic use	antb	7.10
27288428	C3540708	Antibiotics, Gynecological	antb	7.10
27288428	C3540710	Antibiotics, ophthalmologic	antb	7.10
27288428	C3540705	Antifungal Antibiotics, Topical	antb	7.10
27288428	C3540709	antibiotics, intestinal	antb	7.10
27288428	C3539655	CDISC Findings Class	inpr	5.18
27288428	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
27288428	C2607943	findings aspects	ftcn	5.18
27288428	C1705535	suggestion	idcn	3.98
27288428	C0442027	Oral	spco	3.68
27288428	C1524063	Use of	ftcn	3.61
27288428	C0348016	Intravenous	spco	3.43
27288428	C0392756	Reduced	qlco	3.43
27288428	C0004083	Mental association	menp	13.01
27288428	C0001688	aspects of adverse effects	ftcn	10.06
27288428	C0086543	Cataract	acab	9.74
27288428	C0220781	Anabolism	biof	6.58
27288428	C1554077	Excluded - Conformance Inclusion	idcn	5.18
27288428	C2828389	Exclusion	acty	5.18
27288428	C1518422	Negation	ftcn	5.18
27288428	C1441672	Observed	ftcn	5.18
27288428	C0879626	Adverse effects	patf	3.75
27288428	C0596306	Chemical Association	phpr	3.55
27288428	C0699792	Relationship by association	socb	3.55
27288428	C0439849	Relationships	qlco	3.55
27288428	C1546944	Event Seriousness - Significant	qlco	3.48
27288428	C0750502	Significant	idcn	3.48
27288428	C0237881	Statistical Significance	qnco	3.48
27288428	C1522492	Formation	ftcn	3.43
27288428	C0439634	Formations	spco	3.43
27288428	C0332149	Possible	qlco	3.43
27288428	C2362652	Possible diagnosis	qlco	3.43
27288428	C1705910	Possibly Related to Intervention	qlco	3.43
27288428	C3264621	ivacaftor	orch	14.64
27288428	C3264621	ivacaftor	phsu	14.64
27288428	C0282443	Review [Publication Type]	inpr	11.49
27288428	C0030755	Pediatrics	bmod	9.73
27288428	C0030705	Patients	podg	6.58
27288428	C1552617	Act Class - review	idcn	5.18
27288428	C1704419	Effective	qlco	5.18
27288428	C1280519	Effectiveness	qlco	5.18
27288428	C1705535	suggestion	idcn	5.18
27288428	C0443303	short-term	tmco	3.68
27288428	C0001779	Age	orga	3.42
27288428	C1521725	Pediatric	qlco	3.42
24934256	C0040363	Togo	geoa	17.80
24934256	C0041260	Tryptophanase	aapp	17.80
24934256	C0041260	Tryptophanase	enzy	17.80
24934256	C0021368	Inflammation	patf	11.49
24934256	C0442886	Secondary Infections	dsyn	9.93
24934256	C0010674	Cystic Fibrosis	dsyn	9.77
24934256	C0000768	Congenital Abnormality	cgab	6.59
24934256	C1960278	RECONCILE	orch	5.18
24934256	C1960278	RECONCILE	phsu	5.18
24934256	C1883351	To	qlco	5.18
24934256	C0947630	Scientific Study	lbpr	3.68
24934256	C0272183	Qualitative abnormality of granulocyte	dsyn	3.65
24934256	C0027361	Persons	popg	3.56
24934256	C1286282	Birth outcome	clna	3.55
24934256	C2825142	Experimental Result	fndg	3.55
24934256	C1274040	Result	ftcn	3.55
24934256	C1546471	What subject filter - Result	idcn	3.55
24934256	C0678226	Due to	ftcn	3.48
24934256	C1737329	Dysmorphism	cgab	3.43
24934256	C1457869	Defect	ftcn	3.43
24934256	C0009738	Congo	geoa	16.04
24934256	C1136254	Microbicides	phsu	13.01
24934256	C0031843	physiological aspects	phsf	13.00
24934256	C0026882	Mutation	genf	9.99
24934256	C0030705	Patients	podg	6.74
24934256	C0033684	Proteins	aapp	6.70
24934256	C0033684	Proteins	bacs	6.70
24934256	C0557651	Room of building - Study	mnob	5.18
24934256	C2603343	Study	resa	5.18
24934256	C1709305	Occur (action)	acty	3.59
24934256	C2745955	Occurrence	tmco	3.59
24934256	C0221099	Impaired	ftcn	3.55
24934256	C1622891	Mast cell degranulation	celf	3.55
24934256	C0542341	Function	ftcn	3.54
24934256	C0700205	Function Axis	clas	3.54
24934256	C1705273	Mathematical Operator	inpr	3.54
24934256	C3811819	CFTR wt Allele	gngm	3.42
24934256	C1704735	Regulator	cnce	3.42
24934256	C1704734	Regulator Device Component	mnob	3.42
24934256	C0182953	Regulators (device)	medd	3.42
24934256	C0332454	disrupted	qlco	3.42
24934256	C2752508	fully spanning the plasma membrane	celc	3.42
24934256	C1167322	integral to membrane	celc	3.42
24934256	C0010837	Cytoplasmic Granules	celc	25.63
24934256	C0030685	Patient Discharge	hlca	20.95
24934256	C0027950	neutrophil	cell	19.49
24934256	C0018353	Guanosine Triphosphate	nnon	19.19
24934256	C0009738	Congo	geoa	16.09
24934256	C0027627	Neoplasm Metastasis	neop	13.14
24934256	C0851285	Regulation	gora	9.86
24934256	C0439180	% release (qualifier value)	qnco	5.18
24934256	C0680255	Discharge (release)	hlca	5.18
24934256	C1963578	Release (procedure)	topp	5.18
24934256	C1283071	Release - action (qualifier value)	ftcn	5.18
24934256	C0391871	Released (action)	ftcn	5.18
24934256	C0332452	defective	ftcn	5.18
24934256	C0599896	trafficking	celf	5.18
24934256	C0175668	Secondary to	tmco	3.68
24934256	C0205436	second (number)	qnco	3.68
24934256	C0449432	Component object	mnob	3.63
24934256	C2245434	activation of protein binding	moft	3.59
24934256	C0007634	Cells	cell	3.57
24934256	C3282337	Cells [Chemical/Ingredient]	cell	3.57
24934256	C1707455	Comparison	acty	3.57
24934256	C2587213	Control function	ftcn	3.57
24934256	C1882979	Scientific Control	cnce	3.57
24934256	C3274648	True Control Status	qlco	3.57
24934256	C0243148	control aspects	qlco	3.57
24934256	C1550141	control substance	sbst	3.57
24934256	C3853628	Granule	sbst	3.55
24934256	C3853573	Granules dose form	bodm	3.55
24934256	C1314939	Involvement with	ftcn	3.55
24934256	C1327622	Regulation of biological process	biof	3.55
24934256	C2753894	tertiary granule	celc	3.53
24934256	C0439092	Less Than	qnco	3.50
24934256	C0547044	Smaller	qlco	3.50
24934256	C3811819	CFTR wt Allele	gngm	3.48
24934256	C3152252	Molecular Mass	qnco	3.43
24934256	C3890211	Low Mitosis-Karyorrhexis Index	qnco	3.42
24934256	C1419195	RAB27A gene	gngm	3.42
24934256	C0205251	low	qlco	3.42
24934256	C1550472	low confidentiality	inpr	3.42
24934256	C4048187	low exposure	qlco	3.42
24934256	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
24934256	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
24934256	C0027950	neutrophil	cell	19.34
24934256	C0009738	Congo	geoa	16.18
24934256	C1383501	Cytoplasmic matrix	celc	16.04
24934256	C0037473	Sodium	bacs	14.64
24934256	C0037473	Sodium	elii	14.64
24934256	C0031843	physiological aspects	phsf	13.02
24934256	C0015127	Etiology aspects	ftcn	9.84
24934256	C0441712	Mechanism (attribute)	ftcn	5.18
24934256	C1706376	Mechanism Component of Device	mnob	5.18
24934256	C0597484	Sodium Cation	elii	5.18
24934256	C3714642	Sodium Drug Class	phsu	5.18
24934256	C3541959	Sodium supplements	phsu	5.18
24934256	C1326962	ion homeostasis	phsf	3.75
24934256	C0240291	mg reduced	fndg	3.75
24934256	C0085679	Hyperchloremia	dsyn	3.62
24934256	C0332152	Before	tmco	3.57
24934256	C3811819	CFTR wt Allele	gngm	3.57
24934256	C0221099	Impaired	ftcn	3.57
24934256	C1522538	Leading	ftcn	3.57
24934256	C1622891	Mast cell degranulation	celf	3.57
24934256	C0444706	Measured	qlco	3.57
24934256	C3541902	Measured Tumor Identification	diap	3.57
24934256	C1413365	CFTR gene	gngm	3.56
24934256	C0542341	Function	ftcn	3.56
24934256	C0700205	Function Axis	clas	3.56
24934256	C1705273	Mathematical Operator	inpr	3.56
24934256	C0332452	defective	ftcn	3.56
24934256	C1524003	Science of Etiology	cnce	3.53
24934256	C0392747	Changing	ftcn	3.48
24934256	C0018353	Guanosine Triphosphate	nnon	19.31
24934256	C0004268	Attention	menp	13.08
24934256	C0024467	Magnesium	elii	12.93
24934256	C2827718	In Vitro Route of Administration	ftcn	5.18
24934256	C0021135	In Vitro [Publication Type]	inpr	5.18
24934256	C1533691	in vitro	qlco	5.18
24934256	C1515655	in vivo	spco	5.18
24934256	C3899403	Decreased Concentration	sosy	3.70
24934256	C0424099	Reduced concentration	fndg	3.70
24934256	C1446561	Concentration measurement	qnco	3.61
24934256	C0086045	Mental concentration	menp	3.61
24934256	C1689898	% bound (qualifier value)	qnco	3.54
24934256	C1167622	Binding (Molecular Function)	moft	3.54
24934256	C1145667	Binding action	acty	3.54
24934256	C2349209	Bound (value)	cnce	3.54
24934256	C0332297	Bounded by	spco	3.54
24934256	C0205216	Decreased	qnco	3.54
24934256	C0442797	Decreasing	qlco	3.54
24934256	C0441889	Levels (qualifier value)	qlco	3.54
24934256	C1419195	RAB27A gene	gngm	3.54
24934256	C0392756	Reduced	qlco	3.54
24934256	C2825142	Experimental Result	fndg	3.51
24934256	C1274040	Result	ftcn	3.51
24934256	C1546471	What subject filter - Result	idcn	3.51
24934256	C0240291	mg reduced	fndg	3.50
24934256	C2348270	Dietary Magnesium	elii	3.47
24934256	C3714621	Magnesium Drug Class	phsu	3.47
24934256	C3540792	Magnesium supplements	inch	3.47
24934256	C3540792	Magnesium supplements	phsu	3.47
24934256	C0027950	neutrophil	cell	19.32
24934256	C1383501	Cytoplasmic matrix	celc	16.16
24934256	C0022009	Ion Channel	aapp	16.12
24934256	C0022009	Ion Channel	bacs	16.12
24934256	C0162388	Killing	socb	14.64
24934256	C3264621	ivacaftor	orch	13.08
24934256	C3264621	ivacaftor	phsu	13.08
24934256	C0022023	Ions	elii	9.86
24934256	C0521009	Bacterial	qlco	5.18
24934256	C0861064	lead increased	fndg	3.60
24934256	C1879547	Activation action	acty	3.59
24934256	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.58
24934256	C3242455	HL7PublishingDomain <patient administration>	inpr	3.58
24934256	C3242279	healthcare operations <patient administration>	ocac	3.58
24934256	C1622891	Mast cell degranulation	celf	3.57
24934256	C1700702	Iontophoresis Route of Drug Administration	ftcn	3.55
24934256	C0441889	Levels (qualifier value)	qlco	3.55
24934256	C1882115	Normalize	resa	3.55
24934256	C2825142	Experimental Result	fndg	3.52
24934256	C1274040	Result	ftcn	3.52
24934256	C1546471	What subject filter - Result	idcn	3.52
24934256	C1419195	RAB27A gene	gngm	3.45
24934256	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24934256	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24934256	C0027950	neutrophil	cell	19.20
24934256	C0009738	Congo	geoa	16.05
24934256	C3264621	ivacaftor	orch	13.05
24934256	C3264621	ivacaftor	phsu	13.05
24934256	C0030705	Patients	podg	6.72
24934256	C1456348	Confirm	qlco	5.18
24934256	C0750484	Confirmation	idcn	5.18
24934256	C0521093	Confirmed by	qlco	5.18
24934256	C2825142	Experimental Result	fndg	3.98
24934256	C1274040	Result	ftcn	3.98
24934256	C1546471	What subject filter - Result	idcn	3.98
24934256	C0205202	Corrected	qlco	3.59
24934256	C0814225	benefit	qnco	3.55
24934256	C1515926	Alteration	idcn	3.52
24934256	C1706712	Additional Therapy	fndg	3.44
24934256	C3811819	CFTR wt Allele	gngm	3.44
24934256	C0175630	Circulating	ftcn	3.43
24934256	C0205102	Internal	spco	3.43
24934256	C0439674	Intrinsic origin	ftcn	3.43
24934256	C1413365	CFTR gene	gngm	3.42
24934256	C0205210	Clinical	qlco	3.42
24934256	C1709060	Modulator Device Component	mnob	3.42
24934256	C1553058	Neuropsychologist - Clinical	prog	3.42
24934256	C0237412	Psychologist - Clinical	prog	3.42
24934256	C0497591	Social Worker - Clinical	prog	3.42
24737137	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.45
24737137	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.45
24737137	C0033105	Statistical Prevalence	qnco	22.33
24737137	C0010674	Cystic Fibrosis	dsyn	11.49
24737137	C0026882	Mutation	genf	9.90
24737137	C3541951	Concept model domain	inpr	7.04
24737137	C1880389	Domain (area of knowledge)	ftcn	7.04
24737137	C1883221	Superkingdom (taxonomic category)	cnce	7.04
24737137	C0596901	Membrane	celc	6.79
24737137	C0025255	Tissue membrane	tisu	6.79
24737137	C0678227	Causing	ftcn	5.18
24737137	C1706182	Membrane Device Component	mnob	3.63
24737137	C1705285	Mutation Abnormality	comd	3.59
24737137	C1711300	Span - parameter	cnce	3.59
24737137	C2700613	Span Distance	qnco	3.59
24737137	C2347098	Medical Product Stability	qlco	3.57
24737137	C0205360	Stable status	qlco	3.57
24737137	C0185026	Plication	topp	3.55
24737137	C1413365	CFTR gene	gngm	3.52
24737137	C0205393	Most	qnco	3.45
24737137	C1148916	nucleotide binding	moft	3.45
24737137	C2698172	Application Program Interface	inpr	3.44
24737137	C1708533	Interface Device Component	mnob	3.44
24737137	C0220900	Prevalence aspects	qnco	3.41
24737137	C0053225	Benzoic Acid	orch	24.11
24737137	C0053225	Benzoic Acid	phsu	24.11
24737137	C1449035	SPRR2A protein, human	aapp	13.24
24737137	C1449035	SPRR2A protein, human	bacs	13.24
24737137	C0026882	Mutation	genf	9.99
24737137	C3838680	3+ Answer to Question	fndg	7.30
24737137	C2827736	3+ Score	qnco	7.30
24737137	C2981702	3+ Score, WHO	clas	7.30
24737137	C0439086	<3 (qualifier value)	qnco	7.30
24737137	C0013230	Investigational New Drugs	phsu	6.73
24737137	C0740116	+2	qnco	5.18
24737137	C3816745	1+	fndg	5.18
24737137	C2827734	1+ Score	qnco	5.18
24737137	C2981698	1+ Score, WHO	clas	5.18
24737137	C3833492	2+	fndg	5.18
24737137	C2827735	2+ Score	qnco	5.18
24737137	C2981700	2+ Score, WHO	clas	5.18
24737137	C1161334	Benzoicum acidum, benzoic acid, Homeopathic preparation	orch	5.18
24737137	C1161334	Benzoicum acidum, benzoic acid, Homeopathic preparation	phsu	5.18
24737137	C1705285	Mutation Abnormality	comd	3.68
24737137	C1457869	Defect	ftcn	3.63
24737137	C3252847	VX 809	orch	3.58
24737137	C3252847	VX 809	phsu	3.58
24737137	C0205202	Corrected	qlco	3.55
24737137	C0442758	3/5	qnco	3.51
24737137	C2347098	Medical Product Stability	qlco	3.48
24737137	C0205360	Stable status	qlco	3.48
24737137	C2698172	Application Program Interface	inpr	3.43
24737137	C1708533	Interface Device Component	mnob	3.43
24737137	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
24737137	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
24737137	C0040363	Togo	geoa	17.80
24737137	C0041260	Tryptophanase	aapp	17.80
24737137	C0041260	Tryptophanase	enzy	17.80
24737137	C0079411	Generations	tmco	16.07
24737137	C0027552	Needs	qlco	14.64
24737137	C0010674	Cystic Fibrosis	dsyn	9.87
24737137	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
24737137	C1883351	To	qlco	5.18
24737137	C1280519	Effectiveness	qlco	3.54
24737137	C1707887	Efficacy Study	resa	3.54
24737137	C4054480	Modest Extremity Pain	inpr	3.54
24737137	C2987476	Exist	cnce	3.51
24737137	C1413365	CFTR gene	gngm	3.46
24737137	C3146294	Generation (action)	acty	3.46
24737137	C1561503	Precision - second	idcn	3.46
24737137	C1705190	Second Suffix	qlco	3.46
24737137	C0565930	per second	qnco	3.46
24737137	C0205436	second (number)	qnco	3.46
24737137	C0457385	seconds	tmco	3.46
24737137	C0079613	Adoptive Immunotherapy	topp	25.67
24737137	C0038859	Suppressor Mutation	comd	13.22
24737137	C1869853	SERPINA3 protein, human	aapp	13.05
24737137	C1869853	SERPINA3 protein, human	bacs	13.05
24737137	C1521840	Target	ftcn	5.18
24737137	C3252847	VX 809	orch	5.18
24737137	C3252847	VX 809	phsu	5.18
24737137	C1457869	Defect	ftcn	3.61
24737137	C4048375	Asthma Control Test Questionnaire	inpr	3.59
24737137	C3890007	SERPINA3 wt Allele	gngm	3.59
24737137	C1561503	Precision - second	idcn	3.50
24737137	C1705190	Second Suffix	qlco	3.50
24737137	C0565930	per second	qnco	3.50
24737137	C0205436	second (number)	qnco	3.50
24737137	C0457385	seconds	tmco	3.50
24737137	C0185026	Plication	topp	3.47
24737137	C2698172	Application Program Interface	inpr	3.42
24737137	C1708533	Interface Device Component	mnob	3.42
24737137	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.04
24737137	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.04
24737137	C0019941	Horseradish Peroxidase	aapp	16.05
24737137	C0019941	Horseradish Peroxidase	enzy	16.05
24737137	C0019941	Horseradish Peroxidase	irda	16.05
24737137	C1413365	CFTR gene	gngm	6.97
24737137	C0014609	Epithelium	tisu	6.70
24737137	C0024109	Lung	bpoc	6.70
24737137	C0008109	Chimera organism	orgm	6.58
24737137	C3854307	Presence (property)	qlco	5.18
24737137	C0150312	Present	qnco	5.18
24737137	C0392148	Providing presence (regime/therapy)	topp	5.18
24737137	C1689985	Absence (morphologic abnormality)	anab	3.59
24737137	C0332197	Absent	ftcn	3.59
24737137	C0682523	human cell line	cell	3.58
24737137	C0445022	Loop	spco	3.55
24737137	C1441547	Derivation	qlco	3.54
24737137	C3245521	Derived value	idcn	3.54
24737137	C1278908	Entire lung	bpoc	3.54
24737137	C1705053	Screen Device Component	mnob	3.54
24737137	C1305399	Screening - procedure intent	ftcn	3.54
24737137	C0220908	Screening procedure	hlca	3.54
24737137	C0819757	Structure of parenchyma of lung	tisu	3.54
24737137	C0699040	Cell surface	celc	3.43
24737137	C0205438	Fourth	qnco	3.42
24737137	C1706303	Fourth (suffix)	qlco	3.42
24737137	C0205474	Biochemical	ftcn	3.42
24737137	C3854321	Expression (foundation metadata concept)	idcn	3.42
24737137	C0185117	Expression procedure	topp	3.42
24737137	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24737137	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24737137	C1450275	luminescence	npop	19.20
24737137	C0019941	Horseradish Peroxidase	aapp	16.04
24737137	C0019941	Horseradish Peroxidase	enzy	16.04
24737137	C0019941	Horseradish Peroxidase	irda	16.04
24737137	C0337143	Scaffold	mnob	5.18
24737137	C1524063	Use of	ftcn	5.18
24737137	C0547043	Up	spco	3.59
24737137	C1328819	Small Molecule	orch	3.58
24737137	C1689985	Absence (morphologic abnormality)	anab	3.56
24737137	C0332197	Absent	ftcn	3.56
24737137	C3854307	Presence (property)	qlco	3.55
24737137	C0150312	Present	qnco	3.55
24737137	C0392148	Providing presence (regime/therapy)	topp	3.55
24737137	C0332232	Approximate	qlco	3.55
24737137	C0220909	Aspects of disease screening	ftcn	3.55
24737137	C1710031	Disease Screening	diap	3.55
24737137	C0220908	Screening procedure	hlca	3.55
24737137	C1710477	Trial Screening	resa	3.55
24737137	C1698960	research subject screening	inpr	3.55
24737137	C3854321	Expression (foundation metadata concept)	idcn	3.54
24737137	C0185117	Expression procedure	topp	3.54
24737137	C0205314	New	qlco	3.48
24737137	C0205455	Nine	qnco	3.48
24737137	C0679622	literary novel	inpr	3.48
24737137	C3252847	VX 809	orch	3.46
24737137	C3252847	VX 809	phsu	3.46
24737137	C0699040	Cell surface	celc	3.44
24737137	C4049713	Borg Category-Ratio 10 Perceived Exertion Score 10	inpr	3.43
24737137	C0205289	Maximal (qualifier value)	qlco	3.43
24737137	C0806909	Maximum	qnco	3.43
24737137	C1561536	*Activity (kind of quantity)	idcn	3.43
24737137	C0205177	Active	ftcn	3.43
24737137	C0441655	Activities	acty	3.43
24737137	C3668946	Activity (animal life circumstance)	fndg	3.43
24737137	C4049939	FDA Establishment Activity Terminology	inpr	3.43
24737137	C0439167	Percent Activity	qnco	3.43
24737137	C4049938	Physical Activity Measurement	lbpr	3.43
24737137	C1413365	CFTR gene	gngm	3.42
24737137	C0442805	Increase	ftcn	3.42
24737137	C0205217	Increased	qnco	3.42
24737137	C0023376	Lesotho	geoa	16.04
24737137	C0220908	Screening procedure	hlca	7.14
24737137	C1550043	Container status - Identified	fndg	3.56
24737137	C0205396	Identified	qlco	3.56
24737137	C0205225	Primary	qlco	3.56
24737137	C0439631	Primary operation	topp	3.56
24737137	C1705053	Screen Device Component	mnob	3.56
24737137	C1305399	Screening - procedure intent	ftcn	3.56
24737137	C0439612	True primary (qualifier value)	tmco	3.56
24737137	C0220909	Aspects of disease screening	ftcn	3.54
24737137	C1710031	Disease Screening	diap	3.54
24737137	C1710477	Trial Screening	resa	3.54
24737137	C1698960	research subject screening	inpr	3.54
24737137	C0728893	+5	qnco	3.50
24737137	C0439084	>5	qnco	3.50
24737137	C3887647	Lymphotoxin-Alpha, human	aapp	3.43
24737137	C3887647	Lymphotoxin-Alpha, human	imft	3.43
24737137	C0230426	Structure of left thigh	bpoc	3.43
24737137	C0243071	Analog	chvs	3.42
24737137	C1517331	Further	spco	3.42
24737137	C0205198	Compound	qlco	3.40
24737137	C1706082	Compound (substance)	chem	3.40
24737137	C0008203	Chlorides	inch	16.04
24737137	C0031164	Permeability	npop	9.85
24737137	C1547282	Show	anim	3.98
24737137	C0337143	Scaffold	mnob	3.61
24737137	C3252847	VX 809	orch	3.48
24737137	C3252847	VX 809	phsu	3.48
24737137	C3272558	Chemical or Textual Reference to Actual Test or Parameter	inpr	3.47
24737137	C0220806	Chemicals	chem	3.47
24737137	C0205454	Eight	qnco	3.47
24737137	C0007634	Cells	cell	3.42
24737137	C3282337	Cells [Chemical/Ingredient]	cell	3.42
24737137	C0596019	Chloride Ion	elii	3.42
24737137	C0086418	Homo sapiens	humn	28.65
24737137	C0008203	Chlorides	inch	16.04
24737137	C0019904	Homozygote	orga	9.73
24737137	C0678840	cell conductance	celf	3.54
24737137	C2349001	Human Study Subject	humn	3.54
24737137	C2697811	Investigative Subject	ftcn	3.54
24737137	C0681850	Study Subject	grup	3.54
24737137	C1706203	Subject - topic	idcn	3.54
24737137	C1550501	Subject -direct target	idcn	3.54
24737137	C3252847	VX 809	orch	3.43
24737137	C3252847	VX 809	phsu	3.43
24737137	C2346744	AMINOTHIAZOLE	orch	3.42
24737137	C2346744	AMINOTHIAZOLE	phsu	3.42
24737137	C0205039	Bronchial	bpoc	3.42
24737137	C1442216	Bronchial system	bpoc	3.42
24737137	C0596019	Chloride Ion	elii	3.42
24737137	C0442805	Increase	ftcn	3.42
24737137	C0205217	Increased	qnco	3.42
24737137	C0221908	epithelial	qlco	3.42
24737137	C4049713	Borg Category-Ratio 10 Perceived Exertion Score 10	inpr	3.42
24737137	C0205289	Maximal (qualifier value)	qlco	3.42
24737137	C0806909	Maximum	qnco	3.42
24737137	C1705535	suggestion	idcn	3.98
24737137	C2698671	Other Toxicity Studies: Mechanistic Studies	rnlw	3.75
24737137	C2346744	AMINOTHIAZOLE	orch	3.56
24737137	C2346744	AMINOTHIAZOLE	phsu	3.56
24737137	C1514873	Requirement	ftcn	3.56
24737137	C0079411	Generations	tmco	32.37
24737137	C0040363	Togo	geoa	17.80
24737137	C0041260	Tryptophanase	aapp	17.80
24737137	C0041260	Tryptophanase	enzy	17.80
24737137	C3146294	Generation (action)	acty	6.99
24737137	C2983310	Overcome	acty	5.18
24737137	C1999230	Providing (action)	acty	5.18
24737137	C1883351	To	qlco	5.18
24737137	C2825142	Experimental Result	fndg	3.98
24737137	C1274040	Result	ftcn	3.98
24737137	C1546471	What subject filter - Result	idcn	3.98
24737137	C0205195	Combined	qlco	3.59
24737137	C1273517	Used by	fndg	3.59
24737137	C3811910	combination - answer to question	fndg	3.59
24737137	C1947911	combination of objects	phob	3.59
24737137	C0556981	% proof	qnco	3.55
24737137	C0178566	concept	idcn	3.55
24737137	C0205435	First (number)	qnco	3.48
24737137	C1279901	Firstly	qlco	3.48
24737137	C1561503	Precision - second	idcn	3.48
24737137	C1705190	Second Suffix	qlco	3.48
24737137	C0302350	Therapeutic	ftcn	3.48
24737137	C0087111	Therapeutic procedure	topp	3.48
24737137	C0565930	per second	qnco	3.48
24737137	C0205436	second (number)	qnco	3.48
24737137	C0457385	seconds	tmco	3.48
24737137	C0220909	Aspects of disease screening	ftcn	3.43
24737137	C1710031	Disease Screening	diap	3.43
24737137	C0220908	Screening procedure	hlca	3.43
24737137	C1710477	Trial Screening	resa	3.43
24737137	C1698960	research subject screening	inpr	3.43
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.45
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.45
27585394	C0024117	Chronic Obstructive Airway Disease	dsyn	13.13
27585394	C0031847	physiopathological	ftcn	9.90
27585394	C1521840	Target	ftcn	3.63
27585394	C2986546	Target Lesion Identification	diap	3.63
27585394	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.59
27585394	C3887504	Dysfunction	cnce	3.59
27585394	C0277785	Functional disorder	patf	3.59
27585394	C1880177	Contribution	acty	3.55
27585394	C0699748	Pathogenesis	patf	3.55
27585394	C0543483	pathogenic aspects	ftcn	3.55
27585394	C1413365	CFTR gene	gngm	3.52
27585394	C0302350	Therapeutic	ftcn	3.48
27585394	C0087111	Therapeutic procedure	topp	3.48
27585394	C3245505	potential	qlco	3.48
27585394	C0439661	Acquired (qualifier value)	tmco	3.45
27585394	C3245488	Acquired Name	inpr	3.45
27585394	C0040363	Togo	geoa	17.80
27585394	C0041260	Tryptophanase	aapp	17.80
27585394	C0041260	Tryptophanase	enzy	17.80
27585394	C0162585	Ion Transport	celf	14.64
27585394	C3264621	ivacaftor	orch	13.01
27585394	C3264621	ivacaftor	phsu	13.01
27585394	C0026687	Mucociliary Clearance	clna	13.00
27585394	C1280500	Effect	qlco	7.26
27585394	C1883351	To	qlco	5.18
27585394	C2741958	VX-770	orch	5.18
27585394	C1874451	Basis	phsu	3.68
27585394	C1527178	Basis - conceptual entity	ftcn	3.68
27585394	C1947951	Anatomical Apparatus	anst	3.63
27585394	C0243111	manufactured apparatus	mnob	3.63
27585394	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.59
27585394	C1555029	Reverse	ftcn	3.52
27585394	C0239059	Cigarette smoke (substance)	hops	3.45
27585394	C0441712	Mechanism (attribute)	ftcn	3.45
27585394	C1706376	Mechanism Component of Device	mnob	3.45
27585394	C0205178	acute	tmco	3.43
27585394	C0086418	Homo sapiens	humn	57.90
27585394	C3264621	ivacaftor	orch	14.64
27585394	C3264621	ivacaftor	phsu	14.64
27585394	C0006255	Bronchi	bpoc	9.99
27585394	C0301863	"""U"" lymphocyte"	cell	3.71
27585394	C0239059	Cigarette smoke (substance)	hops	3.61
27585394	C0024496	Main Bronchus	bpoc	3.60
27585394	C0221908	epithelial	qlco	3.60
27585394	C0332157	Exposure to	clna	3.56
27585394	C2828366	Extract (substance)	sbst	3.56
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
27585394	C0031843	physiological aspects	phsf	13.09
27585394	C0525026	Biotinylation	lbpr	13.03
27585394	C3854321	Expression (foundation metadata concept)	idcn	5.18
27585394	C0185117	Expression procedure	topp	5.18
27585394	C0542341	Function	ftcn	3.63
27585394	C0700205	Function Axis	clas	3.63
27585394	C1705273	Mathematical Operator	inpr	3.63
27585394	C0179874	Chamber (physical object)	mnob	3.57
27585394	C0444706	Measured	qlco	3.57
27585394	C3541902	Measured Tumor Identification	diap	3.57
27585394	C0205148	Surface	spco	3.57
27585394	C1413365	CFTR gene	gngm	3.48
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27585394	C0920367	Tomography, Optical Coherence	diap	19.37
27585394	C0019638	Histology	bmod	13.01
27585394	C0037813	Mass Spectrometry	lbpr	9.84
27585394	C0001204	Acrolein	irda	9.73
27585394	C0001204	Acrolein	orch	9.73
27585394	C0014609	Epithelium	tisu	6.56
27585394	C1514534	Protein Analysis	mbrt	3.56
27585394	C1513264	Microanatomic Structure	anst	3.55
27585394	C0444706	Measured	qlco	3.54
27585394	C3541902	Measured Tumor Identification	diap	3.54
27585394	C1998793	Purifying	ftcn	3.54
27585394	C2699488	Resolution	cnce	3.54
27585394	C1706463	Resolution Property	qnco	3.54
27585394	C1514893	physiologic resolution	patf	3.54
27585394	C0392747	Changing	ftcn	3.52
27585394	C3889737	Data Change Date	tmco	3.52
27585394	C3840684	Modification	inpr	3.52
27585394	C1554963	ResponseLevel - modification	ftcn	3.52
27585394	C0458827	Airway structure	bpoc	3.42
27585394	C0178987	Artificial Airways	medd	3.42
27585394	C1413365	CFTR gene	gngm	3.42
27585394	C1441547	Derivation	qlco	3.42
27585394	C3245521	Derived value	idcn	3.42
27585394	C0542341	Function	ftcn	3.42
27585394	C0205245	Functional	ftcn	3.42
27585394	C2700217	Functional Relationship	cnce	3.42
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27585394	C0023376	Lesotho	geoa	16.08
27585394	C0392756	Reduced	qlco	5.18
27585394	C0521116	Current (present time)	tmco	3.55
27585394	C1705970	Electrical Current	npop	3.55
27585394	C3887647	Lymphotoxin-Alpha, human	aapp	3.47
27585394	C3887647	Lymphotoxin-Alpha, human	imft	3.47
27585394	C0369773	P Blood group antibodies	aapp	3.47
27585394	C0369773	P Blood group antibodies	imft	3.47
27585394	C2603361	P prime	clna	3.47
27585394	C0230426	Structure of left thigh	bpoc	3.47
27585394	C1413365	CFTR gene	gngm	3.43
27585394	C0007634	Cells	cell	3.43
27585394	C3282337	Cells [Chemical/Ingredient]	cell	3.43
27585394	C1701901	Conditional	qlco	3.43
27585394	C0851827	Dependent - ability	qlco	3.43
27585394	C1415484	HBE1 gene	gngm	3.43
27585394	C2827566	HBE1 wt Allele	gngm	3.43
27585394	C3844844	Hb E	fndg	3.43
27585394	C3244310	dependent	ftcn	3.43
27585394	C0086418	Homo sapiens	humn	28.74
27585394	C0023376	Lesotho	geoa	16.08
27585394	C0006255	Bronchi	bpoc	9.99
27585394	C3887647	Lymphotoxin-Alpha, human	aapp	3.47
27585394	C3887647	Lymphotoxin-Alpha, human	imft	3.47
27585394	C0369773	P Blood group antibodies	aapp	3.47
27585394	C0369773	P Blood group antibodies	imft	3.47
27585394	C2603361	P prime	clna	3.47
27585394	C0230426	Structure of left thigh	bpoc	3.47
27585394	C1282918	Minute (diminutive)	qnco	3.57
27585394	C2347166	Minute Unit of Plane Angle	qnco	3.57
27585394	C0439232	Minute of time	tmco	3.57
27585394	C0702093	Per Minute	tmco	3.57
27585394	C0700321	Small	qnco	3.57
27585394	C0332157	Exposure to	clna	3.44
27585394	C0274281	Injury due to exposure to external cause	inpo	3.44
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.30
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.30
27585394	C0033204	Probability	qnco	16.17
27585394	C0023376	Lesotho	geoa	16.08
27585394	C1413365	CFTR gene	gngm	7.23
27585394	C0442797	Decreasing	qlco	5.18
27585394	C0332157	Exposure to	clna	5.18
27585394	C0274281	Injury due to exposure to external cause	inpo	5.18
27585394	C1314939	Involvement with	ftcn	5.18
27585394	C0441712	Mechanism (attribute)	ftcn	5.18
27585394	C1706376	Mechanism Component of Device	mnob	5.18
27585394	C0175566	Open	spco	5.18
27585394	C0392756	Reduced	qlco	3.55
27585394	C0301630	Reduction (chemical)	npop	3.55
27585394	C0441610	Reduction - action	topp	3.55
27585394	C3887647	Lymphotoxin-Alpha, human	aapp	3.47
27585394	C3887647	Lymphotoxin-Alpha, human	imft	3.47
27585394	C0369773	P Blood group antibodies	aapp	3.47
27585394	C0369773	P Blood group antibodies	imft	3.47
27585394	C2603361	P prime	clna	3.47
27585394	C0230426	Structure of left thigh	bpoc	3.47
27585394	C0332232	Approximate	qlco	3.43
27585394	C0439799	Channel	spco	3.43
27585394	C1706095	Channel Object	cnce	3.43
27585394	C0205263	Induce (action)	ftcn	3.43
27585394	C0205548	Stat (do immediately)	tmco	3.43
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
27585394	C1547311	Patient Condition Code - Stable	inpr	3.68
27585394	C0205360	Stable status	qlco	3.68
27585394	C3854321	Expression (foundation metadata concept)	idcn	3.63
27585394	C0185117	Expression procedure	topp	3.63
27585394	C0332157	Exposure to	clna	3.57
27585394	C0274281	Injury due to exposure to external cause	inpo	3.57
27585394	C0392756	Reduced	qlco	3.57
27585394	C0205191	chronic	tmco	3.57
27585394	C1413365	CFTR gene	gngm	3.48
27585394	C0205148	Surface	spco	3.48
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.04
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.04
27585394	C0039798	therapeutic aspects	ftcn	22.48
27585394	C0024337	Lysine	aapp	14.64
27585394	C0024337	Lysine	bacs	14.64
27585394	C0024337	Lysine	phsu	14.64
27585394	C0010654	Cysteine	aapp	12.96
27585394	C0010654	Cysteine	bacs	12.96
27585394	C0001204	Acrolein	irda	9.88
27585394	C0001204	Acrolein	orch	9.88
27585394	C1413365	CFTR gene	gngm	6.96
27585394	C0523760	Lysine measurement	lbpr	5.18
27585394	C0332148	Probable diagnosis	qlco	5.18
27585394	C0750492	Probably	idcn	5.18
27585394	C0332454	disrupted	qlco	5.18
27585394	C1709915	Residue	cnce	3.63
27585394	C1882936	Residue after Decontamination Medical Device Problem	evnt	3.63
27585394	C1533734	Administration procedure	topp	3.55
27585394	C1705169	Biomaterial Treatment	cnce	3.55
27585394	C0087111	Therapeutic procedure	topp	3.55
27585394	C1522326	Treating	ftcn	3.55
27585394	C3538994	Treatment Epoch	resa	3.55
27585394	C3887704	treatment - ActInformationManagementReason	hlca	3.55
27585394	C0392747	Changing	ftcn	3.54
27585394	C3889737	Data Change Date	tmco	3.54
27585394	C2825142	Experimental Result	fndg	3.54
27585394	C3840684	Modification	inpr	3.54
27585394	C1554963	ResponseLevel - modification	ftcn	3.54
27585394	C1274040	Result	ftcn	3.54
27585394	C1546471	What subject filter - Result	idcn	3.54
27585394	C1998793	Purifying	ftcn	3.43
27585394	C0023376	Lesotho	geoa	16.08
27585394	C0392756	Reduced	qlco	5.18
27585394	C0007634	Cells	cell	3.63
27585394	C3282337	Cells [Chemical/Ingredient]	cell	3.63
27585394	C1415484	HBE1 gene	gngm	3.63
27585394	C2827566	HBE1 wt Allele	gngm	3.63
27585394	C3844844	Hb E	fndg	3.63
27585394	C0205125	Depth	spco	3.61
27585394	C0205225	Primary	qlco	3.48
27585394	C0439631	Primary operation	topp	3.48
27585394	C0439612	True primary (qualifier value)	tmco	3.48
27585394	C0458827	Airway structure	bpoc	3.47
27585394	C0178987	Artificial Airways	medd	3.47
27585394	C1304698	Liquid (finding)	fndg	3.47
27585394	C1546699	Liquid NOS - Specimen Source Codes	inpr	3.47
27585394	C1561501	Liquid Specimen	sbst	3.47
27585394	C0301571	Liquid diet	topp	3.47
27585394	C0302908	Liquid substance	sbst	3.47
27585394	C3887647	Lymphotoxin-Alpha, human	aapp	3.47
27585394	C3887647	Lymphotoxin-Alpha, human	imft	3.47
27585394	C0369773	P Blood group antibodies	aapp	3.47
27585394	C0369773	P Blood group antibodies	imft	3.47
27585394	C2603361	P prime	clna	3.47
27585394	C0230426	Structure of left thigh	bpoc	3.47
27585394	C0205148	Surface	spco	3.47
27585394	C0015422	Eyelash	bpoc	19.34
27585394	C0023376	Lesotho	geoa	16.08
27585394	C0439603	Frequencies (time pattern)	tmco	3.63
27585394	C3898838	How Often	inpr	3.63
27585394	C1561548	Kind of quantity - Frequency	qlco	3.63
27585394	C0871396	Spatial Frequency	qnco	3.63
27585394	C1705502	Statistical Frequency	qnco	3.63
27585394	C0376249	With frequency	qnco	3.63
27585394	C1288305	Entire eyelash	bpoc	3.57
27585394	C3887647	Lymphotoxin-Alpha, human	aapp	3.47
27585394	C3887647	Lymphotoxin-Alpha, human	imft	3.47
27585394	C0369773	P Blood group antibodies	aapp	3.47
27585394	C0369773	P Blood group antibodies	imft	3.47
27585394	C2603361	P prime	clna	3.47
27585394	C0230426	Structure of left thigh	bpoc	3.47
27585394	C0023376	Lesotho	geoa	16.08
27585394	C3264621	ivacaftor	orch	14.64
27585394	C3264621	ivacaftor	phsu	14.64
27585394	C3853333	Sixty minutes	tmco	5.18
27585394	C0814472	co-treatment	hlca	3.59
27585394	C3887647	Lymphotoxin-Alpha, human	aapp	3.47
27585394	C3887647	Lymphotoxin-Alpha, human	imft	3.47
27585394	C0369773	P Blood group antibodies	aapp	3.47
27585394	C0369773	P Blood group antibodies	imft	3.47
27585394	C2603361	P prime	clna	3.47
27585394	C0230426	Structure of left thigh	bpoc	3.47
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27585394	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27585394	C0086439	Hypokinesia	sosy	16.20
27585394	C0392760	Affecting	ftcn	5.18
27585394	C1314939	Involvement with	ftcn	5.18
27585394	C0332289	Transmitted by	ftcn	5.18
27585394	C0239059	Cigarette smoke (substance)	hops	3.75
27585394	C0700219	Cigarette smoking behavior	inbe	3.75
27585394	C0205148	Surface	spco	3.68
27585394	C2267000	Reduction Activity [MoA]	moft	3.58
27585394	C0458827	Airway structure	bpoc	3.50
27585394	C0178987	Artificial Airways	medd	3.50
27585394	C1413365	CFTR gene	gngm	3.43
27585394	C0205178	acute	tmco	3.43
27585394	C0024117	Chronic Obstructive Airway Disease	dsyn	13.10
27585394	C0006277	Bronchitis	dsyn	12.88
27585394	C0030705	Patients	podg	6.58
27585394	C1280500	Effect	qlco	5.18
27585394	C2827718	In Vitro Route of Administration	ftcn	5.18
27585394	C0021135	In Vitro [Publication Type]	inpr	5.18
27585394	C1533691	in vitro	qlco	5.18
27585394	C1882932	Representation (action)	acty	3.98
27585394	C0205343	Reversible	ftcn	3.56
27585394	C0679199	strategy	menp	3.55
27585394	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.46
27585394	C0302350	Therapeutic	ftcn	3.43
27585394	C0087111	Therapeutic procedure	topp	3.43
27585394	C3245505	potential	qlco	3.43
27030675	C0010674	Cystic Fibrosis	dsyn	10.06
27030675	C0001721	Affect (mental function)	menp	9.86
27030675	C3899988	Autosomal Recessive Disorder	dsyn	3.81
27030675	C3842584	70%	fndg	3.55
27030675	C0027361	Persons	popg	3.55
27030675	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
27030675	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
27030675	C0015127	Etiology aspects	ftcn	9.86
27030675	C0012634	Disease	dsyn	9.74
27030675	C0033684	Proteins	aapp	6.75
27030675	C0033684	Proteins	bacs	6.75
27030675	C0243067	defects aspect	ftcn	3.59
27030675	C1413365	CFTR gene	gngm	3.58
27030675	C1280464	Manifestation of	qlco	3.57
27030675	C1524003	Science of Etiology	cnce	3.55
27030675	C0205210	Clinical	qlco	3.43
27030675	C1553058	Neuropsychologist - Clinical	prog	3.43
27030675	C0237412	Psychologist - Clinical	prog	3.43
27030675	C0497591	Social Worker - Clinical	prog	3.43
27030675	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.16
27030675	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.16
27030675	C1413365	CFTR gene	gngm	14.45
27030675	C0031843	physiological aspects	phsf	13.02
27030675	C0162340	Comprehension	menp	13.00
27030675	C0001721	Affect (mental function)	menp	11.49
27030675	C2717881	Candidate Gene Identification	mbrt	9.89
27030675	C0026882	Mutation	genf	9.85
27030675	C0678594	structure	spco	5.18
27030675	C1527118	Protein Function	moft	3.60
27030675	C0815043	Protein, Organized by Function	aapp	3.60
27030675	C0542341	Function	ftcn	3.56
27030675	C0700205	Function Axis	clas	3.56
27030675	C1705273	Mathematical Operator	inpr	3.56
27030675	C1880355	Discover	acty	3.55
27030675	C1708698	Light Emitting Diode Device Component	mnob	3.54
27030675	C1883310	One Thousand	qnco	3.54
27030675	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.68
27030675	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.68
27030675	C0005508	Biological Availability	qnco	12.89
27030675	C0026882	Mutation	genf	9.88
27030675	C0015127	Etiology aspects	ftcn	9.85
27030675	C1280477	Progress	ftcn	5.18
27030675	C1521840	Target	ftcn	5.18
27030675	C2986546	Target Lesion Identification	diap	5.18
27030675	C1272688	status - In progress	ftcn	5.18
27030675	C1552740	Entity Determiner - specific	inpr	3.57
27030675	C0205369	Specific qualifier value	qlco	3.57
27030675	C2981279	Decade	qnco	3.56
27030675	C1444637	Past	tmco	3.56
27030675	C0678723	Biologic Development	orgf	3.54
27030675	C1527148	Development	ftcn	3.54
27030675	C0243107	development aspects	phsf	3.54
27030675	C1524003	Science of Etiology	cnce	3.54
27030675	C1881534	Make - Instruction Imperative	ftcn	3.53
27030675	C0332452	defective	ftcn	3.48
27030675	C1328819	Small Molecule	orch	3.43
27030675	C0442027	Oral	spco	3.42
27030675	C0023981	Longitudinal Studies	resa	22.31
27030675	C0026882	Mutation	genf	9.87
27030675	C0237428	Optimism	menp	9.85
27030675	C0010674	Cystic Fibrosis	dsyn	9.77
27030675	C0087111	Therapeutic procedure	topp	3.57
27030675	C2349182	Correct (qualifier)	qlco	3.44
27030675	C0868955	editing	ocac	3.44
27030675	C0872178	gene replacement	topp	3.44
27030675	C3846446	Prospective, NOS	fndg	3.38
27030675	C0039798	therapeutic aspects	ftcn	22.48
27030675	C3852684	lumacaftor	orch	14.64
27030675	C3852684	lumacaftor	phsu	14.64
27030675	C2718059	Precision Medicine	topp	12.90
27030675	C3264621	ivacaftor	orch	12.89
27030675	C3264621	ivacaftor	phsu	12.89
27030675	C0012634	Disease	dsyn	9.74
27030675	C1882932	Representation (action)	acty	5.18
27030675	C1533734	Administration procedure	topp	3.55
27030675	C1705169	Biomaterial Treatment	cnce	3.55
27030675	C0087111	Therapeutic procedure	topp	3.55
27030675	C1522326	Treating	ftcn	3.55
27030675	C3538994	Treatment Epoch	resa	3.55
27030675	C3887704	treatment - ActInformationManagementReason	hlca	3.55
27030675	C1414672	FOXD3 gene	gngm	3.54
27030675	C2984892	FOXD3 wt Allele	gngm	3.54
27030675	C2346845	Approval (document)	inpr	3.53
27030675	C0205540	Approved	qlco	3.53
27030675	C2697909	Letter of Authorization	rnlw	3.53
27030675	C0332185	Recent	tmco	3.43
27030675	C0348080	Condition	qlco	3.43
27030675	C3864998	Condition:Find:Pt:^Patient:Nom	clna	3.43
27030675	C1705253	Logical Condition	cnce	3.43
27030675	C3495919	Enthesitis-Related Arthritis	dsyn	3.42
27030675	C0205314	New	qlco	3.42
27030675	C0010674	Cystic Fibrosis	dsyn	11.49
27030675	C0012634	Disease	dsyn	9.78
27030675	C3687832	DRUGS	topp	5.18
27030675	C0013227	Pharmaceutical Preparations	phsu	5.18
27030675	C0392747	Changing	ftcn	3.59
27030675	C1825598	IMPACT gene	gngm	3.54
27030675	C4049986	Impact	qlco	3.54
27030675	C0595998	Household composition	fndg	3.42
27030675	C0027361	Persons	popg	3.42
27030675	C1446409	Positive	qlco	3.42
27030675	C2825490	Positive Charge	qlco	3.42
27030675	C1514241	Positive Finding	fndg	3.42
27030675	C3812269	Positive Number	cnce	3.42
27030675	C0439178	percent positive cells	qnco	3.42
27030675	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27030675	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27030675	C0031843	physiological aspects	phsf	13.03
27030675	C0162340	Comprehension	menp	13.01
27030675	C0282443	Review [Publication Type]	inpr	11.49
27030675	C0025119	Medicine in Art	idcn	9.74
27030675	C1552617	Act Class - review	idcn	5.18
27030675	C0359589	Provide (product)	food	5.18
27030675	C1999230	Providing (action)	acty	5.18
27030675	C0678723	Biologic Development	orgf	3.59
27030675	C1527148	Development	ftcn	3.59
27030675	C0243107	development aspects	phsf	3.59
27030675	C0542341	Function	ftcn	3.57
27030675	C0700205	Function Axis	clas	3.57
27030675	C1705273	Mathematical Operator	inpr	3.57
27030675	C1519814	Update	tmco	3.57
27030675	C1301808	Geographic state	geoa	3.54
27030675	C1442792	State	ftcn	3.54
27030675	C3148680	US State	geoa	3.54
27030675	C1413365	CFTR gene	gngm	3.44
27030675	C0678594	structure	spco	3.43
27030675	C0205234	Focal	spco	3.42
27030675	C1285542	Has focus	ftcn	3.42
27030675	C1521840	Target	ftcn	3.42
27030675	C3854260	Advance	tmco	3.42
27030675	C0725066	Advance -- medical device	medd	3.42
27158420	C0026565	Mortality Vital Statistics	qnco	20.95
27158420	C0026538	Morbidity - disease rate	qnco	19.20
27158420	C0007457	Caucasoid Race	popg	12.88
27158420	C0026566	Aspects of mortality statistics	qnco	11.49
27158420	C0010674	Cystic Fibrosis	dsyn	10.06
27158420	C0012634	Disease	dsyn	9.85
27158420	C1257890	Population Group	popg	9.73
27158420	C0035204	Respiration Disorders	dsyn	8.34
27158420	C0205393	Most	qnco	6.88
27158420	C0032659	geographic population	qnco	6.57
27158420	C1527428	Remaining	qlco	5.18
27158420	C0035242	Respiratory Tract Diseases	dsyn	5.18
27158420	C0449416	Source	fndg	3.55
27158420	C1705919	Term Source	inpr	3.55
27158420	C0441748	Autosomal recessive inheritance	genf	3.43
27158420	C2347946	Relevance	qlco	3.43
27158420	C0220880	morbidity aspects	inpr	3.43
27158420	C0043157	Caucasians	popg	3.42
27158420	C0205214	Common (qualifier value)	qnco	3.42
27158420	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
27158420	C1522138	shared attribute	ftcn	3.42
27158420	C0040405	X-Ray Computed Tomography	diap	22.68
27158420	C0242656	Disease Progression	patf	14.64
27158420	C0332183	Frequently	tmco	5.18
27158420	C0449258	Progression	ftcn	5.18
27158420	C1552357	Radiologic Technologist - Computed Tomography	prog	3.75
27158420	C0544688	complication of disease	patf	3.60
27158420	C1516647	Clinical Trials, Monitoring	resa	3.56
27158420	C1283169	Monitoring - action	hlca	3.56
27158420	C0150369	Preventive monitoring	hlca	3.56
27158420	C1273517	Used by	fndg	3.56
27158420	C0015333	Exposure to radiation	inpo	16.37
27158420	C0007673	Central African Republic	geoa	16.04
27158420	C0023175	Lead	elii	13.02
27158420	C0023175	Lead	hops	13.02
27158420	C0034519	Electromagnetic Radiation	npop	12.94
27158420	C0851346	Radiation	npop	6.63
27158420	C1522449	Therapeutic radiology procedure	topp	6.63
27158420	C2986588	Cumulative Exposure	phpr	3.78
27158420	C0439234	year	tmco	3.63
27158420	C3275067	Cardiac Lead Procedure	topp	3.56
27158420	C2699424	Concern	idcn	3.56
27158420	C2348269	Dietary Lead	elii	3.56
27158420	C1522538	Leading	ftcn	3.56
27158420	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.56
27158420	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.56
27158420	C0442805	Increase	ftcn	3.54
27158420	C1511559	Cumulative	qlco	3.48
27158420	C3715153	Fifteen	qnco	3.48
27158420	C1517741	Last	qlco	3.48
27158420	C1524020	Radiation Ionizing Radiotherapy	topp	3.48
27158420	C1524021	Radiotherapy Research	resa	3.48
27158420	C0560559	Unit of radiation dose	qnco	3.48
27158420	C1524063	Use of	ftcn	3.43
27158420	C3813556	Cancer/Testis Antigen	aapp	3.42
27158420	C3888140	Computed Tomography Study File	inpr	3.42
27158420	C1880834	Fold in Medical Device Material	phpr	3.42
27158420	C0332462	Folded structure	spco	3.42
27158420	C3540513	PCYT1A wt Allele	gngm	3.42
27158420	C0205452	Six	qnco	3.42
27158420	C0040363	Togo	geoa	17.80
27158420	C0041260	Tryptophanase	aapp	17.80
27158420	C0041260	Tryptophanase	enzy	17.80
27158420	C0007673	Central African Republic	geoa	16.04
27158420	C1550543	Fulfill	phpr	10.42
27158420	C1883351	To	qlco	5.18
27158420	C0806487	image quality	qlco	3.75
27158420	C0679199	strategy	menp	3.63
27158420	C0805586	Challenge	hlca	3.55
27158420	C0798503	Challenge:Type:Point in time:^Patient:Nominal	clna	3.55
27158420	C3274764	Proficiency Testing Challenge	cnce	3.55
27158420	C3889426	Content Type Requirement	ftcn	3.52
27158420	C1514873	Requirement	ftcn	3.52
27158420	C1879533	Acceptable	qlco	3.48
27158420	C3539083	Acceptable (foundation metadata concept)	qlco	3.48
27158420	C0178602	Dosage	qnco	3.48
27158420	C1114758	Dose number:Number:Point in time:^Patient:Quantitative	clna	3.48
27158420	C0392756	Reduced	qlco	3.48
27158420	C0301630	Reduction (chemical)	npop	3.48
27158420	C0441610	Reduction - action	topp	3.48
27158420	C0869039	Unit dose	qnco	3.48
27158420	C0814933	medical profession	bmod	3.45
27158420	C2827442	Diagnostic Quality	qlco	3.44
27158420	C3813556	Cancer/Testis Antigen	aapp	3.42
27158420	C3888140	Computed Tomography Study File	inpr	3.42
27158420	C3540513	PCYT1A wt Allele	gngm	3.42
27158420	C0007673	Central African Republic	geoa	16.21
27158420	C0034525	Effects of radiation	biof	13.09
27158420	C0034519	Electromagnetic Radiation	npop	13.01
27158420	C0041701	United Nations	orgt	12.91
27158420	C0178602	Dosage	qnco	7.31
27158420	C1114758	Dose number:Number:Point in time:^Patient:Quantitative	clna	7.31
27158420	C0869039	Unit dose	qnco	7.31
27158420	C0851346	Radiation	npop	6.70
27158420	C1522449	Therapeutic radiology procedure	topp	6.70
27158420	C0030705	Patients	podg	6.59
27158420	C0036397	Science	ocdi	6.58
27158420	C0205224	Essential	qlco	5.18
27158420	C1514756	Receive	qlco	3.98
27158420	C2698650	Optimization	acty	3.63
27158420	C3813556	Cancer/Testis Antigen	aapp	3.59
27158420	C3888140	Computed Tomography Study File	inpr	3.59
27158420	C3540513	PCYT1A wt Allele	gngm	3.59
27158420	C0237506	chance	qlco	3.57
27158420	C2986497	Cumulative Dose	cnce	3.55
27158420	C1546944	Event Seriousness - Significant	qlco	3.55
27158420	C0750502	Significant	idcn	3.55
27158420	C0237881	Statistical Significance	qnco	3.55
27158420	C1524020	Radiation Ionizing Radiotherapy	topp	3.54
27158420	C1524021	Radiotherapy Research	resa	3.54
27158420	C0560559	Unit of radiation dose	qnco	3.54
27158420	C2699414	Committee	grup	3.42
27158420	C3817553	100%	qnco	3.42
27158420	C1979886	Excess	qlco	3.42
27158420	C0567415	Atom (substance)	elii	3.38
27158420	C1706222	NCI Concept Atom	cnce	3.38
27158420	C0009738	Congo	geoa	16.21
27158420	C0011923	Diagnostic Imaging	diap	9.90
27158420	C0040833	trends qualifier	tmco	9.88
27158420	C0282443	Review [Publication Type]	inpr	9.81
27158420	C1706852	Article	inpr	3.68
27158420	C2698650	Optimization	acty	3.68
27158420	C3811819	CFTR wt Allele	gngm	3.59
27158420	C0079595	Imaging Techniques	diap	3.59
27158420	C1521798	trend	tmco	3.57
27158420	C1552617	Act Class - review	idcn	3.50
27158420	C0178602	Dosage	qnco	3.50
27158420	C1114758	Dose number:Number:Point in time:^Patient:Quantitative	clna	3.50
27158420	C0869039	Unit dose	qnco	3.50
27158420	C0521116	Current (present time)	tmco	3.44
27158420	C1705970	Electrical Current	npop	3.44
27158420	C0205314	New	qlco	3.43
27158420	C0678723	Biologic Development	orgf	3.41
27158420	C1527148	Development	ftcn	3.41
27158420	C0243107	development aspects	phsf	3.41
26823621	C0282461	Phase 3 Clinical Trials	resa	22.55
26823621	C0016590	Formularies as Topic	inpr	19.20
26823621	C0282448	Monograph	inpr	13.35
26823621	C3687832	DRUGS	topp	5.18
26823621	C0332177	Monthly (qualifier value)	tmco	5.18
26823621	C0013227	Pharmaceutical Preparations	phsu	5.18
26823621	C1514756	Receive	qlco	5.18
26823621	C1283071	Release - action (qualifier value)	ftcn	5.18
26823621	C0391871	Released (action)	ftcn	5.18
26823621	C0439231	month	tmco	5.18
26823621	C0750546	newly	idcn	5.18
26823621	C0439507	per month (qualifier value)	tmco	5.18
26823621	C3843715	5-6	fndg	3.58
26823621	C0442749	6/5	fndg	3.58
26823621	C1609436	Document completion status - Documented	inpr	3.55
26823621	C1301725	Documented	hlca	3.55
26823621	C0205170	Good	qlco	3.55
26823621	C0205087	Late	tmco	3.55
26823621	C3146287	Well	mnob	3.55
26823621	C3242716	subscriber	grup	3.52
26823621	C3245478	ActInformationPrivacyReason <service>	idcn	3.43
26823621	C0557854	Services	ocac	3.43
26823621	C2825316	Software Service	mnob	3.43
26823621	C1553526	Substance Admin Substitution - formulary	hlca	3.43
26823621	C0086186	Committee, Drug	hcro	17.80
26823621	C0031321	Pharmaceutical Services	hlca	9.88
26823621	C0031322	Pharmacy facility	hcro	9.88
26823621	C0282448	Monograph	inpr	8.34
26823621	C0031336	Pharmacy (field)	bmod	6.72
26823621	C3244303	Pharmacy domain	inpr	3.57
26823621	C1521840	Target	ftcn	3.57
26823621	C0031321	Pharmaceutical Services	hlca	19.88
26823621	C0006147	Breast Feeding	orgf	19.24
26823621	C0028677	Discipline of Nursing	bmod	12.93
26823621	C0028697	Nursing Services	hlca	10.01
26823621	C0031322	Pharmacy facility	hcro	9.77
26823621	C0028678	nursing therapy	topp	9.77
26823621	C0282448	Monograph	inpr	6.70
26823621	C0031336	Pharmacy (field)	bmod	6.62
26823621	C1514756	Receive	qlco	5.18
26823621	C3242716	subscriber	grup	3.63
26823621	C3827682	Useful	qlco	3.59
26823621	C3244303	Pharmacy domain	inpr	3.47
26823621	C0681473	agenda	inpr	3.45
26823621	C1538566	PAGE1 gene	gngm	3.44
26823621	C0332177	Monthly (qualifier value)	tmco	3.42
26823621	C1706244	Summary (document)	inpr	3.42
26823621	C1552616	summary - ActRelationshipSubset	inpr	3.42
26823621	C0450442	Agent	chvf	3.40
26823621	C1254351	Pharmacologic Substance	phsu	3.40
26823621	C1521826	Protocol Agent	inpr	3.40
26823621	C0206176	Drug Utilization Review	hlca	16.10
26823621	C0332177	Monthly (qualifier value)	tmco	5.18
26823621	C1999230	Providing (action)	acty	5.18
26823621	C0439231	month	tmco	5.18
26823621	C0439507	per month (qualifier value)	tmco	5.18
26823621	C0240320	medication use	fndg	3.47
26823621	C1880156	Comprehensive	qlco	3.45
26823621	C1521840	Target	ftcn	3.45
26823621	C2986546	Target Lesion Identification	diap	3.45
26823621	C0033161	Printing	ocac	9.90
26823621	C0282448	Monograph	inpr	8.34
26823621	C0700221	Intravascular line	medd	3.61
26823621	C1550648	Line Specimen	sbst	3.61
26823621	C1552960	Line Unit of Length	qnco	3.61
26823621	C0205132	Linear	spco	3.61
26823621	C1519246	Send (transmission)	ftcn	3.59
26823621	C0470187	Availability of	ftcn	3.47
26823621	C0040363	Togo	geoa	17.80
26823621	C0041260	Tryptophanase	aapp	17.80
26823621	C0041260	Tryptophanase	enzy	17.80
26823621	C0027552	Needs	qlco	13.02
26823621	C0282448	Monograph	inpr	6.83
26823621	C1880202	Customize	acty	5.18
26823621	C1550543	Fulfill	phpr	5.18
26823621	C1883351	To	qlco	5.18
26823621	C0686904	Patient need for (contextual qualifier)	ftcn	3.56
26823621	C1547538	Facility	idcn	3.43
26823621	C0016590	Formularies as Topic	inpr	19.32
26823621	C0282443	Review [Publication Type]	inpr	9.94
26823621	C0034037	Publishing	ocac	8.34
26823621	C0282448	Monograph	inpr	6.71
26823621	C1948052	Now (temporal qualifier)	tmco	5.18
26823621	C1704324	Scientific Publication	inpr	5.18
26823621	C1552617	Act Class - review	idcn	3.63
26823621	C3245478	ActInformationPrivacyReason <service>	idcn	3.55
26823621	C0332177	Monthly (qualifier value)	tmco	3.55
26823621	C0557854	Services	ocac	3.55
26823621	C2825316	Software Service	mnob	3.55
26823621	C1553526	Substance Admin Substitution - formulary	hlca	3.55
26823621	C0456387	Class	inpr	3.48
26823621	C1705943	Class (taxonomic)	clas	3.48
26823621	C0013227	Pharmaceutical Preparations	phsu	3.48
26823621	C1254351	Pharmacologic Substance	phsu	3.48
26823621	C0016590	Formularies as Topic	inpr	19.20
26823621	C0282443	Review [Publication Type]	inpr	9.88
26823621	C0034037	Publishing	ocac	8.34
26823621	C1707391	Choose (action)	acty	5.18
26823621	C0260123	hospital pharmacies	hcro	5.18
26823621	C0392337	cooperation	socb	3.55
26823621	C1185738	Column (anatomic)	bpoc	3.44
26823621	C1706132	Column (arrangement)	idcn	3.44
26823621	C1553526	Substance Admin Substitution - formulary	hlca	3.43
26823621	C0016590	Formularies as Topic	inpr	38.73
26823621	C1553526	Substance Admin Substitution - formulary	hlca	7.00
26823621	C0021425	Information Services	ocac	6.72
26823621	C0282448	Monograph	inpr	6.58
26823621	C1947967	Call (Instruction)	ftcn	5.18
26823621	C0679006	Decision	menp	5.18
26823621	C0205172	More	ftcn	3.42
26823621	C3885614	brexpiprazole	orch	14.64
26823621	C3885614	brexpiprazole	phsu	14.64
26823621	C1121991	cangrelor	nnon	14.64
26823621	C1121991	cangrelor	phsu	14.64
26823621	C3886073	lesinurad	orch	14.64
26823621	C3886073	lesinurad	phsu	14.64
26823621	C3264621	ivacaftor	orch	13.14
26823621	C3264621	ivacaftor	phsu	13.14
26823621	C3852684	lumacaftor	orch	12.96
26823621	C3852684	lumacaftor	phsu	12.96
26823621	C0282448	Monograph	inpr	6.62
26823621	C1831828	TALIMOGENE LAHERPAREPVEC	virs	5.18
26823621	C1522168	Topical Route of Drug Administration	ftcn	3.58
26823621	C1555712	topic - ActClassContainer	inpr	3.58
26823621	C3828193	September	tmco	3.47
26823621	C0036043	Safety	hcpp	16.12
26823621	C1121991	cangrelor	nnon	13.05
26823621	C1121991	cangrelor	phsu	13.05
26823621	C1705187	Safety Study	resa	3.50
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
28785019	C0023175	Lead	elii	13.02
28785019	C0023175	Lead	hops	13.02
28785019	C0008972	Clinical Research	resa	6.70
28785019	C0033684	Proteins	aapp	6.57
28785019	C0033684	Proteins	bacs	6.57
28785019	C3275067	Cardiac Lead Procedure	topp	3.56
28785019	C0205210	Clinical	qlco	3.56
28785019	C2348269	Dietary Lead	elii	3.56
28785019	C1522538	Leading	ftcn	3.56
28785019	C1553058	Neuropsychologist - Clinical	prog	3.56
28785019	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.56
28785019	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.56
28785019	C0237412	Psychologist - Clinical	prog	3.56
28785019	C0497591	Social Worker - Clinical	prog	3.56
28785019	C0814225	benefit	qnco	3.56
28785019	C0449982	Type of restoration	inpr	3.54
28785019	C1413365	CFTR gene	gngm	3.46
28785019	C0542341	Function	ftcn	3.42
28785019	C0205245	Functional	ftcn	3.42
28785019	C2700217	Functional Relationship	cnce	3.42
28785019	C1705285	Mutation Abnormality	comd	3.42
28785019	C1704735	Regulator	cnce	3.42
28785019	C1704734	Regulator Device Component	mnob	3.42
28785019	C0182953	Regulators (device)	medd	3.42
28785019	C1709060	Modulator Device Component	mnob	3.40
28785019	C0030705	Patients	podg	6.62
28785019	C0947630	Scientific Study	lbpr	5.18
28785019	C1547282	Show	anim	3.98
28785019	C0871261	Response process	orga	3.61
28785019	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.47
28785019	C0205250	High	qlco	3.47
28785019	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.47
28785019	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.47
28785019	C0439828	Variable (uniformity)	qlco	3.47
28785019	C0040363	Togo	geoa	17.80
28785019	C0041260	Tryptophanase	aapp	17.80
28785019	C0041260	Tryptophanase	enzy	17.80
28785019	C0005516	Biological Markers	clna	8.34
28785019	C1883351	To	qlco	5.18
28785019	C2985627	Study Objective	idcn	3.60
28785019	C0681890	predictive	qlco	3.56
28785019	C4055223	Clinical Response	fndg	3.46
28785019	C0086418	Homo sapiens	humn	28.79
28785019	C0028429	Nose	bpoc	26.04
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
28785019	C0000096	1-Methyl-3-isobutylxanthine	orch	22.35
28785019	C0000096	1-Methyl-3-isobutylxanthine	phsu	22.35
28785019	C0021966	Iodides	inch	16.25
28785019	C0917964	Colforsin	orch	16.04
28785019	C0917964	Colforsin	phsu	16.04
28785019	C0031843	physiological aspects	phsf	13.09
28785019	C0010453	Anthropological Culture	idcn	13.01
28785019	C1516048	Assessed	acty	5.18
28785019	C0681814	research study	resa	5.18
28785019	C0221138	Blood group antibody I	aapp	3.63
28785019	C0221138	Blood group antibody I	imft	3.63
28785019	C0542341	Function	ftcn	3.63
28785019	C0700205	Function Axis	clas	3.63
28785019	C1705273	Mathematical Operator	inpr	3.63
28785019	C0521116	Current (present time)	tmco	3.59
28785019	C1705970	Electrical Current	npop	3.59
28785019	C1515655	in vivo	spco	3.59
28785019	C1704632	Disease Response	fndg	3.55
28785019	C2911692	Response (communication)	menp	3.55
28785019	C1706817	Response (statement)	inpr	3.55
28785019	C0871261	Response process	orga	3.55
28785019	C0221908	epithelial	qlco	3.55
28785019	C1413365	CFTR gene	gngm	3.48
28785019	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.47
28785019	C2984839	Device Short Circuit Evaluation Result	ftcn	3.47
28785019	C2741958	VX-770	orch	3.47
28785019	C1705241	Delta (difference)	qnco	3.43
28785019	C1705242	Different	qlco	3.43
28785019	C3245505	potential	qlco	3.43
28785019	C0016315	Fluorescence	npop	22.47
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
28785019	C0220825	Evaluation	hlca	13.01
28785019	C3854321	Expression (foundation metadata concept)	idcn	3.63
28785019	C0185117	Expression procedure	topp	3.63
28785019	C0596119	apical membrane	celc	3.58
28785019	C1709793	Quantitation	qnco	3.55
28785019	C1413365	CFTR gene	gngm	3.48
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
28785019	C0030705	Patients	podg	13.87
28785019	C0031843	physiological aspects	phsf	13.14
28785019	C0019425	Heterozygote	orga	9.99
28785019	C0019904	Homozygote	orga	9.86
28785019	C0026882	Mutation	genf	9.74
28785019	C0017431	Genotype	orga	6.60
28785019	C0205235	Discriminate	qlco	3.98
28785019	C0542341	Function	ftcn	3.68
28785019	C0700205	Function Axis	clas	3.68
28785019	C1705273	Mathematical Operator	inpr	3.68
28785019	C0242485	Measurement	ftcn	3.63
28785019	C2587213	Control function	ftcn	3.60
28785019	C0332197	Absent	ftcn	3.59
28785019	C2699517	Absent Adverse Event	fndg	3.59
28785019	C0332152	Before	tmco	3.59
28785019	C1522538	Leading	ftcn	3.59
28785019	C3898900	Healthy	qlco	3.50
28785019	C1609982	Residual	qlco	3.50
28785019	C1413365	CFTR gene	gngm	3.44
28785019	C4050466	Borg Category-Ratio 10 Perceived Exertion Score 5	inpr	3.43
28785019	C1705285	Mutation Abnormality	comd	3.43
28785019	C0205082	Severe (severity modifier)	qlco	3.43
28785019	C4050465	Severe Extremity Pain	inpr	3.43
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
28785019	C0021966	Iodides	inch	16.23
28785019	C0068515	neodymium pyrocatechin disulfonate	orch	12.96
28785019	C0242485	Measurement	ftcn	3.68
28785019	C0221138	Blood group antibody I	aapp	3.61
28785019	C0221138	Blood group antibody I	imft	3.61
28785019	C0205111	Apical	spco	3.55
28785019	C1413365	CFTR gene	gngm	3.55
28785019	C0007634	Cells	cell	3.55
28785019	C0178539	Cellular	lbpr	3.55
28785019	C1707520	Correlation	qlco	3.55
28785019	C3854321	Expression (foundation metadata concept)	idcn	3.55
28785019	C0185117	Expression procedure	topp	3.55
28785019	C3539725	SMPD1 wt Allele	gngm	3.50
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
28785019	C0021966	Iodides	inch	16.04
28785019	C3852684	lumacaftor	orch	13.09
28785019	C3852684	lumacaftor	phsu	13.09
28785019	C0442805	Increase	ftcn	5.18
28785019	C0205217	Increased	qnco	5.18
28785019	C1704632	Disease Response	fndg	3.54
28785019	C2911692	Response (communication)	menp	3.54
28785019	C1706817	Response (statement)	inpr	3.54
28785019	C0871261	Response process	orga	3.54
28785019	C1413365	CFTR gene	gngm	3.48
28785019	C0221138	Blood group antibody I	aapp	3.42
28785019	C0221138	Blood group antibody I	imft	3.42
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.01
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.01
28785019	C1413365	CFTR gene	gngm	6.94
28785019	C0456079	Disease classification level	clas	3.63
28785019	C1547707	Floor - story of building	geoa	3.63
28785019	C2946261	Level	phsu	3.63
28785019	C0441889	Levels (qualifier value)	qlco	3.63
28785019	C3854321	Expression (foundation metadata concept)	idcn	3.55
28785019	C0185117	Expression procedure	topp	3.55
28785019	C2700323	Wild Type Unspecified - zebrafish	fish	3.48
28785019	C0205111	Apical	spco	3.42
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
28785019	C0456079	Disease classification level	clas	3.54
28785019	C1547707	Floor - story of building	geoa	3.54
28785019	C2946261	Level	phsu	3.54
28785019	C0441889	Levels (qualifier value)	qlco	3.54
28785019	C1413365	CFTR gene	gngm	3.42
28785019	C0007634	Cells	cell	3.42
28785019	C3282337	Cells [Chemical/Ingredient]	cell	3.42
28785019	C1414369	ELANE gene	gngm	3.42
28785019	C3538705	ELANE wt Allele	gngm	3.42
28785019	C2700323	Wild Type Unspecified - zebrafish	fish	3.42
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.10
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.10
28785019	C0010453	Anthropological Culture	idcn	14.64
28785019	C1413365	CFTR gene	gngm	7.02
28785019	C0030705	Patients	podg	6.58
28785019	C0220814	Cultural aspects	ftcn	5.18
28785019	C1414369	ELANE gene	gngm	5.18
28785019	C3538705	ELANE wt Allele	gngm	5.18
28785019	C0430400	Laboratory culture	lbpr	5.18
28785019	C2242979	Microbial culture (procedure)	lbpr	5.18
28785019	C0332293	Treated with	topp	3.64
28785019	C3481639	Volume expired during 1.0 s of forced expiration percent change:VPctDiff:Pt:Respiratory system:Qn	clna	3.61
28785019	C1707520	Correlation	qlco	3.56
28785019	C0456079	Disease classification level	clas	3.56
28785019	C1547707	Floor - story of building	geoa	3.56
28785019	C2946261	Level	phsu	3.56
28785019	C0441889	Levels (qualifier value)	qlco	3.56
28785019	C0439231	month	tmco	3.55
28785019	C1709060	Modulator Device Component	mnob	3.54
28785019	C1947976	Correction (change)	ftcn	3.43
28785019	C1705565	Correction Report	inpr	3.43
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.97
28785019	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.97
28785019	C0007585	Cell Culture Techniques	lbpr	16.37
28785019	C0031843	physiological aspects	phsf	12.89
28785019	C1413365	CFTR gene	gngm	6.90
28785019	C1999230	Providing (action)	acty	5.18
28785019	C3887511	Evidence	idcn	3.68
28785019	C1947976	Correction (change)	ftcn	3.56
28785019	C1705565	Correction Report	inpr	3.56
28785019	C2986411	Improvement	cnce	3.56
28785019	C0205435	First (number)	qnco	3.50
28785019	C1279901	Firstly	qlco	3.50
28785019	C1414369	ELANE gene	gngm	3.48
28785019	C3538705	ELANE wt Allele	gngm	3.48
28785019	C0542341	Function	ftcn	3.43
28785019	C0700205	Function Axis	clas	3.43
28785019	C1705273	Mathematical Operator	inpr	3.43
28785019	C1546767	Specimen Source Codes - Respiratory	inpr	3.43
28785019	C0521346	respiratory	ftcn	3.43
28785019	C1709060	Modulator Device Component	mnob	3.41
25169789	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25169789	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25169789	C3264621	ivacaftor	orch	14.64
25169789	C3264621	ivacaftor	phsu	14.64
25169789	C0026882	Mutation	genf	9.94
25169789	C0010674	Cystic Fibrosis	dsyn	9.77
25169789	C0030705	Patients	podg	6.71
25169789	C2697524	Graph Node	cnce	5.18
25169789	C0442805	Increase	ftcn	5.18
25169789	C3264627	Kalydeco	phsu	5.18
25169789	C0230003	Vertex	blor	5.18
25169789	C1159591	chloride transport	celf	5.18
25169789	C1705285	Mutation Abnormality	comd	3.63
25169789	C3476289	Opening time	fndg	3.58
25169789	C0441731	Type 3	clas	3.53
25169789	C1413365	CFTR gene	gngm	3.42
25169789	C0439799	Channel	spco	3.42
25169789	C1706095	Channel Object	cnce	3.42
25169789	C0043094	Weight Gain	fndg	25.76
25169789	C3264621	ivacaftor	orch	12.96
25169789	C3264621	ivacaftor	phsu	12.96
25169789	C0242481	Research Activities	resa	9.99
25169789	C0035168	research	resa	9.99
25169789	C0042153	utilization qualifier	ftcn	9.99
25169789	C0035245	Respiratory physiology	ortf	6.62
25169789	C0332282	Following	tmco	5.18
25169789	C0231290	Status post	tmco	5.18
25169789	C1547282	Show	anim	3.98
25169789	C0457083	Usage	ftcn	3.68
25169789	C1947944	Use - dosing instruction imperative	inpr	3.68
25169789	C2986411	Improvement	cnce	3.56
25169789	C1546944	Event Seriousness - Significant	qlco	3.43
25169789	C0750502	Significant	idcn	3.43
25169789	C0237881	Statistical Significance	qnco	3.43
25169789	C0018681	Headache	sosy	17.80
25169789	C0040363	Togo	geoa	17.80
25169789	C0041260	Tryptophanase	aapp	17.80
25169789	C0041260	Tryptophanase	enzy	17.80
25169789	C3264621	ivacaftor	orch	14.64
25169789	C3264621	ivacaftor	phsu	14.64
25169789	C0041912	Upper Respiratory Infections	dsyn	11.49
25169789	C0205170	Good	qlco	5.18
25169789	C0027424	Nasal congestion (finding)	sosy	5.18
25169789	C0581381	Recurrent upper respiratory tract infection	dsyn	5.18
25169789	C1883351	To	qlco	5.18
25169789	C3146287	Well	mnob	5.18
25169789	C1547282	Show	anim	3.98
25169789	C1705413	Adverse Event Domain	inpr	3.59
25169789	C0877248	Adverse event	patf	3.59
25169789	C1704459	Device Component System	mnob	3.43
25169789	C0449913	System	ftcn	3.43
25169789	C1553451	System - kit	mnob	3.43
25169789	C0009738	Congo	geoa	17.80
25169789	C3264621	ivacaftor	orch	12.89
25169789	C3264621	ivacaftor	phsu	12.89
25169789	C0205469	Pathological aspects	ftcn	9.85
25169789	C0030664	Pathology	bmod	9.85
25169789	C0007320	Case Reports Publication Type	inpr	8.34
25169789	C0085973	Case Study	inpr	8.34
25169789	C0030705	Patients	podg	6.57
25169789	C3811819	CFTR wt Allele	gngm	5.18
25169789	C3853626	Case report:Find:Pt:{Setting}:Doc:{Author Type}	clna	5.18
25169789	C1547282	Show	anim	3.98
25169789	C1280500	Effect	qlco	3.56
25169789	C2348382	Effect, Appearance	qlco	3.56
25169789	C0677042	Pathology processes	patf	3.54
25169789	C1446409	Positive	qlco	3.43
25169789	C2825490	Positive Charge	qlco	3.43
25169789	C1514241	Positive Finding	fndg	3.43
25169789	C3812269	Positive Number	cnce	3.43
25169789	C0439178	percent positive cells	qnco	3.43
25169789	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.42
25169789	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.42
25169789	C0580836	Old	tmco	3.42
25169789	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.42
25169789	C0439508	per year	tmco	3.42
25169789	C0439234	year	tmco	3.42
25169789	C0030471	Nasal sinus	bsoj	19.79
25169789	C0007673	Central African Republic	geoa	16.12
25169789	C3264621	ivacaftor	orch	12.89
25169789	C3264621	ivacaftor	phsu	12.89
25169789	C0016169	pathologic fistula	anab	9.99
25169789	C0012634	Disease	dsyn	9.73
25169789	C1547282	Show	anim	3.98
25169789	C1305231	Sinus - general anatomical term	bsoj	3.68
25169789	C0439231	month	tmco	3.56
25169789	C0547047	Decrease	qnco	3.55
25169789	C0392756	Reduced	qlco	3.55
25169789	C2699488	Resolution	cnce	3.54
25169789	C1706463	Resolution Property	qnco	3.54
25169789	C1514893	physiologic resolution	patf	3.54
25169789	C3813556	Cancer/Testis Antigen	aapp	3.50
25169789	C3888140	Computed Tomography Study File	inpr	3.50
25169789	C3540513	PCYT1A wt Allele	gngm	3.50
25169789	C1524063	Use of	ftcn	3.46
25169789	C0728893	+5	qnco	3.43
25169789	C0439084	>5	qnco	3.43
25169789	C1457887	Symptoms	sosy	3.42
25169789	C0683368	Symptoms aspect	ftcn	3.42
25169789	C0725685	Compleat Liquid Nutrition	food	3.42
25169789	C0205197	Complete	qlco	3.42
25169789	C3853530	Data operation - complete	ftcn	3.42
25169789	C0449584	Opacification	qlco	3.42
25169789	C1882150	Opacification of Medical Device Material	phpr	3.42
25169789	C3264621	ivacaftor	orch	25.95
25169789	C3264621	ivacaftor	phsu	25.95
25169789	C0040363	Togo	geoa	17.80
25169789	C0041260	Tryptophanase	aapp	17.80
25169789	C0041260	Tryptophanase	enzy	17.80
25169789	C0009738	Congo	geoa	16.04
25169789	C0220825	Evaluation	hlca	14.64
25169789	C0027552	Needs	qlco	14.64
25169789	C0242481	Research Activities	resa	11.49
25169789	C0035168	research	resa	11.49
25169789	C0205469	Pathological aspects	ftcn	9.99
25169789	C0030664	Pathology	bmod	9.99
25169789	C1280500	Effect	qlco	7.17
25169789	C2348382	Effect, Appearance	qlco	7.17
25169789	C0205172	More	ftcn	5.18
25169789	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
25169789	C1883351	To	qlco	5.18
25169789	C1555307	promise	idcn	3.98
25169789	C0677042	Pathology processes	patf	3.68
25169789	C0225377	Structure of upper respiratory tract cavity	bsoj	3.55
25169789	C1446409	Positive	qlco	3.43
25169789	C2825490	Positive Charge	qlco	3.43
25169789	C1514241	Positive Finding	fndg	3.43
25169789	C3812269	Positive Number	cnce	3.43
25169789	C0439178	percent positive cells	qnco	3.43
25169789	C3811819	CFTR wt Allele	gngm	3.43
24081349	C0010674	Cystic Fibrosis	dsyn	20.02
24081349	C0031843	physiological aspects	phsf	13.02
24081349	C0003075	Anions	elii	12.89
24081349	C0376315	Manufactured form	mnob	8.34
24081349	C0439799	Channel	spco	7.01
24081349	C1706095	Channel Object	cnce	7.01
24081349	C0033684	Proteins	aapp	6.79
24081349	C0033684	Proteins	bacs	6.79
24081349	C0014597	Epithelial Cells	cell	6.60
24081349	C1689985	Absence (morphologic abnormality)	anab	5.18
24081349	C0332197	Absent	ftcn	5.18
24081349	C1522492	Formation	ftcn	5.18
24081349	C0348078	Qualitative form	qlco	5.18
24081349	C0542341	Function	ftcn	3.56
24081349	C0700205	Function Axis	clas	3.56
24081349	C1705273	Mathematical Operator	inpr	3.56
24081349	C1280464	Manifestation of	qlco	3.55
24081349	C0205210	Clinical	qlco	3.54
24081349	C2825142	Experimental Result	fndg	3.54
24081349	C1553058	Neuropsychologist - Clinical	prog	3.54
24081349	C0237412	Psychologist - Clinical	prog	3.54
24081349	C1274040	Result	ftcn	3.54
24081349	C0497591	Social Worker - Clinical	prog	3.54
24081349	C1546471	What subject filter - Result	idcn	3.54
24081349	C1273342	Epithelial cell count (procedure)	lbpr	3.45
24081349	C0332452	defective	ftcn	3.43
24081349	C0009738	Congo	geoa	16.30
24081349	C3899988	Autosomal Recessive Disorder	dsyn	5.18
24081349	C2985434	Disease-causing Mutation	comd	4.19
24081349	C3811819	CFTR wt Allele	gngm	3.68
24081349	C0456387	Class	inpr	3.68
24081349	C1705943	Class (taxonomic)	clas	3.68
24081349	C4019422	Classes - encounter	hlca	3.68
24081349	C0332849	Divide	ftcn	3.59
24081349	C0205451	Five	qnco	3.59
24081349	C0205452	Six	qnco	3.50
24081349	C0026882	Mutation	genf	9.91
24081349	C0205214	Common (qualifier value)	qnco	3.56
24081349	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.56
24081349	C1522138	shared attribute	ftcn	3.56
24081349	C1883310	One Thousand	qnco	3.50
24081349	C4050554	Per Thousand	qnco	3.50
24081349	C0441887	Class 3	inpr	3.48
24081349	C3842590	10%	fndg	3.46
24081349	C0456387	Class	inpr	3.46
24081349	C1705943	Class (taxonomic)	clas	3.46
24081349	C0205309	Known	qlco	3.46
24081349	C0205393	Most	qnco	3.43
24081349	C0026882	Mutation	genf	19.58
24081349	C3264621	ivacaftor	orch	13.14
24081349	C3264621	ivacaftor	phsu	13.14
24081349	C0042153	utilization qualifier	ftcn	9.88
24081349	C0040223	Time	tmco	6.76
24081349	C0030705	Patients	podg	6.71
24081349	C0013227	Pharmaceutical Preparations	phsu	5.18
24081349	C1254351	Pharmacologic Substance	phsu	5.18
24081349	C0175566	Open	spco	3.60
24081349	C3541383	Time (foundation metadata concept)	tmco	3.60
24081349	C1159592	transepithelial chloride transport	celf	3.60
24081349	C0205540	Approved	qlco	3.57
24081349	C1720467	Only - dosing instruction fragment	inpr	3.57
24081349	C0205171	Singular	qnco	3.57
24081349	C0457083	Usage	ftcn	3.57
24081349	C1947944	Use - dosing instruction imperative	inpr	3.57
24081349	C2827718	In Vitro Route of Administration	ftcn	3.49
24081349	C0021135	In Vitro [Publication Type]	inpr	3.49
24081349	C1533691	in vitro	qlco	3.49
24081349	C0442805	Increase	ftcn	3.46
24081349	C0205217	Increased	qnco	3.46
24081349	C1705285	Mutation Abnormality	comd	3.43
24081349	C3842590	10%	fndg	3.42
24081349	C0009738	Congo	geoa	16.16
24081349	C3264621	ivacaftor	orch	13.02
24081349	C3264621	ivacaftor	phsu	13.02
24081349	C0004268	Attention	menp	12.89
24081349	C0026882	Mutation	genf	9.73
24081349	C0030705	Patients	podg	6.59
24081349	C3273238	Regulatory Report	inpr	5.18
24081349	C0684224	Report (document)	inpr	5.18
24081349	C0700287	Reporting	hlca	5.18
24081349	C1882115	Normalize	resa	3.55
24081349	C3811819	CFTR wt Allele	gngm	3.55
24081349	C2986411	Improvement	cnce	3.54
24081349	C0428295	Cystic fibrosis sweat test	lbpr	3.45
24081349	C1304760	Sweat chloride level result	lbtr	3.45
24081349	C1516635	Clinical Treatment	topp	3.44
24081349	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.43
24081349	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.43
24081349	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.43
24081349	C0725685	Compleat Liquid Nutrition	food	3.43
24081349	C0205197	Complete	qlco	3.43
24081349	C1446561	Concentration measurement	qnco	3.43
24081349	C3853530	Data operation - complete	ftcn	3.43
24081349	C0086045	Mental concentration	menp	3.43
24081349	C1705285	Mutation Abnormality	comd	3.42
24081349	C0456962	Rapid	qlco	3.42
24081349	C0439230	week	tmco	3.42
24081349	C3264621	ivacaftor	orch	14.64
24081349	C3264621	ivacaftor	phsu	14.64
24081349	C0042153	utilization qualifier	ftcn	9.90
24081349	C0026882	Mutation	genf	9.73
24081349	C0030705	Patients	podg	6.70
24081349	C3539655	CDISC Findings Class	inpr	5.18
24081349	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
24081349	C2607943	findings aspects	ftcn	5.18
24081349	C1705535	suggestion	idcn	5.18
24081349	C0457083	Usage	ftcn	3.59
24081349	C1947944	Use - dosing instruction imperative	inpr	3.59
24081349	C0750591	consider	idcn	3.59
24081349	C0205309	Known	qlco	3.42
28836688	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
28836688	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
28836688	C0021966	Iodides	inch	17.80
28836688	C0010674	Cystic Fibrosis	dsyn	9.95
28836688	C0014609	Epithelium	tisu	6.71
28836688	C0221138	Blood group antibody I	aapp	5.18
28836688	C0221138	Blood group antibody I	imft	5.18
28836688	C0439799	Channel	spco	5.18
28836688	C1706095	Channel Object	cnce	5.18
28836688	C1413365	CFTR gene	gngm	3.68
28836688	C1705285	Mutation Abnormality	comd	3.57
28836688	C0521378	biliary	ftcn	3.56
28836688	C0023884	Liver	bpoc	8.34
28836688	C1278929	Entire liver	bpoc	5.18
28836688	C2346688	Liver Flavor	food	5.18
28836688	C0736268	Liver parenchyma	bpoc	5.18
28836688	C3686472	Biliary epithelial cell	cell	3.59
28836688	C0007465	Cause of Death	fndg	22.57
28836688	C0009738	Congo	geoa	16.16
28836688	C0030705	Patients	podg	6.70
28836688	C1882932	Representation (action)	acty	5.18
28836688	C1859539	Progressive liver disease	fndg	3.73
28836688	C4050444	Cause of death:Find:Pt:^Patient:Nom	clna	3.64
28836688	C3842590	10%	fndg	3.55
28836688	C3811819	CFTR wt Allele	gngm	3.55
28836688	C1709305	Occur (action)	acty	3.55
28836688	C2745955	Occurrence	tmco	3.55
28836688	C0205210	Clinical	qlco	3.46
28836688	C1553058	Neuropsychologist - Clinical	prog	3.46
28836688	C0237412	Psychologist - Clinical	prog	3.46
28836688	C0497591	Social Worker - Clinical	prog	3.46
28836688	C0332152	Before	tmco	3.43
28836688	C1522538	Leading	ftcn	3.43
28836688	C0205437	Third	qnco	3.43
28836688	C0086418	Homo sapiens	humn	28.66
28836688	C0036536	Process of secretion	biof	19.40
28836688	C0162340	Comprehension	menp	13.02
28836688	C0021368	Inflammation	patf	11.49
28836688	C0031847	physiopathological	ftcn	9.74
28836688	C0036537	Bodily secretions	bdsu	6.79
28836688	C0086272	Experimental Model	inpr	6.60
28836688	C0181113	Hamper	mnob	3.98
28836688	C1880177	Contribution	acty	3.59
28836688	C1706202	Search - action	acty	3.56
28836688	C1552603	search - EntityNameUse	inpr	3.56
28836688	C0332268	Lacking	qlco	3.55
28836688	C0221099	Impaired	ftcn	3.48
28836688	C1880198	Cure (remedy)	cnce	3.43
28836688	C0277785	Functional disorder	patf	3.43
28836688	C1441547	Derivation	qlco	3.42
28836688	C3245521	Derived value	idcn	3.42
28836688	C0086418	Homo sapiens	humn	28.79
28836688	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
28836688	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
28836688	C0009738	Congo	geoa	16.18
28836688	C2717959	Induced Pluripotent Stem Cells	cell	14.64
28836688	C0030705	Patients	podg	6.79
28836688	C1292732	Investigates	ftcn	5.18
28836688	C1524063	Use of	ftcn	5.18
28836688	C0441712	Mechanism (attribute)	ftcn	3.68
28836688	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.63
28836688	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.63
28836688	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.63
28836688	C2986479	Healthy Control	qlco	3.60
28836688	C1441547	Derivation	qlco	3.57
28836688	C3245521	Derived value	idcn	3.57
28836688	C3811819	CFTR wt Allele	gngm	3.56
28836688	C0392747	Changing	ftcn	3.56
28836688	C3686472	Biliary epithelial cell	cell	3.53
28836688	C0007634	Cells	cell	3.50
28836688	C0178539	Cellular	lbpr	3.50
28836688	C1413365	CFTR gene	gngm	3.48
28836688	C0086418	Homo sapiens	humn	28.65
28836688	C0007589	Cell Differentiation process	celf	9.73
28836688	C0872351	monolayer	clnd	3.56
28836688	C1507394	Clinical trial protocol document	inpr	3.54
28836688	C1522729	Library Protocol	inpr	3.54
28836688	C3715209	Protocol - answer to question	fndg	3.54
28836688	C0442711	Protocols documentation	inpr	3.54
28836688	C2348563	Study Protocol	inpr	3.54
28836688	C2945687	Differentiation	ftcn	3.42
28836688	C1511938	Histopathologic Grade differentiation	clna	3.42
28836688	C0205314	New	qlco	3.42
28836688	C0679622	literary novel	inpr	3.42
28836688	C3686472	Biliary epithelial cell	cell	3.41
28836688	C0014609	Epithelium	tisu	6.58
28836688	C1547282	Show	anim	5.18
28836688	C0596963	polarity	qnco	5.18
28836688	C2825142	Experimental Result	fndg	3.98
28836688	C1274040	Result	ftcn	3.98
28836688	C1546471	What subject filter - Result	idcn	3.98
28836688	C3686472	Biliary epithelial cell	cell	3.63
28836688	C0544458	Secretion, functional	ftcn	3.58
28836688	C0521378	biliary	ftcn	3.42
28836688	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
28836688	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
28836688	C0086597	Mediate	socb	5.18
28836688	C0127400	Mediator brand of benfluorex hydrochloride	orch	5.18
28836688	C0127400	Mediator brand of benfluorex hydrochloride	phsu	5.18
28836688	C3252847	VX 809	orch	5.18
28836688	C3252847	VX 809	phsu	5.18
28836688	C2263233	body fluid secretion	celf	5.18
28836688	C1413365	CFTR gene	gngm	3.68
28836688	C1150553	cAMP-dependent protein kinase activity	moft	3.68
28836688	C2741958	VX-770	orch	3.64
28836688	C3687832	DRUGS	topp	3.61
28836688	C0013227	Pharmaceutical Preparations	phsu	3.61
28836688	C2349182	Correct (qualifier)	qlco	3.59
28836688	C1273517	Used by	fndg	3.59
28836688	C1561611	Admission Level of Care Code - Improved	inpr	3.57
28836688	C0332272	Better	qlco	3.57
28836688	C0221099	Impaired	ftcn	3.57
28836688	C0184511	Improved	qlco	3.57
28836688	C3686472	Biliary epithelial cell	cell	3.54
28836688	C1328819	Small Molecule	orch	3.50
28836688	C0205448	Two	qnco	3.47
28836688	C0033382	Proline	aapp	32.33
28836688	C0033382	Proline	bacs	32.33
28836688	C0282625	src-Family Kinases	aapp	25.51
28836688	C0282625	src-Family Kinases	enzy	25.51
28836688	C0021966	Iodides	inch	17.80
28836688	C0031715	Phosphorylation	moft	13.02
28836688	C0079904	NF-kappa B	aapp	12.96
28836688	C0079904	NF-kappa B	imft	12.96
28836688	C0333348	inflammatory	ftcn	7.13
28836688	C2987124	Patient Reported Outcome	inpr	6.95
28836688	C0523852	Proline measurement	lbpr	6.95
28836688	C0442805	Increase	ftcn	6.94
28836688	C0205217	Increased	qnco	6.94
28836688	C0221138	Blood group antibody I	aapp	5.18
28836688	C0221138	Blood group antibody I	imft	5.18
28836688	C0332257	Including (qualifier)	ftcn	5.18
28836688	C1336636	TLR4 gene	gngm	5.18
28836688	C1547282	Show	anim	3.98
28836688	C3686472	Biliary epithelial cell	cell	3.63
28836688	C1879547	Activation action	acty	3.61
28836688	C2755608	chemokine secretion	celf	3.58
28836688	C1158886	Protein phosphorylation	moft	3.56
28836688	C0079633	Interleukin-8	aapp	24.11
28836688	C0079633	Interleukin-8	imft	24.11
28836688	C1180307	F-Actin	aapp	16.07
28836688	C1180307	F-Actin	bacs	16.07
28836688	C1698756	CXCL8 protein, human	aapp	14.64
28836688	C1698756	CXCL8 protein, human	bacs	14.64
28836688	C1449159	CCL2 protein, human	aapp	13.14
28836688	C1449159	CCL2 protein, human	imft	13.14
28836688	C1366571	CXCL8 gene	gngm	5.18
28836688	C1705592	IL8 wt Allele	gngm	5.18
28836688	C3541339	Metacarpophalangeal Joint 1	bpoc	3.68
28836688	C3537076	Cytoskeletal Process	celf	3.56
28836688	C1371460	Cytoskeleton Alteration [PE]	celf	3.56
28836688	C1622186	filamentous actin location	celc	3.45
28836688	C0039798	therapeutic aspects	ftcn	22.48
28836688	C0010853	Cytoskeleton	celc	19.25
28836688	C0205216	Decreased	qnco	5.18
28836688	C0442797	Decreasing	qlco	5.18
28836688	C1417819	NPY6R gene	gngm	5.18
28836688	C0392756	Reduced	qlco	5.18
28836688	C0333348	inflammatory	ftcn	5.18
28836688	C0243067	defects aspect	ftcn	3.63
28836688	C1533734	Administration procedure	topp	3.56
28836688	C1705169	Biomaterial Treatment	cnce	3.56
28836688	C0087111	Therapeutic procedure	topp	3.56
28836688	C1522326	Treating	ftcn	3.56
28836688	C3538994	Treatment Epoch	resa	3.56
28836688	C3887704	treatment - ActInformationManagementReason	hlca	3.56
28836688	C1561611	Admission Level of Care Code - Improved	inpr	3.48
28836688	C0332272	Better	qlco	3.48
28836688	C0184511	Improved	qlco	3.48
28836688	C1999216	Inhibitor	qlco	3.43
28836688	C3853644	Proto-Oncogene Tyrosine-Protein Kinase Src, human	aapp	3.43
28836688	C3853644	Proto-Oncogene Tyrosine-Protein Kinase Src, human	enzy	3.43
28836688	C3714800	SCID-Repopulating Cell	cell	3.43
28836688	C3463820	Inhibition	acty	13.03
28836688	C0021467	Psychological inhibition	menp	13.03
28836688	C0021469	Metabolic Inhibition	moft	3.57
28836688	C1628982	Percent inhibition	qnco	3.57
28836688	C2263233	body fluid secretion	celf	3.56
28836688	C0001554	Administration occupational activities	ocac	3.55
28836688	C1533734	Administration procedure	topp	3.55
28836688	C2741958	VX-770	orch	3.45
28836688	C3853644	Proto-Oncogene Tyrosine-Protein Kinase Src, human	aapp	3.44
28836688	C3853644	Proto-Oncogene Tyrosine-Protein Kinase Src, human	enzy	3.44
28836688	C3714800	SCID-Repopulating Cell	cell	3.44
28836688	C3252847	VX 809	orch	3.43
28836688	C3252847	VX 809	phsu	3.43
28836688	C0231683	Gait normal	fndg	3.42
28836688	C0441889	Levels (qualifier value)	qlco	3.42
28836688	C2347086	Mean Percent of Normal	qnco	3.42
28836688	C0205307	Normal	qlco	3.42
28836688	C0439166	Percent normal	qnco	3.42
27469186	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
27469186	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
27469186	C0040363	Togo	geoa	17.80
27469186	C0041260	Tryptophanase	aapp	17.80
27469186	C0041260	Tryptophanase	enzy	17.80
27469186	C0010674	Cystic Fibrosis	dsyn	11.49
27469186	C0012634	Disease	dsyn	9.74
27469186	C1521840	Target	ftcn	5.18
27469186	C2986546	Target Lesion Identification	diap	5.18
27469186	C1883351	To	qlco	5.18
27469186	C0418624	Nonadministration of necessary drug or medicine	fndg	3.70
27469186	C0205540	Approved	qlco	3.57
27469186	C1709060	Modulator Device Component	mnob	3.56
27469186	C1457869	Defect	ftcn	3.56
27469186	C1413365	CFTR gene	gngm	3.55
27469186	C0237401	Individual	humn	3.54
27469186	C0027361	Persons	popg	3.54
27469186	C1709510	Personalized	qlco	3.47
27469186	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.03
27469186	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.03
27469186	C0040363	Togo	geoa	17.80
27469186	C0041260	Tryptophanase	aapp	17.80
27469186	C0041260	Tryptophanase	enzy	17.80
27469186	C0031843	physiological aspects	phsf	14.64
27469186	C0282443	Review [Publication Type]	inpr	11.49
27469186	C1552617	Act Class - review	idcn	5.18
27469186	C0542341	Function	ftcn	5.18
27469186	C0700205	Function Axis	clas	5.18
27469186	C1705273	Mathematical Operator	inpr	5.18
27469186	C1883351	To	qlco	5.18
27469186	C1273517	Used by	fndg	5.18
27469186	C0679199	strategy	menp	5.18
27469186	C0470187	Availability of	ftcn	3.64
27469186	C1709060	Modulator Device Component	mnob	3.54
27469186	C1413365	CFTR gene	gngm	3.44
27469186	C0087111	Therapeutic procedure	topp	3.44
27469186	C0039798	therapeutic aspects	ftcn	44.98
27469186	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27469186	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27469186	C0040363	Togo	geoa	17.80
27469186	C0041260	Tryptophanase	aapp	17.80
27469186	C0041260	Tryptophanase	enzy	17.80
27469186	C0009738	Congo	geoa	16.12
27469186	C0023185	Learning	menp	13.02
27469186	C3264621	ivacaftor	orch	13.02
27469186	C3264621	ivacaftor	phsu	13.02
27469186	C1257890	Population Group	popg	9.99
27469186	C0030695	Patient Monitoring	hlca	9.74
27469186	C0016884	Future	tmco	8.34
27469186	C0087111	Therapeutic procedure	topp	6.90
27469186	C0032659	geographic population	qnco	6.83
27469186	C0449445	Approach	spco	5.18
27469186	C1292724	Procedural approach	ftcn	5.18
27469186	C1883351	To	qlco	5.18
27469186	C2584313	Discussion (communication)	socb	3.98
27469186	C0205342	Responsive	ftcn	3.57
27469186	C0205221	Disseminated	spco	3.56
27469186	C1704632	Disease Response	fndg	3.55
27469186	C2911692	Response (communication)	menp	3.55
27469186	C1706817	Response (statement)	inpr	3.55
27469186	C0871261	Response process	orga	3.55
27469186	C3811819	CFTR wt Allele	gngm	3.50
27469186	C1363945	Therapy Object (animal model)	fndg	3.44
27469186	C1533734	Administration procedure	topp	3.43
27469186	C1705169	Biomaterial Treatment	cnce	3.43
27469186	C0181904	Biomedical Monitors	medd	3.43
27469186	C1413365	CFTR gene	gngm	3.43
27469186	C1704646	Monitor Device Component	mnob	3.43
27469186	C1521743	Monitor, occupation	prog	3.43
27469186	C0596972	Monitoring Device	medd	3.43
27469186	C0150369	Preventive monitoring	hlca	3.43
27469186	C1522326	Treating	ftcn	3.43
27469186	C3538994	Treatment Epoch	resa	3.43
27469186	C3887704	treatment - ActInformationManagementReason	hlca	3.43
27469186	C1709060	Modulator Device Component	mnob	3.41
27469186	C0039798	therapeutic aspects	ftcn	22.48
27469186	C0023671	Life Expectancy	grpa	20.95
27469186	C0009738	Congo	geoa	17.80
27469186	C0040363	Togo	geoa	17.80
27469186	C0041260	Tryptophanase	aapp	17.80
27469186	C0041260	Tryptophanase	enzy	17.80
27469186	C0034380	Quality of life	idcn	14.64
27469186	C0030705	Patients	podg	13.44
27469186	C0012634	Disease	dsyn	11.49
27469186	C0018017	objective (goal)	inpr	11.49
27469186	C1571704	Act Mood - Goal	idcn	5.18
27469186	C3811819	CFTR wt Allele	gngm	5.18
27469186	C0205229	Expanding	spco	5.18
27469186	C1272745	Improving (qualifier value)	qlco	5.18
27469186	C0518214	Perceived quality of life	sosy	5.18
27469186	C1883351	To	qlco	5.18
27469186	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.68
27469186	C0205099	Central	spco	3.68
27469186	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.68
27469186	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.68
27469186	C0087111	Therapeutic procedure	topp	3.56
27469186	C1363945	Therapy Object (animal model)	fndg	3.56
27469186	C1709510	Personalized	qlco	3.43
28666755	C0040363	Togo	geoa	17.80
28666755	C0041260	Tryptophanase	aapp	17.80
28666755	C0041260	Tryptophanase	enzy	17.80
28666755	C0027552	Needs	qlco	13.01
28666755	C1136254	Microbicides	phsu	12.89
28666755	C0010674	Cystic Fibrosis	dsyn	9.77
28666755	C0024109	Lung	bpoc	6.58
28666755	C1883351	To	qlco	5.18
28666755	C2827774	Current Therapy	topp	3.59
28666755	C0027361	Persons	popg	3.56
28666755	C0686904	Patient need for (contextual qualifier)	ftcn	3.55
28666755	C0876973	Infectious disease of lung	dsyn	3.45
28666755	C0151317	Chronic infectious disease	dsyn	3.45
28666755	C2963144	Clear	qlco	3.43
28666755	C1278908	Entire lung	bpoc	3.43
28666755	C1709157	Negative Surgical Margin	fndg	3.43
28666755	C0205314	New	qlco	3.43
28666755	C0819757	Structure of parenchyma of lung	tisu	3.43
28666755	C0205191	chronic	tmco	3.43
28666755	C0009738	Congo	geoa	32.38
28666755	C0039798	therapeutic aspects	ftcn	22.61
28666755	C3264621	ivacaftor	orch	14.64
28666755	C3264621	ivacaftor	phsu	14.64
28666755	C3811819	CFTR wt Allele	gngm	7.00
28666755	C0557651	Room of building - Study	mnob	5.18
28666755	C2603343	Study	resa	5.18
28666755	C1533734	Administration procedure	topp	3.68
28666755	C1705169	Biomaterial Treatment	cnce	3.68
28666755	C0087111	Therapeutic procedure	topp	3.68
28666755	C1522326	Treating	ftcn	3.68
28666755	C3538994	Treatment Epoch	resa	3.68
28666755	C3887704	treatment - ActInformationManagementReason	hlca	3.68
28666755	C1149574	antimicrobial peptide activity	moft	3.63
28666755	C0205314	New	qlco	3.46
28666755	C1704735	Regulator	cnce	3.46
28666755	C1704734	Regulator Device Component	mnob	3.46
28666755	C0182953	Regulators (device)	medd	3.46
28666755	C2752508	fully spanning the plasma membrane	celc	3.46
28666755	C1167322	integral to membrane	celc	3.46
28666755	C0679622	literary novel	inpr	3.46
28666755	C0033809	Pseudomonas aeruginosa	bact	24.11
28666755	C0038172	Staphylococcus aureus	bact	24.11
28666755	C0038402	Streptococcus	bact	16.12
28666755	C0663932	SLPI protein, human	aapp	14.64
28666755	C0663932	SLPI protein, human	imft	14.64
28666755	C0663932	SLPI protein, human	rcpt	14.64
28666755	C0540333	DEFB4A protein, human	aapp	13.20
28666755	C0540333	DEFB4A protein, human	imft	13.20
28666755	C0540333	DEFB4A protein, human	phsu	13.20
28666755	C3264621	ivacaftor	orch	13.02
28666755	C3264621	ivacaftor	phsu	13.02
28666755	C1413106	CAMP gene	gngm	5.18
28666755	C1962990	Pseudomonas aeruginosa (antigen)	imft	5.18
28666755	C1366565	SLPI gene	gngm	5.18
28666755	C1318973	Staphylococcus aureus infection	dsyn	5.18
28666755	C1424276	HM13 gene	gngm	3.68
28666755	C1271650	Antimicrobial activity	lbtr	3.59
28666755	C0457243	Ampere	qnco	3.43
28666755	C0205210	Clinical	qlco	3.43
28666755	C1764827	Isolate - microorganism	bacs	3.43
28666755	C1553058	Neuropsychologist - Clinical	prog	3.43
28666755	C0237412	Psychologist - Clinical	prog	3.43
28666755	C0497591	Social Worker - Clinical	prog	3.43
28666755	C1546767	Specimen Source Codes - Respiratory	inpr	3.43
28666755	C0521346	respiratory	ftcn	3.43
28666755	C0001084	Achromobacter	bact	19.27
28666755	C1424276	HM13 gene	gngm	3.68
28666755	C0318290	Stenotrophomonas maltophilia	bact	24.11
28666755	C0012222	Diffusion	npop	13.14
28666755	C0162388	Killing	socb	12.94
28666755	C0005507	Biological Assay	lbpr	6.75
28666755	C0040223	Time	tmco	6.63
28666755	C1524063	Use of	ftcn	5.18
28666755	C1696141	Diffusion - RouteOfAdministration	ftcn	3.68
28666755	C1510438	Assay	lbpr	3.59
28666755	C0243073	assay qualifier	qlco	3.59
28666755	C0920847	Circumpennate	cnce	3.50
28666755	C0442038	Radial	cnce	3.50
28666755	C0681205	Sacrifice	idcn	3.48
28666755	C3541383	Time (foundation metadata concept)	tmco	3.48
28666755	C1550555	kill - ActRelationshipJoin	ftcn	3.48
28666755	C0040341	Tobramycin	antb	39.00
28666755	C0040341	Tobramycin	orch	39.00
28666755	C0026809	Mus	mamm	28.71
28666755	C3264621	ivacaftor	orch	26.07
28666755	C3264621	ivacaftor	phsu	26.07
28666755	C0162388	Killing	socb	13.03
28666755	C0009450	Communicable Diseases	dsyn	9.78
28666755	C0040223	Time	tmco	6.72
28666755	C3714514	Infection	patf	6.63
28666755	C1707455	Comparison	acty	5.18
28666755	C1524063	Use of	ftcn	5.18
28666755	C3853906	Digital Model Attachment	inpr	3.63
28666755	C3161035	Model	inpr	3.63
28666755	C3714583	Model - style/design	cnce	3.63
28666755	C3274659	Model Number	inpr	3.63
28666755	C0681205	Sacrifice	idcn	3.57
28666755	C3541383	Time (foundation metadata concept)	tmco	3.57
28666755	C1550555	kill - ActRelationshipJoin	ftcn	3.57
28666755	C1561536	*Activity (kind of quantity)	idcn	3.55
28666755	C0205177	Active	ftcn	3.55
28666755	C0441655	Activities	acty	3.55
28666755	C3668946	Activity (animal life circumstance)	fndg	3.55
28666755	C4049939	FDA Establishment Activity Terminology	inpr	3.55
28666755	C0439167	Percent Activity	qnco	3.55
28666755	C4049938	Physical Activity Measurement	lbpr	3.55
28666755	C1515655	in vivo	spco	3.45
28666755	C1413106	CAMP gene	gngm	3.44
28666755	C0033727	Protons	elii	19.27
28666755	C0392366	Tests (qualifier value)	inpr	5.18
28666755	C2732473	Ductal Carcinoma In Situ with Microinvasion	neop	3.98
28666755	C0427978	Minimum Inhibitory Concentration measurement	lbpr	3.98
28666755	C0281162	cisplatin/ifosfamide/mitomycin protocol	topp	3.98
28666755	C1413106	CAMP gene	gngm	3.68
28666755	C0457243	Ampere	qnco	3.63
28666755	C3542016	Concept model range (foundation metadata concept)	inpr	3.55
28666755	C1514721	Range	qnco	3.55
28666755	C2348147	Sample Range	qnco	3.55
28666755	C0564385	/hour	qnco	3.50
28666755	C0369286	H NOS Antibodies	aapp	3.50
28666755	C0369286	H NOS Antibodies	imft	3.50
28666755	C0441932	Hepatic Involvement	clas	3.50
28666755	C0205177	Active	ftcn	3.48
28666755	C3888249	Active License	qlco	3.48
28666755	C0205393	Most	qnco	3.48
28666755	C3853793	active (HL7 RoleLink)	idcn	3.48
28666755	C3838679	4+ Answer to question	fndg	5.18
28666755	C0439339	Unit per Liter	qnco	3.74
28666755	C0001084	Achromobacter	bact	20.95
28666755	C2827757	Antimicrobial Resistance Result	lbtr	5.18
28666755	C1514892	Resistance Process	phsf	5.18
28666755	C0332325	Resistant (qualifier value)	ftcn	5.18
28666755	C1550464	resistant - Observation Interpretation Susceptibility	idcn	5.18
28666755	C0439339	Unit per Liter	qnco	3.74
28666755	C0663932	SLPI protein, human	aapp	14.64
28666755	C0663932	SLPI protein, human	imft	14.64
28666755	C0663932	SLPI protein, human	rcpt	14.64
28666755	C1271650	Antimicrobial activity	lbtr	5.18
28666755	C1366565	SLPI gene	gngm	5.18
28666755	C0456685	U/hour	qnco	3.53
28666755	C0040341	Tobramycin	antb	19.22
28666755	C0040341	Tobramycin	orch	19.22
28666755	C1413106	CAMP gene	gngm	3.68
28666755	C0450367	4/5	qnco	3.53
28666755	C0038402	Streptococcus	bact	16.08
28666755	C1424276	HM13 gene	gngm	3.61
28666755	C0450346	2/5	qnco	3.50
28666755	C1875400	ISOLATE COMPOUND	phsu	5.18
28666755	C1764827	Isolate - microorganism	bacs	5.18
28666755	C0038402	Streptococcus	bact	16.05
28666755	C3264621	ivacaftor	orch	13.14
28666755	C3264621	ivacaftor	phsu	13.14
28666755	C0544570	Bactericidal activity	phsf	3.61
28666755	C1424276	HM13 gene	gngm	3.43
28666755	C0547047	Decrease	qnco	3.61
28666755	C2347634	Population Mean	qnco	3.61
28666755	C0392756	Reduced	qlco	3.61
28666755	C2348143	Sample Mean	qnco	3.61
28666755	C0444504	Statistical mean	qnco	3.61
28666755	C1690986	log10	qnco	3.61
28666755	C1880521	Enzyme Unit per Milliliter	qnco	3.76
28666755	C0439340	Kilounit per Liter	qnco	3.76
28666755	C2945590	Unit per Milliliter	qnco	3.76
28666755	C1561536	*Activity (kind of quantity)	idcn	3.57
28666755	C0205177	Active	ftcn	3.57
28666755	C0441655	Activities	acty	3.57
28666755	C3668946	Activity (animal life circumstance)	fndg	3.57
28666755	C4049939	FDA Establishment Activity Terminology	inpr	3.57
28666755	C0439167	Percent Activity	qnco	3.57
28666755	C4049938	Physical Activity Measurement	lbpr	3.57
28666755	C0450355	31	inpr	3.47
28666755	C3842591	0%	fndg	3.61
28666755	C0443172	Changed status	qnco	3.61
28666755	C0392747	Changing	ftcn	3.61
28666755	C1705241	Delta (difference)	qnco	3.61
28666755	C2347634	Population Mean	qnco	3.61
28666755	C2348143	Sample Mean	qnco	3.61
28666755	C0444504	Statistical mean	qnco	3.61
28666755	C1690986	log10	qnco	3.61
28666755	C1880521	Enzyme Unit per Milliliter	qnco	3.76
28666755	C0439340	Kilounit per Liter	qnco	3.76
28666755	C2945590	Unit per Milliliter	qnco	3.76
28666755	C1561536	*Activity (kind of quantity)	idcn	3.56
28666755	C0205177	Active	ftcn	3.56
28666755	C0441655	Activities	acty	3.56
28666755	C3668946	Activity (animal life circumstance)	fndg	3.56
28666755	C4049939	FDA Establishment Activity Terminology	inpr	3.56
28666755	C0439167	Percent Activity	qnco	3.56
28666755	C4049938	Physical Activity Measurement	lbpr	3.56
28666755	C1708235	Genus	clas	3.41
28666755	C0040341	Tobramycin	antb	19.20
28666755	C0040341	Tobramycin	orch	19.20
28666755	C3264621	ivacaftor	orch	12.89
28666755	C3264621	ivacaftor	phsu	12.89
28666755	C1690986	log10	qnco	3.68
28666755	C0547047	Decrease	qnco	3.59
28666755	C0442797	Decreasing	qlco	3.59
28666755	C0392756	Reduced	qlco	3.59
28666755	C2347634	Population Mean	qnco	3.50
28666755	C2348143	Sample Mean	qnco	3.50
28666755	C0444504	Statistical mean	qnco	3.50
28666755	C0728893	+5	qnco	5.18
28666755	C0439084	>5	qnco	5.18
28666755	C1880521	Enzyme Unit per Milliliter	qnco	3.76
28666755	C0439340	Kilounit per Liter	qnco	3.76
28666755	C2945590	Unit per Milliliter	qnco	3.76
28666755	C2603362	S prime	clna	5.18
28666755	C0565930	per second	qnco	5.18
28666755	C1880521	Enzyme Unit per Milliliter	qnco	3.57
28666755	C0439340	Kilounit per Liter	qnco	3.57
28666755	C2945590	Unit per Milliliter	qnco	3.57
28666755	C0038402	Streptococcus	bact	16.12
28666755	C1424276	HM13 gene	gngm	3.68
28666755	C3264621	ivacaftor	orch	13.14
28666755	C3264621	ivacaftor	phsu	13.14
28666755	C1271650	Antimicrobial activity	lbtr	3.59
28666755	C0026809	Mus	mamm	28.69
28666755	C0009450	Communicable Diseases	dsyn	9.76
28666755	C3714514	Infection	patf	6.61
28666755	C1515657	In Vivo Model	resa	3.69
28666755	C0040363	Togo	geoa	35.81
28666755	C0041260	Tryptophanase	aapp	35.81
28666755	C0041260	Tryptophanase	enzy	35.81
28666755	C0009738	Congo	geoa	17.80
28666755	C3264621	ivacaftor	orch	14.64
28666755	C3264621	ivacaftor	phsu	14.64
28666755	C1883351	To	qlco	10.42
28666755	C0035243	Respiratory Tract Infections	dsyn	9.77
28666755	C1561536	*Activity (kind of quantity)	idcn	5.18
28666755	C0205177	Active	ftcn	5.18
28666755	C0441655	Activities	acty	5.18
28666755	C3668946	Activity (animal life circumstance)	fndg	5.18
28666755	C0457243	Ampere	qnco	5.18
28666755	C3811819	CFTR wt Allele	gngm	5.18
28666755	C2349975	Enhance (action)	acty	5.18
28666755	C4049939	FDA Establishment Activity Terminology	inpr	5.18
28666755	C0332282	Following	tmco	5.18
28666755	C0205217	Increased	qnco	5.18
28666755	C0439167	Percent Activity	qnco	5.18
28666755	C4049938	Physical Activity Measurement	lbpr	5.18
28666755	C0231290	Status post	tmco	5.18
28666755	C0443264	Modulated	spco	3.68
28666755	C0338237	Antibiotic therapy	topp	3.61
28666755	C3245505	potential	qlco	3.57
28666755	C1517331	Further	spco	3.50
28666755	C0237400	Actual	qlco	3.44
28666755	C3272377	Real Data Type	inpr	3.44
28666755	C0723712	Therapeutic brand of coal tar	orch	3.44
28666755	C0723712	Therapeutic brand of coal tar	phsu	3.44
28666755	C0087111	Therapeutic procedure	topp	3.44
28366727	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
28366727	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
28366727	C0043240	Wound Healing	orgf	14.64
28366727	C0010674	Cystic Fibrosis	dsyn	10.06
28366727	C0015127	Etiology aspects	ftcn	9.94
28366727	C1550043	Container status - Identified	fndg	5.18
28366727	C0205396	Identified	qlco	5.18
28366727	C2347098	Medical Product Stability	qlco	5.18
28366727	C0205360	Stable status	qlco	5.18
28366727	C0374711	Surgical repair	topp	5.18
28366727	C1524003	Science of Etiology	cnce	3.63
28366727	C0243067	defects aspect	ftcn	3.59
28366727	C1413365	CFTR gene	gngm	3.56
28366727	C0449788	Count of entities	qnco	3.56
28366727	C0237753	Numbers	qnco	3.56
28366727	C1709694	Processing (action)	acty	3.56
28366727	C0596988	mutant	comd	3.56
28366727	C0599896	trafficking	celf	3.56
28366727	C0185026	Plication	topp	3.45
28366727	C0549177	Large	qnco	3.43
28366727	C3264621	ivacaftor	orch	14.64
28366727	C3264621	ivacaftor	phsu	14.64
28366727	C3852684	lumacaftor	orch	14.64
28366727	C3852684	lumacaftor	phsu	14.64
28366727	C3252847	VX 809	orch	5.18
28366727	C3252847	VX 809	phsu	5.18
28366727	C1555307	promise	idcn	5.18
28366727	C1547282	Show	anim	3.98
28366727	C0205195	Combined	qlco	3.59
28366727	C1273517	Used by	fndg	3.59
28366727	C3811910	combination - answer to question	fndg	3.59
28366727	C1947911	combination of objects	phob	3.59
28366727	C1522427	best (quality)	qlco	3.50
28366727	C0162340	Comprehension	menp	14.64
28366727	C0441712	Mechanism (attribute)	ftcn	3.56
28366727	C1706376	Mechanism Component of Device	mnob	3.56
28366727	C0205224	Essential	qlco	3.55
28366727	C3252847	VX 809	orch	3.46
28366727	C3252847	VX 809	phsu	3.46
28366727	C0332272	Better	qlco	3.43
28366727	C0678723	Biologic Development	orgf	3.43
28366727	C1527148	Development	ftcn	3.43
28366727	C0243107	development aspects	phsf	3.43
28366727	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
28366727	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
28366727	C0043240	Wound Healing	orgf	12.93
28366727	C0010834	Cytoplasm	celc	12.88
28366727	C0205435	First (number)	qnco	6.93
28366727	C1279901	Firstly	qlco	6.93
28366727	C1413927	DCLK1 gene	gngm	5.18
28366727	C0392366	Tests (qualifier value)	inpr	5.18
28366727	C0681842	prediction	idcn	5.18
28366727	C1519623	Transmembrane Domain	amas	3.75
28366727	C1148916	nucleotide binding	moft	3.68
28366727	C3541951	Concept model domain	inpr	3.61
28366727	C1880389	Domain (area of knowledge)	ftcn	3.61
28366727	C0185026	Plication	topp	3.61
28366727	C1883221	Superkingdom (taxonomic category)	cnce	3.61
28366727	C0243067	defects aspect	ftcn	3.57
28366727	C1704675	Interaction	ftcn	3.51
28366727	C3252847	VX 809	orch	3.50
28366727	C3252847	VX 809	phsu	3.50
28366727	C0374711	Surgical repair	topp	3.47
28366727	C1413365	CFTR gene	gngm	3.44
28366727	C1709694	Processing (action)	acty	3.44
28366727	C0521449	Cytoplasmic	blor	3.42
28366727	C0445022	Loop	spco	3.42
28366727	C0033414	Promotion (action)	acty	3.42
28366727	C0010654	Cysteine	aapp	26.00
28366727	C0010654	Cysteine	bacs	26.00
28366727	C0012771	Disulfides	chvs	20.95
28366727	C0040363	Togo	geoa	17.80
28366727	C0041260	Tryptophanase	aapp	17.80
28366727	C0041260	Tryptophanase	enzy	17.80
28366727	C1524024	analysis aspect	ftcn	13.02
28366727	C0684010	Rabbi	prog	12.93
28366727	C0079866	Mutagenesis Process	moft	9.99
28366727	C1709915	Residue	cnce	7.23
28366727	C1882936	Residue after Decontamination Medical Device Problem	evnt	7.23
28366727	C0332220	Cross-linking	ftcn	5.18
28366727	C1292732	Investigates	ftcn	5.18
28366727	C0884358	Performed	ftcn	5.18
28366727	C1883351	To	qlco	5.18
28366727	C3146302	Mutagenesis Procedure	lbpr	3.68
28366727	C0596988	mutant	comd	3.68
28366727	C1704675	Interaction	ftcn	3.56
28366727	C0936012	Analysis	resa	3.56
28366727	C0002778	Analysis of substances	lbpr	3.56
28366727	C1706395	Protein Truncation Abnormality	comd	3.50
28366727	C3252847	VX 809	orch	3.48
28366727	C3252847	VX 809	phsu	3.48
28366727	C2603358	R prime	clna	3.47
28366727	C0205090	Right	spco	3.47
28366727	C1413927	DCLK1 gene	gngm	3.46
28366727	C0033414	Promotion (action)	acty	3.43
28366727	C0018042	Golgi Apparatus	celc	24.11
28366727	C0014239	Endoplasmic Reticulum	celc	22.49
28366727	C3245499	Colombia	geoa	13.01
28366727	C0150312	Present	qnco	7.45
28366727	C3252847	VX 809	orch	5.18
28366727	C3252847	VX 809	phsu	5.18
28366727	C1254042	Anatomical maturation	phsf	3.68
28366727	C0678723	Biologic Development	orgf	3.68
28366727	C0870861	Human maturation	phpr	3.68
28366727	C0596988	mutant	comd	3.61
28366727	C3854307	Presence (property)	qlco	3.55
28366727	C0392148	Providing presence (regime/therapy)	topp	3.55
28366727	C0033414	Promotion (action)	acty	3.48
28366727	C1518422	Negation	ftcn	3.48
28366727	C1720467	Only - dosing instruction fragment	inpr	3.47
28366727	C1706395	Protein Truncation Abnormality	comd	3.47
28366727	C0205171	Singular	qnco	3.47
28366727	C0556154	Complex carbohydrate	orch	3.44
28366727	C1883712	Add - instruction imperative	ftcn	3.42
28366727	C0337094	Exit	spco	3.42
28366727	C0332287	In addition to	ftcn	3.42
28366727	C0033684	Proteins	aapp	6.59
28366727	C0033684	Proteins	bacs	6.59
28366727	C0332220	Cross-linking	ftcn	3.64
28366727	C1413927	DCLK1 gene	gngm	3.56
28366727	C3854321	Expression (foundation metadata concept)	idcn	3.54
28366727	C0185117	Expression procedure	topp	3.54
28366727	C1514568	Protein Truncation	moft	3.44
28366727	C1706395	Protein Truncation Abnormality	comd	3.44
28366727	C3252847	VX 809	orch	3.43
28366727	C3252847	VX 809	phsu	3.43
28366727	C3854307	Presence (property)	qlco	3.42
28366727	C0150312	Present	qnco	3.42
28366727	C0392148	Providing presence (regime/therapy)	topp	3.42
28366727	C0033414	Promotion (action)	acty	3.40
28366727	C0018517	Half-Life	tmco	9.88
28366727	C0007634	Cells	cell	5.18
28366727	C3282337	Cells [Chemical/Ingredient]	cell	5.18
28366727	C0442805	Increase	ftcn	5.18
28366727	C0205217	Increased	qnco	5.18
28366727	C3252847	VX 809	orch	5.18
28366727	C3252847	VX 809	phsu	5.18
28366727	C3854307	Presence (property)	qlco	3.56
28366727	C0150312	Present	qnco	3.56
28366727	C0392148	Providing presence (regime/therapy)	topp	3.56
28366727	C3854321	Expression (foundation metadata concept)	idcn	3.55
28366727	C0185117	Expression procedure	topp	3.55
28366727	C1706395	Protein Truncation Abnormality	comd	3.42
28366727	C0596988	mutant	comd	3.42
28366727	C1660003	protein maturation	celf	3.42
28366727	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
28366727	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
28366727	C0033414	Promotion (action)	acty	7.46
28366727	C1254042	Anatomical maturation	phsf	5.18
28366727	C0678723	Biologic Development	orgf	5.18
28366727	C0870861	Human maturation	phpr	5.18
28366727	C1705535	suggestion	idcn	5.18
28366727	C2825142	Experimental Result	fndg	3.98
28366727	C1274040	Result	ftcn	3.98
28366727	C1546471	What subject filter - Result	idcn	3.98
28366727	C2347098	Medical Product Stability	qlco	3.59
28366727	C0205360	Stable status	qlco	3.59
28366727	C1413927	DCLK1 gene	gngm	3.55
28366727	C0441712	Mechanism (attribute)	ftcn	3.55
28366727	C1706376	Mechanism Component of Device	mnob	3.55
28366727	C1704675	Interaction	ftcn	3.52
28366727	C1413365	CFTR gene	gngm	3.45
28366727	C3252847	VX 809	orch	3.45
28366727	C3252847	VX 809	phsu	3.45
24251786	C0040363	Togo	geoa	35.81
24251786	C0041260	Tryptophanase	aapp	35.81
24251786	C0041260	Tryptophanase	enzy	35.81
24251786	C0242612	Codon, Nonsense	nusq	22.48
24251786	C0015127	Etiology aspects	ftcn	19.82
24251786	C0027552	Needs	qlco	14.64
24251786	C0012634	Disease	dsyn	11.49
24251786	C1883351	To	qlco	10.42
24251786	C0010674	Cystic Fibrosis	dsyn	9.76
24251786	C1524003	Science of Etiology	cnce	7.13
24251786	C2349975	Enhance (action)	acty	5.18
24251786	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
24251786	C0087111	Therapeutic procedure	topp	5.18
24251786	C1522326	Treating	ftcn	5.18
24251786	C1292734	Treatment intent	ftcn	5.18
24251786	C1718097	New medications	phsu	3.75
24251786	C0544885	Nonsense mutation	comd	3.64
24251786	C0439181	% suppression	qnco	3.61
24251786	C0301625	Metabolic Suppression	orgf	3.61
24251786	C0728721	Psychological suppression	menp	3.61
24251786	C0221103	Visual Suppression	patf	3.61
24251786	C0009738	Congo	geoa	16.04
24251786	C0002556	Aminoglycosides	orch	9.77
24251786	C0002556	Aminoglycosides	phsu	9.77
24251786	C3853906	Digital Model Attachment	inpr	5.18
24251786	C3161035	Model	inpr	5.18
24251786	C3714583	Model - style/design	cnce	5.18
24251786	C3274659	Model Number	inpr	5.18
24251786	C0392366	Tests (qualifier value)	inpr	5.18
24251786	C0243072	derivatives	chvs	3.61
24251786	C0439181	% suppression	qnco	3.57
24251786	C4048286	Coagulation Factor V, Human	aapp	3.57
24251786	C4048286	Coagulation Factor V, Human	bacs	3.57
24251786	C0301625	Metabolic Suppression	orgf	3.57
24251786	C0728721	Psychological suppression	menp	3.57
24251786	C0221103	Visual Suppression	patf	3.57
24251786	C0724584	coagulation factor IX, human	aapp	3.57
24251786	C0724584	coagulation factor IX, human	bacs	3.57
24251786	C0724584	coagulation factor IX, human	phsu	3.57
24251786	C4048712	factor IX complex	aapp	3.57
24251786	C4048712	factor IX complex	bacs	3.57
24251786	C4048712	factor IX complex	phsu	3.57
24251786	C0205549	Series	qnco	3.55
24251786	C2348044	Series - set of composite instances	inpr	3.55
24251786	C3536835	Aminoglycoside [EPC]	phsu	3.47
24251786	C0003233	Antibiotics, Aminoglycoside	antb	3.47
24251786	C0003233	Antibiotics, Aminoglycoside	orch	3.47
24251786	C0205314	New	qlco	3.47
24251786	C1883254	Synthesis	acty	3.47
24251786	C3811819	CFTR wt Allele	gngm	3.43
24251786	C0009221	Codon (nucleotide sequence)	nusq	22.47
24251786	C0033105	Statistical Prevalence	qnco	22.33
24251786	C0004793	Base Sequence	nusq	16.25
24251786	C0162326	DNA Sequence	nusq	16.25
24251786	C0162327	RNA Sequence	nusq	16.25
24251786	C0009738	Congo	geoa	16.07
24251786	C0024075	Luciferases	aapp	12.93
24251786	C0024075	Luciferases	enzy	12.93
24251786	C0024075	Luciferases	irda	12.93
24251786	C4048286	Coagulation Factor V, Human	aapp	7.05
24251786	C4048286	Coagulation Factor V, Human	bacs	7.05
24251786	C0724584	coagulation factor IX, human	aapp	7.05
24251786	C0724584	coagulation factor IX, human	bacs	7.05
24251786	C0724584	coagulation factor IX, human	phsu	7.05
24251786	C4048712	factor IX complex	aapp	7.05
24251786	C4048712	factor IX complex	bacs	7.05
24251786	C4048712	factor IX complex	phsu	7.05
24251786	C2700400	Contain (action)	acty	5.18
24251786	C0332256	Containing (qualifier)	ftcn	5.18
24251786	C0150312	Present	qnco	5.18
24251786	C1524063	Use of	ftcn	5.18
24251786	C0033414	Promotion (action)	acty	3.98
24251786	C0449255	Context	fndg	3.63
24251786	C1519249	Sequence	ftcn	3.63
24251786	C3853789	Sequence - TransmissionRelationshipTypeCode	inpr	3.63
24251786	C0542559	contextual factors	ftcn	3.63
24251786	C1704459	Device Component System	mnob	3.61
24251786	C0449913	System	ftcn	3.61
24251786	C1553451	System - kit	mnob	3.61
24251786	C0544885	Nonsense mutation	comd	3.61
24251786	C1095825	Codon Genus	plnt	3.54
24251786	C0205276	Local	spco	3.48
24251786	C1554184	Dual	anim	3.47
24251786	C1709908	Reported By	grup	3.47
24251786	C0335038	Reporter (occupation)	prog	3.47
24251786	C1705915	Reporter Object	cnce	3.47
24251786	C1522485	Tracer	irda	3.47
24251786	C3811819	CFTR wt Allele	gngm	3.45
24251786	C0205450	Four	qnco	3.45
24251786	C1704735	Regulator	cnce	3.45
24251786	C1704734	Regulator Device Component	mnob	3.45
24251786	C0182953	Regulators (device)	medd	3.45
24251786	C2752508	fully spanning the plasma membrane	celc	3.45
24251786	C1167322	integral to membrane	celc	3.45
24251786	C0205393	Most	qnco	3.43
24251786	C0441987	Side	spco	3.42
24251786	C0205449	Three	qnco	3.42
24251786	C0220900	Prevalence aspects	qnco	3.41
24251786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.12
24251786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.12
24251786	C0034703	Rats, Inbred F344	mamm	28.68
24251786	C0282641	Transgenes	gngm	19.32
24251786	C3854019	Gentamicin	antb	12.91
24251786	C3854019	Gentamicin	orch	12.91
24251786	C0546866	Gentamicin Sulfate (USP)	antb	12.91
24251786	C0546866	Gentamicin Sulfate (USP)	orch	12.91
24251786	C0002556	Aminoglycosides	orch	11.49
24251786	C0002556	Aminoglycosides	phsu	11.49
24251786	C0040132	Thyroid Gland	bpoc	9.73
24251786	C1413365	CFTR gene	gngm	7.05
24251786	C0003233	Antibiotics, Aminoglycoside	antb	5.18
24251786	C0003233	Antibiotics, Aminoglycoside	orch	5.18
24251786	C0392366	Tests (qualifier value)	inpr	5.18
24251786	C3854321	Expression (foundation metadata concept)	idcn	3.61
24251786	C0185117	Expression procedure	topp	3.61
24251786	C1282910	Upper	spco	3.59
24251786	C1159591	chloride transport	celf	3.58
24251786	C0443225	Full	qlco	3.47
24251786	C1444754	Length	qnco	3.47
24251786	C1706316	Length of Trial	resa	3.47
24251786	C0007634	Cells	cell	3.42
24251786	C3282337	Cells [Chemical/Ingredient]	cell	3.42
24251786	C3540038	THYROID DIAGNOSTIC RADIOPHARMACEUTICALS	irda	3.42
24251786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.29
24251786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.29
24251786	C0086418	Homo sapiens	humn	28.69
24251786	C0040363	Togo	geoa	16.16
24251786	C0041260	Tryptophanase	aapp	16.16
24251786	C0041260	Tryptophanase	enzy	16.16
24251786	C0009738	Congo	geoa	16.07
24251786	C0031843	physiological aspects	phsf	14.64
24251786	C1413365	CFTR gene	gngm	7.21
24251786	C0542341	Function	ftcn	5.18
24251786	C0700205	Function Axis	clas	5.18
24251786	C1705273	Mathematical Operator	inpr	5.18
24251786	C1711178	Bronchial Epithelial Cell	cell	3.67
24251786	C0459205	Type of activity	inpr	3.60
24251786	C1514292	Pre-Clinical Model	inpr	3.56
24251786	C1883351	To	qlco	3.55
24251786	C0445392	Wild	inpr	3.55
24251786	C3811819	CFTR wt Allele	gngm	3.46
24251786	C0205225	Primary	qlco	3.46
24251786	C0439631	Primary operation	topp	3.46
24251786	C0439612	True primary (qualifier value)	tmco	3.46
24251786	C0205227	Endogenous	ftcn	3.42
24251786	C3854321	Expression (foundation metadata concept)	idcn	3.42
24251786	C0185117	Expression procedure	topp	3.42
24251786	C0205250	High	qlco	3.42
24251786	C2347946	Relevance	qlco	3.42
24251786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
24251786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
24251786	C3264621	ivacaftor	orch	14.64
24251786	C3264621	ivacaftor	phsu	14.64
24251786	C1517331	Further	spco	5.18
24251786	C2741958	VX-770	orch	5.18
24251786	C0007634	Cells	cell	3.68
24251786	C3282337	Cells [Chemical/Ingredient]	cell	3.68
24251786	C1280519	Effectiveness	qlco	3.68
24251786	C1707887	Efficacy Study	resa	3.68
24251786	C4048286	Coagulation Factor V, Human	aapp	3.63
24251786	C4048286	Coagulation Factor V, Human	bacs	3.63
24251786	C0724584	coagulation factor IX, human	aapp	3.63
24251786	C0724584	coagulation factor IX, human	bacs	3.63
24251786	C0724584	coagulation factor IX, human	phsu	3.63
24251786	C4048712	factor IX complex	aapp	3.63
24251786	C4048712	factor IX complex	bacs	3.63
24251786	C4048712	factor IX complex	phsu	3.63
24251786	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.58
24251786	C1883712	Add - instruction imperative	ftcn	3.55
24251786	C2349975	Enhance (action)	acty	3.55
24251786	C0332287	In addition to	ftcn	3.55
24251786	C0458827	Airway structure	bpoc	3.50
24251786	C0178987	Artificial Airways	medd	3.50
24251786	C1413365	CFTR gene	gngm	3.50
24251786	C0086418	Homo sapiens	humn	28.70
24251786	C0206610	Mice, Inbred CFTR	mamm	28.66
24251786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
24251786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
24251786	C0282641	Transgenes	gngm	19.38
24251786	C0040710	Translating	ocac	16.18
24251786	C0015272	Exhibits as Topic	inpr	16.06
24251786	C0009738	Congo	geoa	16.03
24251786	C0031843	physiological aspects	phsf	13.00
24251786	C3854019	Gentamicin	antb	12.91
24251786	C3854019	Gentamicin	orch	12.91
24251786	C0546866	Gentamicin Sulfate (USP)	antb	12.91
24251786	C0546866	Gentamicin Sulfate (USP)	orch	12.91
24251786	C1280519	Effectiveness	qlco	5.18
24251786	C1707887	Efficacy Study	resa	5.18
24251786	C1515655	in vivo	spco	5.18
24251786	C1705535	suggestion	idcn	3.98
24251786	C1292721	Has property	ftcn	3.61
24251786	C0871161	Property (attribute)	qlco	3.61
24251786	C2825142	Experimental Result	fndg	3.59
24251786	C1274040	Result	ftcn	3.59
24251786	C1546471	What subject filter - Result	idcn	3.59
24251786	C1282910	Upper	spco	3.59
24251786	C0205210	Clinical	qlco	3.57
24251786	C1553058	Neuropsychologist - Clinical	prog	3.57
24251786	C0237412	Psychologist - Clinical	prog	3.57
24251786	C0497591	Social Worker - Clinical	prog	3.57
24251786	C0814225	benefit	qnco	3.57
24251786	C0542341	Function	ftcn	3.54
24251786	C0700205	Function Axis	clas	3.54
24251786	C1705273	Mathematical Operator	inpr	3.54
24251786	C2827718	In Vitro Route of Administration	ftcn	3.53
24251786	C0021135	In Vitro [Publication Type]	inpr	3.53
24251786	C1533691	in vitro	qlco	3.53
24251786	C1413365	CFTR gene	gngm	3.47
24251786	C3640814	Favorable	qlco	3.47
24251786	C0201734	Pharmacokinetic study	resa	3.47
24251786	C0679845	treatment model	inpr	3.43
24251786	C3811819	CFTR wt Allele	gngm	3.42
24251786	C3854019	Gentamicin	antb	12.89
24251786	C3854019	Gentamicin	orch	12.89
24251786	C0546866	Gentamicin Sulfate (USP)	antb	12.89
24251786	C0546866	Gentamicin Sulfate (USP)	orch	12.89
24251786	C1519523	Tissue Model	emod	3.57
24251786	C0677881	Cytotoxic Chemotherapy	topp	3.56
24251786	C1511636	cytotoxic	ftcn	3.56
24251786	C1705938	Base - General Qualifier	idcn	3.42
24251786	C1527178	Basis - conceptual entity	ftcn	3.42
24251786	C0235280	Ototoxicity	inpo	3.42
24251786	C0039798	therapeutic aspects	ftcn	22.46
24251786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
24251786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
24251786	C0002556	Aminoglycosides	orch	20.04
24251786	C0002556	Aminoglycosides	phsu	20.04
24251786	C0079411	Generations	tmco	16.09
24251786	C3854019	Gentamicin	antb	14.64
24251786	C3854019	Gentamicin	orch	14.64
24251786	C0546866	Gentamicin Sulfate (USP)	antb	14.64
24251786	C0546866	Gentamicin Sulfate (USP)	orch	14.64
24251786	C0052080	antineoplaston A10	orch	12.91
24251786	C0052080	antineoplaston A10	phsu	12.91
24251786	C1999230	Providing (action)	acty	12.80
24251786	C0003233	Antibiotics, Aminoglycoside	antb	7.35
24251786	C0003233	Antibiotics, Aminoglycoside	orch	7.35
24251786	C3887511	Evidence	idcn	5.18
24251786	C2825142	Experimental Result	fndg	3.98
24251786	C1274040	Result	ftcn	3.98
24251786	C1546471	What subject filter - Result	idcn	3.98
24251786	C2986411	Improvement	cnce	3.55
24251786	C1533734	Administration procedure	topp	3.54
24251786	C1705169	Biomaterial Treatment	cnce	3.54
24251786	C0087111	Therapeutic procedure	topp	3.54
24251786	C1522326	Treating	ftcn	3.54
24251786	C3538994	Treatment Epoch	resa	3.54
24251786	C3887704	treatment - ActInformationManagementReason	hlca	3.54
24251786	C1883254	Synthesis	acty	3.50
24251786	C0205435	First (number)	qnco	3.48
24251786	C1279901	Firstly	qlco	3.48
24251786	C3146294	Generation (action)	acty	3.48
24251786	C0678793	therapeutic index	qnco	3.44
24251786	C0544885	Nonsense mutation	comd	3.43
24251786	C1880834	Fold in Medical Device Material	phpr	3.42
24251786	C0332462	Folded structure	spco	3.42
24251786	C1510941	Array	spco	3.42
24251786	C1413365	CFTR gene	gngm	3.42
24251786	C0332464	Widening	spco	3.42
24251786	C1555307	promise	idcn	3.40
23818513	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
23818513	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
23818513	C0031843	physiological aspects	phsf	13.01
23818513	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	12.93
23818513	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	12.93
23818513	C0003075	Anions	elii	12.93
23818513	C0010674	Cystic Fibrosis	dsyn	10.06
23818513	C0026882	Mutation	genf	9.86
23818513	C0015127	Etiology aspects	ftcn	9.83
23818513	C0851285	Regulation	gora	9.77
23818513	C0033684	Proteins	aapp	6.75
23818513	C0033684	Proteins	bacs	6.75
23818513	C0014609	Epithelium	tisu	6.67
23818513	C0439799	Channel	spco	3.61
23818513	C1706095	Channel Object	cnce	3.61
23818513	C1167182	Apical plasma membrane	celc	3.59
23818513	C1413365	CFTR gene	gngm	3.58
23818513	C0542341	Function	ftcn	3.55
23818513	C0700205	Function Axis	clas	3.55
23818513	C1517945	Loss	qnco	3.55
23818513	C1705273	Mathematical Operator	inpr	3.55
23818513	C1327616	Cell secretion	celf	3.54
23818513	C1524003	Science of Etiology	cnce	3.52
23818513	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
23818513	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
23818513	C0055363	Chloride Channels	aapp	19.31
23818513	C0055363	Chloride Channels	bacs	19.31
23818513	C0597295	Protein Biosynthesis	moft	17.80
23818513	C0040712	Language Translations	inpr	14.64
23818513	C1314792	Etiology	ftcn	13.06
23818513	C0026882	Mutation	genf	9.85
23818513	C1413365	CFTR gene	gngm	6.90
23818513	C1550043	Container status - Identified	fndg	5.18
23818513	C1519614	Genetic Translation Process	genf	5.18
23818513	C0205396	Identified	qlco	5.18
23818513	C0230625	cell process structure	celc	3.96
23818513	C0596611	Gene Mutation	genf	3.56
23818513	C0221099	Impaired	ftcn	3.43
23818513	C3828842	Nearly	qlco	3.42
23818513	C0681760	2000s	tmco	3.40
23818513	C0009738	Congo	geoa	49.07
23818513	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.01
23818513	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.01
23818513	C0039798	therapeutic aspects	ftcn	22.49
23818513	C0002085	Alleles	gngm	19.40
23818513	C0055363	Chloride Channels	aapp	19.38
23818513	C0055363	Chloride Channels	bacs	19.38
23818513	C0376649	Addresses (publication format)	inpr	14.34
23818513	C0031843	physiological aspects	phsf	13.02
23818513	C3811819	CFTR wt Allele	gngm	10.61
23818513	C1442065	Address	spco	8.00
23818513	C1413365	CFTR gene	gngm	6.94
23818513	C0678227	Causing	ftcn	5.18
23818513	C0205210	Clinical	qlco	3.57
23818513	C2825142	Experimental Result	fndg	3.57
23818513	C1553058	Neuropsychologist - Clinical	prog	3.57
23818513	C0237412	Psychologist - Clinical	prog	3.57
23818513	C1274040	Result	ftcn	3.57
23818513	C0497591	Social Worker - Clinical	prog	3.57
23818513	C0087111	Therapeutic procedure	topp	3.57
23818513	C1363945	Therapy Object (animal model)	fndg	3.57
23818513	C1546471	What subject filter - Result	idcn	3.57
23818513	C0814225	benefit	qnco	3.57
23818513	C0542341	Function	ftcn	3.56
23818513	C0700205	Function Axis	clas	3.56
23818513	C1705273	Mathematical Operator	inpr	3.56
23818513	C0243067	defects aspect	ftcn	3.55
23818513	C0596988	mutant	comd	3.48
23818513	C1527178	Basis - conceptual entity	ftcn	3.47
23818513	C1457869	Defect	ftcn	3.47
23818513	C0230625	cell process structure	celc	3.42
23818513	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.99
23818513	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.99
23818513	C0040363	Togo	geoa	17.80
23818513	C0041260	Tryptophanase	aapp	17.80
23818513	C0041260	Tryptophanase	enzy	17.80
23818513	C0699040	Cell surface	celc	5.18
23818513	C1883351	To	qlco	5.18
23818513	C1551357	intended - ParticipationSignature	fndg	5.18
23818513	C1283828	intent	qlco	5.18
23818513	C0221284	Leptocyte	cell	3.54
23818513	C3272919	Target Cell Count	lbpr	3.54
23818513	C2939170	target cells (lab result)	lbtr	3.54
23818513	C1561536	*Activity (kind of quantity)	idcn	3.54
23818513	C0205177	Active	ftcn	3.54
23818513	C0441655	Activities	acty	3.54
23818513	C3668946	Activity (animal life circumstance)	fndg	3.54
23818513	C4049939	FDA Establishment Activity Terminology	inpr	3.54
23818513	C0439167	Percent Activity	qnco	3.54
23818513	C4049938	Physical Activity Measurement	lbpr	3.54
23818513	C0596988	mutant	comd	3.42
23818513	C1413365	CFTR gene	gngm	3.40
23818513	C0282443	Review [Publication Type]	inpr	11.49
23818513	C1552617	Act Class - review	idcn	5.18
23818513	C1706852	Article	inpr	5.18
23818513	C0205309	Known	qlco	5.18
23818513	C1874451	Basis	phsu	3.68
23818513	C1527178	Basis - conceptual entity	ftcn	3.68
23818513	C1516634	research clinical testing	resa	3.64
23818513	C2825142	Experimental Result	fndg	3.63
23818513	C1274040	Result	ftcn	3.63
23818513	C1546471	What subject filter - Result	idcn	3.63
23818513	C1880355	Discover	acty	3.56
23818513	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.45
23818513	C0441712	Mechanism (attribute)	ftcn	3.45
23818513	C1706376	Mechanism Component of Device	mnob	3.45
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
23757197	C0005367	Bicarbonates	inch	20.95
23757197	C0005367	Bicarbonates	phsu	20.95
23757197	C0008203	Chlorides	inch	16.07
23757197	C0031843	physiological aspects	phsf	13.05
23757197	C0007603	Plasma membrane	celc	11.49
23757197	C0010674	Cystic Fibrosis	dsyn	10.06
23757197	C0026882	Mutation	genf	9.90
23757197	C0015127	Etiology aspects	ftcn	9.86
23757197	C0019247	Hereditary Diseases	dsyn	6.91
23757197	C2722820	Bicarbonate preparation	orch	5.18
23757197	C2722820	Bicarbonate preparation	phsu	5.18
23757197	C0439799	Channel	spco	5.18
23757197	C1706095	Channel Object	cnce	5.18
23757197	C0973231	bicarbonate ion	inch	5.18
23757197	C0678594	structure	spco	5.18
23757197	C0392747	Changing	ftcn	3.79
23757197	C1836348	Severe disorder	fndg	3.78
23757197	C0314603	Genetic	ftcn	3.63
23757197	C0017296	gene therapy	topp	3.63
23757197	C0542341	Function	ftcn	3.59
23757197	C0700205	Function Axis	clas	3.59
23757197	C1705273	Mathematical Operator	inpr	3.59
23757197	C0205326	Permeable	ftcn	3.59
23757197	C1524003	Science of Etiology	cnce	3.55
23757197	C4050466	Borg Category-Ratio 10 Perceived Exertion Score 5	inpr	3.48
23757197	C0205082	Severe (severity modifier)	qlco	3.48
23757197	C4050465	Severe Extremity Pain	inpr	3.48
23757197	C1413365	CFTR gene	gngm	3.45
23757197	C0596019	Chloride Ion	elii	3.45
23757197	C0009738	Congo	geoa	16.04
23757197	C0023884	Liver	bpoc	8.34
23757197	C0024109	Lung	bpoc	8.34
23757197	C0030274	Pancreas	bpoc	8.34
23757197	C1883709	Damage	ftcn	5.18
23757197	C1278929	Entire liver	bpoc	5.18
23757197	C1278931	Entire pancreas	bpoc	5.18
23757197	C2346688	Liver Flavor	food	5.18
23757197	C0736268	Liver parenchyma	bpoc	5.18
23757197	C0178784	Organ	bpoc	5.18
23757197	C0010957	Tissue damage	inpo	5.18
23757197	C1159585	anion transport	celf	3.59
23757197	C3811819	CFTR wt Allele	gngm	3.43
23757197	C0332452	defective	ftcn	3.43
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
23757197	C0009738	Congo	geoa	16.09
23757197	C0031843	physiological aspects	phsf	12.90
23757197	C0015127	Etiology aspects	ftcn	11.49
23757197	C0026882	Mutation	genf	9.94
23757197	C1524003	Science of Etiology	cnce	5.18
23757197	C1517945	Loss	qnco	3.57
23757197	C0439064	Numerous	qnco	3.50
23757197	C3811819	CFTR wt Allele	gngm	3.48
23757197	C1413365	CFTR gene	gngm	3.44
23757197	C0542341	Function	ftcn	3.44
23757197	C0700205	Function Axis	clas	3.44
23757197	C1705273	Mathematical Operator	inpr	3.44
23757197	C0026882	Mutation	genf	9.85
23757197	C0441887	Class 3	inpr	3.44
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.51
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.51
23757197	C0040223	Time	tmco	8.34
23757197	C0547047	Decrease	qnco	5.18
23757197	C0392756	Reduced	qlco	5.18
23757197	C3541383	Time (foundation metadata concept)	tmco	5.18
23757197	C1457869	Defect	ftcn	3.68
23757197	C1301808	Geographic state	geoa	3.68
23757197	C0175566	Open	spco	3.68
23757197	C1442792	State	ftcn	3.68
23757197	C3148680	US State	geoa	3.68
23757197	C1413365	CFTR gene	gngm	3.59
23757197	C0680968	spending	qnco	3.55
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.00
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.00
23757197	C0014239	Endoplasmic Reticulum	celc	22.38
23757197	C0007603	Plasma membrane	celc	11.49
23757197	C0026882	Mutation	genf	9.94
23757197	C0005528	Biological Transport	celf	9.86
23757197	C1457869	Defect	ftcn	5.18
23757197	C0599896	trafficking	celf	5.18
23757197	C1660003	protein maturation	celf	3.60
23757197	C1254042	Anatomical maturation	phsf	3.56
23757197	C0678723	Biologic Development	orgf	3.56
23757197	C0870861	Human maturation	phpr	3.56
23757197	C3495449	Mobility aid	medd	3.55
23757197	C1317949	transport (device)	mnob	3.55
23757197	C0441886	Class 2	inpr	3.53
23757197	C1413365	CFTR gene	gngm	3.43
23757197	C0031453	Phenylalanine	aapp	16.05
23757197	C0031453	Phenylalanine	bacs	16.05
23757197	C0031453	Phenylalanine	phsu	16.05
23757197	C1511760	Deletion Mutation	genf	13.02
23757197	C0369773	P Blood group antibodies	aapp	5.18
23757197	C0369773	P Blood group antibodies	imft	5.18
23757197	C2603361	P prime	clna	5.18
23757197	C1880274	Deletion (action)	acty	3.56
23757197	C1442161	Gene Deletion Abnormality	comd	3.56
23757197	C0202174	blood phenylalanine measurement by Guthrie microbiologic assay	lbpr	3.43
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
23757197	C3178846	Mutation Rate	qlco	16.15
23757197	C0009738	Congo	geoa	16.04
23757197	C0030705	Patients	podg	6.58
23757197	C0599896	trafficking	celf	5.18
23757197	C3842584	70%	fndg	3.68
23757197	C3842582	90%	fndg	3.68
23757197	C0439087	<90	qnco	3.68
23757197	C0439083	>90	qnco	3.68
23757197	C0678227	Causing	ftcn	3.68
23757197	C1457869	Defect	ftcn	3.68
23757197	C3811819	CFTR wt Allele	gngm	3.42
23757197	C0205393	Most	qnco	3.42
23757197	C0243067	defects aspect	ftcn	3.68
23757197	C2983310	Overcome	acty	3.59
23757197	C0205448	Two	qnco	3.50
23757197	C0567416	Molecule	sbst	3.47
23757197	C0013227	Pharmaceutical Preparations	phsu	3.45
23757197	C1254351	Pharmacologic Substance	phsu	3.45
23757197	C1947967	Call (Instruction)	ftcn	3.44
23757197	C0679006	Decision	menp	3.44
23757197	C0041714	United States Food and Drug Administration	hcro	25.69
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
23757197	C0002085	Alleles	gngm	19.31
23757197	C0009738	Congo	geoa	16.04
23757197	C0206243	Carrying	acty	14.64
23757197	C3264621	ivacaftor	orch	13.05
23757197	C3264621	ivacaftor	phsu	13.05
23757197	C0332185	Recent	tmco	5.18
23757197	C2741958	VX-770	orch	5.18
23757197	C0205309	Known	qlco	3.59
23757197	C2697524	Graph Node	cnce	3.57
23757197	C1254351	Pharmacologic Substance	phsu	3.57
23757197	C1135440	Procedures involving the use of pharmaceuticals	topp	3.57
23757197	C0230003	Vertex	blor	3.57
23757197	C0205540	Approved	qlco	3.56
23757197	C0237463	Agencies	orgt	3.54
23757197	C1535514	European race	popg	3.54
23757197	C0013227	Pharmaceutical Preparations	phsu	3.54
23757197	C0239307	ethnic european	popg	3.54
23757197	C3264627	Kalydeco	phsu	3.48
23757197	C1413365	CFTR gene	gngm	3.42
23757197	C0205447	One	qnco	3.42
23757197	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.42
23757197	C3242455	HL7PublishingDomain <patient administration>	inpr	3.42
23757197	C3242279	healthcare operations <patient administration>	ocac	3.42
23757197	C3811819	CFTR wt Allele	gngm	3.42
23757197	C0026882	Mutation	genf	9.94
23757197	C0030705	Patients	podg	6.71
23757197	C1705285	Mutation Abnormality	comd	3.63
23757197	C0450346	2/5	qnco	3.61
23757197	C0009924	Contrast Media	irda	14.64
23757197	C1979874	Contrast	qlco	5.18
23757197	C0184511	Improved	qlco	5.18
23757197	C0369773	P Blood group antibodies	aapp	5.18
23757197	C0369773	P Blood group antibodies	imft	5.18
23757197	C2603361	P prime	clna	5.18
23757197	C3252847	VX 809	orch	3.75
23757197	C3252847	VX 809	phsu	3.75
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.56
23757197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.56
23757197	C0008976	Clinical Trials	resa	20.95
23757197	C1096775	Clinical Trial [Publication Type]	inpr	11.49
23757197	C2827718	In Vitro Route of Administration	ftcn	5.18
23757197	C0021135	In Vitro [Publication Type]	inpr	5.18
23757197	C1533691	in vitro	qlco	5.18
23757197	C0599896	trafficking	celf	5.18
23757197	C1413365	CFTR gene	gngm	3.63
23757197	C0557651	Room of building - Study	mnob	3.59
23757197	C2603343	Study	resa	3.59
23757197	C0015127	Etiology aspects	ftcn	9.85
23757197	C0243067	defects aspect	ftcn	3.68
23757197	C1524003	Science of Etiology	cnce	3.54
23757197	C0439064	Numerous	qnco	3.50
23757197	C0033204	Probability	qnco	17.80
23757197	C1524059	mechanism of action qualifier	ftcn	13.21
23757197	C0031327	Drug Kinetics	phsf	10.06
23757197	C0026882	Mutation	genf	9.94
23757197	C1564139	Mutant Proteins	aapp	9.76
23757197	C0009429	Combined Modality Therapy	topp	6.79
23757197	C0332148	Probable diagnosis	qlco	5.18
23757197	C1704537	Osteopathic Combined Method	topp	3.64
23757197	C1705285	Mutation Abnormality	comd	3.63
23757197	C1705242	Different	qlco	3.44
23757197	C0009738	Congo	geoa	16.09
23757197	C0220825	Evaluation	hlca	14.64
23757197	C0282443	Review [Publication Type]	inpr	11.49
23757197	C0013217	pharmacotherapeutic	ftcn	9.75
23757197	C0008972	Clinical Research	resa	6.79
23757197	C0013216	Pharmacotherapy	topp	6.59
23757197	C1552617	Act Class - review	idcn	5.18
23757197	C1457869	Defect	ftcn	3.63
23757197	C0449438	Status	qlco	3.57
23757197	C1527178	Basis - conceptual entity	ftcn	3.48
23757197	C3811819	CFTR wt Allele	gngm	3.48
23757197	C1517586	Investigational	qlco	3.44
23757197	C1554668	Pharmacist - Pharmacotherapy	prog	3.44
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
23457166	C0001721	Affect (mental function)	menp	11.49
23457166	C0010674	Cystic Fibrosis	dsyn	10.06
23457166	C0026882	Mutation	genf	9.95
23457166	C0015127	Etiology aspects	ftcn	9.85
23457166	C0033684	Proteins	aapp	6.75
23457166	C0033684	Proteins	bacs	6.75
23457166	C1413365	CFTR gene	gngm	3.58
23457166	C1524003	Science of Etiology	cnce	3.54
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
23457166	C0053548	Bicarbonate Ions	elii	19.38
23457166	C0008203	Chlorides	inch	16.07
23457166	C0040671	Psychological Transfer	menp	13.02
23457166	C0026882	Mutation	genf	11.49
23457166	C0220781	Anabolism	biof	8.34
23457166	C1825598	IMPACT gene	gngm	5.18
23457166	C4049986	Impact	qlco	5.18
23457166	C1883254	Synthesis	acty	5.18
23457166	C4054723	Influence	cnce	3.98
23457166	C1167182	Apical plasma membrane	celc	3.59
23457166	C1705822	Transfer Technique	ftcn	3.56
23457166	C0596019	Chloride Ion	elii	3.45
23457166	C0439799	Channel	spco	3.43
23457166	C1706095	Channel Object	cnce	3.43
23457166	C0221908	epithelial	qlco	3.42
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
23457166	C0282686	Respiratory System Agents	phsu	14.64
23457166	C0031847	physiopathological	ftcn	9.94
23457166	C0022023	Ions	elii	9.80
23457166	C0017189	Gastrointestinal tract structure	bdsy	8.34
23457166	C0023884	Liver	bpoc	8.34
23457166	C0030274	Pancreas	bpoc	8.34
23457166	C0036537	Bodily secretions	bdsu	6.70
23457166	C1281182	Entire gastrointestinal tract	bdsy	5.18
23457166	C1278929	Entire liver	bpoc	5.18
23457166	C1278931	Entire pancreas	bpoc	5.18
23457166	C1269561	Entire respiratory system	bdsy	5.18
23457166	C2346688	Liver Flavor	food	5.18
23457166	C0736268	Liver parenchyma	bpoc	5.18
23457166	C3541375	RESPIRATORY SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS	irda	5.18
23457166	C0035237	Respiratory System	bdsy	5.18
23457166	C0425442	Respiratory System Finding	fndg	5.18
23457166	C0521362	gastrointestinal	spco	5.18
23457166	C0460002	body system	bdsy	3.75
23457166	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.63
23457166	C3887504	Dysfunction	cnce	3.63
23457166	C0277785	Functional disorder	patf	3.63
23457166	C2825142	Experimental Result	fndg	3.55
23457166	C1397014	Imbalance	sosy	3.55
23457166	C1274040	Result	ftcn	3.55
23457166	C1546471	What subject filter - Result	idcn	3.55
23457166	C0221908	epithelial	qlco	3.55
23457166	C1700702	Iontophoresis Route of Drug Administration	ftcn	3.49
23457166	C1413365	CFTR gene	gngm	3.48
23457166	C0439064	Numerous	qnco	3.48
23457166	C0443302	Several	qnco	3.48
23457166	C0039798	therapeutic aspects	ftcn	22.48
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
23457166	C0040363	Togo	geoa	17.80
23457166	C0041260	Tryptophanase	aapp	17.80
23457166	C0041260	Tryptophanase	enzy	17.80
23457166	C0009738	Congo	geoa	16.04
23457166	C0242481	Research Activities	resa	11.49
23457166	C0035168	research	resa	11.49
23457166	C2717881	Candidate Gene Identification	mbrt	9.90
23457166	C0012634	Disease	dsyn	9.74
23457166	C1413365	CFTR gene	gngm	6.93
23457166	C0000768	Congenital Abnormality	cgab	6.85
23457166	C1883351	To	qlco	5.18
23457166	C1737329	Dysmorphism	cgab	3.70
23457166	C1521840	Target	ftcn	3.59
23457166	C1880355	Discover	acty	3.56
23457166	C0205234	Focal	spco	3.55
23457166	C1285542	Has focus	ftcn	3.55
23457166	C1533734	Administration procedure	topp	3.55
23457166	C1705169	Biomaterial Treatment	cnce	3.55
23457166	C0087111	Therapeutic procedure	topp	3.55
23457166	C1522326	Treating	ftcn	3.55
23457166	C3538994	Treatment Epoch	resa	3.55
23457166	C3887704	treatment - ActInformationManagementReason	hlca	3.55
23457166	C3811819	CFTR wt Allele	gngm	3.43
23457166	C0392747	Changing	ftcn	3.41
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.18
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.18
23457166	C0026882	Mutation	genf	9.99
23457166	C0376636	Disease Management	hlca	9.77
23457166	C1413365	CFTR gene	gngm	7.11
23457166	C1521840	Target	ftcn	5.18
23457166	C2986546	Target Lesion Identification	diap	5.18
23457166	C0017296	gene therapy	topp	3.75
23457166	C0679199	strategy	menp	3.61
23457166	C0205309	Known	qlco	3.57
23457166	C0678723	Biologic Development	orgf	3.56
23457166	C1527148	Development	ftcn	3.56
23457166	C0243107	development aspects	phsf	3.56
23457166	C1709060	Modulator Device Component	mnob	3.54
23457166	C0332257	Including (qualifier)	ftcn	3.48
23457166	C0001554	Administration occupational activities	ocac	3.47
23457166	C1292732	Investigates	ftcn	3.47
23457166	C3273539	Management Occupations	ocdi	3.47
23457166	C1273870	Management procedure	ocac	3.47
23457166	C1328819	Small Molecule	orch	3.46
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
23457166	C2718002	High-Throughput Screening Assays	lbpr	10.02
23457166	C1524063	Use of	ftcn	5.18
23457166	C1516329	Cell Culture System	mbrt	3.98
23457166	C0332283	Followed by	tmco	3.64
23457166	C1709060	Modulator Device Component	mnob	3.59
23457166	C1709630	Preclinical	qlco	3.57
23457166	C1519941	Validation	resa	3.57
23457166	C1550043	Container status - Identified	fndg	3.55
23457166	C0205396	Identified	qlco	3.55
23457166	C1413365	CFTR gene	gngm	3.48
23457166	C0039798	therapeutic aspects	ftcn	22.48
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
23457166	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
23457166	C0009738	Congo	geoa	16.04
23457166	C3264621	ivacaftor	orch	13.09
23457166	C3264621	ivacaftor	phsu	13.09
23457166	C0026882	Mutation	genf	9.73
23457166	C0030705	Patients	podg	6.70
23457166	C1709060	Modulator Device Component	mnob	5.18
23457166	C0205447	One	qnco	5.18
23457166	C0332185	Recent	tmco	3.68
23457166	C0205540	Approved	qlco	3.56
23457166	C0442027	Oral	spco	3.56
23457166	C0087111	Therapeutic procedure	topp	3.56
23457166	C1363945	Therapy Object (animal model)	fndg	3.56
23457166	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.53
23457166	C1413365	CFTR gene	gngm	3.42
23457166	C3811819	CFTR wt Allele	gngm	3.42
23457166	C1705285	Mutation Abnormality	comd	3.42
23457166	C0009738	Congo	geoa	16.05
23457166	C3264621	ivacaftor	orch	12.89
23457166	C3264621	ivacaftor	phsu	12.89
23457166	C0025118	Medicine	bmod	6.70
23457166	C1518422	Negation	ftcn	5.18
23457166	C1720467	Only - dosing instruction fragment	inpr	5.18
23457166	C1882932	Representation (action)	acty	5.18
23457166	C0205171	Singular	qnco	5.18
23457166	C0678723	Biologic Development	orgf	3.56
23457166	C0444503	Breakthrough	qlco	3.56
23457167	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
23457167	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
23457167	C0017337	Genes	gngm	16.22
23457167	C0010674	Cystic Fibrosis	dsyn	10.06
23457167	C0012634	Disease	dsyn	9.92
23457167	C0026882	Mutation	genf	9.90
23457167	C0015127	Etiology aspects	ftcn	9.86
23457167	C0033684	Proteins	aapp	8.34
23457167	C0033684	Proteins	bacs	8.34
23457167	C0596019	Chloride Ion	elii	5.18
23457167	C2327105	Surface of epithelial cell	celc	5.18
23457167	C1413365	CFTR gene	gngm	3.58
23457167	C2700640	Encode (action)	acty	3.57
23457167	C1704735	Regulator	cnce	3.57
23457167	C1704734	Regulator Device Component	mnob	3.57
23457167	C0182953	Regulators (device)	medd	3.57
23457167	C1524003	Science of Etiology	cnce	3.55
23457167	C1273518	Responsible to	fndg	3.55
23457167	C0441748	Autosomal recessive inheritance	genf	3.50
23457167	C3151529	Lethal	fndg	3.47
23457167	C1159591	chloride transport	celf	3.45
23457167	C0026882	Mutation	genf	9.94
23457167	C0332281	Associated with	qlco	3.64
23457167	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.62
23457167	C0443264	Modulated	spco	3.57
23457167	C0332452	defective	ftcn	3.57
23457167	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
23457167	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
23457167	C0009738	Congo	geoa	16.16
23457167	C3264621	ivacaftor	orch	13.14
23457167	C3264621	ivacaftor	phsu	13.14
23457167	C0026882	Mutation	genf	9.86
23457167	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	5.18
23457167	C0205447	One	qnco	3.63
23457167	C1413365	CFTR gene	gngm	3.55
23457167	C1948062	Copy (object)	mnob	3.55
23457167	C1705285	Mutation Abnormality	comd	3.55
23457167	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.55
23457167	C3242455	HL7PublishingDomain <patient administration>	inpr	3.55
23457167	C3242279	healthcare operations <patient administration>	ocac	3.55
23457167	C0205540	Approved	qlco	3.54
23457167	C3811819	CFTR wt Allele	gngm	3.54
23457167	C1435727	FABP6 protein, human	aapp	3.54
23457167	C1435727	FABP6 protein, human	bacs	3.54
23457167	C0001779	Age	orga	3.44
23457167	C0008976	Clinical Trials	resa	19.21
23457167	C3264621	ivacaftor	orch	12.89
23457167	C3264621	ivacaftor	phsu	12.89
23457167	C0282443	Review [Publication Type]	inpr	11.49
23457167	C0008059	Child	aggp	9.90
23457167	C0033333	Program Development	hlca	9.88
23457167	C1096775	Clinical Trial [Publication Type]	inpr	9.75
23457167	C0205653	Adolescent (age group)	aggp	9.74
23457167	C0001675	Adult	aggp	9.74
23457167	C0332257	Including (qualifier)	ftcn	5.18
23457167	C1709940	Reviewed	qlco	5.18
23457167	C0680063	Offspring	famg	3.59
23457167	C0947630	Scientific Study	lbpr	3.55
23457167	C0205448	Two	qnco	3.43
23457167	C2947019	Pivot	food	3.38
23457167	C1709557	Pivot Device Component	medd	3.38
23457167	C0039798	therapeutic aspects	ftcn	22.39
23457167	C0035245	Respiratory physiology	ortf	6.62
23457167	C0024109	Lung	bpoc	6.59
23457167	C3273238	Regulatory Report	inpr	5.18
23457167	C0684224	Report (document)	inpr	5.18
23457167	C0700287	Reporting	hlca	5.18
23457167	C0947630	Scientific Study	lbpr	5.18
23457167	C0086045	Mental concentration	menp	3.63
23457167	C1948053	Period (temporal qualifier)	tmco	3.61
23457167	C0439531	per period (qualifier value)	tmco	3.61
23457167	C0392756	Reduced	qlco	3.56
23457167	C0301630	Reduction (chemical)	npop	3.56
23457167	C0441610	Reduction - action	topp	3.56
23457167	C0428295	Cystic fibrosis sweat test	lbpr	3.53
23457167	C1304760	Sweat chloride level result	lbtr	3.53
23457167	C2986411	Improvement	cnce	3.53
23457167	C1533734	Administration procedure	topp	3.47
23457167	C1705169	Biomaterial Treatment	cnce	3.47
23457167	C0087111	Therapeutic procedure	topp	3.47
23457167	C1522326	Treating	ftcn	3.47
23457167	C3538994	Treatment Epoch	resa	3.47
23457167	C0332174	Weekly	tmco	3.47
23457167	C3887704	treatment - ActInformationManagementReason	hlca	3.47
23457167	C0439230	week	tmco	3.47
23457167	C2709248	Pulmonary (qualifier value)	qlco	3.43
23457167	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.43
23457167	C0443318	Sustained	ftcn	3.43
23457167	C0009738	Congo	geoa	16.04
23457167	C3264621	ivacaftor	orch	14.64
23457167	C3264621	ivacaftor	phsu	14.64
23457167	C0026882	Mutation	genf	9.99
23457167	C0025118	Medicine	bmod	6.58
23457167	C1704419	Effective	qlco	5.18
23457167	C1280519	Effectiveness	qlco	5.18
23457167	C1705285	Mutation Abnormality	comd	3.68
23457167	C3495919	Enthesitis-Related Arthritis	dsyn	3.55
23457167	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.54
23457167	C3242455	HL7PublishingDomain <patient administration>	inpr	3.54
23457167	C3242279	healthcare operations <patient administration>	ocac	3.54
23457167	C1516615	Clinical Management	hlca	3.43
23457167	C0013227	Pharmaceutical Preparations	phsu	3.43
23457167	C3811819	CFTR wt Allele	gngm	3.42
23457167	C0205170	Good	qlco	3.42
23457167	C3146287	Well	mnob	3.42
23457167	C3264621	ivacaftor	orch	12.90
23457167	C3264621	ivacaftor	phsu	12.90
23457167	C1709323	Open Label Study	resa	5.18
23457167	C3273238	Regulatory Report	inpr	5.18
23457167	C0684224	Report (document)	inpr	5.18
23457167	C0700287	Reporting	hlca	5.18
23457167	C0443252	Long-term	tmco	3.68
23457167	C0439230	week	tmco	3.63
23457167	C1280500	Effect	qlco	3.57
23457167	C1517331	Further	spco	3.48
23457168	C0031268	Pet Animal	anim	17.80
23457168	C0012634	Disease	dsyn	9.74
23457168	C0335343	Companions	popg	8.34
23457168	C0011900	Diagnosis	fndg	5.18
23457168	C0348026	Diagnostic	ftcn	5.18
23457168	C1280519	Effectiveness	qlco	5.18
23457168	C1707887	Efficacy Study	resa	5.18
23457168	C0682323	Partner in relationship	famg	5.18
23457168	C1524063	Use of	ftcn	5.18
23457168	C0430022	diagnostic procedure	diap	5.18
23457168	C2346874	Attractive	qlco	3.68
23457168	C1285572	Phenotype determination	lbpr	3.57
23457168	C1314763	Phenotyping (qualifier value)	ftcn	3.57
23457168	C0449445	Approach	spco	3.55
23457168	C1292724	Procedural approach	ftcn	3.55
23457168	C1947933	care activity	acty	3.51
23457168	C0442824	Very	qlco	3.50
23457168	C2984081	Very Much	qlco	3.50
23457168	C0205363	Stratified	qlco	3.43
23457168	C1522326	Treating	ftcn	3.43
23457168	C0001688	aspects of adverse effects	ftcn	10.06
23457168	C0376315	Manufactured form	mnob	8.34
23457168	C0449445	Approach	spco	5.18
23457168	C1522492	Formation	ftcn	5.18
23457168	C0348078	Qualitative form	qlco	5.18
23457168	C0879626	Adverse effects	patf	3.75
23457168	C1518422	Negation	ftcn	3.68
23457168	C3245505	potential	qlco	3.48
23457168	C0027651	Neoplasms	neop	7.46
23457168	C3665472	Chemotherapy	topp	6.72
23457168	C0013216	Pharmacotherapy	topp	6.72
23457168	C1708225	Gene Signature	ftcn	4.12
23457168	C0392920	Chemotherapy Regimen	topp	3.57
23457168	C1552740	Entity Determiner - specific	inpr	3.57
23457168	C0205369	Specific qualifier value	qlco	3.57
23457168	C0278627	oncology field	bmod	3.55
23457168	C2235729	birth data single birth	fndg	3.54
23457168	C0039798	therapeutic aspects	ftcn	22.35
23457168	C0004096	Asthma	dsyn	16.04
23457168	C0005527	Biological Response Modifier Therapy	topp	8.34
23457168	C0521116	Current (present time)	tmco	5.18
23457168	C0557651	Room of building - Study	mnob	3.98
23457168	C2603343	Study	resa	3.98
23457168	C0449445	Approach	spco	3.54
23457168	C1292724	Procedural approach	ftcn	3.54
23457168	C1533734	Administration procedure	topp	3.42
23457168	C2984299	Asthma Pathway	ftcn	3.42
23457168	C1705169	Biomaterial Treatment	cnce	3.42
23457168	C0205363	Stratified	qlco	3.42
23457168	C0087111	Therapeutic procedure	topp	3.42
23457168	C1522326	Treating	ftcn	3.42
23457168	C3538994	Treatment Epoch	resa	3.42
23457168	C3887704	treatment - ActInformationManagementReason	hlca	3.42
23457168	C0079870	Mutagenesis, Site-Directed	genf	16.17
23457168	C0010674	Cystic Fibrosis	dsyn	11.49
23457168	C0087111	Therapeutic procedure	topp	5.18
23457168	C0456387	Class	inpr	3.55
23457168	C1705943	Class (taxonomic)	clas	3.55
23457168	C4019422	Classes - encounter	hlca	3.55
23457168	C1552740	Entity Determiner - specific	inpr	3.55
23457168	C0542341	Function	ftcn	3.55
23457168	C0205245	Functional	ftcn	3.55
23457168	C2700217	Functional Relationship	cnce	3.55
23457168	C0205369	Specific qualifier value	qlco	3.55
23457168	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
23457168	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
23457168	C3264621	ivacaftor	orch	13.14
23457168	C3264621	ivacaftor	phsu	13.14
23457168	C0041703	United States	geoa	12.89
23457168	C0026882	Mutation	genf	9.90
23457168	C0031847	physiopathological	ftcn	9.71
23457168	C0033684	Proteins	aapp	6.60
23457168	C0033684	Proteins	bacs	6.60
23457168	C0454713	European country	geoa	4.12
23457168	C0470187	Availability of	ftcn	3.56
23457168	C0205435	First (number)	qnco	3.56
23457168	C1279901	Firstly	qlco	3.56
23457168	C1413365	CFTR gene	gngm	3.50
23457168	C3889626	Annexin A6, human	aapp	3.47
23457168	C3889626	Annexin A6, human	bacs	3.47
23457168	C2945616	protein iii	aapp	3.47
23457168	C2945616	protein iii	bacs	3.47
23457168	C2698969	Canadian Cardiovascular Society Grading Scale Class III	fndg	3.46
23457168	C0441887	Class 3	inpr	3.46
23457168	C0456387	Class	inpr	3.45
23457168	C1705943	Class (taxonomic)	clas	3.45
23457168	C1948052	Now (temporal qualifier)	tmco	3.43
23457168	C0087111	Therapeutic procedure	topp	3.43
23457168	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.41
23457168	C3887504	Dysfunction	cnce	3.41
23457168	C0277785	Functional disorder	patf	3.41
23457168	C0026882	Mutation	genf	20.01
23457168	C0037981	Spirometry	diap	17.80
23457168	C1705285	Mutation Abnormality	comd	7.32
23457168	C0030705	Patients	podg	6.59
23457168	C0947630	Scientific Study	lbpr	3.56
23457168	C2986411	Improvement	cnce	3.52
23457168	C2698969	Canadian Cardiovascular Society Grading Scale Class III	fndg	3.49
23457168	C0441887	Class 3	inpr	3.49
23457168	C0205214	Common (qualifier value)	qnco	3.46
23457168	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.46
23457168	C0205393	Most	qnco	3.46
23457168	C1522138	shared attribute	ftcn	3.46
23457168	C1546944	Event Seriousness - Significant	qlco	3.43
23457168	C3898777	Important	qlco	3.43
23457168	C0750502	Significant	idcn	3.43
23457168	C0237881	Statistical Significance	qnco	3.43
23457168	C1274040	Result	ftcn	3.41
23457168	C2947019	Pivot	food	3.39
23457168	C1709557	Pivot Device Component	medd	3.39
23457168	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
23457168	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
23457168	C0038164	Staphylococcal Protein A	aapp	12.90
23457168	C0038164	Staphylococcal Protein A	imft	12.90
23457168	C0038164	Staphylococcal Protein A	irda	12.90
23457168	C0026882	Mutation	genf	9.87
23457168	C0031847	physiopathological	ftcn	9.69
23457168	C0392756	Reduced	qlco	5.18
23457168	C0428295	Cystic fibrosis sweat test	lbpr	3.75
23457168	C1304760	Sweat chloride level result	lbtr	3.75
23457168	C1705285	Mutation Abnormality	comd	3.56
23457168	C1280500	Effect	qlco	3.54
23457168	C2348382	Effect, Appearance	qlco	3.54
23457168	C1413365	CFTR gene	gngm	3.42
23457168	C0542341	Function	ftcn	3.42
23457168	C0205245	Functional	ftcn	3.42
23457168	C2700217	Functional Relationship	cnce	3.42
23457168	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.38
23457168	C3887504	Dysfunction	cnce	3.38
23457168	C0277785	Functional disorder	patf	3.38
23457168	C3840786	Greatly	fndg	5.18
23457168	C0449820	Score	qnco	3.63
23457168	C3854129	Symptom:Find:Pt:^Patient:Nom	clna	3.63
23457168	C1457887	Symptoms	sosy	3.63
23457168	C1561611	Admission Level of Care Code - Improved	inpr	3.57
23457168	C0332272	Better	qlco	3.57
23457168	C0456079	Disease classification level	clas	3.57
23457168	C1547707	Floor - story of building	geoa	3.57
23457168	C0184511	Improved	qlco	3.57
23457168	C2946261	Level	phsu	3.57
23457168	C0441889	Levels (qualifier value)	qlco	3.57
23457168	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.56
23457168	C3242455	HL7PublishingDomain <patient administration>	inpr	3.56
23457168	C3242279	healthcare operations <patient administration>	ocac	3.56
23457168	C1705163	Data Transformation	resa	3.38
23457168	C3714584	Transformation, function	phsf	3.38
23457168	C0040682	cell transformation	celf	3.38
23457168	C1510411	metaplastic cell transformation	patf	3.38
23457168	C0009738	Congo	geoa	35.81
23457168	C0040363	Togo	geoa	17.80
23457168	C0041260	Tryptophanase	aapp	17.80
23457168	C0041260	Tryptophanase	enzy	17.80
23457168	C0023175	Lead	elii	13.03
23457168	C0023175	Lead	hops	13.03
23457168	C3811819	CFTR wt Allele	gngm	10.42
23457168	C0026882	Mutation	genf	9.85
23457168	C3540027	Adrenergic and dopaminergic agents combinations	phsu	5.18
23457168	C3539975	Aluminium antacid compound combinations	phsu	5.18
23457168	C3539963	Amide local anesthetic combinations	orch	5.18
23457168	C3539963	Amide local anesthetic combinations	phsu	5.18
23457168	C3539979	Antiinfective irrigating solution combinations	phsu	5.18
23457168	C3540722	Beta-lactamase sensitive penicillin combinations	antb	5.18
23457168	C3540722	Beta-lactamase sensitive penicillin combinations	orch	5.18
23457168	C3539977	Calcium antacid compound combinations	phsu	5.18
23457168	C3540720	Caries prophylactic agent combinations	phsu	5.18
23457168	C3539972	Combination solutions for parenteral nutrition	phsu	5.18
23457168	C0453882	Combinations (Undergarment)	mnob	5.18
23457168	C2349182	Correct (qualifier)	qlco	5.18
23457168	C3539968	Enema combinations	phsu	5.18
23457168	C3540026	Hepatitis vaccine combinations	aapp	5.18
23457168	C3540026	Hepatitis vaccine combinations	imft	5.18
23457168	C3540026	Hepatitis vaccine combinations	phsu	5.18
23457168	C3540723	Insulins and analogs for injection, fast-acting combinations	phsu	5.18
23457168	C3539974	Insulins and analogs for injection, intermediate-acting combinations	phsu	5.18
23457168	C3539967	Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations	phsu	5.18
23457168	C3540719	Intermediate-acting sulfonamide combinations	orch	5.18
23457168	C3540719	Intermediate-acting sulfonamide combinations	phsu	5.18
23457168	C3539965	Local hemostatic combinations	phsu	5.18
23457168	C3539959	Long-acting sulfonamide combinations	orch	5.18
23457168	C3539959	Long-acting sulfonamide combinations	phsu	5.18
23457168	C3539956	Magnesium antacid compound combinations	phsu	5.18
23457168	C3854036	Other anti-dementia drug combinations in ATC	phsu	5.18
23457168	C3539973	Other antifungal combinations for topical use in ATC	phsu	5.18
23457168	C3539960	Other intestinal adsorbent combinations in ATC	phsu	5.18
23457168	C3540028	Other irrigating solution combinations in ATC	phsu	5.18
23457168	C3539976	Penicillins with extended spectrum combinations	antb	5.18
23457168	C3539976	Penicillins with extended spectrum combinations	orch	5.18
23457168	C3539961	Platelet aggregation inhibitor combinations excl. heparin	phsu	5.18
23457168	C3540740	Potassium supplement combinations	phsu	5.18
23457168	C0332148	Probable diagnosis	qlco	5.18
23457168	C0750492	Probably	idcn	5.18
23457168	C3539182	Salt solution combinations	phsu	5.18
23457168	C3539181	Short-acting sulfonamide combinations	orch	5.18
23457168	C3539181	Short-acting sulfonamide combinations	phsu	5.18
23457168	C3539969	Specific immunoglobulin combinations	aapp	5.18
23457168	C3539969	Specific immunoglobulin combinations	imft	5.18
23457168	C3539969	Specific immunoglobulin combinations	phsu	5.18
23457168	C1883351	To	qlco	5.18
23457168	C3539970	combination drugs used in erectile dysfunction	phsu	5.18
23457168	C3539978	expectorant combinations excluding combinations with cough suppressants	phsu	5.18
23457168	C3540724	expectorant combinations, excl. combinations with cough suppressants	phsu	5.18
23457168	C3540031	gonadotropin combinations	aapp	5.18
23457168	C3540031	gonadotropin combinations	horm	5.18
23457168	C3540031	gonadotropin combinations	phsu	5.18
23457168	C3539966	insulins and analogs for injection combinations, long-acting	phsu	5.18
23457168	C3539964	local opthalmologic anesthetic combinations	phsu	5.18
23457168	C3539955	lung surfactant combinations	phsu	5.18
23457168	C3539957	opium alkaloids and derivative combination cough suppressants	phsu	5.18
23457168	C3540030	other cough suppressant combinations in ATC	phsu	5.18
23457168	C3540721	other nasal preparation combinations in ATC	phsu	5.18
23457168	C3539971	otologic analgesic and anesthetic combinations	phsu	5.18
23457168	C3539954	topical antibiotic combinations	phsu	5.18
23457168	C3539962	vitamin D and analog combinations	phsu	5.18
23457168	C1718097	New medications	phsu	3.64
23457168	C3275067	Cardiac Lead Procedure	topp	3.57
23457168	C2348269	Dietary Lead	elii	3.57
23457168	C1522538	Leading	ftcn	3.57
23457168	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.57
23457168	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.57
23457168	C1457869	Defect	ftcn	3.55
23457168	C0449445	Approach	spco	3.54
23457168	C1705938	Base - General Qualifier	idcn	3.54
23457168	C1527178	Basis - conceptual entity	ftcn	3.54
23457168	C0456387	Class	inpr	3.54
23457168	C1705943	Class (taxonomic)	clas	3.54
23457168	C0542341	Function	ftcn	3.54
23457168	C0205245	Functional	ftcn	3.54
23457168	C2700217	Functional Relationship	cnce	3.54
23457168	C0205363	Stratified	qlco	3.42
23457168	C1709483	Patient Base	qnco	3.41
23457168	C1522647	Developmental Therapeutics Program	resa	3.40
23457168	C0556496	Developmental therapy	topp	3.40
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.23
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.23
25879443	C0009264	Cold Temperature	npop	24.11
25879443	C0039798	therapeutic aspects	ftcn	22.54
25879443	C0010453	Anthropological Culture	idcn	14.64
25879443	C1413365	CFTR gene	gngm	7.15
25879443	C0376315	Manufactured form	mnob	6.69
25879443	C0220814	Cultural aspects	ftcn	5.18
25879443	C0430400	Laboratory culture	lbpr	5.18
25879443	C2242979	Microbial culture (procedure)	lbpr	5.18
25879443	C1533734	Administration procedure	topp	3.61
25879443	C1705169	Biomaterial Treatment	cnce	3.61
25879443	C0087111	Therapeutic procedure	topp	3.61
25879443	C1522326	Treating	ftcn	3.61
25879443	C3538994	Treatment Epoch	resa	3.61
25879443	C3887704	treatment - ActInformationManagementReason	hlca	3.61
25879443	C0699040	Cell surface	celc	3.61
25879443	C1511758	Degradation Pathway	cnce	3.58
25879443	C3810541	Adverse Event Emergency Room Visit	inbe	3.55
25879443	C0332281	Associated with	qlco	3.55
25879443	C3811131	Estrogen Receptor Measurement	lbpr	3.55
25879443	C1881707	Medical Device Material Degradation	phpr	3.55
25879443	C1522492	Formation	ftcn	3.54
25879443	C0348078	Qualitative form	qlco	3.54
25879443	C1328819	Small Molecule	orch	3.47
25879443	C0596988	mutant	comd	3.42
25879443	C0699900	Catabolism	orgf	8.34
25879443	C0456962	Rapid	qlco	5.18
25879443	C0243125	degradation aspects	ftcn	5.18
25879443	C1185625	Anatomical compartments	inpr	3.56
25879443	C2986730	Compartmental Model Region	spco	3.56
25879443	C1521840	Target	ftcn	3.56
25879443	C1883468	Unstable Medical Device Problem	evnt	3.56
25879443	C0443343	Unstable status	fndg	3.56
25879443	C0521450	lysosomal	blor	3.56
25879443	C0699040	Cell surface	celc	3.46
25879443	C0086418	Homo sapiens	humn	28.66
25879443	C0009264	Cold Temperature	npop	22.40
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
25879443	C0040363	Togo	geoa	17.80
25879443	C0041260	Tryptophanase	aapp	17.80
25879443	C0041260	Tryptophanase	enzy	17.80
25879443	C0077678	ubiquitin-protein ligase	aapp	16.40
25879443	C0077678	ubiquitin-protein ligase	enzy	16.40
25879443	C0162340	Comprehension	menp	14.64
25879443	C0035820	Social Role	socb	13.01
25879443	C0031227	Personnel Turnover	qnco	12.89
25879443	C0014139	Endocytosis	celf	9.91
25879443	C0699900	Catabolism	orgf	6.71
25879443	C0014597	Epithelial Cells	cell	6.60
25879443	C0812242	CBL gene	gngm	5.18
25879443	C1707078	CBL wt Allele	gngm	5.18
25879443	C1333202	DAB2 gene	gngm	5.18
25879443	C0600596	DNA Microarray Chip	resd	5.18
25879443	C1333302	Disabled Homolog 2 Protein	aapp	5.18
25879443	C1333302	Disabled Homolog 2 Protein	bacs	5.18
25879443	C0332128	Examined	fndg	5.18
25879443	C1417660	NEDD4L gene	gngm	5.18
25879443	C1883351	To	qlco	5.18
25879443	C1418270	PARK2 gene	gngm	3.78
25879443	C3887950	Associated Persons Domain	inpr	3.68
25879443	C2984285	Endocytosis Pathway	ftcn	3.60
25879443	C1705810	Generic Role	cnce	3.55
25879443	C0441712	Mechanism (attribute)	ftcn	3.55
25879443	C1706376	Mechanism Component of Device	mnob	3.55
25879443	C0243125	degradation aspects	ftcn	3.55
25879443	C3871154	{Role}	inpr	3.55
25879443	C0205449	Three	qnco	3.47
25879443	C1413365	CFTR gene	gngm	3.46
25879443	C1273342	Epithelial cell count (procedure)	lbpr	3.45
25879443	C0427861	Human cells	lbtr	3.45
25879443	C1706710	Adapter Device Component	mnob	3.43
25879443	C0458827	Airway structure	bpoc	3.43
25879443	C0178987	Artificial Airways	medd	3.43
25879443	C0243127	Biochemical turnover	ftcn	3.43
25879443	C0456962	Rapid	qlco	3.43
25879443	C0443331	Turnover technique	hlca	3.43
25879443	C0205448	Two	qnco	3.43
25879443	C1704241	complex (molecular entity)	chvs	3.43
25879443	C0221908	epithelial	qlco	3.43
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
25879443	C1099354	RNA, Small Interfering	bacs	19.19
25879443	C1099354	RNA, Small Interfering	nnon	19.19
25879443	C0018790	Cardiac Arrest	dsyn	10.18
25879443	C0014139	Endocytosis	celf	9.87
25879443	C1333202	DAB2 gene	gngm	5.18
25879443	C1333302	Disabled Homolog 2 Protein	aapp	5.18
25879443	C1333302	Disabled Homolog 2 Protein	bacs	5.18
25879443	C2825142	Experimental Result	fndg	3.98
25879443	C1274040	Result	ftcn	3.98
25879443	C1546471	What subject filter - Result	idcn	3.98
25879443	C1706084	(City) Block	geoa	3.87
25879443	C0237477	Arrested progression	tmco	3.87
25879443	C2828370	Block (unit of measure)	qnco	3.87
25879443	C1533157	Block Specimens	sbst	3.87
25879443	C3811660	Block Unit of Distance	qnco	3.87
25879443	C0332206	Blocking	ftcn	3.87
25879443	C0392351	Law enforcement arrest	gora	3.87
25879443	C0233660	Mental blocking	mobd	3.87
25879443	C0028778	Obstruction	patf	3.87
25879443	C0521111	Retarded	qlco	3.87
25879443	C2984285	Endocytosis Pathway	ftcn	3.56
25879443	C0333668	Depletion	ftcn	3.55
25879443	C0450388	69	qnco	3.43
25879443	C1413365	CFTR gene	gngm	3.43
25879443	C3887950	Associated Persons Domain	inpr	3.42
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
25879443	C0018517	Half-Life	tmco	9.88
25879443	C0442805	Increase	ftcn	5.18
25879443	C0205217	Increased	qnco	5.18
25879443	C0333668	Depletion	ftcn	3.68
25879443	C3887950	Associated Persons Domain	inpr	3.63
25879443	C1333202	DAB2 gene	gngm	3.50
25879443	C1333302	Disabled Homolog 2 Protein	aapp	3.50
25879443	C1333302	Disabled Homolog 2 Protein	bacs	3.50
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.96
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.96
25879443	C0077678	ubiquitin-protein ligase	aapp	16.04
25879443	C0077678	ubiquitin-protein ligase	enzy	16.04
25879443	C0009924	Contrast Media	irda	14.64
25879443	C0018517	Half-Life	tmco	9.88
25879443	C0014139	Endocytosis	celf	9.74
25879443	C0333668	Depletion	ftcn	7.25
25879443	C1413365	CFTR gene	gngm	6.89
25879443	C1979874	Contrast	qlco	5.18
25879443	C0442805	Increase	ftcn	5.18
25879443	C0205217	Increased	qnco	5.18
25879443	C1280500	Effect	qlco	3.55
25879443	C2348382	Effect, Appearance	qlco	3.55
25879443	C0600596	DNA Microarray Chip	resd	3.50
25879443	C2984285	Endocytosis Pathway	ftcn	3.43
25879443	C0205148	Surface	spco	3.42
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.23
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.23
25879443	C1519751	Ubiquitination	moft	51.87
25879443	C0040363	Togo	geoa	17.80
25879443	C0041260	Tryptophanase	aapp	17.80
25879443	C0041260	Tryptophanase	enzy	17.80
25879443	C0031227	Personnel Turnover	qnco	13.02
25879443	C1413365	CFTR gene	gngm	10.55
25879443	C0030695	Patient Monitoring	hlca	10.28
25879443	C0014139	Endocytosis	celf	9.73
25879443	C1883351	To	qlco	5.18
25879443	C0181904	Biomedical Monitors	medd	3.98
25879443	C1704646	Monitor Device Component	mnob	3.98
25879443	C1521743	Monitor, occupation	prog	3.98
25879443	C0596972	Monitoring Device	medd	3.98
25879443	C0150369	Preventive monitoring	hlca	3.98
25879443	C0449247	Time course	tmco	3.58
25879443	C0243127	Biochemical turnover	ftcn	3.56
25879443	C1709305	Occur (action)	acty	3.56
25879443	C2745955	Occurrence	tmco	3.56
25879443	C0443331	Turnover technique	hlca	3.56
25879443	C2984285	Endocytosis Pathway	ftcn	3.42
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.29
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.29
25879443	C1519751	Ubiquitination	moft	25.62
25879443	C0040363	Togo	geoa	17.80
25879443	C0041260	Tryptophanase	aapp	17.80
25879443	C0041260	Tryptophanase	enzy	17.80
25879443	C0041538	Ubiquitin	aapp	13.01
25879443	C0041538	Ubiquitin	bacs	13.01
25879443	C1413365	CFTR gene	gngm	7.21
25879443	C0439659	Beginning	tmco	5.18
25879443	C0442805	Increase	ftcn	5.18
25879443	C1883351	To	qlco	5.18
25879443	C2825142	Experimental Result	fndg	3.98
25879443	C1274040	Result	ftcn	3.98
25879443	C1546471	What subject filter - Result	idcn	3.98
25879443	C1705535	suggestion	idcn	3.98
25879443	C1524029	Mouse MIN NOS	neop	3.57
25879443	C0702093	Per Minute	tmco	3.57
25879443	C3813700	Percent per Minute	qnco	3.57
25879443	C1185625	Anatomical compartments	inpr	3.55
25879443	C2986730	Compartmental Model Region	spco	3.55
25879443	C0687676	Post	tmco	3.55
25879443	C1704687	Post Device Component	mnob	3.55
25879443	C0444746	Endocyte	cell	3.49
25879443	C0871786	internalization	menp	3.44
25879443	C0337051	Environmental pool	geoa	3.42
25879443	C2349200	Pool (action)	ftcn	3.42
25879443	C1509144	Sample pool	clna	3.42
25879443	C0205148	Surface	spco	3.42
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.03
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.03
25879443	C1099354	RNA, Small Interfering	bacs	19.20
25879443	C1099354	RNA, Small Interfering	nnon	19.20
25879443	C3463820	Inhibition	acty	14.64
25879443	C0014139	Endocytosis	celf	11.49
25879443	C1413365	CFTR gene	gngm	6.96
25879443	C2984285	Endocytosis Pathway	ftcn	5.18
25879443	C3252847	VX 809	orch	5.18
25879443	C3252847	VX 809	phsu	5.18
25879443	C0332206	Blocking	ftcn	3.59
25879443	C0028778	Obstruction	patf	3.59
25879443	C0007634	Cells	cell	3.57
25879443	C3282337	Cells [Chemical/Ingredient]	cell	3.57
25879443	C1522326	Treating	ftcn	3.57
25879443	C0600596	DNA Microarray Chip	resd	3.43
25879443	C0687676	Post	tmco	3.42
25879443	C1704687	Post Device Component	mnob	3.42
25879443	C0444746	Endocyte	cell	3.38
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.96
25879443	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.96
25879443	C1519751	Ubiquitination	moft	25.63
25879443	C0034378	quality control	ftcn	9.87
25879443	C1413365	CFTR gene	gngm	6.89
25879443	C0600596	DNA Microarray Chip	resd	5.18
25879443	C2825142	Experimental Result	fndg	3.98
25879443	C1274040	Result	ftcn	3.98
25879443	C1546471	What subject filter - Result	idcn	3.98
25879443	C1705117	Increment	qnco	3.63
25879443	C2825408	Stair (equipment)	mnob	3.63
25879443	C1261552	Step (specific stage)	cnce	3.63
25879443	C3814463	Step Unit of Distance	qnco	3.63
25879443	C1704379	Treatment Step	ftcn	3.63
25879443	C1561524	Quality Control Specimen	ftcn	3.56
25879443	C1610034	Specimen Source Codes - Quality Control	inpr	3.56
25879443	C1511545	Critical	qlco	3.48
25879443	C0699040	Cell surface	celc	3.45
25879443	C0687676	Post	tmco	3.43
25879443	C1704687	Post Device Component	mnob	3.43
25879443	C0205100	Peripheral	spco	3.42
25879443	C0444746	Endocyte	cell	3.38
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.42
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.42
28087700	C0031843	physiological aspects	phsf	13.00
28087700	C0010674	Cystic Fibrosis	dsyn	10.06
28087700	C0026882	Mutation	genf	9.90
28087700	C0015127	Etiology aspects	ftcn	9.86
28087700	C0007603	Plasma membrane	celc	9.84
28087700	C0439799	Channel	spco	5.18
28087700	C1706095	Channel Object	cnce	5.18
28087700	C2347098	Medical Product Stability	qlco	5.18
28087700	C0205360	Stable status	qlco	5.18
28087700	C0332454	disrupted	qlco	5.18
28087700	C3854321	Expression (foundation metadata concept)	idcn	3.63
28087700	C0185117	Expression procedure	topp	3.63
28087700	C1524003	Science of Etiology	cnce	3.55
28087700	C0542341	Function	ftcn	3.54
28087700	C0700205	Function Axis	clas	3.54
28087700	C1705273	Mathematical Operator	inpr	3.54
28087700	C1413365	CFTR gene	gngm	3.49
28087700	C0596019	Chloride Ion	elii	3.42
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.02
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.02
28087700	C0009738	Congo	geoa	17.80
28087700	C0040363	Togo	geoa	17.80
28087700	C0041260	Tryptophanase	aapp	17.80
28087700	C0041260	Tryptophanase	enzy	17.80
28087700	C3264621	ivacaftor	orch	13.14
28087700	C3264621	ivacaftor	phsu	13.14
28087700	C3852684	lumacaftor	orch	13.09
28087700	C3852684	lumacaftor	phsu	13.09
28087700	C1413365	CFTR gene	gngm	6.95
28087700	C3811819	CFTR wt Allele	gngm	5.18
28087700	C1948052	Now (temporal qualifier)	tmco	5.18
28087700	C0947630	Scientific Study	lbpr	5.18
28087700	C0087111	Therapeutic procedure	topp	5.18
28087700	C1883351	To	qlco	5.18
28087700	C1522326	Treating	ftcn	5.18
28087700	C1292734	Treatment intent	ftcn	5.18
28087700	C1273517	Used by	fndg	5.18
28087700	C1705535	suggestion	idcn	5.18
28087700	C1328819	Small Molecule	orch	3.68
28087700	C1280500	Effect	qlco	3.56
28087700	C0205448	Two	qnco	3.47
28087700	C2347098	Medical Product Stability	qlco	3.43
28087700	C0205360	Stable status	qlco	3.43
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28087700	C0009738	Congo	geoa	16.08
28087700	C0026882	Mutation	genf	9.92
28087700	C1292732	Investigates	ftcn	5.18
28087700	C1705285	Mutation Abnormality	comd	3.61
28087700	C1825598	IMPACT gene	gngm	3.56
28087700	C4049986	Impact	qlco	3.56
28087700	C1444783	Instability	fndg	3.55
28087700	C3811819	CFTR wt Allele	gngm	3.47
28087700	C0205214	Common (qualifier value)	qnco	3.47
28087700	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.47
28087700	C0205393	Most	qnco	3.47
28087700	C1522138	shared attribute	ftcn	3.47
28087700	C1413365	CFTR gene	gngm	3.43
28087700	C0205198	Compound	qlco	3.41
28087700	C1706082	Compound (substance)	chem	3.41
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	92.53
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	92.53
28087700	C0040363	Togo	geoa	35.81
28087700	C0041260	Tryptophanase	aapp	35.81
28087700	C0041260	Tryptophanase	enzy	35.81
28087700	C0087136	Unmarried	fndg	22.56
28087700	C0037179	Unmarried person	popg	22.56
28087700	C0034869	Records	inpr	16.21
28087700	C1413365	CFTR gene	gngm	10.59
28087700	C1883351	To	qlco	10.42
28087700	C1257890	Population Group	popg	9.94
28087700	C0439799	Channel	spco	7.53
28087700	C1706095	Channel Object	cnce	7.53
28087700	C0596019	Chloride Ion	elii	7.31
28087700	C0032659	geographic population	qnco	6.79
28087700	C1516048	Assessed	acty	5.18
28087700	C0521116	Current (present time)	tmco	5.18
28087700	C0884358	Performed	ftcn	5.18
28087700	C0557651	Room of building - Study	mnob	5.18
28087700	C2603343	Study	resa	5.18
28087700	C1273517	Used by	fndg	5.18
28087700	C0205171	Singular	qnco	3.63
28087700	C3853788	Record - QueryRequestLimit	qnco	3.59
28087700	C0439751	Entire	qnco	3.48
28087700	C0439806	Gross (qualifier value)	qlco	3.48
28087700	C0237401	Individual	humn	3.48
28087700	C0027361	Persons	popg	3.48
28087700	C1998793	Purifying	ftcn	3.48
28087700	C0444667	Whole	qnco	3.48
28087700	C0009264	Cold Temperature	npop	22.38
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.37
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.37
28087700	C0031843	physiological aspects	phsf	12.91
28087700	C0007603	Plasma membrane	celc	9.77
28087700	C0439799	Channel	spco	7.08
28087700	C1706095	Channel Object	cnce	7.08
28087700	C0596901	Membrane	celc	6.60
28087700	C0025255	Tissue membrane	tisu	6.60
28087700	C1547282	Show	anim	3.98
28087700	C0994894	Patch Dosage Form	medd	3.58
28087700	C0392747	Changing	ftcn	3.48
28087700	C0521116	Current (present time)	tmco	3.46
28087700	C1705970	Electrical Current	npop	3.46
28087700	C0175566	Open	spco	3.46
28087700	C0806140	flow	npop	3.46
28087700	C3161472	Cellular Membrane	celc	3.46
28087700	C1183428	Solocyte	cell	3.45
28087700	C1413365	CFTR gene	gngm	3.45
28087700	C1880497	Empty (qualifier)	qlco	3.45
28087700	C1996904	Free (available (qualifier))	qlco	3.45
28087700	C0332296	Free of (attribute)	ftcn	3.45
28087700	C0542341	Function	ftcn	3.45
28087700	C0700205	Function Axis	clas	3.45
28087700	C0745777	Lost	ftcn	3.45
28087700	C3815882	Lost Medical Device	fndg	3.45
28087700	C1705273	Mathematical Operator	inpr	3.45
28087700	C1706182	Membrane Device Component	mnob	3.45
28087700	C0456962	Rapid	qlco	3.45
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.28
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.28
28087700	C1413365	CFTR gene	gngm	7.20
28087700	C1883559	Wild Type	gngm	3.59
28087700	C0597571	thermostability	npop	3.59
28087700	C1707455	Comparison	acty	3.55
28087700	C1998793	Purifying	ftcn	3.55
28087700	C0439092	Less Than	qnco	3.50
28087700	C0547044	Smaller	qlco	3.50
28087700	C3842590	10%	fndg	3.48
28087700	C0332232	Approximate	qlco	3.48
28087700	C0443225	Full	qlco	3.47
28087700	C1444754	Length	qnco	3.47
28087700	C1706316	Length of Trial	resa	3.47
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.11
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.11
28087700	C3852684	lumacaftor	orch	13.14
28087700	C3852684	lumacaftor	phsu	13.14
28087700	C1413365	CFTR gene	gngm	7.04
28087700	C0439799	Channel	spco	5.18
28087700	C1706095	Channel Object	cnce	5.18
28087700	C0184512	Stabilized (qualifier value)	qlco	5.18
28087700	C0443225	Full	qlco	3.46
28087700	C1444754	Length	qnco	3.46
28087700	C1706316	Length of Trial	resa	3.46
28087700	C1998793	Purifying	ftcn	3.46
28087700	C0596019	Chloride Ion	elii	3.42
28087700	C0205421	Deferred	tmco	3.42
28087700	C3272602	Delayed Testing	qlco	3.42
28087700	C0237401	Individual	humn	3.42
28087700	C0027361	Persons	popg	3.42
28087700	C2937276	Slight (qualifier value)	qlco	3.42
28087700	C0750482	Slightly (qualifier value)	qlco	3.42
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.52
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.52
28087700	C0009924	Contrast Media	irda	14.64
28087700	C3264621	ivacaftor	orch	12.92
28087700	C3264621	ivacaftor	phsu	12.92
28087700	C1979874	Contrast	qlco	5.18
28087700	C1413365	CFTR gene	gngm	3.59
28087700	C0521110	Accelerated	ftcn	3.48
28087700	C0439799	Channel	spco	3.48
28087700	C1706095	Channel Object	cnce	3.48
28087700	C0443225	Full	qlco	3.45
28087700	C1517331	Further	spco	3.45
28087700	C1444754	Length	qnco	3.45
28087700	C1706316	Length of Trial	resa	3.45
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.99
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.99
28087700	C3852684	lumacaftor	orch	14.64
28087700	C3852684	lumacaftor	phsu	14.64
28087700	C3245499	Colombia	geoa	13.01
28087700	C3264621	ivacaftor	orch	12.92
28087700	C3264621	ivacaftor	phsu	12.92
28087700	C1413365	CFTR gene	gngm	6.92
28087700	C0521116	Current (present time)	tmco	5.18
28087700	C0439590	Prolonged	tmco	5.18
28087700	C0205191	chronic	tmco	3.68
28087700	C0596019	Chloride Ion	elii	3.60
28087700	C0439806	Gross (qualifier value)	qlco	3.46
28087700	C0007634	Cells	cell	3.42
28087700	C3282337	Cells [Chemical/Ingredient]	cell	3.42
28087700	C0087136	Unmarried	fndg	22.40
28087700	C0037179	Unmarried person	popg	22.40
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
28087700	C3245499	Colombia	geoa	12.91
28087700	C0007603	Plasma membrane	celc	10.09
28087700	C0991556	Transdermal Patch	medd	8.34
28087700	C0439799	Channel	spco	6.97
28087700	C1706095	Channel Object	cnce	6.97
28087700	C0596901	Membrane	celc	6.79
28087700	C0025255	Tissue membrane	tisu	6.79
28087700	C1533128	Body tissue patch material	bodm	5.18
28087700	C0445403	Human patch material	bodm	5.18
28087700	C1518422	Negation	ftcn	5.18
28087700	C1707974	Patch - Extended Release Film	bodm	5.18
28087700	C0994894	Patch Dosage Form	medd	5.18
28087700	C1706366	Patch Dosing Unit	qnco	5.18
28087700	C0332461	Plaque (lesion)	fndg	5.18
28087700	C1305400	Surgical patch	medd	5.18
28087700	C3161472	Cellular Membrane	celc	3.78
28087700	C0474395	Behavior showing increased motor activity	fndg	3.65
28087700	C0456079	Disease classification level	clas	3.63
28087700	C1547707	Floor - story of building	geoa	3.63
28087700	C2946261	Level	phsu	3.63
28087700	C0441889	Levels (qualifier value)	qlco	3.63
28087700	C1706182	Membrane Device Component	mnob	3.63
28087700	C1153410	channel activity	moft	3.61
28087700	C2347098	Medical Product Stability	qlco	3.57
28087700	C0205360	Stable status	qlco	3.57
28087700	C1183428	Solocyte	cell	3.53
28087700	C1880497	Empty (qualifier)	qlco	3.48
28087700	C1996904	Free (available (qualifier))	qlco	3.48
28087700	C0332296	Free of (attribute)	ftcn	3.48
28087700	C0205171	Singular	qnco	3.48
28087700	C1413365	CFTR gene	gngm	3.45
28087700	C3840786	Greatly	fndg	3.45
28087700	C0442805	Increase	ftcn	3.45
28087700	C0205217	Increased	qnco	3.45
28087700	C0205191	chronic	tmco	3.45
28087700	C0442043	Temporal - Regional site descriptor	spco	3.44
28087700	C2362314	Temporal -Temporal Qualifier	tmco	3.44
28087700	C0917903	Conclude Resin	bodm	27.26
28087700	C0917903	Conclude Resin	orch	27.26
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28087700	C3852684	lumacaftor	orch	13.14
28087700	C3852684	lumacaftor	phsu	13.14
28087700	C3264621	ivacaftor	orch	12.94
28087700	C3264621	ivacaftor	phsu	12.94
28087700	C0680220	majority	socb	5.18
28087700	C0439799	Channel	spco	3.98
28087700	C1706095	Channel Object	cnce	3.98
28087700	C0814472	co-treatment	hlca	3.75
28087700	C2347098	Medical Product Stability	qlco	3.54
28087700	C0205360	Stable status	qlco	3.54
28087700	C0205191	chronic	tmco	3.50
28087700	C0679993	small groups	grpa	3.43
28087700	C1413365	CFTR gene	gngm	3.42
28087700	C0596019	Chloride Ion	elii	3.42
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28087700	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28087700	C0009738	Congo	geoa	16.05
28087700	C0162340	Comprehension	menp	13.01
28087700	C1880022	Characterization	acty	3.54
28087700	C0679993	small groups	grpa	3.44
28087700	C1522647	Developmental Therapeutics Program	resa	3.43
28087700	C0556496	Developmental therapy	topp	3.43
28087700	C3811819	CFTR wt Allele	gngm	3.43
28087700	C1280500	Effect	qlco	3.43
28087700	C1413365	CFTR gene	gngm	3.42
23856023	C0039798	therapeutic aspects	ftcn	22.48
23856023	C0023671	Life Expectancy	grpa	19.35
23856023	C0010674	Cystic Fibrosis	dsyn	9.76
23856023	C0449445	Approach	spco	5.18
23856023	C2826771	Birth Year	tmco	3.60
23856023	C1533734	Administration procedure	topp	3.55
23856023	C1705169	Biomaterial Treatment	cnce	3.55
23856023	C0087111	Therapeutic procedure	topp	3.55
23856023	C1522326	Treating	ftcn	3.55
23856023	C3538994	Treatment Epoch	resa	3.55
23856023	C3887704	treatment - ActInformationManagementReason	hlca	3.55
23856023	C2986411	Improvement	cnce	3.55
23856023	C0442805	Increase	ftcn	3.55
23856023	C1708698	Light Emitting Diode Device Component	mnob	3.55
23856023	C0439509	/40	tmco	3.44
23856023	C3842587	40%	qnco	3.44
23856023	C0205448	Two	qnco	3.42
23856023	C2981279	Decade	qnco	3.40
23856023	C0030705	Patients	podg	13.37
23856023	C0016674	France	geoa	9.90
23856023	C1257890	Population Group	popg	9.87
23856023	C0001675	Adult	aggp	9.74
23856023	C0032659	geographic population	qnco	6.71
23856023	C0442808	Increasing	ftcn	5.18
23856023	C0332283	Followed by	tmco	3.59
23856023	C3842586	50%	fndg	3.57
23856023	C3843766	<50	fndg	3.57
23856023	C0521116	Current (present time)	tmco	3.57
23856023	C1706450	Legal Adult	humn	3.43
23856023	C0027617	Neonatal Screening	diap	25.51
23856023	C0010674	Cystic Fibrosis	dsyn	11.49
23856023	C1552821	justify	ftcn	3.98
23856023	C3854260	Advance	tmco	3.63
23856023	C0725066	Advance -- medical device	medd	3.63
23856023	C0302350	Therapeutic	ftcn	3.50
23856023	C0087111	Therapeutic procedure	topp	3.50
23856023	C0205246	Generalized	spco	3.42
23856023	C0021149	Incidence	qnco	45.20
23856023	C0481667	Live Birth	qlco	22.36
23856023	C0220856	incidence of cases	ftcn	7.13
23856023	C1547282	Show	anim	5.18
23856023	C0439234	year	tmco	3.60
23856023	C1511726	Data	idcn	3.55
23856023	C3714741	Data (eukaryote)	euka	3.55
23856023	C3245479	Data call receiving device	medd	3.55
23856023	C0205108	Distal	spco	3.55
23856023	C1272684	Accepted	qlco	3.46
23856023	C1548435	Referral status - Accepted	idcn	3.46
23856023	C0724000	Twenties	aggp	3.46
23856023	C3715212	Twenty	qnco	3.46
23856023	C2698722	CF-1 Mouse	mamm	3.43
23856023	C0220909	Aspects of disease screening	ftcn	3.43
23856023	C1710031	Disease Screening	diap	3.43
23856023	C0220908	Screening procedure	hlca	3.43
23856023	C1710477	Trial Screening	resa	3.43
23856023	C1698960	research subject screening	inpr	3.43
23856023	C0205087	Late	tmco	3.41
23856023	C0041236	TRYPSIN	aapp	22.48
23856023	C0041236	TRYPSIN	enzy	22.48
23856023	C0041236	TRYPSIN	phsu	22.48
23856023	C0009738	Congo	geoa	16.09
23856023	C0026882	Mutation	genf	9.73
23856023	C0868928	Case (situation)	ftcn	7.23
23856023	C0521116	Current (present time)	tmco	5.18
23856023	C0439508	per year	tmco	5.18
23856023	C0439234	year	tmco	5.18
23856023	C0872193	immunoreaction	orgf	3.82
23856023	C0597879	immunoreactivity	moft	3.82
23856023	C1533148	Case unit dose	qnco	3.63
23856023	C1706256	Clinical Study Case	cnce	3.56
23856023	C0442726	Detected (finding)	fndg	3.56
23856023	C3891454	Dosing Days to Detection	tmco	3.56
23856023	C0332283	Followed by	tmco	3.56
23856023	C1706255	Packaging Case	medd	3.56
23856023	C0597198	Performance	inbe	3.56
23856023	C1882330	performance - action	acty	3.56
23856023	C1705938	Base - General Qualifier	idcn	3.55
23856023	C1527178	Basis - conceptual entity	ftcn	3.55
23856023	C0178602	Dosage	qnco	3.55
23856023	C0449864	Threshold	qlco	3.54
23856023	C3811819	CFTR wt Allele	gngm	3.48
23856023	C0220909	Aspects of disease screening	ftcn	3.43
23856023	C1710031	Disease Screening	diap	3.43
23856023	C0220908	Screening procedure	hlca	3.43
23856023	C1710477	Trial Screening	resa	3.43
23856023	C1698960	research subject screening	inpr	3.43
23856023	C3842588	30%	fndg	3.42
23856023	C0205214	Common (qualifier value)	qnco	3.42
23856023	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
23856023	C1706202	Search - action	acty	3.42
23856023	C1552603	search - EntityNameUse	inpr	3.42
23856023	C1522138	shared attribute	ftcn	3.42
23856023	C0005615	Birth	orgf	19.36
23856023	C0040363	Togo	geoa	17.80
23856023	C0041260	Tryptophanase	aapp	17.80
23856023	C0041260	Tryptophanase	enzy	17.80
23856023	C0023175	Lead	elii	14.64
23856023	C0023175	Lead	hops	14.64
23856023	C0008059	Child	aggp	9.90
23856023	C0010674	Cystic Fibrosis	dsyn	9.77
23856023	C3275067	Cardiac Lead Procedure	topp	5.18
23856023	C2348269	Dietary Lead	elii	5.18
23856023	C1554077	Excluded - Conformance Inclusion	idcn	5.18
23856023	C2828389	Exclusion	acty	5.18
23856023	C1522538	Leading	ftcn	5.18
23856023	C1442948	Plumbum metallicum, homeopathic preparation	inch	5.18
23856023	C1442948	Plumbum metallicum, homeopathic preparation	phsu	5.18
23856023	C0430179	Sweat test	lbpr	5.18
23856023	C1883351	To	qlco	5.18
23856023	C0680063	Offspring	famg	3.59
23856023	C1457887	Symptoms	sosy	3.56
23856023	C0683368	Symptoms aspect	ftcn	3.56
23856023	C0332149	Possible	qlco	3.48
23856023	C2362652	Possible diagnosis	qlco	3.48
23856023	C1705910	Possibly Related to Intervention	qlco	3.48
23856023	C0205558	False Negative	lbtr	3.43
23856023	C0220909	Aspects of disease screening	ftcn	3.42
23856023	C1710031	Disease Screening	diap	3.42
23856023	C0220908	Screening procedure	hlca	3.42
23856023	C1710477	Trial Screening	resa	3.42
23856023	C1698960	research subject screening	inpr	3.42
23856023	C0298973	Ataxia Telangiectasia Mutated Proteins	aapp	25.52
23856023	C0298973	Ataxia Telangiectasia Mutated Proteins	enzy	25.52
23856023	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
23856023	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
23856023	C0010674	Cystic Fibrosis	dsyn	9.76
23856023	C0018017	objective (goal)	inpr	9.74
23856023	C0470187	Availability of	ftcn	5.18
23856023	C0087111	Therapeutic procedure	topp	5.18
23856023	C1709060	Modulator Device Component	mnob	3.59
23856023	C3858838	therapeutic class	inpr	3.59
23856023	C0686907	Consequence of	ftcn	3.57
23856023	C1457869	Defect	ftcn	3.55
23856023	C1413365	CFTR gene	gngm	3.48
23856023	C1947967	Call (Instruction)	ftcn	3.45
23856023	C0679006	Decision	menp	3.45
23856023	C1571704	Act Mood - Goal	idcn	3.43
23856023	C2349182	Correct (qualifier)	qlco	3.43
23856023	C0205108	Distal	spco	3.43
23856023	C0205314	New	qlco	3.43
23856023	C0542341	Function	ftcn	3.42
23856023	C0205245	Functional	ftcn	3.42
23856023	C2700217	Functional Relationship	cnce	3.42
23856023	C0206243	Carrying	acty	14.64
23856023	C3264621	ivacaftor	orch	13.14
23856023	C3264621	ivacaftor	phsu	13.14
23856023	C0026882	Mutation	genf	9.99
23856023	C0030705	Patients	podg	6.71
23856023	C1705285	Mutation Abnormality	comd	3.68
23856023	C0444454	Access	spco	3.56
23856023	C1554204	Role Class - access	ftcn	3.56
23856023	C3828193	September	tmco	3.56
23856023	C0683312	Categories	inpr	3.55
23856023	C3889287	Digital Content Category	clas	3.55
23856023	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.53
23856023	C0456387	Class	inpr	3.43
23856023	C1705943	Class (taxonomic)	clas	3.43
23856023	C1318228	Market	geoa	3.43
23856023	C0205314	New	qlco	3.43
23856023	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
23856023	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
23856023	C0027365	Name	inpr	20.95
23856023	C0206243	Carrying	acty	14.64
23856023	C3264621	ivacaftor	orch	12.90
23856023	C3264621	ivacaftor	phsu	12.90
23856023	C0026882	Mutation	genf	9.94
23856023	C0030705	Patients	podg	6.83
23856023	C0567416	Molecule	sbst	5.18
23856023	C0205314	New	qlco	3.68
23856023	C1705285	Mutation Abnormality	comd	3.63
23856023	C0678723	Biologic Development	orgf	3.59
23856023	C1527148	Development	ftcn	3.59
23856023	C0243107	development aspects	phsf	3.59
23856023	C1280500	Effect	qlco	3.57
23856023	C2348382	Effect, Appearance	qlco	3.57
23856023	C2986495	Synergistic	qlco	3.57
23856023	C2699424	Concern	idcn	3.50
23856023	C1413365	CFTR gene	gngm	3.48
23856023	C0205214	Common (qualifier value)	qnco	3.48
23856023	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.48
23856023	C0205393	Most	qnco	3.48
23856023	C1522138	shared attribute	ftcn	3.48
21349786	C0043240	Wound Healing	orgf	12.96
21349786	C0030351	Paper	mnob	11.49
21349786	C1564139	Mutant Proteins	aapp	10.06
21349786	C0010674	Cystic Fibrosis	dsyn	9.74
21349786	C3889645	Clinical Trial Final Report	inpr	5.18
21349786	C1547566	Paper Authorization	idcn	5.18
21349786	C3273238	Regulatory Report	inpr	5.18
21349786	C0684224	Report (document)	inpr	5.18
21349786	C0700287	Reporting	hlca	5.18
21349786	C0332529	Consistency	qlco	3.55
21349786	C0449445	Approach	spco	3.54
21349786	C0374711	Surgical repair	topp	3.50
21349786	C0332452	defective	ftcn	3.48
21349786	C0683465	novel AODU treatment method	topp	3.43
21349786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
21349786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
21349786	C0055363	Chloride Channels	aapp	19.52
21349786	C0055363	Chloride Channels	bacs	19.52
21349786	C0037494	Sodium Chloride	bacs	16.21
21349786	C0037494	Sodium Chloride	inch	16.21
21349786	C0037494	Sodium Chloride	phsu	16.21
21349786	C0206136	Sodium Chloride, Dietary	food	13.05
21349786	C0010674	Cystic Fibrosis	dsyn	9.77
21349786	C0024109	Lung	bpoc	8.34
21349786	C0030274	Pancreas	bpoc	8.34
21349786	C0036140	Salts	chvs	6.74
21349786	C0030705	Patients	podg	6.71
21349786	C1413365	CFTR gene	gngm	5.18
21349786	C2700640	Encode (action)	acty	5.18
21349786	C1278931	Entire pancreas	bpoc	5.18
21349786	C0332257	Including (qualifier)	ftcn	5.18
21349786	C1547699	MIME encoding	idcn	5.18
21349786	C1159569	fluid transport	celf	3.61
21349786	C0678941	Gene Mutant	gngm	3.60
21349786	C0596611	Gene Mutation	genf	3.60
21349786	C1314939	Involvement with	ftcn	3.59
21349786	C0221908	epithelial	qlco	3.48
21349786	C0439064	Numerous	qnco	3.43
21349786	C0178784	Organ	bpoc	3.43
21349786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.04
21349786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.04
21349786	C0026882	Mutation	genf	30.21
21349786	C0055363	Chloride Channels	aapp	19.22
21349786	C0055363	Chloride Channels	bacs	19.22
21349786	C0004340	Australia	geoa	12.89
21349786	C1705285	Mutation Abnormality	comd	7.06
21349786	C0030705	Patients	podg	6.71
21349786	C0205214	Common (qualifier value)	qnco	3.68
21349786	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.68
21349786	C1522138	shared attribute	ftcn	3.68
21349786	C0150312	Present	qnco	3.59
21349786	C0728893	+5	qnco	3.56
21349786	C0439084	>5	qnco	3.56
21349786	C1280500	Effect	qlco	3.55
21349786	C0175566	Open	spco	3.55
21349786	C1882151	Opening	spco	3.55
21349786	C0205393	Most	qnco	3.50
21349786	C1413365	CFTR gene	gngm	3.48
21349786	C1705242	Different	qlco	3.43
21349786	C0332452	defective	ftcn	3.43
21349786	C0040363	Togo	geoa	35.81
21349786	C0041260	Tryptophanase	aapp	35.81
21349786	C0041260	Tryptophanase	enzy	35.81
21349786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
21349786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
21349786	C0599331	Nasal Epithelium	tisu	16.21
21349786	C0008203	Chlorides	inch	16.12
21349786	C0085732	Ability	orga	14.64
21349786	C1883351	To	qlco	10.42
21349786	C0242391	Cell Membrane Proteins	aapp	10.03
21349786	C0242391	Cell Membrane Proteins	rcpt	10.03
21349786	C0010674	Cystic Fibrosis	dsyn	9.90
21349786	C0030705	Patients	podg	6.71
21349786	C0043227	Work	ocac	6.59
21349786	C1299581	Able (finding)	fndg	5.18
21349786	C0450442	Agent	chvf	5.18
21349786	C1550718	Entity Name Part Type - given	idcn	5.18
21349786	C1442162	GIVEN	cnce	5.18
21349786	C1947971	Give - dosing instruction imperative	ftcn	5.18
21349786	C3244317	Given name	inpr	5.18
21349786	C2827718	In Vitro Route of Administration	ftcn	5.18
21349786	C0021135	In Vitro [Publication Type]	inpr	5.18
21349786	C0442805	Increase	ftcn	5.18
21349786	C0205309	Known	qlco	5.18
21349786	C1254351	Pharmacologic Substance	phsu	5.18
21349786	C1521826	Protocol Agent	inpr	5.18
21349786	C2741958	VX-770	orch	5.18
21349786	C1533691	in vitro	qlco	5.18
21349786	C1547282	Show	anim	3.98
21349786	C1179841	Plasma membrane protein	aapp	3.72
21349786	C1179841	Plasma membrane protein	bacs	3.72
21349786	C0439228	day	tmco	3.68
21349786	C0459205	Type of activity	inpr	3.64
21349786	C3812881	Author	prog	3.56
21349786	C1705241	Delta (difference)	qnco	3.55
21349786	C1705242	Different	qlco	3.55
21349786	C0444706	Measured	qlco	3.55
21349786	C3541902	Measured Tumor Identification	diap	3.55
21349786	C0442027	Oral	spco	3.55
21349786	C3245505	potential	qlco	3.55
21349786	C0596019	Chloride Ion	elii	3.50
21349786	C1413365	CFTR gene	gngm	3.46
21349786	C0445392	Wild	inpr	3.43
21349786	C0004268	Attention	menp	13.01
21349786	C0038989	Sweat Glands	bpoc	9.74
21349786	C0428295	Cystic fibrosis sweat test	lbpr	3.59
21349786	C1304760	Sweat chloride level result	lbtr	3.59
21349786	C1159591	chloride transport	celf	3.56
21349786	C1446561	Concentration measurement	qnco	3.55
21349786	C0444706	Measured	qlco	3.55
21349786	C3541902	Measured Tumor Identification	diap	3.55
21349786	C0086045	Mental concentration	menp	3.55
21349786	C0450442	Agent	chvf	3.42
21349786	C1254351	Pharmacologic Substance	phsu	3.42
21349786	C1521826	Protocol Agent	inpr	3.42
21349786	C0016529	Forced expiratory volume function	ortf	19.41
21349786	C1561566	FEV1 Adverse Event	fndg	5.18
21349786	C0442805	Increase	ftcn	5.18
21349786	C0205217	Increased	qnco	5.18
21349786	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	5.18
21349786	C2741958	VX-770	orch	5.18
21349786	C1306036	Forced expiratory volume procedure	diap	3.64
21349786	C1561503	Precision - second	idcn	3.43
21349786	C1705190	Second Suffix	qlco	3.43
21349786	C0565930	per second	qnco	3.43
21349786	C0205436	second (number)	qnco	3.43
21349786	C0457385	seconds	tmco	3.43
21349786	C0017979	Glycosuria	fndg	17.80
21349786	C0001688	aspects of adverse effects	ftcn	10.06
21349786	C0332257	Including (qualifier)	ftcn	5.18
21349786	C0221201	Macular rash	sosy	5.18
21349786	C0879626	Adverse effects	patf	3.75
21349786	C0702240	Elevation	spco	3.56
21349786	C0439775	Elevation procedure	topp	3.56
21349786	C2585282	Blood glucose concentration	fndg	3.50
21349786	C0001688	aspects of adverse effects	ftcn	11.49
21349786	C0879626	Adverse effects	patf	5.18
21349786	C0457454	Discontinuation (procedure)	hlca	3.55
21349786	C1444662	Discontinued	fndg	3.55
21349786	C0013227	Pharmaceutical Preparations	phsu	3.55
21349786	C1254351	Pharmacologic Substance	phsu	3.55
21349786	C2699488	Resolution	cnce	3.55
21349786	C3714811	Resolved	fndg	3.55
21349786	C3897700	Resolved License	ftcn	3.55
21349786	C1514893	physiologic resolution	patf	3.55
21349786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
21349786	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
21349786	C0040363	Togo	geoa	17.80
21349786	C0041260	Tryptophanase	aapp	17.80
21349786	C0041260	Tryptophanase	enzy	17.80
21349786	C0699040	Cell surface	celc	5.18
21349786	C0439799	Channel	spco	5.18
21349786	C1706095	Channel Object	cnce	5.18
21349786	C2827718	In Vitro Route of Administration	ftcn	5.18
21349786	C0021135	In Vitro [Publication Type]	inpr	5.18
21349786	C0442805	Increase	ftcn	5.18
21349786	C1999230	Providing (action)	acty	5.18
21349786	C2584321	Reaching	orgf	5.18
21349786	C1883351	To	qlco	5.18
21349786	C1533691	in vitro	qlco	5.18
21349786	C1547282	Show	anim	3.98
21349786	C2741958	VX-770	orch	3.75
21349786	C1561536	*Activity (kind of quantity)	idcn	3.56
21349786	C0205177	Active	ftcn	3.56
21349786	C0441655	Activities	acty	3.56
21349786	C3668946	Activity (animal life circumstance)	fndg	3.56
21349786	C4049939	FDA Establishment Activity Terminology	inpr	3.56
21349786	C0439167	Percent Activity	qnco	3.56
21349786	C4049938	Physical Activity Measurement	lbpr	3.56
21349786	C1413365	CFTR gene	gngm	3.43
21349786	C0039798	therapeutic aspects	ftcn	22.35
21349786	C0040363	Togo	geoa	17.80
21349786	C0041260	Tryptophanase	aapp	17.80
21349786	C0041260	Tryptophanase	enzy	17.80
21349786	C0010674	Cystic Fibrosis	dsyn	9.75
21349786	C0700364	Appearance	qlco	5.18
21349786	C2316203	Family history of hereditary disease	fndg	5.18
21349786	C2924406	Genetic disorders screening	lbpr	5.18
21349786	C2362652	Possible diagnosis	qlco	5.18
21349786	C0557651	Room of building - Study	mnob	5.18
21349786	C2603343	Study	resa	5.18
21349786	C1883351	To	qlco	5.18
21349786	C2347129	Milestone	cnce	3.54
21349786	C1533734	Administration procedure	topp	3.42
21349786	C1705169	Biomaterial Treatment	cnce	3.42
21349786	C0087111	Therapeutic procedure	topp	3.42
21349786	C1522326	Treating	ftcn	3.42
21349786	C3538994	Treatment Epoch	resa	3.42
21349786	C3887704	treatment - ActInformationManagementReason	hlca	3.42
25732475	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
25732475	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
25732475	C0017337	Genes	gngm	16.22
25732475	C0008203	Chlorides	inch	16.05
25732475	C0015127	Etiology aspects	ftcn	9.86
25732475	C0010674	Cystic Fibrosis	dsyn	9.76
25732475	C0026882	Mutation	genf	9.74
25732475	C0033684	Proteins	aapp	6.79
25732475	C0033684	Proteins	bacs	6.79
25732475	C2700640	Encode (action)	acty	5.18
25732475	C1547699	MIME encoding	idcn	5.18
25732475	C1159589	bicarbonate transport	celf	3.61
25732475	C1413365	CFTR gene	gngm	3.58
25732475	C1517945	Loss	qnco	3.56
25732475	C1524003	Science of Etiology	cnce	3.55
25732475	C1704735	Regulator	cnce	3.48
25732475	C1704734	Regulator Device Component	mnob	3.48
25732475	C0182953	Regulators (device)	medd	3.48
25732475	C0678226	Due to	ftcn	3.46
25732475	C0596019	Chloride Ion	elii	3.43
25732475	C0221908	epithelial	qlco	3.43
25732475	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25732475	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25732475	C0017337	Genes	gngm	16.08
25732475	C3264621	ivacaftor	orch	13.14
25732475	C3264621	ivacaftor	phsu	13.14
25732475	C0026882	Mutation	genf	9.73
25732475	C0392760	Affecting	ftcn	5.18
25732475	C0205217	Increased	qnco	5.18
25732475	C1314939	Involvement with	ftcn	5.18
25732475	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.68
25732475	C1159591	chloride transport	celf	3.58
25732475	C0439799	Channel	spco	3.50
25732475	C1706095	Channel Object	cnce	3.50
25732475	C1552740	Entity Determiner - specific	inpr	3.47
25732475	C0205369	Specific qualifier value	qlco	3.47
25732475	C1515655	in vivo	spco	3.44
25732475	C1413365	CFTR gene	gngm	3.42
25732475	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.08
25732475	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.08
25732475	C0015272	Exhibits as Topic	inpr	35.81
25732475	C0026882	Mutation	genf	19.84
25732475	C0002085	Alleles	gngm	19.33
25732475	C3264621	ivacaftor	orch	14.64
25732475	C3264621	ivacaftor	phsu	14.64
25732475	C0031843	physiological aspects	phsf	14.64
25732475	C0205540	Approved	qlco	7.15
25732475	C1705285	Mutation Abnormality	comd	7.15
25732475	C1413365	CFTR gene	gngm	7.01
25732475	C0542341	Function	ftcn	5.18
25732475	C0700205	Function Axis	clas	5.18
25732475	C1705273	Mathematical Operator	inpr	5.18
25732475	C1948052	Now (temporal qualifier)	tmco	5.18
25732475	C0243067	defects aspect	ftcn	3.68
25732475	C0392366	Tests (qualifier value)	inpr	3.59
25732475	C1524062	Additional	ftcn	3.56
25732475	C0205454	Eight	qnco	3.56
25732475	C0205161	Abnormal	qlco	3.50
25732475	C2699333	Abnormal Reference Range	inpr	3.50
25732475	C2347472	Percent of Abnormal Cells	qnco	3.50
25732475	C1609982	Residual	qlco	3.43
25732475	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
25732475	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
25732475	C0015272	Exhibits as Topic	inpr	17.80
25732475	C0031843	physiological aspects	phsf	13.09
25732475	C0026882	Mutation	genf	11.49
25732475	C1705285	Mutation Abnormality	comd	5.18
25732475	C0542341	Function	ftcn	3.63
25732475	C0700205	Function Axis	clas	3.63
25732475	C1705273	Mathematical Operator	inpr	3.63
25732475	C0441888	Class 4	inpr	3.53
25732475	C1413365	CFTR gene	gngm	3.48
25732475	C1609982	Residual	qlco	3.48
25732475	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.52
25732475	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.52
25732475	C0039798	therapeutic aspects	ftcn	22.35
25732475	C0037981	Spirometry	diap	16.07
25732475	C3264621	ivacaftor	orch	13.01
25732475	C3264621	ivacaftor	phsu	13.01
25732475	C0238598	Young Adult	aggp	12.91
25732475	C0019425	Heterozygote	orga	9.78
25732475	C0013109	Drama	inpr	9.69
25732475	C3273238	Regulatory Report	inpr	5.18
25732475	C0684224	Report (document)	inpr	5.18
25732475	C0700287	Reporting	hlca	5.18
25732475	C2986411	Improvement	cnce	3.63
25732475	C1413365	CFTR gene	gngm	3.60
25732475	C1882115	Normalize	resa	3.59
25732475	C0439508	per year	tmco	3.55
25732475	C0439234	year	tmco	3.55
25732475	C0392756	Reduced	qlco	3.55
25732475	C0301630	Reduction (chemical)	npop	3.55
25732475	C0441610	Reduction - action	topp	3.55
25732475	C0205210	Clinical	qlco	3.48
25732475	C1706089	Marked	qlco	3.48
25732475	C0522501	Massive	qlco	3.48
25732475	C1553058	Neuropsychologist - Clinical	prog	3.48
25732475	C0237412	Psychologist - Clinical	prog	3.48
25732475	C0497591	Social Worker - Clinical	prog	3.48
25732475	C0205198	Compound	qlco	3.46
25732475	C1706082	Compound (substance)	chem	3.46
25732475	C0581602	Structural modification	topp	3.44
25732475	C1533734	Administration procedure	topp	3.43
25732475	C1705169	Biomaterial Treatment	cnce	3.43
25732475	C1435727	FABP6 protein, human	aapp	3.43
25732475	C1435727	FABP6 protein, human	bacs	3.43
25732475	C0087111	Therapeutic procedure	topp	3.43
25732475	C1522326	Treating	ftcn	3.43
25732475	C3538994	Treatment Epoch	resa	3.43
25732475	C3887704	treatment - ActInformationManagementReason	hlca	3.43
25732475	C0458827	Airway structure	bpoc	3.42
25732475	C0178987	Artificial Airways	medd	3.42
25732475	C0444708	Radiographic	npop	3.42
25732475	C0009738	Congo	geoa	16.18
25732475	C3264621	ivacaftor	orch	14.64
25732475	C3264621	ivacaftor	phsu	14.64
25732475	C0026882	Mutation	genf	9.74
25732475	C0030705	Patients	podg	6.59
25732475	C0868928	Case (situation)	ftcn	5.18
25732475	C1706256	Clinical Study Case	cnce	5.18
25732475	C1706255	Packaging Case	medd	5.18
25732475	C1705535	suggestion	idcn	5.18
25732475	C3811819	CFTR wt Allele	gngm	3.56
25732475	C0814225	benefit	qnco	3.56
25732475	C3245505	potential	qlco	3.43
29040544	C0002085	Alleles	gngm	19.38
29040544	C0010674	Cystic Fibrosis	dsyn	9.88
29040544	C0019425	Heterozygote	orga	9.87
29040544	C0026882	Mutation	genf	9.74
29040544	C0030705	Patients	podg	6.70
29040544	C3842586	50%	fndg	3.55
29040544	C3843766	<50	fndg	3.55
29040544	C0332232	Approximate	qlco	3.55
29040544	C0205447	One	qnco	3.47
29040544	C0521114	Infrequent	tmco	3.43
29040544	C1705285	Mutation Abnormality	comd	3.43
29040544	C0522498	Rare	qlco	3.43
29040544	C1514917	Retinoic Acid Response Element	gngm	3.43
29040544	C0015272	Exhibits as Topic	inpr	17.80
29040544	C0243067	defects aspect	ftcn	3.68
29040544	C0596988	mutant	comd	3.63
29040544	C0542341	Function	ftcn	3.50
29040544	C0205245	Functional	ftcn	3.50
29040544	C2700217	Functional Relationship	cnce	3.50
29040544	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
29040544	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
29040544	C0009738	Congo	geoa	16.12
29040544	C0023175	Lead	elii	13.03
29040544	C0023175	Lead	hops	13.03
29040544	C0013081	Down-Regulation	moft	13.02
29040544	C2362652	Possible diagnosis	qlco	5.18
29040544	C2741958	VX-770	orch	5.18
29040544	C0599946	Attenuation	acty	3.98
29040544	C0427861	Human cells	lbtr	3.70
29040544	C0418624	Nonadministration of necessary drug or medicine	fndg	3.70
29040544	C1280500	Effect	qlco	3.68
29040544	C2348382	Effect, Appearance	qlco	3.68
29040544	C0596988	mutant	comd	3.68
29040544	C0332157	Exposure to	clna	3.61
29040544	C0274281	Injury due to exposure to external cause	inpo	3.61
29040544	C2826170	Immortalization	mbrt	3.59
29040544	C0205474	Biochemical	ftcn	3.57
29040544	C3275067	Cardiac Lead Procedure	topp	3.57
29040544	C2348269	Dietary Lead	elii	3.57
29040544	C1522538	Leading	ftcn	3.57
29040544	C0181586	Leads (device)	medd	3.57
29040544	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.57
29040544	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.57
29040544	C3811819	CFTR wt Allele	gngm	3.50
29040544	C0443252	Long-term	tmco	3.50
29040544	C0458827	Airway structure	bpoc	3.47
29040544	C0178987	Artificial Airways	medd	3.47
29040544	C1720467	Only - dosing instruction fragment	inpr	3.47
29040544	C0205225	Primary	qlco	3.47
29040544	C0439631	Primary operation	topp	3.47
29040544	C0205171	Singular	qnco	3.47
29040544	C0439612	True primary (qualifier value)	tmco	3.47
29040544	C1413365	CFTR gene	gngm	3.43
29040544	C0542341	Function	ftcn	3.43
29040544	C0205245	Functional	ftcn	3.43
29040544	C2700217	Functional Relationship	cnce	3.43
29040544	C0086418	Homo sapiens	humn	28.71
29040544	C0040363	Togo	geoa	17.80
29040544	C0041260	Tryptophanase	aapp	17.80
29040544	C0041260	Tryptophanase	enzy	17.80
29040544	C0009738	Congo	geoa	16.04
29040544	C0014609	Epithelium	tisu	6.75
29040544	C0542341	Function	ftcn	5.18
29040544	C0205245	Functional	ftcn	5.18
29040544	C2700217	Functional Relationship	cnce	5.18
29040544	C1883351	To	qlco	5.18
29040544	C1444647	Wanted	fndg	5.18
29040544	C1705938	Base - General Qualifier	idcn	3.57
29040544	C1527178	Basis - conceptual entity	ftcn	3.57
29040544	C0518609	consideration	fndg	3.57
29040544	C1280500	Effect	qlco	3.55
29040544	C2348382	Effect, Appearance	qlco	3.55
29040544	C3854321	Expression (foundation metadata concept)	idcn	3.54
29040544	C0185117	Expression procedure	topp	3.54
29040544	C0458827	Airway structure	bpoc	3.48
29040544	C0178987	Artificial Airways	medd	3.48
29040544	C2741958	VX-770	orch	3.44
29040544	C0332157	Exposure to	clna	3.42
29040544	C0274281	Injury due to exposure to external cause	inpo	3.42
29040544	C0205191	chronic	tmco	3.42
29040544	C0205474	Biochemical	ftcn	3.42
29040544	C3811819	CFTR wt Allele	gngm	3.42
29040544	C0521114	Infrequent	tmco	3.42
29040544	C1709694	Processing (action)	acty	3.42
29040544	C0522498	Rare	qlco	3.42
29040544	C1514917	Retinoic Acid Response Element	gngm	3.42
29040544	C0596988	mutant	comd	3.42
29040544	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
29040544	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
29040544	C0014441	Enzyme-Linked Immunosorbent Assay	lbpr	16.25
29040544	C0599331	Nasal Epithelium	tisu	16.18
29040544	C0020985	Immunoblotting	lbpr	13.03
29040544	C0030695	Patient Monitoring	hlca	9.82
29040544	C0205039	Bronchial	bpoc	7.44
29040544	C1442216	Bronchial system	bpoc	7.44
29040544	C0030705	Patients	podg	6.74
29040544	C1441547	Derivation	qlco	5.18
29040544	C3245521	Derived value	idcn	5.18
29040544	C3828338	Reprogram	acty	5.18
29040544	C0682523	human cell line	cell	3.59
29040544	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.59
29040544	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.59
29040544	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.59
29040544	C3854307	Presence (property)	qlco	3.57
29040544	C0150312	Present	qnco	3.57
29040544	C0392148	Providing presence (regime/therapy)	topp	3.57
29040544	C3854321	Expression (foundation metadata concept)	idcn	3.56
29040544	C0185117	Expression procedure	topp	3.56
29040544	C0221908	epithelial	qlco	3.54
29040544	C0699040	Cell surface	celc	3.53
29040544	C0181904	Biomedical Monitors	medd	3.51
29040544	C1704646	Monitor Device Component	mnob	3.51
29040544	C1521743	Monitor, occupation	prog	3.51
29040544	C0596972	Monitoring Device	medd	3.51
29040544	C0150369	Preventive monitoring	hlca	3.51
29040544	C2984839	Device Short Circuit Evaluation Result	ftcn	3.44
29040544	C1689985	Absence (morphologic abnormality)	anab	3.44
29040544	C0332197	Absent	ftcn	3.44
29040544	C1413365	CFTR gene	gngm	3.44
29040544	C0596988	mutant	comd	3.43
29040544	C0521116	Current (present time)	tmco	3.42
29040544	C1705970	Electrical Current	npop	3.42
29040544	C0242485	Measurement	ftcn	3.42
29040544	C1709060	Modulator Device Component	mnob	3.42
29040544	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
29040544	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
29040544	C0004268	Attention	menp	13.02
29040544	C1704419	Effective	qlco	3.60
29040544	C1280519	Effectiveness	qlco	3.60
29040544	C1446561	Concentration measurement	qnco	3.56
29040544	C0086045	Mental concentration	menp	3.56
29040544	C2741958	VX-770	orch	3.49
29040544	C4049713	Borg Category-Ratio 10 Perceived Exertion Score 10	inpr	3.46
29040544	C2825407	Half	qnco	3.46
29040544	C0205289	Maximal (qualifier value)	qlco	3.46
29040544	C0806909	Maximum	qnco	3.46
29040544	C1879547	Activation action	acty	3.43
29040544	C1413365	CFTR gene	gngm	3.43
29040544	C0086418	Homo sapiens	humn	28.66
29040544	C0040363	Togo	geoa	17.80
29040544	C0041260	Tryptophanase	aapp	17.80
29040544	C0041260	Tryptophanase	enzy	17.80
29040544	C0599331	Nasal Epithelium	tisu	16.04
29040544	C0004268	Attention	menp	13.14
29040544	C0024109	Lung	bpoc	6.72
29040544	C1883351	To	qlco	5.18
29040544	C1446561	Concentration measurement	qnco	3.68
29040544	C0086045	Mental concentration	menp	3.68
29040544	C0814225	benefit	qnco	3.68
29040544	C1278908	Entire lung	bpoc	3.57
29040544	C1514873	Requirement	ftcn	3.57
29040544	C0819757	Structure of parenchyma of lung	tisu	3.57
29040544	C0205210	Clinical	qlco	3.50
29040544	C1553058	Neuropsychologist - Clinical	prog	3.50
29040544	C0237412	Psychologist - Clinical	prog	3.50
29040544	C0497591	Social Worker - Clinical	prog	3.50
29040544	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
29040544	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
29040544	C0013081	Down-Regulation	moft	12.89
29040544	C0600495	Inhibitory Concentration 50	qnco	12.88
29040544	C0205216	Decreased	qnco	5.18
29040544	C2827758	Antimicrobial Susceptibility Result	lbtr	3.56
29040544	C0220898	Predisposition	orga	3.56
29040544	C0231204	Susceptible	ftcn	3.56
29040544	C1517378	Gain	qnco	3.55
29040544	C0205451	Five	qnco	3.54
29040544	C0521114	Infrequent	tmco	3.54
29040544	C0522498	Rare	qlco	3.54
29040544	C1514917	Retinoic Acid Response Element	gngm	3.54
29040544	C0205458	Twelve	qnco	3.54
29040544	C0596988	mutant	comd	3.54
29040544	C0332157	Exposure to	clna	3.54
29040544	C0274281	Injury due to exposure to external cause	inpo	3.54
29040544	C1517586	Investigational	qlco	3.50
29040544	C3245491	investigational monitoring program	hlca	3.50
29040544	C3842584	70%	fndg	3.43
29040544	C2741958	VX-770	orch	3.43
29040544	C1413365	CFTR gene	gngm	3.42
29040544	C0542341	Function	ftcn	3.42
29040544	C0205245	Functional	ftcn	3.42
29040544	C2700217	Functional Relationship	cnce	3.42
29040544	C0205225	Primary	qlco	3.42
29040544	C0439631	Primary operation	topp	3.42
29040544	C0439612	True primary (qualifier value)	tmco	3.42
29040544	C3842589	20%	fndg	3.42
29040544	C0205191	chronic	tmco	3.42
29040544	C1709060	Modulator Device Component	mnob	3.40
29040544	C0086418	Homo sapiens	humn	28.66
29040544	C0026882	Mutation	genf	11.49
29040544	C1705285	Mutation Abnormality	comd	5.18
29040544	C0332157	Exposure to	clna	3.61
29040544	C0205191	chronic	tmco	3.56
29040544	C0596988	mutant	comd	3.55
29040544	C1709630	Preclinical	qlco	3.50
29040544	C0205198	Compound	qlco	3.48
29040544	C1706082	Compound (substance)	chem	3.48
29040544	C1552740	Entity Determiner - specific	inpr	3.48
29040544	C0205369	Specific qualifier value	qlco	3.48
29040544	C2741958	VX-770	orch	3.46
29040544	C0458827	Airway structure	bpoc	3.42
29040544	C0178987	Artificial Airways	medd	3.42
29040544	C3161035	Model	inpr	3.42
29040544	C0221908	epithelial	qlco	3.42
29040544	C0009738	Congo	geoa	16.04
29040544	C2718059	Precision Medicine	topp	13.00
29040544	C1510823	Advocate (person)	ocdi	3.98
29040544	C0449445	Approach	spco	3.63
29040544	C1280500	Effect	qlco	3.55
29040544	C3898777	Important	qlco	3.49
29040544	C3687832	DRUGS	topp	3.43
29040544	C0013227	Pharmaceutical Preparations	phsu	3.43
29040544	C3811819	CFTR wt Allele	gngm	3.42
29040544	C2945599	Mild (qualifier value)	qlco	3.42
29040544	C0547040	Minimal	qlco	3.42
29040544	C1524031	Minimum	qlco	3.42
29040544	C0596988	mutant	comd	3.42
29040544	C1707391	Choose (action)	acty	3.41
25688481	C0039798	therapeutic aspects	ftcn	22.48
25688481	C0015695	Fatty Liver	dsyn	11.49
25688481	C2711227	Steatohepatitis	dsyn	11.49
25688481	C0010674	Cystic Fibrosis	dsyn	9.77
25688481	C0030705	Patients	podg	6.71
25688481	C0023895	Liver diseases	dsyn	6.64
25688481	C0332257	Including (qualifier)	ftcn	5.18
25688481	C0439801	Limited (extensiveness)	ftcn	5.18
25688481	C4050251	Limited Lifting Ability	inpr	5.18
25688481	C2674459	Limited Walking Ability	fndg	5.18
25688481	C3542948	Limited component (foundation metadata concept)	inpr	5.18
25688481	C1533734	Administration procedure	topp	3.56
25688481	C1705169	Biomaterial Treatment	cnce	3.56
25688481	C0087111	Therapeutic procedure	topp	3.56
25688481	C1522326	Treating	ftcn	3.56
25688481	C3538994	Treatment Epoch	resa	3.56
25688481	C3887704	treatment - ActInformationManagementReason	hlca	3.56
25688481	C0009738	Congo	geoa	32.26
25688481	C3264621	ivacaftor	orch	12.89
25688481	C3264621	ivacaftor	phsu	12.89
25688481	C1257890	Population Group	popg	9.73
25688481	C3811819	CFTR wt Allele	gngm	6.88
25688481	C0030705	Patients	podg	6.57
25688481	C0032659	geographic population	qnco	6.57
25688481	C2349182	Correct (qualifier)	qlco	5.18
25688481	C3242274	new therapy	fndg	3.75
25688481	C0678723	Biologic Development	orgf	3.56
25688481	C1527148	Development	ftcn	3.56
25688481	C0243107	development aspects	phsf	3.56
25688481	C1457869	Defect	ftcn	3.54
25688481	C0470187	Availability of	ftcn	3.53
25688481	C3245505	potential	qlco	3.48
25688481	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.42
25688481	C0439799	Channel	spco	3.42
25688481	C1706095	Channel Object	cnce	3.42
25688481	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.42
25688481	C1704735	Regulator	cnce	3.42
25688481	C1704734	Regulator Device Component	mnob	3.42
25688481	C0182953	Regulators (device)	medd	3.42
25688481	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.42
25688481	C1515021	Subgroup	clas	3.42
25688481	C1079230	Subgroup A Nepoviruses	virs	3.42
25688481	C2752508	fully spanning the plasma membrane	celc	3.42
25688481	C1167322	integral to membrane	celc	3.42
25688481	C0039798	therapeutic aspects	ftcn	22.61
25688481	C0009738	Congo	geoa	16.05
25688481	C3264621	ivacaftor	orch	12.96
25688481	C3264621	ivacaftor	phsu	12.96
25688481	C0205653	Adolescent (age group)	aggp	9.88
25688481	C0015695	Fatty Liver	dsyn	9.77
25688481	C2711227	Steatohepatitis	dsyn	9.77
25688481	C1709305	Occur (action)	acty	5.18
25688481	C0150312	Present	qnco	5.18
25688481	C0449450	Presentation	idcn	5.18
25688481	C1533734	Administration procedure	topp	3.68
25688481	C1705169	Biomaterial Treatment	cnce	3.68
25688481	C0087111	Therapeutic procedure	topp	3.68
25688481	C1522326	Treating	ftcn	3.68
25688481	C3538994	Treatment Epoch	resa	3.68
25688481	C3887704	treatment - ActInformationManagementReason	hlca	3.68
25688481	C2986411	Improvement	cnce	3.56
25688481	C2372007	Hypothesizing	menp	3.55
25688481	C0441712	Mechanism (attribute)	ftcn	3.55
25688481	C1706376	Mechanism Component of Device	mnob	3.55
25688481	C3811819	CFTR wt Allele	gngm	3.44
25688481	C1546944	Event Seriousness - Significant	qlco	3.43
25688481	C0750502	Significant	idcn	3.43
25688481	C0237881	Statistical Significance	qnco	3.43
27126691	C3264621	ivacaftor	orch	13.14
27126691	C3264621	ivacaftor	phsu	13.14
27126691	C0026882	Mutation	genf	10.06
27126691	C0033363	Projection Defense Mechanism	menp	9.99
27126691	C0010674	Cystic Fibrosis	dsyn	9.75
27126691	C0016538	Projections and Predictions	inpr	6.83
27126691	C0332268	Lacking	qlco	5.18
27126691	C0348018	Spatial Projection	spco	3.68
27126691	C0205210	Clinical	qlco	3.63
27126691	C1553058	Neuropsychologist - Clinical	prog	3.63
27126691	C0237412	Psychologist - Clinical	prog	3.63
27126691	C0497591	Social Worker - Clinical	prog	3.63
27126691	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.56
27126691	C3242455	HL7PublishingDomain <patient administration>	inpr	3.56
27126691	C3242279	healthcare operations <patient administration>	ocac	3.56
27126691	C0443252	Long-term	tmco	3.53
27126691	C4050363	Comprehensive Score for Financial Toxicity	inpr	3.50
27126691	C0220812	Cost aspects	ftcn	3.50
27126691	C0010186	Financial cost	qnco	3.50
27126691	C0444503	Breakthrough	qlco	3.42
27126691	C3264621	ivacaftor	orch	12.90
27126691	C3264621	ivacaftor	phsu	12.90
27126691	C3538928	Usual	qlco	7.40
27126691	C1947933	care activity	acty	7.40
27126691	C0016538	Projections and Predictions	inpr	7.13
27126691	C0439044	Living Alone	fndg	5.18
27126691	C0557651	Room of building - Study	mnob	5.18
27126691	C0205171	Singular	qnco	5.18
27126691	C2603343	Study	resa	5.18
27126691	C0679994	alone - group size	grpa	5.18
27126691	C1274040	Result	ftcn	3.98
27126691	C4050363	Comprehensive Score for Financial Toxicity	inpr	3.57
27126691	C0220812	Cost aspects	ftcn	3.57
27126691	C0010186	Financial cost	qnco	3.57
27126691	C1707455	Comparison	acty	3.42
27126691	C0004927	Behavior	inbe	6.71
27126691	C3853906	Digital Model Attachment	inpr	3.63
27126691	C3161035	Model	inpr	3.63
27126691	C3714583	Model - style/design	cnce	3.63
27126691	C3274659	Model Number	inpr	3.63
27126691	C1555684	Transaction counts and value totals - Payor	inpr	3.50
27126691	C4071830	Lifetime	tmco	3.48
27126691	C0032952	Prednisone	horm	58.64
27126691	C0032952	Prednisone	orch	58.64
27126691	C0032952	Prednisone	phsu	58.64
27126691	C0044955	prednylidene	orch	39.42
27126691	C0044955	prednylidene	phsu	39.42
27126691	C0023376	Lesotho	geoa	32.66
27126691	C0016529	Forced expiratory volume function	ortf	19.41
27126691	C0024128	Lung Transplantation	topp	14.64
27126691	C0011065	Cessation of life	orgf	11.49
27126691	C1561566	FEV1 Adverse Event	fndg	10.58
27126691	C0429706	Forced expiratory volume in 1 second finding	fndg	10.58
27126691	C0849974	Pulmonary Function Test/Forced Expiratory Volume 1	diap	10.58
27126691	C0439509	/40	tmco	7.29
27126691	C3842587	40%	qnco	7.29
27126691	C3887647	Lymphotoxin-Alpha, human	aapp	7.28
27126691	C3887647	Lymphotoxin-Alpha, human	imft	7.28
27126691	C0230426	Structure of left thigh	bpoc	7.28
27126691	C0740116	+2	qnco	5.18
27126691	C0728893	+5	qnco	5.18
27126691	C3816745	1+	fndg	5.18
27126691	C2827734	1+ Score	qnco	5.18
27126691	C2981698	1+ Score, WHO	clas	5.18
27126691	C3833492	2+	fndg	5.18
27126691	C2827735	2+ Score	qnco	5.18
27126691	C2981700	2+ Score, WHO	clas	5.18
27126691	C3838680	3+ Answer to Question	fndg	5.18
27126691	C2827736	3+ Score	qnco	5.18
27126691	C2981702	3+ Score, WHO	clas	5.18
27126691	C3842584	70%	fndg	5.18
27126691	C0439086	<3 (qualifier value)	qnco	5.18
27126691	C0439084	>5	qnco	5.18
27126691	C1306577	Death (finding)	fndg	5.18
27126691	C3853906	Digital Model Attachment	inpr	5.18
27126691	C3161035	Model	inpr	5.18
27126691	C3714583	Model - style/design	cnce	5.18
27126691	C3274659	Model Number	inpr	5.18
27126691	C1306036	Forced expiratory volume procedure	diap	3.64
27126691	C0683314	personal health	fndg	3.63
27126691	C0205451	Five	qnco	3.56
27126691	C0332529	Consistency	qlco	3.53
27126691	C0034036	Publications	inpr	9.88
27126691	C0034036	Publications	mnob	9.88
27126691	C0023866	Literature	inpr	6.72
27126691	C0034037	Publishing	ocac	6.72
27126691	C1708517	Input	cnce	3.98
27126691	C3541890	Extracted Lead	fndg	3.57
27126691	C0185115	Extraction	topp	3.57
27126691	C1704324	Scientific Publication	inpr	3.57
27126691	C0006347	Budgets	inpr	12.94
27126691	C0750572	Estimated	qnco	5.18
27126691	C1825598	IMPACT gene	gngm	3.63
27126691	C4049986	Impact	qlco	3.63
27126691	C0009738	Congo	geoa	16.16
27126691	C3264621	ivacaftor	orch	12.90
27126691	C3264621	ivacaftor	phsu	12.90
27126691	C1257890	Population Group	popg	9.86
27126691	C0032659	geographic population	qnco	6.70
27126691	C0750572	Estimated	qnco	5.18
27126691	C2986411	Improvement	cnce	3.57
27126691	C3811819	CFTR wt Allele	gngm	3.55
27126691	C1707455	Comparison	acty	3.55
27126691	C1518422	Negation	ftcn	3.55
27126691	C1706462	Reference Object	cnce	3.55
27126691	C1274040	Result	ftcn	3.42
27126691	C3264621	ivacaftor	orch	13.14
27126691	C3264621	ivacaftor	phsu	13.14
27126691	C0332281	Associated with	qlco	3.72
27126691	C1552713	Data Type Interval	inpr	3.61
27126691	C1272706	Interval	tmco	3.61
27126691	C1552654	Parameterized Data Type - Interval	inpr	3.61
27126691	C0870373	credibility	qlco	3.54
27126691	C0450389	71	inpr	3.63
27126691	C0376558	Life	idcn	9.94
27126691	C3842589	20%	fndg	3.68
27126691	C0439234	year	tmco	3.63
27126691	C1524062	Additional	ftcn	3.48
27126691	C0010182	Costa Rica	geoa	13.09
27126691	C3538993	Complete Response with Incomplete Bone Marrow Recovery	fndg	3.63
27126691	C1704519	Cranial Rhythmic Impulse	phsf	3.63
27126691	C1826843	RNH1 gene	gngm	3.63
27126691	C0382778	U-18	orch	13.24
27126691	C0382778	U-18	phsu	13.24
27126691	C0080071	Quality-Adjusted Life Years	tmco	19.62
27126691	C1524062	Additional	ftcn	3.46
27126691	C0080071	Quality-Adjusted Life Years	tmco	38.97
27126691	C0009738	Congo	geoa	32.45
27126691	C0038952	Continuance of life	acty	16.77
27126691	C3264621	ivacaftor	orch	13.14
27126691	C3264621	ivacaftor	phsu	13.14
27126691	C0220921	survival aspects	ftcn	10.42
27126691	C3811819	CFTR wt Allele	gngm	7.07
27126691	C0332281	Associated with	qlco	3.72
27126691	C0679739	peer	popg	3.63
27126691	C0205163	Equal	qlco	3.57
27126691	C0439185	Equivalent Weight	qnco	3.57
27126691	C3887622	Gap (space)	spco	3.56
27126691	C3538928	Usual	qlco	3.56
27126691	C1947933	care activity	acty	3.56
27126691	C2986411	Improvement	cnce	3.55
27126691	C1518422	Negation	ftcn	3.48
27126691	C0450387	68	inpr	3.44
27126691	C4050363	Comprehensive Score for Financial Toxicity	inpr	3.63
27126691	C0220812	Cost aspects	ftcn	3.63
27126691	C0010186	Financial cost	qnco	3.63
27126691	C3838680	3+ Answer to Question	fndg	3.48
27126691	C2827736	3+ Score	qnco	3.48
27126691	C2981702	3+ Score, WHO	clas	3.48
27126691	C0439086	<3 (qualifier value)	qnco	3.48
27126691	C1705117	Increment	qnco	3.48
27126691	C4071830	Lifetime	tmco	3.48
27126691	C0006347	Budgets	inpr	12.96
27126691	C3842591	0%	fndg	5.18
27126691	C1825598	IMPACT gene	gngm	3.68
27126691	C4049986	Impact	qlco	3.68
27126691	C0332177	Monthly (qualifier value)	tmco	5.18
27126691	C0439231	month	tmco	5.18
27126691	C0439507	per month (qualifier value)	tmco	5.18
27126691	C2698041	Member Organization	prog	3.57
27126691	C0680022	member	popg	3.57
27126691	C0009738	Congo	geoa	32.28
27126691	C0026565	Mortality Vital Statistics	qnco	20.95
27126691	C0026538	Morbidity - disease rate	qnco	19.45
27126691	C0080071	Quality-Adjusted Life Years	tmco	19.34
27126691	C3264621	ivacaftor	orch	12.92
27126691	C3264621	ivacaftor	phsu	12.92
27126691	C0026566	Aspects of mortality statistics	qnco	11.49
27126691	C0026882	Mutation	genf	9.99
27126691	C0376558	Life	idcn	9.91
27126691	C3811819	CFTR wt Allele	gngm	6.90
27126691	C0030705	Patients	podg	6.59
27126691	C1705285	Mutation Abnormality	comd	3.68
27126691	C0220880	morbidity aspects	inpr	3.68
27126691	C0439234	year	tmco	3.60
27126691	C1269909	Moved from	ftcn	3.50
27126691	C1299988	Moved to	ftcn	3.50
27126691	C2699029	Relocation of home or business	acty	3.50
27126691	C0442805	Increase	ftcn	3.46
27126691	C0205217	Increased	qnco	3.46
27126691	C1518422	Negation	ftcn	3.42
27126691	C0679739	peer	popg	3.42
27126691	C3264621	ivacaftor	orch	13.14
27126691	C3264621	ivacaftor	phsu	13.14
27126691	C0006347	Budgets	inpr	12.96
27126691	C4050363	Comprehensive Score for Financial Toxicity	inpr	5.18
27126691	C0220812	Cost aspects	ftcn	5.18
27126691	C0010186	Financial cost	qnco	5.18
27126691	C0439801	Limited (extensiveness)	ftcn	5.18
27126691	C4050251	Limited Lifting Ability	inpr	5.18
27126691	C2674459	Limited Walking Ability	fndg	5.18
27126691	C3542948	Limited component (foundation metadata concept)	inpr	5.18
27126691	C1825598	IMPACT gene	gngm	3.68
27126691	C4049986	Impact	qlco	3.68
27126691	C0205393	Most	qnco	3.56
27126691	C3538928	Usual	qlco	3.56
27126691	C1947933	care activity	acty	3.56
25025956	C0021641	Insulin	aapp	22.35
25025956	C0021641	Insulin	horm	22.35
25025956	C0021641	Insulin	phsu	22.35
25025956	C0015127	Etiology aspects	ftcn	9.86
25025956	C0439673	Unknown	qlco	3.56
25025956	C1524003	Science of Etiology	cnce	3.55
25025956	C0868928	Case (situation)	ftcn	3.43
25025956	C1533148	Case unit dose	qnco	3.43
25025956	C0241863	diabetic	fndg	3.43
25025956	C0231179	Insufficiency	ftcn	3.43
25025956	C3714501	Insulin Drug Class	horm	3.43
25025956	C3714501	Insulin Drug Class	phsu	3.43
25025956	C1579433	Insulin [EPC]	phsu	3.43
25025956	C1533581	Recombinant Insulin	aapp	3.43
25025956	C1533581	Recombinant Insulin	horm	3.43
25025956	C1533581	Recombinant Insulin	phsu	3.43
25025956	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
25025956	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
25025956	C0021641	Insulin	aapp	22.43
25025956	C0021641	Insulin	horm	22.43
25025956	C0021641	Insulin	phsu	22.43
25025956	C0010674	Cystic Fibrosis	dsyn	19.80
25025956	C0015272	Exhibits as Topic	inpr	17.80
25025956	C0017337	Genes	gngm	17.80
25025956	C0030705	Patients	podg	13.78
25025956	C0011849	Diabetes Mellitus	dsyn	13.08
25025956	C0012634	Disease	dsyn	11.49
25025956	C0026882	Mutation	genf	9.90
25025956	C0015127	Etiology aspects	ftcn	9.86
25025956	C0001675	Adult	aggp	9.73
25025956	C1413365	CFTR gene	gngm	5.18
25025956	C2700640	Encode (action)	acty	5.18
25025956	C1547699	MIME encoding	idcn	5.18
25025956	C0231179	Insufficiency	ftcn	3.68
25025956	C0011847	Diabetes	dsyn	3.61
25025956	C0445223	Related personal status	fndg	3.61
25025956	C0439849	Relationships	qlco	3.61
25025956	C1524003	Science of Etiology	cnce	3.55
25025956	C3714501	Insulin Drug Class	horm	3.50
25025956	C3714501	Insulin Drug Class	phsu	3.50
25025956	C1579433	Insulin [EPC]	phsu	3.50
25025956	C1533581	Recombinant Insulin	aapp	3.50
25025956	C1533581	Recombinant Insulin	horm	3.50
25025956	C1533581	Recombinant Insulin	phsu	3.50
25025956	C0547043	Up	spco	3.44
25025956	C3842586	50%	fndg	3.42
25025956	C3843766	<50	fndg	3.42
25025956	C1706450	Legal Adult	humn	3.42
25025956	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
25025956	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
25025956	C0030281	Structure of beta Cell of islet	cell	13.06
25025956	C0013790	Electricity	npop	12.89
25025956	C0017725	Glucose	bacs	12.89
25025956	C0017725	Glucose	orch	12.89
25025956	C0017725	Glucose	phsu	12.89
25025956	C1413365	CFTR gene	gngm	5.18
25025956	C1547282	Show	anim	5.18
25025956	C1704735	Regulator	cnce	3.55
25025956	C1704734	Regulator Device Component	mnob	3.55
25025956	C0182953	Regulators (device)	medd	3.55
25025956	C1701901	Conditional	qlco	3.42
25025956	C0851827	Dependent - ability	qlco	3.42
25025956	C0442828	Electrical (qualifier value)	ftcn	3.42
25025956	C3244310	dependent	ftcn	3.42
25025956	C0026809	Mus	mamm	58.06
25025956	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.12
25025956	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.12
25025956	C3887642	Hippocampus Proper	bpoc	27.26
25025956	C0001272	Action Potentials	celf	14.64
25025956	C0017725	Glucose	bacs	14.64
25025956	C0017725	Glucose	orch	14.64
25025956	C0017725	Glucose	phsu	14.64
25025956	C0013790	Electricity	npop	12.96
25025956	C0007600	Cultured Cell Line	cell	9.99
25025956	C0025914	House mice	mamm	7.30
25025956	C0025929	Laboratory mice	mamm	7.30
25025956	C1413365	CFTR gene	gngm	7.05
25025956	C0740116	+2	qnco	5.18
25025956	C3833492	2+	fndg	5.18
25025956	C2827735	2+ Score	qnco	5.18
25025956	C2981700	2+ Score, WHO	clas	5.18
25025956	C0449265	Elicited by	qlco	5.18
25025956	C1256369	insulin secretion	celf	5.18
25025956	C1816453	membrane depolarization	celf	5.18
25025956	C0695434	oscillations	topp	5.18
25025956	C0439818	Bursting sensation quality	qlco	3.68
25025956	C1520150	Wild Type Mouse	mamm	3.63
25025956	C0521116	Current (present time)	tmco	3.63
25025956	C0007634	Cells	cell	3.61
25025956	C3282337	Cells [Chemical/Ingredient]	cell	3.61
25025956	C0392756	Reduced	qlco	3.59
25025956	C0243077	inhibitors	chvf	3.59
25025956	C0332161	Attenuated by (contextual qualifier)	qlco	3.57
25025956	C0599946	Attenuation	acty	3.57
25025956	C0596988	mutant	comd	3.57
25025956	C1707455	Comparison	acty	3.56
25025956	C1269647	Entire cell	cell	3.53
25025956	C0442828	Electrical (qualifier value)	ftcn	3.50
25025956	C0205225	Primary	qlco	3.47
25025956	C0439631	Primary operation	topp	3.47
25025956	C0439612	True primary (qualifier value)	tmco	3.47
25025956	C0026882	Mutation	genf	9.73
25025956	C3252847	VX 809	orch	3.75
25025956	C3252847	VX 809	phsu	3.75
25025956	C0243067	defects aspect	ftcn	3.55
25025956	C0007634	Cells	cell	3.43
25025956	C3282337	Cells [Chemical/Ingredient]	cell	3.43
25025956	C1705285	Mutation Abnormality	comd	3.42
25025956	C0750546	newly	idcn	3.42
25025956	C1880355	Discover	acty	3.40
25025956	C0039798	therapeutic aspects	ftcn	22.40
25025956	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
25025956	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
25025956	C0023693	Light	npop	16.16
25025956	C0011849	Diabetes Mellitus	dsyn	13.14
25025956	C0030281	Structure of beta Cell of islet	cell	13.06
25025956	C0035820	Social Role	socb	13.03
25025956	C0017725	Glucose	bacs	12.93
25025956	C0017725	Glucose	orch	12.93
25025956	C0017725	Glucose	phsu	12.93
25025956	C2362652	Possible diagnosis	qlco	5.18
25025956	C0150312	Present	qnco	5.18
25025956	C0449450	Presentation	idcn	5.18
25025956	C0443289	Revealed	qlco	5.18
25025956	C2825142	Experimental Result	fndg	3.98
25025956	C1274040	Result	ftcn	3.98
25025956	C1546471	What subject filter - Result	idcn	3.98
25025956	C0011847	Diabetes	dsyn	3.68
25025956	C0234388	Electrical activity of brain	ortf	3.65
25025956	C0679199	strategy	menp	3.63
25025956	C1705810	Generic Role	cnce	3.57
25025956	C3871154	{Role}	inpr	3.57
25025956	C4050248	Borg Scale Rating of Perceived Exertion Score 11	inpr	3.55
25025956	C1881376	Light (qualifier)	qlco	3.55
25025956	C3842678	Light - subjective measurement	fndg	3.55
25025956	C1306462	Light color	ftcn	3.55
25025956	C0332240	Unknown (origin) (qualifier value)	ftcn	3.50
25025956	C1533734	Administration procedure	topp	3.48
25025956	C1705169	Biomaterial Treatment	cnce	3.48
25025956	C0087111	Therapeutic procedure	topp	3.48
25025956	C1522326	Treating	ftcn	3.48
25025956	C3538994	Treatment Epoch	resa	3.48
25025956	C3245505	potential	qlco	3.48
25025956	C3887704	treatment - ActInformationManagementReason	hlca	3.48
25025956	C0205263	Induce (action)	ftcn	3.47
25025956	C1413365	CFTR gene	gngm	3.44
25025956	C0699748	Pathogenesis	patf	3.42
25025956	C0543483	pathogenic aspects	ftcn	3.42
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
21976485	C0055363	Chloride Channels	aapp	19.52
21976485	C0055363	Chloride Channels	bacs	19.52
21976485	C0017337	Genes	gngm	16.22
21976485	C0031843	physiological aspects	phsf	13.02
21976485	C0010674	Cystic Fibrosis	dsyn	10.06
21976485	C0026882	Mutation	genf	9.90
21976485	C0015127	Etiology aspects	ftcn	9.86
21976485	C0030274	Pancreas	bpoc	8.34
21976485	C0035245	Respiratory physiology	ortf	6.73
21976485	C1278931	Entire pancreas	bpoc	5.18
21976485	C0178784	Organ	bpoc	5.18
21976485	C1413365	CFTR gene	gngm	3.58
21976485	C0542341	Function	ftcn	3.56
21976485	C0700205	Function Axis	clas	3.56
21976485	C1705273	Mathematical Operator	inpr	3.56
21976485	C1524003	Science of Etiology	cnce	3.55
21976485	C1514873	Requirement	ftcn	3.55
21976485	C0221908	epithelial	qlco	3.48
21976485	C1704735	Regulator	cnce	3.43
21976485	C1704734	Regulator Device Component	mnob	3.43
21976485	C0182953	Regulators (device)	medd	3.43
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	92.43
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	92.43
21976485	C0014239	Endoplasmic Reticulum	celc	22.39
21976485	C0009738	Congo	geoa	16.05
21976485	C0206243	Carrying	acty	14.64
21976485	C1314792	Etiology	ftcn	14.64
21976485	C0162847	protein folding	moft	13.14
21976485	C0015127	Etiology aspects	ftcn	11.49
21976485	C1413365	CFTR gene	gngm	10.65
21976485	C0026882	Mutation	genf	9.94
21976485	C0030705	Patients	podg	6.72
21976485	C0699040	Cell surface	celc	5.18
21976485	C0699809	Does carry	fndg	5.18
21976485	C1524003	Science of Etiology	cnce	5.18
21976485	C1705285	Mutation Abnormality	comd	3.63
21976485	C0185026	Plication	topp	3.61
21976485	C0332294	Resulting in	ftcn	3.59
21976485	C0442822	trace amount	qnco	3.57
21976485	C1709694	Processing (action)	acty	3.56
21976485	C0332452	defective	ftcn	3.47
21976485	C3811819	CFTR wt Allele	gngm	3.44
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
21976485	C0040363	Togo	geoa	17.80
21976485	C0041260	Tryptophanase	aapp	17.80
21976485	C0041260	Tryptophanase	enzy	17.80
21976485	C0030705	Patients	podg	8.34
21976485	C1328819	Small Molecule	orch	5.18
21976485	C0087111	Therapeutic procedure	topp	5.18
21976485	C1883351	To	qlco	5.18
21976485	C1522326	Treating	ftcn	5.18
21976485	C1292734	Treatment intent	ftcn	5.18
21976485	C0679199	strategy	menp	3.63
21976485	C2349182	Correct (qualifier)	qlco	3.59
21976485	C1709694	Processing (action)	acty	3.56
21976485	C0205447	One	qnco	3.48
21976485	C1413365	CFTR gene	gngm	3.43
21976485	C0039798	therapeutic aspects	ftcn	22.48
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
21976485	C0009738	Congo	geoa	16.05
21976485	C1524059	mechanism of action qualifier	ftcn	13.01
21976485	C0031330	Pharmacology	bmod	9.86
21976485	C0205179	Advanced phase	qlco	3.57
21976485	C0678723	Biologic Development	orgf	3.57
21976485	C0205210	Clinical	qlco	3.57
21976485	C1527148	Development	ftcn	3.57
21976485	C1553058	Neuropsychologist - Clinical	prog	3.57
21976485	C0237412	Psychologist - Clinical	prog	3.57
21976485	C0497591	Social Worker - Clinical	prog	3.57
21976485	C0243107	development aspects	phsf	3.57
21976485	C1533734	Administration procedure	topp	3.56
21976485	C1705169	Biomaterial Treatment	cnce	3.56
21976485	C0087111	Therapeutic procedure	topp	3.56
21976485	C1522326	Treating	ftcn	3.56
21976485	C3538994	Treatment Epoch	resa	3.56
21976485	C3887704	treatment - ActInformationManagementReason	hlca	3.56
21976485	C1413365	CFTR gene	gngm	3.50
21976485	C2827718	In Vitro Route of Administration	ftcn	3.44
21976485	C0021135	In Vitro [Publication Type]	inpr	3.44
21976485	C3252847	VX 809	orch	3.44
21976485	C3252847	VX 809	phsu	3.44
21976485	C1533691	in vitro	qlco	3.44
21976485	C3811819	CFTR wt Allele	gngm	3.43
21976485	C0086418	Homo sapiens	humn	57.79
21976485	C0009738	Congo	geoa	49.36
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.95
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.95
21976485	C0014239	Endoplasmic Reticulum	celc	22.36
21976485	C0036536	Process of secretion	biof	19.31
21976485	C0008203	Chlorides	inch	16.03
21976485	C0030705	Patients	podg	13.52
21976485	C3811819	CFTR wt Allele	gngm	10.90
21976485	C0007600	Cultured Cell Line	cell	10.05
21976485	C0019904	Homozygote	orga	9.90
21976485	C0026882	Mutation	genf	9.73
21976485	C0007635	Cultured Cells	cell	6.90
21976485	C1413365	CFTR gene	gngm	6.88
21976485	C0036537	Bodily secretions	bdsu	6.69
21976485	C0014597	Epithelial Cells	cell	6.58
21976485	C0456079	Disease classification level	clas	5.18
21976485	C1547707	Floor - story of building	geoa	5.18
21976485	C2946261	Level	phsu	5.18
21976485	C0441889	Levels (qualifier value)	qlco	5.18
21976485	C3282338	Cells, Cultured [Chemical/Ingredient]	cell	3.74
21976485	C3842586	50%	fndg	3.68
21976485	C3843766	<50	fndg	3.68
21976485	C3890233	Exposure as Collected Domain	idcn	3.68
21976485	C0332281	Associated with	qlco	3.64
21976485	C0312860	Neutrophil migration, function	celf	3.61
21976485	C3890923	Nuclear Medicine Study File	inpr	3.61
21976485	C0205039	Bronchial	bpoc	3.60
21976485	C1442216	Bronchial system	bpoc	3.60
21976485	C0221908	epithelial	qlco	3.60
21976485	C1548221	Bed Status - Isolated	idcn	3.59
21976485	C0205409	Isolated	ftcn	3.59
21976485	C2945599	Mild (qualifier value)	qlco	3.57
21976485	C1511332	Bronchial Secretion	bdsu	3.55
21976485	C1709694	Processing (action)	acty	3.54
21976485	C3252847	VX 809	orch	3.43
21976485	C3252847	VX 809	phsu	3.43
21976485	C1273342	Epithelial cell count (procedure)	lbpr	3.42
21976485	C1561611	Admission Level of Care Code - Improved	inpr	3.42
21976485	C0332272	Better	qlco	3.42
21976485	C0184511	Improved	qlco	3.42
21976485	C0332232	Approximate	qlco	3.42
21976485	C0596019	Chloride Ion	elii	3.42
21976485	C2349975	Enhance (action)	acty	3.42
21976485	C1518422	Negation	ftcn	3.42
21976485	C1711178	Bronchial Epithelial Cell	cell	3.41
21976485	C0332453	Disruption	ftcn	3.38
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.15
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.15
21976485	C0087136	Unmarried	fndg	22.39
21976485	C0037179	Unmarried person	popg	22.39
21976485	C0033204	Probability	qnco	16.23
21976485	C0015272	Exhibits as Topic	inpr	16.14
21976485	C0012655	Disease susceptibility	clna	13.03
21976485	C0597304	Proteolysis	moft	12.90
21976485	C0007603	Plasma membrane	celc	9.76
21976485	C1413365	CFTR gene	gngm	7.08
21976485	C0205474	Biochemical	ftcn	7.02
21976485	C0040223	Time	tmco	6.71
21976485	C0332257	Including (qualifier)	ftcn	5.18
21976485	C1521970	Characteristics	qlco	3.68
21976485	C0175566	Open	spco	3.61
21976485	C3252847	VX 809	orch	3.59
21976485	C3252847	VX 809	phsu	3.59
21976485	C1547045	*Susceptibility	qnco	3.57
21976485	C0220898	Predisposition	orga	3.57
21976485	C2348205	Similarity	qlco	3.57
21976485	C1264642	Susceptibility (property) (qualifier value)	ftcn	3.57
21976485	C0205202	Corrected	qlco	3.55
21976485	C3541383	Time (foundation metadata concept)	tmco	3.55
21976485	C0237096	residence	spco	3.55
21976485	C0542341	Function	ftcn	3.50
21976485	C0205245	Functional	ftcn	3.50
21976485	C2700217	Functional Relationship	cnce	3.50
21976485	C0439799	Channel	spco	3.47
21976485	C1706095	Channel Object	cnce	3.47
21976485	C0205171	Singular	qnco	3.47
21976485	C0231683	Gait normal	fndg	3.44
21976485	C2347086	Mean Percent of Normal	qnco	3.44
21976485	C0205307	Normal	qlco	3.44
21976485	C0439166	Percent normal	qnco	3.44
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.03
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.03
21976485	C0036576	Genetic Selection	genf	9.83
21976485	C1413365	CFTR gene	gngm	6.96
21976485	C3252847	VX 809	orch	3.75
21976485	C3252847	VX 809	phsu	3.75
21976485	C1280519	Effectiveness	qlco	3.59
21976485	C1707887	Efficacy Study	resa	3.59
21976485	C1707391	Choose (action)	acty	3.52
21976485	C0205172	More	ftcn	3.50
21976485	C0684224	Report (document)	inpr	3.47
21976485	C0700287	Reporting	hlca	3.47
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.97
21976485	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.97
21976485	C0376649	Addresses (publication format)	inpr	8.34
21976485	C1413365	CFTR gene	gngm	6.89
21976485	C1442065	Address	spco	5.18
21976485	C1882932	Representation (action)	acty	5.18
21976485	C3252847	VX 809	orch	3.75
21976485	C3252847	VX 809	phsu	3.75
21976485	C0456387	Class	inpr	3.56
21976485	C1705943	Class (taxonomic)	clas	3.56
21976485	C1457869	Defect	ftcn	3.55
21976485	C1709694	Processing (action)	acty	3.42
27768743	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.97
27768743	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.97
27768743	C0038990	Sweating	fndg	38.93
27768743	C0031843	physiological aspects	phsf	25.93
27768743	C0038984	Sweat	bdsu	19.90
27768743	C0011923	Diagnostic Imaging	diap	11.49
27768743	C1413365	CFTR gene	gngm	6.90
27768743	C0542341	Function	ftcn	6.90
27768743	C0700205	Function Axis	clas	6.90
27768743	C1705273	Mathematical Operator	inpr	6.90
27768743	C0079595	Imaging Techniques	diap	5.18
27768743	C1999230	Providing (action)	acty	5.18
27768743	C1521828	Rate	qnco	3.56
27768743	C0871208	Rating (action)	acty	3.56
27768743	C3827682	Useful	qlco	3.56
27768743	C3542016	Concept model range (foundation metadata concept)	inpr	3.55
27768743	C1514721	Range	qnco	3.55
27768743	C2348147	Sample Range	qnco	3.55
27768743	C2004068	Beta (qualifier)	qlco	3.46
27768743	C0439096	Beta greek letter	inpr	3.46
27768743	C0330390	Beta plant	plnt	3.46
27768743	C1948023	Stimulation (motivation)	npop	3.46
27768743	C0444706	Measured	qlco	3.43
27768743	C0449770	Measured from	qnco	3.43
27768743	C0475806	1/3 meter (distance vision finding)	fndg	3.43
27768743	C0443225	Full	qlco	3.43
27768743	C0205132	Linear	spco	3.43
27768743	C1706276	Near	qlco	3.43
27768743	C3828842	Nearly	qlco	3.43
27768743	C0010674	Cystic Fibrosis	dsyn	11.49
27768743	C0007294	Genetic Carriers	fndg	9.90
27768743	C0205615	Well Differentiated	qlco	5.18
27768743	C2911653	Encounter due to being a cystic fibrosis carrier	fndg	3.66
27768743	C0948452	carrier of cystic fibrosis (history)	fndg	3.66
27768743	C2349001	Human Study Subject	humn	3.56
27768743	C2697811	Investigative Subject	ftcn	3.56
27768743	C0681850	Study Subject	grup	3.56
27768743	C1706203	Subject - topic	idcn	3.56
27768743	C1550501	Subject -direct target	idcn	3.56
27768743	C2587213	Control function	ftcn	3.43
27768743	C1882979	Scientific Control	cnce	3.43
27768743	C3274648	True Control Status	qlco	3.43
27768743	C0243148	control aspects	qlco	3.43
27768743	C1550141	control substance	sbst	3.43
27768743	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.02
27768743	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.02
27768743	C0040363	Togo	geoa	35.81
27768743	C0041260	Tryptophanase	aapp	35.81
27768743	C0041260	Tryptophanase	enzy	35.81
27768743	C3264621	ivacaftor	orch	13.09
27768743	C3264621	ivacaftor	phsu	13.09
27768743	C0011923	Diagnostic Imaging	diap	11.49
27768743	C1883351	To	qlco	10.42
27768743	C1413365	CFTR gene	gngm	6.95
27768743	C0700364	Appearance	qlco	5.18
27768743	C0442726	Detected (finding)	fndg	5.18
27768743	C3891454	Dosing Days to Detection	tmco	5.18
27768743	C0079595	Imaging Techniques	diap	5.18
27768743	C1299582	Unable	fndg	5.18
27768743	C1515187	Take	hlca	3.98
27768743	C0935587	level of functioning	qlco	3.64
27768743	C2349001	Human Study Subject	humn	3.63
27768743	C2697811	Investigative Subject	ftcn	3.63
27768743	C0681850	Study Subject	grup	3.63
27768743	C1706203	Subject - topic	idcn	3.63
27768743	C1550501	Subject -direct target	idcn	3.63
27768743	C1709060	Modulator Device Component	mnob	3.48
27768743	C1561611	Admission Level of Care Code - Improved	inpr	3.43
27768743	C0332272	Better	qlco	3.43
27768743	C0184511	Improved	qlco	3.43
27768743	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
27768743	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
27768743	C0038990	Sweating	fndg	19.19
27768743	C0038984	Sweat	bdsu	9.73
27768743	C0020517	Hypersensitivity	patf	6.72
27768743	C1709793	Quantitation	qnco	5.18
27768743	C0427965	Antimicrobial susceptibility	fndg	3.57
27768743	C1511883	Diagnostic Sensitivity	qnco	3.57
27768743	C2346484	Increased Sensitivy	phpr	3.57
27768743	C0312418	Personality Sensitivity	menp	3.57
27768743	C2349185	Signal Sensitivity	qlco	3.57
27768743	C0036667	Statistical sensitivity	qnco	3.57
27768743	C1522640	stimulus sensitivity	qlco	3.57
27768743	C1275506	Imaging modality	ftcn	3.55
27768743	C1413365	CFTR gene	gngm	3.42
27768743	C1701901	Conditional	qlco	3.42
27768743	C0851827	Dependent - ability	qlco	3.42
27768743	C0441889	Levels (qualifier value)	qlco	3.42
27768743	C3890211	Low Mitosis-Karyorrhexis Index	qnco	3.42
27768743	C3244310	dependent	ftcn	3.42
27768743	C0205251	low	qlco	3.42
27768743	C1550472	low confidentiality	inpr	3.42
27768743	C4048187	low exposure	qlco	3.42
27768743	C1516048	Assessed	acty	3.40
27768743	C1521828	Rate	qnco	3.40
27768743	C0871208	Rating (action)	acty	3.40
27768743	C0040363	Togo	geoa	17.80
27768743	C0041260	Tryptophanase	aapp	17.80
27768743	C0041260	Tryptophanase	enzy	17.80
27768743	C0021966	Iodides	inch	16.09
27768743	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	14.64
27768743	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	14.64
27768743	C0020517	Hypersensitivity	patf	8.34
27768743	C0427965	Antimicrobial susceptibility	fndg	5.18
27768743	C1511883	Diagnostic Sensitivity	qnco	5.18
27768743	C0443211	Established	qlco	5.18
27768743	C2346484	Increased Sensitivy	phpr	5.18
27768743	C0312418	Personality Sensitivity	menp	5.18
27768743	C2349185	Signal Sensitivity	qlco	5.18
27768743	C0036667	Statistical sensitivity	qnco	5.18
27768743	C1883351	To	qlco	5.18
27768743	C1524063	Use of	ftcn	5.18
27768743	C1522640	stimulus sensitivity	qlco	5.18
27768743	C1720154	Inject - dosing instruction imperative	ftcn	3.98
27768743	C0678420	Cocktail	food	3.63
27768743	C0947630	Scientific Study	lbpr	3.63
27768743	C0221138	Blood group antibody I	aapp	3.48
27768743	C0221138	Blood group antibody I	imft	3.48
27768743	C0178602	Dosage	qnco	3.48
27768743	C1114758	Dose number:Number:Point in time:^Patient:Quantitative	clna	3.48
27768743	C0869039	Unit dose	qnco	3.48
27768743	C3542016	Concept model range (foundation metadata concept)	inpr	3.45
27768743	C0205250	High	qlco	3.45
27768743	C1514721	Range	qnco	3.45
27768743	C2348147	Sample Range	qnco	3.45
27768743	C0004259	Atropine	orch	25.51
27768743	C0004259	Atropine	phsu	25.51
27768743	C0040363	Togo	geoa	17.80
27768743	C0041260	Tryptophanase	aapp	17.80
27768743	C0041260	Tryptophanase	enzy	17.80
27768743	C0021966	Iodides	inch	16.30
27768743	C0022245	Isoproterenol	orch	16.09
27768743	C0022245	Isoproterenol	phsu	16.09
27768743	C0026815	Muscarinic Agents	phsu	16.07
27768743	C0024501	Maintenance	acty	7.13
27768743	C1706084	(City) Block	geoa	5.18
27768743	C2828370	Block (unit of measure)	qnco	5.18
27768743	C1533157	Block Specimens	sbst	5.18
27768743	C0332206	Blocking	ftcn	5.18
27768743	C0028778	Obstruction	patf	5.18
27768743	C0392756	Reduced	qlco	5.18
27768743	C1883351	To	qlco	5.18
27768743	C0702248	Aminophylline level - finding	lbtr	3.72
27768743	C0221138	Blood group antibody I	aapp	3.68
27768743	C0221138	Blood group antibody I	imft	3.68
27768743	C0596235	Calcium ion	elii	3.68
27768743	C0596235	Calcium ion	phsu	3.68
27768743	C0702240	Elevation	spco	3.59
27768743	C0439775	Elevation procedure	topp	3.59
27768743	C1299351	Abnormally high	qlco	3.56
27768743	C0456079	Disease classification level	clas	3.56
27768743	C1547707	Floor - story of building	geoa	3.56
27768743	C0205250	High	qlco	3.56
27768743	C3889660	High Mitosis-Karyorrhexis Index	qnco	3.56
27768743	C2946261	Level	phsu	3.56
27768743	C0441889	Levels (qualifier value)	qlco	3.56
27768743	C2700149	Value Above Reference Range	inpr	3.56
27768743	C3887512	high - ActExposureLevelCode	idcn	3.56
27768743	C1161352	Atropinum, atropine	phsu	3.43
27768743	C0034869	Records	inpr	16.03
27768743	C0005507	Biological Assay	lbpr	7.13
27768743	C1948023	Stimulation (motivation)	npop	5.18
27768743	C1510438	Assay	lbpr	3.98
27768743	C0243073	assay qualifier	qlco	3.98
27768743	C1285092	Gland	bpoc	3.68
27768743	C0871261	Response process	orga	3.56
27768743	C3842589	20%	fndg	3.43
27768743	C1524029	Mouse MIN NOS	neop	3.43
27768743	C0702093	Per Minute	tmco	3.43
27768743	C3813700	Percent per Minute	qnco	3.43
27768743	C0445247	Same	qlco	3.43
27768743	C3853788	Record - QueryRequestLimit	qnco	3.41
27768743	C3842591	0%	fndg	5.18
27768743	C1704632	Disease Response	fndg	3.54
27768743	C2911692	Response (communication)	menp	3.54
27768743	C1706817	Response (statement)	inpr	3.54
27768743	C0871261	Response process	orga	3.54
27768743	C0678420	Cocktail	food	3.42
27768743	C1948037	Dilute (action)	ftcn	3.42
27768743	C0079240	Dilution technique	lbpr	3.42
27768743	C1708728	Event Log	inpr	3.42
27768743	C2986775	Logarithm	ocac	3.42
27768743	C1948023	Stimulation (motivation)	npop	3.42
27768743	C0040363	Togo	geoa	17.80
27768743	C0041260	Tryptophanase	aapp	17.80
27768743	C0041260	Tryptophanase	enzy	17.80
27768743	C0027778	Netherlands	geoa	9.74
27768743	C0022885	Laboratory Procedures	lbpr	7.47
27768743	C0392366	Tests (qualifier value)	inpr	7.47
27768743	C3817553	100%	qnco	5.18
27768743	C1327616	Cell secretion	celf	5.18
27768743	C0456984	Test Result	fndg	5.18
27768743	C0039593	Testing	ftcn	5.18
27768743	C1883351	To	qlco	5.18
27768743	C1524029	Mouse MIN NOS	neop	3.68
27768743	C0702093	Per Minute	tmco	3.68
27768743	C3813700	Percent per Minute	qnco	3.68
27768743	C0871261	Response process	orga	3.68
27768743	C0442726	Detected (finding)	fndg	3.56
27768743	C1511790	Detection	topp	3.56
27768743	C1690016	% volume (qualifier value)	qlco	3.55
27768743	C1285092	Gland	bpoc	3.55
27768743	C0449468	Volume	qnco	3.55
27768743	C1705102	Volume (publication)	inpr	3.55
27768743	C2700258	Volume Measurement	lbpr	3.55
27768743	C3842589	20%	fndg	3.50
27768743	C0205418	Aggregate	qlco	3.43
27768743	C0332621	Aggregation	ftcn	3.43
27768743	C3892223	Per Nanoliter	qnco	3.43
27768743	C0560008	nanolitre	qnco	3.43
27768743	C0678420	Cocktail	food	3.68
27768743	C0728893	+5	qnco	3.57
27768743	C0439084	>5	qnco	3.57
27768743	C1704632	Disease Response	fndg	3.57
27768743	C2911692	Response (communication)	menp	3.57
27768743	C1706817	Response (statement)	inpr	3.57
27768743	C0871261	Response process	orga	3.57
27768743	C0443225	Full	qlco	3.50
27768743	C0036536	Process of secretion	biof	19.31
27768743	C0027778	Netherlands	geoa	9.85
27768743	C0036537	Bodily secretions	bdsu	6.70
27768743	C0871261	Response process	orga	3.55
27768743	C1690016	% volume (qualifier value)	qlco	3.54
27768743	C0205418	Aggregate	qlco	3.54
27768743	C0332621	Aggregation	ftcn	3.54
27768743	C0022885	Laboratory Procedures	lbpr	3.54
27768743	C3892223	Per Nanoliter	qnco	3.54
27768743	C0456984	Test Result	fndg	3.54
27768743	C0039593	Testing	ftcn	3.54
27768743	C0392366	Tests (qualifier value)	inpr	3.54
27768743	C0449468	Volume	qnco	3.54
27768743	C1705102	Volume (publication)	inpr	3.54
27768743	C2700258	Volume Measurement	lbpr	3.54
27768743	C0560008	nanolitre	qnco	3.54
27768743	C0442726	Detected (finding)	fndg	3.42
27768743	C1511790	Detection	topp	3.42
27768743	C3842591	0%	fndg	5.18
27768743	C0678420	Cocktail	food	5.18
27768743	C1948037	Dilute (action)	ftcn	5.18
27768743	C1720119	Dilute - dosing instruction imperative	ftcn	5.18
27768743	C0205172	More	ftcn	5.18
27768743	C1948023	Stimulation (motivation)	npop	3.57
27768743	C1292856	Stimulation procedure	topp	3.57
27768743	C0011923	Diagnostic Imaging	diap	11.49
27768743	C0442726	Detected (finding)	fndg	5.18
27768743	C1511790	Detection	topp	5.18
27768743	C0079595	Imaging Techniques	diap	5.18
27768743	C3842591	0%	fndg	3.56
27768743	C1327616	Cell secretion	celf	3.56
27768743	C1285092	Gland	bpoc	3.56
27768743	C1521828	Rate	qnco	3.56
27768743	C0871208	Rating (action)	acty	3.56
27768743	C0919414	Arabic numeral 0	qnco	5.18
27768743	C0678420	Cocktail	food	3.68
27768743	C0205397	seen	qlco	3.59
27768743	C1704632	Disease Response	fndg	3.56
27768743	C2911692	Response (communication)	menp	3.56
27768743	C1706817	Response (statement)	inpr	3.56
27768743	C0871261	Response process	orga	3.56
27768743	C0443225	Full	qlco	3.50
27768743	C0036536	Process of secretion	biof	19.41
27768743	C0040363	Togo	geoa	17.80
27768743	C0041260	Tryptophanase	aapp	17.80
27768743	C0041260	Tryptophanase	enzy	17.80
27768743	C0023376	Lesotho	geoa	16.07
27768743	C0036537	Bodily secretions	bdsu	6.79
27768743	C3842591	0%	fndg	5.18
27768743	C0205418	Aggregate	qlco	5.18
27768743	C0332621	Aggregation	ftcn	5.18
27768743	C0442726	Detected (finding)	fndg	5.18
27768743	C1511790	Detection	topp	5.18
27768743	C1883351	To	qlco	5.18
27768743	C1275506	Imaging modality	ftcn	3.75
27768743	C1521828	Rate	qnco	3.55
27768743	C0871208	Rating (action)	acty	3.55
27768743	C3887647	Lymphotoxin-Alpha, human	aapp	3.45
27768743	C3887647	Lymphotoxin-Alpha, human	imft	3.45
27768743	C0230426	Structure of left thigh	bpoc	3.45
27768743	C0599638	Drinking Water	sbst	22.47
27768743	C0043047	Water	inch	19.31
27768743	C0043047	Water	phsu	19.31
27768743	C0027778	Netherlands	geoa	9.94
27768743	C3892223	Per Nanoliter	qnco	3.63
27768743	C0560008	nanolitre	qnco	3.63
27768743	C3816745	1+	fndg	3.54
27768743	C2827734	1+ Score	qnco	3.54
27768743	C2981698	1+ Score, WHO	clas	3.54
27768743	C1510992	Average	qnco	3.54
27768743	C2825518	Average of Value Derivation Technique	qnco	3.54
27768743	C0205112	Basal	spco	3.54
27768743	C2349001	Human Study Subject	humn	3.54
27768743	C2697811	Investigative Subject	ftcn	3.54
27768743	C0022885	Laboratory Procedures	lbpr	3.54
27768743	C1517945	Loss	qnco	3.54
27768743	C0681850	Study Subject	grup	3.54
27768743	C1706203	Subject - topic	idcn	3.54
27768743	C1550501	Subject -direct target	idcn	3.54
27768743	C0456984	Test Result	fndg	3.54
27768743	C0039593	Testing	ftcn	3.54
27768743	C0392366	Tests (qualifier value)	inpr	3.54
27768743	C1550678	Water Specimen	inch	3.54
27768743	C0555206	Chiari malformation type II	cgab	3.50
27768743	C0555206	Chiari malformation type II	dsyn	3.50
27768743	C0439479	sq. cm	qnco	3.50
27768743	C1300564	g/m2	qnco	3.43
27768743	C0027778	Netherlands	geoa	9.94
27768743	C3892223	Per Nanoliter	qnco	3.63
27768743	C0560008	nanolitre	qnco	3.63
27768743	C0555206	Chiari malformation type II	cgab	3.50
27768743	C0555206	Chiari malformation type II	dsyn	3.50
27768743	C0439479	sq. cm	qnco	3.50
27768743	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
27768743	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
27768743	C0036536	Process of secretion	biof	19.20
27768743	C0040363	Togo	geoa	17.80
27768743	C0041260	Tryptophanase	aapp	17.80
27768743	C0041260	Tryptophanase	enzy	17.80
27768743	C0011923	Diagnostic Imaging	diap	11.49
27768743	C0036537	Bodily secretions	bdsu	6.58
27768743	C0442726	Detected (finding)	fndg	5.18
27768743	C3891454	Dosing Days to Detection	tmco	5.18
27768743	C0079595	Imaging Techniques	diap	5.18
27768743	C1514873	Requirement	ftcn	5.18
27768743	C0700321	Small	qnco	5.18
27768743	C1883351	To	qlco	5.18
27768743	C1881189	Increased Device Sensitivity	phpr	3.61
27768743	C2346484	Increased Sensitivy	phpr	3.61
27768743	C1413365	CFTR gene	gngm	3.57
27768743	C0442805	Increase	ftcn	3.55
27768743	C0205217	Increased	qnco	3.55
27768743	C1709060	Modulator Device Component	mnob	3.54
27768743	C3898777	Important	qlco	3.43
27768743	C1521828	Rate	qnco	3.41
27768743	C0871208	Rating (action)	acty	3.41
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.41
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.41
21724857	C0040363	Togo	geoa	17.80
21724857	C0041260	Tryptophanase	aapp	17.80
21724857	C0041260	Tryptophanase	enzy	17.80
21724857	C0010674	Cystic Fibrosis	dsyn	11.49
21724857	C2983310	Overcome	acty	5.18
21724857	C1547282	Show	anim	5.18
21724857	C1883351	To	qlco	5.18
21724857	C1551357	intended - ParticipationSignature	fndg	5.18
21724857	C1283828	intent	qlco	5.18
21724857	C0205198	Compound	qlco	3.59
21724857	C1706082	Compound (substance)	chem	3.59
21724857	C2985434	Disease-causing Mutation	comd	3.57
21724857	C1555307	promise	idcn	3.56
21724857	C1413365	CFTR gene	gngm	3.48
21724857	C1709060	Modulator Device Component	mnob	3.48
21724857	C1516634	research clinical testing	resa	3.46
21724857	C1546944	Event Seriousness - Significant	qlco	3.43
21724857	C0750502	Significant	idcn	3.43
21724857	C0237881	Statistical Significance	qnco	3.43
21724857	C0162340	Comprehension	menp	14.64
21724857	C0441712	Mechanism (attribute)	ftcn	5.18
21724857	C1706376	Mechanism Component of Device	mnob	5.18
21724857	C1518422	Negation	ftcn	5.18
21724857	C0205198	Compound	qlco	3.98
21724857	C1706082	Compound (substance)	chem	3.98
21724857	C3266814	Action	acty	3.59
21724857	C0441472	Clinical action	ftcn	3.59
21724857	C2603362	S prime	clna	3.59
21724857	C0565930	per second	qnco	3.59
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
21724857	C0031715	Phosphorylation	moft	13.01
21724857	C0376525	Dimerization	npop	9.86
21724857	C0851285	Regulation	gora	9.73
21724857	C3541951	Concept model domain	inpr	6.87
21724857	C1880389	Domain (area of knowledge)	ftcn	6.87
21724857	C1883221	Superkingdom (taxonomic category)	cnce	6.87
21724857	C2248445	activation of ion transport	celf	3.68
21724857	C1158886	Protein phosphorylation	moft	3.55
21724857	C1148916	nucleotide binding	moft	3.45
21724857	C1413365	CFTR gene	gngm	3.43
21724857	C1704735	Regulator	cnce	3.42
21724857	C0220905	regulatory	rnlw	3.42
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.12
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.12
21724857	C0220825	Evaluation	hlca	14.64
21724857	C1413365	CFTR gene	gngm	7.04
21724857	C0005507	Biological Assay	lbpr	6.79
21724857	C0332257	Including (qualifier)	ftcn	5.18
21724857	C0205217	Increased	qnco	5.18
21724857	C1524063	Use of	ftcn	5.18
21724857	C1561536	*Activity (kind of quantity)	idcn	3.68
21724857	C0205177	Active	ftcn	3.68
21724857	C0441655	Activities	acty	3.68
21724857	C3668946	Activity (animal life circumstance)	fndg	3.68
21724857	C4049939	FDA Establishment Activity Terminology	inpr	3.68
21724857	C0439167	Percent Activity	qnco	3.68
21724857	C4049938	Physical Activity Measurement	lbpr	3.68
21724857	C1510438	Assay	lbpr	3.63
21724857	C0205198	Compound	qlco	3.63
21724857	C1706082	Compound (substance)	chem	3.63
21724857	C0243073	assay qualifier	qlco	3.63
21724857	C0872187	high throughput screening	diap	3.62
21724857	C3540763	VARIOUS DRUG CLASSES IN ATC	phsu	3.55
21724857	C0440102	Various patch test substance	irda	3.55
21724857	C0679199	strategy	menp	3.55
21724857	C3540765	various allergen extracts	imft	3.55
21724857	C3540765	various allergen extracts	phsu	3.55
21724857	C3540008	various antiinfectives and antiseptics for local oral treatment	phsu	3.55
21724857	C3540766	various antiseptic throat preparations	phsu	3.55
21724857	C3540762	various other agents for local oral treatment in ATC	phsu	3.55
21724857	C3540769	various other intestinal adsorbents in ATC	phsu	3.55
21724857	C3540761	various other nasal preparations in ATC	phsu	3.55
21724857	C1880355	Discover	acty	3.52
21724857	C0205455	Nine	qnco	3.50
21724857	C0750546	newly	idcn	3.48
21724857	C0031715	Phosphorylation	moft	13.09
21724857	C0684010	Rabbi	prog	12.94
21724857	C0150312	Present	qnco	5.18
21724857	C1158886	Protein phosphorylation	moft	3.63
21724857	C1705241	Delta (difference)	qnco	3.53
21724857	C1705242	Different	qlco	3.53
21724857	C2603358	R prime	clna	3.48
21724857	C0205090	Right	spco	3.48
21724857	C1280500	Effect	qlco	3.43
21724857	C0009738	Congo	geoa	16.30
21724857	C0031715	Phosphorylation	moft	13.14
21724857	C0332257	Including (qualifier)	ftcn	5.18
21724857	C1955473	Others - Allergy	fndg	5.18
21724857	C1948023	Stimulation (motivation)	npop	5.18
21724857	C3539125	other medicated shampoos in ATC	phsu	5.18
21724857	C3811819	CFTR wt Allele	gngm	3.68
21724857	C1280500	Effect	qlco	3.68
21724857	C2348382	Effect, Appearance	qlco	3.68
21724857	C1158886	Protein phosphorylation	moft	3.68
21724857	C3714596	Little NOS	fndg	3.50
21724857	C2986815	Robust	qlco	3.50
21724857	C0700321	Small	qnco	3.50
21724857	C2700395	Smallest	qnco	3.50
21724857	C1532633	Kilounit per Kilogram	qnco	5.18
21724857	C2608091	Unit/gram	qnco	5.18
21724857	C2713814	VRT 532	orch	14.64
21724857	C2741958	VX-770	orch	5.18
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.16
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.16
21724857	C0034703	Rats, Inbred F344	mamm	28.74
21724857	C0009738	Congo	geoa	16.30
21724857	C2713814	VRT 532	orch	13.05
21724857	C0040132	Thyroid Gland	bpoc	9.77
21724857	C0376315	Manufactured form	mnob	8.34
21724857	C1413365	CFTR gene	gngm	7.09
21724857	C1522492	Formation	ftcn	5.18
21724857	C0348078	Qualitative form	qlco	5.18
21724857	C1524063	Use of	ftcn	5.18
21724857	C3811819	CFTR wt Allele	gngm	3.68
21724857	C3161035	Model	inpr	3.63
21724857	C0007634	Cells	cell	3.61
21724857	C3282337	Cells [Chemical/Ingredient]	cell	3.61
21724857	C0935616	Chamber (anatomical)	bpoc	3.55
21724857	C0179874	Chamber (physical object)	mnob	3.55
21724857	C0947630	Scientific Study	lbpr	3.55
21724857	C1879547	Activation action	acty	3.55
21724857	C3540763	VARIOUS DRUG CLASSES IN ATC	phsu	3.50
21724857	C0440102	Various patch test substance	irda	3.50
21724857	C3540765	various allergen extracts	imft	3.50
21724857	C3540765	various allergen extracts	phsu	3.50
21724857	C3540008	various antiinfectives and antiseptics for local oral treatment	phsu	3.50
21724857	C3540766	various antiseptic throat preparations	phsu	3.50
21724857	C3540762	various other agents for local oral treatment in ATC	phsu	3.50
21724857	C3540769	various other intestinal adsorbents in ATC	phsu	3.50
21724857	C3540761	various other nasal preparations in ATC	phsu	3.50
21724857	C0205448	Two	qnco	3.48
21724857	C0221908	epithelial	qlco	3.48
21724857	C3540038	THYROID DIAGNOSTIC RADIOPHARMACEUTICALS	irda	3.47
21724857	C1707455	Comparison	acty	3.42
21724857	C1883708	Then	tmco	3.42
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.04
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.04
21724857	C0009738	Congo	geoa	16.08
21724857	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	12.93
21724857	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	12.93
21724857	C1879547	Activation action	acty	7.09
21724857	C1413365	CFTR gene	gngm	6.97
21724857	C1518422	Negation	ftcn	5.18
21724857	C1883559	Wild Type	gngm	3.65
21724857	C0521116	Current (present time)	tmco	3.61
21724857	C0086597	Mediate	socb	3.47
21724857	C0127400	Mediator brand of benfluorex hydrochloride	orch	3.47
21724857	C0127400	Mediator brand of benfluorex hydrochloride	phsu	3.47
21724857	C3811819	CFTR wt Allele	gngm	3.46
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
21724857	C0917964	Colforsin	orch	16.08
21724857	C0917964	Colforsin	phsu	16.08
21724857	C0009924	Contrast Media	irda	14.64
21724857	C2713814	VRT 532	orch	12.93
21724857	C0521116	Current (present time)	tmco	7.24
21724857	C1705970	Electrical Current	npop	7.24
21724857	C1979874	Contrast	qlco	5.18
21724857	C2984839	Device Short Circuit Evaluation Result	ftcn	3.61
21724857	C0086597	Mediate	socb	3.46
21724857	C0127400	Mediator brand of benfluorex hydrochloride	orch	3.46
21724857	C0127400	Mediator brand of benfluorex hydrochloride	phsu	3.46
21724857	C1879547	Activation action	acty	3.45
21724857	C1413365	CFTR gene	gngm	3.45
21724857	C0205081	Moderate (severity modifier)	qlco	3.45
21724857	C1881878	Moderation	qlco	3.45
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.07
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.07
21724857	C0031715	Phosphorylation	moft	26.23
21724857	C0684010	Rabbi	prog	26.08
21724857	C0009738	Congo	geoa	16.30
21724857	C2713814	VRT 532	orch	13.22
21724857	C0010934	Dactinomycin	aapp	13.03
21724857	C0010934	Dactinomycin	antb	13.03
21724857	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	12.88
21724857	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	12.88
21724857	C1518422	Negation	ftcn	7.23
21724857	C1158886	Protein phosphorylation	moft	7.20
21724857	C2603358	R prime	clna	7.05
21724857	C0205090	Right	spco	7.05
21724857	C1413365	CFTR gene	gngm	6.99
21724857	C3539655	CDISC Findings Class	inpr	5.18
21724857	C1314939	Involvement with	ftcn	5.18
21724857	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
21724857	C2741958	VX-770	orch	5.18
21724857	C2607943	findings aspects	ftcn	5.18
21724857	C3811819	CFTR wt Allele	gngm	3.68
21724857	C1548228	Combined result	inpr	3.62
21724857	C0678226	Due to	ftcn	3.61
21724857	C1704259	Biochemical Pathway	moft	3.56
21724857	C1705987	Pathway (interactions)	cnce	3.56
21724857	C0442808	Increasing	ftcn	3.55
21724857	C0279023	chemosensitization/potentiation	topp	3.54
21724857	C0205217	Increased	qnco	3.47
21724857	C1879547	Activation action	acty	3.42
21724857	C0205227	Endogenous	ftcn	3.42
21724857	C0086597	Mediate	socb	3.42
21724857	C0127400	Mediator brand of benfluorex hydrochloride	orch	3.42
21724857	C0127400	Mediator brand of benfluorex hydrochloride	phsu	3.42
21724857	C0596988	mutant	comd	3.42
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.03
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.03
21724857	C0040363	Togo	geoa	17.80
21724857	C0041260	Tryptophanase	aapp	17.80
21724857	C0041260	Tryptophanase	enzy	17.80
21724857	C0085732	Ability	orga	12.89
21724857	C0005507	Biological Assay	lbpr	8.34
21724857	C0205198	Compound	qlco	6.97
21724857	C1706082	Compound (substance)	chem	6.97
21724857	C1413365	CFTR gene	gngm	6.96
21724857	C1510438	Assay	lbpr	5.18
21724857	C0205217	Increased	qnco	5.18
21724857	C0150312	Present	qnco	5.18
21724857	C0449450	Presentation	idcn	5.18
21724857	C0557651	Room of building - Study	mnob	5.18
21724857	C2603343	Study	resa	5.18
21724857	C1883351	To	qlco	5.18
21724857	C3827682	Useful	qlco	5.18
21724857	C0243073	assay qualifier	qlco	5.18
21724857	C1561536	*Activity (kind of quantity)	idcn	3.68
21724857	C0205177	Active	ftcn	3.68
21724857	C0441655	Activities	acty	3.68
21724857	C3668946	Activity (animal life circumstance)	fndg	3.68
21724857	C4049939	FDA Establishment Activity Terminology	inpr	3.68
21724857	C0439167	Percent Activity	qnco	3.68
21724857	C4049938	Physical Activity Measurement	lbpr	3.68
21724857	C0332307	Type - attribute	qlco	3.55
21724857	C1299581	Able (finding)	fndg	3.43
21724857	C0205448	Two	qnco	3.43
21724857	C1879547	Activation action	acty	3.42
21724857	C0441712	Mechanism (attribute)	ftcn	3.42
21724857	C1706376	Mechanism Component of Device	mnob	3.42
21724857	C1709630	Preclinical	qlco	3.42
21724857	C1532633	Kilounit per Kilogram	qnco	5.18
21724857	C2608091	Unit/gram	qnco	5.18
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
21724857	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
21724857	C0040363	Togo	geoa	17.80
21724857	C0041260	Tryptophanase	aapp	17.80
21724857	C0041260	Tryptophanase	enzy	17.80
21724857	C0014003	Employment	qlco	11.49
21724857	C1879547	Activation action	acty	5.18
21724857	C3687625	Demonstrates	acty	5.18
21724857	C0557351	Employed	fndg	5.18
21724857	C1883351	To	qlco	5.18
21724857	C3853838	activate - Data Operation	ftcn	5.18
21724857	C1515877	activate biological process	ftcn	5.18
21724857	C1413365	CFTR gene	gngm	3.68
21724857	C0449788	Count of entities	qnco	3.56
21724857	C0237753	Numbers	qnco	3.56
21724857	C0596988	mutant	comd	3.50
21724857	C1705242	Different	qlco	3.43
21724857	C0441712	Mechanism (attribute)	ftcn	3.43
23923627	C1138555	Pharmacogenomics	bmod	16.30
23923627	C2718059	Precision Medicine	topp	12.91
23923627	C0337095	Entrance	spco	5.18
23923627	C3539073	In the Field	spco	3.64
23923627	C0039798	therapeutic aspects	ftcn	22.36
23923627	C0087113	Treatment Effectiveness	qlco	19.34
23923627	C0040363	Togo	geoa	17.80
23923627	C0041260	Tryptophanase	aapp	17.80
23923627	C0041260	Tryptophanase	enzy	17.80
23923627	C0001688	aspects of adverse effects	ftcn	9.77
23923627	C0376315	Manufactured form	mnob	6.71
23923627	C0016884	Future	tmco	6.66
23923627	C1883351	To	qlco	5.18
23923627	C2699424	Concern	idcn	3.63
23923627	C1522492	Formation	ftcn	3.56
23923627	C0348078	Qualitative form	qlco	3.56
23923627	C0392756	Reduced	qlco	3.56
23923627	C0301630	Reduction (chemical)	npop	3.56
23923627	C0441610	Reduction - action	topp	3.56
23923627	C0879626	Adverse effects	patf	3.46
23923627	C1836348	Severe disorder	fndg	3.44
23923627	C2937289	Adapt (substance)	orch	3.43
23923627	C0087111	Therapeutic procedure	topp	3.43
23923627	C1363945	Therapy Object (animal model)	fndg	3.43
23923627	C0298973	Ataxia Telangiectasia Mutated Proteins	aapp	26.20
23923627	C0298973	Ataxia Telangiectasia Mutated Proteins	enzy	26.20
23923627	C0041714	United States Food and Drug Administration	hcro	25.54
23923627	C3264621	ivacaftor	orch	14.64
23923627	C3264621	ivacaftor	phsu	14.64
23923627	C0376649	Addresses (publication format)	inpr	7.13
23923627	C1442065	Address	spco	3.98
23923627	C3192263	Vemurafenib	orch	3.68
23923627	C3192263	Vemurafenib	phsu	3.68
23923627	C3687832	DRUGS	topp	3.61
23923627	C0013227	Pharmaceutical Preparations	phsu	3.61
23923627	C0205540	Approved	qlco	3.47
23923627	C0205435	First (number)	qnco	3.47
23923627	C1279901	Firstly	qlco	3.47
23923627	C0001688	aspects of adverse effects	ftcn	19.93
23923627	C0008976	Clinical Trials	resa	19.22
23923627	C3264621	ivacaftor	orch	12.89
23923627	C3264621	ivacaftor	phsu	12.89
23923627	C1096775	Clinical Trial [Publication Type]	inpr	9.76
23923627	C0032042	Placebos	topp	8.34
23923627	C0879626	Adverse effects	patf	7.24
23923627	C1706408	Placebo Control	resa	5.18
23923627	C0439861	Substance	sbst	5.18
23923627	C3192263	Vemurafenib	orch	5.18
23923627	C3192263	Vemurafenib	phsu	5.18
23923627	C1696465	placebo	bodm	5.18
23923627	C1547282	Show	anim	3.98
23923627	C0205195	Combined	qlco	3.55
23923627	C2945599	Mild (qualifier value)	qlco	3.55
23923627	C2825142	Experimental Result	fndg	3.52
23923627	C1274040	Result	ftcn	3.52
23923627	C1546471	What subject filter - Result	idcn	3.52
23923627	C1555307	promise	idcn	3.41
23923627	C0026882	Mutation	genf	9.86
23923627	C0376649	Addresses (publication format)	inpr	6.57
23923627	C0678723	Biologic Development	orgf	3.68
23923627	C1527148	Development	ftcn	3.68
23923627	C0243107	development aspects	phsf	3.68
23923627	C0750484	Confirmation	idcn	3.59
23923627	C0521093	Confirmed by	qlco	3.59
23923627	C1709630	Preclinical	qlco	3.59
23923627	C1280519	Effectiveness	qlco	3.57
23923627	C1707887	Efficacy Study	resa	3.57
23923627	C1705285	Mutation Abnormality	comd	3.55
23923627	C0205210	Clinical	qlco	3.50
23923627	C1553058	Neuropsychologist - Clinical	prog	3.50
23923627	C0237412	Psychologist - Clinical	prog	3.50
23923627	C0497591	Social Worker - Clinical	prog	3.50
23923627	C0205198	Compound	qlco	3.43
23923627	C1706082	Compound (substance)	chem	3.43
23923627	C1552740	Entity Determiner - specific	inpr	3.43
23923627	C0205369	Specific qualifier value	qlco	3.43
23923627	C1442065	Address	spco	3.42
24030637	C0040363	Togo	geoa	17.80
24030637	C0041260	Tryptophanase	aapp	17.80
24030637	C0041260	Tryptophanase	enzy	17.80
24030637	C3264621	ivacaftor	orch	13.14
24030637	C3264621	ivacaftor	phsu	13.14
24030637	C0023636	License	rnlw	13.05
24030637	C0242373	Licensing	gora	13.05
24030637	C0042153	utilization qualifier	ftcn	9.90
24030637	C0015127	Etiology aspects	ftcn	9.86
24030637	C0010674	Cystic Fibrosis	dsyn	9.76
24030637	C0087111	Therapeutic procedure	topp	5.18
24030637	C1883351	To	qlco	5.18
24030637	C1522326	Treating	ftcn	5.18
24030637	C1292734	Treatment intent	ftcn	5.18
24030637	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.69
24030637	C0013227	Pharmaceutical Preparations	phsu	3.68
24030637	C1254351	Pharmacologic Substance	phsu	3.68
24030637	C1548573	Licensed - Location characteristic ID	inpr	3.59
24030637	C3889832	Licensed as Wholesale Drug Distributor or Third Party Logistics Provider	qlco	3.59
24030637	C0457083	Usage	ftcn	3.59
24030637	C1947944	Use - dosing instruction imperative	inpr	3.59
24030637	C1524003	Science of Etiology	cnce	3.55
24030637	C0205435	First (number)	qnco	3.50
24030637	C1279901	Firstly	qlco	3.50
24030637	C3264627	Kalydeco	phsu	3.50
24030637	C0021966	Iodides	inch	17.80
24030637	C0033204	Probability	qnco	16.30
24030637	C3264621	ivacaftor	orch	13.14
24030637	C3264621	ivacaftor	phsu	13.14
24030637	C0221138	Blood group antibody I	aapp	5.18
24030637	C0221138	Blood group antibody I	imft	5.18
24030637	C0442805	Increase	ftcn	5.18
24030637	C0205217	Increased	qnco	5.18
24030637	C0175566	Open	spco	3.68
24030637	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
24030637	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
24030637	C0039798	therapeutic aspects	ftcn	22.48
24030637	C0026882	Mutation	genf	20.16
24030637	C0206243	Carrying	acty	14.64
24030637	C0001792	Elderly (population group)	popg	14.64
24030637	C0010674	Cystic Fibrosis	dsyn	9.76
24030637	C0030705	Patients	podg	8.34
24030637	C1705285	Mutation Abnormality	comd	7.47
24030637	C0001779	Age	orga	5.18
24030637	C1413365	CFTR gene	gngm	5.18
24030637	C0699809	Does carry	fndg	5.18
24030637	C1999167	Old age	popg	5.18
24030637	C1159591	chloride transport	celf	5.18
24030637	C2349975	Enhance (action)	acty	3.98
24030637	C3176933	Country number	inpr	3.56
24030637	C3259240	Country number:Find:Pt:^Patient:Nom	clna	3.56
24030637	C0439799	Channel	spco	3.56
24030637	C1706095	Channel Object	cnce	3.56
24030637	C1533734	Administration procedure	topp	3.55
24030637	C1705169	Biomaterial Treatment	cnce	3.55
24030637	C1444656	Indicated	fndg	3.55
24030637	C0087111	Therapeutic procedure	topp	3.55
24030637	C1522326	Treating	ftcn	3.55
24030637	C3538994	Treatment Epoch	resa	3.55
24030637	C3887704	treatment - ActInformationManagementReason	hlca	3.55
24030637	C3850123	Clinical Effectiveness	qlco	19.38
24030637	C3264621	ivacaftor	orch	12.89
24030637	C3264621	ivacaftor	phsu	12.89
24030637	C0282443	Review [Publication Type]	inpr	11.49
24030637	C0031330	Pharmacology	bmod	9.87
24030637	C1552617	Act Class - review	idcn	5.18
24030637	C3146298	Indication	idcn	5.18
24030637	C0392360	Indication of (contextual qualifier)	idcn	5.18
24030637	C1511726	Data	idcn	3.68
24030637	C3714741	Data (eukaryote)	euka	3.68
24030637	C3245479	Data call receiving device	medd	3.68
24030637	C0205234	Focal	spco	3.56
24030637	C1285542	Has focus	ftcn	3.56
24030637	C0205464	pharmacological	ftcn	3.56
24030637	C2347946	Relevance	qlco	3.55
24030637	C3274448	Tolerability Study	resa	3.50
24030637	C1524063	Use of	ftcn	3.45
24030637	C0282461	Phase 3 Clinical Trials	resa	22.61
24030637	C0013072	Double-Blind Method	resa	17.80
24030637	C0001792	Elderly (population group)	popg	14.64
24030637	C0031843	physiological aspects	phsf	14.64
24030637	C3264621	ivacaftor	orch	12.93
24030637	C3264621	ivacaftor	phsu	12.93
24030637	C0026882	Mutation	genf	9.99
24030637	C0010674	Cystic Fibrosis	dsyn	9.79
24030637	C0024109	Lung	bpoc	6.76
24030637	C0032042	Placebos	topp	6.60
24030637	C0030705	Patients	podg	6.59
24030637	C3845262	6+11	fndg	5.18
24030637	C0001779	Age	orga	5.18
24030637	C0542341	Function	ftcn	5.18
24030637	C0700205	Function Axis	clas	5.18
24030637	C1705273	Mathematical Operator	inpr	5.18
24030637	C1999167	Old age	popg	5.18
24030637	C3875154	Relative to	idcn	3.72
24030637	C1705285	Mutation Abnormality	comd	3.68
24030637	C2828392	Standard (document)	inpr	3.68
24030637	C1442989	Standard (qualifier)	qlco	3.68
24030637	C1947933	care activity	acty	3.68
24030637	C0332174	Weekly	tmco	3.63
24030637	C0439230	week	tmco	3.63
24030637	C1278908	Entire lung	bpoc	3.60
24030637	C0819757	Structure of parenchyma of lung	tisu	3.60
24030637	C0205195	Combined	qlco	3.59
24030637	C1273517	Used by	fndg	3.59
24030637	C3811910	combination - answer to question	fndg	3.59
24030637	C1947911	combination of objects	phob	3.59
24030637	C0439234	year	tmco	3.57
24030637	C0205448	Two	qnco	3.48
24030637	C0442027	Oral	spco	3.47
24030637	C1561611	Admission Level of Care Code - Improved	inpr	3.46
24030637	C0332272	Better	qlco	3.46
24030637	C0184511	Improved	qlco	3.46
24030637	C1706408	Placebo Control	resa	3.45
24030637	C1696465	placebo	bodm	3.45
24030637	C0005910	Body Weight	orga	24.11
24030637	C0035647	Risk	idcn	19.19
24030637	C0032042	Placebos	topp	8.34
24030637	C0024109	Lung	bpoc	6.58
24030637	C1706408	Placebo Control	resa	5.18
24030637	C0947630	Scientific Study	lbpr	5.18
24030637	C1305866	Weighing patient	diap	5.18
24030637	C1696465	placebo	bodm	5.18
24030637	C0013227	Pharmaceutical Preparations	phsu	3.57
24030637	C1254351	Pharmacologic Substance	phsu	3.57
24030637	C0205397	seen	qlco	3.57
24030637	C2986411	Improvement	cnce	3.52
24030637	C1879746	Aspect (characteristic)	qlco	3.51
24030637	C1547011	Aspect - Kind of quantity	qnco	3.51
24030637	C0518906	health & life quality	inpr	3.47
24030637	C1546944	Event Seriousness - Significant	qlco	3.42
24030637	C2709248	Pulmonary (qualifier value)	qlco	3.42
24030637	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.42
24030637	C0750502	Significant	idcn	3.42
24030637	C0237881	Statistical Significance	qnco	3.42
24030637	C0445223	Related personal status	fndg	3.42
24030637	C0439849	Relationships	qlco	3.42
24030637	C0005910	Body Weight	orga	24.11
24030637	C0039798	therapeutic aspects	ftcn	22.47
24030637	C3264621	ivacaftor	orch	12.89
24030637	C3264621	ivacaftor	phsu	12.89
24030637	C0035245	Respiratory physiology	ortf	6.60
24030637	C1314677	Maintaining (action)	ftcn	5.18
24030637	C1305866	Weighing patient	diap	5.18
24030637	C1709323	Open Label Study	resa	3.56
24030637	C1280500	Effect	qlco	3.56
24030637	C0449381	Observation parameter	fndg	3.55
24030637	C1533734	Administration procedure	topp	3.55
24030637	C1705169	Biomaterial Treatment	cnce	3.55
24030637	C0347984	During	tmco	3.55
24030637	C0205136	Over (spatial)	spco	3.55
24030637	C0087111	Therapeutic procedure	topp	3.55
24030637	C1522326	Treating	ftcn	3.55
24030637	C3538994	Treatment Epoch	resa	3.55
24030637	C3887704	treatment - ActInformationManagementReason	hlca	3.55
24030637	C0231448	Extension	ftcn	3.54
24030637	C1880641	Telephone Extension Number	cnce	3.54
24030637	C0549178	Continuous	idcn	3.42
24030637	C0018681	Headache	sosy	17.80
24030637	C0030193	Pain	sosy	16.30
24030637	C3264621	ivacaftor	orch	13.14
24030637	C3264621	ivacaftor	phsu	13.14
24030637	C0041912	Upper Respiratory Infections	dsyn	11.49
24030637	C0521367	Oropharyngeal	blor	9.81
24030637	C0027424	Nasal congestion (finding)	sosy	5.18
24030637	C1962977	Pain NOS Adverse Event	fndg	3.68
24030637	C0205170	Good	qlco	3.63
24030637	C3146287	Well	mnob	3.63
24030637	C1705413	Adverse Event Domain	inpr	3.58
24030637	C0877248	Adverse event	patf	3.58
24030637	C0205214	Common (qualifier value)	qnco	3.55
24030637	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.55
24030637	C0205393	Most	qnco	3.55
24030637	C1522138	shared attribute	ftcn	3.55
24030637	C3264621	ivacaftor	orch	14.64
24030637	C3264621	ivacaftor	phsu	14.64
24030637	C0010674	Cystic Fibrosis	dsyn	11.49
24030637	C0026882	Mutation	genf	9.99
24030637	C0030705	Patients	podg	6.58
24030637	C0205229	Expanding	spco	5.18
24030637	C1705285	Mutation Abnormality	comd	3.68
24030637	C0683525	treatment options	topp	3.59
24030637	C1518601	Options	ftcn	3.55
24030637	C2827774	Current Therapy	topp	3.45
24030637	C0521116	Current (present time)	tmco	3.43
24030637	C1705970	Electrical Current	npop	3.43
24030637	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24030637	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24030637	C0042153	utilization qualifier	ftcn	9.75
24030637	C0026882	Mutation	genf	9.74
24030637	C0030705	Patients	podg	6.71
24030637	C0543488	Interested	menp	3.59
24030637	C3245505	potential	qlco	3.57
24030637	C0457083	Usage	ftcn	3.44
24030637	C1947944	Use - dosing instruction imperative	inpr	3.44
24030637	C1413365	CFTR gene	gngm	3.43
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.12
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.12
28360110	C0003075	Anions	elii	12.88
28360110	C0596902	Membrane Transport Proteins	aapp	12.88
28360110	C0596902	Membrane Transport Proteins	bacs	12.88
28360110	C0851285	Regulation	gora	11.49
28360110	C1413365	CFTR gene	gngm	7.05
28360110	C1522492	Formation	ftcn	5.18
28360110	C0205431	Formed	ftcn	5.18
28360110	C0542341	Function	ftcn	3.68
28360110	C1706221	Associate - assistant	prog	3.59
28360110	C0750490	Associate - relationship	idcn	3.59
28360110	C1704241	complex (molecular entity)	chvs	3.57
28360110	C0086282	Family member	famg	3.56
28360110	C0040363	Togo	geoa	17.80
28360110	C0041260	Tryptophanase	aapp	17.80
28360110	C0041260	Tryptophanase	enzy	17.80
28360110	C0004083	Mental association	menp	14.64
28360110	C0039869	Thinking, function	menp	11.49
28360110	C1883351	To	qlco	5.18
28360110	C0337143	Scaffold	mnob	3.56
28360110	C1704675	Interaction	ftcn	3.53
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
28360110	C0851285	Regulation	gora	19.89
28360110	C0040363	Togo	geoa	17.80
28360110	C0041260	Tryptophanase	aapp	17.80
28360110	C0041260	Tryptophanase	enzy	17.80
28360110	C0297119	sodium-hydrogen exchanger regulatory factor	aapp	13.03
28360110	C0014609	Epithelium	tisu	6.79
28360110	C1883351	To	qlco	5.18
28360110	C1547282	Show	anim	3.98
28360110	C1413365	CFTR gene	gngm	3.68
28360110	C0439259	kilocalorie	qnco	3.59
28360110	C1420236	SLC9A3R1 gene	gngm	3.57
28360110	C0458827	Airway structure	bpoc	3.50
28360110	C0178987	Artificial Airways	medd	3.50
28360110	C1956036	PDZ Domains	spco	25.58
28360110	C0072393	Protein S	aapp	13.14
28360110	C0072393	Protein S	enzy	13.14
28360110	C0014609	Epithelium	tisu	6.69
28360110	C0086282	Family member	famg	3.75
28360110	C1418948	PROS1 gene	gngm	3.68
28360110	C1422675	SLC26A9 gene	gngm	3.59
28360110	C0458827	Airway structure	bpoc	3.57
28360110	C0178987	Artificial Airways	medd	3.57
28360110	C0150312	Present	qnco	3.57
28360110	C0086418	Homo sapiens	humn	28.65
28360110	C0036536	Process of secretion	biof	19.40
28360110	C0015272	Exhibits as Topic	inpr	17.80
28360110	C0009738	Congo	geoa	16.04
28360110	C0003075	Anions	elii	12.94
28360110	C0036537	Bodily secretions	bdsu	6.79
28360110	C1547282	Show	anim	3.98
28360110	C0596130	attribution	menp	3.59
28360110	C0599333	Epithelium of bronchus	bpoc	3.55
28360110	C1422675	SLC26A9 gene	gngm	3.45
28360110	C3811819	CFTR wt Allele	gngm	3.42
28360110	C0013018	Donor person	popg	3.42
28360110	C1527169	Encounter due to being a donor	fndg	3.42
28360110	C1518422	Negation	ftcn	3.42
28360110	C0205225	Primary	qlco	3.42
28360110	C0439631	Primary operation	topp	3.42
28360110	C0439612	True primary (qualifier value)	tmco	3.42
28360110	C0036536	Process of secretion	biof	19.40
28360110	C0009738	Congo	geoa	16.12
28360110	C0003075	Anions	elii	12.94
28360110	C0036537	Bodily secretions	bdsu	6.79
28360110	C0013018	Donor person	popg	3.68
28360110	C1527169	Encounter due to being a donor	fndg	3.68
28360110	C0332197	Absent	ftcn	3.59
28360110	C2699517	Absent Adverse Event	fndg	3.59
28360110	C3811819	CFTR wt Allele	gngm	3.50
28360110	C1415484	HBE1 gene	gngm	3.45
28360110	C2827566	HBE1 wt Allele	gngm	3.45
28360110	C3844844	Hb E	fndg	3.45
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
28360110	C0035820	Social Role	socb	12.94
28360110	C0600138	Does play	fndg	5.18
28360110	C0332128	Examined	fndg	5.18
28360110	C0599896	trafficking	celf	5.18
28360110	C1704675	Interaction	ftcn	3.59
28360110	C0443172	Changed status	qnco	3.56
28360110	C0392747	Changing	ftcn	3.56
28360110	C1413365	CFTR gene	gngm	3.55
28360110	C1517945	Loss	qnco	3.55
28360110	C0449234	Concept Attribute	idcn	3.52
28360110	C1882133	Object Attribute	qlco	3.52
28360110	C1704772	Protection Element Attribute	cnce	3.52
28360110	C1705810	Generic Role	cnce	3.48
28360110	C3871154	{Role}	inpr	3.48
28360110	C1561536	*Activity (kind of quantity)	idcn	3.43
28360110	C0205177	Active	ftcn	3.43
28360110	C0441655	Activities	acty	3.43
28360110	C3668946	Activity (animal life circumstance)	fndg	3.43
28360110	C4049939	FDA Establishment Activity Terminology	inpr	3.43
28360110	C0439167	Percent Activity	qnco	3.43
28360110	C4049938	Physical Activity Measurement	lbpr	3.43
28360110	C1422675	SLC26A9 gene	gngm	3.43
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.42
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.42
28360110	C0015272	Exhibits as Topic	inpr	16.59
28360110	C1422675	SLC26A9 gene	gngm	7.46
28360110	C1413365	CFTR gene	gngm	7.35
28360110	C0599896	trafficking	celf	5.18
28360110	C0007634	Cells	cell	3.59
28360110	C3282337	Cells [Chemical/Ingredient]	cell	3.59
28360110	C1707455	Comparison	acty	3.59
28360110	C0392756	Reduced	qlco	3.55
28360110	C0301630	Reduction (chemical)	npop	3.55
28360110	C0441610	Reduction - action	topp	3.55
28360110	C2700323	Wild Type Unspecified - zebrafish	fish	3.50
28360110	C0596988	mutant	comd	3.48
28360110	C0521116	Current (present time)	tmco	3.43
28360110	C1705970	Electrical Current	npop	3.43
28360110	C1546944	Event Seriousness - Significant	qlco	3.43
28360110	C0750502	Significant	idcn	3.43
28360110	C0237881	Statistical Significance	qnco	3.43
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
28360110	C0015272	Exhibits as Topic	inpr	17.80
28360110	C0376322	Protein Glycosylation	moft	16.30
28360110	C0017982	glycosylation	npop	16.30
28360110	C0007603	Plasma membrane	celc	9.76
28360110	C0205216	Decreased	qnco	5.18
28360110	C0442797	Decreasing	qlco	5.18
28360110	C0150312	Present	qnco	5.18
28360110	C0392756	Reduced	qlco	5.18
28360110	C1422675	SLC26A9 gene	gngm	5.18
28360110	C1413365	CFTR gene	gngm	3.57
28360110	C3854321	Expression (foundation metadata concept)	idcn	3.55
28360110	C0185117	Expression procedure	topp	3.55
28360110	C0439855	Complex	qlco	3.50
28360110	C1704241	complex (molecular entity)	chvs	3.50
28360110	C0043094	Weight Gain	fndg	25.63
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
28360110	C0297119	sodium-hydrogen exchanger regulatory factor	aapp	13.02
28360110	C0439259	kilocalorie	qnco	5.18
28360110	C1422675	SLC26A9 gene	gngm	3.68
28360110	C1704675	Interaction	ftcn	3.57
28360110	C1420236	SLC9A3R1 gene	gngm	3.56
28360110	C1413365	CFTR gene	gngm	3.55
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28360110	C0439259	kilocalorie	qnco	5.18
28360110	C1413365	CFTR gene	gngm	3.42
28360110	C0442805	Increase	ftcn	3.42
28360110	C0205217	Increased	qnco	3.42
28360110	C1704675	Interaction	ftcn	3.42
28360110	C1720467	Only - dosing instruction fragment	inpr	3.42
28360110	C1422675	SLC26A9 gene	gngm	3.42
28360110	C0205171	Singular	qnco	3.42
28360110	C1514562	Protein Domain	amas	19.20
28360110	C0004083	Mental association	menp	13.03
28360110	C0026882	Mutation	genf	9.86
28360110	C0205216	Decreased	qnco	5.18
28360110	C0442797	Decreasing	qlco	5.18
28360110	C0392756	Reduced	qlco	5.18
28360110	C1561536	*Activity (kind of quantity)	idcn	3.68
28360110	C0205177	Active	ftcn	3.68
28360110	C0441655	Activities	acty	3.68
28360110	C3668946	Activity (animal life circumstance)	fndg	3.68
28360110	C4049939	FDA Establishment Activity Terminology	inpr	3.68
28360110	C0439167	Percent Activity	qnco	3.68
28360110	C4049938	Physical Activity Measurement	lbpr	3.68
28360110	C0596306	Chemical Association	phpr	3.57
28360110	C0699792	Relationship by association	socb	3.57
28360110	C0439849	Relationships	qlco	3.57
28360110	C1705285	Mutation Abnormality	comd	3.55
28360110	C0439259	kilocalorie	qnco	3.44
28360110	C1422675	SLC26A9 gene	gngm	3.43
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.56
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.56
28360110	C0009738	Congo	geoa	16.18
28360110	C2349182	Correct (qualifier)	qlco	3.98
28360110	C1413365	CFTR gene	gngm	3.63
28360110	C1561536	*Activity (kind of quantity)	idcn	3.59
28360110	C0205177	Active	ftcn	3.59
28360110	C0441655	Activities	acty	3.59
28360110	C3668946	Activity (animal life circumstance)	fndg	3.59
28360110	C4049939	FDA Establishment Activity Terminology	inpr	3.59
28360110	C0439167	Percent Activity	qnco	3.59
28360110	C4049938	Physical Activity Measurement	lbpr	3.59
28360110	C3811819	CFTR wt Allele	gngm	3.57
28360110	C1415484	HBE1 gene	gngm	3.57
28360110	C2827566	HBE1 wt Allele	gngm	3.57
28360110	C3844844	Hb E	fndg	3.57
28360110	C0599896	trafficking	celf	3.57
28360110	C0443127	Aberrant	qlco	3.48
28360110	C3252847	VX 809	orch	3.47
28360110	C3252847	VX 809	phsu	3.47
28360110	C1422675	SLC26A9 gene	gngm	3.45
28360110	C0917903	Conclude Resin	bodm	27.26
28360110	C0917903	Conclude Resin	orch	27.26
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
28360110	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
28360110	C1514562	Protein Domain	amas	19.31
28360110	C0023175	Lead	elii	13.00
28360110	C0023175	Lead	hops	13.00
28360110	C1422675	SLC26A9 gene	gngm	7.43
28360110	C1457869	Defect	ftcn	5.18
28360110	C0599896	trafficking	celf	5.18
28360110	C1413365	CFTR gene	gngm	3.57
28360110	C1659465	retention within cell	celf	3.56
28360110	C0332324	Sensitive	ftcn	3.56
28360110	C3275067	Cardiac Lead Procedure	topp	3.54
28360110	C2348269	Dietary Lead	elii	3.54
28360110	C1522538	Leading	ftcn	3.54
28360110	C0181586	Leads (device)	medd	3.54
28360110	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.54
28360110	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.54
26091951	C0004048	Inspiration function	orgf	58.57
26091951	C0010674	Cystic Fibrosis	dsyn	30.29
26091951	C0011682	Desiccation	npop	25.97
26091951	C0004521	Aztreonam	antb	25.76
26091951	C0004521	Aztreonam	orch	25.76
26091951	C0079613	Adoptive Immunotherapy	topp	25.65
26091951	C0039798	therapeutic aspects	ftcn	22.61
26091951	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.49
26091951	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.49
26091951	C0003237	Antibiotics, Antitubercular	antb	22.36
26091951	C0009316	Colistin	aapp	22.36
26091951	C0009316	Colistin	antb	22.36
26091951	C0032861	Powder dose form	bodm	19.63
26091951	C0040341	Tobramycin	antb	19.36
26091951	C0040341	Tobramycin	orch	19.36
26091951	C0040363	Togo	geoa	17.80
26091951	C0041260	Tryptophanase	aapp	17.80
26091951	C0041260	Tryptophanase	enzy	17.80
26091951	C0003232	Antibiotics	antb	16.05
26091951	C3264621	ivacaftor	orch	14.64
26091951	C3264621	ivacaftor	phsu	14.64
26091951	C0024730	Mannitol	orch	13.08
26091951	C0024730	Mannitol	phsu	13.08
26091951	C0023636	License	rnlw	13.05
26091951	C0242373	Licensing	gora	13.05
26091951	C1869853	SERPINA3 protein, human	aapp	13.03
26091951	C1869853	SERPINA3 protein, human	bacs	13.03
26091951	C0031847	physiopathological	ftcn	9.81
26091951	C0205222	Dry	qlco	6.94
26091951	C1512080	Dryness (characteristic)	qlco	6.94
26091951	C1382110	powder physical state	sbst	6.94
26091951	C0015176	Europe	geoa	6.74
26091951	C0450442	Agent	chvf	5.18
26091951	C2349182	Correct (qualifier)	qlco	5.18
26091951	C1947931	Direct (qualifier)	qlco	5.18
26091951	C0332257	Including (qualifier)	ftcn	5.18
26091951	C1254351	Pharmacologic Substance	phsu	5.18
26091951	C1521826	Protocol Agent	inpr	5.18
26091951	C1883351	To	qlco	5.18
26091951	C0597385	Respiratory airway clearance	ortf	3.75
26091951	C1457869	Defect	ftcn	3.68
26091951	C1321013	Hydration status	fndg	3.68
26091951	C0332185	Recent	tmco	3.68
26091951	C0087111	Therapeutic procedure	topp	3.68
26091951	C1363945	Therapy Object (animal model)	fndg	3.68
26091951	C0678941	Gene Mutant	gngm	3.65
26091951	C0596611	Gene Mutation	genf	3.65
26091951	C1718138	Number of medications	fndg	3.60
26091951	C1548573	Licensed - Location characteristic ID	inpr	3.59
26091951	C3889832	Licensed as Wholesale Drug Distributor or Third Party Logistics Provider	qlco	3.59
26091951	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.58
26091951	C3242455	HL7PublishingDomain <patient administration>	inpr	3.58
26091951	C3242279	healthcare operations <patient administration>	ocac	3.58
26091951	C4048375	Asthma Control Test Questionnaire	inpr	3.57
26091951	C1413365	CFTR gene	gngm	3.57
26091951	C3890007	SERPINA3 wt Allele	gngm	3.57
26091951	C1512346	Patient Visit	hlca	3.56
26091951	C0449788	Count of entities	qnco	3.56
26091951	C0237753	Numbers	qnco	3.56
26091951	C0333052	Version	ftcn	3.56
26091951	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.51
26091951	C3887504	Dysfunction	cnce	3.51
26091951	C0277785	Functional disorder	patf	3.51
26091951	C0458827	Airway structure	bpoc	3.50
26091951	C0178987	Artificial Airways	medd	3.50
26091951	C1527178	Basis - conceptual entity	ftcn	3.50
26091951	C0442027	Oral	spco	3.50
26091951	C3540469	AICDA wt Allele	gngm	3.48
26091951	C1269765	Assisted (qualifier value)	qlco	3.48
26091951	C0449435	Manufactured aid	mnob	3.48
26091951	C1705211	Inhalation Dosing Unit	qnco	3.45
26091951	C0205535	Inhalation Route of Drug Administration	ftcn	3.45
26091951	C3540706	Antibiotic throat preparations	antb	3.43
26091951	C3540707	Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	antb	3.43
26091951	C3540704	Antibiotics for systemic use	antb	3.43
26091951	C3540708	Antibiotics, Gynecological	antb	3.43
26091951	C3540710	Antibiotics, ophthalmologic	antb	3.43
26091951	C3540705	Antifungal Antibiotics, Topical	antb	3.43
26091951	C3540709	antibiotics, intestinal	antb	3.43
26091951	C1524062	Additional	ftcn	3.42
26091951	C1546944	Event Seriousness - Significant	qlco	3.42
26091951	C0750502	Significant	idcn	3.42
26091951	C0237881	Statistical Significance	qnco	3.42
26091951	C0008976	Clinical Trials	resa	19.41
26091951	C0009738	Congo	geoa	16.05
26091951	C0242373	Licensing	gora	14.64
26091951	C3264621	ivacaftor	orch	12.89
26091951	C3264621	ivacaftor	phsu	12.89
26091951	C0026882	Mutation	genf	9.99
26091951	C1096775	Clinical Trial [Publication Type]	inpr	9.95
26091951	C0015127	Etiology aspects	ftcn	9.87
26091951	C0015196	Evaluation Studies	inpr	6.76
26091951	C0030705	Patients	podg	6.59
26091951	C1947931	Direct (qualifier)	qlco	5.18
26091951	C3840786	Greatly	fndg	5.18
26091951	C3889833	Structured Product Labeling Licensing Terminology	inpr	5.18
26091951	C1521840	Target	ftcn	5.18
26091951	C2986546	Target Lesion Identification	diap	5.18
26091951	C0679830	patient assessment	hlca	3.60
26091951	C0687676	Post	tmco	3.59
26091951	C1704687	Post Device Component	mnob	3.59
26091951	C1524003	Science of Etiology	cnce	3.56
26091951	C0947630	Scientific Study	lbpr	3.56
26091951	C0597535	Success	socb	3.56
26091951	C0678723	Biologic Development	orgf	3.55
26091951	C1527148	Development	ftcn	3.55
26091951	C0243107	development aspects	phsf	3.55
26091951	C1553904	continuing therapy	idcn	3.44
26091951	C3811819	CFTR wt Allele	gngm	3.43
26091951	C1706089	Marked	qlco	3.43
26091951	C0522501	Massive	qlco	3.43
26091951	C1522326	Treating	ftcn	3.43
26091951	C2348205	Similarity	qlco	3.43
26091951	C0003209	Anti-Inflammatory Agents	phsu	14.64
26091951	C0003204	Anti-Infective Agents	phsu	12.92
26091951	C0035139	Surgical Replantation	topp	9.78
26091951	C0008972	Clinical Research	resa	8.34
26091951	C0521116	Current (present time)	tmco	5.18
26091951	C0332257	Including (qualifier)	ftcn	5.18
26091951	C0087111	Therapeutic procedure	topp	5.18
26091951	C0920330	Pancreatic enzyme	aapp	3.75
26091951	C0920330	Pancreatic enzyme	enzy	3.75
26091951	C0920330	Pancreatic enzyme	phsu	3.75
26091951	C0449788	Count of entities	qnco	3.56
26091951	C0237753	Numbers	qnco	3.56
26091951	C0559956	Replacement	ftcn	3.48
26091951	C1555302	Replacement - supply	hlca	3.48
26091951	C0432616	Blood group antibody A	aapp	3.46
26091951	C0432616	Blood group antibody A	imft	3.46
26091951	C0008976	Clinical Trials	resa	19.23
26091951	C0009738	Congo	geoa	16.21
26091951	C0023636	License	rnlw	13.05
26091951	C0242373	Licensing	gora	13.05
26091951	C0220825	Evaluation	hlca	13.02
26091951	C0282443	Review [Publication Type]	inpr	11.49
26091951	C1096775	Clinical Trial [Publication Type]	inpr	9.77
26091951	C0087111	Therapeutic procedure	topp	7.45
26091951	C1552617	Act Class - review	idcn	5.18
26091951	C1706852	Article	inpr	5.18
26091951	C0332185	Recent	tmco	5.18
26091951	C3811819	CFTR wt Allele	gngm	3.59
26091951	C1548573	Licensed - Location characteristic ID	inpr	3.59
26091951	C3889832	Licensed as Wholesale Drug Distributor or Third Party Logistics Provider	qlco	3.59
26091951	C1261322	Evaluation procedure	hlca	3.56
26091951	C0750528	presently	idcn	3.55
26091951	C0242481	Research Activities	resa	9.90
26091951	C0035168	research	resa	9.90
26091951	C0012634	Disease	dsyn	9.74
26091951	C2584313	Discussion (communication)	socb	5.18
26091951	C1883712	Add - instruction imperative	ftcn	3.63
26091951	C0332287	In addition to	ftcn	3.63
26091951	C0871489	teams	grup	3.57
26091951	C0805586	Challenge	hlca	3.56
26091951	C0087111	Therapeutic procedure	topp	3.56
26091951	C3245505	potential	qlco	3.56
26091951	C1947978	Encounter	bhvr	3.55
26091951	C1512346	Patient Visit	hlca	3.55
26091951	C0545082	Visit	bhvr	3.55
26091951	C0205210	Clinical	qlco	3.44
26091951	C1553058	Neuropsychologist - Clinical	prog	3.44
26091951	C0237412	Psychologist - Clinical	prog	3.44
26091951	C0497591	Social Worker - Clinical	prog	3.44
26091951	C0348080	Condition	qlco	3.43
26091951	C3864998	Condition:Find:Pt:^Patient:Nom	clna	3.43
26091951	C1705253	Logical Condition	cnce	3.43
26091951	C1874964	DELIVER (Dietary Supplement)	phsu	3.41
26091951	C0308779	DELIVER (veterinary product)	orch	3.41
26091951	C0308779	DELIVER (veterinary product)	phsu	3.41
26091951	C1705822	Transfer Technique	ftcn	3.41
27482545	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
27482545	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
27482545	C0009219	Coding	ocac	22.47
27482545	C0017337	Genes	gngm	16.22
27482545	C0010674	Cystic Fibrosis	dsyn	10.06
27482545	C0026882	Mutation	genf	9.90
27482545	C0033684	Proteins	aapp	6.70
27482545	C0033684	Proteins	bacs	6.70
27482545	C2825142	Experimental Result	fndg	3.59
27482545	C1274040	Result	ftcn	3.59
27482545	C1546471	What subject filter - Result	idcn	3.59
27482545	C1413365	CFTR gene	gngm	3.58
27482545	C0919279	A Codes	clas	3.55
27482545	C0439799	Channel	spco	3.55
27482545	C1706095	Channel Object	cnce	3.55
27482545	C0805701	Code	inpr	3.55
27482545	C1704735	Regulator	cnce	3.55
27482545	C1704734	Regulator Device Component	mnob	3.55
27482545	C0182953	Regulators (device)	medd	3.55
27482545	C3889831	eTMF Content Model Code	inpr	3.55
27482545	C0009738	Congo	geoa	16.04
27482545	C0026882	Mutation	genf	9.86
27482545	C1153487	protein channel activity	moft	3.60
27482545	C1705285	Mutation Abnormality	comd	3.55
27482545	C3811819	CFTR wt Allele	gngm	3.43
27482545	C0205214	Common (qualifier value)	qnco	3.43
27482545	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.43
27482545	C0205393	Most	qnco	3.43
27482545	C1522138	shared attribute	ftcn	3.43
27482545	C0205216	Decreased	qnco	3.42
27482545	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27482545	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27482545	C0009738	Congo	geoa	16.04
27482545	C0031330	Pharmacology	bmod	9.73
27482545	C0013216	Pharmacotherapy	topp	6.60
27482545	C0549255	Excitation	acty	3.98
27482545	C0449445	Approach	spco	3.55
27482545	C0678723	Biologic Development	orgf	3.54
27482545	C1527148	Development	ftcn	3.54
27482545	C0243107	development aspects	phsf	3.54
27482545	C0683465	novel AODU treatment method	topp	3.44
27482545	C1328819	Small Molecule	orch	3.44
27482545	C3811819	CFTR wt Allele	gngm	3.42
27482545	C0205314	New	qlco	3.42
27482545	C0679622	literary novel	inpr	3.42
27482545	C0205464	pharmacological	ftcn	3.42
27482545	C1413365	CFTR gene	gngm	3.42
27482545	C1709060	Modulator Device Component	mnob	3.42
27482545	C0205198	Compound	qlco	3.40
27482545	C1706082	Compound (substance)	chem	3.40
27482545	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.12
27482545	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.12
27482545	C3264621	ivacaftor	orch	13.14
27482545	C3264621	ivacaftor	phsu	13.14
27482545	C3852684	lumacaftor	orch	13.14
27482545	C3852684	lumacaftor	phsu	13.14
27482545	C1413365	CFTR gene	gngm	7.05
27482545	C1269765	Assisted (qualifier value)	qlco	5.18
27482545	C1552861	Help document	inpr	5.18
27482545	C0442805	Increase	ftcn	5.18
27482545	C0205217	Increased	qnco	5.18
27482545	C1153410	channel activity	moft	3.68
27482545	C0699040	Cell surface	celc	3.44
27482545	C0041714	United States Food and Drug Administration	hcro	25.50
27482545	C0039798	therapeutic aspects	ftcn	22.47
27482545	C0009738	Congo	geoa	16.04
27482545	C4033633	ivacaftor / lumacaftor	phsu	12.92
27482545	C0026882	Mutation	genf	9.73
27482545	C0030705	Patients	podg	6.58
27482545	C1882932	Representation (action)	acty	5.18
27482545	C1254351	Pharmacologic Substance	phsu	3.68
27482545	C1135440	Procedures involving the use of pharmaceuticals	topp	3.68
27482545	C0205195	Combined	qlco	3.56
27482545	C3811910	combination - answer to question	fndg	3.56
27482545	C1947911	combination of objects	phob	3.56
27482545	C1948062	Copy (object)	mnob	3.55
27482545	C0087111	Therapeutic procedure	topp	3.54
27482545	C1363945	Therapy Object (animal model)	fndg	3.54
27482545	C2697524	Graph Node	cnce	3.50
27482545	C0230003	Vertex	blor	3.50
27482545	C1705285	Mutation Abnormality	comd	3.42
27482545	C0205448	Two	qnco	3.42
27482545	C0205540	Approved	qlco	3.42
27482545	C3811819	CFTR wt Allele	gngm	3.42
27482545	C0205435	First (number)	qnco	3.42
27482545	C1279901	Firstly	qlco	3.42
27482545	C0039798	therapeutic aspects	ftcn	22.49
27482545	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
27482545	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
27482545	C0026882	Mutation	genf	9.94
27482545	C0009429	Combined Modality Therapy	topp	8.34
27482545	C0030705	Patients	podg	8.34
27482545	C0035245	Respiratory physiology	ortf	6.60
27482545	C0556895	Combination electrotherapy	topp	5.18
27482545	C1947931	Direct (qualifier)	qlco	5.18
27482545	C0870432	Display - arrangement	ftcn	5.18
27482545	C0013227	Pharmaceutical Preparations	phsu	5.18
27482545	C1254351	Pharmacologic Substance	phsu	5.18
27482545	C1521840	Target	ftcn	5.18
27482545	C2986546	Target Lesion Identification	diap	5.18
27482545	C1515187	Take	hlca	3.98
27482545	C1705285	Mutation Abnormality	comd	3.63
27482545	C1533734	Administration procedure	topp	3.57
27482545	C1705169	Biomaterial Treatment	cnce	3.57
27482545	C0087111	Therapeutic procedure	topp	3.57
27482545	C1522326	Treating	ftcn	3.57
27482545	C3538994	Treatment Epoch	resa	3.57
27482545	C3887704	treatment - ActInformationManagementReason	hlca	3.57
27482545	C2986411	Improvement	cnce	3.52
27482545	C1413365	CFTR gene	gngm	3.48
27482545	C0205435	First (number)	qnco	3.44
27482545	C1279901	Firstly	qlco	3.44
27482545	C4054480	Modest Extremity Pain	inpr	3.43
27482545	C1720467	Only - dosing instruction fragment	inpr	3.43
27482545	C0205171	Singular	qnco	3.43
27482545	C0039798	therapeutic aspects	ftcn	22.48
27482545	C0008976	Clinical Trials	resa	19.23
27482545	C0009738	Congo	geoa	16.04
27482545	C4033633	ivacaftor / lumacaftor	phsu	13.04
27482545	C0163712	Relate - vinyl resin	orch	12.98
27482545	C0242481	Research Activities	resa	9.81
27482545	C0035168	research	resa	9.81
27482545	C1096775	Clinical Trial [Publication Type]	inpr	9.77
27482545	C0087111	Therapeutic procedure	topp	7.01
27482545	C0016884	Future	tmco	6.59
27482545	C0030705	Patients	podg	6.58
27482545	C1706852	Article	inpr	5.18
27482545	C0750591	consider	idcn	5.18
27482545	C1880355	Discover	acty	3.63
27482545	C1511726	Data	idcn	3.56
27482545	C3714741	Data (eukaryote)	euka	3.56
27482545	C3245479	Data call receiving device	medd	3.56
27482545	C1518601	Options	ftcn	3.56
27482545	C1533734	Administration procedure	topp	3.55
27482545	C1705169	Biomaterial Treatment	cnce	3.55
27482545	C1522326	Treating	ftcn	3.55
27482545	C3538994	Treatment Epoch	resa	3.55
27482545	C3887704	treatment - ActInformationManagementReason	hlca	3.55
27482545	C1280519	Effectiveness	qlco	3.49
27482545	C1707887	Efficacy Study	resa	3.49
27482545	C0332185	Recent	tmco	3.43
27482545	C3811819	CFTR wt Allele	gngm	3.43
27482545	C0205393	Most	qnco	3.43
26823603	C0036536	Process of secretion	biof	19.40
26823603	C0017362	Genes, Regulator	gngm	19.20
26823603	C0008203	Chlorides	inch	16.09
26823603	C0026882	Mutation	genf	9.85
26823603	C0010674	Cystic Fibrosis	dsyn	9.74
26823603	C0033684	Proteins	aapp	6.83
26823603	C0033684	Proteins	bacs	6.83
26823603	C0036537	Bodily secretions	bdsu	6.79
26823603	C0332294	Resulting in	ftcn	3.64
26823603	C0699040	Cell surface	celc	3.61
26823603	C0332452	defective	ftcn	3.57
26823603	C0599896	trafficking	celf	3.56
26823603	C0678941	Gene Mutant	gngm	3.55
26823603	C0596611	Gene Mutation	genf	3.55
26823603	C1705285	Mutation Abnormality	comd	3.54
26823603	C0596019	Chloride Ion	elii	3.48
26823603	C0221099	Impaired	ftcn	3.48
26823603	C0205214	Common (qualifier value)	qnco	3.42
26823603	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
26823603	C0205393	Most	qnco	3.42
26823603	C1704735	Regulator	cnce	3.42
26823603	C1704734	Regulator Device Component	mnob	3.42
26823603	C0182953	Regulators (device)	medd	3.42
26823603	C2752508	fully spanning the plasma membrane	celc	3.42
26823603	C1167322	integral to membrane	celc	3.42
26823603	C1522138	shared attribute	ftcn	3.42
26823603	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
26823603	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
26823603	C1564139	Mutant Proteins	aapp	11.49
26823603	C0013216	Pharmacotherapy	topp	6.91
26823603	C0033684	Proteins	aapp	6.63
26823603	C0033684	Proteins	bacs	6.63
26823603	C2244223	cellular homeostasis	celf	3.78
26823603	C1561536	*Activity (kind of quantity)	idcn	3.55
26823603	C0205177	Active	ftcn	3.55
26823603	C0441655	Activities	acty	3.55
26823603	C3668946	Activity (animal life circumstance)	fndg	3.55
26823603	C1413365	CFTR gene	gngm	3.55
26823603	C1947931	Direct (qualifier)	qlco	3.55
26823603	C4049939	FDA Establishment Activity Terminology	inpr	3.55
26823603	C0439167	Percent Activity	qnco	3.55
26823603	C4049938	Physical Activity Measurement	lbpr	3.55
26823603	C0392747	Changing	ftcn	3.50
26823603	C0070798	Phosphatidylinositol 4,5-Diphosphate	bacs	30.42
26823603	C0070798	Phosphatidylinositol 4,5-Diphosphate	orch	30.42
26823603	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
26823603	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
26823603	C0025979	Microfilaments	celc	22.37
26823603	C0031715	Phosphorylation	moft	13.03
26823603	C0059973	ezrin	aapp	12.90
26823603	C0059973	ezrin	bacs	12.90
26823603	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	12.89
26823603	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	12.89
26823603	C0596901	Membrane	celc	6.58
26823603	C0025255	Tissue membrane	tisu	6.58
26823603	C3538724	Proximal Interphalangeal Joint 2	bpoc	5.18
26823603	C1547282	Show	anim	5.18
26823603	C0184512	Stabilized (qualifier value)	qlco	5.18
26823603	C0577538	Tethered	ftcn	5.18
26823603	C0596119	apical membrane	celc	3.61
26823603	C1148645	phosphatidylinositol binding	moft	3.57
26823603	C1158886	Protein phosphorylation	moft	3.57
26823603	C1413365	CFTR gene	gngm	3.55
26823603	C0728893	+5	qnco	3.50
26823603	C0439084	>5	qnco	3.50
26823603	C1879547	Activation action	acty	3.50
26823603	C1421450	EZR gene	gngm	3.44
26823603	C0542339	Inferior	spco	3.43
26823603	C1706182	Membrane Device Component	mnob	3.43
26823603	C1264637	Substance amount	qnco	3.43
26823603	C1883357	Together	qlco	3.42
26823603	C0079613	Adoptive Immunotherapy	topp	27.26
26823603	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
26823603	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
26823603	C0036536	Process of secretion	biof	19.19
26823603	C0001271	Actins	aapp	16.12
26823603	C0001271	Actins	bacs	16.12
26823603	C0008203	Chlorides	inch	16.04
26823603	C1869853	SERPINA3 protein, human	aapp	14.64
26823603	C1869853	SERPINA3 protein, human	bacs	14.64
26823603	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	13.14
26823603	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	13.14
26823603	C0004340	Australia	geoa	12.96
26823603	C0027627	Neoplasm Metastasis	neop	12.92
26823603	C0059973	ezrin	aapp	12.89
26823603	C0059973	ezrin	bacs	12.89
26823603	C0010674	Cystic Fibrosis	dsyn	9.79
26823603	C0029246	Organization administrative structures	orgt	6.83
26823603	C0036537	Bodily secretions	bdsu	6.57
26823603	C4048375	Asthma Control Test Questionnaire	inpr	5.18
26823603	C3890007	SERPINA3 wt Allele	gngm	5.18
26823603	C3252847	VX 809	orch	5.18
26823603	C3252847	VX 809	phsu	5.18
26823603	C1552679	Organization Name	inpr	3.68
26823603	C1300196	Organized	ftcn	3.68
26823603	C0029237	Physiologic Organization	phsf	3.68
26823603	C1522486	Professional Organization or Group	prog	3.68
26823603	C0220885	organizational	qlco	3.68
26823603	C0007634	Cells	cell	3.60
26823603	C3282337	Cells [Chemical/Ingredient]	cell	3.60
26823603	C3854321	Expression (foundation metadata concept)	idcn	3.55
26823603	C0185117	Expression procedure	topp	3.55
26823603	C1328819	Small Molecule	orch	3.53
26823603	C0442805	Increase	ftcn	3.50
26823603	C0458827	Airway structure	bpoc	3.46
26823603	C0178987	Artificial Airways	medd	3.46
26823603	C0175668	Secondary to	tmco	3.46
26823603	C0205436	second (number)	qnco	3.46
26823603	C0205111	Apical	spco	3.43
26823603	C1421450	EZR gene	gngm	3.43
26823603	C1879547	Activation action	acty	3.42
26823603	C0205225	Primary	qlco	3.42
26823603	C0439631	Primary operation	topp	3.42
26823603	C0439612	True primary (qualifier value)	tmco	3.42
26823603	C1413365	CFTR gene	gngm	3.42
26823603	C0596019	Chloride Ion	elii	3.42
26823603	C1701901	Conditional	qlco	3.42
26823603	C0851827	Dependent - ability	qlco	3.42
26823603	C3244310	dependent	ftcn	3.42
26823603	C0040363	Togo	geoa	35.81
26823603	C0041260	Tryptophanase	aapp	35.81
26823603	C0041260	Tryptophanase	enzy	35.81
26823603	C0059973	ezrin	aapp	25.92
26823603	C0059973	ezrin	bacs	25.92
26823603	C0039798	therapeutic aspects	ftcn	22.54
26823603	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
26823603	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
26823603	C0007776	Cerebral cortex	bpoc	22.35
26823603	C0036536	Process of secretion	biof	19.38
26823603	C0008203	Chlorides	inch	16.08
26823603	C0001271	Actins	aapp	16.05
26823603	C0001271	Actins	bacs	16.05
26823603	C0035820	Social Role	socb	13.01
26823603	C0064678	latrunculin B	orch	12.96
26823603	C0050063	8-chloro-cyclic adenosine monophosphate	nnon	12.88
26823603	C0050063	8-chloro-cyclic adenosine monophosphate	phsu	12.88
26823603	C0001613	Adrenal Cortex	bpoc	12.88
26823603	C0022655	Structure of cortex of kidney	bpoc	12.88
26823603	C1883351	To	qlco	10.42
26823603	C0012634	Disease	dsyn	10.28
26823603	C1879547	Activation action	acty	7.22
26823603	C1701901	Conditional	qlco	6.92
26823603	C0851827	Dependent - ability	qlco	6.92
26823603	C3244310	dependent	ftcn	6.92
26823603	C1421450	EZR gene	gngm	6.89
26823603	C0036537	Bodily secretions	bdsu	6.76
26823603	C0029246	Organization administrative structures	orgt	6.71
26823603	C0301363	5-Trimethoxyamphetamine	orch	5.18
26823603	C0301363	5-Trimethoxyamphetamine	phsu	5.18
26823603	C1555029	Reverse	ftcn	5.18
26823603	C1519522	Tissue Microarray	resd	5.18
26823603	C3853838	activate - Data Operation	ftcn	5.18
26823603	C1515877	activate biological process	ftcn	5.18
26823603	C0348080	Condition	qlco	3.98
26823603	C3864998	Condition:Find:Pt:^Patient:Nom	clna	3.98
26823603	C1705253	Logical Condition	cnce	3.98
26823603	C1533734	Administration procedure	topp	3.61
26823603	C1705169	Biomaterial Treatment	cnce	3.61
26823603	C1280500	Effect	qlco	3.61
26823603	C0087111	Therapeutic procedure	topp	3.61
26823603	C1522326	Treating	ftcn	3.61
26823603	C3538994	Treatment Epoch	resa	3.61
26823603	C3887704	treatment - ActInformationManagementReason	hlca	3.61
26823603	C1552679	Organization Name	inpr	3.56
26823603	C1300196	Organized	ftcn	3.56
26823603	C0029237	Physiologic Organization	phsf	3.56
26823603	C1522486	Professional Organization or Group	prog	3.56
26823603	C2986904	Respiratory Domain	idcn	3.56
26823603	C0556581	Retinol equivalents	qnco	3.56
26823603	C0220885	organizational	qlco	3.56
26823603	C3854321	Expression (foundation metadata concept)	idcn	3.55
26823603	C0185117	Expression procedure	topp	3.55
26823603	C1705810	Generic Role	cnce	3.55
26823603	C3871154	{Role}	inpr	3.55
26823603	C0337051	Environmental pool	geoa	3.54
26823603	C2349200	Pool (action)	ftcn	3.54
26823603	C1509144	Sample pool	clna	3.54
26823603	C3252847	VX 809	orch	3.50
26823603	C3252847	VX 809	phsu	3.50
26823603	C0205263	Induce (action)	ftcn	3.47
26823603	C1413365	CFTR gene	gngm	3.46
26823603	C0596019	Chloride Ion	elii	3.46
26823603	C3834263	Inactive - answer to question	fndg	3.42
26823603	C3890554	Physical Inactivity	dora	3.42
26823603	C0205254	Sedentary	qlco	3.42
26823603	C0596988	mutant	comd	3.42
26823603	C0205411	Adequate	qlco	3.42
26823603	C2346753	Amplitude	spco	3.42
26823603	C0542339	Inferior	spco	3.42
26823603	C1264637	Substance amount	qnco	3.42
26823603	C0205410	Sufficient	qlco	3.42
26823603	C3244320	Create data operation	ftcn	3.41
26823603	C1706214	Creation	acty	3.41
23616952	C0010674	Cystic Fibrosis	dsyn	10.06
23616952	C0012634	Disease	dsyn	9.94
23616952	C0001721	Affect (mental function)	menp	9.87
23616952	C0376558	Life	idcn	9.78
23616952	C3842588	30%	fndg	3.56
23616952	C0027361	Persons	popg	3.56
23616952	C0441636	Surgical shortening - action	topp	3.48
23616952	C0041703	United States	geoa	14.64
23616952	C3842584	70%	fndg	3.48
23616952	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.59
23616952	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.59
23616952	C0009219	Coding	ocac	22.47
23616952	C0017362	Genes, Regulator	gngm	19.52
23616952	C0009738	Congo	geoa	16.30
23616952	C0026882	Mutation	genf	9.90
23616952	C0015127	Etiology aspects	ftcn	9.86
23616952	C0033684	Proteins	aapp	6.70
23616952	C0033684	Proteins	bacs	6.70
23616952	C3811819	CFTR wt Allele	gngm	3.68
23616952	C1413365	CFTR gene	gngm	3.66
23616952	C1524003	Science of Etiology	cnce	3.55
23616952	C0919279	A Codes	clas	3.54
23616952	C0805701	Code	inpr	3.54
23616952	C3889831	eTMF Content Model Code	inpr	3.54
23616952	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
23616952	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
23616952	C0022023	Ions	elii	19.54
23616952	C0005367	Bicarbonates	inch	19.27
23616952	C0005367	Bicarbonates	phsu	19.27
23616952	C0008203	Chlorides	inch	17.80
23616952	C0596902	Membrane Transport Proteins	aapp	13.03
23616952	C0596902	Membrane Transport Proteins	bacs	13.03
23616952	C1700702	Iontophoresis Route of Drug Administration	ftcn	6.85
23616952	C0014597	Epithelial Cells	cell	6.59
23616952	C0036537	Bodily secretions	bdsu	6.59
23616952	C0596019	Chloride Ion	elii	5.18
23616952	C2587213	Control function	ftcn	5.18
23616952	C2239193	Controlling (action)	phpr	5.18
23616952	C1321013	Hydration status	fndg	5.18
23616952	C1413365	CFTR gene	gngm	3.68
23616952	C0439799	Channel	spco	3.68
23616952	C1706095	Channel Object	cnce	3.68
23616952	C1555710	Act Class - Attestable unit	inpr	3.56
23616952	C0486616	Composition	clna	3.56
23616952	C2722820	Bicarbonate preparation	orch	3.50
23616952	C2722820	Bicarbonate preparation	phsu	3.50
23616952	C0973231	bicarbonate ion	inch	3.50
23616952	C0221908	epithelial	qlco	3.43
23616952	C0439064	Numerous	qnco	3.42
23616952	C0443302	Several	qnco	3.42
23616952	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
23616952	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
23616952	C0009738	Congo	geoa	16.05
23616952	C0018896	Helping Behavior	socb	14.64
23616952	C0031843	physiological aspects	phsf	13.09
23616952	C0376636	Disease Management	hlca	9.88
23616952	C1269765	Assisted (qualifier value)	qlco	5.18
23616952	C0557034	Assisting (procedure)	hlca	5.18
23616952	C1521721	Supportive assistance	cnce	3.68
23616952	C0542341	Function	ftcn	3.63
23616952	C0700205	Function Axis	clas	3.63
23616952	C1705273	Mathematical Operator	inpr	3.63
23616952	C0205234	Focal	spco	3.59
23616952	C1285542	Has focus	ftcn	3.59
23616952	C0087111	Therapeutic procedure	topp	3.59
23616952	C0001554	Administration occupational activities	ocac	3.57
23616952	C3273539	Management Occupations	ocdi	3.57
23616952	C1273870	Management procedure	ocac	3.57
23616952	C3854260	Advance	tmco	3.53
23616952	C0725066	Advance -- medical device	medd	3.53
23616952	C0521116	Current (present time)	tmco	3.50
23616952	C1413365	CFTR gene	gngm	3.48
23616952	C0596988	mutant	comd	3.48
23616952	C0872152	drug development	bmod	3.46
23616952	C3811819	CFTR wt Allele	gngm	3.44
23616952	C0332185	Recent	tmco	3.43
23616952	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.23
23616952	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.23
23616952	C0008203	Chlorides	inch	16.09
23616952	C3264621	ivacaftor	orch	14.64
23616952	C3264621	ivacaftor	phsu	14.64
23616952	C0282443	Review [Publication Type]	inpr	9.99
23616952	C1413365	CFTR gene	gngm	7.16
23616952	C0678723	Biologic Development	orgf	5.18
23616952	C1527148	Development	ftcn	5.18
23616952	C2827718	In Vitro Route of Administration	ftcn	5.18
23616952	C0021135	In Vitro [Publication Type]	inpr	5.18
23616952	C0332257	Including (qualifier)	ftcn	5.18
23616952	C0442805	Increase	ftcn	5.18
23616952	C0205217	Increased	qnco	5.18
23616952	C1328819	Small Molecule	orch	5.18
23616952	C1883559	Wild Type	gngm	5.18
23616952	C0243107	development aspects	phsf	5.18
23616952	C1533691	in vitro	qlco	5.18
23616952	C1515655	in vivo	spco	5.18
23616952	C1552617	Act Class - review	idcn	3.68
23616952	C0596545	Experience	menp	3.56
23616952	C0237607	Practice Experience	menp	3.56
23616952	C0521116	Current (present time)	tmco	3.50
23616952	C1705970	Electrical Current	npop	3.50
23616952	C0596019	Chloride Ion	elii	3.48
23616952	C2741958	VX-770	orch	3.46
23616952	C0205210	Clinical	qlco	3.43
23616952	C1553058	Neuropsychologist - Clinical	prog	3.43
23616952	C0237412	Psychologist - Clinical	prog	3.43
23616952	C0497591	Social Worker - Clinical	prog	3.43
23616952	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.39
23616952	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.39
23616952	C0009738	Congo	geoa	16.07
23616952	C0026882	Mutation	genf	9.94
23616952	C0007603	Plasma membrane	celc	9.90
23616952	C0014597	Epithelial Cells	cell	6.74
23616952	C0596901	Membrane	celc	6.71
23616952	C0025255	Tissue membrane	tisu	6.71
23616952	C2985434	Disease-causing Mutation	comd	3.66
23616952	C1705285	Mutation Abnormality	comd	3.63
23616952	C3161472	Cellular Membrane	celc	3.59
23616952	C0392752	Localized	spco	3.55
23616952	C1706182	Membrane Device Component	mnob	3.55
23616952	C0221908	epithelial	qlco	3.55
23616952	C0332452	defective	ftcn	3.50
23616952	C1413365	CFTR gene	gngm	3.48
23616952	C3811819	CFTR wt Allele	gngm	3.45
23616952	C0205214	Common (qualifier value)	qnco	3.45
23616952	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.45
23616952	C0205437	Third	qnco	3.45
23616952	C1522138	shared attribute	ftcn	3.45
23616952	C0039798	therapeutic aspects	ftcn	22.43
23616952	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
23616952	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
23616952	C0009738	Congo	geoa	17.80
23616952	C0023980	Longevity	tmco	17.80
23616952	C0034380	Quality of life	idcn	14.64
23616952	C0031843	physiological aspects	phsf	12.89
23616952	C0013217	pharmacotherapeutic	ftcn	11.49
23616952	C0013216	Pharmacotherapy	topp	8.34
23616952	C0030705	Patients	podg	6.59
23616952	C1561611	Admission Level of Care Code - Improved	inpr	5.18
23616952	C0332272	Better	qlco	5.18
23616952	C3811819	CFTR wt Allele	gngm	5.18
23616952	C0184511	Improved	qlco	5.18
23616952	C0332257	Including (qualifier)	ftcn	5.18
23616952	C0522501	Massive	qlco	5.18
23616952	C0518214	Perceived quality of life	sosy	5.18
23616952	C1554668	Pharmacist - Pharmacotherapy	prog	5.18
23616952	C0332149	Possible	qlco	5.18
23616952	C2362652	Possible diagnosis	qlco	5.18
23616952	C1705910	Possibly Related to Intervention	qlco	5.18
23616952	C2828008	Burden	idcn	3.68
23616952	C0449259	Clinical course	tmco	3.61
23616952	C0449982	Type of restoration	inpr	3.55
23616952	C1533734	Administration procedure	topp	3.50
23616952	C1705169	Biomaterial Treatment	cnce	3.50
23616952	C0087111	Therapeutic procedure	topp	3.50
23616952	C1522326	Treating	ftcn	3.50
23616952	C3538994	Treatment Epoch	resa	3.50
23616952	C3887704	treatment - ActInformationManagementReason	hlca	3.50
23616952	C0205411	Adequate	qlco	3.43
23616952	C1413365	CFTR gene	gngm	3.43
23616952	C0542341	Function	ftcn	3.43
23616952	C0700205	Function Axis	clas	3.43
23616952	C1705273	Mathematical Operator	inpr	3.43
23616952	C0205410	Sufficient	qlco	3.43
26962591	C0238598	Young Adult	aggp	13.10
26962591	C0006823	Canada	geoa	12.90
26962591	C0010674	Cystic Fibrosis	dsyn	10.06
26962591	C0012634	Disease	dsyn	9.94
26962591	C0008059	Child	aggp	9.90
26962591	C0019247	Hereditary Diseases	dsyn	6.62
26962591	C0348080	Condition	qlco	3.63
26962591	C3864998	Condition:Find:Pt:^Patient:Nom	clna	3.63
26962591	C1705253	Logical Condition	cnce	3.63
26962591	C0680063	Offspring	famg	3.59
26962591	C0441748	Autosomal recessive inheritance	genf	3.53
26962591	C0392760	Affecting	ftcn	3.45
26962591	C0205214	Common (qualifier value)	qnco	3.45
26962591	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.45
26962591	C1705232	Death Related to Adverse Event	fndg	3.45
26962591	C1302234	Fatal	qlco	3.45
26962591	C1314939	Involvement with	ftcn	3.45
26962591	C0205393	Most	qnco	3.45
26962591	C1522138	shared attribute	ftcn	3.45
26962591	C0008633	Chromosomes	celc	22.49
26962591	C0017362	Genes, Regulator	gngm	19.42
26962591	C0009738	Congo	geoa	16.08
26962591	C0026882	Mutation	genf	9.90
26962591	C0015127	Etiology aspects	ftcn	9.86
26962591	C0205453	Seven	qnco	3.57
26962591	C1524003	Science of Etiology	cnce	3.55
26962591	C3811819	CFTR wt Allele	gngm	3.46
26962591	C2752508	fully spanning the plasma membrane	celc	3.46
26962591	C1167322	integral to membrane	celc	3.46
26962591	C0599638	Drinking Water	sbst	22.49
26962591	C0043047	Water	inch	19.34
26962591	C0043047	Water	phsu	19.34
26962591	C0017337	Genes	gngm	17.80
26962591	C0008203	Chlorides	inch	16.18
26962591	C0037494	Sodium Chloride	bacs	16.07
26962591	C0037494	Sodium Chloride	inch	16.07
26962591	C0037494	Sodium Chloride	phsu	16.07
26962591	C0206136	Sodium Chloride, Dietary	food	12.91
26962591	C0005528	Biological Transport	celf	9.90
26962591	C0007603	Plasma membrane	celc	9.79
26962591	C0036140	Salts	chvs	6.60
26962591	C0025255	Tissue membrane	tisu	6.59
26962591	C0439799	Channel	spco	5.18
26962591	C1706095	Channel Object	cnce	5.18
26962591	C0596293	cell water	celc	3.62
26962591	C3495449	Mobility aid	medd	3.59
26962591	C1317949	transport (device)	mnob	3.59
26962591	C0596019	Chloride Ion	elii	3.57
26962591	C2700640	Encode (action)	acty	3.57
26962591	C1550678	Water Specimen	inch	3.57
26962591	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
26962591	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
26962591	C0205469	Pathological aspects	ftcn	9.90
26962591	C0030664	Pathology	bmod	9.90
26962591	C0031847	physiopathological	ftcn	9.76
26962591	C0017189	Gastrointestinal tract structure	bdsy	8.34
26962591	C0024109	Lung	bpoc	8.34
26962591	C0036537	Bodily secretions	bdsu	6.83
26962591	C1413365	CFTR gene	gngm	5.18
26962591	C1281182	Entire gastrointestinal tract	bdsy	5.18
26962591	C0521362	gastrointestinal	spco	5.18
26962591	C0460002	body system	bdsy	3.75
26962591	C0332294	Resulting in	ftcn	3.72
26962591	C0205393	Most	qnco	3.68
26962591	C0677042	Pathology processes	patf	3.59
26962591	C0439064	Numerous	qnco	3.48
26962591	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.45
26962591	C3887504	Dysfunction	cnce	3.45
26962591	C0277785	Functional disorder	patf	3.45
26962591	C0023671	Life Expectancy	grpa	19.33
26962591	C0009738	Congo	geoa	16.04
26962591	C1561607	Overall	qlco	9.86
26962591	C0282416	Overall Publication Type	inpr	9.86
26962591	C0600673	Statistics (publications)	inpr	6.71
26962591	C0038952	Continuance of life	acty	6.71
26962591	C0030705	Patients	podg	6.58
26962591	C0442805	Increase	ftcn	5.18
26962591	C0205217	Increased	qnco	5.18
26962591	C2827774	Current Therapy	topp	4.12
26962591	C0679252	cure of disease	fndg	3.57
26962591	C1705938	Base - General Qualifier	idcn	3.56
26962591	C1527178	Basis - conceptual entity	ftcn	3.56
26962591	C0332185	Recent	tmco	3.56
26962591	C0038215	Science of Statistics	ocdi	3.56
26962591	C0238884	canadian	fndg	3.56
26962591	C0220921	survival aspects	ftcn	3.55
26962591	C3811819	CFTR wt Allele	gngm	3.43
26962591	C1522240	Process	phpr	3.42
26962591	C1184743	bony process	bpoc	3.42
26962591	C2939193	Median (qualifier value)	spco	3.42
26962591	C0876920	Median Statistical Measurement	qnco	3.42
26962591	C0549183	Midline (qualifier value)	spco	3.42
26962591	C1948052	Now (temporal qualifier)	tmco	3.42
26962591	C2347635	Population Median	qnco	3.42
26962591	C2348144	Sample Median	qnco	3.42
26962591	C0439234	year	tmco	3.42
26962591	C0039798	therapeutic aspects	ftcn	22.36
26962591	C0021368	Inflammation	patf	19.96
26962591	C0009738	Congo	geoa	16.05
26962591	C0392209	Nutritional status	fndg	12.90
26962591	C0031843	physiological aspects	phsf	12.90
26962591	C0168634	BaseLine dental cement	bodm	12.89
26962591	C0018017	objective (goal)	inpr	9.87
26962591	C0033085	Biologic Preservation	lbpr	6.72
26962591	C0024501	Maintenance	acty	6.72
26962591	C0035245	Respiratory physiology	ortf	6.63
26962591	C0028707	Science of nutrition	bmod	6.59
26962591	C0740116	+2	qnco	5.18
26962591	C3816745	1+	fndg	5.18
26962591	C2827734	1+ Score	qnco	5.18
26962591	C2981698	1+ Score, WHO	clas	5.18
26962591	C3833492	2+	fndg	5.18
26962591	C2827735	2+ Score	qnco	5.18
26962591	C2981700	2+ Score, WHO	clas	5.18
26962591	C3838680	3+ Answer to Question	fndg	5.18
26962591	C2827736	3+ Score	qnco	5.18
26962591	C2981702	3+ Score, WHO	clas	5.18
26962591	C0439086	<3 (qualifier value)	qnco	5.18
26962591	C0332282	Following	tmco	5.18
26962591	C1948052	Now (temporal qualifier)	tmco	5.18
26962591	C0231290	Status post	tmco	5.18
26962591	C1457887	Symptoms	sosy	5.18
26962591	C0683368	Symptoms aspect	ftcn	5.18
26962591	C0743630	exacerbation acute	fndg	3.78
26962591	C0876973	Infectious disease of lung	dsyn	3.75
26962591	C0599546	lung preservation	lbpr	3.62
26962591	C0456079	Disease classification level	clas	3.59
26962591	C1547707	Floor - story of building	geoa	3.59
26962591	C2946261	Level	phsu	3.59
26962591	C0441889	Levels (qualifier value)	qlco	3.59
26962591	C1514402	Preservation Technique	lbpr	3.57
26962591	C0449982	Type of restoration	inpr	3.56
26962591	C1546767	Specimen Source Codes - Respiratory	inpr	3.48
26962591	C0521346	respiratory	ftcn	3.48
26962591	C1547996	Diagnostic Service Section ID - Pulmonary Function	inpr	3.46
26962591	C0231921	Pulmonary function	ortf	3.46
26962591	C3160731	Pulmonary function (finding)	fndg	3.46
26962591	C0205411	Adequate	qlco	3.44
26962591	C0542341	Function	ftcn	3.44
26962591	C0700205	Function Axis	clas	3.44
26962591	C1705273	Mathematical Operator	inpr	3.44
26962591	C1442959	Nutrition function	orgf	3.44
26962591	C0518896	Nutrition outcomes	inpr	3.44
26962591	C0205410	Sufficient	qlco	3.44
26962591	C1442488	Baseline	qnco	3.43
26962591	C3811819	CFTR wt Allele	gngm	3.43
26962591	C0087111	Therapeutic procedure	topp	3.43
26962591	C1363945	Therapy Object (animal model)	fndg	3.43
26962591	C0021966	Iodides	inch	17.80
26962591	C0031330	Pharmacology	bmod	9.81
26962591	C0949766	Physical therapy	topp	6.71
26962591	C0221138	Blood group antibody I	aapp	5.18
26962591	C0221138	Blood group antibody I	imft	5.18
26962591	C3687832	DRUGS	topp	3.68
26962591	C0013227	Pharmaceutical Preparations	phsu	3.68
26962591	C0679199	strategy	menp	3.63
26962591	C0205195	Combined	qlco	3.55
26962591	C0332529	Consistency	qlco	3.55
26962591	C3811910	combination - answer to question	fndg	3.55
26962591	C1947911	combination of objects	phob	3.55
26962591	C0205464	pharmacological	ftcn	3.50
26962591	C0302350	Therapeutic	ftcn	3.48
26962591	C0087111	Therapeutic procedure	topp	3.48
26962591	C0003237	Antibiotics, Antitubercular	antb	24.11
26962591	C0003232	Antibiotics	antb	17.80
26962591	C0021966	Iodides	inch	17.80
26962591	C0003209	Anti-Inflammatory Agents	phsu	14.64
26962591	C3540706	Antibiotic throat preparations	antb	5.18
26962591	C3540707	Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	antb	5.18
26962591	C3540704	Antibiotics for systemic use	antb	5.18
26962591	C3540708	Antibiotics, Gynecological	antb	5.18
26962591	C3540710	Antibiotics, ophthalmologic	antb	5.18
26962591	C3540705	Antifungal Antibiotics, Topical	antb	5.18
26962591	C0221138	Blood group antibody I	aapp	5.18
26962591	C0221138	Blood group antibody I	imft	5.18
26962591	C3540709	antibiotics, intestinal	antb	5.18
26962591	C3687832	DRUGS	topp	3.68
26962591	C0013227	Pharmaceutical Preparations	phsu	3.68
26962591	C0087111	Therapeutic procedure	topp	3.68
26962591	C3536808	Mucolytic [EPC]	phsu	3.50
26962591	C1521739	Nutritional	qlco	3.50
26962591	C2707262	Nutritional:-:Point in time:^Patient:-	clna	3.50
26962591	C0026698	mucolytic agents	phsu	3.50
26962591	C0521974	Diet, High-Fat	topp	17.80
26962591	C1556156	Nutrition, Calories	qnco	3.68
26962591	C1879985	calorie unit of energy	qnco	3.68
26962591	C0439259	kilocalorie	qnco	3.68
26962591	C1372785	Pancreatic Enzymatic Replacement [PE]	ortf	3.57
26962591	C1299351	Abnormally high	qlco	3.50
26962591	C0205250	High	qlco	3.50
26962591	C3889660	High Mitosis-Karyorrhexis Index	qnco	3.50
26962591	C2700149	Value Above Reference Range	inpr	3.50
26962591	C3887512	high - ActExposureLevelCode	idcn	3.50
26962591	C0231179	Insufficiency	ftcn	3.42
26962591	C2348077	Date Fruit	food	27.26
26962591	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
26962591	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
26962591	C0376649	Addresses (publication format)	inpr	7.13
26962591	C0000768	Congenital Abnormality	cgab	6.85
26962591	C0205202	Corrected	qlco	5.18
26962591	C0011008	Date in time	tmco	5.18
26962591	C0087111	Therapeutic procedure	topp	5.18
26962591	C1442065	Address	spco	3.98
26962591	C1737329	Dysmorphism	cgab	3.70
26962591	C0542341	Function	ftcn	3.56
26962591	C0205245	Functional	ftcn	3.56
26962591	C0205161	Abnormal	qlco	3.43
26962591	C2699333	Abnormal Reference Range	inpr	3.43
26962591	C1413365	CFTR gene	gngm	3.43
26962591	C2347472	Percent of Abnormal Cells	qnco	3.43
26962591	C0039798	therapeutic aspects	ftcn	22.48
26962591	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26962591	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26962591	C0009738	Congo	geoa	16.05
26962591	C0001792	Elderly (population group)	popg	14.64
26962591	C3264621	ivacaftor	orch	13.14
26962591	C3264621	ivacaftor	phsu	13.14
26962591	C0006823	Canada	geoa	13.03
26962591	C0026882	Mutation	genf	9.86
26962591	C0030705	Patients	podg	8.34
26962591	C1413365	CFTR gene	gngm	6.92
26962591	C0018684	Health	idcn	6.72
26962591	C0001779	Age	orga	5.18
26962591	C1999167	Old age	popg	5.18
26962591	C0580836	Old	tmco	3.98
26962591	C0439234	year	tmco	3.68
26962591	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.63
26962591	C0678941	Gene Mutant	gngm	3.58
26962591	C0596611	Gene Mutation	genf	3.58
26962591	C0205540	Approved	qlco	3.57
26962591	C1533734	Administration procedure	topp	3.56
26962591	C1705169	Biomaterial Treatment	cnce	3.56
26962591	C0087111	Therapeutic procedure	topp	3.56
26962591	C1522326	Treating	ftcn	3.56
26962591	C3538994	Treatment Epoch	resa	3.56
26962591	C3887704	treatment - ActInformationManagementReason	hlca	3.56
26962591	C1705285	Mutation Abnormality	comd	3.55
26962591	C0205452	Six	qnco	3.50
26962591	C0456387	Class	inpr	3.46
26962591	C1705943	Class (taxonomic)	clas	3.46
26962591	C0205435	First (number)	qnco	3.46
26962591	C1279901	Firstly	qlco	3.46
26962591	C0442027	Oral	spco	3.46
26962591	C3811819	CFTR wt Allele	gngm	3.43
26962591	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
26962591	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
26962591	C0008203	Chlorides	inch	16.05
26962591	C0851285	Regulation	gora	9.88
26962591	C0007603	Plasma membrane	celc	9.77
26962591	C0040223	Time	tmco	8.34
26962591	C0043227	Work	ocac	6.74
26962591	C0175566	Open	spco	5.18
26962591	C0013227	Pharmaceutical Preparations	phsu	5.18
26962591	C1254351	Pharmacologic Substance	phsu	5.18
26962591	C3541383	Time (foundation metadata concept)	tmco	5.18
26962591	C2349975	Enhance (action)	acty	3.98
26962591	C1159571	water transport	celf	3.61
26962591	C0439799	Channel	spco	3.59
26962591	C1706095	Channel Object	cnce	3.59
26962591	C1327622	Regulation of biological process	biof	3.57
26962591	C1879547	Activation action	acty	3.48
26962591	C1413365	CFTR gene	gngm	3.48
26962591	C0596019	Chloride Ion	elii	3.44
26962591	C0026410	Mongolia	geoa	12.89
26962591	C0470187	Availability of	ftcn	3.55
26962591	C0993159	Oral Tablet	bodm	3.44
26962591	C2346927	Magnesium Cation	elii	3.42
26962591	C2346927	Magnesium Cation	phsu	3.42
26962591	C1960952	Milligram percent	qnco	3.42
26962591	C0439269	mg/dL	qnco	3.42
26962591	C0026410	Mongolia	geoa	13.14
26962591	C0006823	Canada	geoa	12.93
26962591	C0018684	Health	idcn	6.62
26962591	C2346927	Magnesium Cation	elii	3.68
26962591	C2346927	Magnesium Cation	phsu	3.68
26962591	C1960952	Milligram percent	qnco	3.68
26962591	C0439269	mg/dL	qnco	3.68
26962591	C0178602	Dosage	qnco	3.61
26962591	C1114758	Dose number:Number:Point in time:^Patient:Quantitative	clna	3.61
26962591	C0034866	Recommendation	idcn	3.61
26962591	C0869039	Unit dose	qnco	3.61
26962591	C0456695	/12h	tmco	3.58
26962591	C1292430	12 hours	tmco	3.58
26962591	C2700400	Contain (action)	acty	3.42
26962591	C0332256	Containing (qualifier)	ftcn	3.42
26962591	C0453819	Fatty food	food	3.42
26962591	C0006823	Canada	geoa	13.01
26962591	C0018684	Health	idcn	6.71
26962591	C0947322	Manufacturer Name	inpr	5.18
26962591	C0034866	Recommendation	idcn	3.68
26962591	C1705938	Base - General Qualifier	idcn	3.55
26962591	C1527178	Basis - conceptual entity	ftcn	3.55
26962591	C3146298	Indication	idcn	3.55
26962591	C0392360	Indication of (contextual qualifier)	idcn	3.55
26962591	C0745732	List	cnce	3.48
26962591	C3272378	Sequence Data Type	inpr	3.48
26962591	C0039798	therapeutic aspects	ftcn	22.48
26962591	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26962591	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26962591	C0040363	Togo	geoa	17.80
26962591	C0041260	Tryptophanase	aapp	17.80
26962591	C0041260	Tryptophanase	enzy	17.80
26962591	C0009738	Congo	geoa	16.05
26962591	C0220825	Evaluation	hlca	14.64
26962591	C1955832	Review, Systematic	inpr	11.49
26962591	C0026882	Mutation	genf	9.86
26962591	C1413365	CFTR gene	gngm	6.92
26962591	C0030705	Patients	podg	6.62
26962591	C1883351	To	qlco	5.18
26962591	C0580836	Old	tmco	3.98
26962591	C1510829	Age-Years	tmco	3.70
26962591	C0678941	Gene Mutant	gngm	3.58
26962591	C0596611	Gene Mutation	genf	3.58
26962591	C1533734	Administration procedure	topp	3.56
26962591	C1705169	Biomaterial Treatment	cnce	3.56
26962591	C0087111	Therapeutic procedure	topp	3.56
26962591	C1522326	Treating	ftcn	3.56
26962591	C3538994	Treatment Epoch	resa	3.56
26962591	C3887704	treatment - ActInformationManagementReason	hlca	3.56
26962591	C1280500	Effect	qlco	3.55
26962591	C1705285	Mutation Abnormality	comd	3.55
26962591	C3264622	ivacaftor 150 MG	clnd	3.48
26962591	C0205452	Six	qnco	3.47
26962591	C3811819	CFTR wt Allele	gngm	3.43
25037130	C0009738	Congo	geoa	16.30
25037130	C0041703	United States	geoa	14.64
25037130	C0021289	Infant, Newborn	aggp	13.03
25037130	C0376558	Life	idcn	9.78
25037130	C0205393	Most	qnco	5.18
25037130	C0559758	Multisystem disorder	dsyn	5.18
25037130	C3811819	CFTR wt Allele	gngm	3.68
25037130	C0441636	Surgical shortening - action	topp	3.63
25037130	C0011900	Diagnosis	fndg	3.57
25037130	C2939425	Neonatal (qualifier value)	tmco	3.57
25037130	C2239178	Newborn (finding)	fndg	3.57
25037130	C1705053	Screen Device Component	mnob	3.57
25037130	C1305399	Screening - procedure intent	ftcn	3.57
25037130	C0220908	Screening procedure	hlca	3.57
25037130	C3842586	50%	fndg	3.56
25037130	C3843766	<50	fndg	3.56
25037130	C1301808	Geographic state	geoa	3.56
25037130	C0884358	Performed	ftcn	3.56
25037130	C0314603	Genetic	ftcn	3.48
25037130	C0017296	gene therapy	topp	3.48
25037130	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
25037130	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
25037130	C0009738	Congo	geoa	16.05
25037130	C0038164	Staphylococcal Protein A	aapp	12.90
25037130	C0038164	Staphylococcal Protein A	imft	12.90
25037130	C0038164	Staphylococcal Protein A	irda	12.90
25037130	C0031847	physiopathological	ftcn	9.69
25037130	C0024115	Lung diseases	dsyn	6.62
25037130	C1444637	Past	tmco	5.18
25037130	C1521840	Target	ftcn	5.18
25037130	C0087111	Therapeutic procedure	topp	3.56
25037130	C1280500	Effect	qlco	3.54
25037130	C3811819	CFTR wt Allele	gngm	3.43
25037130	C1413365	CFTR gene	gngm	3.42
25037130	C0522506	Downstream	spco	3.42
25037130	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.38
25037130	C3887504	Dysfunction	cnce	3.38
25037130	C0277785	Functional disorder	patf	3.38
25037130	C0009738	Congo	geoa	49.20
25037130	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
25037130	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
25037130	C3811819	CFTR wt Allele	gngm	10.75
25037130	C0392347	Hope (emotion)	menp	9.86
25037130	C0027361	Persons	popg	7.00
25037130	C0016884	Future	tmco	6.83
25037130	C1521840	Target	ftcn	5.18
25037130	C3242274	new therapy	fndg	3.65
25037130	C1457869	Defect	ftcn	3.56
25037130	C0470187	Availability of	ftcn	3.54
25037130	C0475806	1/3 meter (distance vision finding)	fndg	3.50
25037130	C1706276	Near	qlco	3.50
25037130	C1413365	CFTR gene	gngm	3.46
25037130	C1709060	Modulator Device Component	mnob	3.46
25037130	C0683525	treatment options	topp	3.45
25037130	C0441835	Group A	clas	3.44
25037130	C1527178	Basis - conceptual entity	ftcn	3.43
25037130	C1561611	Admission Level of Care Code - Improved	inpr	3.43
25037130	C0332272	Better	qlco	3.43
25037130	C0184511	Improved	qlco	3.43
25037130	C0205172	More	ftcn	3.43
25037130	C0439801	Limited (extensiveness)	ftcn	3.42
25037130	C4050251	Limited Lifting Ability	inpr	3.42
25037130	C2674459	Limited Walking Ability	fndg	3.42
25037130	C3542948	Limited component (foundation metadata concept)	inpr	3.42
25037130	C3179154	Best Practices	idcn	16.37
25037130	C0376298	Consensus	socb	16.17
25037130	C0009738	Congo	geoa	16.04
25037130	C0162791	Guidelines	inpr	13.01
25037130	C0033137	Primary Health Care	hlca	13.00
25037130	C0242479	Interdisciplinary Studies	ocac	9.87
25037130	C1947933	care activity	acty	7.00
25037130	C0282423	Guideline [Publication Type]	inpr	6.71
25037130	C1415493	HCFC1 gene	gngm	5.18
25037130	C0442603	Office	mnob	3.63
25037130	C0449445	Approach	spco	3.56
25037130	C1999230	Providing (action)	acty	3.56
25037130	C0205210	Clinical	qlco	3.55
25037130	C1553058	Neuropsychologist - Clinical	prog	3.55
25037130	C0237412	Psychologist - Clinical	prog	3.55
25037130	C0497591	Social Worker - Clinical	prog	3.55
25037130	C0220845	guiding characteristics	inpr	3.55
25037130	C0871489	teams	grup	3.54
25037130	C1947931	Direct (qualifier)	qlco	3.52
25037130	C0439851	Direct type of relationship	qlco	3.52
25037130	C3811819	CFTR wt Allele	gngm	3.42
25037130	C3810851	Center of town	fndg	3.42
25037130	C0205099	Central	spco	3.42
26385858	C2348077	Date Fruit	food	25.67
26385858	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26385858	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26385858	C0038164	Staphylococcal Protein A	aapp	12.88
26385858	C0038164	Staphylococcal Protein A	imft	12.88
26385858	C0038164	Staphylococcal Protein A	irda	12.88
26385858	C0010674	Cystic Fibrosis	dsyn	9.92
26385858	C0012634	Disease	dsyn	9.87
26385858	C0016059	Fibrosis	patf	9.87
26385858	C0026882	Mutation	genf	9.86
26385858	C1413365	CFTR gene	gngm	6.91
26385858	C3264627	Kalydeco	phsu	5.18
26385858	C0013227	Pharmaceutical Preparations	phsu	3.63
26385858	C1254351	Pharmacologic Substance	phsu	3.63
26385858	C1879547	Activation action	acty	3.61
26385858	C0332281	Associated with	qlco	3.61
26385858	C0334054	cystic disease	dsyn	3.60
26385858	C0011008	Date in time	tmco	3.59
26385858	C1704419	Effective	qlco	3.59
26385858	C1280519	Effectiveness	qlco	3.59
26385858	C0596611	Gene Mutation	genf	3.57
26385858	C3854321	Expression (foundation metadata concept)	idcn	3.54
26385858	C0185117	Expression procedure	topp	3.54
26385858	C0205540	Approved	qlco	3.48
26385858	C1720467	Only - dosing instruction fragment	inpr	3.48
26385858	C0205171	Singular	qnco	3.48
26385858	C0439799	Channel	spco	3.47
26385858	C1706095	Channel Object	cnce	3.47
26385858	C0243067	defects aspect	ftcn	3.47
26385858	C3828842	Nearly	qlco	3.42
26385858	C0542341	Function	ftcn	3.42
26385858	C0205245	Functional	ftcn	3.42
26385858	C2700217	Functional Relationship	cnce	3.42
26385858	C0700321	Small	qnco	3.42
26385858	C1515021	Subgroup	clas	3.42
26385858	C0596988	mutant	comd	3.42
26385858	C0681760	2000s	tmco	3.40
26385858	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
26385858	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
26385858	C0040363	Togo	geoa	17.80
26385858	C0041260	Tryptophanase	aapp	17.80
26385858	C0041260	Tryptophanase	enzy	17.80
26385858	C0027552	Needs	qlco	13.14
26385858	C0162340	Comprehension	menp	13.00
26385858	C1524059	mechanism of action qualifier	ftcn	12.90
26385858	C0026882	Mutation	genf	9.87
26385858	C0031327	Drug Kinetics	phsf	9.75
26385858	C1516048	Assessed	acty	5.18
26385858	C1413365	CFTR gene	gngm	5.18
26385858	C0521116	Current (present time)	tmco	5.18
26385858	C2349975	Enhance (action)	acty	5.18
26385858	C1517331	Further	spco	5.18
26385858	C3264627	Kalydeco	phsu	5.18
26385858	C1883351	To	qlco	5.18
26385858	C0686904	Patient need for (contextual qualifier)	ftcn	3.68
26385858	C3888054	DEFINITION - NCI Thesaurus Property	cnce	3.54
26385858	C1704788	Definition	inpr	3.54
26385858	C3539107	Definition (core metadata concept)	inpr	3.54
26385858	C1550452	definition - ActMoodCompletionTrack	idcn	3.54
26385858	C0439609	Urgent	tmco	3.50
26385858	C3272275	Urgent Procedure	topp	3.50
26385858	C2945843	Site of	qlco	3.44
26385858	C0332149	Possible	qlco	3.43
26385858	C2362652	Possible diagnosis	qlco	3.43
26385858	C1705910	Possibly Related to Intervention	qlco	3.43
26385858	C1167622	Binding (Molecular Function)	moft	3.42
26385858	C1145667	Binding action	acty	3.42
26385858	C0723712	Therapeutic brand of coal tar	orch	3.42
26385858	C0723712	Therapeutic brand of coal tar	phsu	3.42
26385858	C0087111	Therapeutic procedure	topp	3.42
26385858	C1709060	Modulator Device Component	mnob	3.40
26385858	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
26385858	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
26385858	C0040363	Togo	geoa	17.80
26385858	C0041260	Tryptophanase	aapp	17.80
26385858	C0041260	Tryptophanase	enzy	17.80
26385858	C0079870	Mutagenesis, Site-Directed	genf	16.09
26385858	C0032520	Polymerase Chain Reaction	mbrt	12.91
26385858	C0026882	Mutation	genf	9.87
26385858	C1413365	CFTR gene	gngm	6.93
26385858	C0205352	Simple	qlco	5.18
26385858	C1883351	To	qlco	5.18
26385858	C0872257	rapid technique	diap	3.73
26385858	C0596611	Gene Mutation	genf	3.60
26385858	C0534010	One-Step dentin bonding system	bodm	3.46
26385858	C0534010	One-Step dentin bonding system	orch	3.46
26385858	C1705938	Base - General Qualifier	idcn	3.45
26385858	C1527178	Basis - conceptual entity	ftcn	3.45
26385858	C4050242	Pathologic Complete Response	fndg	3.45
26385858	C3853643	Probe with target amplification technique	lbpr	3.45
26385858	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
26385858	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
26385858	C0040363	Togo	geoa	17.80
26385858	C0041260	Tryptophanase	aapp	17.80
26385858	C0041260	Tryptophanase	enzy	17.80
26385858	C1511760	Deletion Mutation	genf	13.44
26385858	C0025663	Methods	inpr	8.34
26385858	C1704689	Bearing Device Component	medd	5.18
26385858	C0369773	P Blood group antibodies	aapp	5.18
26385858	C0369773	P Blood group antibodies	imft	5.18
26385858	C2603361	P prime	clna	5.18
26385858	C0449851	Techniques	ftcn	5.18
26385858	C0871511	Test Method	lbpr	5.18
26385858	C1883351	To	qlco	5.18
26385858	C1273517	Used by	fndg	5.18
26385858	C1880274	Deletion (action)	acty	3.98
26385858	C1442161	Gene Deletion Abnormality	comd	3.98
26385858	C0596988	mutant	comd	3.68
26385858	C1413365	CFTR gene	gngm	3.50
26385858	C0369773	P Blood group antibodies	aapp	5.18
26385858	C0369773	P Blood group antibodies	imft	5.18
26385858	C2603361	P prime	clna	5.18
26385858	C0369773	P Blood group antibodies	aapp	5.18
26385858	C0369773	P Blood group antibodies	imft	5.18
26385858	C2603361	P prime	clna	5.18
26385858	C1512796	Insertion Mutation	genf	16.05
26385858	C0071590	polyhistidine	aapp	12.89
26385858	C0369773	P Blood group antibodies	aapp	5.18
26385858	C0369773	P Blood group antibodies	imft	5.18
26385858	C2603361	P prime	clna	5.18
26385858	C1706395	Protein Truncation Abnormality	comd	3.56
26385858	C0441587	Clinical act of insertion	hlca	3.43
26385858	C0021107	Implantation procedure	topp	3.43
26385858	C1883719	Insert (object)	ftcn	3.43
26385858	C1710492	LINC01194 gene	gngm	3.43
26385858	C0181496	Labels (device)	mnob	3.43
26385858	C0037293	Skin tag	neop	3.43
26385858	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26385858	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26385858	C0016315	Fluorescence	npop	22.35
26385858	C0220825	Evaluation	hlca	13.01
26385858	C0005456	Binding Sites	rcpt	12.91
26385858	C0020792	Identification (Psychology)	menp	12.89
26385858	C0013175	Drug Evaluation	resa	9.89
26385858	C0012634	Disease	dsyn	9.81
26385858	C0031437	Phenotype	orga	6.83
26385858	C0005507	Biological Assay	lbpr	6.70
26385858	C0020517	Hypersensitivity	patf	6.57
26385858	C3844638	Either	fndg	5.18
26385858	C1524063	Use of	ftcn	5.18
26385858	C0205170	Good	qlco	3.68
26385858	C1285572	Phenotype determination	lbpr	3.68
26385858	C3146287	Well	mnob	3.68
26385858	C0872291	Time Interval	tmco	3.65
26385858	C0332168	Time frame (qualifier value)	tmco	3.65
26385858	C1261322	Evaluation procedure	hlca	3.55
26385858	C1510438	Assay	lbpr	3.54
26385858	C0243073	assay qualifier	qlco	3.54
26385858	C2827396	Scientific Equipment	mnob	3.52
26385858	C0336791	Tool, device (physical object)	mnob	3.52
26385858	C1299351	Abnormally high	qlco	3.50
26385858	C0205250	High	qlco	3.50
26385858	C3889660	High Mitosis-Karyorrhexis Index	qnco	3.50
26385858	C2700149	Value Above Reference Range	inpr	3.50
26385858	C3887512	high - ActExposureLevelCode	idcn	3.50
26385858	C0332174	Weekly	tmco	3.46
26385858	C0439230	week	tmco	3.46
26385858	C0682969	Ligand Binding Domain	amas	3.45
26385858	C0683154	drug response	orgf	3.45
26385858	C1153415	ion channel activity	moft	3.45
26385858	C0332282	Following	tmco	3.43
26385858	C0205396	Identified	qlco	3.43
26385858	C1709060	Modulator Device Component	mnob	3.43
26385858	C0871261	Response process	orga	3.43
26385858	C1413365	CFTR gene	gngm	3.42
26385858	C0332324	Sensitive	ftcn	3.42
26385858	C3245505	potential	qlco	3.42
26385858	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26385858	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26385858	C0040363	Togo	geoa	17.80
26385858	C0041260	Tryptophanase	aapp	17.80
26385858	C0041260	Tryptophanase	enzy	17.80
26385858	C0025664	Methods aspects	inpr	11.49
26385858	C0025663	Methods	inpr	8.34
26385858	C0596988	mutant	comd	7.01
26385858	C0016884	Future	tmco	6.62
26385858	C0562342	Empowered	menp	5.18
26385858	C1171285	Enabling	menp	5.18
26385858	C0205393	Most	qnco	5.18
26385858	C0456962	Rapid	qlco	5.18
26385858	C1547282	Show	anim	5.18
26385858	C2985566	Targeted Therapy	topp	5.18
26385858	C0449851	Techniques	ftcn	5.18
26385858	C1883351	To	qlco	5.18
26385858	C1555307	promise	idcn	3.98
26385858	C3687832	DRUGS	topp	3.68
26385858	C0013227	Pharmaceutical Preparations	phsu	3.68
26385858	C0557651	Room of building - Study	mnob	3.61
26385858	C2603343	Study	resa	3.61
26385858	C0015264	Exertion	orgf	3.58
26385858	C1707455	Comparison	acty	3.55
26385858	C0556981	% proof	qnco	3.47
26385858	C0349674	Intellectual scale	inpr	3.47
26385858	C0549177	Large	qnco	3.47
26385858	C3536777	Scale Device Component	mnob	3.47
26385858	C1947916	Scaling	acty	3.47
26385858	C0175659	Weight measurement scales	medd	3.47
26385858	C0178566	concept	idcn	3.47
26385858	C0680240	agreement	socb	3.43
26385858	C1413365	CFTR gene	gngm	3.43
26385858	C0439064	Numerous	qnco	3.43
26385858	C0392762	Quantitative	qnco	3.43
27277131	C0040363	Togo	geoa	35.81
27277131	C0041260	Tryptophanase	aapp	35.81
27277131	C0041260	Tryptophanase	enzy	35.81
27277131	C0009738	Congo	geoa	16.04
27277131	C1883351	To	qlco	10.42
27277131	C2828394	Prenatal (temporal qualifier)	tmco	6.89
27277131	C0678804	prenatal	aggp	6.89
27277131	C0949266	Therapies, Investigational	topp	6.73
27277131	C0004271	Attitude	menp	6.71
27277131	C0376554	Knowledge	inpr	6.70
27277131	C0017431	Genotype	orga	6.58
27277131	C1516048	Assessed	acty	5.18
27277131	C0521116	Current (present time)	tmco	5.18
27277131	C1705970	Electrical Current	npop	5.18
27277131	C3245512	HL7PublishingSubSection <practice>	inpr	5.18
27277131	C0237607	Practice Experience	menp	5.18
27277131	C1709701	Project	cnce	5.18
27277131	C2948600	Aim	phsu	3.98
27277131	C1947946	Aim (idea)	idcn	3.98
27277131	C3540472	Ancestry-Informative Marker	ftcn	3.98
27277131	C3890193	CD5L wt Allele	gngm	3.98
27277131	C2744535	CD69 protein, human	aapp	3.98
27277131	C2744535	CD69 protein, human	imft	3.98
27277131	C3540471	CD69 wt Allele	gngm	3.98
27277131	C2585119	Experimental therapeutic procedure	topp	3.57
27277131	C2584313	Discussion (communication)	socb	3.56
27277131	C0557061	Discussion (procedure)	topp	3.56
27277131	C0205540	Approved	qlco	3.43
27277131	C0205314	New	qlco	3.43
27277131	C0679622	literary novel	inpr	3.43
27277131	C0587719	Genetic counselor	prog	3.43
27277131	C3811819	CFTR wt Allele	gngm	3.42
27277131	C1552740	Entity Determiner - specific	inpr	3.42
27277131	C0205369	Specific qualifier value	qlco	3.42
27277131	C1521840	Target	ftcn	3.42
27277131	C0087111	Therapeutic procedure	topp	3.42
27277131	C0542559	contextual factors	ftcn	3.42
27277131	C1318139	{Setting}	qnco	3.42
27277131	C0009738	Congo	geoa	32.42
27277131	C0030551	parent	idcn	19.20
27277131	C0011109	Decision Making	menp	12.91
27277131	C0087111	Therapeutic procedure	topp	7.06
27277131	C3811819	CFTR wt Allele	gngm	7.04
27277131	C0376554	Knowledge	inpr	6.70
27277131	C1514756	Receive	qlco	5.18
27277131	C0518906	health & life quality	inpr	3.63
27277131	C3669012	Fetal diagnosis	fndg	3.61
27277131	C0392760	Affecting	ftcn	3.59
27277131	C1314939	Involvement with	ftcn	3.59
27277131	C3245505	potential	qlco	3.57
27277131	C1522240	Process	phpr	3.55
27277131	C1184743	bony process	bpoc	3.55
27277131	C1521840	Target	ftcn	3.48
27277131	C0470187	Availability of	ftcn	3.44
27277131	C1825598	IMPACT gene	gngm	3.44
27277131	C4049986	Impact	qlco	3.44
27277131	C0445223	Related personal status	fndg	3.42
27277131	C0439849	Relationships	qlco	3.42
27277131	C0237401	Individual	humn	3.40
27277131	C0027361	Persons	popg	3.40
27277131	C0009738	Congo	geoa	32.26
27277131	C0039798	therapeutic aspects	ftcn	22.46
27277131	C1704338	diagnosis aspect	qlco	22.34
27277131	C0038951	Surveys	inpr	17.80
27277131	C0040363	Togo	geoa	17.80
27277131	C0041260	Tryptophanase	aapp	17.80
27277131	C0041260	Tryptophanase	enzy	17.80
27277131	C0010210	Counseling	hlca	13.00
27277131	C3264621	ivacaftor	orch	12.91
27277131	C3264621	ivacaftor	phsu	12.91
27277131	C0033053	Prenatal Diagnosis	diap	12.89
27277131	C0040456	Impacted tooth	anab	9.85
27277131	C0237607	Practice Experience	menp	7.44
27277131	C3811819	CFTR wt Allele	gngm	6.88
27277131	C0017431	Genotype	orga	6.69
27277131	C1883351	To	qlco	5.18
27277131	C1524063	Use of	ftcn	5.18
27277131	C0871010	opinion	menp	5.18
27277131	C2983265	CDISC SEND Study Design Terminology	inpr	3.98
27277131	C1707689	Design	acty	3.98
27277131	C2700205	FDA Approval	inpr	3.75
27277131	C0920724	prenatal experience	menp	3.60
27277131	C1875307	INTRODUCTION device	mnob	3.59
27277131	C1293116	Introduction procedure	hlca	3.59
27277131	C1706256	Clinical Study Case	cnce	3.59
27277131	C0587719	Genetic counselor	prog	3.57
27277131	C0470187	Availability of	ftcn	3.56
27277131	C0850266	prenatal counseling	topp	3.56
27277131	C3245512	HL7PublishingSubSection <practice>	inpr	3.54
27277131	C1533734	Administration procedure	topp	3.54
27277131	C1705169	Biomaterial Treatment	cnce	3.54
27277131	C0341618	Counsel - legal	prog	3.54
27277131	C0740209	Encounter due to counseling	fndg	3.54
27277131	C1552740	Entity Determiner - specific	inpr	3.54
27277131	C0333125	Impacted	ftcn	3.54
27277131	C0205314	New	qlco	3.54
27277131	C0205369	Specific qualifier value	qlco	3.54
27277131	C0087111	Therapeutic procedure	topp	3.54
27277131	C1522326	Treating	ftcn	3.54
27277131	C3538994	Treatment Epoch	resa	3.54
27277131	C3887704	treatment - ActInformationManagementReason	hlca	3.54
27277131	C0011900	Diagnosis	fndg	3.42
27277131	C1704656	Diagnosis Study	resa	3.42
27277131	C0034394	Questionnaires	inpr	16.18
27277131	C1519246	Send (transmission)	ftcn	5.18
27277131	C0587719	Genetic counselor	prog	3.61
27277131	C1706422	Questionnaire Domain	inpr	3.56
27277131	C0332232	Approximate	qlco	3.46
27277131	C3829466	January	qlco	3.43
27277131	C0030551	parent	idcn	19.22
27277131	C0033204	Probability	qnco	17.80
27277131	C0282122	Respondents	popg	16.30
27277131	C0009738	Congo	geoa	16.05
27277131	C0033053	Prenatal Diagnosis	diap	13.07
27277131	C0030971	Perception	menp	9.81
27277131	C0814225	benefit	qnco	7.40
27277131	C2584313	Discussion (communication)	socb	5.18
27277131	C1999230	Providing (action)	acty	5.18
27277131	C1514756	Receive	qlco	3.98
27277131	C2708735	Treatment information	inpr	3.62
27277131	C2708734	Treatment information:Finding:Point in time:^Patient:Narrative	clna	3.62
27277131	C0449295	Limitation	ftcn	3.59
27277131	C1521828	Rate	qnco	3.59
27277131	C0871208	Rating (action)	acty	3.59
27277131	C3245505	potential	qlco	3.50
27277131	C3811819	CFTR wt Allele	gngm	3.43
27277131	C0587719	Genetic counselor	prog	3.58
27277131	C0450388	69	qnco	3.47
27277131	C0205447	One	qnco	3.45
27277131	C2828394	Prenatal (temporal qualifier)	tmco	3.45
27277131	C0678804	prenatal	aggp	3.45
27277131	C0038951	Surveys	inpr	16.18
27277131	C0282122	Respondents	popg	17.80
27277131	C0018767	Hearing	phsf	16.15
27277131	C1444656	Indicated	fndg	5.18
27277131	C2003901	Never (frequency)	tmco	5.18
27277131	C3844332	Not sure	fndg	3.78
27277131	C2825142	Experimental Result	fndg	3.63
27277131	C1274040	Result	ftcn	3.63
27277131	C1546471	What subject filter - Result	idcn	3.63
27277131	C0013227	Pharmaceutical Preparations	phsu	3.57
27277131	C1254351	Pharmacologic Substance	phsu	3.57
27277131	C3833465	HEAR - answer to question	fndg	3.54
27277131	C3842583	80%	fndg	3.50
27277131	C0039798	therapeutic aspects	ftcn	22.61
27277131	C0034754	Reading (activity)	dora	17.80
27277131	C0376558	Life	idcn	9.73
27277131	C0013987	Emotions	menp	7.13
27277131	C0520510	Materials	sbst	5.18
27277131	C1571885	Professional Counselor	prog	5.18
27277131	C1999230	Providing (action)	acty	5.18
27277131	C1705179	Reading (datum presentation)	fndg	5.18
27277131	C1533734	Administration procedure	topp	3.68
27277131	C1705169	Biomaterial Treatment	cnce	3.68
27277131	C0087111	Therapeutic procedure	topp	3.68
27277131	C1522326	Treating	ftcn	3.68
27277131	C3538994	Treatment Epoch	resa	3.68
27277131	C3887704	treatment - ActInformationManagementReason	hlca	3.68
27277131	C1825598	IMPACT gene	gngm	3.54
27277131	C4049986	Impact	qlco	3.54
27277131	C0205314	New	qlco	3.50
27277131	C0392760	Affecting	ftcn	3.42
27277131	C1546944	Event Seriousness - Significant	qlco	3.42
27277131	C0237401	Individual	humn	3.42
27277131	C1314939	Involvement with	ftcn	3.42
27277131	C0027361	Persons	popg	3.42
27277131	C0750502	Significant	idcn	3.42
27277131	C0237881	Statistical Significance	qnco	3.42
27277131	C0039798	therapeutic aspects	ftcn	48.50
27277131	C0041714	United States Food and Drug Administration	hcro	25.76
27277131	C0040363	Togo	geoa	17.80
27277131	C0041260	Tryptophanase	aapp	17.80
27277131	C0041260	Tryptophanase	enzy	17.80
27277131	C1533734	Administration procedure	topp	10.42
27277131	C1705169	Biomaterial Treatment	cnce	10.42
27277131	C0087111	Therapeutic procedure	topp	10.42
27277131	C1522326	Treating	ftcn	10.42
27277131	C3538994	Treatment Epoch	resa	10.42
27277131	C3887704	treatment - ActInformationManagementReason	hlca	10.42
27277131	C0030705	Patients	podg	6.72
27277131	C0017431	Genotype	orga	6.71
27277131	C0242291	Fetal Tissue	tisu	6.58
27277131	C0015965	Fetus	emst	6.58
27277131	C0205540	Approved	qlco	5.18
27277131	C1707391	Choose (action)	acty	5.18
27277131	C1883351	To	qlco	5.18
27277131	C0871010	opinion	menp	5.18
27277131	C2584313	Discussion (communication)	socb	3.57
27277131	C1533716	Information	idcn	3.57
27277131	C0470187	Availability of	ftcn	3.56
27277131	C0521116	Current (present time)	tmco	3.50
27277131	C0392760	Affecting	ftcn	3.43
27277131	C1314939	Involvement with	ftcn	3.43
27277131	C1305737	Entire fetus	anst	3.43
27277131	C0237401	Individual	humn	3.41
27277131	C0027361	Persons	popg	3.41
27277131	C0040363	Togo	geoa	17.80
27277131	C0041260	Tryptophanase	aapp	17.80
27277131	C0041260	Tryptophanase	enzy	17.80
27277131	C0030705	Patients	podg	6.71
27277131	C1611835	Specialist	prog	6.59
27277131	C3899394	Definitely	inpr	5.18
27277131	C2584313	Discussion (communication)	socb	5.18
27277131	C0205543	Referring	ftcn	5.18
27277131	C1883351	To	qlco	5.18
27277131	C0087111	Therapeutic procedure	topp	3.63
27277131	C1517331	Further	spco	3.48
27277131	C1521840	Target	ftcn	3.48
27277131	C0087009	Hospital specialist	prog	3.43
27277131	C2348234	Specialist Physician	prog	3.43
27277131	C0009738	Congo	geoa	17.80
27277131	C2828394	Prenatal (temporal qualifier)	tmco	6.93
27277131	C0678804	prenatal	aggp	6.93
27277131	C3811819	CFTR wt Allele	gngm	5.18
27277131	C1444656	Indicated	fndg	5.18
27277131	C0587719	Genetic counselor	prog	3.61
27277131	C2584313	Discussion (communication)	socb	3.56
27277131	C0557061	Discussion (procedure)	topp	3.56
27277131	C0456079	Disease classification level	clas	3.56
27277131	C1547707	Floor - story of building	geoa	3.56
27277131	C2946261	Level	phsu	3.56
27277131	C0441889	Levels (qualifier value)	qlco	3.56
27277131	C0683579	scenario	ftcn	3.55
27277131	C1521840	Target	ftcn	3.43
27277131	C0087111	Therapeutic procedure	topp	3.43
27277131	C0205423	Certain (qualifier value)	qlco	3.43
27277131	C1704787	Definitely Related to Intervention	qlco	3.43
27277131	C0542559	contextual factors	ftcn	3.43
27277131	C1318139	{Setting}	qnco	3.43
27277131	C0039798	therapeutic aspects	ftcn	24.11
27277131	C0600269	Familiarity	menp	16.18
27277131	C0035820	Social Role	socb	12.89
27277131	C2713449	Information Sharing	socb	9.93
27277131	C0030971	Perception	menp	9.87
27277131	C1533734	Administration procedure	topp	5.18
27277131	C1705169	Biomaterial Treatment	cnce	5.18
27277131	C1331418	Comfort	menp	5.18
27277131	C0449295	Limitation	ftcn	5.18
27277131	C0087111	Therapeutic procedure	topp	5.18
27277131	C1522326	Treating	ftcn	5.18
27277131	C3538994	Treatment Epoch	resa	5.18
27277131	C3887704	treatment - ActInformationManagementReason	hlca	5.18
27277131	C2584313	Discussion (communication)	socb	3.98
27277131	C2349001	Human Study Subject	humn	3.98
27277131	C2697811	Investigative Subject	ftcn	3.98
27277131	C0681850	Study Subject	grup	3.98
27277131	C1706203	Subject - topic	idcn	3.98
27277131	C1550501	Subject -direct target	idcn	3.98
27277131	C0683525	treatment options	topp	3.75
27277131	C1571885	Professional Counselor	prog	3.68
27277131	C1561602	counselor	fndg	3.68
27277131	C0332479	Shapes	spco	3.57
27277131	C0449911	View	spco	3.57
27277131	C0522512	With shape	spco	3.57
27277131	C0459471	Interpretation Process	inpr	3.55
27277131	C3173575	Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal	clna	3.55
27277131	C0205314	New	qlco	3.48
27277131	C0237844	Counselor Role	socb	3.44
27277131	C0587719	Genetic counselor	prog	3.44
27277131	C0814225	benefit	qnco	3.43
27277131	C1705810	Generic Role	cnce	3.42
27277131	C0314603	Genetic	ftcn	3.42
27277131	C0017296	gene therapy	topp	3.42
27277131	C3871154	{Role}	inpr	3.42
27277131	C0038951	Surveys	inpr	17.80
27277131	C0018767	Hearing	phsf	16.17
27277131	C3264621	ivacaftor	orch	13.05
27277131	C3264621	ivacaftor	phsu	13.05
27277131	C2003901	Never (frequency)	tmco	5.18
27277131	C0587719	Genetic counselor	prog	3.63
27277131	C3833465	HEAR - answer to question	fndg	3.55
27277131	C0332152	Before	tmco	3.46
27277131	C3264627	Kalydeco	phsu	3.43
27277131	C0040363	Togo	geoa	35.81
27277131	C0041260	Tryptophanase	aapp	35.81
27277131	C0041260	Tryptophanase	enzy	35.81
27277131	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
27277131	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
27277131	C0085732	Ability	orga	14.64
27277131	C0010210	Counseling	hlca	14.64
27277131	C0027552	Needs	qlco	14.64
27277131	C1883351	To	qlco	10.42
27277131	C0026882	Mutation	genf	9.85
27277131	C0039401	Educational process of instructing	edac	6.70
27277131	C1299581	Able (finding)	fndg	5.18
27277131	C0332272	Better	qlco	5.18
27277131	C0341618	Counsel - legal	prog	5.18
27277131	C0740209	Encounter due to counseling	fndg	5.18
27277131	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
27277131	C1571885	Professional Counselor	prog	5.18
27277131	C0470187	Availability of	ftcn	3.56
27277131	C2584313	Discussion (communication)	socb	3.56
27277131	C0557061	Discussion (procedure)	topp	3.56
27277131	C1705938	Base - General Qualifier	idcn	3.54
27277131	C1527178	Basis - conceptual entity	ftcn	3.54
27277131	C1413365	CFTR gene	gngm	3.54
27277131	C1705285	Mutation Abnormality	comd	3.54
27277131	C0087111	Therapeutic procedure	topp	3.54
27277131	C0683525	treatment options	topp	3.46
27277131	C0205314	New	qlco	3.43
23666117	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.45
23666117	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.45
23666117	C0031843	physiological aspects	phsf	14.64
23666117	C0026882	Mutation	genf	9.91
23666117	C0007603	Plasma membrane	celc	9.84
23666117	C0010674	Cystic Fibrosis	dsyn	9.79
23666117	C3541951	Concept model domain	inpr	6.92
23666117	C1880389	Domain (area of knowledge)	ftcn	6.92
23666117	C1883221	Superkingdom (taxonomic category)	cnce	6.92
23666117	C0542341	Function	ftcn	5.18
23666117	C0700205	Function Axis	clas	5.18
23666117	C1705273	Mathematical Operator	inpr	5.18
23666117	C2347098	Medical Product Stability	qlco	5.18
23666117	C0205360	Stable status	qlco	5.18
23666117	C3854321	Expression (foundation metadata concept)	idcn	3.63
23666117	C0185117	Expression procedure	topp	3.63
23666117	C1705285	Mutation Abnormality	comd	3.60
23666117	C0185026	Plication	topp	3.59
23666117	C1413365	CFTR gene	gngm	3.52
23666117	C0205214	Common (qualifier value)	qnco	3.46
23666117	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.46
23666117	C0205393	Most	qnco	3.46
23666117	C1522138	shared attribute	ftcn	3.46
23666117	C1948027	Couple (action)	ftcn	3.45
23666117	C1148916	nucleotide binding	moft	3.45
23666117	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
23666117	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
23666117	C0162340	Comprehension	menp	12.94
23666117	C0872152	drug development	bmod	5.18
23666117	C0181113	Hamper	mnob	3.98
23666117	C3252847	VX 809	orch	3.75
23666117	C3252847	VX 809	phsu	3.75
23666117	C0441712	Mechanism (attribute)	ftcn	3.63
23666117	C1706376	Mechanism Component of Device	mnob	3.63
23666117	C0814225	benefit	qnco	3.63
23666117	C0205210	Clinical	qlco	3.48
23666117	C0439801	Limited (extensiveness)	ftcn	3.48
23666117	C4050251	Limited Lifting Ability	inpr	3.48
23666117	C2674459	Limited Walking Ability	fndg	3.48
23666117	C3542948	Limited component (foundation metadata concept)	inpr	3.48
23666117	C1553058	Neuropsychologist - Clinical	prog	3.48
23666117	C0237412	Psychologist - Clinical	prog	3.48
23666117	C0497591	Social Worker - Clinical	prog	3.48
23666117	C1413365	CFTR gene	gngm	3.42
23666117	C1517586	Investigational	qlco	3.42
23666117	C3245491	investigational monitoring program	hlca	3.42
23666117	C1555307	promise	idcn	3.40
23666117	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
23666117	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
23666117	C0038859	Suppressor Mutation	comd	12.91
23666117	C0026377	Molecular Conformation	spco	12.89
23666117	C0596901	Membrane	celc	6.58
23666117	C0025255	Tissue membrane	tisu	6.58
23666117	C1272684	Accepted	qlco	5.18
23666117	C1550718	Entity Name Part Type - given	idcn	5.18
23666117	C0443211	Established	qlco	5.18
23666117	C1442162	GIVEN	cnce	5.18
23666117	C1947971	Give - dosing instruction imperative	ftcn	5.18
23666117	C3244317	Given name	inpr	5.18
23666117	C0332148	Probable diagnosis	qlco	5.18
23666117	C0750492	Probably	idcn	5.18
23666117	C0243067	defects aspect	ftcn	3.63
23666117	C1947976	Correction (change)	ftcn	3.60
23666117	C1705565	Correction Report	inpr	3.60
23666117	C1293130	Stabilization	topp	3.57
23666117	C2698172	Application Program Interface	inpr	3.55
23666117	C1708533	Interface Device Component	mnob	3.55
23666117	C1280500	Effect	qlco	3.55
23666117	C2348382	Effect, Appearance	qlco	3.55
23666117	C0205225	Primary	qlco	3.48
23666117	C0439631	Primary operation	topp	3.48
23666117	C0439612	True primary (qualifier value)	tmco	3.48
23666117	C1413365	CFTR gene	gngm	3.46
23666117	C2986815	Robust	qlco	3.46
23666117	C2945843	Site of	qlco	3.44
23666117	C1706182	Membrane Device Component	mnob	3.43
23666117	C1561503	Precision - second	idcn	3.42
23666117	C1705190	Second Suffix	qlco	3.42
23666117	C0565930	per second	qnco	3.42
23666117	C0205436	second (number)	qnco	3.42
23666117	C0457385	seconds	tmco	3.42
23666117	C3541951	Concept model domain	inpr	3.41
23666117	C1880389	Domain (area of knowledge)	ftcn	3.41
23666117	C1711300	Span - parameter	cnce	3.41
23666117	C2700613	Span Distance	qnco	3.41
23666117	C1883221	Superkingdom (taxonomic category)	cnce	3.41
23666117	C2698967	Canadian Cardiovascular Society Grading Scale Class I	fndg	5.18
23666117	C2698968	Canadian Cardiovascular Society Grading Scale Class II	fndg	5.18
23666117	C0441885	Class 1	clas	5.18
23666117	C0441886	Class 2	inpr	5.18
23666117	C0184512	Stabilized (qualifier value)	qlco	5.18
23666117	C1521840	Target	ftcn	5.18
23666117	C2986546	Target Lesion Identification	diap	5.18
23666117	C2698172	Application Program Interface	inpr	3.59
23666117	C1708533	Interface Device Component	mnob	3.59
23666117	C1513403	Molecular Target	chvf	3.57
23666117	C1513403	Molecular Target	chvs	3.57
23666117	C0470187	Availability of	ftcn	3.42
23666117	C0086418	Homo sapiens	humn	28.71
23666117	C0243041	Molecular Chaperones	aapp	9.89
23666117	C0243041	Molecular Chaperones	bacs	9.89
23666117	C0184512	Stabilized (qualifier value)	qlco	5.18
23666117	C2698969	Canadian Cardiovascular Society Grading Scale Class III	fndg	3.61
23666117	C0441887	Class 3	inpr	3.61
23666117	C4053457	Surrogate	famg	3.56
23666117	C3272558	Chemical or Textual Reference to Actual Test or Parameter	inpr	3.47
23666117	C0220806	Chemicals	chem	3.47
23666117	C1720467	Only - dosing instruction fragment	inpr	3.47
23666117	C0205171	Singular	qnco	3.47
23666117	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
23666117	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
23666117	C0599155	Missense Mutation	genf	13.22
23666117	C0021853	Intestines	bpoc	9.81
23666117	C0007603	Plasma membrane	celc	9.75
23666117	C0010674	Cystic Fibrosis	dsyn	9.74
23666117	C0029250	Organoids	tisu	6.83
23666117	C3252847	VX 809	orch	5.18
23666117	C3252847	VX 809	phsu	5.18
23666117	C0205198	Compound	qlco	3.98
23666117	C1706082	Compound (substance)	chem	3.98
23666117	C2698172	Application Program Interface	inpr	3.61
23666117	C1708533	Interface Device Component	mnob	3.61
23666117	C3854321	Expression (foundation metadata concept)	idcn	3.55
23666117	C0185117	Expression procedure	topp	3.55
23666117	C0243067	defects aspect	ftcn	3.54
23666117	C1292984	Procedure on intestine	hlca	3.50
23666117	C2349182	Correct (qualifier)	qlco	3.48
23666117	C1711178	Bronchial Epithelial Cell	cell	3.43
23666117	C1413365	CFTR gene	gngm	3.42
23666117	C0542341	Function	ftcn	3.42
23666117	C0205245	Functional	ftcn	3.42
23666117	C2700217	Functional Relationship	cnce	3.42
23666117	C2347098	Medical Product Stability	qlco	3.42
23666117	C0205360	Stable status	qlco	3.42
23666117	C0039798	therapeutic aspects	ftcn	22.35
23666117	C0010674	Cystic Fibrosis	dsyn	9.75
23666117	C1882932	Representation (action)	acty	5.18
23666117	C0205195	Combined	qlco	3.55
23666117	C3811910	combination - answer to question	fndg	3.55
23666117	C1947911	combination of objects	phob	3.55
23666117	C0449445	Approach	spco	3.55
23666117	C0678594	structure	spco	3.43
23666117	C1704419	Effective	qlco	3.42
23666117	C1280519	Effectiveness	qlco	3.42
23666117	C0087111	Therapeutic procedure	topp	3.42
23666117	C1363945	Therapy Object (animal model)	fndg	3.42
23666117	C1706050	Guide Device Component	mnob	3.41
23666117	C0302614	Guide device	medd	3.41
23666117	C0181090	Professional guide	prog	3.41
29039559	C0233324	Term Birth	orgf	22.90
29039559	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.55
29039559	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.55
29039559	C0010674	Cystic Fibrosis	dsyn	10.06
29039559	C0026882	Mutation	genf	9.99
29039559	C0015127	Etiology aspects	ftcn	9.82
29039559	C2826302	Reported Term	inpr	3.98
29039559	C1705313	Term (lexical)	idcn	3.98
29039559	C1515273	Term (temporal)	tmco	3.98
29039559	C1705285	Mutation Abnormality	comd	3.68
29039559	C1413365	CFTR gene	gngm	3.62
29039559	C0596611	Gene Mutation	genf	3.55
29039559	C1524003	Science of Etiology	cnce	3.51
29039559	C1542147	Main	qlco	3.50
29039559	C0039798	therapeutic aspects	ftcn	22.48
29039559	C0030705	Patients	podg	6.58
29039559	C1524063	Use of	ftcn	3.58
29039559	C0205195	Combined	qlco	3.57
29039559	C3811910	combination - answer to question	fndg	3.57
29039559	C1947911	combination of objects	phob	3.57
29039559	C0087111	Therapeutic procedure	topp	3.55
29039559	C1363945	Therapy Object (animal model)	fndg	3.55
29039559	C1705938	Base - General Qualifier	idcn	3.55
29039559	C1527178	Basis - conceptual entity	ftcn	3.55
29039559	C4033620	ORKAMBI	phsu	3.55
29039559	C0023175	Lead	elii	13.03
29039559	C0023175	Lead	hops	13.03
29039559	C0035245	Respiratory physiology	ortf	6.74
29039559	C0030705	Patients	podg	6.58
29039559	C4033620	ORKAMBI	phsu	5.18
29039559	C1441672	Observed	ftcn	5.18
29039559	C3275067	Cardiac Lead Procedure	topp	3.57
29039559	C2348269	Dietary Lead	elii	3.57
29039559	C2986411	Improvement	cnce	3.57
29039559	C1522538	Leading	ftcn	3.57
29039559	C0181586	Leads (device)	medd	3.57
29039559	C1442948	Plumbum metallicum, homeopathic preparation	inch	3.57
29039559	C1442948	Plumbum metallicum, homeopathic preparation	phsu	3.57
29039559	C0392756	Reduced	qlco	3.55
29039559	C0301630	Reduction (chemical)	npop	3.55
29039559	C0441610	Reduction - action	topp	3.55
29039559	C1280519	Effectiveness	qlco	3.43
29039559	C1707887	Efficacy Study	resa	3.43
29039559	C0205329	Progressive	ftcn	3.43
29039559	C0040363	Togo	geoa	35.81
29039559	C0041260	Tryptophanase	aapp	35.81
29039559	C0041260	Tryptophanase	enzy	35.81
29039559	C0035820	Social Role	socb	13.03
29039559	C0065751	matrine	orch	12.90
29039559	C0065751	matrine	phsu	12.90
29039559	C1883351	To	qlco	10.42
29039559	C1280500	Effect	qlco	5.18
29039559	C2348382	Effect, Appearance	qlco	5.18
29039559	C0442808	Increasing	ftcn	5.18
29039559	C1292732	Investigates	ftcn	5.18
29039559	C1705178	Order (action)	acty	5.18
29039559	C1705176	Order (arrangement)	qlco	5.18
29039559	C1705175	Order (document)	inpr	5.18
29039559	C1705177	Order (taxonomic)	clas	5.18
29039559	C2983310	Overcome	acty	5.18
29039559	C1882348	Permutation	qlco	5.18
29039559	C3889825	Sequence of Planned Assessment Schedule	inpr	5.18
29039559	C3266814	Action	acty	3.57
29039559	C0441472	Clinical action	ftcn	3.57
29039559	C1705810	Generic Role	cnce	3.57
29039559	C3871154	{Role}	inpr	3.57
29039559	C2948600	Aim	phsu	3.55
29039559	C1947946	Aim (idea)	idcn	3.55
29039559	C3540472	Ancestry-Informative Marker	ftcn	3.55
29039559	C3890193	CD5L wt Allele	gngm	3.55
29039559	C2744535	CD69 protein, human	aapp	3.55
29039559	C2744535	CD69 protein, human	imft	3.55
29039559	C3540471	CD69 wt Allele	gngm	3.55
29039559	C0205198	Compound	qlco	3.55
29039559	C1706082	Compound (substance)	chem	3.55
29039559	C1880774	Financial Disclosure Form	mnob	3.55
29039559	C0150312	Present	qnco	3.43
29039559	C0449450	Presentation	idcn	3.43
29039559	C0557651	Room of building - Study	mnob	3.43
29039559	C2603343	Study	resa	3.43
29039559	C0034703	Rats, Inbred F344	mamm	28.72
29039559	C0065751	matrine	orch	13.05
29039559	C0065751	matrine	phsu	13.05
29039559	C0040132	Thyroid Gland	bpoc	9.77
29039559	C1880774	Financial Disclosure Form	mnob	7.04
29039559	C1514559	Protein Overexpression	genf	3.98
29039559	C0332293	Treated with	topp	3.72
29039559	C0301863	"""U"" lymphocyte"	cell	3.71
29039559	C1706528	And/Or	cnce	3.58
29039559	C0449788	Count of entities	qnco	3.55
29039559	C0237753	Numbers	qnco	3.55
29039559	C3540038	THYROID DIAGNOSTIC RADIOPHARMACEUTICALS	irda	3.46
29039559	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
29039559	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
29039559	C0040363	Togo	geoa	17.80
29039559	C0041260	Tryptophanase	aapp	17.80
29039559	C0041260	Tryptophanase	enzy	17.80
29039559	C0085732	Ability	orga	14.64
29039559	C0065751	matrine	orch	14.64
29039559	C0065751	matrine	phsu	14.64
29039559	C0004083	Mental association	menp	13.02
29039559	C1299581	Able (finding)	fndg	5.18
29039559	C0442805	Increase	ftcn	5.18
29039559	C0205217	Increased	qnco	5.18
29039559	C1883351	To	qlco	5.18
29039559	C2825142	Experimental Result	fndg	3.98
29039559	C1274040	Result	ftcn	3.98
29039559	C1546471	What subject filter - Result	idcn	3.98
29039559	C1561536	*Activity (kind of quantity)	idcn	3.68
29039559	C0205177	Active	ftcn	3.68
29039559	C0441655	Activities	acty	3.68
29039559	C3668946	Activity (animal life circumstance)	fndg	3.68
29039559	C4049939	FDA Establishment Activity Terminology	inpr	3.68
29039559	C0439167	Percent Activity	qnco	3.68
29039559	C4049938	Physical Activity Measurement	lbpr	3.68
29039559	C0596306	Chemical Association	phpr	3.56
29039559	C3854307	Presence (property)	qlco	3.56
29039559	C0150312	Present	qnco	3.56
29039559	C0392148	Providing presence (regime/therapy)	topp	3.56
29039559	C0699792	Relationship by association	socb	3.56
29039559	C0439849	Relationships	qlco	3.56
29039559	C1413365	CFTR gene	gngm	3.50
29039559	C0542341	Function	ftcn	3.50
29039559	C0205245	Functional	ftcn	3.50
29039559	C2700217	Functional Relationship	cnce	3.50
29039559	C0439799	Channel	spco	3.43
29039559	C1706095	Channel Object	cnce	3.43
29039559	C1880774	Financial Disclosure Form	mnob	3.43
29039559	C0205314	New	qlco	5.18
29039559	C0679622	literary novel	inpr	5.18
29039559	C1707455	Comparison	acty	3.59
29039559	C1705938	Base - General Qualifier	idcn	3.57
29039559	C1527178	Basis - conceptual entity	ftcn	3.57
29039559	C2825142	Experimental Result	fndg	3.54
29039559	C1274040	Result	ftcn	3.54
29039559	C1546471	What subject filter - Result	idcn	3.54
29039559	C1880774	Financial Disclosure Form	mnob	3.50
29039559	C1704419	Effective	qlco	3.48
29039559	C1280519	Effectiveness	qlco	3.48
29039559	C0205172	More	ftcn	3.48
28245962	C0086418	Homo sapiens	humn	28.71
28245962	C0242738	ATP-Binding Cassette Transporters	aapp	17.80
28245962	C0242738	ATP-Binding Cassette Transporters	bacs	17.80
28245962	C0152244	Bone Cysts, Aneurysmal	dsyn	13.09
28245962	C0004268	Attention	menp	12.94
28245962	C0038164	Staphylococcal Protein A	aapp	12.89
28245962	C0038164	Staphylococcal Protein A	imft	12.89
28245962	C0038164	Staphylococcal Protein A	irda	12.89
28245962	C0005528	Biological Transport	celf	11.49
28245962	C0376315	Manufactured form	mnob	8.34
28245962	C1522492	Formation	ftcn	5.18
28245962	C3495449	Mobility aid	medd	5.18
28245962	C0348078	Qualitative form	qlco	5.18
28245962	C1317949	transport (device)	mnob	5.18
28245962	C3890225	Active Breathing Coordinator-Mediated Radiation Therapy	topp	3.63
28245962	C0812409	Gradient	qnco	3.63
28245962	C1883220	Superfamily	cnce	3.55
28245962	C3891814	Substrate	sbst	3.53
28245962	C1710236	Substrate Device Component	mnob	3.53
28245962	C1446561	Concentration measurement	qnco	3.48
28245962	C1701901	Conditional	qlco	3.48
28245962	C0851827	Dependent - ability	qlco	3.48
28245962	C1442080	Energy	qnco	3.48
28245962	C0542479	Energy, Physics	npop	3.48
28245962	C3898777	Important	qlco	3.48
28245962	C0086045	Mental concentration	menp	3.48
28245962	C0424589	Vitality	fndg	3.48
28245962	C3244310	dependent	ftcn	3.48
28245962	C0682529	biological membrane	celc	3.46
28245962	C0205454	Eight	qnco	3.42
28245962	C3816449	Forty	qnco	3.42
28245962	C2752508	fully spanning the plasma membrane	celc	3.42
28245962	C1167322	integral to membrane	celc	3.42
28245962	C0596902	Membrane Transport Proteins	aapp	12.88
28245962	C0596902	Membrane Transport Proteins	bacs	12.88
28245962	C3714634	Biological Processes	biof	6.60
28245962	C0521114	Infrequent	tmco	5.18
28245962	C0522498	Rare	qlco	5.18
28245962	C1514917	Retinoic Acid Response Element	gngm	5.18
28245962	C1836348	Severe disorder	fndg	3.70
28245962	C2316203	Family history of hereditary disease	fndg	3.68
28245962	C2924406	Genetic disorders screening	lbpr	3.68
28245962	C0314603	Genetic	ftcn	3.61
28245962	C0017296	gene therapy	topp	3.61
28245962	C1550043	Container status - Identified	fndg	3.59
28245962	C0205396	Identified	qlco	3.59
28245962	C0678941	Gene Mutant	gngm	3.56
28245962	C2349001	Human Study Subject	humn	3.55
28245962	C2697811	Investigative Subject	ftcn	3.55
28245962	C0681850	Study Subject	grup	3.55
28245962	C1706203	Subject - topic	idcn	3.55
28245962	C1550501	Subject -direct target	idcn	3.55
28245962	C3898777	Important	qlco	3.49
28245962	C4050466	Borg Category-Ratio 10 Perceived Exertion Score 5	inpr	3.47
28245962	C0332183	Frequently	tmco	3.47
28245962	C4050225	Often - answer to question	inpr	3.47
28245962	C0205082	Severe (severity modifier)	qlco	3.47
28245962	C4050465	Severe Extremity Pain	inpr	3.47
28245962	C0332232	Approximate	qlco	3.42
28245962	C2825407	Half	qnco	3.42
28245962	C0040363	Togo	geoa	35.81
28245962	C0041260	Tryptophanase	aapp	35.81
28245962	C0041260	Tryptophanase	enzy	35.81
28245962	C0242738	ATP-Binding Cassette Transporters	aapp	17.80
28245962	C0242738	ATP-Binding Cassette Transporters	bacs	17.80
28245962	C0085732	Ability	orga	12.89
28245962	C1883351	To	qlco	10.42
28245962	C0162429	Malnutrition	dsyn	9.94
28245962	C1623416	deficiency aspects	qlco	9.94
28245962	C2984318	ABC Transporter Pathway	ftcn	5.18
28245962	C0805586	Challenge	hlca	3.68
28245962	C0798503	Challenge:Type:Point in time:^Patient:Nominal	clna	3.68
28245962	C3274764	Proficiency Testing Challenge	cnce	3.68
28245962	C0205419	Variant	qlco	3.68
28245962	C0011155	Deficiency	ftcn	3.63
28245962	C0332152	Before	tmco	3.59
28245962	C1522538	Leading	ftcn	3.59
28245962	C0243067	defects aspect	ftcn	3.59
28245962	C0567416	Molecule	sbst	3.55
28245962	C0521116	Current (present time)	tmco	3.50
28245962	C1705970	Electrical Current	npop	3.50
28245962	C3845273	Missense	fndg	3.50
28245962	C0205263	Induce (action)	ftcn	3.48
28245962	C1521991	Molecular	qlco	3.48
28245962	C1299581	Able (finding)	fndg	3.43
28245962	C0205314	New	qlco	3.43
28245962	C0302350	Therapeutic	ftcn	3.43
28245962	C0087111	Therapeutic procedure	topp	3.43
28245962	C3245505	potential	qlco	3.43
28245962	C0021966	Iodides	inch	17.80
28245962	C0242738	ATP-Binding Cassette Transporters	aapp	16.19
28245962	C0242738	ATP-Binding Cassette Transporters	bacs	16.19
28245962	C0010674	Cystic Fibrosis	dsyn	11.49
28245962	C0282443	Review [Publication Type]	inpr	11.49
28245962	C0012634	Disease	dsyn	9.92
28245962	C0015127	Etiology aspects	ftcn	9.83
28245962	C0376649	Addresses (publication format)	inpr	8.34
28245962	C0013216	Pharmacotherapy	topp	6.72
28245962	C1552617	Act Class - review	idcn	5.18
28245962	C1442065	Address	spco	5.18
28245962	C0221138	Blood group antibody I	aapp	5.18
28245962	C0221138	Blood group antibody I	imft	5.18
28245962	C0205435	First (number)	qnco	5.18
28245962	C1279901	Firstly	qlco	5.18
28245962	C1280477	Progress	ftcn	5.18
28245962	C1272688	status - In progress	ftcn	5.18
28245962	C1999230	Providing (action)	acty	3.57
28245962	C0205419	Variant	qlco	3.55
28245962	C1524003	Science of Etiology	cnce	3.52
28245962	C0332183	Frequently	tmco	3.47
28245962	C0205393	Most	qnco	3.47
28245962	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.56
28245962	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.56
28245962	C1413365	CFTR gene	gngm	7.13
28245962	C3811819	CFTR wt Allele	gngm	3.48
28245962	C0242738	ATP-Binding Cassette Transporters	aapp	32.91
28245962	C0242738	ATP-Binding Cassette Transporters	bacs	32.91
28245962	C0678236	Rare Diseases	dsyn	13.24
28245962	C0108800	CD69 antigen	aapp	12.98
28245962	C0108800	CD69 antigen	imft	12.98
28245962	C0015127	Etiology aspects	ftcn	11.49
28245962	C2984318	ABC Transporter Pathway	ftcn	7.53
28245962	C0033684	Proteins	aapp	6.70
28245962	C0033684	Proteins	bacs	6.70
28245962	C2584313	Discussion (communication)	socb	5.18
28245962	C1524003	Science of Etiology	cnce	5.18
28245962	C0267792	hepatobiliary disease	dsyn	3.75
28245962	C1883708	Then	tmco	3.68
28245962	C1516084	Attempt	evnt	3.59
28245962	C1522168	Topical Route of Drug Administration	ftcn	3.57
28245962	C0205419	Variant	qlco	3.57
28245962	C1555712	topic - ActClassContainer	inpr	3.57
28245962	C0205172	More	ftcn	3.55
28245962	C2349182	Correct (qualifier)	qlco	3.54
28245962	C0243067	defects aspect	ftcn	3.54
28245962	C0205435	First (number)	qnco	3.48
28245962	C1279901	Firstly	qlco	3.48
28245962	C1711359	Hepatobiliary System	bdsy	3.48
28245962	C0521114	Infrequent	tmco	3.48
28245962	C0522498	Rare	qlco	3.48
28245962	C1514917	Retinoic Acid Response Element	gngm	3.48
28245962	C1555307	promise	idcn	3.45
22878883	C0282461	Phase 3 Clinical Trials	resa	22.52
22878883	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
22878883	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
22878883	C2930764	ataluren	orch	14.64
22878883	C2930764	ataluren	phsu	14.64
22878883	C0004268	Attention	menp	13.09
22878883	C0028429	Nose	bpoc	13.09
22878883	C3264621	ivacaftor	orch	12.88
22878883	C3264621	ivacaftor	phsu	12.88
22878883	C0010674	Cystic Fibrosis	dsyn	9.77
22878883	C0005516	Biological Markers	clna	6.75
22878883	C0030705	Patients	podg	6.71
22878883	C2741958	VX-770	orch	5.18
22878883	C1446561	Concentration measurement	qnco	3.63
22878883	C1705241	Delta (difference)	qnco	3.63
22878883	C1705242	Different	qlco	3.63
22878883	C0086045	Mental concentration	menp	3.63
22878883	C3245505	potential	qlco	3.63
22878883	C1413365	CFTR gene	gngm	3.58
22878883	C1524063	Use of	ftcn	3.56
22878883	C2349179	End Point	qlco	3.55
22878883	C1280519	Effectiveness	qlco	3.55
22878883	C1707887	Efficacy Study	resa	3.55
22878883	C0428295	Cystic fibrosis sweat test	lbpr	3.53
22878883	C1304760	Sweat chloride level result	lbtr	3.53
22878883	C4036059	Drug-disease	fndg	3.42
22878883	C0392747	Changing	ftcn	3.40
22878883	C0040363	Togo	geoa	17.80
22878883	C0041260	Tryptophanase	aapp	17.80
22878883	C0041260	Tryptophanase	enzy	17.80
22878883	C0028429	Nose	bpoc	12.89
22878883	C0010674	Cystic Fibrosis	dsyn	11.49
22878883	C0282443	Review [Publication Type]	inpr	11.49
22878883	C0034036	Publications	inpr	9.88
22878883	C0034036	Publications	mnob	9.88
22878883	C0021853	Intestines	bpoc	9.74
22878883	C0023866	Literature	inpr	6.72
22878883	C0030705	Patients	podg	6.59
22878883	C1552617	Act Class - review	idcn	5.18
22878883	C0428295	Cystic fibrosis sweat test	lbpr	5.18
22878883	C1304760	Sweat chloride level result	lbtr	5.18
22878883	C1883351	To	qlco	5.18
22878883	C2349101	Validity (characteristic)	qnco	5.18
22878883	C2948600	Aim	phsu	3.56
22878883	C1947946	Aim (idea)	idcn	3.56
22878883	C3540472	Ancestry-Informative Marker	ftcn	3.56
22878883	C3890193	CD5L wt Allele	gngm	3.56
22878883	C2744535	CD69 protein, human	aapp	3.56
22878883	C2744535	CD69 protein, human	imft	3.56
22878883	C3540471	CD69 wt Allele	gngm	3.56
22878883	C0242485	Measurement	ftcn	3.56
22878883	C0205342	Responsive	ftcn	3.50
22878883	C2347947	Reliability (characteristic)	qnco	3.44
22878883	C0521116	Current (present time)	tmco	3.43
22878883	C1705241	Delta (difference)	qnco	3.43
22878883	C1705242	Different	qlco	3.43
22878883	C1705970	Electrical Current	npop	3.43
22878883	C1292984	Procedure on intestine	hlca	3.43
22878883	C1709701	Project	cnce	3.43
22878883	C3245505	potential	qlco	3.43
22878883	C0282443	Review [Publication Type]	inpr	9.86
22878883	C0005516	Biological Markers	clna	6.72
22878883	C3830601	Data Property	inpr	3.58
22878883	C1516695	Collected	idcn	3.57
22878883	C1516698	Collection (action)	ftcn	3.57
22878883	C1512888	International	idcn	3.55
22878883	C1709940	Reviewed	qlco	3.55
22878883	C0871489	teams	grup	3.55
22878883	C2349101	Validity (characteristic)	qnco	5.18
22878883	C0205342	Responsive	ftcn	3.82
22878883	C1511726	Data	idcn	3.57
22878883	C3714741	Data (eukaryote)	euka	3.57
22878883	C3245479	Data call receiving device	medd	3.57
22878883	C2347947	Reliability (characteristic)	qnco	3.44
22878883	C1135957	Narration	socb	16.04
22878883	C2584313	Discussion (communication)	socb	3.98
22878883	C1883712	Add - instruction imperative	ftcn	3.63
22878883	C0332287	In addition to	ftcn	3.63
22878883	C0508431	answer questions	topp	3.56
22878883	C0871489	teams	grup	3.55
22878883	C3641827	Agree	inpr	3.52
22878883	C0205450	Four	qnco	3.43
22878883	C0028429	Nose	bpoc	12.89
22878883	C1516695	Collected	idcn	5.18
22878883	C1516698	Collection (action)	ftcn	5.18
22878883	C1511726	Data	idcn	5.18
22878883	C3714741	Data (eukaryote)	euka	5.18
22878883	C3245479	Data call receiving device	medd	5.18
22878883	C2347947	Reliability (characteristic)	qnco	5.18
22878883	C2349101	Validity (characteristic)	qnco	5.18
22878883	C0205342	Responsive	ftcn	3.50
22878883	C1705241	Delta (difference)	qnco	3.43
22878883	C1705242	Different	qlco	3.43
22878883	C3245505	potential	qlco	3.43
22878883	C0004268	Attention	menp	13.01
22878883	C2349101	Validity (characteristic)	qnco	5.18
22878883	C0205342	Responsive	ftcn	3.82
22878883	C1511726	Data	idcn	3.63
22878883	C3714741	Data (eukaryote)	euka	3.63
22878883	C3245479	Data call receiving device	medd	3.63
22878883	C0428295	Cystic fibrosis sweat test	lbpr	3.58
22878883	C1304760	Sweat chloride level result	lbtr	3.58
22878883	C1446561	Concentration measurement	qnco	3.55
22878883	C0086045	Mental concentration	menp	3.55
22878883	C0150312	Present	qnco	3.55
22878883	C2347947	Reliability (characteristic)	qnco	3.55
22878883	C0021853	Intestines	bpoc	9.87
22878883	C0205342	Responsive	ftcn	3.82
22878883	C1533716	Information	idcn	3.68
22878883	C2349101	Validity (characteristic)	qnco	3.68
22878883	C2347947	Reliability (characteristic)	qnco	3.59
22878883	C1514873	Requirement	ftcn	3.59
22878883	C0521116	Current (present time)	tmco	3.56
22878883	C1705970	Electrical Current	npop	3.56
22878883	C0242485	Measurement	ftcn	3.56
22878883	C1292984	Procedure on intestine	hlca	3.56
22878883	C1517331	Further	spco	3.50
22878883	C0086715	Normal Range	qnco	11.49
22878883	C0242481	Research Activities	resa	11.49
22878883	C0035168	research	resa	11.49
22878883	C1516695	Collected	idcn	5.18
22878883	C1516698	Collection (action)	ftcn	5.18
22878883	C1553874	Concept Status - Proposed	qlco	5.18
22878883	C1578820	Edit Status - Proposed	qlco	5.18
22878883	C1517331	Further	spco	5.18
22878883	C3889426	Content Type Requirement	ftcn	3.98
22878883	C1514873	Requirement	ftcn	3.98
22878883	C2349179	End Point	qlco	3.69
22878883	C0205449	Three	qnco	3.48
22878883	C0040363	Togo	geoa	35.81
22878883	C0041260	Tryptophanase	aapp	35.81
22878883	C0041260	Tryptophanase	enzy	35.81
22878883	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
22878883	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
22878883	C0242821	Human body	humn	16.18
22878883	C1883351	To	qlco	10.42
22878883	C0242481	Research Activities	resa	9.87
22878883	C0035168	research	resa	9.87
22878883	C0162488	Surrogate Endpoints	qlco	8.34
22878883	C0043227	Work	ocac	6.59
22878883	C0005516	Biological Markers	clna	6.59
22878883	C1883712	Add - instruction imperative	ftcn	5.18
22878883	C1706050	Guide Device Component	mnob	5.18
22878883	C0302614	Guide device	medd	5.18
22878883	C0181090	Professional guide	prog	5.18
22878883	C0183683	Support, device	medd	5.18
22878883	C1521721	Supportive assistance	cnce	5.18
22878883	C1533716	Information	idcn	3.68
22878883	C1268086	Body structure	anst	3.57
22878883	C0460148	Human body structure	anst	3.57
22878883	C0033414	Promotion (action)	acty	3.56
22878883	C3827682	Useful	qlco	3.50
22878883	C0205146	Area	spco	3.43
22878883	C1413365	CFTR gene	gngm	3.43
22878883	C1517331	Further	spco	3.43
22878883	C0017446	Geographic Locations	geoa	3.43
23104983	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
23104983	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
23104983	C0087136	Unmarried	fndg	22.47
23104983	C0037179	Unmarried person	popg	22.47
23104983	C1511760	Deletion Mutation	genf	13.00
23104983	C0010674	Cystic Fibrosis	dsyn	9.99
23104983	C0015127	Etiology aspects	ftcn	9.82
23104983	C0002520	Amino Acids	aapp	6.72
23104983	C0002520	Amino Acids	bacs	6.72
23104983	C0002520	Amino Acids	phsu	6.72
23104983	C1413365	CFTR gene	gngm	5.18
23104983	C1622120	protein destabilization	celf	3.62
23104983	C2917660	Amino Acid [EPC]	phsu	3.56
23104983	C1880274	Deletion (action)	acty	3.54
23104983	C1442161	Gene Deletion Abnormality	comd	3.54
23104983	C0205171	Singular	qnco	3.54
23104983	C1524003	Science of Etiology	cnce	3.51
23104983	C0678226	Due to	ftcn	3.50
23104983	C0040363	Togo	geoa	35.81
23104983	C0041260	Tryptophanase	aapp	35.81
23104983	C0041260	Tryptophanase	enzy	35.81
23104983	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
23104983	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
23104983	C0008976	Clinical Trials	resa	20.95
23104983	C0162340	Comprehension	menp	14.64
23104983	C1524059	mechanism of action qualifier	ftcn	13.21
23104983	C1096775	Clinical Trial [Publication Type]	inpr	11.49
23104983	C1883351	To	qlco	10.42
23104983	C0031327	Drug Kinetics	phsf	10.06
23104983	C1280519	Effectiveness	qlco	5.18
23104983	C1707887	Efficacy Study	resa	5.18
23104983	C1521975	Entered	qlco	5.18
23104983	C1517331	Further	spco	5.18
23104983	C0872187	high throughput screening	diap	3.68
23104983	C1254042	Anatomical maturation	phsf	3.63
23104983	C0678723	Biologic Development	orgf	3.63
23104983	C0205198	Compound	qlco	3.63
23104983	C1706082	Compound (substance)	chem	3.63
23104983	C0870861	Human maturation	phpr	3.63
23104983	C1550043	Container status - Identified	fndg	3.56
23104983	C0205396	Identified	qlco	3.56
23104983	C1413365	CFTR gene	gngm	3.48
23104983	C0023376	Lesotho	geoa	17.80
23104983	C0015127	Etiology aspects	ftcn	10.28
23104983	C1880834	Fold in Medical Device Material	phpr	7.40
23104983	C0332462	Folded structure	spco	7.40
23104983	C0013230	Investigational New Drugs	phsu	6.83
23104983	C0728893	+5	qnco	5.18
23104983	C0439084	>5	qnco	5.18
23104983	C0332257	Including (qualifier)	ftcn	5.18
23104983	C3887647	Lymphotoxin-Alpha, human	aapp	5.18
23104983	C3887647	Lymphotoxin-Alpha, human	imft	5.18
23104983	C0230426	Structure of left thigh	bpoc	5.18
23104983	C1524003	Science of Etiology	cnce	3.98
23104983	C1547282	Show	anim	3.98
23104983	C3842590	10%	fndg	3.68
23104983	C1704444	Multiplicative Product	qnco	3.68
23104983	C1806781	Short	qnco	3.68
23104983	C2350002	Short Value	qnco	3.68
23104983	C1282927	Shortened	qlco	3.68
23104983	C3252847	VX 809	orch	3.68
23104983	C3252847	VX 809	phsu	3.68
23104983	C1514468	product	enty	3.68
23104983	C1634625	% live	qlco	3.63
23104983	C0442805	Increase	ftcn	3.63
23104983	C1548795	Live - Specimen Condition	qlco	3.63
23104983	C2982691	Reside	acty	3.63
23104983	C1254042	Anatomical maturation	phsf	3.57
23104983	C0678723	Biologic Development	orgf	3.57
23104983	C0870861	Human maturation	phpr	3.57
23104983	C0439064	Numerous	qnco	3.56
23104983	C0443302	Several	qnco	3.56
23104983	C0740116	+2	qnco	3.50
23104983	C3833492	2+	fndg	3.50
23104983	C2827735	2+ Score	qnco	3.50
23104983	C2981700	2+ Score, WHO	clas	3.50
23104983	C0205286	Mature	tmco	3.50
23104983	C1704243	Greater	qnco	3.48
23104983	C0205393	Most	qnco	3.48
23104983	C0205198	Compound	qlco	3.41
23104983	C1706082	Compound (substance)	chem	3.41
23104983	C0597304	Proteolysis	moft	14.64
23104983	C0026377	Molecular Conformation	spco	12.89
23104983	C1561607	Overall	qlco	9.78
23104983	C0282416	Overall Publication Type	inpr	9.78
23104983	C0332220	Cross-linking	ftcn	5.18
23104983	C0456685	U/hour	qnco	3.78
23104983	C1301808	Geographic state	geoa	3.63
23104983	C1442792	State	ftcn	3.63
23104983	C3148680	US State	geoa	3.63
23104983	C1883468	Unstable Medical Device Problem	evnt	3.63
23104983	C0443343	Unstable status	fndg	3.63
23104983	C0237834	Resistance (Psychotherapeutic)	menp	3.59
23104983	C1514892	Resistance Process	phsf	3.59
23104983	C2348205	Similarity	qlco	3.57
23104983	C0221191	Judge	prog	3.55
23104983	C1883559	Wild Type	gngm	3.48
23104983	C0040363	Togo	geoa	17.80
23104983	C0041260	Tryptophanase	aapp	17.80
23104983	C0041260	Tryptophanase	enzy	17.80
23104983	C0015127	Etiology aspects	ftcn	9.82
23104983	C0039808	Thermodynamics	ocdi	6.66
23104983	C1883351	To	qlco	5.18
23104983	C2347098	Medical Product Stability	qlco	3.68
23104983	C0205360	Stable status	qlco	3.68
23104983	C2698172	Application Program Interface	inpr	3.63
23104983	C1708533	Interface Device Component	mnob	3.63
23104983	C0332290	Consistent with	idcn	3.61
23104983	C1705242	Different	qlco	3.54
23104983	C0184512	Stabilized (qualifier value)	qlco	3.54
23104983	C1880834	Fold in Medical Device Material	phpr	3.54
23104983	C0332462	Folded structure	spco	3.54
23104983	C0392747	Changing	ftcn	3.51
23104983	C3889737	Data Change Date	tmco	3.51
23104983	C3840684	Modification	inpr	3.51
23104983	C1554963	ResponseLevel - modification	ftcn	3.51
23104983	C1524003	Science of Etiology	cnce	3.51
23104983	C3147236	ERVW-3 gene	gngm	3.48
23104983	C3252847	VX 809	orch	3.43
23104983	C3252847	VX 809	phsu	3.43
23104983	C1254042	Anatomical maturation	phsf	3.42
23104983	C0678723	Biologic Development	orgf	3.42
23104983	C0870861	Human maturation	phpr	3.42
23104983	C1948023	Stimulation (motivation)	npop	3.42
23104983	C0441987	Side	spco	3.55
23104983	C1511806	Developmental Process	ortf	3.54
23104983	C0243083	associated disease	patf	3.43
23104983	C2698172	Application Program Interface	inpr	3.42
23104983	C3147236	ERVW-3 gene	gngm	3.42
23104983	C1708533	Interface Device Component	mnob	3.42
23104983	C0205198	Compound	qlco	3.42
23104983	C1706082	Compound (substance)	chem	3.42
23104983	C0596988	mutant	comd	3.42
23104983	C0033414	Promotion (action)	acty	3.40
23104983	C0010834	Cytoplasm	celc	12.96
23104983	C1280500	Effect	qlco	7.49
23104983	C2698172	Application Program Interface	inpr	5.18
23104983	C1708533	Interface Device Component	mnob	5.18
23104983	C0459471	Interpretation Process	inpr	5.18
23104983	C3173575	Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal	clna	5.18
23104983	C0558058	Reflecting	menp	5.18
23104983	C0181687	loops	medd	3.68
23104983	C2945843	Site of	qlco	3.57
23104983	C0442632	Boat dock	mnob	3.57
23104983	C1880157	Computation (action)	acty	3.57
23104983	C1516769	Computational Technique	resa	3.57
23104983	C1522290	Docking -molecular interaction	moft	3.57
23104983	C3844638	Either	fndg	3.57
23104983	C1521721	Supportive assistance	cnce	3.57
23104983	C1704675	Interaction	ftcn	3.56
23104983	C3266814	Action	acty	3.55
23104983	C1524062	Additional	ftcn	3.55
23104983	C1254042	Anatomical maturation	phsf	3.55
23104983	C0678723	Biologic Development	orgf	3.55
23104983	C0441472	Clinical action	ftcn	3.55
23104983	C0870861	Human maturation	phpr	3.55
23104983	C0521449	Cytoplasmic	blor	3.50
23104983	C3252847	VX 809	orch	3.46
23104983	C3252847	VX 809	phsu	3.46
23104983	C0596988	mutant	comd	3.43
23104983	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
23104983	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
23104983	C0013230	Investigational New Drugs	phsu	6.72
23104983	C3539655	CDISC Findings Class	inpr	5.18
23104983	C0205197	Complete	qlco	5.18
23104983	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
23104983	C1527428	Remaining	qlco	5.18
23104983	C0443289	Revealed	qlco	5.18
23104983	C2607943	findings aspects	ftcn	5.18
23104983	C1706853	Assembly (construction)	acty	3.98
23104983	C2698977	Capability	qlco	3.98
23104983	C1413365	CFTR gene	gngm	3.68
23104983	C1883468	Unstable Medical Device Problem	evnt	3.68
23104983	C0443343	Unstable status	fndg	3.68
23104983	C0680582	control system	rnlw	3.68
23104983	C0332306	Quality	qlco	3.61
23104983	C3898777	Important	qlco	3.54
23104983	C0449295	Limitation	ftcn	3.54
23104983	C0007634	Cells	cell	3.47
23104983	C0178539	Cellular	lbpr	3.47
23104983	C3642217	Per Liter	qnco	5.18
23104983	C0439394	liter/second	qnco	5.18
23104983	C1706495	upper case letter ell	inpr	5.18
23104983	C0369773	P Blood group antibodies	aapp	5.18
23104983	C0369773	P Blood group antibodies	imft	5.18
23104983	C2603361	P prime	clna	5.18
23104983	C2348662	Concept Unique Identifier	inpr	5.18
23104983	C3642217	Per Liter	qnco	5.18
23104983	C1707476	UMLS Concept Unique Identifier	inpr	5.18
23104983	C0439394	liter/second	qnco	5.18
23104983	C1706495	upper case letter ell	inpr	5.18
23104983	C2603360	T prime	clna	5.18
23104983	C0369718	N not otherwise specified Antibody	aapp	5.18
23104983	C0369718	N not otherwise specified Antibody	imft	5.18
23104983	C0441922	N+ (tumor staging)	inpr	5.18
23104983	C0684010	Rabbi	prog	13.14
23104983	C2603358	R prime	clna	3.68
23104983	C0205090	Right	spco	3.68
23104983	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
23104983	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
23104983	C0026377	Molecular Conformation	spco	12.86
23104983	C1564139	Mutant Proteins	aapp	11.49
23104983	C0184512	Stabilized (qualifier value)	qlco	5.18
23104983	C1254042	Anatomical maturation	phsf	3.57
23104983	C0678723	Biologic Development	orgf	3.57
23104983	C0870861	Human maturation	phpr	3.57
23104983	C0205246	Generalized	spco	3.44
23104983	C2348867	Global	qlco	3.44
23104983	C1413365	CFTR gene	gngm	3.43
23460825	C0242194	Anion Exchange Protein 1, Erythrocyte	aapp	27.26
23460825	C0242194	Anion Exchange Protein 1, Erythrocyte	bacs	27.26
23460825	C1704380	Distal Renal Tubular Acidosis	dsyn	20.95
23460825	C0015127	Etiology aspects	ftcn	11.49
23460825	C1564139	Mutant Proteins	aapp	9.92
23460825	C0012634	Disease	dsyn	9.86
23460825	C0026882	Mutation	genf	9.86
23460825	C1420193	SLC4A1 gene	gngm	6.92
23460825	C2700640	Encode (action)	acty	5.18
23460825	C1547699	MIME encoding	idcn	5.18
23460825	C1524003	Science of Etiology	cnce	5.18
23460825	C0596611	Gene Mutation	genf	3.58
23460825	C0599896	trafficking	celf	3.56
23460825	C0678226	Due to	ftcn	3.45
23460825	C1412384	AMH gene	gngm	3.43
23460825	C3538735	AMH wt Allele	gngm	3.43
23460825	C1333208	DHX16 gene	gngm	3.43
23460825	C0332183	Frequently	tmco	3.43
23460825	C0687670	Mullerian duct inhibiting substance	aapp	3.43
23460825	C0687670	Mullerian duct inhibiting substance	horm	3.43
23460825	C4050225	Often - answer to question	inpr	3.43
23460825	C0058442	dirhodium tetraacetate	orch	26.10
23460825	C0058442	dirhodium tetraacetate	phsu	26.10
23460825	C0014239	Endoplasmic Reticulum	celc	22.53
23460825	C0018042	Golgi Apparatus	celc	22.47
23460825	C0598829	Madin Darby Canine Kidney Cells	cell	13.09
23460825	C0007603	Plasma membrane	celc	9.86
23460825	C1425254	OSGEP gene	gngm	7.40
23460825	C0596988	mutant	comd	7.21
23460825	C0333118	Retained	ftcn	7.15
23460825	C1292732	Investigates	ftcn	5.18
23460825	C0557651	Room of building - Study	mnob	5.18
23460825	C2603343	Study	resa	5.18
23460825	C0599896	trafficking	celf	3.55
23460825	C0205448	Two	qnco	3.48
23460825	C0009264	Cold Temperature	npop	22.46
23460825	C0017861	Glycerin	bacs	14.64
23460825	C0017861	Glycerin	orch	14.64
23460825	C0017861	Glycerin	phsu	14.64
23460825	C0012403	Dimethyl Sulfoxide	orch	12.90
23460825	C0012403	Dimethyl Sulfoxide	phsu	12.90
23460825	C3252847	VX 809	orch	3.75
23460825	C3252847	VX 809	phsu	3.75
23460825	C0087111	Therapeutic procedure	topp	3.57
23460825	C1425254	OSGEP gene	gngm	3.56
23460825	C0596988	mutant	comd	3.56
23460825	C0599896	trafficking	celf	3.56
23460825	C0087111	Therapeutic procedure	topp	5.18
23460825	C1412384	AMH gene	gngm	3.68
23460825	C3538735	AMH wt Allele	gngm	3.68
23460825	C1333208	DHX16 gene	gngm	3.68
23460825	C1880834	Fold in Medical Device Material	phpr	3.68
23460825	C0332462	Folded structure	spco	3.68
23460825	C0687670	Mullerian duct inhibiting substance	aapp	3.68
23460825	C0687670	Mullerian duct inhibiting substance	horm	3.68
23460825	C0596988	mutant	comd	3.63
23460825	C0599896	trafficking	celf	3.59
23460825	C1280500	Effect	qlco	3.56
23460825	C2348382	Effect, Appearance	qlco	3.56
23460825	C1425254	OSGEP gene	gngm	3.48
23460825	C1546944	Event Seriousness - Significant	qlco	3.43
23460825	C0750502	Significant	idcn	3.43
23460825	C0237881	Statistical Significance	qnco	3.43
23460825	C0039798	therapeutic aspects	ftcn	22.61
23460825	C0012403	Dimethyl Sulfoxide	orch	13.14
23460825	C0012403	Dimethyl Sulfoxide	phsu	13.14
23460825	C0031843	physiological aspects	phsf	13.00
23460825	C0598829	Madin Darby Canine Kidney Cells	cell	12.89
23460825	C0032105	Plasma	bdsu	12.88
23460825	C0007603	Plasma membrane	celc	9.73
23460825	C1533734	Administration procedure	topp	3.68
23460825	C1705169	Biomaterial Treatment	cnce	3.68
23460825	C0087111	Therapeutic procedure	topp	3.68
23460825	C1522326	Treating	ftcn	3.68
23460825	C3538994	Treatment Epoch	resa	3.68
23460825	C3887704	treatment - ActInformationManagementReason	hlca	3.68
23460825	C0682568	membrane by function	bpoc	3.55
23460825	C0542341	Function	ftcn	3.54
23460825	C0700205	Function Axis	clas	3.54
23460825	C1705273	Mathematical Operator	inpr	3.54
23460825	C1720467	Only - dosing instruction fragment	inpr	3.50
23460825	C0205171	Singular	qnco	3.50
23460825	C1425254	OSGEP gene	gngm	3.42
23460825	C1550098	Plasma, NOS (not otherwise specified)	bdsu	3.42
23460825	C0058442	dirhodium tetraacetate	orch	26.04
23460825	C0058442	dirhodium tetraacetate	phsu	26.04
23460825	C0039798	therapeutic aspects	ftcn	22.56
23460825	C0031843	physiological aspects	phsf	13.02
23460825	C0599896	trafficking	celf	7.45
23460825	C0596988	mutant	comd	7.01
23460825	C1547282	Show	anim	5.18
23460825	C0681814	research study	resa	5.18
23460825	C1533734	Administration procedure	topp	3.63
23460825	C1705169	Biomaterial Treatment	cnce	3.63
23460825	C0087111	Therapeutic procedure	topp	3.63
23460825	C1522326	Treating	ftcn	3.63
23460825	C3538994	Treatment Epoch	resa	3.63
23460825	C3887704	treatment - ActInformationManagementReason	hlca	3.63
23460825	C0542341	Function	ftcn	3.56
23460825	C0700205	Function Axis	clas	3.56
23460825	C1705273	Mathematical Operator	inpr	3.56
23460825	C1425254	OSGEP gene	gngm	3.55
23460825	C0333118	Retained	ftcn	3.55
23460825	C3272558	Chemical or Textual Reference to Actual Test or Parameter	inpr	3.48
23460825	C0220806	Chemicals	chem	3.48
23460825	C0205447	One	qnco	3.48
23460825	C0040363	Togo	geoa	17.80
23460825	C0041260	Tryptophanase	aapp	17.80
23460825	C0041260	Tryptophanase	enzy	17.80
23460825	C0058442	dirhodium tetraacetate	orch	12.89
23460825	C0058442	dirhodium tetraacetate	phsu	12.89
23460825	C0037633	Solutions	sbst	6.71
23460825	C0030705	Patients	podg	6.58
23460825	C1999230	Providing (action)	acty	5.18
23460825	C0947630	Scientific Study	lbpr	5.18
23460825	C1883351	To	qlco	5.18
23460825	C1553525	therapeutic - generic - SubstanceAdminSubstitution	inpr	3.45
22698459	C0007457	Caucasoid Race	popg	12.88
22698459	C0010674	Cystic Fibrosis	dsyn	10.06
22698459	C0019247	Hereditary Diseases	dsyn	6.71
22698459	C2826244	Life Threatening	fndg	3.43
22698459	C1517874	Life Threatening Adverse Event	fndg	3.43
22698459	C3537125	Life Threatening or Disabling Adverse Event	fndg	3.43
22698459	C1546953	Life threatening - Event Consequence	idcn	3.43
22698459	C0043157	Caucasians	popg	3.42
22698459	C0205214	Common (qualifier value)	qnco	3.42
22698459	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
22698459	C0205393	Most	qnco	3.42
22698459	C1522138	shared attribute	ftcn	3.42
22698459	C0009586	Comprehensive Health Care	hlca	10.06
22698459	C0038952	Continuance of life	acty	8.34
22698459	C0040223	Time	tmco	6.74
22698459	C0220921	survival aspects	ftcn	5.18
22698459	C1519441	Specialized Center Grant	hcro	3.74
22698459	C0729338	Care provision regimes	hlca	3.64
22698459	C1514811	Bibliographic Reference	inpr	3.63
22698459	C1706462	Reference Object	cnce	3.63
22698459	C1561611	Admission Level of Care Code - Improved	inpr	3.59
22698459	C0332272	Better	qlco	3.59
22698459	C0184511	Improved	qlco	3.59
22698459	C3541383	Time (foundation metadata concept)	tmco	3.59
22698459	C0205172	More	ftcn	3.48
22698459	C0678226	Due to	ftcn	3.45
22698459	C1279919	Early	tmco	3.43
22698459	C0162340	Comprehension	menp	13.01
22698459	C0031847	physiopathological	ftcn	9.86
22698459	C0679252	cure of disease	fndg	3.60
22698459	C0277785	Functional disorder	patf	3.55
22698459	C3854260	Advance	tmco	3.52
22698459	C0725066	Advance -- medical device	medd	3.52
22698459	C0344211	Supportive care	topp	3.45
22698459	C1704243	Greater	qnco	3.43
22698459	C0549177	Large	qnco	3.43
22698459	C0220825	Evaluation	hlca	13.05
22698459	C0311448	Abnormal protein	aapp	5.18
22698459	C0311448	Abnormal protein	bacs	5.18
22698459	C3844638	Either	fndg	5.18
22698459	C0679199	strategy	menp	3.63
22698459	C1552578	Act Class - investigation	inpr	3.59
22698459	C1261322	Evaluation procedure	hlca	3.59
22698459	C2948600	Aim	phsu	3.55
22698459	C1947946	Aim (idea)	idcn	3.55
22698459	C3540472	Ancestry-Informative Marker	ftcn	3.55
22698459	C3890193	CD5L wt Allele	gngm	3.55
22698459	C2744535	CD69 protein, human	aapp	3.55
22698459	C2744535	CD69 protein, human	imft	3.55
22698459	C3540471	CD69 wt Allele	gngm	3.55
22698459	C0302350	Therapeutic	ftcn	3.48
22698459	C0087111	Therapeutic procedure	topp	3.48
22698459	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
22698459	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
22698459	C0282443	Review [Publication Type]	inpr	11.49
22698459	C0013217	pharmacotherapeutic	ftcn	9.75
22698459	C0031847	physiopathological	ftcn	9.75
22698459	C0013216	Pharmacotherapy	topp	6.59
22698459	C1552617	Act Class - review	idcn	5.18
22698459	C0567416	Molecule	sbst	3.68
22698459	C3900053	Amenable	qlco	3.57
22698459	C0233820	Insight	menp	3.57
22698459	C1413365	CFTR gene	gngm	3.44
22698459	C0277785	Functional disorder	patf	3.44
22698459	C1554668	Pharmacist - Pharmacotherapy	prog	3.44
22698459	C0008976	Clinical Trials	resa	19.52
22698459	C2930764	ataluren	orch	14.64
22698459	C2930764	ataluren	phsu	14.64
22698459	C3264621	ivacaftor	orch	14.64
22698459	C3264621	ivacaftor	phsu	14.64
22698459	C1096775	Clinical Trial [Publication Type]	inpr	10.06
22698459	C1999230	Providing (action)	acty	5.18
22698459	C1524063	Use of	ftcn	5.18
22698459	C3252847	VX 809	orch	5.18
22698459	C3252847	VX 809	phsu	5.18
22698459	C1511726	Data	idcn	3.68
22698459	C3714741	Data (eukaryote)	euka	3.68
22698459	C3245479	Data call receiving device	medd	3.68
22698459	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
22698459	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
22698459	C1318700	Phosphodiesterase 5 inhibitor	phsu	19.23
22698459	C0013217	pharmacotherapeutic	ftcn	9.74
22698459	C0013216	Pharmacotherapy	topp	6.59
22698459	C0243071	Analog	chvs	5.18
22698459	C0529793	sildenafil	orch	5.18
22698459	C0529793	sildenafil	phsu	5.18
22698459	C3245505	potential	qlco	3.56
22698459	C1511726	Data	idcn	3.54
22698459	C3714741	Data (eukaryote)	euka	3.54
22698459	C3245479	Data call receiving device	medd	3.54
22698459	C1413365	CFTR gene	gngm	3.43
22698459	C1554668	Pharmacist - Pharmacotherapy	prog	3.43
22698459	C1709630	Preclinical	qlco	3.42
22698459	C0009738	Congo	geoa	17.80
22698459	C0042153	utilization qualifier	ftcn	9.88
22698459	C0242481	Research Activities	resa	9.86
22698459	C0035168	research	resa	9.86
22698459	C0205210	Clinical	qlco	7.11
22698459	C1553058	Neuropsychologist - Clinical	prog	7.11
22698459	C0237412	Psychologist - Clinical	prog	7.11
22698459	C0497591	Social Worker - Clinical	prog	7.11
22698459	C0243071	Analog	chvs	5.18
22698459	C3811819	CFTR wt Allele	gngm	5.18
22698459	C0529793	sildenafil	orch	5.18
22698459	C0529793	sildenafil	phsu	5.18
22698459	C0185125	Application procedure	hlca	3.68
22698459	C0678536	Speed (motion)	qnco	3.68
22698459	C0457083	Usage	ftcn	3.57
22698459	C1947944	Use - dosing instruction imperative	inpr	3.57
22698459	C0678723	Biologic Development	orgf	3.56
22698459	C1527148	Development	ftcn	3.56
22698459	C0243107	development aspects	phsf	3.56
22698459	C3242274	new therapy	fndg	3.45
22698459	C0456387	Class	inpr	3.43
22698459	C1705943	Class (taxonomic)	clas	3.43
22698459	C3687832	DRUGS	topp	3.43
22698459	C0013227	Pharmaceutical Preparations	phsu	3.43
27659740	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
27659740	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
27659740	C0040363	Togo	geoa	17.80
27659740	C0041260	Tryptophanase	aapp	17.80
27659740	C0041260	Tryptophanase	enzy	17.80
27659740	C3264621	ivacaftor	orch	13.14
27659740	C3264621	ivacaftor	phsu	13.14
27659740	C0031843	physiological aspects	phsf	13.14
27659740	C0026882	Mutation	genf	9.92
27659740	C0010674	Cystic Fibrosis	dsyn	9.81
27659740	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	5.18
27659740	C0150312	Present	qnco	5.18
27659740	C1883351	To	qlco	5.18
27659740	C0542341	Function	ftcn	3.68
27659740	C0700205	Function Axis	clas	3.68
27659740	C1705273	Mathematical Operator	inpr	3.68
27659740	C1547647	Patient Outcome	idcn	3.58
27659740	C1413365	CFTR gene	gngm	3.50
27659740	C0205210	Clinical	qlco	3.44
27659740	C1553058	Neuropsychologist - Clinical	prog	3.44
27659740	C0237412	Psychologist - Clinical	prog	3.44
27659740	C0497591	Social Worker - Clinical	prog	3.44
27659740	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27659740	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27659740	C0009738	Congo	geoa	16.04
27659740	C0206243	Carrying	acty	14.64
27659740	C3264621	ivacaftor	orch	12.90
27659740	C3264621	ivacaftor	phsu	12.90
27659740	C0026882	Mutation	genf	9.87
27659740	C0030705	Patients	podg	6.58
27659740	C1292732	Investigates	ftcn	5.18
27659740	C0940836	functional measurement	diap	3.58
27659740	C1280500	Effect	qlco	3.57
27659740	C1413365	CFTR gene	gngm	3.42
27659740	C3811819	CFTR wt Allele	gngm	3.42
27659740	C0037047	Sibling	famg	19.40
27659740	C0206243	Carrying	acty	14.64
27659740	C0001792	Elderly (population group)	popg	14.64
27659740	C0001779	Age	orga	5.18
27659740	C1999167	Old age	popg	5.18
27659740	C0369773	P Blood group antibodies	aapp	5.18
27659740	C0369773	P Blood group antibodies	imft	5.18
27659740	C2603361	P prime	clna	5.18
27659740	C0205448	Two	qnco	3.48
27659740	C0337514	Sister	famg	19.45
27659740	C0026882	Mutation	genf	9.94
27659740	C0019425	Heterozygote	orga	9.88
27659740	C0580836	Old	tmco	3.68
27659740	C1705285	Mutation Abnormality	comd	3.63
27659740	C0205448	Two	qnco	3.50
27659740	C0205198	Compound	qlco	3.44
27659740	C1706082	Compound (substance)	chem	3.44
27659740	C0369773	P Blood group antibodies	aapp	5.18
27659740	C0369773	P Blood group antibodies	imft	5.18
27659740	C2603361	P prime	clna	5.18
27659740	C0086418	Homo sapiens	humn	28.87
27659740	C0086582	Males	orga	9.94
27659740	C0019904	Homozygote	orga	9.88
27659740	C0025266	Male population group	popg	6.79
27659740	C0580836	Old	tmco	3.48
27659740	C0026882	Mutation	genf	9.94
27659740	C1705285	Mutation Abnormality	comd	3.63
27659740	C0870604	Female child	aggp	3.55
27659740	C0580836	Old	tmco	3.43
27659740	C0369773	P Blood group antibodies	aapp	5.18
27659740	C0369773	P Blood group antibodies	imft	5.18
27659740	C2603361	P prime	clna	5.18
27659740	C0039798	therapeutic aspects	ftcn	22.51
27659740	C3264621	ivacaftor	orch	12.91
27659740	C3264621	ivacaftor	phsu	12.91
27659740	C0026882	Mutation	genf	9.94
27659740	C3274784	Commence	acty	3.98
27659740	C1533734	Administration procedure	topp	3.59
27659740	C1705169	Biomaterial Treatment	cnce	3.59
27659740	C0087111	Therapeutic procedure	topp	3.59
27659740	C1522326	Treating	ftcn	3.59
27659740	C3538994	Treatment Epoch	resa	3.59
27659740	C3887704	treatment - ActInformationManagementReason	hlca	3.59
27659740	C0068515	neodymium pyrocatechin disulfonate	orch	13.14
27659740	C0030705	Patients	podg	8.34
27659740	C0369773	P Blood group antibodies	aapp	5.18
27659740	C0369773	P Blood group antibodies	imft	5.18
27659740	C2603361	P prime	clna	5.18
27659740	C3539725	SMPD1 wt Allele	gngm	3.68
27659740	C2986411	Improvement	cnce	3.63
27659740	C0848894	normal patient	fndg	3.60
27659740	C0884358	Performed	ftcn	3.59
27659740	C0205210	Clinical	qlco	3.48
27659740	C1553058	Neuropsychologist - Clinical	prog	3.48
27659740	C0237412	Psychologist - Clinical	prog	3.48
27659740	C0497591	Social Worker - Clinical	prog	3.48
27659740	C0205450	Four	qnco	3.43
27659740	C0449445	Approach	spco	3.41
27659740	C0019425	Heterozygote	orga	9.92
27659740	C0369773	P Blood group antibodies	aapp	5.18
27659740	C0369773	P Blood group antibodies	imft	5.18
27659740	C2603361	P prime	clna	5.18
27659740	C0205198	Compound	qlco	3.47
27659740	C1706082	Compound (substance)	chem	3.47
27659740	C0037047	Sibling	famg	19.40
27659740	C0036536	Process of secretion	biof	19.37
27659740	C0036537	Bodily secretions	bdsu	6.75
27659740	C0884358	Performed	ftcn	3.59
27659740	C0428295	Cystic fibrosis sweat test	lbpr	3.48
27659740	C1304760	Sweat chloride level result	lbtr	3.48
27659740	C2004068	Beta (qualifier)	qlco	3.46
27659740	C0439096	Beta greek letter	inpr	3.46
27659740	C0330390	Beta plant	plnt	3.46
27659740	C0599756	adrenergic	ftcn	3.46
27659740	C0030705	Patients	podg	6.79
27659740	C1561611	Admission Level of Care Code - Improved	inpr	5.18
27659740	C0332272	Better	qlco	5.18
27659740	C0184511	Improved	qlco	5.18
27659740	C0369773	P Blood group antibodies	aapp	5.18
27659740	C0369773	P Blood group antibodies	imft	5.18
27659740	C2603361	P prime	clna	5.18
27659740	C0341318	Enterocutaneous Fistula	anab	17.80
27659740	C3264621	ivacaftor	orch	13.05
27659740	C3264621	ivacaftor	phsu	13.05
27659740	C0020883	Creation of ileostomy	topp	12.89
27659740	C1518422	Negation	ftcn	10.42
27659740	C0019904	Homozygote	orga	9.77
27659740	C0026882	Mutation	genf	9.77
27659740	C0030705	Patients	podg	6.76
27659740	C0392747	Changing	ftcn	5.18
27659740	C0430179	Sweat test	lbpr	5.18
27659740	C0399935	Ileectomy	topp	3.61
27659740	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.60
27659740	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.60
27659740	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.60
27659740	C1705285	Mutation Abnormality	comd	3.46
27659740	C1550267	Body Parts - Ileostomy	bpoc	3.43
27659740	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.01
27659740	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.01
27659740	C0040363	Togo	geoa	17.80
27659740	C0041260	Tryptophanase	aapp	17.80
27659740	C0041260	Tryptophanase	enzy	17.80
27659740	C1413365	CFTR gene	gngm	6.94
27659740	C1883351	To	qlco	5.18
27659740	C2825142	Experimental Result	fndg	3.98
27659740	C1274040	Result	ftcn	3.98
27659740	C1546471	What subject filter - Result	idcn	3.98
27659740	C1280519	Effectiveness	qlco	3.63
27659740	C1707887	Efficacy Study	resa	3.63
27659740	C3898777	Important	qlco	3.49
27659740	C1709060	Modulator Device Component	mnob	3.48
27659740	C1561536	*Activity (kind of quantity)	idcn	3.42
27659740	C0205177	Active	ftcn	3.42
27659740	C0441655	Activities	acty	3.42
27659740	C3668946	Activity (animal life circumstance)	fndg	3.42
27659740	C1705242	Different	qlco	3.42
27659740	C4049939	FDA Establishment Activity Terminology	inpr	3.42
27659740	C0242485	Measurement	ftcn	3.42
27659740	C0439167	Percent Activity	qnco	3.42
27659740	C4049938	Physical Activity Measurement	lbpr	3.42
24095197	C0010674	Cystic Fibrosis	dsyn	10.06
24095197	C0026882	Mutation	genf	9.86
24095197	C3899988	Autosomal Recessive Disorder	dsyn	5.18
24095197	C1552738	described	idcn	5.18
24095197	C2235729	birth data single birth	fndg	3.91
24095197	C0457165	Class 6	inpr	3.62
24095197	C0439745	Grouped	spco	3.57
24095197	C0205172	More	ftcn	3.55
24095197	C0040363	Togo	geoa	17.80
24095197	C0041260	Tryptophanase	aapp	17.80
24095197	C0041260	Tryptophanase	enzy	17.80
24095197	C0012634	Disease	dsyn	11.49
24095197	C0025118	Medicine	bmod	6.72
24095197	C1707959	Example	cnce	5.18
24095197	C1883351	To	qlco	5.18
24095197	C0205170	Good	qlco	3.68
24095197	C3146287	Well	mnob	3.68
24095197	C0442504	Place	spco	3.59
24095197	C1704765	Place - dosing instruction imperative	ftcn	3.59
24095197	C1882509	put - instruction imperative	acty	3.59
24095197	C0013227	Pharmaceutical Preparations	phsu	3.57
24095197	C0814225	benefit	qnco	3.57
24095197	C0039798	therapeutic aspects	ftcn	24.11
24095197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.38
24095197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.38
24095197	C0026882	Mutation	genf	11.49
24095197	C2948600	Aim	phsu	10.85
24095197	C1947946	Aim (idea)	idcn	10.85
24095197	C3540472	Ancestry-Informative Marker	ftcn	10.85
24095197	C3890193	CD5L wt Allele	gngm	10.85
24095197	C2744535	CD69 protein, human	aapp	10.85
24095197	C2744535	CD69 protein, human	imft	10.85
24095197	C3540471	CD69 wt Allele	gngm	10.85
24095197	C2349182	Correct (qualifier)	qlco	10.70
24095197	C1457869	Defect	ftcn	7.26
24095197	C1704257	Molecular Genetic Abnormality	fndg	5.18
24095197	C1705285	Mutation Abnormality	comd	5.18
24095197	C0087111	Therapeutic procedure	topp	5.18
24095197	C1363945	Therapy Object (animal model)	fndg	5.18
24095197	C0017296	gene therapy	topp	5.18
24095197	C0449445	Approach	spco	3.60
24095197	C1292724	Procedural approach	ftcn	3.60
24095197	C1527178	Basis - conceptual entity	ftcn	3.50
24095197	C0521116	Current (present time)	tmco	3.46
24095197	C1705242	Different	qlco	3.46
24095197	C0442824	Very	qlco	3.46
24095197	C2984081	Very Much	qlco	3.46
24095197	C0040363	Togo	geoa	17.80
24095197	C0041260	Tryptophanase	aapp	17.80
24095197	C0041260	Tryptophanase	enzy	17.80
24095197	C0439659	Beginning	tmco	5.18
24095197	C1547282	Show	anim	5.18
24095197	C1883351	To	qlco	5.18
24095197	C2825142	Experimental Result	fndg	3.63
24095197	C1274040	Result	ftcn	3.63
24095197	C1546471	What subject filter - Result	idcn	3.63
24095197	C0567416	Molecule	sbst	3.56
24095197	C1555307	promise	idcn	3.48
24095197	C0678723	Biologic Development	orgf	3.43
24095197	C1527148	Development	ftcn	3.43
24095197	C0439064	Numerous	qnco	3.43
24095197	C0443302	Several	qnco	3.43
24095197	C0243107	development aspects	phsf	3.43
24095197	C0035553	Ribosomes	celc	24.11
24095197	C0242612	Codon, Nonsense	nusq	22.39
24095197	C0040363	Togo	geoa	17.80
24095197	C0041260	Tryptophanase	aapp	17.80
24095197	C0041260	Tryptophanase	enzy	17.80
24095197	C2930764	ataluren	orch	13.14
24095197	C2930764	ataluren	phsu	13.14
24095197	C0026882	Mutation	genf	9.74
24095197	C1881534	Make - Instruction Imperative	ftcn	5.18
24095197	C0567416	Molecule	sbst	5.18
24095197	C1869204	PTC 124	orch	5.18
24095197	C1883351	To	qlco	5.18
24095197	C2983265	CDISC SEND Study Design Terminology	inpr	3.98
24095197	C1707689	Design	acty	3.98
24095197	C0332324	Sensitive	ftcn	3.58
24095197	C1273518	Responsible to	fndg	3.56
24095197	C2698967	Canadian Cardiovascular Society Grading Scale Class I	fndg	3.46
24095197	C0441885	Class 1	clas	3.46
24095197	C0439092	Less Than	qnco	3.42
24095197	C0547044	Smaller	qlco	3.42
24095197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
24095197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
24095197	C3852684	lumacaftor	orch	13.14
24095197	C3852684	lumacaftor	phsu	13.14
24095197	C0026882	Mutation	genf	9.87
24095197	C2825142	Experimental Result	fndg	5.18
24095197	C1274040	Result	ftcn	5.18
24095197	C3252847	VX 809	orch	5.18
24095197	C3252847	VX 809	phsu	5.18
24095197	C1546471	What subject filter - Result	idcn	5.18
24095197	C0332183	Frequently	tmco	3.68
24095197	C2698968	Canadian Cardiovascular Society Grading Scale Class II	fndg	3.61
24095197	C0441886	Class 2	inpr	3.61
24095197	C1947931	Direct (qualifier)	qlco	3.53
24095197	C0439851	Direct type of relationship	qlco	3.53
24095197	C1413365	CFTR gene	gngm	3.50
24095197	C0205393	Most	qnco	3.50
24095197	C2348077	Date Fruit	food	25.67
24095197	C3264621	ivacaftor	orch	13.14
24095197	C3264621	ivacaftor	phsu	13.14
24095197	C0001675	Adult	aggp	11.49
24095197	C0026882	Mutation	genf	9.73
24095197	C2741958	VX-770	orch	5.18
24095197	C1547282	Show	anim	3.98
24095197	C0205447	One	qnco	3.68
24095197	C0011008	Date in time	tmco	3.59
24095197	C3844028	Child 6	fndg	3.56
24095197	C1318228	Market	geoa	3.55
24095197	C1280519	Effectiveness	qlco	3.54
24095197	C1707887	Efficacy Study	resa	3.54
24095197	C1720467	Only - dosing instruction fragment	inpr	3.50
24095197	C0205171	Singular	qnco	3.50
24095197	C2698969	Canadian Cardiovascular Society Grading Scale Class III	fndg	3.44
24095197	C0441887	Class 3	inpr	3.44
24095197	C0001779	Age	orga	3.42
24095197	C0205170	Good	qlco	3.42
24095197	C1705285	Mutation Abnormality	comd	3.42
24095197	C0026882	Mutation	genf	9.74
24095197	C0521116	Current (present time)	tmco	5.18
24095197	C3687832	DRUGS	topp	5.18
24095197	C0013227	Pharmaceutical Preparations	phsu	5.18
24095197	C0205195	Combined	qlco	3.57
24095197	C3811910	combination - answer to question	fndg	3.57
24095197	C1947911	combination of objects	phob	3.57
24095197	C1516648	Clinical Trial, Other	resa	3.56
24095197	C0205214	Common (qualifier value)	qnco	3.42
24095197	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.42
24095197	C3540763	VARIOUS DRUG CLASSES IN ATC	phsu	3.42
24095197	C0440102	Various patch test substance	irda	3.42
24095197	C1522138	shared attribute	ftcn	3.42
24095197	C3540765	various allergen extracts	imft	3.42
24095197	C3540765	various allergen extracts	phsu	3.42
24095197	C3540008	various antiinfectives and antiseptics for local oral treatment	phsu	3.42
24095197	C3540766	various antiseptic throat preparations	phsu	3.42
24095197	C3540762	various other agents for local oral treatment in ATC	phsu	3.42
24095197	C3540769	various other intestinal adsorbents in ATC	phsu	3.42
24095197	C3540761	various other nasal preparations in ATC	phsu	3.42
24095197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
24095197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
24095197	C1413365	CFTR gene	gngm	5.18
24095197	C0439234	year	tmco	3.63
24095197	C1524084	Designated	ftcn	3.56
24095197	C1521840	Target	ftcn	3.56
24095197	C2986546	Target Lesion Identification	diap	3.56
24095197	C0302350	Therapeutic	ftcn	3.56
24095197	C0087111	Therapeutic procedure	topp	3.56
24095197	C1517741	Last	qlco	3.48
24095197	C0040363	Togo	geoa	17.80
24095197	C0041260	Tryptophanase	aapp	17.80
24095197	C0041260	Tryptophanase	enzy	17.80
24095197	C3264621	ivacaftor	orch	13.14
24095197	C3264621	ivacaftor	phsu	13.14
24095197	C0010674	Cystic Fibrosis	dsyn	9.76
24095197	C1720467	Only - dosing instruction fragment	inpr	5.18
24095197	C0359589	Provide (product)	food	5.18
24095197	C1999230	Providing (action)	acty	5.18
24095197	C0205171	Singular	qnco	5.18
24095197	C0087111	Therapeutic procedure	topp	5.18
24095197	C1883351	To	qlco	5.18
24095197	C1522326	Treating	ftcn	5.18
24095197	C1292734	Treatment intent	ftcn	5.18
24095197	C0013227	Pharmaceutical Preparations	phsu	3.68
24095197	C1254351	Pharmacologic Substance	phsu	3.68
24095197	C1457869	Defect	ftcn	3.55
24095197	C1704632	Disease Response	fndg	3.54
24095197	C2911692	Response (communication)	menp	3.54
24095197	C1706817	Response (statement)	inpr	3.54
24095197	C0871261	Response process	orga	3.54
24095197	C0205435	First (number)	qnco	3.50
24095197	C1279901	Firstly	qlco	3.50
24095197	C2360800	Number of patients	fndg	3.46
24095197	C1527178	Basis - conceptual entity	ftcn	3.43
24095197	C0700321	Small	qnco	3.42
24095197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
24095197	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
24095197	C0026882	Mutation	genf	9.86
24095197	C1514873	Requirement	ftcn	5.18
24095197	C1718097	New medications	phsu	3.75
24095197	C0205214	Common (qualifier value)	qnco	3.55
24095197	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.55
24095197	C1522138	shared attribute	ftcn	3.55
24095197	C1883709	Damage	ftcn	3.52
24095197	C0010957	Tissue damage	inpo	3.52
24095197	C2698977	Capability	qlco	3.52
27804127	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.47
27804127	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.47
27804127	C0010674	Cystic Fibrosis	dsyn	10.06
27804127	C0012634	Disease	dsyn	9.94
27804127	C0015127	Etiology aspects	ftcn	9.86
27804127	C0376558	Life	idcn	9.78
27804127	C1561536	*Activity (kind of quantity)	idcn	3.59
27804127	C0205177	Active	ftcn	3.59
27804127	C0441655	Activities	acty	3.59
27804127	C3668946	Activity (animal life circumstance)	fndg	3.59
27804127	C4049939	FDA Establishment Activity Terminology	inpr	3.59
27804127	C0439167	Percent Activity	qnco	3.59
27804127	C4049938	Physical Activity Measurement	lbpr	3.59
27804127	C0332452	defective	ftcn	3.59
27804127	C1524003	Science of Etiology	cnce	3.55
27804127	C1413365	CFTR gene	gngm	3.55
27804127	C0439801	Limited (extensiveness)	ftcn	3.48
27804127	C1636779	% deficient	qnco	3.45
27804127	C0011155	Deficiency	ftcn	3.45
27804127	C0041714	United States Food and Drug Administration	hcro	25.56
27804127	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27804127	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27804127	C3264621	ivacaftor	orch	13.05
27804127	C3264621	ivacaftor	phsu	13.05
27804127	C3852684	lumacaftor	orch	12.88
27804127	C3852684	lumacaftor	phsu	12.88
27804127	C0030705	Patients	podg	6.71
27804127	C4033620	ORKAMBI	phsu	5.18
27804127	C0332185	Recent	tmco	5.18
27804127	C1521840	Target	ftcn	5.18
27804127	C2986546	Target Lesion Identification	diap	5.18
27804127	C0205195	Combined	qlco	3.59
27804127	C2346845	Approval (document)	inpr	3.54
27804127	C0205540	Approved	qlco	3.54
27804127	C2697909	Letter of Authorization	rnlw	3.54
27804127	C1413365	CFTR gene	gngm	3.43
27804127	C0022752	Knowledge Bases	inpr	19.36
27804127	C0009738	Congo	geoa	17.80
27804127	C4033633	ivacaftor / lumacaftor	phsu	12.91
27804127	C0282443	Review [Publication Type]	inpr	11.49
27804127	C0009671	Conflict (Psychology)	inbe	9.73
27804127	C0034036	Publications	inpr	9.73
27804127	C0034036	Publications	mnob	9.73
27804127	C0009429	Combined Modality Therapy	topp	6.91
27804127	C0036397	Science	ocdi	6.58
27804127	C0023866	Literature	inpr	6.58
27804127	C0030705	Patients	podg	6.58
27804127	C1552617	Act Class - review	idcn	5.18
27804127	C3811819	CFTR wt Allele	gngm	5.18
27804127	C3889645	Clinical Trial Final Report	inpr	5.18
27804127	C3888055	Cover (physical object)	mnob	5.18
27804127	C1999244	Cover - action	ftcn	5.18
27804127	C1707529	Cover Device Component	medd	5.18
27804127	C0180153	Covers (device)	medd	5.18
27804127	C3273238	Regulatory Report	inpr	5.18
27804127	C0684224	Report (document)	inpr	5.18
27804127	C0700287	Reporting	hlca	5.18
27804127	C0556895	Combination electrotherapy	topp	3.75
27804127	C0205210	Clinical	qlco	3.68
27804127	C1553058	Neuropsychologist - Clinical	prog	3.68
27804127	C0237412	Psychologist - Clinical	prog	3.68
27804127	C0497591	Social Worker - Clinical	prog	3.68
27804127	C1880198	Cure (remedy)	cnce	3.55
27804127	C0939785	The Magic Bullet	orch	3.53
27804127	C0939785	The Magic Bullet	phsu	3.53
27804127	C1706387	Issue (document)	inpr	3.52
27804127	C0033213	Problem	fndg	3.52
27804127	C1522634	Question (inquiry)	inpr	3.50
27804127	C0444503	Breakthrough	qlco	3.48
27804127	C0332185	Recent	tmco	3.42
27804127	C0680220	majority	socb	3.42
27804127	C0814230	veterans alcoholism screening test (VAST)	inpr	3.42
27288484	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27288484	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27288484	C3264621	ivacaftor	orch	14.64
27288484	C3264621	ivacaftor	phsu	14.64
27288484	C0010674	Cystic Fibrosis	dsyn	9.75
27288484	C0026882	Mutation	genf	9.73
27288484	C0030705	Patients	podg	6.70
27288484	C2741958	VX-770	orch	3.75
27288484	C0205540	Approved	qlco	3.57
27288484	C0205210	Clinical	qlco	3.57
27288484	C1553058	Neuropsychologist - Clinical	prog	3.57
27288484	C0237412	Psychologist - Clinical	prog	3.57
27288484	C0497591	Social Worker - Clinical	prog	3.57
27288484	C0457083	Usage	ftcn	3.57
27288484	C1413365	CFTR gene	gngm	3.42
27288484	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.51
27288484	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.51
27288484	C0005456	Binding Sites	rcpt	14.64
27288484	C0205198	Compound	qlco	5.18
27288484	C1706082	Compound (substance)	chem	5.18
27288484	C0682969	Ligand Binding Domain	amas	5.18
27288484	C0439673	Unknown	qlco	5.18
27288484	C1413365	CFTR gene	gngm	3.59
27288484	C2603362	S prime	clna	3.59
27288484	C0565930	per second	qnco	3.59
27288484	C1328819	Small Molecule	orch	3.53
27288484	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
27288484	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
27288484	C1413365	CFTR gene	gngm	5.18
27288484	C1517378	Gain	qnco	3.59
27288484	C0439799	Channel	spco	3.57
27288484	C1706095	Channel Object	cnce	3.57
27288484	C1280500	Effect	qlco	3.57
27288484	C2348382	Effect, Appearance	qlco	3.57
27288484	C0233820	Insight	menp	3.56
27288484	C1707455	Comparison	acty	3.55
27288484	C1705285	Mutation Abnormality	comd	3.55
27288484	C1522634	Question (inquiry)	inpr	3.43
27288484	C1532633	Kilounit per Kilogram	qnco	5.18
27288484	C2608091	Unit/gram	qnco	5.18
27288484	C0086418	Homo sapiens	humn	30.42
27288484	C0026809	Mus	mamm	30.42
27288484	C0043343	Xenopus laevis	amph	30.42
27288484	C0043342	Xenopus <genus>	amph	27.26
27288484	C0003459	Anura	amph	20.95
27288484	C1527389	Salientia	amph	20.95
27288484	C0025914	House mice	mamm	5.18
27288484	C0025929	Laboratory mice	mamm	5.18
27288484	C0034650	Rana <genus>	amph	5.18
27288484	C1504663	Xenopus subgenus	amph	5.18
27288484	C0040363	Togo	geoa	35.81
27288484	C0041260	Tryptophanase	aapp	35.81
27288484	C0041260	Tryptophanase	enzy	35.81
27288484	C1524059	mechanism of action qualifier	ftcn	26.16
27288484	C0376565	Anti-HIV Agents	phsu	22.34
27288484	C0920472	Drug Discovery	resa	16.04
27288484	C1136288	Computers, Molecular	phob	16.04
27288484	C1883351	To	qlco	10.42
27288484	C0031327	Drug Kinetics	phsf	10.08
27288484	C0031330	Pharmacology	bmod	9.73
27288484	C0205195	Combined	qlco	5.18
27288484	C0150312	Present	qnco	3.68
27288484	C0449450	Presentation	idcn	3.68
27288484	C0557651	Room of building - Study	mnob	3.68
27288484	C2603343	Study	resa	3.68
27288484	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.60
27288484	C0449445	Approach	spco	3.54
27288484	C0205314	New	qlco	3.44
27288484	C0332149	Possible	qlco	3.44
27288484	C2362652	Possible diagnosis	qlco	3.44
27288484	C1705910	Possibly Related to Intervention	qlco	3.44
27288484	C1880355	Discover	acty	3.42
27288484	C3540469	AICDA wt Allele	gngm	3.40
27288484	C1269765	Assisted (qualifier value)	qlco	3.40
27288484	C0449435	Manufactured aid	mnob	3.40
27288484	C1622765	PRF1 protein, human	aapp	44.63
27288484	C1622765	PRF1 protein, human	bacs	44.63
27288484	C1539372	EXOSC10 gene	gngm	27.22
27288484	C0015272	Exhibits as Topic	inpr	16.02
27288484	C1384585	Blood group antigen P2	imft	15.79
27288484	C3669031	Bone structure of middle phalanx	bpoc	15.79
27288484	C3669035	Bone structure of proximal phalanx	bpoc	15.79
27288484	C1419693	RPLP2 gene	gngm	15.79
27288484	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	orch	14.64
27288484	C0049330	5-nitro-2-(3-phenylpropylamino)benzoic acid	phsu	14.64
27288484	C0005456	Binding Sites	rcpt	14.64
27288484	C2933330	N-(2-naphthalenyl)-((3,5-dibromo-2,4-dihydroxyphenyl)methylene)glycine hydrazide	aapp	14.64
27288484	C2933330	N-(2-naphthalenyl)-((3,5-dibromo-2,4-dihydroxyphenyl)methylene)glycine hydrazide	bacs	14.64
27288484	C1412751	BCAT1 gene	gngm	10.42
27288484	C3669027	Bone structure of distal phalanx	bpoc	10.42
27288484	C1427831	SLC10A3 gene	gngm	10.42
27288484	C0004927	Behavior	inbe	6.71
27288484	C0740116	+2	qnco	5.18
27288484	C3816745	1+	fndg	5.18
27288484	C2827734	1+ Score	qnco	5.18
27288484	C2981698	1+ Score, WHO	clas	5.18
27288484	C3833492	2+	fndg	5.18
27288484	C2827735	2+ Score	qnco	5.18
27288484	C2981700	2+ Score, WHO	clas	5.18
27288484	C3838680	3+ Answer to Question	fndg	5.18
27288484	C2827736	3+ Score	qnco	5.18
27288484	C2981702	3+ Score, WHO	clas	5.18
27288484	C0439086	<3 (qualifier value)	qnco	5.18
27288484	C1417808	NPPB gene	gngm	5.18
27288484	C1518422	Negation	ftcn	5.18
27288484	C0237876	Sharing (Social Behavior)	socb	5.18
27288484	C2741958	VX-770	orch	5.18
27288484	C0205198	Compound	qlco	3.98
27288484	C1706082	Compound (substance)	chem	3.98
27288484	C2825142	Experimental Result	fndg	3.98
27288484	C1274040	Result	ftcn	3.98
27288484	C1546471	What subject filter - Result	idcn	3.98
27288484	C1705535	suggestion	idcn	3.98
27288484	C0442796	Additive	qlco	3.68
27288484	C1280500	Effect	qlco	3.68
27288484	C1550602	additive ingredient	sbst	3.68
27288484	C2707008	Behavior:-:Point in time:^Patient:-	clna	3.55
27288484	C1701901	Conditional	qlco	3.54
27288484	C0851827	Dependent - ability	qlco	3.54
27288484	C3244310	dependent	ftcn	3.54
27288484	C1705242	Different	qlco	3.44
27288484	C1552740	Entity Determiner - specific	inpr	3.43
27288484	C1335144	Orthologous Gene	gngm	3.43
27288484	C0205369	Specific qualifier value	qlco	3.43
27288484	C0542560	Academic degree	inpr	3.42
27288484	C2348088	Degree Unit of Plane Angle	qnco	3.42
27288484	C0449286	Degree or extent	qnco	3.42
27288484	C0441889	Levels (qualifier value)	qlco	3.42
27288484	C0086597	Mediate	socb	3.42
27288484	C0127400	Mediator brand of benfluorex hydrochloride	orch	3.42
27288484	C0127400	Mediator brand of benfluorex hydrochloride	phsu	3.42
27288484	C1948023	Stimulation (motivation)	npop	3.42
27288484	C1292856	Stimulation procedure	topp	3.42
27288484	C1280519	Effectiveness	qlco	3.42
27288484	C1707887	Efficacy Study	resa	3.42
27288484	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
27288484	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
27288484	C0015272	Exhibits as Topic	inpr	17.80
27288484	C2933330	N-(2-naphthalenyl)-((3,5-dibromo-2,4-dihydroxyphenyl)methylene)glycine hydrazide	aapp	12.94
27288484	C2933330	N-(2-naphthalenyl)-((3,5-dibromo-2,4-dihydroxyphenyl)methylene)glycine hydrazide	bacs	12.94
27288484	C1550043	Container status - Identified	fndg	5.18
27288484	C0205396	Identified	qlco	5.18
27288484	C1524063	Use of	ftcn	5.18
27288484	C0678594	structure	spco	5.18
27288484	C0449445	Approach	spco	3.63
27288484	C2348205	Similarity	qlco	3.57
27288484	C0279023	chemosensitization/potentiation	topp	3.56
27288484	C0205314	New	qlco	3.48
27288484	C0205449	Three	qnco	3.48
27288484	C0870071	modeling	resa	3.48
27288484	C0599740	pharmacophore	rcpt	3.48
27288484	C1413365	CFTR gene	gngm	3.43
27288484	C1552740	Entity Determiner - specific	inpr	3.43
27288484	C1335144	Orthologous Gene	gngm	3.43
27288484	C0205369	Specific qualifier value	qlco	3.43
27288484	C0039798	therapeutic aspects	ftcn	22.48
27288484	C0010674	Cystic Fibrosis	dsyn	9.76
27288484	C0303231	Lead compound	chvs	3.64
27288484	C0872152	drug development	bmod	3.60
27288484	C0678723	Biologic Development	orgf	3.56
27288484	C1527148	Development	ftcn	3.56
27288484	C0243107	development aspects	phsf	3.56
27288484	C1533734	Administration procedure	topp	3.55
27288484	C1705169	Biomaterial Treatment	cnce	3.55
27288484	C0087111	Therapeutic procedure	topp	3.55
27288484	C1522326	Treating	ftcn	3.55
27288484	C3538994	Treatment Epoch	resa	3.55
27288484	C3887704	treatment - ActInformationManagementReason	hlca	3.55
27288484	C1718097	New medications	phsu	3.46
27288484	C0205314	New	qlco	3.43
27288484	C0086418	Homo sapiens	humn	28.74
27288484	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
27288484	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
27288484	C1524059	mechanism of action qualifier	ftcn	12.94
27288484	C0005456	Binding Sites	rcpt	12.91
27288484	C0020792	Identification (Psychology)	menp	12.89
27288484	C0031330	Pharmacology	bmod	9.78
27288484	C1524063	Use of	ftcn	7.45
27288484	C1335144	Orthologous Gene	gngm	6.94
27288484	C0008109	Chimera organism	orgm	6.79
27288484	C0004927	Behavior	inbe	6.70
27288484	C1705535	suggestion	idcn	5.18
27288484	C1413365	CFTR gene	gngm	3.68
27288484	C0449445	Approach	spco	3.63
27288484	C2707008	Behavior:-:Point in time:^Patient:-	clna	3.55
27288484	C2828360	Traverse	cnce	3.48
27288484	C0205396	Identified	qlco	3.43
27288484	C1552740	Entity Determiner - specific	inpr	3.42
27288484	C0205369	Specific qualifier value	qlco	3.42
27288484	C0205198	Compound	qlco	3.40
27288484	C1706082	Compound (substance)	chem	3.40
28554721	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.81
28554721	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.81
28554721	C0242821	Human body	humn	16.18
28554721	C1413365	CFTR gene	gngm	3.88
28554721	C1268086	Body structure	anst	3.57
28554721	C0460148	Human body structure	anst	3.57
28554721	C0009488	Comorbidity	idcn	14.64
28554721	C0010674	Cystic Fibrosis	dsyn	9.92
28554721	C0205319	Manifest	ftcn	7.33
28554721	C1280464	Manifestation of	qlco	7.33
28554721	C0205393	Most	qnco	3.56
28554721	C1947933	care activity	acty	3.56
28554721	C1546767	Specimen Source Codes - Respiratory	inpr	3.50
28554721	C0521346	respiratory	ftcn	3.50
28554721	C0439064	Numerous	qnco	3.47
28554721	C0178784	Organ	bpoc	3.47
28554721	C0205402	Prominent	qlco	3.47
28554721	C0001811	Aging	orgf	13.05
28554721	C0009488	Comorbidity	idcn	12.90
28554721	C0683971	general population	popg	5.18
28554721	C0442805	Increase	ftcn	3.59
28554721	C0205217	Increased	qnco	3.59
28554721	C0449788	Count of entities	qnco	3.57
28554721	C0237753	Numbers	qnco	3.57
28554721	C0009738	Congo	geoa	17.80
28554721	C0038952	Continuance of life	acty	13.24
28554721	C0011065	Cessation of life	orgf	9.86
28554721	C0001675	Adult	aggp	9.74
28554721	C0013109	Drama	inpr	9.69
28554721	C0221423	Illness (finding)	sosy	7.21
28554721	C0220921	survival aspects	ftcn	6.90
28554721	C3811819	CFTR wt Allele	gngm	5.18
28554721	C0596545	Experience	menp	3.98
28554721	C0237607	Practice Experience	menp	3.98
28554721	C0205447	One	qnco	3.56
28554721	C2986411	Improvement	cnce	3.55
28554721	C0231335	Childhood	tmco	3.55
28554721	C1306577	Death (finding)	fndg	3.55
28554721	C1510411	metaplastic cell transformation	patf	3.55
28554721	C1706450	Legal Adult	humn	3.43
28554721	C0009738	Congo	geoa	32.46
28554721	C0023980	Longevity	tmco	17.80
28554721	C0009488	Comorbidity	idcn	12.89
28554721	C0001675	Adult	aggp	9.77
28554721	C3811819	CFTR wt Allele	gngm	7.07
28554721	C1144866	Multi-disciplinary team	hlca	3.72
28554721	C2360800	Number of patients	fndg	3.62
28554721	C0442805	Increase	ftcn	3.59
28554721	C0205217	Increased	qnco	3.59
28554721	C0442808	Increasing	ftcn	3.55
28554721	C2348042	Parallel Lesion	qlco	3.52
28554721	C2826345	Parallel Study	resa	3.52
28554721	C1706450	Legal Adult	humn	3.46
28554721	C1947933	care activity	acty	3.43
28554721	C0009738	Congo	geoa	16.04
28554721	C0001811	Aging	orgf	12.89
28554721	C0009488	Comorbidity	idcn	12.88
28554721	C0282443	Review [Publication Type]	inpr	11.49
28554721	C0001675	Adult	aggp	9.73
28554721	C1552617	Act Class - review	idcn	5.18
28554721	C1947971	Give - dosing instruction imperative	ftcn	5.18
28554721	C0814812	overview	inpr	3.54
28554721	C1706450	Legal Adult	humn	3.42
28554721	C0599755	cohort	popg	3.42
28554721	C0332281	Associated with	qlco	3.42
28554721	C3811819	CFTR wt Allele	gngm	3.42
28554721	C1548559	Dispense Method - Traditional	idcn	3.42
28554721	C0443324	Traditional origin	ftcn	3.42
28554721	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.31
28554721	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.31
28554721	C0009738	Congo	geoa	32.43
28554721	C0039798	therapeutic aspects	ftcn	22.49
28554721	C0040363	Togo	geoa	17.80
28554721	C0041260	Tryptophanase	aapp	17.80
28554721	C0041260	Tryptophanase	enzy	17.80
28554721	C0031843	physiological aspects	phsf	13.14
28554721	C0009488	Comorbidity	idcn	12.89
28554721	C1413365	CFTR gene	gngm	10.63
28554721	C0031847	physiopathological	ftcn	9.86
28554721	C3811819	CFTR wt Allele	gngm	7.05
28554721	C0205421	Deferred	tmco	5.18
28554721	C2349975	Enhance (action)	acty	5.18
28554721	C1882932	Representation (action)	acty	5.18
28554721	C1555029	Reverse	ftcn	5.18
28554721	C1883351	To	qlco	5.18
28554721	C3245505	potential	qlco	5.18
28554721	C0332281	Associated with	qlco	3.72
28554721	C0542341	Function	ftcn	3.68
28554721	C0700205	Function Axis	clas	3.68
28554721	C1705273	Mathematical Operator	inpr	3.68
28554721	C1533734	Administration procedure	topp	3.57
28554721	C1705169	Biomaterial Treatment	cnce	3.57
28554721	C0087111	Therapeutic procedure	topp	3.57
28554721	C1522326	Treating	ftcn	3.57
28554721	C3538994	Treatment Epoch	resa	3.57
28554721	C3887704	treatment - ActInformationManagementReason	hlca	3.57
28554721	C0686907	Consequence of	ftcn	3.56
28554721	C0678723	Biologic Development	orgf	3.55
28554721	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.55
28554721	C1527148	Development	ftcn	3.55
28554721	C3887504	Dysfunction	cnce	3.55
28554721	C0205234	Focal	spco	3.55
28554721	C0277785	Functional disorder	patf	3.55
28554721	C1285542	Has focus	ftcn	3.55
28554721	C0243107	development aspects	phsf	3.55
28554721	C0332185	Recent	tmco	3.43
28554721	C1709060	Modulator Device Component	mnob	3.41
28554721	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
28554721	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
28554721	C0039798	therapeutic aspects	ftcn	22.35
28554721	C0009738	Congo	geoa	17.80
28554721	C3264621	ivacaftor	orch	13.03
28554721	C3264621	ivacaftor	phsu	13.03
28554721	C0009488	Comorbidity	idcn	12.90
28554721	C3811819	CFTR wt Allele	gngm	5.18
28554721	C3887511	Evidence	idcn	3.63
28554721	C0470187	Availability of	ftcn	3.53
28554721	C1413365	CFTR gene	gngm	3.42
28554721	C1825598	IMPACT gene	gngm	3.42
28554721	C4049986	Impact	qlco	3.42
28554721	C0087111	Therapeutic procedure	topp	3.42
28554721	C1363945	Therapy Object (animal model)	fndg	3.42
28554723	C0010674	Cystic Fibrosis	dsyn	10.06
28554723	C0392760	Affecting	ftcn	3.54
28554723	C1314939	Involvement with	ftcn	3.54
28554723	C3899988	Autosomal Recessive Disorder	dsyn	3.44
28554723	C0237401	Individual	humn	3.40
28554723	C0027361	Persons	popg	3.40
28554723	C0026565	Mortality Vital Statistics	qnco	20.95
28554723	C0026538	Morbidity - disease rate	qnco	19.45
28554723	C0026566	Aspects of mortality statistics	qnco	11.49
28554723	C0015127	Etiology aspects	ftcn	9.84
28554723	C1298233	Disorder of system	ftcn	3.75
28554723	C0746102	Chronic lung disease	dsyn	3.68
28554723	C0220880	morbidity aspects	inpr	3.68
28554723	C1524003	Science of Etiology	cnce	3.53
28554723	C1542147	Main	qlco	3.50
28554723	C0205225	Primary	qlco	3.50
28554723	C0439064	Numerous	qnco	3.48
28554723	C0027617	Neonatal Screening	diap	27.26
28554723	C0039798	therapeutic aspects	ftcn	22.56
28554723	C0040363	Togo	geoa	17.80
28554723	C0041260	Tryptophanase	aapp	17.80
28554723	C0041260	Tryptophanase	enzy	17.80
28554723	C0683572	Adult Children	famg	16.21
28554723	C0242479	Interdisciplinary Studies	ocac	9.81
28554723	C0162425	Intention - mental process	menp	9.72
28554723	C0033325	Forecast of outcome	hlca	8.34
28554723	C0454664	Country	geoa	5.18
28554723	C3854082	Prognosis:Find:Pt:^Patient:Nom	clna	5.18
28554723	C1883351	To	qlco	5.18
28554723	C1947933	care activity	acty	5.18
28554723	C0449445	Approach	spco	3.68
28554723	C1533734	Administration procedure	topp	3.63
28554723	C1705169	Biomaterial Treatment	cnce	3.63
28554723	C0231220	Symptomatic	ftcn	3.63
28554723	C0087111	Therapeutic procedure	topp	3.63
28554723	C1522326	Treating	ftcn	3.63
28554723	C3538994	Treatment Epoch	resa	3.63
28554723	C3887704	treatment - ActInformationManagementReason	hlca	3.63
28554723	C1561611	Admission Level of Care Code - Improved	inpr	3.56
28554723	C0332272	Better	qlco	3.56
28554723	C0184511	Improved	qlco	3.56
28554723	C2981279	Decade	qnco	3.53
28554723	C0521116	Current (present time)	tmco	3.43
28554723	C1550453	Act Mood - intent	ftcn	3.41
28554723	C0522510	With intensity	qlco	3.41
28554723	C1283828	intent	qlco	3.41
28554723	C0023671	Life Expectancy	grpa	19.20
28554723	C0009738	Congo	geoa	17.80
28554723	C0012634	Disease	dsyn	9.84
28554723	C0376558	Life	idcn	9.74
28554723	C3811819	CFTR wt Allele	gngm	5.18
28554723	C2981279	Decade	qnco	3.55
28554723	C1836348	Severe disorder	fndg	3.55
28554723	C4050419	Borg Category-Ratio 10 Perceived Exertion Score 7	inpr	3.43
28554723	C0205438	Fourth	qnco	3.43
28554723	C1706303	Fourth (suffix)	qlco	3.43
28554723	C3641272	Very severe	qlco	3.43
28554723	C2598519	Current age	tmco	3.43
28554723	C2939193	Median (qualifier value)	spco	3.42
28554723	C0876920	Median Statistical Measurement	qnco	3.42
28554723	C0549183	Midline (qualifier value)	spco	3.42
28554723	C2347635	Population Median	qnco	3.42
28554723	C2348144	Sample Median	qnco	3.42
28554723	C0442824	Very	qlco	3.42
28554723	C2984081	Very Much	qlco	3.42
28554723	C0010531	Cyclic AMP-Dependent Protein Kinases	aapp	28.72
28554723	C0010531	Cyclic AMP-Dependent Protein Kinases	enzy	28.72
28554723	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.50
28554723	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.50
28554723	C0005367	Bicarbonates	inch	20.95
28554723	C0005367	Bicarbonates	phsu	20.95
28554723	C0008203	Chlorides	inch	17.80
28554723	C0017337	Genes	gngm	16.22
28554723	C0003075	Anions	elii	13.06
28554723	C2744579	ATP8A2 protein, human	aapp	12.92
28554723	C2744579	ATP8A2 protein, human	enzy	12.92
28554723	C0012634	Disease	dsyn	11.49
28554723	C0026882	Mutation	genf	9.90
28554723	C0005528	Biological Transport	celf	9.88
28554723	C0015127	Etiology aspects	ftcn	9.86
28554723	C0033684	Proteins	aapp	6.79
28554723	C0033684	Proteins	bacs	6.79
28554723	C0013832	Electrolytes	inch	6.59
28554723	C0013832	Electrolytes	phsu	6.59
28554723	C2722820	Bicarbonate preparation	orch	5.18
28554723	C2722820	Bicarbonate preparation	phsu	5.18
28554723	C0439799	Channel	spco	5.18
28554723	C1706095	Channel Object	cnce	5.18
28554723	C0596019	Chloride Ion	elii	5.18
28554723	C2700640	Encode (action)	acty	5.18
28554723	C0973231	bicarbonate ion	inch	5.18
28554723	C1413365	CFTR gene	gngm	3.58
28554723	C3495449	Mobility aid	medd	3.57
28554723	C1317949	transport (device)	mnob	3.57
28554723	C1524003	Science of Etiology	cnce	3.55
28554723	C1704735	Regulator	cnce	3.48
28554723	C1704734	Regulator Device Component	mnob	3.48
28554723	C0182953	Regulators (device)	medd	3.48
28554723	C1879547	Activation action	acty	3.45
28554723	C3536863	Electrolyte [EPC]	phsu	3.44
28554723	C0026882	Mutation	genf	9.87
28554723	C1518422	Negation	ftcn	5.18
28554723	C0684224	Report (document)	inpr	5.18
28554723	C0700287	Reporting	hlca	5.18
28554723	C0686907	Consequence of	ftcn	3.68
28554723	C0681760	2000s	tmco	3.53
28554723	C0542341	Function	ftcn	3.50
28554723	C0205245	Functional	ftcn	3.50
28554723	C2700217	Functional Relationship	cnce	3.50
28554723	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	68.45
28554723	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	68.45
28554723	C0031843	physiological aspects	phsf	29.46
28554723	C0162695	New Drug Approval	gora	19.35
28554723	C0040363	Togo	geoa	17.80
28554723	C0041260	Tryptophanase	aapp	17.80
28554723	C0041260	Tryptophanase	enzy	17.80
28554723	C0085732	Ability	orga	14.64
28554723	C0162340	Comprehension	menp	13.05
28554723	C0542341	Function	ftcn	10.42
28554723	C0700205	Function Axis	clas	10.42
28554723	C1705273	Mathematical Operator	inpr	10.42
28554723	C0242481	Research Activities	resa	9.78
28554723	C0035168	research	resa	9.78
28554723	C0026882	Mutation	genf	9.74
28554723	C1299581	Able (finding)	fndg	5.18
28554723	C1280477	Progress	ftcn	5.18
28554723	C1883351	To	qlco	5.18
28554723	C1272688	status - In progress	ftcn	5.18
28554723	C1510464	Protein Structure	aapp	3.75
28554723	C0175168	Protein, Organized by Structure	aapp	3.75
28554723	C0015264	Exertion	orgf	3.63
28554723	C0678594	structure	spco	3.63
28554723	C0686907	Consequence of	ftcn	3.59
28554723	C1167622	Binding (Molecular Function)	moft	3.56
28554723	C1145667	Binding action	acty	3.56
28554723	C0332452	defective	ftcn	3.56
28554723	C1881534	Make - Instruction Imperative	ftcn	3.55
28554723	C1881345	LED Therapy	topp	3.54
28554723	C0205448	Two	qnco	3.54
28554723	C1413365	CFTR gene	gngm	3.48
28554723	C0026882	Mutation	genf	19.82
28554723	C1552740	Entity Determiner - specific	inpr	7.13
28554723	C0205369	Specific qualifier value	qlco	7.13
28554723	C0087111	Therapeutic procedure	topp	3.63
28554723	C0470187	Availability of	ftcn	3.59
28554723	C1705285	Mutation Abnormality	comd	3.48
28554723	C1720467	Only - dosing instruction fragment	inpr	3.48
28554723	C0205171	Singular	qnco	3.48
28554723	C0150312	Present	qnco	3.45
28554723	C0449450	Presentation	idcn	3.45
28554723	C0009738	Congo	geoa	16.04
28554723	C2718059	Precision Medicine	topp	13.05
28554723	C0012634	Disease	dsyn	9.77
28554723	C1280500	Effect	qlco	3.61
28554723	C2348382	Effect, Appearance	qlco	3.61
28554723	C0332149	Possible	qlco	3.47
28554723	C2362652	Possible diagnosis	qlco	3.47
28554723	C1705910	Possibly Related to Intervention	qlco	3.47
28554723	C0392747	Changing	ftcn	3.44
28554723	C3811819	CFTR wt Allele	gngm	3.43
28554723	C0205435	First (number)	qnco	3.43
28554723	C1279901	Firstly	qlco	3.43
28554723	C1524059	mechanism of action qualifier	ftcn	13.13
28554723	C0031327	Drug Kinetics	phsf	9.97
28554723	C0678723	Biologic Development	orgf	3.59
28554723	C1527148	Development	ftcn	3.59
28554723	C0243107	development aspects	phsf	3.59
28554723	C1705242	Different	qlco	3.43
28554723	C0205198	Compound	qlco	3.41
28554723	C1706082	Compound (substance)	chem	3.41
28554723	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.36
28554723	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.36
28554723	C0031843	physiological aspects	phsf	12.89
28554723	C1517331	Further	spco	5.18
28554723	C3540027	Adrenergic and dopaminergic agents combinations	phsu	3.56
28554723	C3539975	Aluminium antacid compound combinations	phsu	3.56
28554723	C3539963	Amide local anesthetic combinations	orch	3.56
28554723	C3539963	Amide local anesthetic combinations	phsu	3.56
28554723	C3539979	Antiinfective irrigating solution combinations	phsu	3.56
28554723	C3540722	Beta-lactamase sensitive penicillin combinations	antb	3.56
28554723	C3540722	Beta-lactamase sensitive penicillin combinations	orch	3.56
28554723	C3539977	Calcium antacid compound combinations	phsu	3.56
28554723	C3540720	Caries prophylactic agent combinations	phsu	3.56
28554723	C3539972	Combination solutions for parenteral nutrition	phsu	3.56
28554723	C0453882	Combinations (Undergarment)	mnob	3.56
28554723	C1947976	Correction (change)	ftcn	3.56
28554723	C1705565	Correction Report	inpr	3.56
28554723	C3539968	Enema combinations	phsu	3.56
28554723	C3540026	Hepatitis vaccine combinations	aapp	3.56
28554723	C3540026	Hepatitis vaccine combinations	imft	3.56
28554723	C3540026	Hepatitis vaccine combinations	phsu	3.56
28554723	C3540723	Insulins and analogs for injection, fast-acting combinations	phsu	3.56
28554723	C3539974	Insulins and analogs for injection, intermediate-acting combinations	phsu	3.56
28554723	C3539967	Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations	phsu	3.56
28554723	C3540719	Intermediate-acting sulfonamide combinations	orch	3.56
28554723	C3540719	Intermediate-acting sulfonamide combinations	phsu	3.56
28554723	C3539965	Local hemostatic combinations	phsu	3.56
28554723	C3539959	Long-acting sulfonamide combinations	orch	3.56
28554723	C3539959	Long-acting sulfonamide combinations	phsu	3.56
28554723	C3539956	Magnesium antacid compound combinations	phsu	3.56
28554723	C3854036	Other anti-dementia drug combinations in ATC	phsu	3.56
28554723	C3539973	Other antifungal combinations for topical use in ATC	phsu	3.56
28554723	C3539960	Other intestinal adsorbent combinations in ATC	phsu	3.56
28554723	C3540028	Other irrigating solution combinations in ATC	phsu	3.56
28554723	C3539976	Penicillins with extended spectrum combinations	antb	3.56
28554723	C3539976	Penicillins with extended spectrum combinations	orch	3.56
28554723	C3539961	Platelet aggregation inhibitor combinations excl. heparin	phsu	3.56
28554723	C3540740	Potassium supplement combinations	phsu	3.56
28554723	C3539182	Salt solution combinations	phsu	3.56
28554723	C3539181	Short-acting sulfonamide combinations	orch	3.56
28554723	C3539181	Short-acting sulfonamide combinations	phsu	3.56
28554723	C3539969	Specific immunoglobulin combinations	aapp	3.56
28554723	C3539969	Specific immunoglobulin combinations	imft	3.56
28554723	C3539969	Specific immunoglobulin combinations	phsu	3.56
28554723	C3539970	combination drugs used in erectile dysfunction	phsu	3.56
28554723	C3539978	expectorant combinations excluding combinations with cough suppressants	phsu	3.56
28554723	C3540724	expectorant combinations, excl. combinations with cough suppressants	phsu	3.56
28554723	C3540031	gonadotropin combinations	aapp	3.56
28554723	C3540031	gonadotropin combinations	horm	3.56
28554723	C3540031	gonadotropin combinations	phsu	3.56
28554723	C3539966	insulins and analogs for injection combinations, long-acting	phsu	3.56
28554723	C3539964	local opthalmologic anesthetic combinations	phsu	3.56
28554723	C3539955	lung surfactant combinations	phsu	3.56
28554723	C3539957	opium alkaloids and derivative combination cough suppressants	phsu	3.56
28554723	C3540030	other cough suppressant combinations in ATC	phsu	3.56
28554723	C3540721	other nasal preparation combinations in ATC	phsu	3.56
28554723	C3539971	otologic analgesic and anesthetic combinations	phsu	3.56
28554723	C3539954	topical antibiotic combinations	phsu	3.56
28554723	C3539962	vitamin D and analog combinations	phsu	3.56
28554723	C1413365	CFTR gene	gngm	3.43
28554723	C0542341	Function	ftcn	3.43
28554723	C0700205	Function Axis	clas	3.43
28554723	C1705273	Mathematical Operator	inpr	3.43
28554723	C0205314	New	qlco	3.43
28554723	C0205198	Compound	qlco	3.41
28554723	C1706082	Compound (substance)	chem	3.41
28554723	C0017337	Genes	gngm	32.57
28554723	C0079925	Antisense Oligonucleotides	bacs	24.11
28554723	C0079925	Antisense Oligonucleotides	irda	24.11
28554723	C0079925	Antisense Oligonucleotides	nnon	24.11
28554723	C0242612	Codon, Nonsense	nusq	22.43
28554723	C0040363	Togo	geoa	17.80
28554723	C0041260	Tryptophanase	aapp	17.80
28554723	C0041260	Tryptophanase	enzy	17.80
28554723	C0034754	Reading (activity)	dora	16.07
28554723	C0035696	RNA, Messenger	bacs	12.89
28554723	C0035696	RNA, Messenger	nnon	12.89
28554723	C2349182	Correct (qualifier)	qlco	5.18
28554723	C0332257	Including (qualifier)	ftcn	5.18
28554723	C1883351	To	qlco	5.18
28554723	C0679199	strategy	menp	5.18
28554723	C0868955	editing	ocac	3.68
28554723	C0449445	Approach	spco	3.63
28554723	C1292724	Procedural approach	ftcn	3.63
28554723	C3687832	DRUGS	topp	3.60
28554723	C0013227	Pharmaceutical Preparations	phsu	3.60
28554723	C1457869	Defect	ftcn	3.55
28554723	C0017296	gene therapy	topp	3.53
28554723	C0332452	defective	ftcn	3.50
28554723	C1705179	Reading (datum presentation)	fndg	3.46
28554723	C1527178	Basis - conceptual entity	ftcn	3.42
28554723	C0456079	Disease classification level	clas	3.42
28554723	C1547707	Floor - story of building	geoa	3.42
28554723	C2946261	Level	phsu	3.42
28554723	C0441889	Levels (qualifier value)	qlco	3.42
28554723	C0009738	Congo	geoa	17.80
28554723	C0040363	Togo	geoa	17.80
28554723	C0041260	Tryptophanase	aapp	17.80
28554723	C0041260	Tryptophanase	enzy	17.80
28554723	C0027552	Needs	qlco	14.64
28554723	C3811819	CFTR wt Allele	gngm	5.18
28554723	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
28554723	C1883351	To	qlco	5.18
28554723	C0679199	strategy	menp	5.18
28554723	C0087111	Therapeutic procedure	topp	3.55
28554723	C0683521	patient condition	fndg	3.44
28554723	C0392747	Changing	ftcn	3.41
24039402	C0006267	Bronchiectasis	dsyn	11.49
24039402	C0010674	Cystic Fibrosis	dsyn	10.06
24039402	C0376558	Life	idcn	9.81
24039402	C0036537	Bodily secretions	bdsu	6.71
24039402	C0035245	Respiratory physiology	ortf	6.62
24039402	C0559758	Multisystem disorder	dsyn	5.18
24039402	C0439801	Limited (extensiveness)	ftcn	3.68
24039402	C1859117	Recurrent pulmonary infections	fndg	3.65
24039402	C0332152	Before	tmco	3.56
24039402	C1880022	Characterization	acty	3.56
24039402	C1522538	Leading	ftcn	3.56
24039402	C1280412	Thick	qlco	3.56
24039402	C0868945	deterioration	phpr	3.56
24039402	C0311419	viscous	ftcn	3.56
24039402	C0205329	Progressive	ftcn	3.43
24039402	C0009738	Congo	geoa	32.47
24039402	C0008203	Chlorides	inch	16.05
24039402	C0015127	Etiology aspects	ftcn	9.86
24039402	C0031847	physiopathological	ftcn	9.85
24039402	C0021699	Integral Membrane Proteins	aapp	9.74
24039402	C3811819	CFTR wt Allele	gngm	7.08
24039402	C1159571	water transport	celf	5.18
24039402	C1517945	Loss	qnco	3.59
24039402	C1273518	Responsible to	fndg	3.57
24039402	C1524003	Science of Etiology	cnce	3.55
24039402	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.54
24039402	C3887504	Dysfunction	cnce	3.54
24039402	C0277785	Functional disorder	patf	3.54
24039402	C0596019	Chloride Ion	elii	3.44
24039402	C1704735	Regulator	cnce	3.42
24039402	C1704734	Regulator Device Component	mnob	3.42
24039402	C0182953	Regulators (device)	medd	3.42
24039402	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.03
24039402	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.03
24039402	C0162340	Comprehension	menp	13.01
24039402	C0031847	physiopathological	ftcn	9.73
24039402	C0026882	Mutation	genf	9.73
24039402	C1947931	Direct (qualifier)	qlco	5.18
24039402	C1521840	Target	ftcn	5.18
24039402	C2986546	Target Lesion Identification	diap	5.18
24039402	C0683607	allowing	socb	5.18
24039402	C1457869	Defect	ftcn	3.63
24039402	C0678723	Biologic Development	orgf	3.54
24039402	C1527148	Development	ftcn	3.54
24039402	C0243107	development aspects	phsf	3.54
24039402	C1413365	CFTR gene	gngm	3.48
24039402	C1328819	Small Molecule	orch	3.44
24039402	C1561611	Admission Level of Care Code - Improved	inpr	3.42
24039402	C0332272	Better	qlco	3.42
24039402	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.42
24039402	C3887504	Dysfunction	cnce	3.42
24039402	C0277785	Functional disorder	patf	3.42
24039402	C0184511	Improved	qlco	3.42
24039402	C1552740	Entity Determiner - specific	inpr	3.42
24039402	C1705285	Mutation Abnormality	comd	3.42
24039402	C0205369	Specific qualifier value	qlco	3.42
24039402	C0205198	Compound	qlco	3.40
24039402	C1706082	Compound (substance)	chem	3.40
24039402	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.39
24039402	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.39
24039402	C0233324	Term Birth	orgf	22.38
24039402	C0040363	Togo	geoa	17.80
24039402	C0041260	Tryptophanase	aapp	17.80
24039402	C0041260	Tryptophanase	enzy	17.80
24039402	C0009738	Congo	geoa	16.04
24039402	C3264621	ivacaftor	orch	13.14
24039402	C3264621	ivacaftor	phsu	13.14
24039402	C0023636	License	rnlw	12.88
24039402	C0242373	Licensing	gora	12.88
24039402	C0012634	Disease	dsyn	9.78
24039402	C0026882	Mutation	genf	9.77
24039402	C0030705	Patients	podg	6.57
24039402	C1521840	Target	ftcn	5.18
24039402	C2986546	Target Lesion Identification	diap	5.18
24039402	C1883351	To	qlco	5.18
24039402	C3245505	potential	qlco	5.18
24039402	C0392747	Changing	ftcn	3.59
24039402	C0205198	Compound	qlco	3.54
24039402	C1706082	Compound (substance)	chem	3.54
24039402	C1413365	CFTR gene	gngm	3.47
24039402	C1705285	Mutation Abnormality	comd	3.47
24039402	C2826302	Reported Term	inpr	3.45
24039402	C1705313	Term (lexical)	idcn	3.45
24039402	C1515273	Term (temporal)	tmco	3.45
24039402	C1328819	Small Molecule	orch	3.43
24039402	C3811819	CFTR wt Allele	gngm	3.42
24039402	C0205435	First (number)	qnco	3.42
24039402	C1279901	Firstly	qlco	3.42
24039402	C1548573	Licensed - Location characteristic ID	inpr	3.42
24039402	C3889832	Licensed as Wholesale Drug Distributor or Third Party Logistics Provider	qlco	3.42
24039402	C0043094	Weight Gain	fndg	27.26
24039402	C0233324	Term Birth	orgf	22.45
24039402	C0008976	Clinical Trials	resa	20.95
24039402	C3264621	ivacaftor	orch	13.14
24039402	C3264621	ivacaftor	phsu	13.14
24039402	C0034380	Quality of life	idcn	12.93
24039402	C1096775	Clinical Trial [Publication Type]	inpr	11.49
24039402	C0035245	Respiratory physiology	ortf	8.34
24039402	C0392756	Reduced	qlco	7.06
24039402	C1550718	Entity Name Part Type - given	idcn	5.18
24039402	C1442162	GIVEN	cnce	5.18
24039402	C1947971	Give - dosing instruction imperative	ftcn	5.18
24039402	C3244317	Given name	inpr	5.18
24039402	C0585361	Twice a day	tmco	5.18
24039402	C2911647	Weight Gain Adverse Event	fndg	5.18
24039402	C0175795	oral medication	topp	5.18
24039402	C1547282	Show	anim	3.98
24039402	C0428295	Cystic fibrosis sweat test	lbpr	3.75
24039402	C1304760	Sweat chloride level result	lbtr	3.75
24039402	C0442805	Increase	ftcn	3.55
24039402	C0301630	Reduction (chemical)	npop	3.55
24039402	C0441610	Reduction - action	topp	3.55
24039402	C0814225	benefit	qnco	3.55
24039402	C2986411	Improvement	cnce	3.55
24039402	C2826302	Reported Term	inpr	3.52
24039402	C1705313	Term (lexical)	idcn	3.52
24039402	C1515273	Term (temporal)	tmco	3.52
24039402	C0205216	Decreased	qnco	3.48
24039402	C0442797	Decreasing	qlco	3.48
24039402	C0518214	Perceived quality of life	sosy	3.47
24039402	C0588446	Informing patient	hlca	3.44
24039402	C0449788	Count of entities	qnco	3.43
24039402	C0237753	Numbers	qnco	3.43
24039402	C1546767	Specimen Source Codes - Respiratory	inpr	3.43
24039402	C0521346	respiratory	ftcn	3.43
24039402	C3264621	ivacaftor	orch	26.56
24039402	C3264621	ivacaftor	phsu	26.56
24039402	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24039402	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24039402	C0009738	Congo	geoa	16.16
24039402	C0211067	PAVe protocol 1	topp	14.64
24039402	C0023636	License	rnlw	13.05
24039402	C0242373	Licensing	gora	13.05
24039402	C0026882	Mutation	genf	9.91
24039402	C0042153	utilization qualifier	ftcn	9.90
24039402	C1257890	Population Group	popg	9.86
24039402	C0030705	Patients	podg	6.83
24039402	C0032659	geographic population	qnco	6.70
24039402	C0521116	Current (present time)	tmco	5.18
24039402	C1720467	Only - dosing instruction fragment	inpr	5.18
24039402	C0205171	Singular	qnco	5.18
24039402	C0814225	benefit	qnco	5.18
24039402	C1704259	Biochemical Pathway	moft	3.68
24039402	C1705987	Pathway (interactions)	cnce	3.68
24039402	C1705285	Mutation Abnormality	comd	3.60
24039402	C1272684	Accepted	qlco	3.59
24039402	C0443211	Established	qlco	3.59
24039402	C1548573	Licensed - Location characteristic ID	inpr	3.59
24039402	C3889832	Licensed as Wholesale Drug Distributor or Third Party Logistics Provider	qlco	3.59
24039402	C0457083	Usage	ftcn	3.59
24039402	C1947944	Use - dosing instruction imperative	inpr	3.59
24039402	C0332232	Approximate	qlco	3.55
24039402	C3811819	CFTR wt Allele	gngm	3.55
24039402	C0678723	Biologic Development	orgf	3.50
24039402	C0458003	Developmental (qualifier value)	qlco	3.50
24039402	C0205172	More	ftcn	3.50
24039402	C0205447	One	qnco	3.46
24039402	C1413365	CFTR gene	gngm	3.43
24039402	C1709060	Modulator Device Component	mnob	3.41
24039402	C0039798	therapeutic aspects	ftcn	22.48
24039402	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
24039402	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
24039402	C0040363	Togo	geoa	17.80
24039402	C0041260	Tryptophanase	aapp	17.80
24039402	C0041260	Tryptophanase	enzy	17.80
24039402	C0009738	Congo	geoa	16.18
24039402	C1511760	Deletion Mutation	genf	12.88
24039402	C0012634	Disease	dsyn	9.87
24039402	C1257890	Population Group	popg	9.87
24039402	C0032659	geographic population	qnco	6.71
24039402	C1883351	To	qlco	5.18
24039402	C0683607	allowing	socb	5.18
24039402	C3842582	90%	fndg	3.56
24039402	C0439087	<90	qnco	3.56
24039402	C0439083	>90	qnco	3.56
24039402	C1533734	Administration procedure	topp	3.56
24039402	C1705169	Biomaterial Treatment	cnce	3.56
24039402	C3811819	CFTR wt Allele	gngm	3.56
24039402	C0087111	Therapeutic procedure	topp	3.56
24039402	C1522326	Treating	ftcn	3.56
24039402	C3538994	Treatment Epoch	resa	3.56
24039402	C0814225	benefit	qnco	3.56
24039402	C3887704	treatment - ActInformationManagementReason	hlca	3.56
24039402	C1709060	Modulator Device Component	mnob	3.54
24039402	C0392747	Changing	ftcn	3.53
24039402	C1413365	CFTR gene	gngm	3.42
24039402	C1880274	Deletion (action)	acty	3.42
24039402	C1442161	Gene Deletion Abnormality	comd	3.42
26115565	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.41
26115565	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.41
26115565	C0032214	Play	dora	14.64
26115565	C0035820	Social Role	socb	13.00
26115565	C0005528	Biological Transport	celf	11.49
26115565	C0015127	Etiology aspects	ftcn	11.49
26115565	C0010674	Cystic Fibrosis	dsyn	9.74
26115565	C0022023	Ions	elii	9.74
26115565	C0600138	Does play	fndg	5.18
26115565	C3495449	Mobility aid	medd	5.18
26115565	C1524003	Science of Etiology	cnce	5.18
26115565	C1317949	transport (device)	mnob	5.18
26115565	C0596611	Gene Mutation	genf	3.56
26115565	C1457869	Defect	ftcn	3.55
26115565	C1705810	Generic Role	cnce	3.54
26115565	C3871154	{Role}	inpr	3.54
26115565	C1413365	CFTR gene	gngm	3.48
26115565	C1521970	Characteristics	qlco	3.43
26115565	C1700702	Iontophoresis Route of Drug Administration	ftcn	3.43
26115565	C0221908	epithelial	qlco	3.43
26115565	C0205099	Central	spco	3.42
26115565	C1879652	Central Minus	lbpr	3.42
26115565	C0699748	Pathogenesis	patf	3.42
26115565	C0543483	pathogenic aspects	ftcn	3.42
26115565	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.10
26115565	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.10
26115565	C0039798	therapeutic aspects	ftcn	22.47
26115565	C0162585	Ion Transport	celf	12.91
26115565	C1314792	Etiology	ftcn	12.87
26115565	C0022023	Ions	elii	9.99
26115565	C0031847	physiopathological	ftcn	9.88
26115565	C0031330	Pharmacology	bmod	9.73
26115565	C0376558	Life	idcn	9.73
26115565	C1413365	CFTR gene	gngm	7.02
26115565	C0439799	Channel	spco	5.18
26115565	C1706095	Channel Object	cnce	5.18
26115565	C0205166	Long	qlco	5.18
26115565	C1706317	Long Variable	qlco	5.18
26115565	C1700702	Iontophoresis Route of Drug Administration	ftcn	3.68
26115565	C0205432	Compensated	qlco	3.57
26115565	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.57
26115565	C3887504	Dysfunction	cnce	3.57
26115565	C0277785	Functional disorder	patf	3.57
26115565	C0449445	Approach	spco	3.56
26115565	C2346874	Attractive	qlco	3.56
26115565	C1521840	Target	ftcn	3.56
26115565	C0750591	consider	idcn	3.56
26115565	C1947976	Correction (change)	ftcn	3.55
26115565	C1705565	Correction Report	inpr	3.55
26115565	C0087111	Therapeutic procedure	topp	3.54
26115565	C1363945	Therapy Object (animal model)	fndg	3.54
26115565	C1523987	Alternative	cnce	3.50
26115565	C0596988	mutant	comd	3.43
26115565	C1457869	Defect	ftcn	3.42
26115565	C0205464	pharmacological	ftcn	3.42
26115565	C0439801	Limited (extensiveness)	ftcn	3.42
26115565	C0039798	therapeutic aspects	ftcn	22.47
26115565	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
26115565	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
26115565	C0009738	Congo	geoa	16.05
26115565	C0030705	Patients	podg	13.35
26115565	C0162585	Ion Transport	celf	12.90
26115565	C3264621	ivacaftor	orch	12.88
26115565	C3264621	ivacaftor	phsu	12.88
26115565	C0026882	Mutation	genf	9.94
26115565	C2347129	Milestone	cnce	3.68
26115565	C1875307	INTRODUCTION device	mnob	3.54
26115565	C1293116	Introduction procedure	hlca	3.54
26115565	C0234402	Stimulus	phpr	3.54
26115565	C0087111	Therapeutic procedure	topp	3.54
26115565	C1363945	Therapy Object (animal model)	fndg	3.54
26115565	C0205164	Major	qlco	3.50
26115565	C0205082	Severe (severity modifier)	qlco	3.50
26115565	C1413365	CFTR gene	gngm	3.48
26115565	C1552740	Entity Determiner - specific	inpr	3.48
26115565	C0205369	Specific qualifier value	qlco	3.48
26115565	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.44
26115565	C3811819	CFTR wt Allele	gngm	3.43
26115565	C1704419	Effective	qlco	3.42
26115565	C1280519	Effectiveness	qlco	3.42
26115565	C0332185	Recent	tmco	3.42
26115565	C1515021	Subgroup	clas	3.42
26115565	C1079230	Subgroup A Nepoviruses	virs	3.42
26115565	C1709060	Modulator Device Component	mnob	3.40
26115565	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	45.18
26115565	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	45.18
26115565	C0040363	Togo	geoa	17.80
26115565	C0041260	Tryptophanase	aapp	17.80
26115565	C0041260	Tryptophanase	enzy	17.80
26115565	C0282443	Review [Publication Type]	inpr	11.49
26115565	C0026882	Mutation	genf	9.78
26115565	C1413365	CFTR gene	gngm	7.11
26115565	C1552617	Act Class - review	idcn	5.18
26115565	C2584313	Discussion (communication)	socb	5.18
26115565	C0332257	Including (qualifier)	ftcn	5.18
26115565	C1883351	To	qlco	5.18
26115565	C2983265	CDISC SEND Study Design Terminology	inpr	3.98
26115565	C1707689	Design	acty	3.98
26115565	C0444503	Breakthrough	qlco	3.68
26115565	C0332185	Recent	tmco	3.50
26115565	C0596988	mutant	comd	3.50
26115565	C0205214	Common (qualifier value)	qnco	3.48
26115565	C3245511	Common Specifications in HL7 V3 Publishing	inpr	3.48
26115565	C1705285	Mutation Abnormality	comd	3.48
26115565	C1522138	shared attribute	ftcn	3.48
26115565	C1709060	Modulator Device Component	mnob	3.42
26115565	C0009738	Congo	geoa	32.70
26115565	C0384156	epithelial sodium channel	aapp	22.38
26115565	C0026565	Mortality Vital Statistics	qnco	19.36
26115565	C0026538	Morbidity - disease rate	qnco	19.20
26115565	C0008203	Chlorides	inch	16.30
26115565	C0026566	Aspects of mortality statistics	qnco	9.90
26115565	C0015127	Etiology aspects	ftcn	9.87
26115565	C3811819	CFTR wt Allele	gngm	7.31
26115565	C1523987	Alternative	cnce	6.96
26115565	C0024115	Lung diseases	dsyn	6.91
26115565	C0030705	Patients	podg	6.60
26115565	C1427656	ANO1 gene	gngm	5.18
26115565	C3889446	ANO1 wt Allele	gngm	5.18
26115565	C0439799	Channel	spco	5.18
26115565	C1706095	Channel Object	cnce	5.18
26115565	C1422675	SLC26A9 gene	gngm	5.18
26115565	C0596019	Chloride Ion	elii	3.68
26115565	C1517331	Further	spco	3.68
26115565	C0205164	Major	qlco	3.56
26115565	C1524003	Science of Etiology	cnce	3.56
26115565	C0205082	Severe (severity modifier)	qlco	3.56
26115565	C3540429	epithelial sodium channel activity	moft	3.46
26115565	C0220880	morbidity aspects	inpr	3.43
26115565	C1521840	Target	ftcn	3.40
26115565	C2986546	Target Lesion Identification	diap	3.40
26115565	C0040363	Togo	geoa	35.81
26115565	C0041260	Tryptophanase	aapp	35.81
26115565	C0041260	Tryptophanase	enzy	35.81
26115565	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26115565	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26115565	C0009738	Congo	geoa	16.16
26115565	C0027552	Needs	qlco	14.64
26115565	C0162585	Ion Transport	celf	12.95
26115565	C1883351	To	qlco	10.42
26115565	C0030705	Patients	podg	6.59
26115565	C0017431	Genotype	orga	6.58
26115565	C1881534	Make - Instruction Imperative	ftcn	5.18
26115565	C2983310	Overcome	acty	5.18
26115565	C0686904	Patient need for (contextual qualifier)	ftcn	5.18
26115565	C0087111	Therapeutic procedure	topp	3.60
26115565	C0470187	Availability of	ftcn	3.57
26115565	C0205234	Focal	spco	3.57
26115565	C1285542	Has focus	ftcn	3.57
26115565	C3811819	CFTR wt Allele	gngm	3.55
26115565	C1704419	Effective	qlco	3.46
26115565	C1280519	Effectiveness	qlco	3.46
26115565	C0443264	Modulated	spco	3.46
26115565	C1413365	CFTR gene	gngm	3.42
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	24.11
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	24.11
27402691	C0034851	Conditions, Recessive Genetic	biof	19.58
27402691	C0015127	Etiology aspects	ftcn	10.28
27402691	C0010674	Cystic Fibrosis	dsyn	10.06
27402691	C0026882	Mutation	genf	9.87
27402691	C1413365	CFTR gene	gngm	5.18
27402691	C1524003	Science of Etiology	cnce	3.98
27402691	C1705285	Mutation Abnormality	comd	3.56
27402691	C3151529	Lethal	fndg	3.47
27402691	C0041714	United States Food and Drug Administration	hcro	25.65
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
27402691	C0009738	Congo	geoa	16.05
27402691	C0026882	Mutation	genf	9.78
27402691	C2741958	VX-770	orch	3.75
27402691	C1709060	Modulator Device Component	mnob	3.63
27402691	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.58
27402691	C3242455	HL7PublishingDomain <patient administration>	inpr	3.58
27402691	C3242279	healthcare operations <patient administration>	ocac	3.58
27402691	C0205540	Approved	qlco	3.57
27402691	C1413365	CFTR gene	gngm	3.48
27402691	C0205435	First (number)	qnco	3.48
27402691	C1279901	Firstly	qlco	3.48
27402691	C1705285	Mutation Abnormality	comd	3.48
27402691	C3811819	CFTR wt Allele	gngm	3.43
27402691	C0009738	Congo	geoa	16.17
27402691	C0019904	Homozygote	orga	9.90
27402691	C0185026	Plication	topp	5.18
27402691	C4033620	ORKAMBI	phsu	3.68
27402691	C2741958	VX-770	orch	3.68
27402691	C0243067	defects aspect	ftcn	3.68
27402691	C2700400	Contain (action)	acty	3.61
27402691	C0332256	Containing (qualifier)	ftcn	3.61
27402691	C0013227	Pharmaceutical Preparations	phsu	3.61
27402691	C1254351	Pharmacologic Substance	phsu	3.61
27402691	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.56
27402691	C3242455	HL7PublishingDomain <patient administration>	inpr	3.56
27402691	C3242279	healthcare operations <patient administration>	ocac	3.56
27402691	C0205540	Approved	qlco	3.55
27402691	C3811819	CFTR wt Allele	gngm	3.55
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.34
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.34
27402691	C0026882	Mutation	genf	19.58
27402691	C0002085	Alleles	gngm	19.19
27402691	C0009738	Congo	geoa	16.16
27402691	C0019425	Heterozygote	orga	9.87
27402691	C0030705	Patients	podg	6.70
27402691	C3842588	30%	fndg	3.55
27402691	C3811819	CFTR wt Allele	gngm	3.55
27402691	C2700640	Encode (action)	acty	3.54
27402691	C1547699	MIME encoding	idcn	3.54
27402691	C1705285	Mutation Abnormality	comd	3.43
27402691	C1413365	CFTR gene	gngm	3.42
27402691	C1705242	Different	qlco	3.42
27402691	C0521114	Infrequent	tmco	3.42
27402691	C0205447	One	qnco	3.42
27402691	C0522498	Rare	qlco	3.42
27402691	C1514917	Retinoic Acid Response Element	gngm	3.42
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.48
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.48
27402691	C0039798	therapeutic aspects	ftcn	22.48
27402691	C0019425	Heterozygote	orga	19.65
27402691	C0040363	Togo	geoa	17.80
27402691	C0041260	Tryptophanase	aapp	17.80
27402691	C0041260	Tryptophanase	enzy	17.80
27402691	C0030705	Patients	podg	6.83
27402691	C1883351	To	qlco	5.18
27402691	C3252847	VX 809	orch	5.18
27402691	C3252847	VX 809	phsu	5.18
27402691	C2741958	VX-770	orch	5.18
27402691	C0597535	Success	socb	3.68
27402691	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.56
27402691	C3242455	HL7PublishingDomain <patient administration>	inpr	3.56
27402691	C3242279	healthcare operations <patient administration>	ocac	3.56
27402691	C1413365	CFTR gene	gngm	3.56
27402691	C1709060	Modulator Device Component	mnob	3.56
27402691	C0087111	Therapeutic procedure	topp	3.56
27402691	C1363945	Therapy Object (animal model)	fndg	3.56
27402691	C0439801	Limited (extensiveness)	ftcn	3.50
27402691	C4050251	Limited Lifting Ability	inpr	3.50
27402691	C2674459	Limited Walking Ability	fndg	3.50
27402691	C3542948	Limited component (foundation metadata concept)	inpr	3.50
27402691	C0033105	Statistical Prevalence	qnco	22.34
27402691	C0009738	Congo	geoa	16.16
27402691	C0026882	Mutation	genf	9.92
27402691	C0030705	Patients	podg	6.70
27402691	C1705285	Mutation Abnormality	comd	3.61
27402691	C3811819	CFTR wt Allele	gngm	3.55
27402691	C0150312	Present	qnco	3.55
27402691	C0521114	Infrequent	tmco	3.47
27402691	C0205172	More	ftcn	3.47
27402691	C0522498	Rare	qlco	3.47
27402691	C1514917	Retinoic Acid Response Element	gngm	3.47
27402691	C0220900	Prevalence aspects	qnco	3.42
27402691	C0039798	therapeutic aspects	ftcn	22.35
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27402691	C0009738	Congo	geoa	16.08
27402691	C0030705	Patients	podg	6.77
27402691	C1292732	Investigates	ftcn	5.18
27402691	C0557651	Room of building - Study	mnob	5.18
27402691	C2603343	Study	resa	5.18
27402691	C3826168	Human physiology	bmod	3.56
27402691	C1280519	Effectiveness	qlco	3.54
27402691	C3811819	CFTR wt Allele	gngm	3.47
27402691	C3252847	VX 809	orch	3.44
27402691	C3252847	VX 809	phsu	3.44
27402691	C2741958	VX-770	orch	3.44
27402691	C1711178	Bronchial Epithelial Cell	cell	3.43
27402691	C0087111	Therapeutic procedure	topp	3.42
27402691	C1363945	Therapy Object (animal model)	fndg	3.42
27402691	C1413365	CFTR gene	gngm	3.42
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27402691	C1415484	HBE1 gene	gngm	7.01
27402691	C2827566	HBE1 wt Allele	gngm	7.01
27402691	C0150312	Present	qnco	5.18
27402691	C1948023	Stimulation (motivation)	npop	5.18
27402691	C3252847	VX 809	orch	5.18
27402691	C3252847	VX 809	phsu	5.18
27402691	C1561536	*Activity (kind of quantity)	idcn	3.55
27402691	C0205177	Active	ftcn	3.55
27402691	C0441655	Activities	acty	3.55
27402691	C3668946	Activity (animal life circumstance)	fndg	3.55
27402691	C4049939	FDA Establishment Activity Terminology	inpr	3.55
27402691	C0439167	Percent Activity	qnco	3.55
27402691	C4049938	Physical Activity Measurement	lbpr	3.55
27402691	C1413365	CFTR gene	gngm	3.42
27402691	C0205172	More	ftcn	3.42
27402691	C0015272	Exhibits as Topic	inpr	16.59
27402691	C1881707	Medical Device Material Degradation	phpr	5.18
27402691	C1457869	Defect	ftcn	3.68
27402691	C3810541	Adverse Event Emergency Room Visit	inbe	3.57
27402691	C3811131	Estrogen Receptor Measurement	lbpr	3.57
27402691	C1415484	HBE1 gene	gngm	3.57
27402691	C2827566	HBE1 wt Allele	gngm	3.57
27402691	C2826170	Immortalization	mbrt	3.57
27402691	C0333118	Retained	ftcn	3.57
27402691	C0185026	Plication	topp	3.50
27402691	C0031843	physiological aspects	phsf	13.09
27402691	C0205202	Corrected	qlco	5.18
27402691	C3252847	VX 809	orch	3.75
27402691	C3252847	VX 809	phsu	3.75
27402691	C1457869	Defect	ftcn	3.63
27402691	C0542341	Function	ftcn	3.63
27402691	C0700205	Function Axis	clas	3.63
27402691	C1705273	Mathematical Operator	inpr	3.63
27402691	C0439799	Channel	spco	3.48
27402691	C1706095	Channel Object	cnce	3.48
27402691	C0185026	Plication	topp	3.48
27402691	C0079613	Adoptive Immunotherapy	topp	26.06
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27402691	C0040363	Togo	geoa	17.80
27402691	C0041260	Tryptophanase	aapp	17.80
27402691	C0041260	Tryptophanase	enzy	17.80
27402691	C1869853	SERPINA3 protein, human	aapp	13.44
27402691	C1869853	SERPINA3 protein, human	bacs	13.44
27402691	C0022023	Ions	elii	9.88
27402691	C1883351	To	qlco	5.18
27402691	C2741958	VX-770	orch	5.18
27402691	C4048375	Asthma Control Test Questionnaire	inpr	3.98
27402691	C3890007	SERPINA3 wt Allele	gngm	3.98
27402691	C3252847	VX 809	orch	3.64
27402691	C3252847	VX 809	phsu	3.64
27402691	C1314939	Involvement with	ftcn	3.57
27402691	C1700702	Iontophoresis Route of Drug Administration	ftcn	3.57
27402691	C0007613	Cell physiology	celf	3.55
27402691	C1413365	CFTR gene	gngm	3.42
27402691	C1522326	Treating	ftcn	3.42
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27402691	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27402691	C0031843	physiological aspects	phsf	12.89
27402691	C0030705	Patients	podg	8.34
27402691	C0205540	Approved	qlco	5.18
27402691	C4033620	ORKAMBI	phsu	5.18
27402691	C0947630	Scientific Study	lbpr	5.18
27402691	C2741958	VX-770	orch	5.18
27402691	C1554093	HL7CommitteeIDInRIM <Patient Administration>	inpr	3.60
27402691	C3242455	HL7PublishingDomain <patient administration>	inpr	3.60
27402691	C3242279	healthcare operations <patient administration>	ocac	3.60
27402691	C1413365	CFTR gene	gngm	3.42
27402691	C0542341	Function	ftcn	3.42
27402691	C0700205	Function Axis	clas	3.42
27402691	C1705273	Mathematical Operator	inpr	3.42
27402691	C0205172	More	ftcn	3.42
26322933	C0039798	therapeutic aspects	ftcn	22.48
26322933	C0010674	Cystic Fibrosis	dsyn	9.77
26322933	C0087111	Therapeutic procedure	topp	3.56
26322933	C1363945	Therapy Object (animal model)	fndg	3.56
26322933	C1444637	Past	tmco	3.55
26322933	C1272688	status - In progress	ftcn	3.55
26322933	C2981279	Decade	qnco	3.52
26322933	C0679560	Genetic screening method	lbpr	16.26
26322933	C0009738	Congo	geoa	16.04
26322933	C0015127	Etiology aspects	ftcn	9.85
26322933	C0031847	physiopathological	ftcn	9.73
26322933	C0332285	Within	spco	3.57
26322933	C1280477	Progress	ftcn	3.56
26322933	C1272688	status - In progress	ftcn	3.56
26322933	C1524003	Science of Etiology	cnce	3.54
26322933	C3854260	Advance	tmco	3.54
26322933	C0725066	Advance -- medical device	medd	3.54
26322933	C3811819	CFTR wt Allele	gngm	3.42
26322933	C3887505	DYSFUNCTION - SKIN DISORDERS	dsyn	3.42
26322933	C3887504	Dysfunction	cnce	3.42
26322933	C0277785	Functional disorder	patf	3.42
26322933	C1704735	Regulator	cnce	3.42
26322933	C1704734	Regulator Device Component	mnob	3.42
26322933	C0182953	Regulators (device)	medd	3.42
26322933	C2752508	fully spanning the plasma membrane	celc	3.42
26322933	C1167322	integral to membrane	celc	3.42
26322933	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
26322933	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
26322933	C0009738	Congo	geoa	16.05
26322933	C0376636	Disease Management	hlca	9.88
26322933	C0026882	Mutation	genf	9.87
26322933	C0805586	Challenge	hlca	5.18
26322933	C0798503	Challenge:Type:Point in time:^Patient:Nominal	clna	5.18
26322933	C3274764	Proficiency Testing Challenge	cnce	5.18
26322933	C1413365	CFTR gene	gngm	3.68
26322933	C0001554	Administration occupational activities	ocac	3.57
26322933	C3273539	Management Occupations	ocdi	3.57
26322933	C1273870	Management procedure	ocac	3.57
26322933	C0205172	More	ftcn	3.56
26322933	C0681749	1900s	tmco	3.53
26322933	C1280014	Faulty	qlco	3.50
26322933	C3811819	CFTR wt Allele	gngm	3.44
26322933	C0041714	United States Food and Drug Administration	hcro	25.75
26322933	C0233324	Term Birth	orgf	22.90
26322933	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.43
26322933	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.43
26322933	C0012634	Disease	dsyn	9.87
26322933	C0332185	Recent	tmco	5.18
26322933	C1521840	Target	ftcn	5.18
26322933	C2986546	Target Lesion Identification	diap	5.18
26322933	C2826302	Reported Term	inpr	3.98
26322933	C1705313	Term (lexical)	idcn	3.98
26322933	C1515273	Term (temporal)	tmco	3.98
26322933	C1457869	Defect	ftcn	3.68
26322933	C1709060	Modulator Device Component	mnob	3.63
26322933	C3687832	DRUGS	topp	3.61
26322933	C0013227	Pharmaceutical Preparations	phsu	3.61
26322933	C0205540	Approved	qlco	3.55
26322933	C1413365	CFTR gene	gngm	3.50
26322933	C0314603	Genetic	ftcn	3.50
26322933	C0017296	gene therapy	topp	3.50
26322933	C0443264	Modulated	spco	3.43
26322933	C0683243	innovativeness	menp	3.42
26322933	C0040363	Togo	geoa	17.80
26322933	C0041260	Tryptophanase	aapp	17.80
26322933	C0041260	Tryptophanase	enzy	17.80
26322933	C0031831	Physicians	prog	13.01
26322933	C0282443	Review [Publication Type]	inpr	11.49
26322933	C1552617	Act Class - review	idcn	5.18
26322933	C1706050	Guide Device Component	mnob	5.18
26322933	C0302614	Guide device	medd	5.18
26322933	C0181090	Professional guide	prog	5.18
26322933	C0359589	Provide (product)	food	5.18
26322933	C1999230	Providing (action)	acty	5.18
26322933	C1883351	To	qlco	5.18
26322933	C0240320	medication use	fndg	3.60
26322933	C1516596	Classification Scheme	cnce	3.44
26322933	C1272684	Accepted	qlco	3.42
26322933	C0443211	Established	qlco	3.42
26322933	C0205352	Simple	qlco	3.42
26322933	C0039798	therapeutic aspects	ftcn	45.08
26322933	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
26322933	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
26322933	C0040363	Togo	geoa	17.80
26322933	C0041260	Tryptophanase	aapp	17.80
26322933	C0041260	Tryptophanase	enzy	17.80
26322933	C0026882	Mutation	genf	9.73
26322933	C0030705	Patients	podg	8.34
26322933	C0087111	Therapeutic procedure	topp	7.01
26322933	C1883351	To	qlco	5.18
26322933	C2986411	Improvement	cnce	3.63
26322933	C0457165	Class 6	inpr	3.60
26322933	C0470187	Availability of	ftcn	3.56
26322933	C1709450	Pair	qlco	3.56
26322933	C0205463	Physiological	ftcn	3.56
26322933	C1363945	Therapy Object (animal model)	fndg	3.56
26322933	C0805586	Challenge	hlca	3.55
26322933	C0798503	Challenge:Type:Point in time:^Patient:Nominal	clna	3.55
26322933	C3274764	Proficiency Testing Challenge	cnce	3.55
26322933	C0542341	Function	ftcn	3.48
26322933	C0205245	Functional	ftcn	3.48
26322933	C2700217	Functional Relationship	cnce	3.48
26322933	C0205393	Most	qnco	3.48
26322933	C1533734	Administration procedure	topp	3.42
26322933	C1705169	Biomaterial Treatment	cnce	3.42
26322933	C1413365	CFTR gene	gngm	3.42
26322933	C1522326	Treating	ftcn	3.42
26322933	C3538994	Treatment Epoch	resa	3.42
26322933	C3887704	treatment - ActInformationManagementReason	hlca	3.42
26322933	C0681749	1900s	tmco	3.40
26322933	C0039798	therapeutic aspects	ftcn	22.39
26322933	C0085421	Drug Monitoring	hlca	13.17
26322933	C0001688	aspects of adverse effects	ftcn	11.49
26322933	C0013217	pharmacotherapeutic	ftcn	9.81
26322933	C0013216	Pharmacotherapy	topp	6.66
26322933	C0879626	Adverse effects	patf	5.18
26322933	C0750591	consider	idcn	5.18
26322933	C1516647	Clinical Trials, Monitoring	resa	3.61
26322933	C1283169	Monitoring - action	hlca	3.61
26322933	C0150369	Preventive monitoring	hlca	3.61
26322933	C0392360	Indication of (contextual qualifier)	idcn	3.59
26322933	C0087111	Therapeutic procedure	topp	3.47
26322933	C1363945	Therapy Object (animal model)	fndg	3.47
26322933	C0457454	Discontinuation (procedure)	hlca	3.45
26322933	C1444662	Discontinued	fndg	3.45
26209275	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	44.96
26209275	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	44.96
26209275	C3850123	Clinical Effectiveness	qlco	19.34
26209275	C0040363	Togo	geoa	17.80
26209275	C0041260	Tryptophanase	aapp	17.80
26209275	C0041260	Tryptophanase	enzy	17.80
26209275	C0043240	Wound Healing	orgf	14.64
26209275	C1413365	CFTR gene	gngm	6.89
26209275	C0439799	Channel	spco	5.18
26209275	C1706095	Channel Object	cnce	5.18
26209275	C2700399	Include (action)	acty	5.18
26209275	C0332257	Including (qualifier)	ftcn	5.18
26209275	C2983310	Overcome	acty	5.18
26209275	C0374711	Surgical repair	topp	5.18
26209275	C1883351	To	qlco	5.18
26209275	C1552866	include - SetOperator	idcn	5.18
26209275	C0015264	Exertion	orgf	3.98
26209275	C0678723	Biologic Development	orgf	3.56
26209275	C1527148	Development	ftcn	3.56
26209275	C0243107	development aspects	phsf	3.56
26209275	C1457869	Defect	ftcn	3.55
26209275	C0567416	Molecule	sbst	3.43
26209275	C0302350	Therapeutic	ftcn	3.43
26209275	C0087111	Therapeutic procedure	topp	3.43
26209275	C0596988	mutant	comd	3.43
26209275	C0332452	defective	ftcn	3.42
26209275	C1709060	Modulator Device Component	mnob	3.40
26209275	C0020792	Identification (Psychology)	menp	13.00
26209275	C0030705	Patients	podg	6.59
26209275	C3264627	Kalydeco	phsu	5.18
26209275	C1883727	Taken	cnce	5.18
26209275	C0470187	Availability of	ftcn	3.57
26209275	C2741958	VX-770	orch	3.56
26209275	C0439780	Forward	spco	3.54
26209275	C0205396	Identified	qlco	3.54
26209275	C1704243	Greater	qnco	3.50
26209275	C0549177	Large	qnco	3.50
26209275	C1948052	Now (temporal qualifier)	tmco	3.44
26209275	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
26209275	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
26209275	C1514562	Protein Domain	amas	19.37
26209275	C0040363	Togo	geoa	17.80
26209275	C0041260	Tryptophanase	aapp	17.80
26209275	C0041260	Tryptophanase	enzy	17.80
26209275	C1521840	Target	ftcn	5.18
26209275	C1883351	To	qlco	5.18
26209275	C1705535	suggestion	idcn	3.98
26209275	C1413365	CFTR gene	gngm	3.68
26209275	C0459205	Type of activity	inpr	3.62
26209275	C0205198	Compound	qlco	3.59
26209275	C1706082	Compound (substance)	chem	3.59
26209275	C1328819	Small Molecule	orch	3.58
26209275	C1948023	Stimulation (motivation)	npop	3.57
26209275	C1292856	Stimulation procedure	topp	3.57
26209275	C2698977	Capability	qlco	3.52
26209275	C0596988	mutant	comd	3.50
26209275	C1153410	channel activity	moft	3.48
26209275	C1880371	Diversity	qlco	3.48
26209275	C0220807	Chemical Structure	inpr	3.44
26209275	C0445392	Wild	inpr	3.43
26209275	C1705242	Different	qlco	3.42
26209275	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.61
26209275	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.61
26209275	C0205198	Compound	qlco	8.00
26209275	C1706082	Compound (substance)	chem	8.00
26209275	C1515974	Anatomic Site	blor	5.18
26209275	C1167622	Binding (Molecular Function)	moft	5.18
26209275	C1145667	Binding action	acty	5.18
26209275	C1550043	Container status - Identified	fndg	5.18
26209275	C0205396	Identified	qlco	5.18
26209275	C0205145	Site	spco	5.18
26209275	C2825164	Study Site	spco	5.18
26209275	C1413365	CFTR gene	gngm	3.68
26209275	C0441712	Mechanism (attribute)	ftcn	3.57
26209275	C0596988	mutant	comd	3.50
26209275	C0040363	Togo	geoa	17.80
26209275	C0041260	Tryptophanase	aapp	17.80
26209275	C0041260	Tryptophanase	enzy	17.80
26209275	C0005456	Binding Sites	rcpt	12.91
26209275	C0020792	Identification (Psychology)	menp	12.89
26209275	C0376554	Knowledge	inpr	6.66
26209275	C0086272	Experimental Model	inpr	6.60
26209275	C1999230	Providing (action)	acty	5.18
26209275	C0558058	Reflecting	menp	5.18
26209275	C1883351	To	qlco	5.18
26209275	C3887622	Gap (space)	spco	3.68
26209275	C0332268	Lacking	qlco	3.55
26209275	C2945843	Site of	qlco	3.43
26209275	C1548787	Appropriate	qlco	3.43
26209275	C1167622	Binding (Molecular Function)	moft	3.42
26209275	C1145667	Binding action	acty	3.42
26209275	C0205396	Identified	qlco	3.42
26209275	C0026809	Mus	mamm	30.42
26209275	C0086418	Homo sapiens	humn	28.66
26209275	C0004927	Behavior	inbe	6.83
26209275	C1707455	Comparison	acty	5.18
26209275	C2707008	Behavior:-:Point in time:^Patient:-	clna	3.68
26209275	C0597694	Xenopus oocyte	cell	3.62
26209275	C1704632	Disease Response	fndg	3.59
26209275	C2911692	Response (communication)	menp	3.59
26209275	C1706817	Response (statement)	inpr	3.59
26209275	C0871261	Response process	orga	3.59
26209275	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.58
26209275	C0439799	Channel	spco	3.50
26209275	C1706095	Channel Object	cnce	3.50
26209275	C0205314	New	qlco	3.45
26209275	C0679622	literary novel	inpr	3.45
26209275	C0205309	Known	qlco	3.43
26209275	C2933330	N-(2-naphthalenyl)-((3,5-dibromo-2,4-dihydroxyphenyl)methylene)glycine hydrazide	aapp	26.36
26209275	C2933330	N-(2-naphthalenyl)-((3,5-dibromo-2,4-dihydroxyphenyl)methylene)glycine hydrazide	bacs	26.36
26209275	C0010834	Cytoplasm	celc	13.02
26209275	C0441987	Side	spco	7.27
26209275	C4048755	Apply	ftcn	5.18
26209275	C1561536	*Activity (kind of quantity)	idcn	3.68
26209275	C0205177	Active	ftcn	3.68
26209275	C0441655	Activities	acty	3.68
26209275	C3668946	Activity (animal life circumstance)	fndg	3.68
26209275	C4049939	FDA Establishment Activity Terminology	inpr	3.68
26209275	C0439167	Percent Activity	qnco	3.68
26209275	C4049938	Physical Activity Measurement	lbpr	3.68
26209275	C0332206	Blocking	ftcn	3.57
26209275	C0442805	Increase	ftcn	3.57
26209275	C0205217	Increased	qnco	3.57
26209275	C0028778	Obstruction	patf	3.57
26209275	C0521449	Cytoplasmic	blor	3.56
26209275	C1947931	Direct (qualifier)	qlco	3.56
26209275	C0521119	Extracellular	celc	3.50
26209275	C0017628	Glyburide	orch	17.80
26209275	C0017628	Glyburide	phsu	17.80
26209275	C0015272	Exhibits as Topic	inpr	16.59
26209275	C0029045	Oocytes	cell	16.18
26209275	C0029974	Ovum	cell	13.03
26209275	C0332206	Blocking	ftcn	7.23
26209275	C0596901	Membrane	celc	6.58
26209275	C0025255	Tissue membrane	tisu	6.58
26209275	C0028778	Obstruction	patf	5.18
26209275	C1720467	Only - dosing instruction fragment	inpr	5.18
26209275	C0205171	Singular	qnco	5.18
26209275	C1554187	Gender Status - Intact	fndg	3.57
26209275	C0205266	Intact	qlco	3.57
26209275	C1280500	Effect	qlco	3.56
26209275	C2348382	Effect, Appearance	qlco	3.56
26209275	C0233660	Mental blocking	mobd	3.43
26209275	C1706182	Membrane Device Component	mnob	3.43
26209275	C0994894	Patch Dosage Form	medd	3.43
26209275	C3267922	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]	phsu	3.43
26209275	C2741958	VX-770	orch	3.43
26209275	C1273517	Used by	fndg	3.43
26209275	C0442805	Increase	ftcn	3.42
26209275	C0205217	Increased	qnco	3.42
26209275	C0005456	Binding Sites	rcpt	14.64
26209275	C0031330	Pharmacology	bmod	9.78
26209275	C1999230	Providing (action)	acty	5.18
26209275	C1705535	suggestion	idcn	5.18
26209275	C2825142	Experimental Result	fndg	3.98
26209275	C1274040	Result	ftcn	3.98
26209275	C1546471	What subject filter - Result	idcn	3.98
26209275	C0427965	Antimicrobial susceptibility	fndg	3.63
26209275	C0441712	Mechanism (attribute)	ftcn	3.57
26209275	C1706376	Mechanism Component of Device	mnob	3.57
26209275	C0871532	tool use	fndg	3.56
26209275	C0205464	pharmacological	ftcn	3.48
24997884	C0041714	United States Food and Drug Administration	hcro	25.65
24997884	C0004268	Attention	menp	13.01
24997884	C0018684	Health	idcn	6.71
24997884	C0030705	Patients	podg	6.59
24997884	C0205450	Four	qnco	5.18
24997884	C0231617	Catch - Finding of sensory dimension of pain	sosy	3.98
24997884	C1521991	Molecular	qlco	3.63
24997884	C0205314	New	qlco	3.63
24997884	C1551338	Entity	enty	3.59
24997884	C0205540	Approved	qlco	3.57
24997884	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	3.43
24997884	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	3.43
24997884	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	3.43
24997884	C1880177	Contribution	acty	3.43
24997884	C1546944	Event Seriousness - Significant	qlco	3.43
24997884	C0750502	Significant	idcn	3.43
24997884	C0237881	Statistical Significance	qnco	3.43
24997884	C3264621	ivacaftor	orch	14.64
24997884	C3264621	ivacaftor	phsu	14.64
24997884	C2346845	Approval (document)	inpr	3.59
24997884	C0205540	Approved	qlco	3.59
24997884	C2697909	Letter of Authorization	rnlw	3.59
24997884	C0205435	First (number)	qnco	3.57
24997884	C1279901	Firstly	qlco	3.57
24997884	C3264627	Kalydeco	phsu	3.50
24997884	C0039798	therapeutic aspects	ftcn	22.61
24997884	C0015127	Etiology aspects	ftcn	9.88
24997884	C0010674	Cystic Fibrosis	dsyn	9.79
24997884	C0000768	Congenital Abnormality	cgab	6.59
24997884	C1521840	Target	ftcn	5.18
24997884	C2986546	Target Lesion Identification	diap	5.18
24997884	C1533734	Administration procedure	topp	3.68
24997884	C1705169	Biomaterial Treatment	cnce	3.68
24997884	C0087111	Therapeutic procedure	topp	3.68
24997884	C1522326	Treating	ftcn	3.68
24997884	C3538994	Treatment Epoch	resa	3.68
24997884	C3887704	treatment - ActInformationManagementReason	hlca	3.68
24997884	C1524003	Science of Etiology	cnce	3.57
24997884	C0205447	One	qnco	3.56
24997884	C0205435	First (number)	qnco	3.50
24997884	C1279901	Firstly	qlco	3.50
24997884	C4019266	Birth defects diagnosis:Find:Pt:^Patient:Nar	clna	3.43
24997884	C0220810	Congenital defects	cgab	3.43
24997884	C2718059	Precision Medicine	topp	12.90
24997884	C1707959	Example	cnce	3.54
24997884	C1555307	promise	idcn	3.42
24997884	C0206526	Tuberculosis, Multidrug-Resistant	dsyn	48.50
24997884	C0041296	Tuberculosis	dsyn	20.95
24997884	C0085732	Ability	orga	13.05
24997884	C1664205	bedaquiline	antb	12.90
24997884	C1664205	bedaquiline	orch	12.90
24997884	C0030705	Patients	podg	8.34
24997884	C1704788	Definition	inpr	5.18
24997884	C0332148	Probable diagnosis	qlco	5.18
24997884	C0750492	Probably	idcn	5.18
24997884	C1999230	Providing (action)	acty	5.18
24997884	C3539106	Sufficiently defined concept definition status (core metadata concept)	inpr	5.18
24997884	C1516606	Clinical Data	inpr	3.64
24997884	C1705938	Base - General Qualifier	idcn	3.57
24997884	C1527178	Basis - conceptual entity	ftcn	3.57
24997884	C0814225	benefit	qnco	3.57
24997884	C1561536	*Activity (kind of quantity)	idcn	3.54
24997884	C0205177	Active	ftcn	3.54
24997884	C0441655	Activities	acty	3.54
24997884	C3668946	Activity (animal life circumstance)	fndg	3.54
24997884	C2827757	Antimicrobial Resistance Result	lbtr	3.54
24997884	C4049939	FDA Establishment Activity Terminology	inpr	3.54
24997884	C0439167	Percent Activity	qnco	3.54
24997884	C4049938	Physical Activity Measurement	lbpr	3.54
24997884	C1514892	Resistance Process	phsf	3.54
24997884	C0332325	Resistant (qualifier value)	ftcn	3.54
24997884	C1550464	resistant - Observation Interpretation Susceptibility	idcn	3.54
24997884	C3530521	Sirturo	phsu	3.50
24997884	C1292711	Part of	spco	3.43
24997884	C0439064	Numerous	qnco	3.42
24997884	C0013227	Pharmaceutical Preparations	phsu	3.42
24997884	C1254351	Pharmacologic Substance	phsu	3.42
24997884	C2945654	Regimen - CHV concept	inpr	3.42
24997884	C2347946	Relevance	qlco	3.42
24997884	C0205448	Two	qnco	3.42
24997884	C1549486	Major medical	idcn	3.41
24997884	C0040808	Treatment Protocols	topp	32.79
24997884	C0041714	United States Food and Drug Administration	hcro	27.26
24997884	C0206526	Tuberculosis, Multidrug-Resistant	dsyn	22.53
24997884	C0087113	Treatment Effectiveness	qlco	19.31
24997884	C1664205	bedaquiline	antb	14.64
24997884	C1664205	bedaquiline	orch	14.64
24997884	C0042153	utilization qualifier	ftcn	9.85
24997884	C0024826	Marketing	ocac	9.73
24997884	C0001675	Adult	aggp	9.73
24997884	C3830550	December	qlco	7.40
24997884	C0009429	Combined Modality Therapy	topp	6.59
24997884	C0024109	Lung	bpoc	6.58
24997884	C0030705	Patients	podg	6.58
24997884	C4055445	Approved for Human Use Product	qlco	5.18
24997884	C0034866	Recommendation	idcn	5.18
24997884	C1883708	Then	tmco	5.18
24997884	C3274448	Tolerability Study	resa	5.18
24997884	C1548284	Charge type - Grant	idcn	3.98
24997884	C0018173	funding grant	qnco	3.98
24997884	C2945654	Regimen - CHV concept	inpr	3.63
24997884	C1524063	Use of	ftcn	3.56
24997884	C0392360	Indication of (contextual qualifier)	idcn	3.56
24997884	C0237834	Resistance (Psychotherapeutic)	menp	3.56
24997884	C1514892	Resistance Process	phsf	3.56
24997884	C1524004	Authorization documentation	inpr	3.55
24997884	C2699414	Committee	grup	3.55
24997884	C0680281	authorization	socb	3.55
24997884	C0457083	Usage	ftcn	3.54
24997884	C1947944	Use - dosing instruction imperative	inpr	3.54
24997884	C1704419	Effective	qlco	3.48
24997884	C1280519	Effectiveness	qlco	3.48
24997884	C0556895	Combination electrotherapy	topp	3.44
24997884	C1292711	Part of	spco	3.44
24997884	C0237463	Agencies	orgt	3.42
24997884	C1701901	Conditional	qlco	3.42
24997884	C1963686	Conditional (Substitution Condition)	ftcn	3.42
24997884	C1535514	European race	popg	3.42
24997884	C3530521	Sirturo	phsu	3.42
24997884	C0239307	ethnic european	popg	3.42
24997884	C1706450	Legal Adult	humn	3.42
24997884	C0449719	Part	spco	3.42
24997884	C1709471	Part Dosing Unit	qnco	3.42
24997884	C2709248	Pulmonary (qualifier value)	qlco	3.42
24997884	C2707265	Pulmonary:-:Point in time:^Patient:-	clna	3.42
24997884	C0013227	Pharmaceutical Preparations	phsu	3.41
24997884	C0162676	Enzyme Multiplied Immunoassay Technique	lbpr	17.80
24997884	C0182638	Radiopharmaceuticals	irda	17.80
24997884	C0182638	Radiopharmaceuticals	phsu	17.80
24997884	C2742211	florbetapir	orch	13.09
24997884	C0034519	Electromagnetic Radiation	npop	12.90
24997884	C0006104	Brain	bpoc	11.49
24997884	C2936349	Plaque, Amyloid	acab	9.77
24997884	C0333463	Senile Plaques	acab	9.77
24997884	C0043227	Work	ocac	6.74
24997884	C0851346	Radiation	npop	6.59
24997884	C1522449	Therapeutic radiology procedure	topp	6.59
24997884	C2700400	Contain (action)	acty	5.18
24997884	C0332256	Containing (qualifier)	ftcn	5.18
24997884	C1269537	Entire brain	bpoc	5.18
24997884	C0991511	Injectable Solution	bodm	3.77
24997884	C1521840	Target	ftcn	3.59
24997884	C1265611	Quantity	qnco	3.57
24997884	C1314972	Claims attachment	inpr	3.53
24997884	C3714578	Fix	phpr	3.53
24997884	C0205177	Active	ftcn	3.48
24997884	C3888249	Active License	qlco	3.48
24997884	C3473058	Amyvid	elii	3.48
24997884	C3473058	Amyvid	irda	3.48
24997884	C0439861	Substance	sbst	3.48
24997884	C3853793	active (HL7 RoleLink)	idcn	3.48
24997884	C3890211	Low Mitosis-Karyorrhexis Index	qnco	3.44
24997884	C1524020	Radiation Ionizing Radiotherapy	topp	3.44
24997884	C1524021	Radiotherapy Research	resa	3.44
24997884	C0560559	Unit of radiation dose	qnco	3.44
24997884	C0205251	low	qlco	3.44
24997884	C1550472	low confidentiality	inpr	3.44
24997884	C4048187	low exposure	qlco	3.44
24997884	C0040363	Togo	geoa	54.24
24997884	C0041260	Tryptophanase	aapp	54.24
24997884	C0041260	Tryptophanase	enzy	54.24
24997884	C0002395	Alzheimer's Disease	dsyn	17.80
24997884	C1883351	To	qlco	15.79
24997884	C0031831	Physicians	prog	14.64
24997884	C0333463	Senile Plaques	acab	9.74
24997884	C0030705	Patients	podg	8.34
24997884	C2360836	Abortion consent:Finding:Point in time:^Patient:Document	clna	5.18
24997884	C1521724	Alzheimer's Disease Pathway KEGG	patf	5.18
24997884	C0562342	Empowered	menp	5.18
24997884	C1171285	Enabling	menp	5.18
24997884	C2360838	Hysterectomy consent:Finding:Point in time:^Patient:Document	clna	5.18
24997884	C1518422	Negation	ftcn	5.18
24997884	C2360840	Sterilization consent:Finding:Point in time:^Patient:Document	clna	5.18
24997884	C0750558	Unlikely	cnce	5.18
24997884	C1710571	Unlikely Related to Intervention	qlco	5.18
24997884	C0150312	Present	qnco	3.59
24997884	C0449450	Presentation	idcn	3.59
24997884	C1265611	Quantity	qnco	3.56
24997884	C1273937	Not significant	fndg	3.46
24997884	C1705178	Order (action)	acty	3.45
24997884	C1705176	Order (arrangement)	qlco	3.45
24997884	C1705175	Order (document)	inpr	3.45
24997884	C1705177	Order (taxonomic)	clas	3.45
24997884	C1882348	Permutation	qlco	3.45
24997884	C3889825	Sequence of Planned Assessment Schedule	inpr	3.45
24997884	C0033497	Propranolol	orch	24.11
24997884	C0033497	Propranolol	phsu	24.11
24997884	C0001645	Adrenergic beta-Antagonists	phsu	22.68
24997884	C0040363	Togo	geoa	17.80
24997884	C0041260	Tryptophanase	aapp	17.80
24997884	C0041260	Tryptophanase	enzy	17.80
24997884	C0020538	Hypertensive disease	dsyn	11.49
24997884	C0376649	Addresses (publication format)	inpr	8.34
24997884	C1442065	Address	spco	5.18
24997884	C2926615	Ever told by doctor or nurse that you have high blood pressure:Finding:Point in time:^Patient:Ordinal	clna	5.18
24997884	C0439044	Living Alone	fndg	5.18
24997884	C0205171	Singular	qnco	5.18
24997884	C0087111	Therapeutic procedure	topp	5.18
24997884	C1883351	To	qlco	5.18
24997884	C1522326	Treating	ftcn	5.18
24997884	C1292734	Treatment intent	ftcn	5.18
24997884	C1273517	Used by	fndg	5.18
24997884	C0679994	alone - group size	grpa	5.18
24997884	C1522168	Topical Route of Drug Administration	ftcn	3.63
24997884	C1555712	topic - ActClassContainer	inpr	3.63
24997884	C0013227	Pharmaceutical Preparations	phsu	3.56
24997884	C1883357	Together	qlco	3.56
24997884	C1517741	Last	qlco	3.50
24997884	C0033497	Propranolol	orch	22.61
24997884	C0033497	Propranolol	phsu	22.61
24997884	C0206733	Strawberry nevus of skin	neop	16.37
24997884	C0376558	Life	idcn	9.74
24997884	C1517378	Gain	qnco	3.98
24997884	C1522326	Treating	ftcn	3.48
24997884	C0205314	New	qlco	3.43
27983869	C0086418	Homo sapiens	humn	28.68
27983869	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.54
27983869	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.54
27983869	C0010453	Anthropological Culture	idcn	13.05
27983869	C0010674	Cystic Fibrosis	dsyn	9.77
27983869	C0242481	Research Activities	resa	9.74
27983869	C0035168	research	resa	9.74
27983869	C1413365	CFTR gene	gngm	3.61
27983869	C0442732	Vital (qualifier value)	qlco	3.56
27983869	C1875856	Vital High Nitrogen Enteral Nutrition	food	3.56
27983869	C0872152	drug development	bmod	3.55
27983869	C1709060	Modulator Device Component	mnob	3.54
27983869	C0301863	"""U"" lymphocyte"	cell	3.52
27983869	C0205615	Well Differentiated	qlco	3.46
27983869	C0205039	Bronchial	bpoc	3.45
27983869	C1442216	Bronchial system	bpoc	3.45
27983869	C0205225	Primary	qlco	3.45
27983869	C0439631	Primary operation	topp	3.45
27983869	C0439612	True primary (qualifier value)	tmco	3.45
27983869	C0221908	epithelial	qlco	3.45
27983869	C0084340	rhoA GTP-Binding Protein	aapp	28.65
27983869	C0084340	rhoA GTP-Binding Protein	enzy	28.65
27983869	C0233324	Term Birth	orgf	22.90
27983869	C0086734	Operator, Genetic	bacs	22.73
27983869	C0086734	Operator, Genetic	nnon	22.73
27983869	C1527249	Colorectal Cancer	neop	20.95
27983869	C0009402	Colorectal Carcinoma	neop	20.95
27983869	C0085087	3T3 Cells	cell	13.01
27983869	C0010453	Anthropological Culture	idcn	12.99
27983869	C0667301	Y 27632	orch	12.89
27983869	C0667301	Y 27632	phsu	12.89
27983869	C3179110	Feeder Cells	cell	9.86
27983869	C0016030	Fibroblasts	cell	9.72
27983869	C0039421	Technology	ocdi	8.34
27983869	C1413336	CEL gene	gngm	7.35
27983869	C1948049	Cell (compartment)	spco	7.35
27983869	C1704653	Cell Device Component	medd	7.35
27983869	C0007634	Cells	cell	7.35
27983869	C1269647	Entire cell	cell	7.35
27983869	C1522449	Therapeutic radiology procedure	topp	6.57
27983869	C4050364	Cytogenetic Complete Response	fndg	5.18
27983869	C2349975	Enhance (action)	acty	5.18
27983869	C0007595	cell growth	celf	5.18
27983869	C0870809	life span	grpa	5.18
27983869	C2826302	Reported Term	inpr	3.98
27983869	C1705313	Term (lexical)	idcn	3.98
27983869	C1515273	Term (temporal)	tmco	3.98
27983869	C0220814	Cultural aspects	ftcn	3.53
27983869	C0430400	Laboratory culture	lbpr	3.53
27983869	C2242979	Microbial culture (procedure)	lbpr	3.53
27983869	C0728887	Preserving	ftcn	3.50
27983869	C3828338	Reprogram	acty	3.48
27983869	C0301863	"""U"" lymphocyte"	cell	3.44
27983869	C0221908	epithelial	qlco	3.43
27983869	C3537035	kinase inhibitor	aapp	3.42
27983869	C3537035	kinase inhibitor	phsu	3.42
27983869	C1171350	kinase inhibitor [EPC]	phsu	3.42
27983869	C3537023	kinase inhibitor activity	moft	3.42
27983869	C1548980	Blood Product Processing Requirements - Irradiated	idcn	3.42
27983869	C0812234	RHOA gene	gngm	3.42
27983869	C1527249	Colorectal Cancer	neop	19.23
27983869	C0009402	Colorectal Carcinoma	neop	19.23
27983869	C0009738	Congo	geoa	16.07
27983869	C0013865	Electrophysiology (science)	bmod	13.28
27983869	C0205265	Initially	tmco	5.18
27983869	C1446476	Electrophysiology studies	diap	3.82
27983869	C0007634	Cells	cell	3.60
27983869	C3282337	Cells [Chemical/Ingredient]	cell	3.60
27983869	C1415484	HBE1 gene	gngm	3.60
27983869	C2827566	HBE1 wt Allele	gngm	3.60
27983869	C3844844	Hb E	fndg	3.60
27983869	C1521970	Characteristics	qlco	3.57
27983869	C3811819	CFTR wt Allele	gngm	3.46
27983869	C4050364	Cytogenetic Complete Response	fndg	3.46
27983869	C0205229	Expanding	spco	3.46
27983869	C1518422	Negation	ftcn	3.46
27983869	C0439858	classical example	qlco	3.44
27983869	C0543482	morphological	spco	3.44
27983869	C0009738	Congo	geoa	32.42
27983869	C0010405	Cryopreservation	lbpr	24.11
27983869	C0008628	Chromosome Deletion	comd	22.48
27983869	C1527249	Colorectal Cancer	neop	19.23
27983869	C0009402	Colorectal Carcinoma	neop	19.23
27983869	C1449619	Culture Techniques	lbpr	10.06
27983869	C1257890	Population Group	popg	9.90
27983869	C0019904	Homozygote	orga	9.86
27983869	C1301820	Obtain	ftcn	7.46
27983869	C0205449	Three	qnco	7.14
27983869	C3811819	CFTR wt Allele	gngm	7.04
27983869	C0032659	geographic population	qnco	6.75
27983869	C0024109	Lung	bpoc	6.71
27983869	C3539655	CDISC Findings Class	inpr	5.18
27983869	C2926606	Procedure findings:Finding:Point in time:^Patient:Narrative	clna	5.18
27983869	C1524063	Use of	ftcn	5.18
27983869	C2607943	findings aspects	ftcn	5.18
27983869	C2242979	Microbial culture (procedure)	lbpr	3.75
27983869	C0013018	Donor person	popg	3.55
27983869	C1527169	Encounter due to being a donor	fndg	3.55
27983869	C0439858	classical example	qlco	3.48
27983869	C1413336	CEL gene	gngm	3.45
27983869	C1948049	Cell (compartment)	spco	3.45
27983869	C1704653	Cell Device Component	medd	3.45
27983869	C0007634	Cells	cell	3.45
27983869	C2347859	Content Creation Date	tmco	3.45
27983869	C1706214	Creation	acty	3.45
27983869	C4050364	Cytogenetic Complete Response	fndg	3.45
27983869	C1269647	Entire cell	cell	3.45
27983869	C0205452	Six	qnco	3.45
27983869	C1883708	Then	tmco	3.45
27983869	C0040363	Togo	geoa	17.80
27983869	C0041260	Tryptophanase	aapp	17.80
27983869	C0041260	Tryptophanase	enzy	17.80
27983869	C3536832	Air	inch	16.25
27983869	C3536832	Air	phsu	16.25
27983869	C0001861	Air (substance)	sbst	16.25
27983869	C0018270	Growth	orgf	13.09
27983869	C0077803	Ultroser G	phsu	12.95
27983869	C0162867	Tunica Media	tisu	9.91
27983869	C0012634	Disease	dsyn	9.90
27983869	C0009458	Communications Media	inpr	6.76
27983869	C1522449	Therapeutic radiology procedure	topp	6.59
27983869	C0007634	Cells	cell	5.18
27983869	C3282337	Cells [Chemical/Ingredient]	cell	5.18
27983869	C1883351	To	qlco	5.18
27983869	C0205615	Well Differentiated	qlco	5.18
27983869	C0683607	allowing	socb	5.18
27983869	C0200940	Microbial subculture	lbpr	3.98
27983869	C0699799	subculture Social	popg	3.98
27983869	C2698172	Application Program Interface	inpr	3.63
27983869	C2911660	Growth action	acty	3.63
27983869	C1708533	Interface Device Component	mnob	3.63
27983869	C1304698	Liquid (finding)	fndg	3.63
27983869	C1546699	Liquid NOS - Specimen Source Codes	inpr	3.63
27983869	C1561501	Liquid Specimen	sbst	3.63
27983869	C0301571	Liquid diet	topp	3.63
27983869	C0302908	Liquid substance	sbst	3.63
27983869	C1621966	Tissue Growth	ortf	3.63
27983869	C1551331	Transportation Services; Ambulance; Air	hcro	3.63
27983869	C1551331	Transportation Services; Ambulance; Air	mnob	3.63
27983869	C0220844	growth aspects	phsf	3.63
27983869	C1254021	Media layer	tisu	3.60
27983869	C0205134	Curved	spco	3.59
27983869	C0348080	Condition	qlco	3.59
27983869	C3864998	Condition:Find:Pt:^Patient:Nom	clna	3.59
27983869	C1705253	Logical Condition	cnce	3.59
27983869	C2700400	Contain (action)	acty	3.46
27983869	C0332256	Containing (qualifier)	ftcn	3.46
27983869	C3272561	Proprietary Method	inpr	3.46
27983869	C3272599	Proprietary Storage Condition	qlco	3.46
27983869	C1548980	Blood Product Processing Requirements - Irradiated	idcn	3.43
27983869	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.54
27983869	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.54
27983869	C0008628	Chromosome Deletion	comd	22.47
27983869	C0009738	Congo	geoa	16.16
27983869	C0001758	Aftercare	hlca	13.02
27983869	C0019904	Homozygote	orga	9.85
27983869	C3252847	VX 809	orch	3.68
27983869	C3252847	VX 809	phsu	3.68
27983869	C1413365	CFTR gene	gngm	3.61
27983869	C1709060	Modulator Device Component	mnob	3.61
27983869	C0947630	Scientific Study	lbpr	3.61
27983869	C3811819	CFTR wt Allele	gngm	3.54
27983869	C0007634	Cells	cell	3.54
27983869	C3282337	Cells [Chemical/Ingredient]	cell	3.54
27983869	C0884358	Performed	ftcn	3.54
27983869	C0935616	Chamber (anatomical)	bpoc	3.47
27983869	C0179874	Chamber (physical object)	mnob	3.47
27983869	C0007584	Cell Count	lbpr	16.18
27983869	C1711178	Bronchial Epithelial Cell	cell	3.73
27983869	C1527249	Colorectal Cancer	neop	19.24
27983869	C0009402	Colorectal Carcinoma	neop	19.24
27983869	C3536832	Air	inch	16.22
27983869	C3536832	Air	phsu	16.22
27983869	C0001861	Air (substance)	sbst	16.22
27983869	C0010453	Anthropological Culture	idcn	14.64
27983869	C0220814	Cultural aspects	ftcn	5.18
27983869	C0205431	Formed	ftcn	5.18
27983869	C0430400	Laboratory culture	lbpr	5.18
27983869	C2242979	Microbial culture (procedure)	lbpr	5.18
27983869	C0439799	Channel	spco	3.63
27983869	C0007634	Cells	cell	3.61
27983869	C3282337	Cells [Chemical/Ingredient]	cell	3.61
27983869	C1415484	HBE1 gene	gngm	3.61
27983869	C2827566	HBE1 wt Allele	gngm	3.61
27983869	C3844844	Hb E	fndg	3.61
27983869	C2698172	Application Program Interface	inpr	3.60
27983869	C1708533	Interface Device Component	mnob	3.60
27983869	C1304698	Liquid (finding)	fndg	3.60
27983869	C1546699	Liquid NOS - Specimen Source Codes	inpr	3.60
27983869	C1561501	Liquid Specimen	sbst	3.60
27983869	C0301571	Liquid diet	topp	3.60
27983869	C0302908	Liquid substance	sbst	3.60
27983869	C1551331	Transportation Services; Ambulance; Air	hcro	3.60
27983869	C1551331	Transportation Services; Ambulance; Air	mnob	3.60
27983869	C3842590	10%	fndg	3.47
27983869	C4050364	Cytogenetic Complete Response	fndg	3.47
27983869	C0205200	Confluent	qlco	3.46
27983869	C0031843	physiological aspects	phsf	26.09
27983869	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.40
27983869	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.40
27983869	C0008628	Chromosome Deletion	comd	22.35
27983869	C1527249	Colorectal Cancer	neop	19.19
27983869	C0009402	Colorectal Carcinoma	neop	19.19
27983869	C0542341	Function	ftcn	7.06
27983869	C0700205	Function Axis	clas	7.06
27983869	C1705273	Mathematical Operator	inpr	7.06
27983869	C1521816	Cellular Morphology	clna	3.68
27983869	C2700385	Cellular Morphology (discipline)	bmod	3.68
27983869	C0243091	cellular morphology qualifier	qlco	3.68
27983869	C1280500	Effect	qlco	3.56
27983869	C2348382	Effect, Appearance	qlco	3.56
27983869	C0449286	Degree or extent	qnco	3.54
27983869	C1546944	Event Seriousness - Significant	qlco	3.54
27983869	C1704240	Magnitude	qnco	3.54
27983869	C0750502	Significant	idcn	3.54
27983869	C0237881	Statistical Significance	qnco	3.54
27983869	C1413365	CFTR gene	gngm	3.48
27983869	C0442808	Increasing	ftcn	3.48
27983869	C3252847	VX 809	orch	3.46
27983869	C3252847	VX 809	phsu	3.46
27983869	C1705241	Delta (difference)	qnco	3.44
27983869	C1705242	Different	qlco	3.44
27983869	C0007634	Cells	cell	3.42
27983869	C3282337	Cells [Chemical/Ingredient]	cell	3.42
27983869	C0439799	Channel	spco	3.42
27983869	C0521116	Current (present time)	tmco	3.42
27983869	C4050364	Cytogenetic Complete Response	fndg	3.42
27983869	C1705970	Electrical Current	npop	3.42
27983869	C0205229	Expanding	spco	3.42
27983869	C0231449	Extended	spco	3.42
27983869	C0231448	Extension	ftcn	3.42
27983869	C0439792	Extent	spco	3.42
27983869	C1415484	HBE1 gene	gngm	3.42
27983869	C2827566	HBE1 wt Allele	gngm	3.42
27983869	C3844844	Hb E	fndg	3.42
27983869	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	aapp	22.35
27983869	C0056889	Cystic Fibrosis Transmembrane Conductance Regulator	bacs	22.35
27983869	C1527249	Colorectal Cancer	neop	19.27
27983869	C0009402	Colorectal Carcinoma	neop	19.27
27983869	C0009738	Congo	geoa	16.04
27983869	C0039421	Technology	ocdi	6.83
27983869	C0205229	Expanding	spco	5.18
27983869	C0699914	Economic supply	qnco	3.54
27983869	C1875802	Healthcare supplies	medd	3.54
27983869	C1999230	Providing (action)	acty	3.54
27983869	C1314650	SUPPLY, NOT OTHERWISE SPECIFIED	medd	3.54
27983869	C1561604	Supply (process)	ftcn	3.54
27983869	C0243163	supply aspects	idcn	3.54
27983869	C1709060	Modulator Device Component	mnob	3.52
27983869	C4050364	Cytogenetic Complete Response	fndg	3.50
27983869	C1413365	CFTR gene	gngm	3.42
27983869	C0179874	Chamber (physical object)	mnob	3.42
27983869	C0039593	Testing	ftcn	3.42
27983869	C0392366	Tests (qualifier value)	inpr	3.42
27983869	C3811819	CFTR wt Allele	gngm	3.42
27983869	C0007634	Cells	cell	3.42
27983869	C3282337	Cells [Chemical/Ingredient]	cell	3.42
27983869	C0542341	Function	ftcn	3.42
27983869	C0205245	Functional	ftcn	3.42
27983869	C2700217	Functional Relationship	cnce	3.42
27983869	C1415484	HBE1 gene	gngm	3.42
27983869	C2827566	HBE1 wt Allele	gngm	3.42
27983869	C3844844	Hb E	fndg	3.42
27983869	C0205225	Primary	qlco	3.42
27983869	C0439631	Primary operation	topp	3.42
27983869	C0439612	True primary (qualifier value)	tmco	3.42
